PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Da Cruz, S; Xenarios, I; Langridge, J; Vilbois, F; Parone, PA; Martinou, JC				Da Cruz, S; Xenarios, I; Langridge, J; Vilbois, F; Parone, PA; Martinou, JC			Proteomic analysis of the mouse liver mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN IDENTIFICATION; FUNCTIONAL-ANALYSIS; MASS-SPECTROMETRY; ATP; STOMATIN; CHANNELS; RECEPTOR; GENES; YME1	Mitochondria play a crucial role in cellular homeostasis, which justifies the increasing interest in mapping the different components of these organelles. Here we have focused our study on the identification of proteins of the mitochondrial inner membrane (MIM). This membrane is of particular interest because, besides the well known components of the respiratory chain complexes, it contains several ion channels and many carrier proteins that certainly play a key role in mitochondrial function and, therefore, deserve to be identified at the molecular level. To achieve this goal we have used a novel approach combining the use of highly purified mouse liver mitochondrial inner membranes, extraction of membrane proteins with organic acid, and two-dimensional liquid chromatography coupled to tandem mass spectrometry. This procedure allowed us to identify 182 proteins that are involved in several biochemical processes, such as the electron transport machinery, the protein import machinery, protein synthesis, lipid metabolism, and ion or substrate transport. The full range of isoelectric point (3.9-12.5), molecular mass ( 6 527 kDa), and hydrophobicity values ( up to 16 transmembrane predicted domains) were represented. In addition, of the 182 proteins found, 20 were unknown or had never previously been associated with the MIM. Overexpression of some of these proteins in mammalian cells confirmed their mitochondrial localization and resulted in severe remodeling of the mitochondrial network. This study provides the first proteome of the MIM and provides a basis for a more detailed study of the newly characterized proteins of this membrane.	Univ Geneva, Dept Cellular Biol, CH-1205 Geneva, Switzerland; Serono Int SA, Serono Pharmaceut Res Inst, CH-1228 Geneva, Switzerland; Micromass UK Ltd, Manchester M23 9LZ, Lancs, England	University of Geneva; Merck & Company; Serono International S.A.	Martinou, JC (corresponding author), Univ Geneva, Dept Cellular Biol, 30 Quai E Ansermet, CH-1205 Geneva, Switzerland.	jean-claude.martinou@cellbio.unige.ch	Xenarios, Ioannis/ABD-5045-2021	Xenarios, Ioannis/0000-0002-3413-6841; martinou, Jean-claude/0000-0002-9847-2051				Anantharaman V, 2002, FEMS MICROBIOL LETT, V207, P55, DOI 10.1016/S0378-1097(01)00515-8; Barnes TM, 1996, J NEUROCHEM, V67, P46; Crompton M, 2002, BIOCHIMIE, V84, P143, DOI 10.1016/S0300-9084(02)01368-8; Fountoulakis M, 2002, ELECTROPHORESIS, V23, P311, DOI 10.1002/1522-2683(200202)23:2<311::AID-ELPS311>3.0.CO;2-0; Garlid KD, 1996, J BIOL CHEM, V271, P8796, DOI 10.1074/jbc.271.15.8796; Goodman MB, 2002, NATURE, V415, P1039, DOI 10.1038/4151039a; Hoppel C, 2001, ARCH BIOCHEM BIOPHYS, V392, P321, DOI 10.1006/abbi.2001.2463; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; Keller A, 2002, ANAL CHEM, V74, P5383, DOI 10.1021/ac025747h; Kremmidiotis G, 2001, GENOMICS, V76, P58, DOI 10.1006/geno.2001.6560; Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L; Martinez LO, 2003, NATURE, V421, P75, DOI 10.1038/nature01250; Millar AH, 2001, PLANT PHYSIOL, V127, P1711, DOI 10.1104/pp.010387; Okamoto Y, 2002, J BIOL CHEM, V277, P46470, DOI 10.1074/jbc.M207779200; Parone PA, 2002, BIOCHIMIE, V84, P105, DOI 10.1016/S0300-9084(02)01380-9; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Rabilloud T, 1998, ELECTROPHORESIS, V19, P1006, DOI 10.1002/elps.1150190616; Stromhaug PE, 1998, BIOCHEM J, V335, P217, DOI 10.1042/bj3350217; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; TAYLOR SW, 2003, NAT BIOTECHNOL, V18, P18; THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418; Wang YJ, 2000, J BIOL CHEM, V275, P8062, DOI 10.1074/jbc.275.11.8062; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307; Xu WH, 2002, SCIENCE, V298, P1029, DOI 10.1126/science.1074360	25	200	213	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41566	41571		10.1074/jbc.M304940200	http://dx.doi.org/10.1074/jbc.M304940200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12865426	hybrid			2022-12-27	WOS:000185847200138
J	Mana-Capelli, S; Mandal, AK; Arguello, JM				Mana-Capelli, S; Mandal, AK; Arguello, JM			Archaeoglobus fulgidus CopB is a thermophilic Cu2+-ATPase - Functional role of its histidine-rich N-terminal metal binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-TYPE ATPASE; WILSONS-DISEASE PROTEIN; MEMBRANE-VESICLES; ESCHERICHIA-COLI; TRANSPORTING ATPASES; COPPER TRANSPORT; CADA; ZNTA; PUMP; METALLOCHAPERONE	P-1B-type ATPases transport heavy metal ions across cellular membranes. Archaeoglobus fulgidus CopB is a member of this subfamily. We have cloned, expressed in Escherichia coli, and functionally characterized this enzyme. CopB and its homologs are distinguished by a metal binding sequence Cys-Pro-His in their sixth transmembrane segment (H6) and a His-rich N-terminal metal binding domain (His-N-MBD). CopB is a thermophilic protein active at 75 degreesC and high ionic strength. It is activated by Cu2+ with high apparent affinity (K-1/2 = 0.28 muM) and partially by Cu+ and Ag+ ( 22 and 55%, respectively). The higher turnover was associated with a faster phosphorylation rate in the presence of Cu2+. A truncated CopB lacking the first 54 amino acids was constructed to characterize the His-N-MBD. This enzyme showed reduced ATPase activity (50% of wild type) but no changes in metal selectivity, ATP dependence, or phosphorylation levels. However, a slower rate of dephosphorylation of the E2P(Cu2+) form was observed for truncated CopB. The data suggest that the presence of the His residue in the putative transmembrane metal binding site of CopB determines a selectivity for this enzyme that is different for that observed in Cu+/Ag+-ATPases carrying a Cys-Pro-Cys sequence. The His-N-MBD appears to have a regulatory role affecting the metal transport rate by controlling the metal release/ dephosphorylation rates.	Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA	Worcester Polytechnic Institute	Arguello, JM (corresponding author), Worcester Polytech Inst, Dept Chem & Biochem, Worcester, MA 01609 USA.	arguello@wpi.edu	Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297				Arguello JM, 2003, ANN NY ACAD SCI, V986, P212, DOI 10.1111/j.1749-6632.2003.tb07162.x; Arnesano F, 2002, GENOME RES, V12, P255, DOI 10.1101/gr.196802; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Bal N, 2001, FEBS LETT, V506, P249, DOI 10.1016/S0014-5793(01)02927-1; BLOSTEIN R, 1983, J BIOL CHEM, V258, P7948; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; da Silva J. J. R. Frausto, 2001, BIOL CHEM ELEMENTS; Fan B, 2002, J BIOL CHEM, V277, P46987, DOI 10.1074/jbc.M208490200; Fatemi N, 2002, J BIOENERG BIOMEMBR, V34, P339, DOI 10.1023/A:1021245902195; GOOD NE, 1966, BIOCHEMISTRY-US, V5, P467, DOI 10.1021/bi00866a011; Huffman DL, 2000, J BIOL CHEM, V275, P18611, DOI 10.1074/jbc.C000172200; Kim R, 1998, BIOTECHNOL LETT, V20, P207, DOI 10.1023/A:1005305330517; Klenk HP, 1997, NATURE, V390, P364, DOI 10.1038/37052; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Lutsenko S, 2003, J MEMBRANE BIOL, V191, P1, DOI 10.1007/s00232-002-1040-6; LUTSENKO S, 1995, BIOCHEMISTRY-US, V34, P15607, DOI 10.1021/bi00048a001; Mandal AK, 2002, J BIOL CHEM, V277, P7201, DOI 10.1074/jbc.M109964200; Melchers K, 1996, J BIOL CHEM, V271, P446, DOI 10.1074/jbc.271.1.446; Mitra B, 2001, BIOCHEMISTRY-US, V40, P7694, DOI 10.1021/bi010576g; ODERMATT A, 1993, J BIOL CHEM, V268, P12775; Okkeri J, 1999, BIOCHEMISTRY-US, V38, P14109, DOI 10.1021/bi9913956; Rensing C, 1998, J BIOL CHEM, V273, P32614, DOI 10.1074/jbc.273.49.32614; Rensing C, 1999, J BACTERIOL, V181, P5891, DOI 10.1128/JB.181.19.5891-5897.1999; Rensing C, 2000, P NATL ACAD SCI USA, V97, P652, DOI 10.1073/pnas.97.2.652; Rutherford JC, 1999, J BIOL CHEM, V274, P25827, DOI 10.1074/jbc.274.36.25827; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Scarborough GA, 2002, J BIOENERG BIOMEMBR, V34, P235, DOI 10.1023/A:1020211016696; Sharma R, 2000, J BIOL CHEM, V275, P3873, DOI 10.1074/jbc.275.6.3873; Solioz M, 1996, TRENDS BIOCHEM SCI, V21, P237; SOLIOZ M, 1995, J BIOL CHEM, V270, P9217, DOI 10.1074/jbc.270.16.9217; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tsai KJ, 2002, J BIOENERG BIOMEMBR, V34, P147, DOI 10.1023/A:1016085301323; TSAI KJ, 1992, J BACTERIOL, V174, P116, DOI 10.1128/jb.174.1.116-121.1992; TSAI KJ, 1993, ARCH BIOCHEM BIOPHYS, V305, P267, DOI 10.1006/abbi.1993.1421; Tsivkovskii R, 2001, J BIOL CHEM, V276, P2234, DOI 10.1074/jbc.M003238200; Voskoboinik I, 1998, FEBS LETT, V435, P178, DOI 10.1016/S0014-5793(98)01059-X; Voskoboinik I, 2001, J BIOL CHEM, V276, P28620, DOI 10.1074/jbc.M103532200; Voskoboinik N, 1999, J BIOL CHEM, V274, P22008, DOI 10.1074/jbc.274.31.22008; VULPE CD, 1995, ANNU REV NUTR, V15, P293, DOI 10.1146/annurev.nu.15.070195.001453; Walker JM, 2002, J BIOL CHEM, V277, P27953, DOI 10.1074/jbc.M203845200; Yoshimizu T, 1998, BIOSCI BIOTECH BIOCH, V62, P1258, DOI 10.1271/bbb.62.1258	42	82	84	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40534	40541		10.1074/jbc.M306907200	http://dx.doi.org/10.1074/jbc.M306907200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12876283	hybrid			2022-12-27	WOS:000185847200015
J	Demarchi, F; Bertoli, C; Sandy, P; Schneider, C				Demarchi, F; Bertoli, C; Sandy, P; Schneider, C			Glycogen synthase kinase-3 beta regulates NF-kappa B1/p105 stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GLYCOGEN-SYNTHASE KINASE-3; REQUIRES PHOSPHORYLATION; PRECURSOR P105; DEATH DOMAIN; MICE LACKING; ACTIVATION; PROTEIN; INHIBITION; UBIQUITINATION	A number of different kinases have been implicated in NF-kappaB regulation and survival function. Here we investigated the molecular cross-talk between glycogen synthase kinase-3beta (GSK-3beta) and the p105 precursor of the NF-kappaB p50 subunit. GSK-3beta forms an in vivo complex with and specifically phosphorylates NF-kappaB1/p105 at Ser-903 and Ser-907 in vitro. In addition, the p105 phosphorylation level is reduced in fibroblasts lacking GSK-3beta as compared with wild-type cells. GSK-3beta has a dual effect on p105: it stabilizes p105 under resting conditions and primes p105 for degradation upon tumor necrosis factor (TNF)-alpha treatment. Indeed, constitutive processing of p105 to p50 occurs at a higher rate in cells lacking GSK-3beta with respect to wild-type cells and can be reduced upon reintroduction of GSK-3beta by transfection. Moreover, p105 degradation in response to TNF-alpha is prevented in GSK-3 beta-/- fibroblasts and by a Ser to Ala point mutation on p105 at positions 903 or 907. Interestingly, the increased sensitiveness to TNF-alpha-induced death occurring in GSK-3 beta -/- fibroblasts, which is coupled to a perturbation of p50/105 ratio, can be reproduced by p105 silencing in wild-type fibroblasts.	Lab Nazl Consorzio Interuniv Biotecnol, I-34012 Trieste, Italy; Univ Udine, Dipartimento Sci & Tecnol Biomed, I-33100 Udine, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Tecnologie Biomediche (ITB-CNR); University of Udine	Schneider, C (corresponding author), Lab Nazl Consorzio Interuniv Biotecnol, Area Sci Pk,Padriciano 99, I-34012 Trieste, Italy.	schneide@lncib.it		Demarchi, Francesca/0000-0003-1565-3162				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Beinke S, 2002, J BIOL CHEM, V277, P24162, DOI 10.1074/jbc.M201576200; Belich MP, 1999, NATURE, V397, P363, DOI 10.1038/16946; Boland MP, 1998, J BIOL CHEM, V273, P15494, DOI 10.1074/jbc.273.25.15494; Coux O, 1998, J BIOL CHEM, V273, P8820, DOI 10.1074/jbc.273.15.8820; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Demarchi F, 2001, J BIOL CHEM, V276, P31738, DOI 10.1074/jbc.M104457200; DUCKETT CS, 1993, MOL CELL BIOL, V13, P1315, DOI 10.1128/MCB.13.3.1315; Foltz DR, 2002, CURR BIOL, V12, P1006, DOI 10.1016/S0960-9822(02)00888-6; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Harhaj EW, 1996, ONCOGENE, V12, P2385; Heissmeyer V, 1999, EMBO J, V18, P4766, DOI 10.1093/emboj/18.17.4766; Hoeflich KP, 2000, NATURE, V406, P86, DOI 10.1038/35017574; Ishikawa H, 1998, J EXP MED, V187, P985, DOI 10.1084/jem.187.7.985; Jia JH, 2002, NATURE, V416, P548, DOI 10.1038/nature733; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Lin L, 2000, EMBO J, V19, P4712, DOI 10.1093/emboj/19.17.4712; Manoukian AS, 2002, ADV CANCER RES, V84, P203, DOI 10.1016/S0065-230X(02)84007-6; MELLITS KH, 1993, NUCLEIC ACIDS RES, V21, P5059, DOI 10.1093/nar/21.22.5059; Nemeth ZH, 2002, J BIOL CHEM, V277, P7713, DOI 10.1074/jbc.M109711200; Orian A, 2000, EMBO J, V19, P2580, DOI 10.1093/emboj/19.11.2580; Orian A, 1999, MOL CELL BIOL, V19, P3664; ORIAN A, 1995, J BIOL CHEM, V270, P21707, DOI 10.1074/jbc.270.37.21707; Ozes ON, 1999, NATURE, V401, P82; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Price MA, 2002, CELL, V108, P823, DOI 10.1016/S0092-8674(02)00664-5; Salmeron A, 2001, J BIOL CHEM, V276, P22215, DOI 10.1074/jbc.M101754200; Schotte P, 2001, J BIOL CHEM, V276, P25939, DOI 10.1074/jbc.M104014200; Schwabe RF, 2002, AM J PHYSIOL-GASTR L, V283, pG204, DOI 10.1152/ajpgi.00016.2002; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; Sheridan CM, 2002, J BIOL CHEM, V277, P48664, DOI 10.1074/jbc.M207029200; Tolnay M, 2002, BIOCHEM J, V363, P127, DOI 10.1042/0264-6021:3630127; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 2002, MOL CELL, V9, P625, DOI 10.1016/S1097-2765(02)00477-X	35	132	143	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39583	39590		10.1074/jbc.M305676200	http://dx.doi.org/10.1074/jbc.M305676200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871932	hybrid			2022-12-27	WOS:000185713800041
J	Indiani, C; O'Donnell, M				Indiani, C; O'Donnell, M			Mechanism of the delta wrench in opening the beta sliding clamp	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-III; ESCHERICHIA-COLI; ACCESSORY PROTEINS; GAMMA-COMPLEX; CRYSTAL-STRUCTURE; LOADER COMPLEX; SUBUNIT; REPLICATION; HOLOENZYME; PURIFICATION	The beta sliding clamp encircles DNA and tethers DNA polymerase III holoenzyme to the template for high processivity. The clamp loader, gamma complex (gamma(3)deltadelta'chipsi), assembles beta around DNA in an ATP-fueled reaction. The delta subunit of the clamp loader opens the beta ring and is referred to as the wrench; ATP modulates contact between beta and delta among other functions. Crystal structures of delta.beta and the gamma3deltadelta' minimal clamp loader make predictions of the clamp loader mechanism, which are tested in this report by mutagenesis. The delta wrench contacts beta at two sites. One site is at the beta dimer interface, where delta appears to distort the interface by via a steric clash between a helix on delta and a loop near the beta interface. The energy for this steric clash is thought to derive from the other site of interaction, in which delta binds to a hydrophobic pocket in beta. The current study demonstrates that rather than a simple steric clash with beta, delta specifically contacts beta at this site, but not through amino acid side chains, and thus is presumably mediated by peptide backbone atoms. The results also imply that the interaction of delta at the hydrophobic site on beta contributes to destabilization of the beta dimer interface rather than acting solely as a grip of delta on beta. Within the gamma complex, delta' is proposed to prevent delta from binding to beta in the absence of ATP. This report demonstrates that one or more gamma subunits also contribute to this role. The results also indicate that delta' acts as a backboard upon which the gamma subunits push to attain the ATP induced change needed for the delta wrench to bind and open the beta ring.	Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	O'Donnell, M (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab DNA Replicat, 1230 York Ave, New York, NY 10021 USA.	odonnel@mail.rockefeller.edu		O'Donnell, Michael/0000-0001-9002-4214	NIGMS NIH HHS [GM38839] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038839, R01GM038839] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baker TA, 1998, CELL, V92, P295, DOI 10.1016/S0092-8674(00)80923-X; Bertram JG, 1998, J BIOL CHEM, V273, P24564, DOI 10.1074/jbc.273.38.24564; BLINKOWA AL, 1990, NUCLEIC ACIDS RES, V18, P1725, DOI 10.1093/nar/18.7.1725; CULLMANN G, 1995, MOL CELL BIOL, V15, P4661; Dalrymple BP, 2001, P NATL ACAD SCI USA, V98, P11627, DOI 10.1073/pnas.191384398; Davey MJ, 2000, CURR OPIN CHEM BIOL, V4, P581, DOI 10.1016/S1367-5931(00)00134-4; DONG ZM, 1993, J BIOL CHEM, V268, P11758; FLOWER AM, 1990, P NATL ACAD SCI USA, V87, P3713, DOI 10.1073/pnas.87.10.3713; Fotedar R, 1996, EMBO J, V15, P4423, DOI 10.1002/j.1460-2075.1996.tb00815.x; Gerik KJ, 1997, J BIOL CHEM, V272, P1256, DOI 10.1074/jbc.272.2.1256; Guenther B, 1997, CELL, V91, P335, DOI 10.1016/S0092-8674(00)80417-1; Gulbis JM, 1996, CELL, V87, P297, DOI 10.1016/S0092-8674(00)81347-1; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; Jeruzalmi D, 2002, CURR OPIN STRUC BIOL, V12, P217, DOI 10.1016/S0959-440X(02)00313-5; Jeruzalmi D, 2001, CELL, V106, P429, DOI 10.1016/S0092-8674(01)00463-9; Jeruzalmi D, 2001, CELL, V106, P417, DOI 10.1016/S0092-8674(01)00462-7; Johnson A, 2003, J BIOL CHEM, V278, P14406, DOI 10.1074/jbc.M212708200; KELMAN Z, 1995, ANNU REV BIOCHEM, V64, P171, DOI 10.1146/annurev.bi.64.070195.001131; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; Leu FP, 2001, J BIOL CHEM, V276, P47185, DOI 10.1074/jbc.M106780200; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; NAKTINIS V, 1995, J BIOL CHEM, V270, P13358, DOI 10.1074/jbc.270.22.13358; Neuwald AF, 1999, GENOME RES, V9, P27; O'Donnell M, 2001, CURR BIOL, V11, pR935, DOI 10.1016/S0960-9822(01)00559-0; ONRUST R, 1993, J BIOL CHEM, V268, P11766; Shiomi Y, 2000, P NATL ACAD SCI USA, V97, P14127, DOI 10.1073/pnas.97.26.14127; Song MS, 2001, J BIOL CHEM, V276, P40668, DOI 10.1074/jbc.M106373200; Stewart J, 2001, J BIOL CHEM, V276, P19182, DOI 10.1074/jbc.M100592200; STUDWELL PS, 1990, J BIOL CHEM, V265, P1171; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; STUDWELLVAUGHAN PS, 1993, J BIOL CHEM, V268, P11785; STUKENBERG PT, 1991, J BIOL CHEM, V266, P11328; TSUCHIHASHI Z, 1990, P NATL ACAD SCI USA, V87, P2516, DOI 10.1073/pnas.87.7.2516; Turner J, 1995, METHOD ENZYMOL, V262, P442; Turner J, 1999, EMBO J, V18, P771, DOI 10.1093/emboj/18.3.771; XIAO H, 1993, J BIOL CHEM, V268, P11779; Yao N, 2000, J BIOL CHEM, V275, P11440, DOI 10.1074/jbc.275.15.11440; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	39	14	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40272	40281		10.1074/jbc.M305828200	http://dx.doi.org/10.1074/jbc.M305828200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851392	hybrid			2022-12-27	WOS:000185713800120
J	Ding, Y; Xu, MQ; Ghosh, I; Chen, XH; Ferrandon, S; Lesage, G; Rao, ZH				Ding, Y; Xu, MQ; Ghosh, I; Chen, XH; Ferrandon, S; Lesage, G; Rao, ZH			Crystal structure of a mini-intein reveals a conserved catalytic module involved in side chain cyclization of asparagine during protein splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; ELECTRON-DENSITY MAPS; CEREVISIAE VMA INTEIN; SACCHAROMYCES-CEREVISIAE; SPLIT INTEIN; ADENOSINE-TRIPHOSPHATASE; BRANCHED INTERMEDIATE; PHENOTYPIC SELECTION; INTERVENING SEQUENCE; HOMING ENDONUCLEASE	We have determined the crystal structure of a 154-residue intein derived from the dnaB gene of Synechocystis sp. strain PCC6803 and refined it to a 2.0-Angstrom resolution. The x-ray structure suggests that this intein possesses two catalytic sites that appear to be separately responsible for splicing and cleavage of the Nand C-terminal scissile bonds. The conserved intein block F residues are the important components of a catalytic site for side chain cyclization of the last intein residue, Asn-154. The data suggest that the imidazole ring of His-143 is involved in the activation of the side chain Ndelta atom of Asn-154, leading to a nucleophilic attack on the carbonyl carbon of Asn-154. Substitution of His-143 with Ala or Gln resulted in the inhibition of C-terminal cleavage. His-153, Asp-136, and a water molecule appear to constitute an oxyanion binding site by contacting the carbonyl oxygen of Asn-154 to stabilize the transition state. The structure and mutagenesis data also support that the close contact between the hydroxyl groups of Thr-138 and Ser-155, whose side chain participates in an S --> O acyl shift, plays an important role in the nucleophile orientation. Our structural modeling suggests that this catalytic module is conserved in the C-terminal subdomains of inteins from diverse organisms.	New England Biolabs Inc, Beverly, MA 01915 USA; Tsing Hua Univ, Sch Life Sci & Engn, Struct Biol Lab, Beijing 100084, Peoples R China; Tsing Hua Univ, Sch Life Sci & Engn, Minist Educ Lab Prot Sci, Beijing 100084, Peoples R China; Chinese Acad Sci, Inst Biophys, Beijing 100101, Peoples R China	Tsinghua University; Tsinghua University; Chinese Academy of Sciences; Institute of Biophysics, CAS	Xu, MQ (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.							BRUICE TC, 1966, BIOORGANIC MECH; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen LX, 2000, J BIOL CHEM, V275, P20431, DOI 10.1074/jbc.M000178200; Chen XH, 2002, ACTA CRYSTALLOGR D, V58, P1201, DOI 10.1107/S0907444902006583; Chong SR, 1998, J BIOL CHEM, V273, P10567, DOI 10.1074/jbc.273.17.10567; Chong SR, 1996, J BIOL CHEM, V271, P22159, DOI 10.1074/jbc.271.36.22159; Chong SR, 1997, J BIOL CHEM, V272, P15587, DOI 10.1074/jbc.272.25.15587; COOPER AA, 1993, EMBO J, V12, P2575, DOI 10.1002/j.1460-2075.1993.tb05913.x; DAVIS EO, 1992, CELL, V71, P201, DOI 10.1016/0092-8674(92)90349-H; Derbyshire V, 1997, P NATL ACAD SCI USA, V94, P11466, DOI 10.1073/pnas.94.21.11466; Duan XQ, 1997, CELL, V89, P555, DOI 10.1016/S0092-8674(00)80237-8; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Evans TC, 2000, J BIOL CHEM, V275, P9091, DOI 10.1074/jbc.275.13.9091; Evans TC, 2002, CHEM REV, V102, P4869, DOI 10.1021/cr9601369; Evans TC, 1999, BIOPOLYMERS, V51, P333, DOI 10.1002/(SICI)1097-0282(1999)51:5<333::AID-BIP3>3.3.CO;2-R; Ghosh I, 2001, J BIOL CHEM, V276, P24051, DOI 10.1074/jbc.M011049200; Hall TMT, 1997, CELL, V91, P85, DOI 10.1016/S0092-8674(01)80011-8; HIRATA R, 1992, BIOCHEM BIOPH RES CO, V188, P40, DOI 10.1016/0006-291X(92)92347-Z; HIRATA R, 1990, J BIOL CHEM, V265, P6726; Hu DL, 2000, J BIOL CHEM, V275, P2705, DOI 10.1074/jbc.275.4.2705; Ichiyanagi K, 2000, J MOL BIOL, V300, P889, DOI 10.1006/jmbi.2000.3873; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANE PM, 1990, SCIENCE, V250, P651, DOI 10.1126/science.2146742; Klabunde T, 1998, NAT STRUCT BIOL, V5, P31, DOI 10.1038/nsb0198-31; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Mathys S, 1999, GENE, V231, P1, DOI 10.1016/S0378-1119(99)00103-1; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mizutani R, 2002, J MOL BIOL, V316, P919, DOI 10.1006/jmbi.2001.5357; Muir TW, 2003, ANNU REV BIOCHEM, V72, P249, DOI 10.1146/annurev.biochem.72.121801.161900; Paulus H, 2000, ANNU REV BIOCHEM, V69, P447, DOI 10.1146/annurev.biochem.69.1.447; PERLER FB, 1994, NUCLEIC ACIDS RES, V22, P1125, DOI 10.1093/nar/22.7.1125; Perler FB, 2000, NUCLEIC ACIDS RES, V28, P344, DOI 10.1093/nar/28.1.344; Pietrokovski S, 1996, TRENDS GENET, V12, P287, DOI 10.1016/0168-9525(96)20005-8; Pietrokovski S, 1998, PROTEIN SCI, V7, P64, DOI 10.1002/pro.5560070106; Poland BW, 2000, J BIOL CHEM, V275, P16408, DOI 10.1074/jbc.275.22.16408; Scott CP, 1999, P NATL ACAD SCI USA, V96, P13638, DOI 10.1073/pnas.96.24.13638; Shao Y, 1996, BIOCHEMISTRY-US, V35, P3810, DOI 10.1021/bi952592h; SHAO Y, 1995, BIOCHEMISTRY-US, V34, P10844, DOI 10.1021/bi00034a017; Shingledecker K, 1998, GENE, V207, P187, DOI 10.1016/S0378-1119(97)00624-0; Southworth MW, 2000, EMBO J, V19, P5019, DOI 10.1093/emboj/19.18.5019; Wang SL, 1997, J BIOL CHEM, V272, P11869, DOI 10.1074/jbc.272.18.11869; Wood DW, 1999, NAT BIOTECHNOL, V17, P889, DOI 10.1038/12879; Wu H, 1998, BBA-PROTEIN STRUCT M, V1387, P422, DOI 10.1016/S0167-4838(98)00157-5; Wu H, 1998, P NATL ACAD SCI USA, V95, P9226, DOI 10.1073/pnas.95.16.9226; XU MQ, 1993, CELL, V75, P1371, DOI 10.1016/0092-8674(93)90623-X; XU MQ, 1994, EMBO J, V13, P5517, DOI 10.1002/j.1460-2075.1994.tb06888.x; Xu MQ, 1996, EMBO J, V15, P5146, DOI 10.1002/j.1460-2075.1996.tb00898.x; Xu MQ, 2001, METHODS, V24, P257, DOI 10.1006/meth.2001.1187	49	116	129	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39133	39142		10.1074/jbc.M306197200	http://dx.doi.org/10.1074/jbc.M306197200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878593	hybrid			2022-12-27	WOS:000185575100127
J	Guerini, D; Pan, B; Carafoli, E				Guerini, D; Pan, B; Carafoli, E			Expression, purification, and characterization of isoform 1 of the plasma membrane Ca2+ pump - Focus on calpain sensitivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALMODULIN-BINDING DOMAIN; HUMAN-ERYTHROCYTE-MEMBRANE; HAND STRUCTURE-DOMAIN; CALCIUM-PUMP; MOLECULAR-CLONING; NEUTRAL PROTEASE; MESSENGER-RNAS; CA-2+-TRANSPORTING ATPASE; ENDOPLASMIC-RETICULUM; POLYACRYLAMIDE GELS	The plasma membrane Ca2+ ATPase isoform 1(PMCA1) is ubiquitously distributed in tissues and cells, but only scarce information is available on its properties. The isoform was overexpressed in Sf9 cells, purified on calmodulin columns, and characterized functionally. The level of expression was very low, but sufficient amounts of the protein could be isolated for biochemical characterization. The affinity of PMCA1 for calmodulin was similar to that of PMCA4, the other ubiquitous PMCA isoform. The affinity of PMCA1 for ATP, evaluated by the formation of the phosphorylated intermediate, was higher than that of the PMCA4 pump. The recombinant PMCA1 pump was a much better substrate for the cAMP-dependent protein kinase than the PMCA2 and PMCA4 isoforms. Pulse and chase experiments on Sf9 cells overexpressing the PMCA pumps showed that PMCA1 was much less stable than the PMCA4 and PMCA2 isoforms, i.e. PMCA1 had a much higher sensitivity to degradation by calpain. The effect of calpain was not the result of a general higher susceptibility of the PMCA1 to proteolytic degradation, because the pattern of degradation by trypsin was the same in the three isoforms.	Univ Padua, Dept Biochem, I-35121 Padua, Italy; ETH, Inst Biochem, CH-8092 Zurich, Switzerland; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Swiss Federal Institutes of Technology Domain; ETH Zurich; Veneto Institute Molecular Medicine	Carafoli, E (corresponding author), Univ Padua, Dept Biochem, I-35121 Padua, Italy.		Carafoli, Ernesto/K-5192-2016	Carafoli, Ernesto/0000-0002-7826-0094				ADAMO HP, 1992, BIOCHEM J, V285, P791, DOI 10.1042/bj2850791; ADAMO HP, 1992, J BIOL CHEM, V267, P14244; BENAIM G, 1984, J BIOL CHEM, V259, P8471; BERGER SL, 1979, BIOCHEMISTRY-US, V18, P5143, DOI 10.1021/bi00590a018; BRANDT P, 1992, J BIOL CHEM, V267, P4376; CARAFOLI E, 1994, FASEB J, V8, P993, DOI 10.1096/fasebj.8.13.7926378; CARAFOLI E, 1993, TRENDS CARDIOVAS MED, V3, P177, DOI 10.1016/1050-1738(93)90003-O; ENYEDI A, 1993, J BIOL CHEM, V268, P10621; ENYEDI A, 1994, J BIOL CHEM, V269, P41; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FALCHETTO R, 1992, PROTEIN SCI, V1, P1613, DOI 10.1002/pro.5560011209; FALCHETTO R, 1991, J BIOL CHEM, V266, P2930; FOLETTI D, 1995, FASEB J, V9, P670, DOI 10.1096/fasebj.9.8.7768360; Genazzani AA, 1999, P NATL ACAD SCI USA, V96, P5797, DOI 10.1073/pnas.96.10.5797; GREEB J, 1989, J BIOL CHEM, V264, P18569; Guerini D, 1999, J BIOL CHEM, V274, P1667, DOI 10.1074/jbc.274.3.1667; GUERINI D, 1995, J BIOL CHEM, V270, P14643, DOI 10.1074/jbc.270.24.14643; HEIM R, 1992, J BIOL CHEM, V267, P24476; HILFIKER H, 1994, J BIOL CHEM, V269, P26178; HOFMANN F, 1994, J BIOL CHEM, V269, P24298; JAMES P, 1989, J BIOL CHEM, V264, P8289; JAMES PH, 1989, BIOCHEMISTRY-US, V28, P4253, DOI 10.1021/bi00436a020; KEETON TP, 1993, J BIOL CHEM, V268, P2740; KESSLER F, 1992, BIOCHEMISTRY-US, V31, P11785, DOI 10.1021/bi00162a016; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; Liu BF, 1996, J BIOL CHEM, V271, P5536, DOI 10.1074/jbc.271.10.5536; MERRIL CR, 1981, ANAL BIOCHEM, V110, P201, DOI 10.1016/0003-2697(81)90136-6; MINAMI Y, 1987, J BIOCHEM-TOKYO, V101, P889, DOI 10.1093/oxfordjournals.jbchem.a121956; MINAMI Y, 1988, J BIOCHEM-TOKYO, V104, P927, DOI 10.1093/oxfordjournals.jbchem.a122585; MOLINARI M, 1995, J BIOL CHEM, V270, P2032, DOI 10.1074/jbc.270.5.2032; MOLINARI M, 1994, J BIOL CHEM, V269, P27992; NEYSES L, 1985, J BIOL CHEM, V260, P283; OLSON S, 1991, GENOMICS, V9, P629, DOI 10.1016/0888-7543(91)90356-J; Paszty K, 2002, J BIOL CHEM, V277, P6822, DOI 10.1074/jbc.M109548200; PHILIPSON K D, 1992, Current Opinion in Cell Biology, V4, P678, DOI 10.1016/0955-0674(92)90089-U; SALAMINO F, 1994, CELL CALCIUM, V15, P28, DOI 10.1016/0143-4160(94)90101-5; SAMBROOK J, 1989, MOLEC CLON LAB MAN, V1; SARKADI B, 1986, J BIOL CHEM, V261, P9552; Schwab BL, 2002, CELL DEATH DIFFER, V9, P818, DOI 10.1038/sj.cdd.4401042; Seiz Preiano Brigitta, 1996, Biochemistry, V35, P7946, DOI 10.1021/bi9527404; SHULL GE, 1988, J BIOL CHEM, V263, P8646; STAHL WL, 1992, MOL BRAIN RES, V16, P223, DOI 10.1016/0169-328X(92)90229-5; STAUFFER TP, 1993, J BIOL CHEM, V268, P25993; STAUFFER TP, 1995, J BIOL CHEM, V270, P12184, DOI 10.1074/jbc.270.20.12184; STREHLER EE, 1990, J BIOL CHEM, V265, P2835; STREHLER EE, 1989, P NATL ACAD SCI USA, V86, P6908, DOI 10.1073/pnas.86.18.6908; SUMMERS MD, 1988, B TEXAS A M U, V1555; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VERMA AK, 1994, J BIOL CHEM, V269, P1687; VERMA AK, 1988, J BIOL CHEM, V263, P14152; WANG KKW, 1988, ARCH BIOCHEM BIOPHYS, V260, P696, DOI 10.1016/0003-9861(88)90498-5; WANG MG, 1994, CYTOGENET CELL GENET, V67, P41, DOI 10.1159/000133794; ZURINI M, 1984, J BIOL CHEM, V259, P618; ZVARITCH E, 1995, J BIOL CHEM, V270, P2679, DOI 10.1074/jbc.270.6.2679	55	58	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38141	38148		10.1074/jbc.M302400200	http://dx.doi.org/10.1074/jbc.M302400200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851406	hybrid			2022-12-27	WOS:000185575100008
J	Mousseau, DD; Chapelsky, S; De Crescenzo, G; Kirkitadze, MD; Magoon, J; Inoue, S; Teplow, DB; O'Connor-McCourt, MD				Mousseau, DD; Chapelsky, S; De Crescenzo, G; Kirkitadze, MD; Magoon, J; Inoue, S; Teplow, DB; O'Connor-McCourt, MD			A direct interaction between transforming growth Factor (TGF)-beta s and amyloid-beta protein affects fibrillogenesis in a TGF-beta receptor-independent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; TRANSGENIC MICE; FIBRIL FORMATION; PLAQUE-FORMATION; DEPOSITION; PEPTIDE; NEURONS; MODELS; GROWTH-FACTOR-BETA-1	Transforming growth factor-beta (TGF-beta) receptor-mediated signaling has been proposed to mediate both the beneficial and deleterious roles for this cytokine in amyloid-beta protein (Abeta) function. In order to assess receptor dependence of these events, we used PC12 cell cultures, which are devoid of TGF-beta receptors. Surprisingly, TGF-beta potentiated the neurotoxic effects of the 40-residue Abeta peptide, Abeta-(1 - 40), in this model suggesting that there may be a direct, receptor-independent interaction between TGF-beta and Abeta- (1 - 40). Surface plasmon resonance confirmed that TGF-beta binds with high affinity directly to Abeta- (1 - 40) and electron microscopy revealed that TGF-beta enhances Abeta- (1 - 40) oligomerization. Immunohistochemical examination of mouse brain revealed that hippocampal CA1 and dentate gyrus, two regions classically associated with Abeta- mediated pathology, lack TGF-beta Type I receptor immunoreactivity, thus indicating that TGF-beta receptor-mediated signaling would not be favored in these regions. Our observations not only provide for a unique, receptor-independent mechanism of action for TGF-beta, but also help to reconcile the literature interpreting the role of TGF-beta in Abeta function. These data support a critical etiological role for this mechanism in neuropathological amyloidoses.	Univ Saskatchewan, Dept Psychiat, Neuropsychiat Res Unit, Cell Signaling Grp, Saskatoon, SK S7N 5E4, Canada; Biotechnol Res Inst, Receptor Signaling & Proteom Grp, Hlth Sector, Montreal, PQ H4P 2R2, Canada; Brigham & Womens Hosp, Ctr Neurol Dis, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; McGill Univ, Dept Anat & Cell Biol, Montreal, PQ H3A 2B2, Canada	University of Saskatchewan; National Research Council Canada; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; McGill University	O'Connor-McCourt, MD (corresponding author), Univ Saskatchewan, Dept Psychiat, Neuropsychiat Res Unit, Cell Signaling Grp, Saskatoon, SK S7N 5E4, Canada.							Arnold SE, 1991, CEREB CORTEX, V1, P103, DOI 10.1093/cercor/1.1.103; Blobe GC, 2001, J BIOL CHEM, V276, P24627, DOI 10.1074/jbc.M100188200; BODMER S, 1990, BIOCHEM BIOPH RES CO, V171, P890, DOI 10.1016/0006-291X(90)91229-L; Calhoun ME, 1999, P NATL ACAD SCI USA, V96, P14088, DOI 10.1073/pnas.96.24.14088; Castillo GM, 1997, J NEUROCHEM, V69, P2452; Chui DH, 1999, NAT MED, V5, P560, DOI 10.1038/8438; De Crescenzo G, 2001, J BIOL CHEM, V276, P29632, DOI 10.1074/jbc.M009765200; De Crescenzo G, 2000, BIOCHEMISTRY-US, V39, P9466, DOI 10.1021/bi992987r; FLANDERS KC, 1991, DEVELOPMENT, V113, P183; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Frautschy SA, 1996, NEUROBIOL AGING, V17, P311, DOI 10.1016/0197-4580(95)02073-X; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Haass C, 2002, NAT MED, V8, P1195, DOI 10.1038/nm1102-1195; Harris-White ME, 1998, J NEUROSCI, V18, P10366; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Holtzman DM, 2000, ANN NEUROL, V47, P739, DOI 10.1002/1531-8249(200006)47:6<739::AID-ANA6>3.0.CO;2-8; Huang SS, 1998, J BIOL CHEM, V273, P27640, DOI 10.1074/jbc.273.42.27640; Inoue S, 2001, INT REV CYTOL, V210, P121; Irizarry MC, 2000, ACTA NEUROPATHOL, V100, P451, DOI 10.1007/s004010000263; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; Kirkitadze MD, 2001, J MOL BIOL, V312, P1103, DOI 10.1006/jmbi.2001.4970; Kirkitadze MD, 2002, J NEUROSCI RES, V69, P567, DOI 10.1002/jnr.10328; Klein WL, 2001, TRENDS NEUROSCI, V24, P219, DOI 10.1016/S0166-2236(00)01749-5; Lesne S, 2003, J BIOL CHEM, V278, P18408, DOI 10.1074/jbc.M300819200; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1990, ANN NY ACAD SCI, V593, P59; McLaurin J, 2000, J STRUCT BIOL, V130, P259, DOI 10.1006/jsbi.2000.4289; Pfeifer M, 2002, SCIENCE, V298, P1379, DOI 10.1126/science.1078259; POULSEN KT, 1994, NEURON, V13, P1245, DOI 10.1016/0896-6273(94)90062-0; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; Ramirez-Alvarado M, 2000, P NATL ACAD SCI USA, V97, P8979, DOI 10.1073/pnas.150091797; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3; Schenk D, 2002, NAT REV NEUROSCI, V3, P824, DOI 10.1038/nrn938; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SturchlerPierrat C, 1997, P NATL ACAD SCI USA, V94, P13287, DOI 10.1073/pnas.94.24.13287; Teplow DB, 1998, AMYLOID, V5, P121, DOI 10.3109/13506129808995290; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Wiesmann C, 2000, NAT STRUCT BIOL, V7, P440; Wyss-Coray T, 2001, NAT MED, V7, P612, DOI 10.1038/87945; WyssCoray T, 1997, NATURE, V389, P603, DOI 10.1038/39321	41	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38715	38722		10.1074/jbc.M304080200	http://dx.doi.org/10.1074/jbc.M304080200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867422	hybrid			2022-12-27	WOS:000185575100077
J	Santiago, TC; Ben Mamoun, C				Santiago, TC; Ben Mamoun, C			Genome expression analysis in yeast reveals novel transcriptional regulation by inositol and choline and new regulatory functions for Opi1p, Ino2p, and Ino4p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPID BIOSYNTHETIC-ENZYMES; SYNTHASE GENES FAS1; C-13 NMR ANALYSIS; SACCHAROMYCES-CEREVISIAE; PHOSPHATIDYLSERINE SYNTHASE; INOSITOL-1-PHOSPHATE SYNTHASE; CDP-DIACYLGLYCEROL; TRANSPORTER GENES; AMINO-ACIDS; PROTEIN	In Saccharomyces cerevisiae, genes encoding phospholipid-synthesizing enzymes are regulated by inositol and choline (IC). The current model suggests that when these precursors become limiting, the transcriptional complex Ino2p-Ino4p activates the expression of these genes, whereas repression requires Opi1p and occurs when IC are available. In this study, microarray-based expression analysis was performed to assess the global transcriptional response to IC in a wild-type strain and in the opi1Delta, ino2Delta, and ino4Delta null mutant strains. Fifty genes were either activated or repressed by IC in the wild-type strain, including three already known IC-repressed genes. We demonstrated that the IC response was not limited to genes involved in membrane biogenesis, but encompassed various metabolic pathways such as biotin synthesis, one-carbon compound metabolism, nitrogen-containing compound transport and degradation, cell wall organization and biogenesis, and acetylCoA metabolism. The expression of a large number of IC-regulated genes did not change in the opi1Delta, ino2Delta, and ino4Delta strains, thus implicating new regulatory elements in the IC response. Our studies revealed that Opi1p, Ino2p, and Ino4p have dual regulatory activities, acting in both positive and negative transcriptional regulation of a large number of genes, most of which are not regulated by IC and only a subset of which is involved in membrane biogenesis. These data provide the first global response profile of yeast to IC and reveal novel regulatory mechanisms by these precursors.	Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, Farmington, CT 06030 USA; Univ Connecticut, Ctr Hlth, Dept Genet & Dev Biol, Farmington, CT 06030 USA	University of Connecticut; University of Connecticut	Ben Mamoun, C (corresponding author), Univ Connecticut, Ctr Hlth, Ctr Microbial Pathogenesis, E7041,263 Farmington Ave, Farmington, CT 06030 USA.							AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ASHBURNER BP, 1995, MOL CELL BIOL, V15, P1709; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BARLOWE C K, 1988, Biofactors, V1, P171; Carman GM, 1999, PROG LIPID RES, V38, P361, DOI 10.1016/S0163-7827(99)00010-7; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; Didion T, 1998, MOL MICROBIOL, V27, P643, DOI 10.1046/j.1365-2958.1998.00714.x; Forsberg H, 2001, CURR GENET, V40, P91, DOI 10.1007/s002940100244; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; HASSLACHER M, 1993, J BIOL CHEM, V268, P10946; Henry SA, 1998, PROG NUCLEIC ACID RE, V61, P133, DOI 10.1016/S0079-6603(08)60826-0; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HOSAKA K, 1994, J BIOCHEM-TOKYO, V115, P131, DOI 10.1093/oxfordjournals.jbchem.a124287; HOSHIZAKI DK, 1990, J BIOL CHEM, V265, P4736; Iraqui I, 1999, MOL CELL BIOL, V19, P989; Jiranek V, 1998, MICROBIOL-UK, V144, P2739, DOI 10.1099/00221287-144-10-2739; Klasson H, 1999, MOL CELL BIOL, V19, P5405; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; KODAKI T, 1991, J BACTERIOL, V173, P7992, DOI 10.1128/jb.173.24.7992-7995.1991; LAI K, 1994, J BIOL CHEM, V269, P2245; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P3987, DOI 10.1093/nar/19.14.3987; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; Murray M, 2000, MOL MICROBIOL, V36, P651, DOI 10.1046/j.1365-2958.2000.01886.x; NIKAWA J, 1991, J BIOL CHEM, V266, P11184; NIKOLOFF DM, 1992, NUCLEIC ACIDS RES, V20, P3253, DOI 10.1093/nar/20.12.3253; OGUR M, 1977, J BACTERIOL, V129, P926, DOI 10.1128/JB.129.2.926-933.1977; Oshiro J, 2000, J BIOL CHEM, V275, P40887, DOI 10.1074/jbc.M008144200; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P7166, DOI 10.1021/bi00189a020; Pasternack LB, 1996, ARCH BIOCHEM BIOPHYS, V326, P158, DOI 10.1006/abbi.1996.0060; PASTERNACK LB, 1994, BIOCHEMISTRY-US, V33, P74, DOI 10.1021/bi00167a010; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SCHULLER HJ, 1992, NUCLEIC ACIDS RES, V20, P5955, DOI 10.1093/nar/20.22.5955; SCHULLER HJ, 1992, EMBO J, V11, P107, DOI 10.1002/j.1460-2075.1992.tb05033.x; SCHULLER HJ, 1995, FEBS LETT, V370, P149, DOI 10.1016/0014-5793(95)00818-T; Schwank S, 1997, CURR GENET, V31, P462, DOI 10.1007/s002940050231; Shen HF, 1997, J BIOL CHEM, V272, P11215; Shen HF, 1998, J BIOL CHEM, V273, P11638, DOI 10.1074/jbc.273.19.11638; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; WHITE MJ, 1991, J BIOL CHEM, V266, P863; Wykoff DD, 2001, GENETICS, V159, P1491	47	69	71	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38723	38730		10.1074/jbc.M303008200	http://dx.doi.org/10.1074/jbc.M303008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871953	hybrid			2022-12-27	WOS:000185575100078
J	Luo, SZ; Baumeister, P; Yang, SJ; Abcouwer, SF; Lee, AS				Luo, SZ; Baumeister, P; Yang, SJ; Abcouwer, SF; Lee, AS			Induction of Grp78/BiP by translational block - Activation of the Grp78 promoter by ATF4 through an upstream ATF/CRE site independent of the endoplasmic reticulum stress elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED-PROTEIN RESPONSE; GLUCOSE-REGULATED PROTEINS; NF-Y CBF; TRANSCRIPTION FACTOR; BINDING-PROTEIN; ER STRESS; CA2+ DEPLETION; CELL-SURVIVAL; MESSENGER-RNA; GENE	Mammalian cells respond to endoplasmic reticulum ( ER) stress by attenuation of protein translation mediated through the PERK-eIF2alpha pathway and transcriptional activation of genes such as Grp78/BiP encoding ER chaperone proteins. The disruption of PERK function or the blocking of eIF2alpha Ser(51) phosphorylation fails to attenuate translation after ER stress and also results in substantial impairment of Grp78/BiP induction by ER stress. While the activation of the Grp78 promoter by the ATF6 pathway through the endoplasmic reticulum stress elements (ERSEs) is well documented, the molecular mechanism linking PERK activation to Grp78 stress induction is unknown. We report here that ATF4, a transcription factor whose translation is up-regulated by the PERK-eIF2alpha pathway, can activate the Grp78 promoter independent of the ERSE. The ATF4-activating site is localized to an ATF/CRE sequence upstream of the ERSEs and is distinct from the C/EBP-ATF composite site previously identified as the ATF4 binding site in the ER stress-inducible chop promoter. In vitro translated ATF4 binding to the ATF/CRE site requires other nuclear co-factors from non-stressed cells, forming a complex that exhibits identical electrophoretic mobility as a thapsigargin-stress induced complex. Here we have identified the closely related ATF1 and CREB1 as nuclear co-factors that form in vivo complexes with endogenous ATF4. ER stress induces CREB1 phosphorylation and ATF1/CREB1 binding to the Grp78 promoter. Through the use of adenoviral vector expression systems, we provide evidence that when ATF4 function is suppressed and its binding partners are not able to compensate for its function, Grp78 induction by Tg and Tu is partially inhibited. Our studies resolve a mechanism responsible for inhibition of Grp78 mRNA induction by ER stress in cells that are functionally null for PERK or devoid of eIF2alpha phosphorylation.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90089 USA; Univ New Mexico, Sch Med, Dept Biochem & Mol Biol, Albuquerque, NM 87131 USA	University of Southern California; University of Southern California; University of New Mexico	Lee, AS (corresponding author), Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, 1441 Eastlake Ave,Rm 5308, Los Angeles, CA 90089 USA.			Yang, Shujie/0000-0003-1753-3068; Abcouwer, Steven F/0000-0003-2580-1288; Lee, Amy/0000-0002-0378-5443	NATIONAL CANCER INSTITUTE [R37CA027607, R29CA072772, R01CA027607] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA72772, CA27607] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDRE S, 1991, MOL ENDOCRINOL, V5, P1862, DOI 10.1210/mend-5-12-1862; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bleckmann SC, 2002, MOL CELL BIOL, V22, P1919, DOI 10.1128/MCB.22.6.1919-1925.2002; Brostrom CO, 1998, PROG NUCLEIC ACID RE, V58, P79; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chen X, 2002, J BIOL CHEM, V277, P13045, DOI 10.1074/jbc.M110636200; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; Gupta P, 2002, J BIOL CHEM, V277, P50550, DOI 10.1074/jbc.M209799200; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hettmann T, 2000, DEV BIOL, V222, P110, DOI 10.1006/dbio.2000.9699; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Jean D, 1998, J BIOL CHEM, V273, P24884, DOI 10.1074/jbc.273.38.24884; Kaufman RJ, 2002, J CLIN INVEST, V110, P1389, DOI 10.1172/JC1200216886; LEE A S, 1992, Current Opinion in Cell Biology, V4, P267, DOI 10.1016/0955-0674(92)90042-B; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lee K, 2002, GENE DEV, V16, P452, DOI 10.1101/gad.964702; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Li WW, 1997, MOL CELL BIOL, V17, P54, DOI 10.1128/MCB.17.1.54; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; LI WWF, 1993, J BIOL CHEM, V268, P12003; Luo S, 2002, BIOCHEM J, V366, P787, DOI 10.1042/BJ20011802; Ma YJ, 2003, J BIOL CHEM, V278, P34864, DOI 10.1074/jbc.M301107200; Ma YJ, 2002, J MOL BIOL, V318, P1351, DOI 10.1016/S0022-2836(02)00234-6; Ma YJ, 2001, CELL, V107, P827, DOI 10.1016/S0092-8674(01)00623-7; Nakagawa T, 2000, J CELL BIOL, V150, P887, DOI 10.1083/jcb.150.4.887; Okada T, 2002, BIOCHEM J, V366, P585, DOI 10.1042/BJ20020391; Pain VM, 1996, EUR J BIOCHEM, V236, P747, DOI 10.1111/j.1432-1033.1996.00747.x; Parker R, 2001, MOL CELL BIOL, V21, P3220, DOI 10.1128/MCB.21.9.3220-3233.2001; Podust LM, 2001, J BIOL CHEM, V276, P505, DOI 10.1074/jbc.M005594200; Rao RV, 2001, J BIOL CHEM, V276, P33869, DOI 10.1074/jbc.M102225200; Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200; Reddy RK, 2002, CANCER RES, V62, P7207; Roy B, 1999, NUCLEIC ACIDS RES, V27, P1437, DOI 10.1093/nar/27.6.1437; Sambrook J., 2002, MOL CLONING LAB MANU; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhou YH, 1998, J NATL CANCER I, V90, P381, DOI 10.1093/jnci/90.5.381; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	50	217	222	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37375	37385		10.1074/jbc.M303619200	http://dx.doi.org/10.1074/jbc.M303619200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871976	hybrid			2022-12-27	WOS:000185437200048
J	Martinez, LO; Agerholm-Larsen, B; Wang, N; Chen, WG; Tall, AR				Martinez, LO; Agerholm-Larsen, B; Wang, N; Chen, WG; Tall, AR			Phosphorylation of a pest sequence in ABCA1 promotes calpain degradation and is reversed by ApoA-I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; HIGH-DENSITY-LIPOPROTEIN; BINDING CASSETTE TRANSPORTER-1; CELLULAR CHOLESTEROL EFFLUX; CORONARY HEART-DISEASE; TANGIER-DISEASE; MEDIATED DEGRADATION; PLASMA-MEMBRANE; TRANSGENIC MICE; ATHEROSCLEROSIS	ATP-binding cassette transporter A1 (ABCA1), the defective molecule in Tangier disease, mediates the apoAI-dependent efflux of excess cholesterol from cells. We recently showed that ABCA1 proteolysis by calpain was dependent on a PEST sequence in the cytoplasmic region of ABCA1 and was reversed by apoA-I interaction with ABCA1. We show here that phosphorylation of ABCA1 in HEK293 cells was reduced by 63 +/- 2.4% after removal of the PEST sequence (ABCA1delPEST) or by incubation of cells with apoAI ( 58 +/- 3.3%). By contrast, ABCA1delPEST showed no further decrease of phosphorylation upon apoAI treatment. To assess the hypothesis that PEST sequence phosphorylation could regulate ABCA1 calpain proteolysis, we mutagenized S/T residues in the PEST sequence and identified Thr-1286 and Thr-1305 as constitutively phosphorylated residues. The ABCA1-T1286A/T1305A mutant was not degraded by calpain and was not further stabilized upon apoA-I treatment. The T1286A/T1305A mutant showed a 3.1-fold increase in cell surface expression and a 2.3-fold increase of apoAI-mediated cholesterol efflux compared with wild type ABCA1. In conclusion, we propose a mechanism of regulation of ABCA1 cell surface expression and function in which the interaction with apoA-I results in dephosphorylation of the ABCA1 PEST sequence and thereby inhibits calpain degradation leading to an increase of ABCA1 cell surface expression.	Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA	Columbia University	Martinez, LO (corresponding author), Columbia Univ, Dept Med, Div Mol Med, New York, NY 10032 USA.		Martinez, Laurent O./ABD-6880-2020; Martinez, Laurent O/B-8343-2015; Tall, Alan/AAT-8528-2021	Martinez, Laurent O./0000-0002-0985-3152; Martinez, Laurent O/0000-0002-0985-3152; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL022682, R01HL022682] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL22682] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P630, DOI 10.1161/01.ATV.0000014804.35824.DA; Arakawa R, 2002, J BIOL CHEM, V277, P22426, DOI 10.1074/jbc.M202996200; Assmann G, 1999, CIRCULATION, V100, P1930, DOI 10.1161/01.CIR.100.18.1930; Beham-Schmid C, 2002, BLOOD, V99, P381, DOI 10.1182/blood.V99.1.381; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; Chiesa G, 1998, ARTERIOSCL THROM VAS, V18, P1417, DOI 10.1161/01.ATV.18.9.1417; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; FRANCIS GA, 1995, J CLIN INVEST, V96, P78, DOI 10.1172/JCI118082; Haidar B, 2002, J LIPID RES, V43, P2087, DOI 10.1194/jlr.M200235-JLR200; HARA H, 1991, J BIOL CHEM, V266, P3080; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; MIYAZAKI A, 1995, ARTERIOSCL THROM VAS, V15, P1882, DOI 10.1161/01.ATV.15.11.1882; Oram JF, 2000, J BIOL CHEM, V275, P34508, DOI 10.1074/jbc.M006738200; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; PLUMP AS, 1994, P NATL ACAD SCI USA, V91, P9607, DOI 10.1073/pnas.91.20.9607; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; SCHAEFER EJ, 1980, ANN INTERN MED, V93, P261, DOI 10.7326/0003-4819-93-2-261; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; See RH, 2002, J BIOL CHEM, V277, P41835, DOI 10.1074/jbc.M204923200; Shen J, 2001, J IMMUNOL, V167, P4919, DOI 10.4049/jimmunol.167.9.4919; Singaraja RR, 2002, J CLIN INVEST, V110, P35, DOI 10.1172/JCI200215748; Sviridov D, 2002, ATHEROSCLEROSIS, V161, P245, DOI 10.1016/S0021-9150(01)00677-3; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Tall AR, 2002, J CLIN INVEST, V110, P899, DOI 10.1172/JCI200216391; Tanaka AR, 2003, J BIOL CHEM, V278, P8815, DOI 10.1074/jbc.M206885200; Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0; Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200; Wang N, 2003, ARTERIOSCL THROM VAS, V23, P1178, DOI 10.1161/01.ATV.0000075912.83860.26; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Williams KJ, 1998, CURR OPIN LIPIDOL, V9, P471, DOI 10.1097/00041433-199810000-00012; Young SG, 1999, NAT GENET, V22, P316, DOI 10.1038/11878; Zha XH, 2003, J BIOL CHEM, V278, P10002, DOI 10.1074/jbc.C300024200	37	160	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37368	37374		10.1074/jbc.M307161200	http://dx.doi.org/10.1074/jbc.M307161200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869555	hybrid			2022-12-27	WOS:000185437200047
J	Nanjundan, M; Sun, J; Zhao, J; Zhou, QS; Sims, PJ; Wiedmer, T				Nanjundan, M; Sun, J; Zhao, J; Zhou, QS; Sims, PJ; Wiedmer, T			Plasma membrane phospholipid scramblase 1 promotes EGF-dependent activation of c-src through the epidermal growth factor receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN SHC; TRANSBILAYER MOVEMENT; PHOSPHOTYROSINE-BINDING; FAMILY; DOMAIN; CELLS; IMMORTALIZATION; PHOSPHORYLATION; PALMITOYLATION; GENE	Phospholipid scramblase (PLSCR1) is a multiply palmitoylated, calcium-binding endofacial membrane protein proposed to mediate transbilayer movement of plasma membrane phospholipids. PLSCR1 is a component of membrane lipid rafts and has been shown to both physically and functionally interact with activated epidermal growth factor (EGF) receptors and other raft-associated cell surface receptors. Cell stimulation by EGF results in Tyr phosphorylation of PLSCR1, its association with both Shc and EGF receptors, and rapid cycling of PLSCR1 between plasma membrane and endosomal compartments. We now report evidence that upon EGF stimulation, PLSCR1 is phosphorylated by c-Src, within the tandem repeat sequence (68)VYNQPVYNQP(77). The in vivo interaction between PLSCR1 and Shc requires the Src-mediated phosphorylation on tyrosines 69 and 74. In in vitro pull down studies, phosphorylated PLSCR1 was found to bind directly to Shc through the phosphotyrosine binding domain. Consistent with the potential role of PLSCR1 in growth factor signaling pathways, granulocyte precursors derived from mice deficient in PLSCR1 show impaired proliferation and maturation under cytokine stimulation. Using PLSCR1 -/- embryonic fibroblasts and kidney epithelial cells, we now demonstrate that deletion of PLSCR1 from the plasma membrane reduces the activation of c-Src by EGF, implying that PLSCR1 normally facilitates receptor-dependent activation of this kinase. We propose that PLSCR1, through its interaction with Shc, promotes Src kinase activation through the EGF receptor.	Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA	Scripps Research Institute	Wiedmer, T (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, MEM-275,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NHLBI NIH HHS [HL63819, HL61200, HL36946] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063819, R01HL061200, R01HL036946] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ahn S, 2002, J BIOL CHEM, V277, P26642, DOI 10.1074/jbc.M201499200; Basse F, 1996, J BIOL CHEM, V271, P17205, DOI 10.1074/jbc.271.29.17205; BELSCHES AP, 1997, FRONT BIOSCI, V2, P501; Brabek J, 2002, BIOCHEM BIOPH RES CO, V296, P664, DOI 10.1016/S0006-291X(02)00884-7; Furstoss O, 2002, EMBO J, V21, P514, DOI 10.1093/emboj/21.4.514; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; Pellicena P, 2002, FRONT BIOSCI-LANDMRK, V7, pD256, DOI 10.2741/pellicen; Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011; PRIGENT SA, 1995, J BIOL CHEM, V270, P22097, DOI 10.1074/jbc.270.38.22097; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; Ravichandran KS, 1997, MOL CELL BIOL, V17, P5540, DOI 10.1128/MCB.17.9.5540; ROMERO MF, 1992, KIDNEY INT, V42, P1130, DOI 10.1038/ki.1992.397; Sato K, 2002, J BIOL CHEM, V277, P29568, DOI 10.1074/jbc.M203179200; Sato K, 1997, FEBS LETT, V410, P136, DOI 10.1016/S0014-5793(97)00539-5; Sato K, 2000, GENES CELLS, V5, P749, DOI 10.1046/j.1365-2443.2000.00358.x; Sims PJ, 2001, THROMB HAEMOSTASIS, V86, P266; Sun J, 2002, BIOCHEMISTRY-US, V41, P6338, DOI 10.1021/bi025610l; Sun J, 2001, J BIOL CHEM, V276, P28984, DOI 10.1074/jbc.M102505200; TEVETHIA MJ, 1984, VIROLOGY, V137, P414, DOI 10.1016/0042-6822(84)90234-4; Tice DA, 1999, P NATL ACAD SCI USA, V96, P1415, DOI 10.1073/pnas.96.4.1415; Wiedmer T, 2000, BBA-BIOMEMBRANES, V1467, P244, DOI 10.1016/S0005-2736(00)00236-4; Wiedmer T, 2003, BIOCHEMISTRY-US, V42, P1227, DOI 10.1021/bi026679w; Woost PG, 1996, KIDNEY INT, V50, P125, DOI 10.1038/ki.1996.295; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Zhao J, 1998, BIOCHEMISTRY-US, V37, P6361, DOI 10.1021/bi980218m; Zhou MM, 1995, J BIOL CHEM, V270, P31119, DOI 10.1074/jbc.270.52.31119; Zhou QS, 2000, BLOOD, V95, P2593, DOI 10.1182/blood.V95.8.2593.008k32_2593_2599; Zhou QS, 2002, BLOOD, V99, P4030, DOI 10.1182/blood-2001-12-0271; Zhou QS, 1997, J BIOL CHEM, V272, P18240, DOI 10.1074/jbc.272.29.18240	29	62	63	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37413	37418		10.1074/jbc.M306182200	http://dx.doi.org/10.1074/jbc.M306182200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871937	hybrid			2022-12-27	WOS:000185437200053
J	Valor, LM; Castillo, M; Ortiz, JA; Criado, M				Valor, LM; Castillo, M; Ortiz, JA; Criado, M			Transcriptional regulation by activation and repression elements located at the 5 '-noncoding region of the human alpha 9 nicotinic receptor subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COCHLEAR HAIR-CELLS; ACETYLCHOLINE-RECEPTOR; FUNCTIONAL-CHARACTERIZATION; 5'-UNTRANSLATED REGION; DNA-BINDING; EXPRESSION; PROMOTER; SOX10; PROTEINS; CLONING	The alpha9 subunit is a component of the neuronal nicotinic acetylcholine receptor gene superfamily that is expressed in very restricted locations. The promoter of the human gene has been analyzed in the human neuroblastoma SH-SY5Y, where alpha9 subunit expression was detected, and in C2C12 cells that do not express alpha9. A proximal promoter region ( from - 322 to + 113) showed maximal transcriptional activity in SH-SY5Y cells, whereas its activity in C1C12 cells was much lower. Two elements unusually located at the 5'-noncoding region exhibited opposite roles. A negative element located between + 15 and + 48 appears to be cell-specific because it was effective in C2C12 but not in SH-SY5Y cells, where it was counterbalanced by the presence of the promoter region 5' to the initiation site. An activating element located between + 66 and + 79 and formed by two adjacent Sox boxes increased the activity of the alpha9 promoter about 4-fold and was even able to activate other promoters. This element interacts with Sox proteins, probably through a cooperative mechanism in which the two Sox boxes are necessary. We propose that the Sox complex provides an initial scaffold that facilitates the recruiting of the transcriptional machinery responsible for alpha9 subunit expression.	Univ Miguel Hernandez, CSIC, Dept Biochem & Mol Biol, Alicante 03550, Spain; Univ Miguel Hernandez, CSIC, Inst Neurociencias, Alicante 03550, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad Miguel Hernandez de Elche; CSIC-UMH - Instituto de Neurociencias de Alicante (IN)	Criado, M (corresponding author), Univ Miguel Hernandez, CSIC, Dept Biochem & Mol Biol, Alicante 03550, Spain.	Manuel.Criado@umh.es	Ortiz Salcedo, José Antonio/HHN-7691-2022; Valor, Luis/ABG-1754-2020; Criado, Manuel/K-5109-2014	Ortiz Salcedo, José Antonio/0000-0003-0505-3032; Criado, Manuel/0000-0002-3953-0346; Valor, Luis M./0000-0002-1229-0565				Andersen B, 2001, ENDOCR REV, V22, P2, DOI 10.1210/er.22.1.2; BESSIS A, 1995, NEUROSCIENCE, V69, P807, DOI 10.1016/0306-4522(95)00303-Z; Burke TW, 1997, GENE DEV, V11, P3020, DOI 10.1101/gad.11.22.3020; Campos-Caro A, 2001, DNA CELL BIOL, V20, P657, DOI 10.1089/104454901753340640; Carrasco-Serrano C, 1998, J BIOL CHEM, V273, P20021, DOI 10.1074/jbc.273.32.20021; Clarkson MJ, 2002, TRENDS ENDOCRIN MET, V13, P106, DOI 10.1016/S1043-2760(01)00541-0; Collignon J, 1996, DEVELOPMENT, V122, P509; ELGOYHEN AB, 1994, CELL, V79, P705, DOI 10.1016/0092-8674(94)90555-X; Flora A, 2000, EUR J PHARMACOL, V393, P85, DOI 10.1016/S0014-2999(00)00040-6; Fornasari D, 1997, MOL PHARMACOL, V51, P250, DOI 10.1124/mol.51.2.250; FORNASARI KI, 1998, NEURONAL NICOTINIC R, P25; Fuchs P, 2002, AUDIOL NEURO-OTOL, V7, P40, DOI 10.1159/000046862; GARCIAGUZMAN M, 1995, EUR J NEUROSCI, V7, P647, DOI 10.1111/j.1460-9568.1995.tb00668.x; GARDNER PD, 1987, MOL BRAIN RES, V3, P69, DOI 10.1016/0169-328X(87)90046-5; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; GrootKormelink PJ, 1997, FEBS LETT, V400, P309, DOI 10.1016/S0014-5793(96)01383-X; HARLEY VR, 1994, NUCLEIC ACIDS RES, V22, P1500, DOI 10.1093/nar/22.8.1500; Hernandez-Torres J, 2001, J BIOL CHEM, V276, P35405, DOI 10.1074/jbc.M104723200; Jagger DJ, 2000, J PHYSIOL-LONDON, V527, P49, DOI 10.1111/j.1469-7793.2000.t01-1-00049.x; Jain N, 1996, J BIOL CHEM, V271, P13530, DOI 10.1074/jbc.271.23.13530; Kamachi Y, 1999, MOL CELL BIOL, V19, P107; Karlin A, 2002, NAT REV NEUROSCI, V3, P102, DOI 10.1038/nrn731; Kuhlbrodt K, 1998, J BIOL CHEM, V273, P23033, DOI 10.1074/jbc.273.36.23033; Kuhlbrodt K, 1998, J NEUROSCI, V18, P237, DOI 10.1523/jneurosci.18-01-00237.1998; Lefebvre V, 1998, EMBO J, V17, P5718, DOI 10.1093/emboj/17.19.5718; Liu Q, 1999, J NEUROSCI, V19, P9747; Maison SF, 2002, J NEUROSCI, V22, P10838; Nguyen VT, 2000, AM J PATHOL, V157, P1377, DOI 10.1016/S0002-9440(10)64651-2; Paule MR, 2000, NUCLEIC ACIDS RES, V28, P1283, DOI 10.1093/nar/28.6.1283; Peirano RI, 2000, MOL CELL BIOL, V20, P3198, DOI 10.1128/MCB.20.9.3198-3209.2000; Rivolta MN, 1998, P ROY SOC B-BIOL SCI, V265, P1595, DOI 10.1098/rspb.1998.0477; Rosenfeld MG, 2000, RECENT PROG HORM RES, V55, P1; Ryan AF, 2002, AUDIOL NEURO-OTOL, V7, P138, DOI 10.1159/000058298; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Simmons DD, 1998, MOL BRAIN RES, V56, P287, DOI 10.1016/S0169-328X(98)00056-4; Valor LM, 2002, J BIOL CHEM, V277, P8866, DOI 10.1074/jbc.M110454200; van der Stoep N, 2002, J IMMUNOL, V169, P5061, DOI 10.4049/jimmunol.169.9.5061; Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409; Yamamoto K, 1999, J BIOL CHEM, V274, P4646, DOI 10.1074/jbc.274.8.4646	39	13	14	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37249	37255		10.1074/jbc.M307043200	http://dx.doi.org/10.1074/jbc.M307043200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860975	hybrid			2022-12-27	WOS:000185437200033
J	Koutsoupakis, C; Soulimane, T; Varotsis, C				Koutsoupakis, C; Soulimane, T; Varotsis, C			Docking site dynamics of ba(3)-cytochrome c oxidase from Thermus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORM INFRARED-SPECTROSCOPY; HEME-COPPER OXIDASES; MOLECULAR-DYNAMICS; CARBON-MONOXIDE; MYOGLOBIN; COMPLEX; TEMPERATURE; POCKET; PHOTODISSOCIATION; HEMOGLOBIN	Ligand trajectories trapped within a docking site or within an internal cavity near the active site of proteins are important issues toward the elucidation of the mechanism of reaction of such complex systems, in which activity requires the shuttling of oriented ligands to and from their active site. The ligand motion within ba(3)-cytochrome c oxidase from Thermus thermophilus has been investigated by measuring time-resolved step-scan Fourier transform infrared difference spectra of photodissociated CO from heme a(3) at ambient temperature. Upon photodissociation, 15 - 20% of the CO is not covalently attached to Cu-B but is trapped within a docking site near the ring A of heme a(3) propionate. Two trajectories of CO that are distinguished spectroscopically and kinetically (nu(CO) = 2131 cm(-1), t(d) = 10 - 35 mus and nu(CO) = 2146 cm(-1), t(d) = 85 mus) are observed. At later times (t(d) = 110 mus) the docking site reorganizes about the CO and quickly establishes an energetic barrier that facilitates equilibration of the ligand with the protein solvent. The time-dependent shift of the CO trajectories we observe is attributed to a conformational motion of the docking site surrounding the ligand. The implications of these results with respect to the ability of the docking site to constrain ligand orientation and the reaction dynamics of the docking site are discussed herein.	Univ Crete, Dept Chem, Iraklion 71409, Greece; Paul Scherrer Inst, OSRA 008, CH-5232 Villigen, Switzerland	University of Crete; Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute	Varotsis, C (corresponding author), Univ Crete, Dept Chem, Iraklion 71409, Greece.	varotsis@edu.uoc.gr		Varotsis, Constantinos/0000-0003-2771-8891				ALBEN JO, 1982, P NATL ACAD SCI-BIOL, V79, P3744, DOI 10.1073/pnas.79.12.3744; ALBEN JO, 1981, P NATL ACAD SCI-BIOL, V78, P234, DOI 10.1073/pnas.78.1.234; Anfinrud P, 1999, P NATL ACAD SCI USA, V96, P8328, DOI 10.1073/pnas.96.15.8328; ANFINRUD PA, 1989, P NATL ACAD SCI USA, V86, P8387, DOI 10.1073/pnas.86.21.8387; DYER RB, 1991, J AM CHEM SOC, V113, P6276, DOI 10.1021/ja00016a057; DYER RB, 1994, BIOCHEMISTRY-US, V33, P500, DOI 10.1021/bi00168a015; EINARSDOTTIR O, 1993, BIOCHEMISTRY-US, V32, P12013, DOI 10.1021/bi00096a011; ELBER R, 1987, SCIENCE, V235, P318, DOI 10.1126/science.3798113; FRAUENFELDER H, 1991, SCIENCE, V254, P1598, DOI 10.1126/science.1749933; Frauenfelder H, 2001, P NATL ACAD SCI USA, V98, P2370, DOI 10.1073/pnas.041614298; Giuffre A, 1999, BIOCHEMISTRY-US, V38, P1057, DOI 10.1021/bi9815389; Giuffre A, 1999, P NATL ACAD SCI USA, V96, P14718, DOI 10.1073/pnas.96.26.14718; Koutsoupakis K, 2003, J BIOL CHEM, V278, P14893, DOI 10.1074/jbc.M210293200; Koutsoupakis K, 2002, J BIOL CHEM, V277, P32860, DOI 10.1074/jbc.M204943200; LIM M, 1995, SCIENCE, V269, P962, DOI 10.1126/science.7638619; LIM MH, 1995, J CHEM PHYS, V102, P4355, DOI 10.1063/1.469484; Lim MH, 1997, NAT STRUCT BIOL, V4, P209, DOI 10.1038/nsb0397-209; Olson JS, 1996, J BIOL CHEM, V271, P17593, DOI 10.1074/jbc.271.30.17593; Pinakoulaki E, 2002, J BIOL CHEM, V277, P32867, DOI 10.1074/jbc.M205568200; Sagnella DE, 1999, P NATL ACAD SCI USA, V96, P14324, DOI 10.1073/pnas.96.25.14324; Soulimane T, 2000, EMBO J, V19, P1766, DOI 10.1093/emboj/19.8.1766; Srajer V, 1996, SCIENCE, V274, P1726, DOI 10.1126/science.274.5293.1726; Stavrakis S, 2002, J AM CHEM SOC, V124, P3814, DOI 10.1021/ja0169825; WOODRUFF WH, 1993, J BIOENERG BIOMEMBR, V25, P177, DOI 10.1007/BF00762859	24	27	28	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36806	36809		10.1074/jbc.M307117200	http://dx.doi.org/10.1074/jbc.M307117200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851397	hybrid			2022-12-27	WOS:000185318300113
J	Wu, RF; Gu, Y; Xu, YC; Nwariaku, FE; Terada, LS				Wu, RF; Gu, Y; Xu, YC; Nwariaku, FE; Terada, LS			Vascular endothelial growth factor causes translocation of p47(phox) to membrane ruffles through WAVE1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; SMOOTH-MUSCLE-CELLS; NADPH OXIDASE ACTIVITY; TYROSINE PHOSPHORYLATION; LIVING CELLS; SIGNAL-TRANSDUCTION; HYDROGEN-PEROXIDE; TERMINAL KINASE; FACTOR RECEPTOR; ACTIVATION	Growth factors initiate cytoskeletal rearrangements tightly coordinated with nuclear signaling events. We hypothesized that the angiogenic growth factor, vascular endothelial growth factor ( VEGF), may utilize oxidants that are site-directed to a complex critical to both cytoskeletal and mitogenic signaling. We identified the WASP-family verprolin homologous protein-1 (WAVE1) as a binding partner for the NADPH oxidase adapter p47(phox) within membrane ruffles of VEGF-stimulated cells. Within 15 min of VEGF stimulation, p47(phox) coprecipitated with WAVE1, with the ruffle and oxidase agonist Rac1, and with the Rac1 effector PAK1. VEGF also increased p47(phox) phosphorylation, oxidant production, and ruffle formation, all of which were dependent upon PAK1 kinase activity. The antioxidant Mn(III) tetrakis( 4-benzoic acid) porphyrin and ectopic expression of either the p47-binding WAVE1 domain or the WAVE1-binding p47(phox) domain decreased VEGF-induced ruffling, whereas the active mutant p4-(S303D, S304D, S328D) stimulated oxidant production and formation of circular dorsal ruffles. Both kinase-dead PAK1-(K298A) and Mn ( III) tetrakis(4-benzoic acid) porphyrin decreased c-Jun N-terminal kinase (JNK) activation by VEGF, whereas dominant-negative JNK did not block ruffle formation, suggesting a bifurcation of mitogenic and cytoskeletal signaling events at or distal to the oxidase but proximal to JNK. Thus, WAVE1 may act as a scaffold to recruit the NADPH oxidase to a complex involved with both cytoskeletal regulation and downstream JNK activation.	Vet Adm Med Ctr, Dallas, TX 75216 USA; Univ Texas, SW Med Ctr, Dallas, TX 75216 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Terada, LS (corresponding author), Vet Adm Med Ctr, MC 151,4500 S Lancaster Rd, Dallas, TX 75216 USA.	Lance.Terada@med.va.gov		Terada, Lance/0000-0001-7441-9734	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067256, R01HL061897] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL67256, R01 HL061897, R01 HL067256, R01-HL61897] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ago T, 1999, J BIOL CHEM, V274, P33644, DOI 10.1074/jbc.274.47.33644; Ahern-Djamali SM, 1999, P NATL ACAD SCI USA, V96, P4977, DOI 10.1073/pnas.96.9.4977; Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; Banin S, 1996, CURR BIOL, V6, P981, DOI 10.1016/S0960-9822(02)00642-5; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; Bhunia AK, 2002, J BIOL CHEM, V277, P16396, DOI 10.1074/jbc.M200877200; Dahan I, 2002, J BIOL CHEM, V277, P8421, DOI 10.1074/jbc.M109778200; deMendez I, 1997, MOL CELL BIOL, V17, P2177, DOI 10.1128/MCB.17.4.2177; Dharmawardhane S, 2000, MOL BIOL CELL, V11, P3341, DOI 10.1091/mbc.11.10.3341; Eden S, 2002, NATURE, V418, P790, DOI 10.1038/nature00859; Endo A, 2002, J BIOL CHEM, V277, P23747, DOI 10.1074/jbc.M111794200; Freeman JL, 1996, J BIOL CHEM, V271, P22578, DOI 10.1074/jbc.271.37.22578; Gu Y, 2002, EXP CELL RES, V272, P62, DOI 10.1006/excr.2001.5404; Guinamard R, 1998, FEBS LETT, V434, P431, DOI 10.1016/S0014-5793(98)01016-3; Hahne P, 2001, FEBS LETT, V492, P215, DOI 10.1016/S0014-5793(01)02239-6; HEFFETZ D, 1989, J BIOL CHEM, V264, P10126; Heyworth PG, 1997, HISTOCHEM CELL BIOL, V108, P221, DOI 10.1007/s004180050162; Inanami O, 1998, J BIOL CHEM, V273, P9539, DOI 10.1074/jbc.273.16.9539; Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kheradmand F, 1998, SCIENCE, V280, P898, DOI 10.1126/science.280.5365.898; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kraynov VS, 2000, SCIENCE, V290, P333, DOI 10.1126/science.290.5490.333; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Moldovan L, 2000, CIRC RES, V86, P549, DOI 10.1161/01.RES.86.5.549; Page K, 1999, J BIOL CHEM, V274, P22065, DOI 10.1074/jbc.274.31.22065; Pedram A, 1998, J BIOL CHEM, V273, P26722, DOI 10.1074/jbc.273.41.26722; Plattner R, 1999, GENE DEV, V13, P2400, DOI 10.1101/gad.13.18.2400; Price MO, 2002, J BIOL CHEM, V277, P19220, DOI 10.1074/jbc.M200061200; She HY, 1997, MOL BIOL CELL, V8, P1709, DOI 10.1091/mbc.8.9.1709; Soderling SH, 2002, NAT CELL BIOL, V4, P970, DOI 10.1038/ncb886; Sun P, 2003, J BIOL CHEM, V278, P4063, DOI 10.1074/jbc.M208699200; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; Ushio-Fukai M, 2002, CIRC RES, V91, P1160, DOI 10.1161/01.RES.0000046227.65158.F8; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Westphal RS, 2000, EMBO J, V19, P4589, DOI 10.1093/emboj/19.17.4589; Wu Y, 1998, J BIOL CHEM, V273, P5765, DOI 10.1074/jbc.273.10.5765; Xu YX, 2002, J BIOL CHEM, V277, P28051, DOI 10.1074/jbc.M202665200; Zhao Y, 1998, J CELL PHYSIOL, V174, P370, DOI 10.1002/(SICI)1097-4652(199803)174:3<370::AID-JCP11>3.0.CO;2-D	40	73	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36830	36840		10.1074/jbc.M302251200	http://dx.doi.org/10.1074/jbc.M302251200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855698	hybrid			2022-12-27	WOS:000185318300116
J	Huynh, TT; Huynh, VT; Harmon, MA; Phillips, MA				Huynh, TT; Huynh, VT; Harmon, MA; Phillips, MA			Gene knockdown of gamma-glutamylcysteine synthetase by RNA(i) in the parasitic protozoa Trypanosoma brucei demonstrates that it is an essential enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFRICAN TRYPANOSOMIASIS; TRANSFERASE TRANSPEPTIDASE; TRYPANOTHIONE REDUCTASE; BUTHIONINE SULFOXIMINE; CRITHIDIA-FASCICULATA; BINDING DETERMINANTS; LEISHMANIA-DONOVANI; SLEEPING SICKNESS; OXIDATIVE STRESS; AMINO-ACIDS	The parasitic protozoa Trypanosoma brucei utilizes a novel cofactor (trypanothione, T(SH)(2)), which is a conjugate of GSH and spermidine, to maintain cellular redox balance. gamma-Glutamylcysteine synthetase (gamma-GCS) catalyzes the first step in the biosynthesis of GSH. To evaluate the importance of thiol metabolism to the parasite, RNA(i) methods were used to knock down gene expression of gamma-GCS in procyclic T. brucei cells. Induction of gamma-GCS RNA(i) with tetracycline led to cell death within 4-6 days post-induction. Cell death was preceded by the depletion of the gamma-GCS protein and RNA and by the loss of the cellular pools of GSH and T(SH)(2). The addition of GSH (80 muM) to cell cultures rescued the RNA(i) cell death phenotype and restored the intracellular thiol pools to wild-type levels. Treatment of cells with buthionine sulfoximine (BSO), an enzyme-activated inhibitor of gamma-GCS, also resulted in cell death. However, the toxicity of the inhibitor was not reversed by GSH, suggesting that BSO has more than one cellular target. BSO depletes intracellular thiols to a similar extent as gamma-GCS RNA(i); however, addition of GSH did not restore the pools of GSH and T( SH) 2. These data suggest that BSO also acts to inhibit the transport of GSH or its peptide metabolites into the cell. The ability of BSO to inhibit both synthesis and transport of GSH likely makes it a more effective cytotoxic agent than an inhibitor with a single mode of action. Finally the potential for the T(SH)(2) biosynthetic enzymes to be regulated in response to reduced thiol levels was studied. The expression levels of ornithine decarboxylase and of S-adenosylmethionine decarboxylase, two essential enzymes in spermidine biosynthesis, remained constant in induced gamma-GCS RNA(i) cell lines.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Phillips, MA (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	margaret.phillips@utsouthwestern.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034432] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI34432] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbott JJ, 2002, BIOCHEMISTRY-US, V41, P2741, DOI 10.1021/bi0159128; Abbott JJ, 2001, J BIOL CHEM, V276, P42099, DOI 10.1074/jbc.M104672200; ARRICK BA, 1981, J EXP MED, V153, P720, DOI 10.1084/jem.153.3.720; Augustyns K, 2001, CURR PHARM DESIGN, V7, P1117, DOI 10.2174/1381612013397564; BELLOFATTO V, 1987, MOL BIOCHEM PARASIT, V25, P227, DOI 10.1016/0166-6851(87)90086-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brekken DL, 1998, J BIOL CHEM, V273, P26317, DOI 10.1074/jbc.273.41.26317; BRUN R, 1979, ACTA TROP, V36, P289; Burchmore RJS, 2002, CURR PHARM DESIGN, V8, P257, DOI 10.2174/1381612023396159; Carter KC, 2003, ANTIMICROB AGENTS CH, V47, P1529, DOI 10.1128/AAC.47.5.1529-1535.2003; Cottrell TR, 2003, TRENDS MICROBIOL, V11, P37, DOI 10.1016/S0966-842X(02)00004-5; Dormeyer M, 2001, J BIOL CHEM, V276, P10602, DOI 10.1074/jbc.M010352200; Dumas C, 1997, EMBO J, V16, P2590, DOI 10.1093/emboj/16.10.2590; FAIRLAMB AH, 1987, MOL BIOCHEM PARASIT, V24, P185, DOI 10.1016/0166-6851(87)90105-8; FAIRLAMB AH, 1985, SCIENCE, V227, P1485, DOI 10.1126/science.3883489; Fairlamb Alan H., 1997, P149; Fries D.S., 2003, BURGERS MED CHEM DRU, P1033; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P6319, DOI 10.1073/pnas.76.12.6319; GRIFFITH OW, 1981, P NATL ACAD SCI-BIOL, V78, P2777, DOI 10.1073/pnas.78.5.2777; GRIFFITH OW, 1978, P NATL ACAD SCI USA, V75, P5405, DOI 10.1073/pnas.75.11.5405; Grondin K, 1997, EMBO J, V16, P3057, DOI 10.1093/emboj/16.11.3057; Hillebrand H, 2003, J BIOL CHEM, V278, P6809, DOI 10.1074/jbc.M210392200; Jackson LK, 2000, BIOCHEMISTRY-US, V39, P11247, DOI 10.1021/bi001209s; KANG YJ, 1994, TOXICOLOGY, V88, P177, DOI 10.1016/0300-483X(94)90119-8; Karp DR, 2001, J BIOL CHEM, V276, P3798, DOI 10.1074/jbc.M008484200; Kinch LN, 2000, BIOCHEMISTRY-US, V39, P3336, DOI 10.1021/bi991493r; KIRCHHOFF LV, 1994, CURR OPIN INFECT DIS, V7, P542, DOI 10.1097/00001432-199410000-00004; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Ludemann H, 1998, FEBS LETT, V431, P381, DOI 10.1016/S0014-5793(98)00793-5; Lueder DV, 1996, J BIOL CHEM, V271, P17485, DOI 10.1074/jbc.271.29.17485; Luersen K, 2000, BIOCHEM J, V346, P545, DOI 10.1042/0264-6021:3460545; Matovu E, 2001, MICROBES INFECT, V3, P763, DOI 10.1016/S1286-4579(01)01432-0; Mehlotra RK, 1996, CRIT REV MICROBIOL, V22, P295, DOI 10.3109/10408419609105484; Meister A., 1989, METABOLISM FUNCTIONS, P367; Morris JC, 2001, MOL BIOCHEM PARASIT, V117, P111, DOI 10.1016/S0166-6851(01)00334-6; Mulenga C, 2001, NEUROPATH APPL NEURO, V27, P77, DOI 10.1046/j.0305-1846.2001.00306.x; Ngo H, 1998, P NATL ACAD SCI USA, V95, P14687, DOI 10.1073/pnas.95.25.14687; Oza SL, 2002, J BIOL CHEM, V277, P35853, DOI 10.1074/jbc.M204403200; PEGG AE, 1995, J CELL BIOCHEM, P132; PEPIN J, 2000, HUNTERS TROPICAL MED, P643; Reckenfelderbaumer N, 2000, J BIOL CHEM, V275, P7547, DOI 10.1074/jbc.275.11.7547; REED SG, 2000, HUNTERS TROPICAL MED, P653; REPETTO Y, 1987, COMP BIOCHEM PHYS B, V87, P73, DOI 10.1016/0305-0491(87)90472-X; Sagerstrom Charles G., 1996, P83; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schmidt Armin, 2002, Current Topics in Medicinal Chemistry, V2, P1239, DOI 10.2174/1568026023393048; SEED JR, 1989, J PROTOZOOL, V36, P572, DOI 10.1111/j.1550-7408.1989.tb01099.x; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; Tetaud E, 1998, J BIOL CHEM, V273, P19383, DOI 10.1074/jbc.273.31.19383; WANG CC, 1995, ANNU REV PHARMACOL, V35, P93, DOI 10.1146/annurev.pa.35.040195.000521; Wang ZF, 2000, J BIOL CHEM, V275, P40174, DOI 10.1074/jbc.M008405200; Weldrick DP, 1999, FEMS MICROBIOL LETT, V173, P139, DOI 10.1111/j.1574-6968.1999.tb13495.x; Wirtz E, 1998, NUCLEIC ACIDS RES, V26, P4626, DOI 10.1093/nar/26.20.4626; WIRTZ E, 1994, NUCLEIC ACIDS RES, V22, P3887, DOI 10.1093/nar/22.19.3887	54	57	59	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39794	39800		10.1074/jbc.M306306200	http://dx.doi.org/10.1074/jbc.M306306200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888552	hybrid			2022-12-27	WOS:000185713800065
J	Chen, Y; Balakrishnan, M; Roques, BP; Bambara, RA				Chen, Y; Balakrishnan, M; Roques, BP; Bambara, RA			Steps of the acceptor invasion mechanism for HIV-1 minus strand strong stop transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; MURINE LEUKEMIA-VIRUS; RNASE-H ACTIVITY; NUCLEOCAPSID PROTEIN NCP7; REVERSE-TRANSCRIPTASE; DNA-SYNTHESIS; IN-VITRO; RETROVIRAL REPLICATION; SECONDARY STRUCTURE; INTERNAL REGIONS	Minus strand strong stop transfer is obligatory for completion of HIV-1 minus strand synthesis. We previously showed evidence for an acceptor invasion-initiated mechanism for minus strand transfer. In the present study, we examined the major acceptor invasion initiation site using a minus strand transfer system in vitro, containing the 97-nucleotide full-length R region. A series of DNA oligonucleotides complementary to different regions of the cDNA was designed to interfere with transfer. Oligomers covering the region around the base of the TAR hairpin were most effective in inhibiting transfer, suggesting that the hairpin base is a preferred site for acceptor invasion. The strong pausing of reverse transcriptase at the base of the TAR and the concomitant RNase H cleavages 10-19 nucleotides behind the pause site correlated with the location of the invasion site. Oligomers closer to the 5'-end of R also inhibited transfer, though less effectively, presumably by blocking strand exchange and branch migration. We propose that pausing of reverse transcriptase at the base of TAR increases RNase H cleavages, creating gaps for acceptor invasion and transfer initiation. Strand exchange then propagates by branch migration, displacing the fragmented donor RNA, including the fragment at the 5' terminus. The primer terminus switches to the acceptor, completing the transfer. Nucleocapsid (NC) protein stimulated transfer efficiency by 5-7-fold. NC enhanced RNase H cleavages close to the TAR base, creating more effective invasion sites for efficient transfer. Most likely, NC also stimulates transfer by promoting strand exchange invasion and branch migration.	Univ Rochester, Med Ctr, Dept Biochem & Biophys, Rochester, NY 14642 USA; Univ Rochester, Ctr Canc, Rochester, NY 14642 USA; UER Sci Pharmaceut & Biol, Dept Pharmacochim Mol & Struct, CNRS, URA D1500,INSERM,U266, F-75270 Paris, France	University of Rochester; University of Rochester; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Bambara, RA (corresponding author), Univ Rochester, Med Ctr, Dept Biochem & Biophys, Box 712,601 Elmwood Ave, Rochester, NY 14642 USA.				PHS HHS [49573] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Allain B, 1998, J MOL BIOL, V277, P225, DOI 10.1006/jmbi.1997.1596; ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; Balakrishnan M, 2003, J VIROL, V77, P4710, DOI 10.1128/JVI.77.8.4710-4721.2003; BERKHOUT B, 1995, J MOL BIOL, V252, P59, DOI 10.1006/jmbi.1994.0475; Berkhout B, 2001, RNA, V7, P1097, DOI 10.1017/S1355838201002035; Berkhout B, 1998, VIROLOGY, V249, P211, DOI 10.1006/viro.1998.9321; Brule F, 2000, NUCLEIC ACIDS RES, V28, P634, DOI 10.1093/nar/28.2.634; Cameron CE, 1997, P NATL ACAD SCI USA, V94, P6700, DOI 10.1073/pnas.94.13.6700; Chen Y, 2003, J BIOL CHEM, V278, P8006, DOI 10.1074/jbc.M210959200; Cheslock SR, 2000, J VIROL, V74, P9571, DOI 10.1128/JVI.74.20.9571-9579.2000; Dang Q, 2001, J VIROL, V75, P809, DOI 10.1128/JVI.75.2.809-820.2001; Derebail SS, 2003, J BIOL CHEM, V278, P15702, DOI 10.1074/jbc.M211701200; DEROCQUIGNY H, 1991, BIOCHEM BIOPH RES CO, V180, P1010, DOI 10.1016/S0006-291X(05)81166-0; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; Driscoll MD, 2000, J VIROL, V74, P8785, DOI 10.1128/JVI.74.19.8785-8792.2000; Driscoll MD, 2001, J VIROL, V75, P672, DOI 10.1128/JVI.75.2.672-686.2001; Druillennec S, 1999, J BIOL CHEM, V274, P11283, DOI 10.1074/jbc.274.16.11283; Feng YX, 1996, P NATL ACAD SCI USA, V93, P7577, DOI 10.1073/pnas.93.15.7577; GARCES J, 1991, P ROY SOC B-BIOL SCI, V243, P235, DOI 10.1098/rspb.1991.0037; Golinelli MP, 2001, VIROLOGY, V285, P278, DOI 10.1006/viro.2001.0970; Guo JH, 1997, J VIROL, V71, P5178, DOI 10.1128/JVI.71.7.5178-5188.1997; Guo JH, 1998, J VIROL, V72, P6716, DOI 10.1128/JVI.72.8.6716-6724.1998; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; Hong MK, 2003, J MOL BIOL, V325, P1, DOI 10.1016/S0022-2836(02)01177-4; Hsu M, 2000, NUCLEIC ACIDS RES, V28, P1724, DOI 10.1093/nar/28.8.1724; HU WS, 1990, SCIENCE, V250, P1227, DOI 10.1126/science.1700865; Hwang CK, 2001, P NATL ACAD SCI USA, V98, P12209, DOI 10.1073/pnas.221289898; Johnson PE, 2000, BIOCHEMISTRY-US, V39, P9084, DOI 10.1021/bi000841i; JONES JS, 1994, J VIROL, V68, P207, DOI 10.1128/JVI.68.1.207-216.1994; KHAN R, 1992, J BIOL CHEM, V267, P6689; Kim JK, 1997, J BIOL CHEM, V272, P16769, DOI 10.1074/jbc.272.27.16769; KLARMANN GJ, 1993, J BIOL CHEM, V268, P9793; KLAVER B, 1994, NUCLEIC ACIDS RES, V22, P137, DOI 10.1093/nar/22.2.137; Kulpa D, 1997, EMBO J, V16, P856, DOI 10.1093/emboj/16.4.856; LapadatTapolsky M, 1997, J MOL BIOL, V268, P250, DOI 10.1006/jmbi.1997.0978; LEE YMH, 1991, MOL CELL BIOL, V11, P1419, DOI 10.1128/MCB.11.3.1419; Lener D, 1998, J BIOL CHEM, V273, P33781, DOI 10.1074/jbc.273.50.33781; LOBEL LI, 1985, J VIROL, V53, P447, DOI 10.1128/JVI.53.2.447-455.1985; LUO G, 1990, J VIROL, V64, P4321, DOI 10.1128/JVI.64.9.4321-4328.1990; Negroni M, 1999, J MOL BIOL, V286, P15, DOI 10.1006/jmbi.1998.2460; Ohi Y, 2000, J VIROL, V74, P8324, DOI 10.1128/JVI.74.18.8324-8334.2000; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; Pfeiffer JK, 2001, J VIROL, V75, P11263, DOI 10.1128/JVI.75.23.11263-11274.2001; RAMSEY CA, 1993, J VIROL, V67, P4114, DOI 10.1128/JVI.67.7.4114-4121.1993; Roda RH, 2002, J BIOL CHEM, V277, P46900, DOI 10.1074/jbc.M208638200; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12468, DOI 10.1021/bi971218+; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; Svarovskaia ES, 2000, J VIROL, V74, P7171, DOI 10.1128/JVI.74.15.7171-7178.2000; TANESE N, 1991, J VIROL, V65, P4387, DOI 10.1128/JVI.65.8.4387-4397.1991; TELESNITSKY A, 1992, J VIROL, V66, P615, DOI 10.1128/JVI.66.2.615-622.1992; Telesnitsky A., 1997, P121; Telesnitsky A, 1993, REVERSE TRANSCRIPTAS; Topping R, 1998, J MOL BIOL, V281, P1, DOI 10.1006/jmbi.1998.1929; TSUCHIHASHI Z, 1994, J VIROL, V68, P5863, DOI 10.1128/JVI.68.9.5863-5870.1994; van Wamel JLB, 1998, VIROLOGY, V244, P245, DOI 10.1006/viro.1998.9096; VARMUS HE, 1978, J MOL BIOL, V120, P55, DOI 10.1016/0022-2836(78)90295-4; Williams MC, 2001, P NATL ACAD SCI USA, V98, P6121, DOI 10.1073/pnas.101033198; Wisniewski M, 2000, P NATL ACAD SCI USA, V97, P11978, DOI 10.1073/pnas.210392297; WU WM, 1995, J BIOL CHEM, V270, P325, DOI 10.1074/jbc.270.1.263; Yin PD, 1997, J VIROL, V71, P2487, DOI 10.1128/JVI.71.3.2487-2494.1997; YOU JC, 1993, J BIOL CHEM, V268, P16519; YOU JC, 1994, J BIOL CHEM, V269, P31491	65	44	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38368	38375		10.1074/jbc.M305700200	http://dx.doi.org/10.1074/jbc.M305700200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878597	hybrid			2022-12-27	WOS:000185575100036
J	Cheng, QC; Tikhomirov, O; Zhou, WL; Carpenter, G				Cheng, QC; Tikhomirov, O; Zhou, WL; Carpenter, G			Ectodomain cleavage of ErbB-4 - Characterization of the cleavage site and m80 fragment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR RECEPTOR; AMYLOID PRECURSOR PROTEIN; L-SELECTIN CD62L; INTRACELLULAR DOMAIN; TYROSINE KINASE; GAMMA-SECRETASE; STRUCTURAL REQUIREMENTS; CONVERTING-ENZYME; PROTEOLYSIS	Ectodomain cleavage of the ErbB-4 receptor tyrosine kinase generates a membrane-associated fragment of 80 kDa (m80) that has been subjected to N-terminal sequencing. The sequence obtained shows that the N terminus of this fragment begins with Ser-652 of ErbB-4. When a 12-residue peptide corresponding to ErbB-4 residues 646-657 was incubated with recombinant tumor necrosis factor-alpha-converting enzyme, fragments representing residues 646-651 and 652-657 were obtained. These data indicate that ectodomain cleavage of ErbB-4 occurs between His-651 and Ser-652, placing the cleavage site within the ectodomain stalk region approximately 8 residues prior to the transmembrane domain. Several experiments have characterized other aspects of the m80 ErbB-4 fragment. Inhibition of ErbB-4 tyrosine kinase activity with pan-ErbB tyrosine kinase inhibitors indicates that kinase activity is stringently required for heregulin-dependent, but not 12-O-tetradecanoylphorbol-13-acetate-induced, ErbB-4 ectodomain cleavage and formation of the m80 fragment. When the m80 ErbB-4 fragment is generated by cell treatment with heregulin or 12-O-tetradecanoylphorbol-13-acetate, the fragment associates with intact ErbB-2. However, this fragment does not associate with the intact ErbB-4 molecule.	Vanderbilt Univ, Sch Med, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Carpenter, G (corresponding author), Vanderbilt Univ, Sch Med, Dept Biochem, 221 Kirkland Hall, Nashville, TN 37232 USA.	Graham.Carpenter@mcmail.vanderbilt.edu			NATIONAL CANCER INSTITUTE [R01CA097456, P30CA068485] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593, P30DK020593] Funding Source: NIH RePORTER; NCI NIH HHS [CA97456, CA68485] Funding Source: Medline; NIDDK NIH HHS [DK20593] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 2000, CURR OPIN CELL BIOL, V12, P606, DOI 10.1016/S0955-0674(00)00139-3; Bodovitz S, 1996, J BIOL CHEM, V271, P4436; Carpenter G, 2003, EXP CELL RES, V284, P66, DOI 10.1016/S0014-4827(02)00100-3; CHANTRY A, 1995, J BIOL CHEM, V270, P3068; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Ehehalt R, 2003, J CELL BIOL, V160, P113, DOI 10.1083/jcb.200207113; Elenius K, 1997, J BIOL CHEM, V272, P26761, DOI 10.1074/jbc.272.42.26761; Ferguson KM, 2000, EMBO J, V19, P4632, DOI 10.1093/emboj/19.17.4632; FONTINI MD, 2002, NAT REV MOL CELL BIO, V3, P673; Frears ER, 1999, NEUROREPORT, V10, P1699, DOI 10.1097/00001756-199906030-00014; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; GADELLA TWJ, 1995, J CELL BIOL, V129, P1543, DOI 10.1083/jcb.129.6.1543; Haass C, 2002, TRENDS CELL BIOL, V12, P556, DOI 10.1016/S0962-8924(02)02394-2; Ikezu T, 1998, J BIOL CHEM, V273, P10485, DOI 10.1074/jbc.273.17.10485; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Lee HJ, 2002, J BIOL CHEM, V277, P6318, DOI 10.1074/jbc.M110371200; Lee SJ, 1998, NAT MED, V4, P730, DOI 10.1038/nm0698-730; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; MIGAKI GI, 1995, J EXP MED, V182, P549, DOI 10.1084/jem.182.2.549; Mohan MJ, 2002, BIOCHEMISTRY-US, V41, P9462, DOI 10.1021/bi0260132; Moriki T, 2001, J MOL BIOL, V311, P1011, DOI 10.1006/jmbi.2001.4923; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Mullberg J, 2000, EUR CYTOKINE NETW, V11, P27; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Penuel E, 2002, J BIOL CHEM, V277, P28468, DOI 10.1074/jbc.M202510200; Penuel E, 2001, SEMIN ONCOL, V28, P36, DOI 10.1053/sonc.2001.29711; Phong MC, 2003, BIOCHEM BIOPH RES CO, V300, P563, DOI 10.1016/S0006-291X(02)02886-3; PLOWMAN GD, 1993, P NATL ACAD SCI USA, V90, P1746, DOI 10.1073/pnas.90.5.1746; Rio C, 2000, J BIOL CHEM, V275, P10379, DOI 10.1074/jbc.275.14.10379; Roghani M, 1999, J BIOL CHEM, V274, P3531, DOI 10.1074/jbc.274.6.3531; Sako Y, 2000, NAT CELL BIOL, V2, P168, DOI 10.1038/35004044; Scheuermann S, 2001, J BIOL CHEM, V276, P33923, DOI 10.1074/jbc.M105410200; Schlessinger J, 2002, CELL, V110, P669, DOI 10.1016/S0092-8674(02)00966-2; Schlondorff J, 1999, J CELL SCI, V112, P3603; Simons M, 1998, P NATL ACAD SCI USA, V95, P6460, DOI 10.1073/pnas.95.11.6460; Slichenmyer WJ, 2001, SEMIN ONCOL, V28, P80, DOI 10.1016/S0093-7754(01)90285-4; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Vecchi M, 1996, J BIOL CHEM, V271, P18989, DOI 10.1074/jbc.271.31.18989; Vecchi M, 1998, J BIOL CHEM, V273, P20589, DOI 10.1074/jbc.273.32.20589; Vecchi M, 1997, J CELL BIOL, V139, P995, DOI 10.1083/jcb.139.4.995; YI X, 2002, MOL BIOL CELL, V13, P2547; Zhao LC, 2001, J BIOL CHEM, V276, P30631, DOI 10.1074/jbc.M103748200; Zhou WL, 2000, J BIOL CHEM, V275, P34737, DOI 10.1074/jbc.M003756200; Zhou WL, 2001, ONCOGENE, V20, P3918, DOI 10.1038/sj.onc.1204517; Zhu HJ, 2003, GROWTH FACTORS, V21, P15, DOI 10.1080/0897719031000096424	50	63	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38421	38427		10.1074/jbc.M302111200	http://dx.doi.org/10.1074/jbc.M302111200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869563	hybrid			2022-12-27	WOS:000185575100042
J	Hwang, S; Tamilarasu, N; Kibler, K; Cao, H; Ali, A; Ping, YH; Jeang, KT; Rana, TM				Hwang, S; Tamilarasu, N; Kibler, K; Cao, H; Ali, A; Ping, YH; Jeang, KT; Rana, TM			Discovery of a small molecule Tat-trans-activation-responsive RNA antagonist that potently inhibits human immunodeficiency virus-1 replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG TERMINAL REPEAT; CELLULAR PROTEIN-KINASE; HIV-1 TAR; P-TEFB; TRANSCRIPTION-ELONGATION; IN-VITRO; GENE-EXPRESSION; TYPE-1 TAT; CYCLIN T1; RECOGNITION	Antiretroviral therapy to treat AIDS uses molecules that target the reverse transcriptase and protease enzymes of human immunodeficiency virus, type 1 (HIV-1). A major problem associated with these treatments, however, is the emergence of drug-resistant strains. Thus, there is a compelling need to find drugs against other viral targets. One such target is the interaction between Tat, an HIV-1 regulatory protein essential for viral replication, and trans-activation-responsive (TAR) RNA. Here we describe the design and synthesis of an encoded combinatorial library containing 39,304 unnatural small molecules. Using a rapid high through-put screening technology, we identified 59 compounds. Structure-activity relationship studies led to the synthesis of 19 compounds that bind TAR RNA with high affinities. In the presence of a representative Tat-TAR inhibitor (5 muM TR87), we observed potent and sustained suppression of HIV replication in cultured cells over 24 days. The same concentration of this inhibitor did not exhibit any toxicity in cell cultures or in mice. TR87 was also shown to specifically disrupt Tat-TAR binding in vitro and inhibit Tat-mediated transcriptional activation in vitro and in vivo, providing a strong correlation between its activities and inhibition of HIV-1 replication. These results provide a structural scaffold for further development of new drugs, alone or in combination with other drugs, for treatment of HIV-1-infected individuals. Our results also suggest a general strategy for discovering pharmacophores targeting RNA structures that are essential in progression of other infectious, inflammatory, and genetic diseases.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Chem Biol Program, Worcester, MA 01605 USA; NIAID, Mol Microbiol Lab, NIH, Bethesda, MD 20892 USA	University of Massachusetts System; University of Massachusetts Worcester; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Rana, TM (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Chem Biol Program, 364 Plantat St, Worcester, MA 01605 USA.	tariq.rana@umassmed.edu	Jeang, Kuan-Teh/A-2424-2008	Ping, Yueh-Hsin/0000-0003-2604-9913	NIAID NIH HHS [AI41404, AI45466, R01 AI043198] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043198, Z01AI000547, R56AI041404, R21AI045466, R01AI045466, R01AI041404] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arzumanov A, 2001, BIOCHEMISTRY-US, V40, P14645, DOI 10.1021/bi011279e; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; CHASTAIN M, 1991, PROG NUCLEIC ACID RE, V41, P131; Chow CS, 1997, CHEM REV, V97, P1489, DOI 10.1021/cr960415w; Cullen BR, 1998, CELL, V93, P685, DOI 10.1016/S0092-8674(00)81431-2; DIMITROV DS, 1993, J VIROL, V67, P2182, DOI 10.1128/JVI.67.4.2182-2190.1993; Emerman M, 1998, SCIENCE, V280, P1880, DOI 10.1126/science.280.5371.1880; Filikov AV, 2000, J COMPUT AID MOL DES, V14, P593, DOI 10.1023/A:1008121029716; Gallego J, 2001, ACCOUNTS CHEM RES, V34, P836, DOI 10.1021/ar000118k; Gelus N, 1999, BIOORGAN MED CHEM, V7, P1089, DOI 10.1016/S0968-0896(99)00041-3; Gelus N, 1999, BIOORGAN MED CHEM, V7, P1075, DOI 10.1016/S0968-0896(99)00030-9; Hamy F, 1998, BIOCHEMISTRY-US, V37, P5086, DOI 10.1021/bi972947s; Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548; Hazuda DJ, 2000, SCIENCE, V287, P646, DOI 10.1126/science.287.5453.646; Hermann T, 1998, CURR OPIN BIOTECH, V9, P66, DOI 10.1016/S0958-1669(98)80086-4; HERRMANN CH, 1993, VIROLOGY, V197, P601, DOI 10.1006/viro.1993.1634; HERRMANN CH, 1995, J VIROL, V69, P1612, DOI 10.1128/JVI.69.3.1612-1620.1995; HUANG LM, 1994, EMBO J, V13, P2886, DOI 10.1002/j.1460-2075.1994.tb06583.x; Huq I, 1999, BIOCHEMISTRY-US, V38, P5172, DOI 10.1021/bi982638h; Hwang S, 1999, P NATL ACAD SCI USA, V96, P12997, DOI 10.1073/pnas.96.23.12997; JAKOBOVITS A, 1988, MOL CELL BIOL, V8, P2555, DOI 10.1128/MCB.8.6.2555; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Jones KA, 1997, GENE DEV, V11, P2593, DOI 10.1101/gad.11.20.2593; Karn J, 1999, J MOL BIOL, V293, P235, DOI 10.1006/jmbi.1999.3060; Keen NJ, 1996, P NATL ACAD SCI USA, V93, P2505, DOI 10.1073/pnas.93.6.2505; KUPPUSWAMY M, 1989, NUCLEIC ACIDS RES, V17, P3551, DOI 10.1093/nar/17.9.3551; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Li K, 1997, BIOORGAN MED CHEM, V5, P1157; Lind KE, 2002, CHEM BIOL, V9, P185, DOI 10.1016/S1074-5521(02)00106-0; Litovchick A, 2001, BIOCHEMISTRY-US, V40, P15612, DOI 10.1021/bi0108655; MADORE SJ, 1993, J VIROL, V67, P3703, DOI 10.1128/JVI.67.7.3703-3711.1993; Mancebo HSY, 1997, GENE DEV, V11, P2633, DOI 10.1101/gad.11.20.2633; Mei HY, 1997, BIOORGAN MED CHEM, V5, P1173, DOI 10.1016/S0968-0896(97)00064-3; Mei HY, 1998, BIOCHEMISTRY-US, V37, P14204, DOI 10.1021/bi981308u; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; Ping YH, 2001, J BIOL CHEM, V276, P12951, DOI 10.1074/jbc.M006130200; Ping YH, 1999, J BIOL CHEM, V274, P7399, DOI 10.1074/jbc.274.11.7399; Rana TM, 1999, ARCH BIOCHEM BIOPHYS, V365, P175, DOI 10.1006/abbi.1999.1206; ROSEN CA, 1985, CELL, V41, P813, DOI 10.1016/S0092-8674(85)80062-3; Segal JA, 1999, BRAIN RES, V815, P270, DOI 10.1016/S0006-8993(98)01123-8; Sucheck SJ, 2000, CURR OPIN CHEM BIOL, V4, P678, DOI 10.1016/S1367-5931(00)00142-3; Taube R, 1999, VIROLOGY, V264, P245, DOI 10.1006/viro.1999.9944; Wang XL, 1997, J AM CHEM SOC, V119, P6444, DOI 10.1021/ja963895h; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200; Zhu YR, 1997, GENE DEV, V11, P2622, DOI 10.1101/gad.11.20.2622; ZUCKERMANN RN, 1992, J AM CHEM SOC, V114, P10646, DOI 10.1021/ja00052a076	49	69	74	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39092	39103		10.1074/jbc.M301749200	http://dx.doi.org/10.1074/jbc.M301749200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857725	hybrid			2022-12-27	WOS:000185575100123
J	Miura-Shimura, Y; Duan, L; Rao, NL; Reddi, AL; Shimura, H; Rottapel, R; Druker, BJ; Tsygankov, AY; Band, V; Band, H				Miura-Shimura, Y; Duan, L; Rao, NL; Reddi, AL; Shimura, H; Rottapel, R; Druker, BJ; Tsygankov, AY; Band, V; Band, H			Cbl-mediated ubiquitinylation and negative regulation of Vav	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; PHOSPHOTYROSINE-BINDING DOMAIN; T-CELL-RECEPTOR; SYK TYROSINE KINASE; C-CBL; SIGNAL-TRANSDUCTION; PROTOONCOGENE PRODUCT; RING FINGER; PHOSPHORYLATION SITE; DOWN-MODULATION	The Cbl ubiquitin ligase has emerged as a negative regulator of receptor and non-receptor tyrosine kinases. Cbl is known to associate with the proto-oncogene product Vav, a hematopoietic-restricted Rac guanine nucleotide exchange factor, but the consequences of this interaction remain to be elucidated. Using immortalized T cell lines from Cbl(+/+) and Cbl(-/-) mice, and transfection analyses in 293T cells, we demonstrate that Vav undergoes Cbl-dependent ubiquitinylation under conditions that promote Cbl and Vav phosphorylation. Interaction with Cbl also induced the loss of phosphorylated Vav. In addition, we show that an activated Vav mutant (Vav-Y174F) is more sensitive to Cbl-dependent ubiquitinylation. We demonstrate that the Cbl-dependent ubiquitinylation of Vav requires Cbl/Vav association through phosphorylated Tyr-700 on Cbl, and also requires an intact Cbl RING finger domain. Finally, using transfection analyses in the Jurkat T cell line, we show that Cbl, but not its ubiquitin ligase mutant, can inhibit Vav-dependent signaling. Thus, our findings strongly support the role of Cbl, via its ubiquitin ligase activity, as a negative regulator of activated Vav.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Ctr Neurol Dis, Boston, MA 02115 USA; Princess Margaret Hosp, Ontario Canc Inst, Toronto, ON M5G 2M9, Canada; Oregon Hlth & Sci Univ, Portland, OR 97239 USA; Tufts Univ, New England Med Ctr, Dept Radiat & Canc Biol, Boston, MA 02111 USA; Temple Univ, Sch Med, Dept Microbiol Immunol, Philadelphia, PA 19140 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; Oregon Health & Science University; Tufts Medical Center; Tufts University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Band, H (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Med, ENH Res Inst,Div Mol Oncol, 1001 Univ Pl, Evanston, IL 60201 USA.	h-band@northwestern.edu	shimura, hideki/AAA-2864-2020; Tsygankov, Alexander Y/K-6205-2017	Druker, Brian/0000-0001-8331-8206; Rottapel, Robert/0000-0002-6024-5558	NCI NIH HHS [CA76118, CA75075, CA70195, CA99900, CA99163, CA87986, CA81076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070195, R01CA099900, R01CA087986, R01CA099163, R01CA081076, R01CA076118, R01CA075075] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aghazadeh B, 2000, CELL, V102, P625, DOI 10.1016/S0092-8674(00)00085-4; Andoniou CE, 2000, MOL CELL BIOL, V20, P851, DOI 10.1128/MCB.20.3.851-867.2000; Bachmaier K, 2000, NATURE, V403, P211, DOI 10.1038/35003228; Bustelo XR, 1996, CRIT REV ONCOGENESIS, V7, P65, DOI 10.1615/CritRevOncog.v7.i1-2.50; BUSTELO XR, 1992, NATURE, V356, P68, DOI 10.1038/356068a0; BUSTELO XR, 1992, SCIENCE, V256, P1196, DOI 10.1126/science.256.5060.1196; Chiang YPJ, 2000, NATURE, V403, P216, DOI 10.1038/35003235; Coux O, 1996, ANNU REV BIOCHEM, V65, P801, DOI 10.1146/annurev.bi.65.070196.004101; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; De Sepulveda P, 2000, J BIOL CHEM, V275, P14005, DOI 10.1074/jbc.C000106200; Deckert M, 1996, IMMUNITY, V5, P591, DOI 10.1016/S1074-7613(00)80273-3; Deckert M, 1998, J BIOL CHEM, V273, P8867, DOI 10.1074/jbc.273.15.8867; Fang D, 2001, J BIOL CHEM, V276, P4872, DOI 10.1074/jbc.M008901200; Fang DY, 2001, NAT IMMUNOL, V2, P870, DOI 10.1038/ni0901-870; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Fischer KD, 1998, CURR BIOL, V8, P554, DOI 10.1016/S0960-9822(98)70224-6; FISCHER KD, 1995, NATURE, V374, P474, DOI 10.1038/374474a0; FLIER JS, 1989, NEW ENGL J MED, V321, P1383, DOI 10.1056/NEJM198911163212007; Germani A, 1999, MOL CELL BIOL, V19, P3798; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Han JW, 1997, MOL CELL BIOL, V17, P1346, DOI 10.1128/MCB.17.3.1346; Hawash IY, 2002, J BIOL CHEM, V277, P5683, DOI 10.1074/jbc.M110002200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; HOLSINGER LJ, 1995, P NATL ACAD SCI USA, V92, P9810, DOI 10.1073/pnas.92.21.9810; Holsinger LJ, 1998, CURR BIOL, V8, P563, DOI 10.1016/S0960-9822(98)70225-8; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; Kaminuma O, 2001, MOL CELL BIOL, V21, P3126, DOI 10.1128/MCB.21.9.3126-3136.2001; KATZAV S, 1989, EMBO J, V8, P2283, DOI 10.1002/j.1460-2075.1989.tb08354.x; Krawczyk C, 2000, IMMUNITY, V13, P463, DOI 10.1016/S1074-7613(00)00046-7; Kuhne MR, 2000, J BIOL CHEM, V275, P2185, DOI 10.1074/jbc.275.3.2185; Lee PSW, 1999, EMBO J, V18, P3616, DOI 10.1093/emboj/18.13.3616; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Levkowitz G, 1999, MOL CELL, V4, P1029, DOI 10.1016/S1097-2765(00)80231-2; Lill NL, 2000, J BIOL CHEM, V275, P367, DOI 10.1074/jbc.275.1.367; Liu YC, 2002, TRENDS IMMUNOL, V23, P140, DOI 10.1016/S1471-4906(01)02157-3; Lopez-Lago M, 2000, MOL CELL BIOL, V20, P1678, DOI 10.1128/MCB.20.5.1678-1691.2000; Lupher ML, 1999, IMMUNOL TODAY, V20, P375, DOI 10.1016/S0167-5699(99)01484-X; Lupher ML, 1998, J BIOL CHEM, V273, P35273, DOI 10.1074/jbc.273.52.35273; Lupher ML, 1996, J BIOL CHEM, V271, P24063, DOI 10.1074/jbc.271.39.24063; Lupher ML, 1997, J BIOL CHEM, V272, P33140, DOI 10.1074/jbc.272.52.33140; Marengere LEM, 1997, J IMMUNOL, V159, P70; Meng WY, 1999, NATURE, V398, P84, DOI 10.1038/18050; Miyake S, 1997, CRIT REV ONCOGENESIS, V8, P189, DOI 10.1615/CritRevOncog.v8.i2-3.30; Miyake S, 1998, P NATL ACAD SCI USA, V95, P7927, DOI 10.1073/pnas.95.14.7927; Montaner S, 1998, J BIOL CHEM, V273, P12779, DOI 10.1074/jbc.273.21.12779; Movilla N, 1999, MOL CELL BIOL, V19, P7870; Murphy MA, 1998, MOL CELL BIOL, V18, P4872, DOI 10.1128/MCB.18.8.4872; Naramura M, 2002, NAT IMMUNOL, V3, P1192, DOI 10.1038/ni855; Ota S, 2000, J BIOL CHEM, V275, P414, DOI 10.1074/jbc.275.1.414; Rao N, 2002, J LEUKOCYTE BIOL, V71, P753; Rao N, 2001, EMBO J, V20, P7085, DOI 10.1093/emboj/20.24.7085; Rao N, 2000, J IMMUNOL, V164, P4616, DOI 10.4049/jimmunol.164.9.4616; RAO N, 2002, SIGNAL TRANSDUCTION, V1, P29; Rao NV, 2002, P NATL ACAD SCI USA, V99, P3794, DOI 10.1073/pnas.062055999; Schuebel KE, 1996, ONCOGENE, V13, P363; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; TARAKHOVSKY A, 1995, NATURE, V374, P467, DOI 10.1038/374467a0; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Thien CBF, 2003, J EXP MED, V197, P503, DOI 10.1084/jem.20021498; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Tsygankov AY, 2001, ONCOGENE, V20, P6382, DOI 10.1038/sj.onc.1204781; Turner M, 2002, NAT REV IMMUNOL, V2, P476, DOI 10.1038/nri840; Waterman H, 1999, J BIOL CHEM, V274, P22151, DOI 10.1074/jbc.274.32.22151; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; WU J, 1995, MOL CELL BIOL, V15, P4337; Yokouchi M, 1999, J BIOL CHEM, V274, P31707, DOI 10.1074/jbc.274.44.31707; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	67	49	51	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38495	38504		10.1074/jbc.M305656200	http://dx.doi.org/10.1074/jbc.M305656200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881521	hybrid			2022-12-27	WOS:000185575100051
J	Ferrari, G; Rossi, R; Arosio, D; Vindigni, A; Biamonti, G; Montecucco, A				Ferrari, G; Rossi, R; Arosio, D; Vindigni, A; Biamonti, G; Montecucco, A			Cell cycle-dependent phosphorylation of human DNA ligase I at the cyclin-dependent kinase sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ALPHA-PRIMASE; REPLICATION FACTORIES; NUCLEAR ANTIGEN; SEQUENCE; PCNA; PROTEINS; BINDING; CLONING; DIRECTS; DOMAIN	We have described previously that, during S-phase, human DNA ligase I is phosphorylated on Ser(66), a casein kinase II site. Here we investigate the phosphorylation status of DNA ligase I during the cell cycle by gel shift analysis and electrospray mass spectrometry. We show that three residues (Ser(51), Ser(76), and Ser(91)), which are part of cyclin-dependent kinase sites, are phosphorylated in a cell cycle-dependent manner. Phosphorylation of Ser(91) occurs at G(1)/S transition and depends on a cyclin binding site in the C-terminal part of the protein. This modification is required for the ensuing phosphorylation of Ser(76) detectable in G(2)/M extracts. The substitution of serines at positions 51, 66, 76, and 91 with aspartic acid to mimic the phosphorylated enzyme hampers the association of DNA ligase I with the replication foci. We suggest that the phosphorylation of DNA ligase I and possibly other replicative enzymes is part of the mechanism that directs the disassembly of the replication machinery at the completion of S-phase.	CNR, Ist Genet Mol, I-27100 Pavia, Italy; Int Ctr Genet Engn & Biotechnol, I-34012 Trieste, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); International Center for Genetic Engineering & Biotechnology (ICGEB)	Montecucco, A (corresponding author), CNR, Ist Genet Mol, Via Abbiategrasso 207, I-27100 Pavia, Italy.	montecucco@igm.cnr.it	arosio, daniele/B-3160-2012; Montecucco, Alessandra/B-8041-2015; Ferrari, Giovanni/F-7125-2010; Ferrari, Giovanni/A-3390-2009	Montecucco, Alessandra/0000-0002-9388-9149; BIAMONTI, GIUSEPPE/0000-0001-6804-4315; Ferrari, Giovanni/0000-0002-8863-2496				BARNES DE, 1990, P NATL ACAD SCI USA, V87, P6679, DOI 10.1073/pnas.87.17.6679; Cardoso MC, 1997, J CELL BIOL, V139, P579, DOI 10.1083/jcb.139.3.579; CARDOSO MC, 1993, CELL, V74, P979, DOI 10.1016/0092-8674(93)90721-2; Dehde S, 2001, MOL CELL BIOL, V21, P2581, DOI 10.1128/MCB.21.7.2581-2593.2001; Dimitrova DS, 2000, NAT CELL BIOL, V2, P686, DOI 10.1038/35036309; Frouin I, 2003, EMBO REP, V4, P666, DOI 10.1038/sj.embor.embor886; Frouin I, 2002, EMBO J, V21, P2485, DOI 10.1093/emboj/21.10.2485; Henneke G, 2003, EMBO REP, V4, P252, DOI 10.1038/sj.embor.embor774; HOZAK P, 1994, J CELL SCI, V107, P2191; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; Koundrioukoff S, 2000, J BIOL CHEM, V275, P22882, DOI 10.1074/jbc.M001850200; KRUDE T, 1995, EXP CELL RES, V220, P304, DOI 10.1006/excr.1995.1320; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leonhardt H, 2000, J CELL BIOL, V149, P271, DOI 10.1083/jcb.149.2.271; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; Levin DS, 2000, CURR BIOL, V10, P919, DOI 10.1016/S0960-9822(00)00619-9; Levin DS, 1997, P NATL ACAD SCI USA, V94, P12863, DOI 10.1073/pnas.94.24.12863; Mackenney VJ, 1997, J BIOL CHEM, V272, P11550; Martin IV, 2002, GENOME BIOL, V3; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; MONTECUCCO A, 1995, EMBO J, V14, P5379, DOI 10.1002/j.1460-2075.1995.tb00222.x; Montecucco A, 2001, MOL BIOL CELL, V12, P2109, DOI 10.1091/mbc.12.7.2109; Montecucco A, 1998, EMBO J, V17, P3786, DOI 10.1093/emboj/17.13.3786; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; Ott RD, 2002, MOL CELL BIOL, V22, P5669, DOI 10.1128/MCB.22.16.5669-5678.2002; PETRINI JHJ, 1995, MOL CELL BIOL, V15, P4303; PRIGENT C, 1992, EMBO J, V11, P2925, DOI 10.1002/j.1460-2075.1992.tb05362.x; Rossi R, 1999, EMBO J, V18, P5745, DOI 10.1093/emboj/18.20.5745; SAVINI E, 1994, GENE, V144, P253, DOI 10.1016/0378-1119(94)90386-7; Schub O, 2001, J BIOL CHEM, V276, P38076; Stein Gary S., 1989, P133; Takeda DY, 2001, J BIOL CHEM, V276, P1993, DOI 10.1074/jbc.M005719200; Tom S, 2001, J BIOL CHEM, V276, P24817, DOI 10.1074/jbc.M101673200; TOMKINSON AE, 1990, J BIOL CHEM, V265, P12611; Tomkinson AE, 1997, BIOESSAYS, V19, P893, DOI 10.1002/bies.950191009; Warbrick E, 1998, BIOESSAYS, V20, P195, DOI 10.1002/(SICI)1521-1878(199803)20:3<195::AID-BIES2>3.0.CO;2-R	37	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37761	37767		10.1074/jbc.M304462200	http://dx.doi.org/10.1074/jbc.M304462200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851383	hybrid			2022-12-27	WOS:000185437200094
J	He, M; Burghardt, TP; Vockley, J				He, M; Burghardt, TP; Vockley, J			A novel approach to the characterization of substrate specificity in short/branched chain Acyl-CoA dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A DEHYDROGENASE; RAT-LIVER MITOCHONDRIA; CRYSTAL-STRUCTURES; MOLECULAR-CLONING; CATALYTIC RESIDUE; BETA-OXIDATION; WILD-TYPE; PURIFICATION; IDENTIFICATION; MECHANISM	Rat and human short/branched chain acyl-CoA dehydrogenases exhibit key differences in substrate specificity despite an overall amino acid identity of 85% between them. Rat short/branched chain acyl-CoA dehydrogenases ( SBCAD) are more active toward substrates with longer carbon side chains than human SBCAD, whereas the human enzyme utilizes substrates with longer primary carbon chains. The mechanism underlying this difference in substrate specificity was investigated with a novel surface plasmon resonance assay combined with absorbance and circular dichroism spectroscopy, and kinetics analysis of wild type SBCADs and mutants with altered amino acid residues in the substrate binding pocket. Results show that a relatively few amino acid residues are critical for determining the difference in substrate specificity seen between the human and rat enzymes and that alteration of these residues influences different portions of the enzyme mechanism. Molecular modeling of the SBCAD structure suggests that position 104 at the bottom of the substrate binding pocket is important in determining the length of the primary carbon chain that can be accommodated. Conformational changes caused by alteration of residues at positions 105 and 177 directly affect the rate of electron transfer in the dehydrogenation reactions, and are likely transmitted from the bottom of the substrate binding pocket to beta-sheet 3. Differences between the rat and human enzyme at positions 383, 222, and 220 alter substrate specificity without affecting substrate binding. Modeling predicts that these residues combine to determine the distance between the flavin ring of FAD and the catalytic base, without changing the opening of the substrate binding pocket.	Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Dept Biochem & Mol Biol, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Vockley, J (corresponding author), Mayo Clin & Mayo Fdn, Dept Med Genet, Rochester, MN 55905 USA.	vockley@mayo.edu	Vockley, Jerry/B-5210-2016; Vockley, Jerry/AAF-8523-2020	Vockley, Jerry/0000-0002-8180-6457; Vockley, Jerry/0000-0002-8180-6457	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054936] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR049277] Funding Source: Medline; NIDDK NIH HHS [R01 DK54936] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Andresen BS, 2000, AM J HUM GENET, V67, P1095, DOI 10.1086/303105; AOYAMA T, 1995, J CLIN INVEST, V95, P2465, DOI 10.1172/JCI117947; AUER HE, 1980, J BIOL CHEM, V255, P8157; Battaile KP, 1996, BIOCHEMISTRY-US, V35, P15356, DOI 10.1021/bi961113r; BATTAILE KP, 1995, AM J HUM GENET, V57, P1001; BECKMANN JD, 1985, BIOCHEMISTRY-US, V24, P3922, DOI 10.1021/bi00336a017; BEINERT H, 1957, J BIOL CHEM, V225, P465; Bennett MJ, 2000, CRIT REV CL LAB SCI, V37, P1, DOI 10.1080/10408360091174169; Binzak B, 1998, BBA-PROTEIN STRUCT M, V1382, P137, DOI 10.1016/S0167-4838(97)00161-1; CUMMINGS JG, 1994, BIOCHEMISTRY-US, V33, P788, DOI 10.1021/bi00169a021; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DJORDJEVIC S, 1995, BIOCHEMISTRY-US, V34, P2163, DOI 10.1021/bi00007a009; ENGEL PC, 1971, BIOCHEM J, V125, P879, DOI 10.1042/bj1250879; FINOCCHIARO G, 1988, J BIOL CHEM, V263, P15773; GHISLA S, 1974, BIOCHEMISTRY-US, V13, P589, DOI 10.1021/bi00700a029; Gibson KM, 2000, PEDIATR RES, V47, P830, DOI 10.1203/00006450-200006000-00025; GOODMAN SI, 1995, HUM MOL GENET, V4, P1493; Gopalan KV, 2002, BIOCHEMISTRY-US, V41, P4638, DOI 10.1021/bi011676p; HALL CL, 1979, J BIOL CHEM, V254, P2023; IKEDA Y, 1985, BIOCHEMISTRY-US, V24, P7192, DOI 10.1021/bi00346a027; IKEDA Y, 1985, J BIOL CHEM, V260, P1326; IKEDA Y, 1983, J BIOL CHEM, V258, P1066; IKEDA Y, 1983, J BIOL CHEM, V258, P9477; IKEDA Y, 1983, J BIOL CHEM, V258, P1077; IZAI K, 1992, J BIOL CHEM, V267, P1027; JOHNSON JK, 1994, BIOCHEMISTRY-US, V33, P4738, DOI 10.1021/bi00181a033; JOHNSON JK, 1993, BIOCHEMISTRY-US, V32, P8004, DOI 10.1021/bi00082a023; Karlsson R, 2000, ANAL BIOCHEM, V278, P1, DOI 10.1006/abio.1999.4406; KARLSSON R, 1994, ANAL BIOCHEM, V221, P142, DOI 10.1006/abio.1994.1390; KIM JJP, 1993, P NATL ACAD SCI USA, V90, P7523, DOI 10.1073/pnas.90.16.7523; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee HJ, 1996, BIOCHEMISTRY-US, V35, P12412, DOI 10.1021/bi9607867; MOHSEN AWA, 1995, BIOCHEMISTRY-US, V34, P10146, DOI 10.1021/bi00032a007; MOHSEN AWA, 1995, GENE, V160, P263, DOI 10.1016/0378-1119(95)00256-6; Mohsen AWA, 2001, MOL GENET METAB, V73, P126, DOI 10.1006/mgme.2001.3183; Nandy A, 1996, BIOCHEM SOC T, V24, P105, DOI 10.1042/bst0240105; Nguyen TV, 2002, BIOCHEMISTRY-US, V41, P11126, DOI 10.1021/bi026030r; Nieba L, 1996, ANAL BIOCHEM, V234, P155, DOI 10.1006/abio.1996.0067; Nishina Y, 1998, J BIOCHEM-TOKYO, V124, P200, DOI 10.1093/oxfordjournals.jbchem.a022081; Pellett JD, 2001, BIOCHEMISTRY-US, V40, P7720, DOI 10.1021/bi010206s; PETERSON KL, 1995, BIOCHEMISTRY-US, V34, P14942, DOI 10.1021/bi00045a039; Peterson KM, 2001, PROTEIN SCI, V10, P1822, DOI 10.1110/ps.51401; Peyser YM, 1997, BIOCHEMISTRY-US, V36, P5170, DOI 10.1021/bi970255y; Rodger A., 2000, SPECTROPHOTOMETRY SP, P99; ROE CR, 2001, METABOLIC MOL BASES, P2297; ROZEN R, 1994, GENOMICS, V24, P280, DOI 10.1006/geno.1994.1617; SCHOPFER LM, 1988, BIOCHEMISTRY-US, V27, P6599, DOI 10.1021/bi00417a059; STENBERG E, 1991, J COLLOID INTERF SCI, V143, P513, DOI 10.1016/0021-9797(91)90284-F; Strickland E H, 1974, CRC Crit Rev Biochem, V2, P113, DOI 10.3109/10409237409105445; Sweetman L., 2001, METABOLIC MOL BASES, P2125; Tamaoki H, 1999, J BIOCHEM, V125, P285, DOI 10.1093/oxfordjournals.jbchem.a022285; THORPE C, 1995, FASEB J, V9, P718, DOI 10.1096/fasebj.9.9.7601336; THORPE C, 1979, BIOCHEMISTRY-US, V18, P331, DOI 10.1021/bi00569a016; THORPE C, 1997, ACYL COA DEHYDROGENA, P597; Tiffany KA, 1997, BIOCHEMISTRY-US, V36, P8455, DOI 10.1021/bi970422u; van Aalten DMF, 2001, J MOL BIOL, V309, P181, DOI 10.1006/jmbi.2001.4749; Vockley J, 2000, METHOD ENZYMOL, V324, P241; Vockley J, 2002, CURR OPIN CLIN NUTR, V5, P601, DOI 10.1097/00075197-200211000-00002; Vockley J, 2002, NEUROMUSCULAR DISORD, V12, P235, DOI 10.1016/S0960-8966(01)00308-X; Willard J, 1996, ARCH BIOCHEM BIOPHYS, V331, P127, DOI 10.1006/abbi.1996.0290; YAO KW, 1993, ANAL BIOCHEM, V214, P528, DOI 10.1006/abio.1993.1534; Zhang J, 2002, BIOCHEM BIOPH RES CO, V297, P1033, DOI 10.1016/S0006-291X(02)02336-7	62	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37974	37986		10.1074/jbc.M306882200	http://dx.doi.org/10.1074/jbc.M306882200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855692	hybrid			2022-12-27	WOS:000185437200119
J	Livingstone-Zatchej, M; Marcionelli, R; Moller, K; de Pril, R; Thoma, F				Livingstone-Zatchej, M; Marcionelli, R; Moller, K; de Pril, R; Thoma, F			Repair of UV lesions in silenced chromatin provides in vivo evidence for a compact chromatin structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; CYCLOBUTANE-PYRIMIDINE DIMERS; NUCLEASE-SENSITIVE REGIONS; NUCLEOSOME CORE PARTICLE; INDUCED DNA LESIONS; SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; NONTRANSCRIBED STRAND; DIFFERENTIAL REPAIR; HISTONE ACETYLATION	Genes positioned close to telomeres in yeast are silenced by a heterochromatin-like structure containing Sir proteins. To investigate whether silencing also affects DNA repair, we studied removal of UV lesions by photolyase and nucleotide excision repair (NER) in strains containing the URA3 gene inserted 2 kilobases from a telomere. URA3 was transcriptionally active in sir3Delta mutants, partially silenced in SIR3 cells, or completely silenced by overexpression of SIR3 or deletion of RPD3. The active URA3 showed efficient repair by both pathways. Fast repair of the promoter and 3' end by photolyase reflected a non-nucleosomal structure. Partial silencing had no remarkable effect on photolyase but reduced repair by NER, indicating differential accessibility for the two repair reactions. Complete silencing inhibits NER and photolyase in the coding region as well as in the promoter and the 3'-end. Conventional nuclease footprinting analyses revealed subtle changes in the promoter proximal nucleosome under partially silenced conditions but a pronounced reorganization of chromatin extending over the whole gene in silenced chromatin. Thus, both repair systems are sensitive to chromatin changes associated with silencing and provide direct evidence for a compact structure of heterochromatin.	ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Thoma, F (corresponding author), ETH Honggerberg, Inst Zellbiol, CH-8093 Zurich, Switzerland.							Aboussekhra A, 1998, GENE DEV, V12, P411, DOI 10.1101/gad.12.3.411; Andrulis ED, 1998, NATURE, V394, P592, DOI 10.1038/29100; APARICIO OM, 1994, GENE DEV, V8, P1133, DOI 10.1101/gad.8.10.1133; BANG DD, 1992, NUCLEIC ACIDS RES, V20, P3925, DOI 10.1093/nar/20.15.3925; Braunstein M, 1996, MOL CELL BIOL, V16, P4349; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; CAVALLI G, 1993, EMBO J, V12, P4603, DOI 10.1002/j.1460-2075.1993.tb06149.x; Conconi A, 2002, P NATL ACAD SCI USA, V99, P649, DOI 10.1073/pnas.022373099; de Bruin D, 2000, MOL CELL BIOL, V20, P7991, DOI 10.1128/MCB.20.21.7991-8000.2000; de Bruin D, 2001, NATURE, V409, P109, DOI 10.1038/35051119; DeRubertis F, 1996, NATURE, V384, P589; Dhillon N, 2002, CURR OPIN GENET DEV, V12, P188, DOI 10.1016/S0959-437X(02)00285-X; FRIEDBERG EC, 1995, DNA REPAIR MUTAGENES; Gaillard H, 2003, J BIOL CHEM, V278, P17655, DOI 10.1074/jbc.M300770200; Gasser SM, 2001, GENE, V279, P1, DOI 10.1016/S0378-1119(01)00741-7; Gotta M, 1996, EXPERIENTIA, V52, P1136, DOI 10.1007/BF01952113; Gotta M, 1996, J CELL BIOL, V134, P1349, DOI 10.1083/jcb.134.6.1349; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1997, CURR OPIN CELL BIOL, V9, P383, DOI 10.1016/S0955-0674(97)80011-7; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Hara R, 2002, MOL CELL BIOL, V22, P6779, DOI 10.1128/MCB.22.19.6779-6787.2002; Hara R, 2000, MOL CELL BIOL, V20, P9173, DOI 10.1128/MCB.20.24.9173-9181.2000; HECHT A, 1995, CELL, V80, P583, DOI 10.1016/0092-8674(95)90512-X; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; HUANG JC, 1994, J BIOL CHEM, V269, P19034; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; Kimura A, 2002, NAT GENET, V32, P370, DOI 10.1038/ng993; Kosmoski JV, 1999, BIOCHEMISTRY-US, V38, P9485, DOI 10.1021/bi990297h; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; LivingstoneZatchej M, 1997, NUCLEIC ACIDS RES, V25, P3795, DOI 10.1093/nar/25.19.3795; LOHR D, 1977, BIOCHEMISTRY-US, V16, P463, DOI 10.1021/bi00622a020; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luo KH, 2002, GENE DEV, V16, P1528, DOI 10.1101/gad.988802; Maillet L, 1996, GENE DEV, V10, P1796, DOI 10.1101/gad.10.14.1796; Martin SG, 1999, CELL, V97, P621, DOI 10.1016/S0092-8674(00)80773-4; Meier A, 2002, J BIOL CHEM, V277, P11845, DOI 10.1074/jbc.M110941200; MELLON I, 1987, CELL, V51, P241, DOI 10.1016/0092-8674(87)90151-6; Mills KD, 1999, CELL, V97, P609, DOI 10.1016/S0092-8674(00)80772-2; Moazed D, 2001, MOL CELL, V8, P489, DOI 10.1016/S1097-2765(01)00340-9; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; PALLADINO F, 1993, CELL, V75, P543, DOI 10.1016/0092-8674(93)90388-7; Park JH, 2002, NAT GENET, V32, P273, DOI 10.1038/ng982; Park Y, 2000, GENETICS, V154, P587; Prakash S, 2000, MUTAT RES-FUND MOL M, V451, P13, DOI 10.1016/S0027-5107(00)00037-3; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; Ravindra A, 1999, MOL CELL BIOL, V19, P7944; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; Sancar A, 1996, SCIENCE, V272, P48, DOI 10.1126/science.272.5258.48; Sancar GB, 2000, MUTAT RES-FUND MOL M, V451, P25, DOI 10.1016/S0027-5107(00)00038-5; Schieferstein U, 1998, EMBO J, V17, P306, DOI 10.1093/emboj/17.1.306; Sekinger EA, 1999, EMBO J, V18, P7041, DOI 10.1093/emboj/18.24.7041; Singer MS, 1998, GENETICS, V150, P613; SMERDON MJ, 1990, CELL, V61, P675, DOI 10.1016/0092-8674(90)90479-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sun ZW, 1999, GENETICS, V152, P921; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Suter B, 2000, NUCLEIC ACIDS RES, V28, P4083, DOI 10.1093/nar/28.21.4083; Suter B, 2000, NUCLEIC ACIDS RES, V28, P2060, DOI 10.1093/nar/28.10.2060; Suter B, 1997, EMBO J, V16, P2150, DOI 10.1093/emboj/16.8.2150; Suter B, 1999, METHOD ENZYMOL, V304, P447; Suter B, 2002, J MOL BIOL, V319, P395, DOI 10.1016/S0022-2836(02)00291-7; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; Tanaka S, 1996, J MOL BIOL, V257, P919, DOI 10.1006/jmbi.1996.0212; TERLETH C, 1989, NUCLEIC ACIDS RES, V17, P4433, DOI 10.1093/nar/17.12.4433; TERLETH C, 1990, MOL CELL BIOL, V10, P4678, DOI 10.1128/MCB.10.9.4678; Tham WH, 2001, MOL CELL, V8, P189, DOI 10.1016/S1097-2765(01)00287-8; Tham WH, 2002, ONCOGENE, V21, P512, DOI 10.1038/sj.onc.1205078; THOMA F, 1986, J MOL BIOL, V190, P177, DOI 10.1016/0022-2836(86)90291-3; Thoma F, 1999, EMBO J, V18, P6585, DOI 10.1093/emboj/18.23.6585; THOMA F, 1984, J MOL BIOL, V177, P715, DOI 10.1016/0022-2836(84)90046-9; Thoma F, 1996, METHOD ENZYMOL, V274, P197; Tijsterman M, 1999, MOL CELL BIOL, V19, P934; Ura K, 2001, EMBO J, V20, P2004, DOI 10.1093/emboj/20.8.2004; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Vega-Palas MA, 1998, J BIOL CHEM, V273, P9388, DOI 10.1074/jbc.273.16.9388; VERHAGE R, 1994, MOL CELL BIOL, V14, P6135, DOI 10.1128/MCB.14.9.6135; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WATERS R, 1993, MOL GEN GENET, V239, P28, DOI 10.1007/BF00281597; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392; Wellinger RE, 1997, EMBO J, V16, P5046, DOI 10.1093/emboj/16.16.5046; White CL, 2001, EMBO J, V20, P5207, DOI 10.1093/emboj/20.18.5207; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	85	30	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37471	37479		10.1074/jbc.M306335200	http://dx.doi.org/10.1074/jbc.M306335200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12882973	hybrid			2022-12-27	WOS:000185437200060
J	Paria, BC; Malik, AB; Kwiatek, AM; Rahman, A; May, MJ; Ghosh, S; Tiruppathi, C				Paria, BC; Malik, AB; Kwiatek, AM; Rahman, A; May, MJ; Ghosh, S; Tiruppathi, C			Tumor necrosis factor-alpha induces nuclear factor-kappa B-dependent TRPC1 expression in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THROMBIN-INDUCED INCREASE; OPERATED CATION CHANNELS; TIME-COURSE; CALCIUM; PERMEABILITY; ACTIVATION; RECEPTORS; ENTRY; GENE; HISTAMINE	We investigated the role of tumor necrosis factor-alpha (TNF-alpha) in activating the store-operated Ca2+ channels in endothelial cells via the expression of transient receptor potential channel (TRPC) isoforms. We observed that TNF-alpha exposure of human umbilical vein endothelial cells resulted in TRPC1 mRNA and protein expression, whereas it had no effect on TRPC3, TRPC4, or TRPC5 expression. The TRPC1 expression was associated with increased Ca2+ influx after intracellular Ca2+ store depletion with either thrombin or thapsigargin. We cloned the 5'-regulatory region of the human TRPC1 (hTRPC1) gene which contained a TATA box and CCAAT sequence close to the transcription initiation site. We also identified four nuclear factor-kappaB (NF-kappaB)-binding sites in the 5'-regulatory region. To address the contribution of NF-kappaB in the mechanism of TRPC1 expression, we determined the effects of TNF-alpha on expression of the reporter luciferase after transfection of hTRPC1 promoter-luciferase (hTRPC1-Pro-Luc) construct in the human dermal microvascular endothelial cell line. Reporter activity increased >4-fold at 4 h after TNF-alpha challenge. TNF-alpha-induced increase in reporter activity was markedly reduced by co-expression of either kinase-defective IKKbeta kinase mutant or non-phosphorylatable IkappaB mutant. Treatment with NEMO-binding domain peptide, which prevents NF-kappaB activation by selectively inhibiting IKKgamma interaction with IKK complex, also blocked the TNF-alpha-induced TRPC1 expression. Thus, TNF-alpha induces TRPC1 expression through an NF-kappaB-dependent pathway in endothelial cells, which can trigger augmented Ca2+ entry following Ca2+ store depletion. The augmented Ca2+ entry secondary to TRPC1 expression may be an important mechanism of endothelial injury induced by TNF-alpha.	Univ Illinois, Coll Med, Dept Pharmacol, Chicago, IL 60612 USA; Yale Univ, Sch Med, Immunol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Yale University; Howard Hughes Medical Institute; Yale University	Tiruppathi, C (corresponding author), Univ Illinois, Coll Med, Dept Pharmacol, M-C 868,835 S Wolcott Ave, Chicago, IL 60612 USA.	tiruc@uic.edu		May, Michael/0000-0002-2485-3716; Malik, Asrar/0000-0002-8205-7128	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045638, T32HL007829] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058531] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32-HL-07829, HL45638] Funding Source: Medline; NIGMS NIH HHS [GM-58531] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amerongen GPV, 1998, CIRC RES, V83, P1115, DOI 10.1161/01.RES.83.11.1115; Boulay G, 1997, J BIOL CHEM, V272, P29672, DOI 10.1074/jbc.272.47.29672; Ellis CA, 1999, J BIOL CHEM, V274, P13718, DOI 10.1074/jbc.274.19.13718; Ellis CA, 1999, AM J PHYSIOL-CELL PH, V276, pC38, DOI 10.1152/ajpcell.1999.276.1.C38; Fan J, 2001, AM J PHYSIOL-LUNG C, V281, pL1037, DOI 10.1152/ajplung.2001.281.5.L1037; Freichel M, 2001, NAT CELL BIOL, V3, P121, DOI 10.1038/35055019; Freichel M, 1999, CELL PHYSIOL BIOCHEM, V9, P270, DOI 10.1159/000016321; GARCIA JGN, 1995, J CELL PHYSIOL, V163, P510, DOI 10.1002/jcp.1041630311; Garg AK, 2002, MOL IMMUNOL, V39, P509, DOI 10.1016/S0161-5890(02)00207-9; Groschner K, 1998, FEBS LETT, V437, P101, DOI 10.1016/S0014-5793(98)01212-5; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LIE X, 2000, J BIOL CHEM, V275, P3403; LUM H, 1992, AM J PHYSIOL, V263, pL219, DOI 10.1152/ajplung.1992.263.2.L219; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; May MJ, 1998, IMMUNOL TODAY, V19, P80, DOI 10.1016/S0167-5699(97)01197-3; May MJ, 2000, SCIENCE, V289, P1550, DOI 10.1126/science.289.5484.1550; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Moore TM, 1998, AM J PHYSIOL-LUNG C, V275, pL574, DOI 10.1152/ajplung.1998.275.3.L574; Moy AB, 1996, J CLIN INVEST, V97, P1020, DOI 10.1172/JCI118493; Nilius B, 2001, PHYSIOL REV, V81, P1415, DOI 10.1152/physrev.2001.81.4.1415; PARIA BC, 2002, FASEB J, V16; Prajapati S, 2002, J BIOL CHEM, V277, P24331, DOI 10.1074/jbc.M201393200; Putney JW, 1999, P NATL ACAD SCI USA, V96, P14669, DOI 10.1073/pnas.96.26.14669; Rahman A, 2000, AM J PHYSIOL-CELL PH, V279, pC906, DOI 10.1152/ajpcell.2000.279.4.C906; Sandoval R, 2001, AM J PHYSIOL-LUNG C, V280, pL239, DOI 10.1152/ajplung.2001.280.2.L239; Sandoval R, 2001, J PHYSIOL-LONDON, V533, P433, DOI 10.1111/j.1469-7793.2001.0433a.x; Tiruppathi C, 2002, CIRC RES, V91, P70, DOI 10.1161/01.RES.0000023391.40106.A8; Tiruppathi C, 2001, AM J PHYSIOL-LUNG C, V281, pL958, DOI 10.1152/ajplung.2001.281.4.L958; Tiruppathi C, 2000, P NATL ACAD SCI USA, V97, P7440, DOI 10.1073/pnas.97.13.7440; Tiruppathi C, 2002, VASC PHARMACOL, V39, P173, DOI 10.1016/S1537-1891(03)00007-7; Vanhauwe JF, 2002, J BIOL CHEM, V277, P34143, DOI 10.1074/jbc.M204477200; Vogel SM, 2000, PHYSIOL GENOMICS, V4, P137, DOI 10.1152/physiolgenomics.2000.4.2.137; Wang WC, 1999, AM J PHYSIOL-CELL PH, V276, pC969, DOI 10.1152/ajpcell.1999.276.4.C969; Zazopoulos E, 1997, NATURE, V390, P311, DOI 10.1038/36899; Zhu X, 1998, J BIOL CHEM, V273, P133, DOI 10.1074/jbc.273.1.133	35	74	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37195	37203		10.1074/jbc.M304287200	http://dx.doi.org/10.1074/jbc.M304287200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855710	hybrid			2022-12-27	WOS:000185437200027
J	Yago, T; Leppanen, A; Carlyon, JA; Akkoyunlu, M; Karmakar, S; Fikrig, E; Cummings, RD; McEver, RP				Yago, T; Leppanen, A; Carlyon, JA; Akkoyunlu, M; Karmakar, S; Fikrig, E; Cummings, RD; McEver, RP			Structurally distinct requirements for binding of P-selectin glycoprotein ligand-1 and sialyl Lewis x to Anaplasma phagocytophilum and P-selectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GRANULOCYTIC EHRLICHIOSIS; TICK-BORNE INFECTIONS; N-TERMINAL RESIDUES; LINKED OLIGOSACCHARIDES; LEUKOCYTE RECRUITMENT; TYROSINE SULFATION; HUMAN NEUTROPHILS; AMINO-TERMINUS; UNITED-STATES; MYELOID CELLS	Colonization of neutrophils by the bacterium Anaplasma phagocytophilum causes the disease human granulocytic ehrlichiosis. The pathogen also infects mice, its natural host. Like binding of P-selectin, binding of A. phagocytophilum to human neutrophils requires expression of P-selectin glycoprotein ligand-1 (PSGL-1) and alpha1-3-fucosyltransferases that construct the glycan determinant sialyl Lewis x (sLe(x)). Binding of A. phagocytophilum to murine neutrophils, however, requires expression of alpha1-3-fucosyltransferases but not PSGL-1. To further characterize the molecular features that A. phagocytophilum recognizes, we measured bacterial binding to microspheres bearing specific glycoconjugates or to cells expressing human PSGL-1 and particular glycosyltransferases. Like P-selectin, A. phagocytophilum bound to purified human PSGL-1 and to glycopeptides modeled after the N terminus of human PSGL-1 that presented sLex on an O-glycan. Unlike P-selectin, A. phagocytophilum bound to glycopeptides that contained sLe(x) but lacked tyrosine sulfation or a specific core-2 orientation of sLe(x) on the O-glycan. A. phagocytophilum bound only to glycopeptides that contained a short amino acid sequence found in the N-terminal region of human but not murine PSGL-1. Unlike P-selectin, A. phagocytophilum bound to cells expressing PSGL-1 in cooperation with sLe(x) on both N- and O-glycans. Moreover, bacteria bound to microspheres coupled independently with glycopeptide lacking sLe(x) and with sLex lacking peptide. These results demonstrate that, unlike P-selectin, A. phagocytophilum binds cooperatively to a nonsulfated N- terminal peptide in human PSGL-1 and to sLe(x) expressed on PSGL-1 or other glycoproteins. Distinct bacterial adhesins may mediate these cooperative interactions.	Univ Oklahoma, Cardiovasc Biol Res Program, Hlth Sci Ctr, Oklahoma Med Res Fdn, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Yale Univ, Sch Med, Dept Internal Med, Rheumatol Sect, New Haven, CT 06520 USA	Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Yale University	McEver, RP (corresponding author), Univ Oklahoma, Cardiovasc Biol Res Program, Hlth Sci Ctr, Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA.		Akkoyunlu, Mustafa/I-5712-2012; Akkoyunlu, Mustafa/ABC-9013-2020	Akkoyunlu, Mustafa/0000-0001-9958-4031	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041440, R01AI048075, R21AI054630, R21AI041440, F32AI010554, R56AI041440] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 65631] Funding Source: Medline; NIAID NIH HHS [AI 041440, AI 054630, AI 48075, AI 10554] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AgueroRosenfeld ME, 1996, ANN INTERN MED, V125, P904, DOI 10.7326/0003-4819-125-11-199612010-00006; Akkoyunlu M, 2000, INFECT IMMUN, V68, P1827, DOI 10.1128/IAI.68.4.1827-1833.2000; BAKKEN JS, 1994, JAMA-J AM MED ASSOC, V272, P212, DOI 10.1001/jama.272.3.212; Borges E, 1997, BLOOD, V90, P1934, DOI 10.1182/blood.V90.5.1934; Brunk DK, 1997, BIOPHYS J, V72, P2820, DOI 10.1016/S0006-3495(97)78924-0; CARLYON JA, 2003, IN PRESS BLOOD; CHEN SM, 1994, AM J TROP MED HYG, V50, P52, DOI 10.4269/ajtmh.1994.50.1.TM0500010052; CUMMINGS RD, 1982, J BIOL CHEM, V257, P1230; DUMLER JS, 1995, CLIN INFECT DIS, V20, P1102, DOI 10.1093/clinids/20.5.1102; Dumler JS, 2001, INT J SYST EVOL MICR, V51, P2145, DOI 10.1099/00207713-51-6-2145; ELBEIN AD, 1990, J BIOL CHEM, V265, P15599; Frenette PS, 2000, J EXP MED, V191, P1413, DOI 10.1084/jem.191.8.1413; Goodman JL, 1999, J CLIN INVEST, V103, P407, DOI 10.1172/JCI4230; HARDALO CJ, 1995, CLIN INFECT DIS, V21, P910, DOI 10.1093/clinids/21.4.910; Herron MJ, 2000, SCIENCE, V288, P1653, DOI 10.1126/science.288.5471.1653; Homeister JW, 2001, IMMUNITY, V15, P115, DOI 10.1016/S1074-7613(01)00166-2; HUANG J, 1992, ONCOL RES, V4, P507; Leppanen A, 2002, J BIOL CHEM, V277, P39749, DOI 10.1074/jbc.M206281200; Leppanen A, 1999, J BIOL CHEM, V274, P24838, DOI 10.1074/jbc.274.35.24838; Leppanen A, 2000, J BIOL CHEM, V275, P39569, DOI 10.1074/jbc.M005005200; Li FG, 1996, J BIOL CHEM, V271, P6342, DOI 10.1074/jbc.271.11.6342; Li FG, 1996, J BIOL CHEM, V271, P3255, DOI 10.1074/jbc.271.6.3255; Liu W, 1998, J BIOL CHEM, V273, P7078, DOI 10.1074/jbc.273.12.7078; Magnarelli LA, 1999, J WILDLIFE DIS, V35, P259, DOI 10.7589/0090-3558-35.2.259; Magnarelli LA, 1997, J WILDLIFE DIS, V33, P466, DOI 10.7589/0090-3558-33.3.466; Mahdavi J, 2002, SCIENCE, V297, P573, DOI 10.1126/science.1069076; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; McEver RP, 1997, J CLIN INVEST, V100, P485, DOI 10.1172/JCI119556; McEver RP, 2001, THROMB HAEMOSTASIS, V86, P746; McEver RP, 2002, CURR OPIN CELL BIOL, V14, P581, DOI 10.1016/S0955-0674(02)00367-8; MOORE KL, 1992, J CELL BIOL, V118, P445, DOI 10.1083/jcb.118.2.445; MOORE KL, 1994, J BIOL CHEM, V269, P23318; MOORE KL, 1995, J CELL BIOL, V128, P661, DOI 10.1083/jcb.128.4.661; NORGARD KE, 1993, J BIOL CHEM, V268, P12764; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; POUYANI T, 1995, CELL, V83, P333, DOI 10.1016/0092-8674(95)90174-4; Ramachandran V, 1999, P NATL ACAD SCI USA, V96, P13771, DOI 10.1073/pnas.96.24.13771; Ravyn MD, 2001, J CLIN MICROBIOL, V39, P335, DOI 10.1128/JCM.39.1.335-338.2001; SAKO D, 1995, CELL, V83, P323, DOI 10.1016/0092-8674(95)90173-6; SAKO D, 1993, CELL, V75, P1179, DOI 10.1016/0092-8674(93)90327-M; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; Vestweber D, 1999, PHYSIOL REV, V79, P181, DOI 10.1152/physrev.1999.79.1.181; Walcheck B, 2002, BLOOD, V99, P4063, DOI 10.1182/blood-2001-12-0265; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888; Walker DH, 1997, ARCH PATHOL LAB MED, V121, P785; WILKINS PP, 1995, J BIOL CHEM, V270, P22677, DOI 10.1074/jbc.270.39.22677; Wilkins PP, 1996, J BIOL CHEM, V271, P18732, DOI 10.1074/jbc.271.31.18732; Xia LJ, 2003, BLOOD, V101, P552, DOI 10.1182/blood-2001-11-0036; Yago T, 2002, J CELL BIOL, V158, P787, DOI 10.1083/jcb.200204041; Yang J, 1996, BLOOD, V87, P4176, DOI 10.1182/blood.V87.10.4176.bloodjournal87104176; ZHOU Q, 1991, J CELL BIOL, V115, P557, DOI 10.1083/jcb.115.2.557	51	41	49	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37987	37997		10.1074/jbc.M305778200	http://dx.doi.org/10.1074/jbc.M305778200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847092	hybrid			2022-12-27	WOS:000185437200120
J	Avraham, HK; Lee, TH; Koh, YH; Kim, TA; Jiang, SX; Sussman, M; Samarel, AM; Avraham, S				Avraham, HK; Lee, TH; Koh, YH; Kim, TA; Jiang, SX; Sussman, M; Samarel, AM; Avraham, S			Vascular endothelial growth factor regulates focal adhesion assembly in human brain microvascular endothelial cells through activation of the focal adhesion kinase and related adhesion focal tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; TRANSENDOTHELIAL MIGRATION; PROTEIN; PHOSPHORYLATION; EXPRESSION; INTEGRIN; ANGIOGENESIS; PERMEABILITY; RECEPTOR; FAK	Vascular endothelial growth factor ( VEGF) plays a significant role in blood-brain barrier breakdown and angiogenesis after brain injury. VEGF-induced endothelial cell migration is a key step in the angiogenic response and is mediated by an accelerated rate of focal adhesion complex assembly and disassembly. In this study, we identified the signaling mechanisms by which VEGF regulates human brain microvascular endothelial cell (HBMEC) integrity and assembly of focal adhesions, complexes comprised of scaffolding and signaling proteins organized by adhesion to the extracellular matrix. We found that VEGF treatment of HBMECs plated on laminin or fibronectin stimulated cytoskeletal organization and increased focal adhesion sites. Pretreating cells with VEGF antibodies or with the specific inhibitor SU-1498, which inhibits Flk-1/KDR receptor phosphorylation, blocked the ability of VEGF to stimulate focal adhesion assembly. VEGF induced the coupling of focal adhesion kinase (FAK) to integrin alpha(v)beta(5) and tyrosine phosphorylation of the cytoskeletal components paxillin and p130(cas). Additionally, FAK and related adhesion focal tyrosine kinase (RAFTK)/Pyk2 kinases were tyrosine-phosphorylated by VEGF and found to be important for focal adhesion sites. Overexpression of wild type RAFTK/Pyk2 increased cell spreading and the migration of HBMECs, whereas overexpression of catalytically inactive mutant RAFTK/Pyk2 markedly suppressed HBMEC spreading (similar to70%), adhesion (similar to82%), and migration (similar to65%). Furthermore, blocking of FAK by the dominant-interfering mutant FRNK (FAK-related non-kinase) significantly inhibited HBMEC spreading and migration and also disrupted focal adhesions. Thus, these studies define a mechanism for the regulatory role of VEGF in focal adhesion complex assembly in HBMECs via activation of FAK and RAFTK/Pyk2.	Beth Israel Deaconess Med Ctr, Dept Med, Div Expt Med & Hematol Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Childrens Hosp & Res Fdn, Div Mol Cardiovasc Biol, Cincinnati, OH 45249 USA; Loyola Univ, Stritch Sch Med, Cardiovasc Inst, Chicago, IL 60601 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; Loyola University Chicago	Avraham, S (corresponding author), Beth Israel Deaconess Med Ctr, Harvard Inst Med, Div Expt Med, 4 Blackfan Circle, Boston, MA 02115 USA.	savraham@bidmc.harvard.edu	Samarel, Allen/Q-9810-2019; Sussman, Mark/H-2284-2014	Samarel, Allen/0000-0001-8765-9884; Avraham, Hava/0000-0002-7545-3640; Sussman, Mark/0000-0002-0104-4799	NCI NIH HHS [CA096805, CA76226] Funding Source: Medline; NHLBI NIH HHS [HL51456] Funding Source: Medline; NINDS NIH HHS [NS39558] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA076226, R01CA096805] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL051456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039558] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abedi H, 1997, J BIOL CHEM, V272, P15442, DOI 10.1074/jbc.272.24.15442; Antonetti DA, 1999, J BIOL CHEM, V274, P23463, DOI 10.1074/jbc.274.33.23463; Astier A, 1997, J BIOL CHEM, V272, P19719, DOI 10.1074/jbc.272.32.19719; Avraham H, 2000, CELL SIGNAL, V12, P123, DOI 10.1016/S0898-6568(99)00076-5; Avraham H, 1999, METHODS, V17, P250, DOI 10.1006/meth.1998.0735; AVRAHAM S, 1995, J BIOL CHEM, V270, P27742, DOI 10.1074/jbc.270.46.27742; Barone FC, 1999, J CEREBR BLOOD F MET, V19, P819, DOI 10.1097/00004647-199908000-00001; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Broday DM, 2000, B MATH BIOL, V62, P891, DOI 10.1006/bulm.2000.0183; Browder T, 2000, J BIOL CHEM, V275, P1521, DOI 10.1074/jbc.275.3.1521; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; Davis S, 1996, CELL, V87, P1161, DOI 10.1016/S0092-8674(00)81812-7; del Zoppo G, 2000, BRAIN PATHOL, V10, P95; DelZoppo GJ, 1997, ANN NY ACAD SCI, V823, P132; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; DeVries HE, 1997, PHARMACOL REV, V49, P143; Eliceiri BP, 1999, MOL CELL, V4, P915, DOI 10.1016/S1097-2765(00)80221-X; Eliceiri BP, 2002, J CELL BIOL, V157, P149, DOI 10.1083/jcb.200109079; Esser S, 1998, J CELL SCI, V111, P1853; FAVA RA, 1994, J EXP MED, V180, P341, DOI 10.1084/jem.180.1.341; FOLKMAN J, 1992, J BIOL CHEM, V267, P10931; FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4; FRIEDLANDER M, 1995, SCIENCE, V270, P1500, DOI 10.1126/science.270.5241.1500; GIRARD PR, 1995, J CELL PHYSIOL, V163, P179, DOI 10.1002/jcp.1041630121; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; Govindarajan G, 2000, CIRC RES, V87, P710, DOI 10.1161/01.RES.87.8.710; GUO DQ, 1995, J BIOL CHEM, V270, P6729, DOI 10.1074/jbc.270.12.6729; Heidkamp MC, 2002, CIRC RES, V90, P1282, DOI 10.1161/01.RES.0000023201.41774.EA; Hiregowdara D, 1997, J BIOL CHEM, V272, P10804; ILLC D, 1995, NATURE, V377, P539; Kevil CG, 1998, J BIOL CHEM, V273, P15099, DOI 10.1074/jbc.273.24.15099; Lee TH, 2003, J BIOL CHEM, V278, P5277, DOI 10.1074/jbc.M210063200; Lee TH, 2002, J BIOL CHEM, V277, P10445, DOI 10.1074/jbc.M107348200; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; Li JZ, 1996, BLOOD, V88, P417, DOI 10.1182/blood.V88.2.417.bloodjournal882417; Melendez J, 2002, J BIOL CHEM, V277, P45203, DOI 10.1074/jbc.M204886200; O'Neill GM, 2000, TRENDS CELL BIOL, V10, P111, DOI 10.1016/S0962-8924(99)01714-6; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Park SY, 2000, J BIOL CHEM, V275, P19768, DOI 10.1074/jbc.M909932199; Parsons JT, 2000, ONCOGENE, V19, P5606, DOI 10.1038/sj.onc.1203877; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; PEER J, 1995, LAB INVEST, V72, P638; PIERCE EA, 1995, P NATL ACAD SCI USA, V92, P905, DOI 10.1073/pnas.92.3.905; Radisavljevic Z, 2000, J BIOL CHEM, V275, P20770, DOI 10.1074/jbc.M002448200; Raja S, 1997, J BIOL CHEM, V272, P10941; Richardson A, 1997, MOL CELL BIOL, V17, P6906, DOI 10.1128/MCB.17.12.6906; Richardson A, 1996, NATURE, V380, P538, DOI 10.1038/380538a0; Rubin LL, 1999, ANNU REV NEUROSCI, V22, P11, DOI 10.1146/annurev.neuro.22.1.11; Salgia R, 1996, J BIOL CHEM, V271, P31222, DOI 10.1074/jbc.271.49.31222; SASAKI H, 1995, J BIOL CHEM, V270, P21206, DOI 10.1074/jbc.270.36.21206; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Senger DR, 1997, P NATL ACAD SCI USA, V94, P13612, DOI 10.1073/pnas.94.25.13612; Shono T, 2001, EXP CELL RES, V264, P275, DOI 10.1006/excr.2001.5154; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Soldi R, 1999, EMBO J, V18, P882, DOI 10.1093/emboj/18.4.882; Sorokin A, 2001, J BIOL CHEM, V276, P21521, DOI 10.1074/jbc.M008869200; Stoletov KV, 2001, J BIOL CHEM, V276, P22748, DOI 10.1074/jbc.M009720200; Takahashi T, 1997, ONCOGENE, V14, P2079, DOI 10.1038/sj.onc.1201047; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yang ZJ, 2002, J NEUROSCI RES, V70, P140, DOI 10.1002/jnr.10380; Yoshiji H, 1996, CANCER RES, V56, P2013	63	121	130	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36661	36668		10.1074/jbc.M301253200	http://dx.doi.org/10.1074/jbc.M301253200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844492	hybrid			2022-12-27	WOS:000185318300097
J	Jacobs, FMJ; van der Heide, LP; Wijchers, PJEC; Burbach, JPH; Hoekman, MFM; Smidt, MP				Jacobs, FMJ; van der Heide, LP; Wijchers, PJEC; Burbach, JPH; Hoekman, MFM; Smidt, MP			FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHORYLATION SITES; ENDOPIRIFORM NUCLEUS; FORKHEAD; FKHR; GENE; CONNECTIONS; INSULIN; PAX3	Forkhead transcription factors of the FoxO-group are associated with cellular processes like cell cycle progression and DNA-repair. FoxO function is regulated by protein kinase B (PKB) via the phosphatidylinositol 3-kinase/PKB survival pathway. Phosphorylation of serine and threonine residues in specific PKB phosphorylation motifs leads to exclusion of FoxO-proteins from the nucleus, which excludes them from exerting transactivating activity. Members of the FoxO-group have three highly conserved regions containing a PKB phosphorylation motif. This study describes the cloning and characterization of a novel forkhead domain gene from mouse that appeared to be highly related to the FoxO group of transcription factors and was therefore designated FoxO6. The FoxO6 gene was mapped in region D1 on mouse chromosome 4. In humans, FOXO6 is located on chromosomal region 1p34.1. Embryonic expression of FoxO6 is most apparent in the developing brain, and FoxO6 is expressed in a specific temporal and spatial pattern. Therefore it is probably involved in regulation of specific cellular differentiation. In the adult animal FoxO6 expression is maintained in areas of the nucleus accumbens, cingulate cortex, parts of the amygdala, and in the hippocampus. Structure function analysis of FoxO6 compared with its group members shows that the overall homology is high, but surprisingly a highly conserved region containing multiple phosphorylation sites is lacking. In transfection studies, FoxO6 coupled to GFP showed an unexpected high nuclear localization after stimulation with growth factors, in contrast to the predominant cytosolic localization of FoxO1 and FoxO3. We also show that nuclear export of FoxO6 is mediated through the phosphatidylinositol 3-kinase/PKB pathway. Furthermore, we show using a chimeric approach that we can fully restore the ability of FoxO6 to shuttle between nucleus and cytosol. In conclusion, the data presented here gives a new view on regulation of FoxO-function through multiple phosphorylation events and other mechanisms involved in the nuclear exclusion of FoxO-proteins.	Univ Med Ctr, Rudolf Magnus Inst Neurosci, Dept Pharmacol & Anat, NL-3584 CG Utrecht, Netherlands	Utrecht University; Utrecht University Medical Center	Smidt, MP (corresponding author), Univ Utrecht, Med Ctr, Rudolf Magnus Inst Neurosci, Dept Pharmacol & Anat, POB 85060, NL-3508 TA Utrecht, Netherlands.	m.p.smidt@med.uu.nl	Jacobs, Frank/GSD-3616-2022; Jacobs, Frank/O-1809-2014	Jacobs, Frank/0000-0003-4423-1479; Smidt, Marten/0000-0002-8815-747X; van der Heide, Lars P./0000-0003-1779-425X				Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Alvarez B, 2001, NATURE, V413, P744, DOI 10.1038/35099574; Behan M, 1999, J COMP NEUROL, V408, P532; Beneyto M, 2001, BRAIN RES BULL, V54, P485, DOI 10.1016/S0361-9230(00)00454-8; Biggs WH, 2001, MAMM GENOME, V12, P416, DOI 10.1007/s003350020002; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 2002, J CELL BIOL, V156, P817, DOI 10.1083/jcb.200112059; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; DAVIS RJ, 1995, HUM MOL GENET, V4, P2355, DOI 10.1093/hmg/4.12.2355; EPSTEIN JA, 1995, J BIOL CHEM, V270, P11719, DOI 10.1074/jbc.270.20.11719; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Kaufmann E, 1996, MECH DEVELOP, V57, P3, DOI 10.1016/0925-4773(96)00539-4; Kops GJPL, 1999, J MOL MED-JMM, V77, P656, DOI 10.1007/s001099900050; Kops GJPL, 2002, NATURE, V419, P316, DOI 10.1038/nature01036; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Nakae J, 2000, EMBO J, V19, P989, DOI 10.1093/emboj/19.5.989; Ogg S, 1997, NATURE, V389, P994, DOI 10.1038/40194; PARRY P, 1994, GENE CHROMOSOME CANC, V11, P79, DOI 10.1002/gcc.2870110203; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Rena G, 2001, BIOCHEM J, V354, P605, DOI 10.1042/0264-6021:3540605; So CW, 2003, BLOOD, V101, P633, DOI 10.1182/blood-2002-06-1785; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Zhang XH, 2002, J BIOL CHEM, V277, P45276, DOI 10.1074/jbc.M208063200	25	260	277	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35959	35967		10.1074/jbc.M302804200	http://dx.doi.org/10.1074/jbc.M302804200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857750	hybrid			2022-12-27	WOS:000185318300013
J	Kojima, H; Kanada, H; Shimizu, S; Kasama, E; Shibuya, K; Nakauchi, H; Nagasawa, T; Shibuya, A				Kojima, H; Kanada, H; Shimizu, S; Kasama, E; Shibuya, K; Nakauchi, H; Nagasawa, T; Shibuya, A			CD226 mediates platelet and megakaryocytic cell adhesion to vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL ASSOCIATION; PROPLATELET FORMATION; ACTIVATED PLATELETS; FORMATION INVITRO; IN-VIVO; INTEGRIN; ESTABLISHMENT; AGGREGATION; FIBRINOGEN; MECHANISM	Platelet adhesion to vascular endothelial cells is a pathophysiologically relevant cell-to-cell interaction. However, the mechanisms underlying this cellular interaction are incompletely understood. In search of the ligand for CD226 adhesion molecule expressed on platelets, we found that human umbilical vein endothelial cells (HUVEC) express significant amount of putative CD226 ligand. We demonstrated that thrombin-activated, but not resting, platelets bind to intact HUVEC. Anti-CD226 monoclonal antibody specifically inhibited the binding, indicating that CD226 mediates the intercellular binding between thrombin-activated platelets and HUVEC. We also demonstrated that platelet activation with thrombin induces tyrosine phosphorylation of CD226 as well as CD226-mediated platelet adhesion. Moreover, experiments using mutant transfectants suggested that the tyrosine at residue 322 of CD226 plays an important role for its adhesive function. CD226 was also expressed on primary megakaryocytes and megakaryocytic cell lines. Anti-CD226 monoclonal antibody inhibited binding of megakaryocytic cell lines to HUVEC. Taken together, these results reveal a novel mechanism for adhesion of platelets and megakaryocytic cells to vascular endothelial cells.	Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Inst Basic Med Sci, Dept Immunol, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Japan Sci & Technol Corp, CREST, Tsukuba, Ibaraki 3058575, Japan; Univ Tsukuba, Japan Sci & Technol Corp, PRESTO, Tsukuba, Ibaraki 3058575, Japan; RIKEN, Res Ctr Allergy & Immunol, Lab Immune Receptor, Tsukuba, Ibaraki 3050074, Japan	University of Tsukuba; University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; Japan Science & Technology Agency (JST); University of Tsukuba; RIKEN	Kojima, H (corresponding author), Univ Tsukuba, Inst Clin Med, Div Hematol, Tsukuba, Ibaraki 3058575, Japan.	hkojima@md.tsukuba.ac.jp						AVRAHAM H, 1993, J CLIN INVEST, V91, P2378, DOI 10.1172/JCI116470; Bombeli T, 1999, BLOOD, V93, P3831, DOI 10.1182/blood.V93.11.3831; Bombeli T, 1998, J EXP MED, V187, P329, DOI 10.1084/jem.187.3.329; ELDOR A, 1989, METHOD ENZYMOL, V169, P76; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Frenette PS, 1998, BLOOD, V91, P1318, DOI 10.1182/blood.V91.4.1318; FRENETTE PS, 1995, P NATL ACAD SCI USA, V92, P7450, DOI 10.1073/pnas.92.16.7450; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; Hamada T, 1998, J EXP MED, V188, P539, DOI 10.1084/jem.188.3.539; Hamazaki Y, 1998, ONCOGENE, V16, P2773, DOI 10.1038/sj.onc.1201799; HARKER LA, 1969, J CLIN INVEST, V48, P963, DOI 10.1172/JCI106077; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; KAUFMAN RM, 1965, BLOOD-J HEMATOL, V26, P720, DOI 10.1182/blood.V26.6.720.720; KITAMURA T, 1995, P NATL ACAD SCI USA, V92, P9146, DOI 10.1073/pnas.92.20.9146; Kojima H, 1995, THROMB HAEMOSTASIS, V74, P1541; Komatsu N, 1996, BLOOD, V87, P4552, DOI 10.1182/blood.V87.11.4552.bloodjournal87114552; LANIER LL, 2000, PROTEIN REV WEB, V1, P68; LEVEN RM, 1995, J CELL PHYSIOL, V163, P597, DOI 10.1002/jcp.1041630321; LEVEN RM, 1992, EXP HEMATOL, V20, P1316; Li JM, 1996, J SURG RES, V61, P543, DOI 10.1006/jsre.1996.0161; Massberg S, 1999, BLOOD, V94, P3829, DOI 10.1182/blood.V94.11.3829.423k35_3829_3838; Massberg S, 1998, BLOOD, V92, P507, DOI 10.1182/blood.V92.2.507; Onishi M, 1996, EXP HEMATOL, V24, P324; Rosenblum WI, 1996, STROKE, V27, P709, DOI 10.1161/01.STR.27.4.709; SATO T, 1989, BRIT J HAEMATOL, V72, P184, DOI 10.1111/j.1365-2141.1989.tb07681.x; SCOTT JL, 1989, J BIOL CHEM, V264, P13475; Shibuya A, 1996, IMMUNITY, V4, P573, DOI 10.1016/S1074-7613(00)70060-4; Shibuya A, 1998, J IMMUNOL, V161, P1671; Shibuya K, 1999, IMMUNITY, V11, P615, DOI 10.1016/S1074-7613(00)80136-3; TABLIN F, 1990, J CELL SCI, V97, P59; TROWBRIDGE EA, 1984, CLIN PHYS PHYSIOL M, V5, P145, DOI 10.1088/0143-0815/5/3/007	31	77	86	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36748	36753		10.1074/jbc.M300702200	http://dx.doi.org/10.1074/jbc.M300702200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847109	hybrid			2022-12-27	WOS:000185318300107
J	Zimmermann, J; Kuhne, R; Volkmer-Engert, R; Jarchau, T; Walter, U; Oschkinat, H; Ball, LJ				Zimmermann, J; Kuhne, R; Volkmer-Engert, R; Jarchau, T; Walter, U; Oschkinat, H; Ball, LJ			Design of N-substituted peptomer ligands for EVH1 domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASODILATOR-STIMULATED PHOSPHOPROTEIN; ACTIN-BASED MOTILITY; PROLINE-RICH MOTIFS; LISTERIA-MONOCYTOGENES; SPOT-SYNTHESIS; CELLULOSE MEMBRANES; FOCAL-ADHESION; AXON GUIDANCE; PROTEINS; ENA/VASP	Ena/VASP proteins are implicated in cytoskeletal reorganization during actin-dependent motility processes. Recruitment to subcellular sites of actin polymerization is mediated by the highly conserved N-terminal EVH1 domain, which interacts with target proteins containing proline-rich motifs. The VASP EVH1 domain specifically binds peptides with the consensus motif FPPPP present in all its binding partners, including the Listerial ActA protein. Previous studies have shown that the Phe and first and final Pro residues are highly conserved and cannot be substituted with any other natural amino acid without significant loss of binding affinity. We have incorporated peptoid building blocks ( sarcosine derived, non-natural amino acids) into the peptide SFEFPPPPTEDEL from the Listerial ActA protein and were able to substitute the most highly conserved residues of this motif while maintaining binding to the VASP EVH1 domain with affinities in the range of 45-180 muM. We then used NMR chemical shift perturbations to locate specific domain residues involved in particular interactions. These studies may open up the way for designing selective modulators of VASP function for biological studies and for the development of novel therapeutics for diseases involving pathologically altered cell adhesion or cell motility.	Forschungsinst Mol Pharmakol, D-13125 Berlin, Germany; Humboldt Univ, Univ Klinikum Charite, Inst Med Immunol, D-10098 Berlin, Germany; Univ Wurzburg, Med Klin, Inst Klin Biochem & Pathobiochem, D-97078 Wurzburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Wurzburg	Ball, LJ (corresponding author), Forschungsinst Mol Pharmakol, Robert Rossle Str 10, D-13125 Berlin, Germany.	ball@fmp-berlin.de	Walter, ulrich/W-2478-2017; Ball, Linda J/E-8454-2011	Walter, ulrich/0000-0001-6784-2307; Ball, Linda J/0000-0002-0948-6954; Oschkinat, Hartmut/0000-0002-4384-9544; Volkmer, Rudolf/0000-0003-4710-1143				Ast T, 1999, TETRAHEDRON LETT, V40, P4317, DOI 10.1016/S0040-4039(99)00775-3; Ball LJ, 2000, EMBO J, V19, P4903, DOI 10.1093/emboj/19.18.4903; Ball LJ, 2002, FEBS LETT, V513, P45, DOI 10.1016/S0014-5793(01)03291-4; Bashaw GJ, 2000, CELL, V101, P703, DOI 10.1016/S0092-8674(00)80883-1; Brindle NPJ, 1996, BIOCHEM J, V318, P753, DOI 10.1042/bj3180753; Cameron LA, 2000, NAT REV MOL CELL BIO, V1, P110, DOI 10.1038/35040061; CASE DA, 1997, AMBER 5; Cramer LP, 2002, CURR BIOL, V12, pR417, DOI 10.1016/S0960-9822(02)00912-0; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; Drees B, 2000, J BIOL CHEM, V275, P22503, DOI 10.1074/jbc.M001698200; Fedorov AA, 1999, NAT STRUCT BIOL, V6, P661, DOI 10.1038/10717; Frank R, 1996, Methods Mol Biol, V66, P149; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Hajduk PJ, 1997, J MED CHEM, V40, P3144, DOI 10.1021/jm9703404; Harbeck B, 2000, J BIOL CHEM, V275, P30817, DOI 10.1074/jbc.M005066200; Hoffman LM, 2003, MOL CELL BIOL, V23, P70, DOI 10.1128/MCB.23.1.70-79.2003; Kang F, 1997, BIOCHEMISTRY-US, V36, P8384, DOI 10.1021/bi970065n; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Klostermann A, 2000, J BIOL CHEM, V275, P39647, DOI 10.1074/jbc.M006316200; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; Kramer A, 1998, METH MOL B, V87, P25; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; KRAULIS PJ, 1994, BIOCHEMISTRY-US, V33, P3515, DOI 10.1021/bi00178a008; Krause M, 2000, J CELL BIOL, V149, P181, DOI 10.1083/jcb.149.1.181; Krause M, 2002, J CELL SCI, V115, P4721, DOI 10.1242/jcs.00218; Kuruvilla FG, 2002, NATURE, V416, P653, DOI 10.1038/416653a; Machner MP, 2001, J BIOL CHEM, V276, P40096, DOI 10.1074/jbc.M104279200; NEIDHARDT FC, 1974, J BACTERIOL, V119, P736, DOI 10.1128/JB.119.3.736-747.1974; Nguyen JT, 2000, CHEM BIOL, V7, P463, DOI 10.1016/S1074-5521(00)00130-7; Nguyen JT, 1998, SCIENCE, V282, P2088, DOI 10.1126/science.282.5396.2088; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Prehoda KE, 1999, CELL, V97, P471, DOI 10.1016/S0092-8674(00)80757-6; Reinhard M, 1996, FEBS LETT, V399, P103, DOI 10.1016/S0014-5793(96)01295-1; REINHARD M, 1995, P NATL ACAD SCI USA, V92, P7956, DOI 10.1073/pnas.92.17.7956; Reinhard M, 2001, TRENDS BIOCHEM SCI, V26, P243, DOI 10.1016/S0968-0004(00)01785-0; Renfranz PJ, 2002, CURR OPIN CELL BIOL, V14, P88, DOI 10.1016/S0955-0674(01)00299-X; Shogren-Knaak MA, 2001, ANNU REV CELL DEV BI, V17, P405, DOI 10.1146/annurev.cellbio.17.1.405; VolkmerEngert R, 1997, TETRAHEDRON LETT, V38, P1029, DOI 10.1016/S0040-4039(96)02508-7; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; Yu TW, 2002, NAT NEUROSCI, V5, P1147, DOI 10.1038/nn956	42	15	21	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36810	36818		10.1074/jbc.M305934200	http://dx.doi.org/10.1074/jbc.M305934200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857736	hybrid			2022-12-27	WOS:000185318300114
J	Minic, Z; Herve, G				Minic, Z; Herve, G			Arginine metabolism in the deep sea tube worm Riftia pachyptila and its bacterial endosymbiont	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATABOLIC ORNITHINE CARBAMOYLTRANSFERASE; AUTOTROPHIC CARBON FIXATION; HYDROTHERMAL VENT ANIMALS; PSEUDOMONAS-AERUGINOSA; ESCHERICHIA-COLI; CHEMOAUTOTROPHIC SYMBIONTS; PYRIMIDINE NUCLEOTIDES; INORGANIC CARBON; KINETIC-ANALYSIS; BIOSYNTHESIS	The present study describes the distribution and properties of enzymes involved in arginine metabolism in Riftia pachyptila, a tubeworm living around deep sea hydrothermal vents and known to be engaged in a highly specific symbiotic association with a bacterium. The results obtained show that the arginine biosynthetic enzymes, carbamyl phosphate synthetase, ornithine transcarbamylase, and argininosuccinate synthetase are present in all of the tissues of the worm and in the bacteria. Thus, Riftia and its bacterial endosymbiont can assimilate nitrogen and carbon via this arginine biosynthetic pathway. The kinetic properties of ornithine transcarbamylase strongly suggest that neither Riftia nor the bacteria possess the catabolic form of this enzyme belonging to the arginine deiminase pathway, the absence of this pathway being confirmed by the lack of arginine deiminase activity. Arginine decarboxylase and ornithine decarboxylase are involved in the biosynthesis of polyamines such as putrescine and agmatine. These activities are present in the trophosome, the symbiont-harboring tissue, and are higher in the isolated bacteria than in the trophosome, indicating that these enzymes are of bacterial origin. This finding indicates that Riftia is dependent on its bacterial endosymbiont for the biosynthesis of polyamines that are important for its metabolism and physiology. These results emphasize a particular organization of the arginine metabolism and the exchanges of metabolites between the two partners of this symbiosis.	Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, F-75006 Paris, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Herve, G (corresponding author), Univ Paris 06, Lab Biochim Signaux Regulateurs Cellulaires & Mol, CNRS, UMR 7631, 96 Blvd Raspail, F-75006 Paris, France.	gherve@ccr.jussieu.fr	Minic, Zoran/AAH-2091-2021					ABDELAL ATH, 1977, J BACTERIOL, V129, P1387, DOI 10.1128/JB.129.3.1387-1396.1977; ARP AJ, 1981, SCIENCE, V213, P342, DOI 10.1126/science.213.4505.342; ARP AJ, 1985, B BIOL SOC WASH, V6, P289; BELKIN S, 1986, BIOL BULL, V170, P110, DOI 10.2307/1541384; Bright M, 2000, MAR BIOL, V136, P621, DOI 10.1007/s002270050722; Cabella C, 2001, EUR J BIOCHEM, V268, P940, DOI 10.1046/j.1432-1327.2001.01955.x; CAVANAUGH CM, 1981, SCIENCE, V213, P340, DOI 10.1126/science.213.4505.340; CHILDRESS JJ, 1993, NATURE, V362, P147, DOI 10.1038/362147a0; CHILDRESS JJ, 1984, MAR BIOL, V83, P109, DOI 10.1007/BF00394718; CHILDRESS JJ, 1992, OCEANOGR MAR BIOL, V83, P109; CLARK JL, 1976, ANAL BIOCHEM, V74, P329, DOI 10.1016/0003-2697(76)90213-X; Cohen SS, 1988, GUIDE POLYAMINES; COOPER TG, 1969, J BIOL CHEM, V244, P1081; CUNIN R, 1986, MICROBIOL REV, V50, P314, DOI 10.1128/MMBR.50.3.314-352.1986; De Cian MC, 2000, J EXP BIOL, V203, P2907; De Cian MC, 2003, J EXP BIOL, V206, P399, DOI 10.1242/jeb.00074; DISTEL DL, 1988, J EXP ZOOL, V247, P1, DOI 10.1002/jez.1402470102; EISENSTEIN E, 1984, J BIOL CHEM, V259, P5139; FELBECK H, 1981, NATURE, V293, P291, DOI 10.1038/293291a0; FELBECK H, 1981, SCIENCE, V213, P336, DOI 10.1126/science.213.4505.336; Felbeck Horst, 1988, Oceanologica Acta Special Issue, V8, P131; FISHER CR, 1989, BIOL BULL, V177, P372, DOI 10.2307/1541597; FOX RM, 1971, ANAL BIOCHEM, V41, P578, DOI 10.1016/0003-2697(71)90180-1; GAILL F, 1993, FASEB J, V7, P558, DOI 10.1096/fasebj.7.6.8472894; Graham DE, 2002, J BIOL CHEM, V277, P23500, DOI 10.1074/jbc.M203467200; HAAS D, 1979, J BACTERIOL, V139, P713, DOI 10.1128/JB.139.3.713-720.1979; HENTSCHEL U, 1993, NATURE, V366, P338, DOI 10.1038/366338a0; HOOGENRAAD NJ, 1980, ANAL BIOCHEM, V101, P97, DOI 10.1016/0003-2697(80)90045-7; Jones M.L., 1981, Proceedings of the Biological Society of Washington, V93, P1295; Jones Meredith L., 1988, Oceanologica Acta Special Issue, V8, P69; JOSEPH RL, 1963, BIOCHEM J, V87, P409, DOI 10.1042/bj0870409; Kandpal M, 1997, LIFE SCI, V60, P1793, DOI 10.1016/S0024-3205(97)00139-2; Kochevar Randall E., 1993, Molecular Marine Biology and Biotechnology, V2, P10; KUO LC, 1982, P NATL ACAD SCI-BIOL, V79, P2250, DOI 10.1073/pnas.79.7.2250; Lee RW, 1999, J EXP BIOL, V202, P289; LEE RW, 1996, BIOL BULL, V190, P367; LEE SJ, 1990, J MOL BIOL, V211, P255, DOI 10.1016/0022-2836(90)90025-H; LEGRAIN C, 1977, EUR J BIOCHEM, V80, P401, DOI 10.1111/j.1432-1033.1977.tb11895.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MERCENIER A, 1980, J GEN MICROBIOL, V116, P381; Minic Z, 2002, J BIOL CHEM, V277, P127, DOI 10.1074/jbc.M108035200; Minic Z, 2001, J BIOL CHEM, V276, P23777, DOI 10.1074/jbc.M102249200; Nakada Y, 2001, J BACTERIOL, V183, P6517, DOI 10.1128/JB.183.22.6517-6524.2001; Nelson D.C., 1995, DEEP SEA HYDROTHERMA, P125; POWELL MA, 1986, BIOL BULL, V171, P274, DOI 10.2307/1541923; PRIEUR D, 1995, PLANET SPACE SCI, V43, P115, DOI 10.1016/0032-0633(94)00143-F; Purcarea C, 2001, EXTREMOPHILES, V5, P229, DOI 10.1007/s007920100201; ROBIN JP, 1989, EUR J BIOCHEM, V183, P519, DOI 10.1111/j.1432-1033.1989.tb21080.x; ROCHOVANSKY O, 1977, J BIOL CHEM, V252, P5287; Satriano J, 2001, AM J PHYSIOL-CELL PH, V281, pC329, DOI 10.1152/ajpcell.2001.281.1.C329; SCHIMKE RT, 1966, J BIOL CHEM, V241, P2228; Schneider BL, 1998, J BACTERIOL, V180, P4278, DOI 10.1128/JB.180.16.4278-4286.1998; SCOTT KM, 1994, PHYSIOL ZOOL, V67, P617, DOI 10.1086/physzool.67.3.30163761; Simon V, 2000, MAR BIOL, V136, P115, DOI 10.1007/s002270050014; STALON V, 1987, J GEN MICROBIOL, V133, P2487; STALON V, 1977, EUR J BIOCHEM, V74, P319, DOI 10.1111/j.1432-1033.1977.tb11396.x; STALON V, 1967, BIOCHIM BIOPHYS ACTA, V139, P91, DOI 10.1016/0005-2744(67)90115-5; STALON V, 1972, EUR J BIOCHEM, V29, P25, DOI 10.1111/j.1432-1033.1972.tb01953.x; STEWART V, 1994, ANTON LEEUW INT J G, V66, P37, DOI 10.1007/BF00871631; TABOR CW, 1985, MICROBIOL REV, V49, P81, DOI 10.1128/MMBR.49.1.81-99.1985; Tricot C, 1998, J MOL BIOL, V283, P695, DOI 10.1006/jmbi.1998.2133; TUNNICLIFFE V, 1992, AM SCI, V80, P336; TUNNICLIFFE V, 1991, OCEANOGR MAR BIOL, V29, P319; VANDERWAUVEN C, 1984, J BACTERIOL, V160, P928, DOI 10.1128/JB.160.3.928-934.1984; WARGNIES B, 1978, EUR J BIOCHEM, V89, P203, DOI 10.1111/j.1432-1033.1978.tb20914.x; WEBER K, 1969, J BIOL CHEM, V244, P4406; WEICKMANN JL, 1977, J BIOL CHEM, V252, P2615; WITTICH RM, 1987, MOL BIOCHEM PARASIT, V24, P155, DOI 10.1016/0166-6851(87)90102-2	68	16	16	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40527	40533		10.1074/jbc.M307835200	http://dx.doi.org/10.1074/jbc.M307835200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882969	hybrid			2022-12-27	WOS:000185847200014
J	Gallego, J; Greatorex, J; Zhang, H; Yang, B; Arunachalam, S; Fang, JH; Seamons, J; Lea, S; Pomerantz, RJ; Lever, AML				Gallego, J; Greatorex, J; Zhang, H; Yang, B; Arunachalam, S; Fang, JH; Seamons, J; Lea, S; Pomerantz, RJ; Lever, AML			Rev binds specifically to a purine loop in the SL1 region of the HIV-1 leader RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TYPE-1 PACKAGING SIGNAL; NUCLEOCAPSID PROTEIN; STEM-LOOP; SECONDARY STRUCTURE; GENOME RECOGNITION; RESPONSIVE ELEMENT; NMR STRUCTURE; ENCAPSIDATION; DIMERIZATION	The leader RNA sequence of human immunodeficiency virus type 1 (HIV-1) consists of a complex series of stem loop structures that are critical for viral replication. Three-dimensional structural analysis by NMR of one of these structures, the SL1 stem loop of the packaging signal region, revealed a highly conserved purine rich loop with a structure nearly identical to the Rev-binding loop of the Rev response element. Using band-shift assays, surface plasmon resonance, and further NMR analysis, we demonstrate that this loop binds Rev. HIV-1 appears to have a second Rev-binding site close to the major splice donor site that may have an additional role in the viral life cycle.	Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Thomas Jefferson Univ, Div Infect Dis, Ctr Human Virol, Philadelphia, PA 19107 USA; Univ Oxford, Mol Biophys Lab, Oxford OX1 3QU, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; MRC Laboratory Molecular Biology; Jefferson University; University of Oxford	Lever, AML (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Med, Cambridge CB2 2QQ, England.		Lea, Susan M/B-7678-2009; Gallego, Jose/H-6360-2015	Lea, Susan M/0000-0001-9287-8053; Gallego, Jose/0000-0002-0627-6927	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043876] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43876] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abbink TEM, 2003, J BIOL CHEM, V278, P11601, DOI 10.1074/jbc.M210291200; ALDOVINI A, 1990, J VIROL, V64, P1920, DOI 10.1128/JVI.64.5.1920-1926.1990; Amarasinghe GK, 2000, J MOL BIOL, V299, P145, DOI 10.1006/jmbi.2000.3710; Amarasinghe GK, 2000, J MOL BIOL, V301, P491, DOI 10.1006/jmbi.2000.3979; Amarasinghe GK, 2001, J MOL BIOL, V314, P961, DOI 10.1006/jmbi.2000.5182; BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; Battiste JL, 1996, SCIENCE, V273, P1547, DOI 10.1126/science.273.5281.1547; Berkhout B, 2002, J BIOL CHEM, V277, P19967, DOI 10.1074/jbc.M200950200; BRAY M, 1994, P NATL ACAD SCI USA, V91, P1256, DOI 10.1073/pnas.91.4.1256; CLAVEL F, 1990, J VIROL, V64, P5230, DOI 10.1128/JVI.64.10.5230-5234.1990; CLEVER J, 1995, J VIROL, V69, P2101, DOI 10.1128/JVI.69.4.2101-2109.1995; Clever JL, 1999, J VIROL, V73, P101, DOI 10.1128/JVI.73.1.101-109.1999; Clever JL, 2002, J VIROL, V76, P12381, DOI 10.1128/JVI.76.23.12381-12387.2002; Clever JL, 1997, J VIROL, V71, P3407, DOI 10.1128/JVI.71.5.3407-3414.1997; CULLEN BR, 1992, MICROBIOL REV, V56, P375, DOI 10.1128/MMBR.56.3.375-394.1992; DAGOSTINO DM, 1992, MOL CELL BIOL, V12, P1375, DOI 10.1128/MCB.12.3.1375; Dale T, 2000, RNA, V6, P608, DOI 10.1017/S1355838200992495; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; Dirac AMG, 2002, NUCLEIC ACIDS RES, V30, P2647, DOI 10.1093/nar/gkf381; Gosser Y, 2001, NAT STRUCT BIOL, V8, P146, DOI 10.1038/84138; Greatorex J, 2002, J MOL BIOL, V322, P543, DOI 10.1016/S0022-2836(02)00776-3; HARRISON GP, 1992, J VIROL, V66, P4144, DOI 10.1128/JVI.66.7.4144-4153.1992; Harrison GP, 1998, J VIROL, V72, P5886, DOI 10.1128/JVI.72.7.5886-5896.1998; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Huthoff H, 2002, BIOCHEMISTRY-US, V41, P10439, DOI 10.1021/bi025993n; Kao C, 1999, RNA, V5, P1268, DOI 10.1017/S1355838299991033; KAYE JF, 1995, J VIROL, V69, P6588, DOI 10.1128/JVI.69.10.6588-6592.1995; KIM HJ, 1994, VIROLOGY, V198, P336, DOI 10.1006/viro.1994.1037; KJEMS J, 1992, EMBO J, V11, P1119, DOI 10.1002/j.1460-2075.1992.tb05152.x; LEVER A, 1989, J VIROL, V63, P4085, DOI 10.1128/JVI.63.9.4085-4087.1989; McBride MS, 1996, J VIROL, V70, P2963, DOI 10.1128/JVI.70.5.2963-2973.1996; McBride MS, 1997, J VIROL, V71, P4544, DOI 10.1128/JVI.71.6.4544-4554.1997; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; Price SR, 1998, NATURE, V394, P645, DOI 10.1038/29234; Russell RS, 2003, J VIROL, V77, P84, DOI 10.1128/JVI.77.1.84-96.2003; Schambach A, 2000, MOL THER, V2, P435, DOI 10.1006/mthe.2000.0191; Yuan YQ, 2003, BIOCHEMISTRY-US, V42, P5259, DOI 10.1021/bi034084a; Zeffman A, 2000, J MOL BIOL, V297, P877, DOI 10.1006/jmbi.2000.3611	38	36	36	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40385	40391		10.1074/jbc.M301041200	http://dx.doi.org/10.1074/jbc.M301041200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851400	hybrid			2022-12-27	WOS:000185713800132
J	Song, MS; Chen, WG; Zhang, M; Napoli, JL				Song, MS; Chen, WG; Zhang, M; Napoli, JL			Identification of a mouse short-chain dehydrogenase/reductase gene, retinol dehydrogenase-similar - Function of non-catalytic amino acid residues in enzyme activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESTROGENIC 17-BETA-HYDROXYSTEROID DEHYDROGENASE; MOLECULAR CHARACTERIZATION; CDNA CLONING; INTACT-CELLS; SWISS-MODEL; BIOSYNTHESIS; METABOLISM; REDUCTASE; BINDING	We report a mouse short-chain dehydrogenase/reductase (SDR), retinol dehydrogenase-similar (RDH-S), with intense mRNA expression in liver and kidney. The RDH-S gene localizes to chromosome 10D3 with the SDR subfamily that catalyzes metabolism of retinoids and 3alpha-hydroxysteroids. RDH-S has no activity with prototypical retinoid/steroid substrates, despite 92% amino acid similarity to mouse RDH1. This afforded the opportunity to analyze for functions of non-catalytic SDR residues. We produced RDH-SDelta3 by mutating RDH-S to remove an "additional" Asn residue relative to RDH1 in its center, to convert three residues into RDH1 residues (L121P, S122N, and Q123E), and to substitute RDH1 sequence G(208)FKTCVTSSD for RDH-S sequence F(208)FLTGMASSA. RDH-SDelta3 catalyzed all-trans-retinol and 5alpha-androstane-3alpha,17alpha-diol (3alpha-adiol) metabolism 60-70% as efficiently (V-m/K-m) as RDH1. Conversely, substituting RDH-S sequence F(208)FLTGMASSA into RDH1 produced a chimera ( viz. C3) that was inactive with all-trans-retinol, but was 4-fold more efficient with 3alpha-adiol. A single RDH1 mutation in the C3 region (K210L) reduced efficiency for all-trans-retinol by > 1250-fold. In contrast, the C3 area mutation C212G enhanced efficiency with all-trans-retinol by similar to2.4-fold. This represents a > 6000-fold difference in catalytic efficiency for two enzymes that differ by a single non-catalytic amino acid residue. Another chimera (viz. C5) retained efficiency with all-trans-retinol, but was not saturated and was weakly active with 3alpha-adiol, stemming from three residue differences (K224Q, K229Q, and A230T). The residues studied contribute to the substrate-binding pocket: molecular modeling indicated that they would affect orientation of substrates with the catalytic residues. These data report a new member of the SDR gene family, provide insight into the function of non-catalytic SDR residues, and illustrate that limited changes in the multifunctional SDR yield major alterations in substrate specificity and/or catalytic efficiency.	Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Napoli, JL (corresponding author), Univ Calif Berkeley, Dept Nutr Sci & Toxicol, 119 Morgan Hall,MC3104, Berkeley, CA 94720 USA.	jna@uclink4.berkeley.edu			NIDDK NIH HHS [DK36870] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036870] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Azzi A, 1996, NAT STRUCT BIOL, V3, P665, DOI 10.1038/nsb0896-665; Bailey TL, 1997, J STEROID BIOCHEM, V62, P29, DOI 10.1016/S0960-0760(97)00013-7; Baker ME, 2001, MOL CELL ENDOCRINOL, V171, P211, DOI 10.1016/S0303-7207(00)00414-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Breton R, 1996, STRUCTURE, V4, P905, DOI 10.1016/S0969-2126(96)00098-6; Chai XY, 1997, J BIOL CHEM, V272, P33125, DOI 10.1074/jbc.272.52.33125; Chen WG, 2002, GENE, V294, P141, DOI 10.1016/S0378-1119(02)00757-6; Duax WL, 2000, VITAM HORM, V58, P121, DOI 10.1016/S0083-6729(00)58023-6; Fisher M, 2000, STRUCTURE, V8, P339, DOI 10.1016/S0969-2126(00)00115-5; Gamble MV, 1999, J LIPID RES, V40, P2279; Gamble MV, 2000, BBA-PROTEIN STRUCT M, V1476, P3, DOI 10.1016/S0167-4838(99)00232-0; GHOSH D, 1991, P NATL ACAD SCI USA, V88, P10064, DOI 10.1073/pnas.88.22.10064; GHOSH D, 1995, STRUCTURE, V3, P503, DOI 10.1016/S0969-2126(01)00183-6; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haeseleer F, 1998, J BIOL CHEM, V273, P21790, DOI 10.1074/jbc.273.34.21790; HORTON RM, 1993, METHOD ENZYMOL, V217, P270; Kedishvili NY, 2002, J BIOL CHEM, V277, P28909, DOI 10.1074/jbc.M202588200; Lei Z, 2003, BIOCHEMISTRY-US, V42, P4190, DOI 10.1021/bi026948i; MOORE S, 2002, GENE, V292, P149; Napoli JL, 2001, MOL CELL ENDOCRINOL, V171, P103, DOI 10.1016/S0303-7207(00)00392-0; Napoli JL, 2000, PROG NUCLEIC ACID RE, V63, P139, DOI 10.1016/S0079-6603(08)60722-9; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Su J, 1998, J BIOL CHEM, V273, P17910, DOI 10.1074/jbc.273.28.17910; Su J, 1999, ENDOCRINOLOGY, V140, P5275, DOI 10.1210/endo.140.11.7137; Wang J, 2001, BIOCHEMISTRY-US, V40, P12533, DOI 10.1021/bi011396+; Zhang M, 2001, J BIOL CHEM, V276, P44083, DOI 10.1074/jbc.M105748200; Zhuang R, 2002, BIOCHEMISTRY-US, V41, P3477, DOI 10.1021/bi0119316	28	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40079	40087		10.1074/jbc.M304910200	http://dx.doi.org/10.1074/jbc.M304910200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12855677	hybrid			2022-12-27	WOS:000185713800099
J	Szeto, TH; Rowland, SL; Habrukowich, CL; King, GF				Szeto, TH; Rowland, SL; Habrukowich, CL; King, GF			The MinD membrane targeting sequence is a transplantable lipid-binding helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL-CELL DIVISION; TO-POLE OSCILLATION; ESCHERICHIA-COLI; BACILLUS-SUBTILIS; TOPOLOGICAL REGULATION; NEISSERIA-GONORRHOEAE; DYNAMIC LOCALIZATION; CRYSTAL-STRUCTURE; INHIBITOR MINC; RAPID POLE	MinD is a ubiquitous ATPase that plays a crucial role in selection of the division site in eubacteria, chloroplasts, and probably also Archaea. It was recently demonstrated that membrane localization of MinD is mediated by an 8-12-residue C-terminal motif termed the membrane targeting sequence or MTS. In this study we show that the MinD MTS is a transplantable lipid-binding motif that can effectively target heterologous proteins to the cell membrane. We demonstrate that eubacterial MTSs interact directly with lipid bilayers as an amphipathic helix, with a distinct preference for anionic phospholipids. Moreover, we provide evidence that the phospholipid preference of each MTS, as well as its affinity for biological membranes, has been evolutionarily "tuned" to its specific role in different bacteria. We propose a model to describe how the MTS is coupled to ATP binding to regulate the reversible membrane association of Escherichia coli MinD during its pole-to-pole oscillation cycle.	Univ Connecticut, Ctr Hlth, Dept Biochem, Farmington, CT 06032 USA; Univ Connecticut, Ctr Hlth, Dept Microbiol, Farmington, CT 06032 USA	University of Connecticut; University of Connecticut	King, GF (corresponding author), Univ Connecticut, Ctr Hlth, Dept Biochem, 263 Farmington Ave, Farmington, CT 06032 USA.	glenn@psel.uchc.edu	King, Glenn F/J-5059-2012; Rowland, Susan/M-1928-2016	King, Glenn F/0000-0002-2308-2200; Rowland, Susan/0000-0003-1926-7509	NIAID NIH HHS [AI-048583] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048583] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bains NPS, 1999, LETT PEPT SCI, V6, P381; Bernstein LS, 2000, J BIOL CHEM, V275, P18520, DOI 10.1074/jbc.M000618200; Buddelmeijer N, 2002, CURR OPIN MICROBIOL, V5, P553, DOI 10.1016/S1369-5274(02)00374-0; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CHEN YH, 1974, BIOCHEMISTRY-US, V13, P3350, DOI 10.1021/bi00713a027; Cooper JA, 2000, CURR OPIN CELL BIOL, V12, P97, DOI 10.1016/S0955-0674(99)00062-9; Cordell SC, 2003, P NATL ACAD SCI USA, V100, P7889, DOI 10.1073/pnas.1330742100; Cordell SC, 2001, FEBS LETT, V492, P160, DOI 10.1016/S0014-5793(01)02216-5; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; DEBOER PAJ, 1989, CELL, V56, P641, DOI 10.1016/0092-8674(89)90586-2; DEBOER PAJ, 1991, EMBO J, V10, P4371, DOI 10.1002/j.1460-2075.1991.tb05015.x; DEBOER PAJ, 1992, J BACTERIOL, V174, P63, DOI 10.1128/jb.174.1.63-70.1992; deKruijff B, 1997, CURR TOP MEMBR, V44, P477; Dowhan W, 1998, BBA-REV BIOMEMBRANES, V1376, P455, DOI 10.1016/S0304-4157(98)00013-6; Dunne SJ, 1996, BIOCHEMISTRY-US, V35, P11975, DOI 10.1021/bi960821+; Erickson HP, 1997, TRENDS CELL BIOL, V7, P362, DOI 10.1016/S0962-8924(97)01108-2; Errington J, 2003, MICROBIOL MOL BIOL R, V67, P52, DOI 10.1128/MMBR.67.1.52-65.2003; Fu XL, 2001, P NATL ACAD SCI USA, V98, P980, DOI 10.1073/pnas.031549298; Gerdes K, 2000, MOL MICROBIOL, V37, P455, DOI 10.1046/j.1365-2958.2000.01975.x; Goldberg J, 1998, CELL, V95, P237, DOI 10.1016/S0092-8674(00)81754-7; Hale CA, 2001, EMBO J, V20, P1563, DOI 10.1093/emboj/20.7.1563; Harry EJ, 2003, MOL MICROBIOL, V47, P37, DOI 10.1046/j.1365-2958.2003.03253.x; Harry EJ, 2001, MOL MICROBIOL, V40, P795, DOI 10.1046/j.1365-2958.2001.02370.x; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hu ZL, 2003, MOL MICROBIOL, V47, P345, DOI 10.1046/j.1365-2958.2003.03321.x; Hu ZL, 2003, J BACTERIOL, V185, P196, DOI 10.1128/JB.185.1.196-203.2003; Hu ZL, 2002, P NATL ACAD SCI USA, V99, P6761, DOI 10.1073/pnas.102059099; Hu ZL, 1999, MOL MICROBIOL, V34, P82, DOI 10.1046/j.1365-2958.1999.01575.x; Hu ZL, 2001, MOL CELL, V7, P1337, DOI 10.1016/S1097-2765(01)00273-8; Huang H, 1999, BIOCHEMISTRY-US, V38, P13231, DOI 10.1021/bi990870x; JOHNSON JE, 1994, BIOCHEMISTRY-US, V33, P4327, DOI 10.1021/bi00180a029; Johnson JE, 2002, J BACTERIOL, V184, P2951, DOI 10.1128/JB.184.11.2951-2962.2002; Lutkenhaus J, 2003, MOL MICROBIOL, V48, P295, DOI 10.1046/j.1365-2958.2003.03427.x; Lutkenhaus J, 2002, CURR OPIN MICROBIOL, V5, P548, DOI 10.1016/S1369-5274(02)00376-4; Marston AL, 1998, GENE DEV, V12, P3419, DOI 10.1101/gad.12.21.3419; Marston AL, 1999, MOL MICROBIOL, V33, P84, DOI 10.1046/j.1365-2958.1999.01450.x; Matsumoto K, 1998, J BACTERIOL, V180, P100, DOI 10.1128/JB.180.1.100-106.1998; Mileykovskaya E, 2003, J BIOL CHEM, V278, P22193, DOI 10.1074/jbc.M302603200; Ramirez-Arcos S, 2002, MOL MICROBIOL, V46, P493, DOI 10.1046/j.1365-2958.2002.03168.x; Raskin DM, 1999, J BACTERIOL, V181, P6419, DOI 10.1128/JB.181.20.6419-6424.1999; Raskin DM, 1999, P NATL ACAD SCI USA, V96, P4971, DOI 10.1073/pnas.96.9.4971; Rothfield LI, 2001, CELL, V106, P13, DOI 10.1016/S0092-8674(01)00432-9; Rowland SL, 2000, J BACTERIOL, V182, P613, DOI 10.1128/JB.182.3.613-619.2000; Shih YL, 2003, P NATL ACAD SCI USA, V100, P7865, DOI 10.1073/pnas.1232225100; Shih YL, 2002, EMBO J, V21, P3347, DOI 10.1093/emboj/cdf323; Shimada H, 2002, J BACTERIOL, V184, P556, DOI 10.1128/JB.184.2.556-563.2002; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; Suefuji K, 2002, P NATL ACAD SCI USA, V99, P16776, DOI 10.1073/pnas.262671699; Szeto J, 2001, J BACTERIOL, V183, P6253, DOI 10.1128/JB.183.21.6253-6264.2001; Szeto TH, 2002, P NATL ACAD SCI USA, V99, P15693, DOI 10.1073/pnas.232590599; Wang GS, 2000, J BIOL CHEM, V275, P39811, DOI 10.1074/jbc.C000709200; Wieprecht T, 1999, J MOL BIOL, V294, P785, DOI 10.1006/jmbi.1999.3268; Yamaichi Y, 2000, P NATL ACAD SCI USA, V97, P14656, DOI 10.1073/pnas.97.26.14656; Yu XC, 1999, MOL MICROBIOL, V32, P315, DOI 10.1046/j.1365-2958.1999.01351.x	54	125	128	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40050	40056		10.1074/jbc.M306876200	http://dx.doi.org/10.1074/jbc.M306876200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882967	hybrid			2022-12-27	WOS:000185713800095
J	Bock, HH; Jossin, Y; Liu, PS; Forster, E; May, P; Goffinet, AM; Herz, J				Bock, HH; Jossin, Y; Liu, PS; Forster, E; May, P; Goffinet, AM; Herz, J			Phosphatidylinositol 3-kinase interacts with the adaptor protein Dab1 in response to Reelin signaling and is required for normal cortical lamination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLECKSTRIN HOMOLOGY DOMAIN; INSULIN-RECEPTOR; PHOSPHOINOSITIDE 3-KINASE; TYROSINE PHOSPHORYLATION; DISABLED 1; LIPID RAFTS; BINDING; LOCALIZATION; PREDICTION; MOLECULES	Reelin is a large secreted signaling protein that binds to two members of the low density lipoprotein receptor family, the apolipoprotein E receptor 2 and the very low density lipoprotein receptor, and regulates neuronal positioning during brain development. Reelin signaling requires activation of Src family kinases as well as tyrosine phosphorylation of the intracellular adaptor protein Disabled-1 (Dab1). This results in activation of phosphatidylinositol 3-kinase (PI3K), the serine/threonine kinase Akt, and the inhibition of glycogen synthase kinase 3beta, a protein that is implicated in the regulation of axonal transport. Here we demonstrate that PI3K activation by Reelin requires Src family kinase activity and depends on the Reelin-triggered interaction of Dab1 with the PI3K regulatory subunit p85alpha. Because the Dab1 phosphotyrosine binding domain can interact simultaneously with membrane lipids and with the intracellular domains of apolipoprotein E receptor 2 and very low density lipoprotein receptor, Dab1 is preferentially recruited to the neuronal plasma membrane, where it is phosphorylated. Efficient Dab1 phosphorylation and activation of the Reelin signaling cascade is impaired by cholesterol depletion of the plasma membrane. Using a neuronal migration assay, we also show that PI3K signaling is required for the formation of a normal cortical plate, a step that is dependent upon Reelin signaling.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA; Catholic Univ Louvain, Dev Genet Unit, UCL 7382, B-1200 Brussels, Belgium; Univ Freiburg, Inst Anat, D-79104 Freiburg, Germany	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Universite Catholique Louvain; Cliniques Universitaires Saint-Luc; University of Freiburg	Herz, J (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Joachim.Herz@UTSouthwestern.edu	Bock, Hans/AAF-2635-2021	Jossin, Yves/0000-0001-8466-7432; Forster, Eckart/0000-0002-2478-5610	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL063762, P01HL020948, R01HL063762] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948, R37 HL063762, HL63762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arnaud L, 2003, CURR BIOL, V13, P9, DOI 10.1016/S0960-9822(02)01397-0; Beffert U, 2002, J BIOL CHEM, V277, P49958, DOI 10.1074/jbc.M209205200; Blom N, 1999, J MOL BIOL, V294, P1351, DOI 10.1006/jmbi.1999.3310; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Buchdunger E, 2002, EUR J CANCER, V38, pS28, DOI 10.1016/S0959-8049(02)80600-1; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Caroni P, 2001, EMBO J, V20, P4332, DOI 10.1093/emboj/20.16.4332; de Bergeyck V, 1998, J NEUROSCI METH, V82, P17, DOI 10.1016/S0165-0270(98)00024-7; Dityatev A, 2003, NAT REV NEUROSCI, V4, P456, DOI 10.1038/nrn1115; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; Forster E, 2002, P NATL ACAD SCI USA, V99, P13178, DOI 10.1073/pnas.202035899; Foukas LC, 2003, ARCH BIOCHEM BIOPHYS, V414, P13, DOI 10.1016/S0003-9861(03)00177-2; Funaki M, 2000, CELL SIGNAL, V12, P135, DOI 10.1016/S0898-6568(99)00086-8; Hartfuss E, 2003, DEVELOPMENT, V130, P4597, DOI 10.1242/dev.00654; Herrick TM, 2002, DEVELOPMENT, V129, P787; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; Howell BW, 1999, GENE DEV, V13, P643, DOI 10.1101/gad.13.6.643; Howell BW, 2000, CURR BIOL, V10, P877, DOI 10.1016/S0960-9822(00)00608-4; Howell BW, 1997, EMBO J, V16, P121, DOI 10.1093/emboj/16.1.121; Howell BW, 1999, MOL CELL BIOL, V19, P5179; Jacobs AR, 2001, J BIOL CHEM, V276, P40795, DOI 10.1074/jbc.M105194200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Keshvara L, 2002, J NEUROSCI, V22, P4869, DOI 10.1523/JNEUROSCI.22-12-04869.2002; Keshvara L, 2001, J BIOL CHEM, V276, P16008, DOI 10.1074/jbc.M101422200; Kubo K, 2002, NEUROSCI RES, V43, P381, DOI 10.1016/S0168-0102(02)00068-8; Murata H, 2003, J BIOL CHEM, V278, P21607, DOI 10.1074/jbc.M302934200; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Razzini G, 2000, MOL ENDOCRINOL, V14, P823, DOI 10.1210/me.14.6.823; Rice DS, 2001, ANNU REV NEUROSCI, V24, P1005, DOI 10.1146/annurev.neuro.24.1.1005; Rice DS, 1999, GENE DEV, V13, P2758, DOI 10.1101/gad.13.21.2758; Riddell DR, 2001, J LIPID RES, V42, P998; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Stolt PC, 2003, STRUCTURE, V11, P569, DOI 10.1016/S0969-2126(03)00068-6; Tissir F, 2003, NAT REV NEUROSCI, V4, P496, DOI 10.1038/nrn1113; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Vainshtein I, 2001, J BIOL CHEM, V276, P8073, DOI 10.1074/jbc.M008436200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; VOLIOVITCH H, 1995, J BIOL CHEM, V270, P18083, DOI 10.1074/jbc.270.30.18083; Weeber EJ, 2002, J BIOL CHEM, V277, P39944, DOI 10.1074/jbc.M205147200; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yenush L, 1996, J BIOL CHEM, V271, P24300, DOI 10.1074/jbc.271.39.24300; Yin HL, 2003, ANNU REV PHYSIOL, V65, P761, DOI 10.1146/annurev.physiol.65.092101.142517	47	149	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38772	38779		10.1074/jbc.M306416200	http://dx.doi.org/10.1074/jbc.M306416200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882964	hybrid			2022-12-27	WOS:000185575100084
J	Stojanovic, A; Hwang, I; Khorana, HG; Hwa, J				Stojanovic, A; Hwang, I; Khorana, HG; Hwa, J			Retinitis pigmentosa rhodopsin mutations L125R and A164V perturb critical interhelical interactions - New insights through compensatory mutations and crystal structure analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VITAMIN-A SUPPLEMENTATION; PROTEIN-COUPLED RECEPTOR; LIGHT-DEPENDENT CHANGES; SCHIFF-BASE COUNTERION; BOVINE RHODOPSIN; DISULFIDE BOND; CYSTEINE RESIDUE-110; TERTIARY STRUCTURE; CYTOPLASMIC END; MUTANTS	L125R, a severe retinitis pigmentosa rhodopsin missense mutation, results in rhodopsin protein misfolding, retinal degeneration, and ultimately blindness. The initiating structural events leading to this protein misfolding are unknown. Through the use of compensatory mutations, in conjunction with crystal structure-based molecular analysis, we established that the larger and positively charged Arg replacing Leu(125) sterically hinders both the adjacent Trp(126) and a critical interhelical interaction between transmembrane III (TM III) and transmembrane V (TM V; Glu(122) and His(211) salt bridge). Further, analysis of another retinitis pigmentosa mutation, A164V (TM IV), indicates that the larger Val interferes with residues Leu(119) and Ile(123) on TM III, leading to the disruption of the same critical Glu(122)- His(211) salt bridge (TM III-TM V interaction). Combined, these localized defects in interhelical interactions cause structural changes that interfere with the ability of opsin to bind 11-cis-retinal. These distortions ultimately lead to the formation of an abnormal disulfide bond, severe protein instability, aggregation, and endoplasmic reticulum retention. In the absence of a crystal or NMR structure of each retinitis pigmentosa mutation, compensatory mutagenesis and crystal structure-based analysis are powerful tools in determining the localized molecular disturbances. A detailed understanding of the initiating local perturbations created by missense mutations such as these, not only identifies critical factors required for correct folding and stability, but additionally opens avenues for rational drug design, mimicking the compensatory mutations and stabilizing the protein.	Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, Hanover, NH 03755 USA; MIT, Dept Biol & Chem, Cambridge, MA 02139 USA	Dartmouth College; Massachusetts Institute of Technology (MIT)	Hwa, J (corresponding author), Dartmouth Coll, Sch Med, Dept Pharmacol & Toxicol, 7650 Remsen, Hanover, NH 03755 USA.							Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15493, DOI 10.1021/bi011545o; Altenbach C, 2001, BIOCHEMISTRY-US, V40, P15483, DOI 10.1021/bi011546g; Andres A, 2001, EUR J BIOCHEM, V268, P5696, DOI 10.1046/j.0014-2956.2001.02509.x; Beck M, 1998, BIOCHEMISTRY-US, V37, P7630, DOI 10.1021/bi9801560; BERSON EL, 1993, ARCH OPHTHALMOL-CHIC, V111, P1456, DOI 10.1001/archopht.1993.01090110014001; BOWNDS D, 1967, NATURE, V216, P1178, DOI 10.1038/2161178a0; Creemers AFL, 2002, P NATL ACAD SCI USA, V99, P9101, DOI 10.1073/pnas.112677599; DAVIDSON FF, 1994, P NATL ACAD SCI USA, V91, P4029, DOI 10.1073/pnas.91.9.4029; Garriga P, 1996, P NATL ACAD SCI USA, V93, P4560, DOI 10.1073/pnas.93.10.4560; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hwa J, 1997, P NATL ACAD SCI USA, V94, P10571, DOI 10.1073/pnas.94.20.10571; Hwa J, 1999, P NATL ACAD SCI USA, V96, P1932, DOI 10.1073/pnas.96.5.1932; Hwa J, 2001, P NATL ACAD SCI USA, V98, P4872, DOI 10.1073/pnas.061632798; KARNIK SS, 1990, J BIOL CHEM, V265, P17520; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; KAUSHAL S, 1994, BIOCHEMISTRY-US, V33, P6121, DOI 10.1021/bi00186a011; Klein-Seetharaman J, 2001, BIOCHEMISTRY-US, V40, P12472, DOI 10.1021/bi010746p; Li TS, 1998, P NATL ACAD SCI USA, V95, P11933, DOI 10.1073/pnas.95.20.11933; Lin SW, 1996, BIOCHEMISTRY-US, V35, P11149, DOI 10.1021/bi960858u; NATHANS J, 1990, BIOCHEMISTRY-US, V29, P9746, DOI 10.1021/bi00493a034; Noorwez SM, 2003, J BIOL CHEM, V278, P14442, DOI 10.1074/jbc.M300087200; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Reeves PJ, 1999, P NATL ACAD SCI USA, V96, P1927, DOI 10.1073/pnas.96.5.1927; Sakmar TP, 1998, PROG NUCLEIC ACID RE, V59, P1; SAKMAR TP, 1989, P NATL ACAD SCI USA, V86, P8309, DOI 10.1073/pnas.86.21.8309; Saliba RS, 2002, J CELL SCI, V115, P2907; Shieh T, 1997, J MOL BIOL, V269, P373, DOI 10.1006/jmbi.1997.1035; Stojanovic A, 2002, RECEPTOR CHANNEL, V8, P33, DOI 10.1080/10606820212137; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; Unger VM, 1997, NATURE, V389, P203, DOI 10.1038/38316; WANG JK, 1980, BIOCHEMISTRY-US, V19, P5111, DOI 10.1021/bi00563a027	33	23	24	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39020	39028		10.1074/jbc.M303625200	http://dx.doi.org/10.1074/jbc.M303625200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871954	hybrid			2022-12-27	WOS:000185575100114
J	Yang, ML; Ito, T; May, WS				Yang, ML; Ito, T; May, WS			A novel role for RAX, the cellular activator of PKR, in synergistically stimulating SV40 large T antigen-dependent gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE PKR; RNA-BINDING MOTIFS; DNA-REPLICATION; INDUCED APOPTOSIS; MAMMALIAN-CELLS; IN-VITRO; INTERFERON; ELEMENTS; ORIGIN; TRANSCRIPTION	The double-stranded (ds) RNA-binding protein RAX was discovered as a stress-induced cellular activator of the dsRNA-dependent protein kinase (PKR), a key regulator of protein synthesis in response to viral infection and cellular stress. We now report a novel function of RAX, independent of PKR, to enhance SV40 promoter (origin)/enhancer-dependent gene expression. Several mammalian cell lines including COS-7, CV-1, and HeLa cells were tested. Results reveal that the SV40 large T antigen is required for RAX-mediated, synergistic enhancement of gene expression. RAX augments SV40 regulatory element-dependent DNA replication and transcription. The mechanism requires the SV40 enhancer, a viral transcriptional element that is necessary for efficient SV40 DNA replication in vivo. Mutational analysis reveals that the dsRNA-binding domains of RAX are required for the gene expression enhancing function. Thus, in addition to stimulating PKR activity, RAX can positively regulate both SV40 large T antigen-dependent DNA replication and transcription in a mechanism that may alter the interaction of the cellular factor(s) with the SV40 enhancer via the dsRNA-binding domains of RAX. This novel function of RAX may have implications for regulation of mammalian DNA replication and transcription because of the many similarities between the viral and cellular processes.	Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA; Univ Florida, Dept Med, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	May, WS (corresponding author), Univ Florida, Shands Canc Ctr, POB 100232,1600 SW Archer Rd, Gainesville, FL 32610 USA.			Yang, Mingli/0000-0002-4781-690X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL54083] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alexiadis V, 1998, EMBO J, V17, P3428, DOI 10.1093/emboj/17.12.3428; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; CEREGHINI S, 1984, EMBO J, V3, P1243, DOI 10.1002/j.1460-2075.1984.tb01959.x; CHENG LH, 1989, CELL, V59, P541, DOI 10.1016/0092-8674(89)90037-8; Clemens MJ, 1997, J INTERF CYTOK RES, V17, P503, DOI 10.1089/jir.1997.17.503; DAMNIA B, 1998, MOL CELL BIOL, V18, P1331; DEB S, 1986, MOL CELL BIOL, V6, P1663, DOI 10.1128/MCB.6.5.1663; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DEPAMPHILIS ML, 1986, PAPOVAVIRIDAE, V1, P99; Der SD, 1997, P NATL ACAD SCI USA, V94, P3279, DOI 10.1073/pnas.94.7.3279; FANNING E, 1992, ANNU REV BIOCHEM, V61, P55; Fierro-Monti I, 2000, TRENDS BIOCHEM SCI, V25, P241, DOI 10.1016/S0968-0004(00)01580-2; GLUZMAN Y, 1981, CELL, V23, P175, DOI 10.1016/0092-8674(81)90282-8; Goldman LA, 1996, BIOTECHNIQUES, V21, P1013; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; GRUSS C, 1990, EMBO J, V9, P2911, DOI 10.1002/j.1460-2075.1990.tb07482.x; GUO ZS, 1992, MOL CELL BIOL, V12, P2514, DOI 10.1128/MCB.12.6.2514; HAAS MW, 1991, VIROLOGY, V180, P41, DOI 10.1016/0042-6822(91)90007-X; HERENDEEN D, 1996, EUKARYOTIC DNA REPLI, P29; HERR W, 1986, CELL, V45, P461, DOI 10.1016/0092-8674(86)90332-6; HERSHEY JWB, 1991, ANNU REV BIOCHEM, V60, P717, DOI 10.1146/annurev.bi.60.070191.003441; HOVANESSIAN AG, 1989, J INTERFERON RES, V9, P641, DOI 10.1089/jir.1989.9.641; HU YH, 1993, J INTERFERON RES, V13, P323, DOI 10.1089/jir.1993.13.323; Ito T, 1999, J BIOL CHEM, V274, P15427, DOI 10.1074/jbc.274.22.15427; ITO T, 1994, P NATL ACAD SCI USA, V91, P7455, DOI 10.1073/pnas.91.16.7455; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; JUDWARE R, 1991, MOL CELL BIOL, V11, P3259, DOI 10.1128/MCB.11.6.3259; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; LI JJ, 1984, P NATL ACAD SCI-BIOL, V81, P6973, DOI 10.1073/pnas.81.22.6973; MEURS E, 1990, CELL, V62, P379, DOI 10.1016/0092-8674(90)90374-N; Milavetz BI, 2002, VIROLOGY, V294, P170, DOI 10.1006/viro.2001.1308; Nakajima T, 1997, CELL, V90, P1107, DOI 10.1016/S0092-8674(00)80376-1; Patel CV, 2000, J BIOL CHEM, V275, P37993, DOI 10.1074/jbc.M004762200; Patel RC, 1998, EMBO J, V17, P4379, DOI 10.1093/emboj/17.15.4379; PAULY M, 1992, NUCLEIC ACIDS RES, V20, P975, DOI 10.1093/nar/20.5.975; Peters GA, 2001, MOL CELL BIOL, V21, P1908, DOI 10.1128/MCB.21.6.1908-1920.2001; PROUD CG, 1995, TRENDS BIOCHEM SCI, V20, P241, DOI 10.1016/S0968-0004(00)89025-8; ROBERTSON HD, 1982, CELL, V30, P669, DOI 10.1016/0092-8674(82)90270-7; Ruvolo PP, 2001, J BIOL CHEM, V276, P11754, DOI 10.1074/jbc.M011400200; Simmons DT, 2000, ADV VIRUS RES, V55, P75, DOI 10.1016/S0065-3527(00)55002-7; STJOHNSTON D, 1992, P NATL ACAD SCI USA, V89, P10979, DOI 10.1073/pnas.89.22.10979; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Swaminathan S, 1996, VIROLOGY, V219, P321, DOI 10.1006/viro.1996.0255; THOMIS DC, 1992, P NATL ACAD SCI USA, V89, P10837, DOI 10.1073/pnas.89.22.10837; Tian B, 2001, J BIOL CHEM, V276, P9936, DOI 10.1074/jbc.M007328200; Turner WJ, 2001, J VIROL, V75, P5638, DOI 10.1128/JVI.75.12.5638-5645.2001; Ung TL, 2001, EMBO J, V20, P3728, DOI 10.1093/emboj/20.14.3728; Williams B.R., 2001, SCI STKE, V2001, pre2; Williams DD, 2001, J BIOL CHEM, V276, P3733, DOI 10.1074/jbc.M008041200; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451	50	4	4	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38325	38332		10.1074/jbc.M303420200	http://dx.doi.org/10.1074/jbc.M303420200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874289	hybrid			2022-12-27	WOS:000185575100031
J	Zeiner, GM; Sturm, NR; Campbell, DA				Zeiner, GM; Sturm, NR; Campbell, DA			The Leishmania tarentolae spliced leader contains determinants for association with polysomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							18S RIBOSOMAL-RNA; MESSENGER-RNA; TRYPANOSOMA-BRUCEI; CAENORHABDITIS-ELEGANS; MODIFIED NUCLEOTIDES; PROTEIN-SYNTHESIS; EUKARYOTIC CELLS; DOWNSTREAM BOX; CAP STRUCTURES; SL RNA	In kinetoplastids, every nuclear-derived mRNA contains an identical 39-nucleotide (nt) spliced leader at its 5'-terminus. The spliced leader is derived from substrate spliced leader RNA and joined to pre-mRNA by trans-splicing, thus providing mature mRNAs with an m(7)G cap and additional methylations referred to as cap 4. It was shown previously that mutations spanning nucleotides 10-39 of the spliced leader did not affect substrate spliced leader RNA transcription or trans-splicing in Leishmania tarentolae (Saito, R. M., Elgort, M. G., and Campbell, D. A. (1994) EMBO J. 13, 5460-5469). In this study we examined these sequences for a possible role in translation by assaying the association of mRNAs, which possess mutated spliced leaders, with polysomes. For the nt 28-39 mutated spliced leaders, both the substrate spliced leader RNA and the spliced leader demonstrated a wild-type methylation pattern; spliced nt 28-39 mRNA was found in polysomes. Thus, the nt 28-39 region conserved primary sequence is not a determinant of polysome association. An undermethylated cap 4 structure was present on substrate and mRNA spliced leaders in nt 20-29 mutated exons; nt 20-29 mRNA was not present in polysomes. A differential pattern of cap 4 methylation was seen between the nt 10-19 substrate spliced leader RNA and the nt 10-19 spliced leaders found in the poly(A)(+) population of RNA; the nt 10-19 mRNA was not seen in polysomes. Under-methylated spliced leaders did not associate efficiently with polysomes, suggesting a requirement for the cap 4 and/or primary sequence of the spliced leader in translation. This is the first report demonstrating that the spliced leader contains critical structural or sequence determinants for association with polysomes and, hence, translation.	Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Campbell, DA (corresponding author), Univ Calif Los Angeles, Dept Microbiol Immunol & Mol Genet, 609 Charles E Young Dr E, Los Angeles, CA 90095 USA.			Zeiner, Gusti/0000-0001-7815-5588	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034536, T32AI007323] Funding Source: NIH RePORTER; NIAID NIH HHS [2-T32-AI-07323, AI34536] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALINE RF, 1989, MOL BIOCHEM PARASIT, V32, P169, DOI 10.1016/0166-6851(89)90068-6; Avila AR, 2001, MOL BIOCHEM PARASIT, V117, P169, DOI 10.1016/S0166-6851(01)00346-2; BANGS JD, 1992, J BIOL CHEM, V267, P9805; BOOTHROYD JC, 1982, GENE, V20, P281, DOI 10.1016/0378-1119(82)90046-4; Brecht M, 1998, MOL BIOCHEM PARASIT, V97, P189, DOI 10.1016/S0166-6851(98)00151-0; BRIONES MRS, 1992, MOL BIOCHEM PARASIT, V53, P121, DOI 10.1016/0166-6851(92)90014-B; CROSS GAM, 1970, BIOCHIM BIOPHYS ACTA, V204, P470, DOI 10.1016/0005-2787(70)90167-X; Djikeng A, 2003, RNA, V9, P802, DOI 10.1261/rna.5270203; FLEISCHMANN J, 1994, GENE, V144, P45, DOI 10.1016/0378-1119(94)90201-1; FREISTADT MS, 1987, NUCLEIC ACIDS RES, V15, P9861, DOI 10.1093/nar/15.23.9861; Gibson W, 2000, MOL BIOCHEM PARASIT, V107, P269, DOI 10.1016/S0166-6851(00)00193-6; Gu J, 1996, RNA, V2, P909; HAGENBUCHLE O, 1978, CELL, V13, P551, DOI 10.1016/0092-8674(78)90328-8; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Jankowska-Anyszka M, 1998, J BIOL CHEM, V273, P10538, DOI 10.1074/jbc.273.17.10538; Keiper BD, 2000, J BIOL CHEM, V275, P10590, DOI 10.1074/jbc.275.14.10590; Kuge H, 1995, EMBO J, V14, P6301, DOI 10.1002/j.1460-2075.1995.tb00320.x; Lafontaine DLJ, 1998, MOL CELL BIOL, V18, P2360, DOI 10.1128/MCB.18.4.2360; LAIRD P, 1988, THESIS NETHERLANDS C; Lamontagne J, 1999, J BIOL CHEM, V274, P6602, DOI 10.1074/jbc.274.10.6602; LENARDO MJ, 1985, MOL CELL BIOL, V5, P2487, DOI 10.1128/MCB.5.9.2487; Liang XH, 2002, RNA, V8, P237, DOI 10.1017/S1355838202018290; LIOU RF, 1990, MOL CELL BIOL, V10, P1764, DOI 10.1128/MCB.10.4.1764; Londei P, 1998, BBA-GENE STRUCT EXPR, V1396, P169, DOI 10.1016/S0167-4781(97)00190-5; Lucke S, 1996, EMBO J, V15, P4380, DOI 10.1002/j.1460-2075.1996.tb00811.x; Maden B E, 1990, Prog Nucleic Acid Res Mol Biol, V39, P241, DOI 10.1016/S0079-6603(08)60629-7; Maden BEH, 1997, CHROMOSOMA, V105, P391, DOI 10.1007/s004120050200; MADEN BEH, 1995, BIOCHIMIE, V77, P22, DOI 10.1016/0300-9084(96)88100-4; MAGA JA, 1995, MOL CELL BIOL, V15, P4884; Mandelboim M, 2002, J BIOL CHEM, V277, P35210, DOI 10.1074/jbc.M201910200; MARIN F, 1995, J MOL BIOL, V247, P49; MAROUN LE, 1986, J THEOR BIOL, V120, P85, DOI 10.1016/S0022-5193(86)80019-4; Miyoshi H, 2002, EMBO J, V21, P4680, DOI 10.1093/emboj/cdf473; O'Connor M, 1999, P NATL ACAD SCI USA, V96, P8973, DOI 10.1073/pnas.96.16.8973; Orlando TC, 2002, MEM I OSWALDO CRUZ, V97, P695, DOI 10.1590/S0074-02762002000500020; PELLE R, 1993, MOL BIOCHEM PARASIT, V59, P277, DOI 10.1016/0166-6851(93)90225-M; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; Sachs AB, 1997, CELL, V89, P831, DOI 10.1016/S0092-8674(00)80268-8; SAITO RM, 1994, EMBO J, V13, P5460, DOI 10.1002/j.1460-2075.1994.tb06881.x; Santana DM, 2001, FEMS MICROBIOL LETT, V204, P233, DOI 10.1111/j.1574-6968.2001.tb10890.x; Shatkin AJ, 2000, NAT STRUCT BIOL, V7, P838, DOI 10.1038/79583; SHINE J, 1975, NATURE, V254, P34, DOI 10.1038/254034a0; SPRENGART ML, 1990, NUCLEIC ACIDS RES, V18, P1719, DOI 10.1093/nar/18.7.1719; STUART KD, 1992, P NATL ACAD SCI USA, V89, P8596, DOI 10.1073/pnas.89.18.8596; Sturm NR, 1998, J BIOL CHEM, V273, P18689, DOI 10.1074/jbc.273.30.18689; Sturm NR, 1999, MOL CELL BIOL, V19, P1595; SUTTON RE, 1988, MOL CELL BIOL, V8, P494, DOI 10.1128/MCB.8.1.494; TESTA D, 1977, J VIROL, V24, P786, DOI 10.1128/JVI.24.3.786-793.1977; Tourriere H, 2002, BIOCHIMIE, V84, P821, DOI 10.1016/S0300-9084(02)01445-1; Vassella E, 1996, MOL BIOCHEM PARASIT, V82, P131, DOI 10.1016/0166-6851(96)02726-0; YOUNG JR, 1982, NUCLEIC ACIDS RES, V10, P803, DOI 10.1093/nar/10.3.803; Yu DC, 1998, MOL BIOCHEM PARASIT, V96, P151, DOI 10.1016/S0166-6851(98)00126-1; Yueh A, 2000, GENE DEV, V14, P414; Zeiner GM, 2003, EUKARYOT CELL, V2, P222, DOI 10.1128/EC.2.2.222-230.2003	54	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38269	38275		10.1074/jbc.M304295200	http://dx.doi.org/10.1074/jbc.M304295200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878606	hybrid			2022-12-27	WOS:000185575100024
J	Morse, D; Pischke, SE; Zhou, ZH; Davis, RJ; Flavell, RA; Loop, T; Otterbein, SL; Otterbein, LE; Choi, AMK				Morse, D; Pischke, SE; Zhou, ZH; Davis, RJ; Flavell, RA; Loop, T; Otterbein, SL; Otterbein, LE; Choi, AMK			Suppression of inflammatory cytokine production by carbon monoxide involves the JNK pathway and AP-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME OXYGENASE; KAPPA-B; INTERLEUKIN-6; SEPSIS; KINASE; LIPOPOLYSACCHARIDE; ACTIVATION; BILIRUBIN; ENDOTOXIN; DEFENSE	The stress-inducible protein heme oxygenase-1 provides protection against oxidative stress and modulates pro-inflammatory cytokines. As the sepsis syndrome results from the release of pro-inflammatory mediators, we postulated that heme oxygenase-1 and its enzymatic product CO would protect against lethality in a murine model of sepsis. Mice treated with a lethal dose of lipopolysaccharide (LPS) and subsequently exposed to inhaled CO had significantly better survival and lower serum interleukin (IL)-6 and IL-1beta levels than their untreated counterparts. In vitro, mouse macrophages exposed to LPS and CO had significantly attenuated IL-6 production; this effect was concentration-dependent and occurred at a transcriptional level. The same effect was seen with increased endogenous CO production through overexpression of heme oxygenase-1. Mutation within the AP-1-binding site in the IL-6 promoter diminished the effect of CO on promoter activity, and treatment of macrophages with CO decreased AP-1 binding in an electrophoretic mobility shift assay. Electrophoretic mobility supershift assay indicated that the JunB, JunD, and c-Fos components of AP-1 were particularly affected. Upstream of AP-1, CO decreased JNK phosphorylation in murine macrophages and lung endothelial cells. Mice deficient in the JNK pathway had decreased serum levels of IL-6 and IL-1beta in response to LPS compared with control mice, and no effect of CO on these cytokine levels was seen in Jnk1 or Jnk2 gene-deleted mice. In summary, these results suggest that CO provides protection in a murine model of sepsis through modulation of inflammatory cytokine production. For the first time, the effect of CO is shown to be mediated via the JNK signaling pathway and the transcription factor AP-1.	Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, Pittsburgh, PA 15213 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Dept Biochem & Mol Biol, Worcester, MA 01605 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Univ Hosp, Dept Anesthesia, D-79098 Freiburg, Germany	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; Yale University; Yale University; University of Freiburg	Choi, AMK (corresponding author), Univ Pittsburgh, Sch Med, Div Pulm Allergy & Crit Care Med, NW 628 UPMC Montefiore,3459 5th Ave, Pittsburgh, PA 15213 USA.	choiam@msx.upmc.edu	Pischke, Soeren Erik/AAX-9676-2021; Zhou, Z Hong/HDN-0747-2022	Pischke, Soeren Erik/0000-0003-2543-3251; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL055330, R01HL060234, R29HL055330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042365] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL60234, HL55330] Funding Source: Medline; NIAID NIH HHS [AI42365] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ammit AJ, 2002, AM J RESP CELL MOL, V26, P465, DOI 10.1165/ajrcmb.26.4.4681; Arnalich F, 2000, INFECT IMMUN, V68, P1942, DOI 10.1128/IAI.68.4.1942-1945.2000; Brouard S, 2000, J EXP MED, V192, P1015, DOI 10.1084/jem.192.7.1015; Camhi SL, 1998, AM J RESP CELL MOL, V18, P226, DOI 10.1165/ajrcmb.18.2.2910; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dokter WHA, 1996, LEUKEMIA, V10, P1308; Downard PJ, 1997, J SURG RES, V71, P7, DOI 10.1006/jsre.1997.5135; Eickelberg O, 1999, J BIOL CHEM, V274, P12933, DOI 10.1074/jbc.274.18.12933; Friedman G, 1998, CRIT CARE MED, V26, P2078, DOI 10.1097/00003246-199812000-00045; Fujita T, 2001, NAT MED, V7, P598, DOI 10.1038/87929; Gallagher J, 2001, INTENS CARE MED, V27, P1169, DOI 10.1007/s001340100973; Geppert A, 2002, CRIT CARE MED, V30, P1987, DOI 10.1097/00003246-200209000-00007; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Haustein KO, 2002, J INTERN MED, V252, P130, DOI 10.1046/j.1365-2796.2002.01014.x; Heesen M, 2002, EUR CYTOKINE NETW, V13, P72; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Moncure M, 1999, J TRAUMA, V46, P424, DOI 10.1097/00005373-199903000-00012; Oberle S, 1999, BIOCHEM BIOPH RES CO, V261, P28, DOI 10.1006/bbrc.1999.0941; Otani K, 2000, DIGEST DIS SCI, V45, P2313, DOI 10.1023/A:1005626622203; Otterbein LE, 2000, AM J PHYSIOL-LUNG C, V279, pL1029, DOI 10.1152/ajplung.2000.279.6.L1029; Otterbein LE, 2000, NAT MED, V6, P422, DOI 10.1038/74680; Rodriguez-Gaspar M, 2001, CYTOKINE, V15, P232, DOI 10.1006/cyto.2001.0932; Santana C, 2001, ACTA PAEDIATR, V90, P1176, DOI 10.1080/080352501317061602; Sarady JK, 2002, AM J RESP CELL MOL, V27, P739, DOI 10.1165/rcmb.4816; Selberg O, 2000, CRIT CARE MED, V28, P2793, DOI 10.1097/00003246-200008000-00019; Spittler A, 2000, CLIN INFECT DIS, V31, P1338, DOI 10.1086/317499; Tamion F, 2001, AM J RESP CRIT CARE, V164, P1933, DOI 10.1164/ajrccm.164.10.2010074; Tournier C, 2000, SCIENCE, V288, P870, DOI 10.1126/science.288.5467.870; van der Poll T, 1999, INFECT DIS CLIN N AM, V13, P413, DOI 10.1016/S0891-5520(05)70083-0; Ventura JJ, 2003, MOL CELL BIOL, V23, P2871, DOI 10.1128/MCB.23.8.2871-2882.2003; Wang Y, 2002, BIOCHEM BIOPH RES CO, V296, P742, DOI 10.1016/S0006-291X(02)00930-0; Wenzel RP, 1996, CLIN INFECT DIS, V22, P407, DOI 10.1093/clinids/22.3.407; Yesilkaya A, 2000, GEN PHARMACOL-VASC S, V35, P17, DOI 10.1016/S0306-3623(01)00084-2; Zegdi R, 2002, INTENS CARE MED, V28, P793, DOI 10.1007/s00134-002-1269-7	35	333	366	1	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36993	36998		10.1074/jbc.M302942200	http://dx.doi.org/10.1074/jbc.M302942200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857751	hybrid			2022-12-27	WOS:000185437200004
J	Heller, U; Winklhofer, KF; Heske, J; Reintjes, A; Tatzelt, J				Heller, U; Winklhofer, KF; Heske, J; Reintjes, A; Tatzelt, J			Post-translational import of the prion protein into the endoplasmic reticulum interferes with cell viability - A critical role for the putative transmembrane domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; MOLECULAR CHAPERONES; PRECURSOR PROTEIN; FRAGMENT 106-126; SCRAPIE; NEUROTOXICITY; TRANSLOCATION; PRP; GLYCOSYLATION; CONTAINS	Aberrant folding of the mammalian prion protein (PrP) is linked to prion diseases in humans and animals. We show that during post-translational targeting of PrP to the endoplasmic reticulum (ER) the putative transmembrane domain induces misfolding of PrP in the cytosol and interferes with its import into the ER. Unglycosylated and misfolded PrP with an uncleaved N-terminal signal sequence associates with ER membranes, and, moreover, decreases cell viability. PrP expressed in the cytosol, lacking the N-terminal ER targeting sequence, also adopts a misfolded conformation; however, this has no adverse effect on cell growth. PrP processing, productive ER import, and cellular viability can be restored either by deleting the putative transmembrane domain or by using a N-terminal signal sequence specific for co-translational ER import. Our study reveals that the putative transmembrane domain features in the formation of misfolded PrP conformers and indicates that post-translational targeting of PrP to the ER can decrease cell viability.	Max Planck Inst Biochem, Dept Cellular Biochem, D-82152 Martinsried, Germany	Max Planck Society	Tatzelt, J (corresponding author), Max Planck Inst Biochem, Dept Cellular Biochem, Klopferspitz 18A, D-82152 Martinsried, Germany.	tatzelt@biochem.mpg.de		Winklhofer, Konstanze/0000-0002-7256-8231; Tatzelt, Jorg/0000-0001-5017-5528				Aguzzi A, 2001, NAT REV MOL CELL BIO, V2, P118, DOI 10.1038/35052063; Blochberger TC, 1997, PROTEIN ENG, V10, P1465, DOI 10.1093/protein/10.12.1465; BOLTON DC, 1985, J VIROL, V53, P596, DOI 10.1128/JVI.53.2.596-606.1985; Brown DR, 1996, NATURE, V380, P345, DOI 10.1038/380345a0; Collinge J, 2001, ANNU REV NEUROSCI, V24, P519, DOI 10.1146/annurev.neuro.24.1.519; CONZELMANN A, 1988, EMBO J, V7, P2233, DOI 10.1002/j.1460-2075.1988.tb03063.x; Deli MA, 2000, NEUROREPORT, V11, P3931, DOI 10.1097/00001756-200011270-00064; Drisaldi B, 2003, J BIOL CHEM, V278, P21732, DOI 10.1074/jbc.M213247200; EILERS M, 1986, NATURE, V322, P228, DOI 10.1038/322228a0; ENDO T, 1989, BIOCHEMISTRY-US, V28, P8380, DOI 10.1021/bi00447a017; Fewell SW, 2001, ANNU REV GENET, V35, P149, DOI 10.1146/annurev.genet.35.102401.090313; FORLONI G, 1993, NATURE, V362, P543, DOI 10.1038/362543a0; Galasinski W, 1996, Acta Pol Pharm, V53, P311; Geissler S, 1998, EMBO J, V17, P952, DOI 10.1093/emboj/17.4.952; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Haik S, 2000, NEUROBIOL DIS, V7, P644, DOI 10.1006/nbdi.2000.0316; HARAGUCHI T, 1989, ARCH BIOCHEM BIOPHYS, V274, P1, DOI 10.1016/0003-9861(89)90409-8; Hegde RS, 1999, NATURE, V402, P822, DOI 10.1038/45574; Hegde RS, 1998, SCIENCE, V279, P827, DOI 10.1126/science.279.5352.827; Holscher C, 2001, J BIOL CHEM, V276, P13388, DOI 10.1074/jbc.M007331200; KANE PM, 1992, J BIOL CHEM, V267, P447; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Keenan RJ, 2001, ANNU REV BIOCHEM, V70, P755, DOI 10.1146/annurev.biochem.70.1.755; Kim SJ, 2002, MOL BIOL CELL, V13, P3775, DOI 10.1091/mbc.E02-05-0293; KLEBE RJ, 1969, J CELL BIOL, V43, pA69; Knop M, 1999, YEAST, V15, P963, DOI 10.1002/(SICI)1097-0061(199907)15:10B<963::AID-YEA399>3.0.CO;2-W; KOCISKO DA, 1994, NATURE, V370, P471, DOI 10.1038/370471a0; Kourie JI, 2001, J NEUROSCI RES, V66, P214, DOI 10.1002/jnr.1213; Lin MX, 1997, J BIOL CHEM, V272, P44; LOPEZ CD, 1990, SCIENCE, V248, P226, DOI 10.1126/science.1970195; Ma JY, 2002, SCIENCE, V298, P1781, DOI 10.1126/science.1073725; Ma JY, 1999, NAT CELL BIOL, V1, P358, DOI 10.1038/14053; Maiti NR, 2001, J BIOL CHEM, V276, P2427, DOI 10.1074/jbc.M007862200; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MEADEN P, 1990, MOL CELL BIOL, V10, P3013, DOI 10.1128/MCB.10.6.3013; MULLER G, 1987, EMBO J, V6, P2099, DOI 10.1002/j.1460-2075.1987.tb02476.x; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; NUOFFER C, 1991, MOL CELL BIOL, V11, P27, DOI 10.1128/MCB.11.1.27; Pilon M, 1999, CELL, V97, P679, DOI 10.1016/S0092-8674(00)80780-1; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; RASSOW J, 1989, J CELL BIOL, V109, P1421, DOI 10.1083/jcb.109.4.1421; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; SCHANDEL KA, 1994, MOL CELL BIOL, V14, P7245, DOI 10.1128/MCB.14.11.7245; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHLENSTEDT G, 1987, EMBO J, V6, P699, DOI 10.1002/j.1460-2075.1987.tb04810.x; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; STAHL N, 1987, CELL, V51, P229, DOI 10.1016/0092-8674(87)90150-4; Stewart RS, 2001, MOL BIOL CELL, V12, P881, DOI 10.1091/mbc.12.4.881; TAGLIAVINI F, 1993, P NATL ACAD SCI USA, V90, P9678, DOI 10.1073/pnas.90.20.9678; Tatzelt J, 1996, EMBO J, V15, P6363, DOI 10.1002/j.1460-2075.1996.tb01027.x; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; WALTER P, 1986, ANNU REV CELL BIOL, V2, P499, DOI 10.1146/annurev.cellbio.2.1.499; Wang QQ, 1999, EMBO J, V18, P5972, DOI 10.1093/emboj/18.21.5972; Weissmann C, 1996, COLD SPRING HARB SYM, V61, P511; Winklhofer KF, 2003, TRAFFIC, V4, P313, DOI 10.1034/j.1600-0854.2003.00088.x; Winklhofer KF, 2003, J BIOL CHEM, V278, P14961, DOI 10.1074/jbc.M209942200; Winklhofer KF, 2001, J BIOL CHEM, V276, P45160, DOI 10.1074/jbc.M104873200; YOST CS, 1990, NATURE, V343, P669, DOI 10.1038/343669a0; Zimmermann R, 1998, BIOL CHEM, V379, P275	59	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36139	36147		10.1074/jbc.M304002200	http://dx.doi.org/10.1074/jbc.M304002200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853456	hybrid			2022-12-27	WOS:000185318300034
J	Kaneko, E; Matsuda, M; Yamada, Y; Tachibana, Y; Shimomura, I; Makishima, M				Kaneko, E; Matsuda, M; Yamada, Y; Tachibana, Y; Shimomura, I; Makishima, M			Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR RECEPTOR; CHOLESTEROL ABSORPTION; DIETARY-CHOLESTEROL; LXR; ACID; ABCG8; GENE; IDENTIFICATION; ACTIVATION; EXPRESSION	The nuclear receptors liver X receptor (LXR) alpha and LXRbeta serve as oxysterol receptors and regulate the expression of genes involved in lipid metabolism. LXR activation induces the expression of ATP-binding cassette (ABC) transporters, such as ABCG5 and ABCG8, which inhibit intestinal absorption of cholesterol and phytosterols. Although several synthetic LXR agonists have been generated, these compounds have limited clinical application, because they cause hypertriglycemia by inducing the expression of lipogenic genes in the liver. We synthesized derivatives of phytosterols and found some of them to act as LXR agonists. Among them, YT-32 [(22E)-ergost-22-ene-1alpha,3beta-diol], which is related to ergosterol and brassicasterol, is the most potent LXR agonist. YT-32 directly bound to LXRalpha and LXRbeta and induced the interaction of LXRalpha with cofactors, such as steroid receptor coactivator-1, as effectively as the natural ligands, 22(R)-hydroxycholesterol and 24(S),25-epoxycholesterol. Although the nonsteroidal synthetic LXR agonist T0901317 induced the expression of intestinal ABC transporters and liver lipogenic genes, oral administration of YT-32 selectively activated intestinal ABC transporters in mice. Unlike T0901317 treatment, YT-32 inhibited intestinal cholesterol absorption without increasing plasma triglyceride levels. The phytosterol-derived LXR agonist YT-32 might selectively modulate intestinal cholesterol metabolism.	Osaka Univ, Grad Sch Frontier Biosci, Suita, Osaka 5650871, Japan; Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; Nisshin Flour Milling Co, Pharmaceut Res Ctr, Ooi, Saitama 3568511, Japan	Osaka University; Osaka University	Shimomura, I (corresponding author), Osaka Univ, Grad Sch Frontier Biosci, 2-2 Yamadaoka,H2, Suita, Osaka 5650871, Japan.	ichi@fbs.osaka-u.ac.jp; maxima@fbs.osaka-u.ac.jp						Berge KE, 2000, SCIENCE, V290, P1771, DOI 10.1126/science.290.5497.1771; Collins JL, 2002, J MED CHEM, V45, P1963, DOI 10.1021/jm0255116; Fu X, 2001, J BIOL CHEM, V276, P38378, DOI 10.1074/jbc.M105805200; Glass CK, 2000, GENE DEV, V14, P121; Graf GA, 2002, J CLIN INVEST, V110, P659, DOI 10.1172/JCI200216000; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Inaba T, 2003, J BIOL CHEM, V278, P21344, DOI 10.1074/jbc.M213202200; Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0; Jones P J, 1999, Curr Atheroscler Rep, V1, P230, DOI 10.1007/s11883-999-0037-3; Joseph SB, 2002, J BIOL CHEM, V277, P11019, DOI 10.1074/jbc.M111041200; Joseph SB, 2002, P NATL ACAD SCI USA, V99, P7604, DOI 10.1073/pnas.112059299; Kaplan R, 2003, J LIPID RES, V44, P136, DOI 10.1194/jlr.M200367-JLR200; Lehmann JM, 1997, J BIOL CHEM, V272, P3137, DOI 10.1074/jbc.272.6.3137; Lu KM, 2001, TRENDS ENDOCRIN MET, V12, P314, DOI 10.1016/S1043-2760(01)00433-7; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lu TT, 2001, J BIOL CHEM, V276, P37735, DOI 10.1074/jbc.R100035200; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Moore LB, 2002, MOL ENDOCRINOL, V16, P977, DOI 10.1210/me.16.5.977; Nishizawa H, 2002, J BIOL CHEM, V277, P1586, DOI 10.1074/jbc.M104301200; Ohama T, 2002, BIOCHEM BIOPH RES CO, V296, P625, DOI 10.1016/S0006-291X(02)00853-7; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Plat J, 2002, FASEB J, V16, DOI 10.1096/fj.01-0718hyp; Plosch T, 2002, J BIOL CHEM, V277, P33870, DOI 10.1074/jbc.M206522200; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, NAT MED, V8, P1243, DOI 10.1038/nm1102-1243; Repa JJ, 2002, J BIOL CHEM, V277, P18793, DOI 10.1074/jbc.M109927200; Repa JJ, 2000, SCIENCE, V289, P1524, DOI 10.1126/science.289.5484.1524; Schultz JR, 2000, GENE DEV, V14, P2831, DOI 10.1101/gad.850400; Shimizugawa T, 2002, J BIOL CHEM, V277, P33742, DOI 10.1074/jbc.M203215200; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Song C, 2000, ENDOCRINOLOGY, V141, P4180, DOI 10.1210/en.141.11.4180; Sparrow CP, 2002, J BIOL CHEM, V277, P10021, DOI 10.1074/jbc.M108225200; Tabas I, 2002, J CLIN INVEST, V110, P583, DOI 10.1172/JCI200216381; TACHIBANA Y, 1993, STUDIES NATURAL PROD, V11, P379; Tangirala RK, 2002, P NATL ACAD SCI USA, V99, P11896, DOI 10.1073/pnas.182199799; Wang DQH, 2003, J LIPID RES, V44, P1042, DOI 10.1194/jlr.D200041-JLR200; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033; Willy PJ, 1997, GENE DEV, V11, P289, DOI 10.1101/gad.11.3.289; Yu LQ, 2002, P NATL ACAD SCI USA, V99, P16237, DOI 10.1073/pnas.252582399; Yu LQ, 2003, J BIOL CHEM, V278, P15565, DOI 10.1074/jbc.M301311200; Yu LQ, 2002, J CLIN INVEST, V110, P671, DOI [10.1172/JCI200216001, 10.1172/JCI0216001]	42	154	166	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36091	36098		10.1074/jbc.M304153200	http://dx.doi.org/10.1074/jbc.M304153200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847102	hybrid			2022-12-27	WOS:000185318300029
J	Kordulakova, J; Gilleron, M; Puzo, G; Brennan, PJ; Gicquel, B; Mikusova, K; Jackson, M				Kordulakova, J; Gilleron, M; Puzo, G; Brennan, PJ; Gicquel, B; Mikusova, K; Jackson, M			Identification of the required acyltransferase step in the biosynthesis of the phosphatidylinositol mannosides of Mycobacterium species	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CALMETTE-GUERIN; SURFACTANT PROTEIN-A; MYO-INOSITOL ANCHOR; MULTIACYLATED FORMS; DC-SIGN; TUBERCULOSIS; LIPOARABINOMANNANS; RECOGNITION; LIPOGLYCANS; RECEPTOR	Fatty acyl functions of the glycosylated phosphatidylinositol (GPI) anchors of the phosphatidylinositol mannosides (PIM), lipomannan (LM), and lipoarabinomannan (LAM) of mycobacteria play a critical role in both the physical properties and biological activities of these molecules. In a search for the acyltransferases that acylate the GPI anchors of PIM, LM, and LAM, we examined the function of the mycobacterial Rv2611c gene that encodes a putative acyltransferase involved in the early steps of phosphatidylinositol mannoside synthesis. A Rv2611c mutant of Mycobacterium smegmatis was constructed which exhibited severe growth defects and contained an increased amount of phosphatidylinositol mono- and di-mannosides and a decreased amount of acylated phosphatidylinositol di-mannosides compared with the wild-type parental strain. In cell-free assays, extracts from M. smegmatis overexpressing the M. tuberculosis Rv2611c gene incorporated [C-14]palmitate into acylated phosphatidylinositol mono- and di-mannosides, and transferred cold endogenous fatty acids onto C-14''-labeled phosphatidylinositol mono- and di-mannosides more efficiently than extracts from the wild-type strain. Cell-free extracts from the Rv2611c mutant of M. smegmatis were greatly impaired in these respects. This work provides evidence that Rv2611c is the acyltransferase that catalyzes the acylation of the 6-position of the mannose residue linked to position 2 of myo-inositol in phosphatidylinositol mono- and di-mannosides, with the mono- mannosylated lipid acceptor being the primary substrate of the enzyme. We also provide the first evidence that two distinct pathways lead to the formation of acylated PIM2 from PIM1 in mycobacteria.	Inst Pasteur, Unite Genet Mycobacterienne, F-75724 Paris 15, France; CNRS, Inst Pharmacol & Biol Struct, F-31077 Toulouse, France; Comenius Univ, Fac Nat Sci, Dept Biochem, Bratislava 84215, Slovakia; Colorado State Univ, Dept Microbiol Immunol & Pathol, Ft Collins, CO 80523 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Comenius University Bratislava; Colorado State University	Jackson, M (corresponding author), Inst Pasteur, Unite Genet Mycobacterienne, 25 Rue Dr Roux, F-75724 Paris 15, France.	mjackson@pasteur.fr	Mikusova, Katarina/I-3622-2014; Kordulakova, Jana/I-3887-2014; Jackson, Mary/D-5345-2017	Kordulakova, Jana/0000-0003-2834-0165; Jackson, Mary/0000-0002-9212-0258; Mikusova, Katarina/0000-0002-0100-4877; GILLERON, Martine/0000-0002-2581-3302				BARNES PF, 1992, J IMMUNOL, V149, P541; Besra GS, 1997, J BIOL CHEM, V272, P18460, DOI 10.1074/jbc.272.29.18460; BRENNAN P, 1967, J BIOL CHEM, V242, P3046; BRENNAN P, 1968, J BIOL CHEM, V243, P2975; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P203; Chatterjee D, 1998, GLYCOBIOLOGY, V8, P113, DOI 10.1093/glycob/8.2.113; CHATTERJEE D, 1992, J BIOL CHEM, V267, P6228; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Gilleron M, 2000, J BIOL CHEM, V275, P677, DOI 10.1074/jbc.275.1.677; Gilleron M, 1999, J MOL BIOL, V285, P2147, DOI 10.1006/jmbi.1998.2438; Gilleron M, 2001, J BIOL CHEM, V276, P34896, DOI 10.1074/jbc.M103908200; GILLERON M, 2001, GLYCANS CELL INTERAC, P113; GOREN MB, 1984, MYCOBACTERIA SOURCEB, V1, P379; HILL DL, 1966, J BIOL CHEM, V241, P895; Jackson M, 2000, J BIOL CHEM, V275, P30092, DOI 10.1074/jbc.M004658200; Kang BK, 1998, INFECT IMMUN, V66, P2769, DOI 10.1128/IAI.66.6.2769-2777.1998; KHOO KH, 1995, GLYCOBIOLOGY, V5, P117, DOI 10.1093/glycob/5.1.117; Kordulakova J, 2002, J BIOL CHEM, V277, P31335, DOI 10.1074/jbc.M204060200; Kremer L, 2002, BIOCHEM J, V363, P437, DOI 10.1042/0264-6021:3630437; LEOPOLD K, 1993, ANAL BIOCHEM, V208, P57, DOI 10.1006/abio.1993.1008; Maeda N, 2003, J BIOL CHEM, V278, P5513, DOI 10.1074/jbc.C200586200; Matsumoto K, 1997, BBA-LIPID LIPID MET, V1348, P214, DOI 10.1016/S0005-2760(97)00110-0; Nigou J, 2002, MICROBES INFECT, V4, P945, DOI 10.1016/S1286-4579(02)01621-0; Nigou J, 1997, J BIOL CHEM, V272, P23094, DOI 10.1074/jbc.272.37.23094; Nigou J, 1999, BIOCHEM J, V337, P453, DOI 10.1042/0264-6021:3370453; Nigou J, 2001, J IMMUNOL, V166, P7477, DOI 10.4049/jimmunol.166.12.7477; Nigou J, 2003, BIOCHIMIE, V85, P153, DOI 10.1016/S0300-9084(03)00048-8; PANGBORN MC, 1966, J LIPID RES, V7, P627; Pelicic V, 1997, P NATL ACAD SCI USA, V94, P10955, DOI 10.1073/pnas.94.20.10955; Schaeffer ML, 1999, J BIOL CHEM, V274, P31625, DOI 10.1074/jbc.274.44.31625; SCHLESINGER LS, 1994, J IMMUNOL, V152, P4070; Sidobre S, 2002, BIOCHEM J, V365, P89, DOI 10.1042/BJ20011659; Sidobre S, 2000, J BIOL CHEM, V275, P2415, DOI 10.1074/jbc.275.4.2415; SIELING PA, 1995, SCIENCE, V269, P227, DOI 10.1126/science.7542404; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; Tailleux L, 2003, J EXP MED, V197, P121, DOI 10.1084/jem.20021468; TAKAYAMA K, 1969, BIOCHIM BIOPHYS ACTA, V176, P196, DOI 10.1016/0005-2760(69)90089-7; VENISSE A, 1995, EUR J BIOCHEM, V231, P440, DOI 10.1111/j.1432-1033.1995.tb20717.x; Vercellone A, 1998, FRONT BIOSCI-LANDMRK, V3, pE149	39	86	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36285	36295		10.1074/jbc.M303639200	http://dx.doi.org/10.1074/jbc.M303639200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851411	hybrid			2022-12-27	WOS:000185318300052
J	Thukkani, AK; Albert, CJ; Wildsmith, KR; Messner, MC; Martinson, BD; Hsu, FF; Ford, DA				Thukkani, AK; Albert, CJ; Wildsmith, KR; Messner, MC; Martinson, BD; Hsu, FF; Ford, DA			Myeloperoxidase-derived reactive chlorinating species from human monocytes target plasmalogens in low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-CHLORIDE SYSTEM; HYPOCHLOROUS ACID; PHOSPHOLIPASE A(2); ARACHIDONIC-ACID; PROTEIN-KINASE; NITRIC-OXIDE; ACTIVATION; ATHEROSCLEROSIS; IDENTIFICATION; EXPRESSION	A role for myeloperoxidase (MPO) in atherosclerosis has received considerable attention recently. To identify potential chlorinated lipid products in human low density lipoprotein (LDL), studies were designed to demonstrate that MPO-derived reactive chlorinating species (RCS) target the plasmalogen pool of LDL isolated from peripheral human blood in vitro. The vinyl ether bond of LDL plasmalogens was targeted by MPO-derived RCS, resulting in the release of the 16- and 18-carbon- containing alpha-chloro fatty aldehydes, 2-chloro-hexadecanal and 2-chlorooctadecanal, respectively, from the plasmalogen glycerol backbone. Targeting of the LDL plasmalogen vinyl ether bond was dependent on the presence of MPO-derived RCS. Electrospray ionization mass spectrometric analysis of MPO-treated LDL demonstrated that a novel population of unsaturated lysophosphatidylcholine molecular species was produced by a phospholipase A(2)-independent mechanism. Unsaturated lysophosphatidylcholine molecular species elicited cyclic AMP response element binding protein phosphorylation in RAW 264.7 cells. Additionally, MPO-mediated targeting of both monocyte and LDL plasmalogen pools was demonstrated in phorbol myristate acetate-stimulated human monocytes, resulting in the production of both 2-chlorohexadecanal and 2-chlorooctadecanal. In contrast, alpha-chloro fatty aldehydes were not produced in phorbol myristate acetate-stimulated mouse monocytes. Collectively, the present studies demonstrate a novel MPO-specific mechanism that mediates the production of a novel group of unsaturated lysophosphatidylcholine molecular species and chlorinated aldehydes from both LDL and monocyte plasmalogen pools that may have important effects during inflammatory reactions mediated by monocytes, most notably atherosclerosis.	St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Washington Univ, Dept Med, St Louis, MO 63110 USA	Saint Louis University; Washington University (WUSTL)	Ford, DA (corresponding author), St Louis Univ, Hlth Sci Ctr, Sch Med, Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	fordda@slu.edu	Ford, David/D-1819-2018	Ford, David/0000-0002-0029-1560; Hsu, Fong-Fu/0000-0001-5368-0183	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000954] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042665] Funding Source: NIH RePORTER; NCRR NIH HHS [RR00954] Funding Source: Medline; NHLBI NIH HHS [R01 HL 42665] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Albert CJ, 2001, J BIOL CHEM, V276, P23733, DOI 10.1074/jbc.M101447200; ALBRICH JM, 1981, P NATL ACAD SCI-BIOL, V78, P210, DOI 10.1073/pnas.78.1.210; BECKERMAN KP, 1993, J IMMUNOL, V150, P888; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brennan ML, 2001, J CLIN INVEST, V107, P419, DOI 10.1172/JCI8797; Caslake MJ, 2000, ATHEROSCLEROSIS, V150, P413, DOI 10.1016/S0021-9150(99)00406-2; DAUGHERTY A, 1994, J CLIN INVEST, V94, P437, DOI 10.1172/JCI117342; Dittmer J, 1969, METHOD ENZYMOL, V14, P482, DOI [DOI 10.1016/S0076-6879(69)14055-0, 10.1016/S0076-6879(69)14055-0]; ENGELMANN B, 1994, BIOCHEM BIOPH RES CO, V204, P1235, DOI 10.1006/bbrc.1994.2595; FORD DA, 1989, P NATL ACAD SCI USA, V86, P3479, DOI 10.1073/pnas.86.10.3479; Ford DA, 1996, FEBS LETT, V394, P99, DOI 10.1016/0014-5793(96)00930-1; Fu XY, 2001, J BIOL CHEM, V276, P41279, DOI 10.1074/jbc.M106958200; GROSS RW, 1985, BIOCHEMISTRY-US, V24, P1662, DOI 10.1021/bi00328a014; GROSS RW, 1984, BIOCHEMISTRY-US, V23, P158, DOI 10.1021/bi00296a026; HAN XL, 1994, P NATL ACAD SCI USA, V91, P10635, DOI 10.1073/pnas.91.22.10635; Hanasaki K, 2002, J BIOL CHEM, V277, P29116, DOI 10.1074/jbc.M202867200; HARRISON JE, 1976, J BIOL CHEM, V251, P1371; Hazen SL, 1996, J BIOL CHEM, V271, P23080, DOI 10.1074/jbc.271.38.23080; Hazen SL, 1999, METHOD ENZYMOL, V300, P88; Hazen SL, 1997, J CLIN INVEST, V99, P2075, DOI 10.1172/JCI119379; HAZEN SL, 1993, J CLIN INVEST, V91, P2513, DOI 10.1172/JCI116487; HEINECKE JW, 1994, BIOCHEMISTRY-US, V33, P10127, DOI 10.1021/bi00199a041; Hsu FF, 1999, INT J MASS SPECTROM, V185, P795, DOI 10.1016/S1387-3806(98)14105-2; Hulthe J, 2001, ARTERIOSCL THROM VAS, V21, P269, DOI 10.1161/01.ATV.21.2.269; HUTERER SJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P204, DOI 10.1016/0005-2760(93)90163-4; JURGENS G, 1993, ARTERIOSCLER THROMB, V13, P1689, DOI 10.1161/01.ATV.13.11.1689; LAMPERT MB, 1983, BLOOD, V62, P645; Macphee Colin H., 2001, Current Opinion in Pharmacology, V1, P121, DOI 10.1016/S1471-4892(01)00024-8; Malle E, 2000, EUR J BIOCHEM, V267, P4495, DOI 10.1046/j.1432-1327.2000.01498.x; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MORRIS JC, 1966, J PHYS CHEM-US, V70, P3798, DOI 10.1021/j100884a007; Murohara T, 1996, CIRC RES, V78, P780, DOI 10.1161/01.RES.78.5.780; Nigam S, 2000, BBA-MOL CELL BIOL L, V1488, P167, DOI 10.1016/S1388-1981(00)00119-0; Page S, 1999, J BIOL CHEM, V274, P11611, DOI 10.1074/jbc.274.17.11611; PAK JH, 1987, BIOCHEMISTRY-US, V26, P4824, DOI 10.1021/bi00389a033; Podrez EA, 1999, J CLIN INVEST, V103, P1547, DOI 10.1172/JCI5549; QUINN MT, 1988, P NATL ACAD SCI USA, V85, P2805, DOI 10.1073/pnas.85.8.2805; Rikitake Y, 2001, BIOCHEM BIOPH RES CO, V281, P1291, DOI 10.1006/bbrc.2001.4510; Sartipy P, 1999, TRENDS CARDIOVAS MED, V9, P232, DOI 10.1016/S1050-1738(00)00030-X; Sugiyama S, 2001, AM J PATHOL, V158, P879, DOI 10.1016/S0002-9440(10)64036-9; Thomas E L, 1986, Methods Enzymol, V132, P569; THOMAS EL, 1982, BIOCHEMISTRY-US, V21, P6299, DOI 10.1021/bi00267a040; Thukkani AK, 2002, J BIOL CHEM, V277, P3842, DOI 10.1074/jbc.M109489200; WEISS SJ, 1982, J CLIN INVEST, V70, P598, DOI 10.1172/JCI110652; Williams SD, 2001, AM J PHYSIOL-HEART C, V281, pH168, DOI 10.1152/ajpheart.2001.281.1.H168; Williams SD, 1997, FEBS LETT, V420, P33, DOI 10.1016/S0014-5793(97)01482-8; WINTERBOURN CC, 1992, ARCH BIOCHEM BIOPHYS, V296, P547, DOI 10.1016/0003-9861(92)90609-Z; Zeng YC, 1998, BIOCHEMISTRY-US, V37, P2346, DOI 10.1021/bi9725172; Zhang ZL, 2001, JAMA-J AM MED ASSOC, V286, P2136, DOI 10.1001/jama.286.17.2136	49	73	77	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36365	36372		10.1074/jbc.M305449200	http://dx.doi.org/10.1074/jbc.M305449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12869568	hybrid			2022-12-27	WOS:000185318300063
J	Dixelius, J; Makinen, T; Wirzenius, M; Karkkainen, MJ; Wernstedt, C; Alitalo, K; Claesson-Welsh, L				Dixelius, J; Makinen, T; Wirzenius, M; Karkkainen, MJ; Wernstedt, C; Alitalo, K; Claesson-Welsh, L			Ligand-induced vascular endothelial growth factor receptor-3 (VEGFR-3) heterodimerization with VEGFR-2 in primary lymphatic endothelial cells regulates tyrosine phosphorylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLT4 RECEPTOR; TUMOR LYMPHANGIOGENESIS; SIGNALING PROPERTIES; BREAST-CANCER; HUMAN TISSUES; EXPRESSION; ANGIOGENESIS; LYMPHEDEMA; PROMOTES; GENE	Vascular endothelial growth factors (VEGFs) regulate the development and growth of the blood and lymphatic vascular systems. Of the three VEGF receptors ( VEGFR), VEGFR-1 and -2 are expressed on blood vessels; VEGFR-2 is found also on lymphatic vessels. VEGFR-3 is expressed mainly on lymphatic vessels but it is also up-regulated in tumor angiogenesis. Although VEGFR-3 is essential for proper lymphatic development, its signal transduction mechanisms are still incompletely understood. Trans-phosphorylation of activated, dimerized receptor tyrosine kinases is known to be critical for the regulation of kinase activity and for receptor interaction with signal transduction molecules. In this study, we have identified five tyrosyl phosphorylation sites in the VEGFR-3 carboxyl-terminal tail. These sites were used both in VEGFR-3 overexpressed in 293 cells and when the endogenous VEGFR-3 was activated in lymphatic endothelial cells. Interestingly, VEGF-C stimulation of lymphatic endothelial cells also induced the formation of VEGFR-3/VEGFR-2 heterodimers, in which VEGFR-3 was phosphorylated only at three of the five sites while the two most carboxyl-terminal tyrosine residues appeared not to be accessible for the VEGFR-2 kinase. Our data suggest that the carboxyl-terminal tail of VEGFR-3 provides important regulatory tyrosine phosphorylation sites with potential signal transduction capacity and that these sites are differentially used in ligand-induced homo- and heterodimeric receptor complexes.	Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, S-75185 Uppsala, Sweden; Univ Helsinki, Biomedicum Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Uppsala Biomed Ctr, Ludwig Inst Canc Res, S-75124 Uppsala, Sweden	Uppsala University; University of Helsinki; Ludwig Institute for Cancer Research	Claesson-Welsh, L (corresponding author), Univ Uppsala, Dept Genet & Pathol, Rudbeck Lab, Dag Hammarskjolds Vag 20, S-75185 Uppsala, Sweden.		Makinen, Taija/CAI-2233-2022; Makinen, Taija/C-5765-2014; Alitalo, Kari K/J-5013-2014	Makinen, Taija/0000-0002-9338-1257; Makinen, Taija/0000-0002-9338-1257; Alitalo, Kari K/0000-0002-7331-0902; Claesson-Welsh, Lena/0000-0003-4275-2000				BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; Claesson-Welsh Lena, 1994, Progress in Growth Factor Research, V5, P37, DOI 10.1016/0955-2235(94)90016-7; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; Ekman S, 1999, ONCOGENE, V18, P2481, DOI 10.1038/sj.onc.1202606; Enholm B, 2001, CIRC RES, V88, P623, DOI 10.1161/01.RES.88.6.623; FOURNIER E, 1995, ONCOGENE, V11, P921; GALLAND F, 1993, ONCOGENE, V8, P1233; Huang K, 2001, INT J BIOCHEM CELL B, V33, P315, DOI 10.1016/S1357-2725(01)00019-X; Hughes DC, 2001, J MOL EVOL, V53, P77, DOI 10.1007/s002390010195; Igarashi K, 1998, BIOCHEM BIOPH RES CO, V251, P77, DOI 10.1006/bbrc.1998.9442; Joukov V, 1997, EMBO J, V16, P3898, DOI 10.1093/emboj/16.13.3898; Jussila L, 1998, CANCER RES, V58, P1599; Karkkainen MJ, 2002, SEMIN CELL DEV BIOL, V13, P9, DOI 10.1006/scdb.2001.0286; Karkkainen MJ, 2000, NAT GENET, V25, P153, DOI 10.1038/75997; Karpanen T, 2001, CANCER RES, V61, P1786; Kubo H, 2000, BLOOD, V96, P546; Lymboussaki A, 1998, AM J PATHOL, V153, P395, DOI 10.1016/S0002-9440(10)65583-6; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; Makinen T, 2001, NAT MED, V7, P199, DOI 10.1038/84651; MATSUMOTO T, 2001, SCI STKE 2001; Matsumura K, 2003, BLOOD, V101, P1367, DOI 10.1182/blood-2002-05-1329; Mattila MMT, 2002, INT J CANCER, V98, P946, DOI 10.1002/ijc.10283; PAJUSOLA K, 1992, CANCER RES, V52, P5738; PAJUSOLA K, 1994, ONCOGENE, V9, P3545; PAJUSOLA K, 1993, ONCOGENE, V8, P2931; Partanen TA, 1999, CANCER-AM CANCER SOC, V86, P2406, DOI 10.1002/(SICI)1097-0142(19991201)86:11<2406::AID-CNCR31>3.3.CO;2-5; Partanen TA, 2000, FASEB J, V14, P2087, DOI 10.1096/fj.99-1049com; Saaristo A, 2002, J EXP MED, V196, P719, DOI 10.1084/jem.20020587; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Valtola R, 1999, AM J PATHOL, V154, P1381, DOI 10.1016/S0002-9440(10)65392-8; Van Der Geer P., 1993, PROTEIN PHOSPHORYLAT, P31; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Witmer AN, 2002, J HISTOCHEM CYTOCHEM, V50, P767, DOI 10.1177/002215540205000603; Witmer AN, 2001, J PATHOL, V195, P490, DOI 10.1002/path.969	35	176	188	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40973	40979		10.1074/jbc.M304499200	http://dx.doi.org/10.1074/jbc.M304499200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881528	hybrid			2022-12-27	WOS:000185847200070
J	Driscoll, HC; Matson, SW; Sayer, JM; Kroth, H; Jerina, DM; Brosh, RM				Driscoll, HC; Matson, SW; Sayer, JM; Kroth, H; Jerina, DM; Brosh, RM			Inhibition of Werner syndrome helicase activity by benzo[c]phenanthrene diol epoxide dA adducts in DNA is both strand- and stereoisomer-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; SYNDROME PROTEIN; SYNDROME CELLS; ESCHERICHIA-COLI; BIOCHEMICAL-CHARACTERIZATION; HOMOLOGOUS RECOMBINATION; SACCHAROMYCES-CEREVISIAE; DEOXYADENOSINE ADDUCTS; SUBSTRATE-SPECIFICITY; SOLUTION CONFORMATION	Helicases are among the first enzymes to encounter DNA damage during DNA processing within the cell and thus are likely to be targets for the adverse effects of DNA lesions induced by environmental chemicals. Here we examined the effect of cis- and trans-opened 3,4-diol 1,2-epoxide (DE) DNA adducts of benzo[c] phenanthrene (BcPh) at N-6 of adenine on helicase activity. These adducts are derived from the highly tumorigenic (-)( 1R, 2S, 3S, 4R)- DE as well as its less carcinogenic (+)( 1S, 2R, 3R, 4S)-DE enantiomer in both of which the benzylic 4-hydroxyl group and epoxide oxygen are trans. The hydrocarbon portions of these adducts intercalate into DNA on the 3' or the 5' side of the adducted deoxyadenosine for the 1S- and 1R-adducts, respectively. These adducts inhibited the human Werner (WRN) syndrome helicase activity in a strand-specific and stereospecific manner. In the strand along which WRN translocates, cis- opened adducts were significantly more effective inhibitors than trans-opened isomers, indicating that WRN unwinding is sensitive to adduct stereochemistry. WRN helicase activity was also inhibited but to a lesser extent by cis- opened BcPh DE adducts in the displaced strand independent of their direction of intercalation, whereas inhibition by the trans-opened stereoisomers in the displaced strand depended on their orientation, such that only adducts oriented toward the advancing helicase inhibited WRN activity. A BcPh DE adduct positioned in the helicase-translocating strand did not sequester WRN, nor affect the rate of ATP hydrolysis relative to an unadducted control. Although the Bloom (BLM) syndrome helicase was also inhibited by a cis- opened adduct in a strand-specific manner, this helicase was not as severely affected as WRN. Because BcPh DEs form substantial amounts of deoxyadenosine adducts at dA, their adverse effects on helicases could contribute to genetic damage and cell transformation induced by these DEs. Thus, the unwinding activity of RecQ helicases is sensitive to the strand, orientation, and stereochemistry of intercalated polycyclic aromatic hydrocarbon adducts.	NIA, Lab Mol Gerontol, NIH, DHHS, Baltimore, MD 21224 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Program Mol & Cellular Biophys, Chapel Hill, NC 27599 USA; NIDDK, Bioorgan Chem Lab, NIH, DHHS, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Brosh, RM (corresponding author), NIA, Lab Mol Gerontol, NIH, DHHS, 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.		Brosh, Robert/AAR-6124-2020	Kroth, Heiko/0000-0002-6936-3921	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031104] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [ZIAAG000741, Z01AG000741] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Agarwal R, 1996, CHEM RES TOXICOL, V9, P586, DOI 10.1021/tx950148+; AGARWAL SK, 1987, J AM CHEM SOC, V109, P2497, DOI 10.1021/ja00242a040; [Anonymous], 1985, BIOACTIVATION FOREIG; Baum M, 2001, CHEM RES TOXICOL, V14, P686, DOI 10.1021/tx000240s; Bennett RJ, 1999, J MOL BIOL, V289, P235, DOI 10.1006/jmbi.1999.2739; BIGGER CAH, 1992, P NATL ACAD SCI USA, V89, P368, DOI 10.1073/pnas.89.1.368; BJORSETH A, 1979, 3 INT S CHEM BIOL CA, P371; Brosh RM, 2000, NUCLEIC ACIDS RES, V28, P2420, DOI 10.1093/nar/28.12.2420; Brosh RM, 2002, J BIOL CHEM, V277, P23236, DOI 10.1074/jbc.M111446200; Brosh RM, 2001, J BIOL CHEM, V276, P3024, DOI 10.1074/jbc.M006784200; BROWN WC, 1989, J BIOL CHEM, V264, P6748; Buterin T, 2000, CANCER RES, V60, P1849; CHENG RZ, 1990, MUTAT RES, V237, P259, DOI 10.1016/0921-8734(90)90008-F; COSMAN M, 1993, BIOCHEMISTRY-US, V32, P12488, DOI 10.1021/bi00097a029; COSMAN M, 1995, BIOCHEMISTRY-US, V34, P1295, DOI 10.1021/bi00004a024; DEVOS RH, 1990, FOOD CHEM TOXICOL, V28, P263, DOI 10.1016/0278-6915(90)90038-O; DIPPLE A, 1987, NATURE, V327, P535, DOI 10.1038/327535a0; Einolf HJ, 1996, CARCINOGENESIS, V17, P2237, DOI 10.1093/carcin/17.10.2237; Frank EG, 2002, NUCLEIC ACIDS RES, V30, P5284, DOI 10.1093/nar/gkf643; Fry M, 1999, J BIOL CHEM, V274, P12797, DOI 10.1074/jbc.274.18.12797; HANAOKA F, 1985, ADV EXP MED BIOL, V190, P439; Harmon FG, 2001, J BIOL CHEM, V276, P232, DOI 10.1074/jbc.M006555200; Huber MD, 2002, NUCLEIC ACIDS RES, V30, P3954, DOI 10.1093/nar/gkf530; Ilankumaran P, 2001, CHEM RES TOXICOL, V14, P1330, DOI 10.1021/tx010092l; *INT AG RES COUNC, 1983, IARC MON EV CARC RIS; International Agency for Research on Cancer, 1985, IARC MON EV CARC RIS; Jerina D M, 1986, Adv Exp Med Biol, V197, P11; Kamath-Loeb AS, 2000, P NATL ACAD SCI USA, V97, P4603, DOI 10.1073/pnas.97.9.4603; Kamath-Loeb AS, 2001, J BIOL CHEM, V276, P16439, DOI 10.1074/jbc.M100253200; Karow JK, 1999, CURR BIOL, V9, P597, DOI 10.1016/S0960-9822(99)80264-4; Kroth H, 2001, CHEM RES TOXICOL, V14, P708, DOI 10.1021/tx0002637; LEVIN W, 1986, CANCER RES, V46, P2257; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; LOWN JW, 1985, BIOCHEMISTRY-US, V24, P4028, DOI 10.1021/bi00336a034; LUNDE G, 1977, NATURE, V268, P518, DOI 10.1038/268518a0; Marians KJ, 2000, STRUCTURE, V8, pR227, DOI 10.1016/S0969-2126(00)00539-6; MATSON SW, 1983, J BIOL CHEM, V258, P4009; Mechanic LE, 2000, J BIOL CHEM, V275, P38337, DOI 10.1074/jbc.M006268200; Mohaghegh P, 2001, NUCLEIC ACIDS RES, V29, P2843, DOI 10.1093/nar/29.13.2843; Mohaghegh P, 2001, HUM MOL GENET, V10, P741, DOI 10.1093/hmg/10.7.741; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAEGELI H, 1993, J BIOL CHEM, V268, P10386; NAEGELI H, 1993, BIOCHEMISTRY-US, V32, P613, DOI 10.1021/bi00053a029; Opresko PL, 2001, J BIOL CHEM, V276, P44677, DOI 10.1074/jbc.M107548200; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651; Pommier Y, 2000, P NATL ACAD SCI USA, V97, P10739, DOI 10.1073/pnas.190312697; Ponten I, 1999, BIOCHEMISTRY-US, V38, P1144, DOI 10.1021/bi982436l; Ponten I, 2000, BIOCHEMISTRY-US, V39, P4136, DOI 10.1021/bi991719q; POOT M, 1992, EXP CELL RES, V202, P267, DOI 10.1016/0014-4827(92)90074-I; Prince PR, 2001, GENE DEV, V15, P933, DOI 10.1101/gad.877001; PRUESSSCHWARTZ D, 1987, CANCER RES, V47, P4032; Saintigny Y, 2002, MOL CELL BIOL, V22, P6971, DOI 10.1128/MCB.22.20.6971-6978.2002; SALK D, 1985, ADV EXP MED BIOL, V190, P305; SAYER JM, 1991, J ORG CHEM, V56, P20, DOI 10.1021/jo00001a007; Shen JC, 2000, TRENDS GENET, V16, P213, DOI 10.1016/S0168-9525(99)01970-8; Shen JC, 1998, NUCLEIC ACIDS RES, V26, P2879, DOI 10.1093/nar/26.12.2879; TAKEUCHI F, 1982, HUM GENET, V60, P365, DOI 10.1007/BF00569220; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; van Brabant AJ, 2000, ANNU REV GENOM HUM G, V1, P409, DOI 10.1146/annurev.genom.1.1.409; VILLANI G, 1994, J BIOL CHEM, V269, P21676; Villani G, 2000, J BIOL CHEM, V275, P33185, DOI 10.1074/jbc.R000011200; Wei SJC, 1996, CANCER RES, V56, P3695; Wu L, 2002, MUTAT RES-FUND MOL M, V509, P35, DOI 10.1016/S0027-5107(02)00225-7; Yong YQ, 1996, CHEM RES TOXICOL, V9, P179, DOI 10.1021/tx950112h; Yu CE, 1996, SCIENCE, V272, P258, DOI 10.1126/science.272.5259.258	66	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41126	41135		10.1074/jbc.M304798200	http://dx.doi.org/10.1074/jbc.M304798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881525	hybrid, Green Published			2022-12-27	WOS:000185847200088
J	Haumaitre, C; Reber, M; Cereghini, S				Haumaitre, C; Reber, M; Cereghini, S			Functions of HNF1 family members in differentiation of the visceral endoderm cell lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1; TRANSCRIPTION FACTORS; MOUSE EMBRYO; HOMEOPROTEIN FAMILY; EPITHELIAL-CELLS; GENE-EXPRESSION; PROMOTER; VHNF1; HNF-1-ALPHA; MUTATIONS	The two members of the hepatocyte nuclear factor 1 (HNF1) transcription factor family, HNF1 and variant HNF1 (vHNF1), show a strong homology in their atypical POU-homeodomain and dimerization domain but differ in their transactivation domains. Moreover, two vHNF1 isoforms generated by alternative splicing are present in all tissues expressing this gene. vHnf1-deficient mouse embryos die soon after implantation due to defective visceral endoderm formation, an extraembryonic tissue essential for development and survival of the embryo proper. In contrast, invalidation of Hnf1, which is expressed at later developmental stages than vHnf1, does not lead to embryonic lethality or developmental defects. To examine the specific or potential equivalent functions of vHNF1 isoforms and HNF1 during the process of visceral endoderm differentiation, we stably reexpressed these factors in vHnf1-deficient embryonic stem cells. Analysis of these embryonic stem cells upon differentiation into embryoid bodies shows that vHNF1 isoforms exhibit specific behaviors depending on particular target genes and cooperate in the establishment of a functional visceral endoderm. Furthermore, forced expression of HNF1 in vHnf1-deficient embryonic stem cells fully restores the formation of a mature visceral endoderm with the correct expression profile of early and late markers of this lineage. Thus, in this context, HNF1 functionally replaces both vHNF1 isoforms, suggesting that the different developmental functions of these transcription factors are mainly due to the acquisition of novel expression patterns.	Hop Enfants Malad, INSERM, U423, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm)	Cereghini, S (corresponding author), Univ Paris 06, CNRS, UMR 7622, 9 Quai St Bernard,Batiment C Porte 718 Case 24, F-75252 Paris, France.	cereghini@necker.fr	Reber, Michael/D-6250-2012; Haumaitre, Cecile/E-5455-2017	Haumaitre, Cecile/0000-0003-3526-7832; Reber, Michael/0000-0001-8842-7276				Acampora D, 2000, INT J DEV BIOL, V44, P669; BACH I, 1991, NUCLEIC ACIDS RES, V19, P3553, DOI 10.1093/nar/19.13.3553; BACH I, 1993, EMBO J, V12, P4229, DOI 10.1002/j.1460-2075.1993.tb06107.x; Barbacci E, 1999, DEVELOPMENT, V126, P4795; Barbera JPM, 2000, DEVELOPMENT, V127, P2433; Beddington RSP, 1998, TRENDS GENET, V14, P277, DOI 10.1016/S0168-9525(98)01499-1; Belaoussoff M, 1998, DEVELOPMENT, V125, P5009; Boj SF, 2001, P NATL ACAD SCI USA, V98, P14481, DOI 10.1073/pnas.241349398; BOSHART M, 1992, GENE, V110, P129, DOI 10.1016/0378-1119(92)90456-Y; Bouchard M, 2000, DEVELOPMENT, V127, P3703; BREWER CB, 1994, METHOD CELL BIOL, V43, P233; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cereghini S, 1996, FASEB J, V10, P267, DOI 10.1096/fasebj.10.2.8641560; CEREGHINI S, 1988, GENE DEV, V2, P957, DOI 10.1101/gad.2.8.957; Cheng AM, 1998, CELL, V95, P793, DOI 10.1016/S0092-8674(00)81702-X; Chi YI, 2002, MOL CELL, V10, P1129, DOI 10.1016/S1097-2765(02)00704-9; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 1999, DEVELOPMENT, V126, P4785; Coffinier C, 1999, MECH DEVELOP, V89, P211, DOI 10.1016/S0925-4773(99)00221-X; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Coucouvanis E, 1999, DEVELOPMENT, V126, P535; DESIMONE V, 1989, NUCLEIC ACIDS RES, V17, P9407, DOI 10.1093/nar/17.22.9407; DESIMONE V, 1991, EMBO J, V10, P1435, DOI 10.1002/j.1460-2075.1991.tb07664.x; Duncan SA, 1997, DEVELOPMENT, V124, P279; Farrington SM, 1997, MECH DEVELOP, V62, P197, DOI 10.1016/S0925-4773(97)00664-3; FEUERMAN MH, 1989, MOL CELL BIOL, V9, P4204, DOI 10.1128/MCB.9.10.4204; Force A, 1999, GENETICS, V151, P1531; Fujikura J, 2002, GENE DEV, V16, P784, DOI 10.1101/gad.968802; HANKS M, 1995, SCIENCE, V269, P679, DOI 10.1126/science.7624797; Hatzis P, 2001, MOL CELL BIOL, V21, P7320, DOI 10.1128/MCB.21.21.7320-7330.2001; Jacquemin P, 2000, MOL CELL BIOL, V20, P4445, DOI 10.1128/MCB.20.12.4445-4454.2000; Koutsourakis M, 1999, DEVELOPMENT, V126, P723; LAZZARO D, 1992, DEVELOPMENT, V114, P469; Le Hir H, 2003, TRENDS BIOCHEM SCI, V28, P215, DOI 10.1016/S0968-0004(03)00052-5; Lee YH, 1998, MOL CELL BIOL, V18, P3059, DOI 10.1128/MCB.18.5.3059; Maye P, 2000, MECH DEVELOP, V94, P117, DOI 10.1016/S0925-4773(00)00304-X; MOLNE M, 1989, NUCLEIC ACIDS RES, V17, P3447, DOI 10.1093/nar/17.9.3447; Morrisey EE, 1998, GENE DEV, V12, P3579, DOI 10.1101/gad.12.22.3579; Nammo T, 2002, DIABETOLOGIA, V45, P1142, DOI 10.1007/s00125-002-0892-8; OTT MO, 1991, MECH DEVELOP, V36, P47, DOI 10.1016/0925-4773(91)90071-D; OTT MO, 1984, EMBO J, V3, P2505, DOI 10.1002/j.1460-2075.1984.tb02164.x; Pontoglio M, 1996, CELL, V84, P575, DOI 10.1016/S0092-8674(00)81033-8; Pontoglio M, 1998, J CLIN INVEST, V101, P2215, DOI 10.1172/JCI2548; Power SC, 1996, MOL CELL BIOL, V16, P778; Reber M, 2001, MECH DEVELOP, V100, P75, DOI 10.1016/S0925-4773(00)00493-7; REYCAMPOS J, 1991, EMBO J, V10, P1445, DOI 10.1002/j.1460-2075.1991.tb07665.x; RINGEISEN F, 1993, J BIOL CHEM, V268, P25706; Rodda SJ, 2002, INT J DEV BIOL, V46, P449; Ryffel GU, 2001, J MOL ENDOCRINOL, V27, P11, DOI 10.1677/jme.0.0270011; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Shih DQ, 2001, DIABETES, V50, P2472, DOI 10.2337/diabetes.50.11.2472; TARAVIRAS S, 1994, MECH DEVELOP, V48, P67, DOI 10.1016/0925-4773(94)90017-5; Thomas H, 2001, HUM MOL GENET, V10, P2089, DOI 10.1093/hmg/10.19.2089; Thomas PQ, 1998, DEVELOPMENT, V125, P85; TOMEI L, 1992, EMBO J, V11, P4119, DOI 10.1002/j.1460-2075.1992.tb05505.x; Wilkie GS, 2003, TRENDS BIOCHEM SCI, V28, P182, DOI 10.1016/S0968-0004(03)00051-3; ZHONG WM, 1994, MOL CELL BIOL, V14, P7276, DOI 10.1128/MCB.14.11.7276; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	58	25	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40933	40942		10.1074/jbc.M304372200	http://dx.doi.org/10.1074/jbc.M304372200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12860991	hybrid			2022-12-27	WOS:000185847200065
J	Rodionov, DA; Vitreschak, AG; Mironov, AA; Gelfand, MS				Rodionov, DA; Vitreschak, AG; Mironov, AA; Gelfand, MS			Comparative Genomics of the vitamin B-12 metabolism and regulation in prokaryotes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COBALAMIN VITAMIN-B-12; SALMONELLA-TYPHIMURIUM; HEMOGLOBIN RECEPTOR; ESCHERICHIA-COLI; ACID A,C-DIAMIDE; BIOSYNTHESIS; GENES; IDENTIFICATION; TRANSPORT; SEQUENCE	Using comparative analysis of genes, operons, and regulatory elements, we describe the cobalamin ( vitamin B-12) biosynthetic pathway in available prokaryotic genomes. Here we found a highly conserved RNA secondary structure, the regulatory B-12 element, which is widely distributed in the upstream regions of cobalamin biosynthetic/transport genes in eubacteria. In addition, the binding signal (CBL-box) for a hypothetical B-12 regulator was identified in some archaea. A search for B-12 elements and CBL-boxes and positional analysis identified a large number of new candidate B-12-regulated genes in various prokaryotes. Among newly assigned functions associated with the cobalamin biosynthesis, there are several new types of cobalt transporters, ChlI and ChlD subunits of the CobN-dependent cobaltochelatase complex, cobalt reductase BluB, adenosyltransferase PduO, several new proteins linked to the lower ligand assembly pathway, L-threonine kinase PduX, and a large number of other hypothetical proteins. Most missing genes detected within the cobalamin biosynthetic pathways of various bacteria were identified as nonorthologous substitutes. The variable parts of the cobalamin metabolism appear to be the cobalt transport and insertion, the CobG/CbiG- and CobF/CbiD-catalyzed reactions, and the lower ligand synthesis pathway. The most interesting result of analysis of B-12 elements is that B-12-independent isozymes of the methionine synthase and ribonucleotide reductase are regulated by B-12 elements in bacteria that have both B-12-dependent and B-12-independent isozymes. Moreover, B-12 regulons of various bacteria are thought to include enzymes from known B-12-dependent or alternative pathways.	State Sci Ctr GosNIIGenetika, Moscow 113545, Russia; Russian Acad Sci, Inst Problems Informat Transmiss, Moscow 101447, Russia; Integrated Genom Moscow, Moscow 117333, Russia	Russian Academy of Sciences	Rodionov, DA (corresponding author), State Sci Ctr GosNIIGenetika, Moscow 113545, Russia.	rodionov@genetika.ru	Mironov, Andrey/C-8024-2012; Gelfand, Mikhail S/F-3425-2012; Rodionov, Dmitry/V-2688-2018	Rodionov, Dmitry/0000-0002-0939-390X; Gelfand, Mikhail/0000-0003-4181-0846				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Banerjee R, 2001, BIOCHEMISTRY-US, V40, P6191, DOI 10.1021/bi0104423; Benning MM, 1998, J BIOL CHEM, V273, P33572, DOI 10.1074/jbc.273.50.33572; Benson DA, 2003, NUCLEIC ACIDS RES, V31, P23, DOI 10.1093/nar/gkg057; BLANCHE F, 1992, J BACTERIOL, V174, P7452, DOI 10.1128/jb.174.22.7452-7454.1992; Bobik TA, 1999, J BACTERIOL, V181, P5967, DOI 10.1128/JB.181.19.5967-5975.1999; Buckel W, 2001, APPL MICROBIOL BIOT, V57, P263, DOI 10.1007/s002530100773; Cadieux N, 2002, J BACTERIOL, V184, P706, DOI 10.1128/JB.184.3.706-717.2002; Cheong CG, 2001, J BIOL CHEM, V276, P37612, DOI 10.1074/jbc.M105390200; Daniel R, 1998, FEMS MICROBIOL REV, V22, P553, DOI 10.1111/j.1574-6976.1998.tb00387.x; DEBUSSCHE L, 1993, J BACTERIOL, V175, P7430, DOI 10.1128/JB.175.22.7430-7440.1993; DEBUSSCHE L, 1992, J BACTERIOL, V174, P7445, DOI 10.1128/jb.174.22.7445-7451.1992; Enright AJ, 1999, NATURE, V402, P86, DOI 10.1038/47056; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; Fonseca MV, 2001, J BIOL CHEM, V276, P32101, DOI 10.1074/jbc.M102510200; Gaudu P, 2000, J BACTERIOL, V182, P1788, DOI 10.1128/JB.182.7.1788-1793.2000; Gelfand M S, 2000, Brief Bioinform, V1, P357, DOI 10.1093/bib/1.4.357; Gelfand MS, 2000, NUCLEIC ACIDS RES, V28, P695, DOI 10.1093/nar/28.3.695; Johnson CLV, 2001, J BACTERIOL, V183, P1577, DOI 10.1128/JB.183.5.1577-1584.2001; Jordan A, 1997, P NATL ACAD SCI USA, V94, P13487, DOI 10.1073/pnas.94.25.13487; Kofoid E, 1999, J BACTERIOL, V181, P5317, DOI 10.1128/JB.181.17.5317-5329.1999; Komeda H, 1997, P NATL ACAD SCI USA, V94, P36, DOI 10.1073/pnas.94.1.36; Koster W, 2001, RES MICROBIOL, V152, P291, DOI 10.1016/S0923-2508(01)01200-1; Martens JH, 2002, APPL MICROBIOL BIOT, V58, P275, DOI 10.1007/s00253-001-0902-7; McGoldrick H, 2002, BIOCHEM SOC T, V30, P646, DOI 10.1042/bst0300646; McMillan DJ, 1998, GENE, V208, P243, DOI 10.1016/S0378-1119(97)00651-3; Mironov AA, 2000, MOL BIOL+, V34, P222, DOI 10.1007/BF02759643; Nahvi A, 2002, CHEM BIOL, V9, P1043, DOI 10.1016/S1074-5521(02)00224-7; Nou XW, 1998, J BACTERIOL, V180, P6719, DOI 10.1128/JB.180.24.6719-6728.1998; O'Toole G. A., 1994, ESCHERICHIA COLI SAL, P710; Olczak T, 2001, J BACTERIOL, V183, P5599, DOI 10.1128/JB.183.19.5599-5608.2001; Overbeek R, 2003, NUCLEIC ACIDS RES, V31, P164, DOI 10.1093/nar/gkg148; POLLICH M, 1995, J BACTERIOL, V177, P4481, DOI 10.1128/jb.177.15.4481-4487.1995; Raux E, 1997, J BACTERIOL, V179, P3202, DOI 10.1128/jb.179.10.3202-3212.1997; Raux E, 1998, BIOCHEM J, V335, P167, DOI 10.1042/bj3350167; Raux E, 2003, BIOCHEM J, V370, P505, DOI 10.1042/BJ20021443; Ravnum S, 2001, MOL MICROBIOL, V39, P1585, DOI 10.1046/j.1365-2958.2001.02346.x; Rodionov DA, 2002, J BIOL CHEM, V277, P48949, DOI 10.1074/jbc.M208965200; ROTH JR, 1993, J BACTERIOL, V175, P3303, DOI 10.1128/jb.175.11.3303-3316.1993; Sauer K, 1999, EUR J BIOCHEM, V261, P674, DOI 10.1046/j.1432-1327.1999.00355.x; Schubert HL, 1999, BIOCHEMISTRY-US, V38, P10660, DOI 10.1021/bi9906773; Scott AI, 2002, BIOCHEM SOC T, V30, P613, DOI 10.1042/bst0300613; Simpson W, 2000, J BACTERIOL, V182, P5737, DOI 10.1128/JB.182.20.5737-5748.2000; SMITH RL, 1993, J BIOL CHEM, V268, P14071; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Thomas MG, 2000, J BACTERIOL, V182, P4227, DOI 10.1128/JB.182.15.4227-4233.2000; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Vitreschak AG, 2003, RNA, V9, P1084, DOI 10.1261/rna.5710303; Vitreschak AG, 2002, NUCLEIC ACIDS RES, V30, P3141, DOI 10.1093/nar/gkf433; VITRESCHAK AG, 2001, P 3 INT C COMPL SYST, P623	50	323	342	2	51	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41148	41159		10.1074/jbc.M305837200	http://dx.doi.org/10.1074/jbc.M305837200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12869542	hybrid			2022-12-27	WOS:000185847200091
J	Akhavan, A; Atanasiu, R; Shrier, A				Akhavan, A; Atanasiu, R; Shrier, A			Identification of a COOH-terminal segment involved in maturation and stability of human ether-a-go-go-related gene potassium channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-QT-SYNDROME; TRANSMEMBRANE CONDUCTANCE REGULATOR; INTRACELLULAR-TRANSPORT; CARDIAC-ARRHYTHMIA; RETENTION SIGNAL; HERG MUTATIONS; WILD-TYPE; PROTEIN; DOMAIN; TRAFFICKING	Mutations in the potassium channel encoded by the human ether-a-go-go-related gene (HERG) have been linked to the congenital long QT syndrome (LQTS), a cardiac disease associated with an increased preponderance of ventricular arrhythmias and sudden death. The COOH terminus of HERG harbors a large number of LQTS mutations and its removal prevents functional expression for reasons that remain unknown. In this study, we show that the COOH terminus of HERG is required for normal trafficking of the ion channel. We have identified a region critical for trafficking between residues 860 and 899 that includes a novel missense mutation at amino acid 861 (HERG(N861I)). Truncations or deletion of residues 860-899, characterized in six different expression systems including a cardiac cell line, resulted in decreased expression levels and an absence of the mature glycosylated form of the HERG protein. Deletion of this region did not interfere with the formation of tetramers but caused retention of the assembled ion channels within the endoplasmic reticulum. Consequently, removal of residues 860-899 resulted in the absence of the ion channels from the cell surface and a more rapid turnover rate than the wild type channels, which was evident very early in biogenesis. This study reveals a novel role of the COOH terminus in the normal biogenesis of HERG channels and suggests defective trafficking as a common mechanism for abnormal channel function resulting from mutations of critical COOH-terminal residues, including the LQTS mutant HERG(N861I).	McGill Univ, Dept Physiol, Montreal, PQ H3G 1Y6, Canada	McGill University	Shrier, A (corresponding author), McGill Univ, Dept Physiol, 3655 Drummond St, Montreal, PQ H3G 1Y6, Canada.	alvin.shrier@mcgill.ca						Abbott GW, 1999, CELL, V97, P175, DOI 10.1016/S0092-8674(00)80728-X; Aydar E, 2001, J PHYSIOL-LONDON, V534, P1, DOI 10.1111/j.1469-7793.2001.t01-3-00001.x; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bermak JC, 2001, NAT CELL BIOL, V3, P492, DOI 10.1038/35074561; Berthet M, 1999, CIRCULATION, V99, P1464, DOI 10.1161/01.CIR.99.11.1464; Brown CR, 1997, J CLIN INVEST, V99, P1432, DOI 10.1172/JCI119302; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; Campomanes CR, 2002, J BIOL CHEM, V277, P8298, DOI 10.1074/jbc.M110276200; Chen J, 1999, J BIOL CHEM, V274, P10113, DOI 10.1074/jbc.274.15.10113; Claycomb WC, 1998, P NATL ACAD SCI USA, V95, P2979, DOI 10.1073/pnas.95.6.2979; CURRAN ME, 1995, CELL, V80, P795, DOI 10.1016/0092-8674(95)90358-5; Delisle BP, 2003, J BIOL CHEM, V278, P35749, DOI 10.1074/jbc.M305787200; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; Eertmoed AL, 1999, J NEUROSCI, V19, P6298; Egan ME, 2002, NAT MED, V8, P485, DOI 10.1038/nm0502-485; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Ficker E, 2000, AM J PHYSIOL-HEART C, V279, pH1748, DOI 10.1152/ajpheart.2000.279.4.H1748; Gentzsch M, 2001, J BIOL CHEM, V276, P1291, DOI 10.1074/jbc.M003672200; Haardt M, 1999, J BIOL CHEM, V274, P21873, DOI 10.1074/jbc.274.31.21873; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; KOPITO RR, 1999, PHYSIOL REV, V79, P167; Kupershmidt S, 2002, J BIOL CHEM, V277, P27442, DOI 10.1074/jbc.M112375200; Kupershmidt S, 1998, J BIOL CHEM, V273, P27231, DOI 10.1074/jbc.273.42.27231; Ma DK, 2001, SCIENCE, V291, P316, DOI 10.1126/science.291.5502.316; Ma JY, 2001, P NATL ACAD SCI USA, V98, P14955, DOI 10.1073/pnas.011578098; Manganas LN, 2001, P NATL ACAD SCI USA, V98, P14055, DOI 10.1073/pnas.241403898; Moss AJ, 2002, CIRCULATION, V105, P794, DOI 10.1161/hc0702.105124; Nufer O, 2002, J CELL SCI, V115, P619; Petrecca K, 1999, J PHYSIOL-LONDON, V515, P41, DOI 10.1111/j.1469-7793.1999.041ad.x; Rajamani S, 2002, CIRCULATION, V105, P2830, DOI 10.1161/01.CIR.0000019513.50928.74; Roti ECR, 2002, J BIOL CHEM, V277, P47779, DOI 10.1074/jbc.M206638200; Rutkowski DT, 2003, J BIOL CHEM, V278, P30365, DOI 10.1074/jbc.M302117200; SANGUINETTI MC, 1995, CELL, V81, P299, DOI 10.1016/0092-8674(95)90340-2; Satler CA, 1996, AM J MED GENET, V65, P27, DOI 10.1002/(SICI)1096-8628(19961002)65:1<27::AID-AJMG4>3.3.CO;2-J; Sato S, 1996, J BIOL CHEM, V271, P635, DOI 10.1074/jbc.271.2.635; Schnell DJ, 2003, CELL, V112, P491, DOI 10.1016/S0092-8674(03)00110-7; Scott DB, 2001, J NEUROSCI, V21, P3063, DOI 10.1523/JNEUROSCI.21-09-03063.2001; Splawski I, 2000, CIRCULATION, V102, P1178, DOI 10.1161/01.CIR.102.10.1178; Tu LW, 1996, J BIOL CHEM, V271, P18904, DOI 10.1074/jbc.271.31.18904; Turner GC, 2000, SCIENCE, V289, P2117, DOI 10.1126/science.289.5487.2117; Vanslyke JK, 2000, MOL BIOL CELL, V11, P1933, DOI 10.1091/mbc.11.6.1933; VERRALL S, 1992, CELL, V68, P23, DOI 10.1016/0092-8674(92)90203-O; Wang JL, 2000, J GEN PHYSIOL, V115, P749, DOI 10.1085/jgp.115.6.749; Wang JM, 2002, NAT NEUROSCI, V5, P963, DOI 10.1038/nn918; WARMKE JW, 1994, P NATL ACAD SCI USA, V91, P3438, DOI 10.1073/pnas.91.8.3438; WHITE SH, 1994, ANNU REV BIOPH BIOM, V23, P407, DOI 10.1146/annurev.bb.23.060194.002203; Zhou ZF, 1998, J BIOL CHEM, V273, P21061, DOI 10.1074/jbc.273.33.21061; Zimmerman CC, 1999, MOL VIS, V5	48	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40105	40112		10.1074/jbc.M307837200	http://dx.doi.org/10.1074/jbc.M307837200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885765	hybrid			2022-12-27	WOS:000185713800102
J	Bentley, J; Itchayanan, D; Barnes, K; McIntosh, E; Tang, XW; Downes, CP; Holman, GD; Whetton, AD; Owen-Lynch, PJ; Baldwin, SA				Bentley, J; Itchayanan, D; Barnes, K; McIntosh, E; Tang, XW; Downes, CP; Holman, GD; Whetton, AD; Owen-Lynch, PJ; Baldwin, SA			Interleukin-3-mediated cell survival signals include phosphatidylinositol 3-kinase-dependent translocation of the glucose transporter GLUT1 to the cell surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; 3T3-L1 ADIPOCYTES; GROWTH-FACTOR; HEMATOPOIETIC-CELLS; PLASMA-MEMBRANE; IN-VITRO; ACTIVATION; APOPTOSIS; LINE; PROLIFERATION	Maintenance of glucose uptake is a key component in the response of hematopoietic cells to survival factors. To investigate the mechanism of this response we employed the interleukin-3 (IL-3)-dependent murine mast cell line IC2.9. In these cells, hexose uptake decreased markedly upon withdrawal of IL-3, whereas its readdition led to rapid (t(1/2) similar to 10 min) stimulation of transport, associated with an similar to4-fold increase in V-max but no change in Km. Immunocytochemistry and photoaffinity labeling revealed that IL-3 caused translocation of intracellular GLUT1 transporters to the cell surface, whereas a second transporter isoform, GLUT3, remained predominantly intracellular. The inhibitory effects of latrunculin B and jasplakinolide, and of nocodazole and colchicine, respectively, revealed a requirement for both the actin and microtubule cytoskeletons in GLUT1 translocation and transport stimulation. Both IL-3 stimulation of transport and GLUT1 translocation were also prevented by the phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002. The time courses for activation of phosphatidylinositol 3-kinase and its downstream target, protein kinase B, by IL-3 were consistent with a role in IL-3-induced transporter translocation and enhanced glucose uptake. We conclude that one component of the survival mechanisms elicited by IL-3 involves the subcellular redistribution of glucose transporters, thus ensuring the supply of a key metabolic substrate.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Univ Dundee, Dept Biochem, Dundee DD1 5EH, Scotland; Univ Bath, Sch Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Leukaemia Res Fund Unit, Manchester M60 1QD, Lancs, England	University of Leeds; University of Dundee; University of Bath; University of Manchester	Baldwin, SA (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Woodhouse Lane, Leeds LS2 9JT, W Yorkshire, England.	s.a.baldwin@leeds.ac.uk		Owen-Lynch, Penelope Jane/0000-0002-5928-2327; tang, xiuwen/0000-0002-6601-1234; Holman, Geoffrey/0000-0001-7045-1358; WHETTON, ANTHONY D/0000-0002-1098-3878				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; Bentley J, 2001, BRIT J HAEMATOL, V112, P212, DOI 10.1046/j.1365-2141.2001.02428.x; Berridge MV, 1996, J IMMUNOL, V156, P4092; BERRIDGE MV, 1995, BIOCHEM J, V305, P843, DOI 10.1042/bj3050843; Bryant NJ, 2002, NAT REV MOL CELL BIO, V3, P267, DOI 10.1038/nrm782; CHAPMAN RS, 1996, HEMATOPOIETIC CELL G, P151; Craddock BL, 1999, J BIOL CHEM, V274, P10633, DOI 10.1074/jbc.274.15.10633; de Groot RP, 1998, CELL SIGNAL, V10, P619, DOI 10.1016/S0898-6568(98)00023-0; Dijkers PF, 1999, ONCOGENE, V18, P3334, DOI 10.1038/sj.onc.1202678; Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584; Emoto M, 2001, J BIOL CHEM, V276, P10677, DOI 10.1074/jbc.M010785200; EVANS CA, 1993, CANCER RES, V53, P1735; Gschwendt M, 1996, FEBS LETT, V392, P77, DOI 10.1016/0014-5793(96)00785-5; Hausdorff SF, 1999, J BIOL CHEM, V274, P24677, DOI 10.1074/jbc.274.35.24677; HENDERSON P J F, 1992, P277; KAN O, 1994, J EXP MED, V180, P917, DOI 10.1084/jem.180.3.917; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; KauffmanZeh A, 1997, NATURE, V385, P544, DOI 10.1038/385544a0; Khan AH, 2002, DIABETOLOGIA, V45, P1475, DOI 10.1007/s00125-002-0974-7; Koumanov F, 1998, BIOCHEM J, V330, P1209, DOI 10.1042/bj3301209; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; MATULONIS U, 1993, EXP HEMATOL, V21, P1460; McCoy KD, 1997, J BIOL CHEM, V272, P17276, DOI 10.1074/jbc.272.28.17276; Molero JC, 2001, J BIOL CHEM, V276, P43829, DOI 10.1074/jbc.M105452200; NAGAMATSU S, 1992, J BIOL CHEM, V267, P467; NEFESH I, 1991, INT IMMUNOL, V3, P827, DOI 10.1093/intimm/3.8.827; Nicholls SE, 1999, EXP HEMATOL, V27, P663, DOI 10.1016/S0301-472X(98)00072-1; Nishida K, 1999, ONCOGENE, V18, P407, DOI 10.1038/sj.onc.1202301; Omata W, 2000, BIOCHEM J, V346, P321, DOI 10.1042/0264-6021:3460321; OWEN PJ, 1993, J BIOL CHEM, V268, P15696; Plas DR, 2001, J BIOL CHEM, V276, P12041, DOI 10.1074/jbc.M010551200; RAO P, 1994, CANCER RES, V54, P777; Shigematsu S, 2002, MOL ENDOCRINOL, V16, P1060, DOI 10.1210/me.16.5.1060; Tang XW, 1997, J BIOL CHEM, V272, P14193, DOI 10.1074/jbc.272.22.14193; Thurmond DC, 2001, MOL MEMBR BIOL, V18, P237; TSAKIRIDIS T, 1994, J BIOL CHEM, V269, P29934; Vander Heiden MG, 2001, MOL CELL BIOL, V21, P5899, DOI 10.1128/MCB.21.17.5899-5912.2001; Walker KS, 1998, BIOCHEM J, V331, P299, DOI 10.1042/bj3310299; Wang QH, 1998, BIOCHEM J, V331, P917, DOI 10.1042/bj3310917; Whiteman EL, 2002, TRENDS ENDOCRIN MET, V13, P444, DOI 10.1016/S1043-2760(02)00662-8; WILKINSON SE, 1993, BIOCHEM J, V294, P335, DOI 10.1042/bj2940335; Zhou SY, 1997, P NATL ACAD SCI USA, V94, P11345, DOI 10.1073/pnas.94.21.11345	43	57	57	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39337	39348		10.1074/jbc.M305689200	http://dx.doi.org/10.1074/jbc.M305689200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869574	hybrid			2022-12-27	WOS:000185713800011
J	Brotz-Oesterhelt, H; Knezevic, I; Bartel, S; Lampe, T; Warnecke-Eberz, U; Ziegelbauer, K; Habich, D; Labischinski, H				Brotz-Oesterhelt, H; Knezevic, I; Bartel, S; Lampe, T; Warnecke-Eberz, U; Ziegelbauer, K; Habich, D; Labischinski, H			Specific and potent inhibition of NAD(+)-dependent DNA ligase by pyridochromanones	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID LIGASE; BACILLUS-SUBTILIS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; MECHANISM; DOMAIN; ADENYLATION; EXPRESSION; COMPLEX; GYRASE	Pyridochromanones were identified by high throughput screening as potent inhibitors of NAD(+)-dependent DNA ligase from Escherichia coli. Further characterization revealed that eubacterial DNA ligases from Gram-negative and Gram-positive sources were inhibited at nanomolar concentrations. In contrast, purified human DNA ligase I was not affected (IC50 > 75 muM), demonstrating remarkable specificity for the prokaryotic target. The binding mode is competitive with the eubacteria-specific cofactor NAD(+), and no intercalation into DNA was detected. Accordingly, the compounds were bactericidal for the prominent human pathogen Staphylococcus aureus in the low mug/ml range, whereas eukaryotic cells were not affected up to 60 mug/ml. The hypothesis that inhibition of DNA ligase is the antibacterial principle was proven in studies with a temperature-sensitive ligase-deficient E. coli strain. This mutant was highly susceptible for pyridochromanones at elevated temperatures but was rescued by heterologous expression of human DNA ligase I. A physiological consequence of ligase inhibition in bacteria was massive DNA degradation, as visualized by fluorescence microscopy of labeled DNA. In summary, the pyridochromanones demonstrate that diverse eubacterial DNA ligases can be addressed by a single inhibitor without affecting eukaryotic ligases or other DNA-binding enzymes, which proves the value of DNA ligase as a novel target in antibacterial therapy.	Bayer AG, Bayer Hlth Care, Pharma Res, Dept Antiinfect, D-42096 Wuppertal, Germany; Bayer AG, Bayer Hlth Care, Pharma Res, Dept Chem, D-42096 Wuppertal, Germany	Bayer AG; Bayer Healthcare Pharmaceuticals; Bayer AG; Bayer Healthcare Pharmaceuticals	Brotz-Oesterhelt, H (corresponding author), Bayer AG, Bayer Hlth Care, Pharma Res, Dept Antiinfect, Aprather Weg 18A, D-42096 Wuppertal, Germany.			Warnecke-Eberz, Ute/0000-0002-2833-5633				ANAGNOSTOPOULOS C, 1961, J BACTERIOL, V81, P741, DOI 10.1128/JB.81.5.741-746.1961; Cheng CH, 1997, NUCLEIC ACIDS RES, V25, P1369, DOI 10.1093/nar/25.7.1369; CHEO DL, 1992, BIOCHIMIE, V74, P755, DOI 10.1016/0300-9084(92)90148-8; Ciarrocchi G, 1999, ANTIMICROB AGENTS CH, V43, P2766, DOI 10.1128/AAC.43.11.2766; DERMODY JJ, 1979, J BACTERIOL, V139, P701, DOI 10.1128/JB.139.2.701-704.1979; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Kaczmarek FS, 2001, J BACTERIOL, V183, P3016, DOI 10.1128/JB.183.10.3016-3024.2001; KAPUSCINSKI J, 1995, BIOTECH HISTOCHEM, V70, P220, DOI 10.3109/10520299509108199; KODAMA K, 1991, NUCLEIC ACIDS RES, V19, P6093, DOI 10.1093/nar/19.22.6093; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; LEHMAN IR, 1974, SCIENCE, V186, P790; LEPECQ JB, 1967, J MOL BIOL, V27, P87, DOI 10.1016/0022-2836(67)90353-1; Liu ZR, 1996, ANAL BIOCHEM, V236, P139, DOI 10.1006/abio.1996.0142; LOVE PE, 1984, J BACTERIOL, V160, P910, DOI 10.1128/JB.160.3.910-920.1984; MODRICH P, 1973, J BIOL CHEM, V248, P7502; MONTECUCCO A, 1991, NUCLEIC ACIDS RES, V19, P1067, DOI 10.1093/nar/19.5.1067; MONTECUCCO A, 1993, BIOCHEM PHARMACOL, V45, P1536, DOI 10.1016/0006-2952(93)90057-4; NOHARA A, 1992, Patent No. 2809720; Odell M, 2000, MOL CELL, V6, P1183, DOI 10.1016/S1097-2765(00)00115-5; Olland AM, 2002, J BIOL CHEM, V277, P3698, DOI 10.1074/jbc.M109670200; Parkhill J, 2001, NATURE, V413, P523, DOI 10.1038/35097083; Petit MA, 2000, NUCLEIC ACIDS RES, V28, P4642, DOI 10.1093/nar/28.23.4642; Singleton MR, 1999, STRUCTURE, V7, P35, DOI 10.1016/S0969-2126(99)80007-0; SODERHALL S, 1973, J BIOL CHEM, V248, P672; Sriskanda V, 2002, J BIOL CHEM, V277, P9695, DOI 10.1074/jbc.M111164200; Sriskanda V, 2001, NUCLEIC ACIDS RES, V29, P4930, DOI 10.1093/nar/29.24.4930; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; SUGINO A, 1978, P NATL ACAD SCI USA, V75, P4838, DOI 10.1073/pnas.75.10.4838; Tan GT, 1996, BIOCHEM J, V314, P993, DOI 10.1042/bj3140993; Timson DJ, 2000, MUTAT RES-DNA REPAIR, V460, P301, DOI 10.1016/S0921-8777(00)00033-1; Tomkinson AE, 1998, MUTAT RES-DNA REPAIR, V407, P1, DOI 10.1016/S0921-8777(97)00050-5; VAARA M, 1991, DRUG EXP CLIN RES, V17, P437; *WHO CDS CSR DRS, 2001, WHOCDSCSRDRS20012; Wilkinson A, 2001, MOL MICROBIOL, V40, P1241, DOI 10.1046/j.1365-2958.2001.02479.x	34	111	115	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39435	39442		10.1074/jbc.M306479200	http://dx.doi.org/10.1074/jbc.M306479200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12867414	hybrid			2022-12-27	WOS:000185713800021
J	Brown, K; Chen, Y; Underhill, TM; Mymryk, JS; Torchia, J				Brown, K; Chen, Y; Underhill, TM; Mymryk, JS; Torchia, J			The coactivator p/CIP/SRC-3 facilitates retinoic acid receptor signaling via recruitment of GCN5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THYROID-HORMONE RECEPTOR; HISTONE ACETYLTRANSFERASE ACTIVITY; YEAST PUTATIVE ADAPTERS; NUCLEAR-RECEPTOR; TRANSCRIPTIONAL COACTIVATOR; ESTROGEN-RECEPTOR; BINDING-PROTEIN; IN-VIVO; SACCHAROMYCES-CEREVISIAE; MUSCLE DIFFERENTIATION	p/CIP/SRC-3 is a member of a family of steroid receptor coactivators/nuclear receptor coactivators (SRC/NCoA) proteins that mediate the transcriptional effects of nuclear hormone receptors (NRs). Using deletion analysis we have mapped the location of two distinct activation domains in p/CIP (AD1 and AD2) capable of activating transcription in mammalian cells when fused to the Gal4-DNA binding domain. In addition to AD1 being coincident with the interaction domain for CBP, we demonstrate a novel in vivo interaction between the AD1 and GCN5. Overexpression of a Gal4-AD1 fusion protein in yeast leads to growth arrest that is relieved by mutation of genes encoding components of the SAGA complex including GCN5, ADA3, and SPT7. In addition, the AD1 of p/CIP and the ADA3 gene are shown to be essential for retinoic acid receptor alpha-dependent transcription in yeast. Transient transfection assays in mammalian cells indicate that GCN5 cooperates with p/CIP as a coactivator of RARalpha-dependent transcription. Down-regulation of GCN5 using small interfering RNA in mammalian cells indicates that the AD1 domain and the RARbeta promoter activity are dependent, in part, on GCN5. Mutational analysis of AD1 has identified two helical motifs that are required for interactions with GCN5 and CBP. Taken together, these results support a model by which p/CIP functions as a ligand-dependent adapter, through specific protein-protein interactions with AD1, to recruit members from at least two distinct families of acetyltransferase proteins to NRs.	London Reg Canc Ctr, Canc Res Labs, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Oncol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Physiol & Pharmacol, London, ON N6A 4L6, Canada; Univ Western Ontario, Dept Microbiol & Immunol, London, ON N6A 4L6, Canada	Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario); Western University (University of Western Ontario)	Torchia, J (corresponding author), London Reg Canc Ctr, Canc Res Labs, 790 Commissioners Rd E, London, ON N6A 4L6, Canada.							Anafi M, 2000, MOL ENDOCRINOL, V14, P718, DOI 10.1210/me.14.5.718; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Blanco JCG, 1998, GENE DEV, V12, P1638, DOI 10.1101/gad.12.11.1638; Brand M, 1999, SCIENCE, V286, P2151, DOI 10.1126/science.286.5447.2151; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; Candau R, 1996, J BIOL CHEM, V271, P5237; Candau R, 1996, MOL CELL BIOL, V16, P593; CHAMBERLAIN NL, 1994, NUCLEIC ACIDS RES, V22, P3181, DOI 10.1093/nar/22.15.3181; Chen DG, 1999, SCIENCE, V284, P2174, DOI 10.1126/science.284.5423.2174; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; Chen HW, 1997, CELL, V90, P569, DOI 10.1016/S0092-8674(00)80516-4; Chen SL, 2000, GENE DEV, V14, P1209; Crews ST, 1999, CURR OPIN GENET DEV, V9, P580, DOI 10.1016/S0959-437X(99)00003-9; Demarest SJ, 2002, NATURE, V415, P549, DOI 10.1038/415549a; Ding XF, 1998, MOL ENDOCRINOL, V12, P302, DOI 10.1210/me.12.2.302; Drysdale CM, 1998, MOL CELL BIOL, V18, P1711, DOI 10.1128/MCB.18.3.1711; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Forsberg EC, 1997, BIOCHEMISTRY-US, V36, P15918, DOI 10.1021/bi971664x; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; Grant PA, 1997, GENE DEV, V11, P1640, DOI 10.1101/gad.11.13.1640; Grant PA, 1998, CELL, V94, P45, DOI 10.1016/S0092-8674(00)81220-9; Gregory PD, 1998, MOL CELL, V1, P495, DOI 10.1016/S1097-2765(00)80050-7; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Hong H, 1996, P NATL ACAD SCI USA, V93, P4948, DOI 10.1073/pnas.93.10.4948; Hong H, 1997, MOL CELL BIOL, V17, P2735, DOI 10.1128/MCB.17.5.2735; Hong H, 1999, J BIOL CHEM, V274, P3496, DOI 10.1074/jbc.274.6.3496; Ikeda M, 1999, MOL CELL ENDOCRINOL, V147, P103, DOI 10.1016/S0303-7207(98)00211-1; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; KELLEHER RJ, 1990, CELL, V61, P1209, DOI 10.1016/0092-8674(90)90685-8; Kim MY, 2001, EMBO J, V20, P6084, DOI 10.1093/emboj/20.21.6084; Koh SS, 2001, J BIOL CHEM, V276, P1089, DOI 10.1074/jbc.M004228200; Korzus E, 1998, SCIENCE, V279, P703, DOI 10.1126/science.279.5351.703; Kraus WL, 1998, GENE DEV, V12, P331, DOI 10.1101/gad.12.3.331; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; Li H, 1998, J BIOL CHEM, V273, P5948, DOI 10.1074/jbc.273.10.5948; Li H, 1997, P NATL ACAD SCI USA, V94, P8479, DOI 10.1073/pnas.94.16.8479; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; List HJ, 2001, J BIOL CHEM, V276, P23763, DOI 10.1074/jbc.M102397200; Liu Z, 1999, P NATL ACAD SCI USA, V96, P9485, DOI 10.1073/pnas.96.17.9485; Ma H, 1999, MOL CELL BIOL, V19, P6164; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; Martinez E, 2001, MOL CELL BIOL, V21, P6782, DOI 10.1128/MCB.21.20.6782-6795.2001; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; ONATE SA, 1995, SCIENCE, V270, P1354; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; Polesskaya A, 2001, EMBO J, V20, P6816, DOI 10.1093/emboj/20.23.6816; Puri PL, 1997, EMBO J, V16, P369, DOI 10.1093/emboj/16.2.369; Roberts SM, 1996, MOL CELL BIOL, V16, P3206; Roberts SM, 1997, GENETICS, V147, P451; Smith CL, 1996, P NATL ACAD SCI USA, V93, P8884, DOI 10.1073/pnas.93.17.8884; Spencer TE, 1997, NATURE, V389, P194, DOI 10.1038/38304; Struhl K, 1998, CELL, V94, P1, DOI 10.1016/S0092-8674(00)81213-1; Suen CS, 1998, J BIOL CHEM, V273, P27645, DOI 10.1074/jbc.273.42.27645; Takeshita A, 1997, J BIOL CHEM, V272, P27629, DOI 10.1074/jbc.272.44.27629; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; TRIEZENBERG SJ, 1988, GENE DEV, V2, P718, DOI 10.1101/gad.2.6.718; Vassilev A, 1998, MOL CELL, V2, P869, DOI 10.1016/S1097-2765(00)80301-9; Voegel JJ, 1998, EMBO J, V17, P507, DOI 10.1093/emboj/17.2.507; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; Walfish PG, 1997, P NATL ACAD SCI USA, V94, P3697, DOI 10.1073/pnas.94.8.3697; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Wei LN, 2003, ANNU REV PHARMACOL, V43, P47, DOI 10.1146/annurev.pharmtox.43.100901.140301; Xu W, 2001, SCIENCE, V294, P2507, DOI 10.1126/science.1065961; Xu WT, 2000, NAT GENET, V26, P229, DOI 10.1038/79973; Yamauchi T, 2000, P NATL ACAD SCI USA, V97, P11303, DOI 10.1073/pnas.97.21.11303; Yanagisawa J, 2002, MOL CELL, V9, P553, DOI 10.1016/S1097-2765(02)00478-1; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079	78	35	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39402	39412		10.1074/jbc.M307832200	http://dx.doi.org/10.1074/jbc.M307832200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885766	hybrid			2022-12-27	WOS:000185713800017
J	Ding, Q; Stewart, J; Olman, MA; Klobe, MR; Gladson, CL				Ding, Q; Stewart, J; Olman, MA; Klobe, MR; Gladson, CL			The pattern of enhancement of Src kinase activity on platelet-derived growth factor stimulation of glioblastoma cells is affected by the integrin engaged	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOCAL ADHESION KINASE; MALIGNANT ASTROCYTOMA; TYROSINE KINASES; MIGRATION; PDGF; RECEPTOR; FYN; ASSOCIATION; ACTIVATION; EXPRESSION	Enhanced expression of both integrin alpha(v)beta(3) and platelet-derived growth factor receptor (PDGFr) has been described in glioblastoma tumors. We therefore explored the possibility that integrin alpha(v)beta(3) cooperates with PDGFr to promote cell migration in glioblastoma cells, and extended the study to identify the Src family members that are activated on PDGF stimulation. Glioblastoma cells utilize integrins alpha(v)beta(3) and alpha(v)beta(5) to mediate vitronectin attachment. We found that physiologic PDGF stimulation (83 pM, 10 min) of vitronectin-adherent cells promoted the specific recruitment of integrin alpha(v)beta(3)-containing focal adhesions to the cell cortex and alpha(v)beta(3)-mediated cell motility. Analysis of PDGFr immunoprecipitates indicated an association of the PDGFr beta with integrin alpha(v)beta(3), but not integrin alpha(v)beta(5). Cells plated onto collagen or laminin, which engage different integrins, exhibited significantly less migration on PDGF stimulation, indicating a cooperation of alpha(v)beta(3) and the PDGFr beta in glioblastoma cells that promotes migration. Further analysis of the cells plated onto vitronectin indicated that PDGF stimulation caused an increase in Src kinase activity, which was associated with integrin alpha(v)beta(3). In the vitronectin-adherent cells, Lyn was associated preferentially with alpha(v)beta(3) both in the presence and absence of PDGF stimulation. In contrast, Fyn was associated with both alpha(v)beta(3) and alpha(v)beta(5). Moreover, PDGF stimulation increased the activity of Lyn, but not Fyn, in vitronectin-adherent cells, and the activity of Fyn, but not Lyn, in laminin-adherent cells. Using cells attached to mAb anti-alpha(v)beta(3) or mAb anti-integrin alpha(6), we confirmed the activation of specific members of the Src kinase family with PDGF stimulation. Down-regulation of Lyn expression by siRNA significantly inhibited the cell migration mediated by integrin alpha(v)beta(3) in PDGF-stimulated cells, demonstrating the PDGFr beta cooperates with integrin alpha(v)beta(3) in promoting the motility of vitronectin-adherent glioblastoma cells through a Lyn kinase-mediated pathway. Notably, the data indicate that engagement of different integrins alters the identity of the Src family members that are activated on stimulation with PDGF.	Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Med, Div Pulm & Crit Care Med, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Gladson, CL (corresponding author), Univ Alabama Birmingham, Dept Pathol, Div Neuropathol, LHRB 567,701 S 19th St, Birmingham, AL 35294 USA.	gladson@uab.edu			NATIONAL CANCER INSTITUTE [R01CA059958, R01CA097110] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058655] Funding Source: NIH RePORTER; NCI NIH HHS [CA97110, CA59958] Funding Source: Medline; NHLBI NIH HHS [HL58655] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Banyard J, 2000, ONCOGENE, V19, P580, DOI 10.1038/sj.onc.1203338; Baron W, 2002, EMBO J, V21, P1957, DOI 10.1093/emboj/21.8.1957; Bertagnolli ME, 1999, BIOCHEM BIOPH RES CO, V260, P790, DOI 10.1006/bbrc.1999.0985; Berwanger B, 2002, CANCER CELL, V2, P377, DOI 10.1016/S1535-6108(02)00179-4; Bishop AL, 2000, BIOCHEM J, V348, P241, DOI 10.1042/0264-6021:3480241; Borges E, 2000, J BIOL CHEM, V275, P39867, DOI 10.1074/jbc.M007040200; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Cary LA, 1996, J CELL SCI, V109, P1787; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Ding Q, 2000, GROWTH FACTORS, V18, P93, DOI 10.3109/08977190009003236; Ding Q, 2002, CANCER RES, V62, P5336; DORAHY DJ, 1995, BIOCHEM J, V309, P481, DOI 10.1042/bj3090481; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2002, METHODS, V26, P199, DOI 10.1016/S1046-2023(02)00023-3; Eliceiri BP, 2001, CIRC RES, V89, P1104, DOI 10.1161/hh2401.101084; GLADSON CL, 1995, J CELL SCI, V108, P947; GLADSON CL, 1991, J CLIN INVEST, V88, P1924, DOI 10.1172/JCI115516; GUHA A, 1995, INT J CANCER, V60, P168, DOI 10.1002/ijc.2910600206; Han NM, 1996, CLIN CANCER RES, V2, P1397; Han XS, 2001, ONCOGENE, V20, P7976, DOI 10.1038/sj.onc.1204996; Hansen K, 1997, BIOCHEM BIOPH RES CO, V241, P355, DOI 10.1006/bbrc.1997.7743; Hauck CR, 2002, IUBMB LIFE, V53, P115, DOI 10.1080/15216540211470; Hauck CR, 2000, J BIOL CHEM, V275, P41092, DOI 10.1074/jbc.M005450200; Hecker TP, 2002, CANCER RES, V62, P2699; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; HERMANSON M, 1992, CANCER RES, V52, P3213; KLEIHUES P, 1993, BRAIN PATHOL, V3, P255, DOI 10.1111/j.1750-3639.1993.tb00752.x; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kralisz U, 1998, BIOCHEM MOL BIOL INT, V45, P735; Ling LX, 1999, J CELL BIOCHEM, V73, P533; Lokker NA, 2002, CANCER RES, V62, P3729; Mariotti A, 2001, J CELL BIOL, V155, P447, DOI 10.1083/jcb.200105017; Martin S, 2003, J NEUROSCI, V23, P1198, DOI 10.1523/JNEUROSCI.23-04-01198.2003; Osterhout DJ, 1999, J CELL BIOL, V145, P1209, DOI 10.1083/jcb.145.6.1209; Pijuan-Thompson V, 1999, EXP CELL RES, V249, P86, DOI 10.1006/excr.1999.4458; PijuanThompson V, 1997, J BIOL CHEM, V272, P2736, DOI 10.1074/jbc.272.5.2736; Rabinowich H, 1996, J IMMUNOL, V157, P3860; Rozen S, 2000, Methods Mol Biol, V132, P365; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schneller M, 1997, EMBO J, V16, P5600, DOI 10.1093/emboj/16.18.5600; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 2000, NAT CELL BIOL, V2, P249, DOI 10.1038/35010517; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Timpson P, 2001, CURR BIOL, V11, P1836, DOI 10.1016/S0960-9822(01)00583-8; Vines CM, 2001, IMMUNITY, V15, P507, DOI 10.1016/S1074-7613(01)00221-7; VUORI K, 1994, SCIENCE, V266, P1576, DOI 10.1126/science.7527156; Wang DY, 2000, J CELL SCI, V113, P4221; Woodard AS, 1998, J CELL SCI, V111, P469; Zeng L, 2003, J CELL BIOL, V160, P137, DOI 10.1083/jcb.200206049	49	88	90	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39882	39891		10.1074/jbc.M304685200	http://dx.doi.org/10.1074/jbc.M304685200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881526	hybrid			2022-12-27	WOS:000185713800075
J	Harada, J; Kokura, K; Kanei-Ishii, C; Nomura, T; Khan, MM; Kim, Y; Ishii, S				Harada, J; Kokura, K; Kanei-Ishii, C; Nomura, T; Khan, MM; Kim, Y; Ishii, S			Requirement of the co-repressor homeodomain-interacting protein kinase 2 for Ski-mediated inhibition of bone morphogenetic protein-induced transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; HISTONE DEACETYLASE COMPLEX; TGF-BETA RECEPTOR; THYROID-HORMONE RECEPTOR; N-COR; COREPRESSOR COMPLEX; SIGNALING PATHWAYS; TUMOR-SUPPRESSOR; SMAD PROTEINS; MAD PROTEINS	Multiple co-repressors such as N-CoR/SMRT, mSin3, and the c-ski proto-oncogene product (c-Ski) mediate the transcriptional repression induced by Mad and the thyroid hormone receptor by recruiting the histone deacetylase complex. c-Ski also binds directly to Smad proteins, which are transcriptional activators in the transforming growth factor-beta (TGF-beta)/bone morphogenetic protein (BMP) signaling pathways, and inhibits TGF-beta/BMP-induced transcriptional activation. However, it remains unknown whether other co-repressor(s) are also involved with Ski in the negative regulation of the TGF-beta/BMP signaling pathways. Here, we report that the co-repressor homeodomain-interacting protein kinase 2 (HIPK2) directly binds to both c-Ski and Smad1. HIPK2 efficiently inhibited Smad1/4-induced transcription from the Smad site-containing promoter. A dominant negative form of HIPK2, in which the ATP binding motif in the kinase domain and the putative phosphorylation sites were mutated, enhanced Smad1/4-dependent transcription and the BMP-induced expression of alkaline phosphatase. Furthermore, the c-Ski-induced inhibition of the Smad1/4-dependent transcription was suppressed by a dominant negative form of HIPK2. The HIPK2 co-repressor activity may be regulated by an un-characterized HIPK2 kinase. These results indicate that HIPK2, together with c-Ski, plays an important role in the negative regulation of BMP-induced transcriptional activation.	RIKEN, Tsukuba Inst, Mol Genet Lab, Tsukuba, Ibaraki 3050074, Japan; NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	RIKEN; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Ishii, S (corresponding author), RIKEN, Tsukuba Inst, Mol Genet Lab, 3-1-1 Koyadai, Tsukuba, Ibaraki 3050074, Japan.		Ishii, Shunsuke/A-5271-2016	Ishii, Shunsuke/0000-0002-6530-2478				Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Attisano L, 2000, CURR OPIN CELL BIOL, V12, P235, DOI 10.1016/S0955-0674(99)00081-2; AYER DE, 1995, CELL, V80, P767, DOI 10.1016/0092-8674(95)90355-0; Baker JC, 1996, GENE DEV, V10, P1880, DOI 10.1101/gad.10.15.1880; Becker W, 1998, J BIOL CHEM, V273, P25893, DOI 10.1074/jbc.273.40.25893; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Chen X, 1997, NATURE, V389, P85, DOI 10.1038/38008; Chen X, 1996, NATURE, V383, P691, DOI 10.1038/383691a0; Choi CY, 1999, J BIOL CHEM, V274, P33194, DOI 10.1074/jbc.274.47.33194; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; Dennler S, 1998, EMBO J, V17, P3091, DOI 10.1093/emboj/17.11.3091; Engelhardt OG, 2003, EXP CELL RES, V283, P36, DOI 10.1016/S0014-4827(02)00025-3; Eppert K, 1996, CELL, V86, P543, DOI 10.1016/S0092-8674(00)80128-2; Graff JM, 1996, CELL, V85, P479, DOI 10.1016/S0092-8674(00)81249-0; Guenther MG, 2000, GENE DEV, V14, P1048; Harvey RP, 1996, DEV BIOL, V178, P203, DOI 10.1006/dbio.1996.0212; Hassig CA, 1997, CELL, V89, P341, DOI 10.1016/S0092-8674(00)80214-7; Hata A, 2000, CELL, V100, P229, DOI 10.1016/S0092-8674(00)81561-5; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang EY, 2000, GENE DEV, V14, P45; Kao HY, 2000, GENE DEV, V14, P55; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim J, 1997, NATURE, V388, P304, DOI 10.1038/40906; Kim YH, 1998, J BIOL CHEM, V273, P25875, DOI 10.1074/jbc.273.40.25875; Kim YH, 1999, P NATL ACAD SCI USA, V96, P12350, DOI 10.1073/pnas.96.22.12350; Kusanagi K, 2000, MOL BIOL CELL, V11, P555, DOI 10.1091/mbc.11.2.555; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Laherty CD, 1998, MOL CELL, V2, P33, DOI 10.1016/S1097-2765(00)80111-2; Li JW, 2000, EMBO J, V19, P4342, DOI 10.1093/emboj/19.16.4342; LI Y, 1986, J VIROL, V57, P1065, DOI 10.1128/JVI.57.3.1065-1072.1986; Liu F, 1996, NATURE, V381, P620, DOI 10.1038/381620a0; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; MaciasSilva M, 1996, CELL, V87, P1215, DOI 10.1016/S0092-8674(00)81817-6; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Nakao A, 1997, EMBO J, V16, P5353, DOI 10.1093/emboj/16.17.5353; NOMURA N, 1989, NUCLEIC ACIDS RES, V17, P5489, DOI 10.1093/nar/17.14.5489; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Sano Y, 1999, J BIOL CHEM, V274, P8949, DOI 10.1074/jbc.274.13.8949; Shi YG, 1998, CELL, V94, P585, DOI 10.1016/S0092-8674(00)81600-1; Shinagawa T, 2000, EMBO J, V19, P2280, DOI 10.1093/emboj/19.10.2280; Stroschein SL, 1999, SCIENCE, V286, P771, DOI 10.1126/science.286.5440.771; Sun Y, 1999, P NATL ACAD SCI USA, V96, P12442, DOI 10.1073/pnas.96.22.12442; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; ten Dijke P, 2000, TRENDS BIOCHEM SCI, V25, P64, DOI 10.1016/S0968-0004(99)01519-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Yingling JM, 1997, MOL CELL BIOL, V17, P7019, DOI 10.1128/MCB.17.12.7019; Zawel L, 1998, MOL CELL, V1, P611, DOI 10.1016/S1097-2765(00)80061-1; Zhang Y, 1997, CELL, V89, P357, DOI 10.1016/S0092-8674(00)80216-0; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	60	50	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38998	39005		10.1074/jbc.M307112200	http://dx.doi.org/10.1074/jbc.M307112200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874272	hybrid			2022-12-27	WOS:000185575100111
J	Hsieh, JC; Sisk, JM; Jurutka, PW; Haussler, CA; Slater, SA; Haussler, MR; Thompson, CC				Hsieh, JC; Sisk, JM; Jurutka, PW; Haussler, CA; Slater, SA; Haussler, MR; Thompson, CC			Physical and functional interaction between the vitamin D receptor and hairless corepressor, two proteins required for hair cycling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEREDITARY 1,25-DIHYDROXYVITAMIN-D-RESISTANT RICKETS; STEROID-HORMONE RECEPTOR; TRANSCRIPTION FACTOR IIB; D-RESPONSIVE ELEMENT; NUCLEAR RECEPTOR; COACTIVATOR INTERACTION; FOLLICLE MORPHOGENESIS; INTESTINAL RECEPTOR; BASAL TRANSCRIPTION; TARGETED ABLATION	Both the vitamin D receptor (VDR) and hairless (hr) genes play a role in the mammalian hair cycle, as inactivating mutations in either result in total alopecia. VDR is a nuclear receptor that functions as a ligand-activated transcription factor, whereas the hairless gene product ( Hr) acts as a corepressor of both the thyroid hormone receptor (TR) and the orphan nuclear receptor, RORalpha. In the present study, we show that VDR-mediated transactivation is strikingly inhibited by coexpression of rat Hr. The repressive effect of Hr is observed on both synthetic and naturally occurring VDR-responsive promoters and also when VDR-mediated transactivation is augmented by overexpression of its heterodimeric partner, retinoid X receptor. Utilizing in vitro pull down methods, we find that Hr binds directly to VDR but insignificantly to nuclear receptors that are not functionally repressed by Hr. Coimmunoprecipitation data demonstrate that Hr and VDR associate in a cellular milieu, suggesting in vivo interaction. The Hr contact site in human VDR is localized to the central portion of the ligand binding domain, a known corepressor docking region in other nuclear receptors separate from the activation function-2 domain. Coimmunoprecipitation and functional studies of Hr deletants reveal that VDR contacts a C-terminal region of Hr that includes motifs required for TR and RORalpha binding. Finally, in situ hybridization analysis of hr and VDR mRNAs in mouse skin demonstrates colocalization in cells of the hair follicle, consistent with a hypothesized intracellular interaction between these proteins to repress VDR target gene expression, in vivo.	Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Univ Arizona, Coll Med, Dept Biochem & Mol Biophys, Tucson, AZ 85724 USA	Johns Hopkins University; Kennedy Krieger Institute; Johns Hopkins University; University of Arizona	Thompson, CC (corresponding author), Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA.	thompsonc@kennedykrieger.org		Jurutka, Peter/0000-0002-4950-9161; Haussler, Mark/0000-0002-7097-1801; Haussler, Carol/0000-0001-8360-3066	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK063930, R01DK033351, R37DK033351] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS041313] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK063930, DK33351] Funding Source: Medline; NINDS NIH HHS [NS41313] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahmad W, 1998, SCIENCE, V279, P720, DOI 10.1126/science.279.5351.720; BAKER AR, 1988, P NATL ACAD SCI USA, V85, P3294, DOI 10.1073/pnas.85.10.3294; Baudino TA, 1998, J BIOL CHEM, V273, P16434, DOI 10.1074/jbc.273.26.16434; BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; Botchkarev VA, 2001, FASEB J, V15, P2205, DOI 10.1096/fj.01-0207com; CACHONGONZALEZ MB, 1994, P NATL ACAD SCI USA, V91, P7717, DOI 10.1073/pnas.91.16.7717; Chen JD, 1996, P NATL ACAD SCI USA, V93, P7567, DOI 10.1073/pnas.93.15.7567; Cichon S, 1998, HUM MOL GENET, V7, P1671, DOI 10.1093/hmg/7.11.1671; CLEMENS TL, 1988, ENDOCRINOLOGY, V122, P1224, DOI 10.1210/endo-122-4-1224; DANIELSEN M, 1989, CANCER RES, V49, pS2286; Dardenne O, 2001, ENDOCRINOLOGY, V142, P3135, DOI 10.1210/en.142.7.3135; DOMINGUEZ CE, 2002, INSIGHTS BIOCH LIFE, P175; Dussault I, 1998, MECH DEVELOP, V70, P147, DOI 10.1016/S0925-4773(97)00187-1; Falzon M, 1996, MOL ENDOCRINOL, V10, P672, DOI 10.1210/me.10.6.672; Foley J, 1998, J INVEST DERMATOL, V111, P1122, DOI 10.1046/j.1523-1747.1998.00428.x; Fu GK, 1997, MOL ENDOCRINOL, V11, P1961, DOI 10.1210/me.11.13.1961; Gill RK, 1998, MOL ENDOCRINOL, V12, P57, DOI 10.1210/mend.12.1.0048; GREEN S, 1988, NUCLEIC ACIDS RES, V16, P369, DOI 10.1093/nar/16.1.369; HAMADA K, 1989, P NATL ACAD SCI USA, V86, P8289, DOI 10.1073/pnas.86.21.8289; Hamilton BA, 1996, NATURE, V379, P736, DOI 10.1038/379736a0; Haussler MR, 1998, J BONE MINER RES, V13, P325, DOI 10.1359/jbmr.1998.13.3.325; HIRST MA, 1985, J CLIN ENDOCR METAB, V60, P490, DOI 10.1210/jcem-60-3-490; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HSIEH JC, 1995, J STEROID BIOCHEM, V53, P583, DOI 10.1016/0960-0760(95)00112-D; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; HUGHES MR, 1988, SCIENCE, V242, P1702, DOI 10.1126/science.2849209; Jabbour SA, 2003, AM J CLIN DERMATOL, V4, P315, DOI 10.2165/00128071-200304050-00003; Jin CH, 1996, MOL ENDOCRINOL, V10, P945, DOI 10.1210/me.10.8.945; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; Jurutka P W, 2001, Rev Endocr Metab Disord, V2, P203, DOI 10.1023/A:1010062929140; Jurutka PW, 2000, MOL ENDOCRINOL, V14, P401, DOI 10.1210/me.14.3.401; Jurutka PW, 1997, J BIOL CHEM, V272, P14592, DOI 10.1074/jbc.272.23.14592; Jurutka PW, 2000, BIOCHEM BIOPH RES CO, V267, P813, DOI 10.1006/bbrc.1999.2044; Koibuchi N, 2000, TRENDS ENDOCRIN MET, V11, P123, DOI 10.1016/S1043-2760(00)00238-1; Kremer R, 1996, J BIOL CHEM, V271, P16310, DOI 10.1074/jbc.271.27.16310; KRISTJANSSON K, 1993, J CLIN INVEST, V92, P12, DOI 10.1172/JCI116539; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Li YC, 1997, P NATL ACAD SCI USA, V94, P9831, DOI 10.1073/pnas.94.18.9831; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; Malloy PJ, 2002, MOL ENDOCRINOL, V16, P2538, DOI 10.1210/me.2002-0152; Malloy PJ, 1999, ENDOCR REV, V20, P156, DOI 10.1210/er.20.2.156; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MANGELSDORF DJ, 1991, CELL, V66, P555, DOI 10.1016/0092-8674(81)90018-0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; Masuyama H, 1997, MOL ENDOCRINOL, V11, P1507, DOI 10.1210/me.11.10.1507; Miller J, 2001, J INVEST DERMATOL, V117, P612, DOI 10.1046/j.0022-202x.2001.01438.x; Moraitis AN, 2002, MOL CELL BIOL, V22, P6831, DOI 10.1128/MCB.22.19.6831-6841.2002; NAKAJIMA S, 1994, MOL ENDOCRINOL, V8, P159, DOI 10.1210/me.8.2.159; Ordentlich P, 1999, P NATL ACAD SCI USA, V96, P2639, DOI 10.1073/pnas.96.6.2639; Panda DK, 2001, P NATL ACAD SCI USA, V98, P7498, DOI 10.1073/pnas.131029498; Panteleyev AA, 2000, AM J PATHOL, V157, P1071, DOI 10.1016/S0002-9440(10)64621-4; Panteleyev AA, 1998, EXP DERMATOL, V7, P249, DOI 10.1111/j.1600-0625.1998.tb00295.x-i1; Peters EMJ, 2001, J INVEST DERMATOL, V117, P173, DOI 10.1046/j.0022-202x.2001.01410.x; PIKE JW, 1983, J BIOL CHEM, V258, P1289; PIKE JW, 1987, J BIOL CHEM, V262, P1305; Potter GB, 2002, MOL ENDOCRINOL, V16, P2547, DOI 10.1210/me.2002-0115; Potter GB, 2001, GENE DEV, V15, P2687, DOI 10.1101/gad.916701; Rachez C, 1999, NATURE, V398, P824, DOI 10.1038/19783; RIZKRABIN M, 1994, J CELL PHYSIOL, V159, P131, DOI 10.1002/jcp.1041590117; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; RUT AR, 1994, CLIN ENDOCRINOL, V41, P581, DOI 10.1111/j.1365-2265.1994.tb01822.x; Sakai Y, 2001, J CLIN INVEST, V107, P961, DOI 10.1172/JCI11676; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; STOYE JP, 1988, CELL, V54, P383, DOI 10.1016/0092-8674(88)90201-2; STUMPF WE, 1979, SCIENCE, V206, P1188, DOI 10.1126/science.505004; Tagami T, 1998, BIOCHEM BIOPH RES CO, V253, P358, DOI 10.1006/bbrc.1998.9799; TERPENING CM, 1991, MOL ENDOCRINOL, V5, P373, DOI 10.1210/mend-5-3-373; Thompson CC, 2000, CEREB CORTEX, V10, P939, DOI 10.1093/cercor/10.10.939; Thompson CC, 1996, J NEUROSCI, V16, P7832; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; Whitfield GK, 1996, MOL ENDOCRINOL, V10, P1617, DOI 10.1210/me.10.12.1617; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Xie ZJ, 2002, J BIOL CHEM, V277, P36987, DOI 10.1074/jbc.M201404200; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yen PM, 1996, J BIOL CHEM, V271, P10910, DOI 10.1074/jbc.271.18.10910; Yoshizawa T, 1997, NAT GENET, V16, P391, DOI 10.1038/ng0897-391	78	159	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38665	38674		10.1074/jbc.M304886200	http://dx.doi.org/10.1074/jbc.M304886200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847098	hybrid			2022-12-27	WOS:000185575100071
J	Whitley, P; Reaves, BJ; Hashimoto, M; Riley, AM; Potter, BVL; Holman, GD				Whitley, P; Reaves, BJ; Hashimoto, M; Riley, AM; Potter, BVL; Holman, GD			Identification of mammalian Vps24p as an effector of phosphatidylinositol 3,5-bisphosphate-dependent endosome compartmentalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TSG101 PROTEIN; FYVE FINGER; PX DOMAINS; CLONING; BINDING; 3-PHOSPHATE; EXPRESSION; DISPLAY; TRAFFICKING; FAB1P	Phosphatidylinositol 3,5-bisphosphate is a membrane lipid found in all eukaryotes so far studied but down-stream effector proteins of this lipid have yet to be identified. Here we report the use of cDNA phage libraries in conjunction with synthetic biotinylated derivatives of phosphatidylinositol 3,5-bisphosphate in the identification of a mammalian phosphatidylinositol 3,5-bisphosphate-binding protein, mVps24p. This protein is orthologous to the Saccharomyces cerevisiae protein, Vps24p, a class-E vacuolar protein-sorting protein. Using in vitro liposome binding and competition assays, we demonstrate that mVps24p selectively binds to phosphatidylinositol 3,5-bisphosphate and phosphatidylinositol 3,4-bisphosphate in preference to other phosphoinositides tested. When expressed in cultured mammalian cells, full-length mVps24p is cytosolic. However, when cells expressing the full-length mVps24p are co-transfected with a mutated form of mVps4p (which is defective in ATP hydrolysis), or when a N-terminal construct of mVps24p is expressed, the class-E cellular phenotype with swollen vacuoles is induced and mVps24p is membrane-associated. Furthermore, the accumulation of the N-terminal mVps24p construct on the swollen endosomal membranes is abrogated when phosphatidylinositol 3,5-bisphosphate synthesis is blocked with wortmannin. These data provide the first direct link between phosphatidylinositol 3,5-bisphosphate and the protein machinery involved in the production of the class-E cellular phenotype. We hypothesize that accumulation of Vps24 on membranes occurs when membrane association (dependent on interaction of phosphatidylinositol 3,5-bisphosphate with the N-terminal domain of the protein) is uncoupled from membrane disassociation (driven by Vps4p).	Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England; Univ Bath, Dept Pharm & Pharmacol, Wolfson Lab Med Chem, Bath BA2 7AY, Avon, England	University of Bath; University of Bath	Whitley, P (corresponding author), Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.	bssprw@bath.ac.uk	Riley, Andrew M/F-3526-2013; Potter, Barry VL/A-1845-2012; Potter, Barry/AAX-4781-2020; Hashimoto, Makoto/B-7837-2012	Riley, Andrew M/0000-0001-9003-3540; Hashimoto, Makoto/0000-0002-5526-8835; Holman, Geoffrey/0000-0001-7045-1358				Abram CL, 2003, J BIOL CHEM, V278, P16844, DOI 10.1074/jbc.M300267200; Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Bishop N, 2000, MOL BIOL CELL, V11, P227, DOI 10.1091/mbc.11.1.227; Bishop N, 2001, J BIOL CHEM, V276, P11735, DOI 10.1074/jbc.M009863200; Cooke FT, 1998, CURR BIOL, V8, P1219, DOI 10.1016/S0960-9822(07)00513-1; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Cozier GE, 2002, J BIOL CHEM, V277, P48730, DOI 10.1074/jbc.M206986200; CRAMERI R, 1994, EUR J BIOCHEM, V226, P53, DOI 10.1111/j.1432-1033.1994.tb20025.x; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Danner S, 2001, P NATL ACAD SCI USA, V98, P12954, DOI 10.1073/pnas.211439598; Dove SK, 2002, CURR BIOL, V12, P885, DOI 10.1016/S0960-9822(02)00891-6; Dove SK, 1997, NATURE, V390, P187, DOI 10.1038/36613; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; Fujita H, 2003, J CELL SCI, V116, P401, DOI 10.1242/jcs.00213; Gary JD, 1998, J CELL BIOL, V143, P65, DOI 10.1083/jcb.143.1.65; Gaullier JM, 2000, J BIOL CHEM, V275, P24595, DOI 10.1074/jbc.M906554199; Howard TL, 2001, J CELL SCI, V114, P2395; Ikonomov OC, 2001, J BIOL CHEM, V276, P26141, DOI 10.1074/jbc.M101722200; Jones DR, 1999, J BIOL CHEM, V274, P18407, DOI 10.1074/jbc.274.26.18407; Karathanassis D, 2002, EMBO J, V21, P5057, DOI 10.1093/emboj/cdf519; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Kutateladze T, 2001, SCIENCE, V291, P1793, DOI 10.1126/science.291.5509.1793; Lindborg M, 1999, J INVEST DERMATOL, V113, P156, DOI 10.1046/j.1523-1747.1999.00661.x; Odorizzi G, 1998, CELL, V95, P847, DOI 10.1016/S0092-8674(00)81707-9; Patki V, 1997, P NATL ACAD SCI USA, V94, P7326, DOI 10.1073/pnas.94.14.7326; Piper RC, 2001, TRAFFIC, V2, P612, DOI 10.1034/j.1600-0854.2001.20904.x; Rao VR, 1999, J BIOL CHEM, V274, P37893, DOI 10.1074/jbc.274.53.37893; RAYMOND CK, 1992, MOL BIOL CELL, V3, P1389, DOI 10.1091/mbc.3.12.1389; Reaves BJ, 2000, J CELL SCI, V113, P4099; RILEY AM, 1988, TETRAHEDRON LETT, V30, P6769; Sankaran VG, 2001, BIOCHEMISTRY-US, V40, P8581, DOI 10.1021/bi010425d; Sbrissa D, 2001, MOL CELL ENDOCRINOL, V181, P35, DOI 10.1016/S0303-7207(01)00539-1; Sche PP, 1999, CHEM BIOL, V6, P707, DOI 10.1016/S1074-5521(00)80018-6; Shaw JD, 2003, TRAFFIC, V4, P479, DOI 10.1034/j.1600-0854.2003.t01-1-00106.x; Shisheva A, 2001, J BIOL CHEM, V276, P11859, DOI 10.1074/jbc.M008437200; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Shisheva A, 1999, MOL CELL BIOL, V19, P623; Stahelin RV, 2003, J BIOL CHEM, V278, P14469, DOI 10.1074/jbc.M212579200; Stahelin RV, 2002, J BIOL CHEM, V277, P26379, DOI 10.1074/jbc.M201106200; Stauffer DR, 2001, J CELL SCI, V114, P2383; Tanaka K, 1997, EUR J BIOCHEM, V245, P512, DOI 10.1111/j.1432-1033.1997.00512.x; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Whiteford CC, 1997, BIOCHEM J, V323, P597, DOI 10.1042/bj3230597; Xie WQ, 1998, P NATL ACAD SCI USA, V95, P1595, DOI 10.1073/pnas.95.4.1595; Yu JW, 2001, J BIOL CHEM, V276, P44179, DOI 10.1074/jbc.M108811200; Zhong Q, 1998, CANCER RES, V58, P2699	47	123	126	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38786	38795		10.1074/jbc.M306864200	http://dx.doi.org/10.1074/jbc.M306864200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878588	hybrid			2022-12-27	WOS:000185575100086
J	Yim, S; Choi, SM; Choi, YY; Lee, N; Chung, J; Park, H				Yim, S; Choi, SM; Choi, YY; Lee, N; Chung, J; Park, H			Insulin and hypoxia share common target genes but not the hypoxia-inducible factor-1 alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR MESSENGER-RNA; PHOSPHATIDYLINOSITOL 3-KINASE; ENDOTHELIN-1 GENE; HIF-ALPHA; FACTOR-I; EXPRESSION; TRANSCRIPTION; ACTIVATION; PROTEIN; KINASE	Both hypoxia and insulin induce common target genes, including vascular endothelial growth factors and several glycolytic enzymes. However, these two signals eventually trigger quite different metabolic pathways. Hypoxia induces glycolysis, resulting in anaerobic ATP production, while insulin increases glycolysis for energy storage. Hypoxia-induced gene expression is mediated by the hypoxia-inducible factor-1 (HIF-1) that consists of HIF-1alpha and the aromatic hydrocarbon nuclear translocator (Arnt). Hypoxia-induced gene expression is initiated by the stabilization of the HIF-1alpha subunit. Here we investigated whether insulin-induced gene expression also requires stabilization of HIF-1alpha. Our results indicate that hypoxia but not insulin stabilizes HIF-1alpha protein levels, whereas both insulin- and hypoxia-induced gene expression require the presence of the Arnt protein. Insulin treatment fails to inactivate proline hydroxylation of HIF-1alpha, which triggers recruitment of the von Hippel-Lindau protein and oxygen-dependent degradation of HIF-1alpha. Insulin-induced gene expression is inhibited by the presence of the phosphoinositide (PI) 3-kinase inhibitor LY294002 and the dominant negative mutant of the p85 subunit of PI 3-kinase, whereas hypoxia-induced gene expression is not. Pyrrolidine dithiocarbamate, a scavenger of H2O2, reduces insulin- induced gene expression but not hypoxia-induced gene expression. Although both hypoxia and insulin induce the expression of common target genes through a hypoxia-responsive element- and Arnt-dependent mechanism, insulin cannot stabilize the HIF-1alpha protein. We believe that insulin activates other putative partner proteins for Arnt in PI 3-kinase- and H2O2-dependent pathways.	Univ Seoul, Dept Life Sci, Seoul 130743, South Korea	University of Seoul	Park, H (corresponding author), Univ Seoul, Dept Life Sci, 90 Cheonnong Dong, Seoul 130743, South Korea.							Alvarez-Tejado M, 2002, J BIOL CHEM, V277, P13508, DOI 10.1074/jbc.M200017200; Arsham AM, 2002, J BIOL CHEM, V277, P15162, DOI 10.1074/jbc.M111162200; BACSI SG, 1995, MOL PHARMACOL, V47, P432; Bae YS, 2000, J BIOL CHEM, V275, P10527, DOI 10.1074/jbc.275.14.10527; Barthel A, 1999, J BIOL CHEM, V274, P20281, DOI 10.1074/jbc.274.29.20281; Bruick RK, 2001, SCIENCE, V294, P1337, DOI 10.1126/science.1066373; Chandel NS, 2000, J BIOL CHEM, V275, P25130, DOI 10.1074/jbc.M001914200; Crews ST, 1998, GENE DEV, V12, P607, DOI 10.1101/gad.12.5.607; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; FERNYHOUGH P, 1994, NEUROSCIENCE, V62, P337, DOI 10.1016/0306-4522(94)90368-9; Fukuda R, 2002, J BIOL CHEM, V277, P38205, DOI 10.1074/jbc.M203781200; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jewell UR, 2001, FASEB J, V15, P1312, DOI 10.1096/fj.00-0732fje; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Ko HSP, 1996, MOL CELL BIOL, V16, P430; KRIEGERBRAUER HI, 1995, BIOCHEM J, V307, P549, DOI 10.1042/bj3070549; Liao JF, 1998, J BIOL CHEM, V273, P27320, DOI 10.1074/jbc.273.42.27320; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; Makino Y, 2001, NATURE, V414, P550, DOI 10.1038/35107085; Masuda S, 1997, BRAIN RES, V746, P63, DOI 10.1016/S0006-8993(96)01186-9; Miele C, 2000, J BIOL CHEM, V275, P21695, DOI 10.1074/jbc.M000805200; Narravula S, 2001, J IMMUNOL, V166, P7543, DOI 10.4049/jimmunol.166.12.7543; OBrien RM, 1996, PHYSIOL REV, V76, P1109, DOI 10.1152/physrev.1996.76.4.1109; Okino ST, 1998, J BIOL CHEM, V273, P23837, DOI 10.1074/jbc.273.37.23837; OLIVER FJ, 1991, J BIOL CHEM, V266, P23251; Osborne TF, 2000, J BIOL CHEM, V275, P32379, DOI 10.1074/jbc.R000017200; Poulaki V, 2002, J CLIN INVEST, V109, P805, DOI 10.1172/JCI200213776; Seagroves TN, 2001, MOL CELL BIOL, V21, P3436, DOI 10.1128/MCB.21.10.3436-3444.2001; Semenza GL, 2000, GENE DEV, V14, P1983; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; Srinivas V, 2001, J BIOL CHEM, V276, P21995, DOI 10.1074/jbc.C100177200; SWANSON HI, 1995, J BIOL CHEM, V270, P26292, DOI 10.1074/jbc.270.44.26292; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Vaulont S, 2000, J BIOL CHEM, V275, P31555, DOI 10.1074/jbc.R000016200; Wang D, 1998, J BIOL CHEM, V273, P25420, DOI 10.1074/jbc.273.39.25420; Yamashita K, 2001, J BIOL CHEM, V276, P12645, DOI 10.1074/jbc.M011344200; Yu F, 2001, P NATL ACAD SCI USA, V98, P9630, DOI 10.1073/pnas.181341498; Yun Z, 2002, DEV CELL, V2, P331, DOI 10.1016/S1534-5807(02)00131-4; Zelzer E, 1997, GENE DEV, V11, P2079, DOI 10.1101/gad.11.16.2079; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085	45	26	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38260	38268		10.1074/jbc.M306016200	http://dx.doi.org/10.1074/jbc.M306016200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876287	hybrid			2022-12-27	WOS:000185575100023
J	Adinolfi, E; Kim, M; Young, MT; Di Virgilio, F; Surprenant, A				Adinolfi, E; Kim, M; Young, MT; Di Virgilio, F; Surprenant, A			Tyrosine phosphorylation of HSP90 within the P2X(7) receptor complex negatively regulates P2X(7) receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; GLUCOCORTICOID-RECEPTOR; P2Z PURINORECEPTOR; P-2Z RECEPTOR; CELL-DEATH; KAPPA-B; KINASE; ACTIVATION; HETEROCOMPLEX; GELDANAMYCIN	The purinergic P2X(7) receptor not only gates the opening of a cationic channel, but also couples to several downstream signaling events such as rapid membrane blebbing, microvesicle shedding, and interleukin-1beta release. Protein-protein interactions are likely to be involved in most of these signaling cascades; and recently, a P2X(7) receptor-protein complex comprising at least 11 distinct proteins has been identified. We have studied one of these interacting proteins, HSP90, in human embryonic kidney cells expressing either human or rat P2X(7) receptors as well as in rat peritoneal macrophages using biochemical ( immunoprecipitation and Western blotting) and functional ( membrane blebbing and currents) assays. We found that HSP90 was tyrosine-phosphorylated in association with the P2X(7) receptor complex, but not in the cytosolic compartment. The HSP90 inhibitor geldanamycin decreased tyrosine phosphorylation of HSP90 and produced a 2-fold increase in the sensitivity of P2X(7) receptors to agonist. Protein expression and tyrosine phosphorylation of a mutant P2X(7) receptor in which a tyrosine in the C-terminal domain was substituted with phenylalanine (Y550F) were not changed, but tyrosine phosphorylation of HSP90 associated with this mutant P2X(7) receptor complex was significantly greater than that associated with the wild-type complex. P2X(7)-Y550F receptors showed a 15-fold lower sensitivity to agonist, which was reversed by geldanamycin. We conclude that selective tyrosine phosphorylation of P2X(7) receptor-associated HSP90 may act as a negative regulator of P2X(7) receptor complex formation and function.	Univ Sheffield, Dept Biomed Sci, Inst Mol Physiol, Sheffield S10 2TN, S Yorkshire, England; Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44100 Ferrara, Italy	University of Sheffield; University of Ferrara	Surprenant, A (corresponding author), Univ Sheffield, Dept Biomed Sci, Inst Mol Physiol, Denny Bldg,Western Bank, Sheffield S10 2TN, S Yorkshire, England.	a.surprenant@sheffield.ac.uk	Young, Mark T/E-8928-2010; Di Virgilio, Francesco/J-3754-2018; Adinolfi, Elena/F-9169-2010; DI VIRGILIO, Francesco/O-4634-2019	Young, Mark T/0000-0002-9615-9002; Di Virgilio, Francesco/0000-0003-3566-1362; Adinolfi, Elena/0000-0001-8129-9929; DI VIRGILIO, Francesco/0000-0003-3566-1362				AHAO C, 2002, EXP CELL RES, V275, P200; Baricordi OR, 1999, J BIOL CHEM, V274, P33206, DOI 10.1074/jbc.274.47.33206; BEERE HM, 2001, SCI STKE; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; Brouet A, 2001, CIRC RES, V89, P866, DOI 10.1161/hh2201.100319; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; Chessell IP, 1998, FEBS LETT, V439, P26, DOI 10.1016/S0014-5793(98)01332-5; Chiozzi P, 1997, J CELL BIOL, V138, P697, DOI 10.1083/jcb.138.3.697; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Di Virgilio F, 1998, CELL DEATH DIFFER, V5, P191; Egerton M, 1996, BIOCHEM BIOPH RES CO, V224, P666, DOI 10.1006/bbrc.1996.1082; FALZONI S, 1995, J CLIN INVEST, V95, P1207, DOI 10.1172/JCI117770; Falzoni S, 2000, MOL BIOL CELL, V11, P3169, DOI 10.1091/mbc.11.9.3169; Ferrari D, 1997, J CELL BIOL, V139, P1635, DOI 10.1083/jcb.139.7.1635; Ferrari D, 1999, FEBS LETT, V447, P71, DOI 10.1016/S0014-5793(99)00270-7; Gu BJ, 2000, AM J PHYSIOL-CELL PH, V279, pC1189, DOI 10.1152/ajpcell.2000.279.4.C1189; Gudipaty L, 2001, AM J PHYSIOL-CELL PH, V280, pC943, DOI 10.1152/ajpcell.2001.280.4.C943; Guo YL, 2001, J BIOL CHEM, V276, P45791, DOI 10.1074/jbc.M105931200; Hayashi T, 1999, NATURE, V397, P72, DOI 10.1038/16269; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Humphreys BD, 2000, J BIOL CHEM, V275, P26792; Husi H, 2000, NAT NEUROSCI, V3, P661, DOI 10.1038/76615; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; Jiang LH, 2000, MOL PHARMACOL, V58, P82, DOI 10.1124/mol.58.1.82; Kanelakis KC, 2002, J BIOL CHEM, V277, P33698, DOI 10.1074/jbc.M204164200; KAPPERSTUCK M, 2001, J PHYSIOL-LONDON, V534, P25; Kim M, 2001, J BIOL CHEM, V276, P23262, DOI 10.1074/jbc.M102253200; Kim M, 2001, EMBO J, V20, P6347, DOI 10.1093/emboj/20.22.6347; Kim SH, 1999, BIOCHEM BIOPH RES CO, V262, P516, DOI 10.1006/bbrc.1999.1229; Le Feuvre RA, 2002, J BIOL CHEM, V277, P3210, DOI 10.1074/jbc.M104388200; LEESMILLER SP, 1989, J BIOL CHEM, V264, P17275; LEESMILLER SP, 1989, J BIOL CHEM, V264, P2431; Lewis J, 2000, J BIOL CHEM, V275, P10519, DOI 10.1074/jbc.275.14.10519; Lopez-Maderuelo MD, 2001, FEBS LETT, V490, P23, DOI 10.1016/S0014-5793(01)02130-5; MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1; Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762; Nollen EAA, 2002, J CELL SCI, V115, P2809; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Pandey P, 2000, EMBO J, V19, P4310, DOI 10.1093/emboj/19.16.4310; Rassendren F, 1997, J BIOL CHEM, V272, P5482, DOI 10.1074/jbc.272.9.5482; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Stebbins CE, 1997, CELL, V89, P239, DOI 10.1016/S0092-8674(00)80203-2; Surprenant A, 2000, J AUTONOM NERV SYST, V81, P249, DOI 10.1016/S0165-1838(00)00123-5; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Virginio C, 1997, NEUROPHARMACOLOGY, V36, P1285, DOI 10.1016/S0028-3908(97)00141-X; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324	49	79	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37344	37351		10.1074/jbc.M301508200	http://dx.doi.org/10.1074/jbc.M301508200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869560	hybrid			2022-12-27	WOS:000185437200044
J	Gao, JM; Choe, H; Bota, D; Wright, PL; Gerard, C; Gerard, NP				Gao, JM; Choe, H; Bota, D; Wright, PL; Gerard, C; Gerard, NP			Sulfation of tyrosine 174 in the human C3a receptor is essential for binding of C3a anaphylatoxin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR LOOP; C5A ANAPHYLATOXIN; HUMAN-COMPLEMENT; AMINO-TERMINUS; HIV-1 ENTRY; MAST-CELLS; CLONING; IDENTIFICATION; EXPRESSION; ACTIVATION	The complement anaphylatoxin C3a and its cellular seven-transmembrane segment receptor, C3aR, are implicated in a variety of pathological inflammatory processes. C3aR is a G-protein-coupled receptor with an exceptionally large second extracellular loop of 172 amino acids. Previously reported deletion studies have shown that at least part of this region plays a critical role in binding C3a. Our data now demonstrate that five tyrosines in the second extracellular loop of the C3aR are posttranslationally modified by the addition of sulfate. Blocking sulfation by mutation of tyrosine to phenylalanine at positions 184, 188, 317, and/or 318 does not affect ligand binding or signal transduction. However, when tyrosine 174 is mutated to phenylalanine, binding of native C3a is completely blocked. This variant efficiently mobilizes calcium in response to synthetic C3a agonist peptides, but not to native C3a. This finding is consistent with a two-site model of ligand association typical of many peptide ligand-receptor interactions and identifies sulfotyrosine 174 as the critical C3a docking site. Tyrosine sulfation in the amino-terminal extracellular domain has been shown to be important in several other seven-transmembrane segment receptors. Our data now demonstrate that tyrosine sulfate in other extracellular domains can function for ligand interactions as well.	Childrens Hosp, Ina Sue Perlmutter Lab, Boston, MA 02115 USA; Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div AIDS, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School	Gerard, NP (corresponding author), Childrens Hosp, Ina Sue Perlmutter Lab, 320 Longwood Ave, Boston, MA 02115 USA.	Norma.Gerard@TCH.harvard.edu			NHLBI NIH HHS [HL36162] Funding Source: Medline; NIAID NIH HHS [AI43891, AI41851] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL036162, R37HL036162] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043891, R01AI041851] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; Ames RS, 1996, J BIOL CHEM, V271, P20231, DOI 10.1074/jbc.271.34.20231; BAEUERLE PA, 1985, J BIOL CHEM, V260, P6434; Bundgaard JR, 1997, J BIOL CHEM, V272, P21700, DOI 10.1074/jbc.272.35.21700; Chao TH, 1999, J BIOL CHEM, V274, P9721, DOI 10.1074/jbc.274.14.9721; Choe H, 2003, CELL, V114, P161, DOI 10.1016/S0092-8674(03)00508-7; COCHRANE CG, 1968, J EXP MED, V127, P371, DOI 10.1084/jem.127.2.371; Crass T, 1999, J BIOL CHEM, V274, P8367, DOI 10.1074/jbc.274.13.8367; Crass T, 1996, EUR J IMMUNOL, V26, P1944, DOI 10.1002/eji.1830260840; DAFFERN PJ, 1995, J EXP MED, V181, P2119, DOI 10.1084/jem.181.6.2119; EMBER JA, 1991, BIOCHEMISTRY-US, V30, P3603, DOI 10.1021/bi00229a003; Farzan M, 1999, CELL, V96, P667, DOI 10.1016/S0092-8674(00)80577-2; Farzan M, 2002, J BIOL CHEM, V277, P29484, DOI 10.1074/jbc.M203361200; Farzan M, 2001, J EXP MED, V193, P1059, DOI 10.1084/jem.193.9.1059; Fong AM, 2002, J BIOL CHEM, V277, P19418, DOI 10.1074/jbc.M201396200; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD NP, 1991, NATURE, V349, P614, DOI 10.1038/349614a0; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; HORTIN G, 1986, J BIOL CHEM, V261, P1786; HUANG SC, 1989, PEPTIDES, V10, P785, DOI 10.1016/0196-9781(89)90114-9; HUGLI TE, 1975, J BIOL CHEM, V250, P8293; Humbles AA, 2000, NATURE, V406, P998, DOI 10.1038/35023175; HUTTNER WB, 1988, ANNU REV PHYSIOL, V50, P363, DOI 10.1146/annurev.ph.50.030188.002051; KARP DR, 1983, J BIOL CHEM, V258, P2745; Kehoe JW, 2000, CHEM BIOL, V7, pR57, DOI 10.1016/S1074-5521(00)00093-4; KOLAKOWSKI LF, 1995, J BIOL CHEM, V270, P18077, DOI 10.1074/jbc.270.30.18077; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; NIEHRS C, 1990, J BIOL CHEM, V265, P9314; Nilsson G, 1996, J IMMUNOL, V157, P1693; Preobrazhensky AA, 2000, J IMMUNOL, V165, P5295, DOI 10.4049/jimmunol.165.9.5295; Roglic A, 1996, BBA-GENE STRUCT EXPR, V1305, P39, DOI 10.1016/0167-4781(95)00209-X; ROSENQUIST GL, 1993, PROTEIN SCI, V2, P215; STIMLER NP, 1980, AM J PATHOL, V100, P327; STIMLERGERARD NP, 1987, J IMMUNOL, V138, P1908; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; VOGT W, 1986, Complement, V3, P177	36	37	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37902	37908		10.1074/jbc.M306061200	http://dx.doi.org/10.1074/jbc.M306061200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871936	hybrid			2022-12-27	WOS:000185437200112
J	Mahmmoud, YA; Cramb, G; Maunsbach, AB; Cutler, CP; Meischke, L; Cornelius, F				Mahmmoud, YA; Cramb, G; Maunsbach, AB; Cutler, CP; Meischke, L; Cornelius, F			Regulation of Na,K-ATPase by PLMS, the phospholemman-like protein from shark - Molecular cloning, sequence, expression, cellular distribution, and functional effects of PLMS	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; NA+,K+-ATPASE PUMP CYCLE; C-TERMINAL DOMAIN; GAMMA-SUBUNIT; SQUALUS-ACANTHIAS; RENAL NA,K-ATPASE; RECTAL GLAND; KINASE-C; INHIBITORY FUNCTION; CHANNEL ACTIVITY	In Na, K-ATPase membrane preparations from shark rectal glands, we have previously identified an FXYD domain-containing protein, phospholemman-like protein from shark, PLMS. This protein was shown to associate and modulate shark Na, K-ATPase activity in vitro. Here we describe the complete coding sequence, expression, and cellular localization of PLMS in the rectal gland of the shark Squalus acanthias. The mature protein contained 74 amino acids, including the N-terminal FXYD motif and a C-terminal protein kinase multisite phosphorylation motif. The sequence is preceded by a 20 amino acid candidate cleavable signal sequence. Immunogold labeling of the Na, K-ATPase alpha-subunit and PLMS showed the presence of alpha and PLMS in the basolateral membranes of the rectal gland cells and suggested their partial colocalization. Furthermore, through controlled proteolysis, the C terminus of PLMS containing the protein kinase phosphorylation domain can be specifically cleaved. Removal of this domain resulted in stimulation of maximal Na, K-ATPase activity, as well as several partial reactions. Both the E-1 similar to P --> E-2-P reaction, which is partially rate-limiting in shark, and the K+ deocclusion reaction, E-2(K) --> E-1, are accelerated. The latter may explain the finding that the apparent Na+ affinity was increased by the specific C-terminal PLMS truncation. Thus, these data are consistent with a model where interaction of the phosphorylation domain of PLMS with the Na, K-ATPase alpha-subunit is important for the modulation of shark Na, K-ATPase activity.	Aarhus Univ, Dept Biophys, DK-8000 Aarhus C, Denmark; Aarhus Univ, Inst Anat, Dept Cell Biol, Water & Salt Res Ctr, DK-8000 Aarhus C, Denmark; Univ St Andrews, Sch Biol, St Andrews KY16 9TS, Fife, Scotland	Aarhus University; Aarhus University; University of St Andrews	Cornelius, F (corresponding author), Aarhus Univ, Dept Biophys, Ole Worms Alle 185, DK-8000 Aarhus C, Denmark.	fc@biophys.au.dk	Cornelius, Flemming/C-1912-2019	Cornelius, Flemming/0000-0003-1566-0020; Cramb, Gordon/0000-0003-4929-951X				Aizman R, 2002, AM J PHYSIOL-RENAL, V283, pF569, DOI 10.1152/ajprenal.00376.2001; Arystarkhova E, 1999, J BIOL CHEM, V274, P33183, DOI 10.1074/jbc.274.47.33183; Arystarkhova E, 2002, J BIOL CHEM, V277, P10162, DOI 10.1074/jbc.M111552200; ATTALI B, 1995, P NATL ACAD SCI USA, V92, P6092, DOI 10.1073/pnas.92.13.6092; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; Beguin P, 1997, EMBO J, V16, P4250, DOI 10.1093/emboj/16.14.4250; Beguin P, 2002, EMBO J, V21, P3264, DOI 10.1093/emboj/cdf330; Beguin P, 2001, EMBO J, V20, P3993, DOI 10.1093/emboj/20.15.3993; BULGER RE, 1963, ANAT REC, V147, P95, DOI 10.1002/ar.1091470108; Chen LSK, 1997, GENOMICS, V41, P435, DOI 10.1006/geno.1997.4665; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CLELAND WW, 1963, BIOCHIM BIOPHYS ACTA, V67, P188; CORNELIUS F, 1992, BIOCHIM BIOPHYS ACTA, V1108, P190, DOI 10.1016/0005-2736(92)90025-H; CORNELIUS F, 1991, BIOCHIM BIOPHYS ACTA, V1067, P227, DOI 10.1016/0005-2736(91)90048-D; Cornelius F, 2003, ANN NY ACAD SCI, V986, P579, DOI 10.1111/j.1749-6632.2003.tb07256.x; Cornelius F, 2003, NEWS PHYSIOL SCI, V18, P119, DOI 10.1152/nips.01434.2003; Cornelius F, 2001, J BIOENERG BIOMEMBR, V33, P415, DOI 10.1023/A:1010671607911; Cornelius F, 1999, BIOPHYS J, V77, P934, DOI 10.1016/S0006-3495(99)76944-4; Crambert G, 2002, P NATL ACAD SCI USA, V99, P11476, DOI 10.1073/pnas.182267299; CRAMBERT G, 2003, SCI STKE; Cutler CP, 2000, AM J PHYSIOL-REG I, V279, pR222, DOI 10.1152/ajpregu.2000.279.1.R222; Daly SE, 1996, J BIOL CHEM, V271, P23683, DOI 10.1074/jbc.271.39.23683; Darman RB, 2001, J BIOL CHEM, V276, P34359, DOI 10.1074/jbc.C100368200; Donnet C, 2001, J BIOL CHEM, V276, P7357, DOI 10.1074/jbc.M009131200; EVELOFF J, 1979, J CELL BIOL, V83, P16, DOI 10.1083/jcb.83.1.16; Fedosova NU, 1995, BIOCHEMISTRY-US, V34, P16806, DOI 10.1021/bi00051a031; Fu XY, 1997, MOL CELL BIOL, V17, P1503, DOI 10.1128/MCB.17.3.1503; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Garty H, 2002, AM J PHYSIOL-RENAL, V283, pF607, DOI 10.1152/ajprenal.00112.2002; GOERTEMILLER CC, 1976, CELL TISSUE RES, V175, P101; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; Humphrey PA, 2002, BIOCHEMISTRY-US, V41, P9496, DOI 10.1021/bi025836o; JORGENSEN PL, 1988, METHOD ENZYMOL, V156, P291; Kaplan JH, 2002, ANNU REV BIOCHEM, V71, P511, DOI 10.1146/annurev.biochem.71.102201.141218; KARLISH SJD, 1978, BIOCHIM BIOPHYS ACTA, V527, P115, DOI 10.1016/0005-2744(78)90261-9; Kimura Y, 1997, J BIOL CHEM, V272, P15061, DOI 10.1074/jbc.272.24.15061; Kimura Y, 1998, J BIOL CHEM, V273, P14238, DOI 10.1074/jbc.273.23.14238; Kruger A, 2003, ANN NY ACAD SCI, V986, P541; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINDBERG O, 1956, METHODS BIOCHEMICAL, V3, P1; Lindzen M, 2003, J BIOL CHEM, V278, P18738, DOI 10.1074/jbc.M213253200; Lupfert C, 2001, BIOPHYS J, V81, P2069, DOI 10.1016/S0006-3495(01)75856-0; Mahmmoud YA, 2000, J BIOL CHEM, V275, P35969, DOI 10.1074/jbc.M005168200; Mahmmoud YA, 2002, BIOPHYS J, V82, P1907, DOI 10.1016/S0006-3495(02)75540-9; MANUSBACH AB, 1998, CELL BIOL LAB HDB, V3, P268; MAUNSBACH AB, 1984, AM J PHYSIOL, V246, pF710, DOI 10.1152/ajprenal.1984.246.5.F710; Meij IC, 2000, NAT GENET, V26, P265, DOI 10.1038/81543; Minor NT, 1998, P NATL ACAD SCI USA, V95, P6521, DOI 10.1073/pnas.95.11.6521; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Moller JV, 1997, J BIOL CHEM, V272, P29015, DOI 10.1074/jbc.272.46.29015; MORRISON BW, 1995, J BIOL CHEM, V270, P2176, DOI 10.1074/jbc.270.5.2176; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Odermatt A, 1998, J BIOL CHEM, V273, P12360, DOI 10.1074/jbc.273.20.12360; PALMER CJ, 1991, J BIOL CHEM, V266, P11126; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PLESNER IW, 1986, BIOCHEM J, V239, P175, DOI 10.1042/bj2390175; Pu HX, 2002, J BIOL CHEM, V277, P20270, DOI 10.1074/jbc.M201009200; Pu HX, 2001, J BIOL CHEM, V276, P20370, DOI 10.1074/jbc.M010836200; Reddy LG, 1999, J BIOL CHEM, V274, P7649, DOI 10.1074/jbc.274.12.7649; SAMBROOK J, 1989, NATURE, V342, P224, DOI 10.1038/342224a0; Segall L, 2002, J BIOL CHEM, V277, P35202, DOI 10.1074/jbc.M206115200; Silva P, 1996, KIDNEY INT, V49, P1552, DOI 10.1038/ki.1996.223; SKOU JC, 1979, BIOCHIM BIOPHYS ACTA, V567, P436, DOI 10.1016/0005-2744(79)90129-3; Sweadner KJ, 2000, GENOMICS, V68, P41, DOI 10.1006/geno.2000.6274; Therien AG, 1997, J BIOL CHEM, V272, P32628, DOI 10.1074/jbc.272.51.32628; Therien AG, 1999, J BIOL CHEM, V274, P12252, DOI 10.1074/jbc.274.18.12252; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Tupling AR, 2002, J BIOL CHEM, V277, P44740, DOI 10.1074/jbc.M206171200; Xu ZC, 1996, J BIOL CHEM, V271, P9313, DOI 10.1074/jbc.271.16.9313	69	59	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37427	37438		10.1074/jbc.M305126200	http://dx.doi.org/10.1074/jbc.M305126200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12874284	hybrid			2022-12-27	WOS:000185437200055
J	Park, CS; Schneider, IC; Haugh, JM				Park, CS; Schneider, IC; Haugh, JM			Kinetic analysis of platelet-derived growth factor receptor/phosphoinositide 3-kinase/Akt signaling in fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; PDGF BETA-RECEPTOR; 3-PHOSPHORYLATED INOSITOL LIPIDS; IMMUNOGLOBULIN-LIKE DOMAINS; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; ACTIVATED LIGAND; TYROSINE KINASES; ALPHA-RECEPTOR; EGF RECEPTORS	Isoforms of the serine-threonine kinase Akt coordinate multiple cell survival pathways in response to stimuli such as platelet-derived growth factor (PDGF). Activation of Akt is a multistep process, which relies on the production of 3'-phosphorylated phosphoinositide (PI) lipids by PI 3-kinases. To quantitatively assess the kinetics of PDGF receptor/PI 3-kinase/Akt signaling in fibroblasts, a systematic study of this pathway was performed, and a mechanistic mathematical model that describes its operation was formulated. We find that PDGF receptor phosphorylation exhibits positive cooperativity with respect to PDGF concentration, and its kinetics are quantitatively consistent with a mechanism in which receptor dimerization is initially mediated by the association of two 1:1 PDGF/PDGF receptor complexes. Receptor phosphorylation is transient at high concentrations of PDGF, consistent with the loss of activated receptors upon endocytosis. By comparison, Akt activation responds to lower PDGF concentrations and exhibits more sustained kinetics. Further analysis and modeling suggest that the pathway is saturated at the level of PI 3-kinase activation, and that the p110alpha catalytic subunit of PI 3-kinase contributes most to PDGF-stimulated 3'-PI production. Thus, at high concentrations of PDGF the kinetics of 3'-PI production are limited by the turnover rate of these lipids, while the Akt response is additionally influenced by the rate of Akt deactivation.	N Carolina State Univ, Dept Chem Engn, Raleigh, NC 27695 USA	University of North Carolina; North Carolina State University	Haugh, JM (corresponding author), N Carolina State Univ, Dept Chem Engn, Box 7905, Raleigh, NC 27695 USA.			Schneider, Ian/0000-0002-4414-3842; Haugh, Jason/0000-0002-2476-4027				Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Anderson KE, 1998, CURR BIOL, V8, P684, DOI 10.1016/S0960-9822(98)70274-X; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bergsten E, 2001, NAT CELL BIOL, V3, P512, DOI 10.1038/35074588; Chiarugi P, 2002, J BIOL CHEM, V277, P37331, DOI 10.1074/jbc.M205203200; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; COOPER JA, 1993, MOL CELL BIOL, V13, P1737, DOI 10.1128/MCB.13.3.1737; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Datta K, 1996, J BIOL CHEM, V271, P30835, DOI 10.1074/jbc.271.48.30835; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEUEL TF, 1991, ANNU REV MED, V42, P567, DOI 10.1146/annurev.me.42.020191.003031; Domin J, 1996, J BIOL CHEM, V271, P21614, DOI 10.1074/jbc.271.35.21614; DUAN DSR, 1991, J BIOL CHEM, V266, P413; Emaduddin M, 1999, BIOCHEM J, V341, P523, DOI 10.1042/0264-6021:3410523; ESCOBEDO JA, 1991, MOL CELL BIOL, V11, P1125, DOI 10.1128/MCB.11.2.1125; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRETTO LJ, 1993, J BIOL CHEM, V268, P3625; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Haugh JM, 2002, J CELL SCI, V115, P303; Haugh JM, 1998, J THEOR BIOL, V195, P187, DOI 10.1006/jtbi.1998.0791; Heinrich R, 2002, MOL CELL, V9, P957, DOI 10.1016/S1097-2765(02)00528-2; HELDIN CH, 1981, P NATL ACAD SCI-BIOL, V78, P3664, DOI 10.1073/pnas.78.6.3664; Heldin CH, 1999, PHYSIOL REV, V79, P1283, DOI 10.1152/physrev.1999.79.4.1283; Heldin CH, 1998, BIOCHIM BIOPHYS ACTA, V1378, P79; HERREN B, 1993, J BIOL CHEM, V268, P15088; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; JACKSON TR, 1992, J BIOL CHEM, V267, P16627; Jones SM, 1999, CURR BIOL, V9, P512, DOI 10.1016/S0960-9822(99)80235-8; KELLY JD, 1991, J BIOL CHEM, V266, P8987; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P21920, DOI 10.1074/jbc.271.36.21920; LaRochelle WJ, 2001, NAT CELL BIOL, V3, P517, DOI 10.1038/35074593; LAUFFENBURGER DA, 1993, RECEPTORS MODELS BIN, P73; Li XR, 2000, NAT CELL BIOL, V2, P302, DOI 10.1038/35010579; Lokker NA, 1997, J BIOL CHEM, V272, P33037, DOI 10.1074/jbc.272.52.33037; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; Miyazawa K, 1998, J BIOL CHEM, V273, P25495, DOI 10.1074/jbc.273.39.25495; Oatey PB, 1999, BIOCHEM J, V344, P511, DOI 10.1042/0264-6021:3440511; Omura T, 1997, J BIOL CHEM, V272, P12676, DOI 10.1074/jbc.272.19.12676; Ostman A, 1989, GROWTH FACTORS, V1, P271, DOI 10.3109/08977198908998003; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Roche S, 1998, MOL CELL BIOL, V18, P7119, DOI 10.1128/MCB.18.12.7119; RodriguezViciana P, 1996, EMBO J, V15, P2442, DOI 10.1002/j.1460-2075.1996.tb00602.x; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SORKIN A, 1993, J CELL PHYSIOL, V156, P373, DOI 10.1002/jcp.1041560221; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; Stephens L, 1998, SCIENCE, V279, P710, DOI 10.1126/science.279.5351.710; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Watton SJ, 1999, CURR BIOL, V9, P433, DOI 10.1016/S0960-9822(99)80192-4; Weiner OD, 2002, CURR OPIN CELL BIOL, V14, P196, DOI 10.1016/S0955-0674(02)00310-1; Wiseman PW, 1999, BIOPHYS J, V76, P963, DOI 10.1016/S0006-3495(99)77260-7	64	81	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37064	37072		10.1074/jbc.M304968200	http://dx.doi.org/10.1074/jbc.M304968200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871957	hybrid			2022-12-27	WOS:000185437200012
J	Tang, ED; Wang, CY; Xiong, Y; Guan, KL				Tang, ED; Wang, CY; Xiong, Y; Guan, KL			A role for NF-kappa B essential modifier/I kappa B kinase-gamma (NEMO/IKK gamma) ubiquitination in the activation of the I kappa B kinase complex by tumor necrosis factor-alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE LIVER DEGENERATION; X-LINKED DISORDER; IKK-BETA SUBUNIT; INCONTINENTIA PIGMENTI; ECTODERMAL DYSPLASIA; DEFICIENT MICE; REGULATORY SUBUNIT; CONJUGATING ENZYME; SIGNALING COMPLEX; LIGASE ACTIVITY	NEMO (NF-kappaB essential modifier)/IKKgamma (IkappaB kinase-gamma) is required for the activation of the IkappaB kinase complex (IKK) by inflammatory stimuli such as tumor necrosis factor (TNF-alpha). Here we show that TNF-alpha stimulates the ubiquitination of NEMO in a manner that does not appear to target it for degradation and that is impaired by mutations in the NEMO zinc finger. Mutations of the zinc finger are found in patients with hypohidrotic ectodermal dysplasia with immunodeficiency (HED-ID) and lead to the impairment of TNF-alpha-stimulated IKK phosphorylation and activation. In addition, the ubiquitination of NEMO is mediated by c-IAP1, an inhibitor of apoptosis protein that is a component of the TNF receptor signaling complex. Thus, the ubiquitination of NEMO mediated by c-IAP1 likely plays an important role in the activation of IKK by TNF-alpha. Also, defective NEMO ubiquitination may be responsible for the impaired cellular NF-kappaB signaling found in patients with HED-ID.	Univ Michigan, Sch Dent, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Program Mol & Cellular Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Dent, Dept Biol & Mat Sci, Lab Mol Signaling & Apoptosis, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Inst Gerontol, Ann Arbor, MI 48109 USA; Univ N Carolina, Dept Biochem & Biophys, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of North Carolina; University of North Carolina Chapel Hill	Guan, KL (corresponding author), Univ Michigan, Sch Dent, Dept Biol Chem, Ann Arbor, MI 48109 USA.		Guan, Kun-Liang/ADK-7088-2022					Aradhya S, 2001, AM J HUM GENET, V68, P765, DOI 10.1086/318806; Baeuerle PA, 1996, CELL, V87, P13, DOI 10.1016/S0092-8674(00)81318-5; Baldwin AS, 2001, J CLIN INVEST, V107, P241, DOI 10.1172/JCI11991; Brown KD, 2002, J BIOL CHEM, V277, P19433, DOI 10.1074/jbc.M111522200; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Devin A, 2000, IMMUNITY, V12, P419, DOI 10.1016/S1074-7613(00)80194-6; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Furukawa M, 2002, J BIOL CHEM, V277, P15758, DOI 10.1074/jbc.M108565200; Furukawa M, 2000, MOL CELL BIOL, V20, P8185, DOI 10.1128/MCB.20.21.8185-8197.2000; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Harhaj EW, 2000, ONCOGENE, V19, P1448, DOI 10.1038/sj.onc.1203445; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Israel A, 2000, TRENDS CELL BIOL, V10, P129, DOI 10.1016/S0962-8924(00)01729-3; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; Li YG, 1999, P NATL ACAD SCI USA, V96, P1042, DOI 10.1073/pnas.96.3.1042; Li ZW, 1999, J EXP MED, V189, P1839, DOI 10.1084/jem.189.11.1839; Makris C, 2002, MOL CELL BIOL, V22, P6573, DOI 10.1128/MCB.22.18.6573-6581.2002; Makris C, 2000, MOL CELL, V5, P969, DOI 10.1016/S1097-2765(00)80262-2; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Miller BS, 2001, J BIOL CHEM, V276, P36320, DOI 10.1074/jbc.M104051200; PICKART CM, 1994, J BIOL CHEM, V269, P7115; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Rudolph D, 2000, GENE DEV, V14, P854; Schmidt-Supprian M, 2000, MOL CELL, V5, P981, DOI 10.1016/S1097-2765(00)80263-4; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Shi CS, 2003, J BIOL CHEM, V278, P15429, DOI 10.1074/jbc.M211796200; Shu HB, 1996, P NATL ACAD SCI USA, V93, P13973, DOI 10.1073/pnas.93.24.13973; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Smahi A, 2000, NATURE, V405, P466; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; VERMA IM, 1995, GENE DEV, V9, P2723, DOI 10.1101/gad.9.22.2723; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Xiao GT, 2000, J BIOL CHEM, V275, P34060, DOI 10.1074/jbc.M002970200; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang JH, 2001, NAT IMMUNOL, V2, P620, DOI 10.1038/89769; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zhang SQ, 2000, IMMUNITY, V12, P301, DOI 10.1016/S1074-7613(00)80183-1; Zonana J, 2000, AM J HUM GENET, V67, P1555, DOI 10.1086/316914	53	178	185	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37297	37305		10.1074/jbc.M303389200	http://dx.doi.org/10.1074/jbc.M303389200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867425	Green Published, hybrid			2022-12-27	WOS:000185437200038
J	Boutell, C; Everett, RD				Boutell, C; Everett, RD			The herpes simplex virus type 1 (HSV-1) regulatory protein ICP0 interacts with and ubiquitinates p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-DEPENDENT DEGRADATION; VIRUS-1-INFECTED CELL PROTEIN-0; TUMOR-SUPPRESSOR; GENE-EXPRESSION; SP100 PROTEINS; DNA-DAMAGE; PML; APOPTOSIS; LIGASE; E3	Herpes simplex virus type 1 regulatory protein ICP0 contains a zinc-binding RING finger and has been shown to induce the proteasome-dependent degradation of a number of cellular proteins in a RING finger-dependent manner during infection. This domain of ICP0 is also required to induce the formation of unanchored polyubiquitin chains in vitro in the presence of ubiquitin-conjugating enzymes UbcH5a and UbcH6. These data indicate that ICP0 has the potential to act as a RING finger ubiquitin ubiquitin-protein isopeptide ligase (E3) and to induce the degradation of certain cellular proteins through ubiquitination and proteasome-mediated degradation. Here we demonstrate that ICP0 is a genuine RING finger ubiquitin E3 ligase that can interact with and mediate the ubiquitination of the major oncoprotein p53 both in vitro and in vivo. Ubiquitination of p53 requires ICP0 to have an intact RING finger domain and occurs independently of its ability to bind to the ubiquitin-specific protease USP7.	MRC, Virol Unit, Glasgow G11 5JR, Lanark, Scotland		Everett, RD (corresponding author), MRC, Virol Unit, Church St, Glasgow G11 5JR, Lanark, Scotland.	r.everett@vir.gla.ac.uk		Boutell, Chris/0000-0002-2970-7785				Bailey D, 2002, J GEN VIROL, V83, P2951, DOI 10.1099/0022-1317-83-12-2951; Boutell C, 2002, J VIROL, V76, P841, DOI 10.1128/JVI.76.2.841-850.2002; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Condreay JP, 1999, P NATL ACAD SCI USA, V96, P127, DOI 10.1073/pnas.96.1.127; Everett RD, 2000, J VIROL, V74, P9994, DOI 10.1128/JVI.74.21.9994-10005.2000; EVERETT RD, 1989, J GEN VIROL, V70, P1185, DOI 10.1099/0022-1317-70-5-1185; Everett RD, 1999, EMBO J, V18, P1526, DOI 10.1093/emboj/18.6.1526; Everett RD, 1998, J VIROL, V72, P6581, DOI 10.1128/JVI.72.8.6581-6591.1998; Everett RD, 2000, BIOESSAYS, V22, P761, DOI 10.1002/1521-1878(200008)22:8<761::AID-BIES10>3.0.CO;2-A; Everett RD, 1997, EMBO J, V16, P1519, DOI 10.1093/emboj/16.7.1519; Fuchs SY, 1998, ONCOGENE, V17, P2543, DOI 10.1038/sj.onc.1202200; Guo A, 2000, NAT CELL BIOL, V2, P730, DOI 10.1038/35036365; Hagglund R, 2002, P NATL ACAD SCI USA, V99, P7889, DOI 10.1073/pnas.122246999; Hagglund R, 2002, P NATL ACAD SCI USA, V99, P631, DOI 10.1073/pnas.022531599; Halford WP, 2001, J VIROL, V75, P6143, DOI 10.1128/JVI.75.13.6143-6153.2001; Halford WP, 2001, J VIROL, V75, P3240, DOI 10.1128/JVI.75.7.3240-3249.2001; Harada JN, 2002, J VIROL, V76, P9194, DOI 10.1128/JVI.76.18.9194-9206.2002; Hobbs WE, 1999, J VIROL, V73, P8245, DOI 10.1128/JVI.73.10.8245-8255.1999; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Kawaguchi Y, 1997, J VIROL, V71, P1019, DOI 10.1128/JVI.71.2.1019-1024.1997; Kawaguchi Y, 1997, J VIROL, V71, P7328, DOI 10.1128/JVI.71.10.7328-7336.1997; Kawaguchi Y, 2001, P NATL ACAD SCI USA, V98, P1877, DOI 10.1073/pnas.041592598; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; Lomonte P, 1999, J VIROL, V73, P9456, DOI 10.1128/JVI.73.11.9456-9467.1999; Lomonte P, 2001, J BIOL CHEM, V276, P5829, DOI 10.1074/jbc.M008547200; LOWE SW, 1993, GENE DEV, V7, P535, DOI 10.1101/gad.7.4.535; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; MEREDITH M, 1995, VIROLOGY, V209, P174, DOI 10.1006/viro.1995.1241; Muller S, 1999, J VIROL, V73, P5137; Parkinson J, 2000, J VIROL, V74, P10006, DOI 10.1128/JVI.74.21.10006-10017.2000; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Pipas JM, 2001, SEMIN CANCER BIOL, V11, P23, DOI 10.1006/scbi.2000.0343; Preston CM, 2000, J GEN VIROL, V81, P1; Querido E, 2001, GENE DEV, V15, P3104, DOI 10.1101/gad.926401; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; Rodriguez MS, 2000, MOL CELL BIOL, V20, P8458, DOI 10.1128/MCB.20.22.8458-8467.2000; ROIZMAN B, 2001, FIELDS VIROLOGY, V2, P2399; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SHOWALTER SD, 1981, INFECT IMMUN, V34, P684, DOI 10.1128/IAI.34.3.684-692.1981; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WILCOCK D, 1991, NATURE, V349, P429, DOI 10.1038/349429a0; Woo RA, 2002, EMBO J, V21, P3000, DOI 10.1093/emboj/cdf307; Woods DB, 2001, EXP CELL RES, V264, P56, DOI 10.1006/excr.2000.5141; YAO F, 1995, J VIROL, V69, P6249, DOI 10.1128/JVI.69.10.6249-6258.1995	49	104	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36596	36602		10.1074/jbc.M300776200	http://dx.doi.org/10.1074/jbc.M300776200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855695	hybrid			2022-12-27	WOS:000185318300090
J	Oh, CD; Chun, JS				Oh, CD; Chun, JS			Signaling mechanisms leading to the regulation of differentiation and apoptosis of articular chondrocytes by insulin-like growth factor-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; OXIDE-INDUCED APOPTOSIS; NITRIC-OXIDE; MESENCHYMAL CELLS; IGF-I; PROTEOGLYCAN SYNTHESIS; SYNOVIAL-FLUID; EXPRESSION; CHONDROGENESIS; CARTILAGE	Cartilage development is initiated by the differentiation of mesenchymal cells into chondrocytes. Differentiated chondrocytes in articular cartilage undergo dedifferentiation and apoptosis during arthritis, in which NO production plays a critical role. Here, we investigated the roles and mechanisms of action of insulin-like growth factor-1 (IGF-1) in the chondrogenesis of mesenchymal cells and the maintenance and survival of differentiated articular chondrocytes. IGF-1 induced chondrogenesis of limb bud mesenchymal cells during micromass culture through the activation of phosphatidylinositol 3-kinase (PI3K) and Akt. PI3K activation is required for the activation of protein kinase C (PKC)-alpha and p38 kinase and inhibition of ERK1/2. These events are necessary for chondrogenesis. The growth factor additionally blocked NO-induced dedifferentiation and apoptosis of primary culture articular chondrocytes. NO production in chondrocytes induced down-regulation of PI3K and Akt activities, which was blocked by IGF-1 treatment. Stimulation of PI3K by IGF-1 resulted in blockage of NO-induced activation of p38 kinase and ERK1/2 and inhibition of PKCalpha and PKCzeta, which in turn suppressed dedifferentiation and apoptosis. Our results collectively indicate that IGF-1 regulates differentiation, maintenance of the differentiated phenotype, and apoptosis of articular chondrocytes via a PI3K pathway that modulates ERK, p38 kinase, and PKC signaling.	Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Buk Gu 500712, Gwangju, South Korea	Gwangju Institute of Science & Technology (GIST)	Chun, JS (corresponding author), Kwangju Inst Sci & Technol, Dept Life Sci, Natl Res Lab, Buk Gu 500712, Gwangju, South Korea.	jschun@kjist.ac.kr		Oh, Chundo/0000-0002-5419-8011				ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Amin Ashok R., 1998, Current Opinion in Rheumatology, V10, P263, DOI 10.1097/00002281-199805000-00018; Blanco FJ, 1998, ARTHRITIS RHEUM, V41, P284, DOI 10.1002/1529-0131(199802)41:2<284::AID-ART12>3.0.CO;2-T; Burtscher I, 1999, CANCER RES, V59, P3923; Chang SH, 1998, J BIOL CHEM, V273, P19213, DOI 10.1074/jbc.273.30.19213; Chrysis D, 2001, J NEUROSCI, V21, P1481, DOI 10.1523/JNEUROSCI.21-05-01481.2001; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Dealy CN, 1996, DEVELOPMENT, V122, P1323; Dealy CN, 1996, DEV BIOL, V177, P291, DOI 10.1006/dbio.1996.0163; Decraene D, 2002, J BIOL CHEM, V277, P32587, DOI 10.1074/jbc.M111106200; DeLise AM, 2000, OSTEOARTHR CARTILAGE, V8, P309, DOI 10.1053/joca.1999.0306; Fernandes JC, 2002, BIORHEOLOGY, V39, P237; Fortier LA, 2001, J ORTHOPAED RES, V19, P720, DOI 10.1016/S0736-0266(00)00070-X; FOSANG AJ, 1991, MATRIX, V11, P17, DOI 10.1016/S0934-8832(11)80223-4; Fukumoto T, 2003, OSTEOARTHR CARTILAGE, V11, P55, DOI 10.1053/joca.2002.0869; Hashimoto S, 1998, ARTHRITIS RHEUM-US, V41, P1266, DOI 10.1002/1529-0131(199807)41:7<1266::AID-ART18>3.0.CO;2-Y; Hidaka K, 2001, INT J BIOCHEM CELL B, V33, P1094, DOI 10.1016/S1357-2725(01)00067-X; Hui W, 2001, CYTOKINE, V16, P31, DOI 10.1006/cyto.2001.0950; Hui W, 2001, ANN RHEUM DIS, V60, P254, DOI 10.1136/ard.60.3.254; Kim B, 2002, J BIOL CHEM, V277, P27393, DOI 10.1074/jbc.M201963200; Kim SJ, 2003, BIOCHEM BIOPH RES CO, V303, P206, DOI 10.1016/S0006-291X(03)00305-X; Kim SJ, 2002, J BIOL CHEM, V277, P33501, DOI 10.1074/jbc.M202862200; Kim SJ, 2002, J BIOL CHEM, V277, P1332, DOI 10.1074/jbc.M107231200; Kim SJ, 2002, J BIOL CHEM, V277, P30375, DOI 10.1074/jbc.M205193200; Kolettas E, 2001, RHEUMATOLOGY, V40, P1146, DOI 10.1093/rheumatology/40.10.1146; Kulik G, 1998, MOL CELL BIOL, V18, P6711, DOI 10.1128/MCB.18.11.6711; Lawlor MA, 2000, MOL CELL BIOL, V20, P8983, DOI 10.1128/MCB.20.23.8983-8995.2000; Loeser RF, 2000, ARTHRITIS RHEUM, V43, P2110, DOI 10.1002/1529-0131(200009)43:9<2110::AID-ANR23>3.0.CO;2-U; Loeser RF, 2000, ARTHRITIS RHEUM-US, V43, P1552, DOI 10.1002/1529-0131(200007)43:7<1552::AID-ANR20>3.0.CO;2-W; Martel-Pelletier J, 1998, INFLAMM RES, V47, P90, DOI 10.1007/s000110050288; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Matsuzaki H, 1999, J NEUROCHEM, V73, P2037; McCarthy TL, 2001, GROWTH HORM IGF RES, V11, P213, DOI 10.1054/ghir.2001.0236; McQueeney K, 2001, GROWTH HORM IGF RES, V11, P346, DOI 10.1054/ghir.2001.0250; Mi ZB, 2000, ARTHRITIS RHEUM, V43, P2563, DOI 10.1002/1529-0131(200011)43:11<2563::AID-ANR25>3.0.CO;2-8; Oh CD, 2000, J BIOL CHEM, V275, P5613, DOI 10.1074/jbc.275.8.5613; Oh CD, 2001, EUR J PHARMACOL, V427, P175, DOI 10.1016/S0014-2999(01)01241-9; Okubo Y, 1998, J BIOL CHEM, V273, P25961, DOI 10.1074/jbc.273.40.25961; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; Poole AR, 1999, FRONT BIOSCI, V4, P662; Ryu JH, 2002, DEVELOPMENT, V129, P5541, DOI 10.1242/dev.00110; Sandell L., 1999, FRONT BIOSCI-LANDMRK, V4, P731; Sandell LJ, 2001, ARTHRITIS RES, V3, P107, DOI 10.1186/ar148; SCHALKWIJK J, 1989, ARTHRITIS RHEUM, V32, P66, DOI 10.1002/anr.1780320111; SCHALKWIJK J, 1989, ARTHRITIS RHEUM, V32, P894; Schneiderman R, 1995, ARCH BIOCHEM BIOPHYS, V324, P173, DOI 10.1006/abbi.1995.9913; Shum L, 2002, ARTHRITIS RES, V4, P94, DOI 10.1186/ar396; Tavera C, 1996, OSTEOARTHR CARTILAGE, V4, P263, DOI 10.1016/S1063-4584(05)80104-9; Thimmaiah KN, 2003, CANCER RES, V63, P364; Valentinis B, 2001, J CLIN PATHOL-MOL PA, V54, P133, DOI 10.1136/mp.54.3.133; Vincent AM, 2002, GROWTH HORM IGF RES, V12, P193, DOI 10.1016/S1096-6374(02)00017-5; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; Yaeger PC, 1997, EXP CELL RES, V237, P318, DOI 10.1006/excr.1997.3781; Yamaguchi A, 2001, J BIOL CHEM, V276, P5256, DOI 10.1074/jbc.M008552200; Yatsugi N, 2000, J Orthop Sci, V5, P150, DOI 10.1007/s007760050142; Yoon JB, 2003, J BIOL CHEM, V278, P15319, DOI 10.1074/jbc.M212520200; Yoon YM, 2000, J BONE MINER RES, V15, P2197, DOI 10.1359/jbmr.2000.15.11.2197; Yoon YM, 2000, J BIOL CHEM, V275, P12353, DOI 10.1074/jbc.275.16.12353; Yoon YM, 2002, J BIOL CHEM, V277, P8412, DOI 10.1074/jbc.M110608200	59	123	135	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36563	36571		10.1074/jbc.M304857200	http://dx.doi.org/10.1074/jbc.M304857200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853454	hybrid			2022-12-27	WOS:000185318300086
J	Sanceau, J; Truchet, S; Bauvois, B				Sanceau, J; Truchet, S; Bauvois, B			Matrix metalloproteinase-9 silencing by RNA interference triggers the migratory-adhesive switch in Ewing's sarcoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYMPH-NODE METASTASIS; NECROSIS-FACTOR-ALPHA; E-CADHERIN; MATRIX METALLOPROTEINASES; IV COLLAGENASE; BETA-CATENIN; TISSUE INHIBITORS; CANCER-CELLS; RELATIVE EXPRESSION; SIGNAL-TRANSDUCTION	Enhanced expression of (pro) matrix metalloproteinase-9 (MMP-9) is associated with human tumor invasion and/or metastasis. COH cells derived from a highly invasive and metastatic Ewing's sarcoma constitutively express proMMP-9. Transfection of a double stranded RNA that targets the MMP-9 mRNA into COH cells depleted the corresponding mRNA and protein as demonstrated by reverse transcriptase-PCR, enzyme-linked immunosorbent assay, and gelatin zymography. proMMP-9 extinction resulted in the following: (i) decreased spreading on extracellular matrix (fibronectin, laminin, collagen IV)-coated surfaces, (ii) inhibition of migration toward fibronectin, and (iii) induced aggregation, which was specifically disrupted by a function-blocking E-cadherin antibody. MMP-9 knockdown concomitantly resulted in increased levels of surface E-cadherin, redistribution at the plasma membrane of beta-catenin, and its physical association with E-cadherin. Moreover, induction of E-cadherin-mediated adhesion was associated with RhoA activation and changes in paxillin cytoskeleton. Finally, an inhibitor of gelatinolytic activity of pro-MMP9 did not reduce COH cell migration confirming that the enzymatic property of COH MMP-9 was not required for migration toward fibronectin. Overall, our observations define a novel critical role for proMMP-9 in providing a cellular switch between stationary and migratory cell phases.	Inst Curie, INSERM, U365, F-75248 Paris 05, France; INSERM, Museum Natl Hist Nat, U565,UMR 8646,MNHN, CNRS, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Museum National d'Histoire Naturelle (MNHN)	Bauvois, B (corresponding author), Inst Curie, INSERM, U365, 26 Rue Ulm, F-75248 Paris 05, France.	bbauvois@curie.fr	Truchet, Sandrine/O-9067-2017; Truchet, Sandrine/G-9753-2014; Bauvois, Brigitte/F-6776-2013	Truchet, Sandrine/0000-0002-7737-9202; Truchet, Sandrine/0000-0002-7737-9202; Bauvois, Brigitte/0000-0002-1751-6922				Alahari SK, 2002, INT REV CYTOL, V220, P145; Anzai H, 1996, DIFFERENTIATION, V60, P119, DOI 10.1046/j.1432-0436.1996.6020119.x; Ashida N, 2001, J BIOL CHEM, V276, P16555, DOI 10.1074/jbc.M009068200; Bannikov GA, 2002, J BIOL CHEM, V277, P16022, DOI 10.1074/jbc.M110931200; Barth AI, 1997, CURR OPIN CELL BIOL, V9, P683, DOI 10.1016/S0955-0674(97)80122-6; BAUVOIS B, 1992, J IMMUNOL, V148, P3912; Bauvois B, 2002, LEUKEMIA, V16, P791, DOI 10.1038/sj.leu.2402472; BERNHARD EJ, 1990, CANCER RES, V50, P3872; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; BONFIL RD, 1992, CLIN EXP METASTAS, V10, P211; Bouman L, 2002, BIOCHEM J, V364, P719, DOI 10.1042/BJ20011854; Bourguignon LYW, 2001, J MAMMARY GLAND BIOL, V6, P287, DOI 10.1023/A:1011371523994; Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2; Braga VMM, 2002, CURR OPIN CELL BIOL, V14, P546, DOI 10.1016/S0955-0674(02)00373-3; Brantl S, 2002, BBA-GENE STRUCT EXPR, V1575, P15, DOI 10.1016/S0167-4781(02)00280-4; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; De Arcangelis A, 2001, INT J CANCER, V94, P44, DOI 10.1002/ijc.1444; DeFife KM, 1999, J HISTOCHEM CYTOCHEM, V47, P65, DOI 10.1177/002215549904700107; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; Farina AR, 1999, CELL GROWTH DIFFER, V10, P353; Fiore E, 2002, ONCOGENE, V21, P5213, DOI 10.1038/sj.onc.1205684; Fukata M, 2001, NAT REV MOL CELL BIO, V2, P887, DOI 10.1038/35103068; Gilmore AP, 2000, J CELL BIOL, V149, P431, DOI 10.1083/jcb.149.2.431; HAMELIN R, 1994, INT J CANCER, V57, P336, DOI 10.1002/ijc.2910570308; Hua J, 1996, CANCER RES, V56, P5279; Huang SY, 2001, ONCOGENE, V20, P4188, DOI 10.1038/sj.onc.1204535; Hummel V, 2001, J NEUROPATH EXP NEUR, V60, P320, DOI 10.1093/jnen/60.4.320; Inoue K, 2002, CLIN CANCER RES, V8, P1863; Janowska-Wieczorek A, 1999, BRIT J HAEMATOL, V105, P402, DOI 10.1046/j.1365-2141.1999.01352.x; Jiang YF, 2002, ONCOGENE, V21, P2245, DOI 10.1038/sj.onc.1205291; Juliano RL, 2002, ANNU REV PHARMACOL, V42, P283, DOI 10.1146/annurev.pharmtox.42.090401.151133; Kaibuchi K, 1999, CURR OPIN CELL BIOL, V11, P591, DOI 10.1016/S0955-0674(99)00014-9; Kaihara T, 2001, PATHOBIOLOGY, V69, P172, DOI 10.1159/000048772; Knudsen KA, 1998, J CELL BIOCHEM, P168; Kondraganti S, 2000, CANCER RES, V60, P6851; Kossakowska AE, 2000, LEUKEMIA LYMPHOMA, V39, P485, DOI 10.3109/10428190009113379; Kubota S, 1996, CANCER LETT, V98, P233; Kuniyasu H, 1999, CLIN CANCER RES, V5, P25; Kuniyasu H, 2000, CLIN CANCER RES, V6, P2295; Kupferman ME, 2000, AM J PATHOL, V157, P1777, DOI 10.1016/S0002-9440(10)64815-8; Lakka SS, 2002, ONCOGENE, V21, P8011, DOI 10.1038/sj.onc.1205894; LIBRACH CL, 1991, J CELL BIOL, V113, P437, DOI 10.1083/jcb.113.2.437; Liu SC, 2000, J BIOL CHEM, V275, P22736, DOI 10.1074/jbc.M000388200; Llorens A, 1998, LAB INVEST, V78, P1131; Lynch CC, 2002, DIFFERENTIATION, V70, P561, DOI 10.1046/j.1432-0436.2002.700909.x; MACDOUGALL JR, 1995, EXP CELL RES, V218, P508, DOI 10.1006/excr.1995.1185; Marchenko GN, 2002, BIOCHEM J, V363, P253, DOI 10.1042/0264-6021:3630253; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Morini M, 2000, INT J CANCER, V87, P336, DOI 10.1002/1097-0215(20000801)87:3<336::AID-IJC5>3.0.CO;2-3; Muller T, 2002, EXP CELL RES, V280, P119, DOI 10.1006/excr.2002.5630; Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359; Opdenakker G, 2002, Verh K Acad Geneeskd Belg, V64, P105; Orsulic S, 1999, J CELL SCI, V112, P1237; Paddison PJ, 2002, P NATL ACAD SCI USA, V99, P1443, DOI 10.1073/pnas.032652399; Panetti TS, 2002, FRONT BIOSCI-LANDMRK, V7, pD143, DOI 10.2741/panetti; Paulussen M, 2001, ANN ONCOL, V12, P1619, DOI 10.1023/A:1013148730966; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Ridley AJ, 2001, J CELL SCI, V114, P2713; ROY S, 2000, CLIN CANCER RES, V6, P790; SALGIA R, 1995, J BIOL CHEM, V270, P5039, DOI 10.1074/jbc.270.10.5039; Sanceau J, 2000, ONCOGENE, V19, P3372, DOI 10.1038/sj.onc.1203670; Sanceau J, 2002, J BIOL CHEM, V277, P35766, DOI 10.1074/jbc.M202959200; Sato F, 1999, BRIT J CANCER, V80, P1366, DOI 10.1038/sj.bjc.6690530; Slaton JW, 2001, CLIN CANCER RES, V7, P2840; Spessotto P, 2002, J CELL BIOL, V158, P1133, DOI 10.1083/jcb.200202120; Sun CX, 2002, J CELL SCI, V115, P3991, DOI 10.1242/jcs.00094; Takahashi C, 1998, P NATL ACAD SCI USA, V95, P13221, DOI 10.1073/pnas.95.22.13221; Takahashi M, 2002, ONCOGENE, V21, P5861, DOI 10.1038/sj.onc.1205755; Tomanek RJ, 2000, ANAT RECORD, V261, P126, DOI 10.1002/1097-0185(20000615)261:3<126::AID-AR7>3.0.CO;2-4; Trocme C, 1998, J BIOL CHEM, V273, P20677, DOI 10.1074/jbc.273.32.20677; Truchet S, 2001, MOL REPROD DEV, V60, P319, DOI 10.1002/mrd.1094; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Vizirianakis IS, 2002, INT J ONCOL, V21, P135; WATANABE H, 1993, J CELL SCI, V104, P991; Westphal JR, 2000, INT J CANCER, V86, P768, DOI 10.1002/(SICI)1097-0215(20000615)86:6<768::AID-IJC3>3.3.CO;2-5; Wong NACS, 2002, AM J PATHOL, V160, P389, DOI 10.1016/S0002-9440(10)64856-0; Yu Q, 1999, GENE DEV, V13, P35, DOI 10.1101/gad.13.1.35; Zhai Y, 2002, AM J PATHOL, V160, P1229, DOI 10.1016/S0002-9440(10)62550-3; Zhang CH, 1996, J IMMUNOL, V157, P3980	82	103	110	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36537	36546		10.1074/jbc.M304300200	http://dx.doi.org/10.1074/jbc.M304300200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847101	Green Published, hybrid			2022-12-27	WOS:000185318300083
J	Tate, JJ; Cooper, TG				Tate, JJ; Cooper, TG			Tor1/2 regulation of retrograde gene expression in Saccharomyces cerevisiae derives indirectly as a consequence of alterations in ammonia metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITROGEN CATABOLITE REPRESSION; RTG-DEPENDENT MITOCHONDRIA; GLUTAMATE-DEHYDROGENASE; METHIONINE SULFOXIMINE; NUCLEAR-LOCALIZATION; INHIBITION; RAPAMYCIN; YEAST; COMMUNICATION; MECHANISM	Retrograde genes of Saccharomyces cerevisiae encode the enzymes needed to synthesize alpha-ketoglutarate, required for ammonia assimilation, when mitochondria are damaged or non-functional because of glucose fermentation. Therefore, it is not surprising that a close association exists between control of the retrograde regulon and expression of nitrogen catabolic genes. Expression of these latter genes is nitrogen catabolite repression (NCR)-sensitive, i.e. expression is low with good nitrogen sources (e.g. glutamine) and high when only poor (e.g. proline) or limiting nitrogen sources are available. It has been reported recently that both NCR-sensitive and retrograde gene expression is negatively regulated by glutamine and induced by treating cells with the Tor1/2 inhibitor, rapamycin. These conclusions predict that NCR-sensitive and retrograde gene expression should respond in parallel to nitrogen sources, ranging from those that highly repress NCR-sensitive transcription to those that elicit minimal NCR. Because this prediction did not accommodate earlier observations that CIT2 ( a retrograde gene) expression is higher in glutamine than proline containing medium, we investigated retrograde regulation further. We show that (i) retrograde gene expression correlates with intracellular ammonia and alpha-ketoglutarate generated by a nitrogen source rather than the severity of NCR it elicits, and (ii) in addition to its known regulation by NCR, NAD-glutamate dehydrogenase (GDH2) gene expression is down-regulated by ammonia under conditions where NCR is minimal. Therefore, intracellular ammonia plays a pivotal dual role, regulating the interface of nitrogen and carbon metabolism at the level of ammonia assimilation and production. Our results also indicate the effects of rapamycin treatment on CIT2 transcription, and hence Tor1/2 regulation of retrograde gene expression occur indirectly as a consequence of alterations in ammonia and glutamate metabolism.	Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Cooper, TG (corresponding author), Univ Tennessee, Dept Mol Sci, Memphis, TN 38163 USA.	tcooper@utmem.edu		Cooper, Terrance G./0000-0002-7651-9963	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035642] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35642, R01 GM035642] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beck T, 1999, NATURE, V402, P689, DOI 10.1038/45287; Bertram PG, 2000, J BIOL CHEM, V275, P35727, DOI 10.1074/jbc.M004235200; BOSSINGER J, 1975, BIOCHEM BIOPH RES CO, V66, P889, DOI 10.1016/0006-291X(75)90723-8; Cardenas ME, 1999, GENE DEV, V13, P3271, DOI 10.1101/gad.13.24.3271; CHELSTOWSKA A, 1995, J BIOL CHEM, V270, P18141, DOI 10.1074/jbc.270.30.18141; COOPER AJL, 1976, J BIOL CHEM, V251, P6674; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; Cox KH, 2002, J BIOL CHEM, V277, P37559, DOI 10.1074/jbc.M204879200; Cox KH, 1999, YEAST, V15, P703, DOI 10.1002/(SICI)1097-0061(19990615)15:8<703::AID-YEA413>3.0.CO;2-Z; Cox KH, 2000, J BIOL CHEM, V275, P17611, DOI 10.1074/jbc.M001648200; Crespo JL, 2002, P NATL ACAD SCI USA, V99, P6784, DOI 10.1073/pnas.102687599; Crespo JL, 2002, MICROBIOL MOL BIOL R, V66, P579, DOI 10.1128/MMBR.66.4.579-591.2002; Dilova I, 2002, CURR BIOL, V12, P389, DOI 10.1016/S0960-9822(02)00677-2; DUBOIS E, 1974, EUR J BIOCHEM, V48, P603, DOI 10.1111/j.1432-1033.1974.tb03803.x; Edskes HK, 1999, GENETICS, V153, P585; GRIFFITH OW, 1978, J BIOL CHEM, V253, P2333; Hofman-Bang J, 1999, MOL BIOTECHNOL, V12, P35, DOI 10.1385/MB:12:1:35; Komeili A, 2000, J CELL BIOL, V151, P863, DOI 10.1083/jcb.151.4.863; LIAO XS, 1993, CELL, V72, P61, DOI 10.1016/0092-8674(93)90050-Z; LIAO XS, 1991, MOL CELL BIOL, V11, P38, DOI 10.1128/MCB.11.1.38; Liu ZC, 2001, EMBO J, V20, P7209, DOI 10.1093/emboj/20.24.7209; MILLER SM, 1991, MOL CELL BIOL, V11, P6229, DOI 10.1128/MCB.11.12.6229; PETERSEN JGL, 1988, GENETICS, V119, P527; Pierce MM, 2001, P NATL ACAD SCI USA, V98, P13213, DOI 10.1073/pnas.181486098; Rai R, 2003, J BIOL CHEM, V278, P12826, DOI 10.1074/jbc.M212186200; RICHMAN PG, 1973, J BIOL CHEM, V248, P6684; Sekito T, 2000, MOL BIOL CELL, V11, P2103, DOI 10.1091/mbc.11.6.2103; Sekito T, 2002, MOL BIOL CELL, V13, P795, DOI 10.1091/mbc.01-10-0473; Shamji AF, 2000, CURR BIOL, V10, P1574, DOI 10.1016/S0960-9822(00)00866-6; SUMRADA R, 1976, J BACTERIOL, V125, P1048, DOI 10.1128/JB.125.3.1048-1056.1976; Tate JJ, 2002, J BIOL CHEM, V277, P20477, DOI 10.1074/jbc.M200962200; TUROSCY V, 1982, J BACTERIOL, V151, P1237, DOI 10.1128/JB.151.3.1237-1246.1982; Velot C, 1996, GENETICS, V144, P893; WATSON TG, 1977, J GEN MICROBIOL, V103, P123, DOI 10.1099/00221287-103-1-123; WATSON TG, 1976, J GEN MICROBIOL, V96, P263, DOI 10.1099/00221287-96-2-263; ZHEGCHANG L, 1999, MOL CELL BIOL, V19, P6720	36	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36924	36933		10.1074/jbc.M301829200	http://dx.doi.org/10.1074/jbc.M301829200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851403	hybrid, Green Accepted			2022-12-27	WOS:000185318300126
J	Blum, G; Gazit, A; Levitzki, A				Blum, G; Gazit, A; Levitzki, A			Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTANT; TYROSINE KINASE; ANTISENSE RNA; WILMS-TUMOR; CELLS; EXPRESSION; PHENOTYPE; APOPTOSIS; SUBSTRATE; PATHWAYS	Because insulin-like growth factor-1 (IGF-1) and its receptor play a pivotal role in many cancers, it is an attractive target for the design of inhibitors. Here we present a new family of bioisostere inhibitors, based on the structure of AG 538. AG 538 is a substrate-competitive inhibitor of the IGF-1 receptor (IGF-1R), with an IC50 = 61 nM in a cell-free kinase assay (Blum, G., Gazit, A., and Levitzki, A. ( 2000) Biochemistry 39, 15705 - 15712). AG 538 is a low molecular weight compound containing two catechol rings, which are sensitive to oxidation in cells. We have therefore prepared and examined catechol bioisosteres of AG 538. These AG 538 bioisosteres possess similar biological properties to AG 538; they inhibit IGF-1R by a substrate-competitive mechanism and are non-competitive vis a vis ATP. They inhibit IGF-1R kinase activity in the sub-micromolar concentration range in cell-free assays. IGF-1 induced IGF-1R autophosphorylation; IRS-1 phosphorylation and protein kinase B activation are inhibited at a low micromolar concentration range when applied to intact cells. These inhibitors also block the formation of colonies in soft agar by prostate and breast cancer cells. The ability to replace catechol groups with a moiety that is more stable in cells may aid in developing non-catechol-containing substrate-competitive inhibitors targeted toward IGF-1R and possibly against other protein-tyrosine kinases.	Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Sect Cellular Signaling, IL-91904 Jerusalem, Israel; Hebrew Univ Jerusalem, Inst Chem, Dept Organ Chem, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem	Levitzki, A (corresponding author), Hebrew Univ Jerusalem, Alexander Silberman Inst Life Sci, Dept Biol Chem, Sect Cellular Signaling, IL-91904 Jerusalem, Israel.	levitzki@vms.huji.ac.il						AMBROSE D, 1994, J CELL PHYSIOL, V159, P92, DOI 10.1002/jcp.1041590113; ARTEAGA CL, 1989, CANCER RES, V49, P6237; Baserga R, 1997, EXP CELL RES, V236, P1, DOI 10.1006/excr.1997.3732; Ben-Bassat H, 1995, Exp Dermatol, V4, P82, DOI 10.1111/j.1600-0625.1995.tb00227.x; Blum G, 2000, BIOCHEMISTRY-US, V39, P15705, DOI 10.1021/bi001516y; Boney CM, 2001, CELL GROWTH DIFFER, V12, P379; Brodt P, 2001, J BIOL CHEM, V276, P33608, DOI 10.1074/jbc.M102754200; Brodt P, 2000, BIOCHEM PHARMACOL, V60, P1101, DOI 10.1016/S0006-2952(00)00422-6; Carter WG, 1996, BIOCHEMISTRY-US, V35, P14340, DOI 10.1021/bi960732x; DAmbrosio C, 1997, CANCER RES, V57, P3264; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Dunn SE, 1998, CANCER RES, V58, P3353; GANSLER T, 1989, AM J PATHOL, V135, P961; GAZIT A, 1991, J MED CHEM, V34, P1896, DOI 10.1021/jm00110a022; Hailey J, 2002, MOL CANCER THER, V1, P1349; Horowitz D, 2000, J IMMUNOL METHODS, V244, P49, DOI 10.1016/S0022-1759(00)00253-2; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; JOHNS IB, 1964, J ORG CHEM, V29, P1970, DOI 10.1021/jo01030a076; Karni R, 2003, FEBS LETT, V537, P47, DOI 10.1016/S0014-5793(03)00069-3; Kurihara S, 2000, ENDOCR J, V47, P739, DOI 10.1507/endocrj.47.739; LEROITH D, 1994, HORM RES, V41, P74, DOI 10.1159/000183964; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; LONG L, 1995, CANCER RES, V55, P1006; MALESKI RJ, 1991, J HETEROCYCLIC CHEM, V28, P1937, DOI 10.1002/jhet.5570280822; Nakamura K, 2000, CANCER RES, V60, P760; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Peruzzi F, 1999, MOL CELL BIOL, V19, P7203, DOI 10.1128/mcb.19.10.7203; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; Reiss K, 1998, CLIN CANCER RES, V4, P2647; RESNICOFF M, 1995, CANCER RES, V55, P2463; Reuveni H, 2002, BIOCHEMISTRY-US, V41, P10304, DOI 10.1021/bi0202530; RUBIN R, 1995, LAB INVEST, V73, P311; Schweigert N, 2001, ENVIRON MICROBIOL, V3, P81, DOI 10.1046/j.1462-2920.2001.00176.x; SHAPIRO DN, 1994, J CLIN INVEST, V94, P1235, DOI 10.1172/JCI117441; SZELL T, 1981, J CHEM ENG DATA, V26, P230, DOI 10.1021/je00024a043; Ucar H, 1998, J MED CHEM, V41, P1138, DOI 10.1021/jm970682+; Ucar H, 1998, TETRAHEDRON, V54, P1763, DOI 10.1016/S0040-4020(97)10400-8; WERNER H, 1993, P NATL ACAD SCI USA, V90, P5828, DOI 10.1073/pnas.90.12.5828; YOUS S, 1994, J ORG CHEM, V59, P1574, DOI 10.1021/jo00085a052	39	98	111	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40442	40454		10.1074/jbc.M305490200	http://dx.doi.org/10.1074/jbc.M305490200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12869569	hybrid			2022-12-27	WOS:000185847200005
J	Mateo, R; Diaz, A; Baranowski, E; Mateu, MG				Mateo, R; Diaz, A; Baranowski, E; Mateu, MG			Complete alanine scanning of intersubunit interfaces in a foot-and-mouth disease virus capsid reveals critical contributions of many side chains to particle stability and viral function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PROTEIN INTERACTIONS; AMINO-ACID SUBSTITUTIONS; ICOSAHEDRAL VIRUSES; CELL-CULTURE; MUTATIONAL ANALYSIS; DIMER INTERFACE; COAT PROTEIN; FG LOOP; REPLICATION; RESIDUES	Spherical virus capsids are large, multimeric protein shells whose assembly and stability depend on the establishment of multiple non-covalent interactions between many polypeptide subunits. In a foot-and-mouth disease virus capsid, 42 amino acid side chains per protomer are involved in noncovalent interactions between pentameric subunits that function as assembly/disassembly intermediates. We have individually truncated to alanine these 42 side chains and assessed their relevance for completion of the virus life cycle and capsid stability. Most mutations provoked a drastic reduction in virus yields. Nearly all of these critical mutations led to virions whose thermal inactivation rates differed from that of the parent virus, and many affected also early steps in the viral cycle. Rapid selection of genotypic revertants or variants with forward or compensatory mutations that restored viability was occasionally detected. The results with this model virus indicate the following. (i) Most of the residues at the interfaces between capsid subunits are critically important for viral function, in part but not exclusively because of their involvement in intersubunit recognition. Each hydrogen bond and salt bridge buried at the subunit interfaces may be important for capsid stability. (ii) New mutations able to restore viability may arise frequently at the subunit interfaces during virus evolution. (iii) A few interfacial side chains are functionally tolerant to truncation and may provide adequate mutation sites for the engineering of a thermostable capsid, potentially useful as an improved vaccine.	Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Mateu, MG (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain.		Baranowski, Eric/I-2655-2013; Mateu, Mauricio/ABF-2146-2021	Mateu, Mauricio/0000-0002-2915-1529; Baranowski, Eric/0000-0003-0660-1854				ACHARYA R, 1989, NATURE, V337, P709, DOI 10.1038/337709a0; Axblom C, 1998, VIROLOGY, V249, P80, DOI 10.1006/viro.1998.9279; Baker TS, 1999, MICROBIOL MOL BIOL R, V63, P862, DOI 10.1128/MMBR.63.4.862-922.1999; Baranowski E, 1998, J VIROL, V72, P6362, DOI 10.1128/JVI.72.8.6362-6372.1998; Bertolotti-Ciarlet A, 2002, J VIROL, V76, P4044, DOI 10.1128/JVI.76.8.4044-4055.2002; CARRILLO EC, 1984, VIROLOGY, V135, P542, DOI 10.1016/0042-6822(84)90208-3; Chiu W., 1997, STRUCTURAL BIOL VIRU; Chow M., 1997, STRUCTURAL BIOL VIRU, P157; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; Curry S, 1996, STRUCTURE, V4, P135, DOI 10.1016/S0969-2126(96)00017-2; Curry S, 1997, J VIROL, V71, P9743, DOI 10.1128/JVI.71.12.9743-9752.1997; Dall'Acqua W, 1998, BIOCHEMISTRY-US, V37, P9266, DOI 10.1021/bi980270i; DIEZ J, 1990, J VIROL, V64, P5519; Domingo E, 1997, ANNU REV MICROBIOL, V51, P151, DOI 10.1146/annurev.micro.51.1.151; Ellard FM, 1999, J GEN VIROL, V80, P1911, DOI 10.1099/0022-1317-80-8-1911; FILMAN DJ, 1989, EMBO J, V8, P1567, DOI 10.1002/j.1460-2075.1989.tb03541.x; FOGUEL D, 1995, BIOCHEMISTRY-US, V34, P1120, DOI 10.1021/bi00004a003; Fry EE, 1999, EMBO J, V18, P543, DOI 10.1093/emboj/18.3.543; Johnson J. E., 1999, ENCY VIROLOGY, P1946; Johnson JE, 1996, P NATL ACAD SCI USA, V93, P27, DOI 10.1073/pnas.93.1.27; Knipe T, 1997, J VIROL, V71, P2851, DOI 10.1128/JVI.71.4.2851-2856.1997; LAU FTK, 1989, BIOCHEMISTRY-US, V28, P6841, DOI 10.1021/bi00443a010; LEA S, 1994, STRUCTURE, V2, P123, DOI 10.1016/S0969-2126(00)00014-9; LEA S, 1995, STRUCTURE, V3, P571, DOI 10.1016/S0969-2126(01)00191-5; LILJAS L, 1986, PROG BIOPHYS MOL BIO, V48, P1, DOI 10.1016/0079-6107(86)90008-8; Limn CK, 2000, J VIROL, V74, P8658, DOI 10.1128/JVI.74.18.8658-8669.2000; Lu B, 1998, VIROLOGY, V244, P13, DOI 10.1006/viro.1998.9099; MATEU MG, 1994, J VIROL, V68, P1407, DOI 10.1128/JVI.68.3.1407-1417.1994; Mateu MG, 1998, EMBO J, V17, P2748, DOI 10.1093/emboj/17.10.2748; MATEU MG, 1995, VIRUS RES, V38, P1, DOI 10.1016/0168-1702(95)00048-U; Mateu MG, 1996, J BIOL CHEM, V271, P12814, DOI 10.1074/jbc.271.22.12814; McInerney GM, 2000, J GEN VIROL, V81, P1699, DOI 10.1099/0022-1317-81-7-1699; MILLA ME, 1994, NAT STRUCT BIOL, V1, P518, DOI 10.1038/nsb0894-518; MOSSER AG, 1993, J VIROL, V67, P1246, DOI 10.1128/JVI.67.3.1246-1254.1993; Myers DP, 2001, BIOCHEMISTRY-US, V40, P13230, DOI 10.1021/bi0155908; Oliveira AC, 2000, J BIOL CHEM, V275, P16037, DOI 10.1074/jbc.M910145199; Reddy VS, 1998, BIOPHYS J, V74, P546, DOI 10.1016/S0006-3495(98)77813-0; Reddy VS, 2001, J VIROL, V75, P11943, DOI 10.1128/JVI.75.24.11943-11947.2001; ROSSMANN MG, 1989, ANNU REV BIOCHEM, V58, P533, DOI 10.1146/annurev.bi.58.070189.002533; ROSSMANN MG, 1997, STRUCTURAL BIOL VIRU, P105; Rueckert RR, 1996, VIROLOGY, P609; Ruiz-Jarabo CM, 2000, J VIROL, V74, P3543, DOI 10.1128/JVI.74.8.3543-3547.2000; SAIZ JC, 1994, J VIROL, V68, P4557; Samuel AR, 2001, TRENDS GENET, V17, P421, DOI 10.1016/S0168-9525(01)02374-5; Sastri M, 1999, J MOL BIOL, V289, P905, DOI 10.1006/jmbi.1999.2786; SAYLE RA, 1995, TRENDS BIOCHEM SCI, V20, P374, DOI 10.1016/S0968-0004(00)89080-5; Sengchanthalangsy LL, 1999, J MOL BIOL, V289, P1029, DOI 10.1006/jmbi.1999.2823; SOBRINO F, 1983, VIROLOGY, V128, P310, DOI 10.1016/0042-6822(83)90258-1; Sobrino F, 2001, VET RES, V32, P1, DOI 10.1051/vetres:2001106; Stonehouse NJ, 1996, J MOL BIOL, V256, P330, DOI 10.1006/jmbi.1996.0089; VASQUEZ C, 1979, VIROLOGY, V97, P195, DOI 10.1016/0042-6822(79)90387-8; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wu P, 2000, J VIROL, V74, P8635, DOI 10.1128/JVI.74.18.8635-8647.2000; ZIBERT A, 1990, J VIROL, V64, P2467, DOI 10.1128/JVI.64.6.2467-2473.1990; ZLOTNICK A, 1994, J MOL BIOL, V241, P59, DOI 10.1006/jmbi.1994.1473	55	50	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41019	41027		10.1074/jbc.M304990200	http://dx.doi.org/10.1074/jbc.M304990200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12857761	Green Published, hybrid			2022-12-27	WOS:000185847200076
J	Nicolet, Y; Lockridge, O; Masson, P; Fontecilla-Camps, JC; Nachon, F				Nicolet, Y; Lockridge, O; Masson, P; Fontecilla-Camps, JC; Nachon, F			Crystal structure of human butyrylcholinesterase and of its complexes with substrate and products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVE-SITE GORGE; PERIPHERAL SITE; SNAKE-VENOM; ACETYLCHOLINESTERASE; BINDING; FASCICULIN; INHIBITION; MOLSCRIPT; TOXICITY; RESIDUES	Cholinesterases are among the most efficient enzymes known. They are divided into two groups: acetylcholinesterase, involved in the hydrolysis of the neurotransmitter acetylcholine, and butyrylcholinesterase of unknown function. Several crystal structures of the former have shown that the active site is located at the bottom of a deep and narrow gorge, raising the question of how substrate and products enter and leave. Human butyrylcholinesterase (BChE) has attracted attention because it can hydrolyze toxic esters such as cocaine or scavenge organophosphorus pesticides and nerve agents. Here we report the crystal structures of several recombinant truncated human BChE complexes and conjugates and provide a description for mechanistically relevant non-productive substrate and product binding. As expected, the structure of BChE is similar to a previously published theoretical model of this enzyme and to the structure of Torpedo acetylcholinesterase. The main difference between the experimentally determined BChE structure and its model is found at the acyl binding pocket that is significantly bigger than expected. An electron density peak close to the catalytic Ser(198) has been modeled as bound butyrate.	UJF, Cristallog & Cristallogenese Prot Lab, Inst Biol Struct Jean Pierre Ebel, CNRS,CEA, F-38027 Grenoble 1, France; Univ Nebraska, Med Ctr, Eppley Res Inst, Omaha, NE 68198 USA; Serv Sante Armees, Ctr Rech, Unite Enzymol, F-38702 La Tronche, France	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); University of Nebraska System; University of Nebraska Medical Center	Fontecilla-Camps, JC (corresponding author), UJF, Cristallog & Cristallogenese Prot Lab, Inst Biol Struct Jean Pierre Ebel, CNRS,CEA, 41 Rue Jules Horowitz, F-38027 Grenoble 1, France.	juan@lccp.ibs.fr	Yvain, Nicolet/AAP-9763-2020; Masson, Patrick/AAA-7213-2019; Masson, Patrick YM/J-3964-2013	Yvain, Nicolet/0000-0002-4189-7067; Masson, Patrick/0000-0002-7837-3662; Masson, Patrick YM/0000-0002-7837-3662				Allon N, 1998, TOXICOL SCI, V43, P121; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Behra M, 2002, NAT NEUROSCI, V5, P111, DOI 10.1038/nn788; Bourne Y, 1999, J BIOL CHEM, V274, P2963, DOI 10.1074/jbc.274.5.2963; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; BROOMFIELD CA, 1991, J PHARMACOL EXP THER, V259, P633; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHATONNET A, 1989, BIOCHEM J, V260, P625, DOI 10.1042/bj2600625; DAWSON RM, 1994, J APPL TOXICOL, V14, P317, DOI 10.1002/jat.2550140502; De Ferrari GV, 2001, J BIOL CHEM, V276, P23282, DOI 10.1074/jbc.M009596200; Enyedy IJ, 1998, J AM CHEM SOC, V120, P8043, DOI 10.1021/ja973131h; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HAREL M, 1992, P NATL ACAD SCI USA, V89, P10827, DOI 10.1073/pnas.89.22.10827; Harel M, 2000, PROTEIN SCI, V9, P1063, DOI 10.1110/ps.9.6.1063; HARRIS LW, 1966, SCIENCE, V154, P404, DOI 10.1126/science.154.3747.404; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaplan D, 2001, BIOCHEMISTRY-US, V40, P7433, DOI 10.1021/bi010181x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kryger G, 2000, ACTA CRYSTALLOGR D, V56, P1385, DOI 10.1107/S0907444900010659; Lockridge O, 2000, NEUROTOXICOLOGY, V21, P113; Mack A, 2000, PROG NEUROBIOL, V60, P607, DOI 10.1016/S0301-0082(99)00047-7; Masson P, 2003, EUR J BIOCHEM, V270, P315, DOI 10.1046/j.1432-1033.2003.03388.x; Masson P, 1997, BIOCHEMISTRY-US, V36, P2266, DOI 10.1021/bi962484a; MASSOULIE J, 1993, PROG BRAIN RES, V98, P139; MATTHEWS DA, 1977, J BIOL CHEM, V252, P8875; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meshorer E, 2002, SCIENCE, V295, P508, DOI 10.1126/science.1066752; Millard CB, 1999, BIOCHEMISTRY-US, V38, P7032, DOI 10.1021/bi982678l; Nachon F, 1998, BIOCHEMISTRY-US, V37, P10507, DOI 10.1021/bi980536l; Nachon F, 2002, EUR J BIOCHEM, V269, P630, DOI 10.1046/j.0014-2956.2001.02692.x; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RAVEH L, 1993, BIOCHEM PHARMACOL, V45, P2465, DOI 10.1016/0006-2952(93)90228-O; ROUSSEL A, 1989, TURBO COMPUTER PROGR; Saxena A, 1997, BIOCHEMISTRY-US, V36, P14642, DOI 10.1021/bi971425+; SIELECKI AR, 1979, J MOL BIOL, V134, P781, DOI 10.1016/0022-2836(79)90486-8; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; vanAalten DMF, 1996, J COMPUT AID MOL DES, V10, P255, DOI 10.1007/BF00355047; VELLOM DC, 1993, BIOCHEMISTRY-US, V32, P12, DOI 10.1021/bi00052a003; Weik M, 2000, P NATL ACAD SCI USA, V97, P623, DOI 10.1073/pnas.97.2.623	46	620	632	2	56	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41141	41147		10.1074/jbc.M210241200	http://dx.doi.org/10.1074/jbc.M210241200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12869558	hybrid			2022-12-27	WOS:000185847200090
J	Kowanetz, K; Szymkiewicz, I; Haglund, K; Kowanetz, M; Husnjak, K; Taylor, JD; Soubeyran, P; Engstrom, U; Ladbury, JE; Dikic, I				Kowanetz, K; Szymkiewicz, I; Haglund, K; Kowanetz, M; Husnjak, K; Taylor, JD; Soubeyran, P; Engstrom, U; Ladbury, JE; Dikic, I			Identification of a novel proline-arginine motif involved in CIN85-dependent clustering of Cbl and down-regulation of epidermal growth factor receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADAPTER PROTEIN; SH3 DOMAIN; C-CBL; BINDING MOTIF; EGF RECEPTOR; TYROSINE PHOSPHORYLATION; PLASMA-MEMBRANE; LIGAND; CIN85; WW	CIN85 is a multidomain adaptor protein implicated in Cbl-mediated down-regulation of receptor tyrosine kinases. CIN85 binding to Cbl is increased after growth factor stimulation and is critical for targeting receptor tyrosine kinases to clathrin-mediated endocytosis. Here we report the identification of a novel polyproline-arginine motif (PXXXPR), specifically recognized by the SH3 domains of CIN85 and its homologue CMS/CD2AP. This motif was indispensable for CIN85 binding to Cbl/Cbl-b, to other CIN85 SH3 domains' effectors, and for mediating an intramolecular interaction between the SH3-A domain and the proline-rich region of CIN85. Individual SH3 domains of CIN85 bound to PXXXPR peptides of Cbl/Cbl-b with micromolar affinities, whereas an extended structure of two or three SH3 domains bound with higher stoichiometry and increased affinity to the same peptides. This enabled full size CIN85 to simultaneously interact with multiple Cbl molecules, promoting their clustering in mammalian cells. The ability of CIN85 to cluster Cbl was important for ligand-induced stabilization of CIN85.Cbl.epidermal growth factor receptor complexes, as well as for epidermal growth factor receptor degradation in the lysosome. Thus, specific interactions of CIN85 SH3 domains with the PXXXPR motif in Cbl play multiple roles in down-regulation of receptor tyrosine kinases.	Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, D-60590 Frankfurt, Germany; Ludwig Inst Canc Res, S-75124 Uppsala, Sweden; Rudjer Boskovic Inst, Div Mol Med, Zagreb 10000, Croatia; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Goethe University Frankfurt; Ludwig Institute for Cancer Research; Rudjer Boskovic Institute; University of London; University College London	Dikic, I (corresponding author), Goethe Univ Frankfurt, Sch Med, Inst Biochem 2, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	Ivan.Dikic@biochem2.de	Pilecka, Iwona/AAT-9114-2021; Soubeyran, Philippe/P-1758-2018; Haglund, Kaisa/B-3927-2017; Taylor, Jonathan/A-1416-2013; Dikic, Ivan/O-4650-2015; Husnjak, Koraljka/C-3717-2015; Soubeyran, Pierre-Louis/F-4523-2012	Pilecka, Iwona/0000-0002-5057-346X; Haglund, Kaisa/0000-0002-7946-3299; Taylor, Jonathan/0000-0003-0119-433X; Dikic, Ivan/0000-0001-8156-9511; Husnjak, Koraljka/0000-0003-0573-6239; Soubeyran, Pierre-Louis/0000-0003-3244-7299; Taylor, Jonathan/0000-0002-9797-3989; Soubeyran, Philippe/0000-0002-5876-3217; Ladbury, John/0000-0002-6328-7200				Bogler O, 2000, NEURO-ONCOLOGY, V2, P6, DOI 10.1093/neuonc/2.1.6; Brodin L, 2000, CURR OPIN NEUROBIOL, V10, P312, DOI 10.1016/S0959-4388(00)00097-0; Cesareni G, 2002, FEBS LETT, V513, P38, DOI 10.1016/S0014-5793(01)03307-5; de Melker AA, 2001, J CELL SCI, V114, P2167; Dikic I, 2002, FEBS LETT, V529, P110, DOI 10.1016/S0014-5793(02)03188-5; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Ettenberg S A, 1999, Mol Cell Biol Res Commun, V2, P111, DOI 10.1006/mcbr.1999.0157; Feshchenko EA, 1998, J BIOL CHEM, V273, P8323, DOI 10.1074/jbc.273.14.8323; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hutchings NJ, 2003, J BIOL CHEM, V278, P22396, DOI 10.1074/jbc.M302540200; Joazeiro CAP, 2000, SCIENCE, V289, P2061, DOI 10.1126/science.289.5487.2061; Kami K, 2002, EMBO J, V21, P4268, DOI 10.1093/emboj/cdf428; Kato M, 2000, J BIOL CHEM, V275, P37481, DOI 10.1074/jbc.M007251200; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kirsch KH, 2001, J BIOL CHEM, V276, P4957, DOI 10.1074/jbc.M005784200; Ladbury JE, 2000, CHEM BIOL, V7, pR3, DOI 10.1016/S1074-5521(00)00067-3; Levkowitz G, 1998, GENE DEV, V12, P3663, DOI 10.1101/gad.12.23.3663; Lewitzky M, 2001, ONCOGENE, V20, P1052, DOI 10.1038/sj.onc.1204202; Longva KE, 2002, J CELL BIOL, V156, P843, DOI 10.1083/jcb.200106056; Lu PJ, 2002, J BIOL CHEM, V277, P2381, DOI 10.1074/jbc.C100228200; Lu PJ, 1999, SCIENCE, V283, P1325, DOI 10.1126/science.283.5406.1325; Lynch DK, 2003, J BIOL CHEM, V278, P21805, DOI 10.1074/jbc.M211407200; Macias MJ, 2002, FEBS LETT, V513, P30, DOI 10.1016/S0014-5793(01)03290-2; Mayer BJ, 2001, J CELL SCI, V114, P1253; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Mongiovi AM, 1999, EMBO J, V18, P5300, DOI 10.1093/emboj/18.19.5300; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; Nishizawa K, 1998, P NATL ACAD SCI USA, V95, P14897, DOI 10.1073/pnas.95.25.14897; O'Brien R, 1998, J MOL BIOL, V279, P117, DOI 10.1006/jmbi.1998.1743; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Renzoni DA, 1996, BIOCHEMISTRY-US, V35, P15646, DOI 10.1021/bi9620969; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Stang E, 2000, J BIOL CHEM, V275, P13940, DOI 10.1074/jbc.275.18.13940; Szymkiewicz I, 2002, J BIOL CHEM, V277, P39666, DOI 10.1074/jbc.M205535200; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thien CBF, 2001, MOL CELL, V7, P355, DOI 10.1016/S1097-2765(01)00183-6; Tibaldi EV, 2003, INT IMMUNOL, V15, P313, DOI 10.1093/intimm/dxg032; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; Watanabe S, 2000, BIOCHEM BIOPH RES CO, V278, P167, DOI 10.1006/bbrc.2000.3760; Waterman H, 2001, FEBS LETT, V490, P142, DOI 10.1016/S0014-5793(01)02117-2	44	102	107	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39735	39746		10.1074/jbc.M304541200	http://dx.doi.org/10.1074/jbc.M304541200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874286	hybrid			2022-12-27	WOS:000185713800059
J	Zhu, C; Rao, K; Xiong, HB; Gagnidze, K; Li, FL; Horvath, C; Plevy, S				Zhu, C; Rao, K; Xiong, HB; Gagnidze, K; Li, FL; Horvath, C; Plevy, S			Activation of the murine interleukin-12 p40 promoter by functional interactions between NFAT and ICSBP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE-BINDING-PROTEIN; CELLULAR PHOSPHATASE CALCINEURIN; INTERFERON REGULATORY FACTORS; GENE PROMOTER; IFN-GAMMA; TRANSCRIPTIONAL ACTIVATION; PERITONEAL-MACROPHAGES; MONOCYTIC CELLS; FACTOR-I; T-CELLS	Interleukin (IL)-12 is a heterodimeric cytokine that is critical for the development of a T-helper-1 immune response and immunity against intracellular pathogens. The IL-12 p40 gene product, expressed specifically in macrophages and dendritic cells, heterodimerizes with p35 to form bioactive IL-12, and heterodimerizes with p19 to comprise the cytokine IL-23. Regulation of the murine IL-12 p40 promoter is complex. Multiple cis-acting elements have been characterized that are involved in activation by bacterial products. However, molecular mechanisms through which interferon (IFN)-gamma and bacterial products synergistically activate IL-12 p40 gene expression are less clear. In this study, a composite NFAT/ICSBP binding site at -68 to -54 is identified that is functionally important for p40 promoter activation by lipopolysaccharide (LPS) and LPS plus IFN-gamma. DNA binding of NFAT and ICSBP is demonstrated on the endogenous promoter by chromatin immunoprecipitation. NFAT is required for ICSBP binding to this region. Overexpression of NFAT and ICSBP synergistically activates the p40 promoter. A dominant negative NFAT molecule attenuates LPS- and IFN-gamma-activated endogenous IL-12 p40 mRNA expression. A physical association between NFAT and ICSBP in the absence of DNA is detected by co-immunoprecipitation of endogenous proteins. Three NFAT domains are required for ICSBP interaction. Finally, in LPS- and IFN-gamma-activated RAW-264.7 cells, the association between NFAT and ICSBP is abrogated by IL-10 priming.	Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA 15261 USA; CUNY Mt Sinai Sch Med, Immunobiol Ctr, New York, NY 10029 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai	Plevy, S (corresponding author), Univ Pittsburgh, Sch Med, Div Gastroenterol Hepatol & Nutr, Scaife Hall,Rm S857,3550 Terrace St, Pittsburgh, PA 15261 USA.							Adorini L, 1999, CELL MOL LIFE SCI, V55, P1610, DOI 10.1007/s000180050400; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; BOVOLENTA C, 1994, P NATL ACAD SCI USA, V91, P5046, DOI 10.1073/pnas.91.11.5046; Cappiello MG, 2001, J IMMUNOL, V166, P4498, DOI 10.4049/jimmunol.166.7.4498; Chow CW, 1999, MOL CELL BIOL, V19, P2300; Conboy IM, 1999, P NATL ACAD SCI USA, V96, P6324, DOI 10.1073/pnas.96.11.6324; Cooper AM, 2002, J IMMUNOL, V168, P1322, DOI 10.4049/jimmunol.168.3.1322; DANDREA A, 1992, J EXP MED, V176, P1387, DOI 10.1084/jem.176.5.1387; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DRIGGERS PH, 1990, P NATL ACAD SCI USA, V87, P3743, DOI 10.1073/pnas.87.10.3743; GUBLER U, 1991, P NATL ACAD SCI USA, V88, P4143, DOI 10.1073/pnas.88.10.4143; Kim YM, 1999, J IMMUNOL, V163, P2000; Lohoff M, 1997, IMMUNITY, V6, P681, DOI 10.1016/S1074-7613(00)80444-6; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Luo C, 1996, MOL CELL BIOL, V16, P3955; Ma XJ, 1997, J BIOL CHEM, V272, P10389; Ma XJ, 1996, J EXP MED, V183, P147, DOI 10.1084/jem.183.1.147; Ma XJ, 1996, ANN NY ACAD SCI, V795, P357, DOI 10.1111/j.1749-6632.1996.tb52692.x; Macian F, 2000, EMBO J, V19, P4783, DOI 10.1093/emboj/19.17.4783; Mamane Y, 1999, GENE, V237, P1, DOI 10.1016/S0378-1119(99)00262-0; Marecki S, 2001, J IMMUNOL, V166, P6829, DOI 10.4049/jimmunol.166.11.6829; Maruyama S, 2003, J IMMUNOL, V170, P997, DOI 10.4049/jimmunol.170.2.997; Masumi A, 2002, FEBS LETT, V531, P348, DOI 10.1016/S0014-5793(02)03556-1; McElligott DL, 1997, J IMMUNOL, V159, P4180; Meraro D, 1999, J IMMUNOL, V163, P6468; Miskin JE, 2000, J VIROL, V74, P9412, DOI 10.1128/JVI.74.20.9412-9420.2000; Miskin JE, 1998, SCIENCE, V281, P562, DOI 10.1126/science.281.5376.562; MURPHY TL, 1995, MOL CELL BIOL, V15, P5258; Oppmann B, 2000, IMMUNITY, V13, P715, DOI 10.1016/S1074-7613(00)00070-4; Plevy SE, 1997, MOL CELL BIOL, V17, P4572, DOI 10.1128/MCB.17.8.4572; POLITIS AD, 1992, J IMMUNOL, V148, P801; POLITIS AD, 1994, J IMMUNOL, V152, P2270; RADDASSI K, 1994, CELL IMMUNOL, V153, P443, DOI 10.1006/cimm.1994.1041; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rehli M, 2000, J BIOL CHEM, V275, P9773, DOI 10.1074/jbc.275.13.9773; Rengarajan J, 2002, J EXP MED, V195, P1003, DOI 10.1084/jem.20011128; Salkowski CA, 1999, J IMMUNOL, V163, P1529; SchartonKersten T, 1997, J EXP MED, V186, P1523, DOI 10.1084/jem.186.9.1523; Sharf R, 1997, J BIOL CHEM, V272, P9785; Sherman MA, 1999, J IMMUNOL, V162, P2820; Sutterwala FS, 1997, J EXP MED, V185, P1977, DOI 10.1084/jem.185.11.1977; Taniguchi T, 2001, ANNU REV IMMUNOL, V19, P623, DOI 10.1146/annurev.immunol.19.1.623; TRINCHIERI G, 1995, ANNU REV IMMUNOL, V13, P251, DOI 10.1146/annurev.immunol.13.1.251; Wang IM, 2000, J IMMUNOL, V165, P271, DOI 10.4049/jimmunol.165.1.271; Weinmann AS, 1999, IMMUNITY, V11, P665, DOI 10.1016/S1074-7613(00)80141-7; West MA, 1996, J TRAUMA, V41, P647, DOI 10.1097/00005373-199610000-00009; Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238; Wu CY, 1999, J IMMUNOL, V162, P807; Zhu C, 2001, J BIOL CHEM, V276, P18519, DOI 10.1074/jbc.M100440200	49	91	94	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39372	39382		10.1074/jbc.M306441200	http://dx.doi.org/10.1074/jbc.M306441200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12876285	hybrid			2022-12-27	WOS:000185713800014
J	Zhu, M; Li, J; Fink, AL				Zhu, M; Li, J; Fink, AL			The association of alpha-synuclein with membranes affects bilayer structure, stability, and fibril formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PARKINSONS-DISEASE; VESICLE PERMEABILIZATION; FATTY-ACIDS; BINDING; PROTEIN; PHOSPHOLIPIDS; MODEL; AGGREGATION; MUTATION; GROWTH	The aggregation of alpha-synuclein is believed to be a critical factor in the etiology of Parkinson's disease. alpha-Synuclein is an abundant neuronal protein of unknown function, which is enriched in the presynaptic terminals of neurons. Although alpha-synuclein is found predominantly in the cytosolic fractions, membrane-bound alpha-synuclein has been suggested to play an important role in fibril formation. The effects of alpha-synuclein on lipid bilayers of different compositions were determined using fluorescent environment-specific probes located at various depths. alpha-Synuclein-membrane interactions were found to affect both protein and membrane properties. Our results indicate that in addition to electrostatic interactions, hydrophobic interactions are important in the association of the protein with the bilayer, and lead to disruption of the membrane. The latter was observed by atomic force microscopy and fluorescent dye leakage from vesicles. The kinetics of alpha-synuclein fibril formation were significantly affected by the protein association and subsequent membrane disruption, and reflected the conformation of alpha-synuclein. The ability of alpha-synuclein to disrupt membranes correlated with the binding affinity of alpha-synuclein for the particular membrane composition, and to the induced helical conformation of alpha-synuclein. Protofibrillar or fibrillar alpha-synuclein caused a much more rapid destruction of the membrane than soluble monomeric alpha-synuclein, indicating that protofibrils (oligomers) or fibrils are likely to be significantly neurotoxic.	Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of California System; University of California Santa Cruz	Fink, AL (corresponding author), Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA.	enzyme@cats.ucsc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039985] Funding Source: NIH RePORTER; NINDS NIH HHS [NS39985] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bagatolli LA, 1999, PHOTOCHEM PHOTOBIOL, V70, P557, DOI 10.1562/0031-8655(1999)070<0557:AMFTIO>2.3.CO;2; Balasubramanian SV, 2000, PHARMACEUT RES, V17, P344, DOI 10.1023/A:1007561308498; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; El-Agnaf OMA, 2002, BIOCHEM SOC T, V30, P559; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Epand RM, 1999, CHEM PHYS LIPIDS, V101, P57, DOI 10.1016/S0009-3084(99)00055-9; Fang Y, 1997, BBA-BIOMEMBRANES, V1324, P309, DOI 10.1016/S0005-2736(96)00236-2; Fink AL, 1998, FOLD DES, V3, pR9, DOI 10.1016/S1359-0278(98)00002-9; Irizarry MC, 1996, J NEUROPATH EXP NEUR, V55, P889, DOI 10.1097/00005072-199608000-00004; Jenco JM, 1998, BIOCHEMISTRY-US, V37, P4901, DOI 10.1021/bi972776r; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Lee HJ, 2002, J BIOL CHEM, V277, P671, DOI 10.1074/jbc.M107045200; Lee JCM, 2001, LANGMUIR, V17, P3592, DOI 10.1021/la001678v; McLean PJ, 2000, J BIOL CHEM, V275, P8812, DOI 10.1074/jbc.275.12.8812; Munishkina LA, 2003, BIOCHEMISTRY-US, V42, P2720, DOI 10.1021/bi027166s; Narayanan V, 2001, BIOCHEMISTRY-US, V40, P9927, DOI 10.1021/bi002952n; Nielsen L, 2001, BIOCHEMISTRY-US, V40, P6036, DOI 10.1021/bi002555c; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Perrin RJ, 2001, J BIOL CHEM, V276, P41958, DOI 10.1074/jbc.M105022200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Reviakine I, 2000, LANGMUIR, V16, P1806, DOI 10.1021/la9903043; RIGAUD JL, 1977, BIOCHIM BIOPHYS ACTA, V469, P246, DOI 10.1016/0005-2736(77)90160-2; SEMBLE SC, 2001, J BIOPHYS ACTA, V1510, P152; Sharon R, 2001, P NATL ACAD SCI USA, V98, P9110, DOI 10.1073/pnas.171300598; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; STEWART JCM, 1980, ANAL BIOCHEM, V104, P10, DOI 10.1016/0003-2697(80)90269-9; Tang ZY, 2000, LANGMUIR, V16, P1696, DOI 10.1021/la981491s; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Volles MJ, 2002, BIOCHEMISTRY-US, V41, P4595, DOI 10.1021/bi0121353; Volles MJ, 2001, BIOCHEMISTRY-US, V40, P7812, DOI 10.1021/bi0102398; Walde P, 2001, BIOMOL ENG, V18, P143, DOI 10.1016/S1389-0344(01)00088-0; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Yang ZH, 1999, LANGMUIR, V15, P1731, DOI 10.1021/la980839g; Zhu M, 2003, J BIOL CHEM, V278, P16873, DOI 10.1074/jbc.M210136200	41	264	274	0	47	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40186	40197		10.1074/jbc.M305326200	http://dx.doi.org/10.1074/jbc.M305326200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885775	hybrid			2022-12-27	WOS:000185713800112
J	Caspi, M; Coquelle, FM; Koifman, C; Levy, T; Arai, H; Aoki, J; De Mey, JR; Reiner, O				Caspi, M; Coquelle, FM; Koifman, C; Levy, T; Arai, H; Aoki, J; De Mey, JR; Reiner, O			LIS1 missense mutations - Variable phenotypes result from unpredictable alterations in biochemical and cellular properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLATELET-ACTIVATING-FACTOR; ACETYLHYDROLASE CATALYTIC SUBUNITS; LISSENCEPHALY GENE-PRODUCT; PROTEIN BETA-SUBUNIT; CYTOPLASMIC DYNEIN; ASPERGILLUS-NIDULANS; NUCLEAR MIGRATION; NEURONAL MIGRATION; BAND HETEROTOPIA; BRAIN	Mutations in one allele of the human LIS1 gene cause a severe brain malformation, lissencephaly. Although most LIS1 mutations involve deletions, several point mutations with a single amino acid alteration were described. Patients carrying these mutations reveal variable phenotypic manifestations. We have analyzed the functional importance of these point mutations by examining protein stability, folding, intracellular localization, and protein-protein interactions. Our data suggest that the mutated proteins were affected at different levels, and no single assay could be used to predict the lissencephaly phenotype. Most interesting are those mutant proteins that retain partial folding and interactions. In the case of LIS1 mutated in F31S, the cellular phenotype may be modified by overexpression of specific interacting proteins. Overexpression of the PAF-AH alpha1 subunit dissolved aggregates induced by this mutant protein and increased its half-life. Overexpression of NudE or NudEL localized this mutant protein to spindle poles and kinetochores but had no effect on protein stability. Our results implicate that there are probably different biochemical and cellular mechanisms obstructed in each patient yielding the varied lissencephaly phenotypes.	Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel; Ctr Univ Orsay, CNRS, UMR 146, Inst Curie,Sect Rech, F-91405 Orsay, France; Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan	Weizmann Institute of Science; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay; University of Tokyo	Reiner, O (corresponding author), Weizmann Inst Sci, Dept Mol Genet, IL-76100 Rehovot, Israel.		Reiner, Orly/E-9455-2010	Reiner, Orly/0000-0001-7560-9599; Aoki, Junken/0000-0001-9435-1896; COQUELLE, Frederic/0000-0002-5483-8787				Aumais JP, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-24-j0002.2001; BARKOVICH AJ, 1994, ANN NEUROL, V36, P609, DOI 10.1002/ana.410360409; Beckwith SM, 1998, J CELL BIOL, V143, P1239, DOI 10.1083/jcb.143.5.1239; BONIFACINO JS, 1999, CURRENT PROTOCOLS CE; Busson S, 1998, CURR BIOL, V8, P541, DOI 10.1016/S0960-9822(98)70208-8; Cahana A, 2001, P NATL ACAD SCI USA, V98, P6429, DOI 10.1073/pnas.101122598; Cardoso C, 2002, HUM MUTAT, V19, P4, DOI 10.1002/humu.10028; Cardoso C, 2000, HUM MOL GENET, V9, P3019, DOI 10.1093/hmg/9.20.3019; Caspi M, 2000, HUM MOL GENET, V9, P2205, DOI 10.1093/oxfordjournals.hmg.a018911; Coquelle FM, 2002, MOL CELL BIOL, V22, P3089, DOI 10.1128/MCB.22.9.3089-3102.2002; des Portes V, 1998, CELL, V92, P51; Dobyns WB, 1999, NEUROLOGY, V53, P270, DOI 10.1212/WNL.53.2.270; DOBYNS WB, 1993, JAMA-J AM MED ASSOC, V270, P2838, DOI 10.1001/jama.270.23.2838; Efimov VP, 2000, J CELL BIOL, V150, P681, DOI 10.1083/jcb.150.3.681; Emes RD, 2001, HUM MOL GENET, V10, P2813, DOI 10.1093/hmg/10.24.2813; Faulkner NE, 2000, NAT CELL BIOL, V2, P784, DOI 10.1038/35041020; Feng YY, 2000, NEURON, V28, P665, DOI 10.1016/S0896-6273(00)00145-8; Fogli A, 1999, ANN NEUROL, V45, P154, DOI 10.1002/1531-8249(199902)45:2<154::AID-ANA4>3.0.CO;2-P; GarciaHiguera I, 1996, BIOCHEMISTRY-US, V35, P13985, DOI 10.1021/bi9612879; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HOFFMANN B, 2001, J BIOL CHEM, V16, P16; Horesh D, 1999, HUM MOL GENET, V8, P1599, DOI 10.1093/hmg/8.9.1599; Kitagawa M, 2000, FEBS LETT, V479, P57, DOI 10.1016/S0014-5793(00)01856-1; Koizumi H, 2003, J BIOL CHEM, V278, P12489, DOI 10.1074/jbc.M211836200; Leventer RJ, 2001, NEUROLOGY, V57, P416, DOI 10.1212/WNL.57.3.416; LO NC, 1997, HUM MOL GENET, V6, P157; Manya H, 1998, J BIOL CHEM, V273, P18567, DOI 10.1074/jbc.273.29.18567; Morris NR, 1998, TRENDS CELL BIOL, V8, P467, DOI 10.1016/S0962-8924(98)01389-0; Morris SM, 1998, CURR BIOL, V8, P603, DOI 10.1016/S0960-9822(98)70232-5; NEER EJ, 1994, NATURE, V371, P297, DOI 10.1038/371297a0; Niethammer M, 2000, NEURON, V28, P697, DOI 10.1016/S0896-6273(00)00147-1; Pilz DT, 1999, HUM MOL GENET, V8, P1757, DOI 10.1093/hmg/8.9.1757; Pilz DT, 1998, HUM MOL GENET, V7, P2029, DOI 10.1093/hmg/7.13.2029; Pilz DT, 1998, GENET MED, V1, P29; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Reiner O, 2000, NEURON, V28, P633, DOI 10.1016/S0896-6273(00)00142-2; Sapir T, 1999, EUR J BIOCHEM, V266, P1011, DOI 10.1046/j.1432-1327.1999.00942.x; Sapir T, 1997, EMBO J, V16, P6977, DOI 10.1093/emboj/16.23.6977; Sasaki S, 2000, NEURON, V28, P681, DOI 10.1016/S0896-6273(00)00146-X; Sheffield PJ, 2000, PROTEINS, V39, P1, DOI 10.1002/(SICI)1097-0134(20000401)39:1<1::AID-PROT1>3.0.CO;2-N; Smith DS, 2000, NAT CELL BIOL, V2, P767, DOI 10.1038/35041000; Sweeney KJ, 2001, MECH DEVELOP, V101, P21, DOI 10.1016/S0925-4773(00)00543-8; Sweeney KJ, 2000, MECH DEVELOP, V92, P263, DOI 10.1016/S0925-4773(00)00242-2; TAI CY, 2002, J CELL BIOL, V11, P11; Xiang X, 2000, CURR BIOL, V10, P603, DOI 10.1016/S0960-9822(00)00488-7; XIANG X, 1995, MOL BIOL CELL, V6, P297, DOI 10.1091/mbc.6.3.297; XIANG X, 1994, P NATL ACAD SCI USA, V91, P2100, DOI 10.1073/pnas.91.6.2100	48	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38740	38748		10.1074/jbc.M301147200	http://dx.doi.org/10.1074/jbc.M301147200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885786	hybrid			2022-12-27	WOS:000185575100080
J	Daiho, T; Yamasaki, K; Wang, GL; Danko, S; Iizuka, H; Suzuki, H				Daiho, T; Yamasaki, K; Wang, GL; Danko, S; Iizuka, H; Suzuki, H			Deletions of any single residues in Glu(40)-Ser(48) loop connecting a domain and the first transmembrane helix of sarcoplasmic reticulum Ca2+-ATPase result in almost complete inhibition of conformational transition and hydrolysis of phosphoenzyme intermediate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL CONSEQUENCES; AMINO-ACIDS; DARIERS-DISEASE; ADENOSINE-TRIPHOSPHATE; ENERGY TRANSDUCTION; CALCIUM-TRANSPORT; ATP2A2 MUTATIONS; CATALYTIC SITE; STEADY-STATE; COS-1 CELLS	Possible roles of the Glu(40)-Ser(48) loop connecting A domain and the first transmembrane helix (M1) in sarcoplasmic reticulum Ca2+-ATPase (SERCA1a) were explored by mutagenesis. Deletions of any single residues in this loop caused almost complete loss of Ca2+-ATPase activity, while their substitutions had no or only slight effects. Single deletions or substitutions in the adjacent N- and C-terminal regions of the loop (His(32)-Asn(39) and Leu(49)-Ile(54)) had no or only slight effects except two specific substitutions of Asn(39) found in SERCA2b in Darier's disease pedigrees. All the single deletion mutants for the Glu(40)-Ser(48) loop and the specific Asn(39) mutants formed phosphoenzyme intermediate (EP) from ATP, but their isomeric transition from ADP-sensitive EP (E1P) to ADP-insensitive EP (E2P) was almost completely or strongly inhibited. Hydrolysis of E2P formed from P-i was also dramatically slowed in these deletion mutants. On the other hand, the rates of the Ca2+-induced enzyme activation and subsequent E1P formation from ATP were not altered by the deletions and substitutions. The results indicate that the Glu(40)-Ser(48) loop, with its appropriate length (but not with specific residues) and with its appropriate junction to A domain, is a critical element for the E1P to E2P transition and formation of the proper structure of E2P, therefore, most likely for the large rotational movement of A domain and resulting in its association with P and N domains. Results further suggest that the loop functions to coordinate this movement of A domain and the unique motion of M1 during the E1P to E2P transition.	Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan; Asahikawa Med Coll, Dept Dermatol, Asahikawa, Hokkaido 0788510, Japan	Asahikawa Medical College; Asahikawa Medical College	Suzuki, H (corresponding author), Asahikawa Med Coll, Dept Biochem, Asahikawa, Hokkaido 0788510, Japan.	hisuzuki@asahikawa-med.ac.jp						Ahn W, 2003, J BIOL CHEM, V278, P20795, DOI 10.1074/jbc.M301638200; ANDERSEN JP, 1989, J BIOL CHEM, V264, P21018; CLARKE DM, 1989, J BIOL CHEM, V264, P11246; CLARKE DM, 1990, J BIOL CHEM, V265, P22223; CLARKE DM, 1990, J BIOL CHEM, V265, P14088; Clausen JD, 2003, J BIOL CHEM, V278, P20245, DOI 10.1074/jbc.M301122200; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; Daiho T, 1999, J BIOL CHEM, V274, P23910, DOI 10.1074/jbc.274.34.23910; Daiho T, 1999, FEBS LETT, V444, P54, DOI 10.1016/S0014-5793(99)00027-7; Danko S, 2001, FEBS LETT, V505, P129, DOI 10.1016/S0014-5793(01)02801-0; Danko S, 2001, FEBS LETT, V489, P277, DOI 10.1016/S0014-5793(01)02111-1; DEMEIS L, 1980, BIOCHEMISTRY-US, V19, P4252, DOI 10.1021/bi00559a017; DEMEIS L, 1989, BIOCHIM BIOPHYS ACTA, V973, P333, DOI 10.1016/S0005-2728(89)80440-2; DUPONT Y, 1983, FEBS LETT, V156, P93, DOI 10.1016/0014-5793(83)80255-5; EBASHI S, 1962, J CELL BIOL, V14, P389, DOI 10.1083/jcb.14.3.389; HASSELBACH W, 1961, BIOCHEM Z, V333, P518; IMAMURA Y, 1989, J BIOCHEM-TOKYO, V105, P775, DOI 10.1093/oxfordjournals.jbchem.a122743; INESI G, 1982, Z NATURFORSCH C, V37, P685; Jacobsen NJO, 1999, HUM MOL GENET, V8, P1631, DOI 10.1093/hmg/8.9.1631; Juul B, 2000, INT CONGR SER, V1207, P233; KANAZAWA T, 1970, J BIOCHEM-TOKYO, V67, P693, DOI 10.1093/oxfordjournals.jbchem.a129297; Kato S, 2003, J BIOL CHEM, V278, P9624, DOI 10.1074/jbc.M208861200; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; LEMAIRE M, 1990, J BIOL CHEM, V265, P1111; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Ma HL, 2003, J BIOL CHEM, V278, P28938, DOI 10.1074/jbc.M304120200; MacLennan DH, 1997, J BIOL CHEM, V272, P28815, DOI 10.1074/jbc.272.46.28815; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; Moller JV, 2002, J BIOL CHEM, V277, P38647, DOI 10.1074/jbc.M204603200; Moller JV, 1996, BBA-REV BIOMEMBRANES, V1286, P1, DOI 10.1016/0304-4157(95)00017-8; Patchornik G, 2000, P NATL ACAD SCI USA, V97, P11954, DOI 10.1073/pnas.220332897; PICK U, 1982, J BIOL CHEM, V257, P6120; Rice WJ, 1996, J BIOL CHEM, V271, P31412, DOI 10.1074/jbc.271.49.31412; Ringpfeil F, 2001, EXP DERMATOL, V10, P19, DOI 10.1034/j.1600-0625.2001.100103.x; Ruiz-Perez VL, 1999, HUM MOL GENET, V8, P1621, DOI 10.1093/hmg/8.9.1621; Sakuntabhai A, 1999, NAT GENET, V21, P271, DOI 10.1038/6784; SHIGEKAWA M, 1978, J BIOL CHEM, V253, P1451; SUZUKI H, 1987, J BIOL CHEM, V262, P15448; SUZUKI H, 1989, J BIOL CHEM, V264, P920; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; VILSEN B, 1991, J BIOL CHEM, V266, P16157; VILSEN B, 1991, J BIOL CHEM, V266, P18839; VILSEN B, 1989, J BIOL CHEM, V264, P21024; WEBER K, 1969, J BIOL CHEM, V244, P4406; ZHANG Z, 1995, J BIOL CHEM, V270, P16283	46	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39197	39204		10.1074/jbc.M305200200	http://dx.doi.org/10.1074/jbc.M305200200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857730	hybrid			2022-12-27	WOS:000185575100134
J	Jakobi, R; McCarthy, CC; Koeppel, MA; Stringer, DK				Jakobi, R; McCarthy, CC; Koeppel, MA; Stringer, DK			Caspase-activated PAK-2 is regulated by subcellular targeting and proteasomal degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE GAMMA-PAK; KAPPA-B-ALPHA; MOLECULAR-CLONING; P21-ACTIVATED KINASE; PROTECTS CELLS; CLEAVAGE; AUTOPHOSPHORYLATION; TRANSLOCATION; DEUBIQUITINATION; UBIQUITINATION	p21-activated protein kinases (PAKs) are a family of serine/threonine protein kinases that are activated by binding of the p21 G proteins Cdc42 or Rac. The ubiquitous PAK-2 (gamma-PAK) is unique among the PAK isoforms because it is also activated through proteolytic cleavage by caspases or caspase-like proteases. In response to stress stimulants such as tumor necrosis factor alpha or growth factor withdrawal, PAK-2 is activated as a full-length enzyme and as a proteolytic PAK-2p34 fragment. Activation of full-length PAK-2 stimulates cell survival, whereas proteolytic activation of PAK-2p34 is involved in programmed cell death. Here we provide evidence that the proapoptotic effect of PAK-2p34 is regulated by subcellular targeting and degradation by the proteasome. Full-length PAK-2 is localized in the cytoplasm, whereas the proteolytic PAK-2p34 fragment translocates to the nucleus. Subcellular localization of PAK-2 is regulated by nuclear localization and nuclear export signal motifs. A nuclear export signal motif within the regulatory domain prevents nuclear localization of full-length PAK-2. Proteolytic activation removes most of the regulatory domain and disrupts the nuclear export signal. The activated PAK-2p34 fragment contains a nuclear localization signal and translocates to the nucleus. However, levels of activated PAK-2p34 are tightly regulated through ubiquitination and degradation by the proteasome. Inhibition of degradation by blocking polyubiquitination results in significantly increased levels of PAK-2p34 and as a consequence, in stimulation of programmed cell death. Therefore, nuclear targeting and inhibition of degradation appear to be critical for stimulation of the cell death response by PAK-2p34.	Med Coll Wisconsin, Dept Pharmacol & Toxicol, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Jakobi, R (corresponding author), Univ Hlth Sci, Dept Biochem, 1750 Independence Ave, Kansas City, MO 64106 USA.	rjakobi@uhs.edu						AARONSON SA, 1968, J CELL PHYSIOL, V72, P141, DOI 10.1002/jcp.1040720208; Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; BAGRODIA S, 1995, J BIOL CHEM, V270, P22731, DOI 10.1074/jbc.270.39.22731; Bagrodia S, 1999, TRENDS CELL BIOL, V9, P350, DOI 10.1016/S0962-8924(99)01618-9; BROCKMAN JA, 1995, MOL CELL BIOL, V15, P2809; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; Chan WH, 1998, J PROTEIN CHEM, V17, P485, DOI 10.1023/A:1022578820147; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; ELLISON MJ, 1991, J BIOL CHEM, V266, P21150; GEY GO, 1952, CANCER RES, V12, P264; Gnesutta N, 2001, J BIOL CHEM, V276, P14414, DOI 10.1074/jbc.M011046200; HACKETT AJ, 1977, J NATL CANCER I, V58, P1795, DOI 10.1093/jnci/58.6.1795; Hofmann A, 1996, P NATL ACAD SCI USA, V93, P5185, DOI 10.1073/pnas.93.11.5185; JAKOBI R, 1992, J BIOL CHEM, V267, P23894; Jakobi R, 1996, J BIOL CHEM, V271, P6206, DOI 10.1074/jbc.271.11.6206; Jakobi R, 2002, BIOTECHNIQUES, V33, P1218, DOI 10.2144/02336bm07; Jakobi R, 2001, BIOTECHNIQUES, V30, P476, DOI 10.2144/01303bm02; Jakobi R, 2001, J BIOL CHEM, V276, P16624, DOI 10.1074/jbc.M007753200; Jakobi R, 2000, EUR J BIOCHEM, V267, P4414, DOI 10.1046/j.1432-1327.2000.01488.x; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; Knaus UG, 1998, INT J BIOCHEM CELL B, V30, P857, DOI 10.1016/S1357-2725(98)00059-4; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Lee N, 1997, P NATL ACAD SCI USA, V94, P13642, DOI 10.1073/pnas.94.25.13642; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Li MY, 2002, NATURE, V416, P648, DOI 10.1038/nature737; MANSER E, 1995, J BIOL CHEM, V270, P25070, DOI 10.1074/jbc.270.42.25070; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MARTIN GA, 1995, EMBO J, V14, P1970, DOI 10.1002/j.1460-2075.1995.tb07189.x; Roig J, 2001, VITAM HORM, V62, P167, DOI 10.1016/S0083-6729(01)62004-1; Rudel T, 1998, J IMMUNOL, V160, P7; Rudel T, 1997, SCIENCE, V276, P1571, DOI 10.1126/science.276.5318.1571; Salomoni P, 2002, NAT CELL BIOL, V4, pE152, DOI 10.1038/ncb0602-e152; SARKAR G, 1990, BIOTECHNIQUES, V8, P404; Schlesinger TK, 2002, J BIOL CHEM, V277, P10283, DOI 10.1074/jbc.M106885200; Schurmann A, 2000, MOL CELL BIOL, V20, P453, DOI 10.1128/MCB.20.2.453-461.2000; Sells MA, 1997, TRENDS CELL BIOL, V7, P162, DOI 10.1016/S0962-8924(97)01003-9; Tang TK, 1998, J CELL BIOCHEM, V70, P442, DOI 10.1002/(SICI)1097-4644(19980915)70:4<442::AID-JCB2>3.3.CO;2-N; Tang Y, 2000, J BIOL CHEM, V275, P9106, DOI 10.1074/jbc.275.13.9106; TEO M, 1995, J BIOL CHEM, V270, P26690, DOI 10.1074/jbc.270.44.26690; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Walter BN, 1998, J BIOL CHEM, V273, P28733, DOI 10.1074/jbc.273.44.28733; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; Yang F, 2001, J BIOL CHEM, V276, P15345, DOI 10.1074/jbc.M010311200	47	58	63	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38675	38685		10.1074/jbc.M306494200	http://dx.doi.org/10.1074/jbc.M306494200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12853446	hybrid			2022-12-27	WOS:000185575100072
J	Ohtake, S; Kimata, K; Habuchi, O				Ohtake, S; Kimata, K; Habuchi, O			A unique nonreducing terminal modification of chondroitin sulfate by N-acetylgalactosamine 4-sulfate 6-O-sulfotransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RABBIT THROMBOMODULIN PROTEOGLYCAN; MOLECULAR-CLONING; GLYCOSAMINOGLYCAN SULFOTRANSFERASES; SQUID CARTILAGE; ACID RESIDUES; EXPRESSION; 6-SULFOTRANSFERASE; PURIFICATION; CLEAVAGE; HEPARIN	N-Acetylgalactosamine 4-sulfate 6-O-sulfotransferase (GalNAc4S-6ST) transfers sulfate from 3'-phosphoadenosine 5'-phosphosulfate (PAPS) to position 6 of N-acetylgalactosamine 4-sulfate (GalNAc(4SO(4))). We previously identified human GalNAc4S-6ST cDNA and showed that the recombinant GalNAc4S-6ST could transfer sulfate efficiently to the nonreducing terminal GalNAc(4SO(4)) residues. We here present evidence that GalNAc4S-6ST should be involved in a unique nonreducing terminal modification of chondroitin sulfate A (CSA). From the nonreducing terminal of CS-A, a GlcA-containing oligosaccharide (Oligo I) that could serve as an acceptor for GalNAc4S-6ST was obtained after chondroitinase ACII digestion. Oligo I was found to be GalNAc(4SO(4))-GlcA(2SO(4))-GalNAc(6SO(4)) because GalNAc(4SO(4)) and DeltaHexA(2SO(4))-GalNAc(6SO(4)) were formed after chondroitinase ABC digestion. When Oligo I was used as the acceptor for GalNAc4S-6ST, sulfate was transferred to position 6 of GalNAc(4SO(4)) located at the nonreducing end of Oligo I. Oligo I was much better acceptor for GalNAc4S-6ST than GalNAc(4SO(4))-GlcA-GalNAc(6SO(4)). An oligosaccharide (Oligo II) whose structure is identical to that of the sulfated Oligo I was obtained from CS-A after chondroitinase ACII digestion, indicating that the terminal modification occurs under the physiological conditions. When CS-A was incubated with [S-35]PAPS and GalNAc4S-6ST and the S-35-labeled product was digested with chondroitinase ACII, a S-35-labeled trisaccharide (Oligo III) containing [ 35S] GalNAc(4,6-SO4) residue at the nonreducing end was obtained. Oligo III behaved identically with the sulfated Oligos I and II. These results suggest that GalNAc4S-6ST may be involved in the terminal modification of CS-A, through which a highly sulfated nonreducing terminal sequence is generated.	Aichi Univ Educ, Dept Chem, Aichi 4488542, Japan; Aichi Med Univ, Inst Mol Sci Med, Aichi 4801195, Japan	Aichi University Education; Aichi Medical University	Habuchi, O (corresponding author), Aichi Univ Educ, Dept Chem, Igaya Cho, Aichi 4488542, Japan.							BOURIN MC, 1990, BIOCHEM J, V270, P419, DOI 10.1042/bj2700419; BOURIN MC, 1990, J BIOL CHEM, V265, P15424; CONRAD HE, 1980, BIOCHEM J, V191, P355, DOI 10.1042/bj1910355; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; DELFERT DM, 1985, ANAL BIOCHEM, V148, P303, DOI 10.1016/0003-2697(85)90233-7; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; FUKUTA M, 1995, J BIOL CHEM, V270, P18575, DOI 10.1074/jbc.270.31.18575; HABUCHI O, 1980, BIOCHIM BIOPHYS ACTA, V616, P208, DOI 10.1016/0005-2744(80)90139-4; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; HABUCHI O, 1993, J BIOL CHEM, V268, P21968; Habuchi O, 2002, ANAL BIOCHEM, V310, P129, DOI 10.1016/S0003-2697(02)00277-4; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; HIYAMA K, 1975, J BIOL CHEM, V250, P1824; INOUE H, 1986, J BIOL CHEM, V261, P4460; Ishihara M, 1997, J BIOCHEM-TOKYO, V121, P345; Ito Y, 2000, J BIOL CHEM, V275, P34728, DOI 10.1074/jbc.M909633199; Kang HG, 2002, J BIOL CHEM, V277, P34766, DOI 10.1074/jbc.M204907200; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kitagawa H, 2000, J BIOL CHEM, V275, P21075, DOI 10.1074/jbc.M002101200; Kobayashi M, 1999, J BIOL CHEM, V274, P10474, DOI 10.1074/jbc.274.15.10474; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDWIGS U, 1987, BIOCHEM J, V245, P795, DOI 10.1042/bj2450795; MIDURA RJ, 1995, J BIOL CHEM, V270, P8009, DOI 10.1074/jbc.270.14.8009; NAKANISHI Y, 1981, J BIOL CHEM, V256, P5443; Ohtake S, 2001, J BIOL CHEM, V276, P43894, DOI 10.1074/jbc.M104922200; OTSU K, 1985, BIOCHEM J, V227, P37, DOI 10.1042/bj2270037; Plaas AHK, 1998, J BIOL CHEM, V273, P12642, DOI 10.1074/jbc.273.20.12642; Plaas AHK, 1997, J BIOL CHEM, V272, P20603, DOI 10.1074/jbc.272.33.20603; SHAKLEE PN, 1985, J BIOL CHEM, V260, P6064; STROMINGER JL, 1959, J BIOL CHEM, V234, P3263; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; Sugahara K, 1996, EUR J BIOCHEM, V239, P865, DOI 10.1111/j.1432-1033.1996.0865u.x; Ueoka C, 2000, J BIOL CHEM, V275, P37407, DOI 10.1074/jbc.M002538200; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975	36	40	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38443	38452		10.1074/jbc.M306132200	http://dx.doi.org/10.1074/jbc.M306132200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874280	hybrid			2022-12-27	WOS:000185575100045
J	Rauchenberger, R; Borges, E; Thomassen-Wolf, E; Rom, E; Adar, R; Yaniv, Y; Malka, M; Chumakov, I; Kotzer, S; Resnitzky, D; Knappik, A; Reiffert, S; Prassler, J; Jury, K; Waldherr, D; Bauer, S; Kretzschmar, T; Yayon, A; Rothe, C				Rauchenberger, R; Borges, E; Thomassen-Wolf, E; Rom, E; Adar, R; Yaniv, Y; Malka, M; Chumakov, I; Kotzer, S; Resnitzky, D; Knappik, A; Reiffert, S; Prassler, J; Jury, K; Waldherr, D; Bauer, S; Kretzschmar, T; Yayon, A; Rothe, C			Human combinatorial Fab library yielding specific and functional antibodies against the human fibroblast growth factor receptor 3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FREQUENT FGFR3 MUTATIONS; BY-PASSING IMMUNIZATION; MONOCLONAL-ANTIBODIES; ESCHERICHIA-COLI; HIGH-AFFINITY; TYROSINE KINASES; DISPLAY LIBRARY; KINETIC ASPECTS; LIGHT-CHAIN; FULLY HUMAN	The human combinatorial antibody library Fab 1 (HuCAL(R)-Fab 1) was generated by transferring the heavy and light chain variable regions from the previously constructed single-chain Fv library (Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., Hoess, A., Wolle, J., Pluckthun, A., and Virnekas, B. (2000) J. Mol. Biol. 296, 57-86), diversified in both complementarity-determining regions 3 into a novel Fab display vector, yielding 2.1 x 10(10) different antibody fragments. The modularity has been retained in the Fab display and screening plasmids, ensuring rapid conversion into various antibody formats as well as antibody optimization using prebuilt maturation cassettes. HuCAL(R)-Fab 1 was challenged against the human fibroblast growth factor receptor 3, a potential therapeutic antibody target, against which, to the best of our knowledge, no functional antibodies could be generated so far. A unique screening mode was designed utilizing recombinant functional proteins and cell lines differentially expressing fibroblast growth factor receptor isoforms diversified in expression and receptor dependence. Specific Fab fragments with subnanomolar affinities were isolated by selection without any maturation steps as determined by fluorescence flow cytometry. Some of the selected Fab fragments completely inhibit target-mediated cell proliferation, rendering them the first monoclonal antibodies against fibroblast growth factor receptors having significant function blocking activity. This study validates HuCAL(R)-Fab 1 as a valuable source for the generation of target-specific antibodies for therapeutic applications.	ProChon Biotech Ltd, IL-76114 Rehovot, Israel; MorphoSys AG, D-82152 Martinsried, Germany; Weizmann Inst Sci, IL-76100 Rehovot, Israel	MorphoSys; Weizmann Institute of Science	Yayon, A (corresponding author), ProChon Biotech Ltd, Kiryat Weizmann Sci Pk,POB 1482, IL-76114 Rehovot, Israel.	yayon@prochon.co.il; rothe@morphosys.de	Knappik, Achim/D-3677-2011	Knappik, Achim/0000-0002-2693-6750				Adar R, 2002, J BONE MINER RES, V17, P860, DOI 10.1359/jbmr.2002.17.5.860; ALEXANDRU I, 1980, MOL IMMUNOL, V17, P1351, DOI 10.1016/0161-5890(80)90004-8; Ausubel FM, 1998, CURRENT PROTOCOLS MO; AVIVI A, 1991, ONCOGENE, V6, P1089; Baca M, 1997, J BIOL CHEM, V272, P10678; BARBAS CF, 1993, GENE, V137, P57, DOI 10.1016/0378-1119(93)90251-W; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIGELOW CC, 1974, BIOCHEMISTRY-US, V13, P4602, DOI 10.1021/bi00719a021; Billerey C, 2001, AM J PATHOL, V158, P1955, DOI 10.1016/S0002-9440(10)64665-2; Burke D, 1998, TRENDS BIOCHEM SCI, V23, P59, DOI 10.1016/S0968-0004(97)01170-5; Cappellen D, 1999, NAT GENET, V23, P18, DOI 10.1038/12615; CARTER P, 1992, BIO-TECHNOL, V10, P163, DOI 10.1038/nbt0292-163; CHAMOW SM, 1994, J IMMUNOL, V153, P4268; Chellaiah A, 1999, J BIOL CHEM, V274, P34785, DOI 10.1074/jbc.274.49.34785; Chesi M, 2001, BLOOD, V97, P729, DOI 10.1182/blood.V97.3.729; de Haard HJ, 1999, J BIOL CHEM, V274, P18218, DOI 10.1074/jbc.274.26.18218; DEKRUIF J, 1995, J MOL BIOL, V248, P97, DOI 10.1006/jmbi.1995.0204; DUENAS M, 1995, GENE, V158, P61, DOI 10.1016/0378-1119(95)00077-J; Ewert S, 2003, J MOL BIOL, V325, P531, DOI 10.1016/S0022-2836(02)01237-8; GARRARD LJ, 1991, BIO-TECHNOL, V9, P1373, DOI 10.1038/nbt1291-1373; Ge L, 1995, ANTIBODY ENG, P229; GIVOL D, 1992, FASEB J, V6, P3362, DOI 10.1096/fasebj.6.15.1464370; GORDON IL, 1995, CYTOMETRY, V20, P238, DOI 10.1002/cyto.990200307; GRIFFITHS AD, 1994, EMBO J, V13, P3245, DOI 10.1002/j.1460-2075.1994.tb06626.x; HAN IS, 1993, MOL ENDOCRINOL, V7, P889, DOI 10.1210/me.7.7.889; Hanes J, 2000, NAT BIOTECHNOL, V18, P1287, DOI 10.1038/82407; HECHT D, 1995, GROWTH FACTORS, V12, P223, DOI 10.3109/08977199509036882; HOLLIGER P, 1993, P NATL ACAD SCI USA, V90, P6444, DOI 10.1073/pnas.90.14.6444; HOOGENBOOM HR, 1992, J MOL BIOL, V227, P381, DOI 10.1016/0022-2836(92)90894-P; JAFFERS GJ, 1986, TRANSPLANTATION, V41, P572, DOI 10.1097/00007890-198605000-00004; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jirholt P, 1998, GENE, V215, P471, DOI 10.1016/S0378-1119(98)00317-5; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; Kanai M, 1997, J BIOL CHEM, V272, P6621, DOI 10.1074/jbc.272.10.6621; KLEIN M, 1979, BIOCHEMISTRY-US, V18, P1473, DOI 10.1021/bi00575a014; KLINT P, 1999, FRONT BIOSCI, V4, P165; Knappik A, 2000, J MOL BIOL, V296, P57, DOI 10.1006/jmbi.1999.3444; KNAPPIK A, 1993, BIO-TECHNOL, V11, P77, DOI 10.1038/nbt0193-77; Kohfeldt E, 1997, FEBS LETT, V414, P557, DOI 10.1016/S0014-5793(97)01070-3; KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0; Krebs B, 2001, J IMMUNOL METHODS, V254, P67, DOI 10.1016/S0022-1759(01)00398-2; Kretzschmar T, 2002, CURR OPIN BIOTECH, V13, P598, DOI 10.1016/S0958-1669(02)00380-4; Li ZH, 2001, BLOOD, V97, P2413, DOI 10.1182/blood.V97.8.2413; LOHNING C, 2000, Patent No. 0105950; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MARKS JD, 1993, BIO-TECHNOL, V11, P1145, DOI 10.1038/nbt1093-1145; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; Monsonego-Ornan E, 2000, MOL CELL BIOL, V20, P516, DOI 10.1128/MCB.20.2.516-522.2000; MOVVA NR, 1980, J BIOL CHEM, V255, P27; Nagy ZA, 2002, NAT MED, V8, P801, DOI 10.1038/nm736; NARAMURA M, 1993, CANCER IMMUNOL IMMUN, V37, P343, DOI 10.1007/BF01518458; Naski M.C., 1998, FRONT BIOSCI-LANDMRK, V3, pd781, DOI [10.2741/a321, DOI 10.2741/A321]; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; NISSIM A, 1994, EMBO J, V13, P692, DOI 10.1002/j.1460-2075.1994.tb06308.x; Park BW, 2000, NAT BIOTECHNOL, V18, P194, DOI 10.1038/72651; PERELSON AS, 1989, IMMUNOL REV, V110, P5, DOI 10.1111/j.1600-065X.1989.tb00025.x; PerezCastro AV, 1997, GENOMICS, V41, P10, DOI 10.1006/geno.1997.4616; PETERS K, 1993, DEV BIOL, V155, P423, DOI 10.1006/dbio.1993.1040; PICKEN RN, 1983, INFECT IMMUN, V42, P269, DOI 10.1128/IAI.42.1.269-275.1983; PRICKETT KS, 1989, BIOTECHNIQUES, V7, P580; Pritchard MP, 1997, ARCH BIOCHEM BIOPHYS, V345, P342, DOI 10.1006/abbi.1997.0265; Robinson D, 1999, CLIN ORTHOP RELAT R, pS163; ROWE ES, 1976, BIOCHEMISTRY-US, V15, P905, DOI 10.1021/bi00649a028; SANNA PP, 1995, P NATL ACAD SCI USA, V92, P6439, DOI 10.1073/pnas.92.14.6439; Sblattero D, 2000, NAT BIOTECHNOL, V18, P75, DOI 10.1038/71958; Schmidt TGM, 1996, J MOL BIOL, V255, P753, DOI 10.1006/jmbi.1996.0061; Sheets MD, 1998, P NATL ACAD SCI USA, V95, P6157, DOI 10.1073/pnas.95.11.6157; SHIANG R, 1994, CELL, V78, P335, DOI 10.1016/0092-8674(94)90302-6; Sibley K, 2002, BRIT J HAEMATOL, V118, P514, DOI 10.1046/j.1365-2141.2002.03618.x; SKERRA A, 1991, PROTEIN ENG, V4, P971, DOI 10.1093/protein/4.8.971; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; Sleeman M, 2001, GENE, V271, P171, DOI 10.1016/S0378-1119(01)00518-2; SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944; Soderlind E, 2000, NAT BIOTECHNOL, V18, P852, DOI 10.1038/78458; Stratowa C, 1999, ANTI-CANCER DRUG DES, V14, P393; TAVORMINA PL, 1995, HUM MOL GENET, V4, P2175, DOI 10.1093/hmg/4.11.2175; van Rhijn BWG, 2002, J PATHOL, V198, P245, DOI 10.1002/path.1202; Vaughan TJ, 1996, NAT BIOTECHNOL, V14, P309, DOI 10.1038/nbt0396-309; VENKATESWARAN S, 1992, HYBRIDOMA, V11, P729, DOI 10.1089/hyb.1992.11.729; VIRNEKAS B, 1994, NUCLEIC ACIDS RES, V22, P5600, DOI 10.1093/nar/22.25.5600; Voss S, 1997, PROTEIN ENG, V10, P975, DOI 10.1093/protein/10.8.975; Wang Q, 2000, MECH DEVELOP, V90, P283, DOI 10.1016/S0925-4773(99)00241-5; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; WEIDNER KM, 1992, J BIOL CHEM, V267, P10281; Witte L, 1998, CANCER METAST REV, V17, P155, DOI 10.1023/A:1006094117427; WU TT, 1993, PROTEINS, V16, P1, DOI 10.1002/prot.340160102; Yang XD, 1999, CANCER RES, V59, P1236; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	90	99	160	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38194	38205		10.1074/jbc.M303164200	http://dx.doi.org/10.1074/jbc.M303164200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12842902	hybrid			2022-12-27	WOS:000185575100015
J	van Hennik, PB; ten Klooster, JP; Halstead, JR; Voermans, C; Anthony, EC; Divecha, N; Hordijk, PL				van Hennik, PB; ten Klooster, JP; Halstead, JR; Voermans, C; Anthony, EC; Divecha, N; Hordijk, PL			The C-terminal domain of Rac1 contains two motifs that control targeting and signaling specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CELL ADHESION; RHO GTPASES; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; ACTIVATION; MIGRATION; PAK; TRANSFORMATION; ABNORMALITIES; ESTABLISHMENT; ASSOCIATION	Rho-like GTPases control a wide range of cellular functions such as integrin- and cadherin-mediated adhesion, cell motility, and gene expression. The hypervariable C-terminal domain of these GTPases has been implicated in membrane association and effector binding. We found that cell-permeable peptides, encoding the C termini of Rac1, Rac2, RhoA, and Cdc42, interfere with GTPase signaling in a specific fashion in a variety of cellular models. Pull-down assays showed that the C terminus of Rac1 does not associate to either RhoGDI or to Pak. In contrast, the C terminus of Rac1 (but not Rac2 or Cdc42) binds to phosphatidylinositol 4,5-phosphate kinase (PIP5K) via amino acids 185-187 (RKR). Moreover, Rac1 associates to the adapter protein Crk via the N-terminal Src homology 3 (SH3) domain of Crk and the proline-rich stretch in the Rac1 C terminus. These differential interactions mediate Rac1 localization, as well as Rac1 signaling, toward membrane ruffling, cell-cell adhesion, and migration. These data show that the C-terminal, hypervariable domain of Rac1 encodes two distinct binding motifs for signaling proteins and regulates intracellular targeting and differential signaling in a unique and non-redundant fashion.	CLB, Sanquin Res, Dept Expt Immunohematol, NL-1066 CX Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Landsteiner Lab, NL-1066 CX Amsterdam, Netherlands; Netherlands Canc Inst, Div Cellular Biochem, NL-1066 CX Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Netherlands Cancer Institute	Hordijk, PL (corresponding author), CLB, Sanquin Res, Dept Expt Immunohematol, Plesmanlaan 125, NL-1066 CX Amsterdam, Netherlands.	p.hordijk@sanquin.nl	Voermans, Carlijn/GPP-3405-2022	Hordijk, Peter/0000-0002-3348-078X; divecha, nullin/0000-0001-9695-6039; ten Klooster, Jean Paul/0000-0002-4979-7482				Alblas J, 2001, MOL BIOL CELL, V12, P2137, DOI 10.1091/mbc.12.7.2137; Braga VMM, 1997, J CELL BIOL, V137, P1421, DOI 10.1083/jcb.137.6.1421; Cho SY, 2002, J CELL BIOL, V156, P725, DOI 10.1083/jcb.200111032; Croker BA, 2002, IMMUNOL CELL BIOL, V80, P231, DOI 10.1046/j.1440-1711.2002.01077.x; Croker BA, 2002, J IMMUNOL, V168, P3376, DOI 10.4049/jimmunol.168.7.3376; del Pozo MA, 2000, EMBO J, V19, P2008, DOI 10.1093/emboj/19.9.2008; del Pozo MA, 1999, EUR J IMMUNOL, V29, P3609; Divecha N, 2002, CURR BIOL, V12, P582, DOI 10.1016/S0960-9822(02)00769-8; Divecha N, 2000, EMBO J, V19, P5440, DOI 10.1093/emboj/19.20.5440; Feller SM, 2001, ONCOGENE, V20, P6348, DOI 10.1038/sj.onc.1204779; GREEN M, 1988, CELL, V55, P1179, DOI 10.1016/0092-8674(88)90262-0; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; HEYWORTH PG, 1994, J BIOL CHEM, V269, P30749; Ho A, 2001, CANCER RES, V61, P474; Hordijk PL, 1997, SCIENCE, V278, P1464, DOI 10.1126/science.278.5342.1464; Insall RH, 2001, DEV CELL, V1, P743, DOI 10.1016/S1534-5807(01)00086-7; Kiyokawa E, 1997, CRIT REV ONCOGENESIS, V8, P329, DOI 10.1615/CritRevOncog.v8.i4.30; Knaus UG, 1998, J BIOL CHEM, V273, P21512, DOI 10.1074/jbc.273.34.21512; Kodama A, 1999, ONCOGENE, V18, P3996, DOI 10.1038/sj.onc.1202773; Kreck ML, 1996, BIOCHEMISTRY-US, V35, P15683, DOI 10.1021/bi962064l; Li W, 2001, ONCOGENE, V20, P6403, DOI 10.1038/sj.onc.1204782; Manser E, 1998, MOL CELL, V1, P183, DOI 10.1016/S1097-2765(00)80019-2; Mayer BJ, 2001, J CELL SCI, V114, P1253; Michaelson D, 2001, J CELL BIOL, V152, P111, DOI 10.1083/jcb.152.1.111; Nievers MG, 1997, J CELL SCI, V110, P389; Olofsson B, 1999, CELL SIGNAL, V11, P545, DOI 10.1016/S0898-6568(98)00063-1; Pike LJ, 1998, J BIOL CHEM, V273, P22298, DOI 10.1074/jbc.273.35.22298; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; Roberts AW, 1999, IMMUNITY, V10, P183, DOI 10.1016/S1074-7613(00)80019-9; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Rozelle AL, 2000, CURR BIOL, V10, P311, DOI 10.1016/S0960-9822(00)00384-5; Sander EE, 1999, J CELL BIOL, V147, P1009, DOI 10.1083/jcb.147.5.1009; Takaishi K, 1997, J CELL BIOL, V139, P1047, DOI 10.1083/jcb.139.4.1047; Tao W, 2002, BLOOD, V100, P1679, DOI 10.1182/blood.V100.5.1679.h81702001679_1679_1688; Tolias KF, 2000, CURR BIOL, V10, P153, DOI 10.1016/S0960-9822(00)00315-8; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; van Wetering S, 2002, J CELL SCI, V115, P1837; Vastrik I, 1999, CURR BIOL, V9, P991, DOI 10.1016/S0960-9822(99)80447-3; Voermans C, 1999, EXP HEMATOL, V27, P1806, DOI 10.1016/S0301-472X(99)00113-7; Voermans C, 2001, EXP HEMATOL, V29, P1456, DOI 10.1016/S0301-472X(01)00740-8; Westwick JK, 1997, MOL CELL BIOL, V17, P1324, DOI 10.1128/MCB.17.3.1324; Worthylake RA, 2001, J CELL BIOL, V154, P147, DOI 10.1083/jcb.200103048; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; Zondag GCM, 2000, J CELL BIOL, V149, P775, DOI 10.1083/jcb.149.4.775	44	86	87	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39166	39175		10.1074/jbc.M307001200	http://dx.doi.org/10.1074/jbc.M307001200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874273	hybrid			2022-12-27	WOS:000185575100130
J	Calero, G; Gupta, P; Nonato, MC; Tandel, S; Biehl, ER; Hofmann, SL; Clardy, J				Calero, G; Gupta, P; Nonato, MC; Tandel, S; Biehl, ER; Hofmann, SL; Clardy, J			The crystal structure of palmitoyl protein thioesterase-2 (PPT2) reveals the basis for divergent substrate specificities of the two lysosomal thioesterases, PPT1 and PPT2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; MOLECULAR-CLONING; OPEN CONFORMATION; LIPASE; EXPRESSION; MUTATIONS	Mutations in palmitoyl protein thioesterase-1 (PPT1) have been found to cause the infantile form of neuronal ceroid lipofuscinosis, which is a lysosomal storage disorder characterized by impaired degradation of fatty acid-modified proteins with accumulation of amorphous granular deposits in cortical neurons, leading to mental retardation and death. Palmitoyl protein thioesterase-2 (PPT2) is a second lysosomal hydrolase that shares a 26% identity with PPT1. A previous study had suggested that palmitoyl-CoA was the preferred substrate of PPT2. Furthermore, PPT2 did not hydrolyze palmitate from the several S-palmitoylated protein substrates. Interestingly, PPT2 deficiency in a recent transgenic mouse model is associated with a form of neuronal ceroid lipofuscinosis, suggesting that PPT1 and -2 perform nonredundant roles in lysosomal thioester catabolism. In the current paper, we present the crystal structure of PPT2 at a resolution of 2.7 Angstrom. Comparisons of the structures of PPT1 and - 2 show very similar architectural features; however, conformational differences in helix alpha4 lead to a solvent-exposed lipid-binding groove in PPT1. The limited space between two parallel loops (beta3-alphaA and beta8-alphaF) located immediately above the lipid-binding groove in PPT2 restricts the binding of fatty acids with bulky head groups, and this binding groove is significantly larger in PPT1. This structural difference accounts for the ability of PPT2 to hydrolyze an unbranched structure such as palmitoyl-CoA but not palmitoylcysteine or palmitoylated proteins. Furthermore, differences in fatty acid chain length specificity of PPT1 and - 2, also reported here, are explained by the structure and may provide a biochemical basis for their non-redundant roles.	Cornell Univ, Dept Chem & Biol Chem, Ithaca, NY 14853 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; So Methodist Univ, Dept Chem, Dallas, TX 75275 USA	Cornell University; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Southern Methodist University	Clardy, J (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.		Nonato, Maria Cristina C/C-5659-2012	Nonato, Maria Cristina C/0000-0002-4916-1505	NCI NIH HHS [CA59021] Funding Source: Medline; NINDS NIH HHS [NS35323] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA059021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035323] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTON GJ, 1993, PROTEIN ENG, V6, P37, DOI 10.1093/protein/6.1.37; Bellizzi JJ, 2000, P NATL ACAD SCI USA, V97, P4573, DOI 10.1073/pnas.080508097; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMP LA, 1993, J BIOL CHEM, V268, P22566; CAMP LA, 1994, J BIOL CHEM, V269, P23212; CHRISTOPHER JA, 1998, SPOCK; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Das AK, 2000, J BIOL CHEM, V275, P23847, DOI 10.1074/jbc.M002758200; Devedjiev Y, 2000, STRUCTURE, V8, P1137, DOI 10.1016/S0969-2126(00)00529-3; Esnouf R. M., 1997, J MOL GRAPHICS, V15, P133; Gupta P, 2001, P NATL ACAD SCI USA, V98, P13566, DOI 10.1073/pnas.251485198; Hofmann SL, 1999, MOL GENET METAB, V66, P234, DOI 10.1006/mgme.1999.2803; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; Knudsen J, 1981, Methods Enzymol, V71 Pt C, P200, DOI 10.1016/0076-6879(81)71028-0; Lang D, 1996, J MOL BIOL, V259, P704, DOI 10.1006/jmbi.1996.0352; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mitchison HM, 1998, HUM MOL GENET, V7, P291, DOI 10.1093/hmg/7.2.291; Nardini M, 2000, J BIOL CHEM, V275, P31219, DOI 10.1074/jbc.M003903200; NOBLE MEM, 1993, FEBS LETT, V331, P123, DOI 10.1016/0014-5793(93)80310-Q; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peltonen L, 2000, CURR OPIN GENET DEV, V10, P299, DOI 10.1016/S0959-437X(00)00086-1; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Schrag JD, 1997, STRUCTURE, V5, P187, DOI 10.1016/S0969-2126(97)00178-0; Soyombo AA, 1997, J BIOL CHEM, V272, P27456, DOI 10.1074/jbc.272.43.27456; van Diggelen OP, 1999, MOL GENET METAB, V66, P240, DOI 10.1006/mgme.1999.2809; VESA J, 1995, NATURE, V376, P584, DOI 10.1038/376584a0	28	32	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37957	37964		10.1074/jbc.M301225200	http://dx.doi.org/10.1074/jbc.M301225200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855696	hybrid			2022-12-27	WOS:000185437200118
J	Cattaruzza, M; Slodowski, W; Stojakovic, M; Krzesz, R; Hecker, M				Cattaruzza, M; Slodowski, W; Stojakovic, M; Krzesz, R; Hecker, M			Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENE-EXPRESSION; INHIBITION; CYTOKINES; IL-10; D-3	Interleukin-10 (IL-10) is a potent anti-inflammatory cytokine in Th1 cell-mediated chronic inflammatory diseases such as, e. g. Crohn's disease. Moreover, IL-10 has been shown to limit the progression of atherosclerosis, presumably by influencing endothelial cell function. Here we demonstrate that under pro-inflammatory conditions expression of the human IL-10 receptor gene is enhanced in endothelial cells in vitro and in vivo. Subsequent exposure to IL-10 results in an up-regulation of both endothelial nitric-oxide synthase (NOS-3) expression and activity. Gel mobility shift analyses and decoy oligonucleotide experiments suggest that this effect of IL-10 is mediated through activation of the transcription factor STAT-3 ( signal transducer and activator of transcription-3). One functional consequence of IL-10 up-regulation of NOS-3 abundance in cultured endothelial cells is the attenuation of CD154-induced IL-12 p40 expression. Moreover, CD154-induced IL-12 p40 expression is enhanced after blockade of NOS-3 activity but attenuated in the presence of exogenous nitric oxide. Increased NOS-3 expression may, thus, be one mechanism by which IL-10 exerts its anti-inflammatory effects in Th1 cell-mediated chronic inflammatory diseases.	Univ Gottingen, Sch Med, Dept Cardiovasc Physiol, D-37073 Gottingen, Germany	University of Gottingen	Hecker, M (corresponding author), Univ Gottingen, Sch Med, Dept Cardiovasc Physiol, Humboldtallee 23, D-37073 Gottingen, Germany.	hecker@veg-physiol.med.uni-goettingen.de						Asadullah K, 1999, ARCH DERMATOL, V135, P187, DOI 10.1001/archderm.135.2.187; Busse R, 1996, J VASC RES, V33, P181, DOI 10.1159/000159147; Cattaruzza M, 2000, BRIT J PHARMACOL, V129, P1155, DOI 10.1038/sj.bjp.0703192; Clark A, 2000, ARTHRITIS RES, V2, P172, DOI 10.1186/ar83; Fedorak RN, 2000, GASTROENTEROLOGY, V119, P1473, DOI 10.1053/gast.2000.20229; Gunnett CA, 2000, AM J PHYSIOL-HEART C, V279, pH1555, DOI 10.1152/ajpheart.2000.279.4.H1555; Harrison DG, 1997, CLIN CARDIOL, V20, P11; HECKER M, 1994, N-S ARCH PHARMACOL, V351, P426; Jirapongsananuruk O, 2000, J ALLERGY CLIN IMMUN, V106, P981, DOI 10.1067/mai.2000.110101; Kelm M, 1999, BBA-BIOENERGETICS, V1411, P273, DOI 10.1016/S0005-2728(99)00020-1; Kinlay S, 2001, CURR OPIN LIPIDOL, V12, P383, DOI 10.1097/00041433-200108000-00003; Kotenko SV, 1997, EMBO J, V16, P5894, DOI 10.1093/emboj/16.19.5894; Krieglstein CF, 2001, AM J HYPERTENS, V14, p44S, DOI 10.1016/S0895-7061(01)02069-6; Krzesz R, 1999, FEBS LETT, V453, P191, DOI 10.1016/S0014-5793(99)00683-3; Kubes P, 2000, AM J MED, V109, P150, DOI 10.1016/S0002-9343(00)00480-0; Lee TS, 1999, ARTERIOSCL THROM VAS, V19, P734, DOI 10.1161/01.ATV.19.3.734; Libby P, 1995, J CARDIOVASC PHARM, V25, pS9, DOI 10.1097/00005344-199500252-00003; Lienenluke B, 2000, EUR J IMMUNOL, V30, P2864, DOI 10.1002/1521-4141(200010)30:10<2864::AID-IMMU2864>3.0.CO;2-W; Madsen KL, 1999, INFLAMM BOWEL DIS, V5, P262, DOI 10.1097/00054725-199911000-00004; Mallat Z, 1999, CIRC RES, V85, pE17, DOI 10.1161/01.RES.85.8.e17; Michel G, 1997, INFLAMM RES, V46, P32, DOI 10.1007/s000110050042; Morishita R, 1998, CIRC RES, V82, P1023, DOI 10.1161/01.RES.82.10.1023; Romagnani P, 1997, CURR OPIN IMMUNOL, V9, P793, DOI 10.1016/S0952-7915(97)80180-X; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; Shevach EM, 1999, SPRINGER SEMIN IMMUN, V21, P249, DOI 10.1007/s002810050066; Southan GJ, 1996, BIOCHEM PHARMACOL, V51, P383, DOI 10.1016/0006-2952(95)02099-3; Suzuki A, 2001, J EXP MED, V193, P471, DOI 10.1084/jem.193.4.471; Uyemura K, 1996, J CLIN INVEST, V97, P2130, DOI 10.1172/JCI118650; von der Thusen JH, 2001, FASEB J, V15, P2730, DOI 10.1096/fj.01-0483fje; Wagner AH, 2001, FASEB J, V15, P2121, DOI 10.1096/fj.01-0123com; Wagner AH, 2002, BRIT J PHARMACOL, V136, P143, DOI 10.1038/sj.bjp.0704678	31	44	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37874	37880		10.1074/jbc.M301670200	http://dx.doi.org/10.1074/jbc.M301670200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857749	hybrid			2022-12-27	WOS:000185437200108
J	Keramaris, E; Hirao, A; Slack, RS; Mak, TW; Park, DS				Keramaris, E; Hirao, A; Slack, RS; Mak, TW; Park, DS			Ataxia telangiectasia-mutated protein can regulate p53 and neuronal death independent of Chk2 in response to DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CENTRAL-NERVOUS-SYSTEM; INDUCED CELL-DEATH; CORTICAL-NEURONS; INDUCED PHOSPHORYLATION; CYTOSINE-ARABINOSIDE; IONIZING-RADIATION; TUMOR-SUPPRESSOR; TRANSGENIC MICE; CASPASE 3	DNA damage is a key initiator of neuronal death. We have previously shown that the tumor suppressor p53, in conjunction with cyclin-dependent kinases (CDKs), regulates the mitochondrial pathway of death in neurons exposed to genotoxic agents. However, the mechanisms by which p53 is regulated is unclear. Presently, we show that p53 is phosphorylated on Ser-15 following DNA damage and this occurs independently of the CDK pathway. Instead, we show that p53 phosphorylation, stability, as well as neuronal death is regulated, in part, by the ataxia telangiectasia-mutated (ATM) protein. Previous reports have suggested that ATM regulation of p53 occurs through Chk2. However, in our present paradigms, we show that ATM functions separately from Chk2 to regulate p53 stability and neuronal death. Chk2 deficiency does not affect p53 stability or neuronal death induced by Topoisomerase I or II inhibition. Taken together, our results provide a model by which DNA damage can activate an ATM-dependent, Chk2-independent pathway of p53-mediated neuronal death.	Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Res Program, Ottawa, ON K1H 8M5, Canada; Univ Toronto, Ontario Canc Inst, Dept Med Biophys, Toronto, ON M5G 2C1, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Park, DS (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Neurosci Res Program, Ottawa, ON K1H 8M5, Canada.	dpark@uottawa.ca		Slack, Ruth/0000-0002-1552-2835; Park, David/0000-0002-4490-3784				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bates S, 1998, NATURE, V395, P124, DOI 10.1038/25867; Brouillet E, 1999, PROG NEUROBIOL, V59, P427, DOI 10.1016/S0301-0082(99)00005-2; Burns TF, 1999, J CELL PHYSIOL, V181, P231, DOI 10.1002/(SICI)1097-4652(199911)181:2<231::AID-JCP5>3.0.CO;2-L; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Caspari T, 2000, CURR BIOL, V10, pR315, DOI 10.1016/S0960-9822(00)00439-5; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; CRUMRINE RC, 1994, J CEREBR BLOOD F MET, V14, P887, DOI 10.1038/jcbfm.1994.119; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Dumaz N, 2001, BIOCHEM J, V359, P459, DOI 10.1042/0264-6021:3590459; Fortin A, 2001, J CELL BIOL, V155, P207, DOI 10.1083/jcb.200105137; Ghahremani MH, 2002, J BIOL CHEM, V277, P35586, DOI 10.1074/jbc.M204362200; Giovanni A, 2000, J BIOL CHEM, V275, P11553, DOI 10.1074/jbc.275.16.11553; Grunewald T, 1999, NAT MED, V5, P1354, DOI 10.1038/70918; Heintz N, 1996, CURR OPIN NEUROL, V9, P137, DOI 10.1097/00019052-199604000-00014; Herzog KH, 1998, SCIENCE, V280, P1089, DOI 10.1126/science.280.5366.1089; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Johnson MD, 1999, J NEUROSCI, V19, P2996; Keramaris E, 2000, MOL CELL NEUROSCI, V15, P368, DOI 10.1006/mcne.2000.0838; Khosravi R, 1999, P NATL ACAD SCI USA, V96, P14973, DOI 10.1073/pnas.96.26.14973; Liu QH, 2000, GENE DEV, V14, P1448; Mandir AS, 1999, P NATL ACAD SCI USA, V96, P5774, DOI 10.1073/pnas.96.10.5774; MANSFIELD SH, 1994, AM J NEURORADIOL, V15, P1178; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; McGahan L, 1998, MOL BRAIN RES, V56, P133, DOI 10.1016/S0169-328X(98)00038-2; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; Morris EJ, 2001, J NEUROSCI, V21, P5017, DOI 10.1523/JNEUROSCI.21-14-05017.2001; Morrison RS, 1996, J NEUROSCI, V16, P1337; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Park DS, 1998, J CELL BIOL, V143, P457, DOI 10.1083/jcb.143.2.457; Park DS, 2000, J NEUROSCI, V20, P3104, DOI 10.1523/JNEUROSCI.20-09-03104.2000; SAKHI S, 1994, P NATL ACAD SCI USA, V91, P7525, DOI 10.1073/pnas.91.16.7525; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Shieh SY, 2000, GENE DEV, V14, P289; Shiloh Y, 1996, J CLIN IMMUNOL, V16, P254, DOI 10.1007/BF01541389; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Stefanis L, 1996, J BIOL CHEM, V271, P30663, DOI 10.1074/jbc.271.48.30663; Takai H, 2000, GENE DEV, V14, P1439; Trimmer PA, 1996, NEURODEGENERATION, V5, P233, DOI 10.1006/neur.1996.0031; VOGEL H, 1993, CANCER, V71, P1303, DOI 10.1002/1097-0142(19930215)71:4<1303::AID-CNCR2820710422>3.0.CO;2-6; WINKELMAN MD, 1983, ANN NEUROL, V14, P520, DOI 10.1002/ana.410140505; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002; Xiang H, 1996, J NEUROSCI, V16, P6753; Xiang H, 1998, J NEUROSCI, V18, P1363	49	38	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37782	37789		10.1074/jbc.M304049200	http://dx.doi.org/10.1074/jbc.M304049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857758	hybrid			2022-12-27	WOS:000185437200097
J	Lee, JY; Ye, JP; Gao, ZG; Youn, HS; Lee, WH; Zhao, L; Sizemore, N; Hwang, DH				Lee, JY; Ye, JP; Gao, ZG; Youn, HS; Lee, WH; Zhao, L; Sizemore, N; Hwang, DH			Reciprocal modulation of toll-like receptor-4 signaling pathways involving MyD88 and phosphatidylinositol 3-kinase/AKT by saturated and polyunsaturated fatty acids	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; MITOGEN-INDUCIBLE CYCLOOXYGENASE; CONFERS LIPOPOLYSACCHARIDE RESPONSIVENESS; ACTIVATED PROTEIN-KINASE; INNATE IMMUNE-RESPONSE; HUMAN COLON-CANCER; ADAPTER PROTEIN; CPG-DNA; TRANSCRIPTIONAL ACTIVITY; RELA/P65 SUBUNIT	Toll-like receptor-4 (TLR4) can be activated by non-bacterial agonists, including saturated fatty acids. However, downstream signaling pathways activated by non-bacterial agonists are not known. Thus, we determined the downstream signaling pathways derived from saturated fatty acid-induced TLR4 activation. Saturated fatty acid (lauric acid)-induced NFkappaB activation was inhibited by a dominant-negative mutant of TLR4, MyD88, IRAK-1, TRAF6, or IkappaBalpha in macrophages (RAW264.7) and 293T cells transfected with TLR4 and MD2. Lauric acid induced the transient phosphorylation of AKT. LY294002, dominant-negative (DN) phosphatidylinositol 3-kinase (PI3K), or AKT(DN) inhibited NFkappaB activation, p65 transactivation, and cyclooxygenase-2 (COX-2) expression induced by lauric acid or constitutively active (CA) TLR4. AKT(DN) blocked MyD88-induced NFkappaB activation, suggesting that AKT is a MyD88-dependent downstream signaling component of TLR4. AKT(CA) was sufficient to induce NFkappaB activation and COX-2 expression. These results demonstrate that NFkappaB activation and COX-2 expression induced by lauric acid are at least partly mediated through the TLR4/PI3K/AKT signaling pathway. In contrast, docosahexaenoic acid (DHA) inhibited the phosphorylation of AKT induced by lipopolysaccharide or lauric acid. DHA also suppressed NFkappaB activation induced by TLR4(CA), but not MyD88(CA) or AKT(CA), suggesting that the molecular targets of DHA are signaling components upstream of MyD88 and AKT. Together, these results suggest that saturated and polyunsaturated fatty acids reciprocally modulate the activation of TLR4 and its downstream signaling pathways involving MyD88/IRAK/TRAF6 and PI3K/AKT and further suggest the possibility that TLR4-mediated target gene expression and cellular responses are also differentially modulated by saturated and unsaturated fatty acids.	ARS, Western Human Nutr Res Ctr, USDA, Davis, CA 95616 USA; Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Cleveland Clin Fdn, Cleveland, OH 44195 USA	United States Department of Agriculture (USDA); University of California System; University of California Davis; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Cleveland Clinic Foundation	Hwang, DH (corresponding author), ARS, Western Human Nutr Res Ctr, USDA, Meyer Hall,1 Shields Ave, Davis, CA 95616 USA.		Ye, Jianping/N-1998-2017	Ye, Jianping/0000-0003-3875-365X	NCI NIH HHS [CA75613] Funding Source: Medline; NIDDK NIH HHS [DK41868] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075613] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041868] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Akira S, 2003, CURR OPIN IMMUNOL, V15, P5, DOI 10.1016/S0952-7915(02)00013-4; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexopoulou L, 2001, NATURE, V413, P732, DOI 10.1038/35099560; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Burns K, 1998, J BIOL CHEM, V273, P12203, DOI 10.1074/jbc.273.20.12203; Byrd-Leifer CA, 2001, EUR J IMMUNOL, V31, P2448, DOI 10.1002/1521-4141(200108)31:8&lt;2448::AID-IMMU2448&gt;3.0.CO;2-N; Cardone MH, 1998, SCIENCE, V282, P1318, DOI 10.1126/science.282.5392.1318; CHANMUGAM P, 1995, J BIOL CHEM, V270, P5418, DOI 10.1074/jbc.270.10.5418; Chuang TH, 2000, EUR CYTOKINE NETW, V11, P372; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Du X, 2000, EUR CYTOKINE NETW, V11, P362; EBERHART CE, 1994, GASTROENTEROLOGY, V107, P1183, DOI 10.1016/0016-5085(94)90246-1; Faure E, 2000, J BIOL CHEM, V275, P11058, DOI 10.1074/jbc.275.15.11058; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Fruman DA, 1999, BIOCHEM SOC T, V27, P624, DOI 10.1042/bst0270624; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; HAZIOT A, 1988, J IMMUNOL, V141, P547; Hemmi H, 2002, NAT IMMUNOL, V3, P196, DOI 10.1038/ni758; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hwang D, 1998, J NATL CANCER I, V90, P455, DOI 10.1093/jnci/90.6.455; Hwang D, 1997, BIOCHEM PHARMACOL, V54, P87, DOI 10.1016/S0006-2952(97)00154-8; Ishii KJ, 2002, J EXP MED, V196, P269, DOI 10.1084/jem.20020773; Jefferies CA, 2000, J BIOL CHEM, V275, P3114, DOI 10.1074/jbc.275.5.3114; Jiang QQ, 2000, J IMMUNOL, V165, P3541, DOI 10.4049/jimmunol.165.7.3541; Kaisho T, 2001, J IMMUNOL, V166, P5688, DOI 10.4049/jimmunol.166.9.5688; KARGMAN SL, 1995, CANCER RES, V55, P2556; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KITCHENS RL, 1992, J EXP MED, V176, P485, DOI 10.1084/jem.176.2.485; Koul D, 2001, J BIOL CHEM, V276, P11402, DOI 10.1074/jbc.M007806200; KRAUSS JH, 1989, EUR J BIOCHEM, V180, P519, DOI 10.1111/j.1432-1033.1989.tb14677.x; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lee JY, 2003, J LIPID RES, V44, P479, DOI 10.1194/jlr.M200361-JLR200; Lee JY, 2001, J BIOL CHEM, V276, P16683, DOI 10.1074/jbc.M011695200; LEE SH, 1992, J BIOL CHEM, V267, P25934; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Manna SK, 2000, FEBS LETT, V473, P113, DOI 10.1016/S0014-5793(00)01501-5; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Monick MM, 2001, J IMMUNOL, V166, P4713, DOI 10.4049/jimmunol.166.7.4713; MUNFORD RS, 1986, SCIENCE, V234, P203, DOI 10.1126/science.3529396; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Ojaniemi M, 2003, EUR J IMMUNOL, V33, P597, DOI 10.1002/eji.200323376; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Ozes ON, 1999, NATURE, V401, P82; Paik JH, 2000, J BIOL CHEM, V275, P28173; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; QURESHI N, 1991, INFECT IMMUN, V59, P441, DOI 10.1128/IAI.59.1.441-444.1991; Qureshi ST, 1999, J EXP MED, V189, P615, DOI 10.1084/jem.189.4.615; Reddy SAG, 2000, J IMMUNOL, V164, P1355, DOI 10.4049/jimmunol.164.3.1355; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; Salh B, 1998, J IMMUNOL, V161, P6947; SANO H, 1995, CANCER RES, V55, P3785; Schnare M, 2000, CURR BIOL, V10, P1139, DOI 10.1016/S0960-9822(00)00700-4; Seki E, 2001, J IMMUNOL, V166, P2651, DOI 10.4049/jimmunol.166.4.2651; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; Sizemore N, 1999, MOL CELL BIOL, V19, P4798; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Takeuchi O, 1999, GENE, V231, P59, DOI 10.1016/S0378-1119(99)00098-0; Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; WRIGHT SD, 1990, SCIENCE, V249, P1431, DOI 10.1126/science.1698311; Yamamoto M, 2002, NATURE, V420, P324, DOI 10.1038/nature01182; Yamamoto M, 2002, J IMMUNOL, V169, P6668, DOI 10.4049/jimmunol.169.12.6668; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	82	409	431	1	35	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37041	37051		10.1074/jbc.M305213200	http://dx.doi.org/10.1074/jbc.M305213200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865424	hybrid			2022-12-27	WOS:000185437200010
J	Cok, SJ; Acton, SJ; Morrison, AR				Cok, SJ; Acton, SJ; Morrison, AR			The proximal region of the 3 '-untranslated region of cyclooxygenase-2 is recognized by a multimeric protein complex containing HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; AU-RICH ELEMENT; CYTOPLASMIC SHUTTLING PROTEIN; BINDING PROTEIN; GENE-EXPRESSION; MESANGIAL CELLS; STABILIZATION; SEQUENCE; DESTABILIZATION; TRISTETRAPROLIN	Cyclooxygenase-2 (COX-2) is an early response gene induced in renal mesangial cells by interleukin-1beta (IL-1beta). The 3'-untranslated region (3'-UTR) of COX-2 mRNA plays an important role in IL-1beta induction by regulating message stability and translational efficiency. The first 60 nucleotides of the 3'-UTR of COX-2 are highly conserved and contain multiple copies of the regulatory sequence AUUUA. Introduction of the 60-nucleotide sequence into the 3'-UTR of a heterologous reporter gene resulted in a 70% decrease in reporter gene expression. Electrophoretic mobility shift assays (EMSAs) demonstrated that mesangial cell nuclear fractions contain a multimeric protein complex that bound this region of COX-2 mRNA in a sequence-specific manner. We identified four members of the protein-RNA complex as HuR, TIA-1, TIAR, and the heterogeneous nuclear ribonucleoprotein U (hnRNP U). Treatment of mesangial cells with IL-1beta caused an increase in cytosolic HuR, which was accompanied by an increase in COX-2 mRNA that co-immunoprecipitated with cytosolic HuR. Therefore, we propose that HuR binds to the proximal region of the 3'-UTR of COX-2 following stimulation by IL-1beta and increases the expression of COX-2 mRNA by facilitating its transport out of the nucleus.	Washington Univ, Sch Med, Wohl Clin, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Mol Biol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pharmacol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	Morrison, AR (corresponding author), Washington Univ, Sch Med, Wohl Clin, Dept Med, 4940 Parkview Pl,Rm 8843, St Louis, MO 63110 USA.	Morrison@pcg.wustl.edu			NIDDK NIH HHS [DK 59932] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059932] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Anant S, 2001, J BIOL CHEM, V276, P47338, DOI 10.1074/jbc.M104911200; Atasoy U, 1998, J CELL SCI, V111, P3145; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Chandrasekharan NV, 2002, P NATL ACAD SCI USA, V99, P13926, DOI 10.1073/pnas.162468699; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; DeMaria CT, 1996, J BIOL CHEM, V271, P12179, DOI 10.1074/jbc.271.21.12179; Dixon DA, 2000, J BIOL CHEM, V275, P11750, DOI 10.1074/jbc.275.16.11750; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; Eggert M, 1997, J BIOL CHEM, V272, P28471, DOI 10.1074/jbc.272.45.28471; Fan XHC, 1998, P NATL ACAD SCI USA, V95, P15293, DOI 10.1073/pnas.95.26.15293; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gou Q, 1998, BIOCHEM BIOPH RES CO, V242, P508, DOI 10.1006/bbrc.1997.7994; Guan ZH, 1996, AM J PHYSIOL-RENAL, V270, pF634, DOI 10.1152/ajprenal.1996.270.4.F634; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Hamilton BJN, 1997, J BIOL CHEM, V272, P28732, DOI 10.1074/jbc.272.45.28732; Jang BC, 2003, J BIOL CHEM, V278, P2773, DOI 10.1074/jbc.C200620200; Kedersha N, 2000, J CELL BIOL, V151, P1257, DOI 10.1083/jcb.151.6.1257; KILEDJIAN M, 1992, EMBO J, V11, P2655, DOI 10.1002/j.1460-2075.1992.tb05331.x; KRUYS V, 1994, BIOCHIMIE, V76, P862, DOI 10.1016/0300-9084(94)90188-0; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Loflin P, 1999, GENE DEV, V13, P1884, DOI 10.1101/gad.13.14.1884; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Ross J, 1996, TRENDS GENET, V12, P171, DOI 10.1016/0168-9525(96)10016-0; RZYMKIEWICZ D, 1994, AM J PHYSIOL, V266, pF39, DOI 10.1152/ajprenal.1994.266.1.F39; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; SRIVASTAVA SK, 1994, AM J PHYSIOL, V267, pF504, DOI 10.1152/ajprenal.1994.267.3.F504; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	40	120	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36157	36162		10.1074/jbc.M302547200	http://dx.doi.org/10.1074/jbc.M302547200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855701	hybrid			2022-12-27	WOS:000185318300036
J	Myers, FA; Chong, W; Evans, DR; Thorne, AW; Crane-Robinson, C				Myers, FA; Chong, W; Evans, DR; Thorne, AW; Crane-Robinson, C			Acetylation of histone H2B mirrors that of H4 and H3 at the chicken beta-globin locus but not at housekeeping genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN CHROMATIN-STRUCTURE; DNASE-I SENSITIVITY; CONTROL REGION; PROTEIN; TRANSCRIPTION; ACTIVATION; GAS41; HYPERACETYLATION; BOUNDARIES; INSULATOR	Acetylation of histones H4 and H3 targeted to promoters/ enhancers is linked to the activation of transcription, whereas widespread, long range acetylation of the same histones has been linked to the requirement for open chromatin at transcriptionally active loci and regions of V(D)J recombination. Using affinity-purified polyclonal antibodies to tetra/tri-acetylated histone H2B in chromatin immunoprecipitation (ChIP) assays with mononucleosomes from 15-day chicken embryo erythrocytes, a high resolution distribution of H2B acetylation has been determined and compared with that of H4 and H3 at the same genes/loci. At the beta-globin locus, the H2B acetylation is high throughout and in general mirrors that of H3 and H4, consistent with the observation of co-precipitation of hyperacetylated H4 together with the hyperacetylated H2B. In contrast, at the weakly expressed genes glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and Gas41 ( housekeeping) and carbonic anhydrase ( tissue specific), very little or no hyperacetylated H2B was found despite the presence of acetylated H4 and H3 at their promoters and proximal transcribed sequences. At the inactive lysozyme and ovalbumin genes essentially no acetylation of H2B, H3, or H4 was observed. Acetylation of H2B appears to be principally a feature of only the most actively transcribed genes/loci.	Univ Portsmouth, Fac Sci, Inst Biomed & Biomol Sci, Biophys Labs, Portsmouth PO1 2DT, Hants, England	University of Portsmouth	Crane-Robinson, C (corresponding author), Univ Portsmouth, Fac Sci, Inst Biomed & Biomol Sci, Biophys Labs, Portsmouth PO1 2DT, Hants, England.	colyn.crane-robinson@port.ac.uk	, thorne/AAC-4984-2020	, thorne/0000-0002-8670-2358; Myers, Fiona/0000-0001-5568-1817				Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bender MA, 2000, MOL CELL, V5, P387, DOI 10.1016/S1097-2765(00)80433-5; BOHM L, 1982, EUR J BIOCHEM, V123, P299, DOI 10.1111/j.1432-1033.1982.tb19767.x; Bonifer C, 1997, J BIOL CHEM, V272, P26075, DOI 10.1074/jbc.272.42.26075; BONNER WM, 1980, EUR J BIOCHEM, V109, P17, DOI 10.1111/j.1432-1033.1980.tb04762.x; Bresnick EH, 1997, P NATL ACAD SCI USA, V94, P4566, DOI 10.1073/pnas.94.9.4566; Bulger M, 2002, CURR OPIN GENET DEV, V12, P170, DOI 10.1016/S0959-437X(02)00283-6; Chong SY, 2002, NUCLEIC ACIDS RES, V30, P463, DOI 10.1093/nar/30.2.463; Chung JH, 1997, P NATL ACAD SCI USA, V94, P575, DOI 10.1073/pnas.94.2.575; CHUNG JH, 1993, CELL, V74, P505, DOI 10.1016/0092-8674(93)80052-G; Debernardi S, 2002, BLOOD, V99, P275, DOI 10.1182/blood.V99.1.275; Dorigo B, 2003, J MOL BIOL, V327, P85, DOI 10.1016/S0022-2836(03)00025-1; Elefant F, 2000, J BIOL CHEM, V275, P13827, DOI 10.1074/jbc.275.18.13827; Elefant F, 2000, EMBO J, V19, P6814, DOI 10.1093/emboj/19.24.6814; Epner E, 1998, MOL CELL, V2, P447, DOI 10.1016/S1097-2765(00)80144-6; Forsberg EC, 2001, BIOESSAYS, V23, P820, DOI 10.1002/bies.1117; Forsberg EC, 2000, P NATL ACAD SCI USA, V97, P14494, DOI 10.1073/pnas.97.26.14494; Harborth J, 2000, J BIOL CHEM, V275, P31979, DOI 10.1074/jbc.M000994200; HEBBES TR, 1989, MOL IMMUNOL, V26, P865, DOI 10.1016/0161-5890(89)90143-0; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HEBBES TR, 1994, EMBO J, V13, P1823, DOI 10.1002/j.1460-2075.1994.tb06451.x; HEBBES TR, 1988, EMBO J, V7, P1395, DOI 10.1002/j.1460-2075.1988.tb02956.x; Ho YG, 2002, MOL CELL, V9, P291, DOI 10.1016/S1097-2765(02)00447-1; Litt MD, 2001, EMBO J, V20, P2224, DOI 10.1093/emboj/20.9.2224; Litt MD, 2001, SCIENCE, V293, P2453, DOI 10.1126/science.1064413; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Myers FA, 2001, J BIOL CHEM, V276, P20197, DOI 10.1074/jbc.M009472200; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; Reik A, 1998, MOL CELL BIOL, V18, P5992, DOI 10.1128/MCB.18.10.5992; Saitoh N, 2000, EMBO J, V19, P2315, DOI 10.1093/emboj/19.10.2315; Schubeler D, 2000, GENE DEV, V14, P940; Schubeler D, 2001, P NATL ACAD SCI USA, V98, P11432, DOI 10.1073/pnas.201394698; Wu JS, 2001, MOL CELL, V7, P117, DOI 10.1016/S1097-2765(01)00160-5; Zimmermann K, 2002, J BIOL CHEM, V277, P18626, DOI 10.1074/jbc.M200572200	34	39	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36315	36322		10.1074/jbc.M305822200	http://dx.doi.org/10.1074/jbc.M305822200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865423	hybrid			2022-12-27	WOS:000185318300056
J	Venkataramaiah, TH; Plapp, BV				Venkataramaiah, TH; Plapp, BV			Formamides mimic aldehydes and inhibit liver alcohol dehydrogenases and ethanol metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID AMIDES; TERNARY COMPLEXES; BINDING; PYRAZOLE; 4-METHYLPYRAZOLE; NICOTINAMIDE; SPECIFICITY; SIMULATION; SULFOXIDES; CATALYSIS	Formamides are unreactive analogues of the aldehyde substrates of alcohol dehydrogenases and are useful for structure-function studies and for specific inhibition of alcohol metabolism. They bind to the enzyme-NADH complex and are uncompetitive inhibitors against varied concentrations of alcohol. Fourteen new branched chain and chiral formamides were prepared and tested as inhibitors of purified Class I liver alcohol dehydrogenases: horse (EqADH E), human (HsADH1C*2), and mouse (MmADH1). In general, larger, substituted formamides, such as N-1-ethylheptylformamide, are better inhibitors of HsADH1C*2 and MmADH1 than of EqADH, reflecting a few differences in amino acid residues that change the sizes of the active sites. In contrast, the linear, alkyl (n-propyl and n-butyl) formamides are better inhibitors of EqADH and MmADH1 than of HsADH1C*2, probably because water disrupts van der Waals interactions. These enzymes are also inhibited strongly by sulfoxides and 4-substituted pyrazoles. The structure of EqADH complexed with NADH and (R)-N-1-methylhexylformamide was determined by x-ray crystallography at 1.6 Angstrom resolution. The structure resembles the expected Michaelis complex with NADH and aldehyde, and shows for the first time that the reduced nicotinamide ring of NADH is puckered, as predicted for the transition state for hydride transfer. Metabolism of ethanol in mice was inhibited by several formamides. The data were fitted with kinetic simulation to a mechanism that describes the non-linear progress curves and yields estimates of the in vivo inhibition constants and the rate constants for elimination of inhibitors. Some small formamides, such as N-isopropylformamide, may be useful inhibitors in vivo.	Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA	University of Iowa	Plapp, BV (corresponding author), Univ Iowa, Dept Biochem, Iowa City, IA 52242 USA.	bv-plapp@uiowa.edu	Plapp, Bryce V/F-6353-2010; ID, IMCACAT/D-5867-2014		NIAAA NIH HHS [AA00279] Funding Source: Medline	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		ALMARSSON O, 1993, J AM CHEM SOC, V115, P2125, DOI 10.1021/ja00059a005; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARSHOP BA, 1983, ANAL BIOCHEM, V130, P134, DOI 10.1016/0003-2697(83)90660-7; BEASLEY VR, 1980, VET HUM TOXICOL, V22, P255; BEAVEN GH, 1952, ADV PROTEIN CHEM, V7, P319, DOI 10.1016/S0065-3233(08)60022-4; BOSRON WF, 1980, ENZYMATIC BASIS DETO, V1, P131; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; CHADHA VK, 1985, J MED CHEM, V28, P36, DOI 10.1021/jm00379a009; CHADHA VK, 1983, J MED CHEM, V26, P916, DOI 10.1021/jm00360a024; Charlier HA, 2000, J BIOL CHEM, V275, P11569, DOI 10.1074/jbc.275.16.11569; Cho H, 1998, BIOCHEMISTRY-US, V37, P4482, DOI 10.1021/bi9727040; Cho H, 1997, BIOCHEMISTRY-US, V36, P382, DOI 10.1021/bi9624604; CHOU JY, 1978, TOXICOL APPL PHARM, V43, P33, DOI 10.1016/S0041-008X(78)80030-1; Cleland W W, 1979, Methods Enzymol, V63, P103; DAHLBOM R, 1974, BIOCHEM BIOPH RES CO, V57, P549, DOI 10.1016/0006-291X(74)90581-6; DAMGAARD SE, 1982, EUR J BIOCHEM, V125, P593, DOI 10.1111/j.1432-1033.1982.tb06724.x; Davis GJ, 1996, J BIOL CHEM, V271, P17057, DOI 10.1074/jbc.271.29.17057; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; EDENBERG HJ, 1997, COMPREHENSIVE TOXICO, V3, P119; EKLUND H, 1982, J BIOL CHEM, V257, P4349; EKLUND H, 1982, BIOCHEMISTRY-US, V21, P4858, DOI 10.1021/bi00263a005; FREUDENREICH C, 1984, J AM CHEM SOC, V106, P3344, DOI 10.1021/ja00323a048; HAVRE P, 1977, ARCH BIOCHEM BIOPHYS, V182, P14, DOI 10.1016/0003-9861(77)90278-8; HURLEY TD, 1994, J MOL BIOL, V239, P415, DOI 10.1006/jmbi.1994.1382; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALANT H, 1971, BIOL ALCOHOL, V1, P1; LUMENG L, 1979, BIOCHEM PHARMACOL, V28, P1547, DOI 10.1016/0006-2952(79)90471-4; Luo J, 2001, J AM CHEM SOC, V123, P11952, DOI 10.1021/ja0109747; MCMARTIN KE, 1975, BIOCHEM MED METAB B, V13, P319, DOI 10.1016/0006-2944(75)90171-4; MCMARTIN KE, 1980, ARCH BIOCHEM BIOPHYS, V199, P606, DOI 10.1016/0003-9861(80)90318-5; Meijers R, 2001, J BIOL CHEM, V276, P9316, DOI 10.1074/jbc.M010870200; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Niederhut MS, 2001, PROTEIN SCI, V10, P697, DOI 10.1110/ps.45001; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Plapp B V, 1975, Adv Exp Med Biol, V56, P77; PLAPP BV, 1970, J BIOL CHEM, V245, P1727; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; Plapp BV, 2003, CHEM-BIOL INTERACT, V143, P183, DOI 10.1016/S0009-2797(02)00202-8; PLAPP BV, 1984, ARCH BIOCHEM BIOPHYS, V230, P30, DOI 10.1016/0003-9861(84)90083-3; PLAPP BV, 1975, BIOCH PHARM ETHANOL, P77; PLAPP BV, 1994, MOL BASIS ALCOHOL US, P311; PORTER CC, 1976, LIFE SCI, V18, P953, DOI 10.1016/0024-3205(76)90414-8; Ramaswamy S, 1997, BIOCHEMISTRY-US, V36, P3522, DOI 10.1021/bi962491z; Ramaswamy S, 1999, BIOCHEMISTRY-US, V38, P13951, DOI 10.1021/bi991731i; RAMASWAMY S, 1994, BIOCHEMISTRY-US, V33, P5230, DOI 10.1021/bi00183a028; Rubach JK, 2003, BIOCHEMISTRY-US, V42, P2907, DOI 10.1021/bi0272656; Schindler JF, 1998, J MED CHEM, V41, P1696, DOI 10.1021/jm9707380; SEKHAR VC, 1990, BIOCHEMISTRY-US, V29, P4289, DOI 10.1021/bi00470a005; STONE CL, 1989, J BIOL CHEM, V264, P11112; SUN HW, 1992, J MOL EVOL, V34, P522, DOI 10.1007/BF00160465; WINER AD, 1960, ACTA CHEM SCAND, V14, P1729, DOI 10.3891/acta.chem.scand.14-1729; WU YD, 1995, J AM CHEM SOC, V117, P4100, DOI 10.1021/ja00119a026	53	22	23	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36699	36706		10.1074/jbc.M305419200	http://dx.doi.org/10.1074/jbc.M305419200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855684	hybrid			2022-12-27	WOS:000185318300101
J	Wong, WK; Chen, K; Shih, JC				Wong, WK; Chen, K; Shih, JC			Decreased methylation and transcription repressor Sp3 up-regulated human monoamine oxidase (MAO) B expression during Caco-2 differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITOR SPECIFICITIES; ACTIVE-SITE; GENES; SUBSTRATE; ASTROCYTES	Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of neuroactive and dietary monoamines such as serotonin, tyramine, and phenylethylamine. Here we show that MAO B, but not MAO A, gene expression was induced during Caco-2 cell differentiation; thus this cell line was used as a model system to study the gene regulation unique for MAO B. Luciferase and gel shift assays showed that transcription factors Sp1 and Sp3 binding to -246 and -99 bp were responsible for the observed gene activation. Overexpression of Sp3 inhibited the induction of MAO B gene by Sp1, and the expression of Sp3 was decreased during Caco-2 cell differentiation. Computer analysis revealed a putative CpG island containing 22 potential CpG methylation sites between -261 and -58 bp. In vitro methylation of MAO B promoter with 5-aza-2'-deoxycytidine, a DNA methyltransferase inhibitor, up-regulated MAO B gene expression in both HeLa and Caco-2 cells. Sodium bisulfite sequencing showed a gradually reduced methylation of the CpG sites during Caco-2 cell differentiation. These results suggested that MAO B gene expression is selectively induced by a decreased Sp3/Sp1 ratio and reduced DNA methylation. This new information may provide insights on the tissue-specific expression of these two isoenzymes.	Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Univ So Calif, Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California	Shih, JC (corresponding author), Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, 1985 Zonal Ave,PSC 528, Los Angeles, CA 90089 USA.	jcshih@usc.edu			NIMH NIH HHS [R01 MH37020, R37 MH39085] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH037020, R37MH039085] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BACH AWJ, 1988, P NATL ACAD SCI USA, V85, P4934, DOI 10.1073/pnas.85.13.4934; BOND PA, 1977, CLIN CHIM ACTA, V80, P317, DOI 10.1016/0009-8981(77)90039-0; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Cesura AM, 1996, EUR J BIOCHEM, V236, P996, DOI 10.1111/j.1432-1033.1996.00996.x; Chen K, 1996, J NEUROCHEM, V66, P797; EGASHIRA T, 1976, JPN J PHARMACOL, V26, P493, DOI 10.1254/jjp.26.493; Geha RM, 2000, J NEUROCHEM, V75, P1304, DOI 10.1046/j.1471-4159.2000.751304.x; Geha RM, 2002, J BIOL CHEM, V277, P17209, DOI 10.1074/jbc.M110920200; Geha RM, 2001, J BIOL CHEM, V276, P9877, DOI 10.1074/jbc.M006972200; Gershon MD, 1999, ALIMENT PHARM THER, V13, P15; Gershon MD, 1998, AM J PHYSIOL-GASTR L, V275, pG869, DOI 10.1152/ajpgi.1998.275.5.G869; Gershon Michael D, 2003, Rev Gastroenterol Disord, V3 Suppl 2, pS25; GIDONI D, 1985, SCIENCE, V230, P511, DOI 10.1126/science.2996137; GRIMSBY J, 1991, P NATL ACAD SCI USA, V88, P3637, DOI 10.1073/pnas.88.9.3637; Grimsby J, 1997, NAT GENET, V17, P206, DOI 10.1038/ng1097-206; GRIMSBY J, 1990, J NEUROCHEM, V55, P1166, DOI 10.1111/j.1471-4159.1990.tb03121.x; Kennett SB, 1997, NUCLEIC ACIDS RES, V25, P3110, DOI 10.1093/nar/25.15.3110; Knoll J, 1972, Adv Biochem Psychopharmacol, V5, P393; LAN NC, 1989, GENOMICS, V4, P552, DOI 10.1016/0888-7543(89)90279-6; LEVITT P, 1982, P NATL ACAD SCI-BIOL, V79, P6385, DOI 10.1073/pnas.79.20.6385; Markowitz AJ, 1995, AM J PHYSIOL-GASTR L, V269, pG925, DOI 10.1152/ajpgi.1995.269.6.G925; Oreland L., 1993, MONOAMINE OXIDASE BA, P219; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Pieper RO, 1999, NUCLEIC ACIDS RES, V27, P3229, DOI 10.1093/nar/27.15.3229; Rebrin I, 2001, J BIOL CHEM, V276, P29499, DOI 10.1074/jbc.M100431200; SAURA J, 1994, NEUROSCIENCE, V62, P15, DOI 10.1016/0306-4522(94)90311-5; Shih JC, 1999, AM J HUM GENET, V65, P593, DOI 10.1086/302562; Shih JC, 1999, ANNU REV NEUROSCI, V22, P197, DOI 10.1146/annurev.neuro.22.1.197; TSUGENO Y, 1995, J BIOCHEM-TOKYO, V118, P974, DOI 10.1093/jb/118.5.974; WESTLUND KN, 1985, SCIENCE, V230, P181, DOI 10.1126/science.3875898; WEYLER W, 1985, J BIOL CHEM, V260, P3199; Wong WK, 2002, J BIOL CHEM, V277, P22222, DOI 10.1074/jbc.M202844200; Wong WK, 2001, MOL PHARMACOL, V59, P852, DOI 10.1124/mol.59.4.852; WU HF, 1993, MOL PHARMACOL, V43, P888; Zhou BP, 1998, J BIOL CHEM, V273, P14862, DOI 10.1074/jbc.273.24.14862; ZHU QS, 1994, J NEUROSCI, V14, P7393; ZHU QS, 1992, J NEUROSCI, V12, P4437; ZWEIBAUM A, 1989, ADAPTATION DEV GASTR	38	46	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36227	36235		10.1074/jbc.M305549200	http://dx.doi.org/10.1074/jbc.M305549200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855685	hybrid			2022-12-27	WOS:000185318300044
J	Ng, HH; Dole, S; Struhl, K				Ng, HH; Dole, S; Struhl, K			The Rtf1 component of the Paf1 transcriptional elongation complex is required for ubiquitination of histone H2B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; REGULATES H3 METHYLATION; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; ACTIVE GENES; SET DOMAIN; IN-VIVO; YEAST; METHYLTRANSFERASE; RAD6	In yeast cells, the Rtf1 and Paf1 components of the Paf1 transcriptional elongation complex are important for recruitment of Set1, the histone H3-lysine 4 (H3-Lys(4)) methylase, to a highly localized domain at the 5' portion of active mRNA coding regions. Here, we show that Rtf1 is essential for global methylation of H3-Lys(4) and H3-Lys(79), but not H3-Lys(36). This role of Rtf1 resembles that of Rad6, which mediates ubiquitination of histone H2B at lysine 123. Indeed, Rtf1 is required for H2B ubiquitination, suggesting that its effects on H3-Lys(4) and H3-Lys(79) methylation are an indirect consequence of its effect on H2B ubiquitination. Rtf1 is important for telomeric silencing, with loss of H3-Lys(4) and H3-Lys(79) methylation synergistically reducing Sir2 association with telomeric DNA. Dot1, the H3-Lys(79) methylase, associates with transcriptionally active genes, but unlike the association of Set1 and Set2 (the H3-Lys(36) methylase), this association is largely independent of Rtf1. We suggest that Rtf1 affects genome-wide ubiquitination of H2B by a mechanism that is distinct from its function as a transcriptional elongation factor.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Natl Univ Singapore, Dept Biol Sci, Singapore 117543, Singapore; Genome Inst Singapore, Singapore 117528, Singapore	Harvard University; Harvard Medical School; National University of Singapore; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS)	Struhl, K (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, C2-315,240 Longwood Ave, Boston, MA 02115 USA.	kevin@hms.harvard.edu	Ng, Huck Hui/A-1135-2009		NIGMS NIH HHS [GM 53720, GM 30186] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030186, R01GM030186] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Costa PJ, 2000, GENETICS, V156, P535; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Huang HH, 1997, MOL CELL BIOL, V17, P6693, DOI 10.1128/MCB.17.11.6693; Hwang WW, 2003, MOL CELL, V11, P261, DOI 10.1016/S1097-2765(02)00826-2; Kelly TJ, 2000, MOL CELL BIOL, V20, P7051, DOI 10.1128/MCB.20.19.7051-7058.2000; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Lacoste N, 2002, J BIOL CHEM, V277, P30421, DOI 10.1074/jbc.C200366200; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Min JR, 2003, CELL, V112, P711, DOI 10.1016/S0092-8674(03)00114-4; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Proft M, 2002, MOL CELL, V9, P1307, DOI 10.1016/S1097-2765(02)00557-9; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Strahl BD, 2002, MOL CELL BIOL, V22, P1298, DOI 10.1128/MCB.22.5.1298-1306.2002; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zhang ZG, 2000, NATURE, V408, P221, DOI 10.1038/35041601	38	215	220	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33625	33628		10.1074/jbc.C300270200	http://dx.doi.org/10.1074/jbc.C300270200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12876293	hybrid			2022-12-27	WOS:000185047500005
J	Suzuki, R; Tobe, K; Terauchi, Y; Komeda, K; Kubota, N; Eto, K; Yamauchi, T; Azuma, K; Kaneto, H; Taguchi, T; Koga, T; German, MS; Watada, H; Kawamori, R; Wright, CVE; Kajimoto, Y; Kimura, S; Nagai, R; Kadowaki, T				Suzuki, R; Tobe, K; Terauchi, Y; Komeda, K; Kubota, N; Eto, K; Yamauchi, T; Azuma, K; Kaneto, H; Taguchi, T; Koga, T; German, MS; Watada, H; Kawamori, R; Wright, CVE; Kajimoto, Y; Kimura, S; Nagai, R; Kadowaki, T			Pdx1 expression in Irs2-deficient mouse beta-cells is regulated in a strain-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-RECEPTOR SUBSTRATE-2; GLUCOSE-INTOLERANCE; MICE LACKING; GENE; DIFFERENTIATION; ACTIVATION; RESISTANCE; DISRUPTION; MUTATIONS; KNOCKOUT	We previously demonstrated that Irs2(-/-) mice develop diabetes due to beta-cell growth failure and insulin resistance; however, glucose-induced insulin secretion was increased in islets isolated from Irs2(-/-) mice. Pdx-1, a transcription factor important for maintenance of the beta-cell function, was recently reported to be severely reduced in Irs2(-/-) murine beta-cells. We report herein that Pdx-1 expression, including the amount of Pdx-1 localized in the nucleus, is not down-regulated in our Irs2(-/-) murine beta-cells with a C57BL/6 background. We have also demonstrated the expression of upstream genes of Pdx-1, such as HNF3beta and HNF1alpha, as well as its downstream genes, including insulin, Glut2, and Nkx6.1, to be well preserved. We have further demonstrated Pdx-1 expression to also be preserved in beta-cells of 30-week-old diabetic Irs2(-/-) mice. In addition, surprisingly, even in Irs2(-/-) mice on a high fat diet with markedly elevated blood glucose, exceeding 400 mg/dl, Pdx-1 expression was not reduced. Furthermore, we found Pdx-1 to be markedly decreased in certain severely diabetic Irs2(-/-) mice with a mixed C57BL/6J x 129Sv background. We conclude that 1) Pdx-1 expression in Irs2(-/-) mice is regulated in a strain-dependent manner, 2) Irs2(-/-) mice develop diabetes associated with beta-cell growth failure even when Pdx1 expression is preserved, and 3) Pdx-1 expression is preserved in severely hyperglycemic Irs2(-/-) mice with a C57BL/6 background on a high fat diet.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Saitama 3320012, Japan; Tokyo Med Univ, Anim Res Ctr, Div Lab Anim Sci, Tokyo 1608402, Japan; Juntendo Univ, Sch Med, Dept Med Metab & Endocrinol, Tokyo 1138421, Japan; Osaka Univ, Grad Sch Med, Dept Internal Med & Therapeut, Suita, Osaka 5650871, Japan; Sankyo Co Ltd, Biomed Res Labs, Tokyo 1408710, Japan; Univ Calif San Francisco, Hormone Res Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Vanderbilt Univ, Dev Biol Program, Nashville, TN 37232 USA	University of Tokyo; Japan Science & Technology Agency (JST); Tokyo Medical University; Juntendo University; Osaka University; Daiichi Sankyo Company Limited; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Vanderbilt University	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.	kadowaki-3im@h.u-tokyo.ac.jp	Terauchi, Yasuo/AAO-4347-2020; Suzuki, Ryo/AAA-2736-2019; Kubota, Naoto/N-7892-2015	Suzuki, Ryo/0000-0002-2965-6906; Taguchi, Takashi/0000-0003-1019-2619; Watada, Hirotaka/0000-0001-5961-1816				Accili D, 2001, J CLIN INVEST, V108, P1575, DOI 10.1172/JCI200114454; Ahlgren U, 1998, GENE DEV, V12, P1763, DOI 10.1101/gad.12.12.1763; ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Bernal-Mizrachi E, 2001, J CLIN INVEST, V108, P1631, DOI 10.1172/JCI13785; Bonny C, 1997, MOL CELL ENDOCRINOL, V135, P59, DOI 10.1016/S0303-7207(97)00190-1; Brissova M, 2002, J BIOL CHEM, V277, P11225, DOI 10.1074/jbc.M111272200; Duncan SA, 1998, SCIENCE, V281, P692, DOI 10.1126/science.281.5377.692; Dutta S, 1998, NATURE, V392, P560, DOI 10.1038/33311; Edlund H, 1998, DIABETES, V47, P1817, DOI 10.2337/diabetes.47.12.1817; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Harmon JS, 1999, DIABETES, V48, P1995, DOI 10.2337/diabetes.48.10.1995; Higaki Y, 1999, J BIOL CHEM, V274, P20791, DOI 10.1074/jbc.274.30.20791; Huang HP, 2002, MOL ENDOCRINOL, V16, P541, DOI 10.1210/me.16.3.541; Jetton TL, 2001, DIABETOLOGIA, V44, P2056, DOI 10.1007/s001250100011; Jonas JC, 1999, J BIOL CHEM, V274, P14112, DOI 10.1074/jbc.274.20.14112; JONSSON J, 1994, NATURE, V371, P606, DOI 10.1038/371606a0; Kadowaki T, 2000, J CLIN INVEST, V106, P459, DOI 10.1172/JCI10830; Kido Y, 2000, J CLIN INVEST, V105, P199, DOI 10.1172/JCI7917; Kubota N, 2000, DIABETES, V49, P1880, DOI 10.2337/diabetes.49.11.1880; Kubota N, 1999, MOL CELL, V4, P597, DOI 10.1016/S1097-2765(00)80210-5; Kulkarni RN, 2002, NAT GENET, V31, P111, DOI 10.1038/ng872; Kulkarni RN, 1999, CELL, V96, P329, DOI 10.1016/S0092-8674(00)80546-2; Kushner JA, 2002, J CLIN INVEST, V109, P1193, DOI 10.1172/JCI200214439; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Nakae J, 2001, ENDOCR REV, V22, P818, DOI 10.1210/edrv.22.6.0452; Nakai J, 2002, NAT GENET, V32, P245, DOI 10.1038/ng890; Offield MF, 1996, DEVELOPMENT, V122, P983; PEERS B, 1994, MOL ENDOCRINOL, V8, P1798, DOI 10.1210/me.8.12.1798; Pende M, 2000, NATURE, V408, P994, DOI 10.1038/35050135; Poitout V, 2002, ENDOCRINOLOGY, V143, P339, DOI 10.1210/en.143.2.339; Qiu J, 2001, ENDOCRINOLOGY, V142, P3421, DOI 10.1210/en.142.8.3421; Saltiel AR, 2001, CELL, V104, P517, DOI 10.1016/S0092-8674(01)00239-2; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shih DQ, 2002, P NATL ACAD SCI USA, V99, P3818, DOI 10.1073/pnas.062605899; Shih DQ, 2001, P NATL ACAD SCI USA, V98, P14189, DOI 10.1073/pnas.251558998; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Stoffers DA, 1998, J CLIN INVEST, V102, P232, DOI 10.1172/JCI2242; Stoffers DA, 1997, NAT GENET, V17, P138, DOI 10.1038/ng1097-138; Sussel L, 1998, DEVELOPMENT, V125, P2213; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; Terauchi Y, 2003, J BIOL CHEM, V278, P14284, DOI 10.1074/jbc.M211045200; Tuttle RL, 2001, NAT MED, V7, P1133, DOI 10.1038/nm1001-1133; Virkamaki A, 1999, J CLIN INVEST, V103, P931, DOI 10.1172/JCI6609; Waeber G, 1996, MOL ENDOCRINOL, V10, P1327, DOI 10.1210/me.10.11.1327; Wang HY, 2001, J BIOL CHEM, V276, P25279, DOI 10.1074/jbc.M101233200; Watada H, 2000, J BIOL CHEM, V275, P34224, DOI 10.1074/jbc.M004981200; Watada H, 1996, DIABETES, V45, P1478, DOI 10.2337/diabetes.45.11.1478; Watada H, 1996, DIABETES, V45, P1826, DOI 10.2337/diabetes.45.12.1826; White MF, 1998, MOL CELL BIOCHEM, V182, P3, DOI 10.1023/A:1006806722619; Withers DJ, 1999, NAT GENET, V23, P32, DOI 10.1038/12631; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; Xuan SH, 2002, J CLIN INVEST, V110, P1011, DOI 10.1172/JCI200215276	52	27	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43691	43698		10.1074/jbc.M307004200	http://dx.doi.org/10.1074/jbc.M307004200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12869553	hybrid			2022-12-27	WOS:000186157000118
J	Fiordalisi, JJ; Johnson, RL; Weinbaum, CA; Sakabe, K; Chen, Z; Casey, PJ; Cox, AD				Fiordalisi, JJ; Johnson, RL; Weinbaum, CA; Sakabe, K; Chen, Z; Casey, PJ; Cox, AD			High affinity for farnesyltransferase and alternative prenylation contribute individually to K-Ras4B resistance to farnesyltransferase inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FARNESYL-PROTEIN TRANSFERASE; K-RAS; N-RAS; H-RAS; PHOSPHOINOSITIDE 3-KINASE; ISOPRENOID MODIFICATION; MAMMALIAN-CELLS; PLASMA-MEMBRANE; CANCER-CELLS; IN-VITRO	Farnesyltransferase inhibitors (FTIs) block Ras farnesylation, subcellular localization and activity, and inhibit the growth of Ras-transformed cells. Although FTIs are ineffective against K-Ras4B, the Ras isoform most commonly mutated in human cancers, they can inhibit the growth of tumors containing oncogenic K-Ras4B, implicating other farnesylated proteins or suggesting distinct functions for farnesylated and for geranylgeranylated K-Ras, which is generated when farnesyltransferase is inhibited. In addition to bypassing FTI blockade through geranylgeranylation, K-Ras4B resistance to FTIs may also result from its higher affinity for farnesyltransferase. Using chimeric Ras proteins containing all combinations of Ras background, CAAX motif, and K-Ras polybasic domain, we show that either a polybasic domain or an alternatively prenylated CAAX renders Ras prenylation, Ras-induced Elk-1 activation, and anchorage-independent cell growth FTI-resistant. The polybasic domain alone increases the affinity of Ras for farnesyltransferase, implying independent roles for each K-Ras4B sequence element in FTI resistance. Using microarray analysis and colony formation assays, we confirm that K-Ras function is independent of the identity of the prenyl group and, therefore, that FTI inhibition of K-Ras transformed cells is likely to be independent of K-Ras inhibition. Our results imply that relevant FTI targets will lack both polybasic and potentially geranylgeranylated methionine-CAAX motifs.	Univ N Carolina, Dept Radiat Oncol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Pharmacol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Duke Univ, Dept Pharmacol, Durham, NC 27710 USA; Duke Univ, Dept Canc Biol, Durham, NC 27710 USA; Duke Univ, Dept Biochem, Durham, NC 27710 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Duke University; Duke University; Duke University	Fiordalisi, JJ (corresponding author), Univ N Carolina, Dept Radiat Oncol, CB 7512, Chapel Hill, NC 27599 USA.	fiordali@med.unc.edu		Casey, Patrick/0000-0002-7366-9309; Cox, Adrienne D./0000-0002-4901-2454				Allal C, 2000, J BIOL CHEM, V275, P31001, DOI 10.1074/jbc.M005264200; Ashar HR, 2000, J BIOL CHEM, V275, P30451, DOI 10.1074/jbc.M003469200; Baum Charles, 2003, Curr Oncol Rep, V5, P99, DOI 10.1007/s11912-003-0096-5; BOS JL, 1989, CANCER RES, V49, P4682; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; Castro AF, 2003, J BIOL CHEM, V278, P32493, DOI 10.1074/jbc.C300226200; Chen Z, 2000, J BIOL CHEM, V275, P41251, DOI 10.1074/jbc.M006687200; Choy E, 1999, CELL, V98, P69, DOI 10.1016/S0092-8674(00)80607-8; Clark GJ, 1997, J BIOL CHEM, V272, P10608; CLARK GJ, 1995, METHOD ENZYMOL, V255, P395; COX AD, 1995, METHOD ENZYMOL, V255, P195; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; Cox AD, 2002, CURR OPIN PHARMACOL, V2, P388, DOI 10.1016/S1471-4892(02)00181-9; COX AD, 1994, J BIOL CHEM, V269, P19203; Cox AD, 1997, BIOCHIM BIOPHYS ACTA, V1333, P51; Crespo NC, 2001, J BIOL CHEM, V276, P16161, DOI 10.1074/jbc.M006213200; Du W, 1999, CANCER RES, V59, P5492; Fiordalis JJ, 2002, J BIOL CHEM, V277, P10813, DOI 10.1074/jbc.M107684200; Fiordalisi JJ, 2001, METHOD ENZYMOL, V332, P3; Ganguly AK, 2001, CURR MED CHEM, V8, P1419, DOI 10.2174/0929867013372021; Gibbs JB, 1997, ANNU REV PHARMACOL, V37, P143, DOI 10.1146/annurev.pharmtox.37.1.143; Gotoh T, 2001, J BIOL CHEM, V276, P38029; HAUSER CA, 1995, METHOD ENZYMOL, V255, P412; JACKSON JH, 1994, P NATL ACAD SCI USA, V91, P12730, DOI 10.1073/pnas.91.26.12730; JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221; Johnson L, 1997, GENE DEV, V11, P2468, DOI 10.1101/gad.11.19.2468; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; Lerner EC, 1997, ONCOGENE, V15, P1283, DOI 10.1038/sj.onc.1201296; Leventis R, 1998, BIOCHEMISTRY-US, V37, P7640, DOI 10.1021/bi973077h; Matallanas D, 2003, J BIOL CHEM, V278, P4572, DOI 10.1074/jbc.M209807200; MOORES SL, 1991, J BIOL CHEM, V266, P14603; Niv H, 2002, J CELL BIOL, V157, P865, DOI 10.1083/jcb.200202009; Ohkanda Junko, 2002, Current Topics in Medicinal Chemistry, V2, P303, DOI 10.2174/1568026023394281; Prendergast GC, 2001, EXPERT OPIN INV DRUG, V10, P2105, DOI 10.1517/13543784.10.12.2105; Prior IA, 2003, J CELL BIOL, V160, P165, DOI 10.1083/jcb.200209091; Prior IA, 2001, J CELL SCI, V114, P1603; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; Rowell CA, 1997, J BIOL CHEM, V272, P14093, DOI 10.1074/jbc.272.22.14093; Roy MO, 2000, BIOCHEMISTRY-US, V39, P8298, DOI 10.1021/bi000512q; Rubiol I, 1999, EUR J BIOCHEM, V266, P70, DOI 10.1046/j.1432-1327.1999.00815.x; SASSEVILLE AMJ, 1995, J CELL SCI, V108, P273; SEBTI SM, 2003, IN PRESS NAT REV CAN; Shields JM, 2000, TRENDS CELL BIOL, V10, P147, DOI 10.1016/S0962-8924(00)01740-2; Solski PA, 2002, CELL GROWTH DIFFER, V13, P363; Strickland CL, 1998, BIOCHEMISTRY-US, V37, P16601, DOI 10.1021/bi981197z; SUN JZ, 1995, CANCER RES, V55, P4243; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P10499, DOI 10.1073/pnas.95.18.10499; Suzuki N, 1998, P NATL ACAD SCI USA, V95, P15356, DOI 10.1073/pnas.95.26.15356; Tamanoi F, 2001, J CELL BIOCHEM, V84, P64, DOI 10.1002/jcb.10067; Tamanoi F, 2001, CELL MOL LIFE SCI, V58, P1636, DOI 10.1007/PL00000802; Whyte DB, 1997, J BIOL CHEM, V272, P14459, DOI 10.1074/jbc.272.22.14459; Yan J, 1998, J BIOL CHEM, V273, P24052, DOI 10.1074/jbc.273.37.24052; Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200; Zhang FL, 1997, J BIOL CHEM, V272, P10232	55	72	72	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41718	41727		10.1074/jbc.M305733200	http://dx.doi.org/10.1074/jbc.M305733200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12882980	Green Published, hybrid			2022-12-27	WOS:000185989500022
J	Kanaji, S; Kanaji, T; Furihata, K; Kato, K; Ware, JL; Kunicki, TJ				Kanaji, S; Kanaji, T; Furihata, K; Kato, K; Ware, JL; Kunicki, TJ			Convulxin binds to native, human glycoprotein Ib alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VON-WILLEBRAND-FACTOR; RECEPTOR-GAMMA-CHAIN; C-TYPE LECTIN; PLATELET-AGGREGATING PROTEIN; IX-V COMPLEX; ALPHA(2)BETA(1) INTEGRIN; ACTIVATES PLATELETS; TYROSINE SULFATION; COLLAGEN; VENOM	Convulxin (CVX), a C-type snake protein from Crotalus durissus terrificus venom, is the quintessential agonist for studies of the collagen receptor, glycoprotein VI ( GPVI) and its role in platelet adhesion to collagens. In this study, CVX, purified from venom, behaves as expected, i.e. it binds to platelet GPVI and recombinant human GPVI, induces platelet aggregation and platelet prothrombinase activity, and binds uniquely to GPVI in ligand blots of SDS-denatured proteins. Nonetheless, we find that CVX has a dual specificity for both GPVI and native but not denatured human GPIbalpha. First, CVX binds to human GPIbalpha expressed on the surface of CHO cells. Second, CVX binds weakly to murine platelet GPIbalpha but more strongly to human platelet GPIbalpha, as evidenced by comparative binding to wild-type, GPVI(-/-), FcRgamma (-/-), and human GPIb transgenic mice. Third, the binding of CVX to human GPIbalpha is inhibited by soluble, recombinant human GPVI. Fourth, CVX binding to GPIbalpha is disrupted by phenylalanine substitutions at GPIbalpha tyrosine-276, tyrosine-278, and tyrosine-279, which also disrupts von Willebrand factor and alpha-thrombin binding to GPIbalpha. Fifth, CVX binding to GPIbalpha on Chinese hamster ovary cell transfectants is inhibited by function-blocking murine monoclonal anti-GPIbalpha antibodies. Lastly, CVX fails to bind to denatured GPIbalpha in detergent extracts of platelets. Three separate preparations of CVX (two purified by the authors; one obtained commercially) produced equivalent results. These results indicate that CVX exhibits dual specificity for both native GPIbalpha and GPVI. Furthermore, the binding site on GPIbalpha for CVX may be close to that for von Willebrand factor. Therefore, a contribution of GPIbalpha to CVX-induced platelet responses needs to be carefully re-evaluated.	Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, La Jolla, CA 92037 USA	Scripps Research Institute	Kunicki, TJ (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, Div Expt Hemostasis & Thrombosis, Roon Res Ctr Arteriosclerosis & Thrombosis, 10550 N Torrey Pines Rd,Maildrop MEM150, La Jolla, CA 92037 USA.	tomk@scripps.edu	Kanaji, Taisuke/AAN-1458-2021	Kanaji, Taisuke/0000-0002-3588-6038	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050545, R01HL046979] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050545, HL50545, R01 HL050545-12, HL46979] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Andrews RK, 2001, HAEMOSTASIS, V31, P155; Bergmeier W, 2001, J BIOL CHEM, V276, P25121, DOI 10.1074/jbc.M103892200; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Dong JF, 2001, BLOOD, V97, P162, DOI 10.1182/blood.V97.1.162; Dormann D, 2001, BLOOD, V97, P929, DOI 10.1182/blood.V97.4.929; Du XY, 2002, THROMB HAEMOSTASIS, V87, P692, DOI 10.1055/s-0037-1613067; Falati S, 1999, BLOOD, V94, P1648, DOI 10.1182/blood.V94.5.1648.417k31_1648_1656; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Furihata K, 2001, ARTERIOSCL THROM VAS, V21, P1857, DOI 10.1161/hq1001.096643; Goto S, 1998, J CLIN INVEST, V101, P479, DOI 10.1172/JCI973; HANDA M, 1986, J BIOL CHEM, V261, P2579; HUANG TF, 1995, BIOCHEM J, V309, P1021, DOI 10.1042/bj3091021; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JandrotPerrus M, 1997, J BIOL CHEM, V272, P27035, DOI 10.1074/jbc.272.43.27035; Kato K, 2003, BLOOD, V102, P1701, DOI 10.1182/blood-2003-03-0717; Leduc M, 1998, BIOCHEM J, V333, P389, DOI 10.1042/bj3330389; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Navdaev A, 2001, J BIOL CHEM, V276, P20882, DOI 10.1074/jbc.M101585200; Niedergang F, 2000, BIOCHEM BIOPH RES CO, V273, P246, DOI 10.1006/bbrc.2000.2940; Polgar J, 1997, J BIOL CHEM, V272, P13576, DOI 10.1074/jbc.272.21.13576; Sullam PM, 1998, J BIOL CHEM, V273, P5331, DOI 10.1074/jbc.273.9.5331; TENG CM, 1993, THROMB HAEMOSTASIS, V69, P286; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200; Ware J, 1997, BLOOD CELL MOL DIS, V23, P292, DOI 10.1006/bcmd.1997.0146; Ware J, 2000, P NATL ACAD SCI USA, V97, P2803, DOI 10.1073/pnas.050582097; Wu Y, 2001, BLOOD, V97, P3836, DOI 10.1182/blood.V97.12.3836	27	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39452	39460		10.1074/jbc.M300199200	http://dx.doi.org/10.1074/jbc.M300199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881531	hybrid			2022-12-27	WOS:000185713800023
J	Sharpe, IA; Palant, E; Schroeder, CI; Kaye, DM; Adams, DJ; Alewood, PF; Lewis, RJ				Sharpe, IA; Palant, E; Schroeder, CI; Kaye, DM; Adams, DJ; Alewood, PF; Lewis, RJ			Inhibition of the norepinephrine transporter by the venom peptide x-MrIA - Site of action, Na+ dependence, and structure-activity relationship	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL NORADRENALINE CARRIER; BIOGENIC-AMINE TRANSPORTERS; DOPAMINE TRANSPORTER; MOLECULAR-CLONING; NMR-SPECTROSCOPY; OMEGA-CONOTOXINS; RAT; EXPRESSION; BINDING; CELLS	chi-Conopeptide MrIA (chi-MrIA) is a 13-residue peptide contained in the venom of the predatory marine snail Conus marmoreus that has been found to inhibit the norepinephrine transporter (NET). We investigated whether chi-MrIA targeted the other members of the monoamine transporter family and found no effect of the peptide (100 muM) on the activity of the dopamine transporter and the serotonin transporter, indicating a high specificity of action. The binding of the NET inhibitors, [H-3] nisoxetine and [H-3] mazindol, to the expressed rat and human NET was inhibited by chi-MrIA with the conopeptide displaying a slight preference toward the rat isoform. For both radioligands, saturation binding studies showed that the inhibition by chi-MrIA was competitive in nature. It has previously been demonstrated that chi-MrIA does not compete with norepinephrine, unlike classically described NET inhibitors such as nisoxetine and mazindol that do. This pattern of behavior implies that the binding site for chi-MrIA on the NET overlaps the antidepressant binding site and is wholly distinct from the substrate binding site. The inhibitory effect of chi-MrIA was found to be dependent on Na+ with the conopeptide becoming a less effective blocker of [H-3] norepinephrine by the NET under the conditions of reduced extracellular Na+. In this respect, chi-MrIA is similar to the antidepressant inhibitors of the NET. The structure-activity relationship of chi-MrIA was investigated by alanine scanning. Four residues in the first cysteine-bracketed loop of chi-MrIA and a His in loop 2 played a dominant role in the interaction between chi-MrIA and the NET. Halpha chemical shift comparisons indicated that side-chain interactions at these key positions were structurally perturbed by the replacement of Gly-6. From these data, we present a model of the structure of chi-MrIA that shows the relative orientation of the key binding residues. This model provides a new molecular caliper for probing the structure of the NET.	Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Univ Queensland, Sch Biomed Sci, St Lucia, Qld 4072, Australia; Xenome Ltd, Indooroopilly, Qld 4068, Australia; Baker Heart Res Inst, Prahran, Vic 3181, Australia	University of Queensland; University of Queensland; Baker Heart and Diabetes Institute	Lewis, RJ (corresponding author), Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia.	r.lewis@imb.uq.edu.au	Schroeder, Cristina I./K-2042-2014; Lewis, Richard J/E-8674-2013; Lewis, Richard/T-8763-2019; Kaye, David/AAF-1202-2021; Adams, David/J-9125-2014; Adams, David John/K-3578-2019	Schroeder, Cristina I./0000-0002-6737-6374; Lewis, Richard J/0000-0003-3470-923X; Lewis, Richard/0000-0003-3470-923X; Adams, David/0000-0002-7030-2288; Adams, David John/0000-0002-7030-2288; Kaye, David/0000-0003-4058-0372				*ACC INC, 2001, INS 2 MOD ENV VERS 9; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BONISCH H, 1994, ANN NY ACAD SCI, V733, P193, DOI 10.1111/j.1749-6632.1994.tb17269.x; Bonisch H, 1999, J AUTON PHARMACOL, V19, P327; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Bruss M, 1997, MOL BRAIN RES, V52, P257, DOI 10.1016/S0169-328X(97)00267-2; Bryan-Lluka LJ, 2003, J BIOL CHEM, V278, P40324, DOI 10.1074/jbc.M213101200; Buck KJ, 1995, MOL PHARMACOL, V48, P1030; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Eisenhofer G, 1996, CIRCULATION, V93, P1667, DOI 10.1161/01.CIR.93.9.1667; Eshleman AJ, 1999, J PHARMACOL EXP THER, V289, P877; FRIEDRICH U, 1986, N-S ARCH PHARMACOL, V333, P246, DOI 10.1007/BF00512937; Gehrmann J, 1998, J MOL BIOL, V278, P401, DOI 10.1006/jmbi.1998.1701; GIROS B, 1992, MOL PHARMACOL, V42, P383; GRAEFE KH, 1988, HDB EXP PHARM, V90, P193; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; Klimek V, 1997, J NEUROSCI, V17, P8451; KOPPEL G, 1995, CHEM BIOL, V2, P483, DOI 10.1016/1074-5521(95)90265-1; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; LEEDHAM JA, 1985, ARCH INT PHARMACOD T, V277, P39; Lewis RJ, 2000, J BIOL CHEM, V275, P35335, DOI 10.1074/jbc.M002252200; MACK F, 1979, N-S ARCH PHARMACOL, V310, P1, DOI 10.1007/BF00499868; McIntosh JM, 2000, J BIOL CHEM, V275, P32391, DOI 10.1074/jbc.M003619200; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nielsen KJ, 1999, J MED CHEM, V42, P415, DOI 10.1021/jm981052q; Nielsen KJ, 2000, J MOL RECOGNIT, V13, P55, DOI 10.1002/(SICI)1099-1352(200003/04)13:2<55::AID-JMR488>3.0.CO;2-O; NIELSON C, 2002, 10 WORLD C PAIN SAN, P278; Olivera BM, 2001, TOXICON, V39, P7, DOI 10.1016/S0041-0101(00)00157-4; PACHOLCZYK T, 1991, NATURE, V350, P350, DOI 10.1038/350350a0; Paczkowski FA, 2001, MOL BRAIN RES, V97, P32, DOI 10.1016/S0169-328X(01)00295-9; Paczkowski FA, 2002, N-S ARCH PHARMACOL, V365, P312, DOI 10.1007/s00210-002-0528-z; Paczkowski FA, 1999, J PHARMACOL EXP THER, V290, P761; Percy E, 1999, BRIT J PHARMACOL, V128, P774, DOI 10.1038/sj.bjp.0702831; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Rothman RB, 1999, SYNAPSE, V33, P239, DOI 10.1002/(SICI)1098-2396(19990901)33:3<239::AID-SYN8>3.0.CO;2-R; Roubert C, 2001, J BIOL CHEM, V276, P8254, DOI 10.1074/jbc.M009798200; Rudnick G, 1997, NEUROTRANSMITTER TRA, P73; SARIN VK, 1981, ANAL BIOCHEM, V117, P147, DOI 10.1016/0003-2697(81)90704-1; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SCHOMIG E, 1988, N-S ARCH PHARMACOL, V337, P626; Shannon JR, 2000, NEW ENGL J MED, V342, P541, DOI 10.1056/NEJM200002243420803; Sharpe IA, 2001, NAT NEUROSCI, V4, P902, DOI 10.1038/nn0901-902; SILVERTHORN ML, 1995, J PHARMACOL EXP THER, V273, P213; Singer A, 1999, J PHARMACOL EXP THER, V290, P1363; STAMPE P, 1994, BIOCHEMISTRY-US, V33, P443, DOI 10.1021/bi00168a008; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Sucic S, 2002, MOL BRAIN RES, V108, P40, DOI 10.1016/S0169-328X(02)00512-0; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K, 1986, NMR PROTEINS NUCL AC; ZEITNER CJ, 1986, N-S ARCH PHARMACOL, V334, P397, DOI 10.1007/BF00569377	53	63	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40317	40323		10.1074/jbc.M213030200	http://dx.doi.org/10.1074/jbc.M213030200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885787	Green Submitted, hybrid			2022-12-27	WOS:000185713800124
J	Ziouzenkova, O; Asatryan, L; Sahady, D; Orasanu, G; Perrey, S; Cutak, B; Hassell, T; Akiyama, TE; Berger, JP; Sevanian, A; Plutzky, J				Ziouzenkova, O; Asatryan, L; Sahady, D; Orasanu, G; Perrey, S; Cutak, B; Hassell, T; Akiyama, TE; Berger, JP; Sevanian, A; Plutzky, J			Dual roles for lipolysis and oxidation in peroxisome proliferation-activator receptor responses to electronegative low density lipoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; PPAR-ALPHA; KAPPA-B; ADHESION MOLECULE; CORONARY EVENTS; GENE-EXPRESSION; GAMMA LIGANDS; OXIDIZED LDL; LIPASE; CIII	Low density lipoprotein (LDL) exists in various forms that possess unique characteristics, including particle content and metabolism. One circulating subfraction, electronegative LDL (LDL(-)), which is increased in familial hypercholesterolemia and diabetes, is implicated in accelerated atherosclerosis. Cellular responses to LDL(-) remain poorly described. Here we demonstrate that LDL(-) increases tumor necrosis factor alpha (TNFalpha)-induced inflammatory responses through NFkappaB and AP-1 activation with corresponding increases in vascular cell adhesion molecule-1 (VCAM1) expression. LDL receptor overexpression increased these effects. In contrast, exposing LDL(-) to the key lipolytic enzyme lipoprotein lipase (LPL) reversed these responses, inhibiting VCAM1 below levels seen with TNFalpha alone. LPL is known to act on lipoproteins to generate endogenous peroxisomal proliferator-activated receptor alpha (PPARalpha) ligand, thus limiting inflammation. These responses varied according to the lipoprotein substrate triglyceride content (very low density lipoprotein >> LDL > high density lipoprotein). The PPARalpha activation seen with LDL, however, was disproportionately high. We show here that MUT LDL activates PPARalpha to an extent proportional to its LDL(-) content. As compared with LDL(-) alone, LPL-treated LDL(-) increased PPARalpha activation 20-fold in either cell-based transfection or radioligand displacement assays. LPL-treated LDL(-) suppressed NFkappaB and AP-1 activation, increasing expression of the PPARalpha target gene IkappaBalpha, although only in the genetic presence of PPARalpha and with intact LPL hydrolysis. Mass spectrometry reveals that LPL-treatment of either LDL or LDL(-) releases hydroxy-octadecadienoic acids (HODEs), potent PPARalpha activators. These findings suggest LPL-mediated PPARalpha activation as an alternative catabolic pathway that may limit inflammatory responses to LDL(-).	Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, Boston, MA 02115 USA; Univ So Calif, Sch Pharm, Dept Mol Pharmacol & Toxicol, Los Angeles, CA 90089 USA; Sigma Aldrich, St Louis, MO 63103 USA; Merck Res Labs, Rahway, NJ 07065 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Southern California; Merck KGaA; MilliporeSigma; Merck & Company	Plutzky, J (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Cardiovasc, 77 Av Louis Pasteur,NRB 740, Boston, MA 02115 USA.	jplutzky@rics.bwh.harvard.edu	perrey, stephane/B-7483-2008; Ziouzenkova, Ouliana/B-3690-2012; Plutzky, Jorge/V-3410-2019; Ziouzenkova, Ouliana/AAM-1971-2020	perrey, stephane/0000-0002-8741-629X; Ziouzenkova, Ouliana/0000-0003-2449-2591; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050350] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL050350, HL50350] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AVOGARO P, 1988, ARTERIOSCLEROSIS, V8, P79, DOI 10.1161/01.ATV.8.1.79; Berger JP, 2003, MOL ENDOCRINOL, V17, P662, DOI 10.1210/me.2002-0217; CAZZOLATO G, 1991, FREE RADICAL BIO MED, V11, P247, DOI 10.1016/0891-5849(91)90120-R; Davies SS, 2001, J BIOL CHEM, V276, P16015, DOI 10.1074/jbc.M100878200; Delerive P, 2000, FEBS LETT, V471, P34, DOI 10.1016/S0014-5793(00)01364-8; Delerive P, 2000, J BIOL CHEM, V275, P36703, DOI 10.1074/jbc.M004045200; Devchand PR, 1996, NATURE, V384, P39, DOI 10.1038/384039a0; Elbrecht A, 1999, J BIOL CHEM, V274, P7913, DOI 10.1074/jbc.274.12.7913; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FORMAN BM, 1995, CELL, V83, P803, DOI 10.1016/0092-8674(95)90193-0; Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0; HODIS HN, 1994, J LIPID RES, V35, P669; Huang JT, 1999, NATURE, V400, P378, DOI 10.1038/22572; Jackson SM, 1999, ARTERIOSCL THROM VAS, V19, P2094, DOI 10.1161/01.ATV.19.9.2094; KHAN BV, 1995, J CLIN INVEST, V95, P1262, DOI 10.1172/JCI117776; Lee H, 2000, CIRC RES, V87, P516; Lee SJ, 2003, ARTERIOSCL THROM VAS, V23, P853, DOI 10.1161/01.ATV.0000066131.01313.EB; Lee SST, 1996, ANN NY ACAD SCI, V804, P524, DOI 10.1111/j.1749-6632.1996.tb18642.x; Li DY, 2002, J PHARMACOL EXP THER, V302, P601, DOI 10.1124/jpet.102.034959; LI H, 1993, ARTERIOSCLER THROMB, V13, P197, DOI 10.1161/01.ATV.13.2.197; Marelli-Berg FM, 2000, J IMMUNOL METHODS, V244, P205, DOI 10.1016/S0022-1759(00)00258-1; Marx N, 1999, CIRCULATION, V99, P3125, DOI 10.1161/01.CIR.99.24.3125; Maziere C, 1997, FEBS LETT, V409, P351, DOI 10.1016/S0014-5793(97)00545-0; Merkel M, 2002, J LIPID RES, V43, P1997, DOI 10.1194/jlr.R200015-JLR200; Nagy L, 1998, CELL, V93, P229, DOI 10.1016/S0092-8674(00)81574-3; PEDERSEN TR, 1994, LANCET, V344, P1383; Roebuck KA, 1999, J LEUKOCYTE BIOL, V65, P291, DOI 10.1002/jlb.65.3.291; Sacks FM, 2000, CIRCULATION, V102, P1886, DOI 10.1161/01.CIR.102.16.1886; Sanchez-Quesada JL, 2003, ATHEROSCLEROSIS, V166, P261, DOI 10.1016/S0021-9150(02)00374-X; Sanchez-Quesada JL, 2002, J LIPID RES, V43, P699; SanchezQuesada JL, 1996, DIABETOLOGIA, V39, P1469, DOI 10.1007/s001250050600; Sevanian A, 1996, ARTERIOSCL THROM VAS, V16, P784, DOI 10.1161/01.ATV.16.6.784; Steinberg D, 1997, CIRCULATION, V95, P1062; Sugiyama S, 1998, ARTERIOSCL THROM VAS, V18, P568, DOI 10.1161/01.ATV.18.4.568; Vedie B, 1998, ARTERIOSCL THROM VAS, V18, P1780, DOI 10.1161/01.ATV.18.11.1780; Wang XS, 1999, BIOCHEM J, V343, P347, DOI 10.1042/0264-6021:3430347; Ziouzenkova O, 1999, J BIOL CHEM, V274, P18916, DOI 10.1074/jbc.274.27.18916; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100; Ziouzenkova O, 2000, BLOOD PURIFICAT, V18, P169, DOI 10.1159/000014415	39	52	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39874	39881		10.1074/jbc.M306786200	http://dx.doi.org/10.1074/jbc.M306786200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878589	Green Accepted, hybrid			2022-12-27	WOS:000185713800074
J	Chang, DC; McWatters, HG; Williams, JA; Gotter, AL; Levine, JD; Reppert, SM				Chang, DC; McWatters, HG; Williams, JA; Gotter, AL; Levine, JD; Reppert, SM			Constructing a feedback loop with circadian clock molecules from the silkmoth, Antheraea pernyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA-PERIOD; POSITIONAL CLONING; PROTEIN; TRANSCRIPTION; GENE; PAS; SEQUENCE; TIMELESS; MECHANISMS; HOMOLOG	Circadian clocks are important regulators of behavior and physiology. The circadian clock of Drosophila depends on an autoinhibitory feedback loop involving dCLOCK, CYCLE (also called dBMAL, for Drosophila brain and muscle ARNT-like protein), dPERIOD, and dTIMELESS. Recent studies suggest that the clock mechanism in other insect species may differ strikingly from that of Drosophila. We cloned Clock, Bmal, and Timeless homologs (apClock, apBmal, and apTimeless) from the silkmoth Antheraea pernyi, from which a Period homolog (apPeriod) has already been cloned. In Schneider 2 (S2) cell culture assays, apCLOCK:apBMAL activates transcription through an E-box enhancer element found in the 5' region of the apPeriod gene. Furthermore, apPERIOD can robustly inhibit apCLOCK:apBMAL-mediated transactivation, and apTIMELESS can augment this inhibition. Thus, a complete feedback loop, resembling that found in Drosophila, can be constructed from silkmoth CLOCK, BMAL, PERIOD, and TIMELESS. Our results suggest that the circadian autoinhibitory feedback loop discovered in Drosophila is likely to be widespread among insects. However, whereas the transactivation domain in Drosophila lies in the C terminus of dCLOCK, in A. pernyi, it lies in the C terminus of apBMAL, which is highly conserved with the C termini of BMALs in other insects (except Drosophila) and in vertebrates. Our analysis sheds light on the molecular function and evolution of clock genes in the animal kingdom.	Univ Massachusetts, Sch Med, Dept Neurobiol, Med Ctr, Worcester, MA 01605 USA; Massachusetts Gen Hosp, MassGen Hosp Children, Lab Dev Chronobiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Program Neurosci, Boston, MA 02115 USA	University of Massachusetts System; University of Massachusetts Worcester; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Reppert, SM (corresponding author), Univ Massachusetts, Sch Med, Dept Neurobiol, Med Ctr, 364 Plantat St, Worcester, MA 01605 USA.	steven.reppert@umassmed.edu		Chang, Dennis/0000-0002-7640-762X	NINDS NIH HHS [R01-NS39303] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039303] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allada R, 1998, CELL, V93, P791, DOI 10.1016/S0092-8674(00)81440-3; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Benna C, 2000, CURR BIOL, V10, pR512, DOI 10.1016/S0960-9822(00)00594-7; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Cermakian N, 2000, P NATL ACAD SCI USA, V97, P4339, DOI 10.1073/pnas.97.8.4339; Chang DC, 2003, CURR BIOL, V13, P758, DOI 10.1016/S0960-9822(03)00286-0; CURTIN KD, 1995, NEURON, V14, P365, DOI 10.1016/0896-6273(95)90292-9; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; Dehal P, 2002, SCIENCE, V298, P2157, DOI 10.1126/science.1080049; Froy O, 2002, CURR BIOL, V12, P147, DOI 10.1016/S0960-9822(01)00656-X; Gaunt MW, 2002, MOL BIOL EVOL, V19, P748, DOI 10.1093/oxfordjournals.molbev.a004133; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gorlich D, 1999, ANNU REV CELL DEV BI, V15, P607, DOI 10.1146/annurev.cellbio.15.1.607; Goto SG, 2002, J INSECT PHYSIOL, V48, P803, DOI 10.1016/S0022-1910(02)00108-7; Gotter AL, 1999, NEURON, V24, P953, DOI 10.1016/S0896-6273(00)81042-9; Gotter AL, 2000, NAT NEUROSCI, V3, P755, DOI 10.1038/77653; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; Hogenesch JB, 2000, J NEUROSCI, V20, part. no.; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Ishikawa T, 2002, GENES CELLS, V7, P1073, DOI 10.1046/j.1365-2443.2002.00579.x; Jeon M, 1999, SCIENCE, V286, P1141, DOI 10.1126/science.286.5442.1141; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lee C, 2001, CELL, V107, P855, DOI 10.1016/S0092-8674(01)00610-9; Lee C, 1999, MOL CELL BIOL, V19, P5316; LEVINE JD, 1995, NEURON, V15, P147, DOI 10.1016/0896-6273(95)90072-1; Maemura K, 2000, J BIOL CHEM, V275, P36847, DOI 10.1074/jbc.C000629200; Markova EP, 2003, COMP BIOCHEM PHYS B, V134, P535, DOI 10.1016/S1096-4959(03)00004-6; MYERS MP, 1995, SCIENCE, V270, P805, DOI 10.1126/science.270.5237.805; Ousley A, 1998, GENETICS, V148, P815; Ponting CP, 1997, CURR BIOL, V7, pR674, DOI 10.1016/S0960-9822(06)00352-6; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; REPPERT SM, 1994, NEURON, V13, P1167, DOI 10.1016/0896-6273(94)90054-X; Rutila JE, 1998, CELL, V93, P805, DOI 10.1016/S0092-8674(00)81441-5; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sauman I, 1996, NEURON, V17, P889, DOI 10.1016/S0896-6273(00)80220-2; Shafer OT, 2002, J NEUROSCI, V22, P5946; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Takahata S, 2000, GENES CELLS, V5, P739, DOI 10.1046/j.1365-2443.2000.00363.x; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Vodovar N, 2002, CURR BIOL, V12, pR610, DOI 10.1016/S0960-9822(02)01130-2; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Williams JA, 2001, ANNU REV PHYSIOL, V63, P729, DOI 10.1146/annurev.physiol.63.1.729; Wise S, 2002, J COMP NEUROL, V447, P366, DOI 10.1002/cne.10242; Young MW, 2001, NAT REV GENET, V2, P702, DOI 10.1038/35088576; Zavodska R, 2003, J BIOL RHYTHM, V18, P106, DOI 10.1177/0748730403251711	51	56	61	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38149	38158		10.1074/jbc.M306937200	http://dx.doi.org/10.1074/jbc.M306937200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869551	hybrid			2022-12-27	WOS:000185575100009
J	Conjard, A; Komaty, O; Delage, H; Boghossian, M; Martin, M; Ferrier, B; Baverel, G				Conjard, A; Komaty, O; Delage, H; Boghossian, M; Martin, M; Ferrier, B; Baverel, G			Inhibition of glutamine synthetase in the mouse kidney - A novel mechanism of adaptation to metabolic acidosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PIG RENAL-CORTEX; AMMONIA METABOLISM; RAT NEPHRON; TUBULES; STARVATION; ENZYMES; LIVER; GENE; GLUCONEOGENESIS; DEHYDROGENASE	As part of a study on the regulation of renal ammonia-genesis in the mouse kidney, we investigated the effect of chronic metabolic acidosis on glutamine synthesis by isolated mouse renal proximal tubules. The results obtained reveal that, in tubules from control mice, glutamine synthesis occurred at high rates from glutamate and proline and, to a lesser extent, from ornithine, alanine, and aspartate. A 48 h, metabolic acidosis caused a marked inhibition of glutamine synthesis from near-physiological concentrations of both alanine and proline that were avidly metabolized by the tubules; metabolic acidosis also greatly stimulated glutamine utilization and metabolism. These effects were accompanied by a large increase (i) in alanine, proline, and glutamine gluconeogenesis and (ii) in ammonia accumulation from proline and glutamine. In the renal cortex of acidotic mice, the activity of phosphoenolpyruvate carboxykinase increased 4-fold, but that of glutamate dehydrogenase did not change; in contrast with what is known in the rat renal cortex, metabolic acidosis markedly diminished the glutamine synthetase activity and protein level, but not the glutamine synthetase mRNA level in the mouse renal cortex. These results strongly suggest that, in the mouse kidney, glutamine synthetase is an important regulatory component of the availability of the ammonium ions to be excreted for defending systemic acid-base balance. Furthermore, they show that, in rodents, the regulation of renal glutamine synthetase is species-specific.	Fac Med Laennec, INSERM, U499, Lab Physiopathol Metab & Renale, F-69372 Lyon 08, France	Institut National de la Sante et de la Recherche Medicale (Inserm)	Baverel, G (corresponding author), Fac Med Laennec, INSERM, U499, Lab Physiopathol Metab & Renale, Rue G Paradin, F-69372 Lyon 08, France.			Duplany, Agnes/0000-0002-3485-1597				BAVEREL G, 1980, BIOCHEM J, V188, P873, DOI 10.1042/bj1880873; BAVEREL G, 1990, BIOCHEM J, V268, P437, DOI 10.1042/bj2680437; Baverel G, 1984, GLUTAMINE METABOLISM, P187; BERL S, 1984, GLUTAMINE METABOLISM, P223; BURCH HB, 1978, AM J PHYSIOL, V235, pF246, DOI 10.1152/ajprenal.1978.235.3.F246; BURCH HB, 1978, BIOCHEM BIOPH RES CO, V82, P498, DOI 10.1016/0006-291X(78)90902-6; Chauvin MF, 1997, J BIOL CHEM, V272, P4705, DOI 10.1074/jbc.272.8.4705; Conjard A, 2002, J BIOL CHEM, V277, P29444, DOI 10.1074/jbc.M111335200; Conjard A, 2002, BIOCHEM J, V368, P301, DOI 10.1042/BJ20020331; CURTHOYS NP, 1973, J BIOL CHEM, V248, P162; Curthoys NP, 2001, AM J PHYSIOL-RENAL, V281, pF381, DOI 10.1152/ajprenal.2001.281.3.F381; DAMIAN AC, 1970, AM J PHYSIOL, V218, P1249, DOI 10.1152/ajplegacy.1970.218.5.1249; Ferrier B, 1999, BIOCHEM J, V337, P543, DOI 10.1042/0264-6021:3370543; FORISSIER M, 1981, BIOCHEM J, V200, P27, DOI 10.1042/bj2000027; Hallemeesch MM, 2001, LAB ANIM-UK, V35, P101, DOI 10.1258/0023677011911426; HANSON RW, 1997, ANNU REV BIOCHEM, V66, P203; Iyer RK, 2002, MOL CELL BIOL, V22, P4491, DOI 10.1128/MCB.22.13.4491-4498.2002; JANICKI RH, 1969, AM J PHYSIOL, V216, P1107, DOI 10.1152/ajplegacy.1969.216.5.1107; Kew S, 1999, J NUTR, V129, P1524, DOI 10.1093/jn/129.8.1524; KREBS HANS ADOLF, 1935, BIOCHEM JOUR, V29, P1951; KUO CF, 1989, J MOL BIOL, V208, P45, DOI 10.1016/0022-2836(89)90086-7; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX G, 1976, AM J PHYSIOL, V231, P1068, DOI 10.1152/ajplegacy.1976.231.4.1068; LieVenema H, 1997, BIOCHEM J, V323, P611, DOI 10.1042/bj3230611; NAGAMI GT, 1986, J CLIN INVEST, V78, P124, DOI 10.1172/JCI112540; OWEN EE, 1963, J CLIN INVEST, V42, P263, DOI 10.1172/JCI104713; OWEN OE, 1969, J CLIN INVEST, V48, P574, DOI 10.1172/JCI106016; Passonneau J.V., 1993, ENZYMATIC ANAL PRACT; PRUSINER S, 1970, ANAL BIOCHEM, V37, P429, DOI 10.1016/0003-2697(70)90069-2; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RICHTERICH RW, 1958, AM J PHYSIOL, V195, P316, DOI 10.1152/ajplegacy.1958.195.2.316; SCHOOLWERTH AC, 1994, AM J PHYSIOL, V267, pF400, DOI 10.1152/ajprenal.1994.267.3.F400; TIZIANELLO A, 1980, J CLIN INVEST, V65, P1162, DOI 10.1172/JCI109771; WATFORD M, 1991, CONTRIB NEPHROL, V92, P211; WEIL-MALHERBE HANS, 1935, BIOCHEM JOUR, V29, P2077; WRIGHT PA, 1990, AM J PHYSIOL, V259, pF53, DOI 10.1152/ajprenal.1990.259.1.F53; WU C, 1963, COMP BIOCHEM PHYSIOL, V8, P335, DOI 10.1016/0010-406X(63)90169-5	38	34	34	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38159	38166		10.1074/jbc.M302885200	http://dx.doi.org/10.1074/jbc.M302885200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871952	hybrid			2022-12-27	WOS:000185575100010
J	Ishikawa, T; Jiang, C; Stutts, MJ; Marunaka, Y; Rotin, D				Ishikawa, T; Jiang, C; Stutts, MJ; Marunaka, Y; Rotin, D			Regulation of the epithelial Na+ channel by cytosolic ATP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; TOAD URINARY-BLADDER; SODIUM-CHANNEL; PSEUDOHYPOALDOSTERONISM TYPE-1; LIDDLE-SYNDROME; XENOPUS OOCYTES; DOWN-REGULATION; GAMMA-SUBUNIT; BETA-SUBUNIT; CELLS	The epithelial Na+ channel (ENaC), composed of three subunits (alphabetagamma), is expressed in various Na+-absorbing epithelia and plays a critical role in salt and water balance and in the regulation of blood pressure. By using patch clamp techniques, we have examined the effect of cytosolic ATP on the activity of the rat alphabetagammaENaC (rENaC) stably expressed in NIH-3T3 cells and in Madin-Darby canine kidney epithelial cells. The inward whole-cell current attributable to rENaC activity ran down when these cells were dialyzed with an ATP-free pipette solution in the conventional whole-cell voltage-clamping technique. This run down was prevented by 2 mM ATP (but not by AMP or ADP) in the pipette solution or by the poorly or non-hydrolyzable analogues of ATP (adenosine 5'-O-(thiotriphosphate) and adenosine 5'-(beta,gamma-imino)triphosphate) in both cell lines, suggesting that protection from run down was mediated through non-hydrolytic nucleotide binding. Accordingly, we demonstrate binding of ATP (but not AMP) to alpharENaC expressed in Madin-Darby canine kidney cells, which was inhibited upon mutation of the two putative nucleotide-binding motifs of alpharENaC. Single channel analyses indicated that the run down of currents observed in the whole-cell recording was attributable to run down of channel activity, defined as NPo (the product of the number of channels and open probability). We propose that this novel ATP regulation of ENaC may be, at least in part, involved in the fine-tuning of ENaC activity under physiologic and pathophysiologic conditions.	Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Physiol Lab, Sapporo, Hokkaido 0600818, Japan; Hosp Sick Children, Cell Biol Program, Toronto, ON M5G 1X8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5G 1X8, Canada; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Mol Cell Physiol, Kyoto 6020841, Japan; Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Resp Mol Med, Kyoto 6020841, Japan; Univ N Carolina, Cyst Fibrosis Pulm Res & Treatment Ctr, Chapel Hill, NC 27599 USA	Hokkaido University; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; Kyoto Prefectural University of Medicine; Kyoto Prefectural University of Medicine; University of North Carolina; University of North Carolina Chapel Hill	Ishikawa, T (corresponding author), Hokkaido Univ, Grad Sch Vet Med, Dept Biomed Sci, Physiol Lab, Sapporo, Hokkaido 0600818, Japan.			Marunaka, Yoshinori/0000-0003-3846-0937				Abriel H, 1999, J PHYSIOL-LONDON, V516, P31, DOI 10.1111/j.1469-7793.1999.031aa.x; Awayda MS, 1996, J GEN PHYSIOL, V108, P49, DOI 10.1085/jgp.108.1.49; Awayda MS, 1999, AM J PHYSIOL-CELL PH, V277, pC216, DOI 10.1152/ajpcell.1999.277.2.C216; BARRY PH, 1991, J MEMBRANE BIOL, V121, P101, DOI 10.1007/BF01870526; Bond T, 1999, J GEN PHYSIOL, V113, P441, DOI 10.1085/jgp.113.3.441; CANESSA CM, 1994, NATURE, V367, P463, DOI 10.1038/367463a0; CANESSA CM, 1993, NATURE, V361, P467, DOI 10.1038/361467a0; Chabot H, 1999, J MEMBRANE BIOL, V169, P175, DOI 10.1007/s002329900529; Chalfant ML, 1999, AM J PHYSIOL-CELL PH, V276, pC477, DOI 10.1152/ajpcell.1999.276.2.C477; Chang SS, 1996, NAT GENET, V12, P248, DOI 10.1038/ng0396-248; Chraibi A, 2001, CELL PHYSIOL BIOCHEM, V11, P115, DOI 10.1159/000047799; Chraibi A, 1999, J PHARMACOL EXP THER, V290, P341; FRINDT G, 1995, AM J PHYSIOL-RENAL, V268, pF480, DOI 10.1152/ajprenal.1995.268.3.F480; Garty H, 1997, PHYSIOL REV, V77, P359, DOI 10.1152/physrev.1997.77.2.359; GARTY H, 1983, J MEMBRANE BIOL, V74, P15, DOI 10.1007/BF01870591; Grunder S, 1997, EMBO J, V16, P899, DOI 10.1093/emboj/16.5.899; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANSSON JH, 1995, P NATL ACAD SCI USA, V92, P11495, DOI 10.1073/pnas.92.25.11495; HANSSON JH, 1995, NAT GENET, V11, P76, DOI 10.1038/ng0995-76; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Hilgemann DW, 1997, ANNU REV PHYSIOL, V59, P193, DOI 10.1146/annurev.physiol.59.1.193; Hummler E, 1996, NAT GENET, V12, P325, DOI 10.1038/ng0396-325; Ishikawa T, 1998, J GEN PHYSIOL, V111, P825, DOI 10.1085/jgp.111.6.825; JORGENSEN PL, 1980, PHYSIOL REV, V60, P864; Kellenberger S, 1998, J CLIN INVEST, V101, P2741, DOI 10.1172/JCI2837; Mall M, 1996, FEBS LETT, V381, P47, DOI 10.1016/0014-5793(96)00079-8; Mall M, 1998, J CLIN INVEST, V102, P15, DOI 10.1172/JCI2729; Mirshahi M, 2001, OPHTHALMIC RES, V33, P7, DOI 10.1159/000055635; PALMER LG, 1980, J MEMBRANE BIOL, V57, P59, DOI 10.1007/BF01868986; Palmer LG, 1998, J PHYSIOL-LONDON, V509, P151, DOI 10.1111/j.1469-7793.1998.151bo.x; PAULMICHL M, 1992, NATURE, V356, P238, DOI 10.1038/356238a0; PUSCH M, 1988, PFLUG ARCH EUR J PHY, V411, P204, DOI 10.1007/BF00582316; RINDT G, 1996, AM J PHYSIOL, V271, pF1086; SHIMKETS RA, 1994, CELL, V79, P407, DOI 10.1016/0092-8674(94)90250-X; Staub O, 1996, EMBO J, V15, P2371, DOI 10.1002/j.1460-2075.1996.tb00593.x; Strautnieks SS, 1996, NAT GENET, V13, P248, DOI 10.1038/ng0696-248; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; STUTTS MJ, 1988, J APPL PHYSIOL, V64, P253, DOI 10.1152/jappl.1988.64.1.253; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037	40	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38276	38286		10.1074/jbc.M307216200	http://dx.doi.org/10.1074/jbc.M307216200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876281	Green Published, hybrid			2022-12-27	WOS:000185575100025
J	Ng, YP; He, W; Ip, NY				Ng, YP; He, W; Ip, NY			Leukemia inhibitory factor receptor signaling negatively modulates nerve growth factor-induced neurite outgrowth in PC12 cells and sympathetic neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CILIARY NEUROTROPHIC FACTOR; MESSENGER-RNAS; TERMINAL DIFFERENTIATION; RAC1 ACTIVATION; CNTF RECEPTOR; MAH CELLS; EXPRESSION; INTERLEUKIN-6; STAT3; KINASE	Nerve growth factor (NGF) is required for the development of sympathetic neurons and subsets of sensory neurons. Our current knowledge on the molecular mechanisms underlying the biological functions of NGF is in part based on the studies with PC12 rat pheochromocytoma cells, which differentiate into sympathetic neuron-like cells upon NGF treatment. Here we report that the expression of leukemia inhibitory factor receptor (LIFR), one of the signaling molecules shared by several neuropoietic cytokines of the interleukin-6 family, is specifically up-regulated in PC12 cells following treatment with NGF. Attenuation of LIFR signaling through stable transfection of antisense- or dominant negative-LIFR constructs enhances NGF-induced neurite extension in PC12 cells. On the contrary, overexpression of LIFR retards the growth of neurites. More importantly, whereas NGF-induced Rac1 activity is enhanced in antisense- LIFR and dominant negative-LIFR expressing PC12 cells, it is reduced in LIFR expressing PC12 cells. Following combined treatment with NGF and ciliary neurotrophic factor, sympathetic neurons exhibit attenuated neurite growth and branching. On the other hand, in sympathetic neurons lacking LIFR, neurite growth and branching is enhanced when compared with wild type controls. Taken together, our findings demonstrate that LIFR expression can be specifically induced by NGF and, besides its known function in cell survival and phenotype development, activated LIFR signaling can exert negative regulatory effects on neurite extension and branching of sympathetic neurons.	Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Hong Kong, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Mol Neurosci Ctr, Hong Kong, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Ip, NY (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Biotechnol Res Inst, Clear Water Bay, Hong Kong, Hong Kong, Peoples R China.	BOIP@UST.HK		Ip, Nancy Yuk-Yu/0000-0002-2763-8907				BANNER LR, 1994, P NATL ACAD SCI USA, V91, P7109, DOI 10.1073/pnas.91.15.7109; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Elson GCA, 2000, NAT NEUROSCI, V3, P867, DOI 10.1038/78765; Gallo G, 2000, J NEUROBIOL, V44, P159, DOI 10.1002/1097-4695(200008)44:2<159::AID-NEU6>3.0.CO;2-H; GREENE LA, 1995, CURR OPIN NEUROBIOL, V5, P579, DOI 10.1016/0959-4388(95)80062-X; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Guo X, 1999, J NEUROSCI, V19, P2113; Guo X, 1997, DEV BRAIN RES, V104, P101, DOI 10.1016/S0165-3806(97)00142-9; He W, 2002, FEBS LETT, V514, P214, DOI 10.1016/S0014-5793(02)02367-0; Heinrich PC, 2003, BIOCHEM J, V374, P1, DOI 10.1042/BJ20030407; HUANG EJ, 2003, IN PRESS ANN REV BIO; Ihara S, 1997, EMBO J, V16, P5345, DOI 10.1093/emboj/16.17.5345; Ihara S, 1996, J BIOCHEM, V120, P865; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; IP FCF, 1995, J NEUROCHEM, V65, P2393; IP NY, 1994, NEURON, V13, P443, DOI 10.1016/0896-6273(94)90359-X; Ip NY, 1996, ANNU REV NEUROSCI, V19, P491; ISHII DN, 1975, J NEUROCHEM, V25, P843, DOI 10.1111/j.1471-4159.1975.tb04416.x; KALMAN D, 1990, NEURON, V4, P355, DOI 10.1016/0896-6273(90)90048-K; Koblar SA, 1998, P NATL ACAD SCI USA, V95, P3178, DOI 10.1073/pnas.95.6.3178; KORSCHING S, 1988, DEV BIOL, V126, P40, DOI 10.1016/0012-1606(88)90236-9; Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909; LEWIS SE, 1994, J NEUROCHEM, V63, P429; Man D, 2003, J BIOL CHEM, V278, P23285, DOI 10.1074/jbc.M301976200; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Moon C, 2002, P NATL ACAD SCI USA, V99, P9015, DOI 10.1073/pnas.132131699; MURPHY M, 1993, DEVELOPMENT, V117, P1173; Ng J, 2002, NATURE, V416, P442, DOI 10.1038/416442a; Nusser N, 2002, J BIOL CHEM, V277, P35840, DOI 10.1074/jbc.M203617200; Ohtani T, 2000, IMMUNITY, V12, P95, DOI 10.1016/S1074-7613(00)80162-4; Pongrac JL, 1998, MOL BRAIN RES, V62, P25, DOI 10.1016/S0169-328X(98)00215-0; Rane SG, 2000, ONCOGENE, V19, P5662, DOI 10.1038/sj.onc.1203925; REEBEN M, 1995, J NEUROSCI RES, V40, P177, DOI 10.1002/jnr.490400206; Shimazaki T, 2001, J NEUROSCI, V21, P7642, DOI 10.1523/JNEUROSCI.21-19-07642.2001; Taga T, 1997, ANNU REV IMMUNOL, V15, P797, DOI 10.1146/annurev.immunol.15.1.797; Torocsik B, 2002, J NEUROSCI, V22, P8971; Turnley AM, 2000, J NEUROCHEM, V74, P889, DOI 10.1046/j.1471-4159.2000.0740889.x; VERDI JM, 1994, P NATL ACAD SCI USA, V91, P3949, DOI 10.1073/pnas.91.9.3949; WARE CB, 1995, DEVELOPMENT, V121, P1283; WONG VV, 1995, J BIOL CHEM, V270, P313, DOI 10.1074/jbc.270.1.313; Wu YY, 2000, J BIOL CHEM, V275, P2147, DOI 10.1074/jbc.275.3.2147; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; Yamaguchi Y, 2001, J BIOL CHEM, V276, P18977, DOI 10.1074/jbc.M100254200; Yasui H, 2001, J BIOL CHEM, V276, P15298, DOI 10.1074/jbc.M008546200; Zaheer A, 1995, NEUROCHEM RES, V20, P1457, DOI 10.1007/BF00970594; Zentrich E, 2002, J BIOL CHEM, V277, P4110, DOI 10.1074/jbc.M107824200	47	24	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38731	38739		10.1074/jbc.M304623200	http://dx.doi.org/10.1074/jbc.M304623200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871977	hybrid			2022-12-27	WOS:000185575100079
J	Rondon, AG; Jimeno, S; Garcia-Rubio, M; Aguilera, A				Rondon, AG; Jimeno, S; Garcia-Rubio, M; Aguilera, A			Molecular evidence that the eukaryotic THO/TREX complex is required for efficient transcription elongation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; WHOLE-CELL EXTRACT; SACCHAROMYCES-CEREVISIAE; MITOTIC RECOMBINATION; GENOMIC INSTABILITY; NUCLEAR EXPORT; YEAST HOMOLOG; GENE; SUB2P; HPR1	THO/TREX is a conserved eukaryotic complex formed by the core THO complex plus proteins involved in mRNA metabolism and export such as Sub2 and Yra1. Mutations in any of the THO/TREX structural genes cause pleiotropic phenotypes such as transcription impairment, increased transcription-associated recombination, and mRNA export defects. To assay the relevance of THO/TREX complex in transcription, we performed in vitro transcription elongation assays in mutant cell extracts using supercoiled DNA templates containing two G-less cassettes. With these assays, we demonstrate that hpr1Delta, tho2Delta, and mft1Delta mutants of the THO complex and sub2 mutants show significant reductions in the efficiency of transcription elongation. The mRNA expression defect of hpr1Delta mutants was not due to an increase in mRNA decay, as determined by mRNA half-life measurements and mRNA time course accumulation experiments in the absence of Rrp6p exoribonuclease. This work demonstrates that THO and Sub2 are required for efficient transcription elongation, providing further evidence for the coupling between transcription and mRNA metabolism and export.	Univ Sevilla, Fac Biol, Dept Genet, E-41012 Seville, Spain	University of Sevilla	Aguilera, A (corresponding author), Univ Sevilla, Fac Biol, Dept Genet, Ave Reina Mercedes 6, E-41012 Seville, Spain.		Jimeno González, Sonia/GJM-5073-2022; Rondon, Ana G/C-2102-2017; Jimeno, Sonia/C-2514-2017; Aguilera, Andres/L-1825-2014; Garcia-Rubio, Maria/C-2061-2017	Jimeno González, Sonia/0000-0002-7034-0081; Aguilera, Andres/0000-0003-4782-1714; Garcia-Rubio, Maria/0000-0003-0981-0555; , Ana/0000-0002-9481-1255				Aguilera A, 2002, EMBO J, V21, P195, DOI 10.1093/emboj/21.3.195; ASO T, 1995, SCIENCE, V269, P1439, DOI 10.1126/science.7660129; BENGAL E, 1991, MOL CELL BIOL, V11, P1195, DOI 10.1128/MCB.11.3.1195; Chavez S, 2000, EMBO J, V19, P5824, DOI 10.1093/emboj/19.21.5824; Chavez S, 1997, GENE DEV, V11, P3459, DOI 10.1101/gad.11.24.3459; Chavez S, 2001, MOL CELL BIOL, V21, P7054, DOI 10.1128/MCB.21.20.7054-7064.2001; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; Fan HY, 2001, MOL CELL BIOL, V21, P5459, DOI 10.1128/MCB.21.16.5459-5470.2001; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Fong YW, 2001, NATURE, V414, P929, DOI 10.1038/414929a; Gallardo M, 2003, J BIOL CHEM, V278, P24225, DOI 10.1074/jbc.M302900200; Gallardo M, 2001, GENETICS, V157, P79; Gatfield D, 2001, CURR BIOL, V11, P1716, DOI 10.1016/S0960-9822(01)00532-2; Hartzog GA, 1998, GENE DEV, V12, P357, DOI 10.1101/gad.12.3.357; Hartzog GA, 2003, CURR OPIN GENET DEV, V13, P119, DOI 10.1016/S0959-437X(03)00024-8; Jensen TH, 2001, CURR BIOL, V11, P1711, DOI 10.1016/S0960-9822(01)00529-2; Jimeno S, 2002, EMBO J, V21, P3526, DOI 10.1093/emboj/cdf335; Kistler AL, 2001, GENE DEV, V15, P42, DOI 10.1101/gad.851301; Lei L, 1999, MOL CELL BIOL, V19, P8372; LeRoy G, 1998, SCIENCE, V282, P1900, DOI 10.1126/science.282.5395.1900; Libri D, 2001, GENE DEV, V15, P36, DOI 10.1101/gad.852101; Libri D, 2002, MOL CELL BIOL, V22, P8254, DOI 10.1128/MCB.22.23.8254-8266.2002; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Orphanides G, 1998, CELL, V92, P105, DOI 10.1016/S0092-8674(00)80903-4; Piruat JI, 1998, EMBO J, V17, P4859, DOI 10.1093/emboj/17.16.4859; Portman DS, 1997, RNA, V3, P527; Prado F, 1997, EMBO J, V16, P2826, DOI 10.1093/emboj/16.10.2826; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; Rondon AG, 2003, EMBO J, V22, P612, DOI 10.1093/emboj/cdg047; Santos-Rosa H, 1998, MOL CELL BIOL, V18, P6826, DOI 10.1128/MCB.18.11.6826; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; Schneiter R, 1999, MOL CELL BIOL, V19, P3415; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SEKIMIZU K, 1976, BIOCHEMISTRY-US, V15, P5064, DOI 10.1021/bi00668a018; Shaw RJ, 2000, MOL CELL BIOL, V20, P7427, DOI 10.1128/MCB.20.20.7427-7437.2000; Shilatifard A, 1996, SCIENCE, V271, P1873, DOI 10.1126/science.271.5257.1873; Shilatifard A, 2003, ANNU REV BIOCHEM, V72, P693, DOI 10.1146/annurev.biochem.72.121801.161551; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Wada T, 2000, MOL CELL, V5, P1067, DOI 10.1016/S1097-2765(00)80272-5; Wada T, 1998, GENE DEV, V12, P343, DOI 10.1101/gad.12.3.343; Wind M, 2000, BIOESSAYS, V22, P327, DOI 10.1002/(SICI)1521-1878(200004)22:4<327::AID-BIES3>3.0.CO;2-4; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; Yamaguchi Y, 1999, CELL, V97, P41, DOI 10.1016/S0092-8674(00)80713-8; Zenklusen D, 2002, MOL CELL BIOL, V22, P8241, DOI 10.1128/MCB.22.23.8241-8253.2002; Zhang M, 2001, GENE DEV, V15, P30, DOI 10.1101/gad.851701	49	91	97	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39037	39043		10.1074/jbc.M305718200	http://dx.doi.org/10.1074/jbc.M305718200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871933	Green Published, hybrid			2022-12-27	WOS:000185575100116
J	Sato, K; Tokmakov, AA; He, CL; Kurokawa, M; Iwasaki, T; Shirouzu, M; Fissore, RA; Yokoyama, S; Fukami, Y				Sato, K; Tokmakov, AA; He, CL; Kurokawa, M; Iwasaki, T; Shirouzu, M; Fissore, RA; Yokoyama, S; Fukami, Y			Reconstitution of Src-dependent phospholipase C gamma phosphorylation and transient calcium release by using membrane rafts and cell-free extracts from Xenopus eggs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEA-URCHIN EGGS; DOMAIN-MEDIATED ACTIVATION; TYROSINE KINASE-ACTIVITY; STARFISH EGGS; GROWTH-FACTOR; PLC-GAMMA; INOSITOL 1,4,5-TRISPHOSPHATE; CA2+ OSCILLATIONS; LIPID RAFTS; MOUSE EGGS	We reported previously that egg membrane rafts serve as a subcellular microdomain for sperm-dependent tyrosine kinase signaling in Xenopus fertilization. Moreover, we demonstrated that raft-associated Src tyrosine kinase was activated by sperm in vitro. Here we show that egg rafts incubated with sperm or hydrogen peroxide (H2O2) can promote Src-dependent phosphorylation of phospholipase Cgamma (PLCgamma) and transient calcium release in the extracts of unfertilized Xenopus eggs. In vivo egg activation by sperm or H2O2 also promotes tyrosine-phosphorylation and raft-translocalization of PLCgamma. Immunodepletion of PLCgamma from the egg extracts inhibits the raft-dependent calcium release. Rafts prepared from H2O2-activated eggs also promote Src-dependent dephosphorylation of p42 mitogen-activated protein kinase and cell cycle transition from metaphase II to interphase in egg extracts. PLCgamma phosphorylation and calcium release in egg extracts can be promoted by rafts prepared from COS-7 cells expressing the Xenopus Src gene. These results demonstrate that the signaling events elicited by fertilization in Xenopus eggs can be reconstituted in vitro. The development of such experimental platforms will allow us to dissect the molecular mechanism of sperm-dependent activation of raft-associated Src and subsequent up-regulation of PLCgamma and egg activation machinery in Xenopus eggs.	Kobe Univ, Fac Sci, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan; Kobe Univ, Fac Sci, Dept Biol, Nada Ku, Kobe, Hyogo 6578501, Japan; RIKEN, Yokohama Inst, Genome Sci Ctr, Yokohama, Kanagawa 2300045, Japan; Univ Massachusetts, Dept Vet & Anim Sci, Amherst, MA 01003 USA	Kobe University; Kobe University; RIKEN; University of Massachusetts System; University of Massachusetts Amherst	Sato, K (corresponding author), Kobe Univ, Fac Sci, Res Ctr Environm Genom, Nada Ku, Kobe, Hyogo 6578501, Japan.	kksato@kobe-u.ac.jp	Shirouzu, Mikako/A-6521-2016; Yokoyama, Shigeyuki/N-6911-2015	Yokoyama, Shigeyuki/0000-0003-3133-7338; Kurokawa, Manabu/0000-0002-4138-5934				Abassi YA, 2000, DEV BIOL, V218, P206, DOI 10.1006/dbio.1999.9582; Abram CL, 2000, EXP CELL RES, V254, P1, DOI 10.1006/excr.1999.4732; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Belton RJ, 2001, MOL REPROD DEV, V59, P294, DOI 10.1002/mrd.1034; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Carroll DJ, 1997, J CELL BIOL, V138, P1303, DOI 10.1083/jcb.138.6.1303; Carroll DJ, 1999, DEV BIOL, V206, P232, DOI 10.1006/dbio.1998.9145; Dupont G, 1996, BIOCHEM J, V316, P583, DOI 10.1042/bj3160583; Evans JD, 2001, BIOESSAYS, V23, P62, DOI 10.1002/1521-1878(200101)23:1&lt;62::AID-BIES1008&gt;3.0.CO;2-7; FUKAMI Y, 1993, J BIOL CHEM, V268, P1132; Giusti AF, 2000, J BIOL CHEM, V275, P16788, DOI 10.1074/jbc.M001091200; Giusti AF, 1999, J BIOL CHEM, V274, P29318, DOI 10.1074/jbc.274.41.29318; Glahn D, 1999, DEV BIOL, V205, P171, DOI 10.1006/dbio.1998.9042; Harlow E., 1988, ANTIBODIES LAB MANUA; Kinsey WH, 2000, DEV BIOL, V225, P253, DOI 10.1006/dbio.2000.9830; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SJ, 1998, DEV BIOL, V193, P195, DOI 10.1006/dbio.1997.8792; LOHKA MJ, 1983, SCIENCE, V220, P719, DOI 10.1126/science.6601299; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; Ma YC, 2000, CELL, V102, P635, DOI 10.1016/S0092-8674(00)00086-6; Mehlmann LM, 1998, DEV BIOL, V203, P221, DOI 10.1006/dbio.1998.9051; Miller BJ, 2000, J CELL BIOL, V149, P1289, DOI 10.1083/jcb.149.6.1289; MIYAZAKI S, 1993, DEV BIOL, V158, P62, DOI 10.1006/dbio.1993.1168; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Rongish BJ, 1999, DEV BIOL, V215, P147, DOI 10.1006/dbio.1999.9472; Runft LL, 2000, DEVELOPMENT, V127, P3227; Runft LL, 2002, DEV BIOL, V245, P237, DOI 10.1006/dbio.2002.0600; Runft LL, 1999, DEV BIOL, V214, P399, DOI 10.1006/dbio.1999.9415; Sato K, 1999, DEV BIOL, V209, P308, DOI 10.1006/dbio.1999.9255; Sato K, 1998, FEBS LETT, V424, P113, DOI 10.1016/S0014-5793(98)00123-9; Sato K, 2002, DEVELOPMENT, V129, P885; Sato K, 2001, DEV GROWTH DIFFER, V43, P55; Sato K, 1996, J BIOL CHEM, V271, P13250, DOI 10.1074/jbc.271.22.13250; Sato KI, 2000, DEV BIOL, V224, P453, DOI 10.1006/dbio.2000.9782; Saunders CM, 2002, DEVELOPMENT, V129, P3533; SCHULTZ RM, 1995, CURR TOP DEV BIOL, V30, P21, DOI 10.1016/S0070-2153(08)60563-3; Sette C, 2002, EMBO J, V21, P5386, DOI 10.1093/emboj/cdf553; Shearer J, 1999, DEVELOPMENT, V126, P2273; Shen SS, 1999, DEV GROWTH DIFFER, V41, P345; SHILLING FM, 1994, DEV BIOL, V162, P590, DOI 10.1006/dbio.1994.1112; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; STEELE RE, 1989, J BIOL CHEM, V264, P10649; Stricker SA, 1999, DEV BIOL, V211, P157, DOI 10.1006/dbio.1999.9340; Swann K, 2001, REPRODUCTION, V122, P839, DOI 10.1530/reprod/122.6.839; Tatton L, 2003, J BIOL CHEM, V278, P4847, DOI 10.1074/jbc.M209321200; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tokmakov AA, 2002, CELL CALCIUM, V32, P11, DOI 10.1016/S0143-4160(02)00078-7; Tokmakov AA, 2001, J CELL BIOCHEM, V82, P89, DOI 10.1002/jcb.1140.abs; WALKER F, 1993, J BIOL CHEM, V268, P19552; Waltenberger J, 1999, CIRC RES, V85, P12; WHITAKER M, 1993, DEVELOPMENT, V117, P1; Wu H, 2001, BIOL REPROD, V64, P1338, DOI 10.1095/biolreprod64.5.1338; YIM DL, 1994, DEV BIOL, V162, P41, DOI 10.1006/dbio.1994.1065	54	48	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38413	38420		10.1074/jbc.M302617200	http://dx.doi.org/10.1074/jbc.M302617200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847104	hybrid			2022-12-27	WOS:000185575100041
J	Webster, JM; Tiwari, S; Weissman, AM; Wojcikiewicz, RJH				Webster, JM; Tiwari, S; Weissman, AM; Wojcikiewicz, RJH			Inositol 1,4,5-trisphosphate receptor ubiquitination is mediated by mammalian Ubc7, a component of the endoplasmic reticulum-associated degradation pathway, and is inhibited by chelation of intracellular Zn2+	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; SH-SY5Y NEUROBLASTOMA-CELLS; MOTILITY FACTOR-RECEPTOR; INDUCED DOWN-REGULATION; ALZHEIMERS-DISEASE; PROTEASOME PATHWAY; CHOLINESTERASE-INHIBITORS; PROTEIN TRANSLOCATION; LIGAND-BINDING; CA2+	In response to activation of certain cell surface receptors, inositol 1,4,5-trisphosphate receptors (InsP(3)Rs), which are located in the endoplasmic reticulum, can be rapidly ubiquitinated and then degraded by the proteasome. Ubiquitination is mediated by the concerted action of ubiquitin-conjugating enzymes (Ubcs or E2s) and ubiquitin-protein ligases (E3s). In the present study we have examined the enzymology of ubiquitination of endogenous InsP(3)Rs in muscarinic agonist-stimulated SH-SY5Y human neuroblastoma cells, focusing our attention on two mammalian E2s, MmUbc6 and MmUbc7, that have been implicated in endoplasmic reticulum-associated degradation (ERAD) and are homologous to the yeast ERAD E2s, Ubc6p and Ubc7p. Analysis of SH-SY5Y cells stably expressing these enzymes and their dominant-negative mutants revealed that MmUbc7 mediates InsP(3)R ubiquitination and down-regulation, but that MmUbc6 does not. These data indicate that InsP(3)Rs are processed by a component of the ERAD pathway and suggest that MmUbc7 may be employed selectively to ubiquitinate proteins, like InsP(3)Rs, that are subject to regulated ERAD. Additional studies showed that the Zn2+ chelator N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine blocked InsP(3)R ubiquitination, suggesting that a RING finger domain- containing E3 is also involved in this process. Finally, muscarinic agonist-induced InsP(3)R ubiquitination was seen in rat brain slices, indicating that the results obtained from SH-SY5Y cells reflect a physiological process.	SUNY Upstate Med Univ, Dept Pharmacol, Syracuse, NY 13210 USA; NCI, Regulat Prot Funct Lab, Ctr Canc Res, Frederick, MD 21702 USA	State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Wojcikiewicz, RJH (corresponding author), SUNY Upstate Med Univ, Dept Pharmacol, 750 E Adams St, Syracuse, NY 13210 USA.	wojcikir@upstate.edu		Webster, Jack/0000-0003-2586-473X	NATIONAL CANCER INSTITUTE [Z01BC009392] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK049194] Funding Source: NIH RePORTER; NIDDK NIH HHS [5R01DK49194] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Auld DS, 2002, PROG NEUROBIOL, V68, P209, DOI 10.1016/S0301-0082(02)00079-5; BALDUINI W, 1991, DEV BRAIN RES, V62, P115, DOI 10.1016/0165-3806(91)90196-P; Banki K, 1996, J BIOL CHEM, V271, P32994, DOI 10.1074/jbc.271.51.32994; Bays NW, 2001, NAT CELL BIOL, V3, P24, DOI 10.1038/35050524; Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bokkala S, 1997, J BIOL CHEM, V272, P12454, DOI 10.1074/jbc.272.19.12454; Botero D, 2002, MOL ENDOCRINOL, V16, P1999, DOI 10.1210/me.2002-0135; Brind S, 2000, DEV BIOL, V223, P251, DOI 10.1006/dbio.2000.9728; CHALLISS RAJ, 1994, NEUROPHARMACOLOGY, V33, P15, DOI 10.1016/0028-3908(94)90092-2; Chimienti F, 2001, BIOCHEM PHARMACOL, V62, P51, DOI 10.1016/S0006-2952(01)00624-4; da Fonseca PCA, 2003, P NATL ACAD SCI USA, V100, P3936, DOI 10.1073/pnas.0536251100; Fang SY, 2001, P NATL ACAD SCI USA, V98, P14422, DOI 10.1073/pnas.251401598; Fisher A, 1996, ANN NY ACAD SCI, V777, P189, DOI 10.1111/j.1749-6632.1996.tb34418.x; Fowler CJ, 1996, ANN NY ACAD SCI, V786, P294, DOI 10.1111/j.1749-6632.1996.tb39072.x; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gonen H, 1999, J BIOL CHEM, V274, P14823, DOI 10.1074/jbc.274.21.14823; Grutzendler J, 2001, DRUGS, V61, P41, DOI 10.2165/00003495-200161010-00005; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hamada K, 2002, J BIOL CHEM, V277, P21115, DOI 10.1074/jbc.C200244200; Hampton RY, 2002, ANNU REV CELL DEV BI, V18, P345, DOI 10.1146/annurev.cellbio.18.032002.131219; Hampton RY, 1997, P NATL ACAD SCI USA, V94, P12944, DOI 10.1073/pnas.94.24.12944; Hampton RY, 2002, CURR OPIN CELL BIOL, V14, P476, DOI 10.1016/S0955-0674(02)00358-7; Hatakeyama S, 2001, J BIOL CHEM, V276, P33111, DOI 10.1074/jbc.M102755200; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; Imai Y, 2001, CELL, V105, P891, DOI 10.1016/S0092-8674(01)00407-X; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; Jarosch E, 2003, INT REV CYTOL, V223, P39; Jellerette T, 2000, DEV BIOL, V223, P238, DOI 10.1006/dbio.2000.9675; Jiang QX, 2002, EMBO J, V21, P3575, DOI 10.1093/emboj/cdf380; Kaneko M, 2002, FEBS LETT, V532, P147, DOI 10.1016/S0014-5793(02)03660-8; Katsanis N, 1998, GENOMICS, V51, P128, DOI 10.1006/geno.1998.5263; Krall WJ, 1999, ANN PHARMACOTHER, V33, P441, DOI 10.1345/aph.18211; Lenk U, 2002, J CELL SCI, V115, P3007; Lester D, 2000, BIOCHEM BIOPH RES CO, V269, P474, DOI 10.1006/bbrc.2000.2302; Liang JS, 2003, J BIOL CHEM, V278, P23984, DOI 10.1074/jbc.M302683200; Lorick KL, 1999, P NATL ACAD SCI USA, V96, P11364, DOI 10.1073/pnas.96.20.11364; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Nadav E, 2003, BIOCHEM BIOPH RES CO, V303, P91, DOI 10.1016/S0006-291X(03)00279-1; Oberdorf J, 1999, BIOCHEM J, V339, P453, DOI 10.1042/0264-6021:3390453; Patel S, 1999, CELL CALCIUM, V25, P247, DOI 10.1054/ceca.1999.0021; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1999, MOL BIOL REP, V26, P125, DOI 10.1023/A:1006913215484; Ravid T, 1999, J BIOL CHEM, V274, P29341, DOI 10.1074/jbc.274.41.29341; Ravid T, 2000, J BIOL CHEM, V275, P35840, DOI 10.1074/jbc.M004793200; Serysheva II, 2003, J BIOL CHEM, V278, P21319, DOI 10.1074/jbc.C300148200; Sharma K, 2000, AM J PHYSIOL-RENAL, V278, pF1022, DOI 10.1152/ajprenal.2000.278.6.F1022; Sipma H, 1998, CELL CALCIUM, V23, P11, DOI 10.1016/S0143-4160(98)90070-7; Snitsarev VA, 1996, BIOPHYS J, V71, P1048, DOI 10.1016/S0006-3495(96)79305-0; SOMMER T, 1993, NATURE, V365, P176, DOI 10.1038/365176a0; Soulsby MD, 2002, CELL CALCIUM, V32, P175, DOI 10.1016/S0143416002001525; Tiwari S, 2001, J BIOL CHEM, V276, P16193, DOI 10.1074/jbc.M007640200; Tovey SC, 2001, J CELL SCI, V114, P3979; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; WARD CL, 1994, J BIOL CHEM, V269, P25710; Webster JM, 2003, EUR J PHARMACOL, V474, P1, DOI 10.1016/S0014-2999(03)02005-3; Willars GB, 2001, J BIOL CHEM, V276, P3123, DOI 10.1074/jbc.M008916200; Wojcikiewicz RJH, 1999, GASTROENTEROLOGY, V116, P1194, DOI 10.1016/S0016-5085(99)70023-5; WOJCIKIEWICZ RJH, 1994, J NEUROCHEM, V63, P177; WOJCIKIEWICZ RJH, 1995, J BIOL CHEM, V270, P11678, DOI 10.1074/jbc.270.19.11678; Wojcikiewicz RJH, 2003, J BIOL CHEM, V278, P940, DOI 10.1074/jbc.M206607200; Wojcikiewicz RJH, 1996, J BIOL CHEM, V271, P16652, DOI 10.1074/jbc.271.28.16652; WOJCIKIEWICZ RJH, 1994, J BIOL CHEM, V269, P7963; WOJCIKIEWICZ RJH, 1991, J BIOL CHEM, V266, P22234; Yang M, 1998, J EXP MED, V187, P835, DOI 10.1084/jem.187.6.835; Zhu CC, 1999, J BIOL CHEM, V274, P3476, DOI 10.1074/jbc.274.6.3476; Zhu CC, 2000, BIOCHEM J, V348, P551, DOI 10.1042/0264-6021:3480551	67	43	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38238	38246		10.1074/jbc.M305600200	http://dx.doi.org/10.1074/jbc.M305600200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869571	hybrid			2022-12-27	WOS:000185575100020
J	Haddad, F; Bodell, PW; Qin, AX; Giger, JM; Baldwin, KM				Haddad, F; Bodell, PW; Qin, AX; Giger, JM; Baldwin, KM			Role of antisense RNA in coordinating cardiac myosin heavy chain gene switching	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-MYOSIN; THYROID-HORMONE; MESSENGER-RNA; HUMAN HEART; RAT-HEART; ISOFORM EXPRESSION; SKELETAL-MUSCLE; TRANSGENIC MICE; TRANSCRIPTION; PROMOTER	A novel mechanism of regulation of cardiac alpha and beta myosin heavy chain gene by naturally occurring antisense transcription was elucidated via pre-mRNA analysis. Herein, we report the expression of an antisense beta myosin heavy chain RNA in the normal rodent myocardium. The pattern of expression of the antisense betaMHC RNA (betaRNA) under altered thyroid state and in diabetes directly correlates with that of the alpha pre-mRNA/mRNA, whereas it negatively correlates with the beta mRNA expression. Rapid amplification of the 5' end shows that this antisense transcript originates 2 kb downstream of the beta gene, and it is transcribed across the entire beta gene from the opposite strand. Our results demonstrate that the beta-alpha myosin heavy chain intergenic DNA possesses a bidirectional transcriptional activity, one direction transcribing the beta gene, and the opposite direction transcribing the antisense beta RNA. This process turns on the alpha expression, and it simultaneously turns off that of the beta and thus coordinates alpha and beta expression in an opposite fashion. Comparative analyses of the intergenic DNA sequence across five mammalian species revealed a conserved region that is proposed to be a common regulatory region for the alpha and antisense beta promoter. This finding unravels the mechanism of cardiac alpha-beta gene switching and implicates the role of cardiac myosin gene organization with their function.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Baldwin, KM (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073473] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL73473-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abraham WT, 2002, MOL MED, V8, P750, DOI 10.1007/BF03402039; ACSADI G, 1991, NEW BIOL, V3, P71; Blanchette M, 2002, GENOME RES, V12, P739, DOI 10.1101/gr.6902; BOHELER KR, 1992, J BIOL CHEM, V267, P12979; Chau YM, 2002, J CLIN ENDOCR METAB, V87, P2674, DOI 10.1210/jc.87.6.2674; CHIZZONITE RA, 1984, J BIOL CHEM, V259, P2628; CLARK WA, 1982, J BIOL CHEM, V257, P5449; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; Elferink CJ, 1996, BIOTECHNIQUES, V20, P470; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; GULICK J, 1991, J BIOL CHEM, V266, P9180; Haddad F, 1997, J MOL CELL CARDIOL, V29, P559, DOI 10.1006/jmcc.1996.0299; Haddad F, 1997, AM J PHYSIOL-ENDOC M, V272, pE856, DOI 10.1152/ajpendo.1997.272.5.E856; HAMILTON N, 1991, MOL CELL BIOCHEM, V106, P133; Hastings ML, 2000, J BIOL CHEM, V275, P11507, DOI 10.1074/jbc.275.15.11507; Herron TJ, 2002, CIRC RES, V90, P1150, DOI 10.1161/01.RES.0000022879.57270.11; IZUMO S, 1986, SCIENCE, V231, P597, DOI 10.1126/science.3945800; KNOTTS S, 1995, NUCLEIC ACIDS RES, V23, P3301, DOI 10.1093/nar/23.16.3301; Kramer C, 2003, NATURE, V421, P948, DOI 10.1038/nature01427; Krenz M, 2003, J BIOL CHEM, V278, P17466, DOI 10.1074/jbc.M210804200; LOMPRE AM, 1984, J BIOL CHEM, V259, P6437; Lowes BD, 1997, J CLIN INVEST, V100, P2315, DOI 10.1172/JCI119770; Luther HP, 1997, J MOL CELL CARDIOL, V29, P27, DOI 10.1006/jmcc.1996.0248; Luther HP, 1998, J CELL BIOCHEM, V70, P110, DOI 10.1002/(SICI)1097-4644(19980701)70:1<110::AID-JCB11>3.3.CO;2-K; Luther HP, 2001, J CELL BIOCHEM, V80, P596, DOI 10.1002/1097-4644(20010315)80:4<596::AID-JCB1014>3.0.CO;2-Y; MAHDAVI V, 1986, MED SCI SPORTS EXERC, V18, P229; Miyata S, 2000, CIRC RES, V86, P386, DOI 10.1161/01.RES.86.4.386; Molkentin JD, 1996, J MOL CELL CARDIOL, V28, P1211, DOI 10.1006/jmcc.1996.0112; Morkin E, 2000, MICROSC RES TECHNIQ, V50, P522, DOI 10.1002/1097-0029(20000915)50:6<522::AID-JEMT9>3.0.CO;2-U; Nakao K, 1997, J CLIN INVEST, V100, P2362, DOI 10.1172/JCI119776; O'Sullivan DC, 2002, AM J PHYSIOL-ENDOC M, V283, pE251, DOI 10.1152/ajpendo.00016.2002; Peters DG, 1999, AM J PHYSIOL-CELL PH, V276, pC1218, DOI 10.1152/ajpcell.1999.276.5.C1218; Reiser PJ, 2001, AM J PHYSIOL-HEART C, V280, pH1814, DOI 10.1152/ajpheart.2001.280.4.H1814; RINDT H, 1993, J BIOL CHEM, V268, P5332; Rougeulle C, 2002, TRENDS GENET, V18, P434, DOI 10.1016/S0168-9525(02)02749-X; SAEZ LJ, 1987, NUCLEIC ACIDS RES, V15, P5443, DOI 10.1093/nar/15.13.5443; Thai MV, 1998, J BIOL CHEM, V273, P14285, DOI 10.1074/jbc.273.23.14285; Vanhee-Brossollet C, 1998, GENE, V211, P1, DOI 10.1016/S0378-1119(98)00093-6; Wasserman WW, 1998, J MOL BIOL, V278, P167, DOI 10.1006/jmbi.1998.1700; WEYDERT A, 1985, P NATL ACAD SCI USA, V82, P7183, DOI 10.1073/pnas.82.21.7183; Wright CE, 1999, AM J PHYSIOL-CELL PH, V276, pC883, DOI 10.1152/ajpcell.1999.276.4.C883; Wright CE, 2001, AM J PHYSIOL-CELL PH, V280, pC1262, DOI 10.1152/ajpcell.2001.280.5.C1262; Wu YF, 2000, TRENDS ENDOCRIN MET, V11, P207, DOI 10.1016/S1043-2760(00)00263-0; Yelin R, 2003, NAT BIOTECHNOL, V21, P379, DOI 10.1038/nbt808; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	45	76	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37132	37138		10.1074/jbc.M305911200	http://dx.doi.org/10.1074/jbc.M305911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851393	hybrid			2022-12-27	WOS:000185437200019
J	Henry, LK; Adkins, EM; Han, Q; Blakely, RD				Henry, LK; Adkins, EM; Han, Q; Blakely, RD			Serotonin and cocaine-sensitive inactivation of human serotonin transporters by methanethiosulfonates targeted to transmembrane domain I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SCANNING MUTAGENESIS; DIFFERENTIALLY ALTER; SUBSTRATE TRANSPORT; GAT-1 PLAYS; DOPAMINE; CLONING; CYSTEINE; ACCESSIBILITY; EXPRESSION; RESIDUES	To explore aqueous accessibility and functional contributions of transmembrane domain (TM) 1 in human serotonin transporter (hSERT) proteins, we utilized the largely methanethiosulfonate (MTS) insensitive hSERT C109A mutant and mutated individual residues of hSERT TM1 to Cys followed by tests of MTS inactivation of 5-hydroxytryptamine (5-HT) transport. Residues in TM1 cytoplasmic to Gly-94 were largely unaffected by Cys substitution, whereas the mutation of residues extracellular to Ile-93 variably diminished transport activity. TM1 Cys substitutions displayed differential sensitivity to MTS reagents, with residues more cytoplasmic to Asp-98 being largely insensitive to MTS inactivation. Aminoethylmethanethiosulfonate (MTSEA), [2-(trimethylammonium) ethyl] methanethiosulfonate bromide (MTSET), and sodium (2-sulfonatoethyl)-methanethiosulfonate ( MTSES) similarly and profoundly inactivated 5-HT transport by SERT mutants D98C, G100C, W103C, and Y107C. MTSEA uniquely inactivated transport activity of S91C, G94C, Y95C but increased activity at I108C. MTSEA and MTSET, but not MTSES, inactivated transport function at N101C. Notably, 5-HT provided partial to complete protection from MTSET inactivation for D98C, G100C, N101C, and Y107C. Equivalent blockade of MTSET inactivation at N101C was observed with 5-HT at both room temperature and at 4degreesC, inconsistent with major conformational changes leading to protection. Notably, cocaine also protected MTSET inactivation of G100C and N101C, although MTS incubations with N101C that eliminate 5-HT transport do not preclude cocaine analog binding nor its inhibition by 5-HT. 5-HT modestly enhanced the inactivation by MTSET at I93C and Y95C, whereas cocaine significantly enhanced MTSET sensitivity at Y107C and I108C. In summary, our studies reveal physical differences in TM1 accessibility to externally applied MTS reagents and reveal sites supporting substrate and antagonist modulation of MTS inactivation. Moreover, we identify a limit to accessibility for membrane-impermeant MTS reagents that may reflect aspects of an occluded permeation pathway.	Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University	Blakely, RD (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Mol Neurosci, Ste 7140 MRBIII, Nashville, TN 37232 USA.	randy.blakely@vanderbilt.edu			NATIONAL INSTITUTE ON DRUG ABUSE [R01DA007390] Funding Source: NIH RePORTER; NIDA NIH HHS [DA07390] Funding Source: Medline; NIMH NIH HHS [MH12399] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adkins EM, 2001, MOL PHARMACOL, V59, P514, DOI 10.1124/mol.59.3.514; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1994, J BIOL CHEM, V269, P14865; Androutsellis-Theotokis A, 2002, J NEUROSCI, V22, P8370; Barker EL, 1999, J NEUROSCI, V19, P4705; Barker EL, 1998, J BIOL CHEM, V273, P19459, DOI 10.1074/jbc.273.31.19459; BARKER EL, 1997, SOC NEUROSCI, V27, P450; Barker Eric L., 1995, P321; Bismuth Y, 1997, J BIOL CHEM, V272, P16096, DOI 10.1074/jbc.272.26.16096; BLAKELY RD, 1991, NATURE, V354, P66, DOI 10.1038/354066a0; Chang AS, 1996, MOL BRAIN RES, V43, P185, DOI 10.1016/S0169-328X(96)00172-6; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Chen JG, 1997, J BIOL CHEM, V272, P28321, DOI 10.1074/jbc.272.45.28321; Chen JG, 1998, J BIOL CHEM, V273, P12675, DOI 10.1074/jbc.273.20.12675; Chen JX, 1998, AM J PHYSIOL-GASTR L, V275, pG433, DOI 10.1152/ajpgi.1998.275.3.G433; Chen NH, 1998, J NEUROSCI, V18, P10257; Chen NH, 2000, J BIOL CHEM, V275, P1608, DOI 10.1074/jbc.275.3.1608; COREY JL, 1994, P NATL ACAD SCI USA, V91, P1188, DOI 10.1073/pnas.91.3.1188; DEMCHYSHYN LL, 1994, P NATL ACAD SCI USA, V91, P5158, DOI 10.1073/pnas.91.11.5158; DORON NK, 1994, J BIOL CHEM, V269, P3063; Ferrer JV, 1998, P NATL ACAD SCI USA, V95, P9238, DOI 10.1073/pnas.95.16.9238; Golovanevsky V, 1999, J BIOL CHEM, V274, P23020, DOI 10.1074/jbc.274.33.23020; HOFFMAN BJ, 1991, SCIENCE, V254, P579, DOI 10.1126/science.1948036; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Hruz PW, 1999, J BIOL CHEM, V274, P36176, DOI 10.1074/jbc.274.51.36176; Javitch JA, 1996, MOL PHARMACOL, V49, P692; Javitch JA, 1998, METHOD ENZYMOL, V296, P331; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KAPLAN RS, 2002, TRANSMEMBRANE TRANSP, P125; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Kilic F, 2000, P NATL ACAD SCI USA, V97, P3106, DOI 10.1073/pnas.060408997; KITAYAMA S, 1992, P NATL ACAD SCI USA, V89, P7782, DOI 10.1073/pnas.89.16.7782; Lee SH, 2000, MOL PHARMACOL, V57, P883; Lin ZC, 2000, FASEB J, V14, P715, DOI 10.1096/fasebj.14.5.715; Madras BK, 1996, SYNAPSE, V24, P340; Meltzer PC, 1997, J MED CHEM, V40, P2661, DOI 10.1021/jm9703045; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Mortensen OV, 1999, MOL BRAIN RES, V71, P120, DOI 10.1016/S0169-328X(99)00178-3; Padbury JF, 1997, MOL BRAIN RES, V45, P163, DOI 10.1016/S0169-328X(96)00309-9; PANTANOWITZ S, 1993, J BIOL CHEM, V268, P3222; Petersen CI, 1999, NAT NEUROSCI, V2, P605, DOI 10.1038/10158; Ponce J, 2000, J BIOL CHEM, V275, P13856, DOI 10.1074/jbc.275.18.13856; QIAN Y, 1995, J NEUROSCI, V15, P1261; QUICK MW, 2002, TRANSMEMBRANE TRANSP, pR13; RAMAMOORTHY S, 1993, P NATL ACAD SCI USA, V90, P2542, DOI 10.1073/pnas.90.6.2542; Ramamoorthy S, 1998, METHOD ENZYMOL, V296, P347; REITH MEA, 1986, BIOCHEM PHARMACOL, V35, P1123, DOI 10.1016/0006-2952(86)90148-6; Reith MEA, 2001, J BIOL CHEM, V276, P29012, DOI 10.1074/jbc.M011785200; Rudnick G., 2002, TRANSMEMBRANE TRANSP, P125; Tatsumi M, 1997, EUR J PHARMACOL, V340, P249, DOI 10.1016/S0014-2999(97)01393-9; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002	52	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37052	37063		10.1074/jbc.M305514200	http://dx.doi.org/10.1074/jbc.M305514200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869570	hybrid			2022-12-27	WOS:000185437200011
J	LaVoie, MJ; Fraering, PC; Ostaszewski, BL; Ye, WJ; Kimberly, WT; Wolfe, MS; Selkoe, DJ				LaVoie, MJ; Fraering, PC; Ostaszewski, BL; Ye, WJ; Kimberly, WT; Wolfe, MS; Selkoe, DJ			Assembly of the gamma-secretase complex involves early formation of an intermediate subcomplex of Aph-1 and nicastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLUE NATIVE ELECTROPHORESIS; MEMBRANE-PROTEIN COMPLEXES; BETA-APP; PRESENILIN; ENDOPROTEOLYSIS; PEN-2; ACCUMULATION; TRAFFICKING; INHIBITORS; FRAGMENTS	The gamma-secretase complex is an unusual multimeric protease responsible for the intramembrane cleavage of a variety of type 1 transmembrane proteins, including the beta-amyloid precursor protein and Notch. Genetic and biochemical data have revealed that this protease consists of the presenilin heterodimer, a highly glycosylated form of nicastrin, and the recently identified gene products, Aph-1 and Pen-2. Whereas current evidence supports the notion that presenilin comprises the active site of the protease and that the other three components are members of the active complex required for proteolytic activity, the individual roles of the three co-factors remain unclear. Here, we demonstrate that endogenous Aph-1 interacts with an immature species of nicastrin, forming a stable intermediate early in the assembly of the gamma-secretase complex, prior to the addition of presenilin and Pen-2. Our data suggest 1) that Aph-1 is involved in the early stages of gamma-secretase assembly through the stabilization and perhaps glycosylation of nicastrin and by scaffolding nicastrin to the immature gamma-secretase complex, and 2) that presenilin, and later Pen-2, bind to this intermediate during the formation of the mature protease.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Selkoe, DJ (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur, Boston, MA 02215 USA.	DSelkoe@rics.bwh.harvard.edu		LaVoie, Matthew/0000-0002-2583-1578; Fraering, Patrick/0000-0002-5841-5327	NATIONAL INSTITUTE ON AGING [P01AG015379, R01AG017574] Funding Source: NIH RePORTER; NIA NIH HHS [AG00222, AG15379, AG17574] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Capell A, 1998, J BIOL CHEM, V273, P3205, DOI 10.1074/jbc.273.6.3205; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2002, P NATL ACAD SCI USA, V99, P2720, DOI 10.1073/pnas.052436599; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; Hu Y, 2003, J CELL BIOL, V161, P685, DOI 10.1083/jcb.200304014; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Luo WJ, 2003, J BIOL CHEM, V278, P7850, DOI 10.1074/jbc.C200648200; Mumm JS, 2000, DEV BIOL, V228, P151, DOI 10.1006/dbio.2000.9960; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ratovitski T, 1997, J BIOL CHEM, V272, P24536, DOI 10.1074/jbc.272.39.24536; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Thinakaran G, 1996, NEURON, V17, P181, DOI 10.1016/S0896-6273(00)80291-3; Tomita T, 2002, FEBS LETT, V520, P117, DOI 10.1016/S0014-5793(02)02802-8; Wolfe MS, 2002, SCIENCE, V296, P2156, DOI 10.1126/science.1073844; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yang DS, 2002, J BIOL CHEM, V277, P28135, DOI 10.1074/jbc.M110871200; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yu G, 1998, J BIOL CHEM, V273, P16470, DOI 10.1074/jbc.273.26.16470; Zhang JM, 1998, J BIOL CHEM, V273, P12436, DOI 10.1074/jbc.273.20.12436	33	180	190	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37213	37222		10.1074/jbc.M303941200	http://dx.doi.org/10.1074/jbc.M303941200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857757	hybrid			2022-12-27	WOS:000185437200029
J	Wickham, ME; Culvenor, JG; Cowman, AF				Wickham, ME; Culvenor, JG; Cowman, AF			Selective inhibition of a two-step egress of malaria parasites from the host erythrocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMODIUM-FALCIPARUM ANTIGENS; PARASITOPHOROUS VACUOLE; CYSTEINE PROTEASE; RECOMBINANT FALCIPAIN-2; FINE-STRUCTURE; PLASMEPSIN II; FOOD VACUOLE; HEMOGLOBINASE; LOCALIZATION; SCHIZONTS	Escape from the host erythrocyte by the invasive stage of the malaria parasite Plasmodium falciparum is a fundamental step in the pathogenesis of malaria of which little is known. Upon merozoite invasion of the host cell, the parasite becomes enclosed within a parasitophorous vacuole, the compartment in which the parasite undergoes growth followed by asexual division to produce 16-32 daughter merozoites. These daughter cells are released upon parasitophorous vacuole and erythrocyte membrane rupture. To examine the process of merozoite release, we used P. falciparum lines expressing green fluorescent protein-chimeric proteins targeted to the compartments from which merozoites must exit: the parasitophorous vacuole and the host erythrocyte cytosol. This allowed visualization of merozoite release in live parasites. Herein we provide the first evidence in live, untreated cells that merozoite release involves a primary rupture of the parasitophorous vacuole membrane followed by a secondary rupture of the erythrocyte plasma membrane. We have confirmed, with the use of immunoelectron microscopy, that parasitophorous vacuole membrane rupture occurs before erythrocyte plasma membrane rupture in untransfected wild-type parasites. We have also demonstrated selective inhibition of each step in this two-step process of exit using different protease inhibitors, implicating the involvement of distinct proteases in each of these steps. This will facilitate the identification of the parasite and host molecules involved in merozoite release.	Univ Melbourne, Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia; Univ Melbourne, Dept Pathol, Melbourne, Vic 3050, Australia	University of Melbourne; Walter & Eliza Hall Institute; University of Melbourne	Cowman, AF (corresponding author), 1G Royal Parade, Melbourne, Vic 3050, Australia.	cowman@wehi.edu.au	Wickham, Mark/A-1396-2009; Cowman, Alan F/C-7642-2013; Wickham, Mark E/HCI-4959-2022	Wickham, Mark/0000-0002-3473-7196; Cowman, Alan F/0000-0001-5145-9004; Wickham, Mark E/0000-0002-3473-7196	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044008] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI44008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AIKAWA M, 1971, EXP PARASITOL, V30, P284, DOI 10.1016/0014-4894(71)90094-4; Ansorge I, 1996, BIOCHEM J, V315, P307, DOI 10.1042/bj3150307; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; BANYAL HS, 1981, J PARASITOL, V67, P623, DOI 10.2307/3280435; CHULAY JD, 1987, J IMMUNOL, V139, P2768; COPPEL RL, 1983, NATURE, V306, P751, DOI 10.1038/306751a0; COWMAN AF, 1985, MODERN APPROACHES VA, P13; DEGUERCY A, 1990, MOL BIOCHEM PARASIT, V38, P233, DOI 10.1016/0166-6851(90)90026-I; DELPLACE P, 1988, BIOL CELL, V64, P215, DOI 10.1016/0248-4900(88)90080-9; DELPLACE P, 1987, MOL BIOCHEM PARASIT, V23, P193, DOI 10.1016/0166-6851(87)90026-0; DHAWAN S, 2003, J BIOL CHEM; Dominguez JN, 1997, J MED CHEM, V40, P2726, DOI 10.1021/jm970266p; Dua M, 2001, MOL BIOCHEM PARASIT, V116, P95, DOI 10.1016/S0166-6851(01)00306-1; Fidock DA, 1997, P NATL ACAD SCI USA, V94, P10931, DOI 10.1073/pnas.94.20.10931; FRANCIS SE, 1994, EMBO J, V13, P306, DOI 10.1002/j.1460-2075.1994.tb06263.x; Greenbaum DC, 2002, SCIENCE, V298, P2002, DOI 10.1126/science.1077426; HADLEY T, 1983, EXP PARASITOL, V55, P306, DOI 10.1016/0014-4894(83)90027-9; Hanspal M, 2002, BLOOD, V100, P1048, DOI 10.1182/blood-2002-01-0101; KNAPP B, 1989, MOL BIOCHEM PARASIT, V32, P73, DOI 10.1016/0166-6851(89)90131-X; LANGRETH SG, 1978, J PROTOZOOL, V25, P443, DOI 10.1111/j.1550-7408.1978.tb04167.x; Lauer S, 2000, EMBO J, V19, P3556, DOI 10.1093/emboj/19.14.3556; Le Bonniec S, 1999, J BIOL CHEM, V274, P14218, DOI 10.1074/jbc.274.20.14218; Li J, 2002, MOL BIOCHEM PARASIT, V120, P177, DOI 10.1016/S0166-6851(01)00452-2; LYON JA, 1986, J IMMUNOL, V136, P2245; Miller SK, 2002, J BIOL CHEM, V277, P47524, DOI 10.1074/jbc.M206974200; Moon RP, 1997, EUR J BIOCHEM, V244, P552, DOI 10.1111/j.1432-1033.1997.00552.x; NWAGWU M, 1992, EXP PARASITOL, V75, P399, DOI 10.1016/0014-4894(92)90253-7; Raphael P, 2000, MOL BIOCHEM PARASIT, V110, P259, DOI 10.1016/S0166-6851(00)00283-8; Reed MB, 2000, NATURE, V403, P906, DOI 10.1038/35002615; RING CS, 1993, P NATL ACAD SCI USA, V90, P3583, DOI 10.1073/pnas.90.8.3583; Rosenthal PJ, 1996, ANTIMICROB AGENTS CH, V40, P1600, DOI 10.1128/AAC.40.7.1600; ROSENTHAL PJ, 1991, J CLIN INVEST, V88, P1467, DOI 10.1172/JCI115456; ROSENTHAL PJ, 1993, J CLIN INVEST, V91, P1052, DOI 10.1172/JCI116262; Salmon BL, 2001, P NATL ACAD SCI USA, V98, P271, DOI 10.1073/pnas.011413198; Shenai BR, 2000, J BIOL CHEM, V275, P29000, DOI 10.1074/jbc.M004459200; Silva AM, 1996, P NATL ACAD SCI USA, V93, P10034, DOI 10.1073/pnas.93.19.10034; STENZEL DJ, 1989, EUR J CELL BIOL, V49, P311; Waller RF, 2000, EMBO J, V19, P1794, DOI 10.1093/emboj/19.8.1794; WARD GE, 1993, J CELL SCI, V106, P237; Wickham ME, 2001, EMBO J, V20, P5636, DOI 10.1093/emboj/20.20.5636	40	124	128	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37658	37663		10.1074/jbc.M305252200	http://dx.doi.org/10.1074/jbc.M305252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857731	hybrid			2022-12-27	WOS:000185437200081
J	Hayashi, I; Ikura, M				Hayashi, I; Ikura, M			Crystal structure of the amino-terminal microtubule-binding domain of end-binding protein 1 (EB1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APC TUMOR-SUPPRESSOR; F-ACTIN; PROGRAM; PLUS; CYTOSKELETON; MAINTENANCE; DYNACTIN; CLIP-170; ENCODES	The end-binding protein 1 (EB1) family is a highly conserved group of proteins that localizes to the plus-ends of microtubules. EB1 has been shown to play an important role in regulating microtubule dynamics and chromosome segregation, but its regulation mechanism is poorly understood. We have determined the 1.45-Angstrom resolution crystal structure of the amino-terminal domain of EB1, which is essential for microtubule binding, and show that it forms a calponin homology ( CH) domain fold that is found in many proteins involved in the actin cytoskeleton. The functional CH domain for actin binding is a tandem pair, whereas EB1 is the first example of a single CH domain that can associate with the microtubule filament. Although our biochemical study shows that microtubule binding of EB1 is electrostatic in part, our mutational analysis suggests that the hydrophobic network, which is partially exposed in our crystal structure, is also important for the association. We propose that, like other actin-binding CH domains, EB1 employs the hydrophobic interaction to bind to microtubules.	Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada; Univ Toronto, Dept Med Biophys, Toronto, ON M5G 2M9, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Hayashi, I (corresponding author), Univ Toronto, Ontario Canc Inst, Div Mol & Struct Biol, Toronto, ON M5G 2M9, Canada.	ihayashi@uhnres.utoronto.ca		Ikura, Mitsuhiko/0000-0002-9524-1303				Askham JM, 2000, ONCOGENE, V19, P1950, DOI 10.1038/sj.onc.1203498; Askham JM, 2002, MOL BIOL CELL, V13, P3627, DOI 10.1091/mbc.E02-01-0061; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Banuelos S, 1998, STRUCTURE, V6, P1419, DOI 10.1016/S0969-2126(98)00141-5; Barth AIM, 2002, J CELL SCI, V115, P1583; Beinhauer JD, 1997, J CELL BIOL, V139, P717, DOI 10.1083/jcb.139.3.717; Berrueta L, 1998, P NATL ACAD SCI USA, V95, P10596, DOI 10.1073/pnas.95.18.10596; Bramham J, 2002, STRUCTURE, V10, P249, DOI 10.1016/S0969-2126(02)00703-7; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CASTRESANA J, 1995, FEBS LETT, V374, P149, DOI 10.1016/0014-5793(95)01098-Y; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; Desai A, 1999, CELL, V96, P69, DOI 10.1016/S0092-8674(00)80960-5; Gimona M, 2002, FEBS LETT, V513, P98, DOI 10.1016/S0014-5793(01)03240-9; Goldsmith SC, 1997, NAT STRUCT BIOL, V4, P708, DOI 10.1038/nsb0997-708; HARRISON CJ, 1994, SCIENCE, V263, P224, DOI 10.1126/science.8284672; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; Juwana JP, 1999, INT J CANCER, V81, P275, DOI 10.1002/(SICI)1097-0215(19990412)81:2<275::AID-IJC18>3.0.CO;2-Z; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li SL, 2002, J BIOL CHEM, V277, P48596, DOI 10.1074/jbc.M208512200; Ligon LA, 2003, MOL BIOL CELL, V14, P1405, DOI 10.1091/mbc.E02-03-0155; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mimori-Kiyosue Y, 2000, CURR BIOL, V10, P865, DOI 10.1016/S0960-9822(00)00600-X; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Morrison EE, 1998, ONCOGENE, V17, P3471, DOI 10.1038/sj.onc.1202247; Nakamura M, 2001, CURR BIOL, V11, P1062, DOI 10.1016/S0960-9822(01)00297-4; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perez F, 1999, CELL, V96, P517, DOI 10.1016/S0092-8674(00)80656-X; Schroer TA, 2001, CURR OPIN CELL BIOL, V13, P92, DOI 10.1016/S0955-0674(00)00179-4; Schuyler SC, 2001, CELL, V105, P421, DOI 10.1016/S0092-8674(01)00364-6; Schwartz K, 1997, MOL BIOL CELL, V8, P2677, DOI 10.1091/mbc.8.12.2677; SU LK, 1995, CANCER RES, V55, P2972; Vaughan KT, 1999, J CELL SCI, V112, P1437	36	134	140	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36430	36434		10.1074/jbc.M305773200	http://dx.doi.org/10.1074/jbc.M305773200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857735	hybrid			2022-12-27	WOS:000185318300071
J	Matsuda, A; Itoh, Y; Koshikawa, N; Akizawa, T; Yana, I; Seiki, M				Matsuda, A; Itoh, Y; Koshikawa, N; Akizawa, T; Yana, I; Seiki, M			Clusterin, an abundant serum factor, is a possible negative regulator of MT6-MMP/MMP-25 produced by neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-TYPE-1 MATRIX-METALLOPROTEINASE; C-TERMINAL DOMAIN; CELL-SURFACE; APOLIPOPROTEIN-J; COMPLEMENT; EXPRESSION; PROTEIN; INHIBITOR; BINDS; ACTIVATION	MT6-MMP/MMP-25 is the latest member of the membrane-type matrix metalloproteinase (MT-MMP) subgroup in the MMP family and is expressed in neutrophils and some brain tumors. The proteolytic activity of MT6-MMP has been studied using recombinant catalytic fragments and shown to degrade several components of the extracellular matrix. However, the activity is possibly modulated further by the C-terminal hemopexin- like domain, because some MMPs are known to interact with other proteins through this domain. To explore the possible function of this domain, we purified a recombinant MT6-MMP with the hemopexin- like domain as a soluble form using a Madin-Darby canine kidney cell line as a producer. Mature and soluble MT6-MMP processed at the furin motif was purified as a 45-kDa protein together with a 46-kDa protein having a single cleavage in the hemopexin- like domain. Interestingly, 73- and 70-kDa proteins were co-purified with the soluble MT6-MMP by forming stable complexes. They were identified as clusterin, a major component of serum, by N-terminal amino acid sequencing. MT1-MMP that also has a hemopexin-like domain did not form a complex with clusterin. MT6-MMP forming a complex with clusterin was detected in human neutrophils as well. The enzyme activity of the soluble MT6-MMP was inactive in the clusterin complex. Purified clusterin was inhibitory against the activity of soluble MT6-MMP. On the other hand, it had no effect on the activities of MMP-2 and soluble MT1-MMP. Because clusterin is an abundant protein in the body fluid in tissues, it may act as a negative regulator of MT6-MMP in vivo.	Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, Tokyo 1088639, Japan; Setsunan Univ, Fac Pharmaceut Sci, Dept Analyt Chem, Osaka 5730101, Japan	University of Tokyo; Setsunan University	Seiki, M (corresponding author), Univ Tokyo, Inst Med Sci, Div Canc Cell Res, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.	mseiki@ims.u-tokyo.ac.jp	Koshikawa, Naohiko/S-7306-2017; Seiki, Motoharu/K-9443-2015	Koshikawa, Naohiko/0000-0002-4539-888X; Itoh, Yoshifumi/0000-0002-2128-2823				BURKEY BF, 1992, J LIPID RES, V33, P1517; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; English WR, 2001, FEBS LETT, V491, P137, DOI 10.1016/S0014-5793(01)02150-0; FRITZ IB, 1983, BIOL REPROD, V28, P1173, DOI 10.1095/biolreprod28.5.1173; GHISO J, 1993, BIOCHEM J, V293, P27, DOI 10.1042/bj2930027; HARTMANN K, 1991, J BIOL CHEM, V266, P9924; Itoh Y, 1999, J BIOL CHEM, V274, P34260, DOI 10.1074/jbc.274.48.34260; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kojima S, 2000, FEBS LETT, V480, P142, DOI 10.1016/S0014-5793(00)01919-0; Liu Z, 2000, CELL, V102, P647, DOI 10.1016/S0092-8674(00)00087-8; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McHattie S, 1999, BIOCHEM BIOPH RES CO, V259, P336, DOI 10.1006/bbrc.1999.0781; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; Michel D, 1997, BIOCHEM J, V328, P45, DOI 10.1042/bj3280045; Mori H, 2002, EMBO J, V21, P3949, DOI 10.1093/emboj/cdf411; MURPHY BF, 1988, J CLIN INVEST, V81, P1858, DOI 10.1172/JCI113531; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Owen CA, 1999, J LEUKOCYTE BIOL, V65, P137, DOI 10.1002/jlb.65.2.137; Partridge SR, 1996, INFECT IMMUN, V64, P4324, DOI 10.1128/IAI.64.10.4324-4329.1996; Pei DQ, 1998, PROTEIN EXPRES PURIF, V13, P277, DOI 10.1006/prep.1998.0894; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Seiki M, 2002, CURR OPIN CELL BIOL, V14, P624, DOI 10.1016/S0955-0674(02)00363-0; SHINOURA N, 1994, CANCER LETT, V86, P143, DOI 10.1016/0304-3835(94)90072-8; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; TSCHOPP J, 1993, J IMMUNOL, V151, P2159; Uekita T, 2001, J CELL BIOL, V155, P1345, DOI 10.1083/jcb.200108112; Velasco G, 2000, CANCER RES, V60, P877; Wallon UM, 1997, J BIOL CHEM, V272, P7473, DOI 10.1074/jbc.272.11.7473; Wang X, 1999, FEBS LETT, V462, P261, DOI 10.1016/S0014-5793(99)01534-3; WILSON MR, 1992, BIOCHIM BIOPHYS ACTA, V1159, P319, DOI 10.1016/0167-4838(92)90062-I; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0	38	47	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36350	36357		10.1074/jbc.M301509200	http://dx.doi.org/10.1074/jbc.M301509200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860995	hybrid			2022-12-27	WOS:000185318300061
J	Perez, A; Barco, R; Fernandez, I; Price-Schiavi, SA; Carraway, KL				Perez, A; Barco, R; Fernandez, I; Price-Schiavi, SA; Carraway, KL			PEA3 transactivates the Muc4/sialomucin complex promoter in mammary epithelial and tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUCIN GENE-EXPRESSION; ETS TRANSCRIPTION FACTOR; SURFACE SIALOMUCIN COMPLEX; MOLECULAR-CLONING; HUMAN-BREAST; GLYCOPROTEIN COMPLEX; ADENOCARCINOMA CELLS; MEMBRANE-PROTEIN; MAP KINASE; RAT MUC4	Sialomucin complex (SMC, rat Muc4) is a heterodimeric glycoprotein composed of two subunits, the mucin component ascites sialoglycoprotein ASGP-1 and the transmembrane subunit ASGP-2, which is aberrantly expressed on the surfaces of a variety of tumor cells. Up-regulation of the Muc4/SMC gene in the 13762 sublines of the rat mammary adenocarcinoma correlates with the overexpression of transcription factor PEA3 and the receptor tyrosine kinase ErbB2. Here we report that PEA3 is capable of transactivating the Muc4/ SMC promoter in a dose-dependent manner via direct attachment to a PEA3 binding site. ERM and ER81, the other two members of the PEA3 subfamily of transcription factors, could not transactivate the Muc4/ SMC promoter. Transcriptional activation of Muc4/ SMC by PEA3 is potentiated by Ras and MEKK1 kinases. These data suggest that expression of PEA3 in mammary tumors leads to up-regulation of Muc4/ SMC transcription, the gene product of which may contribute to the metastatic potential of mammary tumors.	Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33101 USA	University of Miami	Perez, A (corresponding author), Univ Miami, Sch Med, Dept Cell Biol R124, POB 016960, Miami, FL 33101 USA.	aperez6@med.miami.edu			NCI NIH HHS [CA52498, CA-84178] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA084178, R01CA052498] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aslam F, 2001, CANCER RES, V61, P570; AUDIE JP, 1995, HUM REPROD, V10, P98, DOI 10.1093/humrep/10.1.98; AUDIE JP, 1993, J HISTOCHEM CYTOCHEM, V41, P1479, DOI 10.1177/41.10.8245407; BALAGUE C, 1994, GASTROENTEROLOGY, V106, P1054, DOI 10.1016/0016-5085(94)90767-6; BALAGUE C, 1995, GASTROENTEROLOGY, V109, P953, DOI 10.1016/0016-5085(95)90406-9; Benz CC, 1997, ONCOGENE, V15, P1513, DOI 10.1038/sj.onc.1201331; Bieche I, 1997, CANCER GENET CYTOGEN, V98, P75, DOI 10.1016/S0165-4608(96)00410-4; Bojovic BB, 2001, J BIOL CHEM, V276, P4509, DOI 10.1074/jbc.M005509200; Bolshakov VY, 2000, NAT NEUROSCI, V3, P1107, DOI 10.1038/80624; Brown LA, 1998, ONCOGENE, V17, P93, DOI 10.1038/sj.onc.1201911; BROWN TA, 1992, GENE DEV, V6, P2502, DOI 10.1101/gad.6.12b.2502; CARRAWAY KL, 1976, J BIOL CHEM, V251, P6173; CARRAWAY KL, 1992, J CELL SCI, V103, P299; Carraway KL, 1999, J BIOL CHEM, V274, P5263, DOI 10.1074/jbc.274.9.5263; CARRAWAY KL, 1986, MOL CELL BIOCHEM, V72, P109; Carraway KL, 2000, FRONT BIOSCI, V5, pD95, DOI 10.2741/Carraway; Cella N, 1996, DIFFERENTIATION, V61, P113, DOI 10.1046/j.1432-0436.1996.6120113.x; Chandrasekera CP, 2003, J BIOL CHEM, V278, P12482, DOI 10.1074/jbc.M212745200; Chen JH, 1996, ONCOGENE, V13, P1667; ChotteauLelievre A, 1997, ONCOGENE, V15, P937, DOI 10.1038/sj.onc.1201261; Choudhury A, 2000, J BIOCHEM-TOKYO, V128, P233, DOI 10.1093/oxfordjournals.jbchem.a022746; Choudhury A, 2001, TERATOGEN CARCIN MUT, V21, P83, DOI 10.1002/1520-6866(2001)21:1<83::AID-TCM8>3.0.CO;2-3; Copin MC, 2001, FRONT BIOSCI, V6, pD1264, DOI 10.2741/Copin; Crawford HC, 1996, ENZYME PROTEIN, V49, P20, DOI 10.1159/000468614; Crawford HC, 2001, MOL CELL BIOL, V21, P1370, DOI 10.1128/MCB.21.4.1370-1383.2001; deLaunoit Y, 1997, BIOCHEM MOL MED, V61, P127, DOI 10.1006/bmme.1997.2605; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; Domina AM, 2000, J BIOL CHEM, V275, P21688, DOI 10.1074/jbc.M000915200; DOPPLER W, 1989, P NATL ACAD SCI USA, V86, P104, DOI 10.1073/pnas.86.1.104; FRIEDMAN LS, 1995, GENOMICS, V25, P256, DOI 10.1016/0888-7543(95)80133-7; Graves BJ, 1998, ADV CANCER RES, V75, P1, DOI 10.1016/S0065-230X(08)60738-1; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HOLLINGSWORTH MA, 1994, INT J CANCER, V57, P198, DOI 10.1002/ijc.2910570212; HOWARD SC, 1980, BIOCHIM BIOPHYS ACTA, V631, P79, DOI 10.1016/0304-4165(80)90055-0; HOWARD SC, 1982, JNCI-J NATL CANCER I, V69, P33; HULL SR, 1990, BIOCHEM J, V265, P121, DOI 10.1042/bj2650121; Idris N, 1999, BIOL REPROD, V61, P1431, DOI 10.1095/biolreprod61.6.1431; Janknecht R, 1996, ONCOGENE, V13, P1745; Janknecht R, 1996, MOL CELL BIOL, V16, P1550; Jepson S, 2002, ONCOGENE, V21, P7524, DOI 10.1038/sj.onc.1205970; Juang SH, 1996, ONCOGENE, V12, P1033; Kaya M, 1996, ONCOGENE, V12, P221; Komatsu M, 1997, J BIOL CHEM, V272, P33245, DOI 10.1074/jbc.272.52.33245; Komatsu M, 1999, CANCER RES, V59, P2229; LANE EB, 1982, J CELL BIOL, V92, P665, DOI 10.1083/jcb.92.3.665; LEE EYH, 1984, J CELL BIOL, V98, P146, DOI 10.1083/jcb.98.1.146; LENGYEL E, 1995, BBA-MOL CELL RES, V1268, P65, DOI 10.1016/0167-4889(95)00050-3; Li DZ, 1998, J BIOL CHEM, V273, P6812, DOI 10.1074/jbc.273.12.6812; Liao J, 2000, BIOTECHNIQUES, V28, P216, DOI 10.2144/00282bm05; LIN AN, 1995, SCIENCE, V268, P286, DOI 10.1126/science.7716521; MARSHALL CJ, 1994, CURR OPIN GENET DEV, V4, P82, DOI 10.1016/0959-437X(94)90095-7; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; Moniaux N, 1999, BIOCHEM J, V338, P325, DOI 10.1042/0264-6021:3380325; MONTE D, 1994, ONCOGENE, V9, P1397; Nguyen PL, 1996, TUMOR BIOL, V17, P176, DOI 10.1159/000217980; O'Hagan RC, 1998, ONCOGENE, V16, P301, DOI 10.1038/sj.onc.1201547; OHAGAN RC, 1996, ONCOGENE, V18, P6278; Perrais M, 2002, J BIOL CHEM, V277, P32258, DOI 10.1074/jbc.M204862200; Perrais M, 2001, J BIOL CHEM, V276, P30923, DOI 10.1074/jbc.M104204200; Petersen H, 1998, EXP CELL RES, V243, P347, DOI 10.1006/excr.1998.4160; PORCHET N, 1991, BIOCHEM BIOPH RES CO, V175, P414, DOI 10.1016/0006-291X(91)91580-6; Price-Schiavi A, 1998, BIOCHEM J, V335, P457, DOI 10.1042/bj3350457; Price-Schiavi SA, 1998, J BIOL CHEM, V273, P35228, DOI 10.1074/jbc.273.52.35228; Price-Schiavi SA, 2002, INT J CANCER, V99, P783, DOI 10.1002/ijc.10410; Price-Schiavi SA, 2000, BIOCHEM J, V349, P641, DOI 10.1042/0264-6021:3490641; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; Rossi EA, 1996, J BIOL CHEM, V271, P33476, DOI 10.1074/jbc.271.52.33476; Scott GK, 2000, ONCOGENE, V19, P6490, DOI 10.1038/sj.onc.1204041; SEELY KA, 1991, J CELL PHYSIOL, V146, P117, DOI 10.1002/jcp.1041460116; SHENG Z, 1990, J BIOL CHEM, V265, P8505; SHENG ZQ, 1992, J BIOL CHEM, V267, P16341; Shepherd TG, 2001, CURR BIOL, V11, P1739, DOI 10.1016/S0960-9822(01)00536-X; SHERBLOM AP, 1980, J BIOL CHEM, V255, P2051; SHERBLOM AP, 1980, J BIOL CHEM, V255, P783; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; Subbaramaiah K, 2002, J BIOL CHEM, V277, P18649, DOI 10.1074/jbc.M111415200; TRIMBLE MS, 1993, ONCOGENE, V8, P3037; Vandenhaute B, 1997, J HEPATOL, V27, P1057, DOI 10.1016/S0168-8278(97)80150-X; WU K, 1994, J BIOL CHEM, V269, P11950; XIN JH, 1992, GENE DEV, V6, P481, DOI 10.1101/gad.6.3.481; Zhu XY, 2000, ONCOGENE, V19, P4354, DOI 10.1038/sj.onc.1203781	82	20	20	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36942	36952		10.1074/jbc.M300264200	http://dx.doi.org/10.1074/jbc.M300264200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855694	hybrid			2022-12-27	WOS:000185318300128
J	Yoshida, M; Xia, Y				Yoshida, M; Xia, Y			Heat shock protein 90 as an endogenous protein enhancer of inducible nitric-oxide synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HSP90-BASED CHAPERONE SYSTEM; GELDANAMYCIN LEADS; L-ARGININE; HSP90; SUPEROXIDE; GENERATION	Nitric oxide ( NO) generated by inducible NO synthase ( iNOS) plays crucial roles in inflammation and host defense. With an intrinsically bound calmodulin, iNOS is fully active once expressed in cells. Thus, regulation of NO production from iNOS was thought to primarily occur at the enzyme transcriptional level. Here we show that NO synthesis from iNOS can be profoundly modulated by heat shock protein 90 (hsp90) through protein-protein interaction. To study whether hsp90 affects iNOS function, recombinant murine iNOS was purified from an Escherichia coli expression system by affinity chromatography. Hsp90, at physiological concentrations ( 10 - 500 nM), dose-dependently increased iNOS activity. This was a specific effect because neither denatured hsp90 nor irrelevant bovine serum albumin affected iNOS function. Overexpression of hsp90 enhanced NO production in iNOS-transfected cells. On the contrary, hsp90 inhibition dramatically decreased NO formation from iNOS in macrophages. Co-immunoprecipitation studies showed that hsp90 and iNOS associated with each other in cells. Overexpression of iNOS resulted in NO-mediated cellular injury. Hsp90 inhibition markedly attenuated NO formation and prevented cellular injury. These results demonstrated that hsp90 is an allosteric enhancer of iNOS. iNOS is coupled with hsp90 in cells, and this coupling facilitates NO synthesis. In light of the critical role of hsp90 in iNOS-mediated cytotoxic action, modulating the interaction between hsp90 and iNOS may be a new approach to intervene inflammation and immune response.	Ohio State Univ, Davis Heart & Lung Res Inst, Dept Mol & Cellular Biochem, Div Cardiovasc Med, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Xia, Y (corresponding author), Ohio State Univ, Davis Heart & Lung Res Inst 605, 473 W 12th Ave, Columbus, OH 43210 USA.	xia-3@medctr.osu.edu			NIA NIH HHS [AG00835] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bender AT, 1999, J BIOL CHEM, V274, P1472, DOI 10.1074/jbc.274.3.1472; Billecke SS, 2002, J BIOL CHEM, V277, P20504, DOI 10.1074/jbc.M201940200; Blagosklonny MV, 2002, LEUKEMIA, V16, P455, DOI 10.1038/sj.leu.2402415; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Buchner J, 1996, FASEB J, V10, P10, DOI 10.1096/fasebj.10.1.8566529; Csermely P, 1998, PHARMACOL THERAPEUT, V79, P129, DOI 10.1016/S0163-7258(98)00013-8; Dikalov S, 2002, J BIOL CHEM, V277, P25480, DOI 10.1074/jbc.M203271200; Feron O, 1996, J BIOL CHEM, V271, P22810, DOI 10.1074/jbc.271.37.22810; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Fleming I, 2003, AM J PHYSIOL-REG I, V284, pR1, DOI 10.1152/ajpregu.00323.2002; Fontana J, 2002, CIRC RES, V90, P866, DOI 10.1161/01.RES.0000016837.26733.BE; Fulton D, 2001, J PHARMACOL EXP THER, V299, P818; Gratton JP, 2000, J BIOL CHEM, V275, P22268, DOI 10.1074/jbc.M001644200; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Jaffrey SR, 1996, SCIENCE, V274, P774, DOI 10.1126/science.274.5288.774; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; Masters BSS, 1996, FASEB J, V10, P552, DOI 10.1096/fasebj.10.5.8621055; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Papapetropoulos A, 1999, CARDIOVASC RES, V43, P509, DOI 10.1016/S0008-6363(99)00161-3; Pratt WB, 1998, P SOC EXP BIOL MED, V217, P420; Schulte TW, 1996, MOL CELL BIOL, V16, P5839; Song Y, 2002, BIOCHEMISTRY-US, V41, P10616, DOI 10.1021/bi026060u; Song Y, 2001, BIOCHEM J, V355, P357, DOI 10.1042/0264-6021:3550357; Song Y, 2001, AM J PHYSIOL-CELL PH, V281, pC1819, DOI 10.1152/ajpcell.2001.281.6.C1819; Thykjaer T, 2001, BRIT J CANCER, V85, P568, DOI 10.1054/bjoc.2001.1949; Tikhomirov O, 2000, J BIOL CHEM, V275, P26625, DOI 10.1074/jbc.M003114200; Wu CQ, 1996, BIOCHEM BIOPH RES CO, V222, P439, DOI 10.1006/bbrc.1996.0763; Xia Y, 1998, J BIOL CHEM, V273, P22635, DOI 10.1074/jbc.273.35.22635; Xia Y, 1997, P NATL ACAD SCI USA, V94, P6954, DOI 10.1073/pnas.94.13.6954; Zimmermann K, 2002, P NATL ACAD SCI USA, V99, P17167, DOI 10.1073/pnas.252345399	36	105	108	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36953	36958		10.1074/jbc.M305214200	http://dx.doi.org/10.1074/jbc.M305214200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855682	hybrid			2022-12-27	WOS:000185318300129
J	Sheu, L; Pasyk, EA; Ji, JZ; Haung, XH; Gao, XD; Varoqueaux, F; Brose, N; Gaisano, HY				Sheu, L; Pasyk, EA; Ji, JZ; Haung, XH; Gao, XD; Varoqueaux, F; Brose, N; Gaisano, HY			Regulation of insulin exocytosis by Munc13-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; DENSE-CORE VESICLES; SECRETORY GRANULES; SYNAPTIC-TRANSMISSION; TRANSMITTER RELEASE; PANCREATIC-ISLETS; UNC-13 GENE; BETA-CELLS; GLUCOSE; INHIBITION	The slower kinetics of insulin release from pancreatic islet beta cells, as compared with other regulated secretory processes such as chromaffin granule secretion, can in part be explained by the small number of the insulin granules that are docked to the plasma membrane and readily releasable. In type-2 diabetes, the kinetics of insulin secretion become grossly distorted, and, to therapeutically correct this, it is imperative to elucidate the mechanisms that regulate priming and secretion of insulin secretory granules. Munc13-1, a synaptic protein that regulates SNARE complex assembly, is the major protein determining the priming of synaptic vesicles. Here, we demonstrate the presence of Munc13-1 in human, rat, and mouse pancreatic islet beta cells. Expression of Munc13-1, along with its cognate partners, syntaxin 1a and Munc18a, is reduced in the pancreatic islets of type-2 diabetes non-obese Goto-Kakizaki and obese Zucker fa/fa rats. In insulinoma cells, overexpressed Munc13-1-enhanced green fluorescent protein is translocated to the plasma membrane in a temperature-dependent manner. This, in turn, greatly amplifies insulin exocytosis as determined by patch clamp capacitance measurements and radioimmunoassay of the insulin released. The potentiation of exocytosis by Munc13-1 is dependent on endogenously produced diacylglycerol acting on the overexpressed Munc13-1 because it is blocked by a phospholipase C inhibitor (U73122) and abrogated when the diacylglycerol binding-deficient Munc13-1(H567K) mutant is expressed instead of the wild type protein. Our data demonstrate that Munc13-mediated vesicle priming is not restricted to neurotransmitter release but is also functional in insulin secretion, where it is subject to regulation by the diacylglycerol second messenger pathway. In view of our findings, Munc13-1 is a potential drug target for therapeutic optimization of insulin secretion in diabetes.	Univ Toronto, Dept Med, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada; Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; Max Planck Inst Expt Med, Ctr Mol Physiol Brain, D-37075 Gottingen, Germany	University of Toronto; University of Toronto; Max Planck Society; Max Planck Society	Gaisano, HY (corresponding author), Univ Toronto, Dept Med, 1 Kings Coll Circle,Rm 7226, Toronto, ON M5S 1A8, Canada.	herbert.gaisano@utoronto.ca	Varoqueaux, Frederique/AAC-1834-2021; Gimenez, Luis E Diaz/D-9291-2011	Varoqueaux, Frederique/0000-0002-3614-3121; 				AbdelHalim SM, 1996, DIABETES, V45, P934, DOI 10.2337/diabetes.45.7.934; AMMALA C, 1994, P NATL ACAD SCI USA, V91, P4343, DOI 10.1073/pnas.91.10.4343; Aravamudan B, 1999, NAT NEUROSCI, V2, P965, DOI 10.1038/14764; ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Augustin I, 1999, NATURE, V400, P457, DOI 10.1038/22768; Barg S, 2002, NEURON, V33, P287, DOI 10.1016/S0896-6273(02)00563-9; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1998, NEURON, V21, P123, DOI 10.1016/S0896-6273(00)80520-6; Branstrom R, 1998, J BIOL CHEM, V273, P31395, DOI 10.1074/jbc.273.47.31395; BROSE N, 1995, J BIOL CHEM, V270, P25273, DOI 10.1074/jbc.270.42.25273; Brose N, 2000, CURR OPIN NEUROBIOL, V10, P303, DOI 10.1016/S0959-4388(00)00105-7; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; CERASI E, 1967, ACTA ENDOCRINOL-COP, V55, P278, DOI 10.1530/acta.0.0550278; Chan CB, 1999, DIABETES, V48, P997, DOI 10.2337/diabetes.48.5.997; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; Deeney JT, 1996, J BIOL CHEM, V271, P18154, DOI 10.1074/jbc.271.30.18154; Deeney JT, 2000, J BIOL CHEM, V275, P9363, DOI 10.1074/jbc.275.13.9363; Dulubova I, 1999, EMBO J, V18, P4372, DOI 10.1093/emboj/18.16.4372; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Gaisano HY, 2002, ENDOCRINOLOGY, V143, P4218, DOI 10.1210/en.2002-220237; Gromada J, 1999, J PHYSIOL-LONDON, V518, P745, DOI 10.1111/j.1469-7793.1999.0745p.x; Hirose H, 1996, J BIOL CHEM, V271, P5633, DOI 10.1074/jbc.271.10.5633; Huang XH, 2001, AM J PHYSIOL-CELL PH, V281, pC740, DOI 10.1152/ajpcell.2001.281.3.C740; Huang XH, 1998, MOL ENDOCRINOL, V12, P1060, DOI 10.1210/me.12.7.1060; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Kang Y, 2002, DIABETOLOGIA, V45, P231, DOI 10.1007/s00125-001-0718-0; Kashima Y, 2001, J BIOL CHEM, V276, P46046, DOI 10.1074/jbc.M108378200; Komatsu M, 1998, DIABETES, V47, P352, DOI 10.2337/diabetes.47.3.352; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Lackner MR, 1999, NEURON, V24, P335, DOI 10.1016/S0896-6273(00)80848-X; Leung YM, 2002, BIOCHEM BIOPH RES CO, V292, P980, DOI 10.1006/bbrc.2002.6712; Ling ZD, 1996, J CLIN INVEST, V98, P2805, DOI 10.1172/JCI119108; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; Miller KG, 1999, NEURON, V24, P323, DOI 10.1016/S0896-6273(00)80847-8; Nurrish S, 1999, NEURON, V24, P231, DOI 10.1016/S0896-6273(00)80835-1; Ohara-Imaizumi M, 2002, J BIOL CHEM, V277, P3805, DOI 10.1074/jbc.C100712200; OSTENSON CG, 1993, DIABETOLOGIA, V36, P3, DOI 10.1007/BF00399086; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; PETERRIESCH B, 1988, J CLIN INVEST, V81, P1154, DOI 10.1172/JCI113430; Plattner H, 1997, J CELL BIOL, V139, P1709, DOI 10.1083/jcb.139.7.1709; Rhee JS, 2002, CELL, V108, P121, DOI 10.1016/S0092-8674(01)00635-3; Richmond JE, 2001, NATURE, V412, P338, DOI 10.1038/35085583; Richmond JE, 1999, NAT NEUROSCI, V2, P791, DOI 10.1038/12160; Sassa T, 1999, J NEUROSCI, V19, P4772; Scales SJ, 2000, NEURON, V26, P457, DOI 10.1016/S0896-6273(00)81177-0; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; Shimabukuro M, 1998, J BIOL CHEM, V273, P3547, DOI 10.1074/jbc.273.6.3547; Steyer JA, 1997, NATURE, V388, P474, DOI 10.1038/41329; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; Tang SH, 1998, DIABETES, V47, P905, DOI 10.2337/diabetes.47.6.905; Varoqueaux F, 2002, P NATL ACAD SCI USA, V99, P9037, DOI 10.1073/pnas.122623799; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; WOLF BA, 1989, BIOCHEMISTRY-US, V28, P4291, DOI 10.1021/bi00436a026; WOLLHEIM CB, 1996, DIABETES REV, V4, P276; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642; Yang B, 2000, J CELL BIOL, V148, P247, DOI 10.1083/jcb.148.2.247; Yedovitzky M, 1997, J BIOL CHEM, V272, P1417, DOI 10.1074/jbc.272.3.1417	61	91	96	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2003	278	30					27556	27563		10.1074/jbc.M303203200	http://dx.doi.org/10.1074/jbc.M303203200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	702UL	12871971	hybrid			2022-12-27	WOS:000184242700029
J	Pylypenko, O; Vitali, F; Zerbe, K; Robinson, JA; Schlichting, I				Pylypenko, O; Vitali, F; Zerbe, K; Robinson, JA; Schlichting, I			Crystal structure of OxyC, a cytochrome P450 implicated in an oxidative C-C coupling reaction during vancomycin biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPEPTIDE ANTIBIOTICS; PEPTIDE DEFORMYLASE; CYCLIZATION STEPS; IDENTIFICATION; REFINEMENT; RESOLUTION; MOLSCRIPT; MECHANISM; REDUCTASE; P450BM-3	Gene inactivation studies point to the involvement of OxyC in catalyzing the last oxidative phenol coupling reaction during glycopeptide antibiotic biosynthesis. Presently, the substrate and exact timing of the OxyC reaction are unknown. The substrate might be the bicyclic heptapeptide or a thioester derivative bound to a protein carrier domain. OxyC from the vancomycin producer Amycolatopsis orientalis was produced in Escherichia coli and crystallized, and its structure was determined to 1.9 Angstrom resolution. OxyC gave UV-visible spectra characteristic of a P450-like hemoprotein in the low spin ferric state. After reduction to the ferrous state by dithionite the CO-ligated form gave a 450-nm peak in a UV-difference spectrum. The addition of vancomycin aglycone to OxyC produced type I changes to the UV spectrum. OxyC exhibits the typical P450-fold, with the Cys ligand loop containing the signature sequence FGHGX-HXCLG and Cys-356 being the proximal axial thiolate ligand of the heme iron. The observation of a water molecule bound to the heme iron is consistent with the UV-visible spectra of OxyC indicating a low spin heme. A polyethylene glycol molecule occupying the active site might mimic the bicyclic heptapeptide substrate. Analysis of the structure of Oxy-proteins and other P450s indicates regions that might be involved in binding of the redox partner and possibly the protein carrier domain.	Univ Zurich, Inst Organ Chem, CH-8057 Zurich, Switzerland; Max Planck Inst Mol Physiol, Dept Phys Biochem, D-44227 Dortmund, Germany; Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany	University of Zurich; Max Planck Society; Max Planck Society	Schlichting, I (corresponding author), Univ Zurich, Inst Organ Chem, Winterthurerstr 190, CH-8057 Zurich, Switzerland.	ilme.schlichting@mpimf-heidelberg.mpg.de	Schlichting, Ilme/I-1339-2013	Pylypenko, Olena/0000-0001-7073-5238				BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; Becker A, 1998, J BIOL CHEM, V273, P11413, DOI 10.1074/jbc.273.19.11413; Becker A, 1998, NAT STRUCT BIOL, V5, P1053, DOI 10.1038/4162; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P4688, DOI 10.1002/1521-3773(20011217)40:24<4688::AID-ANIE4688>3.0.CO;2-M; Bischoff D, 2001, ANGEW CHEM INT EDIT, V40, P1693, DOI 10.1002/1521-3773(20010504)40:9<1693::AID-ANIE16930>3.0.CO;2-8; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen HW, 2001, CHEM BIOL, V8, P301, DOI 10.1016/S1074-5521(01)00009-6; de Montellano PR Ortiz, 1995, CYTOCHROME P450 STRU; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Haines DC, 2001, BIOCHEMISTRY-US, V40, P13456, DOI 10.1021/bi011197q; HASEMANN CA, 1995, STRUCTURE, V3, P41, DOI 10.1016/S0969-2126(01)00134-4; HASEMANN CA, 1994, J MOL BIOL, V236, P1169, DOI 10.1016/0022-2836(94)90019-1; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kim JJP, 1996, METHOD ENZYMOL, V272, P368, DOI 10.1016/S0076-6879(96)72042-6; KIMATA Y, 1995, BIOCHEM BIOPH RES CO, V208, P96, DOI 10.1006/bbrc.1995.1310; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAUS PFX, 1995, P NATL ACAD SCI USA, V92, P2071, DOI 10.1073/pnas.92.6.2071; MARTINIS SA, 1989, J AM CHEM SOC, V111, P9252, DOI 10.1021/ja00208a031; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Muller JJ, 2001, J BIOL CHEM, V276, P2786, DOI 10.1074/jbc.M008501200; Navaza J, 2001, ACTA CRYSTALLOGR D, V57, P1367, DOI 10.1107/S0907444901012422; Nicolaou KC, 1999, ANGEW CHEM INT EDIT, V38, P2096, DOI 10.1002/(SICI)1521-3773(19990802)38:15<2096::AID-ANIE2096>3.0.CO;2-F; Pelzer S, 1999, ANTIMICROB AGENTS CH, V43, P1565, DOI 10.1128/AAC.43.7.1565; Pootoolal J, 2002, P NATL ACAD SCI USA, V99, P8962, DOI 10.1073/pnas.102285099; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1985, J BIOL CHEM, V260, P6122; RAVICHANDRAN KG, 1993, SCIENCE, V261, P731, DOI 10.1126/science.8342039; Sevrioukova IF, 1999, P NATL ACAD SCI USA, V96, P1863, DOI 10.1073/pnas.96.5.1863; van Wageningen AMA, 1998, CHEM BIOL, V5, P155, DOI 10.1016/S1074-5521(98)90060-6; Williams DH, 1999, ANGEW CHEM INT EDIT, V38, P1173, DOI 10.1002/(SICI)1521-3773(19990503)38:9<1172::AID-ANIE1172>3.0.CO;2-C; Zerbe K, 2002, J BIOL CHEM, V277, P47476, DOI 10.1074/jbc.M206342200	33	77	80	3	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46727	46733		10.1074/jbc.M306486200	http://dx.doi.org/10.1074/jbc.M306486200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12888556	hybrid			2022-12-27	WOS:000186569400063
J	Filipek, R; Rzychon, M; Oleksy, A; Gruca, M; Dubin, A; Potempa, J; Bochtler, M				Filipek, R; Rzychon, M; Oleksy, A; Gruca, M; Dubin, A; Potempa, J; Bochtler, M			The staphostatin-staphopain complex - A forward binding inhibitor in complex with its target cysteine protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAPHYLOCOCCUS-AUREUS; CRYSTAL-STRUCTURE; QUINUPRISTIN-DALFOPRISTIN; PROTEINASE-INHIBITORS; MOLECULAR-BASIS; ACTIVE-SITE; PAPAIN; VIRULENCE; SPECIFICITY; RESISTANCE	Staphostatins are the endogenous inhibitors of the major secreted cysteine proteases of Staphylococcus aureus, the staphopains. Our recent crystal structure of staphostatin B has shown that this inhibitor forms a mixed, eight-stranded beta-barrel with statistically significant similarity to lipocalins, but not to cystatins. We now present the 1.8-Angstrom crystal structure of staphostatin B in complex with an inactive mutant of its target protease. The complex is held together through extensive interactions and buries a total surface area of 2300 Angstrom(2). Unexpectedly for a cysteine protease inhibitor, staphostatin B binds to staphopain B in an almost substrate-like manner. The inhibitor polypeptide chain runs through the protease active site cleft in the forward direction, with residues IG-TS in P2 to P2' positions. Both in the free and complexed forms, the P1 glycine residue of the inhibitor is in a main chain conformation only accessible to glycines. Mutations in this residue lead to a loss of affinity of the inhibitor for protease and convert the inhibitor into a substrate.	Int Inst Mol & Cell Biol, PL-02109 Warsaw, Poland; Max Planck Inst Mol Cell Biol & Genet, D-01309 Dresden, Germany; Jagiellonian Univ, Fac Biotechnol, PL-30387 Krakow, Poland; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Miedzynarodowy Instytut Biologii Molekularnej i Komorkowej; Max Planck Society; Jagiellonian University; University System of Georgia; University of Georgia	Bochtler, M (corresponding author), Int Inst Mol & Cell Biol, Ul Trojdena 4, PL-02109 Warsaw, Poland.		Bochtler, Matthias/A-4514-2010	Bochtler, Matthias/0000-0001-7884-4463				BAILEY CJ, 1995, MED MICROBIOL IMMUN, V184, P53; BERTHOLD H, 1992, BIOTECHNOL LETT, V14, P245, DOI 10.1007/BF01022318; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BURGI HB, 1973, J AM CHEM SOC, V95, P5065, DOI 10.1021/ja00796a058; CHAVIRA R, 1984, ANAL BIOCHEM, V136, P446, DOI 10.1016/0003-2697(84)90242-2; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Coulter SN, 1998, MOL MICROBIOL, V30, P393, DOI 10.1046/j.1365-2958.1998.01075.x; Cowtan K, 1998, ACTA CRYSTALLOGR D, V54, P750, DOI 10.1107/S0907444997016247; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; Delgado G, 2000, PHARMACOTHERAPY, V20, P1469, DOI 10.1592/phco.20.19.1469.34858; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Evans Gerald A., 2002, Curr Infect Dis Rep, V4, P17, DOI 10.1007/s11908-002-0063-6; GEMMELL CG, 1995, J MED MICROBIOL, V43, P318, DOI 10.1099/00222615-43-5-318; Goldstein EJC, 2003, ANTIMICROB AGENTS CH, V47, P337, DOI 10.1128/AAC.47.1.337-341.2003; Harrison MJ, 1997, J AM CHEM SOC, V119, P12285, DOI 10.1021/ja9711472; Hiramatsu K, 2002, CURR OPIN INFECT DIS, V15, P407, DOI 10.1097/00001432-200208000-00009; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; Hoffman B., 1993, ACTA CRYSTALLOGR S, P102; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Ji GY, 1995, P NATL ACAD SCI USA, V92, P12055, DOI 10.1073/pnas.92.26.12055; Kagawa TF, 2000, P NATL ACAD SCI USA, V97, P2235, DOI 10.1073/pnas.040549997; Lee LY, 2002, J CLIN INVEST, V110, P1461, DOI 10.1172/JC1200216318; LEWIS SD, 1976, BIOCHEMISTRY-US, V15, P5009, DOI 10.1021/bi00668a010; Maskalyk J, 2002, CAN MED ASSOC J, V167, P375; Massimi I, 2002, J BIOL CHEM, V277, P41770, DOI 10.1074/jbc.M207162200; Mayville P, 1999, P NATL ACAD SCI USA, V96, P1218, DOI 10.1073/pnas.96.4.1218; McGrath ME, 1999, ANNU REV BIOPH BIOM, V28, P181, DOI 10.1146/annurev.biophys.28.1.181; Moise PA, 2002, J ANTIMICROB CHEMOTH, V50, P1017, DOI 10.1093/jac/dkf215; Palma M, 1999, J BACTERIOL, V181, P2840, DOI 10.1128/JB.181.9.2840-2845.1999; Pearson H, 2002, NATURE, V418, P469, DOI 10.1038/418469b; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Rice K, 2001, INFECT IMMUN, V69, P159, DOI 10.1128/IAI.69.1.159-169.2001; Rzychon M, 2003, MOL MICROBIOL, V49, P1051, DOI 10.1046/j.1365-2958.2003.03613.x; RZYCHON M, 2003, IN PRESS PROTEIN SCI, V12; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; Stennicke HR, 2002, TRENDS BIOCHEM SCI, V27, P94, DOI 10.1016/S0968-0004(01)02045-X; STUBBS MT, 1990, EMBO J, V9, P1939, DOI 10.1002/j.1460-2075.1990.tb08321.x; TRAVIS J, 1995, TRENDS MICROBIOL, V3, P405, DOI 10.1016/S0966-842X(00)88988-X; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; VASSEUR C, 1991, J BIOCHEM BIOPH METH, V22, P195, DOI 10.1016/0165-022X(91)90068-8; Viale P, 2002, J CHEMOTHERAPY, V14, P526, DOI 10.1179/joc.2002.14.5.526; Xu GZ, 2001, NATURE, V410, P494, DOI 10.1038/35068604	44	51	56	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40959	40966		10.1074/jbc.M302926200	http://dx.doi.org/10.1074/jbc.M302926200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12874290	hybrid			2022-12-27	WOS:000185847200068
J	Cozier, GE; Bouyoucef, D; Cullen, PJ				Cozier, GE; Bouyoucef, D; Cullen, PJ			Engineering the phosphoinositide-binding profile of a class I Pleckstrin homology domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUTONS TYROSINE KINASE; GUANINE-NUCLEOTIDE-EXCHANGE; PH-DOMAIN; CRYSTAL-STRUCTURE; INOSITOL 1,3,4,5-TETRAKISPHOSPHATE; PLASMA-MEMBRANE; HIGH-AFFINITY; STRUCTURAL BASIS; BETA-SPECTRIN; PROTEIN	Pleckstrin homology (PH) domains are protein modules that bind with varying degrees of affinity and specificity membrane phosphoinositides. Previously we have shown that although the PH domains of the Ras GTPase-activating proteins GAP1(m) and GAP1(IP4BP) are 63% identical at the amino acid level they possess distinct phosphoinositide-binding profiles. The GAP1(m) PH domain binds phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5) P-3), whereas the domain from GAP1(IP4BP) binds PtdIns(3,4,5) P-3 and phosphatidylinositol 4,5-bisphosphate ( PtdIns(4,5) P-2) equally well. These phosphoinositide specificities are translated into distinct subcellular localizations. GAP1(m) is cytosolic and undergoes a rapid PtdIns(3,4,5) P-3-dependent association with the plasma membrane following growth factor stimulation. In contrast, GAP1(IP4BP) is constitutively associated, in a PtdIns(4,5) P-2-dependent manner, with the plasma membrane (Cozier, G. E., Lockyer, P. J., Reynolds, J. S., Kupzig, S., Bottomley, J. R., Millard, T., Banting, G., and Cullen, P. J. (2000) J. Biol. Chem. 275, 28261 - 28268). In the present study, we have used molecular modeling to identify residues in the GAP1(IP4BP) PH domain predicted to be required for high affinity binding to PtdIns( 4,5) P2. This has allowed the isolation of a mutant, GAP1(IP4BP)( K591T), which while retaining high affinity for PtdIns( 3,4,5) P-3 has a 6-fold reduction in its affinity for PtdIns( 4,5) P-2. Importantly, GAP1(IP4BP)-(K591T) is predominantly localized to the cytosol and undergoes a PtdIns( 3,4,5) P-3- dependent association with the plasma membrane following growth factor stimulation. We have therefore engineered the phosphoinositide-binding profile of the GAP1(IP4BP) PH domain, thereby emphasizing that subtle changes in PH domain structure can have a pronounced effect on phosphoinositide binding and the subcellular localization of GAP1(IP4BP).	Univ Bristol, Sch Med Sci, Dept Biochem,Inositide Grp, Henry Wellcome Integrated Signalling Labs, Bristol BS8 1TD, Avon, England	University of Bristol	Cullen, PJ (corresponding author), Univ Bristol, Sch Med Sci, Dept Biochem,Inositide Grp, Henry Wellcome Integrated Signalling Labs, Bristol BS8 1TD, Avon, England.		Cozier, Gyles/A-5891-2009	Cozier, Gyles/0000-0003-2851-0902; Cullen, Peter/0000-0002-9070-8349				Baraldi E, 1999, STRUCTURE, V7, P449, DOI 10.1016/S0969-2126(99)80057-4; Blomberg N, 2000, STRUCTURE, V8, P1079, DOI 10.1016/S0969-2126(00)00509-8; Cozier G, 2000, BIOCHEM J, V349, P333, DOI 10.1042/0264-6021:3490333; Cozier GE, 2000, J BIOL CHEM, V275, P28261; Cullen PJ, 2000, CURR BIOL, V10, pR876, DOI 10.1016/S0960-9822(00)00818-6; Dhe-Paganon S, 1999, P NATL ACAD SCI USA, V96, P8378, DOI 10.1073/pnas.96.15.8378; DOWNING AK, 1994, CURR BIOL, V4, P884, DOI 10.1016/S0960-9822(00)00197-4; Ferguson KM, 2000, MOL CELL, V6, P373, DOI 10.1016/S1097-2765(00)00037-X; FERGUSON KM, 1994, CELL, V79, P199, DOI 10.1016/0092-8674(94)90190-2; FERGUSON KM, 1995, CELL, V83, P1037, DOI 10.1016/0092-8674(95)90219-8; Fukuda M, 1996, J BIOL CHEM, V271, P30303, DOI 10.1074/jbc.271.48.30303; FUSHMAN D, 1995, P NATL ACAD SCI USA, V92, P816, DOI 10.1073/pnas.92.3.816; Fushman D, 1998, J BIOL CHEM, V273, P2835, DOI 10.1074/jbc.273.5.2835; Garcia P, 1995, BIOCHEMISTRY-US, V34, P16228, DOI 10.1021/bi00049a039; HYVONEN M, 1995, EMBO J, V14, P4676, DOI 10.1002/j.1460-2075.1995.tb00149.x; Hyvonen M, 1997, EMBO J, V16, P3396, DOI 10.1093/emboj/16.12.3396; Jogl G, 2002, EMBO J, V21, P4785, DOI 10.1093/emboj/cdf502; Klarlund JK, 2000, J BIOL CHEM, V275, P32816, DOI 10.1074/jbc.M002435200; Kojima T, 1997, BIOCHEM BIOPH RES CO, V236, P333, DOI 10.1006/bbrc.1997.6947; Koshiba S, 1997, J MOL BIOL, V269, P579, DOI 10.1006/jmbi.1997.1041; LEMMON MA, 1995, P NATL ACAD SCI USA, V92, P10472, DOI 10.1073/pnas.92.23.10472; Lemmon MA, 2000, BIOCHEM J, V350, P1, DOI 10.1042/0264-6021:3500001; Lemmon MA, 2002, FEBS LETT, V513, P71, DOI 10.1016/S0014-5793(01)03243-4; Lemmon MA, 2001, BIOCHEM SOC T, V29, P377, DOI 10.1042/BST0290377; Lietzke SE, 2000, MOL CELL, V6, P385, DOI 10.1016/S1097-2765(00)00038-1; Lockyer PJ, 1997, CURR BIOL, V7, P1007, DOI 10.1016/S0960-9822(06)00423-4; Lockyer PJ, 1999, CURR BIOL, V9, P265, DOI 10.1016/S0960-9822(99)80116-X; MACIAS MJ, 1994, NATURE, V369, P675, DOI 10.1038/369675a0; Maffucci T, 2001, FEBS LETT, V506, P173, DOI 10.1016/S0014-5793(01)02909-X; Ogasawara M, 2000, J BIOL CHEM, V275, P3221, DOI 10.1074/jbc.275.5.3221; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Soisson SM, 1998, CELL, V95, P259, DOI 10.1016/S0092-8674(00)81756-0; Thomas CC, 2002, CURR BIOL, V12, P1256, DOI 10.1016/S0960-9822(02)00972-7; Thomas CC, 2001, BIOCHEM J, V358, P287, DOI 10.1042/0264-6021:3580287; TIMM D, 1994, NAT STRUCT BIOL, V1, P782, DOI 10.1038/nsb1194-782; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Varnai P, 1999, J BIOL CHEM, V274, P10983, DOI 10.1074/jbc.274.16.10983; Venkateswarlu K, 1998, CURR BIOL, V8, P463, DOI 10.1016/S0960-9822(98)70181-2; Walker SA, 2002, J BIOL CHEM, V277, P48779, DOI 10.1074/jbc.M204839200; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; YOON HS, 1994, NATURE, V369, P672, DOI 10.1038/369672a0; ZHANG P, 1995, STRUCTURE, V3, P1185, DOI 10.1016/S0969-2126(01)00254-4; Zheng J, 1997, J BIOL CHEM, V272, P30340, DOI 10.1074/jbc.272.48.30340	43	16	16	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39489	39496		10.1074/jbc.M307785200	http://dx.doi.org/10.1074/jbc.M307785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885767	hybrid			2022-12-27	WOS:000185713800028
J	Tonello, F; Ascenzi, P; Montecucco, C				Tonello, F; Ascenzi, P; Montecucco, C			The metalloproteolytic activity of the anthrax lethal factor is substrate-inhibited	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHASE PEPTIDE-SYNTHESIS; DEPENDENT PROCESS; FACTOR CLEAVES; KINASE-KINASE; TOXIN; MACROPHAGES; RECEPTOR; INACTIVATION; PROTEOLYSIS; PATHWAYS	The anthrax lethal factor (LF) is a Zn2+ endopeptidase specific for mitogen-activated protein kinase kinases (MAPKKs), which are cleaved within their N termini. Here, the proteolytic activity of LF has been investigated using novel chromogenic MAPKK-derived peptide substrates, which allowed us to determine the kinetic parameters of the reaction. LF displayed maximal proteolytic activity at the pH and temperature values of the cell cytosol, which is its site of action. LF undergoes substrate inhibition, in keeping with the non-productive binding geometry of the MAPPK-2 N terminus to LF.	CNR, Ist Neurosci, I-35121 Padua, Italy; Univ Roma Tre, Dipartimento Biol, I-00146 Rome, Italy; Univ Roma Tre, Lab Interdipartimentale Microscopia Elettron, I-00146 Rome, Italy; Univ Padua, Dipartimento Sci Biomed, I-35121 Padua, Italy	Consiglio Nazionale delle Ricerche (CNR); Roma Tre University; Roma Tre University; University of Padua	Tonello, F (corresponding author), CNR, Ist Neurosci, Via G Colombo 3, I-35121 Padua, Italy.		Tonello, Fiorella/G-8957-2013; Tonello, Fiorella/AAM-6737-2021	Tonello, Fiorella/0000-0001-8935-8938; Tonello, Fiorella/0000-0001-8935-8938				Abrami L, 2003, J CELL BIOL, V160, P321, DOI 10.1083/jcb.200211018; Ascenzi P, 2002, FEBS LETT, V531, P384, DOI 10.1016/S0014-5793(02)03609-8; Bradley KA, 2001, NATURE, V414, P225, DOI 10.1038/n35101999; Chopra AP, 2003, J BIOL CHEM, V278, P9402, DOI 10.1074/jbc.M211262200; Cleland W W, 1979, Methods Enzymol, V63, P500; DiBella EE, 1996, BIOCHEMISTRY-US, V35, P4427, DOI 10.1021/bi952617c; Dixon TC, 1999, NEW ENGL J MED, V341, P815, DOI 10.1056/NEJM199909093411107; Duesbery NS, 1998, SCIENCE, V280, P734, DOI 10.1126/science.280.5364.734; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRIEDLANDER AM, 1986, J BIOL CHEM, V261, P7123; Friedlander AM, 2002, CURR TOP MICROBIOL, V271, P33; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; GLADSTONE GP, 1946, BR J EXP PATHOL, V27, P349; HANNA PC, 1994, MOL MED, V1, P7; Johansson A, 2000, J COMB CHEM, V2, P496, DOI 10.1021/cc000022h; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kim SO, 2003, J BIOL CHEM, V278, P7413, DOI 10.1074/jbc.M209279200; KLIMPEL KR, 1994, MOL MICROBIOL, V13, P1093, DOI 10.1111/j.1365-2958.1994.tb00500.x; Lacy DB, 2002, CURR TOP MICROBIOL, V271, P61; Leppla SH, 1999, J APPL MICROBIOL, V87, P284, DOI 10.1046/j.1365-2672.1999.00890.x; Liu SH, 2003, J BIOL CHEM, V278, P5227, DOI 10.1074/jbc.M210321200; Menard A, 1996, BIOCHEM J, V320, P687, DOI 10.1042/bj3200687; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; Mock M, 2003, CELL MICROBIOL, V5, P15, DOI 10.1046/j.1462-5822.2003.00253.x; MORGAN G, 1978, BIOCHEMISTRY-US, V17, P3562, DOI 10.1021/bi00610a022; Pannifer AD, 2001, NATURE, V414, P229, DOI 10.1038/n35101998; Park JM, 2002, SCIENCE, V297, P2048, DOI 10.1126/science.1073163; Pellizzari R, 1999, FEBS LETT, V462, P199, DOI 10.1016/S0014-5793(99)01502-1; Salvati L, 2001, EUR J BIOCHEM, V268, P3253, DOI 10.1046/j.1432-1327.2001.02223.x; Scobie HM, 2003, P NATL ACAD SCI USA, V100, P5170, DOI 10.1073/pnas.0431098100; Tonello F, 2002, NATURE, V418, P386, DOI 10.1038/418386a; Vitale G, 1998, BIOCHEM BIOPH RES CO, V248, P706, DOI 10.1006/bbrc.1998.9040; Vitale G, 2000, BIOCHEM J, V352, P739, DOI 10.1042/0264-6021:3520739; ZIMMERMAN M, 1976, ANAL BIOCHEM, V70, P258, DOI 10.1016/S0003-2697(76)80066-8	34	40	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40075	40078		10.1074/jbc.M306466200	http://dx.doi.org/10.1074/jbc.M306466200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888555	hybrid			2022-12-27	WOS:000185713800098
J	Ward, G; Hadar, Y; Bilkis, I; Dosoretz, CG				Ward, G; Hadar, Y; Bilkis, I; Dosoretz, CG			Mechanistic features of lignin peroxidase-catalyzed oxidation of substituted phenols and 1,2-dimethoxyarenes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON REDOX POTENTIALS; HORSERADISH-PEROXIDASE; VERATRYL ALCOHOL; RADICAL-CATION; COMPOUND I; DERIVATIVES; CHRYSOSPORIUM; ANILINES; MEDIATOR; MODELS	The steady state kinetic parameters K-m and k(cat) for the oxidation of phenolic substrates by lignin peroxidase correlated with the presteady state kinetic parameters K-d and k for the reaction of the enzyme intermediate compound II with the substrates, indicating that the latter is the rate-limiting step in the catalytic cycle. ln K-m and ln K-d values for phenolic substrates correlated with redox properties, unlike ln kcat and ln k. This finding suggests that in contrast to horseradish peroxidase, electron transfer is not the rate-limiting step during oxidation by lignin peroxidase compound II. A mechanism is proposed for lignin peroxidase compound II reactions consisting of an equilibrium electron transfer step followed by a subsequent rate-limiting step. Analysis of the correlation coefficients for linear relationships between ln K-d and ln K-m and different calculated redox parameters supports a mechanism in which the acidic forms of phenols are oxidized by lignin peroxidase and electron transfer is coupled with proton transfer. 1,2-Dimethoxyarenes did not comply with the trend for phenolic substrates, which may be a result of more than one substrate binding site on lignin peroxidase and/or alternative binding modes. This behavior was supported by analogue studies with the 1,2-dimethoxyarenes veratric acid and veratryl aldehyde, both of which are not oxidized by lignin peroxidase. Inclusion of either had little effect on the rate of oxidation of phenolic substrates yet resulted in a decrease in the oxidation rate of 1,2-dimethoxyarene substrates, which was considerable for veratryl alcohol and less pronounced for 3,4-dimethoxyphenethylalcohol and 3,4-dimethoxycinnamic acid, in particular in the presence of veratric acid.	Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel; Technion Israel Inst Technol, Fac Civil & Environm Engn, Div Environm Engn & Sci, IL-32000 Haifa, Israel; Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Dept Plant Pathol & Microbiol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Technion Israel Institute of Technology; Hebrew University of Jerusalem	Bilkis, I (corresponding author), Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, Inst Biochem Food Sci & Nutr, IL-76100 Rehovot, Israel.	bilkis@agri.huji.ac.il	Bilkis, Itzhak/Q-9675-2017	Dosoretz, Carlos G./0000-0002-1759-9203				Baciocchi E, 2002, CHEM COMMUN, P946, DOI 10.1039/b201492k; Baciocchi E, 2001, EUR J ORG CHEM, V2001, P2305; Baciocchi E, 2000, CHEM COMMUN, P393, DOI 10.1039/a908394d; Baciocchi E, 2000, EUR J BIOCHEM, V267, P2705, DOI 10.1046/j.1432-1327.2000.01293.x; Banci L, 1999, BIOCHEMISTRY-US, V38, P3205, DOI 10.1021/bi982139g; Bietti M, 1998, J PHYS CHEM A, V102, P7337, DOI 10.1021/jp9812482; Blodig W, 2001, J MOL BIOL, V305, P851, DOI 10.1006/jmbi.2000.4346; CAI DY, 1993, J BIOTECHNOL, V30, P79, DOI 10.1016/0168-1656(93)90029-M; Candeias LP, 1996, BIOCHEMISTRY-US, V35, P102, DOI 10.1021/bi9514424; Candeias LP, 1997, BIOCHEMISTRY-US, V36, P7081, DOI 10.1021/bi970384e; Choinowski T, 1999, J MOL BIOL, V286, P809, DOI 10.1006/jmbi.1998.2507; DEWAR MJS, 1985, J AM CHEM SOC, V107, P3902, DOI 10.1021/ja00299a024; Doyle WA, 1998, BIOCHEMISTRY-US, V37, P15097, DOI 10.1021/bi981633h; Folkes LK, 1997, FEBS LETT, V412, P305, DOI 10.1016/S0014-5793(97)00792-8; GOODWIN DC, 1995, BIOCHEMISTRY-US, V34, P5060, DOI 10.1021/bi00015a017; HARVEY PJ, 1986, FEBS LETT, V195, P242, DOI 10.1016/0014-5793(86)80168-5; HARVEY PJ, 1995, BIOCHEM SOC T, V23, P262, DOI 10.1042/bst0230262; HARVEY PJ, 1992, BIOCHEM SOC T, V20, P345, DOI 10.1042/bst0200345; Hilal SH, 1995, QUANT STRUCT-ACT REL, V14, P348, DOI 10.1002/qsar.19950140405; Joshi DK, 1996, EUR J BIOCHEM, V237, P45, DOI 10.1111/j.1432-1033.1996.0045n.x; JOVANOVIC SV, 1994, J AM CHEM SOC, V116, P4846, DOI 10.1021/ja00090a032; JOVANOVIC SV, 1991, J PHYS CHEM-US, V95, P10824, DOI 10.1021/j100179a054; KERSTEN PJ, 1990, BIOCHEM J, V268, P475, DOI 10.1042/bj2680475; KHODPE SM, 2000, BIOPHYS CHEM, V88, P103; KODURI RS, 1995, J BIOL CHEM, V270, P22254, DOI 10.1074/jbc.270.38.22254; KODURI RS, 1994, BIOCHEMISTRY-US, V33, P4225, DOI 10.1021/bi00180a016; Li C, 1999, J PHYS CHEM B, V103, P6653, DOI 10.1021/jp983819w; Lin WZ, 1998, RADIAT PHYS CHEM, V53, P425, DOI 10.1016/S0969-806X(97)00318-6; LIND J, 1990, J AM CHEM SOC, V112, P479, DOI 10.1021/ja00158a002; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Park JW, 1999, ENVIRON SCI TECHNOL, V33, P2028, DOI 10.1021/es9810787; Piontek K, 2001, BIOCHEM SOC T, V29, P111, DOI 10.1042/BST0290111; Priyadarsini KI, 1998, FREE RADICAL BIO MED, V24, P933, DOI 10.1016/S0891-5849(97)00382-1; RENGANATHAN V, 1986, BIOCHEMISTRY-US, V25, P1626, DOI 10.1021/bi00355a027; Rothschild N, 1997, APPL ENVIRON MICROB, V63, P857, DOI 10.1128/AEM.63.3.857-861.1997; SAKURADA J, 1990, BIOCHEMISTRY-US, V29, P4093, DOI 10.1021/bi00469a011; Schlegel HB., 2009, GAUSSIAN 09 REVISION; Schoemaker H E, 1994, Bioorg Med Chem, V2, P509, DOI 10.1016/0968-0896(94)80021-9; SEGEL HM, 1975, ENZYME KINETICS, P727; STEENKEN S, 1982, J PHYS CHEM-US, V86, P3661, DOI 10.1021/j100215a033; STEENKEN S, 1979, J PHYS CHEM-US, V83, P1134, DOI 10.1021/j100472a005; Teunissen PJM, 1998, ARCH BIOCHEM BIOPHYS, V360, P233, DOI 10.1006/abbi.1998.0940; TIEN M, 1988, METHOD ENZYMOL, V161, P238; TIEN M, 1986, J BIOL CHEM, V261, P1687; Van Haandel MJH, 1999, BBA-PROTEIN STRUCT M, V1435, P22, DOI 10.1016/S0167-4838(99)00199-5; vanHaandel MJH, 1996, J BIOL INORG CHEM, V1, P460, DOI 10.1007/s007750050079; Ward G, 2002, ENZYME MICROB TECH, V30, P490, DOI 10.1016/S0141-0229(01)00526-9; Ward G, 2001, J BIOL CHEM, V276, P18734, DOI 10.1074/jbc.M009785200; Ward G, 2001, ENZYME MICROB TECH, V29, P34, DOI 10.1016/S0141-0229(01)00336-2; WARDMAN P, 1989, J PHYS CHEM REF DATA, V18, P1637, DOI 10.1063/1.555843	51	23	25	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39726	39734		10.1074/jbc.M303918200	http://dx.doi.org/10.1074/jbc.M303918200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12857756	hybrid			2022-12-27	WOS:000185713800058
J	Barabas, O; Rumlova, M; Erdei, A; Pongracz, V; Pichova, I; Vertessy, BG				Barabas, O; Rumlova, M; Erdei, A; Pongracz, V; Pichova, I; Vertessy, BG			dUTPase and nucleocapsid polypeptides of the Mason-Pfizer monkey virus form a fusion protein in the virion with homotrimeric organization and low catalytic efficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY-TUMOR VIRUS; INFECTIOUS-ANEMIA VIRUS; HIGH-LEVEL EXPRESSION; 3 ACTIVE FORMS; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; NUCLEOTIDE-SEQUENCE; IN-VITRO; BINDING; GAG	Betaretroviruses encode dUTPase, an essential factor in DNA metabolism and repair, in the pro open reading frame located between gag and pol. Ribosomal frame-shifts during expression of retroviral proteins provide a unique possibility for covalent joining of nucleocapsid (NC) and dUTPase within Gag-Pro polyproteins. By developing an antibody against the prototype betaretrovirus Mason-Pfizer monkey virus dUTPase, we demonstrate that i) the NC-dUTPase fusion protein exists both within the virions and infected cells providing the only form of dUTPase, and ii) the retroviral protease does not cleave NC-dUTPase either in the virion or in vitro. We show that recombinant betaretroviral NC-dUTPase and dUTPase are both inefficient catalysts compared with all other dUTPases. Dynamic light scattering and gel filtration confirm that the homotrimeric organization, common among dUTPases, is retained in the NC-dUTPase fusion protein. The betaretroviral dUTPase has been crystallized and single crystals contain homotrimers. Oligonucleotide and Zn2+ binding is well retained in the fusion protein, which is the first example of acquisition of a functional nucleic acid binding module by the DNA repair factor dUTPase. Binding of the hexanucleotide ACTGCC or the octanucleotide (TG)(4) to NC-dUTPase modulates enzymatic function, indicating that the low catalytic activity may be compensated by adequate localization.	Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, H-1518 Budapest, Hungary; Eotvos Lorand Univ, Dept Theoret Chem, H-1518 Budapest, Hungary; Acad Sci Czech Republ, Inst Organ Chem & Biochem, Prague, Czech Republic; Eotvos Lorand Univ, Dept Immunol, Budapest, Hungary; Inst Chem Technol, Dept Biochem & Microbiol, CR-16628 Prague, Czech Republic	Hungarian Academy of Sciences; Hungarian Biological Research Center; Hungarian Research Centre for Natural Sciences; Eotvos Lorand University; Czech Academy of Sciences; Institute of Organic Chemistry & Biochemistry of the Czech Academy of Sciences; Eotvos Lorand University; University of Chemistry & Technology, Prague	Vertessy, BG (corresponding author), Hungarian Acad Sci, Biol Res Ctr, Inst Enzymol, POB 7, H-1518 Budapest, Hungary.	vertessy@enzim.hu	Barabas, Orsolya/F-3961-2012; Vertessy, Beata G/H-6202-2012; Rumlova, Michaela/G-9142-2018; Erdei, Anna/AAN-5988-2020; Rumlova, Michaela/G-6140-2014; Pichova, Iva/G-7917-2014	Barabas, Orsolya/0000-0002-2873-5872; Rumlova, Michaela/0000-0002-5645-8227; Vertessy, Beata G./0000-0002-1288-2982; Erdei, Anna/0000-0002-3622-6680				ANDRADE MA, 1993, PROTEIN ENG, V6, P383, DOI 10.1093/protein/6.4.383; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baldo AM, 1999, J VIROL, V73, P7710, DOI 10.1128/JVI.73.9.7710-7721.1999; BERGMAN AC, 1994, VIROLOGY, V204, P420, DOI 10.1006/viro.1994.1547; BERGMAN AC, 1995, PROTEIN EXPRES PURIF, V6, P379, DOI 10.1006/prep.1995.1050; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Dauter Z, 1999, J MOL BIOL, V285, P655, DOI 10.1006/jmbi.1998.2332; De Guzman RN, 1998, SCIENCE, V279, P384, DOI 10.1126/science.279.5349.384; DIBHAJJ F, 1993, PROTEIN SCI, V2, P231; ELDER JH, 1992, J VIROL, V66, P1791, DOI 10.1128/JVI.66.3.1791-1794.1992; ELHAJJ HH, 1988, J BACTERIOL, V170, P1069, DOI 10.1128/jb.170.3.1069-1075.1988; FERREDAMARE AR, 1994, STRUCTURE, V2, P357, DOI 10.1016/S0969-2126(00)00037-X; Fiser A, 2000, BIOCHEM BIOPH RES CO, V279, P534, DOI 10.1006/bbrc.2000.3994; Fisher RJ, 1998, J VIROL, V72, P1902, DOI 10.1128/JVI.72.3.1902-1909.1998; FITZGERALD DW, 1991, BIOCHEMISTRY-US, V30, P5195, DOI 10.1021/bi00235a012; GADSDEN MH, 1993, EMBO J, V12, P4425, DOI 10.1002/j.1460-2075.1993.tb06127.x; Gao Y, 1998, PROTEIN SCI, V7, P2265, DOI 10.1002/pro.5560071104; Goulian M, 1986, Adv Exp Med Biol, V195 Pt B, P89; GREEN LM, 1990, P NATL ACAD SCI USA, V87, P6403, DOI 10.1073/pnas.87.16.6403; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Harris JM, 1999, J MOL BIOL, V288, P275, DOI 10.1006/jmbi.1999.2680; HRUSKOVAHEIDINGSFELDOVA O, 1995, J BIOL CHEM, V270, P15053, DOI 10.1074/jbc.270.25.15053; JACKS T, 1987, P NATL ACAD SCI USA, V84, P4298, DOI 10.1073/pnas.84.12.4298; KOPPE B, 1994, J VIROL, V68, P2313; Larsson G, 1996, J BIOL CHEM, V271, P24010, DOI 10.1074/jbc.271.39.24010; Larsson G, 1996, NAT STRUCT BIOL, V3, P532, DOI 10.1038/nsb0696-532; LERNER DL, 1995, P NATL ACAD SCI USA, V92, P7480, DOI 10.1073/pnas.92.16.7480; LESLIE AGW, 1992, NEWSLETTER PROTEIN C, V26; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; MCCLURE MA, 1987, P NATL ACAD SCI USA, V84, P2693, DOI 10.1073/pnas.84.9.2693; MCGEOCH DJ, 1990, NUCLEIC ACIDS RES, V18, P4105, DOI 10.1093/nar/18.14.4105; Mol CD, 1996, STRUCTURE, V4, P1077, DOI 10.1016/S0969-2126(96)00114-1; MOORE R, 1987, J VIROL, V61, P480, DOI 10.1128/JVI.61.2.480-490.1987; Morellet N, 1998, J MOL BIOL, V283, P419, DOI 10.1006/jmbi.1998.2098; MORRISON ID, 1985, LANGMUIR, V1, P496, DOI 10.1021/la00064a016; OMICHINSKI JG, 1991, FEBS LETT, V292, P25, DOI 10.1016/0014-5793(91)80825-N; Pearl LH, 1996, NAT STRUCT BIOL, V3, P485, DOI 10.1038/nsb0696-485; Persson R, 2002, PREP BIOCHEM BIOTECH, V32, P157, DOI 10.1081/PB-120004128; Pichova I, 1998, ADV EXP MED BIOL, V436, P105; Prasad GS, 1996, PROTEIN SCI, V5, P2429, DOI 10.1002/pro.5560051205; Prasad GS, 2000, ACTA CRYSTALLOGR D, V56, P1100, DOI 10.1107/S0907444900009197; PYLES RB, 1992, J VIROL, V66, P6706, DOI 10.1128/JVI.66.11.6706-6713.1992; Rumlova M, 2003, VIROLOGY, V310, P310, DOI 10.1016/S0042-6822(03)00128-4; Sambrook J., 2001, MOL CLONING LAB MANU; SONIGO P, 1986, CELL, V45, P375, DOI 10.1016/0092-8674(86)90323-5; STEAGALL WK, 1995, VIROLOGY, V210, P302, DOI 10.1006/viro.1995.1347; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; THREADGILL DS, 1993, J VIROL, V67, P2592, DOI 10.1128/JVI.67.5.2592-2600.1993; Turelli P, 1997, J VIROL, V71, P4522, DOI 10.1128/JVI.71.6.4522-4530.1997; Urbaneja MA, 2000, J BIOL CHEM, V275, P10394, DOI 10.1074/jbc.275.14.10394; Vertessy BG, 1996, BIOCHEM BIOPH RES CO, V219, P294, DOI 10.1006/bbrc.1996.0226; VERTESSY BG, 1994, BBA-PROTEIN STRUCT M, V1205, P146, DOI 10.1016/0167-4838(94)90103-1; Vertessy BG, 1997, PROTEINS, V28, P568, DOI 10.1002/(SICI)1097-0134(199708)28:4<568::AID-PROT10>3.0.CO;2-E; Vuilleumier C, 1999, BIOCHEMISTRY-US, V38, P16816, DOI 10.1021/bi991145p; Wang Y, 2002, RNA, V8, P981, DOI 10.1017/S1355838202024044; Zabransky A, 1998, VIROLOGY, V245, P250, DOI 10.1006/viro.1998.9173	57	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38803	38812		10.1074/jbc.M306967200	http://dx.doi.org/10.1074/jbc.M306967200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869552	hybrid			2022-12-27	WOS:000185575100088
J	Emiliani, C; Urbanelli, L; Racanicchi, L; Orlacchio, A; Pelicci, G; Sorbi, S; Bernardi, G; Orlacchio, A				Emiliani, C; Urbanelli, L; Racanicchi, L; Orlacchio, A; Pelicci, G; Sorbi, S; Bernardi, G; Orlacchio, A			Up-regulation of glycohydrolases in Alzheimer's Disease fibroblasts correlates with Ras activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; ENDOSOMAL-LYSOSOMAL SYSTEM; BETA-PROTEIN; CATHEPSIN-D; MEMBRANE ASSOCIATION; TAU PHOSPHORYLATION; OXIDATIVE STRESS; GENE-EXPRESSION; KINASE CASCADE; GLIAL-CELLS	The lysosomal system is up-regulated in the brain of patients with Alzheimer's Disease (AD), as demonstrated by previous experiments carried out in postmortem samples of brain patients. In this paper we provide evidence that an up-regulation of lysosomal glycohydrolases (alpha-D-mannosidase, beta-D-hexosaminidase, and beta-D-galactosidase) takes place in skin fibroblasts from AD patients affected either by sporadic or familial forms and is detectable also in presymptomatic subjects carrying the above mutations but healthy at the time of skin biopsy. This increase of enzyme activity is consequent to a transcriptional up-regulation. The oncogene Ras appears to be involved in the regulation of enzymatic activity. A parallel increase of Ras transcript and Ras protein, without an increase of p44/p42 MAPK activation was revealed in the same AD fibroblasts. An activation of p38 MAPK already described to occur in neurodegenerative diseases such as Alzheimer's, was also found in fibroblasts derived from AD patients. High levels of expression of the constitutively active form of Ras in normal or AD fibroblasts induced glycohydrolases up-regulation. Overall results demonstrated that glycohydrolases up-regulation, as well as Ras up-regulation, are early markers of AD, detectable at peripheral level, and good candidates to be exploited for diagnostic purposes. These data also provide the first proof for a role of Ras in regulating lysosomal glycohydrolases expression.	Univ Perugia, Dipartimento Sci Biochim & Biotecnol Mol, I-06122 Perugia, Italy; IRCCS Santa Lucia, Neurogenet Lab, I-00179 Rome, Italy; Univ Roma Tor Vergata, Policlin Tor Vergata, Dipartimento Neurosci, I-00133 Rome, Italy; Ist Europeo Oncol, Dipartimento Oncol Sperimentale, I-20141 Milan, Italy; Univ Florence, Dipartimento Sci Neurol & Psichiatr, I-50134 Florence, Italy	University of Perugia; IRCCS Santa Lucia; University of Rome Tor Vergata; Policlin Tor Vergata; IRCCS European Institute of Oncology (IEO); University of Florence	Orlacchio, A (corresponding author), Univ Perugia, Dipartimento Sci Biochim & Biotecnol Mol, Via Giochetto, I-06122 Perugia, Italy.	orly@unipg.it	Orlacchio, Antonio/AAO-5124-2021; Orlacchio, Antonio/A-1968-2014; Urbanelli, Lorena/G-4936-2010; Pelicci, Giuliana/AAA-8921-2022; Emiliani, Carla/G-3738-2010	Orlacchio, Antonio/0000-0002-2602-3281; Orlacchio, Antonio/0000-0002-2602-3281; Pelicci, Giuliana/0000-0003-0986-8255; Emiliani, Carla/0000-0002-6368-1515; Urbanelli, Lorena/0000-0003-0621-8476; sorbi, sandro/0000-0002-0380-6670	Telethon [E.0980] Funding Source: Medline	Telethon(Fondazione Telethon)		Adamec E, 2000, NEUROSCIENCE, V100, P663, DOI 10.1016/S0306-4522(00)00281-5; Atzori C, 2001, J NEUROPATH EXP NEUR, V60, P1190, DOI 10.1093/jnen/60.12.1190; Bahr BA, 2002, J NEUROCHEM, V83, P481, DOI 10.1046/j.1471-4159.2002.01192.x; BENOWITZ LI, 1989, EXP NEUROL, V106, P237, DOI 10.1016/0014-4886(89)90156-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cataldo AM, 1996, J NEUROSCI, V16, P186; CATALDO AM, 1991, P NATL ACAD SCI USA, V88, P10998, DOI 10.1073/pnas.88.24.10998; CATALDO AM, 1995, NEURON, V14, P671, DOI 10.1016/0896-6273(95)90324-0; CITRON M, 1994, P NATL ACAD SCI USA, V91, P11993, DOI 10.1073/pnas.91.25.11993; COLE GM, 1989, NEUROCHEM RES, V14, P933, DOI 10.1007/BF00965926; Connolly GP, 1998, TRENDS PHARMACOL SCI, V19, P171, DOI 10.1016/S0165-6147(98)01202-4; Cosgaya JM, 1996, J NEUROCHEM, V67, P98; CRUTCHER KA, 1993, J NEUROSCI, V13, P2540, DOI 10.1523/JNEUROSCI.13-06-02540.1993; D'Andrea MR, 2001, HISTOPATHOLOGY, V38, P120, DOI 10.1046/j.1365-2559.2001.01082.x; DANIEL PF, 1994, GLYCOBIOLOGY, V4, P551, DOI 10.1093/glycob/4.5.551; Demoz M, 1999, J CELL BIOCHEM, V73, P370, DOI 10.1002/(SICI)1097-4644(19990601)73:3<370::AID-JCB8>3.0.CO;2-N; EMILIANI C, 1995, BIOCHEM J, V305, P363, DOI 10.1042/bj3050363; EVIN G, 1995, BIOCHEMISTRY-US, V34, P14185, DOI 10.1021/bi00043a024; Ferrer I, 2001, J NEURAL TRANSM, V108, P1397, DOI 10.1007/s007020100016; Ferrer I, 2001, BRAIN PATHOL, V11, P144; Fraser PE, 2000, BBA-MOL BASIS DIS, V1502, P1, DOI 10.1016/S0925-4439(00)00028-4; FRESHNEY NW, 1994, CELL, V78, P1039, DOI 10.1016/0092-8674(94)90278-X; Frosch BA, 1999, APMIS, V107, P28, DOI 10.1111/j.1699-0463.1999.tb01523.x; GARTNER U, 1995, NEUROREPORT, V6, P1441; Gartner U, 1999, NEUROSCIENCE, V91, P1, DOI 10.1016/S0306-4522(99)00059-7; GOLDE TE, 1992, SCIENCE, V255, P728, DOI 10.1126/science.1738847; Gomez-Pinilla F, 1990, Neuroreport, V1, P211; HAASS C, 1993, ANN NY ACAD SCI, V695, P109, DOI 10.1111/j.1749-6632.1993.tb23037.x; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Horstmann S, 1998, J NEUROSCI RES, V52, P483, DOI 10.1002/(SICI)1097-4547(19980515)52:4<483::AID-JNR12>3.3.CO;2-Y; JIANG LW, 1990, J BIOL CHEM, V265, P4775; KOO EH, 1994, J BIOL CHEM, V269, P17386; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Mathews PM, 2002, J BIOL CHEM, V277, P5299, DOI 10.1074/jbc.M108161200; McFarlane I, 1999, NEUROSCIENCE, V90, P15, DOI 10.1016/S0306-4522(98)00361-3; Nixon RA, 2001, J ALZHEIMERS DIS, V3, P97, DOI 10.3233/JAD-2001-3114; ORLACCHIO A, 2000, REC RES DEV NEUROCHE, V3, P205; Pasternak SH, 2003, J BIOL CHEM, V278, P26687, DOI 10.1074/jbc.M304009200; Pearson M, 2000, NATURE, V406, P207, DOI 10.1038/35018127; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; Sadot E, 1998, J NEUROCHEM, V70, P428; Selkoe DJ, 2002, SCIENCE, V298, P789, DOI 10.1126/science.1074069; Skaper SD, 1998, MOL CELL NEUROSCI, V12, P179, DOI 10.1006/mcne.1998.0714; SLOANE BF, 1994, J CELL SCI, V107, P373; Smith MA, 2000, BBA-MOL BASIS DIS, V1502, P139, DOI 10.1016/S0925-4439(00)00040-5; Zhu XW, 2000, J NEUROPATH EXP NEUR, V59, P880, DOI 10.1093/jnen/59.10.880; Zhu XW, 2001, J NEUROCHEM, V79, P311, DOI 10.1046/j.1471-4159.2001.00597.x	49	41	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38453	38460		10.1074/jbc.M303030200	http://dx.doi.org/10.1074/jbc.M303030200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878600	hybrid			2022-12-27	WOS:000185575100046
J	Johnson, JL; Cusack, B; Hughes, TF; McCullough, EH; Fauq, A; Romanovskis, P; Spatola, AF; Rosenberry, TL				Johnson, JL; Cusack, B; Hughes, TF; McCullough, EH; Fauq, A; Romanovskis, P; Spatola, AF; Rosenberry, TL			Inhibitors tethered near the acetylcholinesterase active site serve as molecular rulers of the peripheral and acylation sites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; BINDING-SITE; RECEPTOR; SPECIFICITY; FASCICULIN; PROPIDIUM; CYSTEINES; PROTEINS; REVEALS; REAGENT	The acetylcholinesterase (AChE) active site consists of a narrow gorge with two separate ligand binding sites: an acylation site (or A-site) at the bottom of the gorge where substrate hydrolysis occurs and a peripheral site (or P-site) at the gorge mouth. AChE is inactivated by organo-phosphates as they pass through the P-site and phosphorylate the catalytic serine in the A-site. One strategy to protect against organophosphate inactivation is to design cyclic ligands that will bind specifically to the P-site and block the passage of organophosphates but not acetylcholine. To accelerate the process of identifying cyclic compounds with high affinity for the AChE P-site, we introduced a cysteine residue near the rim of the P-site by site-specific mutagenesis to generate recombinant human H287C AChE. Compounds were synthesized with a highly reactive methanethiosulfonyl substituent and linked to this cysteine through a disulfide bond. The advantages of this tethering were demonstrated with H287C AChE modified with six compounds, consisting of cationic trialkyl-ammonium, acridinium, and tacrine ligands with tethers of varying length. Modification by ligands with short tethers had little effect on catalytic properties, but longer tethering resulted in shifts in substrate hydrolysis profiles and reduced affinity for acridinium affinity resin. Molecular modeling calculations indicated that cationic ligands with tethers of intermediate length bound to the P-site, whereas those with long tethers reached the A-site. These binding locations were confirmed experimentally by measuring competitive inhibition constants K-I2 for propidium and tacrine, inhibitors specific for the P- and A-sites, respectively. Values of K-I2 for propidium increased 30- to 100-fold when ligands had either intermediate or long tethers. In contrast, the value of K-I2 for tacrine increased substantially only when ligands had long tethers. These relative changes in propidium and tacrine affinities thus provided a sensitive molecular ruler for assigning the binding locations of the tethered cations.	Mayo Clin Jacksonville, Mayo Fdn Med Educ & Res, Dept Pharmacol, Jacksonville, FL 32224 USA; Mayo Clin Jacksonville, Mayo Fdn Med Educ & Res, Dept Neurosci, Jacksonville, FL 32224 USA; Univ Louisville, Dept Chem, Louisville, KY 40292 USA	Mayo Clinic; Mayo Clinic; University of Louisville	Rosenberry, TL (corresponding author), Mayo Clin Jacksonville, Mayo Fdn Med Educ & Res, Dept Pharmacol, 4500 San Pablo Rd,Birdsall Bldg, Jacksonville, FL 32224 USA.		Cusack, Bernadette/D-4606-2013					Aldridge WN, 1972, FRONTIERS BIOL, V26; [Anonymous], ENZYMES 3E; Bourne Y, 2003, EMBO J, V22, P1, DOI 10.1093/emboj/cdg005; Boyd AE, 2000, J BIOL CHEM, V275, P22401, DOI 10.1074/jbc.M000606200; Bruice T.W., 1982, J PROTEIN CHEM, V1, P47, DOI DOI 10.1007/BF01025550; BURGEN ASV, 1949, BRIT J PHARM CHEMOTH, V4, P219, DOI 10.1111/j.1476-5381.1949.tb00540.x; Carlier PR, 1999, BIOORGAN MED CHEM, V7, P351, DOI 10.1016/S0968-0896(98)00213-2; De Ferrari GV, 2001, J BIOL CHEM, V276, P23282, DOI 10.1074/jbc.M009596200; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; Erlanson DA, 2000, P NATL ACAD SCI USA, V97, P9367, DOI 10.1073/pnas.97.17.9367; Foong LY, 1997, BIOCHEMISTRY-US, V36, P1343, DOI 10.1021/bi9624907; HAAS R, 1985, ANAL BIOCHEM, V148, P154, DOI 10.1016/0003-2697(85)90640-2; HAAS R, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P131; Haldane J. B. S., 1930, ENZYMES, P84; Harel M, 1996, J AM CHEM SOC, V118, P2340, DOI 10.1021/ja952232h; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; Incardona JP, 1996, MOL BIOL CELL, V7, P613, DOI 10.1091/mbc.7.4.613; KARLSSON E, 1984, J PHYSIOLOGY PARIS, V79, P232; Li LT, 2001, CHEM BIOL, V8, P47, DOI 10.1016/S1074-5521(00)00055-7; Mallender WD, 2000, BIOCHEMISTRY-US, V39, P7753, DOI 10.1021/bi000210o; Mallender WD, 1999, J BIOL CHEM, V274, P8491, DOI 10.1074/jbc.274.13.8491; Mallender WD, 2001, MOL PHARMACOL, V59, P619, DOI 10.1124/mol.59.3.619; MARCHOT P, 1993, J BIOL CHEM, V268, P12458; Raves ML, 1997, NAT STRUCT BIOL, V4, P57, DOI 10.1038/nsb0197-57; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; ROSENBERRY TL, 1979, BIOPHYS J, V26, P263, DOI 10.1016/S0006-3495(79)85249-2; ROSENBERRY TL, 1984, J BIOL CHEM, V259, P5643; ROSENBERRY TL, 1982, METHOD ENZYMOL, V82, P325; Rosenberry TL, 1975, ADV ENZYMOLOGY, P43; SILMAN I, 1969, SCIENCE, V164, P1420, DOI 10.1126/science.164.3886.1420; SPATOLA AF, 1993, METHODS NEUROSCIENCE, V13, P19; STAUFFER DA, 1994, BIOCHEMISTRY-US, V33, P6840, DOI 10.1021/bi00188a013; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; Szegletes T, 1999, BIOCHEMISTRY-US, V38, P122, DOI 10.1021/bi9813577; Szegletes T, 1998, BIOCHEMISTRY-US, V37, P4206, DOI 10.1021/bi972158a; TAYLOR P, 1975, BIOCHEMISTRY-US, V14, P1989, DOI 10.1021/bi00680a029; Teissere JA, 2001, J NEUROSCI, V21, P4977, DOI 10.1523/JNEUROSCI.21-14-04977.2001; WILSON IB, 1955, BIOCHIM BIOPHYS ACTA, V18, P168, DOI 10.1016/0006-3002(55)90040-8; WILSON IB, 1951, J BIOL CHEM, V190, P111	39	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38948	38955		10.1074/jbc.M304797200	http://dx.doi.org/10.1074/jbc.M304797200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851386	hybrid			2022-12-27	WOS:000185575100105
J	Maier, HJ; Marienfeld, R; Wirth, T; Baumann, B				Maier, HJ; Marienfeld, R; Wirth, T; Baumann, B			Critical role of RelB serine 368 for dimerization and p100 stabilization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTORS; NUCLEAR-LOCALIZATION; DIFFERENTIAL REGULATION; SIGNALING PATHWAY; NF-KAPPA-B2 P100; IMMUNE-RESPONSES; B/REL FAMILY; I-REL; ACTIVATION	In mature B cells RelB-containing complexes are constitutively present in the nucleus, and they are less susceptible to inhibitory kappaB proteins. In most other cell types inhibitory kappaB proteins prevent nuclear translocation and activation of NFkappaB. We reasoned that this characteristic might be because of post-translational modifications of RelB. In Drosophila, signal-dependent phosphorylation of the Rel homologue Dorsal at serine 317 has been shown to be critical for nuclear import. The evolutionary conservation of this serine prompted us to analyze the function of the corresponding site in RelB. As a model system we used the murine S107 plasmacytoma cell line, which lacks endogenous RelB expression. Analysis of S107 cells expressing wild type RelB and serine 368 mutants reveals that serine 368 is not required for nuclear import but that it is critical for RelB dimerization with other members of the NFkappaB family. Similar effects were obtained when the conserved serine in RelA was mutated. We further demonstrate that expression of functional RelB, but not of serine 368 mutants, severely reduces p52 generation and strongly increases expression of the p52 precursor, p100. Wild type RelB, but not mutant RelB, prolonged p100 half-life. We therefore suggest an inhibitory effect of RelB on p100 processing, which is possibly regulated in a signal-dependent manner.	Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany; Yale Univ, Sch Med, Howard Hughes Med Inst, Immunobiol Sect, New Haven, CT 06520 USA	Ulm University; Howard Hughes Medical Institute; Yale University	Wirth, T (corresponding author), Univ Ulm, Dept Physiol Chem, D-89081 Ulm, Germany.		Wirth, Thomas/X-7172-2019					Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baumann B, 1998, J BIOL CHEM, V273, P11448, DOI 10.1074/jbc.273.19.11448; Baumann B, 2000, P NATL ACAD SCI USA, V97, P4615, DOI 10.1073/pnas.080583397; BAUMANN B, 2002, J BIOL CHEM, V16, P16; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; Bergmann A, 1996, MECH DEVELOP, V60, P109, DOI 10.1016/S0925-4773(96)00607-7; Betts JC, 1996, MOL CELL BIOL, V16, P6363; BOURS V, 1994, ONCOGENE, V9, P1699; BURKLY L, 1995, NATURE, V373, P531, DOI 10.1038/373531a0; Carlotti F, 2000, J BIOL CHEM, V275, P41028, DOI 10.1074/jbc.M006179200; Chen FE, 1998, NATURE, V391, P410, DOI 10.1038/34956; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; Denk A, 2000, CYTOKINE GROWTH F R, V11, P303, DOI 10.1016/S1359-6101(00)00009-5; Derudder E, 2003, J BIOL CHEM, V278, P23278, DOI 10.1074/jbc.M300106200; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dixit V, 2002, CELL, V111, P615, DOI 10.1016/S0092-8674(02)01166-2; DOBRZANSKI P, 1993, MOL CELL BIOL, V13, P1572, DOI 10.1128/MCB.13.3.1572; DOBRZANSKI P, 1995, ONCOGENE, V10, P1003; DOBRZANSKI P, 1994, EMBO J, V13, P4608, DOI 10.1002/j.1460-2075.1994.tb06782.x; Drier EA, 1997, SEMIN CANCER BIOL, V8, P83, DOI 10.1006/scbi.1997.0059; Drier EA, 1999, GENE DEV, V13, P556, DOI 10.1101/gad.13.5.556; Ghosh S, 1998, ANNU REV IMMUNOL, V16, P225, DOI 10.1146/annurev.immunol.16.1.225; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; Govind S, 1999, ONCOGENE, V18, P6875, DOI 10.1038/sj.onc.1203223; Heusch M, 1999, ONCOGENE, V18, P6201, DOI 10.1038/sj.onc.1203022; Huang DB, 1997, STRUCTURE, V5, P1427, DOI 10.1016/S0969-2126(97)00293-1; Kaisho T, 2001, J EXP MED, V193, P417, DOI 10.1084/jem.193.4.417; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Kayagaki N, 2002, IMMUNITY, V17, P515, DOI 10.1016/S1074-7613(02)00425-9; Kirillov A, 1996, NAT GENET, V13, P435, DOI 10.1038/ng0895-435; Kistler B, 1998, J IMMUNOL, V160, P2308; LERNBECHER T, 1994, EMBO J, V13, P4060, DOI 10.1002/j.1460-2075.1994.tb06723.x; LERNBECHER T, 1993, NATURE, V365, P767, DOI 10.1038/365767a0; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIPTAY S, 1994, MOL CELL BIOL, V14, P7695, DOI 10.1128/MCB.14.12.7695; Marienfeld R, 2001, ONCOGENE, V20, P8142, DOI 10.1038/sj.onc.1204884; Mordmuller B, 2003, EMBO REP, V4, P82, DOI 10.1038/embor710; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; ROTH S, 1989, CELL, V59, P1189, DOI 10.1016/0092-8674(89)90774-5; RUBEN SM, 1992, GENE DEV, V6, P745, DOI 10.1101/gad.6.5.745; RYSECK RP, 1995, MOL CELL BIOL, V15, P3100; RYSECK RP, 1992, MOL CELL BIOL, V12, P674, DOI 10.1128/MCB.12.2.674; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; Solan NJ, 2002, J BIOL CHEM, V277, P1405, DOI 10.1074/jbc.M109619200; Weih DS, 2001, J IMMUNOL, V167, P1909, DOI 10.4049/jimmunol.167.4.1909; Weih F, 1997, J IMMUNOL, V158, P5211; WEIH F, 1995, CELL, V80, P331, DOI 10.1016/0092-8674(95)90416-6; WHALEN AM, 1993, J CELL BIOL, V123, P523, DOI 10.1083/jcb.123.3.523; Whiteside ST, 1997, SEMIN CANCER BIOL, V8, P75, DOI 10.1006/scbi.1997.0058; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yilmaz ZB, 2003, EMBO J, V22, P121, DOI 10.1093/emboj/cdg004	58	44	49	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39242	39250		10.1074/jbc.M301521200	http://dx.doi.org/10.1074/jbc.M301521200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874295	hybrid			2022-12-27	WOS:000185575100139
J	Ni, DTN; Matthews, SP; Antoniou, AN; Mazzeo, D; Watts, C				Ni, DTN; Matthews, SP; Antoniou, AN; Mazzeo, D; Watts, C			Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACUOLAR PROCESSING ENZYME; HUMAN PROCATHEPSIN-B; CLASS-II COMPLEXES; DENDRITIC CELLS; SCHISTOSOMA-MANSONI; MAMMALIAN LEGUMAIN; CRYSTAL-STRUCTURE; GENE-EXPRESSION; SERIAL ANALYSIS; ACTIVATION	Mammalian asparaginyl endopeptidase (AEP) or legumain is a recently discovered lysosomal cysteine protease that specifically cleaves after asparagine residues. How this unusually specific lysosomal protease is itself activated is not fully understood. Using purified recombinant pro-enzyme, we show that activation is autocatalytic, requires sequential removal of C- and N-terminal pro-peptides at different pH thresholds, and is bimolecular. Removal of the N-terminal propeptide requires cleavage after aspartic acid rather than asparagine. Cellular processing, either of exogenously added AEP precursor or of pulse-labeled endogenous precursor, introduces at least one further cleavage to yield the final mature lysosomal enzyme. We also provide evidence that in living cells, there is clear compartmental heterogeneity in terms of AEP activation status. Moreover, we show that human monocyte-derived dendritic cells harbor inactive proforms of AEP that become activated upon maturation of dendritic cells with lipopolysaccharide.	Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland	University of Dundee	Watts, C (corresponding author), Univ Dundee, Sch Life Sci, Wellcome Trust Bioctr, Div Cell Biol & Immunol, Dundee DD1 5EH, Scotland.	c.watts@dundee.ac.uk		Antoniou, Antony/0000-0002-6536-7781; Watts, Colin/0000-0001-6183-2087; Matthews, Stephen/0000-0003-3556-962X				Alvarez-Fernandez M, 1999, J BIOL CHEM, V274, P19195, DOI 10.1074/jbc.274.27.19195; Anderton SM, 2002, NAT IMMUNOL, V3, P175, DOI 10.1038/ni756; Antoniou AN, 2000, IMMUNITY, V12, P391, DOI 10.1016/S1074-7613(00)80191-0; Beck H, 2001, EUR J IMMUNOL, V31, P3726, DOI 10.1002/1521-4141(200112)31:12<3726::AID-IMMU3726>3.0.CO;2-O; Boatright KM, 2003, MOL CELL, V11, P529, DOI 10.1016/S1097-2765(03)00051-0; Caffrey CR, 2000, FEBS LETT, V466, P244, DOI 10.1016/S0014-5793(99)01798-6; Cella M, 1997, NATURE, V388, P782, DOI 10.1038/42030; Chen JM, 1998, FEBS LETT, V441, P361, DOI 10.1016/S0014-5793(98)01574-9; Chen JM, 2001, BIOL CHEM, V382, P777, DOI 10.1515/BC.2001.093; Chen JM, 1997, J BIOL CHEM, V272, P8090, DOI 10.1074/jbc.272.12.8090; Chen JM, 2000, BIOCHEM J, V352, P327, DOI 10.1042/0264-6021:3520327; Choi SJ, 1999, J BIOL CHEM, V274, P27747, DOI 10.1074/jbc.274.39.27747; Coulombe R, 1996, EMBO J, V15, P5492, DOI 10.1002/j.1460-2075.1996.tb00934.x; Cygler M, 1996, STRUCTURE, V4, P405, DOI 10.1016/S0969-2126(96)00046-9; Dalton JP, 1995, PARASITOLOGY, V111, P575, DOI 10.1017/S0031182000077052; Dando PM, 1999, BIOCHEM J, V339, P743, DOI 10.1042/0264-6021:3390743; Ding SH, 1997, ARCH BIOCHEM BIOPHYS, V348, P403, DOI 10.1006/abbi.1997.0405; Earnshaw WC, 1999, ANNU REV BIOCHEM, V68, P383, DOI 10.1146/annurev.biochem.68.1.383; Halfon S, 1998, FEBS LETT, V438, P114, DOI 10.1016/S0014-5793(98)01281-2; HARANISHIMURA I, 1993, PLANT CELL, V5, P1651, DOI 10.1105/tpc.5.11.1651; Hashimoto S, 1999, BLOOD, V94, P837, DOI 10.1182/blood.V94.3.837.413k02_837_844; Hashimoto S, 1999, BLOOD, V94, P845, DOI 10.1182/blood.V94.3.845.415k09_845_852; Hiraiwa N, 1999, FEBS LETT, V447, P213, DOI 10.1016/S0014-5793(99)00286-0; Inaba K, 2000, J EXP MED, V191, P927, DOI 10.1084/jem.191.6.927; Johansen HT, 1999, ANAL BIOCHEM, V273, P278, DOI 10.1006/abio.1999.4221; KAUFMAN RJ, 1978, J BIOL CHEM, V253, P5852; KEMBHAVI AA, 1993, ARCH BIOCHEM BIOPHYS, V303, P208, DOI 10.1006/abbi.1993.1274; KLINKERT MQ, 1989, MOL BIOCHEM PARASIT, V33, P113, DOI 10.1016/0166-6851(89)90025-X; Kuroyanagi M, 2002, PLANT CELL PHYSIOL, V43, P143, DOI 10.1093/pcp/pcf035; LaLonde JM, 1999, BIOCHEMISTRY-US, V38, P862, DOI 10.1021/bi9822271; LANZAVECCHIA A, 1985, NATURE, V314, P537, DOI 10.1038/314537a0; Lennon-Dumenil AM, 2002, CURR OPIN IMMUNOL, V14, P15, DOI 10.1016/S0952-7915(01)00293-X; MACH L, 1994, J BIOL CHEM, V269, P13030; Manoury B, 2003, IMMUNITY, V18, P489, DOI 10.1016/S1074-7613(03)00085-2; Manoury B, 2002, NAT IMMUNOL, V3, P169, DOI 10.1038/ni754; Manoury B, 1998, NATURE, V396, P695, DOI 10.1038/25379; Mathieu MA, 2002, MOL BIOCHEM PARASIT, V121, P99, DOI 10.1016/S0166-6851(02)00026-9; Menard R, 1998, J BIOL CHEM, V273, P4478, DOI 10.1074/jbc.273.8.4478; Mikolajczyk J, 2003, J BIOL CHEM, V278, P10458, DOI 10.1074/jbc.M210564200; Pierre P, 1998, CELL, V93, P1135, DOI 10.1016/S0092-8674(00)81458-0; Podobnik M, 1997, J MOL BIOL, V271, P774, DOI 10.1006/jmbi.1997.1218; Quraishi O, 2001, J BIOL CHEM, V276, P8118, DOI 10.1074/jbc.M005851200; ROME LH, 1979, P NATL ACAD SCI USA, V76, P2331, DOI 10.1073/pnas.76.5.2331; Rozman J, 1999, FEBS LETT, V459, P358, DOI 10.1016/S0014-5793(99)01302-2; SALLUSTO F, 1994, J EXP MED, V179, P1109, DOI 10.1084/jem.179.4.1109; Sarandeses CS, 2003, J BIOL CHEM, V278, P13286, DOI 10.1074/jbc.M213005200; SCHIMKE RT, 1978, SCIENCE, V202, P1051, DOI 10.1126/science.715457; Shirahama-Noda K, 2003, J BIOL CHEM, V278, P33194, DOI 10.1074/jbc.M302742200; SHUTOV A D, 1982, Biokhimiya, V47, P814; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; Turk B, 2000, BBA-PROTEIN STRUCT M, V1477, P98, DOI 10.1016/S0167-4838(99)00263-0; Turley SJ, 2000, SCIENCE, V288, P522, DOI 10.1126/science.288.5465.522; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Villadangos JA, 2001, IMMUNITY, V14, P739, DOI 10.1016/S1074-7613(01)00148-0; Waizenegger IC, 2002, CURR BIOL, V12, P1368, DOI 10.1016/S0960-9822(02)01073-4; Yamada K, 1999, J BIOL CHEM, V274, P2563, DOI 10.1074/jbc.274.4.2563	56	138	139	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38980	38990		10.1074/jbc.M305930200	http://dx.doi.org/10.1074/jbc.M305930200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860980	hybrid			2022-12-27	WOS:000185575100109
J	Blocker, D; Pohlmann, K; Haug, G; Bachmeyer, C; Benz, R; Aktories, K; Barth, H				Blocker, D; Pohlmann, K; Haug, G; Bachmeyer, C; Benz, R; Aktories, K; Barth, H			Clostridium botulinum C2 toxin - Low pH-induced pore formation is required for translocation of the enzyme component C2I into the cytosol of host cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTHRAX PROTECTIVE ANTIGEN; LIPID BILAYER-MEMBRANES; PERFRINGENS IOTA-TOXIN; CHANNEL FUNCTION; DELIVERY SYSTEM; BINARY TOXIN; ACTIN; PURIFICATION; INHIBITION; PROTEINS	The binary Clostridium botulinum C2 toxin consists of two individual proteins, the transport component C2II ( 80 kDa) and the enzyme component C2I, which ADP-ribosylates G-actin in the cytosol of cells. Trypsin-activated C2II (C2IIa) forms heptamers that bind to the cell receptor and mediate translocation of C2I from acidic endosomes into the cytosol of target cells. Here, we report that translocation of C2I across cell membranes is accompanied by pore formation of C2IIa. We used a radioactive rubidium release assay to detect C2IIa pores in the membranes of Chinese hamster ovary cells. Pore formation by C2IIa was dependent on the cellular C2 toxin receptor and an acidic pulse. Pores were formed when C2IIa was bound to cells at neutral pH and when cells were subsequently shifted to acidic medium ( pH less than or equal to 5.5), but no pores were detected when C2IIa was added to cells directly in acidic medium. Most likely, acidification induces a change from "pre-pore" to "pore" conformation of C2IIa, and formation of the pore conformation before membrane binding precludes insertion into membranes. When C2I was present during binding of C2IIa to cells prior to the acidification step, C2IIa-mediated rubidium release was decreased, suggesting that C2I interacted with the lumen of the C2IIa pore. A decrease of rubidium efflux was also detected when C2I was added to C2IIa-treated cells after the acidification step, suggesting that C2I interacted with C2IIa in its pore conformation. Moreover, C2I also interacted with C2IIa channels in artificial lipid membranes and blocked them partially. C2I was only translocated across the cell membrane when C2IIa plus C2I were bound to cells at neutral pH and subsequently shifted to acidic pH. When cell-bound C2IIa was exposed to acidic pH prior to C2I addition, only residual intoxication of cells was observed at high toxin concentrations, and binding of C2I to C2IIa was slightly decreased. Overall, C2IIa pores were essential but not sufficient for translocation of C2I. Intoxication of target cells with C2 toxin requires a strictly coordinated pH-dependent sequence of binding, pore formation by C2IIa, and translocation of C2I.	Univ Freiburg, Inst Expt, D-79104 Freiburg, Germany; Univ Freiburg, Klin Pharmakol & Toxikol, D-79104 Freiburg, Germany; Univ Wurzburg, Biozentrum, Theodor Boveri Inst, D-97074 Wurzburg, Germany	University of Freiburg; University of Freiburg; University of Wurzburg	Barth, H (corresponding author), Univ Freiburg, Inst Expt, Albertstr 25,Otto Krayer Haus, D-79104 Freiburg, Germany.	Holger.Barth@pharmakol.uni-freiburg.de	Aktories, Klaus/CAJ-5682-2022; Barth, Holger/E-7920-2013	Aktories, Klaus/0000-0002-5397-0436; Benz, Roland/0000-0002-9510-9265				AKTORIES K, 1992, MOL MICROBIOL, V6, P2905, DOI 10.1111/j.1365-2958.1992.tb01749.x; AKTORIES K, 1986, NATURE, V322, P390, DOI 10.1038/322390a0; Bachmeyer C, 2001, FASEB J, V15, P1658, DOI 10.1096/fj.00-0671fje; Barth H, 2000, J BIOL CHEM, V275, P18704, DOI 10.1074/jbc.M000596200; Barth H, 2002, N-S ARCH PHARMACOL, V366, P501, DOI 10.1007/s00210-002-0626-y; Barth H, 1998, J BIOL CHEM, V273, P29506, DOI 10.1074/jbc.273.45.29506; Barth H, 2002, J BIOL CHEM, V277, P5074, DOI 10.1074/jbc.M109167200; Barth H, 2001, J BIOL CHEM, V276, P10670, DOI 10.1074/jbc.M009445200; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; Eckhardt M, 2000, J BIOL CHEM, V275, P2328, DOI 10.1074/jbc.275.4.2328; FRITZ G, 1995, INFECT IMMUN, V63, P2334, DOI 10.1128/IAI.63.6.2334-2340.1995; Han S, 1999, NAT STRUCT BIOL, V6, P932, DOI 10.1038/13300; Haug G, 2003, J BIOL CHEM, V278, P32266, DOI 10.1074/jbc.M303980200; KLIMPEL KR, 1992, P NATL ACAD SCI USA, V89, P10277, DOI 10.1073/pnas.89.21.10277; Knapp O, 2002, J BIOL CHEM, V277, P6143, DOI 10.1074/jbc.M103939200; Leppla S. H., 1995, Bacterial toxins and virulence factors in disease., P543; Miller CJ, 1999, BIOCHEMISTRY-US, V38, P10432, DOI 10.1021/bi990792d; MILNE JC, 1993, MOL MICROBIOL, V10, P647, DOI 10.1111/j.1365-2958.1993.tb00936.x; MILNE JC, 1994, J BIOL CHEM, V269, P20607; Mourez M, 2002, TRENDS MICROBIOL, V10, P287, DOI 10.1016/S0966-842X(02)02369-7; OHISHI I, 1990, J BIOCHEM-TOKYO, V107, P420, DOI 10.1093/oxfordjournals.jbchem.a123060; OHISHI I, 1987, INFECT IMMUN, V55, P1461, DOI 10.1128/IAI.55.6.1461-1465.1987; OHISHI I, 1980, INFECT IMMUN, V30, P668; Ohishi I, 2000, HANDB EXP PHARM, V145, P253; Olsnes S, 2000, HANDB EXP PHARM, V145, P1; PERELLE S, 1995, INFECT IMMUN, V63, P4967, DOI 10.1128/IAI.63.12.4967-4967.1995; POPOFF MR, 1988, INFECT IMMUN, V56, P2299, DOI 10.1128/IAI.56.9.2299-2306.1988; POPOFF MR, 1988, BIOCHEM BIOPH RES CO, V152, P1361, DOI 10.1016/S0006-291X(88)80435-2; SCHMID A, 1994, J BIOL CHEM, V269, P16706; Sellman BR, 2001, J BIOL CHEM, V276, P8371, DOI 10.1074/jbc.M008309200; SIMPSON LI, 1989, J PHARMACOL EXP THER, V251, P1223; STILES BG, 1986, INFECT IMMUN, V54, P683, DOI 10.1128/IAI.54.3.683-688.1986	32	58	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37360	37367		10.1074/jbc.M305849200	http://dx.doi.org/10.1074/jbc.M305849200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869543	hybrid			2022-12-27	WOS:000185437200046
J	Georlette, D; Damien, B; Blaise, V; Depiereux, E; Uversky, VN; Gerday, C; Feller, G				Georlette, D; Damien, B; Blaise, V; Depiereux, E; Uversky, VN; Gerday, C; Feller, G			Structural and functional adaptations to extreme temperatures in psychrophilic, mesophilic, and thermophilic DNA ligases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLD ADAPTATION; CONFORMATIONAL FLEXIBILITY; ALPHA-AMYLASE; IN-VITRO; STABILITY; PROTEINS; ENZYMES; EXTREMOPHILES; DEHYDROGENASE; FLUCTUATIONS	Psychrophiles, host of permanently cold habitats, display metabolic fluxes comparable to those exhibited by mesophilic organisms at moderate temperatures. These organisms have evolved by producing, among other peculiarities, cold-active enzymes that have the properties to cope with the reduction of chemical reaction rates induced by low temperatures. The emerging picture suggests that these enzymes display a high catalytic efficiency at low temperatures through an improved flexibility of the structural components involved in the catalytic cycle, whereas other protein regions, if not implicated in catalysis, may be even more rigid than their mesophilic counterparts. In return, the increased flexibility leads to a decreased stability of psychrophilic enzymes. In order to gain further advances in the analysis of the activity/flexibility/stability concept, psychrophilic, mesophilic, and thermophilic DNA ligases have been compared by three-dimensional-modeling studies, as well as regards their activity, surface hydrophobicity, structural permeability, conformational stabilities, and irreversible thermal unfolding. These data show that the cold-adapted DNA ligase is characterized by an increased activity at low and moderate temperatures, an overall destabilization of the molecular edifice, especially at the active site, and a high conformational flexibility. The opposite trend is observed in the mesophilic and thermophilic counterparts, the latter being characterized by a reduced low temperature activity, high stability and reduced flexibility. These results strongly suggest a complex relationship between activity, flexibility and stability. In addition, they also indicate that in cold-adapted enzymes, the driving force for denaturation is a large entropy change.	Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium; Fac Univ Notre Dame Paix, Dept Biol, Unite Biol Mol, B-5000 Namur, Belgium; Russian Acad Sci, Inst Biol Instrumentat, Pushchino 142290, Moscow Region, Russia; Univ Calif Santa Cruz, Dept Chem & Biochem, Santa Cruz, CA 95064 USA	University of Liege; University of Namur; Russian Academy of Sciences; University of California System; University of California Santa Cruz	Feller, G (corresponding author), Univ Liege, Biochem Lab, Inst Chem B6, B-4000 Liege, Belgium.	gfeller@ulg.ac.be	Uversky, Vladimir N./F-4515-2011	Uversky, Vladimir N./0000-0002-4037-5857				Blochl E, 1997, EXTREMOPHILES, V1, P14; Cavicchioli R, 2002, CURR OPIN BIOTECH, V13, P253, DOI 10.1016/S0958-1669(02)00317-8; Chakravarty S, 2002, BIOCHEMISTRY-US, V41, P8152, DOI 10.1021/bi025523t; Ciardiello MA, 2000, BBA-PROTEIN STRUCT M, V1543, P11, DOI 10.1016/S0167-4838(00)00186-2; Collins T, 2003, J MOL BIOL, V328, P419, DOI 10.1016/S0022-2836(03)00287-0; D'Amico S, 2003, J BIOL CHEM, V278, P7891, DOI 10.1074/jbc.M212508200; D'Amico S, 2002, PHILOS T R SOC B, V357, P917, DOI 10.1098/rstb.2002.1105; Deming JW, 2002, CURR OPIN MICROBIOL, V5, P301, DOI 10.1016/S1369-5274(02)00329-6; Demirjian DC, 2001, CURR OPIN CHEM BIOL, V5, P144, DOI 10.1016/S1367-5931(00)00183-6; Feller G, 1999, BIOCHEMISTRY-US, V38, P4613, DOI 10.1021/bi982650+; Fields PA, 1998, P NATL ACAD SCI USA, V95, P11476, DOI 10.1073/pnas.95.19.11476; Fields PA, 2001, COMP BIOCHEM PHYS A, V129, P417, DOI 10.1016/S1095-6433(00)00359-7; Fitter J, 2000, BIOPHYS J, V79, P1629, DOI 10.1016/S0006-3495(00)76413-7; Georlette D, 2000, EUR J BIOCHEM, V267, P3502, DOI 10.1046/j.1432-1327.2000.01377.x; Gerday C, 1997, BBA-PROTEIN STRUCT M, V1342, P119, DOI 10.1016/S0167-4838(97)00093-9; Goldberg, 1995, Fold Des, V1, P21; Hernandez G, 2000, P NATL ACAD SCI USA, V97, P3166, DOI 10.1073/pnas.040569697; Hochachka P.W., 1984, BIOCHEMICAL ADAPTATI, P355; Kumar S, 2002, BIOCHEMISTRY-US, V41, P5359, DOI 10.1021/bi012154c; Kumar S, 2001, PROTEINS, V43, P433, DOI 10.1002/prot.1056; Lakowicz J.R., 1983, PRINCIPLES FLUORESCE; Lee JY, 2000, EMBO J, V19, P1119, DOI 10.1093/emboj/19.5.1119; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; Lonhienne T, 2000, BBA-PROTEIN STRUCT M, V1543, P1, DOI 10.1016/S0167-4838(00)00210-7; MATOUSCHEK A, 1994, PROTEIN ENG, V7, P1089, DOI 10.1093/protein/7.9.1089; Miyazaki K, 2000, J MOL BIOL, V297, P1015, DOI 10.1006/jmbi.2000.3612; Pace C N, 1986, Methods Enzymol, V131, P266; Russell N J, 1998, Adv Biochem Eng Biotechnol, V61, P1; SANCHEZRUIZ JM, 1988, BIOCHEMISTRY-US, V27, P1648, DOI 10.1021/bi00405a039; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; Siddiqui KS, 2002, EXTREMOPHILES, V6, P143, DOI 10.1007/s007920100237; Smalas A O, 2000, Biotechnol Annu Rev, V6, P1, DOI 10.1016/S1387-2656(00)06018-X; Sriskanda V, 1999, NUCLEIC ACIDS RES, V27, P3953, DOI 10.1093/nar/27.20.3953; Sriskanda V, 2002, J BIOL CHEM, V277, P9695, DOI 10.1074/jbc.M111164200; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; Svingor A, 2001, J BIOL CHEM, V276, P28121, DOI 10.1074/jbc.M104432200; THORBJARNARDOTTIR SH, 1995, GENE, V161, P1, DOI 10.1016/0378-1119(95)00286-F; Timson DJ, 1999, J MOL BIOL, V285, P73, DOI 10.1006/jmbi.1998.2302; Vanhove M, 1997, BIOCHEM J, V321, P413, DOI 10.1042/bj3210413; Wintrode PL, 2000, J BIOL CHEM, V275, P31635, DOI 10.1074/jbc.M004503200	40	125	137	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37015	37023		10.1074/jbc.M305142200	http://dx.doi.org/10.1074/jbc.M305142200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857762	hybrid, Green Published			2022-12-27	WOS:000185437200007
J	Piri, N; Yamashita, CK; Shih, J; Akhmedov, NB; Farber, DB				Piri, N; Yamashita, CK; Shih, J; Akhmedov, NB; Farber, DB			Differential expression of rod photoreceptor cGMP-phosphodiesterase alpha and beta subunits - mRNA and protein levels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; AUG INITIATOR CODON; GENE-EXPRESSION; RETINAL DEGENERATION; OUTER SEGMENTS; TRANSLATION; CELLS; TRANSCRIPTION; QUANTITATION; NUCLEOTIDES	The catalytic core of photoreceptor-specific cGMP-phosphodiesterase (PDE) consists of two subunits, PDEalpha and PDEbeta, that are homologous and have similar domain organization but are encoded by different genes. We have examined the PDEalpha and PDEbeta mRNA steady-state and protein levels as well as the biosynthesis rate of these proteins in developing and fully differentiated retinas. We have also determined the translational efficiency of PDE subunits and the role of their mRNA structures in regulating protein synthesis. In mature retinas, PDEalpha and PDEbeta are represented by similar to1.5 x 10(8) and 7.5 x 10(8) copies/mug retinal mRNA, respectively. The levels of these transcripts in developing photoreceptors (P10) are approximately 75% of those at P30. Quantification of protein concentration indicated that PDEalpha and PDEbeta are equally expressed in developing and fully differentiated photoreceptors. Furthermore, the PDEalpha/PDEbeta ratios obtained throughout a 2-h pulse-chase period revealed a similar turnover rate for both subunits. The observed discordance between the mRNA and protein levels of PDEalpha and PDEbeta suggested post-transcriptional regulation of their expression. We found that PDEalpha mRNA is translated more efficiently than either of the two PDEbeta transcripts expressed in retina. Therefore, the lower level of PDEalpha mRNA is compensated by its more efficient translation to achieve equimolar expression with PDEbeta. We also analyzed the effect of PDEalpha and PDEbeta mRNA 5'- and 3'-untranslated regions as well as that of their coding regions on protein synthesis. We determined that the PDE-coding regions play a critical role in the differential translation of these subunits.	Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Piri, N (corresponding author), Univ Calif Los Angeles, Sch Med, Jules Stein Eye Inst, 100 Stein Plaza, Los Angeles, CA 90095 USA.	piri@jsei.ucla.edu; farber@jsei.ucla.edu		Farber, Debora/0000-0002-3207-697X	NEI NIH HHS [EY02651] Funding Source: Medline; NATIONAL EYE INSTITUTE [R37EY002651, R01EY002651] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Artemyev NO, 1996, J BIOL CHEM, V271, P25382, DOI 10.1074/jbc.271.41.25382; BAEHR W, 1979, J BIOL CHEM, V254, P1669; BEAVO JA, 1995, PHYSIOL REV, V75, P725, DOI 10.1152/physrev.1995.75.4.725; Conne B, 2000, NAT MED, V6, P637, DOI 10.1038/76211; Cyert MS, 2001, J BIOL CHEM, V276, P20805, DOI 10.1074/jbc.R100012200; Day DA, 1998, J ENDOCRINOL, V157, P361, DOI 10.1677/joe.0.1570361; DETERRE P, 1988, P NATL ACAD SCI USA, V85, P2424, DOI 10.1073/pnas.85.8.2424; DiPolo A, 1996, INVEST OPHTH VIS SCI, V37, P551; DIPOLO A, 1995, P NATL ACAD SCI USA, V92, P4016, DOI 10.1073/pnas.92.9.4016; FARBER DB, 1988, EXP EYE RES, V46, P363, DOI 10.1016/S0014-4835(88)80026-5; FUNG BKK, 1989, BIOCHEMISTRY-US, V28, P3133, DOI 10.1021/bi00434a003; FUNG BKK, 1990, BIOCHEMISTRY-US, V29, P2657, DOI 10.1021/bi00463a006; GEBALLE AP, 1994, TRENDS BIOCHEM SCI, V19, P159, DOI 10.1016/0968-0004(94)90277-1; JACKSON RJ, 1990, CELL, V62, P15, DOI 10.1016/0092-8674(90)90235-7; Jans DA, 2000, BIOESSAYS, V22, P532, DOI 10.1002/(SICI)1521-1878(200006)22:6<532::AID-BIES6>3.0.CO;2-O; JANSEN M, 1995, PEDIATR RES, V37, P681, DOI 10.1203/00006450-199506000-00001; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KOZAK M, 1995, P NATL ACAD SCI USA, V92, P7134, DOI 10.1073/pnas.92.15.7134; Kozak M, 1997, EMBO J, V16, P2482, DOI 10.1093/emboj/16.9.2482; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; Lerner LE, 2002, J BIOL CHEM, V277, P25877, DOI 10.1074/jbc.M201407200; Lerner LE, 2001, J BIOL CHEM, V276, P34999, DOI 10.1074/jbc.M103301200; LIEBHABER SA, 1992, J MOL BIOL, V226, P609, DOI 10.1016/0022-2836(92)90619-U; MENZO S, 1992, J CLIN MICROBIOL, V30, P1752, DOI 10.1128/JCM.30.7.1752-1757.1992; MORABITO MA, 1991, J BIOL CHEM, V266, P9667; Morris DR, 2000, MOL CELL BIOL, V20, P8635, DOI 10.1128/MCB.20.23.8635-8642.2000; PAPERMASTER DS, 1982, METHOD ENZYMOL, V81, P48; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Phelan JK, 2000, EXP EYE RES, V71, P119, DOI 10.1006/exer.2000.0861; PIRIEV NI, 1993, P NATL ACAD SCI USA, V90, P9340, DOI 10.1073/pnas.90.20.9340; RIEDY MC, 1995, BIOTECHNIQUES, V18, P70; STROOP SD, 1992, ADV SEC MESS PHOSPH, V25, P55; Stuart JJ, 2000, BIOCHEM BIOPH RES CO, V274, P641, DOI 10.1006/bbrc.2000.3189; THEODORAKIS NG, 1988, J BIOL CHEM, V263, P14579; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsang SH, 1996, SCIENCE, V272, P1026, DOI 10.1126/science.272.5264.1026; van der Velden AW, 1999, INT J BIOCHEM CELL B, V31, P87, DOI 10.1016/S1357-2725(98)00134-4	37	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36999	37005		10.1074/jbc.M303710200	http://dx.doi.org/10.1074/jbc.M303710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871955	hybrid			2022-12-27	WOS:000185437200005
J	Chong, HR; Guan, KL				Chong, HR; Guan, KL			Regulation of Raf through phosphorylation and N terminus-C terminus interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; V-RAF; ACTIVATION; PROTEIN; MEMBRANE; DEFINITION; ONCOGENE; DELETION; DOMAIN; PAK1	Raf kinase is a key component in regulating the MAPK pathway. B-Raf has been reported as an oncogene and is mutated in 60% of human melanomas. The main focus of Raf regulation studies has been on phosphorylation, dephosphorylation, and scaffolding proteins; however, Raf also has its own auto-regulatory domain. Removal of the N-terminal regulatory domain, initially discovered in the viral Raf oncogene (v-Raf), results in a kinase domain with high basal activity independent of Ras activation. In this report, we show that activating phosphorylations are still required for activity of the truncated C-terminal kinase domain (called 22W). The interaction between the N-terminal regulatory domain and the C-terminal kinase domain is disrupted by activated Ras. Mutations in the Ras binding domain, cysteine-rich domain, or S259A do not affect the inhibition of 22W by the N-terminal domain. When phosphomimetic residues are substituted at the activating sites (DDED) in 22W, this results in a higher basal activity that is no longer inhibited by expression of the N-terminal domain, although binding to the N-terminal domain still occurs. Although the interaction between 22W/DDED and the N-terminal domain may be in a different conformation, the interaction is still disrupted by activated Ras. These data demonstrate that N-terminal domain binding to the kinase domain inhibits the activity of the kinase domain. However, this inhibition is relieved when the C-terminal kinase domain is activated by phosphorylation.	Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Guan, KL (corresponding author), Univ Michigan, Dept Biol Chem, Ann Arbor, MI 48109 USA.	kunliang@umich.edu		Kopera, Huira/0000-0002-8347-5567	NIA NIH HHS [T32-AG00114-18] Funding Source: Medline; NIGMS NIH HHS [5-T32-GM07544] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007544] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [T32AG000114] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BONNER TI, 1985, MOL CELL BIOL, V5, P1400, DOI 10.1128/MCB.5.6.1400; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Cutler RE, 1998, P NATL ACAD SCI USA, V95, P9214, DOI 10.1073/pnas.95.16.9214; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; Dhillon AS, 2002, MOL CELL BIOL, V22, P3237, DOI 10.1128/MCB.22.10.3237-3246.2002; Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Jaumot M, 2001, ONCOGENE, V20, P3949, DOI 10.1038/sj.onc.1204526; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; Mineo C, 1997, J BIOL CHEM, V272, P10345; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; Mott HR, 1996, P NATL ACAD SCI USA, V93, P8312, DOI 10.1073/pnas.93.16.8312; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a; RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218; SHIMIZU K, 1985, P NATL ACAD SCI USA, V82, P5641, DOI 10.1073/pnas.82.17.5641; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STANTON VP, 1987, MOL CELL BIOL, V7, P1171, DOI 10.1128/MCB.7.3.1171; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Yip-Schneider MT, 2000, BIOCHEM J, V351, P151, DOI 10.1042/0264-6021:3510151; Zang MW, 2002, J BIOL CHEM, V277, P4395, DOI 10.1074/jbc.M110000200; Zhang BH, 2000, EMBO J, V19, P5429, DOI 10.1093/emboj/19.20.5429; Zhang BH, 2001, J BIOL CHEM, V276, P31620, DOI 10.1074/jbc.M102808200; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	30	67	69	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36269	36276		10.1074/jbc.M212803200	http://dx.doi.org/10.1074/jbc.M212803200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865432	hybrid			2022-12-27	WOS:000185318300050
J	Hernandez, AI; Blace, N; Crary, JF; Serrano, PA; Leitges, M; Libien, JM; Weinstein, G; Tcherapanov, A; Sacktor, TC				Hernandez, AI; Blace, N; Crary, JF; Serrano, PA; Leitges, M; Libien, JM; Weinstein, G; Tcherapanov, A; Sacktor, TC			Protein kinase M zeta synthesis from a brain mRNA encoding an independent protein kinase C zeta catalytic domain - Implications for the molecular mechanism of memory	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; RAT-BRAIN; SYNAPTIC PLASTICITY; POLYMERASE-II; PKC-ZETA; EXPRESSION; ISOFORM; ACTIVATION; GENE; MAINTENANCE	Protein kinase Mzeta (PKMzeta) is a newly described form of PKC that is necessary and sufficient for the maintenance of hippocampal long term potentiation (LTP) and the persistence of memory in Drosophila. PKMzeta is the independent catalytic domain of the atypical PKCzeta isoform and produces long term effects at synapses because it is persistently active, lacking autoinhibition from the regulatory domain of PKCzeta. PKM has been thought of as a proteolytic fragment of PKC. Here we report that brain PKMzeta is a new PKC isoform, synthesized from a PKMzeta mRNA encoding a PKCzeta catalytic domain without a regulatory domain. Multiple zeta-specific antisera show that PKMzeta is expressed in rat forebrain as the major form of zeta in the near absence of full-length PKCzeta. A PKCzeta knockout mouse, in which the regulatory domain was disrupted and catalytic domain spared, still expresses brain PKMzeta, indicating that this form of PKM is not a PKCzeta proteolytic fragment. Furthermore, the distribution of brain PKMzeta does not correlate with PKCzeta mRNA but instead with an alternate zeta RNA transcript thought incapable of producing protein. In vitro translation of this RNA, however, generates PKMzeta of the same molecular weight as that in brain. Metabolic labeling of hippocampal slices shows increased de novo synthesis of PKMzeta in LTP. Because PKMzeta is a kinase synthesized in an autonomously active form and is necessary and sufficient for maintaining LTP, it serves as an example of a link coupling gene expression directly to synaptic plasticity.	SUNY Downstate Med Ctr, Dept Pharmacol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Physiol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Dept Neurol, Brooklyn, NY 11203 USA; SUNY Downstate Med Ctr, Grad Program Neural & Behav Sci, Brooklyn, NY 11203 USA; Max Planck Inst Expt Endokrinol, D-30625 Hannover, Germany	State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Downstate Medical Center; Max Planck Society	Sacktor, TC (corresponding author), SUNY Downstate Med Ctr, Dept Pharmacol, Box 29,450 Clarkson Ave, Brooklyn, NY 11203 USA.		Leitges, Michael/AAN-1953-2021	Leitges, Michael/0000-0003-4203-6995; Blace, Nancy/0000-0002-6174-6004; Libien, Jenny/0000-0001-6291-4391	NIMH NIH HHS [MH53576, MH057068] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH053576, R01MH057068, R29MH053576] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AKIMOTO K, 1994, J BIOL CHEM, V269, P12677; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANDREA JE, 1995, BIOCHEM J, V310, P835, DOI 10.1042/bj3100835; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEKKER LV, 1995, CURR OPIN STRUC BIOL, V5, P396, DOI 10.1016/0959-440X(95)80103-0; Drier EA, 2002, NAT NEUROSCI, V5, P316, DOI 10.1038/nn820; Dyer JR, 2003, NAT NEUROSCI, V6, P219, DOI 10.1038/nn1018; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Frutos S, 1999, J BIOL CHEM, V274, P10765, DOI 10.1074/jbc.274.16.10765; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; Grunbaum L, 1998, J NEUROSCI, V18, P4384; Hirai T, 2003, J BIOCHEM, V133, P1, DOI 10.1093/jb/mvg017; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Klann E, 1999, PROG NEURO-PSYCHOPH, V23, P359, DOI 10.1016/S0278-5846(99)00002-0; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; LAND M, 1994, J BIOL CHEM, V269, P14820; Leitges M, 2001, MOL CELL, V8, P771, DOI 10.1016/S1097-2765(01)00361-6; Ling DSF, 2002, NAT NEUROSCI, V5, P295, DOI 10.1038/nn829; LISMAN J, 1994, TRENDS NEUROSCI, V17, P406, DOI 10.1016/0166-2236(94)90014-0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; Marshall BS, 2000, DNA CELL BIOL, V19, P707, DOI 10.1089/104454900750058071; Martin SJ, 2000, ANNU REV NEUROSCI, V23, P649, DOI 10.1146/annurev.neuro.23.1.649; MARUYAMA K, 1994, GENE, V138, P171; Merlo E, 2002, NEUROSCIENCE, V112, P161, DOI 10.1016/S0306-4522(02)00049-0; Naik MU, 2000, J COMP NEUROL, V426, P243, DOI 10.1002/1096-9861(20001016)426:2<243::AID-CNE6>3.0.CO;2-8; Newton AC, 2003, BIOCHEM J, V370, P361, DOI 10.1042/BJ20021626; Niino YS, 2001, J BIOL CHEM, V276, P36711, DOI 10.1074/jbc.M104348200; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; ONO Y, 1988, J BIOL CHEM, V263, P6927; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; Osten P, 1996, J NEUROSCI, V16, P2444; Otmakhov N, 1997, J NEUROSCI, V17, P5357; POWELL CM, 1994, J BIOL CHEM, V269, P27958; POWELL CT, 1994, CELL GROWTH DIFFER, V5, P143; Roberson ED, 1999, LEARN MEMORY, V6, P381; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; Sanes JR, 1999, NAT NEUROSCI, V2, P597, DOI 10.1038/10154; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; SELBIE LA, 1993, J BIOL CHEM, V268, P24296; Shilatifard A, 1998, FASEB J, V12, P1437, DOI 10.1096/fasebj.12.14.1437; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SUBLETTE E, 1993, NEUROSCI LETT, V159, P175, DOI 10.1016/0304-3940(93)90827-8; Suzuki Y, 2000, GENOMICS, V64, P286, DOI 10.1006/geno.2000.6076; Suzuki Y, 2001, EMBO REP, V2, P388, DOI 10.1093/embo-reports/kve085; TAKAI Y, 1977, J BIOL CHEM, V252, P7603; VANDERKLISH P, 1995, MOL BRAIN RES, V32, P25, DOI 10.1016/0169-328X(95)00057-Y; Wooten MW, 2000, MOL CELL BIOL, V20, P4494, DOI 10.1128/MCB.20.13.4494-4504.2000; Yeh SH, 2002, J BIOL CHEM, V277, P46720, DOI 10.1074/jbc.M206258200; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; ZHOU GS, 1994, EXP CELL RES, V214, P1, DOI 10.1006/excr.1994.1227	53	216	229	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40305	40316		10.1074/jbc.M307065200	http://dx.doi.org/10.1074/jbc.M307065200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12857744	hybrid			2022-12-27	WOS:000185713800123
J	Lahlou, H; Saint-Laurent, N; Esteve, JP; Eychene, A; Pradayrol, L; Pyronnet, S; Susini, C				Lahlou, H; Saint-Laurent, N; Esteve, JP; Eychene, A; Pradayrol, L; Pyronnet, S; Susini, C			sst2 somatostatin receptor inhibits cell proliferation through Ras-, Rap1-, and B-Raf-dependent ERK2 activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE-PHOSPHATASE SHP-1; SIGNAL-REGULATED KINASE; NERVE GROWTH-FACTOR; G-BETA-GAMMA; PROTEIN-COUPLED RECEPTORS; MAP KINASE; PHOSPHOINOSITIDE 3-KINASE; LYSOPHOSPHATIDIC ACID; SUSTAINED ACTIVATION; MEDIATED ACTIVATION	The G protein-coupled sst2 somatostatin receptor is a critical negative regulator of cell proliferation. sstII prevents growth factor-induced cell proliferation through activation of the tyrosine phosphatase SHP-1 leading to induction of the cyclin-dependent kinase inhibitor p27(Kip1). Here, we investigate the signaling molecules linking sst2 to p27(Kip1). In Chinese hamster ovary-DG-44 cells stably expressing sst2 (CHO/sst2), the somatostatin analogue RC-160 transiently stimulates ERK2 activity and potentiates insulin-stimulated ERK2 activity. RC-160 also stimulates ERK2 activity in pancreatic acini isolated from normal mice, which endogenously express sst2, but has no effect in pancreatic acini derived from sst2 knock-out mice. RC-160-induced p27(Kip1) up-regulation and inhibition of insulin-dependent cell proliferation are both prevented by pretreatment of CHO/sst2 cells with the MEK1/2 inhibitor PD98059. In addition, using dominant negative mutants, we show that sst2-mediated ERK2 stimulation is dependent on the pertussis toxin-sensitive G(i/o) protein, the tyrosine kinase Src, both small G proteins Ras and Rap1, and the MEK kinase B-Raf but is independent of Raf-1. Phosphatidylinositol 3-kinase (PI3K) and both tyrosine phosphatases, SHP-1 and SHP-2, are required upstream of Ras and Rap1. Taken together, our results identify a novel mechanism whereby a G(i/o) protein-coupled receptor inhibits cell proliferation by stimulating ERK signaling via a SHP-1-SHP-2-PI3K/Ras-Rap1/B-Raf/MEK pathway.	CHU Rangueil, IFR31, INSERM, U531, F-31403 Toulouse, France; Ctr Univ, Inst Curie, CNRS, UMR 146, F-91405 Orsay, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay	Susini, C (corresponding author), CHU Rangueil, IFR31, INSERM, U531, 1 Ave Jean Poulhes, F-31403 Toulouse, France.	susinich@toulouse.inserm.fr	Pyronnet, Stéphane/P-2419-2014; Eychene, Alain/M-8838-2017; Nathalie, Saint-Laurent/G-5487-2017	EYCHENE, Alain/0000-0002-6818-7225				Alderton F, 2001, MOL PHARMACOL, V59, P1119, DOI 10.1124/mol.59.5.1119; Antonelli V, 2000, MOL BIOL CELL, V11, P1129, DOI 10.1091/mbc.11.4.1129; Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Auer KL, 1998, FEBS LETT, V436, P131, DOI 10.1016/S0014-5793(98)01074-6; Benali N, 2000, P NATL ACAD SCI USA, V97, P9180, DOI 10.1073/pnas.130196697; Bisotto S, 2001, BIOCHEM J, V360, P77, DOI 10.1042/0264-6021:3600077; Bos JL, 2001, NAT REV MOL CELL BIO, V2, P369, DOI 10.1038/35073073; Bouschet T, 2003, J BIOL CHEM, V278, P4778, DOI 10.1074/jbc.M204652200; Bousquet C, 1998, J BIOL CHEM, V273, P7099, DOI 10.1074/jbc.273.12.7099; Brasselet S, 2002, FEBS LETT, V516, P124, DOI 10.1016/S0014-5793(02)02517-6; Busca R, 2000, EMBO J, V19, P2900, DOI 10.1093/emboj/19.12.2900; BUSCAIL L, 1995, P NATL ACAD SCI USA, V92, P1580, DOI 10.1073/pnas.92.5.1580; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; Cattaneo MG, 2000, FEBS LETT, V481, P271, DOI 10.1016/S0014-5793(00)02012-3; Ceresa BP, 1997, ENDOCRINOLOGY, V138, P4131, DOI 10.1210/en.138.10.4131; Cordelier P, 1997, P NATL ACAD SCI USA, V94, P9343, DOI 10.1073/pnas.94.17.9343; Craddock BL, 2001, J BIOL CHEM, V276, P24274, DOI 10.1074/jbc.M009098200; Cui TX, 2001, CARDIOVASC RES, V49, P863, DOI 10.1016/S0008-6363(00)00299-6; Cunnick JM, 2000, J BIOL CHEM, V275, P13842, DOI 10.1074/jbc.275.18.13842; Das D, 2000, FEBS LETT, V472, P50, DOI 10.1016/S0014-5793(00)01416-2; deRooij J, 1997, ONCOGENE, V14, P623, DOI 10.1038/sj.onc.1201005; Dhillon AS, 2002, ARCH BIOCHEM BIOPHYS, V404, P3, DOI 10.1016/S0003-9861(02)00244-8; Dixon BS, 2002, AM J PHYSIOL-CELL PH, V283, pC193, DOI 10.1152/ajpcell.00289.2001; FERJOUX G, 2003, IN PRESS MOL BIOL CE; Florio T, 1999, MOL ENDOCRINOL, V13, P24, DOI 10.1210/me.13.1.24; Florio T, 2000, J PHYSIOL-PARIS, V94, P239, DOI 10.1016/S0928-4257(00)00214-X; Garcia J, 2001, MOL CELL BIOL, V21, P2659, DOI 10.1128/MCB.21.8.2659-2670.2001; Gendron L, 2003, J BIOL CHEM, V278, P3606, DOI 10.1074/jbc.M202446200; Guillemot L, 2000, J BIOL CHEM, V275, P26349, DOI 10.1074/jbc.M001614200; Held-Feindt J, 2001, MOL BRAIN RES, V87, P12, DOI 10.1016/S0169-328X(00)00225-4; HULLEY P, 2003, EUR J BIOCH S1, V270, P58; Keilhack H, 1998, J BIOL CHEM, V273, P24839, DOI 10.1074/jbc.273.38.24839; Klausen P, 2000, ONCOGENE, V19, P3675, DOI 10.1038/sj.onc.1203707; Kranenburg O, 2001, ONCOGENE, V20, P1540, DOI 10.1038/sj.onc.1204187; LAW SF, 1995, CELL SIGNAL, V7, P1, DOI 10.1016/0898-6568(94)00064-I; Lopez F, 2001, FASEB J, V15, P2300, DOI 10.1096/fj.00-0867fje; Lopez F, 1997, J BIOL CHEM, V272, P24448, DOI 10.1074/jbc.272.39.24448; Luttrell LM, 2002, J CELL SCI, V115, P455; Luttrell LM, 1996, J BIOL CHEM, V271, P19443, DOI 10.1074/jbc.271.32.19443; Ma YC, 2002, CELL MOL LIFE SCI, V59, P456, DOI 10.1007/s00018-002-8438-2; Malumbres M, 2000, MOL CELL BIOL, V20, P2915, DOI 10.1128/MCB.20.8.2915-2925.2000; Meyerhof W, 1998, Rev Physiol Biochem Pharmacol, V133, P55; Morooka T, 1998, J BIOL CHEM, V273, P24285, DOI 10.1074/jbc.273.38.24285; Mulder KM, 2000, CYTOKINE GROWTH F R, V11, P23, DOI 10.1016/S1359-6101(99)00026-X; Okada T, 1999, MOL CELL BIOL, V19, P6057; Pages P, 1999, J BIOL CHEM, V274, P15186, DOI 10.1074/jbc.274.21.15186; Paruchuri S, 2002, J CELL SCI, V115, P1883; Patel YC, 1999, FRONT NEUROENDOCRIN, V20, P157, DOI 10.1006/frne.1999.0183; Perez-Roger I, 1999, EMBO J, V18, P5310, DOI 10.1093/emboj/18.19.5310; Peyssonnaux C, 2001, BIOL CELL, V93, P53, DOI 10.1016/S0248-4900(01)01125-X; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pollak MN, 1998, P SOC EXP BIOL MED, V217, P143; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Ravi RK, 1998, J CLIN INVEST, V101, P153, DOI 10.1172/JCI831; Schmitt JM, 2002, J BIOL CHEM, V277, P43024, DOI 10.1074/jbc.M204006200; Sellers LA, 2000, MOL CELL BIOL, V20, P5974, DOI 10.1128/MCB.20.16.5974-5985.2000; Sellers LA, 1999, J BIOL CHEM, V274, P24280, DOI 10.1074/jbc.274.34.24280; Servant MJ, 2000, J CELL BIOL, V148, P543, DOI 10.1083/jcb.148.3.543; Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000; SHULTZ LD, 1993, CELL, V73, P1445, DOI 10.1016/0092-8674(93)90369-2; Sun HY, 2000, CURR BIOL, V10, P281, DOI 10.1016/S0960-9822(00)00359-6; Svegliati-Baroni G, 1999, HEPATOLOGY, V29, P1743, DOI 10.1002/hep.510290632; Tsukada Y, 2001, J BIOL CHEM, V276, P40968, DOI 10.1074/jbc.M010890200; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Viglietto G, 2002, NAT MED, V8, P1136, DOI 10.1038/nm762; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Woulfe D, 2002, J BIOL CHEM, V277, P23382, DOI 10.1074/jbc.M202212200; Wu CB, 2001, J NEUROSCI, V21, P5406, DOI 10.1523/JNEUROSCI.21-15-05406.2001; Yao H, 1998, J BIOL CHEM, V273, P8240, DOI 10.1074/jbc.273.14.8240; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; York RD, 2000, MOL CELL BIOL, V20, P8069, DOI 10.1128/MCB.20.21.8069-8083.2000; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451; Yue JB, 1999, ONCOGENE, V18, P2033, DOI 10.1038/sj.onc.1202521; Zhang JY, 2000, SEMIN IMMUNOL, V12, P361, DOI 10.1006/smim.2000.0223; Zheng H, 1997, MOL ENDOCRINOL, V11, P1709, DOI 10.1210/me.11.11.1709; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	76	96	100	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39356	39371		10.1074/jbc.M304524200	http://dx.doi.org/10.1074/jbc.M304524200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878607	hybrid			2022-12-27	WOS:000185713800013
J	Merlot, S; Meili, R; Pagliarini, DJ; Maehama, T; Dixon, JE; Firtel, RA				Merlot, S; Meili, R; Pagliarini, DJ; Maehama, T; Dixon, JE; Firtel, RA			A PTEN-related 5-phosphatidylinositol phosphatase localized in the Golgi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; PROTEIN-KINASE-B; DICTYOSTELIUM-DISCOIDEUM; TUMOR-SUPPRESSOR; PHOSPHATIDYLINOSITOL 3-PHOSPHATE; PHOSPHOINOSITIDE PHOSPHATASES; LIPID 2ND-MESSENGER; MYOTUBULAR MYOPATHY; MAMMALIAN-CELLS; PATHWAY	Phosphoinositides play important roles as signaling molecules in different cell compartments by regulating the localization and activity of proteins through their interaction with specific domains. The activity of these lipids depends on which sites on the inositol ring are phosphorylated. Signaling pathways dependent on phosphoinositides phosphorylated at the D3 position of this ring (3-phosphoinositides) are negatively regulated by 3-phosphoinositide-specific phosphatases that include PTEN and myotubularin. Using the conserved PTEN catalytic core motif, we have identified a new protein in the Dictyostelium genome called phospholipid-inositol phosphatase ( PLIP), which defines a new subfamily of phosphoinositide phosphatases clearly distinct from PTEN or other closely related proteins. We show that PLIP is able to dephosphorylate a broad spectrum of phosphoinositides, including 3-phosphoinositides. In contrast to previously characterized phosphoinositide phosphatases, PLIP has a preference for phosphatidylinositol 5-phosphate, a newly discovered phosphoinositide. We found that PLIP is localized in the Golgi, with its phosphatase domain facing the cytoplasmic compartment. PLIP null cells created via homologous recombination are unable to effectively aggregate to form multicellular organisms at low cell densities. The presence of PLIP in the Golgi suggests that it may be involved in membrane trafficking.	Univ Calif San Diego, Ctr Mol Genet, Div Biol Sci, Sect Cell & Dev Biol, La Jolla, CA 92093 USA; Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; Univ Calif San Diego, Sch Med, Dept Pharmacol, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Chem & Biochem, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego	Firtel, RA (corresponding author), Univ Calif San Diego, Ctr Mol Genet, Div Biol Sci, Sect Cell & Dev Biol, Rm 225,9500 Gilman Dr, La Jolla, CA 92093 USA.	rafirtel@ucsd.edu	Maehama, Tomohiko/AAX-8926-2020; Maehama, Tomohiko/HGB-4896-2022	Maehama, Tomohiko/0000-0002-9685-2317; Merlot, Sylvain/0000-0002-9352-1184; Pagliarini, David J./0000-0002-0001-0087	NIGMS NIH HHS [2 T32 GM07752-25] Funding Source: Medline; PHS HHS [18024] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blondeau F, 2000, HUM MOL GENET, V9, P2223, DOI 10.1093/oxfordjournals.hmg.a018913; Burd CG, 1998, MOL CELL, V2, P157, DOI 10.1016/S1097-2765(00)80125-2; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; CARDELLI JA, 1986, ARCH BIOCHEM BIOPHYS, V244, P338, DOI 10.1016/0003-9861(86)90122-0; Chabin-Brion K, 2001, MOL BIOL CELL, V12, P2047, DOI 10.1091/mbc.12.7.2047; Chiang CF, 2001, ARCH BIOCHEM BIOPHYS, V394, P229, DOI 10.1006/abbi.2001.2537; Corvera S, 1999, CURR OPIN CELL BIOL, V11, P460, DOI 10.1016/S0955-0674(99)80066-0; Currie RA, 1999, BIOCHEM J, V337, P575, DOI 10.1042/0264-6021:3370575; Dowler S, 2000, BIOCHEM J, V351, P19, DOI 10.1042/0264-6021:3510019; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Funamoto S, 2001, J CELL BIOL, V153, P795, DOI 10.1083/jcb.153.4.795; Funamoto S, 2002, CELL, V109, P611, DOI 10.1016/S0092-8674(02)00755-9; Gaskins C, 1996, GENE DEV, V10, P118, DOI 10.1101/gad.10.1.118; Gillooly DJ, 2000, EMBO J, V19, P4577, DOI 10.1093/emboj/19.17.4577; Graf R, 1999, BIOL CELL, V91, P471, DOI 10.1016/S0248-4900(99)80088-4; Guipponi M, 2001, HUM GENET, V109, P569, DOI 10.1007/s004390100607; Haugh JM, 2000, J CELL BIOL, V151, P1269, DOI 10.1083/jcb.151.6.1269; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Loovers HM, 2003, J BIOL CHEM, V278, P5652, DOI 10.1074/jbc.M208396200; Ma S, 1999, J CELL BIOL, V147, P1261, DOI 10.1083/jcb.147.6.1261; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Majerus PW, 1999, J BIOL CHEM, V274, P10669, DOI 10.1074/jbc.274.16.10669; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; Meijer HJG, 2001, BIOCHEM J, V360, P491, DOI 10.1042/0264-6021:3600491; Meili R, 1999, EMBO J, V18, P2092, DOI 10.1093/emboj/18.8.2092; Morris JB, 2000, FEBS LETT, V475, P57, DOI 10.1016/S0014-5793(00)01625-2; Parente CA, 1998, CELL, V95, P81, DOI 10.1016/S0092-8674(00)81784-5; Peterson MR, 1999, CURR BIOL, V9, P159, DOI 10.1016/S0960-9822(99)80071-2; Peyrollier K, 2000, BIOCHEM J, V352, P617, DOI 10.1042/0264-6021:3520617; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; Sbrissa D, 2002, J BIOL CHEM, V277, P47276, DOI 10.1074/jbc.M207576200; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Schneider N, 2000, BIOL CELL, V92, P495, DOI 10.1016/S0248-4900(00)01102-3; Servant G, 2000, SCIENCE, V287, P1037, DOI 10.1126/science.287.5455.1037; Shisheva A, 2001, CELL BIOL INT, V25, P1201, DOI 10.1006/cbir.2001.0803; Simonsen A, 2001, CURR OPIN CELL BIOL, V13, P485, DOI 10.1016/S0955-0674(00)00240-4; Simonsen A, 1998, NATURE, V394, P494, DOI 10.1038/28879; Stocker H, 2002, SCIENCE, V295, P2088, DOI 10.1126/science. 1068094; Sun H, 1999, P NATL ACAD SCI USA, V96, P6199, DOI 10.1073/pnas.96.11.6199; SUTOH K, 1993, PLASMID, V30, P150, DOI 10.1006/plas.1993.1042; Taylor GS, 2000, P NATL ACAD SCI USA, V97, P8910, DOI 10.1073/pnas.160255697; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Temesvari LA, 1996, J CELL SCI, V109, P1479; Walker SM, 2001, BIOCHEM J, V360, P277, DOI 10.1042/0264-6021:3600277; WEINER OH, 1993, J CELL BIOL, V123, P23, DOI 10.1083/jcb.123.1.23; Wu Y, 2001, J BIOL CHEM, V276, P21745, DOI 10.1074/jbc.M101480200; WUESTEHUBE LJ, 1989, CELL MOTIL CYTOSKEL, V13, P245, DOI 10.1002/cm.970130404; ZHU QL, 1993, J CELL SCI, V104, P1119	52	26	27	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39866	39873		10.1074/jbc.M306318200	http://dx.doi.org/10.1074/jbc.M306318200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878591	hybrid			2022-12-27	WOS:000185713800073
J	Xu, DZ; Kyriakis, JM				Xu, DZ; Kyriakis, JM			Phosphatidylinositol 3 '-kinase-dependent activation of renal mesangial cell Ki-Ras and ERK by advanced glycation end products	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-B; SIGNALING PATHWAYS; RECEPTOR; STRESS; RAGE; INDUCTION; GROWTH; DOMAIN	Advanced glycation end products (AGEs) are produced by the non-enzymatic glycation of proteins and lipids. AGE levels are pathologically elevated in a number of inflammatory diseases and in diabetes mellitus. There is evidence that AGEs, acting through the receptor for AGEs, contribute to diabetic complications. Nephropathy is a major complication of diabetes mellitus. However, the initiating molecular events that trigger diabetic renal disease are unknown. Renal mesangial cells produce excess extracellular matrix in response to treatment with transforming growth factor-beta, and excess mesangial cell matrix production, by impairing glomerular filtration, contributes to diabetic nephropathy. AGEs are known to trigger the autocrine production and release of transforming growth factor-beta. However, it is unclear how AGEs signal in mesangial cells. Here we show that treatment of mesangial cells with AGEs and with the receptor for AGEs agonist S100 triggers activation of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3'-kinase (PI3K) pathways. AGEs trigger the GTP loading of mesangial cell Ras, and AGE activation of ERK requires Ras. We observe that Ki-Ras, but not Ha-Ras, is the target of AGE action. Surprisingly, inhibition of PI3K blocks both ERK and Ki-Ras activation. We also observe that activation of ERK and the PI3K target kinase protein kinase-B is blocked with free radical scavengers, indicating a role for reactive oxygen species in AGE recruitment of PI3K. Thus, AGEs signal to Ki-Ras and ERK through reactive oxygen species-dependent activation of PI3K.	Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Boston, MA 02111 USA	Tufts Medical Center; Tufts University	Kyriakis, JM (corresponding author), Tufts Univ New England Med Ctr, Mol Cardiol Res Inst, 750 Washington St,Box 8486, Boston, MA 02111 USA.	jkyriakis@tufts-nemc.org		Xu, Dazhong/0000-0001-9264-3342	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK062680, R01DK041513] Funding Source: NIH RePORTER; NIDDK NIH HHS [R02-DK41513, F32-DK62680] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; Antos CL, 2002, P NATL ACAD SCI USA, V99, P907, DOI 10.1073/pnas.231619298; Bain J, 2003, BIOCHEM J, V371, P199, DOI 10.1042/BJ20021535; Bar-Sagi D, 2001, MOL CELL BIOL, V21, P1441, DOI 10.1128/MCB.21.5.1441-1443.2001; Cerione RA, 1996, CURR OPIN CELL BIOL, V8, P216, DOI 10.1016/S0955-0674(96)80068-8; Chan FKM, 2000, SCIENCE, V288, P2351, DOI 10.1126/science.288.5475.2351; Chen S, 2001, KIDNEY INT, V59, P673, DOI 10.1046/j.1523-1755.2001.059002673.x; Choukroun G, 1998, J CLIN INVEST, V102, P1311, DOI 10.1172/JCI3512; Esposito F, 2003, J BIOL CHEM, V278, P20828, DOI 10.1074/jbc.M211841200; Goruppi S, 2002, EMBO J, V21, P5427, DOI 10.1093/emboj/cdf535; GREWAL IS, 1999, AM J PHYSIOL, V276, pF922; Haq S, 2000, J CELL BIOL, V151, P117, DOI 10.1083/jcb.151.1.117; Heidland A, 2001, AM J KIDNEY DIS, V38, pS100, DOI 10.1053/ajkd.2001.27414; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; Huang JS, 1999, BIOCHEM J, V342, P231, DOI 10.1042/0264-6021:3420231; Huttunen HJ, 1999, J BIOL CHEM, V274, P19919, DOI 10.1074/jbc.274.28.19919; Jacob A, 2002, J BIOL CHEM, V277, P23420, DOI 10.1074/jbc.M202485200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; KREISBERG JI, 1986, AM J PHYSIOL, V251, pC505, DOI 10.1152/ajpcell.1986.251.4.C505; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2000, FR MOLEC B, V29, P40; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lander HM, 1997, J BIOL CHEM, V272, P17810, DOI 10.1074/jbc.272.28.17810; Massague J, 1998, ANNU REV BIOCHEM, V67, P753, DOI 10.1146/annurev.biochem.67.1.753; O'Neill LA, 2000, SCI STKE; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schmidt AM, 2001, J CLIN INVEST, V108, P949, DOI 10.1172/JCI200114002; Singh R, 2001, DIABETOLOGIA, V44, P129, DOI 10.1007/s001250051591; Taguchi A, 2000, NATURE, V405, P354, DOI 10.1038/35012626; Taylor SJ, 2001, METHOD ENZYMOL, V333, P333; Wautier JL, 2001, DIABETES METAB, V27, P535; Wautier MP, 2001, AM J PHYSIOL-ENDOC M, V280, pE685, DOI 10.1152/ajpendo.2001.280.5.E685; Wolf G, 1999, KIDNEY INT, V56, P393, DOI 10.1046/j.1523-1755.1999.00590.x; Yamagishi S, 2001, CONTRIB NEPHROL, V134, P30; Yamamoto Y, 2001, J CLIN INVEST, V108, P261, DOI 10.1172/JCI11771; ZIYADEH FN, 1994, J CLIN INVEST, V93, P536, DOI 10.1172/JCI117004	38	50	52	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39349	39355		10.1074/jbc.M302771200	http://dx.doi.org/10.1074/jbc.M302771200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871951	hybrid			2022-12-27	WOS:000185713800012
J	Chattopadhyay, K; Banerjee, KK				Chattopadhyay, K; Banerjee, KK			Unfolding of Vibrio cholerae hemolysin induces oligomerization of the toxin monomer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EL-TOR; ALPHA-HEMOLYSIN; MEMBRANE; CYTOLYSIN; PORE; PROTEINS; CHOLESTEROL; ACTIVATION; HLYA	Vibrio cholerae hemolysin (HlyA) is a pore-forming toxin that exists in two stable forms: a hemolytically active water-soluble monomer with a native molecular weight of 65,000 and a hemolytically inactive SDS-stable heptamer with the configuration of a transmembrane diffusion channel. Transformation of the monomer into the oligomer is spontaneous but very slow in the absence of interaction with specific membrane components like cholesterol and sphingolipids. In this report, we show that mild disruption of the native tertiary structure of HlyA by 1.75 M urea triggered rapid and quantitative conversion of the monomer to an oligomer. Furthermore, the HlyA monomer when unfolded in 8 M urea refolded and reconstituted on renaturation into the oligomer biochemically and functionally similar to the heptamer formed in target lipid bilayer, suggesting that the HlyA polypeptide had a strong propensity to adopt the oligomer as the stable native state in preference to the monomer. On the basis of our results, we propose that (a) the hemolytically active HlyA monomer represents a quasi-stable conformation corresponding to a local free energy minimum and the transmembrane heptameric pore represents a stable conformation corresponding to an absolute free energy minimum and (b) any perturbation of the native tertiary structure of the HlyA monomer causing relaxation of conformational constraints tends to promote self-assembly to the oligomer with membrane components playing at most an accessory role.	Natl Inst Cholera & Enter Dis, Div Immunol & Vaccine Dev, Kolkata 700010, India	Indian Council of Medical Research (ICMR); ICMR - National Institute of Cholera & Enteric Diseases (NICED)	Banerjee, KK (corresponding author), Natl Inst Cholera & Enter Dis, Div Immunol & Vaccine Dev, Kolkata 700010, India.		Chattopadhyay, Kausik/H-5044-2015	Chattopadhyay, Kausik/0000-0001-8529-9475				BORDIER C, 1981, J BIOL CHEM, V256, P1604; Bychkova V. E., 1993, CHEMTRACTS BIOCH MOL, V4, P133; Cantor C. R., 1982, PROTEINS, VV, P145; Chattopadhyay K, 2002, EUR J BIOCHEM, V269, P4351, DOI 10.1046/j.1432-1033.2002.03137.x; Creighton T E, 1986, Methods Enzymol, V131, P156; GOLDBERG SL, 1984, J BACTERIOL, V160, P239, DOI 10.1128/JB.160.1.239-244.1984; Harris JR, 2002, J STRUCT BIOL, V139, P122; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; IKIGAI H, 1987, J BIOL CHEM, V262, P2150; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lesieur C, 1999, J BIOL CHEM, V274, P36722, DOI 10.1074/jbc.274.51.36722; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Montoya M, 2003, BBA-BIOMEMBRANES, V1609, P19, DOI 10.1016/S0005-2736(02)00663-6; Nagamune K, 1996, INFECT IMMUN, V64, P4655, DOI 10.1128/IAI.64.11.4655-4658.1996; Nagamune K, 1997, J BIOL CHEM, V272, P1338, DOI 10.1074/jbc.272.2.1338; Olson R, 2003, PROTEIN SCI, V12, P379, DOI 10.1110/ps.0231703; PARKER MW, 1994, NATURE, V367, P292, DOI 10.1038/367292a0; PTITSYN OB, 1995, PHILOS T ROY SOC B, V348, P35, DOI 10.1098/rstb.1995.0043; Saha N, 1997, J BIOL CHEM, V272, P162, DOI 10.1074/jbc.272.1.162; Schmid F. Z., 1997, PROTEIN STRUCTURE PR, P261; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Van Der Goot Francoise G., 1992, Trends in Cell Biology, V2, P343; WILSON M, 2002, BACTERIAL DIS MECH I, P466; YAMAMOTO K, 1990, INFECT IMMUN, V58, P4106, DOI 10.1128/IAI.58.12.4106-4116.1990; YAMAMOTO K, 1984, INFECT IMMUN, V45, P192, DOI 10.1128/IAI.45.1.192-196.1984; Zitzer A, 1999, J BIOL CHEM, V274, P1375, DOI 10.1074/jbc.274.3.1375	27	23	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38470	38475		10.1074/jbc.M305965200	http://dx.doi.org/10.1074/jbc.M305965200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878594	hybrid			2022-12-27	WOS:000185575100048
J	Kanamori, M; Sandy, P; Marzinotto, S; Benetti, R; Kai, C; Hayashizaki, Y; Schneider, C; Suzuki, H				Kanamori, M; Sandy, P; Marzinotto, S; Benetti, R; Kai, C; Hayashizaki, Y; Schneider, C; Suzuki, H			The PDZ protein tax-interacting protein-1 inhibits beta-catenin transcriptional activity and growth of colorectal cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL MODULES; C-TERMINUS; COMPLEX; DOMAIN; ICAT; ACTIVATION; NUCLEUS; BINDING; ARREST; APC	Wnt signaling is essential during development while deregulation of this pathway frequently leads to the formation of various tumors including colorectal carcinomas. A key component of the pathway is beta-catenin that, in association with TCF-4, directly regulates the expression of Wnt-responsive genes. To identify novel binding partners of beta-catenin that may control its transcriptional activity, we performed a mammalian two-hybrid screen and isolated the Tax-interacting protein (TIP-1). The in vivo complex formation between beta-catenin and TIP-1 was verified by coimmunoprecipitation, and a direct physical association was revealed by glutathione S-transferase pull-down experiments in vitro. By using a panel of deletion mutants of both proteins, we demonstrate that the interaction is mediated by the PDZ (PSD-95/DLG/ZO-1 homology) domain of TIP-1 and requires primarily the last four amino acids of beta-catenin. TIP-1 overexpression resulted in a dose-dependent decrease in the transcriptional activity of beta-catenin when tested on the TOP/FOPFLASH reporter system. Conversely, siRNA-mediated knock-down of endogenous TIP-1 slightly increased endogenous beta-catenin transactivation function. Moreover, we show that overexpression of TIP-1 reduced the proliferation and anchorage-independent growth of colorectal cancer cells. These data suggest that TIP-1 may represent a novel regulatory element in the Wnt/beta-catenin signaling pathway.	RIKEN, Genom Sci Ctr, Lab Genome Explorat Res Grp, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; RIKEN, Genome Sci Lab, Wako, Saitama 3510198, Japan; Lab Nazl Concorzio Interuniv Biotecnol, I-34012 Trieste, Italy	RIKEN; RIKEN	Suzuki, H (corresponding author), RIKEN, Genom Sci Ctr, Lab Genome Explorat Res Grp, Tsurumi Ku, 1-7-22 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.		Hayashizaki, Yoshihide/N-6590-2015; Suzuki, Harukazu/N-9553-2015	Suzuki, Harukazu/0000-0002-8087-0836; BENETTI, Roberta/0000-0001-8863-0821				BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981; Barker N, 2001, EMBO J, V20, P4935, DOI 10.1093/emboj/20.17.4935; Ben-Ze'ev A, 1998, CURR OPIN CELL BIOL, V10, P629, DOI 10.1016/S0955-0674(98)80039-2; Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7; Bienz M, 2002, NAT REV MOL CELL BIO, V3, P328, DOI 10.1038/nrm806; Bienz M, 2003, NAT CELL BIOL, V5, P179, DOI 10.1038/ncb0303-179; Burton M, 2000, J VIROL, V74, P2351, DOI 10.1128/JVI.74.5.2351-2364.2000; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Daniels DL, 2002, MOL CELL, V10, P573, DOI 10.1016/S1097-2765(02)00631-7; Dobrosotskaya IY, 2000, BIOCHEM BIOPH RES CO, V270, P903, DOI 10.1006/bbrc.2000.2471; Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067; Goruppi S, 2001, MOL CELL BIOL, V21, P902, DOI 10.1128/MCB.21.3.902-915.2001; Graham TA, 2002, MOL CELL, V10, P563, DOI 10.1016/S1097-2765(02)00637-8; Harris BZ, 2001, J CELL SCI, V114, P3219; Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839; Hecht A, 1999, J BIOL CHEM, V274, P18017, DOI 10.1074/jbc.274.25.18017; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hsueh YP, 2000, NATURE, V404, P298, DOI 10.1038/35005118; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Kanamori M, 2002, FEBS LETT, V532, P241, DOI 10.1016/S0014-5793(02)03688-8; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Miyagishi M, 2000, J BIOL CHEM, V275, P35170, DOI 10.1074/jbc.C000258200; Monte M, 2003, J BIOL CHEM, V278, P30356, DOI 10.1074/jbc.M302902200; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Olalla L, 2002, J BIOL CHEM, V277, P38939, DOI 10.1074/jbc.C200373200; Olalla L, 2001, FEBS LETT, V488, P116, DOI 10.1016/S0014-5793(00)02373-5; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Perego C, 2000, EMBO J, V19, P3978, DOI 10.1093/emboj/19.15.3978; Polakis P, 2000, GENE DEV, V14, P1837; Reynaud C, 2000, J BIOL CHEM, V275, P33962, DOI 10.1074/jbc.M000465200; Riefler GM, 2001, J BIOL CHEM, V276, P48262, DOI 10.1074/jbc.M106503200; Rousset R, 1998, ONCOGENE, V16, P643, DOI 10.1038/sj.onc.1201567; Sandy P, 2000, ONCOGENE, V19, P188, DOI 10.1038/sj.onc.1203250; Savagner P, 2001, BIOESSAYS, V23, P912, DOI 10.1002/bies.1132; Sekiya T, 2002, CANCER RES, V62, P3322; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Suzuki H, 2001, GENOME RES, V11, P1758, DOI 10.1101/gr.180101; Tago K, 2000, GENE DEV, V14, P1741; Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249; Traweger A, 2003, J BIOL CHEM, V278, P2692, DOI 10.1074/jbc.M206821200	40	63	75	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38758	38764		10.1074/jbc.M306324200	http://dx.doi.org/10.1074/jbc.M306324200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874278	hybrid			2022-12-27	WOS:000185575100082
J	Longobardi, E; Blasi, F				Longobardi, E; Blasi, F			Overexpression of PREP-1 in F9 teratocarcinoma cells leads to a functionally relevant increase of PBX-2 by preventing its degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COOPERATIVE DNA-BINDING; NUCLEAR-LOCALIZATION; HOMEODOMAIN PROTEINS; HOMEOBOX GENES; RETINOIC ACID; HOX; HINDBRAIN; EXTRADENTICLE; HOMOTHORAX; FAMILY	To bind DNA and to be retained in the nucleus, PBX proteins must form heterodimeric complexes with members of the MEINOX family. Therefore the balance between PBX and MEINOX must be an important regulatory feature. We show that overexpression of PREP-1 influences the level of PBX-2 protein maintaining the PREP-1-PBX balance. This effect has important functional consequences. F9 teratocarcinoma cells stably transfected with PREP-1 had an increased DNA binding activity to a PREP-PBX-responsive element. Because PREP-1 binds DNA efficiently only when dimerized to PBX, the increased DNA binding activity suggests that the level of PBX might also have increased. Indeed PREP-1-overexpressing cells had a higher level of PBX-2 and PBX-1b proteins. PBX-2 increase did not depend on increased mRNA level or a higher rate of translation but rather because of a protein stabilization process. Indeed, PBX-2 level drastically decreased after 3 h of cycloheximide treatment in control but not in PREP-1-overexpressing cells and the proteasome inhibitor MG132 prevented PBX-2 decay in control cells. Hence, dimerization with PREP-1 appears to decrease proteasomal degradation of PBX-2. Retinoic acid induces differentiation of F9 teratocarcinoma cells with a cascade synthesis of HOX proteins. In PREP-1-overexpressing cells, HOXb1 induction was more sustained (3 days versus 1 day) and the induced level of MEIS-1b, another TALE (three amino acid loop extension) protein involved in embryonal development, was higher. Thus an increase in PREP-1 leads to changes in the fate-determining HOXb1 and has therefore important functional consequences.	Univ Vita Salute San Raffaele, Dept Mol Biol & Funct Genom, Mol Genet Unit, I-20132 Milan, Italy; DIBIT, I-20132 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica Molecolare (IGM-CNR); Vita-Salute San Raffaele University	Blasi, F (corresponding author), Univ Vita Salute San Raffaele, Dept Mol Biol & Funct Genom, Mol Genet Unit, Via Olgettina 58, I-20132 Milan, Italy.	blasi.francesco@hsr.it		Blasi, Francesco/0000-0001-9406-1784	Telethon [GGP02031] Funding Source: Medline	Telethon(Fondazione Telethon)		Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Berthelsen J, 1998, GENOMICS, V47, P323, DOI 10.1006/geno.1997.5086; Berthelsen J, 1996, J BIOL CHEM, V271, P3822; Berthelsen J, 1998, EMBO J, V17, P1423, DOI 10.1093/emboj/17.5.1423; Berthelsen J, 1998, EMBO J, V17, P1434, DOI 10.1093/emboj/17.5.1434; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Calvo KR, 1999, ONCOGENE, V18, P8033, DOI 10.1038/sj.onc.1203377; CHANG CP, 1995, GENE DEV, V9, P663, DOI 10.1101/gad.9.6.663; Chen HM, 1997, GENOMICS, V41, P193, DOI 10.1006/geno.1997.4632; Dibner C, 2001, DEVELOPMENT, V128, P3415; DiMartino JF, 2001, BLOOD, V98, P618, DOI 10.1182/blood.V98.3.618; Ferretti E, 2000, DEVELOPMENT, V127, P155; Fognani C, 2002, NUCLEIC ACIDS RES, V30, P2043, DOI 10.1093/nar/30.9.2043; GEHRING WJ, 1994, ANNU REV BIOCHEM, V63, P487, DOI 10.1146/annurev.biochem.63.1.487; Jacobs Y, 1999, MOL CELL BIOL, V19, P5134, DOI 10.1128/mcb.19.7.5134; Jaw TJ, 2000, MECH DEVELOP, V91, P279, DOI 10.1016/S0925-4773(99)00316-0; Kilstrup-Nielsen C, 2003, EMBO J, V22, P89, DOI 10.1093/emboj/cdg010; Kim SK, 2002, NAT GENET, V30, P430, DOI 10.1038/ng860; Knoepfler PS, 1997, P NATL ACAD SCI USA, V94, P14553, DOI 10.1073/pnas.94.26.14553; Knoepfler PS, 1997, MECH DEVELOP, V63, P5, DOI 10.1016/S0925-4773(97)00669-2; KNOEPFLER PS, 1995, MOL CELL BIOL, V15, P5811; KRUMLAUF R, 1994, CELL, V78, P191, DOI 10.1016/0092-8674(94)90290-9; Kurant E, 1998, DEVELOPMENT, V125, P1037; Kurant E, 2001, GENETICS, V157, P689; Lin L, 1996, MOL CELL BIOL, V16, P2248; Mann RS, 1996, TRENDS GENET, V12, P258, DOI 10.1016/0168-9525(96)10026-3; Moens CB, 2002, DEV DYNAM, V224, P1, DOI 10.1002/dvdy.10086; MONICA K, 1991, MOL CELL BIOL, V11, P6149, DOI 10.1128/MCB.11.12.6149; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PHELAN ML, 1995, MOL CELL BIOL, V15, P3989; PSPPERL H, 2000, MOL CELL, V6, P255; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; Ryoo HD, 1999, DEVELOPMENT, V126, P5137; Salzberg A, 1999, MECH DEVELOP, V80, P3, DOI 10.1016/S0925-4773(98)00187-7; Sanchez-Font MF, 2003, NUCLEIC ACIDS RES, V31, P2769, DOI 10.1093/nar/gkg396; Selleri L, 2001, DEVELOPMENT, V128, P3543; Shen WF, 1997, J BIOL CHEM, V272, P8198, DOI 10.1074/jbc.272.13.8198; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; Steeman S, 1997, GENOME RES, V7, P142, DOI 10.1101/gr.7.2.142; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; Studer M, 1998, DEVELOPMENT, V125, P1025; Su KH, 1999, J BIOL CHEM, V274, P15194, DOI 10.1074/jbc.274.21.15194; Vlachakis N, 2001, DEVELOPMENT, V128, P1299; Wagner K, 2001, MECH DEVELOP, V103, P127, DOI 10.1016/S0925-4773(01)00349-5; Waskiewicz AJ, 2001, DEVELOPMENT, V128, P4139; Waskiewicz AJ, 2002, DEV CELL, V3, P723, DOI 10.1016/S1534-5807(02)00319-2	49	39	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39235	39241		10.1074/jbc.M304704200	http://dx.doi.org/10.1074/jbc.M304704200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871956	hybrid			2022-12-27	WOS:000185575100138
J	Yoo, YG; Oh, SH; Park, ES; Cho, H; Lee, N; Park, H; Kim, DK; Yu, DY; Seong, JK; Lee, MO				Yoo, YG; Oh, SH; Park, ES; Cho, H; Lee, N; Park, H; Kim, DK; Yu, DY; Seong, JK; Lee, MO			Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1 alpha through activation of mitogen-activated protein kinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HEPATOCELLULAR-CARCINOMA; FACTOR 1-ALPHA; HBX PROTEIN; FACTOR GENE; SIGNAL-TRANSDUCTION; TUMOR ANGIOGENESIS; INDUCED EXPRESSION; DNA-BINDING; ALPHA	Hepatitis B virus X protein (HBx) of the hepatitis B virus was strongly implicated in angiogenesis and metastasis during hepatocarcinogenesis. Here, we explored the possibility of cross-talk between HBx and hypoxia-inducible factor-1alpha (HIF-1alpha), a potent transcriptional inducer of angiogenic factors. First, we showed that stability of HIF-1alpha protein was increased by HBx in HBx-inducible Chang liver cells as well as in transient HBx expression system of non-hepatic cells. Immunofluorescence studies revealed that the HBx-induced HIF-1alpha was partially translocated into the nucleus in majority of cells while additional CoCl2-induced hypoxic condition caused complete nuclear translocation. Second, HBx induced both phosphorylation of HIF-1alpha and activation of p42/p44 mitogen-activated protein kinases (MAPKs), which were synergistically enhanced in the presence of CoCl2. Furthermore, HBx enhanced transcriptional activity of HIF-1alpha in the reporter genes encoding hypoxia response element or VEGF promoter. Either treatment of MEK inhibitor PD98059 or coexpression of dominant-negative MAPK mutants abolished the HBx-induced transcriptional activity and protein stability as well as nuclear translocation of HIF-1alpha, suggesting that HBx activates HIF-1alpha through MAPK pathway. Third, the association of HIF-1alpha with von Hippel-Lindau was decreased but the association with CREB-binding protein was enhanced in the presence of HBx, suggesting the molecular mechanism by which HBx enhances the protein stability and transactivation function of HIF-1alpha. Finally, we demonstrated that expression of HIF-1alpha and vascular endothelial growth factor was increased in the liver of HBx-transgenic mice, suggesting that the cross-talk between HIF-1alpha and HBx may lead to transcriptional activation of HIF-1alpha target genes, which play a critical role in hepatocarcinogenesis.	Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 150742, South Korea; Sejong Univ, Dept Biosci & Biotechnol, Seoul 140747, South Korea; Ajou Univ, Coll Med, Dept Biochem, Suwon 442749, South Korea; Univ Seoul, Dept Life Sci, Seoul 130743, South Korea; Chung Ang Univ, Coll Pharm, Seoul 156756, South Korea; Korea Res Inst Biosci & Biotechnol, Taejon 305600, South Korea	Seoul National University (SNU); Sejong University; Ajou University; University of Seoul; Chung Ang University; Korea Research Institute of Bioscience & Biotechnology (KRIBB)	Seong, JK (corresponding author), Seoul Natl Univ, Coll Vet Med, Lab Dev Biol & Genom, Seoul 150742, South Korea.	snumouse@snu.ac.kr; molee@sejong.ac.kr						Bae MH, 1998, CANCER LETT, V128, P41, DOI 10.1016/S0304-3835(98)00044-5; Benn J, 1996, J VIROL, V70, P4978, DOI 10.1128/JVI.70.8.4978-4985.1996; Blancher C, 1998, CANCER METAST REV, V17, P187, DOI 10.1023/A:1006002419244; Catalano A, 2002, ONCOGENE, V21, P2896, DOI 10.1038/sj.onc.1205382; Cho S, 2001, FEBS LETT, V498, P62, DOI 10.1016/S0014-5793(01)02499-1; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Cromlish JA, 1996, TRENDS MICROBIOL, V4, P270, DOI 10.1016/0966-842X(96)10046-9; Dachs GU, 2000, EUR J CANCER, V36, P1649, DOI 10.1016/S0959-8049(00)00159-3; Diao JY, 2001, CYTOKINE GROWTH F R, V12, P189, DOI 10.1016/S1359-6101(00)00034-4; Ema M, 1997, P NATL ACAD SCI USA, V94, P4273, DOI 10.1073/pnas.94.9.4273; Ema M, 1999, EMBO J, V18, P1905, DOI 10.1093/emboj/18.7.1905; Finkenzeller G, 1997, ONCOGENE, V15, P669, DOI 10.1038/sj.onc.1201219; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Hu ZY, 1999, J VIROL, V73, P7231, DOI 10.1128/JVI.73.9.7231-7240.1999; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Hur E, 2001, MOL PHARMACOL, V59, P1216, DOI 10.1124/mol.59.5.1216; Kallio PJ, 1998, EMBO J, V17, P6573, DOI 10.1093/emboj/17.22.6573; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; KIM KW, 1998, CANCER RES, V58, P48; Kim YB, 2001, HISTOPATHOLOGY, V38, P160, DOI 10.1046/j.1365-2559.2001.01064.x; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lara-Pezzi E, 2001, HEPATOLOGY, V33, P1270, DOI 10.1053/jhep.2001.1270; Lara-Pezzi E, 2001, J HEPATOL, V34, P409, DOI 10.1016/S0168-8278(00)00090-8; Lee MO, 2002, J HEPATOL, V37, P380, DOI 10.1016/S0168-8278(02)00181-2; Lee MO, 2001, BIOCHEM BIOPH RES CO, V288, P1162, DOI 10.1006/bbrc.2001.5910; Lee SW, 2000, BIOCHEM BIOPH RES CO, V268, P456, DOI 10.1006/bbrc.2000.2093; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; Lin Y, 1997, CANCER RES, V57, P5137; Lopez-Ocejo O, 2000, ONCOGENE, V19, P4611, DOI 10.1038/sj.onc.1203817; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Mazure NM, 1997, BLOOD, V90, P3322, DOI 10.1182/blood.V90.9.3322; Minet E, 2000, FEBS LETT, V468, P53, DOI 10.1016/S0014-5793(00)01181-9; Ravi R, 2000, GENE DEV, V14, P34; Richard DE, 2000, J BIOL CHEM, V275, P26765; Richard DE, 1999, J BIOL CHEM, V274, P32631, DOI 10.1074/jbc.274.46.32631; Schraml P, 2002, J PATHOL, V196, P186, DOI 10.1002/path.1034; Semenza GL, 2001, TRENDS MOL MED, V7, P345, DOI 10.1016/S1471-4914(01)02090-1; Sodhi A, 2000, CANCER RES, V60, P4873; Sun X, 2001, GENE THER, V8, P638, DOI 10.1038/sj.gt.3301388; Suzuki H, 1999, INT J ONCOL, V14, P1087; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Toi M, 2001, LANCET ONCOL, V2, P667, DOI 10.1016/S1470-2045(01)00556-3; Vaupel P, 2001, SEMIN ONCOL, V28, P29, DOI 10.1016/S0093-7754(01)90210-6; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; Wiesener MS, 2001, CANCER RES, V61, P5215; Yoong KF, 1999, AM J PATHOL, V154, P693, DOI 10.1016/S0002-9440(10)65316-3; Yu DY, 1999, J HEPATOL, V31, P123, DOI 10.1016/S0168-8278(99)80172-X; Yun C, 2002, CANCER LETT, V184, P97, DOI 10.1016/S0304-3835(02)00187-8; Yun CW, 2000, ONCOGENE, V19, P5163, DOI 10.1038/sj.onc.1203896; Zelzer E, 1998, EMBO J, V17, P5085, DOI 10.1093/emboj/17.17.5085; Zhang ZS, 2000, J BIOL CHEM, V275, P15157, DOI 10.1074/jbc.M910378199; Zhong H, 1998, CANCER RES, V58, P5280	55	134	154	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39076	39084		10.1074/jbc.M305101200	http://dx.doi.org/10.1074/jbc.M305101200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855680	hybrid			2022-12-27	WOS:000185575100121
J	Caricasole, A; Ferraro, T; Iacovelli, L; Barletta, E; Caruso, A; Melchiorri, D; Terstappen, GC; Nicoletti, F				Caricasole, A; Ferraro, T; Iacovelli, L; Barletta, E; Caruso, A; Melchiorri, D; Terstappen, GC; Nicoletti, F			Functional characterization of WNT7A signaling in PC12 cells - Interaction with a FZD5 center dot LRP6 receptor complex and modulation by dickkopf proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TCF TRANSCRIPTION FACTORS; WNT/BETA-CATENIN; BETA-CATENIN; GENE-EXPRESSION; WNT-7A; INDUCTION; HOMOLOG; LITHIUM; PATHWAY; FAMILY	WNT factors represent key mediators of many processes in animal development and homeostasis and act through a receptor complex comprised of members of the Frizzled and low density lipoprotein-related receptors (LRP). In mammals, 19 genes encoding Wingless and Int-related factor (WNTs), 10 encoding Frizzled, and 2 encoding LRP proteins have been identified, but little is known of the identities of individual Frizzled-LRP combinations mediating the effects of specific WNT factors. Additionally, several secreted modulators of WNT signaling have been identified, including at least three members of the Dickkopf family. WNT7A is a WNT family member expressed in the vertebrate central nervous system capable of modulating aspects of neuronal plasticity. Gene knock-out models in the mouse have revealed that WNT7A plays a role in cerebellar maturation, although its function in the development of distal limb structures and of the reproductive tract have been more intensely studied. To identify a receptor complex for this WNT family member, we have analyzed the response of the rat pheochromocytoma cell line PC12 to WNT7A. We find that PC12 cells are capable of responding to WNT7A as measured by increased beta-catenin stability and activation of a T-cell factor-based luciferase reporter construct and that these cells express three members of the Frizzled family (Frizzled-2, -5, and -7) and LRP6. Our functional analysis indicates that WNT7A can specifically act via a Frizzled-5.LRP6 receptor complex in PC12 cells and that this activity can be antagonized by Dickkopf-1 and Dickkopf-3.	Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, I-00185 Rome, Italy; SienaBiotech, I-53100 Siena, Italy; UCL, Wellcome Lab Mol Pharmacol, London WC1E 6BT, England; Ist Ricovero & Cura Carattere Sci, Ist Neurol Mediterraneo Neuromed, I-86077 Pozzilli, Italy	Sapienza University Rome; Siena Biotech; University of London; University College London; IRCCS Neuromed	Caricasole, A (corresponding author), Univ Roma La Sapienza, Dept Human Physiol & Pharmacol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	acaricasole@sienabiotech.it	Nicoletti, Ferdinando/K-4410-2016; Nicoletti, Ferdinando/T-4898-2019; Nicoletti, Ferdinando/A-2446-2010	NICOLETTI, Ferdinando/0000-0003-3366-7269; Nicoletti, Ferdinando/0000-0003-0917-443X				AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Behrens J, 2000, ANN NY ACAD SCI, V910, P21; Bettini E, 2002, NEUROSCI LETT, V317, P50, DOI 10.1016/S0304-3940(01)02405-3; Bournat JC, 2000, J NEUROSCI RES, V61, P21, DOI 10.1002/1097-4547(20000701)61:1<21::AID-JNR3>3.0.CO;2-7; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; Brott BK, 2002, MOL CELL BIOL, V22, P6100, DOI 10.1128/MCB.22.17.6100-6110.2002; Caricasole A, 2002, GENE, V288, P147, DOI 10.1016/S0378-1119(02)00467-5; Caricasole A, 2000, BBA-GENE STRUCT EXPR, V1517, P63, DOI 10.1016/S0167-4781(00)00260-8; Chou AH, 2000, MOL BRAIN RES, V77, P232, DOI 10.1016/S0169-328X(00)00058-9; Dahmen RP, 2001, CANCER RES, V61, P7039; Dale TC, 1998, BIOCHEM J, V329, P209; Dickinson ME, 1992, CURR OPIN GENET DEV, V2, P562, DOI 10.1016/S0959-437X(05)80172-8; Eickholt BJ, 2002, J CELL BIOL, V157, P211, DOI 10.1083/jcb.200201098; Erdreich-Epstein A, 1998, GROWTH FACTORS, V15, P149, DOI 10.3109/08977199809117190; Gan DD, 2001, ONCOGENE, V20, P4864, DOI 10.1038/sj.onc.1204670; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Giarre M, 1998, ANN NY ACAD SCI, V857, P43, DOI 10.1111/j.1749-6632.1998.tb10106.x; Hall AC, 2000, CELL, V100, P525, DOI 10.1016/S0092-8674(00)80689-3; He X, 1997, SCIENCE, V275, P1652, DOI 10.1126/science.275.5306.1652; Holmen SL, 2002, J BIOL CHEM, V277, P34727, DOI 10.1074/jbc.M204989200; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Iacovelli L, 2002, J NEUROCHEM, V82, P216, DOI 10.1046/j.1471-4159.2002.00929.x; Ishikawa T, 2001, DEVELOPMENT, V128, P25; Issack PS, 1998, CELL GROWTH DIFFER, V9, P827; Karasawa T, 2002, J BIOL CHEM, V277, P37479, DOI 10.1074/jbc.M205658200; Kato M, 2002, J CELL BIOL, V157, P303, DOI 10.1083/jcb.200201089; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Lucas FR, 1997, DEV BIOL, V192, P31, DOI 10.1006/dbio.1997.8734; Lucas FR, 1998, J CELL SCI, V111, P1351; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Manji HK, 2000, J CLIN PSYCHIAT, V61, P82; Manji HK, 1999, BIOL PSYCHIAT, V46, P929, DOI 10.1016/S0006-3223(99)00165-1; Mao BY, 2001, NATURE, V411, P321, DOI 10.1038/35077108; Mao BY, 2002, NATURE, V417, P664, DOI 10.1038/nature756; Millar JBA, 2002, GENOME BIOL, V3; Miller C, 1998, DEVELOPMENT, V125, P3201; Miller JR, 1999, ONCOGENE, V18, P7860, DOI 10.1038/sj.onc.1203245; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Nusse R, 2001, NATURE, V411, P254, DOI 10.1038/35077199; Parr BA, 1998, DEV BIOL, V202, P228, DOI 10.1006/dbio.1998.9007; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Patapoutian A, 2000, CURR OPIN NEUROBIOL, V10, P392, DOI 10.1016/S0959-4388(00)00100-8; Pinson KI, 2000, NATURE, V407, P535, DOI 10.1038/35035124; Porfiri E, 1997, ONCOGENE, V15, P2833, DOI 10.1038/sj.onc.1201462; Rees S, 1996, BIOTECHNIQUES, V20, P102; Roose J, 1999, BBA-REV CANCER, V1424, pM23, DOI 10.1016/S0304-419X(99)00026-8; Sala CF, 2000, BIOCHEM BIOPH RES CO, V273, P27, DOI 10.1006/bbrc.2000.2882; Seidensticker MJ, 2000, BBA-MOL CELL RES, V1495, P168, DOI 10.1016/S0167-4889(99)00158-5; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8; Shimizu H, 1997, CELL GROWTH DIFFER, V8, P1349; Slusarski DC, 1997, NATURE, V390, P410, DOI 10.1038/37138; Smalley MJ, 1999, CANCER METAST REV, V18, P215, DOI 10.1023/A:1006369223282; Tamai K, 2000, NATURE, V407, P530, DOI 10.1038/35035117; van Noort M, 2002, DEV BIOL, V244, P1, DOI 10.1006/dbio.2001.0566; Winklbauer R, 2001, NATURE, V413, P856, DOI 10.1038/35101621; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; WOODGETT JR, 2001, SCI STKE; Wu W, 2000, CURR BIOL, V10, P1611, DOI 10.1016/S0960-9822(00)00868-X; YangSnyder J, 1996, CURR BIOL, V6, P1302, DOI 10.1016/S0960-9822(02)70716-1; Zorn AM, 2001, CURR BIOL, V11, pR592, DOI 10.1016/S0960-9822(01)00360-8	62	111	114	1	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37024	37031		10.1074/jbc.M300191200	http://dx.doi.org/10.1074/jbc.M300191200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857724	hybrid			2022-12-27	WOS:000185437200008
J	Cheng, JB; Motola, DL; Mangelsdorf, DJ; Russell, DW				Cheng, JB; Motola, DL; Mangelsdorf, DJ; Russell, DW			De-orphanization of cytochrome P450 2R1 - A microsomal vitamin D 25-hydroxylase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID SYNTHESIS; MOLECULAR-CLONING; HUMAN-LIVER; D-RECEPTOR; RAT; EXPRESSION; CDNA; GENE; CHOLESTEROL; METABOLITE	The conversion of vitamin D into an active ligand for the vitamin D receptor requires 25-hydroxylation in the liver and 1alpha-hydroxylation in the kidney. Mitochondrial and microsomal vitamin D 25-hydroxylase enzymes catalyze the first reaction. The mitochondrial activity is associated with sterol 27-hydroxylase, a cytochrome P450 (CYP27A1); however, the identity of the microsomal enzyme has remained elusive. A cDNA library prepared from hepatic mRNA of sterol 27-hydroxylase-deficient mice was screened with a ligand activation assay to identify an evolutionarily conserved microsomal cytochrome P450 (CYP2R1) with vitamin D 25-hydroxylase activity. Expression of CYP2R1 in cells led to the transcriptional activation of the vitamin D receptor when either vitamin D-2 or D-3 was added to the medium. Thin layer chromatography and radioimmunoassays indicated that the secosteroid product of CYP2R1 was 25-hydroxyvitamin D-3. Co-expression of CYP2R1 with vitamin D 1alpha-hydroxylase (CYP27B1) elicited additive activation of vitamin D-3, whereas co-expression with vitamin D 24-hydroxylase (CYP24A1) caused inactivation. CYP2R1 mRNA is abundant in the liver and testis, and present at lower levels in other tissues. The data suggest that CYP2R1 is a strong candidate for the microsomal vitamin D 25-hydroxylase.	Univ Texas, SW Med Ctr, Dept Pharmacol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Mangelsdorf, DJ (corresponding author), Univ Texas, SW Med Ctr, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	davo.mango@utsouthwestern.edu; david.russell@utsouthwestern.edu		Russell, David/0000-0002-0277-403X; Mangelsdorf, David/0000-0002-4355-0796	NHLBI NIH HHS [P01 HL020948, HL20948] Funding Source: Medline; NIGMS NIH HHS [GM08014] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON S, 1983, J BIOL CHEM, V258, P6777; ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ANDERSSON S, 1986, J BIOL CHEM, V261, P6932; Barletta F, 2002, MOL ENDOCRINOL, V16, P301, DOI 10.1210/me.16.2.301; BHATTACHARYYA MH, 1974, ARCH BIOCHEM BIOPHYS, V160, P58, DOI 10.1016/S0003-9861(74)80008-1; BJORKHEM I, 1978, J BIOL CHEM, V253, P842; BJORKHEM I, 1980, J BIOL CHEM, V255, P5244; BJORKHEM I, 2001, METABOLIC MOL BASES, P2961; BLUNT JW, 1968, BIOCHEMISTRY-US, V7, P3317, DOI 10.1021/bi00850a001; CALI JJ, 1991, J BIOL CHEM, V266, P7779; CHEN KS, 1993, P NATL ACAD SCI USA, V90, P4543, DOI 10.1073/pnas.90.10.4543; Choi M, 2003, CHEM BIOL, V10, P261, DOI 10.1016/S1074-5521(03)00050-4; DAHLBACK H, 1988, BIOCHEM J, V252, P207, DOI 10.1042/bj2520207; EDELSON PJ, 1975, J EXP MED, V142, P1150, DOI 10.1084/jem.142.5.1150; FRASER DR, 1970, NATURE, V228, P764, DOI 10.1038/228764a0; FUKUSHIMA M, 1976, FEBS LETT, V65, P211, DOI 10.1016/0014-5793(76)80482-6; Graham SE, 2002, METHOD ENZYMOL, V357, P15; GUO YD, 1993, P NATL ACAD SCI USA, V90, P8668, DOI 10.1073/pnas.90.18.8668; HAUSSLER MR, 1968, J BIOL CHEM, V243, P4055; HAUSSLER MR, 1969, P NATL ACAD SCI USA, V62, P155, DOI 10.1073/pnas.62.1.155; HOLICK MF, 1971, BIOCHEMISTRY-US, V10, P2799; HOLMBERG I, 1986, SCAND J CLIN LAB INV, V46, P785, DOI 10.3109/00365518609084051; Hosseinpour F, 2000, J BIOL CHEM, V275, P34650, DOI 10.1074/jbc.M004185200; ITOH S, 1995, BBA-GENE STRUCT EXPR, V1264, P26, DOI 10.1016/0167-4781(95)00147-9; Jones G, 1998, PHYSIOL REV, V78, P1193, DOI 10.1152/physrev.1998.78.4.1193; KAWAUCHI H, 1994, BBA-GENE STRUCT EXPR, V1219, P179, DOI 10.1016/0167-4781(94)90266-6; Kleene KC, 2001, MECH DEVELOP, V106, P3, DOI 10.1016/S0925-4773(01)00413-0; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Lund EG, 1998, J BIOL CHEM, V273, P34316, DOI 10.1074/jbc.273.51.34316; MADHOK TC, 1979, BIOCHEM J, V184, P491, DOI 10.1042/bj1840491; Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477; MASUMOTO O, 1988, J BIOL CHEM, V263, P14256; MCDONNELL DP, 1987, SCIENCE, V235, P1214, DOI 10.1126/science.3029866; Nebert DW, 2002, LANCET, V360, P1155, DOI 10.1016/S0140-6736(02)11203-7; Nelson DR, 2003, ARCH BIOCHEM BIOPHYS, V409, P18, DOI 10.1016/S0003-9861(02)00553-2; Nelson DR, 1996, PHARMACOGENETICS, V6, P1, DOI 10.1097/00008571-199602000-00002; OHYAMA Y, 1991, FEBS LETT, V278, P195, DOI 10.1016/0014-5793(91)80115-J; Peterson JA, 1998, STRUCTURE, V6, P1079, DOI 10.1016/S0969-2126(98)00109-9; PONCHON G, 1969, J CLIN INVEST, V48, P2032, DOI 10.1172/JCI106168; PONCHON G, 1969, J CLIN INVEST, V48, P1273, DOI 10.1172/JCI106093; Repa JJ, 2000, J BIOL CHEM, V275, P39685, DOI 10.1074/jbc.M007653200; Rosen H, 1998, J BIOL CHEM, V273, P14805, DOI 10.1074/jbc.273.24.14805; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; SAAREM K, 1985, BIOCHIM BIOPHYS ACTA, V840, P117, DOI 10.1016/0304-4165(85)90168-0; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; SETCHELL BP, 1975, HDB PHYSL, V5; Simoni RD, 2002, J BIOL CHEM, V277, P9623; SU P, 1990, DNA CELL BIOL, V9, P657, DOI 10.1089/dna.1990.9.657; Takeyama K, 1997, SCIENCE, V277, P1827, DOI 10.1126/science.277.5333.1827; Touchstone J. C., 1992, PRACTICE THIN LAYER; USUI E, 1990, FEBS LETT, V262, P135, DOI 10.1016/0014-5793(90)80172-F; WILLY PJ, 1995, GENE DEV, V9, P1033, DOI 10.1101/gad.9.9.1033	52	281	294	0	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38084	38093		10.1074/jbc.M307028200	http://dx.doi.org/10.1074/jbc.M307028200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867411	Green Accepted, hybrid			2022-12-27	WOS:000185437200130
J	Contreras, FX; Villar, AV; Alonso, A; Kolesnick, RN; Goni, FM				Contreras, FX; Villar, AV; Alonso, A; Kolesnick, RN; Goni, FM			Sphingomyelinase activity causes transbilayer lipid translocation in model and cell membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; GH3 PITUITARY-CELLS; PHOSPHOLIPASE-C; LIPOSOME FUSION; PHORBOL ESTERS; HL-60 CELLS; CERAMIDE; APOPTOSIS; DIFFERENTIATION; VESICLES	Ceramide is known to induce structural rearrangements in membrane bilayers, including the formation of ceramide-rich and -poor domains and the efflux of aqueous solutes. This report describes a novel effect of ceramide, namely the induction of transbilayer lipid movements. This effect was demonstrated in both model (large unilamellar vesicles) and cell (erythrocyte ghost) membranes in which ceramide generation took place in situ through the action of an externally added sphingomyelinase. Two different novel assays were developed to detect transbilayer lipid movement. One of the assays required the preparation of vesicles containing a ganglioside only in the outer monolayer and entrapped neuraminidase. Sphingomyelinase activity induced ganglioside hydrolysis under conditions in which no neuraminidase was released from the vesicles. The second assay involved the preparation of liposomes or erythrocyte ghosts labeled with a fluorescent energy donor in their inner leaflets. Sphingomyelin hydrolysis was accompanied by fluorescence energy transfer to an impermeable acceptor in the outer aqueous medium. Ceramide-induced transbilayer lipid movement is explained in terms of another well known property of ceramide, namely the facilitation of lamellar to non-lamellar lipid-phase transitions. Thus, sphingomyelinase generates ceramide on one side of the membrane; ceramide then induces the transient formation of non-lamellar structural intermediates, which cause the loss of lipid asymmetry in the bilayer, i.e. the transbilayer movement of ceramide together with other lipids. As direct targets for ceramide tend to be intracellular, these observations may be relevant to the mechanism of transmembrane signaling by means of the sphingomyelin pathway.	Univ Basque Country, Unidad Biofis, Ctr Mixto CSIC UPV EHU, E-48080 Bilbao, Spain; Univ Basque Country, Dept Bioquim, E-48080 Bilbao, Spain; Mem Sloan Kettering Canc Ctr, Lab Signal Transduct, New York, NY 10021 USA	Consejo Superior de Investigaciones Cientificas (CSIC); University of Basque Country; CSIC - UPV EHU - Instituto Biofisika; University of Basque Country; Memorial Sloan Kettering Cancer Center	Goni, FM (corresponding author), Univ Basque Country, Unidad Biofis, Ctr Mixto CSIC UPV EHU, E-48080 Bilbao, Spain.	gbpgourf@lg.ehu.es	Goni, Felix M/M-5425-2015; Villar, Ana/I-5190-2015; Contreras, Xabier/AAA-8885-2019; Alonso, Alicia/E-5310-2012	Goni, Felix M/0000-0001-6270-9216; Villar, Ana/0000-0003-4588-9598; Alonso, Alicia/0000-0002-2730-7470; Contreras, Xabier/0000-0003-0875-634X				Bai JN, 1997, BIOCHEMISTRY-US, V36, P8840, DOI 10.1021/bi970145r; Basanez G, 1997, BIOPHYS J, V72, P2630, DOI 10.1016/S0006-3495(97)78906-9; Bevers EM, 1999, BBA-MOL CELL BIOL L, V1439, P317, DOI 10.1016/S1388-1981(99)00110-9; Bottcher CJF, 1961, ANAL CHIM ACTA, V24, P203; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; Cremesti A, 2001, J BIOL CHEM, V276, P23954, DOI 10.1074/jbc.M101866200; Cremesti AE, 2002, FEBS LETT, V531, P47, DOI 10.1016/S0014-5793(02)03489-0; CULLIS PR, 1978, BIOCHIM BIOPHYS ACTA, V513, P31, DOI 10.1016/0005-2736(78)90109-8; Dekkers DWC, 2002, BIOCHEM J, V362, P741, DOI 10.1042/0264-6021:3620741; FUSSLE R, 1981, J CELL BIOL, V91, P83, DOI 10.1083/jcb.91.1.83; Goni FM, 2000, BIOSCIENCE REP, V20, P443, DOI 10.1023/A:1010450702670; Grassme H, 2003, NAT MED, V9, P322, DOI 10.1038/nm823; Grassme H, 1997, CELL, V91, P605, DOI 10.1016/S0092-8674(00)80448-1; Grassme H, 2002, J IMMUNOL, V168, P298, DOI 10.4049/jimmunol.168.1.298; Grassme H, 2001, BIOCHEM BIOPH RES CO, V284, P1016, DOI 10.1006/bbrc.2001.5045; Gulbins Erich, 2002, Subcell Biochem, V36, P229; Hannun YA, 2001, BIOCHEMISTRY-US, V40, P4893, DOI 10.1021/bi002836k; Harlow E., 1988, ANTIBODIES LAB MANUA; Holopainen JM, 2000, BIOPHYS J, V78, P830, DOI 10.1016/S0006-3495(00)76640-9; Huwiler A, 1996, P NATL ACAD SCI USA, V93, P6959, DOI 10.1073/pnas.93.14.6959; IKEZAWA H, 1978, BIOCHIM BIOPHYS ACTA, V528, P247; Kamp D, 2001, BIOCHEMISTRY-US, V40, P9438, DOI 10.1021/bi0107492; Kashiwagi K, 2002, J BIOL CHEM, V277, P18037, DOI 10.1074/jbc.M111761200; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick R, 1999, TRENDS BIOCHEM SCI, V24, P224, DOI 10.1016/S0968-0004(99)01408-5; Kolesnick RN, 2000, J CELL PHYSIOL, V184, P285; KOLESNICK RN, 1987, J BIOL CHEM, V262, P9204; KOLESNICK RN, 1989, J BIOL CHEM, V264, P7617; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; KOLESNICK RN, 1988, J BIOL CHEM, V263, P6534; Lin CC, 2000, AM J CHINESE MED, V28, P87, DOI 10.1142/S0192415X00000118; LOZANO J, 1994, J BIOL CHEM, V269, P19200; Luberto C, 2002, NEUROCHEM RES, V27, P609, DOI 10.1023/A:1020267831851; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Mattjus P, 2002, J BIOL CHEM, V277, P19476, DOI 10.1074/jbc.M201305200; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; Montes LR, 2002, J BIOL CHEM, V277, P11788, DOI 10.1074/jbc.M111568200; NIEVA JL, 1989, BIOCHEMISTRY-US, V28, P7364, DOI 10.1021/bi00444a032; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; OKAZAKI T, 1990, J BIOL CHEM, V265, P15823; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Ruiz-Arguello MB, 1998, J BIOL CHEM, V273, P22977, DOI 10.1074/jbc.273.36.22977; RuizArguello MB, 1996, J BIOL CHEM, V271, P26616, DOI 10.1074/jbc.271.43.26616; Simons K, 2000, SCIENCE, V290, P1721, DOI 10.1126/science.290.5497.1721; Siskind LJ, 2000, J BIOL CHEM, V275, P38640, DOI 10.1074/jbc.C000587200; Sprong H, 2001, NAT REV MOL CELL BIO, V2, P504, DOI 10.1038/35080071; Steck T L, 1974, Methods Enzymol, V31, P172; Tepper AD, 2000, J CELL BIOL, V150, P155, DOI 10.1083/jcb.150.1.155; Veiga MP, 1999, BIOPHYS J, V76, P342, DOI 10.1016/S0006-3495(99)77201-2; Villar AV, 1999, FEBS LETT, V457, P71, DOI 10.1016/S0014-5793(99)01010-8; Wybenga LE, 1996, BIOCHEMISTRY-US, V35, P9513, DOI 10.1021/bi9606152; Yan F, 2001, CANCER RES, V61, P963; Zhang YH, 1997, CELL, V89, P63, DOI 10.1016/S0092-8674(00)80183-X; Zhou M, 2002, J MOL BIOL, V315, P435, DOI 10.1006/jmbi.2001.5263	54	98	99	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37169	37174		10.1074/jbc.M303206200	http://dx.doi.org/10.1074/jbc.M303206200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855704	hybrid			2022-12-27	WOS:000185437200024
J	Sage, EH; Reed, M; Funk, SE; Truong, T; Steadele, M; Puolakkainen, P; Maurice, DH; Bassuk, JA				Sage, EH; Reed, M; Funk, SE; Truong, T; Steadele, M; Puolakkainen, P; Maurice, DH; Bassuk, JA			Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL PROLIFERATION; SMOOTH-MUSCLE CELLS; EXTRACELLULAR-MATRIX; ESCHERICHIA-COLI; CHORIOALLANTOIC MEMBRANE; SECRETED PROTEIN; FOLLISTATIN-LIKE; BINDING-SITES; DNA-SYNTHESIS; GROWTH-FACTOR	SPARC, a matricellular protein that affects cellular adhesion and proliferation, is produced in remodeling tissue and in pathologies involving fibrosis and angiogenesis. In this study we have asked whether peptides generated from cleavage of SPARC in the extracellular milieu can regulate angiogenesis. Matrix metalloproteinase (MMP)-3, but not MMP-1 or 9, showed significant activity toward SPARC. Limited digestion of recombinant human (rhu) SPARC with purified catalytic domain of rhuMMP-3 produced three major fragments, which were sequenced after purification by HPLC. Three synthetic peptides (Z-1, Z-2, and Z-3) representing motifs from each fragment were tested in distinct assays of angiogenesis. Peptide Z-1 (3.9 kDa, containing a Cu2+-binding sequence KHGK) exhibited a biphasic effect on [H-3] thymidine incorporation by cultured endothelial cells and stimulated vascular growth in the chick chorioallantoic membrane ( CAM). In contrast, peptides Z-2 (6.1 kDa, containing Ca2+-binding EF hand-1) and Z-3 (2.2 kDa, containing neither Cu2+-binding motifs nor EF hands), inhibited cell proliferation in a concentration-dependent manner and exhibited no effects on vessel growth in the CAM. Reciprocal results were obtained in a migration assay in native collagen gels: peptide Z-1 was ineffective over a range of concentrations, whereas Z-2 or Z-3 stimulated cell migration. Therefore, proteolysis of SPARC by MMP-3 produced peptides that regulate endothelial cell proliferation and/or migration in vitro in a mutually exclusive manner. One of these peptides containing KHGK also demonstrated a concentration-dependent effect on angiogenesis.	Hope Heart Inst, Dept Vasc Biol, Seattle, WA 98104 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Urol, Seattle, WA 98195 USA; Queens Univ, Dept Pharmacol & Toxicol, Kingston, ON K7L 3N6, Canada	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Queens University - Canada	Sage, EH (corresponding author), Hope Heart Inst, Dept Vasc Biol, 1124 Columbia St,Suite 723, Seattle, WA 98104 USA.	hsage@hopeheart.org	Maurice, Donald/AAE-9332-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK047659] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59475] Funding Source: Medline; NIDDK NIH HHS [P50 DK47659] Funding Source: Medline; NIGMS NIH HHS [GM40711] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agnihotri R, 2001, J BIOL CHEM, V276, P28261, DOI 10.1074/jbc.M103608200; Bassuk JA, 1996, ARCH BIOCHEM BIOPHYS, V325, P8, DOI 10.1006/abbi.1996.0002; Bassuk JA, 1996, INT J BIOCHEM CELL B, V28, P1031, DOI 10.1016/1357-2725(96)00036-2; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Bradshaw AD, 2003, J INVEST DERMATOL, V120, P949, DOI 10.1046/j.1523-1747.2003.12241.x; Bradshaw AD, 2003, P NATL ACAD SCI USA, V100, P6045, DOI 10.1073/pnas.1030790100; Bradshaw AD, 2001, J CLIN INVEST, V107, P1049, DOI 10.1172/JCI12939; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Busch E, 2000, J BIOL CHEM, V275, P25508, DOI 10.1074/jbc.M001770200; Colman RW, 2000, BLOOD, V95, P543, DOI 10.1182/blood.V95.2.543; Coussens LM, 2002, SCIENCE, V295, P2387, DOI 10.1126/science.1067100; FUNK SE, 1991, P NATL ACAD SCI USA, V88, P2648, DOI 10.1073/pnas.88.7.2648; FUNK SE, 1993, J CELL PHYSIOL, V154, P53, DOI 10.1002/jcp.1041540108; Gilles C, 1998, CANCER RES, V58, P5529; Hashimoto G, 2002, J BIOL CHEM, V277, P36288, DOI 10.1074/jbc.M201674200; HOFFMAN BJ, 1995, PROTEIN EXPRES PURIF, V6, P646, DOI 10.1006/prep.1995.1085; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; IRUELAARISPE ML, 1995, MOL BIOL CELL, V6, P327, DOI 10.1091/mbc.6.3.327; Kupprion C, 1998, J BIOL CHEM, V273, P29635, DOI 10.1074/jbc.273.45.29635; Kyriakides TR, 1998, J CELL BIOL, V140, P419, DOI 10.1083/jcb.140.2.419; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE TF, 1994, J CELL BIOL, V125, P929, DOI 10.1083/jcb.125.4.929; LANE TF, 1990, J CELL BIOL, V111, P3065, DOI 10.1083/jcb.111.6.3065; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lijnen HR, 2002, ARTERIOSCL THROM VAS, V22, P374, DOI 10.1161/hq0302.104522; Lymn JS, 2002, J CELL SCI, V115, P4353, DOI 10.1242/jcs.00119; MAQUART FX, 1993, J CLIN INVEST, V92, P2368, DOI 10.1172/JCI116842; Marneros AG, 2001, MATRIX BIOL, V20, P337, DOI 10.1016/S0945-053X(01)00151-2; Maurer P, 1997, CELL MOL LIFE SCI, V53, P478, DOI 10.1007/s000180050059; Motamed K, 2002, J CELL BIOCHEM, V84, P759, DOI 10.1002/jcb.10095; Murphy-Ullrich JE, 2001, J CLIN INVEST, V107, P785, DOI 10.1172/JCI12609; MURPHYULLRICH JE, 1995, J CELL BIOCHEM, V57, P341, DOI 10.1002/jcb.240570218; Ortega N, 2002, J CELL SCI, V115, P4201, DOI 10.1242/jcs.00106; Parsons-Wingerter P, 1998, MICROVASC RES, V55, P201, DOI 10.1006/mvre.1998.2073; Pike SE, 1999, BLOOD, V94, P2461, DOI 10.1182/blood.V94.7.2461.419a26_2461_2468; Ponce ML, 1999, CIRC RES, V84, P688, DOI 10.1161/01.RES.84.6.688; POSNETT DN, 1988, J BIOL CHEM, V263, P1719; Puolakkainen P, 1999, DIGEST DIS SCI, V44, P1554, DOI 10.1023/A:1026602708263; RAINES EW, 1992, P NATL ACAD SCI USA, V89, P1281, DOI 10.1073/pnas.89.4.1281; SAGE EH, 1995, J CELL BIOCHEM, V57, P127, DOI 10.1002/jcb.240570113; Sage EH, 1997, TRENDS CELL BIOL, V7, P182; Sage EH, 2001, J CLIN INVEST, V107, P781, DOI 10.1172/JCI12683; SAGE H, 1984, J BIOL CHEM, V259, P3993; Sasaki T, 1997, J BIOL CHEM, V272, P9237; Sasaki T, 1999, MATRIX BIOL, V18, P499, DOI 10.1016/S0945-053X(99)00041-4; Shankavaram UT, 1997, J CELL PHYSIOL, V173, P327, DOI 10.1002/(SICI)1097-4652(199712)173:3<327::AID-JCP4>3.3.CO;2-R; Silence J, 2001, ARTERIOSCL THROM VAS, V21, P1440, DOI 10.1161/hq0901.097004; St Croix B, 2000, SCIENCE, V289, P1197; Sternlicht MD, 2000, ONCOGENE, V19, P1102, DOI 10.1038/sj.onc.1203347; Suzuki K, 1998, BIOL CHEM, V379, P185, DOI 10.1515/bchm.1998.379.2.185; TREMBLE PM, 1993, J CELL BIOL, V121, P1433, DOI 10.1083/jcb.121.6.1433; Vernon RB, 1999, MICROVASC RES, V57, P118, DOI 10.1006/mvre.1998.2122; YOST JC, 1993, J BIOL CHEM, V268, P25790	53	131	139	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37849	37857		10.1074/jbc.M302946200	http://dx.doi.org/10.1074/jbc.M302946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867428	hybrid			2022-12-27	WOS:000185437200105
J	Saito, S; Yamaguchi, H; Higashimoto, Y; Chao, C; Xu, Y; Fornace, AJ; Appella, E; Anderson, CW				Saito, S; Yamaguchi, H; Higashimoto, Y; Chao, C; Xu, Y; Fornace, AJ; Appella, E; Anderson, CW			Phosphorylation site interdependence of human p53 post-translational modifications in response to stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; DNA-DAMAGE; IONIZING-RADIATION; UBIQUITIN SYSTEM; GAMMA-RADIATION; UV-RADIATION; MURINE P53; IN-VITRO; ACTIVATION; ATM	Modification-specific antibodies were used to characterize the phosphorylation and acetylation of human p53 in response to genotoxic (UV, IR, and adriamycin) and non-genotoxic (PALA, taxol, nocodazole) stress in cultured human cells at 14 known modification sites. In A549 cells, phosphorylation or acetylation was induced at most sites by the three DNA damage-inducing agents, but significant differences between agents were observed. IR-induced phosphorylation reached a maximum 2 h after treatment and returned to near pretreatment levels by 72 h; UV light and adriamycin induced a less rapid but more robust and prolonged p53 phosphorylation, which reached a maximum between 8 and 24 h, but persisted ( UV) even 96 h after treatment. Ser(33), Ser(37), Ser(46), and Ser(392) were more efficiently phosphorylated after exposure to UV light than after IR. The non-genotoxic agents PALA, taxol and nocodazole induced p53 accumulation and phosphorylation at Ser(6), Ser(33), Ser(46), and Ser(392). Some phosphorylation at Ser(15) also was observed. Modifications occurred similarly in the HCT116 human colon carcinoma cell line. Analysis of single site mutant p53s indicated clear interdependences between N-terminal phosphorylation sites, which could be classified in four clusters: Ser(6) and Ser(9); Ser(9), Ser(15), Thr(18) and Ser(20); Ser(33) and Ser(37); and Ser(46). We suggest that p53 phosphorylation is regulated through a double cascade involving both the activation of secondary, effector protein kinases as well as intermolecular phosphorylation site interdependencies that check inappropriate p53 inactivation while allowing for signal amplification and the integration of signals from multiple stress pathways.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA; NCI, Cell Biol Lab, NIH, Bethesda, MD 20892 USA; NCI, Basic Res Lab, NIH, Bethesda, MD 20892 USA; Univ Calif San Diego, Mol Biol Sect, Div Biol, La Jolla, CA 92093 USA	United States Department of Energy (DOE); Brookhaven National Laboratory; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of California System; University of California San Diego	Anderson, CW (corresponding author), Brookhaven Natl Lab, Dept Biol, 50 Bell Ave, Upton, NY 11973 USA.		Fornace, Albert J/A-7407-2008	Fornace, Albert J/0000-0001-9695-085X; Xu, Yang/0000-0001-5574-921X; Higashimoto, Yuichiro/0000-0003-1382-8598				Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; ANDERSON CW, 2003, HDB CELL SIGNALING, V3, P237; Appella E, 2001, EUR J BIOCHEM, V268, P2764, DOI 10.1046/j.1432-1327.2001.02225.x; Bech-Otschir D, 2001, EMBO J, V20, P1630, DOI 10.1093/emboj/20.7.1630; Bell S, 2002, J MOL BIOL, V322, P917, DOI 10.1016/S0022-2836(02)00848-3; Brooks CL, 2003, CURR OPIN CELL BIOL, V15, P164, DOI 10.1016/S0955-0674(03)00003-6; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Bulavin DV, 2002, NAT GENET, V31, P210, DOI 10.1038/ng894; Buschmann T, 2001, MOL CELL BIOL, V21, P2743, DOI 10.1128/MCB.21.8.2743-2754.2001; Chao C, 2000, P NATL ACAD SCI USA, V97, P11936, DOI 10.1073/pnas.220252297; Chehab NH, 1999, P NATL ACAD SCI USA, V96, P13777, DOI 10.1073/pnas.96.24.13777; Chernov MV, 2001, J BIOL CHEM, V276, P31819, DOI 10.1074/jbc.M103170200; Damia G, 2001, NEOPLASIA, V3, P10, DOI 10.1038/sj.neo.7900122; Dumaz N, 1999, EMBO J, V18, P7002, DOI 10.1093/emboj/18.24.7002; Freeman DJ, 2003, CANCER CELL, V3, P117, DOI 10.1016/S1535-6108(03)00021-7; Gatti A, 2000, BIOCHEMISTRY-US, V39, P9837, DOI 10.1021/bi992454i; Gostissa M, 1999, EMBO J, V18, P6462, DOI 10.1093/emboj/18.22.6462; Gottlieb TM, 1998, SEMIN CANCER BIOL, V8, P359, DOI 10.1006/scbi.1998.0098; Hammond EM, 2003, J BIOL CHEM, V278, P12207, DOI 10.1074/jbc.M212360200; Hao MM, 1996, J BIOL CHEM, V271, P29380, DOI 10.1074/jbc.271.46.29380; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hofseth LJ, 2003, P NATL ACAD SCI USA, V100, P143, DOI 10.1073/pnas.0237083100; Holmberg CI, 2002, TRENDS BIOCHEM SCI, V27, P619, DOI 10.1016/S0968-0004(02)02207-7; Kapoor M, 1998, P NATL ACAD SCI USA, V95, P2834, DOI 10.1073/pnas.95.6.2834; Kishi H, 2001, J BIOL CHEM, V276, P39115, DOI 10.1074/jbc.M105134200; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Lambert PF, 1998, J BIOL CHEM, V273, P33048, DOI 10.1074/jbc.273.49.33048; Li MY, 2002, J BIOL CHEM, V277, P50607, DOI 10.1074/jbc.C200578200; Linke SP, 1996, GENE DEV, V10, P934, DOI 10.1101/gad.10.8.934; Liu L, 1999, MOL CELL BIOL, V19, P1202; Lu H, 1997, MOL CELL BIOL, V17, P5923, DOI 10.1128/MCB.17.10.5923; Lu H, 1998, P NATL ACAD SCI USA, V95, P6399, DOI 10.1073/pnas.95.11.6399; Meyer KM, 1999, ONCOGENE, V18, P5795, DOI 10.1038/sj.onc.1202977; Michael D, 2003, SEMIN CANCER BIOL, V13, P49, DOI 10.1016/S1044-579X(02)00099-8; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Saito S, 2002, J BIOL CHEM, V277, P12491, DOI 10.1074/jbc.C200093200; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sakaguchi K, 1997, BIOCHEMISTRY-US, V36, P10117, DOI 10.1021/bi970759w; Sakaguchi K, 2000, J BIOL CHEM, V275, P9278, DOI 10.1074/jbc.275.13.9278; Schwartz D, 1998, SEMIN CANCER BIOL, V8, P325, DOI 10.1006/scbi.1998.0095; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Stewart ZA, 2001, ONCOGENE, V20, P113, DOI 10.1038/sj.onc.1204060; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Takekawa M, 2000, EMBO J, V19, P6517, DOI 10.1093/emboj/19.23.6517; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; WANG Y, 1995, NATURE, V376, P88, DOI 10.1038/376088a0; Waterman MJF, 1998, NAT GENET, V19, P175, DOI 10.1038/542; Webley K, 2000, MOL CELL BIOL, V20, P2803, DOI 10.1128/MCB.20.8.2803-2808.2000; Wu ZQ, 2002, MOL CELL BIOL, V22, P2441, DOI 10.1128/MCB.22.8.2441-2449.2002	51	196	204	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37536	37544		10.1074/jbc.M305135200	http://dx.doi.org/10.1074/jbc.M305135200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860987	hybrid			2022-12-27	WOS:000185437200067
J	Tee, AR; Anjum, R; Blenis, J				Tee, AR; Anjum, R; Blenis, J			Inactivation of the tuberous sclerosis complex-1 and-2 gene products occurs by phosphoinositide 3-kinase/Akt-dependent and -independent phosphorylation of tuberin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEINS; RIBOSOMAL S6 KINASE-2; CELL-GROWTH; MAMMALIAN TARGET; MULTIPLE SITES; TSC2; MTOR; INSULIN; ACTIVATION; RHEB	The tuberous sclerosis complex (TSC) is a genetic disorder that is caused through mutations in either one of the two tumor suppressor genes, TSC1 and TSC2, that encode hamartin and tuberin, respectively. Interaction of hamartin with tuberin forms a heterodimer that inhibits signaling by the mammalian target of rapamycin to its downstream targets: eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) and ribosomal protein S6 kinase 1 (S6K1). During mitogenic sufficiency, the phosphoinositide 3-kinase (PI3K)/Akt pathway phosphorylates tuberin on Ser-939 and Thr-1462 that inhibits the tumor suppressor function of the TSC complex. Here we show that tuberin-hamartin heterodimers block protein kinase C (PKC)/MAPK- and phosphatidic acid-mediated signaling toward mammalian target of rapamycin-dependent targets. We also show that two TSC2 mutants derived from TSC patients are defective in repressing phorbol 12-myristate 13-acetate-induced 4E-BP1 phosphorylation. PKC/MAPK signaling leads to phosphorylation of tuberin at sites that overlap with and are distinct from Akt phosphorylation sites. Phosphorylation of tuberin by phorbol 12-myristate 13-acetate was reduced by treatment of cells with either bisindolylmaleimide I or UO126, inhibitors of PKC and MAPK/MEK (MAPK/ERK kinase), respectively, but not by wortmannin ( an inhibitor of PI3K). This work reveals that both PI3K-independent and - dependent mechanisms modulate tuberin phosphorylation in vivo.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.			Tee, Andrew/0000-0002-5577-4631	NIGMS NIH HHS [GM51405] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BLENIS J, 1986, P NATL ACAD SCI USA, V83, P1733, DOI 10.1073/pnas.83.6.1733; Cheadle JP, 2000, HUM GENET, V107, P97, DOI 10.1007/s004390000348; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; Dan HC, 2002, J BIOL CHEM, V277, P35364, DOI 10.1074/jbc.M205838200; Fang YM, 2001, SCIENCE, V294, P1942, DOI 10.1126/science.1066015; Fingar DC, 2002, GENE DEV, V16, P1472, DOI 10.1101/gad.995802; Gao XS, 2002, NAT CELL BIOL, V4, P699, DOI 10.1038/ncb847; Gao XS, 2001, GENE DEV, V15, P1383, DOI 10.1101/gad.901101; Garami A, 2003, MOL CELL, V11, P1457, DOI 10.1016/S1097-2765(03)00220-X; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GREEN AJ, 1994, HUM MOL GENET, V3, P1833, DOI 10.1093/hmg/3.10.1833; GREEN AJ, 1994, NAT GENET, V6, P193, DOI 10.1038/ng0294-193; Herbert TP, 2000, J BIOL CHEM, V275, P11249, DOI 10.1074/jbc.275.15.11249; Herbert TP, 2002, J BIOL CHEM, V277, P11591, DOI 10.1074/jbc.M110367200; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Ito N, 1999, CELL, V96, P529, DOI 10.1016/S0092-8674(00)80657-1; Jaeschke A, 2002, J CELL BIOL, V159, P217, DOI 10.1083/jcb.jcb.200206108; Li Y, 2003, J BIOL CHEM, V278, P13663, DOI 10.1074/jbc.M300862200; Li Y, 2002, J BIOL CHEM, V277, P44593, DOI 10.1074/jbc.C200510200; Liu MY, 2002, CANCER RES, V62, P6475; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Martin KA, 2001, J BIOL CHEM, V276, P7884, DOI 10.1074/jbc.M006969200; McManus EJ, 2002, NAT CELL BIOL, V4, pE214, DOI 10.1038/ncb0902-e214; Nellist M, 2002, J BIOL CHEM, V277, P39417, DOI 10.1074/jbc.M204802200; Nellist M, 2001, HUM MOL GENET, V10, P2889, DOI 10.1093/hmg/10.25.2889; Onda H, 1999, J CLIN INVEST, V104, P687, DOI 10.1172/JCI7319; Park IH, 2002, J BIOL CHEM, V277, P31423, DOI 10.1074/jbc.M204080200; Potter CJ, 2001, CELL, V105, P357, DOI 10.1016/S0092-8674(01)00333-6; Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840; Richards SA, 1999, CURR BIOL, V9, P810, DOI 10.1016/S0960-9822(99)80364-9; Rousseau D, 1996, ONCOGENE, V13, P2415; SANCHEZMARGALET V, 1994, BIOCHEM BIOPH RES CO, V204, P446, DOI 10.1006/bbrc.1994.2480; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Shumway SD, 2003, J BIOL CHEM, V278, P2089, DOI 10.1074/jbc.C200499200; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; Tee AR, 2003, CURR BIOL, V13, P1259, DOI 10.1016/S0960-9822(03)00506-2; Tee AR, 2002, P NATL ACAD SCI USA, V99, P13571, DOI 10.1073/pnas.202476899; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Zhang HB, 2000, GENE DEV, V14, P2712, DOI 10.1101/gad.835000; Zhang Y, 2003, NAT CELL BIOL, V5, P578, DOI 10.1038/ncb999	43	171	180	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37288	37296		10.1074/jbc.M303257200	http://dx.doi.org/10.1074/jbc.M303257200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867426	hybrid			2022-12-27	WOS:000185437200037
J	Matsukawa, J; Nakayama, K; Nagao, T; Ichijo, H; Urushidani, T				Matsukawa, J; Nakayama, K; Nagao, T; Ichijo, H; Urushidani, T			Role of ADP-ribosylation factor 6 (ARF6) in gastric acid secretion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-GAMMA-S; PARIETAL-CELLS; MEMBRANE; ACTIVATION; EXPRESSION; PHOSPHATIDYLINOSITOL; STIMULATION; GLANDS	ADP-ribosylation factor (ARF) proteins are monomeric GTPases that are essential for membrane transport and exocytosis in a number of secretory cells. We investigated ARF6, the activation of which is insensitive to brefeldin A, to determine whether it regulates membrane traffic in gastric parietal cells. ARF6 translocated from cytosol to tubulovesicle in the presence of GTPgammaS, a potential inhibitor of acid secretion in permeabilized cells, whereas under the Mg2+-chelated condition where activity of ARF-GTPase activating protein is inhibited, ARF6 translocated to the apical secretory membrane. Immunohistochemical examination revealed that ARF6 mainly located in parietal cell within the gastric glands, and it translocated from the cytosol to the intracellular canaliculi when the glands were stimulated. These results indicated that the distribution of ARF6 between cytosol and the two different membranes was regulated by its GTPase activity. In cultured gastric glands infected with adenovirus expressing ARF6 Q67L, a mutant lacking GTP hydrolysis activity, gastric acid secretion was inhibited. These results suggest that ARF6 regulates gastric acid secretion in parietal cell and that the GTP hydrolysis cycle of ARF6 is essential for the activation pathway.	Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Tokyo 1130033, Japan; Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068501, Japan; Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan	University of Tokyo; Kyoto University; National Institute of Health Sciences - Japan	Urushidani, T (corresponding author), Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Cell Signaling, Tokyo 1130033, Japan.	urusidani@nihs.go.jp	Nakayama, Kazuhisa/ABF-2924-2020; Matsukawa, Jun/R-4972-2019	Matsukawa, Jun/0000-0001-9457-3683; Nakayama, Kazuhisa/0000-0001-7701-7183; Ichijo, Hidenori/0000-0002-5005-6438				Akagi K, 2001, J BIOL CHEM, V276, P28171, DOI 10.1074/jbc.M101190200; Akagi K, 1999, AM J PHYSIOL-GASTR L, V277, pG736, DOI 10.1152/ajpgi.1999.277.3.G736; BERGLINDH T, 1990, METHOD ENZYMOL, V192, P93; Calhoun BC, 1998, AM J PHYSIOL-CELL PH, V275, pC163, DOI 10.1152/ajpcell.1998.275.1.C163; Chavrier P, 1999, CURR OPIN CELL BIOL, V11, P466, DOI 10.1016/S0955-0674(99)80067-2; CHEW CS, 1989, AM J PHYSIOL, V256, pG254, DOI 10.1152/ajpgi.1989.256.1.G254; Dana RR, 2000, J BIOL CHEM, V275, P32566, DOI 10.1074/jbc.M005406200; Dohke Y, 1998, ARCH BIOCHEM BIOPHYS, V357, P147, DOI 10.1006/abbi.1998.0793; Duman JG, 1999, AM J PHYSIOL-CELL PH, V277, pC361, DOI 10.1152/ajpcell.1999.277.3.C361; Gaschet J, 1999, J BIOL CHEM, V274, P20040, DOI 10.1074/jbc.274.28.20040; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Honda A, 1999, CELL, V99, P521, DOI 10.1016/S0092-8674(00)81540-8; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Jones AT, 1999, J CELL SCI, V112, P3477; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liscovitch M, 2000, BIOCHEM J, V345, P401, DOI 10.1042/0264-6021:3450401; Miller MD, 1996, AM J PHYSIOL-GASTR L, V270, pG962, DOI 10.1152/ajpgi.1996.270.6.G962; Mukherjee S, 2000, P NATL ACAD SCI USA, V97, P5901, DOI 10.1073/pnas.100127097; Muto Y, 2001, AM J PHYSIOL-CELL PH, V280, pC155, DOI 10.1152/ajpcell.2001.280.1.C155; Okamoto CT, 2001, J PHYSIOL-LONDON, V532, P287, DOI 10.1111/j.1469-7793.2001.0287f.x; Omi N, 2001, AM J PHYSIOL-GASTR L, V281, pG786, DOI 10.1152/ajpgi.2001.281.3.G786; Takai Y, 2001, PHYSIOL REV, V81, P153, DOI 10.1152/physrev.2001.81.1.153; TASHIRO K, 2003, IN PRESS J CELL PHYS; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; URUSHIDANI T, 1987, AM J PHYSIOL, V252, pG458, DOI 10.1152/ajpgi.1987.252.4.G458; Urushidani T, 1997, J MEMBRANE BIOL, V159, P99, DOI 10.1007/s002329900274; Vitale N, 2002, J CELL BIOL, V159, P79, DOI 10.1083/jcb.200203027; WALKER MW, 1992, J BIOL CHEM, V267, P3230; Yang CZ, 1998, J BIOL CHEM, V273, P4006, DOI 10.1074/jbc.273.7.4006; ZHANG CJ, 1994, J CELL BIOL, V124, P289, DOI 10.1083/jcb.124.3.289	30	20	20	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36470	36475		10.1074/jbc.M305444200	http://dx.doi.org/10.1074/jbc.M305444200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860984	hybrid			2022-12-27	WOS:000185318300075
J	Misawa, K; Horiba, T; Arimura, N; Hirano, Y; Inoue, J; Emoto, N; Shimano, H; Shimizu, M; Sato, R				Misawa, K; Horiba, T; Arimura, N; Hirano, Y; Inoue, J; Emoto, N; Shimano, H; Shimizu, M; Sato, R			Sterol regulatory element-binding protein-2 interacts with hepatocyte nuclear factor-4 to enhance sterol isomerase gene expression in hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REGULATION; TRANSGENIC MICE; CHOLESTEROL-SYNTHESIS; RECEPTOR; LIVER; ACTIVATION; MUTATIONS; ACID; BIOSYNTHESIS; TAMOXIFEN	In the course of an effort to identify unknown targets genes for sterol regulatory element-binding proteins (SREBPs) by PCR, the gene for ATP citrate-lyase was determined to be one such gene. (Sato, R., Okamoto, A., Inoue, J., Miyamoto, W., Sakai, Y., Emoto, N., Shimano, H., and Maeda, M. (2000) J. Biol. Chem. 275, 12497-12502). We here report that gene expression of sterol Delta(8)-isomerase (SI), which catalyzes the conversion of the 8-ene isomer into the 7-ene isomer in the last steps of the cholesterol biosynthetic pathway, is regulated by SREBPs, mainly by SREBP-2. Luciferase assays using the promoter of the human SI gene revealed that a 200-base pair segment upstream region from the transcription start site contains functional elements required for the activity of the SREBPs, Sp1 and NF-Y. Interestingly, SI gene expression was well regulated by sterols in Caco-2 and HepG2 cells, in contrast with HEK293 and HeLa cells. Overexpression of hepatocyte nuclear factor (HNF)-4 in HEK293 cells augmented expression of SREBP-responsive genes including the SI gene, whereas inactivation of HNF-4 by small interfering RNAs in HepG2 cells reduced the SI gene promoter activity. The in vitro pull-down and in vivo co-immunoprecipitation experiments showed the direct interaction between SREBP-2 and HNF-4. These data provide a novel pathway by which HNF-4 potentiates the SREBP functions and stimulates expression of SREBP-responsive genes in enterohepatic cells.	Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; Kobe Univ, Grad Sch Med, Dept Internal Med, Div Cardiovasc & Resp Med, Kobe, Hyogo 6500017, Japan; Univ Tsukuba, Inst Clin Med, Dept Internal Med, Div Endocrinol & Metab, Tsukuba, Ibaraki 3058575, Japan	University of Tokyo; Kobe University; University of Tsukuba	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	Shimano, Hitoshi/V-1761-2019; Shimano, Hitoshi/AAI-5648-2020; INOUE, Jun/O-7352-2016	Shimano, Hitoshi/0000-0002-5562-5572; INOUE, Jun/0000-0003-4145-3754; Misawa, Koichi/0000-0002-0317-0609; Emoto, Noriaki/0000-0001-6673-2616				Amemiya-Kudo M, 2000, J BIOL CHEM, V275, P31078, DOI 10.1074/jbc.M005353200; Bae SH, 2001, BIOCHEM J, V353, P689, DOI 10.1042/0264-6021:3530689; Braverman N, 1999, NAT GENET, V22, P291, DOI 10.1038/10357; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; De Fabiani E., 2001, J BIOL CHEM, V276, P30708; Derry JMJ, 1999, NAT GENET, V22, P286, DOI 10.1038/10350; Ericsson J, 1998, J BIOL CHEM, V273, P17865, DOI 10.1074/jbc.273.28.17865; Guan GM, 1997, J BIOL CHEM, V272, P10295; HANNER M, 1995, J BIOL CHEM, V270, P7551, DOI 10.1074/jbc.270.13.7551; Hayhurst GP, 2001, MOL CELL BIOL, V21, P1393, DOI 10.1128/MCB.21.4.1393-1403.2001; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Holleran AL, 1998, METABOLISM, V47, P1504, DOI 10.1016/S0026-0495(98)90078-6; Horton JD, 1998, J CLIN INVEST, V101, P2331, DOI 10.1172/JCI2961; Inoue J, 1998, J BIOCHEM-TOKYO, V123, P1191; Jiang GQ, 1997, ARCH BIOCHEM BIOPHYS, V340, P1, DOI 10.1006/abbi.1997.9914; Louet JF, 2002, J BIOL CHEM, V277, P37991, DOI 10.1074/jbc.M205087200; Nagoshi E, 1999, MOL BIOL CELL, V10, P2221, DOI 10.1091/mbc.10.7.2221; Nakahara M, 2002, J BIOL CHEM, V277, P37229, DOI 10.1074/jbc.M206749200; Oliner JD, 1996, GENE DEV, V10, P2903, DOI 10.1101/gad.10.22.2903; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; Paul R, 1998, J PHARMACOL EXP THER, V285, P1296; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Sakakura Y, 2001, BIOCHEM BIOPH RES CO, V286, P176, DOI 10.1006/bbrc.2001.5375; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Sato R, 2000, J BIOL CHEM, V275, P12497, DOI 10.1074/jbc.275.17.12497; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SATO R, 1994, J BIOL CHEM, V269, P17267; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Silve S, 1996, J BIOL CHEM, V271, P22434, DOI 10.1074/jbc.271.37.22434; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Stroup D, 2000, J LIPID RES, V41, P1; Vidal-Puig A, 2001, NATURE, V413, P125, DOI 10.1038/35093198; Yabe D, 2002, P NATL ACAD SCI USA, V99, P16672, DOI 10.1073/pnas.262669399; Yang T, 2002, CELL, V110, P489, DOI 10.1016/S0092-8674(02)00872-3; Yin LY, 2002, J BIOL CHEM, V277, P19554, DOI 10.1074/jbc.M111771200	38	60	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36176	36182		10.1074/jbc.M302387200	http://dx.doi.org/10.1074/jbc.M302387200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855700	hybrid			2022-12-27	WOS:000185318300039
J	Polly, P; Haddadi, LM; Issa, LL; Subramaniam, N; Palmer, SJ; Tay, ESE; Hardeman, EC				Polly, P; Haddadi, LM; Issa, LL; Subramaniam, N; Palmer, SJ; Tay, ESE; Hardeman, EC			hMusTRD1 alpha 1 represses MEF2 activation of the Troponin I slow enhancer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SKELETAL-MUSCLE DIFFERENTIATION; TRANSCRIPTION FACTOR MEF2C; FIBER-TYPE; TFII-I; TRANSGENIC MICE; GENE-EXPRESSION; HISTONE DEACETYLASE; SOLEUS MUSCLE; BINDING PROTEIN; THYROID-HORMONE	The novel transcription factor hMusTRD1alpha1 ( human muscle TFII-I repeat domain-containing protein 1alpha1; previously named MusTRD1; O'Mahoney, J.V., Guven, K. L., Lin, J., Joya, J. E., Robinson, C. S., Wade, R. P., and Hardeman, E. C. (1998) Mol. Cell. Biol. 18, 6641-6652) was identified in a yeast one-hybrid screen as a protein that binds within an upstream enhancer-containing region of the skeletal muscle-specific gene, TNNI1 ( human troponin I slow; hTnI(slow)). It has been proposed that hMusTRD1alpha1 may play an important role in fiber-specific muscle gene expression by virtue of its ability to bind to an Inr-like element (nucleotides -977 to -960) within the hTnI(slow) upstream enhancer-containing region that is necessary for slow fiber-specific expression. In this study we demonstrate that both MEF2C, a known regulator of slow fiber-specific genes, and hMusTRD1alpha1 regulate hTnIslow through the Inr-like element. Co-transfection assays in C2C12 cells and Cos-7 cells demonstrate that hMusTRD1alpha1 represses hTnI(slow) transcription and prevents MEF2C-mediated activation of hTnI(slow) transcription. Gel shift analysis shows that hMusTRD1alpha1 can abrogate MEF2C binding to its cognate site in the hTnI(slow) enhancer. Glutathione S-transferase pull-down assays demonstrate that hMusTRD1alpha1 can interact with both MEF2C and the nuclear receptor co-repressor. The data support the role of hMusTRD1alpha1 as a repressor of slow fiber-specific transcription through mechanisms involving direct interactions with MEF2C and the nuclear receptor co-repressor.	Childrens Med Res Inst, Muscle Dev Unit, Wentworthville, NSW 2145, Australia	Children's Medical Research Institute - Australia	Hardeman, EC (corresponding author), Childrens Med Res Inst, Muscle Dev Unit, Locked Bag 23, Wentworthville, NSW 2145, Australia.	ehardeman@cmri.usyd.edu.au	Hardeman, Edna C/F-8872-2012; Palmer, Stephen/F-2822-2013	Palmer, Stephen/0000-0002-4907-4719; Hardeman, Edna/0000-0003-1649-7712				Bayarsaihan D, 2000, P NATL ACAD SCI USA, V97, P7342, DOI 10.1073/pnas.97.13.7342; Bigard AX, 2000, PFLUG ARCH EUR J PHY, V440, pR259; Buckingham M, 2001, CURR OPIN GENET DEV, V11, P440, DOI 10.1016/S0959-437X(00)00215-X; Calvo S, 1999, MOL CELL BIOL, V19, P515; Calvo S, 2001, MOL CELL BIOL, V21, P8490, DOI 10.1128/MCB.21.24.8490-8503.2001; CAMPIONE M, 1993, J APPL PHYSIOL, V74, P1156, DOI 10.1152/jappl.1993.74.3.1156; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; CORIN SJ, 1995, P NATL ACAD SCI USA, V92, P6185, DOI 10.1073/pnas.92.13.6185; Criswell DS, 1998, J APPL PHYSIOL, V84, P1083, DOI 10.1152/jappl.1998.84.3.1083; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Dunn SE, 2001, J BIOL CHEM, V276, P45243, DOI 10.1074/jbc.M105445200; Esser K, 1999, J BIOL CHEM, V274, P12095, DOI 10.1074/jbc.274.17.12095; ESSER K, 1993, DEV BIOL, V159, P173, DOI 10.1006/dbio.1993.1231; ESSER KA, 1995, AM J PHYSIOL-CELL PH, V268, pC466, DOI 10.1152/ajpcell.1995.268.2.C466; Giger JM, 2000, AM J PHYSIOL-CELL PH, V278, pC1153, DOI 10.1152/ajpcell.2000.278.6.C1153; GUNNING P, 1991, FASEB J, V5, P3064, DOI 10.1096/fasebj.5.15.1835946; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; HAUSCHKA SD, 2001, MYOLOGY; Hong SH, 1997, P NATL ACAD SCI USA, V94, P9028, DOI 10.1073/pnas.94.17.9028; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Huang YF, 1999, NAT NEUROSCI, V2, P867, DOI 10.1038/13165; Hughes SM, 1999, J CELL BIOL, V145, P633, DOI 10.1083/jcb.145.3.633; Hughes SM, 1997, MECH DEVELOP, V61, P151, DOI 10.1016/S0925-4773(96)00631-4; Hughes SM, 1999, CURR OPIN NEUROBIOL, V9, P54, DOI 10.1016/S0959-4388(99)80007-5; Kato Y, 1997, EMBO J, V16, P7054, DOI 10.1093/emboj/16.23.7054; LEVITT LK, 1995, DNA CELL BIOL, V14, P599, DOI 10.1089/dna.1995.14.599; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McKinsey TA, 2001, MOL CELL BIOL, V21, P6312, DOI 10.1128/MCB.21.18.6312-6321.2001; McKinsey TA, 2000, P NATL ACAD SCI USA, V97, P14400, DOI 10.1073/pnas.260501497; MCLENNAN IS, 1994, PROG NEUROBIOL, V44, P119, DOI 10.1016/0301-0082(94)90035-3; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Musaro A, 1999, NATURE, V400, P581, DOI 10.1038/23060; Nakayama M, 1996, MOL CELL BIOL, V16, P2408; Naya FJ, 1999, CURR OPIN CELL BIOL, V11, P683, DOI 10.1016/S0955-0674(99)00036-8; Naya FJ, 2000, J BIOL CHEM, V275, P4545, DOI 10.1074/jbc.275.7.4545; Naya FJ, 1999, DEVELOPMENT, V126, P2045; Nikovits W, 2001, DEVELOPMENT, V128, P2537; O'Mahoney JV, 1998, MOL CELL BIOL, V18, P6641, DOI 10.1128/MCB.18.11.6641; Olson EN, 2000, BIOESSAYS, V22, P510, DOI 10.1002/(SICI)1521-1878(200006)22:6<510::AID-BIES4>3.3.CO;2-T; Roy AL, 1997, EMBO J, V16, P7091, DOI 10.1093/emboj/16.23.7091; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Semsarian C, 1999, NATURE, V400, P576, DOI 10.1038/23054; Spitz F, 1998, J BIOL CHEM, V273, P14975, DOI 10.1074/jbc.273.24.14975; SUTHERLAND CJ, 1993, DEV DYNAM, V196, P25, DOI 10.1002/aja.1001960104; Tassabehji M, 1999, EUR J HUM GENET, V7, P737, DOI 10.1038/sj.ejhg.5200396; TAY ES, 2003, IN PRESS BIOCH J; Tussie-Luna MI, 2001, P NATL ACAD SCI USA, V98, P7789, DOI 10.1073/pnas.141222298; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; Washabaugh CH, 1998, DEV DYNAM, V211, P177, DOI 10.1002/(SICI)1097-0177(199802)211:2<177::AID-AJA6>3.0.CO;2-E; Wen YD, 2003, J BIOL CHEM, V278, P1841, DOI 10.1074/jbc.M206528200; Wu H, 2001, EMBO J, V20, P6414, DOI 10.1093/emboj/20.22.6414; Wu H, 2000, EMBO J, V19, P1963, DOI 10.1093/emboj/19.9.1963; Wu H, 2002, J CLIN INVEST, V109, P1327, DOI 10.1172/JCI200215417; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; Yan XM, 2000, BIOCHEM J, V345, P749, DOI 10.1042/0264-6021:3450749; Zhao M, 1999, MOL CELL BIOL, V19, P21; ZHU L, 1995, DEV BIOL, V169, P487, DOI 10.1006/dbio.1995.1163	59	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36603	36610		10.1074/jbc.M212814200	http://dx.doi.org/10.1074/jbc.M212814200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857748	hybrid			2022-12-27	WOS:000185318300091
J	De Maria, F; Pedersen, JZ; Caccuri, AM; Antonini, G; Turella, P; Stella, L; Lo Bello, M; Federici, G; Ricci, G				De Maria, F; Pedersen, JZ; Caccuri, AM; Antonini, G; Turella, P; Stella, L; Lo Bello, M; Federici, G; Ricci, G			The specific interaction of dinitrosyl-diglutathionyl-iron complex, a natural NO carrier, with the glutathione transferase superfamily - Suggestion for an evolutionary pressure in the direction of the storage of nitric oxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-SPIN-RESONANCE; SULFATE-BINDING POCKET; PROTEUS-MIRABILIS; CRYSTAL-STRUCTURE; S-TRANSFERASES; ACTIVE-SITE; BIOCHEMICAL PATHWAYS; CATALYTIC ACTIVITY; MOLECULAR-CLONING; SUBSTRATE-BINDING	The interaction of dinitrosyl-diglutathionyl-iron complex (DNDGIC), a natural carrier of nitric oxide, with representative members of the human glutathione transferase (GST) superfamily, i.e. GSTA1-1, GSTM2-2, GSTP1-1, and GSTT2-2, has been investigated by means of pre-steady and steady state kinetics, fluorometry, electron paramagnetic resonance, and radiometric experiments. This complex binds with extraordinary affinity to the active site of all these dimeric enzymes; GSTA1-1 shows the strongest interaction (K-D congruent to 10(-10) M), whereas GSTM2-2 and GSTP1-1 display similar and slightly lower affinities (K-D congruent to 10(-9) M). Binding of the complex to GSTA1-1 triggers structural intersubunit communication, which lowers the affinity for DNDGIC in the vacant subunit and also causes a drastic loss of enzyme activity. Negative cooperativity is also found in GSTM2-2 and GSTP1-1, but it does not affect the catalytic competence of the second subunit. Stopped-flow and fluorescence data fit well to a common minimal binding mechanism, which includes an initial interaction with GSH and a slower bimolecular interaction of DNDGIC with one high and one low affinity binding site. Interestingly, the Theta class GSTT2-2, close to the ancestral precursor of GSTs, shows very slow binding kinetics and hundred times lowered affinity (K-D congruent to 10(-7) M), whereas the bacterial GSTB1-1 is not inhibited by DNDGIC. Molecular modeling and EPR data reveal structural details that may explain the observed kinetic data. The optimized interaction with this NO carrier, developed in the more recently evolved GSTs, may be related to the acquired capacity to utilize NO as a signal messenger.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Rome Roma Tre, Dept Biol, I-00146 Rome, Italy; Childrens Hosp IRCCS Bambin Gesu, I-00165 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; Roma Tre University; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	riccig@uniroma2.it	Stella, Lorenzo/A-7996-2010; CACCURI, ANNA MARIA/AFU-2643-2022	Stella, Lorenzo/0000-0002-5489-7381; Antonini, Giovanni/0000-0002-2115-8961; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				Adler V, 1999, EMBO J, V18, P1321, DOI 10.1093/emboj/18.5.1321; Armstrong RN, 1997, CHEM RES TOXICOL, V10, P2, DOI 10.1021/tx960072x; Board PG, 1997, BIOCHEM J, V328, P929; Board PG, 2000, J BIOL CHEM, V275, P24798, DOI 10.1074/jbc.M001706200; BOARD PG, 1987, BIOCHEM J, V248, P937, DOI 10.1042/bj2480937; BOESE M, 1995, J BIOL CHEM, V270, P29244, DOI 10.1074/jbc.270.49.29244; BUETLER TM, 1992, J ENVIRON SCI HEAL C, V10, P181; Caccuri AM, 1999, J BIOL CHEM, V274, P19276, DOI 10.1074/jbc.274.27.19276; Caccuri AM, 2002, BIOCHEMISTRY-US, V41, P4686, DOI 10.1021/bi0158425; Caccuri AM, 2002, J BIOL CHEM, V277, P18777, DOI 10.1074/jbc.M201137200; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 2001, J BIOL CHEM, V276, P5432, DOI 10.1074/jbc.M002818200; Caccuri AM, 1999, BIOCHEM J, V344, P419, DOI 10.1042/0264-6021:3440419; Casalone E, 1998, FEBS LETT, V423, P122, DOI 10.1016/S0014-5793(98)00080-5; DAUBEROSGUTHORPE P, 1988, PROTEINS, V4, P31, DOI 10.1002/prot.340040106; DIRR H, 1994, EUR J BIOCHEM, V220, P645, DOI 10.1111/j.1432-1033.1994.tb18666.x; Dulhunty A, 2001, J BIOL CHEM, V276, P3319, DOI 10.1074/jbc.M007874200; Flanagan JU, 1999, PROTEIN SCI, V8, P2205, DOI 10.1110/ps.8.10.2205; Giannone G, 2000, J PHYSIOL-LONDON, V529, P735, DOI 10.1111/j.1469-7793.2000.00735.x; GILLHAM B, 1971, BIOCHEM J, V121, P667, DOI 10.1042/bj1210667; Kampranis SC, 2000, J BIOL CHEM, V275, P29207, DOI 10.1074/jbc.M002359200; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LITWACK G, 1971, NATURE, V234, P466, DOI 10.1038/234466a0; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; Malyshev IY, 1999, NITRIC OXIDE-BIOL CH, V3, P105, DOI 10.1006/niox.1999.0213; Malysheva IY, 1996, FEBS LETT, V391, P21, DOI 10.1016/0014-5793(96)00691-6; MANNERVIK B, 1985, P NATL ACAD SCI USA, V82, P7202, DOI 10.1073/pnas.82.21.7202; MANNERVIK B, 1988, CRC CR REV BIOCH MOL, V23, P283, DOI 10.3109/10409238809088226; MANNERVIK B, 1986, CHEM SCRIPTA, V26B, P281; Manukhina E B, 1998, Biull Eksp Biol Med, V125, P30; MCDONALD CC, 1965, J AM CHEM SOC, V87, P3319, DOI 10.1021/ja01093a007; Mendes P, 1997, TRENDS BIOCHEM SCI, V22, P361, DOI 10.1016/S0968-0004(97)01103-1; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; Mendes P, 1998, BIOINFORMATICS, V14, P869, DOI 10.1093/bioinformatics/14.10.869; MEYER DJ, 1995, BIOCHEM J, V311, P739, DOI 10.1042/bj3110739; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; Muller B, 1996, BRIT J PHARMACOL, V119, P1281, DOI 10.1111/j.1476-5381.1996.tb16034.x; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; MULSCH A, 1993, BIOCHEM BIOPH RES CO, V196, P1303, DOI 10.1006/bbrc.1993.2394; Mulsch A., 1994, DRUG RES, V44, P408; PEDERSEN JZ, 1988, J MAGN RESON, V77, P369, DOI 10.1016/0022-2364(88)90186-2; Pemble SE, 1996, BIOCHEM J, V319, P749, DOI 10.1042/bj3190749; Perito B, 1996, BIOCHEM J, V318, P157, DOI 10.1042/bj3180157; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; ROSS VL, 1993, BIOCHEM J, V294, P373, DOI 10.1042/bj2940373; Rossjohn J, 1998, STRUCTURE, V6, P309, DOI 10.1016/S0969-2126(98)00034-3; Tan KL, 1996, BIOCHEM J, V319, P315, DOI 10.1042/bj3190315; Turella P, 2003, J BIOL CHEM, V278, P42294, DOI 10.1074/jbc.M305569200; Ueno T, 2000, JPN J PHARMACOL, V82, P95, DOI 10.1254/jjp.82.95; Vanin AF, 1997, NITRIC OXIDE-BIOL CH, V1, P191, DOI 10.1006/niox.1997.0122; VANIN AF, 1991, FEBS LETT, V289, P1, DOI 10.1016/0014-5793(91)80894-9; WILCE MCJ, 1995, EMBO J, V14, P2133, DOI 10.1002/j.1460-2075.1995.tb07207.x; Wilce MCJ, 1994, BIOCHIM BIOPHYS ACTA, V205, P1	54	52	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42283	42293		10.1074/jbc.M305568200	http://dx.doi.org/10.1074/jbc.M305568200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871945	hybrid			2022-12-27	WOS:000185989500088
J	Girardin, SE; Travassos, LH; Herve, M; Blanot, D; Boneca, IG; Philpott, DJ; Sansonetti, PJ; Mengin-Lecreulx, D				Girardin, SE; Travassos, LH; Herve, M; Blanot, D; Boneca, IG; Philpott, DJ; Sansonetti, PJ; Mengin-Lecreulx, D			Peptidoglycan molecular requirements allowing detection by Nod1 and Nod2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ALANINE AMIDASE; N-ACETYLMURAMIC ACID; ESCHERICHIA-COLI; DIAMINOPIMELIC ACID; CELL-WALL; BACTERIAL PEPTIDOGLYCAN; SHIGELLA-FLEXNERI; HOST RECOGNITION; CROHNS-DISEASE; KAPPA-B	Nod1 and Nod2 are mammalian proteins implicated in the intracellular detection of pathogen-associated molecular patterns. Recently, naturally occurring peptidoglycan ( PG) fragments were identified as the microbial motifs sensed by Nod1 and Nod2. Whereas Nod2 detects GlcNAc-MurNAc dipeptide (GM-Di), Nod1 senses a unique diaminopimelate-containing GlcNAc-MurNAc tripeptide muropeptide (GM-Tri(DAP)) found mostly in Gram-negative bacterial PGs. Because Nod1 and Nod2 detect similar yet distinct muropeptides, we further analyzed the molecular sensing specificity of Nod1 and Nod2 toward PG fragments. Using a wide array of natural or modified muramyl peptides, we show here that Nod1 and Nod2 have evolved divergent strategies to achieve PG sensing. By defining the PG structural requirements for Nod1 and Nod2 sensing, this study reveals how PG processing and modifications, either by host or bacterial enzymes, may affect innate immune responses.	Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, F-75724 Paris 15, France; Inst Pasteur, Grp Immun Innee & Signalisat, F-75724 Paris, France; Inst Pasteur, Unite Pathogenie Bacterienne Muqueuses, F-75724 Paris 15, France; Univ Paris 11, CNRS, UMR 8619, Inst Biochim & Biophys Mol & Cellulaire, F-91405 Orsay, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Girardin, SE (corresponding author), Inst Pasteur, INSERM, U389, Unite Pathogenie Microbienne Mol, 28 Rue Dr Roux, F-75724 Paris 15, France.		Boneca, Ivo G/H-1677-2014; Travassos, Leonardo/G-1925-2012	Boneca, Ivo G/0000-0001-8122-509X; Travassos, Leonardo/0000-0003-1323-3797; MENGIN-LECREULX, Dominique/0000-0003-3205-0275				Atrih A, 1999, J BACTERIOL, V181, P3956, DOI 10.1128/JB.181.13.3956-3966.1999; AUGER G, 1995, J PRAK CHEM-CHEM ZTG, V337, P351, DOI 10.1002/prac.19953370176; Auger G, 1998, PROTEIN EXPRES PURIF, V13, P23, DOI 10.1006/prep.1997.0850; Bartoleschi C, 2002, CELL MICROBIOL, V4, P613, DOI 10.1046/j.1462-5822.2002.00216.x; BERGES DA, 1986, J MED CHEM, V29, P89, DOI 10.1021/jm00151a015; Bertrand JA, 1999, J MOL BIOL, V289, P579, DOI 10.1006/jmbi.1999.2800; BLANOT D, 1994, CARBOHYD RES, V252, P107; Chamaillard M, 2003, P NATL ACAD SCI USA, V100, P3455, DOI 10.1073/pnas.0530276100; Chamaillard M, 2003, NAT IMMUNOL, V4, P702, DOI 10.1038/ni945; Chamaillard M, 2003, CELL MICROBIOL, V5, P581, DOI 10.1046/j.1462-5822.2003.00304.x; FLOURET B, 1981, ANAL BIOCHEM, V114, P59, DOI 10.1016/0003-2697(81)90451-6; Gelius E, 2003, BIOCHEM BIOPH RES CO, V306, P988, DOI 10.1016/S0006-291X(03)01096-9; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Girardin SE, 2001, EMBO REP, V2, P736, DOI 10.1093/embo-reports/kve155; Girardin SE, 2003, SCIENCE, V300, P1584, DOI 10.1126/science.1084677; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Inohara N, 2003, NAT REV IMMUNOL, V3, P371, DOI 10.1038/nri1086; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; MENGINLECREULX D, 1988, J BACTERIOL, V170, P2031, DOI 10.1128/jb.170.5.2031-2039.1988; MENGINLECREULX D, 1994, J BACTERIOL, V176, P4321, DOI 10.1128/jb.176.14.4321-4327.1994; MICHAUD C, 1987, EUR J BIOCHEM, V166, P631, DOI 10.1111/j.1432-1033.1987.tb13560.x; MOLLNER S, 1984, ARCH MICROBIOL, V140, P171, DOI 10.1007/BF00454921; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; RICHAUD C, 1993, J BIOL CHEM, V268, P26827; SACHS H, 1953, J AM CHEM SOC, V75, P4608, DOI 10.1021/ja01114a528; Templin MF, 1999, EMBO J, V18, P4108, DOI 10.1093/emboj/18.15.4108; VANHEIJENOORT J, 1969, B SOC CHIM FR, P2743; VANHEIJENOORT J, 1968, B SOC CHIM FR, P2828; VANHEIJENOORT J, 1975, EUR J BIOCHEM, V58, P611	31	499	533	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41702	41708		10.1074/jbc.M307198200	http://dx.doi.org/10.1074/jbc.M307198200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871942	hybrid			2022-12-27	WOS:000185989500020
J	Kinoshita, A; Shah, T; Tangredi, MM; Strickland, DK; Hyman, BT				Kinoshita, A; Shah, T; Tangredi, MM; Strickland, DK; Hyman, BT			The intracellular domain of the low density lipoprotein receptor-related protein modulates transactivation mediated by amyloid precursor protein and Fe65	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIFETIME IMAGING MICROSCOPY; RESONANCE ENERGY-TRANSFER; CARBOXYL-TERMINAL DOMAIN; METHYL-D-ASPARTATE; ALZHEIMERS-DISEASE; ADAPTER PROTEIN; APOE RECEPTOR; BETA-PROTEIN; LRP; COMPLEX	Low density lipoprotein-related protein (LRP) is a transmembrane receptor, localized mainly in hepatocytes, fibroblasts, and neurons. It is implicated in diverse biological processes both as an endocytic receptor and as a signaling molecule. Recent reports show that LRP undergoes sequential proteolytic cleavage in the ectodomain and transmembrane domain. The latter cleavage, mediated by the Alzheimer-related gamma-secretase activity that also cleaves amyloid precursor protein (APP) and Notch, results in the release of the LRP cytoplasmic domain (LRPICD) fragment. This relatively small cytoplasmic fragment has several motifs by which LRP interacts with various intracellular adaptor and scaffold proteins. However, the function of this fragment is largely unknown. Here we show that the LRPICD is translocated to the nucleus, where it colocalizes in the nucleus with a transcription modulator, Tip60, which is known to interact with Fe65 and with the APP-derived intracellular domain. LRPICD dramatically inhibits APP-derived intracellular domain/Fe65 transactivation mediated by Tip60. LRPICD has a close interaction with Tip60 in the nucleus, as shown by a fluorescence resonance energy transfer assay. These observations suggest that LRPICD has a novel signaling function, negatively impacting transcriptional activity of the APP, Fe65, and Tip60 complex in the nucleus, and shed new light on the function of LRP in transcriptional modulation.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Alzheimer Dis Res Lab, Charlestown, MA 02129 USA; Amer Red Cross, Holland Lab, Rockville, MD 20855 USA	Harvard University; Massachusetts General Hospital; American Red Cross	Hyman, BT (corresponding author), Dept Neurol, Alzheimer Unit, 114 16th St,CAGN 2009, Charlestown, MA 02129 USA.				NIA NIH HHS [AG15379, AG12406, P01AG05134] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG012406, R01AG012406, P01AG015379] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bacskai BJ, 2000, P NATL ACAD SCI USA, V97, P11551, DOI 10.1073/pnas.200238297; Bacskai BJ, 2003, J BIOMED OPT, V8, P368, DOI 10.1117/1.1584442; Bastiaens PIH, 1999, TRENDS CELL BIOL, V9, P48, DOI 10.1016/S0962-8924(98)01410-X; Berezovska O, 2003, J NEUROSCI, V23, P4560; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; Cao XW, 2001, SCIENCE, V293, P115, DOI 10.1126/science.1058783; Guenette SY, 2002, J NEUROCHEM, V82, P755, DOI 10.1046/j.1471-4159.2002.01009.x; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Kang DE, 2000, J CLIN INVEST, V106, P1159, DOI 10.1172/JCI11013; Kimberly WT, 2001, J BIOL CHEM, V276, P40288, DOI 10.1074/jbc.C100447200; Kinoshita A, 2003, J CELL SCI, V116, P3339, DOI 10.1242/jcs.00643; Kinoshita A, 2002, J NEUROCHEM, V82, P839, DOI 10.1046/j.1471-4159.2002.01016.x; Kinoshita A, 2002, J BIOL CHEM, V277, P28530, DOI 10.1074/jbc.M203372200; Kinoshita A, 2001, J NEUROSCI, V21, P8354, DOI 10.1523/JNEUROSCI.21-21-08354.2001; Knauer MF, 1996, BRAIN RES, V740, P6, DOI 10.1016/S0006-8993(96)00711-1; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Li YH, 2001, MOL NEUROBIOL, V23, P53; Liu CX, 2001, J BIOL CHEM, V276, P28889, DOI 10.1074/jbc.M102727200; Liu Y, 2000, NAT MED, V6, P1380, DOI 10.1038/82199; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Mikhailenko I, 2001, J BIOL CHEM, V276, P39484, DOI 10.1074/jbc.M104382200; Narita M, 1997, J NEUROCHEM, V69, P1904; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Qiu WQ, 1996, J BIOL CHEM, V271, P8443, DOI 10.1074/jbc.271.14.8443; Qiu ZH, 1999, J NEUROCHEM, V73, P1393, DOI 10.1046/j.1471-4159.1999.0731393.x; Qiu ZH, 2002, J BIOL CHEM, V277, P14458, DOI 10.1074/jbc.M112066200; Quinn KA, 1997, J BIOL CHEM, V272, P23946, DOI 10.1074/jbc.272.38.23946; Quinn KA, 1999, EXP CELL RES, V251, P433, DOI 10.1006/excr.1999.4590; Rebeck GW, 2001, MOL BRAIN RES, V87, P238, DOI 10.1016/S0169-328X(01)00006-7; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; Zhao Q, 2003, BIOCHEMISTRY-US, V42, P3627, DOI 10.1021/bi027117f	36	96	100	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41182	41188		10.1074/jbc.M306403200	http://dx.doi.org/10.1074/jbc.M306403200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888553	hybrid			2022-12-27	WOS:000185847200095
J	Liu, Q; Huang, QQ; Teng, MK; Weeks, CM; Jelsch, C; Zhang, RG; Niu, LW				Liu, Q; Huang, QQ; Teng, MK; Weeks, CM; Jelsch, C; Zhang, RG; Niu, LW			The crystal structure of a novel, inactive, lysine 49 PLA2 from Agkistrodon acutus venom - An ultrahigh resolution, ab initio structure determination	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAY-DIFFRACTION DATA; X-RAY; PHOSPHOLIPASE A(2); CHARGE-DENSITY; ELECTRON-DENSITY; MYOTOXIN-II; PROTEINS; IMPLEMENTATION; REFINEMENT; PARAMETERS	The crystal structure of acutohaemolysin, a lysine 49 phospholipase A2 protein with 1010 non-hydrogen protein atoms and 232 water molecules, has been determined ab initio using the program SnB at an ultrahigh resolution of 0.8 Angstrom. The lack of catalytic activity appears to be related to the presence of Phe(102), which prevents the access of substrate to the active site. The substitution of tryptophan for leucine at residue 10 interferes with dimer formation and may be responsible for the additional loss of hemolytic activity. The ultrahigh resolution of the experimental diffraction data permits alternative conformations to be modeled for disordered residues, many hydrogen atoms to be located, the protonation of the Nepsilon2 atom in the catalytic residue His(48) to be observed experimentally, and the density of the bonding electrons to be analyzed in detail.	Chinese Acad Sci, Key Lab Struct Biol, Hefei 230026, Anhui, Peoples R China; Univ Sci & Technol China, Sch Life Sci, Dept Mol & Cell Biol, Hefei 230026, Anhui, Peoples R China; Hauptman Woodward Med Res Inst, Buffalo, NY 14203 USA; Fac Sci, CNRS, Lab Cristallog & Modelisat Mat Mineraux & Biol, F-54506 Vandoeuvre Les Nancy, France; Argonne Natl Lab, Struct Biol Ctr, Argonne, IL 60439 USA	Chinese Academy of Sciences; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Hauptman Woodward Medical Research Institute; Centre National de la Recherche Scientifique (CNRS); Universite de Lorraine; United States Department of Energy (DOE); Argonne National Laboratory	Niu, LW (corresponding author), Chinese Acad Sci, Key Lab Struct Biol, 96 Jinzhai Rd, Hefei 230026, Anhui, Peoples R China.	lwniu@ustc.edu.cn	Liu, Qun/A-8757-2011	Liu, Qun/0000-0002-1179-290X; jelsch, christian/0000-0002-2655-0313	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P01EB002057] Funding Source: NIH RePORTER; NIBIB NIH HHS [EB-002057] Funding Source: Medline	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Arni RK, 1999, ARCH BIOCHEM BIOPHYS, V366, P177, DOI 10.1006/abbi.1999.1210; Blessing RH, 1996, ACTA CRYSTALLOGR D, V52, P257, DOI 10.1107/S0907444995014053; Coppens P, 1998, ACTA CRYSTALLOGR A, V54, P779, DOI 10.1107/S0108767398008575; COPPENS P, 1997, XRAY CHARGE DENSITIE, P233; Dauter Z, 1997, CURR OPIN STRUC BIOL, V7, P681, DOI 10.1016/S0959-440X(97)80078-4; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Fan CY, 1999, GENET ANAL-BIOMOL E, V15, P15, DOI 10.1016/S1050-3862(98)00033-3; FRANCIS B, 1991, ARCH BIOCHEM BIOPHYS, V284, P352, DOI 10.1016/0003-9861(91)90307-5; FUJINAGA M, 1987, J APPL CRYSTALLOGR, V20, P517, DOI 10.1107/S0021889887086102; Guillot B, 2001, J APPL CRYSTALLOGR, V34, P214, DOI 10.1107/S0021889801001753; GUTIERREZ JM, 1995, TOXICON, V33, P1405, DOI 10.1016/0041-0101(95)00085-Z; HANSEN NK, 1978, ACTA CRYSTALLOGR A, V34, P909, DOI 10.1107/S0567739478001886; Harris TK, 2002, IUBMB LIFE, V53, P85, DOI 10.1080/15216540211468; HOLLAND DR, 1990, J BIOL CHEM, V265, P17649; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Housset D, 2000, ACTA CRYSTALLOGR D, V56, P151, DOI 10.1107/S0907444999014948; Huang QQ, 2000, ACTA CRYSTALLOGR D, V56, P907, DOI 10.1107/S0907444900005643; Jelsch C, 2000, P NATL ACAD SCI USA, V97, P3171, DOI 10.1073/pnas.97.7.3171; Jelsch C, 1998, PROTEINS, V31, P320, DOI 10.1002/(SICI)1097-0134(19980515)31:3<320::AID-PROT8>3.0.CO;2-M; Jelsch C, 1998, ACTA CRYSTALLOGR D, V54, P1306, DOI 10.1107/S0907444998004466; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kuhn P, 1998, BIOCHEMISTRY-US, V37, P13446, DOI 10.1021/bi9813983; Kumar S, 1999, J MOL BIOL, V293, P1241, DOI 10.1006/jmbi.1999.3218; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LECOMTE C, 1986, J AM CHEM SOC, V108, P6942, DOI 10.1021/ja00282a019; Lee WH, 2001, BIOCHEMISTRY-US, V40, P28, DOI 10.1021/bi0010470; Merritt EA, 1999, ACTA CRYSTALLOGR D, V55, P1109, DOI 10.1107/S0907444999003789; MILLER R, 1994, J APPL CRYSTALLOGR, V27, P613, DOI 10.1107/S0021889894000191; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ownby CL, 1999, TOXICON, V37, P411, DOI 10.1016/S0041-0101(98)00188-3; PEDERSEN JZ, 1995, BIOCHEMISTRY-US, V34, P4670, DOI 10.1021/bi00014a021; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Pontius J, 1996, J MOL BIOL, V264, P121, DOI 10.1006/jmbi.1996.0628; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RENETSEDER R, 1985, J BIOL CHEM, V260, P1627; SCOTT DL, 1990, SCIENCE, V250, P1541, DOI 10.1126/science.2274785; Sheldrick G.M., 1997, SHELX 97 MANUAL; SHIMOHIGASHI Y, 1995, J BIOCHEM-TOKYO, V118, P1037, DOI 10.1093/jb/118.5.1037; Spackman MA, 1996, ACTA CRYSTALLOGR B, V52, P1023, DOI 10.1107/S0108768196008294; STEWART RF, 1993, BIOPHYS J, V65, P998, DOI 10.1016/S0006-3495(93)81142-1; Svergun DI, 1998, P NATL ACAD SCI USA, V95, P2267, DOI 10.1073/pnas.95.5.2267; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ward RJ, 1998, TOXICON, V36, P1623, DOI 10.1016/S0041-0101(98)00155-X; Ward RJ, 1998, PROTEIN ENG, V11, P285, DOI 10.1093/protein/11.4.285; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WEEKS CM, 1994, ACTA CRYSTALLOGR A, V50, P210, DOI 10.1107/S0108767393008992; Yamaguchi Y, 1997, BIOCHEM MOL BIOL INT, V43, P19	47	38	40	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41400	41408		10.1074/jbc.M305210200	http://dx.doi.org/10.1074/jbc.M305210200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12871974	hybrid			2022-12-27	WOS:000185847200120
J	Oishi, K; Miyazaki, K; Kadota, K; Kikuno, R; Nagase, T; Atsumi, G; Ohkura, N; Azama, T; Mesaki, M; Yukimasa, S; Kobayashi, H; Iitaka, C; Umehara, T; Horikoshi, M; Kudo, T; Shimizu, Y; Yano, M; Monden, M; Machida, K; Matsuda, J; Horie, S; Todo, T; Ishida, N				Oishi, K; Miyazaki, K; Kadota, K; Kikuno, R; Nagase, T; Atsumi, G; Ohkura, N; Azama, T; Mesaki, M; Yukimasa, S; Kobayashi, H; Iitaka, C; Umehara, T; Horikoshi, M; Kudo, T; Shimizu, Y; Yano, M; Monden, M; Machida, K; Matsuda, J; Horie, S; Todo, T; Ishida, N			Genome-wide expression analysis of mouse liver reveals CLOCK-regulated circadian output genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TISSUE-SPECIFIC EXPRESSION; MUTANT MICE; TRANSCRIPTION; RHYTHMICITY; INCREASE; MUTATION; PROTEIN; PERIOD; MPER2; MODEL	CLOCK is a positive component of a transcription/ translation-based negative feedback loop of the central circadian oscillator in the suprachiasmatic nucleus in mammals. To examine CLOCK-regulated circadian transcription in peripheral tissues, we performed microarray analyses using liver RNA isolated from Clock mutant mice. We also compared expression profiles with those of Cryptochromes (Cry1 and Cry2) double knockout mice. We identified more than 100 genes that fluctuated from day to night and of which expression levels were decreased in Clock mutant mice. In Cry-deficient mice, the expression levels of most CLOCK-regulated genes were elevated to the upper range of normal oscillation. Most of the screened genes had a CLOCK/BMAL1 binding site (E box) in the 5'-flanking region. We found that CLOCK was absolutely concerned with the circadian transcription of one type of liver genes ( such as DBP, TEF, and Usp2) and partially with another ( such as mPer1, mPer2, mDec1, Nocturnin, P450 oxidoreductase, and FKBP51) because the latter were damped but remained rhythmic in the mutant mice. Our results showed that CLOCK and CRY proteins are involved in the transcriptional regulation of many circadian output genes in the mouse liver. In addition to being a core component of the negative feedback loop that drives the circadian oscillator, CLOCK also appears to be involved in various physiological functions such as cell cycle, lipid metabolism, immune functions, and proteolysis in peripheral tissues.	Natl Inst Adv Ind Sci & Technol, Clock Cell Biol Grp, Inst Biol Resources & Funct, Tsukuba, Ibaraki 3058566, Japan; Natl Inst Adv Ind Sci & Technol, Computat Biol Res Ctr, Koto Ku, Tokyo 1350064, Japan; Kazusa DNA Res Inst, Dept Human Gene Res, Lab Human Gene Res 1, Chiba 2920818, Japan; Teikyo Univ, Fac Pharmaceut Sci, Kanagawa 1990195, Japan; Osaka Univ, Grad Sch Med, Dept Surg & Clin Oncol, Osaka 5650871, Japan; Waseda Univ, Sch Human Sci, Dept Hyg & Publ Hlth, Tokorozawa, Saitama 3591192, Japan; Tokyo Inst Technol, Dept Biomol Engn, Kanagawa 2268501, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, Tsukuba, Ibaraki 3002635, Japan; Kyoto Univ, Ctr Radiat Biol, Sakyo Ku, Kyoto 6068501, Japan; Univ Tsukuba, Inst Appl Biochem, Tsukuba, Ibaraki 3058502, Japan; Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, Tokyo 1130032, Japan	National Institute of Advanced Industrial Science & Technology (AIST); National Institute of Advanced Industrial Science & Technology (AIST); Kazusa DNA Research Institute; Teikyo University; Osaka University; Waseda University; Tokyo Institute of Technology; Japan Science & Technology Agency (JST); Kyoto University; University of Tsukuba; University of Tokyo	Ishida, N (corresponding author), Natl Inst Adv Ind Sci & Technol, Clock Cell Biol Grp, Inst Biol Resources & Funct, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	n.ishida@aist.go.jp	Kobayashi, Hisato/AAP-7910-2020; Jansen, Heiko T./A-5770-2008; , Kadota/AAP-2804-2020; Kinoshita, Chisato/AAW-5116-2020; Oishi, Katsutaka/L-6906-2018; Umehara, Takashi/N-5683-2015; Kadota, Koji/C-9168-2011; Umehara, Takashi/AHB-1730-2022; Miyazaki, Koyomi/L-6539-2018	Jansen, Heiko T./0000-0003-0178-396X; , Kadota/0000-0002-3907-4336; Kinoshita, Chisato/0000-0001-5877-0196; Oishi, Katsutaka/0000-0002-4870-0837; Umehara, Takashi/0000-0003-3464-2960; Kadota, Koji/0000-0002-3907-4336; Umehara, Takashi/0000-0003-3464-2960; Miyazaki, Koyomi/0000-0002-5464-1095; Kobayashi, Hisato/0000-0003-3800-4691				Akhtar RA, 2002, CURR BIOL, V12, P540, DOI 10.1016/S0960-9822(02)00759-5; Baggs JE, 2003, CURR BIOL, V13, P189, DOI 10.1016/S0960-9822(03)00014-9; Cassone VM, 2002, NUTRITION, V18, P814, DOI 10.1016/S0899-9007(02)00937-1; Cha JY, 2001, EXP MOL MED, V33, P59, DOI 10.1038/emm.2001.11; Chen L, 2002, MOL CELL BIOL, V22, P4902, DOI 10.1128/MCB.22.13.4902-4913.2002; Cliften P, 2003, SCIENCE, V301, P71, DOI 10.1126/science.1084337; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Debeljak N, 2003, ARCH BIOCHEM BIOPHYS, V409, P159, DOI 10.1016/S0003-9861(02)00418-6; Delaunay F, 2002, TRENDS GENET, V18, P595, DOI 10.1016/S0168-9525(02)02794-4; Desai UJ, 2001, DIABETES, V50, P2287, DOI 10.2337/diabetes.50.10.2287; Etchegaray JP, 2003, NATURE, V421, P177, DOI 10.1038/nature01314; Fonjallaz P, 1996, EMBO J, V15, P351, DOI 10.1002/j.1460-2075.1996.tb00365.x; FORNACE AJ, 1992, ANN NY ACAD SCI, V663, P139, DOI 10.1111/j.1749-6632.1992.tb38657.x; Fu LN, 2002, CELL, V111, P41, DOI 10.1016/S0092-8674(02)00961-3; Honma S, 2002, NATURE, V419, P841, DOI 10.1038/nature01123; Humphries A, 2002, J NEUROENDOCRINOL, V14, P101, DOI 10.1046/j.0007-1331.2001.00738.x; Katzenberg D, 1998, SLEEP, V21, P569, DOI 10.1093/sleep/21.6.569; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lavery DJ, 1999, MOL CELL BIOL, V19, P6488; Lewin TM, 2001, J BIOL CHEM, V276, P24674, DOI 10.1074/jbc.M102036200; Liu GY, 2003, NUCLEIC ACIDS RES, V31, P82, DOI 10.1093/nar/gkg121; Matsuzaka T, 2002, J LIPID RES, V43, P911; Nakamura W, 2002, NAT NEUROSCI, V5, P399, DOI 10.1038/nn843; Oishi K, 2002, BIOCHEM BIOPH RES CO, V298, P198, DOI 10.1016/S0006-291X(02)02427-0; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PANDO MP, 2001, SCI STKE; Peterfy M, 2001, NAT GENET, V27, P121, DOI 10.1038/83685; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Reynolds PD, 1999, J CLIN ENDOCR METAB, V84, P663, DOI 10.1210/jc.84.2.663; Rouyer F, 1997, EMBO J, V16, P3944, DOI 10.1093/emboj/16.13.3944; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Sei H, 2003, NEUROSCIENCE, V117, P785, DOI 10.1016/S0306-4522(02)00909-0; Sei H, 2001, NEUROREPORT, V12, P1461, DOI 10.1097/00001756-200105250-00033; Sommer D, 2002, ARCH BIOCHEM BIOPHYS, V404, P271, DOI 10.1016/S0003-9861(02)00242-4; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Travnickova-Bendova Z, 2002, P NATL ACAD SCI USA, V99, P7728, DOI 10.1073/pnas.102075599; Ueda HR, 2002, NATURE, V418, P534, DOI 10.1038/nature00906; Vermeer H, 2003, J CLIN ENDOCR METAB, V88, P277, DOI 10.1210/jc.2002-020354; VITATERNA MH, 1994, SCIENCE, V264, P719, DOI 10.1126/science.8171325; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Wang Y, 2001, BMC Dev Biol, V1, P9, DOI 10.1186/1471-213X-1-9; Wilsbacher LD, 2002, P NATL ACAD SCI USA, V99, P489, DOI 10.1073/pnas.012248599; Yagita K, 2002, EMBO J, V21, P1301, DOI 10.1093/emboj/21.6.1301	45	271	281	3	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41519	41527		10.1074/jbc.M304564200	http://dx.doi.org/10.1074/jbc.M304564200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12865428	hybrid			2022-12-27	WOS:000185847200132
J	Fraser, DJ; Zumsteg, A; Meyer, UA				Fraser, DJ; Zumsteg, A; Meyer, UA			Nuclear receptors constitutive androstane receptor and pregnane X receptor activate a drug-responsive enhancer of the murine 5-aminolevulinic acid synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVATION; GLUCOCORTICOID-RECEPTOR; SIGNALING PATHWAY; HEME METABOLISM; INDUCTION; CAR; PXR; PROTEIN; CXR; ELEMENTS	Nuclear receptors have been implicated in the transcriptional regulation of expression of a growing number of genes, including cytochromes P450 and 5-aminolevulinate synthase (ALAS1), the first and rate-limiting enzyme in the heme biosynthesis pathway. Although drugs that induce cytochromes P450 also induce ALAS1, the regulatory mechanisms governing these pathways have not been fully elucidated. We have identified a drug-responsive enhancer in the murine ALAS1 gene. This sequence mediates transcriptional activation by a wide range of compounds including typical cytochrome P450 pan-inducers phenobarbital and metyrapone, as well as specific activators of the pregnane X receptor and the constitutive androstane receptor. ALAS1 drug-responsive enhancer sequences were identified by transient transfection of reporter gene constructs in the drug-responsive leghorn male hepatoma cell line. Using the NUBIScan algorithm, DR4 nuclear receptor binding sites were identified within the elements and their roles in mediating transcriptional activation of ALAS1 were confirmed by site-directed mutagenesis. Electrophoretic mobility shift assays demonstrate clear interactions of mouse pregnane X receptor and constitutive androstane receptor on the ADRES. Transactivation assays in CV-1 cells implicate the nuclear receptors as major contributors to transcriptional activation of ALAS1. Moreover, in vivo studies in knock-out animals confirm the induction of ALAS1 is mediated at least in part by nuclear receptors. These studies are the first to explain drug induction via drug response elements for mammalian ALAS1.	Univ Basel, Bioctr, Dept Pharmacol Neurobiol, Div Pharmacol Neurobiol, CH-4056 Basel, Switzerland	University of Basel	Meyer, UA (corresponding author), Univ Basel, Bioctr, Dept Pharmacol Neurobiol, Div Pharmacol Neurobiol, Klingelbergstr 70, CH-4056 Basel, Switzerland.							Akiyama TE, 2003, BBA-GEN SUBJECTS, V1619, P223, DOI 10.1016/S0304-4165(02)00480-4; Anderson K. E., 2001, METABOLIC BASIS INHE; Baader M, 2002, J BIOL CHEM, V277, P15647, DOI 10.1074/jbc.M109882200; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; Cable EE, 2002, DNA CELL BIOL, V21, P323, DOI 10.1089/104454902753759735; Cable EE, 2000, ARCH BIOCHEM BIOPHYS, V384, P280, DOI 10.1006/abbi.2000.2117; Ferguson SS, 2002, MOL PHARMACOL, V62, P737, DOI 10.1124/mol.62.3.737; Fraser DJ, 2002, J BIOL CHEM, V277, P34717, DOI 10.1074/jbc.M204699200; Gerbal-Chaloin S, 2002, J BIOL CHEM, V277, P209, DOI 10.1074/jbc.M107228200; Goodwin B, 2002, ANNU REV PHARMACOL, V42, P1, DOI 10.1146/annurev.pharmtox.42.111901.111051; GRANICK S, 1975, J BIOL CHEM, V250, P9215; Gronemeyer H, 1995, PROTEIN PROFILE, V2, P1173; Handschin C, 2000, J BIOL CHEM, V275, P13362, DOI 10.1074/jbc.275.18.13362; Handschin C, 2000, P NATL ACAD SCI USA, V97, P10769, DOI 10.1073/pnas.97.20.10769; Honkakoski P, 1998, MOL CELL BIOL, V18, P5652, DOI 10.1128/MCB.18.10.5652; IniguezLluhi JA, 1997, J BIOL CHEM, V272, P4149, DOI 10.1074/jbc.272.7.4149; Jones SA, 2002, METHOD ENZYMOL, V357, P161; Jover R, 1996, BIOCHEM BIOPH RES CO, V226, P152, DOI 10.1006/bbrc.1996.1325; Kakizaki S, 2003, BBA-GEN SUBJECTS, V1619, P239, DOI 10.1016/S0304-4165(02)00482-8; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; LATHROP JT, 1993, SCIENCE, V259, P522, DOI 10.1126/science.8424176; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; Lindberg RLP, 1996, NAT GENET, V12, P195, DOI 10.1038/ng0296-195; Maglich JM, 2002, MOL PHARMACOL, V62, P638, DOI 10.1124/mol.62.3.638; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MAY BK, 1995, PROG NUCLEIC ACID RE, V51, P1, DOI 10.1016/S0079-6603(08)60875-2; Paquet Y, 2000, J BIOL CHEM, V275, P38427, DOI 10.1074/jbc.M005776200; Podvinec M, 2002, MOL ENDOCRINOL, V16, P1269, DOI 10.1210/me.16.6.1269; Sassa S, 2002, PHOTODERMATOL PHOTO, V18, P56, DOI 10.1034/j.1600-0781.2002.180202.x; Staudinger JL, 2001, P NATL ACAD SCI USA, V98, P3369, DOI 10.1073/pnas.051551698; Steinmetz ACU, 2001, ANNU REV BIOPH BIOM, V30, P329, DOI 10.1146/annurev.biophys.30.1.329; Sueyoshi T, 2001, ANNU REV PHARMACOL, V41, P123, DOI 10.1146/annurev.pharmtox.41.1.123; Ueda A, 2002, MOL PHARMACOL, V61, P1, DOI 10.1124/mol.61.1.1; WANG H, 2003, J BIOL CHEM, V5, P5; Wei P, 2000, NATURE, V407, P920, DOI 10.1038/35038112; Willson TM, 2002, NAT REV DRUG DISCOV, V1, P259, DOI 10.1038/nrd753	37	54	54	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39392	39401		10.1074/jbc.M306148200	http://dx.doi.org/10.1074/jbc.M306148200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881517	hybrid			2022-12-27	WOS:000185713800016
J	Torres, AM; Wong, HY; Desai, M; Moochhala, S; Kuchel, PW; Kini, RM				Torres, AM; Wong, HY; Desai, M; Moochhala, S; Kuchel, PW; Kini, RM			Identification of a novel family of proteins in snake venoms - Purification and structural characterization of nawaprin from Naja nigricollis snake venom	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHEY ACIDIC PROTEIN; TRANSGLUTAMINASE SUBSTRATE DOMAIN; ELASTASE-SPECIFIC INHIBITOR; ACCELERATED EVOLUTION; CRYSTAL-STRUCTURE; GENE FAMILY; SEQUENCE; ELAFIN; EPIDIDYMIS; SPECTROSCOPY	The three-dimensional structure of nawaprin has been determined by nuclear magnetic resonance spectroscopy. This 51-amino acid residue peptide was isolated from the venom of the spitting cobra, Naja nigricollis, and is the first member of a new family of snake venom proteins referred to as waprins. Nawaprin is relatively flat and disc-like in shape, characterized by a spiral backbone configuration that forms outer and inner circular segments. The two circular segments are held together by four disulfide bonds, three of which are clustered at the base of the molecule. The inner segment contains a short antiparallel beta-sheet, whereas the outer segment is devoid of secondary structures except for a small turn or 3(10) helix. The structure of nawaprin is very similar to elafin, a human leukocyte elastase-specific inhibitor. Although substantial parts of the nawaprin molecule are well defined, the tips of the outer and inner circular segments, which are hypothesized to be critical for binding interactions, are apparently disordered, similar to that found in elafin. The amino acid residues in these important regions in nawaprin are different from those in elafin, suggesting that nawaprin is not an elastase-specific inhibitor and therefore has a different function in the snake venom.	Natl Univ Singapore, Fac Sci, Dept Biol Sci, Singapore 117543, Singapore; Natl Univ Singapore, Fac Sci, Dept Pharm, Singapore 119260, Singapore; Univ Sydney, Sch Mol & Microbial Biosci, Sydney, NSW 2006, Australia; Def Sci & Technol Agcy, Def Med Res Inst, Singapore 117597, Singapore	National University of Singapore; National University of Singapore; University of Sydney; Agency for Science Technology & Research (A*STAR)	Kini, RM (corresponding author), Natl Univ Singapore, Fac Sci, Dept Biol Sci, 14 Sci Dr 4, Singapore 117543, Singapore.	dbskinim@nus.edu.sg	Torres, Allan/GSN-4624-2022; Kini, Manjunatha/H-8029-2012	Kini, Manjunatha/0000-0002-6100-3251; MOOCHHALA, SHABBIR/0000-0003-4521-3192; Kuchel, Philip/0000-0003-4100-7332				ARAKI K, 1989, BIOCHEM BIOPH RES CO, V164, P496, DOI 10.1016/0006-291X(89)91747-6; ARAKI K, 1990, BIOCHEM BIOPH RES CO, V172, P42, DOI 10.1016/S0006-291X(05)80170-6; BAILEY GS, 1998, ENZYMES SNAKE VENOM; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BEG OU, 1986, EUR J BIOCHEM, V159, P195, DOI 10.1111/j.1432-1033.1986.tb09852.x; BRAGANCA BM, 1967, NATURE, V216, P1210, DOI 10.1038/2161210a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CAMPBELL SM, 1984, NUCLEIC ACIDS RES, V12, P8685, DOI 10.1093/nar/12.22.8685; Clauss A, 2002, BIOCHEM J, V368, P233, DOI 10.1042/BJ20020869; CORONEL CE, 1990, J BIOL CHEM, V265, P6854; DEROME AE, 1990, J MAGN RESON, V88, P177, DOI 10.1016/0022-2364(90)90123-Q; EISENBERG SP, 1988, BIOL CHEM H-S      S, V369, P79; ELLERBROCK K, 1994, INT J ANDROL, V17, P314, DOI 10.1111/j.1365-2605.1994.tb01262.x; Fan HY, 1999, ARCH ANDROLOGY, V42, P63, DOI 10.1080/014850199262896; Francart C, 1997, J MOL BIOL, V268, P666, DOI 10.1006/jmbi.1997.0983; Furukawa M, 1996, J BIOL CHEM, V271, P29517, DOI 10.1074/jbc.271.47.29517; Furutani Y, 1998, J BIOCHEM-TOKYO, V124, P491, DOI 10.1093/oxfordjournals.jbchem.a022140; GRUTTER MG, 1988, EMBO J, V7, P345, DOI 10.1002/j.1460-2075.1988.tb02819.x; Hagiwara K, 2003, J IMMUNOL, V170, P1973, DOI 10.4049/jimmunol.170.4.1973; HENNIGHAUSEN LG, 1982, NUCLEIC ACIDS RES, V10, P2677, DOI 10.1093/nar/10.8.2677; HILL RE, 1987, NATURE, V326, P96, DOI 10.1038/326096a0; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; INGLIS AS, 1983, METHOD ENZYMOL, V91, P324; Joseph JS, 1999, BLOOD, V94, P621, DOI 10.1182/blood.V94.2.621.414k25_621_631; Kini R.M., 1997, VENOM PHOSPHOLIPASE; Kini RM, 2002, CLIN EXP PHARMACOL P, V29, P815, DOI 10.1046/j.1440-1681.2002.03725.x; KIRCHHOFF C, 1991, BIOL REPROD, V45, P350, DOI 10.1095/biolreprod45.2.350; KIRCHLOFF C, 1990, INT J ANDROL, V13, P155, DOI 10.1111/j.1365-2605.1990.tb00972.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KOZAKI T, 1994, PEPT CHEM, P405; KUMAR A, 1980, BIOCHEM BIOPH RES CO, V95, P1, DOI 10.1016/0006-291X(80)90695-6; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; McLane MA, 1998, P SOC EXP BIOL MED, V219, P109, DOI 10.3181/00379727-219-44322; Mebs D., 1991, SNAKE TOXINS, P425; NAKASHIMA K, 1993, P NATL ACAD SCI USA, V90, P5964, DOI 10.1073/pnas.90.13.5964; NARA K, 1994, J BIOCHEM, V115, P441, DOI 10.1093/oxfordjournals.jbchem.a124357; OGAWA T, 1992, P NATL ACAD SCI USA, V89, P8557, DOI 10.1073/pnas.89.18.8557; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; RANCE M, 1983, BIOCHEM BIOPH RES CO, V117, P479, DOI 10.1016/0006-291X(83)91225-1; RENFREE MB, 1981, BIOL NEONATE, V40, P29, DOI 10.1159/000241469; Schalkwijk J, 1999, BIOCHEM J, V340, P569, DOI 10.1042/0264-6021:3400569; SCHALKWIJK J, 1990, BRIT J DERMATOL, V122, P631, DOI 10.1111/j.1365-2133.1990.tb07285.x; Si-Tahar M, 2000, GASTROENTEROLOGY, V118, P1061, DOI 10.1016/S0016-5085(00)70359-3; Simpson KJ, 2000, J BIOL CHEM, V275, P23074, DOI 10.1074/jbc.M002161200; STETLER G, 1986, NUCLEIC ACIDS RES, V14, P7883, DOI 10.1093/nar/14.20.7883; TAKASAKI C, 1990, TOXICON, V28, P319, DOI 10.1016/0041-0101(90)90067-H; Tamechika I, 1996, J BIOL CHEM, V271, P7012, DOI 10.1074/jbc.271.12.7012; Tomee JFC, 1998, THORAX, V53, P114, DOI 10.1136/thx.53.2.114; Tsunemi M, 1996, BIOCHEMISTRY-US, V35, P11570, DOI 10.1021/bi960900l; TU AT, 1991, REPTILE VENOMS TOXIN; WIEDOW O, 1990, J BIOL CHEM, V265, P14791; Wuthrich K, 1986, NMR PROTEINS NUCL AC, P117; Yamazaki Y, 2003, ARCH BIOCHEM BIOPHYS, V412, P133, DOI 10.1016/S0003-9861(03)00028-6; Zeeuwen PLJM, 1997, J BIOL CHEM, V272, P20471, DOI 10.1074/jbc.272.33.20471; Zhu J, 2002, CELL, V111, P867, DOI 10.1016/S0092-8674(02)01141-8; [No title captured]	57	49	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40097	40104		10.1074/jbc.M305322200	http://dx.doi.org/10.1074/jbc.M305322200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878611	hybrid			2022-12-27	WOS:000185713800101
J	Giese, B; Au-Yeung, CK; Herrmann, A; Diefenbach, S; Haan, C; Kuster, A; Wortmann, SB; Roderburg, C; Heinrich, PC; Behrmann, I; Muller-Newen, G				Giese, B; Au-Yeung, CK; Herrmann, A; Diefenbach, S; Haan, C; Kuster, A; Wortmann, SB; Roderburg, C; Heinrich, PC; Behrmann, I; Muller-Newen, G			Long term association of the cytokine receptor gp130 and the janus kinase Jak1 revealed by FRAP analysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCER GP130; FLUORESCENCE PHOTOBLEACHING RECOVERY; CELL-SURFACE EXPRESSION; MONOCLONAL-ANTIBODIES; HUMAN-ERYTHROCYTES; TYROSINE KINASES; PROTEIN-KINASE; FERM DOMAIN; INTERLEUKIN-6; REGION	Signal transduction through cytokine receptors is mediated mainly by non-covalently associated Jak tyrosine kinases. By confocal microscopy, the cytokine receptor gp130 and Jak1, fused with either yellow (YFP) or cyan (CFP) fluorescent protein, were found to be colocalized predominantly at intracellular vesicular structures and at the plasma membrane. Quantitative fluorescence recovery after photobleaching (FRAP) analysis at the plasma membrane revealed equal mobilities for gp130-YFP and Jak1-YFP. Thus, Jak1-YFP diffuses like a transmembrane protein indicating that membrane-bound Jak1 does not exchange rapidly with cytosolic Jaks. Applying a novel dual-color FRAP approach we found that immobilization of gp130-CFP by a pair of monoclonal antibodies led to a corresponding immobilization of co-transfected Jak1-YFP. We conclude from these findings that Jak1, once bound to a gp130 molecule, does not exchange between different receptors at the plasma membrane neither via the cytoplasmic compartment nor via a membrane-associated state.	Univ Klinikum RWTH Aachen, Inst Biochem, D-52057 Aachen, Germany	RWTH Aachen University; RWTH Aachen University Hospital	Muller-Newen, G (corresponding author), Univ Klinikum RWTH Aachen, Inst Biochem, Pauwelsstr 30, D-52057 Aachen, Germany.		Wortmann, Saskia/E-6125-2010; Roderburg, Christoph/AAR-3051-2021; Roderburg, Christoph/AHC-8101-2022	Roderburg, Christoph/0000-0002-1409-7697; Behrmann, Iris/0000-0003-3688-3645				AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Barret C, 2000, J CELL BIOL, V151, P1067, DOI 10.1083/jcb.151.5.1067; Bravo J, 2000, EMBO J, V19, P2399, DOI 10.1093/emboj/19.11.2399; Briscoe J, 1996, EMBO J, V15, P799, DOI 10.1002/j.1460-2075.1996.tb00415.x; Dittrich E, 1996, J BIOL CHEM, V271, P5487, DOI 10.1074/jbc.271.10.5487; Gauzzi MC, 1997, P NATL ACAD SCI USA, V94, P11839, DOI 10.1073/pnas.94.22.11839; Girault JA, 1998, MOL MED, V4, P751, DOI 10.1007/BF03401769; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; Haan C, 2000, BIOCHEM J, V349, P261, DOI 10.1042/0264-6021:3490261; Haan C, 2002, BIOCHEM J, V361, P105, DOI 10.1042/0264-6021:3610105; Haan C, 2001, J BIOL CHEM, V276, P37451, DOI 10.1074/jbc.M106135200; Hamada K, 2000, EMBO J, V19, P4449, DOI 10.1093/emboj/19.17.4449; Han BG, 2000, NAT STRUCT BIOL, V7, P871; Heinrich PC, 1998, BIOCHEM J, V334, P297, DOI 10.1042/bj3340297; Huang LJS, 2001, MOL CELL, V8, P1327, DOI 10.1016/S1097-2765(01)00401-4; JACOBSON K, 1995, SCIENCE, V268, P1441, DOI 10.1126/science.7770769; KATZIR Z, 1989, BIOCHEMISTRY-US, V28, P6400, DOI 10.1021/bi00441a036; Klonis N, 2002, EUR BIOPHYS J BIOPHY, V31, P36, DOI 10.1007/s00249-001-0202-2; KNOWLES DW, 1994, BIOPHYS J, V66, P1726, DOI 10.1016/S0006-3495(94)80965-8; Lillemeier BF, 2001, EMBO J, V20, P2508, DOI 10.1093/emboj/20.10.2508; Lippincott-Schwartz J, 2001, NAT REV MOL CELL BIO, V2, P444, DOI 10.1038/35073068; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; Muller-Newen G, 2000, J BIOL CHEM, V275, P4579, DOI 10.1074/jbc.275.7.4579; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; O'Shea JJ, 2002, CELL, V109, pS121, DOI 10.1016/S0092-8674(02)00701-8; Pearson MA, 2000, CELL, V101, P259, DOI 10.1016/S0092-8674(00)80836-3; Pellegrini S, 1997, EUR J BIOCHEM, V248, P615, DOI 10.1111/j.1432-1033.1997.00615.x; QUELLE FW, 1994, MOL CELL BIOL, V14, P4335, DOI 10.1128/MCB.14.7.4335; Radtke S, 2002, J BIOL CHEM, V277, P11297, DOI 10.1074/jbc.M100822200; Ragimbeau J, 2003, EMBO J, V22, P537, DOI 10.1093/emboj/cdg038; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmitz J, 2000, J IMMUNOL, V164, P848, DOI 10.4049/jimmunol.164.2.848; Senaldi G, 1999, P NATL ACAD SCI USA, V96, P11458, DOI 10.1073/pnas.96.20.11458; Siewert E, 1999, EUR J BIOCHEM, V265, P251, DOI 10.1046/j.1432-1327.1999.00719.x; Sloan-Lancaster J, 1998, J CELL BIOL, V143, P613, DOI 10.1083/jcb.143.3.613; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; TANNER JW, 1995, J BIOL CHEM, V270, P6523, DOI 10.1074/jbc.270.12.6523; Teruel MN, 2000, CELL, V103, P181, DOI 10.1016/S0092-8674(00)00109-4; Wells JA, 1996, ANNU REV BIOCHEM, V65, P609, DOI 10.1146/annurev.bi.65.070196.003141; Wijdenes J, 1995, EUR J IMMUNOL, V25, P3474, DOI 10.1002/eji.1830251240; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057	41	45	45	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39205	39213		10.1074/jbc.M303347200	http://dx.doi.org/10.1074/jbc.M303347200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878601	hybrid			2022-12-27	WOS:000185575100135
J	Gobeil, F; Bernier, SG; Vazquez-Tello, A; Brault, S; Beauchamp, MH; Quiniou, C; Marrache, AM; Checchin, D; Sennlaub, F; Hou, X; Nader, M; Bkaily, G; Ribeiro-da-Silva, A; Goetzl, EJ; Chemtob, S				Gobeil, F; Bernier, SG; Vazquez-Tello, A; Brault, S; Beauchamp, MH; Quiniou, C; Marrache, AM; Checchin, D; Sennlaub, F; Hou, X; Nader, M; Bkaily, G; Ribeiro-da-Silva, A; Goetzl, EJ; Chemtob, S			Modulation of pro-inflammatory gene expression by nuclear lysophosphatidic acid receptor type-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; NITRIC-OXIDE SYNTHASE; GROWTH-FACTOR RECEPTOR; SMOOTH-MUSCLE-CELLS; SPHINGOSINE 1-PHOSPHATE; PHOSPHOLIPASE A(2); CEREBRAL-CORTEX; RAT-LIVER; ENDOTHELIAL-CELLS; HYDROGEN-PEROXIDE	Lysophosphatidic acid (LPA) is a bioactive molecule involved in inflammation, immunity, wound healing, and neoplasia. Its pleiotropic actions arise presumably by interaction with their cell surface G protein-coupled receptors. Herein, the presence of the specific nuclear lysophosphatidic acid receptor-1 (LPA(1)R) was revealed in unstimulated porcine cerebral microvascular endothelial cells (pCMVECs), LPA(1)R stably transfected HTC4 rat hepatoma cells, and rat liver tissue using complementary approaches, including radioligand binding experiments, electron- and cryomicroscopy, cell fractionation, and immunoblotting with three distinct antibodies. Co-immunoprecipitation studies in enriched plasmalemmal fractions of unstimulated pCMVEC showed that LPA(1)Rs are dually sequestrated in caveolin-1 and clathrin sub-compartments, whereas in nuclear fractions LPA1R appeared primarily in caveolae. Immunofluorescent assays using a cell-free isolated nuclear system confirmed LPA1R and caveolin-1 co-localization. In pCMVEC, LPA-stimulated increases in cyclooxygenase-2 and inducible nitric-oxide synthase RNA and protein expression were insensitive to caveolea-disrupting agents but sensitive to LPA-generating phospholipase A(2) enzyme and tyrosine kinase inhibitors. Moreover, LPA-induced increases in Ca2+ transients and/or iNOS expression in highly purified rat liver nuclei were prevented by pertussis toxin, phosphoinositide 3-kinase/Akt inhibitor wortmannin and Ca2+ chelator and channel blockers EGTA and SK&F96365, respectively. This study describes for the first time the nucleus as a potential organelle for LPA intracrine signaling in the regulation of pro-inflammatory gene expression.	Univ Sherbrooke, Dept Anat & Cell Biol, Sherbrooke, PQ J1H 5N4, Canada; Hop St Justine, Ctr Rech, Dept Pediat, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Ctr Rech, Dept Ophthalmol, Montreal, PQ H3T 1C5, Canada; Hop St Justine, Ctr Rech, Dept Pharmacol, Montreal, PQ H3T 1C5, Canada; McGill Univ, Dept Pharmacol & Therapeut, Montreal, PQ H3G 1Y6, Canada; Univ Calif San Francisco, Dept Med Microbiol Immunol, San Francisco, CA 94143 USA	University of Sherbrooke; Universite de Montreal; Universite de Montreal; Universite de Montreal; McGill University; University of California System; University of California San Francisco	Gobeil, F (corresponding author), Univ Sherbrooke, Dept Pharmacol, 3001,12th North Ave, Sherbrooke, PQ J1H 5N4, Canada.	Fernand.Gobeil@USherbrooke.ca	Ribeiro-da-Silva, Alfredo/K-4783-2012; Sennlaub, Florian/F-2756-2017	Ribeiro-da-Silva, Alfredo/0000-0002-4125-0255; Sennlaub, Florian/0000-0003-4412-1341; Nader, Moni/0000-0003-2138-5213	NHLBI NIH HHS [HL-31809] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL031809] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Allard J, 1998, EUR J NEUROSCI, V10, P1045, DOI 10.1046/j.1460-9568.1998.00117.x; An SZ, 1998, MOL PHARMACOL, V54, P881, DOI 10.1124/mol.54.5.881; An SZ, 1997, BIOCHEM BIOPH RES CO, V231, P619, DOI 10.1006/bbrc.1997.6150; Baker RR, 1999, BBA-MOL CELL BIOL L, V1438, P253, DOI 10.1016/S1388-1981(99)00057-8; Baker RR, 2000, BBA-MOL CELL BIOL L, V1483, P58, DOI 10.1016/S1388-1981(99)00185-7; Banning AP, 1999, ATHEROSCLEROSIS, V145, P17, DOI 10.1016/S0021-9150(99)00010-6; Bkaily G, 1997, MOL CELL BIOCHEM, V172, P171, DOI 10.1023/A:1006840228104; BOYER CS, 1995, BIOCHEM PHARMACOL, V50, P753, DOI 10.1016/0006-2952(95)00195-6; Bratt T, 2000, BBA-PROTEIN STRUCT M, V1482, P318, DOI 10.1016/S0167-4838(00)00154-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Chun J, 2002, PHARMACOL REV, V54, P265, DOI 10.1124/pr.54.2.265; Cussac D, 2002, J BIOL CHEM, V277, P19882, DOI 10.1074/jbc.M110142200; D'Santos CS, 1998, BBA-MOL CELL BIOL L, V1436, P201, DOI 10.1016/S0005-2760(98)00146-5; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; Dumont I, 1999, J PHARMACOL EXP THER, V291, P627; Fayard JM, 1998, J CELL SCI, V111, P985; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Fukushima N, 2001, ANNU REV PHARMACOL, V41, P507, DOI 10.1146/annurev.pharmtox.41.1.507; Fukushima N, 1998, P NATL ACAD SCI USA, V95, P6151, DOI 10.1073/pnas.95.11.6151; Gaits F, 1997, FEBS LETT, V410, P54, DOI 10.1016/S0014-5793(97)00411-0; Gobeil F, 2003, CAN J PHYSIOL PHARM, V81, P196, DOI 10.1139/Y02-163; Gobeil F, 2002, CIRC RES, V90, P682, DOI 10.1161/01.RES.0000013303.17964.7A; Goetzl EJ, 1998, FASEB J, V12, P1589, DOI 10.1096/fasebj.12.15.1589; Goetzl EJ, 2000, J IMMUNOL, V164, P4996, DOI 10.4049/jimmunol.164.10.4996; Goetzl EJ, 1999, CANCER RES, V59, P4732; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hahn A, 2002, BIOCHEM J, V362, P33, DOI 10.1042/0264-6021:3620033; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; Herrlich A, 1998, P NATL ACAD SCI USA, V95, P8985, DOI 10.1073/pnas.95.15.8985; Ikeda H, 1998, BIOCHEM BIOPH RES CO, V248, P436, DOI 10.1006/bbrc.1998.8983; Im DS, 1997, AM J PHYSIOL-GASTR L, V272, pG1091, DOI 10.1152/ajpgi.1997.272.5.G1091; Isenovic E, 2000, HYPERTENSION, V35, P249, DOI 10.1161/01.HYP.35.1.249; KAUFMANN SH, 1983, J BIOL CHEM, V258, P2710; Kim YJ, 2002, J BIOL CHEM, V277, P9358, DOI 10.1074/jbc.M110987200; Kohno T, 2002, FASEB J, V16, P983, DOI 10.1096/fj.01-0809com; Le PU, 2002, J BIOL CHEM, V277, P3371, DOI 10.1074/jbc.M111240200; Lee H, 2000, AM J PHYSIOL-CELL PH, V278, pC612, DOI 10.1152/ajpcell.2000.278.3.C612; Massfelder T, 1997, P NATL ACAD SCI USA, V94, P13630, DOI 10.1073/pnas.94.25.13630; Miralles C, 2000, FEBS LETT, V476, P253, DOI 10.1016/S0014-5793(00)01748-8; Moolenaar WH, 1999, EXP CELL RES, V253, P230, DOI 10.1006/excr.1999.4702; Nanji AA, 1997, J PHARMACOL EXP THER, V282, P1037; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; NICOTERA P, 1989, P NATL ACAD SCI USA, V86, P453, DOI 10.1073/pnas.86.2.453; Okamoto Y, 2000, J BIOL CHEM, V275, P6439, DOI 10.1074/jbc.275.9.6439; Pages C, 2001, PROSTAG OTH LIPID M, V64, P1, DOI 10.1016/S0090-6980(01)00110-1; Pierce KL, 2001, ONCOGENE, V20, P1532, DOI 10.1038/sj.onc.1204184; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Razani B, 2002, PHARMACOL REV, V54, P431, DOI 10.1124/pr.54.3.431; Re R, 1999, HYPERTENSION, V34, P534, DOI 10.1161/01.HYP.34.4.534; Reiser COA, 1998, BIOCHEM J, V330, P1107; RIBEIRODASILVA A, 1993, IMMUNOHISTOCHEMISTRY, V2, P182; Sadir R, 2001, CYTOKINE, V14, P19, DOI 10.1006/cyto.2000.0854; Sarret P, 1999, J BIOL CHEM, V274, P19294, DOI 10.1074/jbc.274.27.19294; Sautin YY, 2001, AM J PHYSIOL-CELL PH, V281, pC2010, DOI 10.1152/ajpcell.00077.2001; Schwencke C, 1999, J CELL BIOCHEM, V75, P64, DOI 10.1002/(SICI)1097-4644(19991001)75:1<64::AID-JCB7>3.0.CO;2-L; Shin I, 1999, MOL CELLS, V9, P292; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; Subramaniam PS, 2002, J IMMUNOL, V169, P1959, DOI 10.4049/jimmunol.169.4.1959; Tabuchi S, 2000, NEUROCHEM RES, V25, P573, DOI 10.1023/A:1007542532395; THOMSON FJ, 1994, MOL PHARMACOL, V45, P718; Tigyi G, 2001, PROSTAG OTH LIPID M, V64, P47, DOI 10.1016/S0090-6980(01)00107-1; Tiruppathi C, 1996, P NATL ACAD SCI USA, V93, P250, DOI 10.1073/pnas.93.1.250; Van Brocklyn JR, 1998, J CELL BIOL, V142, P229, DOI 10.1083/jcb.142.1.229; Voisin L, 2002, AM J PHYSIOL-CELL PH, V283, pC446, DOI 10.1152/ajpcell.00261.2001; Wheatley M, 1999, HUM REPROD UPDATE, V5, P356, DOI 10.1093/humupd/5.4.356; Zheng YH, 2001, J IMMUNOL, V166, P2317, DOI 10.4049/jimmunol.166.4.2317	67	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38875	38883		10.1074/jbc.M212481200	http://dx.doi.org/10.1074/jbc.M212481200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847111	hybrid			2022-12-27	WOS:000185575100096
J	Kelm, RJ; Wang, SX; Polikandriotis, JA; Strauch, AR				Kelm, RJ; Wang, SX; Polikandriotis, JA; Strauch, AR			Structure/function analysis of mouse Pur beta, a single-stranded DNA-binding repressor of vascular smooth muscle alpha-actin gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERUM RESPONSE FACTOR; MYOFIBROBLAST DIFFERENTIATION; TRANSGENIC MICE; MCAT ENHANCER; CARG ELEMENTS; NIH3T3 CELLS; IN-VITRO; PROMOTER; PROTEIN; EXPRESSION	Plasticity of smooth muscle alpha-actin gene expression in fibroblasts and vascular smooth muscle cells is mediated by opposing effects of transcriptional activators and repressors. Among these factors, three single-stranded DNA-binding proteins, Puralpha, Purbeta, and MSY1, have been implicated as coregulators of a cryptic 5'-enhancer module. In this study, a molecular analysis of Purbeta, the least well characterized member of this group, was conducted. Southwestern and Northwestern blotting of purified Purbeta deletion mutants using smooth muscle alpha-actin-derived probes mapped the minimal single-stranded DNA/RNA-binding domain to a conserved region spanning amino acids 37-263. Quantitative binding assays indicated that the relative affinity and specificity of Purbeta for single-stranded DNA were influenced by purine/pyrimidine content; by non-conserved regions outside amino acids 37-263; and by cell-derived proteins, specifically MSY1. When overexpressed in A7r5 vascular smooth muscle cells, Purbeta (but not Puralpha) inhibited transcription of a smooth muscle-specific mouse alpha-actin promoter transgene. Structural domains required for Purbeta repressor activity included the minimal DNA-binding region and a C-terminal domain required for stabilizing high affinity protein and nucleic acid interactions. Purbeta inhibitory activity in transfected A7r5 cells was potentiated by MSY1, but antagonized by serum response factor, reinforcing the idea that interplay among activators and repressors may account for phenotypic changes in smooth muscle alpha-actin-expressing cell types.	Univ Vermont, Dept Med, Colchester Res Facil, Coll Med, Colchester 05446, Essex, England; Ohio State Univ, Coll Med & Publ Hlth, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA	University System of Ohio; Ohio State University	Kelm, RJ (corresponding author), Univ Vermont, Dept Med, Colchester Res Facil, Coll Med, 208 S Pk Dr, Colchester 05446, Essex, England.	robert.kelm@uvm.edu			NHLBI NIH HHS [HL54281, HL60876] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054281, R01HL060876] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barr SM, 2001, J CELL BIOCHEM, V81, P621, DOI 10.1002/jcb.1099; Becker NA, 2000, J BIOL CHEM, V275, P15384, DOI 10.1074/jbc.M909687199; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P5673, DOI 10.1128/MCB.12.12.5673; Carlini LE, 2002, J BIOL CHEM, V277, P8682, DOI 10.1074/jbc.M109754200; Chen JY, 2002, J MOL CELL CARDIOL, V34, P1345, DOI 10.1006/jmcc.2002.2086; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; Cogan JG, 2002, J BIOL CHEM, V277, P36433, DOI 10.1074/jbc.M203232200; COGAN JG, 1995, J BIOL CHEM, V270, P11310, DOI 10.1074/jbc.270.19.11310; Darbinian N, 1999, ONCOGENE, V18, P6398, DOI 10.1038/sj.onc.1203011; Darbinian N, 2001, J NEUROIMMUNOL, V121, P3, DOI 10.1016/S0165-5728(01)00372-1; Darbinian N, 2001, J CELL BIOCHEM, V80, P589, DOI 10.1002/1097-4644(20010315)80:4<589::AID-JCB1013>3.0.CO;2-0; Darbinian N, 2001, J CELL PHYSIOL, V189, P334, DOI 10.1002/jcp.10029; Ding Y, 1997, NEUROCHEM INT, V31, P45, DOI 10.1016/S0197-0186(96)00127-1; Du KL, 2003, MOL CELL BIOL, V23, P2425, DOI 10.1128/MCB.23.7.2425-2437.2003; Feugate JE, 2002, J CELL BIOL, V156, P161, DOI 10.1083/jcb.200103062; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; FOSTER DN, 1992, J BIOL CHEM, V267, P11995; Gallia GL, 1999, J CELL BIOCHEM, V74, P334, DOI 10.1002/(SICI)1097-4644(19990901)74:3<334::AID-JCB3>3.0.CO;2-O; Gallia GL, 2000, NUCLEIC ACIDS RES, V28, P3197, DOI 10.1093/nar/28.17.3197; Herring BP, 2001, J BIOL CHEM, V276, P14482, DOI 10.1074/jbc.M011585200; Hinz B, 2002, J CELL BIOL, V157, P657, DOI 10.1083/jcb.200201049; Itoh H, 1998, CELL GROWTH DIFFER, V9, P651; JOHNSON EM, 1995, J BIOL CHEM, V270, P24352, DOI 10.1074/jbc.270.41.24352; Kelm RJ, 1999, J BIOL CHEM, V274, P14238, DOI 10.1074/jbc.274.20.14238; Kelm RJ, 1999, J BIOL CHEM, V274, P38268, DOI 10.1074/jbc.274.53.38268; Kelm RJ, 1996, J BIOL CHEM, V271, P24278, DOI 10.1074/jbc.271.39.24278; Kelm RJ, 1997, J BIOL CHEM, V272, P26727, DOI 10.1074/jbc.272.42.26727; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; Lasham A, 2000, GENE, V252, P1, DOI 10.1016/S0378-1119(00)00220-1; Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353; Liu H, 2002, NUCLEIC ACIDS RES, V30, P2417, DOI 10.1093/nar/30.11.2417; MACDONALD GH, 1995, J BIOL CHEM, V270, P3527, DOI 10.1074/jbc.270.8.3527; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; Majesky MW, 2003, CIRC RES, V92, P824, DOI 10.1161/01.RES.0000071525.18323.4C; Manabe I, 2001, CIRC RES, V88, P1127, DOI 10.1161/hh1101.091339; MIN BH, 1990, J BIOL CHEM, V265, P16667; Muralidharan V, 1997, J CELL BIOCHEM, V66, P524, DOI 10.1002/(SICI)1097-4644(19970915)66:4<524::AID-JCB11>3.0.CO;2-B; Nakamura M, 2001, J BIOL CHEM, V276, P18313, DOI 10.1074/jbc.M101127200; Nishida W, 2002, J BIOL CHEM, V277, P7308, DOI 10.1074/jbc.M111824200; Ogut O, 2003, J MOL CELL CARDIOL, V35, P347, DOI 10.1016/S0022-2828(03)00045-2; Phiel CJ, 2001, J BIOL CHEM, V276, P34637, DOI 10.1074/jbc.M105826200; Regan CP, 2000, J CLIN INVEST, V106, P1139, DOI 10.1172/JCI10522; RonnovJessen L, 1996, J CELL BIOL, V134, P67, DOI 10.1083/jcb.134.1.67; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Safak R, 1999, MOL CELL BIOL, V19, P2712; Sartore S, 2001, CIRC RES, V89, P1111, DOI 10.1161/hh2401.100844; Shelley CS, 2002, J IMMUNOL, V168, P3887, DOI 10.4049/jimmunol.168.8.3887; Shelley CS, 2001, BRIT J HAEMATOL, V115, P159, DOI 10.1046/j.1365-2141.2001.03066.x; Stacey DW, 1999, ONCOGENE, V18, P4254, DOI 10.1038/sj.onc.1202795; STOFLET ES, 1992, MOL BIOL CELL, V3, P1073, DOI 10.1091/mbc.3.10.1073; STRAUCH AR, 1999, EXPERT OPIN THER TAR, V3, P279; Subramanian SV, 2002, CARDIOVASC RES, V54, P539, DOI 10.1016/S0008-6363(02)00270-5; SUN SQ, 1995, MOL CELL BIOL, V15, P2429; Tretiakova A, 1999, J CELL PHYSIOL, V181, P160, DOI 10.1002/(SICI)1097-4652(199910)181:1<160::AID-JCP17>3.0.CO;2-H; Tretiakova A, 1998, J BIOL CHEM, V273, P22241, DOI 10.1074/jbc.273.35.22241; TRINKLE LA, 1992, AM J PHYSIOL, V262, pC828, DOI 10.1152/ajpcell.1992.262.4.C828; Wang JW, 1997, J CLIN INVEST, V100, P1425, DOI 10.1172/JCI119663; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhang MY, 2002, J BIOL CHEM, V277, P21285, DOI 10.1074/jbc.M112082200	61	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38749	38757		10.1074/jbc.M306163200	http://dx.doi.org/10.1074/jbc.M306163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874279	hybrid			2022-12-27	WOS:000185575100081
J	Ragona, L; Fogolari, F; Catalano, M; Ugolini, R; Zetta, L; Molinari, H				Ragona, L; Fogolari, F; Catalano, M; Ugolini, R; Zetta, L; Molinari, H			EF loop conformational change triggers ligand binding in beta-lactoglobulins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; ELECTROSTATIC PROPERTIES; RUMINANT; LIPASE; LIPOCALIN; STABILITY; ALBUMIN; PROTEIN; TOOL	beta-Lactoglobulins, belonging to the lipocalin family, are a widely studied group of proteins, characterized by the ability to solubilize and transport hydrophobic ligands, especially fatty acids. Despite many reports, the mechanism of ligand binding and the functional role of these proteins is still unclear, and many contradicting concepts are often encountered in the literature. In the present paper the comparative analysis of the binding properties of beta-lactoglobulins has been performed using sequence-derived information, structure-based electrostatic calculations, docking simulations, and NMR experiments. Our results reveal for the first time the mechanism of beta-lactoglobulin ligand binding, which is completely determined by the opening-closing of EF loop, triggered by Glu(89) protonation. The alkaline shift observed for Glu(89) pK(alpha) in porcine beta-lactoglobulin (pK(alpha) 9.7) with respect to the bovine species (pK(a) 5.5) depends upon the interplay of electrostatic effects of few nearby key residues. Porcine protein is therefore able to bind fatty acids provided that the appropriate pH solution conditions are met (pH > 8.6), where the EF loop conformational change can take place. The unusually high pH of binding detected for porcine beta-lactoglobulin seems to be functional to lipases activity. Theoretical pK(alpha) calculations extended to representative beta-lactoglobulins allowed the identification of key residues involved in structurally and functionally important electrostatic interactions. The results presented here provide a strong indication that the described conformational change is a common feature of all beta-lactoglobulins.	Dipartimento Sci & Tecnol, I-37134 Verona, Italy; CNR, Ist Macromol, Lab Risonanza Magnet Nucl, I-20133 Milan, Italy	Consiglio Nazionale delle Ricerche (CNR)	Molinari, H (corresponding author), Dipartimento Sci & Tecnol, Strada Le Grazie 15, I-37134 Verona, Italy.	molinari@sci.univr.it	Molinari, Henriette/A-1695-2008; Ragona, Laura/AAB-9691-2020; molinari, henriette/ABE-9775-2021	Molinari, Henriette/0000-0002-3678-130X; Ragona, Laura/0000-0003-3893-7117; Fogolari, Federico/0000-0001-9862-250X				ANTOSIEWICZ J, 1994, J MOL BIOL, V238, P415, DOI 10.1006/jmbi.1994.1301; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Burova TV, 2002, EUR J BIOCHEM, V269, P3958, DOI 10.1046/j.1432-1033.2002.03081.x; Collini M, 2003, PROTEIN SCI, V12, P1596, DOI 10.1110/ps.0304403; Fogolari F, 2000, PROTEINS, V39, P317, DOI 10.1002/(SICI)1097-0134(20000601)39:4<317::AID-PROT50>3.0.CO;2-W; Fogolari F, 2002, J MOL RECOGNIT, V15, P377, DOI 10.1002/jmr.577; FRAPIN D, 1994, BIOCHIM BIOPHYS ACTA, V1205, P105; Gasymov OK, 2001, BIOCHEMISTRY-US, V40, P14754, DOI 10.1021/bi0110342; GOODFORD PJ, 1985, J MED CHEM, V28, P849, DOI 10.1021/jm00145a002; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Herrgard S, 2000, BIOCHEMISTRY-US, V39, P2921, DOI 10.1021/bi9916980; Kastenholz MA, 2000, J MED CHEM, V43, P3033, DOI 10.1021/jm000934y; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; MADURA JD, 1995, COMPUT PHYS COMMUN, V91, P57, DOI 10.1016/0010-4655(95)00043-F; Narayan M, 1997, BIOCHEMISTRY-US, V36, P1906, DOI 10.1021/bi9621526; PEREZ MD, 1992, BIOCHIM BIOPHYS ACTA, V1123, P151, DOI 10.1016/0005-2760(92)90105-5; PEREZ MD, 1993, J DAIRY RES, V60, P55, DOI 10.1017/S0022029900027345; PEREZ MD, 1989, J BIOCHEM-TOKYO, V106, P1094, DOI 10.1093/oxfordjournals.jbchem.a122971; Qin BY, 1998, BIOCHEMISTRY-US, V37, P14014, DOI 10.1021/bi981016t; Ragona L, 2000, PROTEIN SCI, V9, P1347, DOI 10.1110/ps.9.7.1347; Sawyer L, 2000, BBA-PROTEIN STRUCT M, V1482, P136, DOI 10.1016/S0167-4838(00)00160-6; TANFORD C, 1959, J BIOL CHEM, V234, P2874; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Ugolini R, 2001, EUR J BIOCHEM, V268, P4477, DOI 10.1046/j.1432-1327.2001.02371.x; Uhrinova S, 2000, BIOCHEMISTRY-US, V39, P3565, DOI 10.1021/bi992629o; VERGER R, 1976, J BIOL CHEM, V251, P3128; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wu SY, 1999, J BIOL CHEM, V274, P170, DOI 10.1074/jbc.274.1.170	28	64	64	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38840	38846		10.1074/jbc.M306269200	http://dx.doi.org/10.1074/jbc.M306269200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857741	hybrid			2022-12-27	WOS:000185575100092
J	Ciani, B; Layfield, R; Cavey, JR; Sheppard, PW; Searle, MS				Ciani, B; Layfield, R; Cavey, JR; Sheppard, PW; Searle, MS			Structure of the ubiquitin-associated domain of p62 (SQSTM1) and implications for mutations that cause Paget's disease of bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN P62; UBA DOMAINS; 26S PROTEASOME; SEQUESTOSOME; PROTEOLYSIS; INTERACT; CHAINS; SIGNAL; SMART	The p62 protein ( also known as SQSTM1) mediates diverse cellular functions including control of NFkappaB signaling and transcriptional activation. p62 binds non-covalently to ubiquitin and co-localizes with ubiquitylated inclusions in a number of human protein aggregation diseases. Mutations in the gene encoding p62 cause Paget's disease of bone ( PDB), a common disorder of the elderly characterized by excessive bone resorption and formation. All of the p62 PDB mutations identified to date cluster within the C-terminal region of the protein, which shows low sequence identity to previously characterized ubiquitin-associated (UBA) domains. We report the first NMR structure of a recombinant polypeptide that contains the C-terminal UBA domain of the human p62 protein ( residues 387 - 436). This sequence, which confers multiubiquitin chain binding, forms a compact three-helix bundle with a structure analogous to the UBA domains of HHR23A but with differences in the loop regions connecting helices that may be involved in binding accessory proteins. We show that the Pro(392) --> Leu PDB substitution mutation modifies the structure of the UBA domain by extending the N terminus of helix 1. In contrast to the p62 PDB deletion mutations that remove the UBA domain and ablate multiubiquitin chain binding, the Pro392 3 Leu substitution does not affect interaction of the UBA domain with multiubiquitin chains. Thus, phenotypically identical substitution and deletion mutations do not appear to predispose to PDB through a mechanism dependent on a common loss of ubiquitin chain binding by p62.	Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England; Sch Chem, Nottingham NG7 2RD, England; Affiniti Res Prod Ltd, Exeter EX2 8NL, Devon, England	University of Nottingham	Layfield, R (corresponding author), Univ Nottingham, Sch Med, Sch Biomed Sci, Nottingham NG7 2UH, England.	robert.layfield@nottingham.ac.uk; mark.searle@nottingham.ac.uk	Ciani, Barbara/A-1679-2012	Ciani, Barbara/0000-0001-7223-4154; Layfield, Robert/0000-0003-0702-3259; Searle, Mark/0000-0001-8387-9978; Cavey, James/0000-0003-4515-0515				Bertolaet BL, 2001, NAT STRUCT BIOL, V8, P417, DOI 10.1038/87575; BRUNGER AT, 1992, XPLOR VERSION 3 1; Chen L, 2001, EMBO REP, V2, P933, DOI 10.1093/embo-reports/kve203; Dieckmann T, 1998, NAT STRUCT BIOL, V5, P1042, DOI 10.1038/4220; Funakoshi M, 2002, P NATL ACAD SCI USA, V99, P745, DOI 10.1073/pnas.012585199; Geetha T, 2002, FEBS LETT, V512, P19, DOI 10.1016/S0014-5793(02)02286-X; Hartmann-Petersen R, 2003, TRENDS BIOCHEM SCI, V28, P26, DOI 10.1016/S0968-0004(02)00002-6; Hocking LJ, 2002, HUM MOL GENET, V11, P2735, DOI 10.1093/hmg/11.22.2735; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hughes AE, 2000, NAT GENET, V24, P45, DOI 10.1038/71667; Kanis J., 1998, PATHOPHYSIOLOGY TREA, VSecond; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1989, J MAGN RESON, V84, P627, DOI 10.1016/0022-2364(89)90130-3; Kuusisto E, 2001, NEUROREPORT, V12, P2085, DOI 10.1097/00001756-200107200-00009; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Laurin N, 2002, AM J HUM GENET, V70, P1582, DOI 10.1086/340731; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; NILGES M, 1988, PROTEIN ENG, V2, P27, DOI 10.1093/protein/2.1.27; Pickart CM, 2000, TRENDS BIOCHEM SCI, V25, P544, DOI 10.1016/S0968-0004(00)01681-9; PIOTTO M, 1992, J BIOMOL NMR, V2, P661, DOI 10.1007/BF02192855; Raasi S, 2003, J BIOL CHEM, V278, P8951, DOI 10.1074/jbc.M212841200; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Shin J, 1998, ARCH PHARM RES, V21, P629, DOI 10.1007/BF02976748; Stumptner C, 2002, HEPATOLOGY, V35, P1053, DOI 10.1053/jhep.2002.32674; Thrower JS, 2000, EMBO J, V19, P94, DOI 10.1093/emboj/19.1.94; Vadlamudi RK, 1996, J BIOL CHEM, V271, P20235, DOI 10.1074/jbc.271.34.20235; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Withers-Ward ES, 2000, BIOCHEMISTRY-US, V39, P14103, DOI 10.1021/bi0017071; Wuthrich K, 1986, NMR NUCL ACIDS PROTE	31	104	108	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37409	37412		10.1074/jbc.M307416200	http://dx.doi.org/10.1074/jbc.M307416200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857745	hybrid			2022-12-27	WOS:000185437200052
J	da Costa, CA; Masliah, E; Checler, F				da Costa, CA; Masliah, E; Checler, F			beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation - Cross-talk with alpha-synuclein and implication for Parkinson's disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALZHEIMERS-DISEASE; PRESYNAPTIC PROTEIN; LEWY BODIES; WILD-TYPE; NEURODEGENERATIVE DISORDERS; NACP/ALPHA-SYNUCLEIN; APOPTOTIC STIMULI; HUMAN BRAIN; P53; AGGREGATION	We have established stable transfectants expressing beta-synuclein in TSM1 neurons. We show that in basal and staurosporine-induced conditions the number of terminal deoxynucleotidyltransferase-mediated dUTP nick end-labeling (TUNEL)- positive beta-synuclein-expressing neurons was drastically lower than in mock-transfected TSM1 cells. This was accompanied by a lower DNA fragmentation as evidenced by the reduction of propidium iodide incorporation measured by fluorescence-activated cell sorter analysis. beta-Synuclein strongly reduces staurosporine-induced caspase 3 activity and immunoreactivity. We establish that beta-synuclein triggers a drastic reduction of p53 expression and transcriptional activity. This was accompanied by increased Mdm2 immunoreactivity while p38 expression appeared enhanced, indicating that beta-synuclein-induced p53 downregulation likely occurs at a post-transcriptional level. We showed previously that alpha-synuclein displays an antiapoptotic function that was abolished by the dopaminergic derived toxin 6-hydroxydopamine (6OHDA). Interestingly, beta-synuclein retains its ability to protect TSM1 neurons even after 6OHDA treatment. Furthermore, beta-synuclein restores the antiapoptotic function of alpha-synuclein in 6OHDA-treated neurons. Altogether, our data document for the first time that beta-synuclein protects neurons from staurosporine and 6OHDA-stimulated caspase activation in a p53-dependent manner. Our observation that beta-synuclein contributes to restoration of the alpha-synuclein antiapoptotic function abolished by 6OHDA may have direct implications for Parkinson's disease pathology. In this context, the cross-talk between these two parent proteins is discussed.	CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, F-06560 Valbonne, France; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur; University of California System; University of California San Diego	Checler, F (corresponding author), CNRS, Inst Pharmacol Mol & Cellulaire, UMR6097, 660 Route Lucioles, F-06560 Valbonne, France.	checler@ipmc.cnrs.fr	da Costa, Cristine Alves/G-8075-2011; Checler, Frederic/C-1241-2009	da Costa, Cristine Alves/0000-0002-7777-005X; Checler, Frederic/0000-0003-2098-1750	NATIONAL INSTITUTE ON AGING [R37AG018440, R01AG018440] Funding Source: NIH RePORTER; NIA NIH HHS [AG18440] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ancolio K, 2000, NEUROSCI LETT, V285, P79, DOI 10.1016/S0304-3940(00)01049-1; Baba M, 1998, AM J PATHOL, V152, P879; Barzilai A, 2003, TRENDS MOL MED, V9, P126, DOI 10.1016/S1471-4914(03)00020-0; Beal MF, 2001, NAT REV NEUROSCI, V2, P325, DOI 10.1038/35072550; Biere AL, 2000, J BIOL CHEM, V275, P34574, DOI 10.1074/jbc.M005514200; Bucciantini M, 2002, NATURE, V416, P507, DOI 10.1038/416507a; Chun J, 1996, MOL CELL NEUROSCI, V7, P304, DOI 10.1006/mcne.1996.0023; COTMAN CW, 1995, MOL NEUROBIOL, V10, P19, DOI 10.1007/BF02740836; Cotman CW, 1998, NEUROBIOL AGING, V19, pS29, DOI 10.1016/S0197-4580(98)00042-6; CURTIUS HC, 1974, J CHROMATOGR, V99, P529, DOI 10.1016/S0021-9673(00)90882-3; da Costa CA, 2000, J BIOL CHEM, V275, P24065, DOI 10.1074/jbc.M002413200; da Costa CA, 2003, CURR MOL MED, V3, P17, DOI 10.2174/1566524033361690; da Costa CA, 2003, J BIOL CHEM, V278, P12064, DOI 10.1074/jbc.M212379200; da Costa CA, 2002, J BIOL CHEM, V277, P50980, DOI 10.1074/jbc.M207825200; da Costa CA, 2002, P NATL ACAD SCI USA, V99, P4043, DOI 10.1073/pnas.062059899; Duan WZ, 2002, ANN NEUROL, V52, P597, DOI 10.1002/ana.10350; El-Agnaf OMA, 2000, J STRUCT BIOL, V130, P300, DOI 10.1006/jsbi.2000.4262; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Ferrigno P, 2000, NEURON, V26, P9, DOI 10.1016/S0896-6273(00)81132-0; Fratiglioni L, 2000, NEUROLOGY, V54, pS10; Giampaoli S, 2000, AGING CLIN EXP RES, V12, P93, DOI 10.1007/BF03339896; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Goedert M, 2001, NAT REV NEUROSCI, V2, P492, DOI 10.1038/35081564; Goedert M, 1998, CURR OPIN NEUROBIOL, V8, P619, DOI 10.1016/S0959-4388(98)80090-1; HAN HY, 1995, CHEM BIOL, V2, P163, DOI 10.1016/1074-5521(95)90071-3; Hashimoto M, 1999, BRAIN PATHOL, V9, P707; Hashimoto M, 2001, NEURON, V32, P213, DOI 10.1016/S0896-6273(01)00462-7; Hirata H, 1997, J NEUROCHEM, V69, P780; Irwin I., 1995, ETIOL PARKINSONS DIS, V1995, P153; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; IWAI A, 1995, BIOCHEMISTRY-US, V34, P10139, DOI 10.1021/bi00032a006; Iwai A, 2000, BBA-MOL BASIS DIS, V1502, P95, DOI 10.1016/S0925-4439(00)00036-3; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jellinger K, 1995, J NEURAL TRANSM-SUPP, P297; JENSEN PH, 1995, BIOCHEM J, V310, P91, DOI 10.1042/bj3100091; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Masliah E, 1996, AM J PATHOL, V148, P201; NAKAJO S, 1993, EUR J BIOCHEM, V217, P1057, DOI 10.1111/j.1432-1033.1993.tb18337.x; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Paitel E, 2003, J BIOL CHEM, V278, P10061, DOI 10.1074/jbc.M211580200; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rockenstein E, 2001, BRAIN RES, V914, P48, DOI 10.1016/S0006-8993(01)02772-X; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takeda A, 1998, AM J PATHOL, V152, P367; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; UEDA K, 1993, P NATL ACAD SCI USA, V90, P11282, DOI 10.1073/pnas.90.23.11282; Wakabayashi K, 1997, NEUROSCI LETT, V239, P45, DOI 10.1016/S0304-3940(97)00891-4; Windisch M, 2002, J MOL NEUROSCI, V19, P63, DOI 10.1007/s12031-002-0012-8; Wolozin B, 2000, ARCH NEUROL-CHICAGO, V57, P793, DOI 10.1001/archneur.57.6.793; Yin YL, 2002, NAT CELL BIOL, V4, P462, DOI 10.1038/ncb801; Zhu YH, 2002, J BIOL CHEM, V277, P22909, DOI 10.1074/jbc.M200042200	54	68	69	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37330	37335		10.1074/jbc.M306083200	http://dx.doi.org/10.1074/jbc.M306083200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867415	hybrid			2022-12-27	WOS:000185437200042
J	Dupont, JL; Karas, M; LeRoith, D				Dupont, JL; Karas, M; LeRoith, D			The cyclin-dependent kinase inhibitor p21C(IP/WAF) is a positive regulator of insulin-like growth factor I-induced cell proliferation in MCF-7 human breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; CDK INHIBITORS; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR MECHANISMS; SIGNAL-TRANSDUCTION; P21; P21(WAF1/CIP1); RECEPTOR; P21(CIP1/WAF1); EXPRESSION	To study the role of IGF-I receptor signaling on cell cycle events we utilized MCF-7 breast cancer cells. IGF-I at physiological concentrations increased the level of p21(CIP/WAF) mRNA after 4 h as well as protein after 8 h by 10- and 6-fold, respectively, in MCF-7 cells. This IGF-1 effect was reduced by 50% in MCF-7-derived cells (SX13), which exhibit a 50% reduction in IGF-1R expression, demonstrating that IGF-1 receptor activation was involved in this process. Preincubation with the ERK1/2 inhibitor U0126 significantly reduced the IGF-1 effect on the amount of p21(CIP/WAF) protein in MCF-7 cells. These results were confirmed by the expression of a dominant negative construct for MEK-1 suggesting that the increase of the abundance of p21(CIP/WAF) in response to IGF-1 occurs via the ERK1/2 mitogen-activated protein kinase pathway. Using an antisense strategy, we demonstrated that abolition of p21(CIP/WAF) expression decreased by 2-fold the IGF-1 effect on cell proliferation in MCF-7. This latter result is explained by a delay in G(1) to S cell cycle progression due partly to a reduction in the activation of some components of cell cycle including the induction of cyclin D1 expression in response to IGF-1. MCF-7 cells transiently overexpressing p21 showed increased basal and IGF-I-induced thymidine incorporation. Taken together, these results define p21(CIP/WAF) as a positive regulator in the cell proliferation induced by IGF-1 in MCF-7 cells.	NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	LeRoith, D (corresponding author), NIDDK, Sect Mol & Cellular Physiol, Diabet Branch, NIH, Rm 8D12,Bldg 10, Bethesda, MD 20892 USA.							ARTEAGA CL, 1989, CANCER RES, V49, P6237; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Bearss DJ, 2002, CANCER RES, V62, P2077; Beier F, 1999, J BIOL CHEM, V274, P30273, DOI 10.1074/jbc.274.42.30273; Braun SE, 1998, BLOOD CELL MOL DIS, V24, P138, DOI 10.1006/bcmd.1998.0181; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEN XB, 1995, CANCER RES, V55, P4257; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Coleman ML, 2003, EMBO J, V22, P2036, DOI 10.1093/emboj/cdg189; Di Cunto F, 1998, SCIENCE, V280, P1069, DOI 10.1126/science.280.5366.1069; DICKSON C, 1995, CANCER LETT, V90, P43, DOI 10.1016/0304-3835(94)03676-A; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; Dupont J, 2000, J BIOL CHEM, V275, P35893, DOI 10.1074/jbc.M006741200; Erber R, 1997, INT J CANCER, V74, P383, DOI 10.1002/(SICI)1097-0215(19970822)74:4<383::AID-IJC4>3.0.CO;2-R; Fantin VR, 1998, J BIOL CHEM, V273, P10726, DOI 10.1074/jbc.273.17.10726; Foster JS, 2001, MOL CELL BIOL, V21, P794, DOI 10.1128/MCB.21.3.794-810.2001; Fukuchi K, 2000, BBA-MOL CELL RES, V1496, P207, DOI 10.1016/S0167-4889(00)00018-5; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; GRANA X, 1995, ONCOGENE, V11, P211; Hu PPC, 1999, J BIOL CHEM, V274, P35381, DOI 10.1074/jbc.274.50.35381; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; Jackson JG, 1998, J BIOL CHEM, V273, P9994, DOI 10.1074/jbc.273.16.9994; Johannessen LE, 1999, BIOCHEM J, V337, P599, DOI 10.1042/0264-6021:3370599; Johnson MR, 1998, ONCOGENE, V16, P2647, DOI 10.1038/sj.onc.1201789; JUNG J, 1995, ONCOGENE, V11, P201; Kanter-Lewensohn L, 2000, GROWTH FACTORS, V17, P193, DOI 10.3109/08977190009001068; KATO JY, 1994, MOL CELL BIOL, V14, P2713, DOI 10.1128/MCB.14.4.2713; Kivinen L, 1999, CELL GROWTH DIFFER, V10, P621; Kleinman D, 1996, ENDOCRINOLOGY, V137, P1089, DOI 10.1210/en.137.3.1089; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; LAVAN BE, 1993, J BIOL CHEM, V268, P5921; Li Y, 2002, J BIOL CHEM, V277, P11352, DOI 10.1074/jbc.M109062200; Liu Y, 1996, CANCER RES, V56, P31; Mantel C, 1996, BLOOD, V88, P3710, DOI 10.1182/blood.V88.10.3710.bloodjournal88103710; Marches R, 1999, P NATL ACAD SCI USA, V96, P8711, DOI 10.1073/pnas.96.15.8711; Mitsuuchi Y, 2000, CANCER RES, V60, P5390; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; NEUENSCHWANDER S, 1995, ENDOCRINOLOGY, V136, P4298, DOI 10.1210/en.136.10.4298; Nolan MK, 1997, INT J CANCER, V72, P828, DOI 10.1002/(SICI)1097-0215(19970904)72:5<828::AID-IJC20>3.0.CO;2-3; Parry D, 1999, MOL CELL BIOL, V19, P1775; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; QUELLE DE, 1995, ONCOGENE, V11, P635; ROSENTHAL SM, 1995, P NATL ACAD SCI USA, V92, P10307, DOI 10.1073/pnas.92.22.10307; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Russell A, 1999, ONCOGENE, V18, P6454, DOI 10.1038/sj.onc.1203030; Sheaff RJ, 2000, MOL CELL, V5, P403, DOI 10.1016/S1097-2765(00)80435-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; Skildum AJ, 2002, J BIOL CHEM, V277, P5145, DOI 10.1074/jbc.M109179200; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; Surmacz E, 1995, CLIN CANCER RES, V1, P1429; Surmacz E, 2000, J MAMMARY GLAND BIOL, V5, P95, DOI 10.1023/A:1009523501499; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Weiss RH, 2000, J BIOL CHEM, V275, P10285, DOI 10.1074/jbc.275.14.10285; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213	59	42	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37256	37264		10.1074/jbc.M302355200	http://dx.doi.org/10.1074/jbc.M302355200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867429	hybrid, Green Submitted			2022-12-27	WOS:000185437200034
J	Kazerounian, S; Aho, S				Kazerounian, S; Aho, S			Characterization of periphilin, a widespread, highly insoluble nuclear protein and potential constituent of the keratinocyte cornified envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLAKIN FAMILY; CELL-ENVELOPE; TISSUE TRANSGLUTAMINASE; INTERMEDIATE-FILAMENTS; DESMOSOMAL PLAQUE; EPITHELIAL-CELLS; PERIPLAKIN; COMPLEXES; ENVOPLAKIN; BINDING	While keratinocytes go through the terminal differentiation and move toward the outer layers of epidermis, multiple proteins become sequentially incorporated into the cornified cell envelope. We have identified through yeast two-hybrid screening a novel protein, periphilin, interacting with periplakin, which is known as a precursor of the cornified cell envelope. Periphilin gene at chromosome 12q12 gives rise to multiple alternatively spliced transcripts. A monoclonal antibody detected the keratinocyte-specific periphilin isoform in undifferentiated keratinocytes in speckle-type nuclear granules and at the nuclear membrane, but in differentiated keratinocytes periphilin localized to the cell periphery and at cell-cell junctions, colocalizing there with periplakin. From cultured keratinocytes, periphilin was solubilized only after urea extraction, indicating the highly insoluble character of this protein. The nuclear localization, mediated through the N-terminal sequences of periphilin protein, is a prerequisite for the formation of insoluble complexes. Although the globular N terminus of periphilin was necessary for the interaction with the periplakin tail, the keratinocyte-specific C terminus was responsible for the homodimerization. The C-terminal helical domain, composed of multiple heptad repeats, serves as a substrate for cross-linking by transglutaminases but also was specifically cleaved by caspase-5 in vitro. In conclusion, the localization pattern and insolubility of periphilin indicate that this novel protein is potentially involved in epithelial differentiation and contributes to epidermal integrity and barrier formation.	Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Jefferson University	Aho, S (corresponding author), Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, 233 S 10th St,BLSB 422, Philadelphia, PA 19107 USA.	Sirpa.Aho@jefferson.edu			PHS HHS [R01-33588] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Aho S, 1997, ANAL BIOCHEM, V253, P270, DOI 10.1006/abio.1997.2394; Aho S, 2000, J CELL BIOL, V148, P1165, DOI 10.1083/jcb.148.6.1165; Brandner JM, 1998, EUR J CELL BIOL, V75, P295, DOI 10.1016/S0171-9335(98)80063-0; Brandner JM, 1997, DIFFERENTIATION, V62, P119, DOI 10.1046/j.1432-0436.1997.6230119.x; Caulin C, 1997, J CELL BIOL, V138, P1379, DOI 10.1083/jcb.138.6.1379; Chen XY, 2002, J BIOL CHEM, V277, P10512, DOI 10.1074/jbc.M108765200; DiColandrea T, 2000, J CELL BIOL, V151, P573, DOI 10.1083/jcb.151.3.573; Fricker M, 1997, J CELL BIOL, V136, P531, DOI 10.1083/jcb.136.3.531; Goepfert TM, 2002, CANCER RES, V62, P4115; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; HARE JF, 1994, J BIOL CHEM, V269, P5981; Hofmann I, 2002, MOL BIOL CELL, V13, P1665, DOI 10.1091/mbc.01-12-0567; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Karashima T, 2002, J CELL SCI, V115, P5027, DOI 10.1242/jcs.00191; Kazerounian S, 2002, EXP DERMATOL, V11, P428, DOI 10.1034/j.1600-0625.2002.110506.x; Keon BH, 1996, J CELL BIOL, V134, P1003, DOI 10.1083/jcb.134.4.1003; Kim JH, 2001, ANN NY ACAD SCI, V928, P65; Kozak M, 1996, MAMM GENOME, V7, P563, DOI 10.1007/s003359900171; Ku NO, 1997, J BIOL CHEM, V272, P33197, DOI 10.1074/jbc.272.52.33197; Le Borgne R, 1998, BBA-MOL CELL RES, V1404, P195, DOI 10.1016/S0167-4889(98)00057-3; Lesort M, 1998, J BIOL CHEM, V273, P11991, DOI 10.1074/jbc.273.20.11991; Line A, 2002, BRIT J CANCER, V86, P1824, DOI 10.1038/sj.bjc.6600321; MA ASP, 1986, J CELL BIOL, V103, P41, DOI 10.1083/jcb.103.1.41; Mann CJ, 1999, J MOL BIOL, V285, P391, DOI 10.1006/jmbi.1998.2298; Marekov LN, 1998, J BIOL CHEM, V273, P17763, DOI 10.1074/jbc.273.28.17763; Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3; Melkonian KA, 1999, J BIOL CHEM, V274, P3910, DOI 10.1074/jbc.274.6.3910; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Mertens C, 2001, P NATL ACAD SCI USA, V98, P7795, DOI 10.1073/pnas.141219498; Mertens C, 1996, J CELL BIOL, V135, P1009, DOI 10.1083/jcb.135.4.1009; MOIR RD, 1994, J CELL BIOL, V125, P1201, DOI 10.1083/jcb.125.6.1201; Nicholson DW, 1999, CELL DEATH DIFFER, V6, P1028, DOI 10.1038/sj.cdd.4400598; Nikolic B, 1996, J CELL BIOL, V134, P1455, DOI 10.1083/jcb.134.6.1455; OUYANG P, 1996, J CELL BIOL, P1027; Ruchaud S, 2002, EMBO J, V21, P1967, DOI 10.1093/emboj/21.8.1967; Ruhrberg C, 1997, J CELL BIOL, V139, P1835, DOI 10.1083/jcb.139.7.1835; Ruhrberg C, 1997, CURR OPIN GENET DEV, V7, P392, DOI 10.1016/S0959-437X(97)80154-2; Schmidt A, 1997, CELL TISSUE RES, V290, P481, DOI 10.1007/s004410050956; Solomon KR, 1998, BIOCHEM J, V334, P325, DOI 10.1042/bj3340325; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; STORCH S, 1999, THESIS G AUGUST U GO; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; Tan JH, 2000, MOL BIOL CELL, V11, P1547, DOI 10.1091/mbc.11.5.1547; van den Heuvel APJ, 2002, J CELL SCI, V115, P3957, DOI 10.1242/jcs.00069; Verderio E, 1998, EXP CELL RES, V239, P119, DOI 10.1006/excr.1997.3874; Wang P, 2002, BIOCHEM BIOPH RES CO, V294, P448, DOI 10.1016/S0006-291X(02)00495-3; Zeuner A, 1999, CELL DEATH DIFFER, V6, P1075, DOI 10.1038/sj.cdd.4400596	47	39	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36707	36717		10.1074/jbc.M303896200	http://dx.doi.org/10.1074/jbc.M303896200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853457	hybrid			2022-12-27	WOS:000185318300102
J	Linster, CL; Van Schaftingen, E				Linster, CL; Van Schaftingen, E			Rapid stimulation of free glucuronate formation by non-glucuronidable xenobiotics in isolated rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ASCORBIC-ACID; FRUCTOSE 2,6-BISPHOSPHATE; METABOLISM; PYROPHOSPHATASE; DEHYDROGENASE; BIOSYNTHESIS; PURIFICATION; TRANSFERASE; MECHANISM; REDUCTASE	Vitamin C synthesis in rat liver is enhanced by several xenobiotics, including aminopyrine and chloretone. The effect of these agents has been linked to induction of enzymes potentially involved in the formation of glucuronate, a precursor of vitamin C. Using isolated rat hepatocytes as a model, we show that a series of agents ( aminopyrine, antipyrine, chloretone, clotrimazole, metyrapone, proadifen, and barbital) induced in a few minutes an up to 15-fold increase in the formation of glucuronate, which was best observed in the presence of sorbinil, an inhibitor of glucuronate reductase. They also caused an similar to2-fold decrease in the concentration of UDP-glucuronate but little if any change in the concentration of UDP-glucose. Depletion of UDP-glucuronate with resorcinol or D-galactosamine markedly decreased the formation of glucuronate both in the presence and in the absence of aminopyrine, confirming the precursor-product relationship between UDP-glucuronate and free glucuronate. Most of the agents did not induce the formation of detectable amounts of glucuronides, indicating that the formation of glucuronate is not due to a glucuronidation-deglucuronidation cycle. With the exception of barbital ( which inhibits glucuronate reductase), all of the above mentioned agents also caused an increase in the concentration of ascorbic acid. They had little effect on glutathione concentration, and their effect on glucuronate and vitamin C formation was not mimicked by glutathione-depleting agents such as diamide and buthionine sulfoximine. It is concluded that the stimulation of vitamin C synthesis exerted by some xenobiotics is mediated through a rapid increase in the conversion of UDP-glucuronate to glucuronate, which does not apparently involve a glucuronidation-deglucuronidation cycle.	Catholic Univ Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium; Christian de Duve Inst Cellular Pathol, B-1200 Brussels, Belgium	Universite Catholique Louvain	Van Schaftingen, E (corresponding author), Catholic Univ Louvain, Physiol Chem Lab, B-1200 Brussels, Belgium.	vanschaftingen@bchm.ucl.ac.be	Van+Schaftingen, Emile/AAF-5532-2020	Linster, Carole/0000-0001-7143-0719; Van Schaftingen, Emile/0000-0002-6199-7647				ASHWELL G, 1960, J BIOL CHEM, V235, P1559; BARTRONS R, 1983, BIOCHEM J, V214, P829, DOI 10.1042/bj2140829; Braun L, 1996, FEBS LETT, V388, P173, DOI 10.1016/0014-5793(96)00548-0; BURNS JJ, 1956, J BIOL CHEM, V223, P897; BURNS JJ, 1957, J BIOL CHEM, V227, P785; EVANS C, 1960, BIOCHIM BIOPHYS ACTA, V41, P9, DOI 10.1016/0006-3002(60)90362-0; GINSBURG V, 1958, BIOCHIM BIOPHYS ACTA, V28, P649, DOI 10.1016/0006-3002(58)90538-9; GRIFFITH OW, 1990, METHOD ENZYMAT AN, V8, P521; HIATT HH, 2001, METABOLIC MOL BASES, V1, P1589; HICKMAN J, 1960, J BIOL CHEM, V235, P1566; HOCHMAN Y, 1984, J BIOL CHEM, V259, P5521; HOLLMANN S, 1962, BIOCHIM BIOPHYS ACTA, V62, P338, DOI 10.1016/0006-3002(62)90048-3; HORIO F, 1993, J NUTR, V123, P2075; HORIO F, 1983, J NUTR SCI VITAMINOL, V29, P233, DOI 10.3177/jnsv.29.233; Horio F, 1997, BIOSCI BIOTECH BIOCH, V61, P109, DOI 10.1271/bbb.61.109; IYANAGI T, 1989, J BIOL CHEM, V264, P21302; KEPPLER DOR, 1970, EUR J BIOCHEM, V17, P246, DOI 10.1111/j.1432-1033.1970.tb01160.x; LEWIS DF, 2001, GUIDE CYTOCHROMES P4, P118; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Margolis JJ, 1929, AM J MED SCI, V177, P348, DOI 10.1097/00000441-192903000-00005; Omaye S T, 1979, Methods Enzymol, V62, P3, DOI 10.1016/0076-6879(79)62181-X; POGELL BM, 1961, J BIOL CHEM, V236, P293; PUHAKAINEN E, 1976, EUR J BIOCHEM, V61, P165, DOI 10.1111/j.1432-1033.1976.tb10007.x; Radominska-Pandya A, 1999, DRUG METAB REV, V31, P817, DOI 10.1081/DMR-100101944; RODRIGUES AD, 1987, BIOCHEM PHARMACOL, V36, P4277, DOI 10.1016/0006-2952(87)90670-8; SATO K, 1993, ARCH BIOCHEM BIOPHYS, V307, P286, DOI 10.1006/abbi.1993.1591; SEGLEN PO, 1973, EXP CELL RES, V82, P391, DOI 10.1016/0014-4827(73)90357-1; Smirnoff N, 2001, VITAM HORM, V61, P241; SRIVASTAVA SK, 1982, CURR EYE RES, V2, P407, DOI 10.3109/02713688209000786; Tanaka E, 1997, J CLIN PHARM THER, V22, P237, DOI 10.1046/j.1365-2710.1997.10875108.x; Trautschold I., 1985, METHODS ENZYMATIC AN, V3rd, P346; VANSCHAFTINGEN E, 1995, EUR J BIOCHEM, V234, P301; VANSCHAFTINGEN E, 1987, EUR J BIOCHEM, V166, P653	33	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36328	36333		10.1074/jbc.M306593200	http://dx.doi.org/10.1074/jbc.M306593200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865420	Green Published, hybrid			2022-12-27	WOS:000185318300058
J	Wang, W; Loh, HH; Law, PY				Wang, W; Loh, HH; Law, PY			The intracellular trafficking of opioid receptors directed by carboxyl tail and a di-leucine motif in Neuro2A cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; C-TERMINAL TAIL; AGONIST-SPECIFIC REGULATION; INDUCED DOWN-REGULATION; NG108-15 HYBRID-CELLS; BETA-ARRESTIN; MEDIATED ENDOCYTOSIS; BETA(2)-ADRENERGIC RECEPTOR; OPIATE RECEPTOR; ALPHA(2)-ADRENERGIC RECEPTORS	The mu- and delta-opioid receptors (MOR and DOR) differ significantly in their intracellular trafficking. MORs recycle back to the cell surface upon agonist treatment, whereas most internalized DORs are targeted to lysosomes for degradation. By exchanging the carboxyl tail domains of MOR and DOR and expressing the receptor chimeras in mouse neuroblastoma Neuro2A cells, it could be demonstrated that the carboxyl tail domain is not the sole determinant in directing the intracellular trafficking in these Neuro2A cells. Deletion of the dileucine motif ( Leu(245)-Leu(246)) within the third intracellular loop of DOR or the mutation of Leu(245) to Met slowed the lysosomal targeting of these delta-opioid receptors. Meanwhile the mutation of Met(264) to Leu increased the rate of agonist-induced receptor internalization and the lysosomal targeting of the wild type and the delta-opioid receptor carboxyl tail chimera of the mu-opioid receptor. These studies suggest interplay between a di-leucine motif and the carboxyl tail in the lysosomal targeting of the receptor.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Law, PY (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	lawxx001@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NATIONAL INSTITUTE ON DRUG ABUSE [K05DA000513, P50DA011806, R01DA007339] Funding Source: NIH RePORTER; NIDA NIH HHS [K05 DA00513, K05 DA70544, DA11806, DA07339] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Bohn LM, 2000, J NEUROCHEM, V74, P574, DOI 10.1046/j.1471-4159.2000.740574.x; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Cen B, 2001, MOL PHARMACOL, V59, P758, DOI 10.1124/mol.59.4.758; Cen B, 2001, J NEUROCHEM, V76, P1887, DOI 10.1046/j.1471-4159.2001.00204.x; Chaipatikul V, 2003, J PHARMACOL EXP THER, V305, P909, DOI 10.1124/jpet.102.046219; CHANG KJ, 1982, NATURE, V296, P446, DOI 10.1038/296446a0; D'Souza-Schorey C, 1998, J CELL BIOL, V140, P603, DOI 10.1083/jcb.140.3.603; D'SOUZA-SCHOREY C, 1995, SCIENCE, V267, P1175, DOI 10.1126/science.7855600; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; DeGraff JL, 1999, J BIOL CHEM, V274, P11253, DOI 10.1074/jbc.274.16.11253; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; Finn AK, 2001, NEURON, V32, P829, DOI 10.1016/S0896-6273(01)00517-7; Gabilondo AM, 1997, P NATL ACAD SCI USA, V94, P12285, DOI 10.1073/pnas.94.23.12285; Georgoussi Z, 1997, BBA-MOL CELL RES, V1359, P263, DOI 10.1016/S0167-4889(97)00097-9; Goodman OB, 1996, NATURE, V383, P447, DOI 10.1038/383447a0; Heilker R, 1996, EMBO J, V15, P2893, DOI 10.1002/j.1460-2075.1996.tb00650.x; Honing S, 1998, EMBO J, V17, P1304, DOI 10.1093/emboj/17.5.1304; Ignatova EG, 1999, J NEUROSCI, V19, P56, DOI 10.1523/JNEUROSCI.19-01-00056.1999; Johnson AO, 2001, MOL BIOL CELL, V12, P367, DOI 10.1091/mbc.12.2.367; Jones SM, 2002, AM J PHYSIOL-CELL PH, V282, pC420, DOI 10.1152/ajpcell.00253.2001; Ko JL, 1999, MOL BRAIN RES, V69, P171, DOI 10.1016/S0169-328X(99)00094-7; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Koch T, 1998, J BIOL CHEM, V273, P13652, DOI 10.1074/jbc.273.22.13652; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; LAW PY, 1982, MOL PHARMACOL, V22, P1; LAW PY, 1984, J BIOL CHEM, V259, P4096; Le Borgne R, 1998, J BIOL CHEM, V273, P29451, DOI 10.1074/jbc.273.45.29451; Li JG, 1999, J BIOL CHEM, V274, P12087, DOI 10.1074/jbc.274.17.12087; Maestri-El Kouhen O, 2000, J BIOL CHEM, V275, P36659, DOI 10.1074/jbc.M006788200; Merkouris M, 1996, MOL PHARMACOL, V50, P985; Mitchell R, 1998, NATURE, V392, P411, DOI 10.1038/32937; Moore RH, 1999, J CELL SCI, V112, P329; Mundell SJ, 1998, BRIT J PHARMACOL, V125, P1594, DOI 10.1038/sj.bjp.0702234; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1999, MOL PHARMACOL, V56, P728; Nakatsu F, 2000, J BIOL CHEM, V275, P26213, DOI 10.1074/jbc.M907720199; Neilan CL, 1999, BRIT J PHARMACOL, V128, P556, DOI 10.1038/sj.bjp.0702816; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Orsini MJ, 1999, J BIOL CHEM, V274, P31076, DOI 10.1074/jbc.274.43.31076; Pak Y, 1999, J BIOL CHEM, V274, P27610, DOI 10.1074/jbc.274.39.27610; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Preisser L, 1999, FEBS LETT, V460, P303, DOI 10.1016/S0014-5793(99)01360-5; Roth BL, 1998, DRUG ALCOHOL DEPEN, V51, P73, DOI 10.1016/S0376-8716(98)00067-2; SADEE W, 1995, ADV EXP MED BIOL, V373, P85; Sandoval Ignacio V., 1994, Trends in Cell Biology, V4, P292, DOI 10.1016/0962-8924(94)90220-8; SANDOVAL IV, 1994, J BIOL CHEM, V269, P6622; Sandoval IV, 2000, J BIOL CHEM, V275, P39874, DOI 10.1074/jbc.M006261200; Schramm NL, 1999, J BIOL CHEM, V274, P24935, DOI 10.1074/jbc.274.35.24935; Schulein R, 1998, MOL PHARMACOL, V54, P525, DOI 10.1124/mol.54.3.525; Setaluri V, 2000, PIGM CELL RES, V13, P128, DOI 10.1034/j.1600-0749.2000.130302.x; Simmen T, 1999, J CELL SCI, V112, P45; Smythies J, 2000, P ROY SOC B-BIOL SCI, V267, P1363, DOI 10.1098/rspb.2000.1151; Tang BL, 1999, FEBS LETT, V446, P211, DOI 10.1016/S0014-5793(99)00195-7; Tsao PI, 2000, J BIOL CHEM, V275, P11130, DOI 10.1074/jbc.275.15.11130; Wang DX, 1999, J BIOL CHEM, V274, P22081, DOI 10.1074/jbc.274.31.22081; Wang HL, 1999, J NEUROCHEM, V72, P1307, DOI 10.1046/j.1471-4159.1999.0721307.x; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Whistler JL, 1999, NEURON, V23, P737, DOI 10.1016/S0896-6273(01)80032-5; Whistler JL, 2001, J BIOL CHEM, V276, P34331, DOI 10.1074/jbc.M104627200; Whistler JL, 1998, P NATL ACAD SCI USA, V95, P9914, DOI 10.1073/pnas.95.17.9914; Wolf R, 1999, MOL PHARMACOL, V55, P263, DOI 10.1124/mol.55.2.263; ZADINA JE, 1993, J PHARMACOL EXP THER, V265, P254; Zaki PA, 2000, J PHARMACOL EXP THER, V292, P1127; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1999, J RECEPT SIGNAL TR R, V19, P301, DOI 10.3109/10799899909036653; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005	72	37	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36848	36858		10.1074/jbc.M301540200	http://dx.doi.org/10.1074/jbc.M301540200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851402	hybrid			2022-12-27	WOS:000185318300118
J	Grabar, TB; Cain, BD				Grabar, TB; Cain, BD			Integration of b subunits of unequal lengths into F1F0-ATP synthase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI ATP SYNTHASE; ESCHERICHIA-COLI; DELTA-SUBUNIT; EPSILON-SUBUNIT; 2ND STALK; DIMERIZATION DOMAIN; MUTAGENIC ANALYSIS; TERMINAL REGION; ALPHA-SUBUNIT; F-0 PARTS	In Escherichia coli the peripheral stalk of F1F0-ATP synthase consists of a parallel dimer of identical b subunits. However, the length of the two b subunits need not be fixed. This led us to ask whether it is possible for two b subunits of unequal length to dimerize in a functional enzyme complex. A two-plasmid expression system has been developed that directs production of b subunits of unequal lengths in the same cell. Two b subunits differing in length have been expressed with either a histidine or V5 epitope tag to facilitate nickel-affinity resin purification ( Ni-resin) and Western blot analysis. The epitope tags did not materially affect enzyme function. The system allowed us to determine whether the different b subunits segregate to form homodimers or, conversely, whether a heterodimer consisting of both the shortened and lengthened b subunits can occur in an intact enzyme complex. Experiments expressing different b subunits lengthened and shortened by up to 7 amino acids were detected in the same enzyme complex. The V5-tagged b subunit shortened by 7 amino acids (b(Delta7-V5)) was detected in Ni-resin-purified membrane preparations only when coexpressed with a histidine-tagged b subunit in the same cell. The results demonstrate that the enzyme complex can tolerate a size difference between the two b subunits of up to 14 amino acids. Moreover, the experiments demonstrated the feasibility of constructing enzyme complexes with non-identical b subunits that will be valuable for research requiring specific chemical modification of a single b subunit.	Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA	State University System of Florida; University of Florida	Cain, BD (corresponding author), Univ Florida, Dept Biochem & Mol Biol, Gainesville, FL 32610 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043495] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM43495] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altendorf K, 2000, J EXP BIOL, V203, P19; ARIS JP, 1985, J BIOL CHEM, V260, P1207; Bulygin VV, 1998, J BIOL CHEM, V273, P31765, DOI 10.1074/jbc.273.48.31765; CAIN BD, 1989, J BIOL CHEM, V264, P3292; Cain BD, 2000, J BIOENERG BIOMEMBR, V32, P365, DOI 10.1023/A:1005575919638; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; DECKERSHEBESTREIT G, 1992, J BIOL CHEM, V267, P12364; DECKERSHEBESTREIT G, 1986, EUR J BIOCHEM, V161, P225, DOI 10.1111/j.1432-1033.1986.tb10146.x; Del Rizzo PA, 2002, BIOCHEMISTRY-US, V41, P6875, DOI 10.1021/bi025736i; Dmitriev O, 1999, J BIOL CHEM, V274, P15598, DOI 10.1074/jbc.274.22.15598; Dunn SD, 2000, J BIOENERG BIOMEMBR, V32, P347, DOI 10.1023/A:1005571818730; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; DUNN SD, 1992, J BIOL CHEM, V267, P7630; Dunn SD, 1998, J BIOL CHEM, V273, P8646, DOI 10.1074/jbc.273.15.8646; Fillingame RH, 1999, NOVART FDN SYMP, V221, P218; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; Greie JC, 2000, EUR J BIOCHEM, V267, P3040, DOI 10.1046/j.1432-1327.2000.01327.x; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCCORMICK KA, 1993, J BIOL CHEM, V268, P24683; MCCORMICK KA, 1991, J BACTERIOL, V173, P7240, DOI 10.1128/jb.173.22.7240-7248.1991; McLachlin DT, 1998, J BIOL CHEM, V273, P15162, DOI 10.1074/jbc.273.24.15162; Nath Sunil, 2002, Adv Biochem Eng Biotechnol, V74, P65; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Noji H, 2001, J BIOL CHEM, V276, P1665, DOI 10.1074/jbc.R000021200; Ogilvie I, 1997, J BIOL CHEM, V272, P16652, DOI 10.1074/jbc.272.26.16652; Pedersen PL, 2000, J BIOENERG BIOMEMBR, V32, P325, DOI 10.1023/A:1005594800983; Prescott M, 2003, J BIOL CHEM, V278, P251, DOI 10.1074/jbc.M204556200; Revington M, 1999, J BIOL CHEM, V274, P31094, DOI 10.1074/jbc.274.43.31094; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; Sawada K, 1997, J BIOL CHEM, V272, P30047, DOI 10.1074/jbc.272.48.30047; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; Sorgen PL, 1998, BIOCHEMISTRY-US, V37, P923, DOI 10.1021/bi972309+; Sorgen PL, 1999, J BIOL CHEM, V274, P36261, DOI 10.1074/jbc.274.51.36261; Sorgen PL, 1998, J BIOL CHEM, V273, P27873, DOI 10.1074/jbc.273.43.27873; TAKEYAMA M, 1988, J BIOL CHEM, V263, P16106; TAMARAPPOO BK, 1992, J BIOL CHEM, V267, P2370; Turina P, 2000, J BIOENERG BIOMEMBR, V32, P373, DOI 10.1023/A:1005528003709; Weber J, 2003, J BIOL CHEM, V278, P13409, DOI 10.1074/jbc.M212037200; Weber J, 2003, J BIOL CHEM, V278, P13623, DOI 10.1074/jbc.C300061200; Wilkens S, 2000, J MOL BIOL, V295, P387, DOI 10.1006/jmbi.1999.3381; Wilkens S, 1998, BBA-BIOENERGETICS, V1365, P93, DOI 10.1016/S0005-2728(98)00048-6; Wilkens S, 2000, J BIOENERG BIOMEMBR, V32, P333, DOI 10.1023/A:1005567717821	44	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34751	34756		10.1074/jbc.M303361200	http://dx.doi.org/10.1074/jbc.M303361200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842903	hybrid			2022-12-27	WOS:000185164400005
J	Hanson, JL; Anest, V; Reuther-Madrid, J; Baldwin, AS				Hanson, JL; Anest, V; Reuther-Madrid, J; Baldwin, AS			Oncoprotein suppression of tumor necrosis factor-induced NF kappa B activation is independent of Raf-controlled pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ABL-MEDIATED TRANSFORMATION; TRANSCRIPTIONAL ACTIVITY; RELA/P65 SUBUNIT; ONCOGENIC RAS; P65 SUBUNIT; DNA-BINDING; APOPTOSIS; KINASE; PHOSPHORYLATION; EXPRESSION	Extensive data indicate that the transcription factor NFkappaB is activated by signals downstream of oncoproteins such as Ras or breakpoint cluster region (BCR)-ABL. Consistent with this, evidence has been presented that NFkappaB activity is required for Ras and BCR-ABL to transform cells. However, it remains unclear whether these oncoproteins activate a full spectrum of NFkappaB-dependent gene expression or whether they may augment or interfere with other stimuli that activate NFkappaB. The data presented here indicate that BCR-ABL expression in 32D myeloid cells or oncogenic Ras expression in murine fibroblasts blocks the ability of tumor necrosis factor (TNF) to activate NFkappaB. This suppression of NFkappaB is manifested by an inhibition of TNF-induced inhibitor of NFkappaB (IKK) activity and NFkappaB DNA binding potential but not by blocking TNF-induced nuclear accumulation of NFkappaB/p65. The inhibition of NFkappaB is not observed in oncogenic Raf-expressing cells and is not fully restored by the suppression of PI3-kinase or MEK pathways. Oncogenic Ras suppresses the ability of TNF to activate the expression of NFkappaB-dependent genes, such as iNOS ( inducible nitric oxide synthase) and RANTES ( regulated on activation normal T-cell expressed and secreted). These studies suggest that the ability of Ras and BCR-ABL to activate NFkappaB involves an uncharacterized pathway that does not involve classic IKK activity and that suppresses the TNF-induced IKK pathway through a Raf/MEK/Erk-independent mechanism.	Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill	Baldwin, AS (corresponding author), Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.				NATIONAL CANCER INSTITUTE [R01CA073756] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI035098, R01AI035098] Funding Source: NIH RePORTER; NCI NIH HHS [CA73756] Funding Source: Medline; NIAID NIH HHS [AI35098] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arsura M, 2000, MOL CELL BIOL, V20, P5381, DOI 10.1128/MCB.20.15.5381-5391.2000; BALDWIN AS, 1988, P NATL ACAD SCI USA, V85, P723, DOI 10.1073/pnas.85.3.723; BOS JL, 1989, CANCER RES, V49, P4682; Campbell SL, 1998, ONCOGENE, V17, P1395, DOI 10.1038/sj.onc.1202174; Chen LF, 2001, SCIENCE, V293, P1653, DOI 10.1126/science.1062374; Chen LF, 2002, EMBO J, V21, P6539, DOI 10.1093/emboj/cdf660; Cortez D, 1996, ONCOGENE, V13, P2589; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; EHRLICH T, 1993, IMMUNOL LETT, V39, P3, DOI 10.1016/0165-2478(93)90156-V; Finco TS, 1997, J BIOL CHEM, V272, P24113, DOI 10.1074/jbc.272.39.24113; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; GISHIZKY ML, 1995, P NATL ACAD SCI USA, V92, P10889, DOI 10.1073/pnas.92.24.10889; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; HASKILL S, 1991, CELL, V65, P1281, DOI 10.1016/0092-8674(91)90022-Q; Jeay S, 2003, MOL CELL BIOL, V23, P2251, DOI 10.1128/MCB.23.7.2251-2263.2003; Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; LANGER SJ, 1992, MOL CELL BIOL, V12, P5355, DOI 10.1128/MCB.12.12.5355; LI CCH, 1994, J BIOL CHEM, V269, P30089; Liu Qingyan, 2001, Molecular Cell Biology Research Communications, V4, P381, DOI 10.1006/mcbr.2001.0304; Madrid LV, 2000, MOL CELL BIOL, V20, P1626, DOI 10.1128/MCB.20.5.1626-1638.2000; Madrid LV, 2001, J BIOL CHEM, V276, P18934, DOI 10.1074/jbc.M101103200; Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812; Mayo MW, 2001, METHOD ENZYMOL, V333, P73; MAYO MW, 2000, BIOCHIM BIOPHYS ACTA, V1470, P55; Mercurio F, 1999, ONCOGENE, V18, P6163, DOI 10.1038/sj.onc.1203174; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Millan O, 2003, ONCOGENE, V22, P477, DOI 10.1038/sj.onc.1206179; NAUMANN M, 1994, EMBO J, V13, P4597, DOI 10.1002/j.1460-2075.1994.tb06781.x; Norris JL, 1999, J BIOL CHEM, V274, P13841, DOI 10.1074/jbc.274.20.13841; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; Perez P, 2000, MOL CARCINOGEN, V27, P272, DOI 10.1002/(SICI)1098-2744(200004)27:4<272::AID-MC5>3.0.CO;2-P; Rees RC, 1999, CANCER IMMUNOL IMMUN, V48, P374, DOI 10.1007/s002620050589; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Reuther JY, 1998, GENE DEV, V12, P968, DOI 10.1101/gad.12.7.968; Sakurai H, 1999, J BIOL CHEM, V274, P30353, DOI 10.1074/jbc.274.43.30353; Sizemore N, 2002, J BIOL CHEM, V277, P3863, DOI 10.1074/jbc.M110572200; Smyth MJ, 2001, NAT IMMUNOL, V2, P293, DOI 10.1038/86297; SOLANA R, 1992, INVAS METAST, V12, P210; Sosic D, 2003, CELL, V112, P169, DOI 10.1016/S0092-8674(03)00002-3; Wang D, 2000, J BIOL CHEM, V275, P32592, DOI 10.1074/jbc.M001358200; Wang D, 1998, J BIOL CHEM, V273, P29411, DOI 10.1074/jbc.273.45.29411; Yang BS, 1996, MOL CELL BIOL, V16, P538; Yeung KC, 2001, MOL CELL BIOL, V21, P7207, DOI 10.1128/MCB.21.21.7207-7217.2001; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6; Zhong HH, 1998, MOL CELL, V1, P661, DOI 10.1016/S1097-2765(00)80066-0	46	23	24	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34910	34917		10.1074/jbc.M304189200	http://dx.doi.org/10.1074/jbc.M304189200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851413	Green Published, hybrid			2022-12-27	WOS:000185164400022
J	Ragab, A; Bodin, S; Viala, C; Chap, H; Payrastre, B; Ragab-Thomas, J				Ragab, A; Bodin, S; Viala, C; Chap, H; Payrastre, B; Ragab-Thomas, J			The tyrosine phosphatase 1B regulates linker for activation of T-cell phosphorylation and platelet aggregation upon Fc gamma RIIa cross-linking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-INDUCED THROMBOCYTOPENIA; THROMBIN-STIMULATED PLATELETS; RECEPTOR GLYCOPROTEIN VI; PHOSPHOLIPASE C-GAMMA-2; MEDIATED ACTIVATION; INSULIN-RECEPTOR; IMMUNOGLOBULIN-G; PROTEIN; COLLAGEN; INTEGRIN	Human platelets express the receptor for immunoglobulin G, FcgammaRIIa, that triggers cell aggregation upon interaction with immune complexes. Here, we report that the rapid tyrosine phosphorylation of the Linker for Activation of T-cell (LAT) in human platelets stimulated by FcgammaRIIa cross-linking was followed by its complete dephosphorylation in an alphaIIb/beta3 integrin-dependent manner. Concomitant to LAT dephosphorylation, the protein tyrosine phosphatase 1B (PTP1B) was activated through a mechanism involving its proteolysis by calpains downstream of integrins. Both PTP1B and LAT were associated with the actin cytoskeleton complex formed during platelet aggregation. Moreover, phospho-LAT appeared as a good substrate of activated PTP1B in vitro and these two proteins interacted upon platelet activation by FcgammaRIIa cross-linking. The permeant substrate-trapping PTP1B (TAT-PTP1B D181A) partly inhibited LAT dephosphorylation in human platelets, strongly suggesting that this tyrosine phosphatase was involved in this regulatory pathway. Using a pharmacological inhibitor, we provide evidence that PTP1B activation and LAT dephosphorylation processes were required for irreversible platelet aggregation. Altogether, our results demonstrate that PTP1B plays an important role in the integrin-mediated dephosphorylation of LAT in human platelets and is involved in the control of irreversible aggregation upon FcgammaRIIa stimulation.	Univ Toulouse 3, Hop Purpan, INSERM,U563,Ctr Physiopathol Toulouse Purpan, Inst Federat Rech 30, F-31059 Toulouse, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Ragab, A (corresponding author), Univ Toulouse 3, Hop Purpan, INSERM,U563,Ctr Physiopathol Toulouse Purpan, Inst Federat Rech 30, Bat C, F-31059 Toulouse, France.			, Bernard/0000-0002-8693-0190				Adachi M, 1996, CELL, V85, P15; ANDERSON CL, 1995, SEMIN THROMB HEMOST, V21, P1, DOI 10.1055/s-2007-1000374; Arabaci G, 1999, J AM CHEM SOC, V121, P5085, DOI 10.1021/ja9906756; Arregui CO, 1998, J CELL BIOL, V143, P861, DOI 10.1083/jcb.143.3.861; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Balsamo J, 1998, J CELL BIOL, V143, P523, DOI 10.1083/jcb.143.2.523; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Bodin S, 2001, BIOCHEMISTRY-US, V40, P15290, DOI 10.1021/bi0109313; Buckley DA, 2002, MOL CELL BIOL, V22, P1998, DOI 10.1128/MCB.22.7.1998-2010.2002; BURRIDGE K, 1995, ANAL BIOCHEM, V232, P56, DOI 10.1006/abio.1995.9961; Chacko GW, 1996, J BIOL CHEM, V271, P10775, DOI 10.1074/jbc.271.18.10775; Cicmil M, 2002, BLOOD, V99, P137, DOI 10.1182/blood.V99.1.137; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; Dadke S, 2000, J BIOL CHEM, V275, P23642, DOI 10.1074/jbc.M001063200; Edmead CE, 1999, FEBS LETT, V459, P27, DOI 10.1016/S0014-5793(99)01209-0; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Flint AJ, 1997, P NATL ACAD SCI USA, V94, P1680, DOI 10.1073/pnas.94.5.1680; Fox JEB, 1996, J BIOL CHEM, V271, P7004, DOI 10.1074/jbc.271.12.7004; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; FRANGIONI JV, 1993, EMBO J, V12, P4843, DOI 10.1002/j.1460-2075.1993.tb06174.x; Gates RE, 1996, ANAL BIOCHEM, V237, P208, DOI 10.1006/abio.1996.0231; Gibbins JM, 1998, J BIOL CHEM, V273, P34437, DOI 10.1074/jbc.273.51.34437; Goldstein BJ, 2000, J BIOL CHEM, V275, P4283, DOI 10.1074/jbc.275.6.4283; Gratacap MP, 1998, J BIOL CHEM, V273, P24314, DOI 10.1074/jbc.273.38.24314; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; Gross BS, 1999, EUR J BIOCHEM, V263, P612, DOI 10.1046/j.1432-1327.1999.00560.x; Ibarrola I, 1997, BBA-MOL CELL RES, V1357, P348, DOI 10.1016/S0167-4889(97)00034-7; Johnson TO, 2002, NAT REV DRUG DISCOV, V1, P696, DOI 10.1038/nrd895; KappersKlunne MC, 1997, BRIT J HAEMATOL, V96, P442, DOI 10.1046/j.1365-2141.1997.d01-2056.x; Kralisz U, 2000, IUBMB LIFE, V49, P33, DOI 10.1080/713803580; Li RY, 1997, THROMB HAEMOSTASIS, V77, P150; LI RY, 1995, EMBO J, V14, P2519, DOI 10.1002/j.1460-2075.1995.tb07249.x; LI RY, 1994, FEBS LETT, V343, P89, DOI 10.1016/0014-5793(94)80613-6; Liu F, 1997, BIOCHEM J, V327, P139, DOI 10.1042/bj3270139; Liu F, 1998, CURR BIOL, V8, P173, DOI 10.1016/S0960-9822(98)70066-1; Liu F, 1996, J BIOL CHEM, V271, P31290, DOI 10.1074/jbc.271.49.31290; Mahadev K, 2001, J BIOL CHEM, V276, P21938, DOI 10.1074/jbc.C100109200; MYERS MP, 2001, J BIOL CHEM, V1, P1; Nagahara H, 1998, NAT MED, V4, P1449, DOI 10.1038/4042; Newman PM, 2000, BLOOD, V96, P182, DOI 10.1182/blood.V96.1.182.013k18_182_187; Nieswandt B, 2000, J BIOL CHEM, V275, P23998, DOI 10.1074/jbc.M003803200; Osdoit S, 2001, J BIOL CHEM, V276, P6703, DOI 10.1074/jbc.M008945200; Pasquet JM, 1999, MOL CELL BIOL, V19, P8326; Poole A, 1997, EMBO J, V16, P2333, DOI 10.1093/emboj/16.9.2333; Rendu F, 1996, PLATELETS, V7, P361; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; Salmeen A, 2000, MOL CELL, V6, P1401, DOI 10.1016/S1097-2765(00)00137-4; Tobin JF, 2002, CURR OPIN DRUG DISC, V5, P500; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	53	25	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40923	40932		10.1074/jbc.M303602200	http://dx.doi.org/10.1074/jbc.M303602200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12857726	hybrid			2022-12-27	WOS:000185847200064
J	Trettel, F; Di Bartolomeo, S; Lauro, C; Catalano, M; Ciotti, MT; Limatola, C				Trettel, F; Di Bartolomeo, S; Lauro, C; Catalano, M; Ciotti, MT; Limatola, C			Ligand-independent CXCR2 dimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR CXCR2; DELTA-OPIOID RECEPTORS; GLUTAMATE RECEPTORS; GRANULE CELLS; HETERODIMERIZATION; DOPAMINE; HOMODIMERIZATION; OLIGOMERIZATION; INTERNALIZATION; SOMATOSTATIN	Homo- and hetero-oligomerization have been reported for several G protein-coupled receptors (GPCRs). The CXCR2 is a GPCR that is activated, among the others, by the chemokines CXCL8 (interleukin-8) and CXCL2 (growth-related gene product beta) to induce cell chemotaxis. We have investigated the oligomerization of CXCR2 receptors expressed in human embryonic kidney cells and generated a series of truncated mutants to determine whether they could negatively regulate the wild-type (wt) receptor functions. CXCR2 receptor oligomerization was also studied by coimmunoprecipitation of green fluorescent protein- and V5-tagged CXCR2. Truncated CXCR2 receptors retained their ability to form oligomers only if the region between the amino acids Ala-106 and Lys-163 was present. In contrast, all of the deletion mutants analyzed were able to form heterodimers with the wt CXCR2 receptor, albeit with different efficiency, competing for wt/wt dimer formation. The truncated CXCR2 mutants were not functional and, when coexpressed with wt CXCR2, interfered with receptor functions, impairing cell signaling and chemotaxis. When CXCR2 was expressed with the AMPA-type glutamate receptor GluR1, CXCR2 dimerization was again impaired in a dose-dependent way, and receptor functions were prejudiced. In contrast, CXCR1, a chemokine receptor that shares many similarities with CXCR2, did not dimerize alone or with CXCR2 and when coexpressed with CXCR2 did not impair receptor signaling and chemotaxis. The formation of CXCR2 dimers was also confirmed in cerebellar neuron cells. Taken together, we conclude from these studies that CXCR2 functions as a dimer and that truncated receptors negatively modulate receptor activities competing for the formation of wt/wt dimers.	Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol, I-00185 Rome, Italy; San Rafaele Pisana, Dipartimento Sci Internist, I-00163 Rome, Italy; CNR, Ist Neurobiol, I-00137 Rome, Italy	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR)	Limatola, C (corresponding author), Univ Roma La Sapienza, Dipartimento Fisiol Umana & Farmacol, Piazzale Aldo Moro 5, I-00185 Rome, Italy.	cristina.limatola@uniroma1.it	Di+Bartolomeo, Sabrina/AAB-9791-2019; Lauro, Clotilde/Q-6110-2016	limatola, cristina/0000-0001-7504-8197; trettel, flavia/0000-0002-7983-2955; DI BARTOLOMEO, Sabrina/0000-0002-5748-1541; Catalano, Myriam/0000-0003-4638-9202	Telethon [E.0912] Funding Source: Medline	Telethon(Fondazione Telethon)		AbdAlla S, 2001, J BIOL CHEM, V276, P39721, DOI 10.1074/jbc.M105253200; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; Babcock GJ, 2003, J BIOL CHEM, V278, P3378, DOI 10.1074/jbc.M210140200; Baggiolini M, 2000, IMMUNOL TODAY, V21, P418, DOI 10.1016/S0167-5699(00)01672-8; Bai M, 1998, J BIOL CHEM, V273, P23605, DOI 10.1074/jbc.273.36.23605; Benkirane M, 1997, J BIOL CHEM, V272, P30603, DOI 10.1074/jbc.272.49.30603; Bouvier M, 2001, NAT REV NEUROSCI, V2, P274, DOI 10.1038/35067575; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Fotiadis D, 2003, NATURE, V421, P127, DOI 10.1038/421127a; George SR, 2000, J BIOL CHEM, V275, P26128, DOI 10.1074/jbc.M000345200; George SR, 1998, J BIOL CHEM, V273, P30244, DOI 10.1074/jbc.273.46.30244; Gomes I, 2000, J NEUROSCI, V20, part. no., DOI 10.1523/JNEUROSCI.20-22-j0007.2000; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; HERBERG JT, 1984, J BIOL CHEM, V259, P9285; Horcher M, 1998, CYTOKINE, V10, P1, DOI 10.1006/cyto.1997.0251; Horuk R, 2001, CYTOKINE GROWTH F R, V12, P313, DOI 10.1016/S1359-6101(01)00014-4; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Ji IH, 2002, MOL ENDOCRINOL, V16, P1299, DOI 10.1210/me.16.6.1299; Jones KA, 1998, NATURE, V396, P674, DOI 10.1038/25348; JONES SA, 1995, FEBS LETT, V364, P211, DOI 10.1016/0014-5793(95)00397-R; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Kaupmann K, 1998, NATURE, V396, P683, DOI 10.1038/25360; Knall C, 1997, P NATL ACAD SCI USA, V94, P3052, DOI 10.1073/pnas.94.7.3052; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Lax P, 2002, J NEUROIMMUNOL, V129, P66, DOI 10.1016/S0165-5728(02)00178-9; Leong SR, 1997, PROTEIN SCI, V6, P609; Limatola C, 2003, J NEUROIMMUNOL, V134, P61, DOI 10.1016/S0165-5728(02)00401-0; Limatola C, 2002, J NEUROIMMUNOL, V123, P9, DOI 10.1016/S0165-5728(01)00472-6; Limatola C, 1999, J BIOL CHEM, V274, P36537, DOI 10.1074/jbc.274.51.36537; Limatola C, 2000, P NATL ACAD SCI USA, V97, P6197, DOI 10.1073/pnas.090105997; Lowman HB, 1997, PROTEIN SCI, V6, P598; Mellado M, 2001, EMBO J, V20, P2497, DOI 10.1093/emboj/20.10.2497; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Nelson G, 2002, NATURE, V416, P199, DOI 10.1038/nature726; Ng GYK, 1996, BIOCHEM BIOPH RES CO, V227, P200, DOI 10.1006/bbrc.1996.1489; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Romano C, 1996, J BIOL CHEM, V271, P28612, DOI 10.1074/jbc.271.45.28612; Scarselli M, 2001, J BIOL CHEM, V276, P30308, DOI 10.1074/jbc.M102297200; Shibata F, 2002, BIOL PHARM BULL, V25, P1217, DOI 10.1248/bpb.25.1217; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Van Brocklyn JR, 2002, BBA-MOL CELL BIOL L, V1582, P89, DOI 10.1016/S1388-1981(02)00141-5; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; White JH, 1998, NATURE, V396, P679, DOI 10.1038/25354; Xu JG, 2003, J BIOL CHEM, V278, P10770, DOI 10.1074/jbc.M207968200; Zhu XY, 1998, BIOCHEMISTRY-US, V37, P15773, DOI 10.1021/bi981162z	48	88	89	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40980	40988		10.1074/jbc.M306815200	http://dx.doi.org/10.1074/jbc.M306815200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12888558	hybrid, Green Published			2022-12-27	WOS:000185847200071
J	Bar, D; Golbik, R; Hubner, G; Lilie, H; Muller, EC; Naumann, M; Otto, A; Reuter, R; Breunig, KD; Kriegel, TM				Bar, D; Golbik, R; Hubner, G; Lilie, H; Muller, EC; Naumann, M; Otto, A; Reuter, R; Breunig, KD; Kriegel, TM			The unique hexokinase of Kluyveromyces lactis - Molecular and functional characterization and evaluation of a role in glucose signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBON CATABOLITE REPRESSION; IN-VIVO PHOSPHORYLATION; SACCHAROMYCES-CEREVISIAE; YEAST HEXOKINASE; TRANSCRIPTIONAL REGULATION; GENE; PII; SUGAR; EXPRESSION; MUTANTS	The Crabtree-negative yeast Kluyveromyces lactis is capable of adjusting its glycolytic flux to the requirements of respiration by tightly regulating glucose uptake. RAG5 encoding the only glucose and fructose phosphorylating enzyme present in K. lactis is required for the up-regulation of glucose transport and also for glucose repression. To understand the significance of the molecular identity and specific function(s) of the corresponding kinase to glucose signaling, RAG5 was overexpressed and its gene product KlHxk1 (Rag5p) isolated and characterized. Stopped-flow kinetics and sedimentation analysis indicated a monomer-homodimer equilibrium of KlHxk1 in a condition of catalysis, i.e. in the presence of substrates and products. The kinetic constants of ATP-dependent glucose phosphorylation identified a 53-kDa monomer as the high affinity/high activity form of the novel enzyme for both glycolytic substrates suggesting a control of glucose phosphorylation at the level of dimer formation and dissociation. In contrast to the highly homologous hexokinase isoenzyme 2 of Saccharomyces cerevisiae (ScHxk2), KlHxk1 was not inhibited by free ATP in a physiological range of nucleotide concentration. Mass spectrometric sequencing of tryptic peptides of KlHxk1 identified unmodified serine at amino acid position 156. The corresponding amino acid in ScHxk2 is serine 157, which represents the autophosphorylation-inactivation site. KlHxk1 did not display, however, the typical pattern of inactivation under the respective in vitro conditions and maintained a high residual glucose phosphorylating activity. The biophysical and functional data are discussed with respect to a possible regulatory role of KlHxk1 in glucose metabolism and signaling in K. lactis.	Tech Univ Dresden, Med Fak Carl Gustav Carus, Inst Physiol Chem, D-01307 Dresden, Germany; Univ Halle Wittenberg, Inst Biochem, D-06120 Halle Saale, Germany; Univ Halle Wittenberg, Inst Biotechnol, D-06120 Halle Saale, Germany; Max Delbruck Ctr Mol Med, D-13092 Berlin, Germany; Univ Leipzig, Fak Med, Inst Biochem, D-04103 Leipzig, Germany; Univ Halle Wittenberg, Inst Genet, D-06120 Halle Saale, Germany	Technische Universitat Dresden; Carl Gustav Carus University Hospital; Martin Luther University Halle Wittenberg; Martin Luther University Halle Wittenberg; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Leipzig University; Martin Luther University Halle Wittenberg	Kriegel, TM (corresponding author), Tech Univ Dresden, Med Fak Carl Gustav Carus, Inst Physiol Chem, Fetscherstr 74, D-01307 Dresden, Germany.							Behlke J, 1998, BIOCHEMISTRY-US, V37, P11989, DOI 10.1021/bi980914m; BENNETT WS, 1980, J MOL BIOL, V140, P183, DOI 10.1016/0022-2836(80)90102-3; Bianchi MM, 1996, MOL MICROBIOL, V19, P27, DOI 10.1046/j.1365-2958.1996.346875.x; Billard P, 1996, J BACTERIOL, V178, P5860, DOI 10.1128/jb.178.20.5860-5866.1996; Bolotin-Fukuhara M, 2000, FEBS LETT, V487, P66, DOI 10.1016/S0014-5793(00)02282-1; Breunig KD, 2000, ENZYME MICROB TECH, V26, P771, DOI 10.1016/S0141-0229(00)00170-8; BREUNIG KD, 1987, MOL CELL BIOL, V7, P4400, DOI 10.1128/MCB.7.12.4400; BREUNIG KD, 1989, MOL GEN GENET, V216, P422, DOI 10.1007/BF00334386; Bui DM, 1996, APPL MICROBIOL BIOT, V45, P102, DOI 10.1007/s002530050655; CARLSON M, 1987, J BACTERIOL, V169, P4873, DOI 10.1128/jb.169.11.4873-4877.1987; DeWinde JH, 1996, EUR J BIOCHEM, V241, P633; DURCHSCHLAG H, 1986, THERMODYNAMIC DATA B, P45; ENTIAN KD, 1984, J BACTERIOL, V158, P29, DOI 10.1128/JB.158.1.29-35.1984; Ernandes JR, 1998, YEAST, V14, P255, DOI 10.1002/(SICI)1097-0061(199802)14:3<255::AID-YEA228>3.0.CO;2-N; FERRERO I, 1978, BIOCHEM BIOPH RES CO, V80, P340, DOI 10.1016/0006-291X(78)90682-4; GANCEDO JM, 1992, EUR J BIOCHEM, V206, P297, DOI 10.1111/j.1432-1033.1992.tb16928.x; GANCEDO JM, 1977, J BIOL CHEM, V252, P4443; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOFFRINI P, 1989, YEAST, V5, P99, DOI 10.1002/yea.320050205; GOFFRINI P, 1995, MICROBIOL-SGM, V141, P441, DOI 10.1099/13500872-141-2-441; Golbik R, 2001, BIOCHEMISTRY-US, V40, P1083, DOI 10.1021/bi001745k; Heidrich K, 1997, BIOCHEMISTRY-US, V36, P1960, DOI 10.1021/bi9623643; Herrero P, 1998, FEBS LETT, V434, P71, DOI 10.1016/S0014-5793(98)00872-2; HERRERO P, 1995, YEAST, V11, P137, DOI 10.1002/yea.320110205; Herrero P, 1999, BIOCHEM J, V343, P319, DOI 10.1042/0264-6021:3430319; Hohmann S, 1999, MICROBIOL-UK, V145, P703, DOI 10.1099/13500872-145-3-703; Kiers J, 1998, YEAST, V14, P459, DOI 10.1002/(SICI)1097-0061(19980330)14:5<459::AID-YEA248>3.0.CO;2-O; Kraakman LS, 1999, BIOCHEM J, V343, P159, DOI 10.1042/0264-6021:3430159; KRIEGEL TM, 1994, BIOCHEMISTRY-US, V33, P148, DOI 10.1021/bi00167a019; Larsson C, 2000, YEAST, V16, P797, DOI 10.1002/1097-0061(20000630)16:9<797::AID-YEA553>3.3.CO;2-X; LOBO Z, 1977, ARCH BIOCHEM BIOPHYS, V182, P639, DOI 10.1016/0003-9861(77)90544-6; Meijer MMC, 1998, J BIOL CHEM, V273, P24102, DOI 10.1074/jbc.273.37.24102; Milkowski C, 2001, J BACTERIOL, V183, P5223, DOI 10.1128/JB.183.18.5223-5229.2001; Moreno F, 2002, FEMS MICROBIOL REV, V26, P83, DOI 10.1111/j.1574-6976.2002.tb00600.x; MORENO F, 1986, EUR J BIOCHEM, V161, P565, DOI 10.1111/j.1432-1033.1986.tb10479.x; ORENTLICHER M, 1977, AM J PHYSIOL, V233, pC127, DOI 10.1152/ajpcell.1977.233.5.C127; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Postic C, 2001, RECENT PROG HORM RES, V56, P195, DOI 10.1210/rp.56.1.195; PRIOR C, 1993, MOL CELL BIOL, V13, P3882, DOI 10.1128/MCB.13.7.3882; Randez-Gil F, 1998, FEBS LETT, V425, P475, DOI 10.1016/S0014-5793(98)00289-0; Randez-Gil F, 1998, MOL CELL BIOL, V18, P2940, DOI 10.1128/MCB.18.5.2940; Rolland F, 2001, TRENDS BIOCHEM SCI, V26, P310, DOI 10.1016/S0968-0004(01)01805-9; Schaffrath R, 2000, FUNGAL GENET BIOL, V30, P173, DOI 10.1006/fgbi.2000.1221; SHERMAN F, 1990, METHOD ENZYMOL, V194, P3; Versele M, 2001, EMBO REP, V2, P574, DOI 10.1093/embo-reports/kve132; VOJTEK AB, 1990, EUR J BIOCHEM, V190, P371, DOI 10.1111/j.1432-1033.1990.tb15585.x; WALSH RB, 1991, GENETICS, V128, P521; Weirich J, 1997, EUR J BIOCHEM, V249, P248, DOI 10.1111/j.1432-1033.1997.t01-1-00248.x; WESOLOWSKI M, 1982, CURR GENET, V150, P137; WESOLOWSKILOUVEL M, 1988, YEAST, V4, P71, DOI 10.1002/yea.320040108; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; Xiao WY, 2000, PLANT MOL BIOL, V44, P451, DOI 10.1023/A:1026501430422; XU LZ, 1995, BIOCHEMISTRY-US, V34, P6083, DOI 10.1021/bi00018a011; ZACHARIAE W, 1993, NUCLEIC ACIDS RES, V21, P69, DOI 10.1093/nar/21.1.69; ZACHARIAE W, 1994, THESIS H HEINE U DUS; Zenke FT, 1996, SCIENCE, V272, P1662, DOI 10.1126/science.272.5268.1662	56	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39280	39286		10.1074/jbc.M305706200	http://dx.doi.org/10.1074/jbc.M305706200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882981	hybrid			2022-12-27	WOS:000185713800004
J	Ben-Zaken, O; Tzaban, S; Tal, Y; Horonchik, L; Esko, JD; Vlodavsky, I; Taraboulos, A				Ben-Zaken, O; Tzaban, S; Tal, Y; Horonchik, L; Esko, JD; Vlodavsky, I; Taraboulos, A			Cellular heparan sulfate participates in the metabolism of prions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; GPI-ANCHORED PROTEINS; BETA-D-XYLOSIDES; CULTURED-CELLS; SCRAPIE ISOFORM; SPONGIFORM ENCEPHALOPATHY; EXTRACELLULAR-MATRIX; INCUBATION PERIOD; AMYLOID PLAQUES; PRP	During prion diseases, the host protein PrPC is refolded into an abnormal conformer "prion" PrPSc. Histological and pharmacological data have suggested that glycosaminoglycans may be involved in the development of prion diseases. Here we present the first direct evidence that cellular glycosaminoglycans play a role in the biogenesis of PrPSc in prion-infected ScN2a cells. When ScN2a cells were incubated with estradiol beta-D-xyloside to inhibit the glycosylation of proteoglycans, PrPSc was vastly reduced. Treating ScN2a-M cells with heparinase III, but not with heparinase I or chondroitinase ABC, caused a profound reduction of PrPSc. In contrast, neither the amount of PrPC nor its subcellular distribution were affected as assayed by immunofluorescence microscopy and flotation procedures. In vitro treatment of ScN2a membranes with heparinase III at either neutral or acidic pH did not reduce the level of protease-resistant PrPSc. The inhibitor of sulfation, sodium chlorate, vastly reduces PrPSc in ScN2a cells (Gabizon, R., Meiner, Z., Halimi, M., and Ben-Sasson, S. A. ( 1993) J. Cell. Physiol. 157, 319-325). Both soluble heparan sulfate and chondroitin sulfate partially restored the level of PrPSc in chlorate-treated cells. We conclude that heparinase III-sensitive, presumably undersulfated, cellular heparan sulfate plays a significant role in the biogenesis of PrPSc in ScN2a cells.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel; Hadassah Univ Hosp, Dept Oncol, IL-91120 Jerusalem, Israel; Univ Calif San Diego, Dept Cellular & Mol Med, Glycobiol Res & Training Ctr, La Jolla, CA 92093 USA; Technion Israel Inst Technol, Bruce Rappaport Fac Med, Canc & Vasc Biol Res Ctr, IL-31096 Haifa, Israel	Hebrew University of Jerusalem; Hebrew University of Jerusalem; University of California System; University of California San Diego; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Taraboulos, A (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Mol Biol, IL-91120 Jerusalem, Israel.				NATIONAL CANCER INSTITUTE [R01CA046462] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033063, R37GM033063] Funding Source: NIH RePORTER; NCI NIH HHS [CA46462] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AVIEZER D, 1994, J BIOL CHEM, V269, P114; BAEUERLE PA, 1986, BIOCHEM BIOPH RES CO, V141, P870, DOI 10.1016/S0006-291X(86)80253-4; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Birkett CR, 2001, EMBO J, V20, P3351, DOI 10.1093/emboj/20.13.3351; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BORCHELT DR, 1992, J BIOL CHEM, V267, P16188; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1994, J VIROL, V68, P2135, DOI 10.1128/JVI.68.4.2135-2141.1994; CAUGHEY B, 1993, J VIROL, V67, P643, DOI 10.1128/JVI.67.2.643-650.1993; COHEN FE, 1994, SCIENCE, V264, P530, DOI 10.1126/science.7909169; Cohlberg JA, 2002, BIOCHEMISTRY-US, V41, P1502, DOI 10.1021/bi011711s; COME JH, 1993, P NATL ACAD SCI USA, V90, P5959, DOI 10.1073/pnas.90.13.5959; Diaz-Nido J, 2002, PEPTIDES, V23, P1323, DOI 10.1016/S0196-9781(02)00068-2; EHLERS B, 1984, J GEN VIROL, V65, P1325, DOI 10.1099/0022-1317-65-8-1325; Filmus J, 2001, J CLIN INVEST, V108, P497, DOI 10.1172/JCI13712; Flechsig E, 2000, NEURON, V27, P399, DOI 10.1016/S0896-6273(00)00046-5; FRITZ TA, 1994, J BIOL CHEM, V269, P300; GABIZON R, 1993, J CELL PHYSIOL, V157, P319, DOI 10.1002/jcp.1041570215; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; GIBBS CJ, 1969, SCIENCE, V165, P1023, DOI 10.1126/science.165.3897.1023; Gilch S, 2001, EMBO J, V20, P3957, DOI 10.1093/emboj/20.15.3957; Graner E, 2000, MOL BRAIN RES, V76, P85, DOI 10.1016/S0169-328X(99)00334-4; GUPTABANSAL R, 1995, J BIOL CHEM, V270, P18666, DOI 10.1074/jbc.270.31.18666; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Iozzo RV, 1998, ANNU REV BIOCHEM, V67, P609, DOI 10.1146/annurev.biochem.67.1.609; ISHAIMICHAELI R, 1992, BIOCHEMISTRY-US, V31, P2080, DOI 10.1021/bi00122a027; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KELLER KM, 1989, BIOCHEMISTRY-US, V28, P8100, DOI 10.1021/bi00446a021; KISILEVSKY R, 1995, NAT MED, V1, P143, DOI 10.1038/nm0295-143; LADOGANA A, 1992, J GEN VIROL, V73, P661, DOI 10.1099/0022-1317-73-3-661; LUGEMWA FN, 1991, J BIOL CHEM, V266, P6674; MACCARANA M, 1993, J BIOL CHEM, V268, P23898; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; McBride PA, 1998, EXP NEUROL, V149, P447, DOI 10.1006/exnr.1997.6740; MCKINLEY MP, 1991, LAB INVEST, V65, P622; MEYER RK, 1986, P NATL ACAD SCI USA, V83, P2310, DOI 10.1073/pnas.83.8.2310; NADER HB, 1990, J BIOL CHEM, V265, P16807; Naslavsky N, 1999, J BIOL CHEM, V274, P20763, DOI 10.1074/jbc.274.30.20763; Naslavsky N, 1997, J BIOL CHEM, V272, P6324, DOI 10.1074/jbc.272.10.6324; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1982, SCIENCE, V216, P136, DOI 10.1126/science.6801762; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rieger R, 1997, NAT MED, V3, P1383, DOI 10.1038/nm1297-1383; ROGERS M, 1993, P NATL ACAD SCI USA, V90, P3182, DOI 10.1073/pnas.90.8.3182; ROGERS M, 1991, J IMMUNOL, V147, P3568; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; SCHWARTZ NB, 1974, P NATL ACAD SCI USA, V71, P4047, DOI 10.1073/pnas.71.10.4047; SCOTT MR, 1992, PROTEIN SCI, V1, P986, DOI 10.1002/pro.5560010804; Shaked GM, 2001, J BIOL CHEM, V276, P14324, DOI 10.1074/jbc.M007815200; SHYNG SL, 1995, J BIOL CHEM, V270, P30221; SNOW AD, 1989, ACTA NEUROPATHOL, V77, P337, DOI 10.1007/BF00687367; SNOW AD, 1994, NEURON, V12, P219, DOI 10.1016/0896-6273(94)90165-1; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; TARABOULOS A, 1992, MOL BIOL CELL, V3, P851, DOI 10.1091/mbc.3.8.851; TELLING GC, 1995, CELL, V83, P79, DOI 10.1016/0092-8674(95)90236-8; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Turnbull J, 2001, TRENDS CELL BIOL, V11, P75, DOI 10.1016/S0962-8924(00)01897-3; TURNBULL JE, 1992, J BIOL CHEM, V267, P10337; Tzaban S, 2002, BIOCHEMISTRY-US, V41, P12868, DOI 10.1021/bi025958g; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; VLODAVSKY I, 1983, CANCER RES, V43, P2704; VLODAVSKY I, 1999, CURRENT PROTOCOLS CE, V1; Warner RG, 2002, J BIOL CHEM, V277, P18421, DOI 10.1074/jbc.M110406200; WILESMITH JW, 1988, VET REC, V123, P638; Wong C, 2001, EMBO J, V20, P377, DOI 10.1093/emboj/20.3.377; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yanai A, 1999, FEBS LETT, V460, P11, DOI 10.1016/S0014-5793(99)01316-2; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325	74	116	125	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40041	40049		10.1074/jbc.M301152200	http://dx.doi.org/10.1074/jbc.M301152200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871949	hybrid			2022-12-27	WOS:000185713800094
J	Hui, DJ; Bhasker, CR; Merrick, WC; Sen, GC				Hui, DJ; Bhasker, CR; Merrick, WC; Sen, GC			Viral stress-inducible protein p56 inhibits translation by blocking the interaction of eIF3 with the ternary complex eIF2 center dot GTP center dot Met-tRNA(i)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOME ENTRY SITE; HEPATITIS-C VIRUS; INITIATION-FACTOR (EIF)-4F; FACTOR 4G EIF4G; INTERFERON; BINDING; RNA; DOMAINS; DISTINCT; SUBUNIT	Viral stress-inducible protein p56 is produced in response to viral stress-inducing agents such as double-stranded RNA and interferon, as well as other poorly understood mechanisms of viral infection. It has been shown previously that p56 is able to bind the eukaryotic initiation factor 3e(eIF3e) (p48/Int-6) subunit of the eukaryotic translation initiation factor eIF3 and function as an inhibitor of translation in vitro and in vivo. The exact mechanism by which p56 is able to interfere with protein synthesis is not understood. Based on the known roles of eIF3 in the initiation pathway, we employed assays designed to individually look at specific functions of eIF3 and the effect of p56 on these eIF3-mediated functions. These assays examined the effect of p56 on ribosome dissociation, the eIF3.eIF4F interaction, and enhancement of the ternary complex eIF2.GTP.Met-tRNA(i) formation. Here we report that p56 is able to inhibit translation initiation specifically at the level of eIF3.ternary complex formation. The effect of p56-mediated inhibition was also examined in two different contexts, cap-mediated and encephalomyocarditis virus internal ribosomal entry site-mediated translation. Whereas cap-dependent initiation was severely inhibited by p56, internal ribosomal entry site-mediated translation appeared to be insensitive to p56.	Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, Cleveland, OH 44195 USA; Case Western Reserve Univ, Sch Med, Grad Program Mol Virol, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Biochem, Cleveland, OH 44106 USA	Cleveland Clinic Foundation; Case Western Reserve University; Case Western Reserve University	Sen, GC (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Biol NC20, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org	Hui, Daniel J/H-8855-2013	Hui, Daniel J/0000-0003-0294-3582	NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026796] Funding Source: NIH RePORTER; NCI NIH HHS [CA-62220, CA-68782] Funding Source: Medline; NIGMS NIH HHS [GM-26796] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTHONY DD, 1991, J BIOL CHEM, V266, P10218; ASANO K, 2000, METH MOL B, V177, P179; BENNE R, 1976, P NATL ACAD SCI USA, V73, P3005, DOI 10.1073/pnas.73.9.3005; BLUYSSEN HAR, 1994, GENOMICS, V24, P137, DOI 10.1006/geno.1994.1591; Chaudhuri J, 1999, J BIOL CHEM, V274, P17975, DOI 10.1074/jbc.274.25.17975; Das AK, 1998, EMBO J, V17, P1192, DOI 10.1093/emboj/17.5.1192; de Veer MJ, 1998, GENOMICS, V54, P267, DOI 10.1006/geno.1998.5555; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Guo JJ, 2000, J VIROL, V74, P1892, DOI 10.1128/JVI.74.4.1892-1899.2000; Guo JJ, 2000, EMBO J, V19, P6891, DOI 10.1093/emboj/19.24.6891; GUPTA NK, 1990, POSTTRANSCRIPTIONAL, P521; Imataka H, 1997, MOL CELL BIOL, V17, P6940, DOI 10.1128/MCB.17.12.6940; Jan E, 2002, J MOL BIOL, V324, P889, DOI 10.1016/S0022-2836(02)01099-9; Johannes G, 1999, P NATL ACAD SCI USA, V96, P13118, DOI 10.1073/pnas.96.23.13118; LAMPHEAR BJ, 1995, J BIOL CHEM, V270, P21975, DOI 10.1074/jbc.270.37.21975; Lytle JR, 2002, RNA, V8, P1045, DOI 10.1017/S1355838202029965; Lytle JR, 2001, J VIROL, V75, P7629, DOI 10.1128/JVI.75.16.7629-7636.2001; Mathews MB, 2000, COLD SPRING HARBOR M, V39, P1; Merrick W C, 1979, Methods Enzymol, V60, P101, DOI 10.1016/S0076-6879(79)60010-1; Merrick W C, 1979, Methods Enzymol, V60, P108, DOI 10.1016/S0076-6879(79)60011-3; MERRICK WC, 1973, P NATL ACAD SCI USA, V70, P2220, DOI 10.1073/pnas.70.8.2220; Niikura T, 1997, BLOOD CELL MOL DIS, V23, P337, DOI 10.1006/bcmd.1997.0151; Olsen DS, 2003, EMBO J, V22, P193, DOI 10.1093/emboj/cdg030; Pestova TV, 1996, MOL CELL BIOL, V16, P6859, DOI 10.1128/mcb.16.12.6859; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; PETERSON DT, 1979, J BIOL CHEM, V254, P2509; Sarnow P, 2003, J VIROL, V77, P2801, DOI 10.1128/JVI.77.5.2801-2806.2003; Sizova DV, 1998, J VIROL, V72, P4775, DOI 10.1128/JVI.72.6.4775-4782.1998; Valasek L, 2002, EMBO J, V21, P5886, DOI 10.1093/emboj/cdf563; VANDERVELDEN A, 1995, VIROLOGY, V214, P82, DOI 10.1006/viro.1995.9952; Wang CF, 2003, J VIROL, V77, P3898, DOI 10.1128/JVI.77.7.3898-3912.2003; WATHELET MG, 1988, FEBS LETT, V231, P164, DOI 10.1016/0014-5793(88)80724-5; YARUS M, 1969, J MOL BIOL, V42, P171, DOI 10.1016/0022-2836(69)90037-0; YODERHILL J, 1993, J BIOL CHEM, V268, P5566; Yu M, 1997, P NATL ACAD SCI USA, V94, P7406, DOI 10.1073/pnas.94.14.7406	36	121	127	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39477	39482		10.1074/jbc.M305038200	http://dx.doi.org/10.1074/jbc.M305038200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885778	hybrid			2022-12-27	WOS:000185713800026
J	Mould, AP; Symonds, EJH; Buckley, PA; Grossmann, JG; McEwan, PA; Barton, SJ; Askari, JA; Craig, SE; Bella, J; Humphries, MJ				Mould, AP; Symonds, EJH; Buckley, PA; Grossmann, JG; McEwan, PA; Barton, SJ; Askari, JA; Craig, SE; Bella, J; Humphries, MJ			Structure of an integrin-ligand complex deduced from solution x-ray scattering and site-directed mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMALL-ANGLE SCATTERING; CRYSTAL-STRUCTURE; CELL-ADHESION; CONFORMATIONAL-CHANGES; EXTRACELLULAR SEGMENT; FIBRONECTIN DEPENDS; LOW-RESOLUTION; BINDING-SITES; SYNERGY SITE; A-DOMAIN	The structural basis of the interaction of integrin heterodimers with their physiological ligands is poorly understood. We have used solution x-ray scattering to visualize the head region of integrin alpha(5)beta(1) in an inactive (Ca2+-occupied) state, and in complex with a fragment of fibronectin containing the RGD and synergy recognition sequences. Shape reconstructions of the data have been interpreted in terms of appropriate molecular models. The scattering data suggest that the head region undergoes no gross conformational changes upon ligand binding but do lend support to a proposed outward movement of the hybrid domain in the beta subunit. Fibronectin is observed to bind across the top of the head region, which contains an alpha subunit beta-propeller and a beta subunit vWF type A domain. The model of the complex indicates that the synergy region binds on the side of the beta-propeller domain. In support of this suggestion, mutagenesis of a prominent loop region on the side of the propeller identifies two residues (Tyr(208) and Ile(210)) involved in recognition of the synergy region. Our data provide the first view of a complex between an integrin and a macromolecular ligand in solution, at a nominal resolution of similar to10 Angstrom.	Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, Manchester M13 9PT, Lancs, England; CLRC, Daresbury Lab, Synchrotron Radiat Dept, Warrington WA4 4AD, Cheshire, England	University of Manchester; STFC Daresbury Laboratory	Mould, AP (corresponding author), Univ Manchester, Wellcome Trust Ctr Cell Matrix Res, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Bella, Jordi/F-3794-2018	Bella, Jordi/0000-0003-0443-4562; Humphries, Martin/0000-0002-4331-6967; Mould, Paul/0000-0003-0076-6228; mcewan, paul/0000-0001-6097-1528				AKIYAMA SK, 1995, CELL ADHES COMMUN, V3, P13, DOI 10.3109/15419069509081275; Altroff H, 2001, J BIOL CHEM, V276, P38885, DOI 10.1074/jbc.M105868200; Altroff H, 2003, J BIOL CHEM, V278, P491, DOI 10.1074/jbc.M209992200; AOTA S, 1994, J BIOL CHEM, V269, P24756; Arnaout MA, 2002, IMMUNOL REV, V186, P125, DOI 10.1034/j.1600-065X.2002.18612.x; Baker TS, 1996, CURR OPIN STRUC BIOL, V6, P585, DOI 10.1016/S0959-440X(96)80023-6; Baneres JL, 2000, J BIOL CHEM, V275, P5888, DOI 10.1074/jbc.275.8.5888; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burrows L, 1999, BIOCHEM J, V344, P527, DOI 10.1042/0264-6021:3440527; Chen J, 1996, CELL ADHES COMMUN, V4, P237, DOI 10.3109/15419069609010769; Coe APF, 2001, J BIOL CHEM, V276, P35854, DOI 10.1074/jbc.M103639200; Copie V, 1998, J MOL BIOL, V277, P663; DANEN EHJ, 1995, J BIOL CHEM, V270, P21612, DOI 10.1074/jbc.270.37.21612; Garcia AJ, 2002, BIOCHEMISTRY-US, V41, P9063, DOI 10.1021/bi025752f; Grossmann JG, 2002, BIOCHEMISTRY-US, V41, P3613, DOI 10.1021/bi015955o; Hantgan RR, 1999, BIOCHEMISTRY-US, V38, P14461, DOI 10.1021/bi9907680; Hantgan RR, 2001, PROTEIN SCI, V10, P1614, DOI 10.1110/ps.3001; Humphries MJ, 2003, TRENDS BIOCHEM SCI, V28, P313, DOI 10.1016/S0968-0004(03)00112-9; Humphries MJ, 2003, CURR OPIN STRUC BIOL, V13, P236, DOI 10.1016/S0959-440X(03)00035-6; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Kamata T, 2001, J BIOL CHEM, V276, P44275, DOI 10.1074/jbc.M107021200; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; Leahy DJ, 1996, CELL, V84, P155, DOI 10.1016/S0092-8674(00)81002-8; Lee C, 2001, IBM SYST J, V40, P592, DOI 10.1147/sj.402.0592; Li FY, 2003, BIOPHYS J, V84, P1252, DOI 10.1016/S0006-3495(03)74940-6; Liddington RC, 2002, J CELL BIOL, V158, P833, DOI 10.1083/jcb.200206011; Loftus JC, 1997, J CLIN INVEST, V100, pS77; Mould AP, 2000, J BIOL CHEM, V275, P20324, DOI 10.1074/jbc.M000572200; MOULD AP, 1995, J BIOL CHEM, V270, P26270, DOI 10.1074/jbc.270.44.26270; Mould AP, 2003, J BIOL CHEM, V278, P17028, DOI 10.1074/jbc.M213139200; Mould AP, 2002, J BIOL CHEM, V277, P19800, DOI 10.1074/jbc.M201571200; Mould AP, 1997, J BIOL CHEM, V272, P17283, DOI 10.1074/jbc.272.28.17283; Mould AP, 1998, BIOCHEM J, V331, P821, DOI 10.1042/bj3310821; Mousa SA, 2002, CURR OPIN CHEM BIOL, V6, P534, DOI 10.1016/S1367-5931(02)00350-2; Redick SD, 2000, J CELL BIOL, V149, P521, DOI 10.1083/jcb.149.2.521; SEMENYUK AV, 1991, J APPL CRYSTALLOGR, V24, P537, DOI 10.1107/S002188989100081X; Sheppard D, 2000, MATRIX BIOL, V19, P203, DOI 10.1016/S0945-053X(00)00065-2; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 2002, CURR OPIN STRUC BIOL, V12, P654, DOI 10.1016/S0959-440X(02)00363-9; Svergun DI, 2001, BIOPHYS J, V80, P2946, DOI 10.1016/S0006-3495(01)76260-1; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, IMMUNOL REV, V186, P141, DOI 10.1034/j.1600-065X.2002.18613.x; Tani PH, 2002, BIOCHEM J, V365, P287, DOI 10.1042/BJ20020067; TOWNSANDREWS E, 1989, REV SCI INSTRUM, V60, P2346, DOI 10.1063/1.1140765; WEISEL JW, 1992, J BIOL CHEM, V267, P16637; Witty M, 2002, EMBO J, V21, P4207, DOI 10.1093/emboj/cdf417; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Xiong JP, 2002, SCIENCE, V296, P151, DOI 10.1126/science.1069040	50	88	89	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39993	39999		10.1074/jbc.M304627200	http://dx.doi.org/10.1074/jbc.M304627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871973	hybrid			2022-12-27	WOS:000185713800088
J	Culbertson, SM; Vassilenko, EI; Morrison, LD; Ingold, KU				Culbertson, SM; Vassilenko, EI; Morrison, LD; Ingold, KU			Paradoxical impact of antioxidants on post-Amadori glycoxidation - Counterintuitive increase in the yields of pentosidine and N-epsilon-carboxymethyllysine using a novel multifunctional pyridoxamine derivative	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCATION END-PRODUCTS; MAILLARD CROSS-LINKS; PROTEIN GLYCATION; IN-VITRO; CHEMICAL MODIFICATION; FRUCTOSAMINE ASSAY; DIABETES-MELLITUS; MASS-SPECTROMETRY; OXIDATIVE STRESS; VASCULAR-DISEASE	The inhibition of post-Amadori advanced glycation end product (AGE) formation by three different classes of AGE inhibitors, carbonyl group traps, chelators, and radical-trapping antioxidants, challenge the current paradigms that: 1) AGE inhibitors will not increase the formation of any AGE product, 2) transition metal ions are required for oxidative formation of AGE, and 3) screening AGE inhibitors only in systems containing transition metal ions represents a valid estimate of potential in vivo mechanisms. This work also introduces a novel multifunctional AGE inhibitor, 6-dimethylaminopyridoxamine (dmaPM), designed to function as a combined carbonyl trap, metal ion chelator, and radical-trapping antioxidant. Other AGE inhibitors including pyridoxamine, aminoguanidine, o-phenylenediamine, dipyridoxylamine, and diethylenetriaminepentaacetic acid were also examined. The results during uninterrupted and interrupted ribose glycations show: 1) an unexpected increase in the yield of pentosidine in the presence of radical-trapping phenolic antioxidants such as Trolox and dmaPM, 2) significant formation of N-epsilon-carboxymethyllysine (CML) in the presence of strong chelators and phenolic antioxidants, which implies that there must be nonradical routes to CML, 3) prevention of intermolecular cross-links with radical-trapping inhibitors, and 4) that dmaPM shows excellent inhibition of AGE. Glucose glycations reveal the expected inhibition of pentosidine and CML with all compounds tested, but in a buffer free of trace metal ions the yield of CML in the presence of radical-trapping antioxidants was between the metal ion-free and metal ion-containing controls. Protein molecular weight analyses support the conclusion that Amadori decomposition pathways are constrained in the presence of metal ion chelators and radical traps.	Natl Res Council Canada, Steacie Inst Mol Sci, Ottawa, ON K1A 0R6, Canada; Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	National Research Council Canada; National Research Council Canada	Culbertson, SM (corresponding author), Natl Res Council Canada, Steacie Inst Mol Sci, 100 Sussex Dr, Ottawa, ON K1A 0R6, Canada.							Ahmed MU, 1997, BIOCHEM J, V324, P565, DOI 10.1042/bj3240565; Anderson MM, 1999, J CLIN INVEST, V104, P103, DOI 10.1172/JCI3042; BAKER JR, 1993, CLIN CHEM, V39, P2460; BAKER JR, 1994, CLIN CHEM, V40, P1950; Baynes J.W., 1996, MAILLARD REACTION CO, P55; Baynes JW, 2000, FREE RADICAL BIO MED, V28, P1708, DOI 10.1016/S0891-5849(00)00228-8; Biemel KM, 2003, BIOCONJUGATE CHEM, V14, P619, DOI 10.1021/bc025653e; Biemel KM, 2002, ANGEW CHEM INT EDIT, V41, P801, DOI 10.1002/1521-3773(20020301)41:5<801::AID-ANIE801>3.0.CO;2-I; Biemel KM, 2001, J BIOL CHEM, V276, P23405, DOI 10.1074/jbc.M102035200; Biemel KM, 2002, J BIOL CHEM, V277, P24907, DOI 10.1074/jbc.M202681200; Bierhaus A, 1998, CARDIOVASC RES, V37, P586, DOI 10.1016/S0008-6363(97)00233-2; Booth AA, 1997, J BIOL CHEM, V272, P5430, DOI 10.1074/jbc.272.9.5430; BUETTNER GR, 1988, J BIOCHEM BIOPH METH, V16, P27, DOI 10.1016/0165-022X(88)90100-5; Costantino L, 1999, MED RES REV, V19, P3, DOI 10.1002/(SICI)1098-1128(199901)19:1<3::AID-MED2>3.3.CO;2-Z; Courderot-Masuyer C, 1999, FUND CLIN PHARMACOL, V13, P535, DOI 10.1111/j.1472-8206.1999.tb00358.x; Culbertson SM, 2003, ORG LETT, V5, P2659, DOI 10.1021/ol0348147; Degenhardt T. P., 1998, MAILLARD REACTION FO, P3; DELANGE RJ, 1989, ANAL BIOCHEM, V177, P300, DOI 10.1016/0003-2697(89)90056-0; Dickinson PJ, 2002, DIABETES-METAB RES, V18, P260, DOI 10.1002/dmrr.305; DUNN JA, 1989, BIOCHEMISTRY-US, V28, P9464, DOI 10.1021/bi00450a033; DUNN JA, 1990, BIOCHEMISTRY-US, V29, P10964, DOI 10.1021/bi00501a014; DYER DG, 1991, J BIOL CHEM, V266, P11654; Elgawish A, 1996, J BIOL CHEM, V271, P12964, DOI 10.1074/jbc.271.22.12964; Fu SL, 1998, BIOCHEM J, V330, P233, DOI 10.1042/bj3300233; GLOMB MA, 1995, J BIOL CHEM, V270, P10017, DOI 10.1074/jbc.270.17.10017; GRANDHEE SK, 1991, J BIOL CHEM, V266, P11649; IKAWA M, 1967, ARCH BIOCHEM BIOPHYS, V118, P497, DOI 10.1016/0003-9861(67)90378-5; Khalifah RG, 1999, BIOCHEM BIOPH RES CO, V257, P251, DOI 10.1006/bbrc.1999.0371; KHALIFAH RG, 2000, Patent No. 0051987; Lapolla A, 2000, MASS SPECTROM REV, V19, P279; LAPOLLA A, 1993, BIOCHIM BIOPHYS ACTA, V1225, P33, DOI 10.1016/0925-4439(93)90118-K; Litchfield JE, 1999, INT J BIOCHEM CELL B, V31, P1297, DOI 10.1016/S1357-2725(99)00091-6; Miyata T, 2000, J AM SOC NEPHROL, V11, P1719, DOI 10.1681/ASN.V1191719; Miyata T, 2000, J AM SOC NEPHROL, V11, P1744, DOI 10.1681/ASN.V1191744; Miyata T, 2002, J AM SOC NEPHROL, V13, P2478, DOI 10.1097/01.ASN.0000032418.67267.F2; Monnier VM, 2001, J CLIN INVEST, V107, P799, DOI 10.1172/JCI12635; Mossine VV, 1999, CHEM RES TOXICOL, V12, P230, DOI 10.1021/tx980209e; Mowri HO, 2000, FREE RADICAL BIO MED, V29, P814, DOI 10.1016/S0891-5849(00)00379-8; Nagai R, 2002, DIABETES, V51, P2833, DOI 10.2337/diabetes.51.9.2833; Nagaraj RH, 2002, ARCH BIOCHEM BIOPHYS, V402, P110, DOI 10.1016/S0003-9861(02)00067-X; Nakagawa T, 2002, J AGR FOOD CHEM, V50, P2418, DOI 10.1021/jf011339n; ODETTI P, 1992, DIABETES, V41, P153, DOI 10.2337/diabetes.41.2.153; Onorato JM, 2000, J BIOL CHEM, V275, P21177, DOI 10.1074/jbc.M003263200; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; Podrez EA, 2002, J BIOL CHEM, V277, P38503, DOI 10.1074/jbc.M203318200; Pratt DA, 2001, J AM CHEM SOC, V123, P4625, DOI 10.1021/ja005679l; Price DL, 2001, J BIOL CHEM, V276, P48967, DOI 10.1074/jbc.M108196200; QUATTRUCCI E, 1992, FOOD ADDIT CONTAM, V9, P515, DOI 10.1080/02652039209374105; Saxena P, 2000, INVEST OPHTH VIS SCI, V41, P1473; Schmidt AM, 1999, CIRC RES, V84, P489, DOI 10.1161/01.RES.84.5.489; Sobal G, 2000, FREE RADICAL RES, V32, P439, DOI 10.1080/10715760000300441; Thornalley PJ, 2000, BIOCHEM PHARMACOL, V60, P55, DOI 10.1016/S0006-2952(00)00287-2; Uchida K, 2000, FREE RADICAL BIO MED, V28, P1685, DOI 10.1016/S0891-5849(00)00226-4; Vinson JA, 1996, J NUTR BIOCHEM, V7, P659, DOI 10.1016/S0955-2863(96)00128-3; Voziyan PA, 2002, J BIOL CHEM, V277, P3397, DOI 10.1074/jbc.M109935200; Weiss MF, 2000, KIDNEY INT, V57, P2571, DOI 10.1046/j.1523-1755.2000.00117.x; WELLSKNECHT KJ, 1995, BIOCHEMISTRY-US, V34, P3702, DOI 10.1021/bi00011a027; WOLFF SP, 1991, FREE RADICAL BIO MED, V10, P339, DOI 10.1016/0891-5849(91)90040-A; YIM HS, 1995, J BIOL CHEM, V270, P28228	59	45	45	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38384	38394		10.1074/jbc.M305099200	http://dx.doi.org/10.1074/jbc.M305099200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878609	hybrid			2022-12-27	WOS:000185575100038
J	Jansson, A; Niemi, J; Mantsala, P; Schneider, G				Jansson, A; Niemi, J; Mantsala, P; Schneider, G			Crystal structure of aclacinomycin methylesterase with bound product analogues - Implications for anthracycline recognition and mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARMINOMYCIN 4-O-METHYLTRANSFERASE; STREPTOMYCES-PURPURASCENS; LATE STEPS; IN-VITRO; BIOSYNTHESIS; ANTIBIOTICS; GENES; DAUNOMYCIN; ACLACINOMYCIN-10-HYDROXYLASE; DAUNORUBICIN	Aclacinomycin methylesterase (RdmC) is one of the tailoring enzymes that modify the aklavinone skeleton in the biosynthesis of anthracyclines in Streptomyces species. The crystal structures of this enzyme from Streptomyces purpurascens in complex with the product analogues 10-decarboxymethylaclacinomycin T and 10-decarboxymethylaclacinomycin A were determined to nominal resolutions of 1.45 and 1.95 Angstrom, respectively. RdmC is built up of two domains. The larger alpha/beta domain shows the common alpha/beta hydrolase fold, whereas the smaller domain is alpha-helical. The active site and substrate binding pocket are located at the interface between the two domains. Decarboxymethylaclacinomycin T and decarboxymethylaclacinomycin A bind close to the catalytic triad (Ser(102)-His(276)-Asp(248)) in a hydrophobic pocket, with the sugar moieties located at the surface of the enzyme. The binding of the ligands is dominated by hydrophobic interactions, and specificity appears to be controlled mainly by the shape of the binding pocket rather than through specific hydrogen bonds. Mechanistic key features consistent with the structure of complexes of RdmC with product analogues are Ser(102) acting as nucleophile and transition state stabilization by an oxyanion hole formed by the backbone amides of residues Gly(32) and Met(103).	Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden; Univ Turku, Dept Biochem & Food Chem, FIN-20014 Turku, Finland	Karolinska Institutet; University of Turku	Schneider, G (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.	gunter@alfa.mbb.ki.se		Schneider, Gunter/0000-0003-0622-5713				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARORA SK, 1985, J ANTIBIOT, V38, P1788, DOI 10.7164/antibiotics.38.1788; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bentley SD, 2002, NATURE, V417, P141, DOI 10.1038/417141a; BOOSER DJ, 1994, DRUGS, V47, P223, DOI 10.2165/00003495-199447020-00002; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Callebaut I, 2000, ANN NY ACAD SCI, V923, P90; CONNORS NC, 1990, J GEN MICROBIOL, V136, P1895, DOI 10.1099/00221287-136-9-1895; Dickens ML, 1997, J BACTERIOL, V179, P2641, DOI 10.1128/jb.179.8.2641-2650.1997; DICKENS ML, 1995, J BACTERIOL, V177, P536, DOI 10.1128/jb.177.3.536-543.1995; DIMARCO A, 1964, NATURE, V201, P706, DOI 10.1038/201706a0; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; HECHT HJ, 1994, NAT STRUCT BIOL, V1, P532, DOI 10.1038/nsb0894-532; Heikinheimo P, 1999, STRUCTURE, V7, pR141, DOI 10.1016/S0969-2126(99)80079-3; Hofmann B, 1998, J MOL BIOL, V279, P889, DOI 10.1006/jmbi.1998.1802; HOPWOOD DA, 1985, NATURE, V314, P642, DOI 10.1038/314642a0; Hopwood DA, 1997, CHEM REV, V97, P2465, DOI 10.1021/cr960034i; Hutchinson CR, 1997, CHEM REV, V97, P2525, DOI 10.1021/cr960022x; Jansson A, 2003, ACTA CRYSTALLOGR D, V59, P1637, DOI 10.1107/S0907444903014100; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KRASSILNIKOV NA, 1939, MIKROBIOLOGIYA, P673; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu GG, 2000, J APPL CRYSTALLOGR, V33, P176, DOI 10.1107/S0021889899012339; MADDURI K, 1995, J BACTERIOL, V177, P3879, DOI 10.1128/jb.177.13.3879-3884.1995; MADDURI K, 1993, J BACTERIOL, V175, P3900, DOI 10.1128/JB.175.12.3900-3904.1993; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Myers CE, 1988, ANTHRACYCLINE ANTHRA, P527; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Niemi J, 1999, BBA-PROTEIN STRUCT M, V1430, P57, DOI 10.1016/S0167-4838(98)00265-9; NIEMI J, 1995, J BACTERIOL, V177, P2942, DOI 10.1128/jb.177.10.2942-2945.1995; NIEMI J, 1994, MICROBIOL-UK, V140, P1351, DOI 10.1099/00221287-140-6-1351; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; Otwinowski Z., 1993, P CCP4 STUD WEEK DAT, P56; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Sciara G, 2003, EMBO J, V22, P205, DOI 10.1093/emboj/cdg031; TANAKA H, 1983, J ANTIBIOT, V36, P601, DOI 10.7164/antibiotics.36.601; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Walczak RJ, 1999, J BACTERIOL, V181, P298, DOI 10.1128/JB.181.1.298-304.1999; Wang YL, 2000, BBA-PROTEIN STRUCT M, V1480, P191, DOI 10.1016/S0167-4838(00)00089-3; Wang YL, 2002, FEMS MICROBIOL LETT, V208, P117, DOI 10.1016/S0378-1097(01)00591-2; YE JS, 1994, J BACTERIOL, V176, P6270, DOI 10.1128/jb.176.20.6270-6280.1994	44	28	29	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39006	39013		10.1074/jbc.M304008200	http://dx.doi.org/10.1074/jbc.M304008200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878604	hybrid			2022-12-27	WOS:000185575100112
J	Kaiser, FJ; Moroy, T; Chang, GTG; Horsthemke, B; Ludecke, HJ				Kaiser, FJ; Moroy, T; Chang, GTG; Horsthemke, B; Ludecke, HJ			The RING finger protein RNF4, a co-regulator of transcription, interacts with the TRPS1 transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNDROME TYPE-I; GENE; IDENTIFICATION; REPRESSION; MECHANISMS; APOPTOSIS	The TRPS1 gene encodes a repressor of GATA-mediated transcription. Mutations in this gene cause the tricho-rhino-phalangeal syndromes, but the affected pathways are unknown. In a yeast two-hybrid screen with the C-terminal part of the murine Trps1 protein as bait, we obtained three yeast clones encoding two overlapping fragments of the 194 amino acids RING finger protein 4 (Rnf4). The overlap narrows down the Trps1-binding region within Rnf4 to amino acids 6-65. This region in Rnf4 is also known to interact with several proteins including steroid receptors. By using truncated Trps1 constructs, the Rnf4-binding region in Trps1 could be assigned to amino acids 985-1184 of 1281. This 200 amino acid region of Trps1 does not contain any predicted protein-protein interacting motif. Complex formation between the human proteins TRPS1 and RNF4 was verified by co-immunoprecipitation from transfected and native mammalian cells. Confocal laser-scanning microscopy revealed that the endogenous proteins are located in distinct structures of the nucleus. Using a luciferase reporter assay, we could demonstrate that the repressional function of TRPS1 is inhibited by RNF4. This finding suggests that RNF4 is a negative regulator of TRPS1 activity.	Univ Klinikum, Inst Humangenet, D-45122 Essen, Germany; Univ Klinikum, Inst Zellbiol, D-45122 Essen, Germany; Erasmus Med Ctr, Dept Reprod & Dev, NL-3000 DR Rotterdam, Netherlands	University of Duisburg Essen; University of Duisburg Essen; Erasmus University Rotterdam; Erasmus MC	Ludecke, HJ (corresponding author), Univ Klinikum, Inst Humangenet, Hufelandstr 55, D-45122 Essen, Germany.		Moroy, Tarik/D-9923-2011					Chang GTG, 2000, J NATL CANCER I, V92, P1414, DOI 10.1093/jnci/92.17.1414; Chang GTG, 1997, CANCER RES, V57, P4075; Chang GTG, 2002, APOPTOSIS, V7, P13, DOI 10.1023/A:1013504710343; Chiariotti L, 1998, GENOMICS, V47, P258, DOI 10.1006/geno.1997.5105; Fedele M, 2000, J BIOL CHEM, V275, P7894, DOI 10.1074/jbc.275.11.7894; Galili N, 2000, DEV DYNAM, V218, P102, DOI 10.1002/(SICI)1097-0177(200005)218:1<102::AID-DVDY9>3.3.CO;2-1; Kaiser FJ, 2003, HUM MOL GENET, V12, P1349, DOI 10.1093/hmg/ddg145; Kunath Melanie, 2002, Gene Expression Patterns, V2, P119, DOI 10.1016/S0925-4773(02)00300-3; Ludecke HJ, 2001, AM J HUM GENET, V68, P81, DOI 10.1086/316926; Lyngso C, 2000, J BIOL CHEM, V275, P26144, DOI 10.1074/jbc.M003405200; Malik TH, 2001, EMBO J, V20, P1715, DOI 10.1093/emboj/20.7.1715; McCarty AS, 2003, MOL CELL, V11, P459, DOI 10.1016/S1097-2765(03)00043-1; Moilanen AM, 1998, MOL CELL BIOL, V18, P5128, DOI 10.1128/MCB.18.9.5128; Momeni P, 2000, NAT GENET, V24, P71, DOI 10.1038/71717; Poukka H, 2000, J BIOL CHEM, V275, P571, DOI 10.1074/jbc.275.1.571; REYNOLDS A, 1989, CURRENT PROTOCOLS MO; Shoichet SA, 2000, P NATL ACAD SCI USA, V97, P4076, DOI 10.1073/pnas.97.8.4076	17	37	45	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38780	38785		10.1074/jbc.M306259200	http://dx.doi.org/10.1074/jbc.M306259200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885770	hybrid			2022-12-27	WOS:000185575100085
J	Kwasnicka, DA; Krakowiak, A; Thacker, C; Brenner, C; Vincent, SR				Kwasnicka, DA; Krakowiak, A; Thacker, C; Brenner, C; Vincent, SR			Coordinate expression of NADPH-dependent flavin reductase, Fre-1, and Hint-related 7meGMP-directed hydrolase, DCS-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHIONINE SYNTHASE REDUCTASE; HUMAN TUMOR-SUPPRESSOR; MESSENGER-RNA; SCHIZOSACCHAROMYCES-POMBE; CAENORHABDITIS-ELEGANS; ENZYMATIC-SYNTHESIS; PROTEIN; FHIT; CLONING; GENE	A novel human cytosolic flavin reductase, Nr1, was recently described that contains FMN, FAD, and NADPH cofactors. Though the targets of the related NADPH-dependent flavoprotein reductases, cytochrome P450 reductase, methionine synthase reductase, and nitric oxide synthase, are known, the cellular function of Nr1 is not clear. To explore expression and regulation of Nr1, we cloned fre-1, the Caenorhabditis elegans ortholog of Nr1, and discovered that it is transcribed as a bicistronic pre-mRNA together with dcs-1, the ortholog of the recently described scavenger mRNA decapping enzyme. We used the novel substrate, 7meGpppBODIPY, to demonstrate that DCS-1 has low micromolar specificity for guanine ribonucleotides with the 7me modification, whereas trimethylated G substrates are poor competitors. Contrary to earlier classification, DCS-1 is not a pyrophosphatase but a distant member of the Hint branch of the histidine triad superfamily of nucleotide hydrolases and transferases. These observations are consistent with the hypothesis that DCS-1 homologs may function in the metabolism of capped oligonucleotides generated following exosome-dependent degradation of short-lived mRNA transcripts. We find that fre-1 and dcs-1 are coordinately expressed through worm development, are induced by heat shock, and have a nearly identical expression profile in human tissues. Furthermore, immunocytochemical analysis of the endogenous proteins in COS cells indicates that both are present in the nucleus and concentrated in a distinct perinuclear structure. Though no connection between these enzymes had been anticipated, our data and data from global expression and protein association studies suggest that the two enzymes jointly participate in responses to DNA damage, heat shock, and other stresses.	Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Brain Res Ctr, Vancouver, BC V6T 1Z3, Canada; Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z3, Canada; Kimmel Canc Ctr, Struct Biol & Bioinformat Program, Philadelphia, PA 19107 USA	University of British Columbia; University of British Columbia; University of British Columbia; Jefferson University	Vincent, SR (corresponding author), Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 1Z3, Canada.	svincent@interchange.ubc.ca	Vincent, Steven R/D-2996-2012; Brenner, Charles/D-6339-2014; Krakowiak, Agnieszka/ABC-8848-2020	Brenner, Charles/0000-0002-4955-3226; Krakowiak, Agnieszka/0000-0002-0273-2972	NCI NIH HHS [CA75954, R01 CA075954-07, R01 CA075954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA075954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Barnes LD, 1996, BIOCHEMISTRY-US, V35, P11529, DOI 10.1021/bi961415t; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Bieganowski P, 2002, J BIOL CHEM, V277, P10852, DOI 10.1074/jbc.M111480200; Blumenthal Thomas, 2003, Nature Reviews Genetics, V4, P112; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRENNER C, 1988, MOL CELL BIOL, V8, P3556, DOI 10.1128/MCB.8.8.3556; Brenner C, 2002, BIOCHEMISTRY-US, V41, P9003, DOI 10.1021/bi025942q; Brenner C, 1997, NAT STRUCT BIOL, V4, P231, DOI 10.1038/nsb0397-231; BRENNER S, 1974, GENETICS, V77, P71; BUCZYNSKI G, 1990, BIOCHIM BIOPHYS ACTA, V1041, P296, DOI 10.1016/0167-4838(90)90288-Q; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; DIGNAM JD, 1975, BIOCHEM BIOPH RES CO, V63, P845, DOI 10.1016/0006-291X(75)90644-0; Ding S, 2001, BIOCHEM J, V356, P613, DOI 10.1042/0264-6021:3560613; Draganescu A, 2000, J BIOL CHEM, V275, P4555, DOI 10.1074/jbc.275.7.4555; FERNANDES M, 1994, NUCLEIC ACIDS RES, V22, P167, DOI 10.1093/nar/22.2.167; Ghosh S, 1996, GENE, V176, P249, DOI 10.1016/0378-1119(96)00260-0; GOODY RS, 1972, BIOCHIM BIOPHYS ACTA, V276, P155, DOI 10.1016/0005-2744(72)90016-2; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Huang T, 2001, MOL CELL BIOL, V21, P1111, DOI 10.1128/MCB.21.4.1111-1120.2001; Huang Y, 1995, BIOCHEM J, V312, P925, DOI 10.1042/bj3120925; Ingelfinger D, 2002, RNA, V8, P1489, DOI 10.1017/S1355838202021726; Kemmeren P, 2002, MOL CELL, V9, P1133, DOI 10.1016/S1097-2765(02)00531-2; Lazarowski ER, 1996, BRIT J PHARMACOL, V117, P203, DOI 10.1111/j.1476-5381.1996.tb15175.x; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Lima CD, 1997, STRUCTURE, V5, P763, DOI 10.1016/S0969-2126(97)00231-1; Liu HD, 2002, EMBO J, V21, P4699, DOI 10.1093/emboj/cdf448; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Miller DM, 1999, BIOTECHNIQUES, V26, P914, DOI 10.2144/99265rr01; Moteki S, 2002, MOL CELL, V10, P599, DOI 10.1016/S1097-2765(02)00660-3; Mouaikel J, 2002, MOL CELL, V9, P891, DOI 10.1016/S1097-2765(02)00484-7; Ohta M, 1996, CELL, V84, P587, DOI 10.1016/S0092-8674(00)81034-X; Pace HC, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-3-r18; Pace HC, 1998, P NATL ACAD SCI USA, V95, P5484, DOI 10.1073/pnas.95.10.5484; Pace HC, 2000, CURR BIOL, V10, P907, DOI 10.1016/S0960-9822(00)00621-7; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Salehi Z, 2002, MOL MICROBIOL, V46, P49, DOI 10.1046/j.1365-2958.2002.03151.x; SCHMIDT HHHW, 1991, P NATL ACAD SCI USA, V88, P365, DOI 10.1073/pnas.88.2.365; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Steiger M, 2003, RNA, V9, P231, DOI 10.1261/rna.2151403; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; VANDOREN K, 1990, MOL CELL BIOL, V10, P1769, DOI 10.1128/MCB.10.4.1769; Verheggen C, 2002, EMBO J, V21, P2736, DOI 10.1093/emboj/21.11.2736; VINCENT S, 1995, NITRIC OXIDE NERVOUS; Wilson A, 1999, MOL GENET METAB, V67, P317, DOI 10.1006/mgme.1999.2879; YASUKOCHI Y, 1976, J BIOL CHEM, V251, P5337; ZORIO DAR, 1994, NATURE, V372, P270, DOI 10.1038/372270a0	48	33	40	0	12	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39051	39058		10.1074/jbc.M306355200	http://dx.doi.org/10.1074/jbc.M306355200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871939	hybrid, Green Accepted			2022-12-27	WOS:000185575100118
J	Lasorsa, FM; Pinton, P; Palmieri, L; Fiermonte, G; Rizzuto, R; Palmieri, F				Lasorsa, FM; Pinton, P; Palmieri, L; Fiermonte, G; Rizzuto, R; Palmieri, F			Recombinant expression of the Ca2+-sensitive aspartate/glutamate carrier increases mitochondrial ATP production in agonist-stimulated chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALATE ASPARTATE SHUTTLE; RAT-LIVER MITOCHONDRIA; GLYCEROL-3-PHOSPHATE DEHYDROGENASE; MAMMALIAN MITOCHONDRIA; ENDOPLASMIC-RETICULUM; CALCIUM; CA2+; METABOLISM; ACTIVATION; SECRETION	The Ca2+-sensitive dehydrogenases of the mitochondrial matrix are, so far, the only known effectors to allow Ca2+ signals to couple the activation of plasma membrane receptors to the stimulation of aerobic metabolism. In this study, we demonstrate a novel mechanism, based on Ca2+- sensitive metabolite carriers of the inner membrane. We expressed in Chinese hamster ovary cells aralar1 and citrin, aspartate/glutamate exchangers that have Ca2+- binding sites in their sequence, and measured mitochondrial Ca2+ and ATP levels as well as cytosolic Ca2+ concentration with targeted recombinant probes. The increase in mitochondrial ATP levels caused by cell stimulation with Ca2+- mobilizing agonists was markedly larger in cells expressing aralar and citrin ( but not truncated mutants lacking the Ca2+-binding site) than in control cells. Conversely, the cytosolic and the mitochondrial Ca2+ signals were the same in control cells and cells expressing the different aralar1 and citrin variants, thus ruling out an indirect effect through the Ca2+- sensitive dehydrogenases. Together, these data show that the decoding of Ca2+ signals in mitochondria depends on the coordinate activity of mitochondrial enzymes and carriers, which may thus represent useful pharmacological targets in this process of major pathophysiological interest.	Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44110 Ferrara, Italy; Univ Ferrara, ICSI, I-44110 Ferrara, Italy; Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy	University of Ferrara; University of Ferrara; Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR)	Palmieri, F (corresponding author), Univ Ferrara, Dept Expt & Diagnost Med, Sect Gen Pathol, I-44110 Ferrara, Italy.		Fiermonte, Giuseppe/F-3159-2010; Pinton, Paolo/J-8025-2012; Rizzuto, Rosario/B-6312-2008; Fiermonte, Giuseppe/D-3680-2018; lasorsa, francesco massimo m/B-7931-2008	Pinton, Paolo/0000-0001-7108-6508; Fiermonte, Giuseppe/0000-0002-6764-9395; lasorsa, francesco massimo m/0000-0001-8418-5222; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [GTF01011] Funding Source: Medline	Telethon(Fondazione Telethon)		Babcock DF, 1997, J CELL BIOL, V136, P833, DOI 10.1083/jcb.136.4.833; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; BROWN GC, 1992, BIOCHEM J, V284, P1; BROWN LJ, 1994, J BIOL CHEM, V269, P14363; Budd SL, 1996, J NEUROCHEM, V67, P2282; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Civelek VN, 1996, BIOCHEM J, V318, P615, DOI 10.1042/bj3180615; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; del Arco A, 2000, BIOCHEM J, V345, P725, DOI 10.1042/0264-6021:3450725; del Arco A, 1998, J BIOL CHEM, V273, P23327, DOI 10.1074/jbc.273.36.23327; Eliasson L, 1997, J PHYSIOL-LONDON, V503, P399, DOI 10.1111/j.1469-7793.1997.399bh.x; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Ferrari D, 1998, J EXP MED, V188, P979, DOI 10.1084/jem.188.5.979; FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293; FRIEL DD, 1994, J NEUROSCI, V14, P4007; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; HANSFORD RG, 1991, J BIOENERG BIOMEMBR, V23, P823, DOI 10.1007/BF00786004; ICHAS F, 1997, CELL, V891, P145; Iijima M, 2001, ADV ENZYME REGUL, V41, P325, DOI 10.1016/S0065-2571(00)00022-4; INDIVERI C, 1987, J BIOL CHEM, V262, P15979; Jouaville LS, 1999, P NATL ACAD SCI USA, V96, P13807, DOI 10.1073/pnas.96.24.13807; JOUAVILLE LS, 1995, NATURE, V377, P438, DOI 10.1038/377438a0; Kennedy ED, 1998, DIABETES METAB, V24, P15; Kobayashi K, 1999, NAT GENET, V22, P159, DOI 10.1038/9667; KOBAYASHI K, 2000, CALCIUM MOL BASIS CA, P557; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; LANOUE KF, 1974, ARCH BIOCHEM BIOPHYS, V161, P544, DOI 10.1016/0003-9861(74)90337-3; LANOUE KF, 1979, ANNU REV BIOCHEM, V48, P871, DOI 10.1146/annurev.bi.48.070179.004255; LEVERVE XM, 1986, EUR J BIOCHEM, V155, P551, DOI 10.1111/j.1432-1033.1986.tb09523.x; MACDONALD MJ, 1981, J BIOL CHEM, V256, P8287; MCCORMACK JG, 1980, BIOCHEM J, V190, P95, DOI 10.1042/bj1900095; MEIJER AJ, 1978, J BIOL CHEM, V253, P2308; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PALMIERI F, 1972, EUR J BIOCHEM, V29, P408, DOI 10.1111/j.1432-1033.1972.tb02003.x; Palmieri L, 2001, EMBO J, V20, P5060, DOI 10.1093/emboj/20.18.5060; Papa S, 2002, BBA-BIOENERGETICS, V1555, P147, DOI 10.1016/S0005-2728(02)00270-0; Patterson GH, 2000, P NATL ACAD SCI USA, V97, P5203, DOI 10.1073/pnas.090098797; Rizzuto R, 1995, METHOD ENZYMOL, V260, P417, DOI 10.1016/0076-6879(95)60155-4; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robb-Gaspers LD, 1998, EMBO J, V17, P4987, DOI 10.1093/emboj/17.17.4987; RUTTER GA, 1992, BIOCHIM BIOPHYS ACTA, V1175, P107, DOI 10.1016/0167-4889(92)90016-5; SCADUTO RC, 1994, EUR J BIOCHEM, V223, P751, DOI 10.1111/j.1432-1033.1994.tb19049.x; Schonau W, 2000, JAHRB INT GERMAN, V32, P10; Simpson PB, 1997, J BIOL CHEM, V272, P22654, DOI 10.1074/jbc.272.36.22654; STERNICZUK A, 1991, EUR J BIOCHEM, V196, P143, DOI 10.1111/j.1432-1033.1991.tb15797.x; STRZELECKI T, 1988, ARCH BIOCHEM BIOPHYS, V264, P310, DOI 10.1016/0003-9861(88)90599-1; SUGANO T, 1988, ARCH BIOCHEM BIOPHYS, V264, P144, DOI 10.1016/0003-9861(88)90579-6; Williamson J. R., 1976, GLUCONEOGENESIS ITS, P165; Zara V, 2003, J MOL BIOL, V325, P399, DOI 10.1016/S0022-2836(02)01236-6; ZARA V, 1992, J BIOL CHEM, V267, P12077	55	115	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38686	38692		10.1074/jbc.M304988200	http://dx.doi.org/10.1074/jbc.M304988200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851387	hybrid			2022-12-27	WOS:000185575100073
J	Pettus, BJ; Bielawska, A; Spiegel, S; Roddy, P; Hannun, YA; Chalfant, CE				Pettus, BJ; Bielawska, A; Spiegel, S; Roddy, P; Hannun, YA; Chalfant, CE			Ceramide kinase mediates cytokine- and calcium ionophore-induced arachidonic acid release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE A(2); INTESTINAL POLYPOSIS; PHOSPHATASE-ACTIVITY; MOLECULAR-CLONING; KNOCKOUT MICE; LIPID KINASE; CELLS; PHOSPHORYLATION; TRANSLOCATION; 1-PHOSPHATE	Despite the importance of prostaglandins, little is known about the regulation of prostanoid synthesis proximal to the activation of cytosolic phospholipase A(2), the initial rate-limiting step. In this study, ceramide-1-phosphate (C-1-P) was shown to be a specific and potent inducer of arachidonic acid (AA) and prostanoid synthesis in cells. This study also demonstrates that two well established activators of AA release and prostanoid synthesis, the cytokine, interleukin-1beta (IL-1beta), and the calcium ionophore, A23187, induce an increase in C-1-P levels within the relevant time-frame of AA release. Furthermore, the enzyme responsible for the production of C-1-P in mammalian cells, ceramide kinase, was activated in response to IL-1beta and A23187. RNA interference targeted to ceramide kinase specifically down-regulated ceramide kinase mRNA and activity with a concomitant decrease of AA release in response to IL-1beta and A23187. Down-regulation of ceramide kinase had no effect on AA release induced by exogenous C-1-P. Collectively, these results indicate that ceramide kinase, via the formation of C-1-P, is an upstream modulator of phospholipase A(2) activation. This study identifies previously unknown roles for ceramide kinase and its product, C-1-P, in AA release and production of eicosanoids and provides clues for potential new targets to block inflammatory responses.	Virginia Commonwealth Univ, Dept Biochem, Richmond, VA 23298 USA; Med Univ S Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA; Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA 23249 USA	Virginia Commonwealth University; Medical University of South Carolina; Hunter Holmes McGuire Veterinary Affairs Medical Center	Chalfant, CE (corresponding author), Virginia Commonwealth Univ, Dept Biochem, Rm 2-003,Sanger Hall,1101 E Marshall St,POB 98061, Richmond, VA 23298 USA.	cechalfant@vcu.edu			NCI NIH HHS [CA87584] Funding Source: Medline; NIGMS NIH HHS [GM43825, GM43880, GM08716] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA087584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880, R37GM043825, R01GM043825, R01GM043880] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arnold R E, 1976, JACEP, V5, P262, DOI 10.1016/S0361-1124(76)80005-6; Bajjalieh S, 2000, METHOD ENZYMOL, V311, P207; BAJJALIEH SM, 1989, J BIOL CHEM, V264, P14354; Balsinde J, 2000, J IMMUNOL, V164, P5398, DOI 10.4049/jimmunol.164.10.5398; BOUDKER O, 1993, J BIOL CHEM, V268, P22150; Brinckmann R, 1996, BIOCHEM J, V318, P305, DOI 10.1042/bj3180305; CARBONARO PA, 1995, CUTIS, V56, P256; Carpio LC, 1999, PROSTAG LEUKOTR ESS, V61, P267, DOI 10.1054/plef.1999.0100; Chalfant CE, 2002, J BIOL CHEM, V277, P12587, DOI 10.1074/jbc.M112010200; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DRESSLER KA, 1990, J BIOL CHEM, V265, P14917; Evans JH, 2001, J BIOL CHEM, V276, P30150, DOI 10.1074/jbc.M100943200; Feldhaus MJ, 2002, J BIOL CHEM, V277, P4285, DOI 10.1074/jbc.M106653200; Funk CD, 2001, SCIENCE, V294, P1871, DOI 10.1126/science.294.5548.1871; GomezMunoz A, 1997, BIOCHEM J, V325, P435, DOI 10.1042/bj3250435; GOMEZMUNOZ A, 1995, MOL PHARMACOL, V47, P883; Gordon RD, 1996, EUR J BIOCHEM, V238, P690, DOI 10.1111/j.1432-1033.1996.0690w.x; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hinkovska-Galcheva VT, 1998, J BIOL CHEM, V273, P33203, DOI 10.1074/jbc.273.50.33203; Hogback S, 2003, BIOCHEM J, V370, P111, DOI 10.1042/bj20020970; Kitatani K, 2000, ARCH BIOCHEM BIOPHYS, V382, P296, DOI 10.1006/abbi.2000.2028; Klapisz E, 2000, J LIPID RES, V41, P1680; Kramer RM, 1997, FEBS LETT, V410, P49, DOI 10.1016/S0014-5793(97)00322-0; KURPIEWSKI G, 1981, BIOCHIM BIOPHYS ACTA, V678, P467, DOI 10.1016/0304-4165(81)90128-8; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; Modur V, 1996, J BIOL CHEM, V271, P13094, DOI 10.1074/jbc.271.22.13094; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Perry DK, 2000, METHOD ENZYMOL, V312, P22; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; REES RS, 1988, TOXICON, V26, P1035, DOI 10.1016/0041-0101(88)90202-4; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; Rile G, 2003, ACTA HAEMATOL-BASEL, V109, P76, DOI 10.1159/000068491; SHARP JD, 1991, J BIOL CHEM, V266, P14850; SHINGHAL R, 1993, J NEUROCHEM, V61, P2279, DOI 10.1111/j.1471-4159.1993.tb07470.x; Sugiura M, 2002, J BIOL CHEM, V277, P23294, DOI 10.1074/jbc.M201535200; Takaku K, 2000, J BIOL CHEM, V275, P34013, DOI 10.1074/jbc.C000586200; TAY A, 1995, GENOMICS, V26, P138, DOI 10.1016/0888-7543(95)80093-2; Williams CS, 1999, ONCOGENE, V18, P7908, DOI 10.1038/sj.onc.1203286; Yamane M, 2000, J BIOCHEM-TOKYO, V128, P827, DOI 10.1093/oxfordjournals.jbchem.a022821; Yamauchi T, 2003, ANTICANCER RES, V23, P245; Zhou HP, 2003, AM J PHYSIOL-GASTR L, V284, pG472, DOI 10.1152/ajpgi.00345.2002	48	184	189	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38206	38213		10.1074/jbc.M304816200	http://dx.doi.org/10.1074/jbc.M304816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855693	hybrid			2022-12-27	WOS:000185575100016
J	Song, K; Cornelius, SC; Reiss, M; Danielpour, D				Song, K; Cornelius, SC; Reiss, M; Danielpour, D			Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT VENTRAL PROSTATE; PROGRAMMED CELL-DEATH; PROTEIN-KINASE B/AKT; FYVE DOMAIN PROTEIN; TGF-BETA; EPITHELIAL-CELLS; SIGNALING PATHWAY; ANDROGEN RECEPTOR; INDUCED APOPTOSIS; CANCER-CELLS	Insulin-like growth factor-I (IGF-I) and transforming growth factor-beta (TGF-beta) have been shown to be oncogenic and tumor suppressive, respectively, on prostate epithelial cells. Here we show that IGF-I inhibits the ability of TGF-beta to regulate expression of several genes in the non-tumorigenic rat prostatic epithelial line, NRP-152. In these cells, IGF-I also inhibits TGF-beta-induced transcriptional responses, as shown by several promoter reporter constructs, suggesting that IGF-I intercepts an early step in TGF-beta signaling. We show that IGF-I does not down-regulate TGF-beta receptor levels, as determined by both receptor cross-linking and Western blot analyses. However, Western blot analysis reveals that IGF-I selectively inhibits the TGF-beta-triggered activation Smad3 but not Smad2, while not altering expression of total Smads 2, 3, or 4. The phosphatidylinositol 3-kinase (PI3K) inhibitor, LY29004 reverses the ability of IGF-I to inhibit TGF-beta-induced transcriptional responses and the activation of Smad3, suggesting that the suppression of TGF-beta signaling by IGF-I is mediated through activation of PI3K. Moreover, we show that enforced expression of dominant-negative PI3K (DN-p85alpha) or phosphatidylinositol 3-phosphate-phosphatase, PTEN, also reverse the suppressive effect of IGF-I on TGF-beta-induced 3TP-luciferase reporter activity, whereas constitutively active PI3K (p110alphaCAAX) completely blocks TGF-beta-induced 3TP-luciferase reporter activity. Further transfection experiments including expression of constitutively active and dominant-negative Akt and rapamycin treatment suggest that suppression of TGF-beta signaling/ Smad3 activation by IGF-I occurs downstream of Akt and through mammalian target of rapamycin activation. In summary, our data suggest that IGF-I inhibits TGF-beta transcriptional responses through selective suppression of Smad3 activation via a PI3K/Akt-dependent pathway.	Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs,Lab 3, Cleveland, OH 44106 USA; Case Western Reserve Univ, Univ Hosp Cleveland, Dept Pharmacol, Cleveland, OH 44106 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ 08901 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey	Danielpour, D (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Canc Ctr, Res Labs,Lab 3, Samuel Gerber Bldg,Ste 200,11001 Cedar Ave, Cleveland, OH 44106 USA.	dxd49@po.cwru.edu	Reiss, Michael/A-8314-2009	Reiss, Michael/0000-0001-8543-8092	NATIONAL CANCER INSTITUTE [P30CA043703] Funding Source: NIH RePORTER; NCI NIH HHS [1R01 CA3069-01, P30CA43703] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdollah S, 1997, J BIOL CHEM, V272, P27678, DOI 10.1074/jbc.272.44.27678; Bakin AV, 2000, J BIOL CHEM, V275, P36803, DOI 10.1074/jbc.M005912200; BASERGA R, 1995, CANCER RES, V55, P249; Baserga R, 1999, EXP CELL RES, V253, P1, DOI 10.1006/excr.1999.4667; Baserga R, 1999, J CELL BIOCHEM, P68; Berven LA, 2000, IMMUNOL CELL BIOL, V78, P447, DOI 10.1046/j.1440-1711.2000.00928.x; Besson A, 1999, EUR J BIOCHEM, V263, P605, DOI 10.1046/j.1432-1327.1999.00542.x; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Brodin G, 1999, CANCER RES, V59, P2731; Chen RH, 1998, ONCOGENE, V17, P1959, DOI 10.1038/sj.onc.1202111; Chen YG, 1997, EMBO J, V16, P3866, DOI 10.1093/emboj/16.13.3866; Chipuk JE, 2001, J BIOL CHEM, V276, P26614, DOI 10.1074/jbc.M100913200; Chipuk JE, 2002, J BIOL CHEM, V277, P1240, DOI 10.1074/jbc.M108855200; CULIG Z, 1994, CANCER RES, V54, P5474; DANIELPOUR D, 1994, CANCER RES, V54, P3413; Danielpour D, 1996, J CELL PHYSIOL, V166, P231, DOI 10.1002/(SICI)1097-4652(199601)166:1<231::AID-JCP24>3.0.CO;2-G; Danielpour D, 1999, J CELL SCI, V112, P169; Danielpour D, 2000, METH MOL B, V142, P29; DiGiovanni J, 2000, P NATL ACAD SCI USA, V97, P3455, DOI 10.1073/pnas.97.7.3455; Downward J, 1998, CURR OPIN CELL BIOL, V10, P262, DOI 10.1016/S0955-0674(98)80149-X; Giovannucci E, 1999, HORM RES, V51, P34, DOI 10.1159/000053160; Goto D, 2001, BIOCHEM BIOPH RES CO, V281, P1100, DOI 10.1006/bbrc.2001.4489; Grammer TC, 1996, CANCER SURV, V27, P271; Griswold-Prenner I, 1998, MOL CELL BIOL, V18, P6595, DOI 10.1128/MCB.18.11.6595; Guo YP, 1999, CANCER RES, V59, P1366; Hayward SW, 1999, PROSTATE, V39, P205; Hocevar BA, 2001, EMBO J, V20, P2789, DOI 10.1093/emboj/20.11.2789; Hsing AY, 1996, CANCER RES, V56, P5146; Huse M, 2001, MOL CELL, V8, P671, DOI 10.1016/S1097-2765(01)00332-X; Jonk LJC, 1998, J BIOL CHEM, V273, P21145, DOI 10.1074/jbc.273.33.21145; Kaplan PJ, 1999, CANCER RES, V59, P2203; Kim IY, 1996, MOL ENDOCRINOL, V10, P107, DOI 10.1210/me.10.1.107; Kunzmann S, 2003, FASEB J, V17, P194, DOI 10.1096/fj.02-0550com; KYPRIANOU N, 1988, ENDOCRINOLOGY, V123, P2124, DOI 10.1210/endo-123-4-2124; KYPRIANOU N, 1989, MOL ENDOCRINOL, V3, P1515, DOI 10.1210/mend-3-10-1515; Larisch-Bloch S, 2000, CELL GROWTH DIFFER, V11, P1; Law BK, 2002, MOL CELL BIOL, V22, P8184, DOI 10.1128/MCB.22.23.8184-8198.2002; Li DM, 1997, CANCER RES, V57, P2124; Lin HK, 2002, EMBO J, V21, P4037, DOI 10.1093/emboj/cdf406; Lin HK, 2001, P NATL ACAD SCI USA, V98, P7200, DOI 10.1073/pnas.121173298; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; LORD APD, 1994, J ENDOCRINOL, V141, P505, DOI 10.1677/joe.0.1410505; LORENZ MC, 1995, J BIOL CHEM, V270, P27531, DOI 10.1074/jbc.270.46.27531; Lucia MS, 1998, J CELL PHYSIOL, V175, P184, DOI 10.1002/(SICI)1097-4652(199805)175:2<184::AID-JCP8>3.0.CO;2-K; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; Miura S, 2000, MOL CELL BIOL, V20, P9346, DOI 10.1128/MCB.20.24.9346-9355.2000; Nicholson KM, 2002, CELL SIGNAL, V14, P381, DOI 10.1016/S0898-6568(01)00271-6; Nickerson T, 1998, ENDOCRINOLOGY, V139, P807, DOI 10.1210/en.139.2.807; Pearson R B, 1995, Prog Cell Cycle Res, V1, P21; Penheiter SG, 2002, MOL CELL BIOL, V22, P4750, DOI 10.1128/MCB.22.13.4750-4759.2002; Petritsch C, 2000, GENE DEV, V14, P3093, DOI 10.1101/gad.854200; Pullen N, 1997, FEBS LETT, V410, P78, DOI 10.1016/S0014-5793(97)00323-2; Rajah R, 1997, J BIOL CHEM, V272, P12181, DOI 10.1074/jbc.272.18.12181; Roberts A.B., 1990, HDB EXPT PHARM PEPTI, V95, P419; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Shin I, 2001, MOL BIOL CELL, V12, P3328, DOI 10.1091/mbc.12.11.3328; Stambolic V, 1998, CELL, V95, P29, DOI 10.1016/S0092-8674(00)81780-8; Stattin P, 2000, J NATL CANCER I, V92, P1910, DOI 10.1093/jnci/92.23.1910; Stewart LMV, 2003, EXP CELL RES, V284, P303, DOI 10.1016/S0014(02)00037-X; Tang BW, 1999, CANCER RES, V59, P4834; tenDijke P, 1996, CURR OPIN CELL BIOL, V8, P139; Tsukazaki T, 1998, CELL, V95, P779, DOI 10.1016/S0092-8674(00)81701-8; Valentinis, 1997, BIOCHIM BIOPHYS ACTA, V1332, P105; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(05)00089-4; Wen Y, 2000, CANCER RES, V60, P6841; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; Wrana JL, 1998, MINER ELECTROL METAB, V24, P120, DOI 10.1159/000057359; Wu RY, 1997, MOL CELL BIOL, V17, P2521, DOI 10.1128/MCB.17.5.2521; Xiao Z, 2000, J BIOL CHEM, V275, P23425, DOI 10.1074/jbc.C000345200; Yamamura Y, 2000, J BIOL CHEM, V275, P36295, DOI 10.1074/jbc.M006023200	72	80	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38342	38351		10.1074/jbc.M304583200	http://dx.doi.org/10.1074/jbc.M304583200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876289	hybrid			2022-12-27	WOS:000185575100033
J	Toustrup-Jensen, M; Vilsen, B				Toustrup-Jensen, M; Vilsen, B			Functional consequences of alterations to Ile(279), Ile(283), Glu(284), His(285), Phe(286), and His(288) in the NH2-terminal part of transmembrane helix M3 of the Na+, K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-KIDNEY NA+,K+-ATPASE; NA,K-ATPASE ALPHA-SUBUNIT; SITE-DIRECTED MUTAGENESIS; SARCOPLASMIC-RETICULUM CA2+-ATPASE; CATION-BINDING POCKET; RENAL NA,K-ATPASE; CONFORMATIONAL-CHANGES; SODIUM-PUMP; SEGMENT M3; COORDINATING RESIDUES	Mutations Ile(279) --> Ala, Ile(283) --> Ala, Glu(284) --> Ala, His(285) --> Ala, His(285) --> Lys, His(285) --> Glu, Phe(286) --> Ala, and His(288) --> Ala in transmembrane helix M3 of the Na+, K+-ATPase were studied. Except for His(285) --> Ala, these mutations were compatible with cell viability, permitting analysis of their effects on the overall and partial reactions of the Na+, K+-transport cycle. In Ile(279) --> Ala and Ile(283) --> Ala, the E-1 form accumulated, whereas in His(285) --> Lys and His(285) --> Glu, E1P accumulated. Phe(286) --> Ala displaced the conformational equilibria of dephosphoenzyme and phosphoenzyme in parallel in favor of E-2 and E2P, respectively, and showed a unique enhancement of the E1P --> E2P transition rate. These effects suggest that M3 undergoes significant rearrangements in relation to E-1 - E-2 and E1P - E2P conformational changes. Because the E-1 - E-2 and E1P - E2P conformational equilibria were differentially affected by some of the mutations, the phosphorylated conformations seem to differ significantly from the dephospho forms in the M3 region. Mutation of His(285) furthermore increased the Na+-activated ATPase activity in the absence of K+ ("Na+-ATPase activity"). Ile(279) --> Ala, Ile(283) --> Ala, and His(288)-->Ala showed reduced Na+ affinity of the E-1 form. The rate of Na+-activated phosphorylation from ATP was reduced in Ile(279) --> Ala and Ile(283) --> Ala, and these mutants showed evidence similar to Glu(329) --> Gln of destabilization of the Na+-occluded state.	Aarhus Univ, Dept Physiol, DK-8000 Aarhus C, Denmark	Aarhus University	Vilsen, B (corresponding author), Aarhus Univ, Dept Physiol, Ole Worms Alle 160, DK-8000 Aarhus C, Denmark.	bv@fi.au.dk		Toustrup-Jensen, Mads Schak/0000-0003-2064-5861; Vilsen, Bente/0000-0002-4727-9382				ANDERSEN JP, 1994, J BIOL CHEM, V269, P15931; ANDERSEN JP, 1995, FEBS LETT, V359, P101, DOI 10.1016/0014-5793(95)00019-6; Andersen JP, 2001, J BIOL CHEM, V276, P23312, DOI 10.1074/jbc.M102384200; Axelsen KB, 1998, J MOL EVOL, V46, P84, DOI 10.1007/PL00006286; Babes A, 2000, BIOPHYS J, V79, P2557, DOI 10.1016/S0006-3495(00)76496-4; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Boxenbaum N, 1998, J BIOL CHEM, V273, P23086, DOI 10.1074/jbc.273.36.23086; CLARKE DM, 1989, NATURE, V339, P476, DOI 10.1038/339476a0; Clausen JD, 2003, BIOCHEMISTRY-US, V42, P2585, DOI 10.1021/bi0271897; ESMANN M, 1985, BIOCHEM BIOPH RES CO, V127, P857, DOI 10.1016/S0006-291X(85)80022-X; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GLYNN IM, 1993, J PHYSIOL-LONDON, V462, P1; GLYNN IM, 1976, J PHYSIOL-LONDON, V256, P465, DOI 10.1113/jphysiol.1976.sp011333; Goldshleger R, 1999, J BIOL CHEM, V274, P16213, DOI 10.1074/jbc.274.23.16213; Hebert H, 2001, J MOL BIOL, V314, P479, DOI 10.1006/jmbi.2001.5137; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; KARLISH SJD, 1985, J PHYSIOL-LONDON, V359, P119, DOI 10.1113/jphysiol.1985.sp015578; KLODOS I, 1994, J BIOL CHEM, V269, P1734; Koenderink JB, 2000, BIOCHEMISTRY-US, V39, P9959, DOI 10.1021/bi0001168; Koster JC, 1996, J BIOL CHEM, V271, P2413, DOI 10.1074/jbc.271.5.2413; Kuntzweiler TA, 1996, J BIOL CHEM, V271, P29682, DOI 10.1074/jbc.271.47.29682; Nielsen JM, 1998, BIOCHEMISTRY-US, V37, P1961, DOI 10.1021/bi972524q; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; Pedersen PA, 1998, BIOCHEMISTRY-US, V37, P17818, DOI 10.1021/bi981898w; Pedersen PA, 1997, FEBS LETT, V400, P206, DOI 10.1016/S0014-5793(96)01381-6; POST RL, 1972, J BIOL CHEM, V247, P6530; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; Skou J. C, 1991, SODIUM PUMP RECENT D, P317; Strock C, 1998, J BIOL CHEM, V273, P15104, DOI 10.1074/jbc.273.24.15104; Sweadner KJ, 2001, BIOCHEM J, V356, P685, DOI 10.1042/0264-6021:3560685; Tal DM, 2001, BIOCHEMISTRY-US, V40, P12505, DOI 10.1021/bi011167n; Toustrup-Jensen M, 2002, J BIOL CHEM, V277, P38607, DOI 10.1074/jbc.M203665200; Toustrup-Jensen M, 2001, BIOCHEMISTRY-US, V40, P5521, DOI 10.1021/bi002367m; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; Toyoshima C, 2002, NATURE, V418, P605, DOI 10.1038/nature00944; Vilsen B, 1999, BIOCHEMISTRY-US, V38, P11389, DOI 10.1021/bi990951t; Vilsen B, 1998, BIOCHEMISTRY-US, V37, P10961, DOI 10.1021/bi9802925; VILSEN B, 1993, BIOCHEMISTRY-US, V32, P13340, DOI 10.1021/bi00211a048; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; VILSEN B, 1992, FEBS LETT, V314, P301, DOI 10.1016/0014-5793(92)81494-7; VILSEN B, 1995, FEBS LETT, V363, P179, DOI 10.1016/0014-5793(95)00313-X; Vilsen B, 1997, BIOCHEMISTRY-US, V36, P13312, DOI 10.1021/bi971030q; Vilsen B, 1997, ANN NY ACAD SCI, V834, P297, DOI 10.1111/j.1749-6632.1997.tb52260.x	44	10	10	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38653	38664		10.1074/jbc.M305521200	http://dx.doi.org/10.1074/jbc.M305521200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847095	hybrid			2022-12-27	WOS:000185575100070
J	Madi, L; Bar-Yehuda, S; Barer, F; Ardon, E; Ochaion, A; Fishman, P				Madi, L; Bar-Yehuda, S; Barer, F; Ardon, E; Ochaion, A; Fishman, P			A3 adenosine receptor activation in melanoma cells - Association between receptor fate and tumor growth inhibition	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; BIOCHEMICAL-CHARACTERIZATION; INTERNALIZATION; DESENSITIZATION; APOPTOSIS; ROLES	Activation of the G(i) protein-coupled A3 adenosine receptor (A3AR) has been implicated in the inhibition of melanoma cell growth by deregulating protein kinase A and key components of the Wnt signaling pathway. Receptor activation results in internalization/recycling events that play an important role in turning on/off receptor-mediated signal transduction pathways. Thus, we hereby examined the association between receptor fate, receptor functionality, and tumor growth inhibition upon activation with the agonist 1-deoxy-1-[6-[[(3-iodophenyl)methyl]amino]-9H-purine-9-yl]-N-methyl-beta-D-ribofuranuronamide (IB-MECA). Results showed that melanoma cells highly expressed A3AR on the cell surface, which was rapidly internalized to the cytosol and "sorted" to the endosomes for recycling and to the lysosomes for degradation. Receptor distribution in the lysosomes was consistent with the down-regulation of receptor protein expression and was followed by mRNA and protein resynthesis. At each stage, receptor functionality was evidenced by the modulation in cAMP level and the downstream effectors protein kinase A, glycogen synthase kinase-3beta, c-Myc, and cyclin D1. The A3AR antagonist MRS 1523 counteracted the internalization process as well as the modulation in the expression of the signaling proteins, demonstrating that the responses are A3AR-mediated. Supporting this notion are the in vivo studies showing tumor growth inhibition upon IB-MECA treatment and reverse of this response when IB-MECA was given in combination with MRS 1523. In addition, in melanoma tumor lesions derived from IB-MECA-treated mice, the expression level A3AR and the downstream key signaling proteins were modulated in the same pattern as was seen in vitro. Altogether, our observations tie the fate of A3AR to modulation of downstream molecular mechanisms leading to tumor growth inhibition both in vitro and in vivo.	Can Fite BioPharma Ltd, IL-49170 Petah Tiqwa, Israel; Tel Aviv Univ, Sackler Fac Med, Rabin Med Ctr,Felsenstein Med Res Ctr, Lab Clin & Tumor Immunol, IL-49100 Petah Tiqwa, Israel	Rabin Medical Center; Tel Aviv University; Sackler Faculty of Medicine	Fishman, P (corresponding author), Can Fite BioPharma Ltd, IL-49170 Petah Tiqwa, Israel.	pfishman@post.tau.ac.il						Appel E, 2001, J MOL NEUROSCI, V17, P285, DOI 10.1385/JMN:17:3:285; Bonvini P, 2000, BBA-MOL CELL RES, V1495, P308, DOI 10.1016/S0167-4889(99)00162-7; Bunemann M, 1999, ANNU REV PHYSIOL, V61, P169, DOI 10.1146/annurev.physiol.61.1.169; Ceresa BP, 2000, CURR OPIN CELL BIOL, V12, P204, DOI 10.1016/S0955-0674(99)00077-0; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; D'Agnano I, 2001, ONCOGENE, V20, P2814, DOI 10.1038/sj.onc.1204392; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Ferguson G, 2002, BIOCHEMISTRY-US, V41, P14748, DOI 10.1021/bi0262911; Ferkey DM, 2000, DEV BIOL, V225, P471, DOI 10.1006/dbio.2000.9816; Fishman P, 2003, CURR TOP MED CHEM, V3, P463, DOI 10.2174/1568026033392147; Fishman P, 2002, ONCOGENE, V21, P4060, DOI 10.1038/sj.onc.1205531; Fishman P, 2001, EXP CELL RES, V269, P230, DOI 10.1006/excr.2001.5327; Gessi S, 2001, BRIT J PHARMACOL, V134, P116, DOI 10.1038/sj.bjp.0704254; Kim SG, 2002, BIOCHEM PHARMACOL, V63, P871, DOI 10.1016/S0006-2952(02)00839-0; Merighi S, 2001, BRIT J PHARMACOL, V134, P1215, DOI 10.1038/sj.bjp.0704352; Merimsky O, 2003, DRUG DEVELOP RES, V58, P386, DOI 10.1002/ddr.10182; Montesinos MC, 2003, ARTHRITIS RHEUM-US, V48, P240, DOI 10.1002/art.10712; Morin PJ, 1999, BIOESSAYS, V21, P1021, DOI 10.1002/(SICI)1521-1878(199912)22:1<1021::AID-BIES6>3.0.CO;2-P; Ohana G, 2001, J CELL PHYSIOL, V186, P19, DOI 10.1002/1097-4652(200101)186:1<19::AID-JCP1011>3.0.CO;2-3; Olah ME, 2000, PHARMACOL THERAPEUT, V85, P55, DOI 10.1016/S0163-7258(99)00051-0; Parrella P, 2001, INVEST OPHTH VIS SCI, V42, P1679; Petrou C, 1997, J BIOL CHEM, V272, P2326; Poulsen SA, 1998, BIOORGAN MED CHEM, V6, P619, DOI 10.1016/S0968-0896(98)00038-8; Robbins PF, 1996, J EXP MED, V183, P1185, DOI 10.1084/jem.183.3.1185; SCHMID SL, 1988, CELL, V52, P73, DOI 10.1016/0092-8674(88)90532-6; Suh BC, 2001, BRIT J PHARMACOL, V134, P132, DOI 10.1038/sj.bjp.0704218; Trincavelli ML, 2002, MOL PHARMACOL, V62, P1373, DOI 10.1124/mol.62.6.1373; Trincavelli ML, 2000, J NEUROCHEM, V75, P1493, DOI 10.1046/j.1471-4159.2000.0751493.x	28	84	86	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42121	42130		10.1074/jbc.M301243200	http://dx.doi.org/10.1074/jbc.M301243200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12865431	hybrid			2022-12-27	WOS:000185989500070
J	Nagae, M; Nozawa, A; Koizumi, N; Sano, H; Hashimoto, H; Sato, M; Shimizu, T				Nagae, M; Nozawa, A; Koizumi, N; Sano, H; Hashimoto, H; Sato, M; Shimizu, T			The crystal structure of the novel calcium-binding protein AtCBL2 from Arabidopsis thaliana	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3-DIMENSIONAL STRUCTURE; SIGNAL-TRANSDUCTION; ABSCISIC-ACID; PLANT-CELLS; KINASE; SALT; CALCINEURIN; SENSOR; MYRISTOYLATION; TRANSCRIPTS	Arabidopsis thaliana calcineurin B-like protein (AtCBL2) is a member of a recently identified family of calcineurin B-like calcium-binding proteins in A. thaliana. The crystal structure of AtCBL2 has been determined at 2.1 Angstrom resolution. The protein forms a compact alpha-helical structure with two pairs of EF-hand motifs. The structure is similar in overall folding topology to the structures of calcineurin B and neuronal calcium sensor 1, but differs significantly in local conformation. The two calcium ions are coordinated in the first and fourth EF-hand motifs, whereas the second and third EF-hand motifs are maintained in the open form by internal hydrogen bonding without coordination of calcium ions. Both a possible site and a possible mechanism for the target binding to AtCBL2 are discussed based on the three-dimensional structure.	Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Nara Inst Sci & Technol, Res & Educ Ctr Genet Informat, Lab Plant Mol Breeding, Nara 6300192, Japan	Yokohama City University; Nara Institute of Science & Technology	Shimizu, T (corresponding author), Yokohama City Univ, Grad Sch Integrated Sci, Tsurumi Ku, 1-7-29 Suehiro Cho, Yokohama, Kanagawa 2300045, Japan.	shimizu@tsurumi.yokohama-cu.ac.jp		Nozawa, Akira/0000-0003-4886-0213; Hashimoto, Hiroshi/0000-0003-1503-6789; Nagae, Masamichi/0000-0002-5470-3807				Albrecht V, 2001, EMBO J, V20, P1051, DOI 10.1093/emboj/20.5.1051; AMES JB, 1995, J BIOL CHEM, V270, P4526, DOI 10.1074/jbc.270.9.4526; Ames JB, 2002, BIOCHEMISTRY-US, V41, P5776, DOI 10.1021/bi012153k; Ames JB, 1999, J BIOL CHEM, V274, P19329, DOI 10.1074/jbc.274.27.19329; Ames JB, 1997, NATURE, V389, P198, DOI 10.1038/38310; Benson LM, 2003, RAPID COMMUN MASS SP, V17, P267, DOI 10.1002/rcm.903; Bourne Y, 2001, J BIOL CHEM, V276, P11949, DOI 10.1074/jbc.M009373200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Chikano H, 2001, MOL GEN GENET, V264, P674, DOI 10.1007/s004380000354; FINN BE, 1995, NAT STRUCT BIOL, V2, P777, DOI 10.1038/nsb0995-777; FLAHERTY KM, 1993, CELL, V75, P709, DOI 10.1016/0092-8674(93)90491-8; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Guo Y, 2002, DEV CELL, V3, P233, DOI 10.1016/S1534-5807(02)00229-0; Guo Y, 2001, PLANT CELL, V13, P1383, DOI 10.1105/tpc.13.6.1383; Halfter U, 2000, P NATL ACAD SCI USA, V97, P3735, DOI 10.1073/pnas.040577697; Hoeflich KP, 2002, CELL, V108, P739, DOI 10.1016/S0092-8674(02)00682-7; Ishitani M, 2000, PLANT CELL, V12, P1667, DOI 10.1105/tpc.12.9.1667; JONES S, 1995, PROG BIOPHYS MOL BIO, V63, P31, DOI 10.1016/0079-6107(94)00008-W; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim KN, 2003, PLANT CELL, V15, P411, DOI 10.1105/tpc.006858; Kim KN, 2000, PLANT PHYSIOL, V124, P1844, DOI 10.1104/pp.124.4.1844; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUBONIWA H, 1995, NAT STRUCT BIOL, V2, P768, DOI 10.1038/nsb0995-768; Kudla J, 1999, P NATL ACAD SCI USA, V96, P4718, DOI 10.1073/pnas.96.8.4718; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu JP, 2000, P NATL ACAD SCI USA, V97, P3730, DOI 10.1073/pnas.060034197; Liu JP, 1998, SCIENCE, V280, P1943, DOI 10.1126/science.280.5371.1943; Luan S, 2002, PLANT CELL, V14, pS389, DOI 10.1105/tpc.001115; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagae M, 2003, ACTA CRYSTALLOGR D, V59, P1079, DOI 10.1107/S0907444903007029; Nakayama N, 2000, TOP BIOL INORG CHEM, V3, P29; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nozawa A, 2001, PLANT CELL PHYSIOL, V42, P976, DOI 10.1093/pcp/pce126; Pflugrath JW, 1999, ACTA CRYSTALLOGR D, V55, P1718, DOI 10.1107/S090744499900935X; Rety S, 1999, NAT STRUCT BIOL, V6, P89; Shi JR, 1999, PLANT CELL, V11, P2393, DOI 10.1105/tpc.11.12.2393; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9; Vijay-Kumar S, 1999, NAT STRUCT BIOL, V6, P80; Xiong LM, 2002, PLANT CELL, V14, pS165, DOI 10.1105/tpc.000596; ZHANG M, 1995, NAT STRUCT BIOL, V2, P758, DOI 10.1038/nsb0995-758; Zhu JK, 2002, ANNU REV PLANT BIOL, V53, P247, DOI 10.1146/annurev.arplant.53.091401.143329; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	49	90	111	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42240	42246		10.1074/jbc.M303630200	http://dx.doi.org/10.1074/jbc.M303630200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871972	hybrid			2022-12-27	WOS:000185989500083
J	de Graffenried, CL; Bertozzi, CR				de Graffenried, CL; Bertozzi, CR			Golgi localization of carbohydrate sulfotransferases is a determinant of L-selectin ligand biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORE 2 BETA-1,6-N-ACETYLGLUCOSAMINYLTRANSFERASE; ENDOTHELIAL-DERIVED LIGAND; SIALYL-LEWIS-X; CELL-LINE; GLCNAC 6-O-SULFOTRANSFERASE; LINKED OLIGOSACCHARIDES; VASCULAR ADDRESSIN; KIN RECOGNITION; BREFELDIN-A; HELA-CELLS	Sulfation of endothelial glycoproteins by the sulfotransferase GlcNAc6ST-2 is a regulatory modification that promotes binding of the leukocyte adhesion molecule L-selectin. GlcNAc6ST-2 is a member of a family of related enzymes that act on similar carbohydrate substrates in vitro but discrete glycoproteins in vivo. We demonstrate that GlcNAc6ST-1, -2, and -3 have <LF>distinct Golgi distributions, with GlcNAc6ST-1 confined to the trans-Golgi network, GlcNAc6ST-3 confined to the early secretory pathway, and GlcNAc6ST-2 distributed throughout the Golgi. Their localization was correlated with preferred activity on either N-linked or O-linked glycoproteins. A chimera comprising the localization domain of GlcNAc6ST-1 fused to the catalytic domain of GlcNAc6ST-2 was confined to the trans-Golgi network and adopted the substrate preference of GlcNAc6ST-1. We propose a model in which Golgi enzyme localization and competition orchestrate the biosynthesis of L-selectin ligands.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	bertozzi@cchem.berkeley.edu	de Graffenried, Christopher/I-6172-2019	de Graffenried, Christopher/0000-0003-3386-6487	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059907] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM59907] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akama TO, 2001, J BIOL CHEM, V276, P16271, DOI 10.1074/jbc.M009995200; Andre P, 2000, P NATL ACAD SCI USA, V97, P3400, DOI 10.1073/pnas.040569797; Aplin JD, 1998, GLYCOBIOLOGY, V8, P269, DOI 10.1093/glycob/8.3.269; Baekkevold ES, 1999, LAB INVEST, V79, P327; Banting G, 1997, BBA-MOL CELL RES, V1355, P209, DOI 10.1016/S0167-4889(96)00146-2; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; Beum PV, 1999, J BIOL CHEM, V274, P24641, DOI 10.1074/jbc.274.35.24641; Bieberich E, 2002, BIOCHEMISTRY-US, V41, P11479, DOI 10.1021/bi0259958; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; BOS K, 1993, EMBO J, V12, P2219, DOI 10.1002/j.1460-2075.1993.tb05870.x; Bowman KG, 2001, BIOCHEMISTRY-US, V40, P5382, DOI 10.1021/bi001750o; BROWN GM, 1994, EUR J BIOCHEM, V224, P281, DOI 10.1111/j.1432-1033.1994.00281.x; CAMPBELL C, 1984, J BIOL CHEM, V259, P1208; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; CHEGE NW, 1990, J CELL BIOL, V111, P893, DOI 10.1083/jcb.111.3.893; Chen SQ, 1999, J CELL BIOL, V144, P185, DOI 10.1083/jcb.144.1.185; Cole NB, 1998, J CELL BIOL, V140, P1, DOI 10.1083/jcb.140.1.1; Cole NB, 1996, SCIENCE, V273, P797, DOI 10.1126/science.273.5276.797; Colley KJ, 1997, GLYCOBIOLOGY, V7, P1, DOI 10.1093/glycob/7.1.1-b; Dalziel M, 2001, J BIOL CHEM, V276, P11007, DOI 10.1074/jbc.M006523200; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Elhammer AP, 1999, GLYCOCONJUGATE J, V16, P171, DOI 10.1023/A:1026465232149; Esko JD, 1991, CURR OPIN CELL BIOL, V3, P805, DOI 10.1016/0955-0674(91)90054-3; Giraudo CG, 2001, P NATL ACAD SCI USA, V98, P1625, DOI 10.1073/pnas.031458398; Gleeson PA, 1998, HISTOCHEM CELL BIOL, V109, P517, DOI 10.1007/s004180050252; Grabenhorst E, 1999, J BIOL CHEM, V274, P36107, DOI 10.1074/jbc.274.51.36107; Grunwell JR, 2002, BIOCHEMISTRY-US, V41, P15590, DOI 10.1021/bi0269557; Hauri HP, 2000, J CELL SCI, V113, P587; Hemmerich S, 2001, DRUG DISCOV TODAY, V6, P27, DOI 10.1016/S1359-6446(00)01581-6; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; Hemmerich S, 2001, IMMUNITY, V15, P237, DOI 10.1016/S1074-7613(01)00188-1; Hemmerich S, 2001, GLYCOBIOLOGY, V11, P75, DOI 10.1093/glycob/11.1.75; HEMMERICH S, 1994, BIOCHEMISTRY-US, V33, P4820, DOI 10.1021/bi00182a010; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Hooper LV, 2001, GLYCOBIOLOGY, V11, p1R, DOI 10.1093/glycob/11.2.1R; Ikehara Y, 1999, GLYCOBIOLOGY, V9, P1213, DOI 10.1093/glycob/9.11.1213; IMAI Y, 1993, NATURE, V361, P555; KAMERLING JP, 1988, FEBS LETT, V241, P246, DOI 10.1016/0014-5793(88)81070-6; Kimura N, 1999, P NATL ACAD SCI USA, V96, P4530, DOI 10.1073/pnas.96.8.4530; Klingbeil CK, 2001, J CELL BIOL, V152, P97, DOI 10.1083/jcb.152.1.97; KUAN SF, 1989, J BIOL CHEM, V264, P19271; Ladinsky MS, 1999, J CELL BIOL, V144, P1135, DOI 10.1083/jcb.144.6.1135; Lawrence MB, 1999, CURR OPIN CHEM BIOL, V3, P659, DOI 10.1016/S1367-5931(99)00023-X; Lee JK, 2003, GLYCOBIOLOGY, V13, P245, DOI 10.1093/glycob/cwg018; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; Lippincott-Schwartz J, 1998, TRENDS CELL BIOL, V8, P16, DOI 10.1016/S0962-8924(97)01199-9; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; Marsh BJ, 2001, P NATL ACAD SCI USA, V98, P2399, DOI 10.1073/pnas.051631998; McCormick C, 2000, P NATL ACAD SCI USA, V97, P668, DOI 10.1073/pnas.97.2.668; MICHIE SA, 1993, AM J PATHOL, V143, P1688; Miles S, 2001, J CELL BIOL, V155, P543, DOI 10.1083/jcb.200103104; Mitsuoka C, 1998, J BIOL CHEM, V273, P11225, DOI 10.1074/jbc.273.18.11225; Munro S, 1998, TRENDS CELL BIOL, V8, P11, DOI 10.1016/S0962-8924(97)01197-5; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; NILSSON T, 1994, EMBO J, V13, P562, DOI 10.1002/j.1460-2075.1994.tb06294.x; NILSSON T, 1993, FEBS LETT, V330, P1, DOI 10.1016/0014-5793(93)80906-B; NOGUCHI S, 1992, EUR J BIOCHEM, V209, P883, DOI 10.1111/j.1432-1033.1992.tb17361.x; NOVIKOFF PM, 1983, P NATL ACAD SCI-BIOL, V80, P4364, DOI 10.1073/pnas.80.14.4364; O'Riordan CR, 2000, GLYCOBIOLOGY, V10, P1225, DOI 10.1093/glycob/10.11.1225; Opat AS, 2001, BIOCHIMIE, V83, P763, DOI 10.1016/S0300-9084(01)01312-8; Opat AS, 2001, BIOCHEM J, V358, P33, DOI 10.1042/0264-6021:3580033; Osman N, 1996, J BIOL CHEM, V271, P33105, DOI 10.1074/jbc.271.51.33105; Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7; Pinhal MAS, 2001, P NATL ACAD SCI USA, V98, P12984, DOI 10.1073/pnas.241175798; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Roth J, 2002, CHEM REV, V102, P285, DOI 10.1021/cr000423j; Rottger S, 1998, J CELL SCI, V111, P45; Sanders WJ, 1999, J BIOL CHEM, V274, P5271, DOI 10.1074/jbc.274.9.5271; Sato TK, 2001, SCIENCE, V294, P1881, DOI 10.1126/science.1065763; Seko A, 2002, GLYCOBIOLOGY, V12, P379, DOI 10.1093/glycob/12.6.379; SHILATIFARD A, 1993, J VIROL, V67, P943, DOI 10.1128/JVI.67.2.943-952.1993; Skrincosky D, 1997, J BIOL CHEM, V272, P22695, DOI 10.1074/jbc.272.36.22695; STANLEY P, 1995, FASEB J, V9, P1436, DOI 10.1096/fasebj.9.14.7589985; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Tangemann K, 1999, J EXP MED, V190, P935, DOI 10.1084/jem.190.7.935; Tsuboi S, 2001, BIOESSAYS, V23, P46, DOI 10.1002/1521-1878(200101)23:1<46::AID-BIES1006>3.3.CO;2-V; Uchimura K, 2002, J BIOL CHEM, V277, P3979, DOI 10.1074/jbc.M106587200; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Van den Steen P, 1998, CRIT REV BIOCHEM MOL, V33, P151; Varki A, 1998, TRENDS CELL BIOL, V8, P34, DOI 10.1016/S0962-8924(97)01198-7; Walcheck B, 2002, BLOOD, V99, P4063, DOI 10.1182/blood-2001-12-0265; Whitehouse C, 1997, J CELL BIOL, V137, P1229, DOI 10.1083/jcb.137.6.1229; Yeh JC, 2001, CELL, V105, P957, DOI 10.1016/S0092-8674(01)00394-4; Zerfaoui M, 2002, GLYCOBIOLOGY, V12, P15, DOI 10.1093/glycob/12.1.15	87	25	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40282	40295		10.1074/jbc.M304928200	http://dx.doi.org/10.1074/jbc.M304928200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12855678	hybrid			2022-12-27	WOS:000185713800121
J	Dutta, PR; Sui, BQ; Nataro, JP				Dutta, PR; Sui, BQ; Nataro, JP			Structure-function analysis of the enteroaggregative Escherichia coli plasmid-encoded toxin autotransporter using scanning linker mutagenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYLORI VACUOLATING TOXIN; SERINE-PROTEASE; DIARRHEA; IDENTIFICATION; PROTEINS; CELLS; PET; ENTEROTOXIN; INVOLVEMENT; SECRETION	The plasmid-encoded toxin (Pet) from enteroaggregative Escherichia coli is a cytopathic serine protease, which is prototypical of a large family of bacterial autotransporter toxins. To further elucidate the structure-function relationships of this toxin, we employed transposon-based scanning linker mutagenesis. A subset of insertions throughout the Pet mature toxin (passenger) domain reduced secretion to the extracellular space. Many of these mutants were undetectable, but secretion of a subset of mutants with insertions in the N-terminal half of the toxin could be restored to wild type secretion levels if cultured in the presence of 0.1% Triton X-100. Secretion of two mutants with insertions at the extreme C terminus was partially restored when co-expressed with a minimal clone of EspP, a related autotransporter protein. Several well secreted mutants with insertions in the N-terminal third of the molecule reduced protease activity over 20-fold, suggesting that the protease domain is located within this N-terminal region of Pet. We have also identified two insertional mutants in the middle of the passenger domain that were proteolytic but no longer cytopathic; these mutants displayed decreased binding and internalization upon incubation with HEp-2 cells. Our data suggest the existence of separate functional domains mediating Pet proteolysis, secretion, and cell interaction.	Univ Maryland, Sch Med, Ctr Vaccine Dev, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Nataro, JP (corresponding author), Univ Maryland, Sch Med, Ctr Vaccine Dev, HSF 480,685 W Baltimore St, Baltimore, MD 21201 USA.				NIAID NIH HHS [5 T32 AI07540-04, AI 43615] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043615, T32AI007540, R56AI043615] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ausubel FM, 1988, MOL REPROD DEV; BHAN MK, 1989, J INFECT DIS, V159, P1061, DOI 10.1093/infdis/159.6.1061; BOYER HW, 1969, J MOL BIOL, V41, P459, DOI 10.1016/0022-2836(69)90288-5; CRAVIOTO A, 1991, LANCET, V337, P262, DOI 10.1016/0140-6736(91)90868-P; DALESSIO JM, 1990, FOCUS, V12, P47; Dutta PR, 2002, INFECT IMMUN, V70, P7105, DOI 10.1128/IAI.70.12.7105-7113.2002; Eslava C, 1998, INFECT IMMUN, V66, P3155, DOI 10.1128/IAI.66.7.3155-3163.1998; ESLAVA C, 1993, GEN M AM SOC MICR AT, pB105; Fink DL, 2001, J BIOL CHEM, V276, P39492, DOI 10.1074/jbc.M106913200; Hayes F, 2000, TRENDS MICROBIOL, V8, P571, DOI 10.1016/S0966-842X(00)01857-6; Henderson IR, 1999, INFECT IMMUN, V67, P5338, DOI 10.1128/IAI.67.10.5338-5344.1999; Henderson IR, 1998, TRENDS MICROBIOL, V6, P370, DOI 10.1016/S0966-842X(98)01318-3; KLAUSER T, 1993, J MOL BIOL, V234, P579, DOI 10.1006/jmbi.1993.1613; Knutton S, 2001, J PEDIATR GASTR NUTR, V33, P32, DOI 10.1097/00005176-200107000-00006; Maurer J, 1999, J BACTERIOL, V181, P7014, DOI 10.1128/JB.181.22.7014-7020.1999; Nataro JP, 1996, INFECT IMMUN, V64, P4761, DOI 10.1128/IAI.64.11.4761-4768.1996; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; Navarro-Garcia F, 2001, INFECT IMMUN, V69, P1053, DOI 10.1128/IAI.69.2.1053-1060.2001; Navarro-Garcia F, 1999, INFECT IMMUN, V67, P2184; NOLAN CM, 1992, PROTEIN TARGETING PR, P1; OHNISHI Y, 1994, J BIOL CHEM, V269, P32800; OLIVER D, 2001, GEN M AM SOC MICR OR; Oliver DC, 2003, MOL MICROBIOL, V47, P1367, DOI 10.1046/j.1365-2958.2003.03377.x; Oliver DC, 2003, J BACTERIOL, V185, P489, DOI 10.1128/JB.185.2.489-495.2003; Presterl E, 1999, EUR J CLIN MICROBIOL, V18, P209, DOI 10.1007/s100960050261; Sheikh J, 2001, MOL MICROBIOL, V41, P983, DOI 10.1046/j.1365-2958.2001.02512.x; TZIPORI S, 1992, INFECT IMMUN, V60, P5302, DOI 10.1128/IAI.60.12.5302-5306.1992; Veiga E, 2002, EMBO J, V21, P2122, DOI 10.1093/emboj/21.9.2122; VELARDE J, 2002, GEN M AM SOC MICR SA; Villaseca JM, 2000, INFECT IMMUN, V68, P5920, DOI 10.1128/IAI.68.10.5920-5927.2000; Wanke CA, 1998, J INFECT DIS, V178, P185, DOI 10.1086/515595; Ye D, 2000, INFECT IMMUN, V68, P4354, DOI 10.1128/IAI.68.7.4354-4357.2000; Ye D, 1999, J BIOL CHEM, V274, P9277, DOI 10.1074/jbc.274.14.9277	33	29	29	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39912	39920		10.1074/jbc.M303595200	http://dx.doi.org/10.1074/jbc.M303595200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878602	hybrid			2022-12-27	WOS:000185713800079
J	Merckx, A; Le Roch, K; Nivez, MP; Dorin, D; Alano, P; Gutierrez, GJ; Nebreda, AR; Goldring, D; Whittle, C; Patterson, S; Chakrabarti, D; Doerig, C				Merckx, A; Le Roch, K; Nivez, MP; Dorin, D; Alano, P; Gutierrez, GJ; Nebreda, AR; Goldring, D; Whittle, C; Patterson, S; Chakrabarti, D; Doerig, C			Identification and initial characterization of three novel cyclin-related proteins of the human malaria parasite Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; CELL-CYCLE; KINASE; EXPRESSION; GENOME; SEQUENCE; ANTIGEN; CLONING	The molecular mechanisms regulating cell proliferation and development during the life cycle of malaria parasites remain to be elucidated. The peculiarities of the cell cycle organization during Plasmodium falciparum schizogony suggest that the modalities of cell cycle control in this organism may differ from those in other eukaryotes. Indeed, existing data concerning Plasmodium cell cycle regulators such as cyclin-dependent kinases reveal structural and functional properties that are divergent from those of their homologues in other systems. The work presented here lies in the context of the exploitation of the recently available P. falciparum genome sequence toward the characterization of putative cell cycle regulators. We describe the in silico identification of three open reading frames encoding proteins with maximal homology to various members of the cyclin family and demonstrate that the corresponding polypeptides are expressed in the erythrocytic stages of the infection. We present evidence that these proteins possess cyclin activity by demonstrating either their association with histone H1 kinase activity in parasite extracts or their ability to activate PfPK5, a P. falciparum cyclin-dependent kinase homologue, in vitro. Furthermore, we show that RINGO, a protein with no sequence homology to cyclins but that is nevertheless a strong activator of mammalian CDK1/2, is also a strong activator of PfPK5 in vitro. This raises the possibility that "cryptic" cell cycle regulators may be found among the 50% of the open reading frames in the P. falciparum genome that display no homology to any known proteins.	Anderson Coll, INSERM, U511 Team, Wellcome Ctr Mol Parasitol, Glasgow G11 6NU, Lanark, Scotland; Ist Super Sanita, I-00161 Rome, Italy; European Mol Biol Lab, D-69117 Heidelberg, Germany; Univ KwaZulu Natal, Sch Mol & Cellular Biosci, ZA-3209 Scottsville, South Africa; Univ Cent Florida, Dept Mol Biol & Microbiol, Orlando, FL 32826 USA	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Glasgow; Istituto Superiore di Sanita (ISS); European Molecular Biology Laboratory (EMBL); University of Kwazulu Natal; State University System of Florida; University of Central Florida	Doerig, C (corresponding author), Anderson Coll, INSERM, U511 Team, Wellcome Ctr Mol Parasitol, 56 Dumbarton Rd, Glasgow G11 6NU, Lanark, Scotland.	cdoer001@udcf.gla.ac.uk	Doerig, Christian/Q-9900-2019; Nebreda, Angel Rodriguez/R-9594-2019; ALANO, PIETRO/C-2946-2016; Gutierrez, Gustavo/AAO-9957-2021; Gutierrez, Gustavo/B-6771-2013	ALANO, PIETRO/0000-0003-0092-9840; Gutierrez, Gustavo/0000-0001-8652-972X; Gutierrez, Gustavo/0000-0003-4133-5002; Doerig, Christian/0000-0002-3188-094X; Goldring, James Philip Dean/0000-0001-6713-9515; Merckx, Anais/0000-0002-9756-7980	NIAID NIH HHS [R01 AI048036-03, AI48036, R01 AI048036] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048036] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALANO P, 1995, EXP PARASITOL, V81, P227, DOI 10.1006/expr.1995.1112; Alano P, 1995, MOL BIOCHEM PARASIT, V74, P143, DOI 10.1016/0166-6851(95)02491-3; Arnot DE, 1998, ANN TROP MED PARASIT, V92, P361, DOI 10.1080/00034989859357; Cross FR, 2000, MOL CELL BIOL, V20, P4782, DOI 10.1128/MCB.20.13.4782-4790.2000; Cross FR, 1999, MOL CELL, V4, P11, DOI 10.1016/S1097-2765(00)80183-5; Doerig C, 2000, Prog Cell Cycle Res, V4, P163; DOERIG C, 1995, MOL BIOCHEM PARASIT, V70, P167, DOI 10.1016/0166-6851(95)00033-W; Doerig C, 2002, INT J PARASITOL, V32, P1575, DOI 10.1016/S0020-7519(02)00186-8; DOERIG C, 2004, IN PRESS PLASMODIUM; Ferby I, 1999, GENE DEV, V13, P2177, DOI 10.1101/gad.13.16.2177; Furstenthal L, 2001, J CELL BIOL, V152, P1267, DOI 10.1083/jcb.152.6.1267; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Gomez EB, 2001, MOL BIOCHEM PARASIT, V113, P97, DOI 10.1016/S0166-6851(00)00382-0; HALDAR K, 1985, J BIOL CHEM, V260, P4969; Holder AA, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P409; Honey S, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.4.e24; Horrocks P, 2000, MOL BIOCHEM PARASIT, V105, P115, DOI 10.1016/S0166-6851(99)00174-7; Irniger S, 2002, FEBS LETT, V532, P7, DOI 10.1016/S0014-5793(02)03657-8; Karaiskou A, 2001, J BIOL CHEM, V276, P36028, DOI 10.1074/jbc.M104722200; Kele Z, 1998, RAPID COMMUN MASS SP, V12, P1564, DOI 10.1002/(SICI)1097-0231(19981030)12:20<1564::AID-RCM351>3.0.CO;2-T; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; KITAGAWA T, 1976, J BIOCHEM-TOKYO, V79, P233, DOI 10.1093/oxfordjournals.jbchem.a131053; Koski LB, 2001, J MOL EVOL, V52, P540, DOI 10.1007/s002390010184; Kumar Rajinder, 2002, Malar J, V1, P5, DOI 10.1186/1475-2875-1-5; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; Le Roch K, 2000, J BIOL CHEM, V275, P8952, DOI 10.1074/jbc.275.12.8952; Li JL, 1996, EUR J BIOCHEM, V241, P805, DOI 10.1111/j.1432-1033.1996.00805.x; Li ZY, 2001, BIOCHEM BIOPH RES CO, V288, P1207, DOI 10.1006/bbrc.2001.5920; Malhotra P, 2002, MOL MICROBIOL, V45, P1245, DOI 10.1046/j.1365-2958.2002.03105.x; McRobert L, 2002, MOL BIOCHEM PARASIT, V119, P273, DOI 10.1016/S0166-6851(01)00429-7; Nairn AC, 2001, NEURON, V32, P174, DOI 10.1016/S0896-6273(01)00469-X; POLSON A, 1985, IMMUNOL INVEST, V14, P323, DOI 10.3109/08820138509022667; READ M, 1993, PARASITOLOGY, V106, P223, DOI 10.1017/S0031182000075041; Ridley RG, 2002, NATURE, V415, P686, DOI 10.1038/415686a; ROSSMACDONALD PB, 1994, EUR J BIOCHEM, V220, P693, DOI 10.1111/j.1432-1033.1994.tb18670.x; Schulman BA, 1998, P NATL ACAD SCI USA, V95, P10453, DOI 10.1073/pnas.95.18.10453; Trembley JH, 2002, J BIOL CHEM, V277, P2589, DOI 10.1074/jbc.M109755200; Umeda M, 1999, MOL GEN GENET, V262, P230, DOI 10.1007/s004380051079; Van Hellemond JJ, 2000, J BIOL CHEM, V275, P8315, DOI 10.1074/jbc.275.12.8315; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; Wirth DF, 2002, NATURE, V419, P495, DOI 10.1038/419495a; Zhang SW, 2002, J BIOL CHEM, V277, P35314, DOI 10.1074/jbc.M202179200	43	61	66	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39839	39850		10.1074/jbc.M301625200	http://dx.doi.org/10.1074/jbc.M301625200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869562	hybrid, Green Published			2022-12-27	WOS:000185713800070
J	Mignen, O; Thompson, JL; Shuttleworth, TJ				Mignen, O; Thompson, JL; Shuttleworth, TJ			Calcineurin directs the reciprocal regulation of calcium entry pathways in nonexcitable cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+ ENTRY; T-LYMPHOCYTES; NUCLEAR IMPORT; HEK293 CELLS; CHANNELS; OSCILLATIONS; ACTIVATION; RECEPTOR; RELEASE; IMMUNOSUPPRESSANT	The reciprocal regulation of noncapacitative and capacitative (or store-operated) Ca2+ entry in nonexcitable cells (Mignen, O., Thompson, J. L., and Shuttleworth, T. J. (2001) J. Biol. Chem. 276, 35676-35683) represents a switching between two distinct Ca2+-selective channels: the noncapacitative arachidonate-regulated Ca2+ channels (ARC channels) and the store- operated Ca2+ channels (SOC channels). This switch is directly associated with the change from oscillatory to sustained Ca2+ signals as agonist concentrations increase and involves a Ca2+-dependent inhibition of the ARC channels. Here we show that this process is mediated via a calcineurin-dependent inhibition of the noncapacitative ARC channels. Pharmacological and molecular inhibition of calcineurin activity (using cyclosporin or the FK506 analogue ascomycin, and a transfected C-terminal domain of the calcineurin inhibitory protein CAIN, respectively) results in a complete reversal of the Ca2+-dependent inhibition of the ARC channels. Agonist concentrations that result in oscillatory Ca2+ signals and specifically activate Ca2+ entry through the ARC channels fail to increase calcineurin activity. However, agonist concentrations that activate the store- operated Ca2+ channels and produce prolonged increases in cytosolic Ca2+ concentrations increase calcineurin activity. Thus, calcineurin is the key mediator of the reciprocal regulation of these co-existing channels, allowing each to play a unique and non-overlapping role in Ca2+ signaling.	Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Rochester, NY 14642 USA	University of Rochester	Shuttleworth, TJ (corresponding author), Univ Rochester, Med Ctr, Dept Physiol & Pharmacol, Box 711,601 Elmwood Ave, Rochester, NY 14642 USA.	trevor_shuttleworth@urmc.rochester.edu	MIGNEN, Olivier/M-3258-2019	MIGNEN, Olivier/0000-0001-7913-6119	NIGMS NIH HHS [GM40457] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berridge MJ, 2000, NAT REV MOL CELL BIO, V1, P11, DOI 10.1038/35036035; Berridge MJ, 1997, J PHYSIOL-LONDON, V499, P291, DOI 10.1113/jphysiol.1997.sp021927; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Broad LM, 1999, J BIOL CHEM, V274, P32881, DOI 10.1074/jbc.274.46.32881; CHAD JE, 1986, J PHYSIOL-LONDON, V378, P31, DOI 10.1113/jphysiol.1986.sp016206; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Crabtree GR, 2001, J BIOL CHEM, V276, P2313, DOI 10.1074/jbc.R000024200; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; FANGER CM, 1995, J CELL BIOL, V131, P655, DOI 10.1083/jcb.131.3.655; GIRARD S, 1993, SCIENCE, V260, P229, DOI 10.1126/science.8385801; Glitsch MD, 2002, EMBO J, V21, P6744, DOI 10.1093/emboj/cdf675; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hartzell HC, 1997, MOL PHARMACOL, V51, P683, DOI 10.1124/mol.51.4.683; Hojo M, 1999, NATURE, V397, P530, DOI 10.1038/17401; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; Kiani A, 2000, IMMUNITY, V12, P359, DOI 10.1016/S1074-7613(00)80188-0; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; Lai MM, 1998, J BIOL CHEM, V273, P18325, DOI 10.1074/jbc.273.29.18325; LIEBERMAN DN, 1994, NATURE, V369, P235, DOI 10.1038/369235a0; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; Luo C, 1996, P NATL ACAD SCI USA, V93, P8907, DOI 10.1073/pnas.93.17.8907; MACKINTOSH C, 1990, FEBS LETT, V277, P137, DOI 10.1016/0014-5793(90)80828-7; Mignen O, 2003, J BIOL CHEM, V278, P10174, DOI 10.1074/jbc.M212536200; Mignen O, 2001, J BIOL CHEM, V276, P21365, DOI 10.1074/jbc.M102311200; Mignen O, 2001, J BIOL CHEM, V276, P35676, DOI 10.1074/jbc.M105626200; Mignen O, 2000, J BIOL CHEM, V275, P9114, DOI 10.1074/jbc.275.13.9114; Peterson LB, 1998, TRANSPLANTATION, V65, P10, DOI 10.1097/00007890-199801150-00004; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; ROONEY TA, 1990, J BIOL CHEM, V265, P10792; Schuhmann K, 1997, J GEN PHYSIOL, V110, P503, DOI 10.1085/jgp.110.5.503; SERAFINI AT, 1995, IMMUNITY, V3, P239, DOI 10.1016/1074-7613(95)90093-4; Shuttleworth TJ, 1998, J BIOL CHEM, V273, P32636, DOI 10.1074/jbc.273.49.32636; Shuttleworth TJ, 1996, J BIOL CHEM, V271, P21720, DOI 10.1074/jbc.271.36.21720; Shuttleworth TJ, 1996, BIOCHEM J, V313, P815, DOI 10.1042/bj3130815; STEMMER PM, 1994, BIOCHEMISTRY-US, V33, P6859, DOI 10.1021/bi00188a015; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; TONG G, 1995, SCIENCE, V267, P1510, DOI 10.1126/science.7878472; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	43	44	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40088	40096		10.1074/jbc.M306365200	http://dx.doi.org/10.1074/jbc.M306365200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874277	hybrid			2022-12-27	WOS:000185713800100
J	Deleris, P; Bacqueville, D; Gayral, S; Carrez, L; Salles, JP; Perret, B; Breton-Douillon, M				Deleris, P; Bacqueville, D; Gayral, S; Carrez, L; Salles, JP; Perret, B; Breton-Douillon, M			SHIP-2 and PTEN are expressed and active in vascular smooth muscle cell nuclei, but only SHIP-2 is associated with nuclear speckles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID PHOSPHATASE-ACTIVITY; TUMOR-SUPPRESSOR PROTEIN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE 3-KINASE; GLIOBLASTOMA CELLS; SIGNALING PATHWAYS; CYCLE ARREST; PC12 CELLS; IN-VITRO; KINASE	Recently, the control of phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3)-dependant signaling by phosphatases has emerged, but there is a shortage of information on intranuclear PtdIns(3,4,5)P-3 phosphatases. Therefore, we investigated the dephosphorylation of [P-32]PtdIns(3,4,5)P-3 specifically labeled on the D-3 position of the inositol ring in membrane-free nuclei isolated from pig aorta vascular smooth muscle cells (VSMCs). In vitro PtdIns(3,4,5)P-3 phosphatase assays revealed the production of both [P-32]PtdIns(3,4)P-2 and inorganic phosphate, demonstrating the presence of PtdIns(3,4,5)P-3 5- and 3-phosphatase activities inside the VSMC nucleus, respectively. Both activities presented the same potency in cellular lysates, whereas the nuclear PtdIns(3,4,5)P-3 5- phosphatase activity appeared to be the most efficient. Immunoblot experiments showed for the first time the expression of the 5- phosphatase SHIP-2 (src homology 2 domain-containing inositol phosphatase) as well as the 3-phosphatase PTEN (phosphatase and tensin homolog deleted on chromosome 10) in VSMC nuclei. In addition, immunoprecipitations from nuclear fractions indicated a [P-32]PtdIns(3,4,5)P-3 dephosphorylation by both SHIP-2 and PTEN. Moreover, confocal microscopy analyses demonstrated that SHIP-2 but not PTEN colocalized with a speckle-specific component, the SC35 splicing factor. These results suggest that SHIP-2 may be the primary enzyme for metabolizing PtdIns(3,4,5)P-3 into PtdIns(3,4)P-2 within the nucleus, thus producing another second messenger, whereas PTEN could down-regulate nuclear phosphoinositide 3-kinase signaling. Finally, intranuclear PtdIns(3,4,5)P-3 phosphatases might be involved in the control of VSMC proliferation and the pathogenesis of vascular proliferative disorders.	Hop Purpan, Dept LML, INSERM,U563, Ctr Physiopathol Toulouse Purpan, F-31059 Toulouse, France; INSERM, U469, F-34094 Montpellier 5, France	CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Breton-Douillon, M (corresponding author), Hop Purpan, Dept LML, INSERM,U563, Ctr Physiopathol Toulouse Purpan, Pl Dr Baylac, F-31059 Toulouse, France.		SALLES, Jean Pierre/K-2998-2014	Gayral, Stephanie/0000-0001-6276-3917; Bertrand, PERRET/0000-0001-7568-445X				Bacqueville D, 1998, BIOCHEM BIOPH RES CO, V244, P630, DOI 10.1006/bbrc.1997.7885; Bacqueville D, 2001, J BIOL CHEM, V276, P22170, DOI 10.1074/jbc.M011572200; Boronenkov IV, 1998, MOL BIOL CELL, V9, P3547, DOI 10.1091/mbc.9.12.3547; Braun-Dullaeus RC, 2001, ARTERIOSCL THROM VAS, V21, P1152, DOI 10.1161/hq0701.092104; BRETON M, 1986, EXP CELL RES, V166, P416, DOI 10.1016/0014-4827(86)90487-8; Calcerrada MC, 2002, FEBS LETT, V514, P361, DOI 10.1016/S0014-5793(02)02401-8; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Didichenko SA, 2001, J BIOL CHEM, V276, P48135, DOI 10.1074/jbc.M104610200; Downes CP, 2001, BIOCHEM SOC T, V29, P846, DOI 10.1042/BST0290846; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; Georgescu MM, 1999, P NATL ACAD SCI USA, V96, P10182, DOI 10.1073/pnas.96.18.10182; Gimm O, 2000, AM J PATHOL, V156, P1693, DOI 10.1016/S0002-9440(10)65040-7; Ginisty H, 1999, J CELL SCI, V112, P761; Ginn-Pease ME, 2003, CANCER RES, V63, P282; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Huang JH, 2002, ARTERIOSCL THROM VAS, V22, P745, DOI 10.1161/01.ATV.0000016358.05294.8D; Huang JH, 2002, J BIOL CHEM, V277, P10760, DOI 10.1074/jbc.M110219200; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Lachyankar MB, 2000, J NEUROSCI, V20, P1404; Li DM, 1998, P NATL ACAD SCI USA, V95, P15406, DOI 10.1073/pnas.95.26.15406; Lu PJ, 1998, BIOCHEMISTRY-US, V37, P5738, DOI 10.1021/bi972551g; Marchisio M, 1998, BIOCHEM BIOPH RES CO, V253, P346, DOI 10.1006/bbrc.1998.9787; Martelli AM, 2001, FEBS LETT, V505, P1, DOI 10.1016/S0014-5793(01)02752-1; Meier R, 1997, J BIOL CHEM, V272, P30491, DOI 10.1074/jbc.272.48.30491; Metjian A, 1999, J BIOL CHEM, V274, P27943, DOI 10.1074/jbc.274.39.27943; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Neri LM, 2002, BBA-MOL CELL BIOL L, V1584, P73, DOI 10.1016/S1388-1981(02)00300-1; Neri LM, 1999, FASEB J, V13, P2299, DOI 10.1096/fasebj.13.15.2299; Osborne SL, 2001, J CELL SCI, V114, P2501; PAYRASTRE B, 1994, FEBS LETT, V341, P113, DOI 10.1016/0014-5793(94)80251-3; Perren A, 2000, AM J PATHOL, V157, P1097, DOI 10.1016/S0002-9440(10)64624-X; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Rameh LE, 1999, J BIOL CHEM, V274, P8347, DOI 10.1074/jbc.274.13.8347; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Scheid MP, 2002, J BIOL CHEM, V277, P9027, DOI 10.1074/jbc.M106755200; Schwartzbauer G, 2001, J BIOL CHEM, V276, P35786, DOI 10.1074/jbc.M102479200; SULTAN C, 1990, BIOCHEM J, V269, P831, DOI 10.1042/bj2690831; Taylor V, 2000, MOL CELL BIOL, V20, P6860, DOI 10.1128/MCB.20.18.6860-6871.2000; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; von Mikecz A, 2000, J CELL BIOL, V150, P265, DOI 10.1083/jcb.150.1.265; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Whiteman DC, 2002, INT J CANCER, V99, P63, DOI 10.1002/ijc.10294; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yu HY, 1998, EUR J BIOCHEM, V251, P281, DOI 10.1046/j.1432-1327.1998.2510281.x; Zheng WH, 2000, J BIOL CHEM, V275, P39152, DOI 10.1074/jbc.M002417200	51	75	80	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38884	38891		10.1074/jbc.M300816200	http://dx.doi.org/10.1074/jbc.M300816200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847108	hybrid			2022-12-27	WOS:000185575100097
J	Galvez, AS; Ulloa, JA; Chiong, M; Criollo, A; Eisner, V; Barros, LF; Lavandero, S				Galvez, AS; Ulloa, JA; Chiong, M; Criollo, A; Eisner, V; Barros, LF; Lavandero, S			Aldose reductase induced by hyperosmotic stress mediates cardiomyocyte apoptosis - Differential effects of sorbitol and mannitol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; VOLUME REGULATORY MECHANISMS; MUSCLE-CELL-GROWTH; VENTRICULAR MYOCYTES; GENE-EXPRESSION; PROTEIN-KINASE; OSMOTIC-STRESS; ISCHEMIC-INJURY; MAMMALIAN-CELLS; HUMAN-TISSUES	Cells adapt to hyperosmotic conditions by several mechanisms, including accumulation of sorbitol via induction of the polyol pathway. Failure to adapt to osmotic stress can result in apoptotic cell death. In the present study, we assessed the role of aldose reductase, the key enzyme of the polyol pathway, in cardiac myocyte apoptosis. Hyperosmotic stress, elicited by exposure of cultured rat cardiac myocytes to the nonpermeant solutes sorbitol and mannitol, caused identical cell shrinkage and adaptive hexose uptake stimulation. In contrast, only sorbitol induced the polyol pathway and triggered stress pathways as well as apoptosis-related signaling events. Sorbitol resulted in activation of the extracellular signal-regulated kinase (ERK), p54 c-Jun N-terminal kinase (JNK), and protein kinase B. Furthermore, sorbitol treatment resulting in induction and activation of aldose reductase, decreased expression of the antiapoptotic protein Bcl-xL, increased DNA fragmentation, and glutathione depletion. Apoptosis was attenuated by aldose reductase inhibition with zopolrestat and also by glutathione replenishment with N-acetylcysteine. In conclusion, our data show that hypertonic shrinkage of cardiac myocytes alone is not sufficient to induce cardiac myocyte apoptosis. Hyperosmolarity-induced cell death is sensitive to the nature of the osmolyte and requires induction of aldose reductase as well as a decrease in intracellular glutathione levels.	Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Bioquim & Biol Mol, Ctr FONDAP Estudios Mol Celula, Santiago 6640750, Chile; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 6640750, Chile; Ctr Estudios Cient, Valdivia, Chile	Universidad de Chile; Universidad de Chile	Lavandero, S (corresponding author), Univ Chile, Fac Ciencias Quim & Farmaceut, Dept Bioquim & Biol Mol, Ctr FONDAP Estudios Mol Celula, Olivos 1007, Santiago 6640750, Chile.	slavander@uchile.cl	Lavandero, Sergio/B-6001-2013; Chiong, M./ABH-5784-2020; Chiong, Mario/I-1043-2013	Lavandero, Sergio/0000-0003-4258-1483; Chiong, M./0000-0002-5174-6545; Chiong, Mario/0000-0002-5174-6545; Criollo, Alfredo/0000-0002-2737-7751				Aida K, 1999, ENDOCRINOLOGY, V140, P609, DOI 10.1210/en.140.2.609; ANDERSON ME, 1980, J BIOL CHEM, V255, P9530; Barros LF, 1999, PFLUG ARCH EUR J PHY, V437, P763, DOI 10.1007/s004240050843; Barros LF, 2001, PFLUG ARCH EUR J PHY, V442, P614; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Better OS, 1997, KIDNEY INT, V52, P886, DOI 10.1038/ki.1997.409; Bialik S, 1999, CIRC RES, V85, P403, DOI 10.1161/01.RES.85.5.403; Bortner CD, 1996, AM J PHYSIOL-CELL PH, V271, pC950, DOI 10.1152/ajpcell.1996.271.3.C950; Bortner CD, 1997, J BIOL CHEM, V272, P32436, DOI 10.1074/jbc.272.51.32436; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; BURG MB, 1995, AM J PHYSIOL-RENAL, V268, pF983, DOI 10.1152/ajprenal.1995.268.6.F983; Castella M, 2003, ANN THORAC SURG, V75, P1238, DOI 10.1016/S0003-4975(02)04499-5; Chen D, 1997, J BIOL CHEM, V272, P27401, DOI 10.1074/jbc.272.43.27401; CHENG W, 1995, J CLIN INVEST, V96, P2247, DOI 10.1172/JCI118280; Cigola E, 1997, EXP CELL RES, V231, P363, DOI 10.1006/excr.1997.3477; Clemo HF, 1997, J GEN PHYSIOL, V110, P297, DOI 10.1085/jgp.110.3.297; COHEN MP, 1986, METABOLISM, V35, P55, DOI 10.1016/0026-0495(86)90188-5; DAS B, 1985, DIABETES, V34, P1145, DOI 10.2337/diabetes.34.11.1145; Delpy E, 1999, CARDIOVASC RES, V43, P398, DOI 10.1016/S0008-6363(99)00142-X; Denkert C, 1998, ARCH BIOCHEM BIOPHYS, V354, P172, DOI 10.1006/abbi.1998.0661; Fliss H, 1996, CIRC RES, V79, P949, DOI 10.1161/01.RES.79.5.949; Foncea R, 1997, J BIOL CHEM, V272, P19115, DOI 10.1074/jbc.272.31.19115; GABBAY KH, 1973, NEW ENGL J MED, V288, P831, DOI 10.1056/NEJM197304192881609; Galvez A, 2001, CELL TISSUE RES, V304, P279, DOI 10.1007/s004410100358; GARCIAPEREZ A, 1989, J BIOL CHEM, V264, P16815; GONZALEZ AM, 1986, DIABETES, V35, P1200, DOI 10.2337/diabetes.35.11.1200; Gual P, 2002, J BIOL CHEM, V277, P43980, DOI 10.1074/jbc.M203042200; Hamaoka R, 1999, J BIOCHEM-TOKYO, V126, P41, DOI 10.1093/oxfordjournals.jbchem.a022434; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HARADA K, 1994, CIRC RES, V74, P1197, DOI 10.1161/01.RES.74.6.1197; HARTWELL RC, 1993, NEUROSURGERY, V32, P444, DOI 10.1227/00006123-199303000-00017; HEMPLING HG, 1987, J CELL PHYSL, V93, P293; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Hwang YC, 2001, FASEB J, V15, P243, DOI 10.1096/fj.01-0368fje; ITOH T, 1994, J CLIN INVEST, V93, P2387, DOI 10.1172/JCI117245; JEFFERY J, 1988, ADV ENZYMOL RAMB, V61, P47; KADOR PF, 1988, MED RES REV, V8, P325, DOI 10.1002/med.2610080302; Kajstura J, 1996, LAB INVEST, V74, P86; KANEKO M, 1990, EXP CELL RES, V188, P135, DOI 10.1016/0014-4827(90)90288-L; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KRACKE GR, 1994, AM J PHYSIOL, V266, pC343, DOI 10.1152/ajpcell.1994.266.2.C343; Lang F, 1998, PHYSIOL REV, V78, P247, DOI 10.1152/physrev.1998.78.1.247; Leu M, 2001, ANAT EMBRYOL, V204, P217, DOI 10.1007/s004290100206; Libioulle C, 1996, J CELL PHYSIOL, V168, P147, DOI 10.1002/(SICI)1097-4652(199607)168:1<147::AID-JCP18>3.0.CO;2-4; Long XL, 1997, J CLIN INVEST, V99, P2635, DOI 10.1172/JCI119452; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maeno E, 2000, P NATL ACAD SCI USA, V97, P9487, DOI 10.1073/pnas.140216197; MAGOVERN GJ, 1984, CIRCULATION, V70, P91; Malek AM, 1998, STROKE, V29, P2631, DOI 10.1161/01.STR.29.12.2631; MALONE JI, 1980, DIABETES, V29, P861, DOI 10.2337/diabetes.29.11.861; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; Michea L, 2002, AM J PHYSIOL-RENAL, V282, pF981, DOI 10.1152/ajprenal.00301.2001; MIKA K, 2003, DIABETES RES CLIN PR, V60, P1; Mizisin AP, 1996, AM J PHYSIOL-RENAL, V270, pF90, DOI 10.1152/ajprenal.1996.270.1.F90; Moor AN, 2000, J MOL CELL CARDIOL, V32, P925, DOI 10.1006/jmcc.2000.1133; Morales MP, 2000, BIOCHEM BIOPH RES CO, V270, P1029, DOI 10.1006/bbrc.2000.2550; MORIYAMA T, 1989, J BIOL CHEM, V264, P16810; Murata M, 2001, CHEM-BIOL INTERACT, V130, P617, DOI 10.1016/S0009-2797(00)00289-1; Nadkarni V, 1999, J BIOL CHEM, V274, P20185, DOI 10.1074/jbc.274.29.20185; Narula J, 1996, NEW ENGL J MED, V335, P1182, DOI 10.1056/NEJM199610173351603; *NIH, 1985, GUID CAR US LAB AN; Paczynski RP, 1997, STROKE, V28, P1437, DOI 10.1161/01.STR.28.7.1437; Paczynski RP, 1997, CRIT CARE CLIN, V13, P105, DOI 10.1016/S0749-0704(05)70298-0; Pulkki KJ, 1997, ANN MED, V29, P339, DOI 10.3109/07853899708999358; Ramasamy R, 2001, AM J PHYSIOL-HEART C, V281, pH515, DOI 10.1152/ajpheart.2001.281.2.H515; Ramasamy R, 1997, DIABETES, V46, P292, DOI 10.2337/diabetes.46.2.292; RAMASAMY R, 1988, AM J PHYSIOL, V275, pH195; ROTIROTI LW, 1973, EXP CELL RES, V79, P295, DOI 10.1016/0014-4827(73)90448-5; RUBIN LJ, 1993, J MOL CELL CARDIOL, V25, P721, DOI 10.1006/jmcc.1993.1084; Ruef J, 1998, CIRCULATION, V97, P1071, DOI 10.1161/01.CIR.97.11.1071; Ruef J, 2000, ARTERIOSCL THROM VAS, V20, P1745, DOI 10.1161/01.ATV.20.7.1745; Sajan MP, 2002, BIOCHEM J, V362, P665, DOI 10.1042/0264-6021:3620665; Saraste A, 2000, CARDIOVASC RES, V45, P528, DOI 10.1016/S0008-6363(99)00384-3; SRIVASTAVA SK, 1984, BIOCHIM BIOPHYS ACTA, V800, P220, DOI 10.1016/0304-4165(84)90399-4; STAHL B, 1989, J NEUROCHEM, V53, P665, DOI 10.1111/j.1471-4159.1989.tb11755.x; STEVENS MJ, 1993, AM J PHYSIOL, V265, pE428, DOI 10.1152/ajpendo.1993.265.3.E428; SURGES R, 1993, PROG DRUG RES, V40, P99; TAKAHASHI M, 1995, INT J CANCER, V62, P749, DOI 10.1002/ijc.2910620617; Teiger E, 1996, J CLIN INVEST, V97, P2891, DOI 10.1172/JCI118747; Terada Y, 2001, KIDNEY INT, V60, P553, DOI 10.1046/j.1523-1755.2001.060002553.x; Trueblood N, 1998, AM J PHYSIOL-HEART C, V275, pH75, DOI 10.1152/ajpheart.1998.275.1.H75; Van der Kaay J, 1999, J BIOL CHEM, V274, P35963, DOI 10.1074/jbc.274.50.35963; VANDERJAGT DL, 1990, J BIOL CHEM, V265, P20982; Wright AR, 1998, PHARMACOL THERAPEUT, V80, P89, DOI 10.1016/S0163-7258(98)00025-4; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; ZHIQING Z, 2000, CARDIOVASC RES, V45, P651	88	80	86	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38484	38494		10.1074/jbc.M211824200	http://dx.doi.org/10.1074/jbc.M211824200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881532	hybrid			2022-12-27	WOS:000185575100050
J	Rehmann, H; Schwede, F; Doskeland, SO; Wittinghofer, A; Bos, JL				Rehmann, H; Schwede, F; Doskeland, SO; Wittinghofer, A; Bos, JL			Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; CGMP-BINDING-SITES; REGULATORY SUBUNIT; FACTOR CDC25(MM); RAP1; RAS; DOMAINS; ANTAGONISTS; MECHANISM; ANALOGS	Epac is a cAMP-dependent exchange factor for the small GTP-binding protein Rap. The activity of Epac is inhibited by a direct interaction between the C-terminal helical part of the cAMP-binding domain, called the lid, and the catalytic region, which is released after binding of cAMP. Herein, we show that the activation properties are very sensitive to modifications of the cyclic nucleotide. Some analogues are inhibitory and others are stimulatory; some are characterized by a much higher activation potential than normal cAMP. Mutational analysis of Epac allows insights into a network of interactions between the cyclic nucleotides and Epac. Mutations in the lid region are able to amplify or to attenuate selectively the activation potency of cAMP analogues. The properties of cAMP analogues previously used for the activation of the cAMP responsive protein kinase A and of 8-(4-chlorophenylthio)-2'-O-methyladenosine-3',5'-cyclicmonophosphate, an analogue highly selective for activation of Epac were investigated in detail.	Univ Med Ctr Utrecht, Dept Physiol Chem, NL-3584 CG Utrecht, Netherlands; Univ Med Ctr Utrecht, Ctr Biomed Genet, NL-3584 CG Utrecht, Netherlands; Max Planck Inst Mol Physiol, D-44227 Dortmund, Germany; BIOLOG Life Sci Inst, D-28071 Bremen, Germany; Univ Bergen, Dept Anat & Cell Biol, Fac Med, N-5009 Bergen, Norway	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Max Planck Society; University of Bergen	Bos, JL (corresponding author), Univ Med Ctr Utrecht, Dept Physiol Chem, Univ Weg 100, NL-3584 CG Utrecht, Netherlands.			Doskeland, Stein Ove/0000-0002-4009-4756				Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOTELHO LHP, 1988, METHOD ENZYMOL, V159, P159; BUTT E, 1990, FEBS LETT, V263, P47, DOI 10.1016/0014-5793(90)80702-K; Christensen AE, 2003, J BIOL CHEM, V278, P35394, DOI 10.1074/jbc.M302179200; COCCETTI P, 1995, BIOCHEM BIOPH RES CO, V206, P253, DOI 10.1006/bbrc.1995.1035; CORBIN JD, 1986, J BIOL CHEM, V261, P1208; de Rooij J, 2000, J BIOL CHEM, V275, P20829, DOI 10.1074/jbc.M001113200; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; Diller TC, 2001, STRUCTURE, V9, P73, DOI 10.1016/S0969-2126(00)00556-6; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Huang LJS, 1998, J BIOL CHEM, V273, P26739, DOI 10.1074/jbc.273.41.26739; Kang GX, 2003, J BIOL CHEM, V278, P8279, DOI 10.1074/jbc.M211682200; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; OGREID D, 1983, J BIOL CHEM, V258, P1041; Reed RB, 1996, J BIOL CHEM, V271, P17570, DOI 10.1074/jbc.271.29.17570; Rehmann H, 2003, J BIOL CHEM, V278, P23508, DOI 10.1074/jbc.M301680200; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; SHABB JB, 1991, J BIOL CHEM, V266, P24320; SHABB JB, 1990, J BIOL CHEM, V265, P16031; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; vandenBerghe N, 1997, ONCOGENE, V15, P845, DOI 10.1038/sj.onc.1201407; VANHAASTERT PJM, 1984, J BIOL CHEM, V259, P20; WEBER IT, 1989, BIOCHEMISTRY-US, V28, P6122, DOI 10.1021/bi00440a059; YAGURA TS, 1981, BIOCHEMISTRY-US, V20, P879, DOI 10.1021/bi00507a035	27	127	130	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38548	38556		10.1074/jbc.M306292200	http://dx.doi.org/10.1074/jbc.M306292200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12888551	hybrid			2022-12-27	WOS:000185575100057
J	Dementiev, A; Simonovic, M; Volz, K; Gettins, PGW				Dementiev, A; Simonovic, M; Volz, K; Gettins, PGW			Canonical inhibitor-like interactions explain reactivity of alpha(1)-proteinase inhibitor Pittsburgh and antithrombin with proteinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CENTER LOOP; CONFORMATIONAL-CHANGE; HEPARIN ACCELERATION; MECHANISM; THROMBIN; SERPIN; COMPLEX; ALPHA(1)-ANTITRYPSIN; ACTIVATION; TRYPSIN	The serpin antithrombin is a slow thrombin inhibitor that requires heparin to enhance its reaction rate. In contrast, alpha(1)-proteinase inhibitor (alpha(1)PI) Pittsburgh (P1 Met --> Arg natural variant) inhibits thrombin 17 times faster than pentasaccharide heparin-activated antithrombin. We present here x-ray structures of free and S195A trypsin-bound alpha(1)PI Pittsburgh, which show that the reactive center loop (RCL) possesses a canonical conformation in the free serpin that does not change upon binding to S195A trypsin and that contacts the proteinase only between P2 and P2'. By inference from the structure of heparin cofactor II bound to S195A thrombin, this RCL conformation is also appropriate for binding to thrombin. Reaction rates of trypsin and thrombin with alpha(1)PI Pittsburgh and antithrombin and their P2 variants show that the low antithrombin-thrombin reaction rate results from the antithrombin RCL sequence at P2 and implies that, in solution, the antithrombin RCL must be in a similar canonical conformation to that found here for alpha(1)PI Pittsburgh, even in the nonheparin-activated state. This suggests a general, limited, canonical-like interaction between serpins and proteinases in their Michaelis complexes.	Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60607 USA; Univ Illinois, Coll Med, Dept Biochem & Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Volz, K (corresponding author), Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60607 USA.			Simonovic, Miljan/0000-0002-1576-2222	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049234, R37HL049234, P01HL064013] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007739] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64013, HL49234] Funding Source: Medline; NIDDK NIH HHS [T32 DK07739] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baglin TP, 2002, P NATL ACAD SCI USA, V99, P11079, DOI 10.1073/pnas.162232399; Bianchini EP, 2002, J BIOL CHEM, V277, P20527, DOI 10.1074/jbc.M201139200; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; CARRELL RW, 1994, STRUCTURE, V2, P257, DOI 10.1016/S0969-2126(00)00028-9; CHREUDER HA, 1994, NAT STRUCT BIOL, V1, P48; Chuang YJ, 2001, J BIOL CHEM, V276, P14961, DOI 10.1074/jbc.M011550200; Elliott PR, 1996, NAT STRUCT BIOL, V3, P676, DOI 10.1038/nsb0896-676; Elliott PR, 1998, J MOL BIOL, V275, P419, DOI 10.1006/jmbi.1997.1458; Futamura A, 2001, BIOCHEMISTRY-US, V40, P6680, DOI 10.1021/bi0029346; Gettins PGW, 2002, CHEM REV, V102, P4751, DOI 10.1021/cr010170+; HOOD DB, 1994, BIOCHEMISTRY-US, V33, P8538, DOI 10.1021/bi00194a020; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Lee KN, 1996, NAT STRUCT BIOL, V3, P497, DOI 10.1038/nsb0696-497; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1991, J BIOL CHEM, V266, P6353; OWEN MC, 1983, NEW ENGL J MED, V309, P694, DOI 10.1056/NEJM198309223091203; Peterson FC, 2000, BIOCHEMISTRY-US, V39, P11884, DOI 10.1021/bi001152+; Peterson FC, 2001, BIOCHEMISTRY-US, V40, P6275, DOI 10.1021/bi0100992; Simonovic M, 2001, P NATL ACAD SCI USA, V98, P11131, DOI 10.1073/pnas.211268598; Stratikos E, 1997, P NATL ACAD SCI USA, V94, P453, DOI 10.1073/pnas.94.2.453; TRAVIS J, 1986, BIOL CHEM H-S, V367, P853, DOI 10.1515/bchm3.1986.367.2.853; vandeLocht A, 1997, EMBO J, V16, P2977, DOI 10.1093/emboj/16.11.2977; Ye S, 2001, NAT STRUCT BIOL, V8, P979, DOI 10.1038/nsb1101-979; Zhou AW, 2001, J BIOL CHEM, V276, P27541, DOI 10.1074/jbc.M102594200	25	72	75	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37881	37887		10.1074/jbc.M305195200	http://dx.doi.org/10.1074/jbc.M305195200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860985	hybrid			2022-12-27	WOS:000185437200109
J	Lacour, S; Kolb, A; Landini, P				Lacour, S; Kolb, A; Landini, P			Nucleotides from-16 to-12 determine specific promoter recognition by bacterial sigma(S)-RNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI RNA-POLYMERASE; GENERAL STRESS-RESPONSE; SIGMA SUBUNIT SYNTHESIS; ESCHERICHIA-COLI; ADAPTIVE RESPONSE; TRANSCRIPTION INITIATION; INTRACELLULAR LEVELS; ADA PROTEIN; REGION 2.5; DNA	The alternative sigma factor sigma(S), mainly active in stationary phase of growth, recognizes in vitro a -10 promoter sequence almost identical to the one for the main sigma factor, sigma(70), thus raising the problem of how specific promoter recognition by sigmaS-RNA polymerase (Esigma(S)) is achieved in vivo. We investigated the promoter features involved in selective recognition by Esigma(S) at the strictly sigma(S)-dependent aidB promoter. We show that the presence of a C nucleotide as first residue of the aidB -10 sequence (-12C), instead of the T nucleotide canonical for sigma(70)-dependent promoters, is the major determinant for selective recognition by Esigma(S). The presence of the -12C does not allow formation of an open complex fully proficient in transcription initiation by Esigma(70). The role of -12C as specific determinant for promoter recognition by Esigma(S) was confirmed by sequence analysis of known Esigma(S)-dependent promoters as well as site-directed mutagenesis at the promoters of the csgB and sprE genes. We propose that Esigma(S), unlike Esigma(70), can recognize both C and T as the first nucleotide in the -10 sequence. Additional promoter features such as the presence of a C nucleotide at position -13, contributing to open complex formation by Esigma(S), and a TG motif found at the unusual -16/-15 location, possibly contributing to initial binding to the promoter, also represent important factors for sigma(S)-dependent transcription. We propose a new sequence, TG(N)(0-2)CCATA(c/a)T, as consensus -10 sequence for promoters exclusively recognized by Esigma(S).	Swiss Fed Inst Environm Technol, EAWAG, CH-8600 Dubendorf, Switzerland; Inst Pasteur, Dept Microbiol Fondamentale & Med, CNRS, URA 1773,Unite Regulat Transcript, F-75724 Paris 15, France	Swiss Federal Institutes of Technology Domain; Swiss Federal Institute of Aquatic Science & Technology (EAWAG); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Landini, P (corresponding author), Swiss Fed Inst Environm Technol, EAWAG, Uberlandstr 133, CH-8600 Dubendorf, Switzerland.	landini@eawag.ch	Landini, Paolo/B-7859-2017	Landini, Paolo/0000-0003-0999-426X; Lacour, Stephan/0000-0002-6066-4189				Barne KA, 1997, EMBO J, V16, P4034, DOI 10.1093/emboj/16.13.4034; Becker G, 2001, MOL MICROBIOL, V39, P1153, DOI 10.1046/j.1365-2958.2001.02313.x; Bordes P, 2000, MOL MICROBIOL, V35, P845, DOI 10.1046/j.1365-2958.2000.01758.x; Bown JA, 1999, J BIOL CHEM, V274, P2263, DOI 10.1074/jbc.274.4.2263; Burr T, 2000, NUCLEIC ACIDS RES, V28, P1864, DOI 10.1093/nar/28.9.1864; Colland F, 1999, EMBO J, V18, P4049, DOI 10.1093/emboj/18.14.4049; Colland F, 2002, GENES CELLS, V7, P233, DOI 10.1046/j.1365-2443.2002.00517.x; Colland F, 2000, EMBO J, V19, P3028, DOI 10.1093/emboj/19.12.3028; EspinosaUrgel M, 1996, MOL MICROBIOL, V21, P657; Gaal T, 2001, MOL MICROBIOL, V42, P939, DOI 10.1046/j.1365-2958.2001.02703.x; GRIBSKOV M, 1983, GENE, V26, P109, DOI 10.1016/0378-1119(83)90180-4; HAWLEY DK, 1983, NUCLEIC ACIDS RES, V11, P2237, DOI 10.1093/nar/11.8.2237; Hengge-Aronis R, 2002, CURR OPIN MICROBIOL, V5, P591, DOI 10.1016/S1369-5274(02)00372-7; Hengge-Aronis R, 1999, CURR OPIN MICROBIOL, V2, P148, DOI 10.1016/S1369-5274(99)80026-5; Hengge-Aronis R, 2002, J MOL MICROB BIOTECH, V4, P341; Hiratsu K, 1995, MOL MICROBIOL, V18, P841, DOI 10.1111/j.1365-2958.1995.18050841.x; Ishihama A, 2000, ANNU REV MICROBIOL, V54, P499, DOI 10.1146/annurev.micro.54.1.499; Jishage M, 1996, J BACTERIOL, V178, P5447, DOI 10.1128/jb.178.18.5447-5451.1996; JISHAGE M, 1995, J BACTERIOL, V177, P6832, DOI 10.1128/jb.177.23.6832-6835.1995; KEILTY S, 1987, J BIOL CHEM, V262, P6389; KUMAR A, 1993, J MOL BIOL, V232, P406, DOI 10.1006/jmbi.1993.1400; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lacour S, 2002, BIOCHEM BIOPH RES CO, V292, P922, DOI 10.1006/bbrc.2002.6744; Landini P, 1998, J BIOL CHEM, V273, P13307, DOI 10.1074/jbc.273.21.13307; LANDINI P, 1994, J BACTERIOL, V176, P6583, DOI 10.1128/JB.176.21.6583-6589.1994; LANDINI P, 1995, J BIOL CHEM, V270, P8285, DOI 10.1074/jbc.270.14.8285; Landini P, 2000, J BACTERIOL, V182, P6543, DOI 10.1128/JB.182.23.6543-6549.2000; Landini P, 1996, MOL MICROBIOL, V20, P947, DOI 10.1111/j.1365-2958.1996.tb02536.x; LANGE R, 1994, GENE DEV, V8, P1600, DOI 10.1101/gad.8.13.1600; Lee SJ, 2001, J BIOL CHEM, V276, P30064, DOI 10.1074/jbc.M102886200; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Maeda H, 2000, NUCLEIC ACIDS RES, V28, P3497, DOI 10.1093/nar/28.18.3497; Marschall C, 1998, J MOL BIOL, V276, P339, DOI 10.1006/jmbi.1997.1533; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; MINCHIN S, 1993, BIOCHEM J, V289, P771, DOI 10.1042/bj2890771; PONNAMBALAM S, 1986, J BIOL CHEM, V261, P6043; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; TANAKA K, 1995, NUCLEIC ACIDS RES, V23, P827, DOI 10.1093/nar/23.5.827; TANAKA K, 1993, P NATL ACAD SCI USA, V90, P3511, DOI 10.1073/pnas.90.8.3511; Vicente M, 1999, MOL MICROBIOL, V33, P8, DOI 10.1046/j.1365-2958.1999.01445.x; VOLKERT MR, 1986, GENETICS, V112, P11; VOLKERT MR, 1994, J BACTERIOL, V176, P7638, DOI 10.1128/JB.176.24.7638-7645.1994; Volkert MR, 2001, CURR OPIN MICROBIOL, V4, P178, DOI 10.1016/S1369-5274(00)00186-7; Wise A, 1996, J BACTERIOL, V178, P2785, DOI 10.1128/jb.178.10.2785-2793.1996; Yang CH, 2002, MOL PLANT MICROBE IN, V15, P472, DOI 10.1094/MPMI.2002.15.5.472	45	30	30	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37160	37168		10.1074/jbc.M305281200	http://dx.doi.org/10.1074/jbc.M305281200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853450	Green Published, hybrid			2022-12-27	WOS:000185437200023
J	Szentirmay, MN; Yang, HX; Pawar, SA; Vinson, C; Sawadogo, M				Szentirmay, MN; Yang, HX; Pawar, SA; Vinson, C; Sawadogo, M			The IGF2 receptor is a USF2-specific target in nontumorigenic mammary epithelial cells but not in breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; TRANSCRIPTION FACTOR USF; FACTOR TYPE-2 RECEPTOR; TUMOR-SUPPRESSOR GENE; PERINATAL LETHALITY; M6P/IGF2 RECEPTOR; PROMOTER ELEMENTS; FETAL OVERGROWTH; BINDING-PROTEINS; CARCINOMA-CELLS	The antiproliferative activities of the USF proteins and the frequent loss of USF function in cancer cells suggest a role for these ubiquitous transcription factors in tumor suppression. However, the cellular targets that mediate the effects of USF on cellular proliferation and transformation remain uncharacterized. IGF2R, with multiple functions in both normal growth and cancer, was investigated here as a possible USF target in both nontumorigenic and tumorigenic breast cell lines. The 5'-flanking sequences of the human IGF2R gene contain multiple, highly conserved E boxes almost identical to the consensus USF DNA-binding sequence. These E boxes were found to be essential for IGF2R promoter activity in the nontumorigenic mammary epithelial cell line MCF-10A. USF1 and USF2 bound the IGF2R promoter in vitro, and both USF1 and USF2, but not c-Myc, were present within the IGF2R promoter-associated chromatin in vivo. Overexpressed USF2, but not USF1, transactivated the IGF2R promoter, and IGF2R mRNA was markedly decreased by expression of a USF-specific dominant negative mutant, identifying IGF2R as a USF2 target. IGF2R promoter-driven expression was USF-independent in both MCF-7 and MDA-MB-231 breast cancer cell lines, suggesting that a defect in USF function may contribute to down-regulation of IGF2R expression in cancer cells.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; NCI, Biochem Lab, NIH, Bethesda, MD 20892 USA	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Sawadogo, M (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.		Pawar, Snehalata/ABD-4557-2020	Pawar, Snehalata/0000-0003-3992-2494	NCI NIH HHS [CA79578] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079578, Z01BC005271, ZIABC005271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aksan I, 1998, MOL CELL BIOL, V18, P6930, DOI 10.1128/MCB.18.12.6930; BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BENDALL AJ, 1994, NUCLEIC ACIDS RES, V22, P2801, DOI 10.1093/nar/22.14.2801; Berthe ML, 2003, EUR J CANCER, V39, P635, DOI 10.1016/S0959-8049(02)00627-5; BLACKWELL TK, 1993, MOL CELL BIOL, V13, P5216, DOI 10.1128/MCB.13.9.5216; Boyd KE, 1999, MOL CELL BIOL, V19, P8393; Boyd KE, 1997, MOL CELL BIOL, V17, P2529, DOI 10.1128/MCB.17.5.2529; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; DeBleser PJ, 1996, HEPATOLOGY, V23, P1530; DENNIS PA, 1991, P NATL ACAD SCI USA, V88, P580, DOI 10.1073/pnas.88.2.580; Desbarats L, 1996, GENE DEV, V10, P447, DOI 10.1101/gad.10.4.447; DESOUZA AT, 1995, NAT GENET, V11, P447, DOI 10.1038/ng1295-447; Galibert MD, 2001, EMBO J, V20, P5022, DOI 10.1093/emboj/20.17.5022; Hankins GR, 1996, ONCOGENE, V12, P2003; Hassan AB, 2003, AM J PATHOL, V162, P3, DOI 10.1016/S0002-9440(10)63791-1; Hermeking H, 2000, P NATL ACAD SCI USA, V97, P2229, DOI 10.1073/pnas.050586197; HODGKINSON CA, 1993, CELL, V74, P395, DOI 10.1016/0092-8674(93)90429-T; Ismail PM, 1999, ONCOGENE, V18, P5582, DOI 10.1038/sj.onc.1202932; Jaiswal AS, 2001, J CELL BIOCHEM, V81, P262, DOI 10.1002/1097-4644(20010501)81:2<262::AID-JCB1041>3.0.CO;2-R; KALSCHEUER VM, 1993, NAT GENET, V5, P74, DOI 10.1038/ng0993-74; KEISS W, 1996, GROWTH REGULAT, V6, P66; Killian JK, 1999, MAMM GENOME, V10, P74, DOI 10.1007/s003359900947; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; Krylov D, 1997, P NATL ACAD SCI USA, V94, P12274, DOI 10.1073/pnas.94.23.12274; Latil A, 2001, CANCER RES, V61, P1919; LAU MMH, 1994, GENE DEV, V8, P2953, DOI 10.1101/gad.8.24.2953; LIU ZY, 1995, MOL ENDOCRINOL, V9, P1477, DOI 10.1210/me.9.11.1477; Lorenzo K, 2000, CANCER RES, V60, P4070; Ludwig T, 1996, DEV BIOL, V177, P517, DOI 10.1006/dbio.1996.0182; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; Luo X, 1996, MOL CELL BIOL, V16, P1367; MORGAN DO, 1987, NATURE, V329, P301, DOI 10.1038/329301a0; O'Gorman DB, 1999, CANCER RES, V59, P5692; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Roy RN, 1999, MOL CELL ENDOCRINOL, V153, P19, DOI 10.1016/S0303-7207(99)00092-1; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Sirito M, 1998, P NATL ACAD SCI USA, V95, P3758, DOI 10.1073/pnas.95.7.3758; SIRITO M, 1994, NUCLEIC ACIDS RES, V22, P427, DOI 10.1093/nar/22.3.427; Souza RF, 1999, ONCOGENE, V18, P4063, DOI 10.1038/sj.onc.1202768; Souza RF, 1996, NAT GENET, V14, P255, DOI 10.1038/ng1196-255; Szutorisz H, 2001, ONCOGENE, V20, P2600, DOI 10.1038/sj.onc.1204346; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; Weiner JK, 1998, J BIOL CHEM, V273, P15913, DOI 10.1074/jbc.273.26.15913; Wu K, 2000, J BIOL CHEM, V275, P35548, DOI 10.1074/jbc.M004390200; XING W, 1980, MOL ENDOCRINOL, V12, P1310; Young LE, 2001, NAT GENET, V27, P153, DOI 10.1038/84769; Zavras AI, 2003, CANCER RES, V63, P296	48	33	34	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37231	37240		10.1074/jbc.M305791200	http://dx.doi.org/10.1074/jbc.M305791200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857727	hybrid			2022-12-27	WOS:000185437200031
J	Tisdale, EJ; Wang, J; Silver, RB; Artalejo, CR				Tisdale, EJ; Wang, J; Silver, RB; Artalejo, CR			Atypical protein kinase C plays a critical role in protein transport from pre-Golgi intermediates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GLYCERALDEHYDE-3-PHOSPHATE DEHYDROGENASE; VESICULAR TRANSPORT; PHOSPHORYLATION; RAB2; PSEUDOSUBSTRATE; ER; INHIBITION; ACTIVATION; ISOENZYMES	The small GTPase Rab2 requires atypical protein kinase C iota/lambda (PKC iota/lambda) kinase activity to promote vesicle budding from normal rat kidney cell microsomes (Tisdale, E. J. (2000) Traffic 1, 702 - 712). The released vesicles lack anterograde-directed cargo but contain coat protein I ( COPI) and the recycling protein p53/p58, suggesting that the vesicles traffic in the retrograde pathway. In this study, we have directly characterized the role of PKC iota/lambda in the early secretory pathway. A peptide corresponding to the unique PKC iota/lambda pseudosubstrate domain was introduced into an in vitro assay that efficiently reconstitutes transport of vesicular stomatitis virus glycoprotein from the endoplasmic reticulum to the cis-medial Golgi compartments. This peptide blocked transport in a dose-dependent manner. Moreover, normal rat kidney cells incubated with Rab2 and the pseudosubstrate peptide displayed abundant swollen or dilated vesicles that contained Rab2, PKC iota/lambda, beta-COP, and p53/p58. Because Rab2, beta-COP, and p53/p58 are marker proteins for pre-Golgi intermediates ( vesicular tubular clusters, VTCs), most probably the swollen vesicles are derived from VTCs. Similar results were obtained when the assays were supplemented with kinase-dead PKC iota/lambda (W274K). Both the pseudosubstrate peptide and kinase-dead PKC iota/lambda in tandem with Rab2 caused sustained membrane association of PKC iota/lambda, suggesting that reverse translocation was inhibited. Importantly, the inhibitory phenotype of kinase-dead PKC iota/lambda was reversed by PKC iota/lambda wild type. These combined results indicate that PKC iota/lambda is essential for protein transport in the early secretory pathway and suggest that PKC iota/lambda kinase activity is required to promote Rab2-mediated vesicle budding at a VTC subcompartment enriched in recycling cargo.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Tisdale, EJ (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 6374 Scott Hall,540 E Canfield Ave, Detroit, MI 48201 USA.	etisdale@med.wayne.edu			NIDDK NIH HHS [R01 DK058921, DK58921] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK058921] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALEXANDER DR, 1989, BIOCHEM J, V260, P893, DOI 10.1042/bj2600893; Aridor M, 1998, J CELL BIOL, V141, P61, DOI 10.1083/jcb.141.1.61; BAILLY E, 1991, NATURE, V350, P715, DOI 10.1038/350715a0; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; BECKERS CJM, 1987, CELL, V50, P523, DOI 10.1016/0092-8674(87)90025-0; BERRA E, 1993, CELL, V74, P555, DOI 10.1016/0092-8674(93)80056-K; Blobe GC, 1996, CANCER SURV, V27, P213; De Renzis S, 2002, NAT CELL BIOL, V4, P124, DOI 10.1038/ncb744; Dutil EM, 2000, J BIOL CHEM, V275, P10697, DOI 10.1074/jbc.275.14.10697; EICHHOLTZ T, 1990, FEBS LETT, V261, P147, DOI 10.1016/0014-5793(90)80657-5; Farese RV, 2002, AM J PHYSIOL-ENDOC M, V283, pE1, DOI 10.1152/ajpendo.00045.2002; Feng X, 2000, J BIOL CHEM, V275, P17024, DOI 10.1074/jbc.275.22.17024; GALLIONE CJ, 1985, J VIROL, V54, P374, DOI 10.1128/JVI.54.2.374-382.1985; Horstmann H, 2002, J CELL SCI, V115, P4263, DOI 10.1242/jcs.00115; HOUSE C, 1987, SCIENCE, V238, P1726, DOI 10.1126/science.3686012; HUG H, 1993, BIOCHEM J, V291, P329, DOI 10.1042/bj2910329; Laudanna C, 1998, J BIOL CHEM, V273, P30306, DOI 10.1074/jbc.273.46.30306; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Moscat J, 2000, EMBO REP, V1, P399, DOI 10.1093/embo-reports/kvd098; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Parekh DB, 2000, EMBO J, V19, P496, DOI 10.1093/emboj/19.4.496; PARKER PJ, 1989, MOL CELL ENDOCRINOL, V65, P1, DOI 10.1016/0303-7207(89)90159-7; PLUTNER H, 1992, J CELL BIOL, V119, P1097, DOI 10.1083/jcb.119.5.1097; SARASTE J, 1991, J CELL SCI, V100, P415; SCHWEIZER A, 1991, J CELL BIOL, V113, P45, DOI 10.1083/jcb.113.1.45; Signorelli P, 2001, FASEB J, V15, P2401, DOI 10.1096/fj.01-0244com; Slepnev VI, 1998, SCIENCE, V281, P821, DOI 10.1126/science.281.5378.821; Tisdale EJ, 1999, MOL BIOL CELL, V10, P1837, DOI 10.1091/mbc.10.6.1837; Tisdale EJ, 2000, TRAFFIC, V1, P702, DOI 10.1034/j.1600-0854.2000.010903.x; Tisdale EJ, 1996, J BIOL CHEM, V271, P29372, DOI 10.1074/jbc.271.46.29372; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; Tisdale EJ, 2002, J BIOL CHEM, V277, P3334, DOI 10.1074/jbc.M109744200; Tisdale EJ, 1997, J CELL BIOL, V137, P581, DOI 10.1083/jcb.137.3.581; Tisdale EJ, 2001, J BIOL CHEM, V276, P2480, DOI 10.1074/jbc.M007567200; Tisdale EJ, 1998, J BIOL CHEM, V273, P17269, DOI 10.1074/jbc.273.27.17269; Toker A., 1998, FRONT BIOSCI-LANDMRK, V3, P1134, DOI 10.2741/A350; VANDERSLUIJS P, 1992, CELL, V70, P729, DOI 10.1016/0092-8674(92)90307-X; WARD NE, 1993, BIOCHEMISTRY-US, V32, P11903, DOI 10.1021/bi00095a020; Wooten MW, 1999, J NEUROSCI RES, V58, P607, DOI 10.1002/(SICI)1097-4547(19991201)58:5<607::AID-JNR1>3.0.CO;2-M	39	7	8	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38015	38021		10.1074/jbc.M305381200	http://dx.doi.org/10.1074/jbc.M305381200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871960	hybrid			2022-12-27	WOS:000185437200123
J	Wang, LB; Atkinson, D; Small, DM				Wang, LB; Atkinson, D; Small, DM			Interfacial properties of an amphipathic alpha-helix consensus peptide of exchangeable apolipoproteins at air/water and oil/water interfaces	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; A-I; SURFACE-ACTIVITIES; LIPID-COMPOSITION; ADSORPTION; PACKING	Amphipathic alpha-helices are the main structure and the major lipid binding motif of exchangeable apolipoproteins. To understand how these apolipoproteins behave at an hydrophobic lipoprotein interface, the interfacial properties of a consensus sequence peptide (CSP) derived from three exchangeable apolipoproteins (A-I, A-IV, and E) were studied using an oil drop tensiometer at air/water (A/W) and dodecane/water (DD/W) interfaces. CSP ((PLAEELRARLRAQLEELRERLG) 2-NH2) contains two 22-amino acid tandem repeat sequences that form amphipathic alpha-helices. CSP, when added into the aqueous phase, lowered the interfacial tension (gamma) of A/W and DD/W in a concentration-dependant fashion. The gamma(A/W) was lowered similar to 24 mN/m, and gamma(DD/W) similar to 31 mN/m, indicating a greater affinity of CSP for DD/W. Using the Gibbs equation for surface, the surface area per CSP molecule was estimated at similar to 702 Angstrom(2) (similar to 16 Angstrom(2)/amino acid) on A/W and similar to 622 Angstrom(2) on DD/W (similar to 14 Angstrom(2)/amino acid) suggesting that adsorbed CSP lies flat with alpha-helices in the plane of both interfaces. At equilibrium gamma, CSP desorbed from the interface when compressed and re-adsorbed when expanded. The adsorption rate was concentration-dependant, but the desorption rate was not. Less CSP desorbed from DD/W than A/W indicating that CSP has higher affinity for DD/W. Dynamic analysis of elasticity shows that the faster the oscillation period (4, 8 s) and the lower the oscillation amplitude the more elastic the surfaces. CSP can be compressed 6 - 12% while remaining on the surface, but large increases in pressure eject it from the surface. We suggest that surface pressure-mediated desorption and readsorption of amphipathic alpha-helices provide lipoprotein stability during remodeling reactions in plasma.	Boston Univ, Sch Med, Dept Physiol & Biophys, Boston, MA 02118 USA	Boston University	Small, DM (corresponding author), Boston Univ, Sch Med, Dept Physiol & Biophys, 715 Albany St,W-302, Boston, MA 02118 USA.	dmsmall@bu.edu		Atkinson, David/0000-0002-4796-7396; Small, Donald/0000-0002-3072-243X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL026335] Funding Source: NIH RePORTER; NHLBI NIH HHS [2P01 HL26335-21] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM NK, 1941, PHYSICS CHEM SURFACE, P107; ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; Benjamins J, 1996, COLLOID SURFACE A, V114, P245, DOI 10.1016/0927-7757(96)03533-9; Benjamins J, 1998, STUD INTERF SCI, V7, P341, DOI 10.1016/S1383-7303(98)80056-2; Bos MA, 2001, ADV COLLOID INTERFAC, V91, P437; BOURILETTE CG, 2001, BIOCHIM BIOPHYS ACTA, V1531, P4; BROUILLETTE CG, 1995, BBA-LIPID LIPID MET, V1256, P103, DOI 10.1016/0005-2760(95)00018-8; CHAO Y, 2002, THESIS BOSTON U SCH; Datta G, 2001, J LIPID RES, V42, P1096; HURTCAMEJO E, 1990, J LIPID RES, V31, P1387; IBDAH JA, 1989, BIOCHEMISTRY-US, V28, P1126, DOI 10.1021/bi00429a029; IBDAH JA, 1988, BIOCHEMISTRY-US, V27, P7155, DOI 10.1021/bi00418a073; IBDAH JA, 1989, BIOCHIM BIOPHYS ACTA, V1004, P300, DOI 10.1016/0005-2760(89)90077-5; KREBS KE, 1988, BIOCHIM BIOPHYS ACTA, V959, P229, DOI 10.1016/0005-2760(88)90195-6; KREBS KE, 1983, BIOCHIM BIOPHYS ACTA, V751, P470, DOI 10.1016/0005-2760(83)90308-9; LABOURDENNE S, 1994, CHEM PHYS LIPIDS, V71, P163, DOI 10.1016/0009-3084(94)90068-X; Lucassen-Reynders EH, 2001, COLLOID SURFACE A, V186, P63, DOI 10.1016/S0927-7757(01)00483-6; McNamara JR, 1996, J LIPID RES, V37, P1924; NOLTE RT, 1992, BIOPHYS J, V63, P1221, DOI 10.1016/S0006-3495(92)81698-3; NOLTE RT, 1994, THESIS BOSTON U SCH; PHILLIPS MC, 1986, METHOD ENZYMOL, V128, P387; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; POWNALL HJ, 1979, BIOCHEMISTRY-US, V18, P574, DOI 10.1021/bi00571a004; RITTER MC, 1977, J BIOL CHEM, V252, P1208; RITTER MC, 1979, J BIOL CHEM, V254, P2517; SCANU AM, 1972, BIOCHIM BIOPHYS ACTA, V265, P471, DOI 10.1016/0304-4157(72)90006-8; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; Segrest JP, 2001, J LIPID RES, V42, P1346; SEGREST JP, 1992, J LIPID RES, V33, P141; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHEN BW, 1980, BIOCHEMISTRY-US, V19, P3643, DOI 10.1021/bi00557a001; TALL AR, 1977, J BIOL CHEM, V252, P4701; WANG L, 2002, BIOPHYS J, P149; WEINBERG RB, 1992, J BIOL CHEM, V267, P8977; Weinberg RB, 2000, J LIPID RES, V41, P1419	36	32	32	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37480	37491		10.1074/jbc.M303133200	http://dx.doi.org/10.1074/jbc.M303133200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12842901	hybrid			2022-12-27	WOS:000185437200061
J	Yang, LK; Manithody, C; Walston, TD; Cooper, ST; Rezaie, AR				Yang, LK; Manithody, C; Walston, TD; Cooper, ST; Rezaie, AR			Thrombomodulin enhances the reactivity of thrombin with protein C inhibitor by providing both a binding site for the serpin and allosterically modulating the activity of thrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR; HEPARIN-BINDING; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; FACTOR XA; SPECIFICITY; ANTITHROMBIN; RESIDUES; DOMAIN; COAGULATION	Thrombomodulin (TM), or its epidermal growth factor-like domains 456 (TM456), enhances the catalytic efficiency of thrombin toward both protein C and protein C inhibitor (PCI) by 2-3 orders of magnitude. Structural and mutagenesis data have indicated that the interaction of basic residues of the heparin-binding exosite of protein C with the acidic residues of TM4 is partially responsible for the efficient activation of the substrate by the thrombin-TM456 complex. Similar to protein C, PCI has a basic exosite (H-helix) that constitutes the heparin-binding site of the serpin. To determine whether TM accelerates the reactivity of thrombin with PCI by providing a binding site for the H-helix of the serpin, an antithrombin (AT) mutant was constructed in which the H-helix of the serpin was replaced with the same region of PCI (AT-PCIH-helix). Unlike PCI, the H-helix of AT is negatively charged. It was discovered that TM456 slightly (<2-fold) impaired the reactivity of AT with thrombin; however, it enhanced the reactivity of AT-PCIH-helix with the protease by an order of magnitude. Further studies revealed that the substitution of Arg(35) of thrombin with an Ala also resulted in an order of magnitude enhancement in reactivity of the protease with both PCI and AT-PCIH-helix independent of TM. We conclude that TM enhances the reactivity of PCI with thrombin by providing both a binding site for the serpin and a conformational modulation of the extended binding pocket of thrombin.	St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, St Louis, MO 63104 USA; Univ Wisconsin, La Crosse, WI 54601 USA	Saint Louis University; University of Wisconsin System	Rezaie, AR (corresponding author), St Louis Univ, Sch Med, Edward A Doisy Dept Biochem & Mol Biol, 1402 S Grand Blvd, St Louis, MO 63104 USA.	rezaiear@slu.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062565, R15HL058222] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 62565, HL58222] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BODE W, 1989, EMBO J, V8, P3467, DOI 10.1002/j.1460-2075.1989.tb08511.x; COOPER ST, 1995, BIOCHEMISTRY-US, V34, P12991, DOI 10.1021/bi00040a009; Djie MZ, 1996, BIOCHEMISTRY-US, V35, P11461, DOI 10.1021/bi952717i; ESMON CT, 1993, THROMB HAEMOSTASIS, V70, P29; FENTON JW, 1995, THROMB HAEMOSTASIS, V74, P493; Fuentes-Prior P, 2000, NATURE, V404, P518, DOI 10.1038/35006683; Gettins P.G.W., 1996, SERPINS STRUCTURE FU; HEEB MJ, 1989, BLOOD, V73, P446; HORREVOETS AJG, 1993, J BIOL CHEM, V268, P779; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 2000, J BIOL CHEM, V275, P15377, DOI 10.1074/jbc.275.20.15377; Huntington JA, 2003, STRUCTURE, V11, P205, DOI 10.1016/S0969-2126(02)00944-9; KUROSAWA S, 1988, J BIOL CHEM, V263, P5993; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; Liu Z, 2000, J BIOL CHEM, V275, P25641, DOI 10.1074/jbc.M003353200; MADISON EL, 1990, P NATL ACAD SCI USA, V87, P3530, DOI 10.1073/pnas.87.9.3530; Mosnier LO, 2001, THROMB HAEMOSTASIS, V86, P1057; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; OLSON ST, 1992, J BIOL CHEM, V267, P12528; Pineda AO, 2002, J BIOL CHEM, V277, P32015, DOI 10.1074/jbc.M205009200; PRATT CW, 1992, J BIOL CHEM, V267, P8795; Rezaie AR, 1997, BIOCHEMISTRY-US, V36, P7437, DOI 10.1021/bi962965u; Rezaie AR, 1998, BIOCHEMISTRY-US, V37, P13138, DOI 10.1021/bi9808518; Rezaie AR, 1998, PROTEIN SCI, V7, P349; REZAIE AR, 1995, J BIOL CHEM, V270, P25336, DOI 10.1074/jbc.270.43.25336; Rezaie AR, 2002, J BIOL CHEM, V277, P1235, DOI 10.1074/jbc.M108544200; Rezaie AR, 1998, BLOOD, V91, P4572, DOI 10.1182/blood.V91.12.4572.412k13_4572_4580; Rezaie AR, 2001, BBA-GEN SUBJECTS, V1528, P167, DOI 10.1016/S0304-4165(01)00189-1; REZAIE AR, 1998, TRENDS CARDIOVAS MED, V13, P8; SUZUKI K, 1987, J BIOL CHEM, V262, P611; TSIANG M, 1992, J BIOL CHEM, V267, P6164; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; WALKER FJ, 1992, FASEB J, V6, P2561, DOI 10.1096/fasebj.6.8.1317308; Yang LK, 2003, J BIOL CHEM, V278, P10484, DOI 10.1074/jbc.M211797200; Yang LK, 2002, BIOCHEMISTRY-US, V41, P6149, DOI 10.1021/bi015899r	37	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37465	37470		10.1074/jbc.M307243200	http://dx.doi.org/10.1074/jbc.M307243200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12878585	hybrid			2022-12-27	WOS:000185437200059
J	Lee, KH; Kim, SJ; Lee, YJ; Jin, JB; Hwang, I				Lee, KH; Kim, SJ; Lee, YJ; Jin, JB; Hwang, I			The M domain of atToc159 plays an essential role in the import of proteins into chloroplasts and chloroplast biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VIVO IMPORT; TRANSIT PEPTIDE; ENVELOPE MEMBRANE; OUTER ENVELOPE; RECEPTOR; IDENTIFICATION; TRAFFICKING; TRANSLOCON; PRECURSOR; COMPONENT	Toc159, a protein located in the outer envelope membrane and the cytosol, is an important component of the receptor complex for nuclear-encoded chloroplast proteins. We investigated the molecular mechanism of protein import into chloroplasts by atToc159 using the ppi2 mutant, which has a T-DNA insertion at atToc159, shows an albino phenotype, and does not survive beyond the seedling stage due to a defect in protein import into chloroplasts. First we established that transiently expressing atToc159 in protoplasts obtained from the white leaf tissues of ppi2 plants complements the protein import defect into chloroplasts. Using this transient expression approach and a series of deletion mutants, we demonstrated that the C-terminal membrane-anchored ( M) domain is targeted to the chloroplast envelope membrane in ppi2 protoplasts, and is sufficient to complement the defect in protein import. The middle GTPase ( G) domain plays an additional critical role in protein import: the atToc159[S/N] and atToc159[D/L] mutants, which have a mutation at the first and second GTP-binding motifs, respectively, do not support protein import into chloroplasts. Leaf cells of transgenic plants expressing the M domain in a ppi2 background contained nearly fully developed chloroplasts with respect to size and density of thylakoid membranes, and displayed about half as much chlorophyll as wild-type cells. In transgenic plants, the isolated M domain localized to the envelope membrane of chloroplasts but not the cytosol. Based on these results, we propose that the M domain is the minimal structure required to support protein import into chloroplasts, while the G domain plays a regulatory role.	Pohang Univ Sci & Technol, Ctr Plant Intracellular Trafficking, Pohang 790784, South Korea; Pohang Univ Sci & Technol, Div Mol & Life Sci, Pohang 790784, South Korea	Pohang University of Science & Technology (POSTECH); Pohang University of Science & Technology (POSTECH)	Hwang, I (corresponding author), Pohang Univ Sci & Technol, Ctr Plant Intracellular Trafficking, Pohang 790784, South Korea.	ihhwang@postech.ac.kr						Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Bruce BD, 1998, PLANT MOL BIOL, V38, P223, DOI 10.1023/A:1006094308805; Chen XJ, 1999, TRENDS CELL BIOL, V9, P222, DOI 10.1016/S0962-8924(99)01554-8; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; DOWNWARD J, 1990, TRENDS BIOCHEM SCI, V15, P469, DOI 10.1016/0968-0004(90)90300-Z; GAVEL Y, 1990, FEBS LETT, V261, P455, DOI 10.1016/0014-5793(90)80614-O; Gutensohn M, 2000, PLANT J, V23, P771, DOI 10.1046/j.1365-313x.2000.00849.x; HAND JM, 1989, EMBO J, V8, P3195, DOI 10.1002/j.1460-2075.1989.tb08478.x; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jarvis P, 1998, SCIENCE, V282, P100, DOI 10.1126/science.282.5386.100; JARVIS P, 2000, BIOCHIM BIOPHYS ACTA, V1541, P64; Jin JB, 2001, PLANT CELL, V13, P1511, DOI 10.1105/tpc.13.7.1511; Keegstra K, 1999, CURR OPIN PLANT BIOL, V2, P471, DOI 10.1016/S1369-5266(99)00021-7; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kim YW, 2001, PLANT PHYSIOL, V127, P1243, DOI 10.1104/pp.010450; KO K, 1989, EMBO J, V8, P3187, DOI 10.1002/j.1460-2075.1989.tb08477.x; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Lee KH, 2002, MOL CELLS, V14, P388; Lee YJ, 2001, PLANT CELL, V13, P2175, DOI 10.1105/tpc.13.10.2175; Niwa Y, 1999, PLANT J, V18, P455, DOI 10.1046/j.1365-313X.1999.00464.x; Rensink WA, 1998, PLANT PHYSIOL, V118, P691, DOI 10.1104/pp.118.2.691; Schleiff E, 2003, J CELL BIOL, V160, P541, DOI 10.1083/jcb.200210060; Schleiff E, 2000, PLANTA, V211, P449, DOI 10.1007/s004250000357; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; SEEDORF M, 1995, PLANT J, V7, P401, DOI 10.1046/j.1365-313X.1995.7030401.x; SERRA EC, 1995, J BIOL CHEM, V270, P19930, DOI 10.1074/jbc.270.34.19930; Sheen J, 2001, PLANT PHYSIOL, V127, P1466, DOI 10.1104/pp.010820; SMEEKENS S, 1986, CELL, V46, P365, DOI 10.1016/0092-8674(86)90657-4; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; Sohn EJ, 2003, PLANT CELL, V15, P1057, DOI 10.1105/tpc.009779; Sohrt K, 2000, J CELL BIOL, V148, P1213, DOI 10.1083/jcb.148.6.1213; Surpin M, 2002, PLANT CELL, V14, pS327, DOI 10.1105/tpc.010446; VANTHOF R, 1995, J BIOL CHEM, V270, P22368, DOI 10.1074/jbc.270.38.22368; VANTHOF R, 1993, J BIOL CHEM, V268, P4037	38	55	58	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36794	36805		10.1074/jbc.M304457200	http://dx.doi.org/10.1074/jbc.M304457200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853455	hybrid			2022-12-27	WOS:000185318300112
J	Molinas, SM; Altabe, SG; Opperdoes, FR; Rider, MH; Michels, PAM; Uttaro, AD				Molinas, SM; Altabe, SG; Opperdoes, FR; Rider, MH; Michels, PAM; Uttaro, AD			The multifunctional isopropyl alcohol dehydrogenase of Phytomonas sp could be the result of a horizontal gene transfer from a bacterium to the trypanosomatid lineage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED ALDEHYDE REDUCTASE; CARBOHYDRATE-METABOLISM; MITOCHONDRIAL; EUPHORBIA; PURIFICATION; EXPRESSION; CRITHIDIA; PROTEINS; CLONING; PLANT	Isopropyl alcohol dehydrogenase (iPDH) is a dimeric mitochondrial alcohol dehydrogenase (ADH), so far detected within the Trypanosomatidae only in the genus Phytomonas. The cloning, sequencing, and heterologous expression of the two gene alleles of the enzyme revealed that it is a zinc-dependent medium-chain ADH. Both polypeptides have 361 amino acids. A mitochondrial targeting sequence was identified. The mature proteins each have 348 amino acids and a calculated molecular mass of 37 kDa. They differ only in one amino acid, which can explain the three isoenzymes and their respective isoelectric points previously found. A phylogenetic analysis locates iPDH within a cluster with fermentative ADHs from bacteria, sharing 74% similarity and 60% identity with Ralstonia eutropha ADH. The characterization of the two bacterially expressed Phytomonas enzymes and the comparison of their kinetic properties with those of the wild-type iPDH and of the R. eutropha ADH strongly support the idea of a horizontal gene transfer event from a bacterium to a trypanosomatid to explain the origin of the iPDH in Phytomonas. Phytomonas iPDH and R. eutropha ADH are able to use a wide range of substrates with similar K-m values such as primary and secondary alcohols, diols, and aldehydes, as well as ketones such as acetone, diacetyl, and acetoin. We speculate that, as for R. eutropha ADH, Phytomonas iPDH acts as a safety valve for the release of excess reducing power.	Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol,Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn, RA-2000 Rosario, Santa Fe, Argentina; Catholic Univ Louvain, Christian de Duve Inst Cellular Pathol, Hormone Metab Res Unit, Trop Dis Res Unit, B-1200 Brussels, Belgium	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); National University of Rosario; Universite Catholique Louvain	Uttaro, AD (corresponding author), Univ Nacl Rosario, Fac Ciencias Bioquim & Farmaceut, Dept Microbiol,Inst Biol Mol & Celular Rosario, Consejo Nacl Invest Cient & Tecn, Suipacha 531, RA-2000 Rosario, Santa Fe, Argentina.	toniuttaro@yahoo.com.ar	Opperdoes, Frederik R/C-8897-2018; Opperdoes, Fred/N-9922-2019; Michels, Paul A/A-5637-2009; Molinas, Sara María/AAA-2490-2022	Opperdoes, Frederik R/0000-0003-1984-3764; Opperdoes, Fred/0000-0003-1984-3764; Michels, Paul A/0000-0003-3726-6104; 				ALLERT S, 1991, EUR J BIOCHEM, V200, P19, DOI 10.1111/j.1432-1033.1991.tb21043.x; ARAUZO S, 1989, FEMS MICROBIOL LETT, V58, P283, DOI 10.1111/j.1574-6968.1989.tb03060.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Branden C.-I., 1975, ENZYMES, V11, P103; CAZZULO JJ, 1985, COMP BIOCHEM PHYS B, V81, P1019, DOI 10.1016/0305-0491(85)90106-3; CHAUMONT F, 1994, MOL BIOCHEM PARASIT, V67, P321, DOI 10.1016/0166-6851(94)00141-3; Chua N. H, 1980, METHOD ENZYMOL, V69, P434; DOLLET M, 1982, CR ACAD SCI III-VIE, V295, P547; Duester G, 1999, BIOCHEM PHARMACOL, V58, P389, DOI 10.1016/S0006-2952(99)00065-9; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; FERREYRA RG, 1993, J BACTERIOL, V175, P1514, DOI 10.1128/JB.175.5.1514-1523.1993; Hausler T, 1997, EUR J CELL BIOL, V73, P240; KEEGAN FP, 1995, J EUKARYOT MICROBIOL, V42, P255, DOI 10.1111/j.1550-7408.1995.tb01575.x; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; Korkhin Y, 1998, J MOL BIOL, V278, P967, DOI 10.1006/jmbi.1998.1750; Maslov DA, 1999, MOL BIOCHEM PARASIT, V99, P207, DOI 10.1016/S0166-6851(99)00028-6; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PERSSON B, 1994, EUR J BIOCHEM, V226, P15, DOI 10.1111/j.1432-1033.1994.tb20021.x; REID MF, 1994, CRIT REV MICROBIOL, V20, P13, DOI 10.3109/10408419409113545; RIDER MH, 1995, EUR J BIOCHEM, V230, P258; ROSSI DA, 1938, ARCH SCI BIOL-BOLOGN, V24, P73; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANCHEZMORENO M, 1992, MOL BIOCHEM PARASIT, V54, P185, DOI 10.1016/0166-6851(92)90111-V; Shafqat J, 1996, P NATL ACAD SCI USA, V93, P5595, DOI 10.1073/pnas.93.11.5595; STEINBUCHEL A, 1984, EUR J BIOCHEM, V141, P555, DOI 10.1111/j.1432-1033.1984.tb08229.x; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Stryer L., 1995, BIOCHEMISTRY-US, V4th ed.; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V90, P337, DOI 10.1016/S0166-6851(97)00142-4; Uttaro AD, 1997, MOL BIOCHEM PARASIT, V85, P213, DOI 10.1016/S0166-6851(97)02830-2; Van Hellemond JJ, 1998, P NATL ACAD SCI USA, V95, P3036, DOI 10.1073/pnas.95.6.3036; Wilm M, 1996, ANAL CHEM, V68, P1, DOI 10.1021/ac9509519	32	13	13	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36169	36175		10.1074/jbc.M305666200	http://dx.doi.org/10.1074/jbc.M305666200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853449	hybrid			2022-12-27	WOS:000185318300038
J	Yasutake, Y; Watanabe, S; Yao, M; Takada, Y; Fukunaga, N; Tanaka, I				Yasutake, Y; Watanabe, S; Yao, M; Takada, Y; Fukunaga, N; Tanaka, I			Crystal structure of the monomeric isocitrate dehydrogenase in the presence of NADP(+) - Insight into the cofactor recognition, catalysis, and evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SP STRAIN ABE-1; NICOTINAMIDE ADENINE-DINUCLEOTIDE; 3-ISOPROPYLMALATE DEHYDROGENASE; THERMUS-THERMOPHILUS; ESCHERICHIA-COLI; SUBSTRATE-SPECIFICITY; PSYCHROPHILIC BACTERIUM; AZOTOBACTER-VINELANDII; ANGSTROM RESOLUTION; PROTEIN-STRUCTURE	NADP(+)-dependent monomeric isocitrate dehydrogenase (IDH) from the nitrogen-fixing bacterium Azotobacter vinelandii (AvIDH) is one of members of the beta-decarboxylating dehydrogenase family and catalyzes the dehydration and decarboxylation of isocitrate to yield 2-oxoglutrate and CO2 in the Krebs cycle. We solved the crystal structure of the AvIDH in complex with cofactor NADP(+) (AvIDH-NADP(+) complex). The final refined model shows the closed form that has never been detected in any previously solved structures of beta-decarboxylating dehydrogenases. The structure also reveals all of the residues that interact with NADP(+). The structure-based sequence alignment reveals that these residues were not conserved in any other dimeric NADP(+)-dependent IDHs. Therefore the NADP(+) specificity of the monomeric and dimeric IDHs was independently acquired through the evolutional process. The AvIDH was known to show an exceptionally high turnover rate. The structure of the AvIDH-NADP(+) complex indicates that one loop, which is not present in the Escherichia coli IDHs, reliably stabilizes the conformation of the nicotinamide mononucleotide of the bound NADP(+) by forming a few hydrogen bonds, and such interactions are considered to be important for the monomeric enzyme to initiate the hydride transfer reaction immediately. Finally, the structure of the AvIDH is compared with that of other dimeric NADP-IDHs. Several structural features demonstrate that the monomeric IDHs are structurally more related to the eukaryotic dimeric IDHs than to the bacterial dimeric IDHs.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Kita Ku, Sapporo, Hokkaido 0600810, Japan	Hokkaido University	Tanaka, I (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Kita Ku, Kita 10,Nishi 8, Sapporo, Hokkaido 0600810, Japan.	tanaka@castor.sci.hokudai.ac.jp	Yasutake, Yoshiaki/H-8079-2018; yao, min/F-5287-2011	Yasutake, Yoshiaki/0000-0002-4521-7516; yao, min/0000-0003-1687-5904				Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BARRERA C R, 1970, Biochimica et Biophysica Acta, V220, P416, DOI 10.1016/0005-2744(70)90273-1; BODOR N, 1990, THEOCHEM-J MOL STRUC, V65, P315; BOLDUC JM, 1995, SCIENCE, V268, P1312, DOI 10.1126/science.7761851; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Ceccarelli C, 2002, J BIOL CHEM, V277, P43454, DOI 10.1074/jbc.M207306200; CHEN RD, 1990, PLANT PHYSIOL BIOCH, V28, P411; Chen RD, 2000, PROTEIN SCI, V9, P2344, DOI 10.1110/ps.9.12.2344; Chen RD, 2000, ARCH BIOCHEM BIOPHYS, V383, P238, DOI 10.1006/abbi.2000.2082; Cherbavaz DB, 2000, J MOL BIOL, V295, P377, DOI 10.1006/jmbi.1999.3195; CHUNG A E, 1970, Archives of Biochemistry and Biophysics, V141, P416, DOI 10.1016/0003-9861(70)90157-8; CHUNG AE, 1969, BIOCHEMISTRY-US, V8, P3175, DOI 10.1021/bi00836a007; Dean AM, 1997, P NATL ACAD SCI USA, V94, P3104, DOI 10.1073/pnas.94.7.3104; Doyle SA, 2001, BIOCHEMISTRY-US, V40, P4234, DOI 10.1021/bi002533q; DUGGLEBY RG, 1970, J BIOL CHEM, V245, P3751; EHRLICH RS, 1990, BIOCHEMISTRY-US, V29, P5179, DOI 10.1021/bi00473a026; EHRLICH RS, 1983, J BIOL CHEM, V258, P7079; FinerMoore J, 1997, BIOCHEMISTRY-US, V36, P13890, DOI 10.1021/bi9711691; Fudou R, 2002, INT J SYST EVOL MICR, V52, P1127, DOI [10.1099/ijs.0.02086-0, 10.1099/00207713-52-4-1127]; Hermoso JA, 2002, J MOL BIOL, V319, P1133, DOI 10.1016/S0022-2836(02)00388-1; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Howell DM, 2000, J BACTERIOL, V182, P5013, DOI 10.1128/JB.182.17.5013-5016.2000; HURLEY JH, 1989, P NATL ACAD SCI USA, V86, P8635, DOI 10.1073/pnas.86.22.8635; Hurley JH, 1996, BIOCHEMISTRY-US, V35, P5670, DOI 10.1021/bi953001q; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; HURLEY JH, 1990, J BIOL CHEM, V265, P3599; IMADA K, 1991, J MOL BIOL, V222, P725, DOI 10.1016/0022-2836(91)90508-4; Imada K, 1998, STRUCTURE, V6, P971, DOI 10.1016/S0969-2126(98)00099-9; ISHII A, 1987, J BIOCHEM, V102, P1489, DOI 10.1093/oxfordjournals.jbchem.a122196; ISHII A, 1993, J BACTERIOL, V175, P6873, DOI 10.1128/jb.175.21.6873-6880.1993; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KADONO S, 1995, J BIOCHEM-TOKYO, V118, P745, DOI 10.1093/oxfordjournals.jbchem.a124975; Kawamoto M, 2001, NUCL INSTRUM METH A, V467, P1375, DOI 10.1016/S0168-9002(01)00672-6; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mesecar AD, 1997, SCIENCE, V277, P202, DOI 10.1126/science.277.5323.202; Miyazaki J, 2003, J BIOL CHEM, V278, P1864, DOI 10.1074/jbc.M205133200; MIYAZAKI K, 1993, FEBS LETT, V332, P35, DOI 10.1016/0014-5793(93)80477-C; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Singh SK, 2001, J BIOL CHEM, V276, P26154, DOI 10.1074/jbc.M101191200; Steen IH, 2001, J BIOL CHEM, V276, P43924, DOI 10.1074/jbc.M105999200; Steen IH, 1997, ARCH MICROBIOL, V168, P412, DOI 10.1007/s002030050516; Stoddard BL, 1998, NAT STRUCT BIOL, V5, P891, DOI 10.1038/2331; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9310, DOI 10.1021/bi00087a008; STODDARD BL, 1993, BIOCHEMISTRY-US, V32, P9317, DOI 10.1021/bi00087a009; SUZUKI M, 1995, J BACTERIOL, V177, P2138, DOI 10.1128/jb.177.8.2138-2142.1995; Tanaka N, 1996, BIOCHEMISTRY-US, V35, P7715, DOI 10.1021/bi951904d; Tanaka N, 1996, STRUCTURE, V4, P33, DOI 10.1016/S0969-2126(96)00007-X; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Wallon G, 1997, J MOL BIOL, V266, P1016, DOI 10.1006/jmbi.1996.0797; WICKEN JS, 1972, BIOCHEMISTRY-US, V11, P4766, DOI 10.1021/bi00775a021; WU YD, 1991, J AM CHEM SOC, V113, P2353, DOI 10.1021/ja00007a002; Yasutake Y, 2002, STRUCTURE, V10, P1637, DOI 10.1016/S0969-2126(02)00904-8; Yasutake Y, 2001, ACTA CRYSTALLOGR D, V57, P1682, DOI 10.1107/S0907444901012823; ZHANG T, 1995, PROTEIN SCI, V4, P84	63	39	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36897	36904		10.1074/jbc.M304091200	http://dx.doi.org/10.1074/jbc.M304091200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855708	hybrid			2022-12-27	WOS:000185318300123
J	van der Slot, AJ; Zuurmond, AM; Bardoel, AFJ; Wijmenga, C; Pruijs, HEH; Sillence, DO; Brinckmann, J; Abraham, DJ; Black, CM; Verzijl, N; DeGroot, J; Hanemaaijer, R; TeKoppele, JM; Huizinga, TWJ; Bank, RA				van der Slot, AJ; Zuurmond, AM; Bardoel, AFJ; Wijmenga, C; Pruijs, HEH; Sillence, DO; Brinckmann, J; Abraham, DJ; Black, CM; Verzijl, N; DeGroot, J; Hanemaaijer, R; TeKoppele, JM; Huizinga, TWJ; Bank, RA			Identification of PLOD2 as telopeptide lysyl hydroxylase, an important enzyme in fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EHLERS-DANLOS-SYNDROME; SYNDROME TYPE-VI; CONGENITAL JOINT CONTRACTURES; COLLAGEN CROSS-LINKING; BRUCK-SYNDROME; POSTTRANSLATIONAL MODIFICATIONS; OSTEOGENESIS IMPERFECTA; FIBROTIC COLLAGEN; GENE PLOD; PYRIDINOLINE	The hallmark of fibrotic processes is an excessive accumulation of collagen. The deposited collagen shows an increase in pyridinoline cross-links, which are derived from hydroxylated lysine residues within the telopeptides. This change in cross-linking is related to irreversible accumulation of collagen in fibrotic tissues. The increase in pyridinoline cross-links is likely to be the result of increased activity of the enzyme responsible for the hydroxylation of the telopeptides ( telopeptide lysyl hydroxylase, or TLH). Although the existence of TLH has been postulated, the gene encoding TLH has not been identified. By analyzing the genetic defect of Bruck syndrome, which is characterized by a pyridinoline deficiency in bone collagen, we found two missense mutations in exon 17 of PLOD2, thereby identifying PLOD2 as a putative TLH gene. Subsequently, we investigated fibroblasts derived from fibrotic skin of systemic sclerosis (SSc) patients and found that PLOD2 mRNA is highly increased indeed. Furthermore, increased pyridinoline cross-link levels were found in the matrix deposited by SSc fibroblasts, demonstrating a clear link between mRNA levels of the putative TLH gene ( PLOD2) and the hydroxylation of lysine residues within the telopeptides. These data underscore the significance of PLOD2 in fibrotic processes.	TNO Prevent & Hlth, Div Biomed Res, Dept Tissue Repair, NL-2301 CE Leiden, Netherlands; Univ Med Ctr Utrecht, Dept Med Genet, NL-3584 EA Utrecht, Netherlands; Univ Med Ctr Utrecht, Dept Pediat Orthoped, NL-3501 CA Utrecht, Netherlands; Childrens Hosp, Dept Pediat & Child Hlth, Westmead, NSW 2145, Australia; Univ Lubeck, Dept Dermatol, D-235552 Lubeck, Germany; UCL Royal Free & Univ Coll Med Sch, Ctr Rheumatol, London NW3 2PF, England; Leiden Univ, Med Ctr, Dept Rheumatol, NL-2300 RC Leiden, Netherlands	Netherlands Organization Applied Science Research; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; University of Sydney; University of Lubeck; University of London; University College London; UCL Medical School; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Bank, RA (corresponding author), TNO Prevent & Hlth, Div Biomed Res, Dept Tissue Repair, POB 2215, NL-2301 CE Leiden, Netherlands.	RA.Bank@pg.tno.nl	Wijmenga, Cisca/D-2173-2009; Wijmenga, Cisca/AAE-7719-2019; DeGroot, Jeroen/C-4585-2012	Wijmenga, Cisca/0000-0002-5635-1614; 				BAILEY AJ, 1985, CIBA F SYMP, V114, P80; BAILEY AJ, 1975, BIOCHIM BIOPHYS ACTA, V405, P412, DOI 10.1016/0005-2795(75)90106-3; Bank RA, 1997, J CHROMATOGR B, V703, P37, DOI 10.1016/S0378-4347(97)00391-5; Bank RA, 1999, P NATL ACAD SCI USA, V96, P1054, DOI 10.1073/pnas.96.3.1054; Bilezikian, 1999, DYNAMICS BONE CARTIL, P3; BRENNER RE, 1993, EUR J PEDIATR, V152, P505, DOI 10.1007/BF01955060; Breslau-Siderius EJ, 1998, J PEDIATR ORTHOP B, V7, P35, DOI 10.1097/01202412-199801000-00006; Brinckmann J, 2001, J INVEST DERMATOL, V117, P269, DOI 10.1046/j.0022-202x.2001.01414.x; Brinckmann J, 1999, J INVEST DERMATOL, V113, P617, DOI 10.1046/j.1523-1747.1999.00735.x; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; EYRE DR, 1984, ANNU REV BIOCHEM, V53, P717, DOI 10.1146/annurev.bi.53.070184.003441; HAUTALA T, 1992, GENOMICS, V13, P62, DOI 10.1016/0888-7543(92)90202-4; HEIKKINEN J, 1994, GENOMICS, V24, P464, DOI 10.1006/geno.1994.1654; Heikkinen J, 1997, AM J HUM GENET, V60, P48; HERBAGE D, 1985, FRONT MATRIX BIOL, V10, P59; Istok R, 2001, CLIN EXP DERMATOL, V26, P545, DOI 10.1046/j.1365-2230.2001.00886.x; LAST JA, 1990, AM REV RESPIR DIS, V141, P307, DOI 10.1164/ajrccm/141.2.307; LEROY EC, 1974, J CLIN INVEST, V54, P880, DOI 10.1172/JCI107827; Leroy JG, 1998, PEDIATR RADIOL, V28, P781, DOI 10.1007/s002470050465; McPherson E, 1997, AM J MED GENET, V70, P28, DOI 10.1002/(SICI)1096-8628(19970502)70:1<28::AID-AJMG6>3.3.CO;2-N; Passoja K, 1998, P NATL ACAD SCI USA, V95, P10482, DOI 10.1073/pnas.95.18.10482; PELTONEN L, 1985, J INVEST DERMATOL, V84, P14, DOI 10.1111/1523-1747.ep12274596; Rautavuoma K, 2000, MATRIX BIOL, V19, P73, DOI 10.1016/S0945-053X(99)00058-X; REISER K, 1992, FASEB J, V6, P2439, DOI 10.1096/fasebj.6.7.1348714; RICARDBLUM S, 1993, CELL MOL BIOL, V39, P723; RICARDBLUM S, 1992, HEPATOLOGY, V15, P599, DOI 10.1002/hep.1840150408; Robins S P, 1982, Methods Biochem Anal, V28, P329, DOI 10.1002/9780470110485.ch8; Robins SP, 1996, CLIN CHEM, V42, P1621; ROBINS SP, 1999, DYNAMICS BONE CARTIL, P31; STEINMANN B, 1995, AM J HUM GENET, V57, P1505; Szpirer C, 1997, MAMM GENOME, V8, P707, DOI 10.1007/s003359900549; Uzawa K, 1998, BIOCHEM BIOPH RES CO, V249, P652, DOI 10.1006/bbrc.1998.8955; Uzawa K, 1999, J BONE MINER RES, V14, P1272, DOI 10.1359/jbmr.1999.14.8.1272; Valtavaara M, 1997, J BIOL CHEM, V272, P6831, DOI 10.1074/jbc.272.11.6831; Valtavaara M, 1998, J BIOL CHEM, V273, P12881, DOI 10.1074/jbc.273.21.12881; Yeowell HN, 1999, MATRIX BIOL, V18, P179, DOI 10.1016/S0945-053X(99)00013-X; Yeowell HN, 1997, P ASSOC AM PHYSICIAN, V109, P383; Yeowell HN, 2000, MOL GENET METAB, V71, P212, DOI 10.1006/mgme.2000.3076	38	278	288	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40967	40972		10.1074/jbc.M307380200	http://dx.doi.org/10.1074/jbc.M307380200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881513	Green Published, hybrid			2022-12-27	WOS:000185847200069
J	Bose, S; French, S; Evans, FJ; Joubert, F; Balaban, RS				Bose, S; French, S; Evans, FJ; Joubert, F; Balaban, RS			Metabolic network control of oxidative phosphorylation - Multiple roles of inorganic phosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CREATINE-KINASE; MITOCHONDRIAL RESPIRATION; MATHEMATICAL-MODEL; OXYGEN-CONSUMPTION; ENERGY-METABOLISM; ISOLATED HEART; RABBIT HEARTS; DEHYDROGENASE; HEMOGLOBIN; TRANSPORT	Phosphate (P-i) is a putative cytosolic signaling molecule in the regulation of oxidative phosphorylation. Here, by using a multiparameter monitoring system, we show that P-i controls oxidative phosphorylation in a balanced fashion, modulating both the generation of useful potential energy and the formation of ATP by F1F0-ATPase in heart and skeletal muscle mitochondria. In these studies the effect of P-i was determined on the mitochondria [NADH], NADH generating capacity, matrix pH, membrane potential, oxygen consumption, and cytochrome reduction level. P-i enhanced NADH generation and was obligatory for electron flow under uncoupled conditions. P-i oxidized cytochrome b (cyto-b) and reduced cytochrome c (cyto-c), potentially improving the coupling between the NADH free energy and the proton motive force. The apparent limitation in reducing equivalent flow between cyto-b and cyto-c in the absence of P-i was confirmed in the intact heart by using optical spectroscopic techniques under conditions with low cytosolic [P-i]. These results demonstrate that P-i signaling results in the balanced modulation of oxidative phosphorylation, by influencing both DeltaG(H+) generation and ATP production, which may contribute to the energy metabolism homeostasis observed in intact systems.	NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Balaban, RS (corresponding author), NHLBI, Cardiac Energet Lab, NIH, Dept Hlth & Human Serv, Bldg 10,Rm BID-161, Bethesda, MD 20892 USA.		Balaban, Robert S/A-7459-2009	Balaban, Robert S/0000-0003-4086-0948; Joubert, Frederic/0000-0003-0239-1052	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL004601, Z01HL004601] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aliev MK, 1998, MOL CELL BIOCHEM, V184, P209, DOI 10.1023/A:1006871903596; AMBROSIO G, 1993, J BIOL CHEM, V268, P18532; Balaban RS, 1996, ANAL BIOCHEM, V237, P274, DOI 10.1006/abio.1996.0239; BALABAN RS, 1980, AM J PHYSIOL, V238, pF50, DOI 10.1152/ajprenal.1980.238.1.F50; BALABAN RS, 1990, AM J PHYSIOL, V258, pC377, DOI 10.1152/ajpcell.1990.258.3.C377; Balaban RS, 2002, J MOL CELL CARDIOL, V34, P1259, DOI 10.1006/jmcc.2002.2082; BALABAN RS, 1986, SCIENCE, V232, P1121, DOI 10.1126/science.3704638; BAYSAL K, 1991, ARCH BIOCHEM BIOPHYS, V291, P383, DOI 10.1016/0003-9861(91)90150-H; BLONDE DJ, 1967, CAN J BIOCHEM CELL B, V45, P641, DOI 10.1139/o67-075; BRAND MD, 1995, BIOCHEM SOC T, V23, P371, DOI 10.1042/bst0230371; BROWN GC, 1992, BIOCHEM J, V284, P1; CHANCE B, 1956, ADV ENZYMOL REL S BI, V17, P65; CHANCE B, 1981, P NATL ACAD SCI-BIOL, V78, P6714, DOI 10.1073/pnas.78.11.6714; Combs CA, 2001, BIOPHYS J, V80, P2018, DOI 10.1016/S0006-3495(01)76172-3; ERNSTER L, 1966, BIOCH MITOCHONDRIA, P29; French SA, 1998, AM J PHYSIOL-CELL PH, V275, pC900, DOI 10.1152/ajpcell.1998.275.3.C900; GARD JK, 1985, BIOPHYS J, V48, P803, DOI 10.1016/S0006-3495(85)83839-X; GARLICK PB, 1992, AM J PHYSIOL, V263, pH497, DOI 10.1152/ajpheart.1992.263.2.H497; GARLID KD, 1980, J BIOL CHEM, V255, P1273; GORMAN MW, 1992, CIRC RES, V70, P1146, DOI 10.1161/01.RES.70.6.1146; GUNTER TE, 1988, AM J PHYSIOL, V255, pC304, DOI 10.1152/ajpcell.1988.255.3.C304; HALESTRAP AP, 1994, BIOCHEM SOC T, V22, P522, DOI 10.1042/bst0220522; HANSFORD RG, 1968, BIOCHEM BIOPH RES CO, V30, P643, DOI 10.1016/0006-291X(68)90561-5; HANSFORD RG, 1972, BIOCHEM J, V127, P271, DOI 10.1042/bj1270271; HARPER ME, 1993, J BIOL CHEM, V268, P14850; HEINEMAN FW, 1992, AM J PHYSIOL, V262, pH255, DOI 10.1152/ajpheart.1992.262.1.H255; Hoffmann J, 1998, PHYS MED BIOL, V43, P3571, DOI 10.1088/0031-9155/43/12/014; IZZARD S, 1973, ARCH BIOCHEM BIOPHYS, V154, P527, DOI 10.1016/0003-9861(73)90005-2; IZZARD S, 1970, P NATL ACAD SCI USA, V67, P702, DOI 10.1073/pnas.67.2.702; JOUBERT FFH, 2004, IN PRESS BIOPHYS J; Jung DW, 1999, AM J PHYSIOL-CELL PH, V277, pC1194, DOI 10.1152/ajpcell.1999.277.6.C1194; JUNG DW, 1990, BIOCHEMISTRY-US, V29, P4121, DOI 10.1021/bi00469a015; KATZ LA, 1989, AM J PHYSIOL, V256, pH265, DOI 10.1152/ajpheart.1989.256.1.H265; KATZ LA, 1988, AM J PHYSIOL, V255, pH189, DOI 10.1152/ajpheart.1988.255.1.H189; Kushnareva YE, 1999, ARCH BIOCHEM BIOPHYS, V363, P155, DOI 10.1006/abbi.1998.1039; LARDY HA, 1952, J BIOL CHEM, V195, P215; MEYER RA, 1984, AM J PHYSIOL, V242, P1; Rodriguez-Zavala JS, 2000, ARCH BIOCHEM BIOPHYS, V379, P78, DOI 10.1006/abbi.2000.1856; ROTTENBERG H, 1974, BIOCHEMISTRY-US, V13, P4811, DOI 10.1021/bi00720a020; SAKS VA, 1993, BIOCHIM BIOPHYS ACTA, V1144, P134, DOI 10.1016/0005-2728(93)90166-D; Spindler M, 2002, AM J PHYSIOL-HEART C, V283, pH680, DOI 10.1152/ajpheart.00800.2001; TAGER JM, 1983, FEBS LETT, V151, P1, DOI 10.1016/0014-5793(83)80330-5; Territo PR, 2000, AM J PHYSIOL-CELL PH, V278, pC423, DOI 10.1152/ajpcell.2000.278.2.C423; Territo PR, 2000, ANAL BIOCHEM, V286, P156, DOI 10.1006/abio.2000.4774; Territo PR, 2001, J BIOL CHEM, V276, P2586, DOI 10.1074/jbc.M002923200; Vicini P, 2000, AM J PHYSIOL-CELL PH, V279, pC213, DOI 10.1152/ajpcell.2000.279.1.C213; WOHLRAB H, 1986, BIOCHIM BIOPHYS ACTA, V853, P115, DOI 10.1016/0304-4173(86)90007-8; ZHANG JY, 1995, AM J PHYSIOL-HEART C, V268, pH1891, DOI 10.1152/ajpheart.1995.268.5.H1891	48	172	172	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39155	39165		10.1074/jbc.M306409200	http://dx.doi.org/10.1074/jbc.M306409200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871940	hybrid			2022-12-27	WOS:000185575100129
J	Piontek, J; Brandt, R				Piontek, J; Brandt, R			Differential and regulated binding of cAMP-dependent protein kinase and protein kinase C isoenzymes to gravin in human model neurons - Evidence that gravin provides a dynamic platform for the localization of kinases during neuronal development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2)-ADRENERGIC RECEPTOR; SUBSTRATE; TAU; PHOSPHORYLATION; CELLS; MICROTUBULE; EXPRESSION; COMPLEXES; SCAFFOLD; SYSTEM	The membrane cortex has an important role in generating and maintaining spatially and functionally distinct domains in neurons. As a tool to functionally characterize molecules of the membrane cortex, we generated novel monoclonal antibodies against a fraction enriched for components of the neuronal membrane skeleton. We obtained two antibodies against the kinase-anchoring protein gravin. Gravin was strongly up-regulated during differentiation of human model neurons (NT2-N neurons) and was enriched at the inner peripheral cortex in close proximity to the plasma membrane where its localization primarily depended on association with membranes. In differentiated neurons, gravin colocalized in putative signaling complexes with protein kinase C (PKCbetaII) and partially with PKCalpha and cAMP-dependent protein kinase (PKA). Colocalization with PKCepsilon was not observed. PKCbetaII, PKCalpha, and PKA but not PKCepsilon coprecipitated with gravin indicating physical interaction. Binding of gravin to PKCalpha required the presence of Ca2+ and was increased after inhibition of PKC. In contrast, binding of PKCbetaII and PKA were independent of Ca2+ and PKC inhibition. Activation of PKC decreased binding of PKCalpha to gravin, decreased its association with the plasma membrane, and reduced the mean size of gravin particles. Taken together the data suggest that gravin provides a dynamic platform to localize kinases in an isoenzyme-specific and activation-dependent manner at specific sites in neurons.	Univ Osnabruck, Dept Neurobiol, D-49076 Osnabruck, Germany; Heidelberg Univ, IZN, Dept Neurobiol, INF 345, D-69120 Heidelberg, Germany	University Osnabruck; Ruprecht Karls University Heidelberg	Brandt, R (corresponding author), Univ Osnabruck, Dept Neurobiol, Barbarastr 11, D-49076 Osnabruck, Germany.	Brandt@biologie.uni-osnabrueck.de	Piontek, Joerg/F-8549-2011; Piontek, Joerg/K-6305-2013	Piontek, Joerg/0000-0002-0880-8915; Brandt, Roland/0000-0003-0101-1257				Audesirk G, 1997, DEV BRAIN RES, V102, P247, DOI 10.1016/S0165-3806(97)00100-4; BENSADOUN A, 1976, ANAL BIOCHEM, V70, P241, DOI 10.1016/S0003-2697(76)80064-4; BIEDLER JL, 1978, CANCER RES, V38, P3751; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brandon EP, 1997, CURR OPIN NEUROBIOL, V7, P397, DOI 10.1016/S0959-4388(97)80069-4; BRANDT R, 1993, J BIOL CHEM, V268, P3414; CABELL L, 1993, INT J DEV NEUROSCI, V11, P357, DOI 10.1016/0736-5748(93)90007-Z; Chapline C, 1998, J BIOL CHEM, V273, P19482, DOI 10.1074/jbc.273.31.19482; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Colledge M, 1999, TRENDS CELL BIOL, V9, P216, DOI 10.1016/S0962-8924(99)01558-5; Dekker LV, 1997, J BIOL CHEM, V272, P12747, DOI 10.1074/jbc.272.19.12747; FAISSNER A, 1990, NEURON, V5, P627, DOI 10.1016/0896-6273(90)90217-4; Fan GF, 2001, J BIOL CHEM, V276, P24005, DOI 10.1074/jbc.M011199200; Faux MC, 1999, BIOCHEM J, V343, P443, DOI 10.1042/0264-6021:3430443; Faux MC, 1997, J BIOL CHEM, V272, P17038, DOI 10.1074/jbc.272.27.17038; Gelman IH, 1998, CELL MOTIL CYTOSKEL, V41, P1; Gelman IH, 2002, FRONT BIOSCI-LANDMRK, V7, pD1782, DOI 10.2741/gelman; GORDON T, 1992, J CLIN INVEST, V90, P992, DOI 10.1172/JCI115976; GROVE BD, 1994, ANAT REC, V239, P231, DOI 10.1002/ar.1092390302; Grove BD, 2001, J VASC RES, V38, P163, DOI 10.1159/000051043; Harlow E., 1988, ANTIBODIES LAB MANUA; Jaken S, 2000, BIOESSAYS, V22, P245, DOI 10.1002/(SICI)1521-1878(200003)22:3<245::AID-BIES6>3.0.CO;2-X; Kempf M, 1996, J NEUROSCI, V16, P5583; KILMARTIN JV, 1982, J CELL BIOL, V93, P576, DOI 10.1083/jcb.93.3.576; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; Lin FB, 2000, J BIOL CHEM, V275, P19025, DOI 10.1074/jbc.275.25.19025; Lin XY, 1996, J BIOL CHEM, V271, P28430, DOI 10.1074/jbc.271.45.28430; LIN XY, 1995, MOL CELL BIOL, V15, P2754; Maas T, 2000, J BIOL CHEM, V275, P15733, DOI 10.1074/jbc.M000389200; McCabe JB, 1999, MOL BIOL CELL, V10, P3771, DOI 10.1091/mbc.10.11.3771; Nauert JB, 1997, CURR BIOL, V7, P52, DOI 10.1016/S0960-9822(06)00027-3; Nelson PJ, 1999, J CELL SCI, V112, P361; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; Paterlini M, 1998, NEUROSCI LETT, V243, P77, DOI 10.1016/S0304-3940(98)00087-1; Piontek J, 1999, J NEUROCHEM, V73, P139, DOI 10.1046/j.1471-4159.1999.0730139.x; PLEASURE SJ, 1992, J NEUROSCI, V12, P1802; Sato N, 1998, J BIOCHEM-TOKYO, V123, P1119; Schneider S, 2001, J NEUROSCI, V21, P920, DOI 10.1523/JNEUROSCI.21-03-00920.2001; Seykora JT, 1996, J BIOL CHEM, V271, P18797, DOI 10.1074/jbc.271.31.18797; Shih ML, 1999, J BIOL CHEM, V274, P1588, DOI 10.1074/jbc.274.3.1588; Sinha P, 2001, PROTEOMICS, V1, P835, DOI 10.1002/1615-9861(200107)1:7<835::AID-PROT835>3.3.CO;2-U; WALAAS SI, 1991, PHARMACOL REV, V43, P299	42	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38970	38979		10.1074/jbc.M306749200	http://dx.doi.org/10.1074/jbc.M306749200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857743	hybrid			2022-12-27	WOS:000185575100108
J	Tsuruta, D; Hopkinson, SB; Lane, KD; Werner, ME; Cryns, VL; Jones, JCR				Tsuruta, D; Hopkinson, SB; Lane, KD; Werner, ME; Cryns, VL; Jones, JCR			Crucial role of the specificity-determining loop of the integrin beta(4) subunit in the binding of cells to laminin-5 and outside-in signal transduction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; ALPHA(6)BETA(4) INTEGRIN; ENDOTHELIAL-CELLS; ALPHA-6-BETA-4 INTEGRIN; CYTOPLASMIC DOMAIN; HEMIDESMOSOMES; ADHESION; CYTOSKELETON; ASSOCIATION; ABSENCE	Within each hemidesmosome, alpha(6)beta(4) integrin plays a crucial role in hemidesmosome assembly by binding to laminin-5 in the basement membrane zone of epithelial tissue. Recent analyses have implicated "specificity-determining loops" (SDLs) in the I-like domain of beta integrin in regulating ligand binding. Here, we investigated the function of an SDL-like motif within the extracellular I-like domain of beta(4) integrin. We generated point mutations within the SDL of beta(4) integrin tagged with green fluorescent protein (GFP-beta(4)K150A and GFP-beta(4)Q155L). We also generated a mutation within the I-like domain of the beta(4) integrin, lying outside the SDL region (GFP- beta(4)V284E). We transfected constructs encoding the mutated beta(4) integrins and a GFP-conjugated wild type beta(4) integrin ( GFP- beta(4)WT) into 804G cells, which assemble hemidesmosomes, and human endothelial cells, which express little endogenous beta(4) integrin. In transfected 804G cells, GFP- beta(4)WT and GFP- beta(4)V284E colocalize with hemidesmosome proteins, whereas hemidesmosomal components in cells expressing GFP- beta(4)K150A and GFP- beta(4)Q155L are aberrantly localized. In endothelial cells, GFP- beta(4)WT and mutant proteins are co-expressed at the cell surface with alpha(6) integrin. When transfected endothelial cells are plated onto laminin-5 matrix, GFP-beta(4)WT and GFP- beta(4)V284E localize with laminin-5, whereas GFP-beta(4)K150A and GFP-beta(4)Q155L do not. GFP-beta(4)WT and GFPbeta(4)V284E expressed in endothelial cells associate with the adaptor protein Shc when the cells are stimulated with laminin-5. However, GFP-beta(4)K150A and GFPbeta(4)Q155L fail to associate with Shc even when laminin-5 is present, thus impacting downstream signaling. These results provide evidence that the SDL segment of the beta(4) integrin subunit is required for ligand binding and is involved in outside-in signaling.	Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA; Northwestern Univ, Feinberg Sch Med, Dept Med, Chicago, IL 60611 USA	Northwestern University; Feinberg School of Medicine; Northwestern University; Feinberg School of Medicine	Jones, JCR (corresponding author), Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Morton 4-616,303 E Chicago Ave, Chicago, IL 60611 USA.		Jones, Jonathan C R/T-9467-2017	Jones, Jonathan C R/0000-0002-1496-4922	NIDDK NIH HHS [R01(24) DK60589] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060589] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Baker SE, 1996, J CELL SCI, V109, P2509; Borradori L, 1999, J INVEST DERMATOL, V112, P411, DOI 10.1046/j.1523-1747.1999.00546.x; Dowling J, 1996, J CELL BIOL, V134, P559, DOI 10.1083/jcb.134.2.559; GeorgesLabouesse E, 1996, NAT GENET, V13, P370, DOI 10.1038/ng0796-370; Giancotti FG, 2000, NAT CELL BIOL, V2, pE13, DOI 10.1038/71397; Goldfinger LE, 1998, J CELL BIOL, V141, P255, DOI 10.1083/jcb.141.1.255; Gonzalez AM, 2002, P NATL ACAD SCI USA, V99, P16075, DOI 10.1073/pnas.252649399; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; Homan SM, 2002, EXP CELL RES, V281, P107, DOI 10.1006/excr.2002.5643; Homan SM, 1998, J CELL SCI, V111, P2717; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; Jones JCR, 1998, BIOESSAYS, V20, P488, DOI 10.1002/(SICI)1521-1878(199806)20:6<488::AID-BIES7>3.0.CO;2-I; Kamata T, 2002, J IMMUNOL, V168, P2296, DOI 10.4049/jimmunol.168.5.2296; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGHOFER M, 1993, J CELL SCI, V105, P753; Mainiero F, 1996, J CELL BIOL, V134, P241, DOI 10.1083/jcb.134.1.241; MAINIERO F, 1995, EMBO J, V14, P4470, DOI 10.1002/j.1460-2075.1995.tb00126.x; Martin KH, 2002, SCIENCE, V296, P1652, DOI 10.1126/science.296.5573.1652; Nievers MG, 1998, J CELL SCI, V111, P1659; Nievers MG, 2000, J CELL SCI, V113, P963; RIDDELLE KS, 1992, J CELL SCI, V103, P475; RIDDELLE KS, 1991, J CELL BIOL, V112, P159, DOI 10.1083/jcb.112.1.159; Schwartz MA, 2002, NAT CELL BIOL, V4, pE65, DOI 10.1038/ncb0402-e65; Schweitzer KM, 1997, LAB INVEST, V76, P25; SPINARDI L, 1993, MOL BIOL CELL, V4, P871, DOI 10.1091/mbc.4.9.871; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; Takagi J, 2002, CELL, V110, P599, DOI 10.1016/S0092-8674(02)00935-2; Takagi J, 2002, BIOCHEMISTRY-US, V41, P4339, DOI 10.1021/bi016047u; Takagi J, 1997, J BIOL CHEM, V272, P19794, DOI 10.1074/jbc.272.32.19794; Trusolino L, 2001, CELL, V107, P643, DOI 10.1016/S0092-8674(01)00567-0; Tsuruta D, 2003, CELL MOTIL CYTOSKEL, V54, P122, DOI 10.1002/cm.10089; Tsuruta D, 2002, FASEB J, V16, P866, DOI 10.1096/fj.01-0878fje; Tuckwell DS, 1997, FEBS LETT, V400, P297, DOI 10.1016/S0014-5793(96)01368-3; vanderNeut R, 1996, NAT GENET, V13, P366, DOI 10.1038/ng0796-366; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535	38	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38707	38714		10.1074/jbc.M301637200	http://dx.doi.org/10.1074/jbc.M301637200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867433	hybrid			2022-12-27	WOS:000185575100076
J	Esteve, E; Smida-Rezgui, S; Sarkozi, S; Szegedi, C; Regaya, I; Chen, LL; Altafaj, X; Rochat, H; Allen, P; Pessah, IN; Marty, I; Sabatier, JM; Jona, I; De Waard, M; Ronjat, M				Esteve, E; Smida-Rezgui, S; Sarkozi, S; Szegedi, C; Regaya, I; Chen, LL; Altafaj, X; Rochat, H; Allen, P; Pessah, IN; Marty, I; Sabatier, JM; Jona, I; De Waard, M; Ronjat, M			Critical amino acid residues determine the binding affinity and the Ca2+ release efficacy of maurocalcine in skeletal muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							II-III-LOOP; DIHYDROPYRIDINE RECEPTOR; RYANODINE RECEPTOR; SARCOPLASMIC-RETICULUM; CALCIUM-RELEASE; CA2+-RELEASE CHANNEL; PANDINUS-IMPERATOR; SCORPION TOXIN; PEPTIDE; ACTIVATOR	Maurocalcine (MCa) is a 33 amino acid residue peptide toxin isolated from the scorpion Scorpio maurus palmatus. MCa and mutated analogues were chemically synthesized, and their interaction with the skeletal muscle ryanodine receptor (RyR1) was studied on purified RyR1, sarcoplasmic reticulum (SR) vesicles, and cultured myotubes. MCa strongly potentiates [H-3] ryanodine binding on SR vesicles (7-fold at pCa 5) with an apparent EC50 of 12 nM. MCa decreases the sensitivity of [H-3] ryanodine binding to inhibitory high Ca2+ concentrations and increases it to the stimulatory low Ca2+ concentrations. In the presence of MCa, purified RyR1 channels show long-lasting openings characterized by a conductance equivalent to 60% of the full conductance. This effect correlates with a global increase in Ca2+ efflux as demonstrated by MCa effects on Ca2+ release from SR vesicles. In addition, we show for the first time that external application of MCa to cultured myotubes produces a cytosolic Ca2+ increase due to Ca2+ release from 4-chloro-m-cresol-sensitive intracellular stores. Using various MCa mutants, we identified a critical role of Arg(24) for MCa binding onto RyR1. All of the other MCa mutants are still able to modify [H-3] ryanodine binding although with a decreased EC50 and a lower stimulation efficacy. All of the active mutants produce both the appearance of a subconductance state and Ca2+ release from SR vesicles. Overall, these data identify some amino acid residues of MCa that support the effect of this toxin on ryanodine binding, RyR1 biophysical properties, and Ca2+ release from SR.	CEA, CIS, INSERM, EMI 9931, F-38054 Grenoble 09, France; Brigham & Womens Hosp, Dept Anesthesia, Boston, MA 02115 USA; Univ Calif Davis, Grad Program Neurosci, Davis, CA 95616 USA; Univ Calif Davis, Dept Mol Biosci, Davis, CA 95616 USA; Fac Med Nord, CNRS UMR 6560, F-13916 Marseille 20, France; Univ Debrecen, Sch Med, Dept Physiol, H-4012 Debrecen, Hungary	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); Harvard University; Brigham & Women's Hospital; University of California System; University of California Davis; University of California System; University of California Davis; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; University of Debrecen	Ronjat, M (corresponding author), CEA, CIS, INSERM, EMI 9931, 17 Rue Martyrs, F-38054 Grenoble 09, France.	mronjat@cea.fr	Marty, Isabelle/N-7114-2017; ESTEVE, Eric/M-7490-2014; Altafaj, Xavier/K-9257-2014; De Waard, Michel/G-7406-2014; Marty, Isabelle/ABF-5362-2020; Pessah, Isaac N/K-7985-2017; Regaya, Imed/L-7899-2018	Altafaj, Xavier/0000-0002-7595-0647; De Waard, Michel/0000-0002-2782-9615; Marty, Isabelle/0000-0003-3625-913X; Pessah, Isaac N/0000-0002-8149-588X; Regaya, Imed/0000-0001-8671-5186; SABATIER, Jean-Marc/0000-0002-9040-5647; Ronjat, Michel/0000-0002-9728-6425; ESTEVE, Eric/0000-0002-4548-9140	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES011269] Funding Source: NIH RePORTER; NIAMS NIH HHS [2P01 AR17605] Funding Source: Medline; NIEHS NIH HHS [1P01 ES11269] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Ahern CA, 2001, BIOPHYS J, V81, P3294, DOI 10.1016/S0006-3495(01)75963-2; Chen L, 2003, J BIOL CHEM, V278, P16095, DOI 10.1074/jbc.M209501200; CORONADO R, 1994, AM J PHYSIOL, V266, pC1485, DOI 10.1152/ajpcell.1994.266.6.C1485; El-Hayek R, 1998, BIOCHEMISTRY-US, V37, P7015, DOI 10.1021/bi972907o; ELHAYEK R, 1995, J BIOL CHEM, V270, P28696, DOI 10.1074/jbc.270.48.28696; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; Fajloun Z, 2000, FEBS LETT, V469, P179, DOI 10.1016/S0014-5793(00)01239-4; Green D, 2003, BIOCHEM J, V370, P517, DOI 10.1042/BJ20021488; Gschwend MH, 1999, PFLUG ARCH EUR J PHY, V438, P101, DOI 10.1007/s004240050885; Gurrola GB, 1999, J BIOL CHEM, V274, P7879, DOI 10.1074/jbc.274.12.7879; HerrmannFrank A, 1996, BBA-GEN SUBJECTS, V1289, P31, DOI 10.1016/0304-4165(95)00131-X; Jona I, 2001, PFLUG ARCH EUR J PHY, V441, P729, DOI 10.1007/s004240000484; KIM DH, 1983, J BIOL CHEM, V258, P9662; LAI FA, 1988, NATURE, V331, P315, DOI 10.1038/331315a0; Lindgren M, 2000, TRENDS PHARMACOL SCI, V21, P99, DOI 10.1016/S0165-6147(00)01447-4; Mackrill JJ, 1999, BIOCHEM J, V337, P345, DOI 10.1042/0264-6021:3370345; Marty I, 2000, J BIOL CHEM, V275, P8206, DOI 10.1074/jbc.275.11.8206; MERRIFIELD B, 1986, SCIENCE, V232, P341, DOI 10.1126/science.3961484; Mosbah A, 2000, PROTEINS, V40, P436, DOI 10.1002/1097-0134(20000815)40:3&lt;436::AID-PROT90&gt;3.0.CO;2-9; O'Reilly FM, 2002, BIOPHYS J, V82, P145, DOI 10.1016/S0006-3495(02)75381-2; PALADE P, 1987, J BIOL CHEM, V262, P6142; Proenza C, 2000, J BIOL CHEM, V275, P29935, DOI 10.1074/jbc.C000464200; Simeoni I, 2001, FEBS LETT, V508, P5, DOI 10.1016/S0014-5793(01)03013-7; VALDIVIA HH, 1992, P NATL ACAD SCI USA, V89, P12185, DOI 10.1073/pnas.89.24.12185; Zamudio FZ, 1997, FEBS LETT, V405, P385, DOI 10.1016/S0014-5793(97)00227-5; ZORZATO F, 1993, MOL PHARMACOL, V44, P1192	26	36	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37822	37831		10.1074/jbc.M305798200	http://dx.doi.org/10.1074/jbc.M305798200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869557	hybrid			2022-12-27	WOS:000185437200102
J	Leissring, MA; Lu, A; Condron, MM; Teplow, DB; Stein, RL; Farris, W; Selkoe, DJ				Leissring, MA; Lu, A; Condron, MM; Teplow, DB; Stein, RL; Farris, W; Selkoe, DJ			Kinetics of amyloid beta-protein degradation determined by novel fluorescence- and fluorescence polarization-based assays	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; ALZHEIMERS-DISEASE; PRECURSOR PROTEIN; IN-VIVO; NEPRILYSIN; PEPTIDES; BRAINS	Proteases that degrade the amyloid beta-protein (Abeta) are important regulators of brain Abeta levels in health and in Alzheimer's disease, yet few practical methods exist to study their detailed kinetics. Here, we describe robust and quantitative Abeta degradation assays based on the novel substrate, fluorescein-Abeta- (1-40)-Lys-biotin (FAbetaB). Liquid chromatography/ mass spectrometric analysis shows that FAbetaB is hydrolyzed at closely similar sites as wild-type Abeta by neprilysin and insulin-degrading enzyme, the two most widely studied Abeta-degrading proteases. The derivatized peptide is an avid substrate and is suitable for use with biological samples and in high throughput compound screening. The assays we have developed are easily implemented and are particularly useful for the generation of quantitative kinetic data, as we demonstrate by determining the kinetic parameters of FAbetaB degradation by several Abeta-degrading proteases, including plasmin, which has not previously been characterized. The use of these assays should yield additional new insights into the biology of Abeta-degrading proteases and facilitate the identification of activators and inhibitors of such enzymes.	Harvard Univ, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Ctr Neurodegenerat & Repair, Lab Drug Discovery Neurodegenerat, Cambridge, MA 02135 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University	Selkoe, DJ (corresponding author), Harvard Inst Med, 77 Ave Louis Pasteur, Boston, MA 02115 USA.		LEISSRING, MALCOLM/AAW-5361-2021	LEISSRING, MALCOLM/0000-0001-7185-4255				Ait-Ghezala G, 2002, NEUROSCI LETT, V325, P87, DOI 10.1016/S0304-3940(02)00243-4; Beaulieu H, 1999, BIOCHEM J, V340, P813, DOI 10.1042/0264-6021:3400813; Bertram L, 2000, SCIENCE, V290, P2302, DOI 10.1126/science.290.5500.2302; Chesneau V, 2000, BIOCHEM J, V351, P509, DOI 10.1042/0264-6021:3510509; Chesneau V, 2000, PROTEIN EXPRES PURIF, V19, P91, DOI 10.1006/prep.2000.1217; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; Ermolieff J, 2000, BIOCHEMISTRY-US, V39, P16263, DOI 10.1021/bi005122i; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; HOWELL S, 1995, PEPTIDES, V16, P647, DOI 10.1016/0196-9781(95)00021-B; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; JAMESON DM, 1995, METHOD ENZYMOL, V246, P283; Karlstrom H, 2002, J BIOL CHEM, V277, P6763, DOI 10.1074/jbc.C100649200; Kimberly WT, 2003, BIOCHEMISTRY-US, V42, P137, DOI 10.1021/bi026888g; Li YJ, 2002, AM J HUM GENET, V70, P985, DOI 10.1086/339815; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Mukherjee A, 2000, J NEUROSCI, V20, P8745; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Selkoe DJ, 2001, NEURON, V32, P177, DOI 10.1016/S0896-6273(01)00475-5; Shirotani K, 2001, J BIOL CHEM, V276, P21895, DOI 10.1074/jbc.M008511200; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206	24	95	96	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37314	37320		10.1074/jbc.M305627200	http://dx.doi.org/10.1074/jbc.M305627200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867419	hybrid			2022-12-27	WOS:000185437200040
J	Rocic, P; Seshiah, P; Griendling, KK				Rocic, P; Seshiah, P; Griendling, KK			Reactive oxygen species sensitivity of angiotensin II-dependent translation initiation in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; FACTOR 4E PHOSPHORYLATION; JURKAT T-CELLS; 4E-BINDING PROTEIN-1; PHOSPHATASE 2A; PHAS-I; PHOSPHATIDYLINOSITOL 3-KINASE; STIMULATES PHOSPHORYLATION; INDUCED HYPERTROPHY; CRITICAL COMPONENT	Translation initiation, the rate-limiting step in protein synthesis, is a key event in vascular smooth muscle cell growth, a major component of vascular disease. Translation initiation is regulated by interaction between PHAS-I and the eukaryotic initiation factor 4E (eIF4E). Although angiotensin II (Ang II)-induced vascular smooth muscle cell hypertrophy requires the generation of reactive oxygen species (ROS), the ROS sensitivity of these events and their upstream activators remain unclear. Here, we investigated the role of ROS in the regulation of PHAS-I phosphorylation on Thr-70 and Ser-65, an event required for the release of eIF4E from PHAS-I. Ang II-induced Ser-65 phosphorylation was ROS-dependent as assessed by pretreatment with ebselen (3.6 +/- 0.2 versus 1.1 +/- 0.2), diphenylene iodonium (3.6 +/- 0.2 versus 1.0 +/- 0.1), and N-acetyl cysteine (3.6 +/- 0.2 versus 1.2 +/- 0.1), but Ang II-stimulated phosphorylation of Thr-70 was ROS-insensitive. Although phosphatidyl-inositol 3-kinase pathway inhibition by LY294004 blocked both Ser-65 and Thr-70 phosphorylation (3.8 +/- 0.1 versus 0.8 +/- 0.1 and 3.2 +/- 0.2 versus 1.0 +/- 0.01, respectively), protein phosphatase 2A inhibition by okadaic acid selectively increased (3.3 +/- 0.1 versus 5.2 +/- 0.1) and p38 mitogen-activated protein kinase inhibition by SB203580 selectively decreased (3.8 +/- 0.1 versus 1.4 +/- 0.3) Ser-65 phosphorylation. Dominant negative Akt adenovirus also inhibited only Ser-65 phosphorylation (3.7 +/- 0.1 versus 1.0 +/- 0.03). These results demonstrate a unique differential ROS sensitivity of two separate residues on PHAS-I, which seems to be explained by the selective involvement of distinct signaling pathways in the regulation of these phosphorylation events.	Emory Univ, Div Cardiol, Atlanta, GA 30322 USA	Emory University	Griendling, KK (corresponding author), Emory Univ, Div Cardiol, 319 WMB,1639 Pierce Dr, Atlanta, GA 30322 USA.	kgriend@emory.edu		Rocic, Petra/0000-0002-5781-3075; Griendling, Kathy/0000-0002-9456-8582	NHLBI NIH HHS [HL58000, HL38206] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL038206, R01HL038206, P01HL058000, R37HL038206] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aronica SM, 1997, BLOOD, V89, P3582, DOI 10.1182/blood.V89.10.3582.3582_3582_3595; BECKMAN JS, 1988, J BIOL CHEM, V263, P6884; BERK BC, 1989, HYPERTENSION, V13, P305, DOI 10.1161/01.HYP.13.4.305; BU X, 1992, FEBS LETT, V301, P15, DOI 10.1016/0014-5793(92)80200-Z; Coffer PJ, 1998, BIOCHEM J, V335, P1; Corvera S, 1998, TRENDS CELL BIOL, V8, P442, DOI 10.1016/S0962-8924(98)01366-X; Diggle TA, 1996, BIOCHEM J, V316, P447, DOI 10.1042/bj3160447; Duncan RF, 2003, BIOCHEM J, V369, P213, DOI 10.1042/BJ20020435; Fleurent M, 1997, J BIOL CHEM, V272, P4006, DOI 10.1074/jbc.272.7.4006; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Gingras AC, 1998, GENE DEV, V12, P502, DOI 10.1101/gad.12.4.502; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; GRIENDLING KK, 1994, CIRC RES, V74, P1141, DOI 10.1161/01.RES.74.6.1141; Griendling KK, 2000, CIRC RES, V86, P494, DOI 10.1161/01.RES.86.5.494; HAGHIGHAT A, 1995, EMBO J, V14, P5701, DOI 10.1002/j.1460-2075.1995.tb00257.x; Hartley D, 2002, J CELL BIOCHEM, V85, P304, DOI 10.1002/jcb.10135; Heesom KJ, 1999, FEBS LETT, V457, P489, DOI 10.1016/S0014-5793(99)01094-7; Lin TA, 1997, DIABETOLOGIA, V40, pS18, DOI 10.1007/s001250051391; LIN TA, 1994, SCIENCE, V266, P653, DOI 10.1126/science.7939721; Liu GM, 2002, J BIOL CHEM, V277, P8810, DOI 10.1074/jbc.M110477200; MAKKINJE A, 1995, J BIOL CHEM, V270, P14824, DOI 10.1074/jbc.270.24.14824; Mendez R, 1996, MOL CELL BIOL, V16, P2857; MOHAZZABH KM, 1994, AM J PHYSIOL, V266, pH2568, DOI 10.1152/ajpheart.1994.266.6.H2568; Morley SJ, 1997, FEBS LETT, V418, P327, DOI 10.1016/S0014-5793(97)01405-1; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Peterson RT, 1999, P NATL ACAD SCI USA, V96, P4438, DOI 10.1073/pnas.96.8.4438; Rajagopalan S, 1996, J CLIN INVEST, V97, P1916, DOI 10.1172/JCI118623; Rane MJ, 2001, J BIOL CHEM, V276, P3517, DOI 10.1074/jbc.M005953200; RAO GN, 1994, J BIOL CHEM, V269, P7180; Rao GN, 2000, J BIOL CHEM, V275, P16993, DOI 10.1074/jbc.275.22.16993; Rao GN, 1999, J BIOL CHEM, V274, P12925, DOI 10.1074/jbc.274.18.12925; Rao RK, 2002, BIOCHEM BIOPH RES CO, V293, P610, DOI 10.1016/S0006-291X(02)00268-1; REURENT M, 1997, J BIOL CHEM, V272, P4006; Rocic P, 2001, AM J PHYSIOL-CELL PH, V280, pC90, DOI 10.1152/ajpcell.2001.280.1.C90; Rybkin II, 2000, J BIOL CHEM, V275, P5460, DOI 10.1074/jbc.275.8.5460; Sabri A, 1998, CIRC RES, V83, P841, DOI 10.1161/01.RES.83.8.841; Seshiah PN, 2002, CIRC RES, V91, P406, DOI 10.1161/01.RES.0000033523.08033.16; Ushio-Fukai M, 1999, J BIOL CHEM, V274, P22699, DOI 10.1074/jbc.274.32.22699; Ushio-Fukai M, 1998, J BIOL CHEM, V273, P15022, DOI 10.1074/jbc.273.24.15022; UshioFukai M, 1996, J BIOL CHEM, V271, P23317, DOI 10.1074/jbc.271.38.23317; Vary TC, 2000, AM J PHYSIOL-ENDOC M, V278, pE58, DOI 10.1152/ajpendo.2000.278.1.E58; WHISLER RL, 1995, ARCH BIOCHEM BIOPHYS, V319, P23, DOI 10.1006/abbi.1995.1263; Zafari AM, 1998, HYPERTENSION, V32, P488, DOI 10.1161/01.HYP.32.3.488	43	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36973	36979		10.1074/jbc.M302099200	http://dx.doi.org/10.1074/jbc.M302099200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860993	hybrid			2022-12-27	WOS:000185318300132
J	Selivanova, OM; Shiryaev, VM; Tiktopulo, EI; Potekhin, SA; Spirin, AS				Selivanova, OM; Shiryaev, VM; Tiktopulo, EI; Potekhin, SA; Spirin, AS			Compact globular structure of Thermus thermophilus ribosomal protein S1 in solution - Sedimentation and calorimetric study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; BINDING-SITE	Ribosomal protein S1 of Thermus thermophilus overexpressed in Escherichia coli cells has been isolated and subjected to studies by analytical sedimentation and differential scanning microcalorimetry techniques. It has been demonstrated that the protein of 60 kDa sediments at s(20,w)(0) = 4.6 S and has the diffusion coefficient D-20,w(0) = 6.7 x 10(-7) cm(2)/s in 25 mM HEPES-NaOH buffer, pH 7.5 (similarly to bovine serum albumin of 66 kDa that sediments at s(20,w)(0) = 4.4 S and D-20,w(0) = 6.0 x 10(-7) cm(2)/s), indicating its compact globular conformation under these conditions. The microcalorimetry study has shown the presence of a cooperative tertiary structure melting at 90 degreesC, but with several (probably three) independent cooperative domains. In the presence of 100 mM NaCl the protein becomes more asymmetric (s(20,w)(0) = 3.1 S) but does not lose its cooperativity and thermostability, this suggesting just the weakening of interdomain ionic interactions. The compact globular conformation of protein S1 seems to be most likely within the ribosome.	Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia	Russian Academy of Sciences	Spirin, AS (corresponding author), Russian Acad Sci, Inst Prot Res, Pushchino 142290, Moscow Region, Russia.	spirin@vega.protres.ru	Potekhin, Sergey A/M-8274-2015; Spirin, Alexander/A-7307-2016; Selivanova, Olga/M-3184-2015					BERESTOWSKAYA NH, 1988, FEBS LETT, V228, P263, DOI 10.1016/0014-5793(88)80012-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bycroft M, 1997, CELL, V88, P235, DOI 10.1016/S0092-8674(00)81844-9; DRAPER DE, 1978, J MOL BIOL, V122, P321, DOI 10.1016/0022-2836(78)90193-6; GIORGINIS S, 1980, J MOL BIOL, V141, P393, DOI 10.1016/0022-2836(80)90253-3; GIRI L, 1977, FEBS LETT, V81, P199, DOI 10.1016/0014-5793(77)80958-7; GRIBSKOV M, 1992, GENE, V119, P107, DOI 10.1016/0378-1119(92)90073-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAUGHREA M, 1977, J MOL BIOL, V112, P399, DOI 10.1016/S0022-2836(77)80189-7; Makhatadze GI, 1995, ADV PROTEIN CHEM, V47, P307, DOI 10.1016/S0065-3233(08)60548-3; ODOM OW, 1984, ARCH BIOCHEM BIOPHYS, V230, P178, DOI 10.1016/0003-9861(84)90099-7; Privalov P L, 1986, Methods Enzymol, V131, P4; Schachman H.K., 1959, ULTRACENTRIFUGATION; Senin AA, 2000, J THERM ANAL CALORIM, V62, P153, DOI 10.1023/A:1010171013669; Shiryaev VM, 2002, FEBS LETT, V525, P88, DOI 10.1016/S0014-5793(02)03092-2; Sorensen MA, 1998, J MOL BIOL, V280, P561, DOI 10.1006/jmbi.1998.1909; SUBRAMANIAN AR, 1983, PROG NUCLEIC ACID RE, V28, P101, DOI 10.1016/S0079-6603(08)60085-9; YOKOTA T, 1979, J BIOCHEM, V86, P1725, DOI 10.1093/oxfordjournals.jbchem.a132693; [No title captured]	19	12	24	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36311	36314		10.1074/jbc.M304713200	http://dx.doi.org/10.1074/jbc.M304713200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860989	hybrid			2022-12-27	WOS:000185318300055
J	Dias-Baruffi, M; Zhu, H; Cho, MJ; Karmakar, S; McEver, RP; Cummings, RD				Dias-Baruffi, M; Zhu, H; Cho, MJ; Karmakar, S; McEver, RP; Cummings, RD			Dimeric galectin-1 induces surface exposure of phosphatidylserine and phagocytic recognition of leukocytes without inducing apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GALACTOSIDE-BINDING LECTIN; MEMBRANE PHOSPHOLIPID ASYMMETRY; ANTICOAGULANT PROTEIN-I; HUMAN-ENDOTHELIAL-CELLS; PLASMA-MEMBRANE; FAS LIGAND; HUMAN NEUTROPHILS; CYSTIC-FIBROSIS; GENERAL FEATURE; T-CELLS	We report that human galectin-1 (dGal-1), a small dimeric beta-galactoside-binding protein, induces phosphatidylserine ( PS) exposure, measured by Annexin V staining, on human promyelocytic HL-60 cells, T leukemic MOLT-4 cells, and fMet-Leu-Phe-activated, but not resting, human neutrophils. This effect of dGal-1 on HL-60 and MOLT-4 cells is enhanced by pretreatment of the cells with neuraminidase, but treatment of resting neutrophils with neuraminidase does not enhance their sensitivity to dGal-1. Although the induction of staining with Annexin V is often associated with apoptosis, the dGal-1-treated HL-60 cells, MOLT-4 cells, and activated neutrophils do not undergo apoptosis, and there is no detectable DNA fragmentation. HL-60 and MOLT-4 cells treated with dGal-1 continue to grow normally. By contrast, camptothecin-treated HL-60 cells, etoposide-treated MOLT-4 cells, and anti-Fas-treated neutrophils exhibit extensive DNA fragmentation and/or cell death. Lactose inhibits the dGal-1-induced effects, indicating that dGal-1-induced signaling requires binding to cell surface beta-galactosides. The dimeric form of Gal-1 is required for signaling, because a monomeric mutant form of Gal-1, termed mGal-1, binds to cells but does not cause these effects. Importantly, dGal-1, but not mGal-1, treatment of HL-60 cells and activated human neutrophils significantly promotes their phagocytosis by activated mouse macrophages. These dGal-1-induced effects are distinguishable from apoptosis, but like apoptotic agents, prepare cells for phagocytic removal. Such effects of dGal-1 may contribute to leukocyte homeostasis.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA; Oklahoma Med Res Fdn, Cardiovasc Biol Res Program, Oklahoma City, OK 73104 USA; Univ Sao Paulo, Sch Pharmaceut Sci Ribeirao Preto SP, BR-14015900 Sao Paulo, Brazil; Jeju Natl Univ, Sch Med, Dept Biochem, Cheju 690756, South Korea	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center; Oklahoma Medical Research Foundation; Universidade de Sao Paulo; Jeju National University	Cummings, RD (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, 975 NE 10th St,BRC417, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu	Baruffi, Marcelo D/I-7199-2015	Baruffi, Marcelo D/0000-0002-2039-1884	NCRR NIH HHS [RR15577] Funding Source: Medline; NHLBI NIH HHS [HL34363] Funding Source: Medline; NIAID NIH HHS [AI48075] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015577] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034363, R37HL034363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI048075] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams L, 1996, BBA-MOL CELL RES, V1312, P137, DOI 10.1016/0167-4889(96)00031-6; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; ALLEN HJ, 1991, TUMOR BIOL, V12, P52, DOI 10.1159/000217688; BAUM LG, 1995, GLYCOCONJUGATE J, V12, P63, DOI 10.1007/BF00731870; Bratton DL, 1997, J BIOL CHEM, V272, P26159, DOI 10.1074/jbc.272.42.26159; Brown SB, 2000, J BIOL CHEM, V275, P5987, DOI 10.1074/jbc.275.8.5987; Cho M, 1996, BIOCHEMISTRY-US, V35, P13081, DOI 10.1021/bi961181d; CHO MJ, 1995, J BIOL CHEM, V270, P5198, DOI 10.1074/jbc.270.10.5198; Colnot C, 1998, IMMUNOLOGY, V94, P290, DOI 10.1046/j.1365-2567.1998.00517.x; COMFURIUS P, 1990, BIOCHIM BIOPHYS ACTA, V1026, P153, DOI 10.1016/0005-2736(90)90058-V; Cooper DNW, 1999, GLYCOBIOLOGY, V9, P979, DOI 10.1093/glycob/9.10.979; COURAUD PO, 1989, J BIOL CHEM, V264, P1310; CROSS AS, 1991, J CLIN INVEST, V88, P2067, DOI 10.1172/JCI115536; Del Giudice E, 2001, EUR CYTOKINE NETW, V12, P510; Dillon SR, 2000, J IMMUNOL, V164, P1322, DOI 10.4049/jimmunol.164.3.1322; Fadeel B, 1999, BIOCHEM BIOPH RES CO, V266, P504, DOI 10.1006/bbrc.1999.1820; Fadeel B, 1998, BLOOD, V92, P4808, DOI 10.1182/blood.V92.12.4808.424k01_4808_4818; Fadok VA, 2001, J CLIN INVEST, V108, P957, DOI 10.1172/JCI14122; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1992, J IMMUNOL, V148, P2207; Fecho K, 1998, J LEUKOCYTE BIOL, V64, P373, DOI 10.1002/jlb.64.3.373; Fecho K, 1998, CELL IMMUNOL, V188, P19, DOI 10.1006/cimm.1998.1339; Galvan M, 2000, J BIOL CHEM, V275, P16730, DOI 10.1074/jbc.M001117200; Hammill AK, 1999, EXP CELL RES, V251, P16, DOI 10.1006/excr.1999.4581; HASLETT C, 1989, CURR OPIN IMMUNOL, V2, P10, DOI 10.1016/0952-7915(89)90091-5; HASLETT C, 1994, PHILOS T ROY SOC B, V345, P327, DOI 10.1098/rstb.1994.0113; HIRABAYASHI J, 1989, FEBS LETT, V250, P161, DOI 10.1016/0014-5793(89)80711-2; Hohlbaum AM, 2001, J IMMUNOL, V167, P6217, DOI 10.4049/jimmunol.167.11.6217; Homburg C H, 1996, Curr Opin Hematol, V3, P94; HOMBURG CHE, 1995, BLOOD, V85, P532; Hsu DK, 2000, AM J PATHOL, V156, P1073, DOI 10.1016/S0002-9440(10)64975-9; IWAI K, 1994, BLOOD, V84, P1201; Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Kopitz J, 2001, J BIOL CHEM, V276, P35917, DOI 10.1074/jbc.M105135200; Krahling S, 1999, CELL DEATH DIFFER, V6, P183, DOI 10.1038/sj.cdd.4400473; Kuypers FA, 1996, BLOOD, V87, P1179, DOI 10.1182/blood.V87.3.1179.bloodjournal8731179; LAGASSE E, 1994, J EXP MED, V179, P1047, DOI 10.1084/jem.179.3.1047; LOTAN R, 1994, GLYCOCONJUGATE J, V11, P462, DOI 10.1007/BF00731282; MARTIN SJ, 1995, J EXP MED, V182, P1545, DOI 10.1084/jem.182.5.1545; Misawa R, 2001, APOPTOSIS, V6, P411, DOI 10.1023/A:1012406121993; OFFNER H, 1990, J NEUROIMMUNOL, V28, P177, DOI 10.1016/0165-5728(90)90032-I; OUTENREATH RL, 1992, J NEUROCYTOL, V21, P788, DOI 10.1007/BF01237904; Pace KE, 1999, J IMMUNOL, V163, P3801; Pace KE, 2000, J IMMUNOL, V165, P2331, DOI 10.4049/jimmunol.165.5.2331; PERILLO NL, 1995, NATURE, V378, P736, DOI 10.1038/378736a0; Perillo NL, 1998, J MOL MED, V76, P402, DOI 10.1007/s001090050232; Perillo NL, 1997, J EXP MED, V185, P1851, DOI 10.1084/jem.185.10.1851; PITTS MJ, 1981, BIOCHEM J, V195, P435, DOI 10.1042/bj1950435; POIRIER F, 1993, DEVELOPMENT, V119, P1229; Puche AC, 1996, DEV BIOL, V179, P274, DOI 10.1006/dbio.1996.0257; Rabinovich G, 1999, J EXP MED, V190, P385, DOI 10.1084/jem.190.3.385; Razi N, 1999, GLYCOBIOLOGY, V9, P1225, DOI 10.1093/glycob/9.11.1225; Rimon G, 1997, J NEUROSCI RES, V48, P563, DOI 10.1002/(SICI)1097-4547(19970615)48:6<563::AID-JNR9>3.0.CO;2-8; SANFORD GL, 1990, FASEB J, V4, P2912, DOI 10.1096/fasebj.4.11.2379767; Savill J, 1997, J LEUKOCYTE BIOL, V61, P375, DOI 10.1002/jlb.61.4.375; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; Schlegel RA, 1996, ADV EXP MED BIOL, V406, P21; Shiratsuchi A, 1998, BIOCHEM BIOPH RES CO, V246, P549, DOI 10.1006/bbrc.1998.8663; Shudo K, 2001, EUR J IMMUNOL, V31, P2504, DOI 10.1002/1521-4141(200108)31:8<2504::AID-IMMU2504>3.0.CO;2-C; SIMS PJ, 1989, J BIOL CHEM, V264, P17049; SORENSON CM, 1990, JNCI-J NATL CANCER I, V82, P749, DOI 10.1093/jnci/82.9.749; Stahnke K, 1998, EXP HEMATOL, V26, P844; TAIT JF, 1989, J BIOL CHEM, V264, P7944; THIAGARAJAN P, 1990, J BIOL CHEM, V265, P17420; Traver D, 1998, IMMUNITY, V9, P47, DOI 10.1016/S1074-7613(00)80587-7; Tyurina YY, 2000, TOXICOLOGY, V148, P93, DOI 10.1016/S0300-483X(00)00199-2; Vandivier RW, 2002, CHEST, V121, p89S, DOI 10.1378/chest.121.3_suppl.89S; Vandivier RW, 2002, J CLIN INVEST, V109, P661, DOI 10.1172/JCI200213572; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; vanEngeland M, 1997, EXP CELL RES, V235, P421, DOI 10.1006/excr.1997.3738; Varki A., 1999, ESSENTIALS GLYCOBIOL; Vespa GNR, 1999, J IMMUNOL, V162, P799; Walzel H, 2000, GLYCOBIOLOGY, V10, P131, DOI 10.1093/glycob/10.2.131; WANG WC, 1988, J BIOL CHEM, V263, P4576; WASANO K, 1990, CELL TISSUE RES, V259, P43, DOI 10.1007/BF00571428; WELLS V, 1991, CELL, V64, P91, DOI 10.1016/0092-8674(91)90211-G; Williamson P, 2001, BIOCHEMISTRY-US, V40, P8065, DOI 10.1021/bi001929z; Zhao J, 1998, J BIOL CHEM, V273, P6603, DOI 10.1074/jbc.273.12.6603; Zhuang JG, 1998, J BIOL CHEM, V273, P15628, DOI 10.1074/jbc.273.25.15628; Zimmerman GA, 1996, J CLIN INVEST, V98, P1699, DOI 10.1172/JCI118967; ZIMMERMAN GA, 1985, J CLIN INVEST, V76, P2235, DOI 10.1172/JCI112232; Zwaal RFA, 1997, BLOOD, V89, P1121, DOI 10.1182/blood.V89.4.1121	86	140	143	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41282	41293		10.1074/jbc.M306624200	http://dx.doi.org/10.1074/jbc.M306624200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12853445	hybrid			2022-12-27	WOS:000185847200107
J	Oak, SA; Zhou, YW; Jarrett, HW				Oak, SA; Zhou, YW; Jarrett, HW			Skeletal muscle signaling pathway through the dystrophin glycoprotein complex and Rac1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-FAMILY GTPASES; BETA-DYSTROGLYCAN; GUANOSINE TRIPHOSPHATASES; MOUSE ALPHA-1-SYNTROPHIN; TYROSINE PHOSPHORYLATION; EXTRACELLULAR-MATRIX; MUSCULAR-DYSTROPHIES; ALPHA-DYSTROGLYCAN; BINDING-SITES; SMOOTH-MUSCLE	The dystrophin glycoprotein complex has been proposed to be involved in signal transduction. Here we have shown that laminin binding causes syntrophin to recruit Rac1 from the rabbit skeletal muscle. Laminin-Sepharose and syntrophin-Sepharose bind a protein complex containing Rac1 from the muscle membranes. The presence of heparin, which inhibits laminin interactions, prevents recruitment of Rac1. The dystrophin glycoprotein complex recruits Rac1 via syntrophin through a Grb2.Sos1 complex. A syntrophin antibody also prevents recruitment of Rac1, suggesting that the signaling complex requires syntrophin. PAK1 is in turn bound by Rac1. c-Jun NH2-terminal kinase-p46 is phosphorylated and activated only when laminin is present, and the p54 isoform is activated when laminin is depleted or binding is inhibited with heparin. In the presence of laminin, c-Jun is activated in both skeletal muscle microsomes and in C2C12 myoblasts, and proliferation increases in C2C12 myoblasts. We postulate that this pathway signals muscle homeostasis and hypertrophy.	Univ Tennessee, Dept Biochem, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Jarrett, HW (corresponding author), Univ Tennessee, Dept Biochem, 858 Madison Ave, Memphis, TN 38163 USA.							Behrens A, 1999, NAT GENET, V21, P326, DOI 10.1038/6854; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; CAMPBELL KP, 1995, CELL, V80, P675, DOI 10.1016/0092-8674(95)90344-5; Cavaldesi M, 1999, J NEUROCHEM, V72, P1648, DOI 10.1046/j.1471-4159.1999.721648.x; Chockalingam PS, 2002, AM J PHYSIOL-CELL PH, V283, pC500, DOI 10.1152/ajpcell.00529.2001; Colledge M, 1997, J NEUROSCI, V17, P5038; Echtermeyer F, 1996, J BIOL CHEM, V271, P2071, DOI 10.1074/jbc.271.4.2071; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; ERVASTI JM, 1993, J CELL BIOL, V122, P809, DOI 10.1083/jcb.122.4.809; Gee SH, 1998, J NEUROSCI, V18, P128; Hasegawa M, 1999, J BIOL CHEM, V274, P12626, DOI 10.1074/jbc.274.18.12626; Hayashi YK, 1998, NAT GENET, V19, P94, DOI 10.1038/ng0598-94; Howard PL, 1999, MUSCLE NERVE, V22, P16, DOI 10.1002/(SICI)1097-4598(199901)22:1<16::AID-MUS5>3.0.CO;2-R; IBRAGHIMOVBESKROVNAYA O, 1992, NATURE, V355, P696, DOI 10.1038/355696a0; Iwata Y, 1998, FEBS LETT, V423, P173, DOI 10.1016/S0014-5793(98)00085-4; Kaibuchi K, 1999, ANNU REV BIOCHEM, V68, P459, DOI 10.1146/annurev.biochem.68.1.459; Kolodziejczyk SM, 2001, CURR BIOL, V11, P1278, DOI 10.1016/S0960-9822(01)00397-9; KOSTROMINOVA TY, 1995, J CELL BIOCHEM, V58, P527, DOI 10.1002/jcb.240580416; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langenbach KJ, 2002, MUSCLE NERVE, V26, P644, DOI 10.1002/mus.10258; MADHAVAN R, 1992, BIOCHEM BIOPH RES CO, V185, P753, DOI 10.1016/0006-291X(92)91690-R; Mayer U, 2003, J BIOL CHEM, V278, P14587, DOI 10.1074/jbc.R200022200; Mayer U, 1997, NAT GENET, V17, P318, DOI 10.1038/ng1197-318; Newbell BJ, 1997, BIOCHEMISTRY-US, V36, P1295, DOI 10.1021/bi962452n; Nguyen HT, 2000, AM J PHYSIOL-CELL PH, V279, pC1155, DOI 10.1152/ajpcell.2000.279.4.C1155; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Oak SA, 2001, BIOCHEMISTRY-US, V40, P11270, DOI 10.1021/bi010490n; Oak SA, 2000, BIOCHEMISTRY-US, V39, P8870, DOI 10.1021/bi0000824; Pall EA, 1996, J BIOL CHEM, V271, P3817; PELICCI G, 1995, ONCOGENE, V11, P899; Rosa G, 1996, BIOCHEM BIOPH RES CO, V223, P272, DOI 10.1006/bbrc.1996.0883; Rowley JA, 2002, J BIOMED MATER RES, V60, P217, DOI 10.1002/jbm.1287; Sasaki T, 2001, FEBS LETT, V509, P181, DOI 10.1016/S0014-5793(01)03167-2; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Sotgia F, 2003, BIOCHEMISTRY-US, V42, P7110, DOI 10.1021/bi0271289; Sotgia F, 2001, BIOCHEMISTRY-US, V40, P14585, DOI 10.1021/bi011247r; Spofford CM, 2001, AM J PHYSIOL-HEART C, V280, pH1354, DOI 10.1152/ajpheart.2001.280.3.H1354; SUNADA Y, 1994, J BIOL CHEM, V269, P13729; SUNADA Y, 1995, CURR OPIN NEUROL, V8, P379, DOI 10.1097/00019052-199510000-00010; Thibault G, 2000, MOL PHARMACOL, V58, P1137, DOI 10.1124/mol.58.5.1137; Tiger CF, 1997, J BIOL CHEM, V272, P28590, DOI 10.1074/jbc.272.45.28590; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VONDERMARK K, 1989, DIFFERENTIATION, V40, P150, DOI 10.1111/j.1432-0436.1989.tb00823.x; Weston C, 2000, J CELL BIOL, V150, P205, DOI 10.1083/jcb.150.1.205; Yamaguchi H, 2000, J BIOL CHEM, V275, P29458, DOI 10.1074/jbc.M003103200; YANG B, 1995, J BIOL CHEM, V270, P11711, DOI 10.1074/jbc.270.20.11711; YOSHIDA M, 1990, J BIOCHEM-TOKYO, V108, P748, DOI 10.1093/oxfordjournals.jbchem.a123276; Yoshida T, 1998, J BIOL CHEM, V273, P1583, DOI 10.1074/jbc.273.3.1583; Zhang BL, 2001, J BIOL CHEM, V276, P8958, DOI 10.1074/jbc.M008720200; Zhang BL, 2000, J BIOL CHEM, V275, P25299, DOI 10.1074/jbc.M001027200; ZHANG SJ, 1995, J BIOL CHEM, V270, P23934, DOI 10.1074/jbc.270.41.23934	52	67	68	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39287	39295		10.1074/jbc.M305551200	http://dx.doi.org/10.1074/jbc.M305551200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885773	hybrid			2022-12-27	WOS:000185713800005
J	McMullen, MR; Cocuzzi, E; Hatzoglou, M; Nagy, LE				McMullen, MR; Cocuzzi, E; Hatzoglou, M; Nagy, LE			Chronic ethanol exposure increases the binding of HuR to the TNF alpha 3 '-untranslated region in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MESSENGER-RNA STABILITY; AU-RICH ELEMENTS; NF-KAPPA-B; LIVER-DISEASE; PLASMA ENDOTOXIN; PROTEIN LIGANDS; IN-VIVO; C-JUN; EXPRESSION	Tumor necrosis factor alpha (TNFalpha) expression is a key mediator of ethanol-induced liver disease. Increased lipopolysaccharide (LPS)-stimulated TNFalpha expression in macrophages after chronic ethanol feeding is associated with a stabilization of TNFalpha mRNA (Kishore, R., McMullen, M. R., and Nagy, L. E. ( 2001) J. Biol. Chem. 276, 41930-41937). Here we show that the 3'-UTR of murine TNFalpha mRNA was sufficient to mediate increased LPS-stimulated expression of a luciferase reporter in RAW 264.7 macrophages after chronic ethanol exposure. Further, we show that HuR, a nuclear/cytoplasmic shuttling protein, which binds to TNFalpha mRNA, is required for increased expression of TNFalpha after chronic ethanol. In Kupffer cells, HuR was primarily localized to the nucleus and then translocated to the cytosol in response to LPS in both pair- and ethanol-fed rats. After chronic ethanol feeding, HuR quantity in the cytosol was greater, both at baseline and in response to LPS, compared with pair- fed controls. Using RNA gel shift assays, we found that LPS treatment increased HuR binding to the 65-nucleotide A + U-rich element of the TNFalpha 3'-UTR by 2-fold over baseline in Kupffer cells from pair- fed rats. After chronic ethanol feeding, HuR binding to the TNFalpha A + U-rich element was increased by more than 5-fold at baseline and in response to LPS, compared with pair- fed controls. Down-regulation of HuR expression by RNA interference prevented the chronic ethanol-induced increase in expression of luciferase reporters containing the TNFalpha 3'-UTR. Taken together, these data demonstrate that increased binding of HuR to the TNFalpha 3'-UTR contributes to increased LPS-stimulated TNFalpha expression in macrophages after chronic ethanol exposure.	Case Western Reserve Univ, Dept Nutr, Cleveland, OH 44106 USA	Case Western Reserve University	Nagy, LE (corresponding author), Case Western Reserve Univ, Dept Nutr, 2123 Abington Rd,Rm 201, Cleveland, OH 44106 USA.	len2@po.cwru.edu			NIAAA NIH HHS [R56 AA011975, AA 11975, R01 AA011975-10, R01 AA011975] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R56AA011975, R01AA011975] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Aldred A, 1999, AM J PHYSIOL-GASTR L, V276, pG98, DOI 10.1152/ajpgi.1999.276.1.G98; BEUTLER B, 1995, J INVEST MED, V43, P227; BODE C, 1987, J HEPATOL, V4, P8, DOI 10.1016/S0168-8278(87)80003-X; Brennan CM, 2000, J CELL BIOL, V151, P1, DOI 10.1083/jcb.151.1.1; Brennan CM, 2001, CELL MOL LIFE SCI, V58, P266, DOI 10.1007/PL00000854; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dixon DA, 2001, J CLIN INVEST, V108, P1657, DOI 10.1172/JCI200112973; Dohrman DP, 1996, P NATL ACAD SCI USA, V93, P10217, DOI 10.1073/pnas.93.19.10217; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; FUKUI H, 1991, J HEPATOL, V12, P162, DOI 10.1016/0168-8278(91)90933-3; Gallouzi IE, 2000, P NATL ACAD SCI USA, V97, P3073, DOI 10.1073/pnas.97.7.3073; Gallouzi IE, 2001, RNA, V7, P1348, DOI 10.1017/s1355838201016089; Gallouzi IE, 2001, SCIENCE, V294, P1895, DOI 10.1126/science.1064693; Gordon AS, 1997, MOL PHARMACOL, V52, P554, DOI 10.1124/mol.52.4.554; Gueydan C, 1999, J BIOL CHEM, V274, P2322, DOI 10.1074/jbc.274.4.2322; Han J, 1990, Eur Cytokine Netw, V1, P71; Hannon GJ, 2002, NATURE, V418, P244, DOI 10.1038/418244a; Hel Z, 1996, MOL CELL BIOL, V16, P5579; HONCHEL R, 1992, ALCOHOL CLIN EXP RES, V16, P665, DOI 10.1111/j.1530-0277.1992.tb00656.x; Jacob CO, 1996, J IMMUNOL, V156, P3043; JACOB CO, 1992, IMMUNOL TODAY, V13, P122, DOI 10.1016/0167-5699(92)90107-I; Kedersha N, 2002, BIOCHEM SOC T, V30, P963, DOI 10.1042/BST0300963; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; KHORUTS A, 1991, HEPATOLOGY, V13, P267, DOI 10.1016/0270-9139(91)92439-F; Kishore R, 2002, AM J PHYSIOL-GASTR L, V282, pG6, DOI 10.1152/ajpgi.00328.2001; Kishore R, 2001, J BIOL CHEM, V276, P41930, DOI 10.1074/jbc.M107181200; KISHORE R, 2003, IN PRESS COMP HEPATO; Kloss S, 2003, J BIOL CHEM, V278, P2377, DOI 10.1074/jbc.M206453200; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Kroeger KM, 1997, MOL IMMUNOL, V34, P391, DOI 10.1016/S0161-5890(97)00052-7; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; Lai WS, 1999, MOL CELL BIOL, V19, P4311; Lee WY, 2000, J BIOL CHEM, V275, P33998, DOI 10.1074/jbc.M005040200; Li HW, 2002, J BIOL CHEM, V277, P44623, DOI 10.1074/jbc.M206187200; Loflin P, 2001, FEBS LETT, V509, P267, DOI 10.1016/S0014-5793(01)03176-3; Marchant A, 1996, J INFLAMM, V46, P114; MCCLAIN CJ, 1989, HEPATOLOGY, V9, P349, DOI 10.1002/hep.1840090302; NANJI AA, 1993, AM J PATHOL, V142, P367; Piecyk M, 2000, EMBO J, V19, P4154, DOI 10.1093/emboj/19.15.4154; Reimund JM, 1996, J CLIN IMMUNOL, V16, P144, DOI 10.1007/BF01540912; Ron D, 2000, FASEB J, V14, P2303, DOI 10.1096/fj.00-0143com; Sakai K, 1999, FEBS LETT, V446, P157, DOI 10.1016/S0014-5793(99)00206-9; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; SHALABY MR, 1989, TRANSPLANTATION, V47, P1057, DOI 10.1097/00007890-198906000-00028; Shi L, 2002, J BIOL CHEM, V277, P14777, DOI 10.1074/jbc.M108967200; Steer JH, 2000, J BIOL CHEM, V275, P18432, DOI 10.1074/jbc.M906304199; Thurman RG, 1998, AM J PHYSIOL-GASTR L, V275, pG605, DOI 10.1152/ajpgi.1998.275.4.G605; Tilg H, 2000, NEW ENGL J MED, V343, P1467, DOI 10.1056/NEJM200011163432007; Wang W, 2002, MOL CELL BIOL, V22, P3425, DOI 10.1128/MCB.22.10.3425-3436.2002; Wang WG, 2000, EMBO J, V19, P2340, DOI 10.1093/emboj/19.10.2340; Wang WG, 2000, MOL CELL BIOL, V20, P760, DOI 10.1128/MCB.20.3.760-769.2000; Yaman I, 2002, J BIOL CHEM, V277, P41539, DOI 10.1074/jbc.M204850200; Yao J, 1997, J BIOL CHEM, V272, P17795, DOI 10.1074/jbc.272.28.17795; Yin M, 1999, GASTROENTEROLOGY, V117, P942, DOI 10.1016/S0016-5085(99)70354-9	57	47	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38333	38341		10.1074/jbc.M304566200	http://dx.doi.org/10.1074/jbc.M304566200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876290	hybrid, Green Accepted			2022-12-27	WOS:000185575100032
J	Tobaben, S; Varoqueaux, F; Brose, N; Stahl, B; Meyer, G				Tobaben, S; Varoqueaux, F; Brose, N; Stahl, B; Meyer, G			A brain-specific isoform of small glutamine-rich tetratricopeptide repeat-containing protein binds to Hsc70 and the cysteine string protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONES; UBIQUITIN LIGASE; DOMAIN; IDENTIFICATION; INTERACTS; COCHAPERONE; PEPTIDE; COMPLEX; FAMILY; HSP90	Small glutamine-rich tetratricopeptide repeat-containing protein (SGT) is a ubiquitously expressed cochaperone of heat shock cognate protein of 70 kDa (Hsc70). SGT binds to the C terminus of Hsc70, a site used by several tetratricopeptide repeat-containing binding partners to recruit Hsc70 into complexes of diverse function. We describe here an isoform of SGT with 60% amino acid sequence identity that we name betaSGT. In contrast to the previously published alphaSGT, betaSGT is almost exclusively expressed in brain. Both isoforms of SGT possess similar binding properties toward Hsc70 and cysteine string protein, a synaptic vesicle-associated J-domain-containing protein. In addition, SGTs oligomerize without preferences among isoforms. The distribution of protein binding motifs on SGTs reveals a modular structure. The N-terminal domains mediate oligomerization. Binding to Hsc70 is impaired by mutations of basic residues within the central tetratricopeptide repeat domain of betaSGT, indicating a two-carboxylate clamp as the binding mode. The tetratricopeptide repeats are also necessary for binding to the cysteine string protein. However, this binding mode is distinct from the two-carboxylate clamp that is involved in Hsc70 binding. The C-terminal regions of SGTs might constitute independent protein interaction domains. We conclude that betaSGT is likely to cooperate with alphaSGT as co-chaperone of Hsc70 in the brain. The modular structure of SGTs allows them to recruit client proteins to Hsc70 and to direct the resulting complex toward downstream proteins that take over the respective client proteins.	Max Planck Inst Expt Med, Dept Mol Neurobiol, D-37075 Gottingen, Germany; Deutsch Forsch Gemeinschaft Ctr Mol Physiol Brain, D-37075 Gottingen, Germany	Max Planck Society	Meyer, G (corresponding author), Max Planck Inst Expt Med, Dept Mol Neurobiol, Hermann Rein Str 3, D-37075 Gottingen, Germany.	gmeyer@em.mpg.de	Varoqueaux, Frederique/AAC-1834-2021	Varoqueaux, Frederique/0000-0002-3614-3121				Angeletti PC, 2002, CELL STRESS CHAPERON, V7, P258, DOI 10.1379/1466-1268(2002)007<0258:SGRPVP>2.0.CO;2; Augustin I, 1999, BIOCHEM J, V337, P363, DOI 10.1042/0264-6021:3370363; Ballinger CA, 1999, MOL CELL BIOL, V19, P4535; Betz A, 1997, J BIOL CHEM, V272, P2520; Blatch GL, 1999, BIOESSAYS, V21, P932, DOI 10.1002/(SICI)1521-1878(199911)21:11<932::AID-BIES5>3.0.CO;2-N; Brinker A, 2002, J BIOL CHEM, V277, P19265, DOI 10.1074/jbc.M109002200; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; Callahan MA, 1998, J VIROL, V72, P5189, DOI 10.1128/JVI.72.6.5189-5197.1998; Chamberlain LH, 1998, BIOCHEM J, V335, P205, DOI 10.1042/bj3350205; Chen SY, 1998, J BIOL CHEM, V273, P35194, DOI 10.1074/jbc.273.52.35194; Cziepluch C, 1998, J VIROL, V72, P4149, DOI 10.1128/JVI.72.5.4149-4156.1998; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Dobson CM, 2002, NATURE, V418, P729, DOI 10.1038/418729a; Fonte V, 2002, P NATL ACAD SCI USA, V99, P9439, DOI 10.1073/pnas.152313999; Frydman J, 1997, TRENDS BIOCHEM SCI, V22, P87, DOI 10.1016/S0968-0004(97)01005-0; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; GUNDERSEN CB, 1994, J BIOL CHEM, V269, P19197; HARTMANN E, 1993, EUR J BIOCHEM, V214, P375, DOI 10.1111/j.1432-1033.1993.tb17933.x; Hohfeld J, 2001, EMBO REP, V2, P885, DOI 10.1093/embo-reports/kve206; Irmer H, 1997, J BIOL CHEM, V272, P2230; Jiang JH, 2001, J BIOL CHEM, V276, P42938, DOI 10.1074/jbc.M101968200; Kaye FJ, 2000, FEBS LETT, V467, P348, DOI 10.1016/S0014-5793(00)01135-2; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Kordes E, 1998, GENOMICS, V52, P90, DOI 10.1006/geno.1998.5385; Liu FH, 1999, J BIOL CHEM, V274, P34425, DOI 10.1074/jbc.274.48.34425; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Muchowskil PJ, 2002, NEURON, V35, P9, DOI 10.1016/S0896-6273(02)00761-4; Odunuga OO, 2003, J BIOL CHEM, V278, P6896, DOI 10.1074/jbc.M206867200; Ohtsuka K, 2000, BRAIN RES BULL, V53, P141, DOI 10.1016/S0361-9230(00)00325-7; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Scheufler C, 2000, CELL, V101, P199, DOI 10.1016/S0092-8674(00)80830-2; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Smith DF, 1998, BIOL CHEM, V379, P283; Stahl B, 1999, EUR J CELL BIOL, V78, P375, DOI 10.1016/S0171-9335(99)80079-X; Takayama S, 2001, NAT CELL BIOL, V3, pE237, DOI 10.1038/ncb1001-e237; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Velten M, 2002, J BIOL CHEM, V277, P259, DOI 10.1074/jbc.M106881200; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wu SJ, 2001, BIOCHEM J, V359, P419, DOI 10.1042/0264-6021:3590419; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zinsmaier KE, 2001, BIOCHEM PHARMACOL, V62, P1, DOI 10.1016/S0006-2952(01)00648-7	43	37	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38376	38383		10.1074/jbc.M301558200	http://dx.doi.org/10.1074/jbc.M301558200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878599	hybrid			2022-12-27	WOS:000185575100037
J	Baars, S; Bachmann, A; Levitzki, A; Rosl, F				Baars, S; Bachmann, A; Levitzki, A; Rosl, F			Tyrphostin AG 555 inhibits bovine papillomavirus transcription by changing the ratio between E2 transactivator/repressor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; ACTIVATED PROTEIN-KINASE; EARLY GENE-EXPRESSION; OPEN READING FRAME; FACTOR-I RECEPTOR; TRANSFORMING PROTEIN; SIGNAL-TRANSDUCTION; MESSENGER-RNAS; TYPE-16 DNA; CELLS	The tyrosine kinase inhibitor ( tyrphostin) AG 555 selectively interferes with viral transcription in bovine papillomavirus type 1 (BPV-1)-transformed fibroblasts and induces suppression of cyclin-dependent kinase activity and cell cycle arrest. Concomitant with inhibition of viral transcription, c-Jun was strongly up-regulated, which was consistent with the observation that AG 555 treatment also led to an activation of the mitogen-activated protein kinase pathway by enhancing phosphorylation of JNK and p38. Increased JNK and p38 activity resulted in higher phosphorylation of the AP-1 family members c-Jun and activating transcription factor 2. Scanning the BPV-1 genome for potential binding sequences, an intragenic AP-1 site (BAP-1) within the E7 open reading frame was detected. Enhanced dimerization of phosphorylated activating transcription factor 2 together with c-Jun and binding to BAP-1 seem to be responsible for viral dysregulation because both suppression of BPV-1 and induction of c-Jun mRNA could be almost entirely abrogated by simultaneous treatment with SB 203580, an inhibitor of p38 mitogen-activated protein kinase activity. Moreover, dissecting the complex transcriptional pattern of episomal BPV-1 with specific primer sets for reverse transcription-PCR analysis, the repressive effect could be attributed to a selective down-regulation of the mRNA encoding the E2 transactivator function in favor of the E2 repressor, whose mRNA level remained constant during AG 555 treatment. These data indicate that tyrphostin AG 555 disturbs the balance of negative and positive regulatory factors necessary to maintain the homeostasis of a virus-transformed phenotype.	Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, Forsch Schwerpunkt Angew Tumorvirol, D-69120 Heidelberg, Germany; Hebrew Univ Jerusalem, Dept Biol Chem, IL-91904 Jerusalem, Israel	Helmholtz Association; German Cancer Research Center (DKFZ); Hebrew University of Jerusalem	Rosl, F (corresponding author), Deutsch Krebsforschungszentrum, Abt Virale Transformat Mech, Forsch Schwerpunkt Angew Tumorvirol, Neuenheimer Feld 242, D-69120 Heidelberg, Germany.	f.roesl@dkfz.de	Bachmann, Anastasia/F-8419-2014					Abroi A, 1996, J VIROL, V70, P6169, DOI 10.1128/JVI.70.9.6169-6179.1996; Alazawi W, 2002, CANCER RES, V62, P6959; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAKER CC, 1987, EMBO J, V6, P1027, DOI 10.1002/j.1460-2075.1987.tb04855.x; BARKSDALE SK, 1993, J VIROL, V67, P5605, DOI 10.1128/JVI.67.9.5605-5616.1993; Ben-Bassat H, 1999, J PHARMACOL EXP THER, V290, P1442; Ben-Bassat H, 1995, Exp Dermatol, V4, P82, DOI 10.1111/j.1600-0625.1995.tb00227.x; BenBassat H, 1997, CANCER RES, V57, P3741; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brenner T, 1998, EXP NEUROL, V154, P489, DOI 10.1006/exnr.1998.6971; CHEN EY, 1982, NATURE, V299, P529, DOI 10.1038/299529a0; CHOE J, 1989, J VIROL, V63, P1743, DOI 10.1128/JVI.63.4.1743-1755.1989; Choi CY, 1997, J BIOL CHEM, V272, P16934, DOI 10.1074/jbc.272.27.16934; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Crusius K, 1997, ONCOGENE, V15, P1437, DOI 10.1038/sj.onc.1201312; DEAN PN, 1974, J CELL BIOL, V60, P523, DOI 10.1083/jcb.60.2.523; DIMAIO D, 1986, P NATL ACAD SCI USA, V83, P1797, DOI 10.1073/pnas.83.6.1797; DURST M, 1985, J GEN VIROL, V66, P1515, DOI 10.1099/0022-1317-66-7-1515; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; Enslen H, 1998, J BIOL CHEM, V273, P1741, DOI 10.1074/jbc.273.3.1741; Eyers PA, 1999, FEBS LETT, V451, P191, DOI 10.1016/S0014-5793(99)00552-9; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; HERMONAT PL, 1988, EMBO J, V7, P2815, DOI 10.1002/j.1460-2075.1988.tb03137.x; HUBBERT NL, 1988, P NATL ACAD SCI USA, V85, P5864, DOI 10.1073/pnas.85.16.5864; HUMMEL M, 1992, J VIROL, V66, P6070, DOI 10.1128/JVI.66.10.6070-6080.1992; Ichijo H, 1999, ONCOGENE, V18, P6087, DOI 10.1038/sj.onc.1203129; JEON S, 1995, P NATL ACAD SCI USA, V92, P1654, DOI 10.1073/pnas.92.5.1654; JEON S, 1995, J VIROL, V69, P2989, DOI 10.1128/JVI.69.5.2989-2997.1995; Kabsch K, 2002, J VIROL, V76, P12162, DOI 10.1128/JVI.76.23.12162-12172.2002; Kansra SV, 1999, PHARMACOL RES, V39, P21, DOI 10.1006/phrs.1998.0402; Karin M, 1997, CURR OPIN CELL BIOL, V9, P240, DOI 10.1016/S0955-0674(97)80068-3; KARLEN S, 1993, J VIROL, V67, P4296, DOI 10.1128/JVI.67.7.4296-4306.1993; KHANDJIAN EW, 1986, ANAL BIOCHEM, V159, P227, DOI 10.1016/0003-2697(86)90332-5; Kim KY, 2003, J MED VIROL, V69, P122, DOI 10.1002/jmv.10256; Klein O, 1999, J VIROL, V73, P3264, DOI 10.1128/JVI.73.4.3264-3272.1999; Kleinberger-Doron N, 1998, EXP CELL RES, V241, P340, DOI 10.1006/excr.1998.4061; KLEINER E, 1986, EMBO J, V5, P1945, DOI 10.1002/j.1460-2075.1986.tb04448.x; LAMBERT PF, 1990, J VIROL, V64, P950, DOI 10.1128/JVI.64.2.950-956.1990; LARSEN JK, 1986, CYTOMETRY, V7, P54, DOI 10.1002/cyto.990070108; LAW MF, 1981, P NATL ACAD SCI-BIOL, V78, P2727, DOI 10.1073/pnas.78.5.2727; LEECHANACHAI P, 1992, ONCOGENE, V7, P19; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; Levitzki A, 1999, PHARMACOL THERAPEUT, V82, P231, DOI 10.1016/S0163-7258(98)00066-7; LI R, 1989, GENE DEV, V3, P510, DOI 10.1101/gad.3.4.510; Lipson KE, 1998, J PHARMACOL EXP THER, V285, P844; MARTIN P, 1989, CELL, V59, P21, DOI 10.1016/0092-8674(89)90866-0; MARUO T, 1992, CANCER, V69, P1182; Mathur SP, 2000, AM J REPROD IMMUNOL, V44, P222, DOI 10.1111/j.8755-8920.2000.440406.x; MORRIONE A, 1995, J VIROL, V69, P5300, DOI 10.1128/JVI.69.9.5300-5303.1995; Nakamura K, 2000, CANCER RES, V60, P760; PETTI L, 1992, P NATL ACAD SCI USA, V89, P6736, DOI 10.1073/pnas.89.15.6736; Powell TJ, 1999, BRIT J DERMATOL, V141, P802, DOI 10.1046/j.1365-2133.1999.03152.x; RABSON MS, 1986, J VIROL, V60, P626, DOI 10.1128/JVI.60.2.626-634.1986; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; ROSL F, 1991, MOL CARCINOGEN, V4, P248, DOI 10.1002/mc.2940040312; ROSL F, 1986, J VIROL, V58, P500; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Soto U, 2000, INT J CANCER, V86, P811, DOI 10.1002/(SICI)1097-0215(20000615)86:6<811::AID-IJC9>3.0.CO;2-J; Soto U, 1999, ONCOGENE, V18, P3187, DOI 10.1038/sj.onc.1202765; SPALHOLZ BA, 1991, J VIROL, V65, P743, DOI 10.1128/JVI.65.2.743-753.1991; SPALHOLZ BA, 1985, CELL, V42, P183, DOI 10.1016/S0092-8674(85)80114-8; STANLEY MA, 1989, INT J CANCER, V43, P672, DOI 10.1002/ijc.2910430422; SZYMANSKI P, 1991, J VIROL, V65, P5710, DOI 10.1128/JVI.65.11.5710-5720.1991; Talora C, 2002, GENE DEV, V16, P2252, DOI 10.1101/gad.988902; Tong XA, 1997, P NATL ACAD SCI USA, V94, P4412, DOI 10.1073/pnas.94.9.4412; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WINOKUR PL, 1992, EMBO J, V11, P4111, DOI 10.1002/j.1460-2075.1992.tb05504.x; zur Hausen H, 2002, NAT REV CANCER, V2, P342, DOI 10.1038/nrc798	72	2	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37306	37313		10.1074/jbc.M304449200	http://dx.doi.org/10.1074/jbc.M304449200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867421	hybrid			2022-12-27	WOS:000185437200039
J	Guillas, I; Jiang, JC; Vionnet, C; Roubaty, C; Uldry, D; Chuard, R; Wang, JQ; Jazwinski, SM; Conzelmann, A				Guillas, I; Jiang, JC; Vionnet, C; Roubaty, C; Uldry, D; Chuard, R; Wang, JQ; Jazwinski, SM; Conzelmann, A			Human homologues of LAG1 reconstitute acyl-CoA-dependent ceramide synthesis in yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; MEMBRANE-PROTEINS; SPHINGOLIPIDS; LONGEVITY; BIOSYNTHESIS; SYNTHASE; DOMAINS; FAMILY; LAC1P	Lag1p and Lac1p are two highly homologous membrane proteins of the endoplasmic reticulum. lag1Delta lac1Delta double mutants in Saccharomyces cerevisiae lack an acyl-CoA-dependent ceramide synthase and are either very sick or nonviable, depending on the genetic background. LAG1 and LAC1 are members of a large eukaryotic gene family that shares the Lag1 motif, and some members of this family additionally contain a DNA-binding HOX homeodomain. Here we show that several human LAG1 homologues can rescue the viability of lag1Delta lac1Delta yeast cells and restore acyl-CoA-dependent ceramide and sphingolipid biosynthesis. When tested in a microsomal assay, Lac1p and Lag1p had a strong preference for C26:0-CoA over C24:0-CoA, C20-CoA, and C16-CoA, whereas some human homologues preferred C24:0-CoA and CoA derivatives with shorter fatty acids. This suggests that LAG1 proteins are related to substrate recognition and to the catalytic activity of ceramide synthase enzymes. CLN8, another human LAG1 homologue implicated in ceroid lipofuscinosis, could not restore viability to lag1Delta lac1Delta yeast mutants.	Univ Fribourg, Dept Med, Div Biochem, CH-1700 Fribourg, Switzerland; Louisiana State Univ, Hlth Sci Ctr, Dept Biochem & Mol Biol, New Orleans, LA 70112 USA	University of Fribourg; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Conzelmann, A (corresponding author), Univ Fribourg, Dept Med, Div Biochem, Rte Musee 5, CH-1700 Fribourg, Switzerland.			Guillas, Isabelle/0000-0002-6073-0529				Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; Benghezal M, 1996, EMBO J, V15, P6575, DOI 10.1002/j.1460-2075.1996.tb01048.x; Canivenc-Gansel E, 1998, GLYCOBIOLOGY, V8, P761, DOI 10.1093/glycob/8.8.761; Dickson RC, 2002, BBA-MOL CELL BIOL L, V1583, P13, DOI 10.1016/S1388-1981(02)00210-X; Dickson RC, 1999, BBA-GEN SUBJECTS, V1426, P347, DOI 10.1016/S0304-4165(98)00135-4; Flury I, 2000, J BIOL CHEM, V275, P24458, DOI 10.1074/jbc.M003844200; Funato K, 2003, J BIOL CHEM, V278, P7325, DOI 10.1074/jbc.M209925200; Guillas I, 2001, EMBO J, V20, P2655, DOI 10.1093/emboj/20.11.2655; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HECHTBERGER P, 1994, EUR J BIOCHEM, V225, P641, DOI 10.1111/j.1432-1033.1994.00641.x; Jiang JC, 1998, GENOME RES, V8, P1259, DOI 10.1101/gr.8.12.1259; Kirchman PA, 1999, GENETICS, V152, P179; Lonka L, 2000, HUM MOL GENET, V9, P1691, DOI 10.1093/hmg/9.11.1691; MERRILL AH, 1993, J BIOL CHEM, V268, P27299; Meyer U, 2000, BIOCHEMISTRY-US, V39, P3461, DOI 10.1021/bi992186o; MORELL P, 1970, J BIOL CHEM, V245, P342; OBRIEN JS, 1964, J LIPID RES, V5, P339; Oh CS, 1997, J BIOL CHEM, V272, P17376, DOI 10.1074/jbc.272.28.17376; PATTON JL, 1991, J BACTERIOL, V173, P3101, DOI 10.1128/JB.173.10.3101-3108.1991; Reggiori F, 1997, EMBO J, V16, P3506, DOI 10.1093/emboj/16.12.3506; ROBSON KJ, 1994, J LIPID RES, V35, P2060; SANTAVUORI P, 1988, BRAIN DEV-JPN, V10, P80, DOI 10.1016/S0387-7604(88)80075-5; Schorling S, 2001, MOL BIOL CELL, V12, P3417, DOI 10.1091/mbc.12.11.3417; SMITH SW, 1974, J BIOL CHEM, V249, P3395; ULLMAN MD, 1972, ARCH BIOCHEM BIOPHYS, V152, P767, DOI 10.1016/0003-9861(72)90272-X; Venkataraman K, 2002, FEBS LETT, V528, P3, DOI 10.1016/S0014-5793(02)03248-9; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Wang E, 2000, METHOD ENZYMOL, V311, P15; WERTZ PW, 1989, COMP BIOCHEM PHYS B, V93, P265, DOI 10.1016/0305-0491(89)90080-1; Winter E, 2002, TRENDS BIOCHEM SCI, V27, P381, DOI 10.1016/S0968-0004(02)02154-0	30	76	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37083	37091		10.1074/jbc.M307554200	http://dx.doi.org/10.1074/jbc.M307554200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869556	hybrid			2022-12-27	WOS:000185437200014
J	Hiriart, E; Bardouillet, L; Manet, E; Gruffat, H; Penin, F; Montserret, R; Farjot, G; Sergeant, A				Hiriart, E; Bardouillet, L; Manet, E; Gruffat, H; Penin, F; Montserret, R; Farjot, G; Sergeant, A			A region of the Epstein-Barr virus (EBV) mRNA export factor EB2 containing an arginine-rich motif mediates direct binding to RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXON-EXON JUNCTIONS; REV RESPONSIVE ELEMENT; NUCLEAR EXPORT; PROTEIN INTERACTIONS; HUMAN HOMOLOG; IN-VIVO; TRANSCRIPTION; INTERACTS; GENE; PEPTIDE	The Epstein-Barr virus (EBV) protein EB2 (also called Mta, SM, or BMLF1) has properties in common with mRNA export factors and is essential for the production of EBV infectious virions. However, to date no RNA-binding motif essential for EB2-mediated mRNA export has been located in the protein. We show here by Northwestern blot analysis that the EB2 protein purified from mammalian cells binds directly to RNA. Furthermore, using overlapping glutathione S-transferase (GST)-EB2 peptides, we have, by RNA electrophoretic mobility shift assays (REMSAs) and Northwestern blotting, located an RNA-binding motif in a 33-amino acid segment of EB2 that has structural features of the arginine-rich RNA-binding motifs (ARMs) also found in many RNA-binding proteins. A synthetic peptide (called Da), which contains this EB2 ARM, bound RNA in REMSA. A GST-Da fusion protein also bound RNA in REMSA without apparent RNA sequence specificity, because similar to10 GST-Da molecules bound at multiple sites on a 180-nucleotide RNA fragment. Importantly, a short deletion in the ARM region impaired both EB2 binding to RNA in vivo and in vitro and EB2-mediated mRNA export without affecting the shuttling of EB2 between the nucleus and the cytoplasm. Moreover, ectopic expression of ARM-deleted EB2 did not rescue the production of infectious virions by 293 cells carrying an EBVDeltaEB2 genome, which suggests that the binding of EB2 to RNA plays an essential role in the EBV productive cycle.	INSERM, U412, Virol Lab, Ens Lyon, F-69364 Lyon 07, France; CNRS, F-75700 Paris, France	Ecole Normale Superieure de Lyon (ENS de LYON); Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Sergeant, A (corresponding author), INSERM, U412, Virol Lab, Ens Lyon, 46 Allee Italie, F-69364 Lyon 07, France.		MANET, Evelyne/G-5644-2019; Gruffat, Henri/I-2407-2016; PENIN, Francois/A-7315-2008	MANET, Evelyne/0000-0001-7619-9982; Gruffat, Henri/0000-0002-4735-6894; Hiriart, Eneko/0000-0003-4379-3672				BATTISTE JL, 1994, BIOCHEMISTRY-US, V33, P2741, DOI 10.1021/bi00176a001; Buisson M, 1999, J VIROL, V73, P4090, DOI 10.1128/JVI.73.5.4090-4100.1999; CHANG DD, 1989, CELL, V59, P789, DOI 10.1016/0092-8674(89)90602-8; CHEN L, 1995, P NATL ACAD SCI USA, V92, P5077, DOI 10.1073/pnas.92.11.5077; CHEVALLIERGRECO A, 1986, EMBO J, V5, P3243, DOI 10.1002/j.1460-2075.1986.tb04635.x; Combet C, 2000, TRENDS BIOCHEM SCI, V25, P147, DOI 10.1016/S0968-0004(99)01540-6; COUNTRYMAN J, 1987, J VIROL, V61, P3672, DOI 10.1128/JVI.61.12.3672-3679.1987; Delecluse HJ, 1999, P NATL ACAD SCI USA, V96, P5188, DOI 10.1073/pnas.96.9.5188; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Farjot G, 2000, J VIROL, V74, P6068, DOI 10.1128/JVI.74.13.6068-6076.2000; Feederle R, 2000, EMBO J, V19, P3080, DOI 10.1093/emboj/19.12.3080; Gatfield D, 2002, J CELL BIOL, V159, P579, DOI 10.1083/jcb.200207128; Gruffat H, 2002, J VIROL, V76, P9635, DOI 10.1128/JVI.76.19.9635-9644.2002; Gruter P, 1998, MOL CELL, V1, P649, DOI 10.1016/S1097-2765(00)80065-9; Hieronymus H, 2003, NAT GENET, V33, P155, DOI 10.1038/ng1080; Hiriart E, 2003, J BIOL CHEM, V278, P335, DOI 10.1074/jbc.M208656200; HOPE TJ, 1991, J VIROL, V65, P6001, DOI 10.1128/JVI.65.11.6001-6007.1991; Huang YQ, 2003, MOL CELL, V11, P837, DOI 10.1016/S1097-2765(03)00089-3; Huang YQ, 2001, MOL CELL, V7, P899, DOI 10.1016/S1097-2765(01)00233-7; Janz A, 2000, J VIROL, V74, P10142, DOI 10.1128/JVI.74.21.10142-10152.2000; Kataoka N, 2001, EMBO J, V20, P6424, DOI 10.1093/emboj/20.22.6424; Kim VN, 2001, EMBO J, V20, P2062, DOI 10.1093/emboj/20.8.2062; Koffa MD, 2001, EMBO J, V20, P5769, DOI 10.1093/emboj/20.20.5769; LAZINSKI D, 1989, CELL, V59, P207, DOI 10.1016/0092-8674(89)90882-9; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Le Hir H, 2000, GENE DEV, V14, P1098; Le Hir H, 2001, EMBO J, V20, P4987, DOI 10.1093/emboj/20.17.4987; Lei EP, 2001, GENE DEV, V15, P1771, DOI 10.1101/gad.892401; Luo MJ, 2001, NATURE, V413, P644, DOI 10.1038/35098106; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; MCCARTHY AM, 1989, J VIROL, V63, P18, DOI 10.1128/JVI.63.1.18-27.1989; Mears WE, 1996, J VIROL, V70, P7445, DOI 10.1128/JVI.70.11.7445-7453.1996; PETERSON RD, 1994, BIOCHEMISTRY-US, V33, P5357, DOI 10.1021/bi00184a001; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; RODRIGUEZ PL, 1994, BIOTECHNIQUES, V17, P702; ROLLER RJ, 1990, J VIROL, V64, P3463, DOI 10.1128/JVI.64.7.3463-3470.1990; ROONEY CM, 1989, J VIROL, V63, P3109, DOI 10.1128/JVI.63.7.3109-3116.1989; Ruvolo V, 1998, P NATL ACAD SCI USA, V95, P8852, DOI 10.1073/pnas.95.15.8852; Ruvolo V, 2001, J VIROL, V75, P6033, DOI 10.1128/JVI.75.13.6033-6041.2001; Sandri-Goldin RM, 1998, GENE DEV, V12, P868, DOI 10.1101/gad.12.6.868; Sciabica KS, 2003, EMBO J, V22, P1608, DOI 10.1093/emboj/cdg166; Semmes OJ, 1998, J VIROL, V72, P9526, DOI 10.1128/JVI.72.12.9526-9534.1998; Smith CA, 2000, MOL CELL, V6, P1067, DOI 10.1016/S1097-2765(00)00105-2; Soliman TM, 2000, J VIROL, V74, P2814, DOI 10.1128/JVI.74.6.2814-2825.2000; Strasser K, 2000, J CELL BIOL, V150, P695, DOI 10.1083/jcb.150.4.695; Strasser K, 2002, NATURE, V417, P304, DOI 10.1038/nature746; Strasser K, 2001, NATURE, V413, P648, DOI 10.1038/35098113; Strasser K, 2000, EMBO J, V19, P410, DOI 10.1093/emboj/19.3.410; Stutz F, 2000, RNA, V6, P638, DOI 10.1017/S1355838200000078; TAN RY, 1995, P NATL ACAD SCI USA, V92, P5282, DOI 10.1073/pnas.92.12.5282; TREISMAN R, 1983, NATURE, V302, P591, DOI 10.1038/302591a0; Zhou ZL, 2000, NATURE, V407, P401, DOI 10.1038/35030160; Zolotukhin AS, 2002, J BIOL CHEM, V277, P3935, DOI 10.1074/jbc.M107598200; Zuker M., 1999, V70, P11	56	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37790	37798		10.1074/jbc.M305925200	http://dx.doi.org/10.1074/jbc.M305925200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857728				2022-12-27	WOS:000185437200098
J	Hughey, RP; Mueller, GM; Bruns, JB; Kinlough, CL; Poland, PA; Harkleroad, KL; Carattino, MD; Kleyman, TR				Hughey, RP; Mueller, GM; Bruns, JB; Kinlough, CL; Poland, PA; Harkleroad, KL; Carattino, MD; Kleyman, TR			Maturation of the epithelial Na+ channel involves proteolytic processing of the alpha- and gamma-subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE EXPRESSION; CLATHRIN-MEDIATED ENDOCYTOSIS; SODIUM-CHANNEL; MEMBRANE TOPOLOGY; A6 CELLS; SERINE PROTEASES; COLLECTING DUCT; XENOPUS-OOCYTES; ENAC; BIOSYNTHESIS	The epithelial Na+ channel (ENaC) is a tetramer of two alpha-, one beta-, and one gamma-subunit, but little is known about its assembly and processing. Because co-expression of mouse ENaC subunits with three different carboxyl-terminal epitope tags produced an amiloride-sensitive sodium current in oocytes, these tagged subunits were expressed in both Chinese hamster ovary or Madin-Darby canine kidney type 1 epithelial cells for further study. When expressed alone alpha- (95 kDa), beta- ( 96 kDa), and gamma-subunits ( 93 kDa) each produced a single band on SDS gels by immunoblotting. However, co-expression of alphabetagamma ENaC subunits revealed a second band for each subunit (65 kDa for alpha, 110 kDa for beta, and 75 kDa for gamma) that exhibited N-glycans that had been processed to complex type based on sensitivity to treatment with neuraminidase, resistance to cleavage by endoglycosidase H, and GalNAc-independent labeling with [H-3]Gal in glycosylation-defective Chinese hamster ovary cells (1d1D). The smaller size of the processed alpha- and gamma-subunits is also consistent with proteolytic cleavage. By using alpha- and gamma-subunits with epitope tags at both the amino and carboxyl termini, proteolytic processing of the alpha- and gamma-subunits was confirmed by isolation of an additional epitope-tagged fragment from the amino terminus (30 kDa for alpha and 18 kDa for gamma) consistent with cleavage within the extracellular loop. The fragments remain stably associated with the channel as shown by immunoblotting of co-immunoprecipitates, suggesting that proteolytic cleavage represents maturation rather than degradation of the channel.	Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kleyman, TR (corresponding author), Univ Pittsburgh, Sch Med, Dept Med, Renal Electrolyte Div, Pittsburgh, PA 15213 USA.	kleyman@pitt.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054787, R37DK051391, R01DK051391, R01DK054354] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54354, DK51391, DK54787] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abrami L, 1998, J BIOL CHEM, V273, P32656, DOI 10.1074/jbc.273.49.32656; Adams CM, 1997, J BIOL CHEM, V272, P27295, DOI 10.1074/jbc.272.43.27295; Ahn YJ, 1999, AM J PHYSIOL-RENAL, V277, pF121, DOI 10.1152/ajprenal.1999.277.1.F121; Altschuler Y, 2000, MOL BIOL CELL, V11, P819, DOI 10.1091/mbc.11.3.819; BREITFELD PP, 1989, METHOD CELL BIOL, V32, P329; Bridges RJ, 2001, AM J PHYSIOL-LUNG C, V281, pL16, DOI 10.1152/ajplung.2001.281.1.L16; CANESSA CM, 1994, AM J PHYSIOL-CELL PH, V267, pC1682, DOI 10.1152/ajpcell.1994.267.6.C1682; Cheng C, 1998, J BIOL CHEM, V273, P22693, DOI 10.1074/jbc.273.35.22693; de la Rosa DA, 2002, J GEN PHYSIOL, V119, P427, DOI 10.1085/jgp.20028559; Donaldson SH, 2002, J BIOL CHEM, V277, P8338, DOI 10.1074/jbc.M105044200; Ellgaard L, 2003, NAT REV MOL CELL BIO, V4, P181, DOI 10.1038/nrm1052; Firsov D, 1998, EMBO J, V17, P344, DOI 10.1093/emboj/17.2.344; Guipponi M, 2002, HUM MOL GENET, V11, P2829, DOI 10.1093/hmg/11.23.2829; Hanwell D, 2002, J BIOL CHEM, V277, P9772, DOI 10.1074/jbc.M110904200; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; JEROME KR, 1991, CANCER RES, V51, P2908; Jovov B, 2002, J BIOL CHEM, V277, P4134, DOI 10.1074/jbc.M108354200; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; Kosari F, 1998, J BIOL CHEM, V273, P13469, DOI 10.1074/jbc.273.22.13469; Kubodera T, 2003, NEUROSCI LETT, V341, P74, DOI 10.1016/S0304-3940(03)00156-3; Li JQ, 2003, J BIOL CHEM, V278, P13867, DOI 10.1074/jbc.M300149200; Malik B, 2001, J BIOL CHEM, V276, P12903, DOI 10.1074/jbc.M010626200; Masilamani S, 1999, J CLIN INVEST, V104, pR19, DOI 10.1172/JCI7840; May A, 1997, J AM SOC NEPHROL, V8, P1813; Planes C, 2002, J BIOL CHEM, V277, P47318, DOI 10.1074/jbc.M209158200; Prince LS, 1998, BIOCHEM J, V336, P705, DOI 10.1042/bj3360705; Puliyanda DP, 2003, BIOCHEM BIOPH RES CO, V303, P52, DOI 10.1016/S0006-291X(03)00215-8; RamseyEwing A, 1996, J BIOL CHEM, V271, P16962, DOI 10.1074/jbc.271.28.16962; RENARD S, 1994, J BIOL CHEM, V269, P12981; Rotin D, 2001, AM J PHYSIOL-RENAL, V281, pF391, DOI 10.1152/ajprenal.2001.281.3.F391; Sheng SH, 2001, J BIOL CHEM, V276, P44091, DOI 10.1074/jbc.M108522200; Shimkets RA, 1997, J BIOL CHEM, V272, P25537, DOI 10.1074/jbc.272.41.25537; SNYDER PM, 1994, J BIOL CHEM, V269, P24379; Snyder PM, 1998, J BIOL CHEM, V273, P681, DOI 10.1074/jbc.273.2.681; Staub O, 2000, KIDNEY INT, V57, P809, DOI 10.1046/j.1523-1755.2000.00919.x; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Vallet V, 1997, NATURE, V389, P607, DOI 10.1038/39329; Vallet VR, 2002, J AM SOC NEPHROL, V13, DOI 10.1681/ASN.V133588; Vuagniaux G, 2000, J AM SOC NEPHROL, V11, P828, DOI 10.1681/ASN.V115828; Vuagniaux G, 2002, J GEN PHYSIOL, V120, P191, DOI 10.1085/jgp.20028598; Weisz OA, 2000, J BIOL CHEM, V275, P39886, DOI 10.1074/jbc.M003822200; WEISZ OA, 1994, METHOD CELL BIOL, V43, P137	43	221	221	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37073	37082		10.1074/jbc.M307003200	http://dx.doi.org/10.1074/jbc.M307003200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871941	hybrid			2022-12-27	WOS:000185437200013
J	Panka, DJ; Mier, JW				Panka, DJ; Mier, JW			Canstatin inhibits Akt activation and induces Fas-dependent apoptosis in endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISTINCT ANTITUMOR PROPERTIES; BASEMENT-MEMBRANE COLLAGEN; TRAIL-INDUCED APOPTOSIS; C-FLIP; CYTOCHROME-C; ALPHA(V)BETA(3) INTEGRIN; MEDIATED APOPTOSIS; CELLULAR FLIP; TUMOR-GROWTH; PROTEIN	Canstatin, a 24-kDa peptide derived from the C-terminal globular non-collagenous (NC1) domain of the alpha2 chain of type IV collagen, was previously shown to induce apoptosis in cultured endothelial cells and to inhibit angiogenesis in vitro and in vivo. In this report, we demonstrate that canstatin inhibits the phosphorylation of Akt, focal adhesion kinase, mammalian target of rapamycin, eukaryotic initiation factor-4E-binding protein-1, and ribosomal S6 kinase in cultured human umbilical vein endothelial cells. It also induces Fas ligand expression, activates procaspases 8 and 9 cleavage, reduces mitochondrial membrane potential, and increases cell death ( as determined by propidium iodide staining). Canstatin-induced activation of procaspases 8 and 9 as well as the induced reduction in mitochondrial membrane potential and cell viability were attenuated by the forced expression of FLICE-inhibitory protein. Canstatin-induced procaspase 8 activation and cell death were also inhibited by a neutralizing anti-Fas antibody. Collectively, these data indicate that canstatin-induced apoptosis is associated with phosphatidylinositol 3-kinase/ Akt inhibition and is dependent upon signaling events transduced through membrane death receptors.	Beth Israel Deaconess Med Ctr, Div Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Mier, JW (corresponding author), Beth Israel Deaconess Med Ctr, Div Oncol, Kirstein 158,330 Brookline Ave, Boston, MA 02215 USA.				NCI NIH HHS [CA93683, CA92954] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA093683, R21CA092954] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoudjit F, 2001, J CELL BIOL, V152, P633, DOI 10.1083/jcb.152.3.633; Bannerman DD, 2001, J BIOL CHEM, V276, P14924, DOI 10.1074/jbc.M100819200; Burns TF, 2001, J BIOL CHEM, V276, P37879; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; Colorado PC, 2000, CANCER RES, V60, P2520; Dancey JE, 2002, HEMATOL ONCOL CLIN N, V16, P1101, DOI 10.1016/S0889-8588(02)00051-5; Daugas E, 2000, FEBS LETT, V476, P118, DOI 10.1016/S0014-5793(00)01731-2; Dhanabal M, 1999, CANCER RES, V59, P189; Dixelius J, 2002, CANCER RES, V62, P1944; Djerbi M, 2001, SCAND J IMMUNOL, V54, P180, DOI 10.1046/j.1365-3083.2001.00941.x; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Fukazawa T, 2001, ONCOGENE, V20, P5225, DOI 10.1038/sj.onc.1204673; Griffith TS, 1998, J IMMUNOL, V161, P2833; HARALABOPOULOS GC, 1994, LAB INVEST, V71, P575; Hyer ML, 2002, CANCER BIOL THER, V1, P401, DOI 10.4161/cbt.1.4.15; Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657; JEFFRIES H, 1996, TRANSLATIONAL CONTRO; Kamphaus GD, 2000, J BIOL CHEM, V275, P1209, DOI 10.1074/jbc.275.2.1209; Kandasamy K, 2003, CANCER RES, V63, P1712; Kataoka T, 2000, CURR BIOL, V10, P640, DOI 10.1016/S0960-9822(00)00512-1; Kim Y, 2002, J BIOL CHEM, V277, P22320, DOI 10.1074/jbc.M202458200; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Maeshima Y, 2000, J BIOL CHEM, V275, P23745, DOI 10.1074/jbc.C000186200; Maeshima Y, 2000, J BIOL CHEM, V275, P21340, DOI 10.1074/jbc.M001956200; Maeshima Y, 2002, SCIENCE, V295, P140, DOI 10.1126/science.1065298; Maeshima Y, 2001, J BIOL CHEM, V276, P31959, DOI 10.1074/jbc.M103024200; Maeshima Y, 2001, J BIOL CHEM, V276, P15240, DOI 10.1074/jbc.M007764200; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; PAULSSON M, 1992, CRIT REV BIOCHEM MOL, V27, P93; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; Scaffidi C, 1999, J BIOL CHEM, V274, P1541, DOI 10.1074/jbc.274.3.1541; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; Suhara T, 2001, CIRC RES, V89, P13, DOI 10.1161/hh1301.092506; Tschopp J, 1998, CURR OPIN IMMUNOL, V10, P552, DOI 10.1016/S0952-7915(98)80223-9; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	37	94	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37632	37636		10.1074/jbc.M307339200	http://dx.doi.org/10.1074/jbc.M307339200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12876280	hybrid			2022-12-27	WOS:000185437200078
J	Crist, SA; Griffith, TS; Ratliff, TL				Crist, SA; Griffith, TS; Ratliff, TL			Structure/function analysis of the murine CD95L promoter reveals the identification of a novel transcriptional repressor and functional CD28 response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAS-LIGAND EXPRESSION; INDUCED CELL-DEATH; T-CELLS; COSTIMULATORY SIGNAL; INDUCED APOPTOSIS; UP-REGULATION; C-FLIPSHORT; IN-VIVO; ACTIVATION; TCR	CD28 costimulation, an important second signal for antigen-mediated T cell activation, is known to enhance expression of several genes important for the regulation of CD4+ T cell effector function including interleukin-2 and CD154. Previous studies demonstrate CD28-mediated enhancement of the transcription and expression of Fas ligand (CD95L) in T cell lines, suggesting a regulatory link between CD28 and CD95L expression. These results served as the basis for structure/function analysis of the CD95L promoter to elucidate the mechanism for CD28-mediated enhancement of CD95L. In this report, we describe a novel response element, located at - 210 to - 201 bp upstream of the transcription start site, that confers CD28 responsiveness to the CD95L gene. This response element is homologous to the CD28 response element (CD28RE) previously identified in the IL-2 promoter and bears structural similarities to a newly identified CD28RE in the CD154 promoter. We further demonstrate that CD28-mediated enhancement of promoter activity correlates with enhanced expression of CD95L mRNA, cell surface expression of CD95L protein, and increased apoptosis of CD95+ target cells. These results demonstrate a direct transcriptional regulatory role for CD28 in CD95L-mediated functional activity in CD4+ T cells. Mutational analysis of the CD95L promoter also reveals a novel transcriptional repressor element located similar to 60 bp 5' of the CD28RE. The repressor element bears sequence homology to an activator protein-1 element, constitutively binds c-Fos but not c-Jun, and is activation-independent.	Univ Iowa, Dept Urol, Iowa City, IA 52242 USA; Univ Iowa, Interdisciplinary Grad Program Immunol, Iowa City, IA 52242 USA	University of Iowa; University of Iowa	Ratliff, TL (corresponding author), Dept Urol, 3206 MERF, Iowa City, IA 52245 USA.	Tim-Ratliff@uiowa.edu						ALI SA, 1995, BIOTECHNIQUES, V18, P746; Appleman LJ, 2000, J IMMUNOL, V164, P144, DOI 10.4049/jimmunol.164.1.144; Bruder JM, 1996, MOL ENDOCRINOL, V10, P35, DOI 10.1210/me.10.1.35; Brunner T, 1996, INT IMMUNOL, V8, P1017, DOI 10.1093/intimm/8.7.1017; Brunner T, 1996, Behring Inst Mitt, P161; Coudronniere N, 2000, P NATL ACAD SCI USA, V97, P3394, DOI 10.1073/pnas.060028097; Diehn M, 2002, P NATL ACAD SCI USA, V99, P11796, DOI 10.1073/pnas.092284399; ELKHATIB M, 1995, CELL IMMUNOL, V163, P237, DOI 10.1006/cimm.1995.1122; ETTINGER R, 1995, J IMMUNOL, V154, P4302; Faris M, 1998, J IMMUNOL, V160, P134; Faris M, 1998, MOL CELL BIOL, V18, P5414, DOI 10.1128/MCB.18.9.5414; FRASER JD, 1991, SCIENCE, V251, P313, DOI 10.1126/science.1846244; GRIFFITH TS, 1995, SCIENCE, V270, P1189, DOI 10.1126/science.270.5239.1189; GURNEY AL, 1992, J BIOL CHEM, V267, P18133; Harhaj EW, 1998, J BIOL CHEM, V273, P25185, DOI 10.1074/jbc.273.39.25185; Harhaj EW, 1996, MOL CELL BIOL, V16, P6736; Holtz-Heppelmann CJ, 1998, J BIOL CHEM, V273, P4416, DOI 10.1074/jbc.273.8.4416; JU ST, 1995, NATURE, V373, P444, DOI 10.1038/373444a0; Kasibhatla S, 1999, J BIOL CHEM, V274, P987, DOI 10.1074/jbc.274.2.987; Kirchhoff S, 2000, EUR J IMMUNOL, V30, P2765, DOI 10.1002/1521-4141(200010)30:10<2765::AID-IMMU2765>3.0.CO;2-W; Kirchhoff S, 2000, J IMMUNOL, V165, P6293, DOI 10.4049/jimmunol.165.11.6293; Latinis KM, 1997, J IMMUNOL, V158, P4602; Latinis KM, 1997, J BIOL CHEM, V272, P31427, DOI 10.1074/jbc.272.50.31427; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LI L, 1992, GENE DEV, V6, P676, DOI 10.1101/gad.6.4.676; Li-Weber M, 1998, EUR J IMMUNOL, V28, P2373, DOI 10.1002/(SICI)1521-4141(199808)28:08<2373::AID-IMMU2373>3.0.CO;2-T; Lindgren H, 2001, J IMMUNOL, V166, P4578, DOI 10.4049/jimmunol.166.7.4578; Maggirwar SB, 1997, MOL CELL BIOL, V17, P2605, DOI 10.1128/MCB.17.5.2605; Matsui K, 2000, J IMMUNOL, V164, P3002, DOI 10.4049/jimmunol.164.6.3002; Matsui K, 1998, J IMMUNOL, V161, P3469; Michel F, 2000, J IMMUNOL, V165, P3820, DOI 10.4049/jimmunol.165.7.3820; Michel F, 2001, IMMUNITY, V15, P935, DOI 10.1016/S1074-7613(01)00244-8; Nagel T, 2000, EUR J IMMUNOL, V30, P1632, DOI 10.1002/1521-4141(200006)30:6<1632::AID-IMMU1632>3.0.CO;2-Q; Norian LA, 1998, J IMMUNOL, V161, P1078; Norian LA, 2000, J IMMUNOL, V164, P4471, DOI 10.4049/jimmunol.164.9.4471; Parra E, 2001, J IMMUNOL, V166, P2437, DOI 10.4049/jimmunol.166.4.2437; Riley JL, 2002, P NATL ACAD SCI USA, V99, P11790, DOI 10.1073/pnas.162359999; ROUVIER E, 1993, J EXP MED, V177, P195, DOI 10.1084/jem.177.1.195; Sabelko-Downes KA, 1999, J NEUROIMMUNOL, V100, P42, DOI 10.1016/S0165-5728(99)00191-5; Sabelko-Downes KA, 1999, J EXP MED, V189, P1195, DOI 10.1084/jem.189.8.1195; Sabelko-Downes KA, 2000, CURR OPIN IMMUNOL, V12, P330, DOI 10.1016/S0952-7915(00)00095-9; Shea-Eaton W, 2002, MOL CELL ENDOCRINOL, V188, P161, DOI 10.1016/S0303-7207(01)00715-8; STALDER T, 1994, J IMMUNOL, V152, P1127; Thilenius ARB, 1999, J IMMUNOL, V162, P643; Villalba M, 1999, J IMMUNOL, V163, P5813; Wang JKM, 1997, CELL IMMUNOL, V179, P153, DOI 10.1006/cimm.1997.1159; Wang JKM, 2000, EUR J IMMUNOL, V30, P931; Wang RD, 1996, J IMMUNOL, V157, P2961; Xiao S, 1999, EUR J IMMUNOL, V29, P3456, DOI 10.1002/(SICI)1521-4141(199911)29:11<3456::AID-IMMU3456>3.3.CO;2-2; Zhang J, 1999, J BIOL CHEM, V274, P26537, DOI 10.1074/jbc.274.37.26537; Zhang J, 2000, BBA-GENE STRUCT EXPR, V1490, P291, DOI 10.1016/S0167-4781(99)00212-2	51	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35950	35958		10.1074/jbc.M306220200	http://dx.doi.org/10.1074/jbc.M306220200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855690	hybrid			2022-12-27	WOS:000185318300012
J	Hussain, I; Hawkins, J; Shikotra, A; Riddell, DR; Faller, A; Dingwall, C				Hussain, I; Hawkins, J; Shikotra, A; Riddell, DR; Faller, A; Dingwall, C			Characterization of the ectodomain shedding of the beta-site amyloid precursor protein-cleaving enzyme 1 (BACE1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-ALPHA; CELL-SURFACE; ALZHEIMERS-DISEASE; CONVERTING-ENZYME; MEMBRANE-PROTEINS; SECRETASE CLEAVAGE; DISINTEGRIN; METALLOPROTEINASE; ACTIVATION	Generation of the amyloid peptide through proteolytic processing of the amyloid precursor protein by beta- and gamma-secretases is central to the etiology of Alzheimer's disease. beta-secretase, known more widely as the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), has been identified as a transmembrane aspartic proteinase, and its ectodomain has been reported to be cleaved and secreted from cells in a soluble form. The extracellular domains of many diverse proteins are known to be cleaved and secreted from cells by a process known as ectodomain shedding. Here we confirm that the ectodomain of BACE1 is secreted from cells and that this processing is up-regulated by agents that activate protein kinase C. A metalloproteinase is involved in the cleavage of BACE1 as hydroxamic acid-based metalloproteinase inhibitors abolish the release of shed BACE1. Using potent and selective inhibitors, we demonstrate that ADAM10 is a strong candidate for the BACE1 sheddase. In addition, we show that the BACE1 sheddase is distinct from alpha-secretase and, importantly, that inhibition of BACE1 shedding does not influence amyloid precursor protein processing at the beta-site.	GlaxoSmithKline Res & Dev Ltd, Neurol & Gastrointestinal Ctr Excellence Drug Dis, Harlow CM19 5AW, Essex, England	GlaxoSmithKline	Hussain, I (corresponding author), GlaxoSmithKline Res & Dev Ltd, Neurol & Gastrointestinal Ctr Excellence Drug Dis, New Frontiers Sci Pk,3rd Ave, Harlow CM19 5AW, Essex, England.	Ishrut_2_Hussain@gsk.com						Amit T, 2001, J ENDOCRINOL, V169, P397, DOI 10.1677/joe.0.1690397; ARRIBAS J, 1995, J CELL BIOL, V128, P433, DOI 10.1083/jcb.128.3.433; Arribas J, 1996, J BIOL CHEM, V271, P11376, DOI 10.1074/jbc.271.19.11376; Benjannet S, 2001, J BIOL CHEM, V276, P10879, DOI 10.1074/jbc.M009899200; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Bodendorf U, 2002, J NEUROCHEM, V80, P799, DOI 10.1046/j.0022-3042.2002.00770.x; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Condon TP, 2001, ANTISENSE NUCLEIC A, V11, P107, DOI 10.1089/108729001750171353; Deng P, 1996, J BIOL CHEM, V271, P16338, DOI 10.1074/jbc.271.27.16338; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; HAASS C, 1992, NATURE, V357, P500, DOI 10.1038/357500a0; Hartmann D, 2002, HUM MOL GENET, V11, P2615, DOI 10.1093/hmg/11.21.2615; Hotoda N, 2002, BIOCHEM BIOPH RES CO, V293, P800, DOI 10.1016/S0006-291X(02)00302-9; Howlett DR, 2000, TRENDS NEUROSCI, V23, P565, DOI 10.1016/S0166-2236(00)01647-7; Hundhausen C, 2003, BLOOD, V102, P1186, DOI 10.1182/blood-2002-12-3775; Huse JT, 2000, J BIOL CHEM, V275, P33729, DOI 10.1074/jbc.M004175200; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Lammich S, 1999, P NATL ACAD SCI USA, V96, P3922, DOI 10.1073/pnas.96.7.3922; Lin XL, 2000, P NATL ACAD SCI USA, V97, P1456, DOI 10.1073/pnas.97.4.1456; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; Moss ML, 1997, NATURE, V385, P733, DOI 10.1038/385733a0; Moss ML, 2002, ESSAYS BIOCHEM, V38, P141, DOI 10.1042/bse0380141; Parvathy S, 1999, BIOCHEMISTRY-US, V38, P9728, DOI 10.1021/bi9906827; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Reddy P, 2000, J BIOL CHEM, V275, P14608, DOI 10.1074/jbc.275.19.14608; SELKOE DJ, 1994, ANNU REV CELL BIOL, V10, P373, DOI 10.1146/annurev.cb.10.110194.002105; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; SISODIA SS, 1992, P NATL ACAD SCI USA, V89, P6075, DOI 10.1073/pnas.89.13.6075; Slack BE, 2001, BIOCHEM J, V357, P787, DOI 10.1042/0264-6021:3570787; TEIXIDO J, 1990, J BIOL CHEM, V265, P6410; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WOLFSBERG TG, 1995, J CELL BIOL, V131, P275, DOI 10.1083/jcb.131.2.275; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; YOSHIDA K, 1992, P NATL ACAD SCI USA, V89, P6443, DOI 10.1073/pnas.89.14.6443	36	50	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36264	36268		10.1074/jbc.M304186200	http://dx.doi.org/10.1074/jbc.M304186200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857759	hybrid			2022-12-27	WOS:000185318300049
J	Mikami, T; Mizumoto, S; Kago, N; Kitagawa, H; Sugahara, K				Mikami, T; Mizumoto, S; Kago, N; Kitagawa, H; Sugahara, K			Specificities of three distinct human chondroitin/dermatan N-acetylgalactosamine 4-O-sulfotransferases demonstrated using partially desulfated dermatan sulfate as an acceptor - Implication of differential roles in dermatan sulfate biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-COFACTOR-II; MOLECULAR-CLONING; STRUCTURAL-ANALYSIS; EXPRESSION CLONING; TRANSFERS SULFATE; BOVINE SERUM; ACID; SULFOTRANSFERASE; PROTEOGLYCANS; MIGRATION	4-O-Sulfation of GalNAc is a high frequency modification of chondroitin sulfate and dermatan sulfate (DS), and three major GalNAc 4-O-sulfotransferases including dermatan 4-O-sulfotransferase-1 (D4ST-1) and chondroitin 4-O-sulfotransferases-1 and -2 (C4ST-1 and -2) have been identified. 4-O-Sulfation of GalNAc during DS biosynthesis had long been postulated to be a prerequisite for iduronic acid (IdoUA) formation by C5-epimerization of GlcUA. This hypothesis has recently been argued based on enzymological studies using microsomes that C5-epimerization precedes 4-O-sulfation, which was further supported by the specificity of the cloned D4ST-1 with predominant preference for IdoUA-GalNAc flanked by GlcUA-GalNAc over IdoUA-GalNAc flanked by IdoUA-GalNAc in exhaustively desulfated dermatan. Whereas the counterproposal explains the initial reactions, apparently it cannot rationalize the synthetic mechanism of IdoUA-GalNAc(4-O-sulfate)-rich clusters typical of mature DS chains. In this study, we examined detailed specificities of the three recombinant human 4-O-sulfotransferases using partially desulfated DS as an acceptor. Enzymatic analysis of the transferase reaction products showed that D4ST-1 far more efficiently transferred sulfate to GalNAc residues in -IdoUA-GalNAc-IdoUA- than in -GlcUA-GalNAc-GlcUA-sequences. In contrast, C4ST-1 showed the opposite preference, and C4ST-2 used GalNAc residues in both sequences to comparable degrees, being consistent with its phylogenetic relations to D4ST-1 and C4ST-1. Structural analysis of the oligosaccharides, which were isolated after chondroitinase AC-I digestion of the S-35-labeled transferase reaction products, revealed for the first time that D4ST-1, as compared with C4ST-1 and C4ST-2, most efficiently utilized GalNAc residues located not only in the sequence -IdoUA-GalNAc-IdoUA- but also in -GlcUA-GalNAc-IdoUA- and -IdoUA-GalNAc-GlcUA-. The isolated oligosaccharide structures also suggest that 4-O-sulfation promotes subsequent 4-O-sulfation of GalNAc in the neighboring disaccharide unit.	Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan	Kobe Pharmaceutical University	Sugahara, K (corresponding author), Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, 4-19-1 Motoyamakita Machi, Kobe, Hyogo 6588558, Japan.	k-sugar@kobepharma-u.ac.jp	Kitagawa, Hiroshi/AAJ-1344-2020	Kitagawa, Hiroshi/0000-0002-9307-7079				Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; BAO X, 2003, IN PRESS SEIKAGAKU; Burge CB, 1998, CURR OPIN STRUC BIOL, V8, P346, DOI 10.1016/S0959-440X(98)80069-9; CHENG F, 1994, GLYCOBIOLOGY, V4, P685, DOI 10.1093/glycob/4.5.685; Eklund E, 2000, ARCH BIOCHEM BIOPHYS, V383, P171, DOI 10.1006/abbi.2000.2043; Elefteriou F, 2001, FEBS LETT, V495, P44, DOI 10.1016/S0014-5793(01)02361-4; Evers MR, 2001, J BIOL CHEM, V276, P36344, DOI 10.1074/jbc.M105848200; FAISSNER A, 1994, J CELL BIOL, V126, P783, DOI 10.1083/jcb.126.3.783; Fansson LA, 2000, MATRIX BIOL, V19, P367, DOI 10.1016/S0945-053X(00)00083-4; GATTI G, 1979, CARBOHYD RES, V68, pC3, DOI 10.1016/S0008-6215(00)84070-7; Habuchi O, 2000, BBA-GEN SUBJECTS, V1474, P115, DOI 10.1016/S0304-4165(00)00016-7; Habuchi O, 2000, SEIKAGAKU, V72, P427; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 2001, GLYCOBIOLOGY, V11, P495, DOI 10.1093/glycob/11.6.495; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Iozzo RV, 1999, J BIOL CHEM, V274, P18843, DOI 10.1074/jbc.274.27.18843; Kakuta Y, 1998, TRENDS BIOCHEM SCI, V23, P129, DOI 10.1016/S0968-0004(98)01182-7; Kang HG, 2002, J BIOL CHEM, V277, P34766, DOI 10.1074/jbc.M204907200; Kang HG, 2001, J BIOL CHEM, V276, P10861, DOI 10.1074/jbc.M011560200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kinsella MG, 1997, J BIOL CHEM, V272, P318; KITAGAWA H, 1995, J BIOCHEM-TOKYO, V117, P1083, DOI 10.1093/oxfordjournals.jbchem.a124810; Kitagawa H, 2001, J BIOL CHEM, V276, P4834, DOI 10.1074/jbc.C000835200; KOLSET SO, 1990, BIOCHIM BIOPHYS ACTA, V1032, P191, DOI 10.1016/0304-419X(90)90004-K; LAFONT F, 1992, DEVELOPMENT, V114, P17; LEWANDOWSKA K, 1999, J BIOL CHEM, V274, P11431; Liaw PCY, 2001, J BIOL CHEM, V276, P20959, DOI 10.1074/jbc.M010584200; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; MAIMONE MM, 1990, J BIOL CHEM, V265, P18263; MALMSTRO.A, 1971, EUR J BIOCHEM, V18, P431, DOI 10.1111/j.1432-1033.1971.tb01260.x; MALMSTROM A, 1975, J BIOL CHEM, V250, P3419; MALMSTROM A, 1984, J BIOL CHEM, V259, P161; Merle B, 1999, J CELL BIOCHEM, V75, P538; Nadanaka S, 1999, FEBS LETT, V452, P185, DOI 10.1016/S0014-5793(99)00597-9; NAGASAWA K, 1979, J BIOCHEM-TOKYO, V86, P1323, DOI 10.1093/oxfordjournals.jbchem.a132648; NANDINI CD, 2003, IN PRESS SEIKAGAKU; Okuda T, 2000, J BIOCHEM, V128, P763, DOI 10.1093/oxfordjournals.jbchem.a022813; Okuda T, 2000, J BIOL CHEM, V275, P40605, DOI 10.1074/jbc.M007983200; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Penc SF, 1998, J BIOL CHEM, V273, P28116, DOI 10.1074/jbc.273.43.28116; Qi MS, 2001, J BIOL CHEM, V276, P15868, DOI 10.1074/jbc.M005911200; ROSENBERG LC, 1985, J BIOL CHEM, V260, P6304; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SILBERT JE, 1986, J BIOL CHEM, V261, P3397; Silbert JE, 2002, IUBMB LIFE, V54, P177, DOI 10.1080/15216540214923; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1994, GLYCOBIOLOGY, V4, P535, DOI 10.1093/glycob/4.4.535; Sugahara K, 1996, J BIOL CHEM, V271, P26745, DOI 10.1074/jbc.271.43.26745; SUGAHARA K, 1989, BIOCHEM BIOPH RES CO, V162, P189, DOI 10.1016/0006-291X(89)91980-3; Sugahara K, 1996, EUR J BIOCHEM, V239, P871, DOI 10.1111/j.1432-1033.1996.0871u.x; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; SUGAHARA K, 2003, 17 INT S GLYC BANG I; Sugiyama E, 1997, GLYCOBIOLOGY, V7, P719, DOI 10.1093/glycob/7.5.719; Tiedemann K, 2001, ARCH BIOCHEM BIOPHYS, V391, P65, DOI 10.1006/abbi.2001.2376; TOLLEFSEN DM, 1983, J BIOL CHEM, V258, P6713; Trowbridge JM, 2002, J BIOL CHEM, V277, P42815, DOI 10.1074/jbc.M204959200; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamada S, 1998, EUR J BIOCHEM, V258, P775, DOI 10.1046/j.1432-1327.1998.2580775.x; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523; YAMAGUCHI Y, 1990, NATURE, V346, P281, DOI 10.1038/346281a0; Yamauchi S, 1999, J BIOL CHEM, V274, P2456, DOI 10.1074/jbc.274.4.2456; Yamauchi S, 2000, J BIOL CHEM, V275, P8975, DOI 10.1074/jbc.275.12.8975; Yoshida K., 1993, DERMATAN SULFATE PRO, P55	64	90	96	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36115	36127		10.1074/jbc.M306044200	http://dx.doi.org/10.1074/jbc.M306044200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847091	hybrid			2022-12-27	WOS:000185318300032
J	Murakami, E; Feng, JY; Lee, H; Hanes, J; Johnson, KA; Anderson, KS				Murakami, E; Feng, JY; Lee, H; Hanes, J; Johnson, KA; Anderson, KS			Characterization of novel reverse transcriptase and other RNA-associated catalytic activities by human DNA polymerase gamma - Importance in mitochondrial DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACCESSORY SUBUNIT; R-LOOP; FIDELITY; PROCESSIVITY; MAINTENANCE; INITIATION; MECHANISM; TOXICITY; CLEAVES; ORIGIN	During mitochondrial DNA ( mtDNA) replication, DNA/RNA heteroduplex intermediates are formed. To understand how and why ribonucleotides are involved in mtDNA replication, we have studied the novel RNA-associated activities of human mitochondrial DNA polymerase (Pol gamma), including reverse transcription, RNA-directed 3' --> 5' DNA excision, RNA-primed DNA synthesis, and ribonucleotide incorporation. Remarkably, Pol gamma catalyzes reverse transcription with a slightly higher efficiency than HIV-1 reverse transcriptase, suggesting that the activity may be physiologically significant, and furthermore, proofreading activity with an RNA template was also observed. RNA-primed DNA synthesis activity is required for initiation of mtDNA replication, and we have found that Pol gamma holoenzyme is capable of performing this reaction at a physiologically relevant rate and that the accessory subunit plays an essential role in the initiation steps. Single ribonucleotides have been found scattered in the mtDNA genome, although their role and significance are not yet defined. Our finding that Pol gamma also incorporates ribonucleotide triphosphates into a DNA primer offers a plausible enzymatic pathway for the origin of the RNA-containing mtDNA genome.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Univ Texas, Inst Mol & Cellular Biol, Austin, TX 78712 USA	Yale University; University of Texas System; University of Texas Austin	Anderson, KS (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St, New Haven, CT 06520 USA.	karen.anderson@yale.edu			NIGMS NIH HHS [GM 044613, GM 49551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049551, R01GM044613] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bogenhagen DF, 2001, PROG NUCLEIC ACID RE, V68, P257; Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200; Carrodeguas JA, 1999, MOL CELL BIOL, V19, P4039; Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8; CHANG DD, 1987, EMBO J, V6, P409, DOI 10.1002/j.1460-2075.1987.tb04770.x; CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6; Fan L, 1999, P NATL ACAD SCI USA, V96, P9527, DOI 10.1073/pnas.96.17.9527; Fan L, 2001, BIOCHEMISTRY-US, V40, P4780, DOI 10.1021/bi010102h; Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200; Feng JY, 1999, BIOCHEMISTRY-US, V38, P9440, DOI 10.1021/bi990709m; GALLO RC, 1970, NATURE, V228, P927, DOI 10.1038/228927a0; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1; Iyengar B, 2002, P NATL ACAD SCI USA, V99, P4483, DOI 10.1073/pnas.072664899; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; KATI WM, 1992, J BIOL CHEM, V267, P25988; Kerr SG, 1997, BIOCHEMISTRY-US, V36, P14056, DOI 10.1021/bi971385+; Lee DY, 1998, J BIOL CHEM, V273, P30614, DOI 10.1074/jbc.273.46.30614; Lee DY, 1997, GENE DEV, V11, P582, DOI 10.1101/gad.11.5.582; Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288; Pinz KG, 2000, J BIOL CHEM, V275, P12509, DOI 10.1074/jbc.275.17.12509; RICCHETTI M, 1993, EMBO J, V12, P387, DOI 10.1002/j.1460-2075.1993.tb05670.x; ROBERTGUROFF M, 1977, BIOCHEMISTRY-US, V16, P2866, DOI 10.1021/bi00632a010; Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409; Suo ZC, 1997, BIOCHEMISTRY-US, V36, P12459, DOI 10.1021/bi971217h; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0; Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9	30	38	39	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36403	36409		10.1074/jbc.M306236200	http://dx.doi.org/10.1074/jbc.M306236200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857740	hybrid			2022-12-27	WOS:000185318300068
J	Nyunoya, T; Powers, LS; Yarovinsky, TO; Butler, NS; Monick, MM; Hunninghake, GW				Nyunoya, T; Powers, LS; Yarovinsky, TO; Butler, NS; Monick, MM; Hunninghake, GW			Hyperoxia induces macrophage cell cycle arrest by adhesion-dependent induction of p21(Cip1) and activation of the retinoblastoma protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH ARREST; EPITHELIAL-CELLS; ALVEOLAR MACROPHAGES; OXIDATIVE STRESS; CDK INHIBITORS; LUNG INJURY; DNA-DAMAGE; KINASE; EXPRESSION; P21(WAF1/CIP1)	Hyperoxia induces growth arrest, apoptosis, necrosis, and morphological changes (spreading and adhesion) in various types of cells. The mechanism of hyperoxia-induced cell growth arrest has not been well elucidated, especially in macrophages. One possible mechanism is a role of cell adhesion in hyperoxia-induced cell cycle arrest. To evaluate this finding, macrophages were cultured in normoxia (21% O-2) or hyperoxia (95% O-2) in adhesion or low adhesion conditions. Incubation of macrophages in hyperoxia induced cell cycle arrest. The hyperoxia-induced cell cycle arrest was prevented by low adhesion conditions. To evaluate pathways potentially involved in hyperoxia-induced growth arrest, we measured extracellular regulated kinase and retinoblastoma protein activation and p21(Cip1) and p53 accumulation. Hyperoxia strongly induced activation of extracellular regulated kinase and retinoblastoma protein as well as up-regulation of p21(Cip1). These effects of hyperoxia were attenuated under low adhesion conditions, suggesting a role for integrin-dependent signaling. The induction of p21(Cip1) and activation of retinoblastoma protein occurred via a p53-independent mechanism. These results suggest that adhesion-dependent pathways are required for hyperoxia-induced cell cycle arrest in macrophages.	Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, Iowa City, IA 52242 USA; Vet Adm Med Ctr, Iowa City, IA 52242 USA	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Nyunoya, T (corresponding author), Univ Iowa, Roy J & Lucille A Carver Coll Med, Div Pulm Crit Care & Occupat Med, 100 Ekstein Med Res Bldg, Iowa City, IA 52242 USA.	toru-nyunoya@uiowa.edu	NYUNOYA, TORU/AAX-1482-2021	NYUNOYA, TORU/0000-0002-0688-4607; Butler, Noah/0000-0002-1429-0796	NCRR NIH HHS [RR00059] Funding Source: Medline; NHLBI NIH HHS [HL-60316] Funding Source: Medline; NIEHS NIH HHS [ES-09607] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000059] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL060316] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P01ES009607] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bai FL, 1998, FEBS LETT, V437, P61, DOI 10.1016/S0014-5793(98)01198-3; Bartek J, 1997, EXP CELL RES, V237, P1, DOI 10.1006/excr.1997.3776; Biggs JR, 1996, J BIOL CHEM, V271, P901, DOI 10.1074/jbc.271.2.901; BOWLES AL, 1979, AM REV RESPIR DIS, V120, P541; CACCIUTTOLO MA, 1993, FREE RADICAL BIO MED, V14, P267, DOI 10.1016/0891-5849(93)90023-N; Cheng MG, 1999, EMBO J, V18, P1571, DOI 10.1093/emboj/18.6.1571; Chin YE, 1996, SCIENCE, V272, P719, DOI 10.1126/science.272.5262.719; Chinery R, 1997, NAT MED, V3, P1233, DOI 10.1038/nm1197-1233; Cicchillitti L, 2003, J BIOL CHEM, V278, P19509, DOI 10.1074/jbc.M300511200; COALSON JJ, 1989, J APPL PHYSIOL, V67, P346, DOI 10.1152/jappl.1989.67.1.346; Corroyer S, 1997, ENDOCRINOLOGY, V138, P3677, DOI 10.1210/en.138.9.3677; Corroyer S, 1996, J BIOL CHEM, V271, P25117, DOI 10.1074/jbc.271.41.25117; DAVIS WB, 1983, NEW ENGL J MED, V309, P878, DOI 10.1056/NEJM198310133091502; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Desmarquest P, 1998, RESP MED, V92, P951, DOI 10.1016/S0954-6111(98)90195-0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Gorospe M, 1997, ONCOGENE, V14, P929, DOI 10.1038/sj.onc.1200897; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; Helt CE, 2001, TOXICOL SCI, V63, P214, DOI 10.1093/toxsci/63.2.214; JUNOD AF, 1987, J APPL PHYSIOL, V62, P10, DOI 10.1152/jappl.1987.62.1.10; KELMAN Z, 1995, NUCLEIC ACIDS RES, V23, P3613, DOI 10.1093/nar/23.18.3613; Kinoshita T, 1997, ONCOGENE, V15, P619, DOI 10.1038/sj.onc.1201234; LaBaer J, 1997, GENE DEV, V11, P847, DOI 10.1101/gad.11.7.847; Li YC, 1997, J BIOL CHEM, V272, P20646, DOI 10.1074/jbc.272.33.20646; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MARTIN WJ, 1989, J LAB CLIN MED, V113, P413; Marwick JA, 2002, ANN NY ACAD SCI, V973, P278, DOI 10.1111/j.1749-6632.2002.tb04649.x; McGrath SA, 1998, AM J RESP CELL MOL, V18, P179, DOI 10.1165/ajrcmb.18.2.2964m; Monick MM, 2002, AM J PHYSIOL-LUNG C, V283, pL390, DOI 10.1152/ajplung.00437.2001; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NERURKAR LS, 1988, ANN ALLERGY, V61, P344; O'Reilly MA, 1998, AM J RESP CELL MOL, V19, P777, DOI 10.1165/ajrcmb.19.5.3200; O'Reilly MA, 2003, AM J PHYSIOL-LUNG C, V284, pL368, DOI 10.1152/ajplung.00299.2002; O'Reilly MA, 2001, AM J RESP CELL MOL, V24, P703, DOI 10.1165/ajrcmb.24.6.4355; O'Reilly PJ, 2003, AM J RESP CELL MOL, V28, P443, DOI 10.1165/rcmb.2002-0153OC; Pavletich NP, 1999, J MOL BIOL, V287, P821, DOI 10.1006/jmbi.1999.2640; Petrache I, 1999, AM J PHYSIOL-LUNG C, V277, pL589, DOI 10.1152/ajplung.1999.277.3.L589; Polyak K, 1996, GENE DEV, V10, P1945, DOI 10.1101/gad.10.15.1945; Pumiglia KM, 1997, P NATL ACAD SCI USA, V94, P448, DOI 10.1073/pnas.94.2.448; Rancourt RC, 2002, J CELL PHYSIOL, V193, P26, DOI 10.1002/jcp.10146; Rancourt RC, 2001, AM J PHYSIOL-LUNG C, V280, pL617, DOI 10.1152/ajplung.2001.280.4.L617; SCHOONEN WGEJ, 1990, MUTAT RES, V237, P173; Sewing A, 1997, MOL CELL BIOL, V17, P5588, DOI 10.1128/MCB.17.9.5588; Shenberger JS, 1999, AM J RESP CELL MOL, V21, P395, DOI 10.1165/ajrcmb.21.3.3604; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SUTTORP N, 1983, AM REV RESPIR DIS, V128, P486, DOI 10.1164/arrd.1983.128.3.486; Waga S, 1998, ANNU REV BIOCHEM, V67, P721, DOI 10.1146/annurev.biochem.67.1.721; Weston CR, 2003, ONCOGENE, V22, P1281, DOI 10.1038/sj.onc.1206261; Woods D, 1997, MOL CELL BIOL, V17, P5598, DOI 10.1128/MCB.17.9.5598; Xue LZ, 2000, J BIOL CHEM, V275, P8817, DOI 10.1074/jbc.275.12.8817; Zeng YX, 1997, NAT GENET, V15, P78, DOI 10.1038/ng0197-78	54	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36099	36106		10.1074/jbc.M304370200	http://dx.doi.org/10.1074/jbc.M304370200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847100	hybrid			2022-12-27	WOS:000185318300030
J	Yun, JH; Chae, HD; Choi, TS; Kim, EH; Bang, YJ; Chung, JK; Choi, KS; Mantovani, R; Shin, DY				Yun, JH; Chae, HD; Choi, TS; Kim, EH; Bang, YJ; Chung, JK; Choi, KS; Mantovani, R; Shin, DY			Cdk2-dependent phosphorylation of the NF-Y transcription factor and its involvement in the p53-p21 signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; CCAAT-BINDING PROTEIN; CELL-CYCLE; MACROPHAGE DIFFERENTIATION; IN-VIVO; COMPLEX; CDC2; P53; REPRESSION; GENE	Recent studies have suggested that the NF-Y transcription factor is involved in transcription repression of the cell cycle regulatory genes in a response to p53 induction or DNA damage. Here we demonstrate the cdk2-dependent phosphorylation of NF-Y and its involvement in transcription repression by the p53-p21 signaling pathway. Cdk2 phosphorylates two serine residues near the DNA-binding domain of the YA subunit of NF-Y. Cyclin A-cdk2 appears to associate with NF-Y both in vitro and in vivo. Furthermore, YA protein is phosphorylated in parallel with a cell cycle-dependent activation of cdk2 kinase and cyclin A expression. YA phosphorylation is unnecessary for heterotrimer formation with the YB-YC dimer. However, NF-Y containing a phosphorylation-deficient mutant form of YA, YA-aa, has its DNA binding activity impaired. Consistently, YA-aa inhibits transcription activation of a NF-Y target promoter, cdc2, by cdk2. These results facilitate the elucidation of the regulatory mechanisms of cell cycle progression involving the p21-cdk2-NF-Y signaling pathway.	Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea; Korea Adv Inst Sci & Technol, Dept Biol Sci, Taejon 305333, South Korea; Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110799, South Korea; Ajou Univ, Coll Med, Inst Med Sci, Suwon 442749, South Korea; Univ Modena & Reggio Emilia, Dipartimento Biol Anim, I-41100 Modena, Italy	Dankook University; Korea Advanced Institute of Science & Technology (KAIST); Seoul National University (SNU); Ajou University; Universita di Modena e Reggio Emilia	Shin, DY (corresponding author), Dankook Univ, Coll Med, Dept Microbiol, Natl Res Lab, Cheonan 330714, South Korea.	dreamer@dku.edu	Chae, Hee-Don/D-2620-2011; Kim, Eunhee/Q-9162-2016; Bang, Yung Jue/J-2759-2012; Kim, Eunhee/AAK-3650-2020	Kim, Eunhee/0000-0001-7143-7769; Bang, Yung Jue/0000-0001-6000-4597; Choi, Kyeong Sook/0000-0003-2331-0856				BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; Currie RA, 1998, J BIOL CHEM, V273, P18220, DOI 10.1074/jbc.273.29.18220; de Borja PF, 2001, EMBO J, V20, P5737; DeAzevedo WF, 1997, EUR J BIOCHEM, V243, P518, DOI 10.1111/j.1432-1033.1997.0518a.x; Dieffenbach C.W., 1995, PCR PRIMER LAB MANUA; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; Farina A, 1999, ONCOGENE, V18, P2818, DOI 10.1038/sj.onc.1202472; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HARPER JW, 1993, CELL, V75, P805; HORIKOSHI N, 1995, MOL CELL BIOL, V15, P227, DOI 10.1128/MCB.15.1.227; Jung MS, 2001, ONCOGENE, V20, P5818, DOI 10.1038/sj.onc.1204748; LI XY, 1992, J BIOL CHEM, V267, P8984; MAHESWARAN S, 1995, GENE DEV, V9, P2143, DOI 10.1101/gad.9.17.2143; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Manni I, 2001, J BIOL CHEM, V276, P5570, DOI 10.1074/jbc.M006052200; Mantovani R, 1998, NUCLEIC ACIDS RES, V26, P1135, DOI 10.1093/nar/26.5.1135; MANTOVANI R, 1994, J BIOL CHEM, V269, P20340; Marziali G, 1997, MOL CELL BIOL, V17, P1387, DOI 10.1128/MCB.17.3.1387; Marziali G, 1999, BLOOD, V93, P519, DOI 10.1182/blood.V93.2.519.402a01_519_526; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; Nasmyth K, 1996, SCIENCE, V274, P1643, DOI 10.1126/science.274.5293.1643; Obaya AJ, 2002, CELL MOL LIFE SCI, V59, P126, DOI 10.1007/s00018-002-8410-1; PANG JH, 1993, J BIOL CHEM, V268, P2909; Park M, 2000, CANCER RES, V60, P542; PARK SP, 2001, CANC RES TREAT, V33, P236; Rogatsky I, 1999, J BIOL CHEM, V274, P22296, DOI 10.1074/jbc.274.32.22296; SABBATINI P, 1995, MOL CELL BIOL, V15, P1060; Saville MK, 1998, ONCOGENE, V17, P2679, DOI 10.1038/sj.onc.1202503; SETO E, 1992, P NATL ACAD SCI USA, V89, P12028, DOI 10.1073/pnas.89.24.12028; SHEN YQ, 1994, P NATL ACAD SCI USA, V91, P8940, DOI 10.1073/pnas.91.19.8940; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Sinha S, 1996, MOL CELL BIOL, V16, P328; TOMMASI S, 1995, MOL CELL BIOL, V15, P6901; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	40	64	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36966	36972		10.1074/jbc.M305178200	http://dx.doi.org/10.1074/jbc.M305178200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857729	hybrid, Green Published			2022-12-27	WOS:000185318300131
J	Ose, T; Fujino, A; Yao, M; Watanabe, N; Honma, M; Tanaka, I				Ose, T; Fujino, A; Yao, M; Watanabe, N; Honma, M; Tanaka, I			Reaction intermediate structures of 1-aminocyclopropane-1-carboxylate deaminase - Insight into PLP-dependent cyclopropane ring-opening reaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATE BINDING-SITE; TRYPTOPHAN SYNTHASE; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; ASPARTATE-AMINOTRANSFERASE; SEMIEMPIRICAL CALCULATIONS; 3-DIMENSIONAL STRUCTURE; ACTIVE-SITE; AMINO-ACID; ENZYME	The pyridoxal 5'-phosphate-dependent enzymes have been evolved to catalyze diverse substrates and to cause the reaction to vary. 1-Aminocyclopropane-1-carboxylate deaminase catalyzes the cyclopropane ring-opening reaction followed by deamination specifically. Since it was discovered in 1978, the enzyme has been widely investigated from the mechanistic and physiological viewpoints because the substrate is a precursor of the plant hormone ethylene and the enzymatic reaction includes a cyclopropane ring-opening. We have previously reported the crystal structure of the native enzyme. Here we report the crystal structures of the two reaction intermediates created by the mutagenesis complexed with the substrate. The substrate was validated in the active site of two forms: 1) covalent-bonded external aldimine with the coenzyme in the K51T form and 2) the non-covalent interaction around the coenzyme in the Y295F form. The orientations of the substrate in both structures were quite different form each other. In concert with other site-specific mutation experiments, this experiment revealed the ingenious and unique strategies that are used to achieve the specific activity. The substrate incorporated into the active site is reactivated by a two-phenol charge relay system to lead to the formation of a Schiff base with the coenzyme. The catalytic Lys(51) residue may play a novel role to abstract the methylene proton from the substrate in cooperation with other factors, the carboxylate group of the substrate and the electron-adjusting apparatuses of the coenzyme.	Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan; Hokkaido Univ, Grad Sch Agr, Div Appl Biosci, Sapporo, Hokkaido 0608589, Japan	Hokkaido University; Hokkaido University	Tanaka, I (corresponding author), Hokkaido Univ, Grad Sch Sci, Div Biol Sci, Sapporo, Hokkaido 0600810, Japan.	tanaka@castor.sci.hokudai.ac.jp	yao, min/F-5287-2011; Fujino, Asa/AAG-4722-2020; Watanabe, Nobuhisa/B-1187-2008	yao, min/0000-0003-1687-5904; Fujino, Asa/0000-0003-0652-5222; Watanabe, Nobuhisa/0000-0002-0118-5815				ADAMS DO, 1979, P NATL ACAD SCI USA, V76, P170, DOI 10.1073/pnas.76.1.170; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burkhard P, 1998, J MOL BIOL, V283, P121, DOI 10.1006/jmbi.1998.2037; BURROUGHS LF, 1957, NATURE, V179, P360, DOI 10.1038/179360a0; Campbell BG, 1996, FEMS MICROBIOL LETT, V138, P207, DOI 10.1016/0378-1097(96)00108-5; CLARK PA, 1993, J AM CHEM SOC, V115, P9789, DOI 10.1021/ja00074a053; CLARK PA, 1993, J AM CHEM SOC, V115, P1894, DOI 10.1021/ja00058a039; Clausen T, 1996, J MOL BIOL, V262, P202, DOI 10.1006/jmbi.1996.0508; Denesyuk AI, 2002, J MOL BIOL, V316, P155, DOI 10.1006/jmbi.2001.5310; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; Gallagher DT, 1998, STRUCTURE, V6, P465, DOI 10.1016/S0969-2126(98)00048-3; Glick BR, 1998, J THEOR BIOL, V190, P63, DOI 10.1006/jtbi.1997.0532; GLICK BR, 1994, CAN J MICROBIOL, V40, P911, DOI 10.1139/m94-146; Hayashi H, 1997, BIOCHEMISTRY-US, V36, P13558, DOI 10.1021/bi971638z; HONMA M, 1985, AGR BIOL CHEM TOKYO, V49, P567, DOI 10.1080/00021369.1985.10866774; HONMA M, 1993, BIOSCI BIOTECH BIOCH, V57, P2090, DOI 10.1271/bbb.57.2090; HONMA M, 1978, AGR BIOL CHEM TOKYO, V42, P1825, DOI 10.1080/00021369.1978.10863261; HONMA M, 1986, AGR BIOL CHEM TOKYO, V50, P3189; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACOBSON CB, 1994, CAN J MICROBIOL, V40, P1019, DOI 10.1139/m94-162; Jansonius JN, 1998, CURR OPIN STRUC BIOL, V8, P759, DOI 10.1016/S0959-440X(98)80096-1; Jhee KH, 1998, J BIOL CHEM, V273, P11417, DOI 10.1074/jbc.273.19.11417; Jia YJ, 1999, BIOSCI BIOTECH BIOCH, V63, P542, DOI 10.1271/bbb.63.542; KLEE HJ, 1991, PLANT CELL, V3, P1187, DOI 10.1105/tpc.3.11.1187; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; Li KQ, 1996, J AM CHEM SOC, V118, P8763, DOI 10.1021/ja960822p; LIU HW, 1984, J AM CHEM SOC, V106, P5335, DOI 10.1021/ja00330a050; LU ZC, 1993, J BIOL CHEM, V268, P8727; Meier M, 2001, EMBO J, V20, P3910, DOI 10.1093/emboj/20.15.3910; Minami R, 1998, J BIOCHEM, V123, P1112; Murakami T, 1997, BIOSCI BIOTECH BIOCH, V61, P506, DOI 10.1271/bbb.61.506; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Reed AJ, 1996, J AGR FOOD CHEM, V44, P388, DOI 10.1021/jf9504071; Rhee S, 1997, BIOCHEMISTRY-US, V36, P7664, DOI 10.1021/bi9700429; Shaw JP, 1997, BIOCHEMISTRY-US, V36, P1329, DOI 10.1021/bi961856c; SHEEHY RE, 1991, J BACTERIOL, V173, P5260, DOI 10.1128/jb.173.17.5260-5265.1991; Thomazeau K, 2001, PROTEIN SCI, V10, P638, DOI 10.1110/ps.44301; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; WALSH C, 1981, BIOCHEMISTRY-US, V20, P7509, DOI 10.1021/bi00529a028; WEBER IT, 1978, NATURE, V274, P433, DOI 10.1038/274433a0; Yao M, 2000, J BIOL CHEM, V275, P34557, DOI 10.1074/jbc.M004681200; YU YB, 1979, ARCH BIOCHEM BIOPHYS, V198, P280, DOI 10.1016/0003-9861(79)90420-X; Zhang ZH, 1997, BIOCHEMISTRY-US, V36, P15999, DOI 10.1021/bi971823c	47	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41069	41076		10.1074/jbc.M305865200	http://dx.doi.org/10.1074/jbc.M305865200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882962	hybrid			2022-12-27	WOS:000185847200081
J	Morishima, A; Ohkubo, N; Maeda, N; Miki, T; Mitsuda, N				Morishima, A; Ohkubo, N; Maeda, N; Miki, T; Mitsuda, N			NF kappa B regulates plasma apolipoprotein A-I and high density lipoprotein cholesterol through inhibition of peroxisome proliferator-activated receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; INNOCENT BYSTANDER; APOA-I; EXPRESSION; GENE; TRANSCRIPTION; MICE; SIGNAL; ATHEROSCLEROSIS; ATHEROGENESIS	The levels of plasma HDL cholesterol and apoA-I in NFkappaB p50 subunit-deficient mice were significantly higher than those in wild-type mice under regular and high fat diets, without any significant difference in the level of total cholesterol. To examine the role of NFkappaB in lipid metabolism, we studied its effect on the regulation of apoA-I secretion from human hepatoma HepG2 cells. Lipopolysaccharide-induced activation of NFkappaB reduced the expression of apoA-I mRNA and protein, whereas adenovirus-mediated expression of IkappaBalpha super-repressor ameliorated the reduction. This IkappaBalpha-induced apoA-I increase was blocked by preincubation with MK886, a selective inhibitor of peroxisome proliferator-activated receptor alpha (PPARalpha), suggesting that NFkappaB inactivation induces apoA-I through activation of PPARalpha. To further support this idea, the expression of IkappaBalpha increased apoA-I promoter activity, and this increase was blocked by preincubation with MK886. Mutations in the putative PPARalpha-binding site in the apoA-I promoter or lack of the site abrogated these changes. Taking these results together, inhibition of NFkappaB increases apoA-I and HDL cholesterol through activation of PPARalpha in vivo and in vitro. Our data suggest a new aspect of lipid metabolism and may lead to a new paradigm for prevention and treatment of atherosclerotic disease.	Ehime Univ, Sch Med, Dept Physiol, Shigenobu, Ehime 7910295, Japan; Ehime Univ, Sch Med, Dept Geriatr Med, Shigenobu, Ehime 7910295, Japan	Ehime University; Ehime University	Mitsuda, N (corresponding author), Ehime Univ, Sch Med, Dept Physiol, Shigenobu, Ehime 7910295, Japan.	mitsuda@m.ehime-u.ac.jp						BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; Baroukh N, 2001, FEBS LETT, V502, P16, DOI 10.1016/S0014-5793(01)02621-7; BEG AA, 1995, NATURE, V376, P167, DOI 10.1038/376167a0; Berthou L, 1996, J CLIN INVEST, V97, P2408, DOI 10.1172/JCI118687; Bisgaier CL, 1998, J LIPID RES, V39, P17; Bocher V, 2002, ANN NY ACAD SCI, V967, P7; BRESLOW JL, 1993, CIRCULATION, V87, P16; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; Collins T, 2001, J CLIN INVEST, V107, P255, DOI 10.1172/JCI10373; DeGeest B, 1997, CIRCULATION, V96, P4349; Delerive P, 1999, J BIOL CHEM, V274, P32048, DOI 10.1074/jbc.274.45.32048; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Epinat JC, 1999, ONCOGENE, V18, P6896, DOI 10.1038/sj.onc.1203218; GORDON DJ, 1989, NEW ENGL J MED, V321, P1311; Hsu MH, 2001, J BIOL CHEM, V276, P27950, DOI 10.1074/jbc.M100258200; Jobin C, 1998, J IMMUNOL, V160, P410; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kehrer JP, 2001, BIOCHEM J, V356, P899, DOI 10.1042/0264-6021:3560899; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; Malek G, 2003, AM J PATHOL, V162, P413, DOI 10.1016/S0002-9440(10)63836-9; MALMENDIER CL, 1985, ATHEROSCLEROSIS, V43, P557; Martin G, 2001, J CLIN INVEST, V107, P1423, DOI 10.1172/JCI10852; Mattson MP, 2001, J CLIN INVEST, V107, P247, DOI 10.1172/JCI11916; MILLER GJ, 1975, LANCET, V1, P16; Mitsuda N, 2001, J BIOL CHEM, V276, P9688, DOI 10.1074/jbc.M006153200; NARAYAN KA, 1965, NATURE, V205, P246, DOI 10.1038/205246a0; Navab M, 2002, CIRCULATION, V105, P290, DOI 10.1161/hc0302.103711; NG DS, 1995, ARTERIOSCL THROM VAS, V15, P2157, DOI 10.1161/01.ATV.15.12.2157; Ohkubo N, 2001, J BIOL CHEM, V276, P3046, DOI 10.1074/jbc.M005070200; Peters JM, 1997, J BIOL CHEM, V272, P27307, DOI 10.1074/jbc.272.43.27307; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; SASTRY KN, 1988, MOL CELL BIOL, V8, P605, DOI 10.1128/MCB.8.2.605; Schneider A, 1999, NAT MED, V5, P554, DOI 10.1038/8432; SEN R, 1986, CELL, V47, P921, DOI 10.1016/0092-8674(86)90807-X; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; SHA WC, 1995, CELL, V80, P321, DOI 10.1016/0092-8674(95)90415-8; She MP, 1999, CLIN EXP PHARMACOL P, V26, P833, DOI 10.1046/j.1440-1681.1999.03139.x; SORCITHOMAS M, 1988, J BIOL CHEM, V263, P5183; Srivastava R, 2000, MOL CELL BIOCHEM, V209, P131, DOI 10.1023/A:1007111830472; SRIVASTAVA RAK, 1992, BIOCHIM BIOPHYS ACTA, V1125, P251, DOI 10.1016/0005-2760(92)90053-X; Srivastava RAK, 1998, METH MOL B, V86, P103; Staels B, 1998, ATHEROSCLEROSIS, V137, pS19, DOI 10.1016/S0021-9150(97)00313-4; STAELS B, 1992, ARTERIOSCLER THROMB, V12, P286, DOI 10.1161/01.ATV.12.3.286; Stein O, 1997, P NATL ACAD SCI USA, V94, P9820, DOI 10.1073/pnas.94.18.9820; Sumida A, 2000, BIOCHEM BIOPH RES CO, V267, P756, DOI 10.1006/bbrc.1999.2029; Tak PP, 2001, J CLIN INVEST, V107, P7, DOI 10.1172/JCI11830; Tamatani M, 1999, J BIOL CHEM, V274, P8531, DOI 10.1074/jbc.274.13.8531; Voyiaziakis E, 1998, J LIPID RES, V39, P313; Vu-Dac N, 1998, J BIOL CHEM, V273, P25713, DOI 10.1074/jbc.273.40.25713; VUDAC N, 1994, J BIOL CHEM, V269, P31012; WILLIAMSON R, 1992, P NATL ACAD SCI USA, V89, P7134, DOI 10.1073/pnas.89.15.7134; ZANNIS VI, 1985, BIOCHEMISTRY-US, V24, P4450, DOI 10.1021/bi00337a028	52	60	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38188	38193		10.1074/jbc.M306336200	http://dx.doi.org/10.1074/jbc.M306336200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882972	hybrid			2022-12-27	WOS:000185575100014
J	Hatsell, S; Medina, L; Merola, J; Haltiwanger, R; Cowin, P				Hatsell, S; Medina, L; Merola, J; Haltiwanger, R; Cowin, P			Plakoglobin is O-glycosylated close to the N-terminal destruction box	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME SYSTEM; JUNCTIONAL PLAQUE PROTEIN; ESTROGEN-RECEPTOR-BETA; APC TUMOR-SUPPRESSOR; MUTATIONAL HOT-SPOT; CELL-CELL ADHESION; E-CADHERIN; GENE-PRODUCT; NUCLEOCYTOPLASMIC PROTEINS; TYROSINE PHOSPHORYLATION	Plakoglobin provides a key linkage in protein chains that connect desmosomal and classical cadherins to the cytoskeleton. It is also present in a significant cytosolic pool that has the capacity to impact on canonical Wnt signaling by competing for interaction with partner proteins of beta-catenin. The closely related protein, beta-catenin, is rapidly targeted for proteasomal degradation by phosphorylation of a "destruction box" within the N-terminal domain. Inhibition of this process forms the basis of Wnt signaling. This destruction box is also found in the N-terminal domain of plakoglobin. We report that plakoglobin is modified by the addition of O-GlcNAc at a single site in close proximity to the destruction box. O-GlcNAc modification has been proposed to counteract phosphorylation, provide protection from proteasomal degradation, mediate signal transduction, silence transcription, and regulate multimolecular protein assembly. This finding has potential implications for understanding the roles of plakoglobin.	NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA; NYU, Sch Med, Dept Dermatol, New York, NY 10016 USA; SUNY Stony Brook, Dept Biochem & Cell Biol, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	New York University; New York University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Cowin, P (corresponding author), NYU, Sch Med, Dept Cell Biol, New York, NY 10016 USA.			Merola, Joseph/0000-0001-6514-4353; Cowin, Pamela/0000-0002-1827-1154; Hatsell, Sarah/0000-0003-1103-6087	NIGMS NIH HHS [GM47429] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047429] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; Aicher B, 1997, J CELL BIOL, V138, P681, DOI 10.1083/jcb.138.3.681; Amit S, 2002, GENE DEV, V16, P1066, DOI 10.1101/gad.230302; Bierkamp C, 1996, DEV BIOL, V180, P780, DOI 10.1006/dbio.1996.0346; Bornslaeger EA, 2001, J CELL SCI, V114, P727; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BRADLEY RS, 1993, J CELL BIOL, V123, P1857, DOI 10.1083/jcb.123.6.1857; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; Castano J, 2002, J BIOL CHEM, V277, P31541, DOI 10.1074/jbc.M204376200; Chan SK, 2002, CELL, V111, P265, DOI 10.1016/S0092-8674(02)01037-1; Charpentier E, 2000, J CELL BIOL, V149, P503, DOI 10.1083/jcb.149.2.503; Cheng XG, 2000, BIOCHEMISTRY-US, V39, P11609, DOI 10.1021/bi000755i; Cheng XG, 2001, J BIOL CHEM, V276, P10570, DOI 10.1074/jbc.M010411200; Chitaev NA, 1996, J CELL BIOL, V133, P359, DOI 10.1083/jcb.133.2.359; CHOU CF, 1993, J BIOL CHEM, V268, P4465; CHOU CF, 1992, J BIOL CHEM, V267, P3901; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Comer FI, 2000, J BIOL CHEM, V275, P29179, DOI 10.1074/jbc.R000010200; COWIN P, 1986, CELL, V46, P1063, DOI 10.1016/0092-8674(86)90706-3; Cowin P, 1996, CURR OPIN CELL BIOL, V8, P56, DOI 10.1016/S0955-0674(96)80049-4; Cox RT, 1999, GENETICS, V153, P319; Dong DLY, 1996, J BIOL CHEM, V271, P20845, DOI 10.1074/jbc.271.34.20845; DONG DLY, 1993, J BIOL CHEM, V268, P16679; FRANKE WW, 1989, P NATL ACAD SCI USA, V86, P4027, DOI 10.1073/pnas.86.11.4027; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; GELDERLOOS JA, 1997, CYTOSKELETAL MEMBRAN; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Haltiwanger RS, 1997, J BIOL CHEM, V272, P8752, DOI 10.1074/jbc.272.13.8752; HALTIWANGER RS, 1992, J BIOL CHEM, V267, P9005; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hart GW, 1996, GLYCOBIOLOGY, V6, P711, DOI 10.1093/glycob/6.7.711; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; HINCK L, 1994, J CELL BIOL, V124, P729, DOI 10.1083/jcb.124.5.729; HOSCHUETZKY H, 1994, J CELL BIOL, V127, P1375, DOI 10.1083/jcb.127.5.1375; Huber O, 1996, MECH DEVELOP, V59, P3, DOI 10.1016/0925-4773(96)00597-7; Kamemura K, 2002, J BIOL CHEM, V277, P19229, DOI 10.1074/jbc.M201729200; KANAI Y, 1995, BIOCHEM BIOPH RES CO, V208, P1067, DOI 10.1006/bbrc.1995.1443; KAPPRELL HP, 1987, EUR J BIOCHEM, V166, P505, DOI 10.1111/j.1432-1033.1987.tb13543.x; KARNOVSKY A, 1995, P NATL ACAD SCI USA, V92, P4522, DOI 10.1073/pnas.92.10.4522; KEARSE KP, 1991, P NATL ACAD SCI USA, V88, P1701, DOI 10.1073/pnas.88.5.1701; Klymkowsky MW, 1999, MOL BIOL CELL, V10, P3151, DOI 10.1091/mbc.10.10.3151; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; Kodama S, 1999, J BIOL CHEM, V274, P27682, DOI 10.1074/jbc.274.39.27682; Kolligs FT, 2000, GENE DEV, V14, P1319; KOUKLIS PD, 1994, J CELL BIOL, V127, P1049, DOI 10.1083/jcb.127.4.1049; Kowalczyk AP, 1998, J CELL SCI, V111, P3045; Kowalczyk AP, 1997, J CELL BIOL, V139, P773, DOI 10.1083/jcb.139.3.773; KU NO, 1995, J BIOL CHEM, V270, P11820, DOI 10.1074/jbc.270.20.11820; Legoix P, 1999, ONCOGENE, V18, P4044, DOI 10.1038/sj.onc.1202800; Lickert H, 2000, J BIOL CHEM, V275, P5090, DOI 10.1074/jbc.275.7.5090; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; MATHUR M, 1994, J BIOL CHEM, V269, P14075; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; McKoy G, 2000, LANCET, V355, P2119, DOI 10.1016/S0140-6736(00)02379-5; Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229; Miravet S, 2002, J BIOL CHEM, V277, P1884, DOI 10.1074/jbc.M110248200; Muller T, 1999, J BIOL CHEM, V274, P10173, DOI 10.1074/jbc.274.15.10173; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; NIEHRS C, 1992, J BIOL CHEM, V267, P15938; OCHIAI A, 1994, BIOCHEM BIOPH RES CO, V205, P73, DOI 10.1006/bbrc.1994.2631; Orford K, 1997, J BIOL CHEM, V272, P24735, DOI 10.1074/jbc.272.40.24735; Park WS, 1999, CANCER RES, V59, P4257; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; Roura S, 1999, J BIOL CHEM, V274, P36734, DOI 10.1074/jbc.274.51.36734; Ruiz P, 1996, J CELL BIOL, V135, P215, DOI 10.1083/jcb.135.1.215; SACCO PA, 1995, J BIOL CHEM, V270, P20201, DOI 10.1074/jbc.270.34.20201; Sadot E, 2000, ONCOGENE, V19, P1992, DOI 10.1038/sj.onc.1203519; Salomon D, 1997, J CELL BIOL, V139, P1325, DOI 10.1083/jcb.139.5.1325; SCHMELZ M, 1993, EUR J CELL BIOL, V61, P274; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; SHIBATA T, 1994, BIOCHEM BIOPH RES CO, V203, P519, DOI 10.1006/bbrc.1994.2213; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Smith EA, 1998, J CELL BIOL, V141, P1229, DOI 10.1083/jcb.141.5.1229; Vallorosi CJ, 2000, J BIOL CHEM, V275, P3328, DOI 10.1074/jbc.275.5.3328; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; van de Wetering M, 2002, CELL, V109, pS13, DOI 10.1016/S0092-8674(02)00709-2; van Noort M, 2002, EXP CELL RES, V276, P264, DOI 10.1006/excr.2002.5520; Vosseller K, 2002, CURR OPIN CHEM BIOL, V6, P851, DOI 10.1016/S1367-5931(02)00384-8; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Wahl JK, 2000, J CELL SCI, V113, P1737; Wahl JK, 1996, J CELL SCI, V109, P1143; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Williams BO, 2000, ONCOGENE, V19, P5720, DOI 10.1038/sj.onc.1203921; Witcher LL, 1996, J BIOL CHEM, V271, P10904, DOI 10.1074/jbc.271.18.10904; WITCHER LW, 2000, THESIS NEW YORK U; Yamamoto M, 1997, J BIOL CHEM, V272, P12492, DOI 10.1074/jbc.272.19.12492; Yang XY, 2002, CELL, V110, P69, DOI 10.1016/S0092-8674(02)00810-3; Yang XY, 2001, P NATL ACAD SCI USA, V98, P6611, DOI 10.1073/pnas.111099998; Zhu WJ, 2001, EMBO J, V20, P5999, DOI 10.1093/emboj/20.21.5999; Zhurinsky J, 2000, J CELL SCI, V113, P3127; Zhurinsky J, 2000, MOL CELL BIOL, V20, P4238, DOI 10.1128/MCB.20.12.4238-4252.2000	95	32	34	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37745	37752		10.1074/jbc.M301346200	http://dx.doi.org/10.1074/jbc.M301346200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847106	hybrid			2022-12-27	WOS:000185437200092
J	Pelicano, H; Feng, L; Zhou, Y; Carew, JS; Hileman, EO; Plunkett, W; Keating, MJ; Huang, P				Pelicano, H; Feng, L; Zhou, Y; Carew, JS; Hileman, EO; Plunkett, W; Keating, MJ; Huang, P			Inhibition of mitochondrial respiration - A novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE PROMYELOCYTIC LEUKEMIA; PERSISTENT OXIDATIVE STRESS; ARSENIC TRIOXIDE AS2O3; CYTOCHROME-C RELEASE; SUPEROXIDE-DISMUTASE; FIBROBLAST PROLIFERATION; LIPID-PEROXIDATION; HYDROGEN-PEROXIDE; DNA FRAGMENTATION	Cancer cells are under intrinsic increased oxidative stress and vulnerable to free radical-induced apoptosis. Here, we report a strategy to hinder mitochondrial electron transport and increase superoxide (O-2(radical anion)) radical generation in human leukemia cells as a novel mechanism to enhance apoptosis induced by anticancer agents. This strategy was first tested in a proof-of-principle study using rotenone, a specific inhibitor of mitochondrial electron transport complex I. Partial inhibition of mitochondrial respiration enhances electron leakage from the transport chain, leading to an increase in O-2(radical anion). generation and sensitization of the leukemia cells to anticancer agents whose action involve free radical generation. Using leukemia cells with genetic alterations in mitochondrial DNA and biochemical approaches, we further demonstrated that As2O3, a clinically active anti-leukemia agent, inhibits mitochondrial respiratory function, increases free radical generation, and enhances the activity of another O-2(radical anion) generating agent against cultured leukemia cells and primary leukemia cells isolated from patients. Our study shows that interfering mitochondrial respiration is a novel mechanism by which As2O3 increases generation of free radicals. This novel mechanism of action provides a biochemical basis for developing new drug combination strategies using As2O3 to enhance the activity of anticancer agents by promoting generation of free radicals.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Expt Therapeut, Houston, TX 77030 USA; Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center	Huang, P (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Pathol, 1515 Holcombe Blvd,Box 89, Houston, TX 77030 USA.	phuang@mdanderson.org		Hileman, Elizabeth/0000-0001-6822-9571	NCI NIH HHS [CA100428, CA77339, CA81534, CA85563] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA077339, R01CA100428, R01CA085563, P01CA081534, P20CA081534] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Chan TS, 2002, FREE RADICAL RES, V36, P421, DOI 10.1080/10715760290021270; Chandel NS, 1998, P NATL ACAD SCI USA, V95, P11715, DOI 10.1073/pnas.95.20.11715; Chen GQ, 1996, BLOOD, V88, P1052; Chen YC, 1998, J CELL PHYSIOL, V177, P324, DOI 10.1002/(SICI)1097-4652(199811)177:2<324::AID-JCP14>3.0.CO;2-9; CHESON BD, 1988, AM J HEMATOL, V29, P152, DOI 10.1002/ajh.2830290307; Devi GS, 2000, CLIN CHIM ACTA, V293, P53, DOI 10.1016/S0009-8981(99)00222-3; EMAUS RK, 1986, BIOCHIM BIOPHYS ACTA, V850, P436, DOI 10.1016/0005-2728(86)90112-X; Esposti MD, 1998, BBA-BIOENERGETICS, V1364, P222, DOI 10.1016/S0005-2728(98)00029-2; Fang J, 2002, CANCER RES, V62, P3138; Fantin VR, 2002, CANCER CELL, V2, P29, DOI 10.1016/S1535-6108(02)00082-X; Fujimura M, 1999, J NEUROSCI, V19, P3414; Gao CF, 2001, EXP CELL RES, V265, P145; Golab J, 2003, J BIOL CHEM, V278, P407, DOI 10.1074/jbc.M209125200; Hail N, 2001, CANCER RES, V61, P6698; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; Heiskanen KM, 1999, J BIOL CHEM, V274, P5654, DOI 10.1074/jbc.274.9.5654; Hileman E. O., 2001, EXPERT OPIN THER TAR, V5, P679; Huang P, 2000, LEUKEMIA, V14, P1405, DOI 10.1038/sj.leu.2401845; Huang P, 1995, CLIN CANCER RES, V1, P1005; Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140; Iwama K, 2001, INT J CANCER, V92, P518, DOI 10.1002/ijc.1220; King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4; Kondo S, 1999, FREE RADICAL BIO MED, V27, P401, DOI 10.1016/S0891-5849(99)00087-8; Li NY, 2003, J BIOL CHEM, V278, P8516, DOI 10.1074/jbc.M210432200; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Macip S, 2002, EMBO J, V21, P2180, DOI 10.1093/emboj/21.9.2180; Martin KR, 2002, HUM EXP TOXICOL, V21, P71, DOI 10.1191/0960327102ht213oa; MCCORD JM, 1995, P SOC EXP BIOL MED, V209, P112; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NICOLETTI I, 1991, J IMMUNOL METHODS, V139, P271, DOI 10.1016/0022-1759(91)90198-O; NICOTERA TM, 1994, CANCER RES, V54, P3884; Nishimura G, 2001, FEBS LETT, V505, P399, DOI 10.1016/S0014-5793(01)02859-9; Niu C, 1999, BLOOD, V94, P3315, DOI 10.1182/blood.V94.10.3315.422k16_3315_3324; Preeta R, 1999, J MOL CELL CARDIOL, V31, P1573, DOI 10.1006/jmcc.1999.0994; Reed JC, 1997, CELL, V91, P559, DOI 10.1016/S0092-8674(00)80442-0; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROBERTSON LE, 1993, BLOOD, V81, P143; Saybasili H, 2001, ANTIOXID REDOX SIGN, V3, P1099, DOI 10.1089/152308601317203602; Shao WL, 1998, J NATL CANCER I, V90, P124, DOI 10.1093/jnci/90.2.124; Shen ZX, 1997, BLOOD, V89, P3354, DOI 10.1182/blood.V89.9.3354; Simon HU, 2000, APOPTOSIS, V5, P415, DOI 10.1023/A:1009616228304; Smith TAD, 2000, BRIT J BIOMED SCI, V57, P170; Staniek K, 2002, FREE RADICAL RES, V36, P381, DOI 10.1080/10715760290021225; SZATROWSKI TP, 1991, CANCER RES, V51, P794; Toyokuni S, 1998, BIOTHERAPY, V11, P147, DOI 10.1023/A:1007934229968; TOYOKUNI S, 1995, FEBS LETT, V358, P1, DOI 10.1016/0014-5793(94)01368-B; Wang TS, 1996, J CELL PHYSIOL, V169, P256, DOI 10.1002/(SICI)1097-4652(199611)169:2<256::AID-JCP5>3.0.CO;2-N; WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309; Wei YH, 1996, ANN NY ACAD SCI, V786, P24, DOI 10.1111/j.1749-6632.1996.tb39049.x; Wood L, 2001, ANTI-CANCER DRUG DES, V16, P209; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zhou Y, 2003, BLOOD, V101, P4098, DOI 10.1182/blood-2002-08-2512	52	397	415	0	34	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37832	37839		10.1074/jbc.M301546200	http://dx.doi.org/10.1074/jbc.M301546200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853461	hybrid			2022-12-27	WOS:000185437200103
J	Zou, H; Lee, J; Umamoto, S; Kilani, AF; Kim, J; Trang, P; Zhou, TH; Liu, FY				Zou, H; Lee, J; Umamoto, S; Kilani, AF; Kim, J; Trang, P; Zhou, TH; Liu, FY			Engineered RNase P ribozymes are efficient in cleaving a human cytomegalovirus mRNA in vitro and are effective in inhibiting viral gene expression and growth in human cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEASE-P; SUBSTRATE-BINDING; ESCHERICHIA-COLI; HAMMERHEAD RIBOZYMES; PROTEIN COFACTOR; ENZYME; SELECTION; CLEAVAGE; INVITRO; SUBUNIT	By using an in vitro selection procedure, we have previously isolated RNase P ribozyme variants that efficiently cleave an mRNA sequence in vitro. In this study, a ribozyme variant was used to target the overlapping region of the mRNAs encoding human cytomegalovirus ( HCMV) major transcription regulatory proteins IE1 and IE2. The variant is about 90 times more efficient in cleaving the IE1/IE2 mRNA sequence in vitro than the ribozyme derived from the wild type RNase P ribozyme. Our results provide the first direct evidence that a point mutation at nucleotide position 80 of RNase P catalytic RNA from Escherichia coli (U-80-->C-80) increases the rate of chemical cleavage, and another mutation at nucleotide position 188 (C-188-->U-188) enhances substrate binding of the ribozyme. Moreover, the variant is more effective in inhibiting viral IE1 and IE2 expression and growth in HCMV-infected cells than the wild type ribozyme. A reduction of about 99% in the expression level of IE1 and IE2 and a reduction of 10,000-fold in viral growth were observed in cells that expressed the variant. In contrast, a reduction of less than 10% in IE1/IE2 expression and viral growth was observed in cells that either did not express the ribozyme or produced a catalytically inactive ribozyme mutant. Thus, engineered RNase P ribozyme variants are highly effective in inhibiting HCMV gene expression and growth. These results also demonstrate the feasibility of engineering highly effective RNase P ribozymes for gene targeting applications, including anti-HCMV gene therapy.	Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Liu, FY (corresponding author), Univ Calif Berkeley, Sch Publ Hlth, Program Infect Dis & Immun, Program Comparat Biochem, 140 Warren Hall, Berkeley, CA 94720 USA.	liu_fy@uclink4.berkeley.edu		Lee, Jarone/0000-0002-4532-8523	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041927] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM054815] Funding Source: NIH RePORTER; NIAID NIH HHS [AI41927] Funding Source: Medline; NIGMS NIH HHS [GM54815] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altman S., 1999, RNA WORLD, P351; ARES M, 1990, GENE DEV, V4, P2132, DOI 10.1101/gad.4.12a.2132; BERTRAND EL, 1994, EMBO J, V13, P2904, DOI 10.1002/j.1460-2075.1994.tb06585.x; BERZALHERRANZ A, 1992, GENE DEV, V6, P129, DOI 10.1101/gad.6.1.129; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; Chen JL, 1998, EMBO J, V17, P1515, DOI 10.1093/emboj/17.5.1515; Cobaleda C, 2000, BLOOD, V95, P731, DOI 10.1182/blood.V95.3.731.003k28_731_737; DAS G, 1988, EMBO J, V7, P503, DOI 10.1002/j.1460-2075.1988.tb02838.x; FEDOR MJ, 1992, BIOCHEMISTRY-US, V31, P12042, DOI 10.1021/bi00163a012; FORSTER AC, 1990, SCIENCE, V249, P783, DOI 10.1126/science.1697102; FRANK DN, 1994, BIOCHEMISTRY-US, V33, P10800, DOI 10.1021/bi00201a030; Frank DN, 1998, ANNU REV BIOCHEM, V67, P153, DOI 10.1146/annurev.biochem.67.1.153; Gold L., 1993, RNA WORLD, P497; Greaves RF, 1998, J VIROL, V72, P366, DOI 10.1128/JVI.72.1.366-379.1998; GREEN R, 1990, NATURE, V347, P406, DOI 10.1038/347406a0; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; Haas ES, 1998, NUCLEIC ACIDS RES, V26, P4093, DOI 10.1093/nar/26.18.4093; HAAS ES, 1994, P NATL ACAD SCI USA, V91, P2527, DOI 10.1073/pnas.91.7.2527; Hsu AW, 2000, NUCLEIC ACIDS RES, V28, P3105, DOI 10.1093/nar/28.16.3105; JOYCE GF, 1992, SCI AM, V267, P90, DOI 10.1038/scientificamerican1292-90; Kawa D, 1998, RNA, V4, P1397, DOI 10.1017/S1355838298980918; Kilani AF, 1999, RNA, V5, P1235, DOI 10.1017/S1355838299990672; Kilani AF, 2000, J BIOL CHEM, V275, P10611, DOI 10.1074/jbc.275.14.10611; Kim JJ, 1997, RNA, V3, P613; Krasilnikov AS, 2003, NATURE, V421, P760, DOI 10.1038/nature01386; Lan N, 1998, SCIENCE, V280, P1593, DOI 10.1126/science.280.5369.1593; LIU FY, 1991, J VIROL, V65, P5149, DOI 10.1128/JVI.65.10.5149-5156.1991; LIU FY, 1995, GENE DEV, V9, P471, DOI 10.1101/gad.9.4.471; Marchini A, 2001, J VIROL, V75, P1870, DOI 10.1128/JVI.75.4.1870-1878.2001; Massire C, 1998, J MOL BIOL, V279, P773, DOI 10.1006/jmbi.1998.1797; MCCLAIN WH, 1987, SCIENCE, V238, P527, DOI 10.1126/science.2443980; MILLER AD, 1989, BIOTECHNIQUES, V7, P980; Mocarski E.S., 2001, FIELDS VIROLOGY, V4th Edn, P2629; NAKAMAYE KL, 1994, BIOCHEMISTRY-US, V33, P1271, DOI 10.1021/bi00171a030; PASS RF, 2001, FIELDS VIROLOGY, P2675; Putlitz JZ, 1999, J VIROL, V73, P4188, DOI 10.1128/JVI.73.5.4188-4196.1999; PYLE AM, 1990, P NATL ACAD SCI USA, V87, P8187, DOI 10.1073/pnas.87.21.8187; ROBERTSON DL, 1990, NATURE, V344, P467, DOI 10.1038/344467a0; Rossi JJ, 1999, CHEM BIOL, V6, pR33, DOI 10.1016/S1074-5521(99)80001-5; SARVER N, 1990, SCIENCE, V247, P1222, DOI 10.1126/science.2107573; SMITH D, 1993, BIOCHEMISTRY-US, V32, P5273, DOI 10.1021/bi00071a001; SMITH D, 1992, J BIOL CHEM, V267, P2429; STENBERG RM, 1989, J VIROL, V63, P2699, DOI 10.1128/JVI.63.6.2699-2708.1989; STENBERG RM, 1985, J VIROL, V56, P665, DOI 10.1128/JVI.56.3.665-675.1985; SZOSTAK JW, 1992, TRENDS BIOCHEM SCI, V17, P89, DOI 10.1016/0968-0004(92)90242-2; Tang J, 1997, RNA, V3, P914; Trang P, 1999, NUCLEIC ACIDS RES, V27, P4590, DOI 10.1093/nar/27.23.4590; Trang P, 2000, P NATL ACAD SCI USA, V97, P5812, DOI 10.1073/pnas.100101797; Tsai HY, 2003, J MOL BIOL, V325, P661, DOI 10.1016/S0022-2836(02)01267-6; Wong-Staal F, 1998, HUM GENE THER, V9, P2407, DOI 10.1089/hum.1998.9.16-2407; YU M, 1993, P NATL ACAD SCI USA, V90, P6340, DOI 10.1073/pnas.90.13.6340; YUAN Y, 1992, P NATL ACAD SCI USA, V89, P8006, DOI 10.1073/pnas.89.17.8006; ZAUG AJ, 1995, RNA, V1, P363; Zhu H, 1997, P NATL ACAD SCI USA, V94, P13985, DOI 10.1073/pnas.94.25.13985	54	14	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37265	37274		10.1074/jbc.M303531200	http://dx.doi.org/10.1074/jbc.M303531200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867424	hybrid			2022-12-27	WOS:000185437200035
J	Wu, XL; Chen, JJ				Wu, XL; Chen, JJ			Autophosphorylation of checkpoint kinase 2 at serine 516 is required for radiation-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; ATAXIA-TELANGIECTASIA; TUMOR-SUPPRESSOR; CDS1 CHK2; PHOSPHORYLATION; ACTIVATION; ATM; P53; THREONINE-68; RESPONSES	In response to ionizing radiation, checkpoint kinase 2 (Chk2) is activated in an ataxia telangiectasia mutation-dependent manner and induces either cell cycle arrest or apoptosis. Chk2 is also autophosphorylated following DNA damage. It is proposed that autophosphorylation of Chk2 may contribute to Chk2 activation. To fully understand the regulation of Chk2, we mapped an in vitro Chk2 autophosphorylation site at C-terminal serine 516 site (Ser-516). Ser-516 of Chk2 is phosphorylated following radiation in vivo, and this phosphorylation depends on the kinase activity of Chk2. Mutation of this autophosphorylation site (S516A) results in reduced Chk2 kinase activity, suggesting that Chk2 autophosphorylation is required for full kinase activation following DNA damage. Moreover, the S516A mutant of Chk2 is defective in ionizing radiation-induced apoptosis, suggesting that Chk2 autophosphorylation is critical for Chk2 function following DNA damage.	Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA	Mayo Clinic	Chen, JJ (corresponding author), Mayo Clin & Mayo Fdn, Dept Oncol, Rochester, MN 55905 USA.	chen.junjie@mayo.edu			NCI NIH HHS [R01 CA92312] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092312] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHN J, 2002, J BIOL CHEM, V16, P16; Ahn JY, 2002, J BIOL CHEM, V277, P19389, DOI 10.1074/jbc.M200822200; Bell DW, 1999, SCIENCE, V286, P2528, DOI 10.1126/science.286.5449.2528; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Chehab NH, 2000, GENE DEV, V14, P278; Curman D, 2001, J BIOL CHEM, V276, P17914, DOI 10.1074/jbc.M100728200; Dasika GK, 1999, ONCOGENE, V18, P7883, DOI 10.1038/sj.onc.1203283; Falck J, 2002, NAT GENET, V30, P290, DOI 10.1038/ng845; Falck J, 2001, NATURE, V410, P842, DOI 10.1038/35071124; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hirao A, 2002, MOL CELL BIOL, V22, P6521, DOI 10.1128/MCB.22.18.6521-6532.2002; Jack MT, 2002, P NATL ACAD SCI USA, V99, P9825, DOI 10.1073/pnas.152053599; Jallepalli PV, 2003, J BIOL CHEM, V278, P20475, DOI 10.1074/jbc.M213159200; Lee CH, 2001, J BIOL CHEM, V276, P30537, DOI 10.1074/jbc.M104414200; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; McGowan CH, 2002, BIOESSAYS, V24, P502, DOI 10.1002/bies.10101; Melchionna R, 2000, NAT CELL BIOL, V2, P762, DOI 10.1038/35036406; MEYN MS, 1995, CANCER RES, V55, P5991; Peters M, 2002, P NATL ACAD SCI USA, V99, P11305, DOI 10.1073/pnas.172382899; Rouse J, 2002, SCIENCE, V297, P547, DOI 10.1126/science.1074740; Shieh SY, 2000, GENE DEV, V14, P289; Takai H, 2002, EMBO J, V21, P5195, DOI 10.1093/emboj/cdf506; Ward IM, 2001, J BIOL CHEM, V276, P47755, DOI 10.1074/jbc.C100587200; Wu XL, 2001, J BIOL CHEM, V276, P2971, DOI 10.1074/jbc.M009727200; Xu JH, 2001, FEBS LETT, V508, P394, DOI 10.1016/S0014-5793(01)03103-9; Xu XZ, 2002, MOL CELL BIOL, V22, P4419, DOI 10.1128/MCB.22.12.4419-4432.2002; YANG S, 2002, NAT CELL BIOL, V28, P28; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	31	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36163	36168		10.1074/jbc.M303795200	http://dx.doi.org/10.1074/jbc.M303795200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855706	hybrid			2022-12-27	WOS:000185318300037
J	Ignatovich, IA; Dizhe, EB; Pavlotskaya, AV; Akifiev, BN; Burov, SV; Orlov, SV; Perevozchikov, AP				Ignatovich, IA; Dizhe, EB; Pavlotskaya, AV; Akifiev, BN; Burov, SV; Orlov, SV; Perevozchikov, AP			Complexes of plasmid DNA with basic domain 47-57 of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY MODIFIED ALBUMINS; ARGININE-RICH PEPTIDES; IN-VIVO; INTRACELLULAR DELIVERY; GENE DELIVERY; POLYELECTROLYTE COMPLEXES; METABOLIC-INHIBITORS; PENETRATING PEPTIDES; BINDING PROTEINS; CELLULAR UPTAKE	Arginine-rich peptides, penetratins, as part of a number of cellular and viral proteins, can penetrate across plasma membrane directly, without participation of endocytosis. We show that one of penetratins, the basic domain 47-57 of human immunodeficiency virus, type 1, transcription factor Tat (Tat peptide), is able to interact with plasmid DNA electrostatically. These interactions result in formation of polyelectrolytic complexes at various negative/positive charge ratios of plasmid DNA and Tat peptide. Plasmid DNA is capable of binding to Tat peptide up to 1.7-fold excess of the complex positive charge. The DNA-Tat complexes can be used for delivery of plasmid DNA into mammalian cells. Transfection efficacy of cultured cells by DNA-Tat complexes is stimulated by free Tat peptide, most likely because it protects DNA-Tat complexes from disruption by anionic proteoglycans of cellular surface. Our data strongly argue in favor of the endocytosis-dependent mechanism of DNA-Tat complex uptake by mammalian cells similarly to internalization of complexes of plasmid DNA with other polycationic carriers. Moreover, different cell lines use different endocytosis-mediated pathways for DNA-Tat complex internalization. Intravenous injections to mice of DNA-Tat complexes in comparison with injections of naked DNA showed an inhibitory effect of DNA-Tat complex positive charge on expression of transferred gene. A low level of foreign gene expression in the liver of mice injected intravenously with positively charged DNA-Tat complexes is accounted for by inactivation of DNA-Tat complexes in the bloodstream due to their interactions with serum albumin. These data should be taken into account in an attempt to develop versatile gene delivery systems based on penetratin application for human disease therapy.	Russian Acad Med Sci, Dept Biochem, Inst Expt Med, St Petersburg 197376, Russia; St Petersburg State Univ, Dept Cell Biol, St Petersburg 199034, Russia; Russian Acad Sci, Inst Macromol Cpds, Lab Peptide Synth, St Petersburg 199004, Russia; St Petersburg State Univ, Dept Embryol, St Petersburg 199034, Russia	Institute of Experimental Medicine; Russian Academy of Medical Sciences; Saint Petersburg State University; Russian Academy of Sciences; Institute of Macromolecular Compounds of the Russian Academy of Sciences; Saint Petersburg State University	Orlov, SV (corresponding author), Russian Acad Med Sci, Dept Biochem, Inst Expt Med, Acad Pavlov St 12, St Petersburg 197376, Russia.		Orlov, Sergey V./N-6823-2014; Dizhe, Ella B./N-6842-2014; Burov, Sergey/P-7225-2015; Perevozchikov, Andrej/M-9744-2015	Orlov, Sergey V./0000-0002-3134-1989; Burov, Sergey/0000-0003-3607-5680; Perevozchikov, Andrej/0000-0001-7049-3224; Dizhe, Ella/0000-0001-5147-4749				ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; *APPL BIOS INC, 1990, INTR CLEAV TECHN; BERLOSE JP, 1996, EUR J BIOCHEM, V271, P18188; BUROV SV, 2002, J PEPT SCI, V8, P188; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dash PR, 1999, GENE THER, V6, P643, DOI 10.1038/sj.gt.3300843; Derossi D, 1998, TRENDS CELL BIOL, V8, P84, DOI 10.1016/S0962-8924(97)01214-2; Dizhe EB, 2001, BIOCHEMISTRY-MOSCOW+, V66, P55, DOI 10.1023/A:1002881612906; DIZHE EB, 2001, RUS J HIV AIDS RELAT, V5, P112; Eguchi A, 2001, J BIOL CHEM, V276, P26204, DOI 10.1074/jbc.M010625200; Futaki S, 2001, BIOCONJUGATE CHEM, V12, P1005, DOI 10.1021/bc015508l; Gottschalk S, 1996, GENE THER, V3, P448; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Haines AMR, 2001, GENE THER, V8, P99, DOI 10.1038/sj.gt.3301314; Ignatovich I A, 2002, Tsitologiia, V44, P455; Jeang KT, 1999, J BIOL CHEM, V274, P28837, DOI 10.1074/jbc.274.41.28837; Kobayashi N, 2001, J PHARMACOL EXP THER, V297, P853; Kramer SD, 2003, BBA-BIOMEMBRANES, V1609, P161, DOI 10.1016/S0005-2736(02)00683-1; Kurzchalia TV, 1999, CURR OPIN CELL BIOL, V11, P424, DOI 10.1016/S0955-0674(99)80061-1; Liu F, 1999, GENE THER, V6, P1258, DOI 10.1038/sj.gt.3300947; MCVICAR JP, 1984, P NATL ACAD SCI-BIOL, V81, P1356, DOI 10.1073/pnas.81.5.1356; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Niidome T, 1999, BIOCONJUGATE CHEM, V10, P773, DOI 10.1021/bc990012d; Osaka G, 1996, J PHARM SCI, V85, P612, DOI 10.1021/js9504494; Perevozchikov A. P., 1997, Molekulyarnaya Biologiya (Moscow), V31, P216; Polyakov V, 2000, BIOCONJUGATE CHEM, V11, P762, DOI 10.1021/bc000008y; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Richard JP, 2003, J BIOL CHEM, V278, P585, DOI 10.1074/jbc.M209548200; Rudolph C, 2003, J BIOL CHEM, V278, P11411, DOI 10.1074/jbc.M211891200; Rusnati M, 1998, J BIOL CHEM, V273, P16027, DOI 10.1074/jbc.273.26.16027; Rusnati M, 1997, J BIOL CHEM, V272, P11313, DOI 10.1074/jbc.272.17.11313; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; Schaffer DV, 1998, J BIOL CHEM, V273, P28004, DOI 10.1074/jbc.273.43.28004; SCHNITZER JE, 1993, J BIOL CHEM, V268, P7562; SCHNITZER JE, 1992, J BIOL CHEM, V267, P24544; Schwarze SR, 1999, SCIENCE, V285, P1569, DOI 10.1126/science.285.5433.1569; Schwarze SR, 2000, TRENDS PHARMACOL SCI, V21, P45, DOI 10.1016/S0165-6147(99)01429-7; Sobolev AS, 1998, J BIOL CHEM, V273, P7928, DOI 10.1074/jbc.273.14.7928; Suzuki T, 2002, J BIOL CHEM, V277, P2437, DOI 10.1074/jbc.M110017200; Torchilin VP, 2001, P NATL ACAD SCI USA, V98, P8786, DOI 10.1073/pnas.151247498; Tyagi M, 2001, J BIOL CHEM, V276, P3254, DOI 10.1074/jbc.M006701200; Vives E, 1997, J BIOL CHEM, V272, P16010, DOI 10.1074/jbc.272.25.16010; Weber PJA, 1998, BIOORG MED CHEM LETT, V8, P597, DOI 10.1016/S0960-894X(98)00084-5; Wender PA, 2000, P NATL ACAD SCI USA, V97, P13003, DOI 10.1073/pnas.97.24.13003; Wolfert MA, 1996, GENE THER, V3, P269; Zuhorn IS, 2002, J BIOL CHEM, V277, P18021, DOI 10.1074/jbc.M111257200	46	172	186	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42625	42636		10.1074/jbc.M301431200	http://dx.doi.org/10.1074/jbc.M301431200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12882958	hybrid			2022-12-27	WOS:000185989500128
J	Price, NJ; Pinheiro, C; Soares, CM; Ashford, DA; Ricardo, CP; Jackson, PA				Price, NJ; Pinheiro, C; Soares, CM; Ashford, DA; Ricardo, CP; Jackson, PA			A biochemical and molecular characterization of LEP1, an extensin peroxidase from lupin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROXYPROLINE-RICH GLYCOPROTEINS; OXIDATIVE CROSS-LINKING; HORSERADISH-PEROXIDASE; SUSPENSION-CULTURES; CRYSTAL-STRUCTURE; PLANT PEROXIDASE; CELL-DIVISION; FERULIC ACID; AMINO-ACID; IN-VITRO	An analysis of apoplastic extensin cross-linking activity in vegetative organs of Lupinus albus indicated that leaves contained the highest specific activity. Assays of peroxidases fractionated from this material demonstrated that this activity could be largely attributed to a soluble and apoplastic 51-kDa peroxidase, denoted LEP1. Relative to other purified peroxidases, LEP1 demonstrates high extensin cross-linking activity and can be classified as an extensin peroxidase (EP). Optimal conditions for the in vitro oxidation of other phenolic substrates included 1.5-3.0 mM peroxide at pH 5.0. EP activity of LEP1 was low under these conditions but optimal and substantially higher with 100 muM peroxide and neutral pH, suggesting that physiological changes in pH and peroxide in muro could heavily influence the extensin cross-linking activity of LEP1 in vivo. Analysis of LEP1 glycans indicated 11-12 N-linked glycans, predominantly the heptasaccharide Man(3)XylFucGlcNAc(2), but also larger structures showing substantial heterogeneity. Comparative assays with horseradish peroxidase isoform C and peanut peroxidases suggested the high level of glycosylation in LEP1 may be responsible for the high solubility of this EP in the apoplastic space. A full-length cDNA corresponding to LEP1 was cloned. Quantitative reverse transcriptase-PCR demonstrated LEP1 induction in apical portions of etiolated hypocotyls 30 - 60 min after exposure to white light, prior to the onset of growth inhibition. Comparative modeling of the translated sequence indicated an unusually unobstructed equatorial cleft across the substrate access channel, which might facilitate interaction with extensin and confer higher EP activity.	Inst Tecnol Quim & Biol, P-2781901 Oeiras, Portugal; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; Inst Agron, P-1349017 Lisbon, Portugal	University of York - UK; Universidade de Lisboa	Jackson, PA (corresponding author), Inst Tecnol Quim & Biol, Apartado 127, P-2781901 Oeiras, Portugal.	Phil@itqb.unl.pt	Pinheiro, Carla/A-4053-2008; Jackson, Phil A. P./N-8128-2019; Soares, Claudio M/E-2675-2012; Jackson, Phil A P/I-4925-2014; Ricardo, Cândido P P/B-7891-2008	Pinheiro, Carla/0000-0002-7799-0183; Jackson, Phil A. P./0000-0002-4564-784X; Soares, Claudio M/0000-0003-1154-556X; Ricardo, Cândido P P/0000-0003-4905-1274				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BILES CL, 1991, PLANT PHYSIOL, V96, P597, DOI 10.1104/pp.96.2.597; Bolwell GP, 1998, PLANT PHYSIOL, V116, P1379, DOI 10.1104/pp.116.4.1379; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BRISSON LF, 1994, PLANT CELL, V6, P1703, DOI 10.1105/tpc.6.12.1703; BROWNLEADER MD, 1995, PLANT PHYSIOL, V109, P1115, DOI 10.1104/pp.109.3.1115; Brownleader MD, 2000, PLANTA, V210, P668, DOI 10.1007/s004250050058; Brownleader MD, 1996, BIOCHEM J, V320, P577, DOI 10.1042/bj3200577; Cano A, 1996, J PLANT PHYSIOL, V147, P721, DOI 10.1016/S0176-1617(11)81484-7; Carpin S, 2001, PLANT CELL, V13, P511, DOI 10.1105/tpc.13.3.511; Carpin S, 1999, PLANT PHYSIOL, V120, P799, DOI 10.1104/pp.120.3.799; CASSAB GI, 1987, J CELL BIOL, V105, P2581, DOI 10.1083/jcb.105.6.2581; Cassab GI, 1998, ANNU REV PLANT PHYS, V49, P281, DOI 10.1146/annurev.arplant.49.1.281; COOPER JB, 1994, PLANT PHYSIOL, V104, P747, DOI 10.1104/pp.104.2.747; COOPER JB, 1984, PLANT PHYSIOL, V76, P414, DOI 10.1104/pp.76.2.414; COOPER JB, 1987, TRENDS BIOCHEM SCI, V12, P24, DOI 10.1016/0968-0004(87)90012-0; Costa J, 1997, EUR J BIOCHEM, V243, P695, DOI 10.1111/j.1432-1033.1997.t01-1-00695.x; De Tullio MC, 1999, PLANTA, V209, P424, DOI 10.1007/s004250050745; DEITS T, 1984, J BIOL CHEM, V259, P3525; Ender F, 2002, PLANT CELL, V14, P1147, DOI 10.1105/tpc.000711; ESQUERRETUGAYE MT, 1979, PLANT PHYSIOL, V64, P320, DOI 10.1104/pp.64.2.320; EVERDEEN DS, 1988, PLANT PHYSIOL, V87, P616, DOI 10.1104/pp.87.3.616; FERRER MA, 1991, J PLANT GROWTH REGUL, V10, P139, DOI 10.1007/BF02279325; Fitchette-Laine AC, 1997, PLANT J, V12, P1411, DOI 10.1046/j.1365-313x.1997.12061411.x; FUJIYAMA K, 1988, EUR J BIOCHEM, V173, P681, DOI 10.1111/j.1432-1033.1988.tb14052.x; Gajhede M, 1997, NAT STRUCT BIOL, V4, P1032, DOI 10.1038/nsb1297-1032; Gray JSS, 1996, GLYCOBIOLOGY, V6, P23, DOI 10.1093/glycob/6.1.23; Hall Q, 2002, PLANT CELL, V14, P1161, DOI 10.1105/tpc.010477; Henriksen A, 1999, J BIOL CHEM, V274, P35005, DOI 10.1074/jbc.274.49.35005; Henriksen A, 2001, PROTEIN SCI, V10, P108, DOI 10.1110/ps.37301; Henriksen A, 1998, BIOCHEMISTRY-US, V37, P8054, DOI 10.1021/bi980234j; Hernandez-Ruiz J, 2000, BBA-PROTEIN STRUCT M, V1478, P78, DOI 10.1016/S0167-4838(00)00017-0; JACKSON P, 1994, PLANTA, V194, P311, DOI 10.1007/BF00197530; Jackson P, 1998, AUST J PLANT PHYSIOL, V25, P261, DOI 10.1071/PP97083; JACKSON P, 1996, PLANT PEROXIDASES BI, P255; JACKSON P, 1999, AUST J PLANT PHYSL, V26, P313; Jackson PAP, 2001, PLANT PHYSIOL, V127, P1065, DOI 10.1104/pp.010192; JOHANSSON A, 1992, PLANT MOL BIOL, V18, P1151, DOI 10.1007/BF00047718; KIELISZEWSKI MJ, 1994, PLANT J, V5, P157, DOI 10.1046/j.1365-313X.1994.05020157.x; Kjaersgard IVH, 1997, PLANT MOL BIOL, V33, P699, DOI 10.1023/A:1005707813801; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kunze I, 1998, PLANTA, V205, P92, DOI 10.1007/s004250050300; Kutschera U, 1996, J EXP BOT, V47, P1387, DOI 10.1093/jxb/47.9.1387; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Magliano TMA, 1998, J EXP BOT, V49, P1491, DOI 10.1093/jexbot/49.326.1491; MCCANN MC, 1990, J CELL SCI, V96, P323; MCMANUS MT, 1988, PLANTA, V175, P506, DOI 10.1007/BF00393072; Melo NS, 1997, FEBS LETT, V415, P186, DOI 10.1016/S0014-5793(97)01121-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Mirza O, 2000, ACTA CRYSTALLOGR D, V56, P372, DOI 10.1107/S0907444999016340; NAKAJIMA R, 1979, J BIOL CHEM, V254, P872; NAKAMURA K, 1993, PLANT PHYSIOL, V101, P1, DOI 10.1104/pp.101.1.1; NEUHAUS JM, 1994, PLANT J, V5, P45, DOI 10.1046/j.1365-313X.1994.5010045.x; Nicholls A., 1992, GRASP GRAPHICAL REPR; Nunan KJ, 1998, PLANT PHYSIOL, V118, P783, DOI 10.1104/pp.118.3.783; Omann F, 1996, AUST J PLANT PHYSIOL, V23, P773, DOI 10.1071/PP9960773; Ostergaard L, 2000, PLANT MOL BIOL, V44, P231, DOI 10.1023/A:1006442618860; QI XY, 1995, PLANT PHYSIOL, V108, P1691, DOI 10.1104/pp.108.4.1691; RASMUSSEN SK, 1991, PLANT MOL BIOL, V16, P317, DOI 10.1007/BF00020562; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Salva I, 2001, PLANT BIOLOGY, V3, P32, DOI 10.1055/s-2001-11746; Schnabelrauch LS, 1996, PLANT J, V9, P477, DOI 10.1046/j.1365-313X.1996.09040477.x; SCHOPFER P, 1994, PLANT PHYSIOL, V104, P1269, DOI 10.1104/pp.104.4.1269; Schuller DJ, 1996, STRUCTURE, V4, P311, DOI 10.1016/S0969-2126(96)00035-4; SWORDS KMM, 1993, PLANT PHYSIOL, V102, P891, DOI 10.1104/pp.102.3.891; TAKAHAMA U, 1993, PLANT CELL PHYSIOL, V34, P809; THEILADE B, 1992, GENE, V118, P261, DOI 10.1016/0378-1119(92)90197-W; THEILADE B, 1993, PLANT PEROXIDASES BI, P321; TIRE C, 1994, PLANTA, V195, P175, DOI 10.1007/BF00199676; Veitch NC, 1997, BIOCHEMISTRY-US, V36, P14751, DOI 10.1021/bi9718402; WAN LG, 1994, BIOCHEM CELL BIOL, V72, P411, DOI 10.1139/o94-055; WELINDER KG, 1979, EUR J BIOCHEM, V96, P483, DOI 10.1111/j.1432-1033.1979.tb13061.x; Welinder KG., 1992, CURR OPIN STRUC BIOL, V2, P388, DOI [10.1016/0959-440x(92)90230-5, DOI 10.1016/0959-440X(92)90230-5]; Wojtaszek P, 1997, FEBS LETT, V405, P95, DOI 10.1016/S0014-5793(97)00166-X; Yang BY, 1996, CARBOHYD RES, V287, P203, DOI 10.1016/0008-6215(96)00073-0; Zhang SQ, 1998, PLANT CELL, V10, P435, DOI 10.1105/tpc.10.3.435; ZIMMERLIN A, 1994, BIOCHEM J, V299, P747, DOI 10.1042/bj2990747	77	47	48	1	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41389	41399		10.1074/jbc.M304519200	http://dx.doi.org/10.1074/jbc.M304519200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882982	hybrid			2022-12-27	WOS:000185847200119
J	Mucenski, ML; Wert, SE; Nation, JM; Loudy, DE; Huelsken, J; Birchmeier, W; Morrisey, EE; Whitsett, JA				Mucenski, ML; Wert, SE; Nation, JM; Loudy, DE; Huelsken, J; Birchmeier, W; Morrisey, EE; Whitsett, JA			beta-catenin is required for specification of proximal/distal cell fate during lung morphogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR-I; DEVELOPING MOUSE LUNG; SURFACTANT PROTEIN-B; GROWTH-FACTOR; CHROMOSOMAL LOCALIZATION; BRANCHING MORPHOGENESIS; RESPIRATORY EPITHELIUM; EXPRESSION; GENE; MICE	The lungs are divided, both structurally and functionally, into two distinct components, the proximal airways, which conduct air, and the peripheral airways, which mediate gas exchange. The mechanisms that control the specification of these two structures during lung development are currently unknown. Here we show that beta-catenin signaling is required for the formation of the distal, but not the proximal, airways. When the gene for beta-catenin was conditionally excised in epithelial cells of the developing mouse lung prior to embryonic day 14.5, the proximal lung tubules grew and differentiated appropriately. The mice, however, died at birth because of respiratory failure. Analysis of the lungs by in situ hybridization and immunohistochemistry, using molecular markers of the epithelial and mesenchymal components of both proximal and peripheral airways, showed that the lungs were composed primarily of proximal airways. These observations establish, for the first time, both the sites and timing of specification of the proximal and peripheral airways in the developing lung, and that beta-catenin is one of the essential components of this specification.	Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; Max Delbrueck Ctr Mol Med, D-13125 Berlin, Germany; Univ Penn, Dept Med, Philadelphia, PA 19104 USA	Cincinnati Children's Hospital Medical Center; Helmholtz Association; Max Delbruck Center for Molecular Medicine; University of Pennsylvania	Mucenski, ML (corresponding author), Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave, Cincinnati, OH 45229 USA.		Huelsken, Joerg/AAC-9581-2021	Huelsken, Joerg/0000-0003-3105-9606	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056387, P50HL056387] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL56387] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bellusci S, 1996, DEVELOPMENT, V122, P1693; Bellusci S, 1997, DEVELOPMENT, V124, P4867; Bellusci S, 1997, DEVELOPMENT, V124, P53; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; DAMOREBRUNO MA, 1992, AM J PHYSIOL, V262, pL40, DOI 10.1152/ajplung.1992.262.1.L40; DasGupta R, 2002, J CELL BIOL, V158, P331, DOI 10.1083/jcb.200204134; De Moerlooze L, 2000, DEVELOPMENT, V127, P483; GAVIN BJ, 1990, GENE DEV, V4, P2319, DOI 10.1101/gad.4.12b.2319; Greenberg JM, 2002, DEV DYNAM, V224, P144, DOI 10.1002/dvdy.10095; HEASMAN J, 1994, CELL, V79, P791, DOI 10.1016/0092-8674(94)90069-8; Huelsken J, 2001, CURR OPIN GENET DEV, V11, P547, DOI 10.1016/S0959-437X(00)00231-8; Huelsken J, 2000, J CELL BIOL, V148, P567, DOI 10.1083/jcb.148.3.567; Huelsken J, 2001, CELL, V105, P533, DOI 10.1016/S0092-8674(01)00336-1; Katoh M, 1996, ONCOGENE, V13, P873; Kimura S, 1996, GENE DEV, V10, P60, DOI 10.1101/gad.10.1.60; KORFHAGEN TR, 1992, AM J PHYSIOL, V263, pL546, DOI 10.1152/ajplung.1992.263.5.L546; Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270; Li CG, 2002, DEV BIOL, V248, P68, DOI 10.1006/dbio.2002.0729; Lu MM, 2001, DEV DYNAM, V222, P667, DOI 10.1002/dvdy.1231; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Malik TH, 2000, BIOCHEM J, V349, P829, DOI 10.1042/bj3490829; Merrill BJ, 2001, GENE DEV, V15, P1688, DOI 10.1101/gad.891401; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Min HS, 1998, GENE DEV, V12, P3156, DOI 10.1101/gad.12.20.3156; Minoo P, 1999, DEV BIOL, V209, P60, DOI 10.1006/dbio.1999.9234; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Perl AKT, 2002, TRANSGENIC RES, V11, P21, DOI 10.1023/A:1013986627504; Perl AKT, 2002, P NATL ACAD SCI USA, V99, P10482, DOI 10.1073/pnas.152238499; Perl AKT, 2003, DEV BIOL, V258, P154, DOI 10.1016/S0012-1606(03)00106-4; Quaggin SE, 1999, DEVELOPMENT, V126, P5771; Sagara N, 1998, BIOCHEM BIOPH RES CO, V252, P117, DOI 10.1006/bbrc.1998.9607; Sauer B, 1998, METHODS, V14, P381, DOI 10.1006/meth.1998.0593; Sekine K, 1999, NAT GENET, V21, P138, DOI 10.1038/5096; Shiratori M, 1996, AM J RESP CELL MOL, V15, P328, DOI 10.1165/ajrcmb.15.3.8810636; Shu WG, 2002, DEVELOPMENT, V129, P4831; STRIPP BR, 1992, J BIOL CHEM, V267, P14703; Tebar M, 2001, MECH DEVELOP, V109, P437, DOI 10.1016/S0925-4773(01)00556-1; TENHAVEOPBROEK AAW, 1991, EXP LUNG RES, V17, P111, DOI 10.3109/01902149109064406; Tepera SB, 2003, J CELL SCI, V116, P1137, DOI 10.1242/jcs.00334; Tichelaar JW, 2000, J BIOL CHEM, V275, P11858, DOI 10.1074/jbc.275.16.11858; Weaver M, 2000, DEVELOPMENT, V127, P2695; Weaver M, 1999, DEVELOPMENT, V126, P4005; Weidenfeld J, 2002, J BIOL CHEM, V277, P21061, DOI 10.1074/jbc.M111702200; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wert SE, 2002, DEV BIOL, V242, P75, DOI 10.1006/dbio.2001.0540; WERT SE, 1993, DEV BIOL, V156, P426, DOI 10.1006/dbio.1993.1090; WILKINSON DG, 1992, WHOLE MOUNT IN SITU; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59; Zhou L, 1996, J HISTOCHEM CYTOCHEM, V44, P1183, DOI 10.1177/44.10.8813084	50	238	242	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40231	40238		10.1074/jbc.M305892200	http://dx.doi.org/10.1074/jbc.M305892200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885771	hybrid			2022-12-27	WOS:000185713800116
J	Oliveira, ME; Gouveia, AM; Pinto, RA; Sa-Miranda, C; Azevedo, JE				Oliveira, ME; Gouveia, AM; Pinto, RA; Sa-Miranda, C; Azevedo, JE			The energetics of Pex5p-mediated peroxisomal protein import	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER PEROXISOMES; TARGETING SIGNAL 1; ACYL-COA OXIDASE; SACCHAROMYCES-CEREVISIAE; IN-VITRO; FIREFLY LUCIFERASE; PTS1 RECEPTOR; YARROWIA-LIPOLYTICA; CYCLING RECEPTOR; PEX5P	Most newly synthesized peroxisomal matrix proteins are targeted to the organelle by Pex5p, the peroxisomal cycling receptor. According to current models of peroxisomal biogenesis, Pex5p interacts with cargo proteins in the cytosol and transports them to the peroxisomal membrane. After delivering the passenger protein into the peroxisomal matrix, Pex5p returns to the cytosol to catalyze additional rounds of transportation. Obviously, such cyclic pathway must require energy, and indeed, data confirming this need are already available. However, the exact step(s) of this cycle where energy input is necessary remains unclear. Here, we present data suggesting that insertion of Pex5p into the peroxisomal membrane does not require ATP hydrolysis. This observation raises the possibility that at the peroxisomal membrane ATP is needed predominantly (if not exclusively) downstream of the protein translocation step to reset the Pex5p-mediated transport system.	Inst Biol Mol & Celular, P-4150180 Oporto, Portugal; Inst Ciencias Biomed Abel Salazar, P-4099003 Oporto, Portugal; Inst Genet Med Jacinto de Magalhaes, P-4050466 Oporto, Portugal	Universidade do Porto; Universidade do Porto	Azevedo, JE (corresponding author), Inst Biol Mol & Celular, Rua Campo Alegre 823, P-4150180 Oporto, Portugal.		Azevedo, Jorge E/A-4113-2008; Gouveia, Alexandra/P-3525-2016; sá Miranda, Maria Clara/K-3920-2013	Azevedo, Jorge E/0000-0001-7714-5302; Gouveia, Alexandra/0000-0001-8784-4246; sá Miranda, Maria Clara/0000-0003-0123-5525; Oliveira, Marcia/0000-0003-2437-2004				Agne B, 2003, MOL CELL, V11, P635, DOI 10.1016/S1097-2765(03)00062-5; Albertini M, 2001, EUR J CELL BIOL, V80, P257, DOI 10.1078/0171-9335-00164; BEHARI R, 1993, J BIOL CHEM, V268, P7315; BELLION E, 1987, CELL, V48, P165, DOI 10.1016/0092-8674(87)90367-9; Brickner DG, 1997, PLANT PHYSIOL, V113, P1213, DOI 10.1104/pp.113.4.1213; Chang CC, 1999, J CELL BIOL, V147, P761, DOI 10.1083/jcb.147.4.761; Collins CS, 2000, MOL CELL BIOL, V20, P7516, DOI 10.1128/MCB.20.20.7516-7526.2000; Crookes WJ, 1998, J BIOL CHEM, V273, P17236, DOI 10.1074/jbc.273.27.17236; Dodt G, 1996, J CELL BIOL, V135, P1763, DOI 10.1083/jcb.135.6.1763; Dodt G, 2001, J BIOL CHEM, V276, P41769, DOI 10.1074/jbc.M106932200; DODT G, 1995, NAT GENET, V9, P115, DOI 10.1038/ng0295-115; Elgersma Y, 1996, J BIOL CHEM, V271, P26375, DOI 10.1074/jbc.271.42.26375; Fransen M, 1998, P NATL ACAD SCI USA, V95, P8087, DOI 10.1073/pnas.95.14.8087; FRANSEN M, 1995, J BIOL CHEM, V270, P7731, DOI 10.1074/jbc.270.13.7731; Fransen M, 2002, MOL CELL PROTEOMICS, V1, P243, DOI 10.1074/mcp.M100025-MCP200; Frydman J, 2001, ANNU REV BIOCHEM, V70, P603, DOI 10.1146/annurev.biochem.70.1.603; Gatto GJ, 2003, BIOCHEMISTRY-US, V42, P1660, DOI 10.1021/bi027034z; Glick BS, 1995, METHOD ENZYMOL, V260, P224, DOI 10.1016/0076-6879(95)60140-6; GLOVER JR, 1994, P NATL ACAD SCI USA, V91, P10541, DOI 10.1073/pnas.91.22.10541; GOULD SJ, 1987, J CELL BIOL, V105, P2923, DOI 10.1083/jcb.105.6.2923; GOULD SJ, 1989, J CELL BIOL, V108, P1657, DOI 10.1083/jcb.108.5.1657; Gould SJ, 2002, NAT REV MOL CELL BIO, V3, P382, DOI 10.1038/nrm807; Gouveia AM, 2003, J BIOL CHEM, V278, P226, DOI 10.1074/jbc.M209498200; Gouveia AM, 2003, J BIOL CHEM, V278, P4389, DOI 10.1074/jbc.C200650200; Gouveia AMM, 1999, ANAL BIOCHEM, V274, P270, DOI 10.1006/abio.1999.4281; Gouveia AMM, 2000, J BIOL CHEM, V275, P32444, DOI 10.1074/jbc.M004366200; Harano T, 2001, BIOCHEM J, V357, P157, DOI 10.1042/0264-6021:3570157; HARTL FU, 1985, ARCH BIOCHEM BIOPHYS, V237, P124, DOI 10.1016/0003-9861(85)90261-9; Hausler T, 1996, J CELL BIOL, V132, P311, DOI 10.1083/jcb.132.3.311; HORNG JT, 1995, EUR J BIOCHEM, V230, P157, DOI 10.1111/j.1432-1033.1995.tb20546.x; IMANAKA T, 1987, J CELL BIOL, V105, P2915, DOI 10.1083/jcb.105.6.2915; Komeili A, 2001, ANNU REV GENET, V35, P341, DOI 10.1146/annurev.genet.35.102401.090720; Lametschwandtner G, 1998, J BIOL CHEM, V273, P33635, DOI 10.1074/jbc.273.50.33635; LEIGHTON F, 1969, J CELL BIOL, V41, P521, DOI 10.1083/jcb.41.2.521; Leiper JM, 1996, J CELL BIOL, V135, P939, DOI 10.1083/jcb.135.4.939; MCCOLLUM D, 1993, J CELL BIOL, V121, P761, DOI 10.1083/jcb.121.4.761; MCNEW JA, 1994, J CELL BIOL, V127, P1245, DOI 10.1083/jcb.127.5.1245; Okumoto K, 2000, J BIOL CHEM, V275, P25700, DOI 10.1074/jbc.M003303200; Oliveira MEM, 2002, BBA-BIOMEMBRANES, V1567, P13, DOI 10.1016/S0005-2736(02)00635-1; Otera H, 2002, MOL CELL BIOL, V22, P1639, DOI 10.1128/MCB.22.6.1639-1655.2002; Pool MR, 1998, EMBO J, V17, P6854, DOI 10.1093/emboj/17.23.6854; Purdue PE, 2001, ANNU REV CELL DEV BI, V17, P701, DOI 10.1146/annurev.cellbio.17.1.701; RAPP S, 1993, EXP CELL RES, V205, P59, DOI 10.1006/excr.1993.1058; Reguenga C, 2001, J BIOL CHEM, V276, P29935, DOI 10.1074/jbc.M104114200; Saidowsky J, 2001, J BIOL CHEM, V276, P34524, DOI 10.1074/jbc.M104647200; Schliebs W, 1999, J BIOL CHEM, V274, P5666, DOI 10.1074/jbc.274.9.5666; Shimizu N, 1999, J BIOL CHEM, V274, P12593, DOI 10.1074/jbc.274.18.12593; SOTO U, 1993, EXP CELL RES, V205, P66, DOI 10.1006/excr.1993.1059; Sparkes IA, 2002, MOL MEMBR BIOL, V19, P171, DOI 10.1080/09687680210159422; Subramani S, 2000, ANNU REV BIOCHEM, V69, P399, DOI 10.1146/annurev.biochem.69.1.399; Terlecky SR, 2001, EXP CELL RES, V263, P98, DOI 10.1006/excr.2000.5111; Titorenko VI, 2002, J CELL BIOL, V156, P481, DOI 10.1083/jcb.200111075; Titorenko VI, 1998, J CELL BIOL, V142, P403, DOI 10.1083/jcb.142.2.403; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WALTON PA, 1994, J CELL BIOL, V125, P1037, DOI 10.1083/jcb.125.5.1037; WALTON PA, 1995, MOL BIOL CELL, V6, P675, DOI 10.1091/mbc.6.6.675; WENDLAND M, 1993, J CELL BIOL, V120, P675, DOI 10.1083/jcb.120.3.675; WIEMER EAC, 1995, J CELL BIOL, V130, P51, DOI 10.1083/jcb.130.1.51; Will GK, 1999, MOL CELL BIOL, V19, P2265	59	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39483	39488		10.1074/jbc.M305089200	http://dx.doi.org/10.1074/jbc.M305089200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885776	hybrid			2022-12-27	WOS:000185713800027
J	El-Azami-El-Idrissi, M; Bauche, C; Loucka, J; Osicka, R; Sebo, P; Ladant, D; Leclerc, C				El-Azami-El-Idrissi, M; Bauche, C; Loucka, J; Osicka, R; Sebo, P; Ladant, D; Leclerc, C			Interaction of Bordetella pertussis adenylate cyclase with CD11b/CD18 - Role of toxin acylation and identification of the main integrin interaction domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL EPITOPES; ANTIGEN-PRESENTING CELLS; IN-VIVO; MACROPHAGE APOPTOSIS; HEMOLYTIC ACTIVITIES; COMPLEMENT RECEPTOR; PROTECTIVE ACTIVITY; LETHAL INFECTION; DENDRITIC CELLS; TARGET-CELLS	Adenylate cyclase toxin (CyaA) is one of the major virulence factors produced by Bordetella pertussis, the whooping cough agent. CyaA belongs to the repeat in toxin protein family and requires a post-translational fatty acylation to form cation-selective channels in target cell membranes and to penetrate into cytosol. We have demonstrated recently that CyaA uses the alpha(M)beta(2) integrin (CD11b/CD18) as a specific cellular receptor. Here we show that the acylation of CyaA is required for a productive and tight interaction of the toxin with cells expressing CD11b. In addition, we demonstrate that the catalytic domain is not required for binding of CyaA to CD11b and that the main integrin interacting domain of CyaA is located in its glycine/aspartate-rich repeat region. These data decipher, for the first time, the interaction of CyaA with CD11b-positive cells and open new prospects for understanding the interaction of Bordetella pertussis with innate and adaptive immune systems.	Inst Pasteur, INSERM, E0352, Unite Biol Regulat Immunitaires, F-75724 Paris 15, France; Inst Pasteur, CNRS, URA 2185, Unite Biochim Interact Macromol, F-75724 Paris, France; Acad Sci Czech Republ, Prague 14220 4, Czech Republic	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Czech Academy of Sciences	Leclerc, C (corresponding author), Inst Pasteur, INSERM, E0352, Unite Biol Regulat Immunitaires, 25 Rue Dr Roux, F-75724 Paris 15, France.		SEBO, Peter/N-2043-2019; SEBO, Peter/F-7423-2011; Osicka, Radim/H-6776-2014; Kovářová, Jiřina/R-4129-2017	SEBO, Peter/0000-0002-9755-7715; SEBO, Peter/0000-0002-9755-7715; Osicka, Radim/0000-0003-2626-5456; LADANT, Daniel/0000-0003-1955-548X	PHS HHS [55000334] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ALTIERI DC, 1988, J BIOL CHEM, V263, P7007; ARCINIEGA JL, 1991, J INFECT DIS, V163, P135, DOI 10.1093/infdis/163.1.135; ARNAOUT MA, 1990, BLOOD, V75, P1037; BARRY EM, 1991, J BACTERIOL, V173, P720, DOI 10.1128/jb.173.2.720-726.1991; Basar T, 2001, J BIOL CHEM, V276, P348, DOI 10.1074/jbc.M006463200; Bell D, 1999, ADV IMMUNOL, V72, P255, DOI 10.1016/S0065-2776(08)60023-1; BELLALOU J, 1990, INFECT IMMUN, V58, P3242, DOI 10.1128/IAI.58.10.3242-3247.1990; BELLER DI, 1982, J EXP MED, V156, P1000, DOI 10.1084/jem.156.4.1000; BETSOU F, 1995, INFECT IMMUN, V63, P3309, DOI 10.1128/IAI.63.9.3309-3315.1995; BETSOU F, 1993, INFECT IMMUN, V61, P3583, DOI 10.1128/IAI.61.9.3583-3589.1993; CONFER DL, 1982, SCIENCE, V217, P948, DOI 10.1126/science.6287574; DIAMOND MS, 1993, J CELL BIOL, V120, P545, DOI 10.1083/jcb.120.2.545; DIAMOND MS, 1990, J CELL BIOL, V111, P3129, DOI 10.1083/jcb.111.6.3129; Fayolle C, 1996, J IMMUNOL, V156, P4697; FRIEDMAN RL, 1987, INFECT IMMUN, V55, P135, DOI 10.1128/IAI.55.1.135-140.1987; Gmira S, 2001, RES MICROBIOL, V152, P889, DOI 10.1016/S0923-2508(01)01272-4; GOODWIN MS, 1990, INFECT IMMUN, V58, P3445, DOI 10.1128/IAI.58.10.3445-3447.1990; Gray MC, 1999, INFECT IMMUN, V67, P4393, DOI 10.1128/IAI.67.9.4393-4399.1999; Gueirard P, 1998, INFECT IMMUN, V66, P1718, DOI 10.1128/IAI.66.4.1718-1725.1998; Guermonprez P, 2000, METHOD ENZYMOL, V326, P527; Guermonprez P, 2002, EUR J IMMUNOL, V32, P3071, DOI 10.1002/1521-4141(200211)32:11<3071::AID-IMMU3071>3.0.CO;2-A; Guermonprez P, 2001, J EXP MED, V193, P1035, DOI 10.1084/jem.193.9.1035; GUISO N, 1989, MICROB PATHOGENESIS, V7, P373, DOI 10.1016/0882-4010(89)90040-5; GUISO N, 1993, EUR J CLIN MICROBIOL, V12, P596, DOI 10.1007/BF01973637; GUISO N, 1991, MICROB PATHOGENESIS, V11, P423, DOI 10.1016/0882-4010(91)90038-C; HACKETT M, 1994, SCIENCE, V266, P433, DOI 10.1126/science.7939682; Harvill ET, 1999, INFECT IMMUN, V67, P1493, DOI 10.1128/IAI.67.3.1493-1500.1999; Hormozi K, 1999, FEMS IMMUNOL MED MIC, V23, P273, DOI 10.1016/S0928-8244(98)00146-1; Ingalls RR, 1998, PROG CLIN BIOL RES, V397, P107; Karimova G, 1998, P NATL ACAD SCI USA, V95, P12532, DOI 10.1073/pnas.95.21.12532; KHELEF N, 1992, MICROB PATHOGENESIS, V12, P227, DOI 10.1016/0882-4010(92)90057-U; KHELEF N, 1994, INFECT IMMUN, V62, P2893, DOI 10.1128/IAI.62.7.2893-2900.1994; KHELEF N, 1993, INFECT IMMUN, V61, P4064, DOI 10.1128/IAI.61.10.4064-4071.1993; KHELEF N, 1995, FEMS MICROBIOL LETT, V134, P27, DOI 10.1016/0378-1097(95)00375-F; Ladant D, 1999, TRENDS MICROBIOL, V7, P172, DOI 10.1016/S0966-842X(99)01468-7; LADANT D, 1992, J BIOL CHEM, V267, P2244; Njamkepo E, 2000, J CELL PHYSIOL, V183, P91, DOI 10.1002/(SICI)1097-4652(200004)183:1<91::AID-JCP11>3.0.CO;2-S; Osicka R, 2000, INFECT IMMUN, V68, P247; PEARSON RD, 1987, J IMMUNOL, V139, P2749; ROGEL A, 1992, J BIOL CHEM, V267, P22599; ROGEL A, 1991, J BIOL CHEM, V266, P3154; ROSE T, 1995, J BIOL CHEM, V270, P26370, DOI 10.1074/jbc.270.44.26370; Sambrook J., 2002, MOL CLONING LAB MANU; SEBO P, 1991, GENE, V104, P19, DOI 10.1016/0378-1119(91)90459-O; WEISS AA, 1989, INFECT IMMUN, V57, P3757, DOI 10.1128/IAI.57.12.3757-3764.1989; WRIGHT SD, 1988, P NATL ACAD SCI USA, V85, P7734, DOI 10.1073/pnas.85.20.7734	46	99	107	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38514	38521		10.1074/jbc.M304387200	http://dx.doi.org/10.1074/jbc.M304387200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885782	hybrid			2022-12-27	WOS:000185575100053
J	Haase, I; Fischer, M; Bacher, A; Schramek, N				Haase, I; Fischer, M; Bacher, A; Schramek, N			Temperature-dependent presteady state kinetics of lumazine synthase from the hyperthermophilic eubacterium Aquifex aeolicus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY RIBOFLAVIN SYNTHASE; CRYSTAL-STRUCTURE ANALYSIS; BACILLUS-SUBTILIS; 6,7-DIMETHYL-8-RIBITYLLUMAZINE SYNTHASE; ANGSTROM RESOLUTION; BIOSYNTHESIS; PURIFICATION; MECHANISM; CATALYSIS; REVEALS	6,7-Dimethyl-8-ribityllumazine synthase (lumazine synthase) catalyzes the condensation of 5-amino-6-ribitylamino- 2,4(1H, 3H)-pyrimidinedione and 3,4-dihydroxy-2- butanone 4-phosphate. Presteady state kinetic experiments using the enzyme from the hyperthermophilic bacterium Aquifex aeolicus were monitored by multiwavelength photometry. An early optical transient absorbing around 330 nm is interpreted as a Schiff base intermediate obtained by reaction of the position 5 amino group of the heterocyclic substrate with the carbonyl group of 3,4-dihydroxy-2-butanone 4-phosphate. A second transient with an absorption maximum at 445 nm represents an intermediate resulting from the elimination of orthophosphate from the Schiff base. The rate-determining step is the subsequent formation of the 7-exomethylene type anion of 6,7-dimethyl-8-ribityllumazine. The rate constants for the three partial reactions identified by the stopped flow experiments show linear Arrhenius relations in the temperature range of 15 - 70 degreesC.	Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, D-85747 Garching, Germany	Technical University of Munich	Schramek, N (corresponding author), Tech Univ Munich, Lehrstuhl Organ Chem & Biochem, Lichtenbergstr 4, D-85747 Garching, Germany.		Fischer, Markus/H-2870-2012; Fischer, Markus/AFT-1856-2022; Fischer, Markus J./G-9477-2012	Fischer, Markus/0000-0001-7243-4199; 				BACHER A, 1986, METHOD ENZYMOL, V122, P192; BACHER A, 1980, J BIOL CHEM, V255, P632; BACHER A, 1986, J MOL BIOL, V187, P75, DOI 10.1016/0022-2836(86)90407-9; Bacher A., 1980, P 6 INT S, P579; BACHER A, 1991, CHEM BIOCH FLAVOPROT, V1, P293; BEACH RL, 1971, J ORG CHEM, V36, P3937, DOI 10.1021/jo00824a020; BOWN DH, 1986, J ORG CHEM, V51, P2461, DOI 10.1021/jo00363a011; CRESSWELL RM, 1960, J CHEM SOC, P4768, DOI 10.1039/jr9600004768; Fischer M, 2003, J MOL BIOL, V326, P783, DOI 10.1016/S0022-2836(02)01473-0; Fischer M, 2002, EUR J BIOCHEM, V269, P519, DOI 10.1046/j.0014-2956.2001.02674.x; Haase I, 2003, EUR J BIOCHEM, V270, P1025, DOI 10.1046/j.1432-1033.2003.03478.x; KIS K, 1995, J BIOL CHEM, V270, P16788, DOI 10.1074/jbc.270.28.16788; KIS K, 1995, BIOCHEMISTRY-US, V34, P2883, DOI 10.1021/bi00009a019; KISTIAKOWSKY GB, 1949, J AM CHEM SOC, V71, P2006, DOI 10.1021/ja01174a029; LADENSTEIN R, 1988, J MOL BIOL, V203, P1045, DOI 10.1016/0022-2836(88)90128-3; LADENSTEIN R, 1983, J BIOL CHEM, V258, P1981; MASSEY V, 1966, J BIOL CHEM, V241, P2347; Meining W, 2000, J MOL BIOL, V299, P181, DOI 10.1006/jmbi.2000.3742; Mortl S, 1996, J BIOL CHEM, V271, P33201, DOI 10.1074/jbc.271.52.33201; NEUBERGER G, 1986, BIOCHEM BIOPH RES CO, V139, P1111, DOI 10.1016/S0006-291X(86)80292-3; Persson K, 1999, PROTEIN SCI, V8, P2355; PFLEIDERER W, 1966, CHEM BER-RECL, V99, P3503, DOI 10.1002/cber.19660991117; Richter G, 1997, METHOD ENZYMOL, V280, P374; RITSERT K, 1995, J MOL BIOL, V253, P151, DOI 10.1006/jmbi.1995.0542; Schramek N, 2003, J AM CHEM SOC, V125, P4460, DOI 10.1021/ja028226k; VOLK R, 1990, J BIOL CHEM, V265, P19479; Zhang XF, 2003, J MOL BIOL, V328, P167, DOI 10.1016/S0022-2836(03)00186-4; Zhang XF, 2001, J MOL BIOL, V306, P1099, DOI 10.1006/jmbi.2000.4435; Zheng YJ, 2000, BIOORG CHEM, V28, P89, DOI 10.1006/bioo.2000.1163	29	15	15	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37909	37915		10.1074/jbc.M303090200	http://dx.doi.org/10.1074/jbc.M303090200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867427	hybrid			2022-12-27	WOS:000185437200113
J	Weibel, P; Hiltbrunner, A; Brand, L; Kessler, F				Weibel, P; Hiltbrunner, A; Brand, L; Kessler, F			Dimerization of Toc-GTPases at the chloroplast protein import machinery	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROTEIN RECEPTOR; OUTER ENVELOPE; MEMBRANE; GTP; MECHANISM; BINDING; DOMAIN; IDENTIFICATION; TRANSLOCATION; BIOGENESIS	Import of chloroplast precursor proteins is controlled by the coordinate action of two homologous GTPases, Toc159 and Toc33, located at the cytosol-outer membrane interface. Recent studies in Arabidopsis showed that the cytosolic form of the precursor binding protein Toc159 is targeted to its receptor at the import machinery, Toc33, via heterodimerization of their GTP-binding domains. Toc33 may also form GDP-bound homodimers, as suggested by the crystal structure of its pea ortholog. Moreover, the structural data suggested that arginine 130 ( Arg(130)) of Arabidopsis Toc33 may function as a GTPase-activating "arginine-finger" at the other monomer in the Toc33 dimer. Here, we demonstrate that Arg(130) of Toc33 does not function as an Arginine-finger. A mutant, Toc33-R130A, binds and hydrolyzes GTP like the wild type. However, we demonstrate that Arg(130) is involved in both homodimerization of Toc33 and in heterodimerization with the GTP-binding domain of Toc159. The dependence of Toc33 homodimerization on Arg(130) is mutual, requiring the presence of Arg(130) at both monomers. As the GTPase is not activated by dimerization, it may be activated independently at either monomer, possibly even before dimerization. Independent regulation of GTPase activity may serve to coordinate the interactions of the GTPases during the import of proteins into the chloroplast.	Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, CH-2007 Neuchatel, Switzerland; ETH, Inst Plant Sci, Plant Physiol & Biochem Grp, CH-8092 Zurich, Switzerland	University of Neuchatel; Swiss Federal Institutes of Technology Domain; ETH Zurich	Kessler, F (corresponding author), Univ Neuchatel, Inst Bot, Lab Physiol Vegetale, Rue Emile Argand 11, CH-2007 Neuchatel, Switzerland.		Kessler, Felix Henrique/AAO-1722-2020	Hiltbrunner, Andreas/0000-0003-0438-5297; Kessler, Felix/0000-0001-6409-5043				Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Bolter B, 1998, P NATL ACAD SCI USA, V95, P15831, DOI 10.1073/pnas.95.26.15831; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen K, 2000, BIOCHEM SOC T, V28, P485, DOI 10.1042/0300-5127:0280485; Cline K, 2000, NATURE, V403, P148, DOI 10.1038/35003082; ECONOMOU A, 1994, CELL, V78, P835, DOI 10.1016/S0092-8674(94)90582-7; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; HILTBRUNNER A, 2001, BIOCH CELL BIOL, V79, P1; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; HIRSCH S, 1994, SCIENCE, V266, P1989, DOI 10.1126/science.7801125; Jackson-Constan D, 2001, PLANT PHYSIOL, V125, P1567, DOI 10.1104/pp.125.4.1567; Jarvis P, 2002, BBA-MOL CELL RES, V1590, P177, DOI 10.1016/S0167-4889(02)00176-3; Jelic M, 2003, BIOCHEMISTRY-US, V42, P5906, DOI 10.1021/bi034001q; Kessler F, 2002, NAT STRUCT BIOL, V9, P81, DOI 10.1038/nsb0202-81; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Liang ZM, 2000, BIOCHEM J, V346, P501, DOI 10.1042/0264-6021:3460501; PERRY SE, 1994, PLANT CELL, V6, P93, DOI 10.1105/tpc.6.1.93; Reumann S, 1999, P NATL ACAD SCI USA, V96, P784, DOI 10.1073/pnas.96.2.784; SCHAGGER H, 1991, ANAL BIOCHEM, V199, P223, DOI 10.1016/0003-2697(91)90094-A; Schleiff E, 2003, P NATL ACAD SCI USA, V100, P4604, DOI 10.1073/pnas.0730860100; Schleiff E, 2002, BIOCHEMISTRY-US, V41, P1934, DOI 10.1021/bi011361+; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; Sun YJ, 2002, NAT STRUCT BIOL, V9, P95, DOI 10.1038/nsb744; Sveshnikova N, 2000, P NATL ACAD SCI USA, V97, P4973, DOI 10.1073/pnas.080491597; WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6	31	42	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37321	37329		10.1074/jbc.M305946200	http://dx.doi.org/10.1074/jbc.M305946200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869544	Green Submitted, hybrid			2022-12-27	WOS:000185437200041
J	Beck, J; Nassal, M				Beck, J; Nassal, M			Efficient hsp90-independent in vitro activation by Hsc70 and Hsp40 of duck hepatitis B virus reverse transcriptase, an assumed Hsp90 client protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION INITIATION COMPLEX; RNA ENCAPSIDATION SIGNAL; STEM-LOOP STRUCTURE; HEAT-SHOCK-PROTEIN; MOLECULAR CHAPERONE; ATPASE ACTIVITY; TYROSINE RESIDUE; DNAJ; BINDING; HSP70	Hsp90 is a specialized chaperone that controls the activity of many key regulator proteins such as steroid hormone receptors (SHRs). Hormone binding, and therefore SHR activation, requires Hsp90, which is loaded onto the receptors by a series of events involving Hsp70, Hsp40, Hop, and p23. The reverse transcriptase (RT) of hepatitis B viruses, small DNA-containing viruses that replicate via an RNA intermediate, has been reported to depend similarly on Hsp90 for enzymatic activity. Using an in vitro reconstitution system consisting of recombinant duck hepatitis B virus RT, purified chaperones, and the authentic RNA template Depsilon, we demonstrate here that this RT can be activated efficiently by just Hsp40 and Hsc70 plus energy, without the need for Hsp90 or other cofactors. The reaction appears to proceed selectively with the Hdj1 variant of Hsp40 but not Hdj2 or its yeast homolog Ydj1. The primary reaction product is a metastable, RNA binding-competent intermediate that decays quickly in the absence of its cognate RNA but, in its presence, accumulates in an initiation-competent form over several hours. Because deletion of the RNase H domain rendered the protein partly chaperone-independent, the chaperones may be needed indirectly to relieve occlusion of the RNA binding site by this domain. Our results do not exclude that other factors contribute to RT activation in vivo, but they challenge a fundamental SHR-like dependence on Hsp90. Thus Hsc70, mostly known for its role in general protein folding, is able to effect activation of a highly specialized target protein.	Univ Hosp freiburg, Dept Internal Med Mol Biol 2, D-79106 Freiburg, Germany	University of Freiburg	Nassal, M (corresponding author), Univ Hosp freiburg, Dept Internal Med Mol Biol 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	nassal2@ukl.uni-freiburg.de	Nassal, Michael/U-4529-2019	Nassal, Michael/0000-0003-2204-9158; Beck, Jurgen/0000-0001-8794-9320				BARTENSCHLAGER R, 1992, EMBO J, V11, P3413, DOI 10.1002/j.1460-2075.1992.tb05420.x; Beck J, 1998, MOL CELL BIOL, V18, P6265, DOI 10.1128/MCB.18.11.6265; Beck J, 1997, VIROLOGY, V227, P500, DOI 10.1006/viro.1996.8329; Beck J, 2001, J VIROL, V75, P7410, DOI 10.1128/JVI.75.16.7410-7419.2001; Beerens N, 2001, J BIOL CHEM, V276, P31247, DOI 10.1074/jbc.M102441200; Blumberg BS, 1997, P NATL ACAD SCI USA, V94, P7121, DOI 10.1073/pnas.94.14.7121; Brehmer D, 2001, NAT STRUCT BIOL, V8, P427, DOI 10.1038/87588; Buchner J, 1998, METHOD ENZYMOL, V290, P409, DOI 10.1016/S0076-6879(98)90034-9; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Cheetham ME, 1998, CELL STRESS CHAPERON, V3, P28, DOI 10.1379/1466-1268(1998)003<0028:SFAEOD>2.3.CO;2; Cheng H, 2001, CURR BIOL, V11, P1771, DOI 10.1016/S0960-9822(01)00540-1; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; Davis GD, 1999, BIOTECHNOL BIOENG, V65, P382, DOI 10.1002/(SICI)1097-0290(19991120)65:4<382::AID-BIT2>3.3.CO;2-9; Dittmar KD, 1998, J BIOL CHEM, V273, P7358, DOI 10.1074/jbc.273.13.7358; Eickbush Thomas H., 1994, P121; Ellis RJ, 2001, TRENDS BIOCHEM SCI, V26, P597, DOI 10.1016/S0968-0004(01)01938-7; Eom CY, 2002, P NATL ACAD SCI USA, V99, P1894, DOI 10.1073/pnas.042689499; Fliss AE, 1999, J BIOL CHEM, V274, P34045, DOI 10.1074/jbc.274.48.34045; Forsythe HL, 2001, J BIOL CHEM, V276, P15571, DOI 10.1074/jbc.C100055200; Gao BC, 1996, J BIOL CHEM, V271, P16792, DOI 10.1074/jbc.271.28.16792; Gassler CS, 2001, J BIOL CHEM, V276, P32538, DOI 10.1074/jbc.M105328200; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hernandez MP, 2002, J BIOL CHEM, V277, P38294, DOI 10.1074/jbc.M206566200; Hernandez MP, 2002, J BIOL CHEM, V277, P11873, DOI 10.1074/jbc.M111445200; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Hu JM, 2000, J VIROL, V74, P11447, DOI 10.1128/JVI.74.24.11447-11455.2000; Jiang RF, 1997, J BIOL CHEM, V272, P6141, DOI 10.1074/jbc.272.10.6141; Kanelakis KC, 1999, J BIOL CHEM, V274, P34134, DOI 10.1074/jbc.274.48.34134; Kanelakis KC, 2000, BIOCHEMISTRY-US, V39, P14314, DOI 10.1021/bi001671c; King C, 1999, BIOCHEMISTRY-US, V38, P12452, DOI 10.1021/bi9902788; KNAUS T, 1993, NUCLEIC ACIDS RES, V21, P3967, DOI 10.1093/nar/21.17.3967; Kosano H, 1998, J BIOL CHEM, V273, P32973, DOI 10.1074/jbc.273.49.32973; Lanford RE, 1999, J VIROL, V73, P1885, DOI 10.1128/JVI.73.3.1885-1893.1999; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LOEB DD, 1995, J VIROL, V69, P6886, DOI 10.1128/JVI.69.11.6886-6891.1995; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Morishima Y, 2000, J BIOL CHEM, V275, P18054, DOI 10.1074/jbc.M000434200; Morishima Y, 2000, J BIOL CHEM, V275, P6894, DOI 10.1074/jbc.275.10.6894; Murphy PJM, 2001, J BIOL CHEM, V276, P30092, DOI 10.1074/jbc.M103773200; Nassal M, 1996, J VIROL, V70, P2764, DOI 10.1128/JVI.70.5.2764-2773.1996; Nassal M, 1999, INTERVIROLOGY, V42, P100, DOI 10.1159/000024970; NASSAL M, 2000, FRONTIERS MOL BIOL D, V26, P1; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; POLLACK JR, 1993, J VIROL, V67, P3254, DOI 10.1128/JVI.67.6.3254-3263.1993; POLLACK JR, 1994, J VIROL, V68, P5579, DOI 10.1128/JVI.68.9.5579-5587.1994; Pratt WB, 1997, ENDOCR REV, V18, P306, DOI 10.1210/er.18.3.306; RADZIWILL G, 1990, J VIROL, V64, P613, DOI 10.1128/JVI.64.2.613-620.1990; Rajapandi T, 2000, J BIOL CHEM, V275, P22597, DOI 10.1074/jbc.M002035200; Richter K, 2001, J CELL PHYSIOL, V188, P281, DOI 10.1002/jcp.1131; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; Schaaf SG, 1999, J BIOL CHEM, V274, P37787, DOI 10.1074/jbc.274.53.37787; SCHAAF SG, 1998, THESIS U HEIDELBERG; Schiene-Fischer C, 2002, NAT STRUCT BIOL, V9, P419, DOI 10.1038/nsb804; SUMMERS J, 1982, CELL, V29, P403, DOI 10.1016/0092-8674(82)90157-X; Tavis JE, 1998, J VIROL, V72, P5789, DOI 10.1128/JVI.72.7.5789-5796.1998; WANG GH, 1993, J VIROL, V67, P6507, DOI 10.1128/JVI.67.11.6507-6512.1993; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; Wang XT, 2002, J VIROL, V76, P5857, DOI 10.1128/JVI.76.12.5857-5865.2002; WEBER M, 1994, J VIROL, V68, P2994, DOI 10.1128/JVI.68.5.2994-2999.1994; Young JC, 2001, J CELL BIOL, V154, P267, DOI 10.1083/jcb.200104079; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	66	78	84	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36128	36138		10.1074/jbc.M301069200	http://dx.doi.org/10.1074/jbc.M301069200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851401	hybrid			2022-12-27	WOS:000185318300033
J	Kovacs, KA; Steinmann, M; Magistretti, PJ; Halfon, O; Cardinaux, JR				Kovacs, KA; Steinmann, M; Magistretti, PJ; Halfon, O; Cardinaux, JR			CCAAT/enhancer-binding protein family members recruit the coactivator CREB-binding protein and trigger its phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL INHIBITORY PROTEIN; RNA-POLYMERASE-II; C/EBP-BETA; GENE-EXPRESSION; DEPENDENT KINASES; MAMMALIAN-CELLS; CBP; ALPHA; P300; ACTIVATION	CCAAT/enhancer-binding protein (C/EBP) family members are transcription factors involved in important physiological processes, such as cellular proliferation and differentiation, regulation of energy homeostasis, inflammation, and hematopoiesis. Transcriptional activation by C/EBPalpha and C/EBPbeta involves the coactivators CREB-binding protein (CBP) and p300, which promote transcription by acetylating histones and recruiting basal transcription factors. In this study, we show that C/EBPdelta is also using CBP as a coactivator. Based on sequence homology with C/EBPalpha and -beta, we identify in C/EBPalpha two conserved amino acid segments that are necessary for the physical interaction with CBP. Using reporter gene assays, we demonstrate that mutation of these residues prevents CBP recruitment and diminishes the transactivating potential of C/EBPdelta. In addition, our results indicate that C/EBP family members not only recruit CBP but specifically induce its phosphorylation. We provide evidence that CBP phosphorylation depends on its interaction with C/EBPdelta and define point mutations within one of the two conserved amino acid segments of C/EBPdelta that abolish CBP phosphorylation as well as transcriptional activation, suggesting that this new mechanism could be important for C/EBP-mediated transcription.	Univ Lausanne, Dept Child Adolescent Psychiat, CH-1005 Lausanne, Switzerland; Univ Lausanne, Ctr Psychiat Neurosci, Dept Psychiat, CH-1005 Lausanne, Switzerland; Univ Lausanne, Inst Physiol, CH-1005 Lausanne, Switzerland	University of Lausanne; University of Lausanne; University of Lausanne	Cardinaux, JR (corresponding author), Ctr Neurosci Psychiat, 1er Etage,Site Cery, CH-1008 Prilly, Switzerland.	Jean-Rene.Cardinaux@hospvd.ch	Cardinaux, Jean-René/G-5391-2012	Cardinaux, Jean-René/0000-0001-6423-0014; Magistretti, Pierre Julius/0000-0002-6678-320X; Kovacs, Krisztian/0000-0001-6251-1007				Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; BANERJEE AC, 1994, ONCOGENE, V9, P1733; Bonny C, 1998, J BIOL CHEM, V273, P1843, DOI 10.1074/jbc.273.4.1843; Cardinaux JR, 1997, MOL BRAIN RES, V51, P220, DOI 10.1016/S0169-328X(97)00241-6; Cardinaux JR, 1996, J NEUROSCI, V16, P919; Cardinaux JR, 2000, GLIA, V29, P91, DOI 10.1002/(SICI)1098-1136(20000101)29:1<91::AID-GLIA9>3.0.CO;2-I; Cardinaux JR, 2000, MOL CELL BIOL, V20, P1546, DOI 10.1128/MCB.20.5.1546-1552.2000; Chan HM, 2001, J CELL SCI, V114, P2363; CHANDRASEKARAN C, 1993, P NATL ACAD SCI USA, V90, P8871, DOI 10.1073/pnas.90.19.8871; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Cohen LE, 1999, J CLIN INVEST, V104, P1123, DOI 10.1172/JCI7308; Colangelo AM, 1998, P NATL ACAD SCI USA, V95, P10920, DOI 10.1073/pnas.95.18.10920; Cortes-Canteli M, 2002, J BIOL CHEM, V277, P5460, DOI 10.1074/jbc.M108761200; Croniger C, 1998, J BIOL CHEM, V273, P31629, DOI 10.1074/jbc.273.48.31629; Cruzalegui FH, 1999, EMBO J, V18, P1335, DOI 10.1093/emboj/18.5.1335; DARLINGTON GJ, 1995, CURR OPIN GENET DEV, V5, P565, DOI 10.1016/0959-437X(95)80024-7; Darlington GJ, 1999, CURR OPIN CELL BIOL, V11, P678, DOI 10.1016/S0955-0674(99)00035-6; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Diehl AM, 1998, J BIOL CHEM, V273, P30843, DOI 10.1074/jbc.273.47.30843; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Duong DT, 2002, J BIOL CHEM, V277, P32234, DOI 10.1074/jbc.M204873200; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Goodman RH, 2000, GENE DEV, V14, P1553; Guo SD, 2001, J BIOL CHEM, V276, P8516, DOI 10.1074/jbc.M008542200; Hardingham GE, 1999, NEURON, V22, P789, DOI 10.1016/S0896-6273(00)80737-0; Hu SC, 1999, NEURON, V22, P799, DOI 10.1016/S0896-6273(00)80738-2; Impey S, 2002, NEURON, V34, P235, DOI 10.1016/S0896-6273(02)00654-2; Janknecht R, 1996, CURR BIOL, V6, P951, DOI 10.1016/S0960-9822(02)00636-X; Janknecht R, 1996, BIOCHEM BIOPH RES CO, V228, P831, DOI 10.1006/bbrc.1996.1740; Jordan M, 1996, NUCLEIC ACIDS RES, V24, P596, DOI 10.1093/nar/24.4.596; Jurado LA, 2002, J BIOL CHEM, V277, P27606, DOI 10.1074/jbc.M201429200; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kievit P, 2001, MOL ENDOCRINOL, V15, P614, DOI 10.1210/me.15.4.614; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kowenz-Leutz E, 1999, MOL CELL, V4, P735, DOI 10.1016/S1097-2765(00)80384-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; Lekstrom-Himes J, 1998, J BIOL CHEM, V273, P28545, DOI 10.1074/jbc.273.44.28545; Liu YZ, 1999, NEUROREPORT, V10, P1239, DOI 10.1097/00001756-199904260-00016; Liu YZ, 1998, J BIOL CHEM, V273, P32400, DOI 10.1074/jbc.273.49.32400; LORIAUX MM, 1994, J BIOL CHEM, V269, P28839; MCKNIGHT SL, 1989, GENE DEV, V3, P2021, DOI 10.1101/gad.3.12b.2021; MCKNIGHT SL, 1991, SCI AM, V264, P54, DOI 10.1038/scientificamerican0491-54; Menard C, 2002, NEURON, V36, P597, DOI 10.1016/S0896-6273(02)01026-7; Mink S, 1997, MOL CELL BIOL, V17, P6609, DOI 10.1128/MCB.17.11.6609; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; NATSUKA S, 1992, BLOOD, V79, P460; NERLOV C, 1995, EMBO J, V14, P4318, DOI 10.1002/j.1460-2075.1995.tb00106.x; NERLOV C, 1994, GENE DEV, V8, P350, DOI 10.1101/gad.8.3.350; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Pedersen TA, 2001, GENE DEV, V15, P3208, DOI 10.1101/gad.209901; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Poli V, 1998, J BIOL CHEM, V273, P29279, DOI 10.1074/jbc.273.45.29279; Ramji DP, 2002, BIOCHEM J, V365, P561, DOI 10.1042/bj20020508; REHFUSS RP, 1991, J BIOL CHEM, V266, P18431; Roesler WJ, 1998, J BIOL CHEM, V273, P14950, DOI 10.1074/jbc.273.24.14950; Roesler WJ, 2001, ANNU REV NUTR, V21, P141, DOI 10.1146/annurev.nutr.21.1.141; Schaufele F, 2001, MOL ENDOCRINOL, V15, P1665, DOI 10.1210/me.15.10.1665; Schwartz C, 2003, EMBO J, V22, P882, DOI 10.1093/emboj/cdg076; SCOTT LM, 1992, BLOOD, V80, P1725; Taubenfeld SM, 2001, NAT NEUROSCI, V4, P813, DOI 10.1038/90520; Taubenfeld SM, 2001, J NEUROSCI, V21, P84, DOI 10.1523/JNEUROSCI.21-01-00084.2001; Vo N, 2001, J BIOL CHEM, V276, P13505, DOI 10.1074/jbc.R000025200; Wilson HL, 2002, MOL CELL ENDOCRINOL, V188, P15, DOI 10.1016/S0303-7207(01)00754-7; Xu L, 1998, NATURE, V395, P301, DOI 10.1038/26270; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang WB, 2001, J BIOL CHEM, V276, P38341, DOI 10.1074/jbc.C100316200; Yuan LW, 2002, BBA-MOL CELL RES, V1592, P205, DOI 10.1016/S0167-4889(02)00327-0; Yuan LW, 2000, J BIOL CHEM, V275, P40946, DOI 10.1074/jbc.M007832200; Yukawa K, 1998, J BIOL CHEM, V273, P31345, DOI 10.1074/jbc.273.47.31345; Zanger K, 1999, MOL ENDOCRINOL, V13, P268, DOI 10.1210/me.13.2.268	72	129	131	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36959	36965		10.1074/jbc.M303147200	http://dx.doi.org/10.1074/jbc.M303147200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857754	hybrid			2022-12-27	WOS:000185318300130
J	Medici, MA; Sciortino, MT; Perri, D; Amici, C; Avitabile, E; Ciotti, M; Balestrieri, E; De Smaele, E; Franzoso, G; Mastino, A				Medici, MA; Sciortino, MT; Perri, D; Amici, C; Avitabile, E; Ciotti, M; Balestrieri, E; De Smaele, E; Franzoso, G; Mastino, A			Protection by herpes simplex virus glycoprotein D against Fas-mediated apoptosis - Role of nuclear factor kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOCKS APOPTOSIS; MONOCLONAL-ANTIBODIES; FUNCTIONAL REGION; PROTEIN-KINASE; CELLS; TYPE-1; ACTIVATION; TNF; INDUCTION; ENTRY	Signals involved in protection against apoptosis by herpes simplex virus 1 (HSV-1) were investigated. Using U937 monocytoid cells as an experimental model, we have demonstrated that HSV-1 rendered these cells resistant to Fas-induced apoptosis promptly after infection. UV-inactivated virus as well as the envelope glycoprotein D (gD) of HSV-1, by itself, exerted a protective effect on Fas-induced apoptosis. NF-kappaB was activated by gD, and protection against Fas-mediated apoptosis by gD was abolished in cells stably transfected with a dominant negative mutant I-kappaBalpha, indicating that NF-kappaB activation plays a role in the antiapoptotic activity of gD in our experimental model. Moreover, NF-kappaB-dependent protection against Fas-mediated apoptosis was associated with decreased levels of caspase-8 activity and with the up-regulation of intracellular antiapoptotic proteins.	Univ Messina, Dept Microbiol Genet & Mol Sci, I-98166 Messina, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Univ Bologna, Dept Expt Pathol, Sect Microbiol & Virol, I-40126 Bologna, Italy; Univ Roma Tor Vergata, Tor Vergata Univ Hosp, Dept Expt Med & Biochem Sci, I-00133 Rome, Italy; Univ Chicago, Gwen Knapp Ctr Lupus & Immunol Res, Chicago, IL 60637 USA	University of Messina; University of Rome Tor Vergata; University of Bologna; University of Rome Tor Vergata; Policlin Tor Vergata; University of Chicago	Mastino, A (corresponding author), Univ Messina, Dept Microbiol Genet & Mol Sci, Salita Sperone 31, I-98166 Messina, Italy.	mastino@med.uniroma2.it	Sciortino, Maria Teresa/B-9425-2012; Mastino, Antonio/A-4686-2008; Franzoso, Guido/GRR-8628-2022; De Smaele, Enrico/C-1124-2013	Sciortino, Maria Teresa/0000-0002-8519-7724; Mastino, Antonio/0000-0002-0338-6450; De Smaele, Enrico/0000-0003-4524-4423; AVITABILE, ELISA/0000-0003-0328-2544; balestrieri, emanuela/0000-0001-5906-5907; Franzoso, Guido/0000-0002-0778-988X				Amici C, 2001, J BIOL CHEM, V276, P28759, DOI 10.1074/jbc.M103408200; Aubert M, 1999, J VIROL, V73, P2803, DOI 10.1128/JVI.73.4.2803-2813.1999; Aubert M, 1999, J VIROL, V73, P10359, DOI 10.1128/JVI.73.12.10359-10370.1999; Aubert M, 2001, J VIROL, V75, P1013, DOI 10.1128/JVI.75.2.1013-1030.2001; Barkett M, 1999, ONCOGENE, V18, P6910, DOI 10.1038/sj.onc.1203238; Barry M, 1998, CURR OPIN IMMUNOL, V10, P422, DOI 10.1016/S0952-7915(98)80116-7; Beg AA, 1996, SCIENCE, V274, P782, DOI 10.1126/science.274.5288.782; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; Clarke P, 2003, J BIOL CHEM, V278, P18092, DOI 10.1074/jbc.M300265200; Cocchi F, 1998, P NATL ACAD SCI USA, V95, P15700, DOI 10.1073/pnas.95.26.15700; Everett H, 1999, TRENDS MICROBIOL, V7, P160, DOI 10.1016/S0966-842X(99)01487-0; FEI S, 2002, NATURE, V419, P634; FEI S, 2001, J VIROL, V75, P215; Galvan V, 2000, J VIROL, V74, P1931, DOI 10.1128/JVI.74.4.1931-1938.2000; Galvan V, 1999, J VIROL, V73, P3219, DOI 10.1128/JVI.73.4.3219-3226.1999; Galvan V, 1998, P NATL ACAD SCI USA, V95, P3931, DOI 10.1073/pnas.95.7.3931; HIGHLANDER SL, 1987, J VIROL, V61, P3356, DOI 10.1128/JVI.61.11.3356-3364.1987; Hikichi Y, 2001, BIOCHEM BIOPH RES CO, V289, P670, DOI 10.1006/bbrc.2001.6039; Ito M, 1997, J INFECT DIS, V175, P1220, DOI 10.1086/593672; Jerome KR, 1999, J VIROL, V73, P8950, DOI 10.1128/JVI.73.11.8950-8957.1999; Jerome KR, 2001, J IMMUNOL, V167, P3928, DOI 10.4049/jimmunol.167.7.3928; Jerome KR, 1998, J VIROL, V72, P436, DOI 10.1128/JVI.72.1.436-441.1998; Kagi D, 1996, ANNU REV IMMUNOL, V14, P207, DOI 10.1146/annurev.immunol.14.1.207; Kieff E, 1998, SEMIN VIROL, V8, P471, DOI 10.1006/smvy.1998.0151; Koyama AH, 1997, J GEN VIROL, V78, P2909, DOI 10.1099/0022-1317-78-11-2909; Koyama AH, 1997, J VIROL, V71, P2567, DOI 10.1128/JVI.71.3.2567-2571.1997; Krummenacher C, 1998, J VIROL, V72, P7064, DOI 10.1128/JVI.72.9.7064-7074.1998; Leopardi R, 1997, P NATL ACAD SCI USA, V94, P7891, DOI 10.1073/pnas.94.15.7891; Leopardi R, 1996, P NATL ACAD SCI USA, V93, P9583, DOI 10.1073/pnas.93.18.9583; Marsters SA, 1997, J BIOL CHEM, V272, P14029, DOI 10.1074/jbc.272.22.14029; Mastino A, 1997, CELL DEATH DIFFER, V4, P629, DOI 10.1038/sj.cdd.4400289; Matteucci C, 1999, CYTOMETRY, V35, P145, DOI 10.1002/(SICI)1097-0320(19990201)35:2<145::AID-CYTO6>3.0.CO;2-2; Mercurio F, 1999, CURR OPIN CELL BIOL, V11, P226, DOI 10.1016/S0955-0674(99)80030-1; Mitsiades CS, 2002, ONCOGENE, V21, P5673, DOI 10.1038/sj.onc.1205664; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; Nagata S, 1997, CELL, V88, P355, DOI 10.1016/S0092-8674(00)81874-7; Nicola AV, 1998, J VIROL, V72, P3595, DOI 10.1128/JVI.72.5.3595-3601.1998; Nicola AV, 1996, J VIROL, V70, P3815, DOI 10.1128/JVI.70.6.3815-3822.1996; O'Brien V, 1998, J GEN VIROL, V79, P1833, DOI 10.1099/0022-1317-79-8-1833; Pahl HL, 1999, ONCOGENE, V18, P6853, DOI 10.1038/sj.onc.1203239; Pan JB, 2001, J GEN VIROL, V82, P171, DOI 10.1099/0022-1317-82-1-171; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; Patel A, 1998, VIROLOGY, V247, P212, DOI 10.1006/viro.1998.9243; Perkins ND, 2000, TRENDS BIOCHEM SCI, V25, P434, DOI 10.1016/S0968-0004(00)01617-0; Rivera-Walsh I, 2000, J BIOL CHEM, V275, P25222, DOI 10.1074/jbc.M000444200; RONG BL, 1992, VIROLOGY, V189, P750, DOI 10.1016/0042-6822(92)90599-K; Rossi A, 1997, P NATL ACAD SCI USA, V94, P746, DOI 10.1073/pnas.94.2.746; Rux AH, 1998, J VIROL, V72, P7091, DOI 10.1128/JVI.72.9.7091-7098.1998; SABBIONI S, 1995, ARCH VIROL, V140, P335, DOI 10.1007/BF01309866; Sciortino MT, 2000, VIROLOGY, V277, P27, DOI 10.1006/viro.2000.0575; SERAFINICESSI F, 1988, J GEN VIROL, V69, P869, DOI 10.1099/0022-1317-69-4-869; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Tamada K, 2000, J IMMUNOL, V164, P4105, DOI 10.4049/jimmunol.164.8.4105; Teodoro JG, 1997, J VIROL, V71, P1739, DOI 10.1128/JVI.71.3.1739-1746.1997; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Zachos G, 2001, J VIROL, V75, P2710, DOI 10.1128/JVI.75.6.2710-2728.2001; Zhou GY, 2001, J VIROL, V75, P6166, DOI 10.1128/JVI.75.13.6166-6172.2001; Zhou GY, 2000, J VIROL, V74, P11782, DOI 10.1128/JVI.74.24.11782-11791.2000; Zhou GY, 2000, J VIROL, V74, P9048, DOI 10.1128/JVI.74.19.9048-9053.2000	60	81	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36059	36067		10.1074/jbc.M306198200	http://dx.doi.org/10.1074/jbc.M306198200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844494	hybrid, Green Published			2022-12-27	WOS:000185318300025
J	Ueki, N; Hayman, MJ				Ueki, N; Hayman, MJ			Direct interaction of Ski with either Smad3 or Smad4 is necessary and sufficient for Ski-mediated repression of transforming growth factor-beta signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL REPRESSION; CO-REPRESSOR; DNA-BINDING; ONCOPROTEIN; RECEPTOR; CELLS; ALPHA; ACTS; MAD	The oncoprotein Ski represses transforming growth factor (TGF)-beta signaling in an N-CoR-independent manner. However, the molecular mechanism(s) underlying this event has not been elucidated. Here, we identify an additional domain in Ski that mediates interaction with Smad3 which is important for this repression. This domain is distinct from the previously reported N-terminal Smad3 binding domain in Ski. Individual alanine substitution of several residues in the domain significantly affected Ski-Smad3 interaction. Furthermore, combined mutations within this domain, together with those in the previously identified Smad3 binding domain, can completely abolish the interaction of Ski with Smad3, while mutation in each domain alone retained partial interaction. By introducing those mutations that abolish direct interaction with Smad3 or Smad4 individually, or in combination, we show that interaction of Ski with either Smad3 or Smad4 is sufficient for Ski-mediated repression of TGF-beta signaling. Furthermore our results clearly demonstrate that Ski does not disrupt Smad3-Smad4 heteromer formation, and recruitment of Ski to the Smad3/4 complex through binding to either Smad3 or Smad4 is both necessary and sufficient for repression.	SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Hayman, MJ (corresponding author), SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA.				NATIONAL CANCER INSTITUTE [R01CA042573] Funding Source: NIH RePORTER; NCI NIH HHS [CA42573] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyoshi S, 1999, J BIOL CHEM, V274, P35269, DOI 10.1074/jbc.274.49.35269; Dahl R, 1998, P NATL ACAD SCI USA, V95, P11187, DOI 10.1073/pnas.95.19.11187; Jepsen K, 2002, J CELL SCI, V115, P689; Khan MM, 2001, MOL CELL, V7, P1233, DOI 10.1016/S1097-2765(01)00257-X; Kim SS, 2002, STRUCTURE, V10, P787, DOI 10.1016/S0969-2126(02)00769-4; Luo KX, 1999, GENE DEV, V13, P2196, DOI 10.1101/gad.13.17.2196; Massague J, 2000, EMBO J, V19, P1745, DOI 10.1093/emboj/19.8.1745; Mizuide M, 2003, J BIOL CHEM, V278, P531, DOI 10.1074/jbc.C200596200; Nicol R, 1999, CELL GROWTH DIFFER, V10, P243; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Qin BY, 2002, GENE DEV, V16, P1950, DOI 10.1101/gad.1002002; Sun Y, 1999, MOL CELL, V4, P499, DOI 10.1016/S1097-2765(00)80201-4; Tokitou F, 1999, J BIOL CHEM, V274, P4485, DOI 10.1074/jbc.274.8.4485; Ueki N, 2003, J BIOL CHEM, V278, P24858, DOI 10.1074/jbc.M303447200; Wang W, 2000, P NATL ACAD SCI USA, V97, P14394, DOI 10.1073/pnas.97.26.14394; Wu JW, 2002, CELL, V111, P357, DOI 10.1016/S0092-8674(02)01006-1; Xu WD, 2000, P NATL ACAD SCI USA, V97, P5924, DOI 10.1073/pnas.090097797; Zheng GX, 1997, J BIOL CHEM, V272, P31855, DOI 10.1074/jbc.272.50.31855	18	40	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	AUG 29	2003	278	35					32489	32492		10.1074/jbc.C300276200	http://dx.doi.org/10.1074/jbc.C300276200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	714FN	12857746	hybrid			2022-12-27	WOS:000184901800002
J	Shouldice, SR; Dougan, DR; Williams, PA; Skene, RJ; Snell, G; Scheibe, D; Kirby, S; Hosfield, DJ; McRee, DE; Schryvers, AB; Tari, LW				Shouldice, SR; Dougan, DR; Williams, PA; Skene, RJ; Snell, G; Scheibe, D; Kirby, S; Hosfield, DJ; McRee, DE; Schryvers, AB; Tari, LW			Crystal structure of Pasteurella haemolytica ferric ion-binding protein a reveals a novel class of bacterial iron-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TRANSFERRIN; N-LOBE; ACTIVE-TRANSPORT; LACTOFERRIN; ANGSTROM; OVOTRANSFERRIN; ACQUISITION; REFINEMENT; CHALLENGE; RECEPTORS	Pasteurellosis caused by the Gram-negative pathogen Pasteurella haemolytica is a serious disease leading to death in cattle. To scavenge growth-limiting iron from the host, the pathogen utilizes the periplasmic ferric ion-binding protein A (PhFbpA) as a component of an ATP-binding cassette transport pathway. We report the 1.2-Angstrom structure of the iron-free (apo) form of PhFbpA, which is a member of the transferrin structural superfamily. The protein structure adopts a closed conformation, allowing us to reliably assign putative iron-coordinating residues. Based on our analysis, PhFbpA utilizes a unique constellation of binding site residues and anions to octahedrally coordinate an iron atom. A surprising finding in the structure is the presence of two formate anions on opposite sides of the iron-binding pocket. The formate ions tether the N- and C-terminal domains of the protein and stabilize the closed structure, also providing clues as to probable candidates for synergistic anions in the iron-loaded state. PhFbpA represents a new class of bacterial iron-binding proteins.	Syrrx Inc, Crystallog, San Diego, CA 92121 USA; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Astex Technol, Cambridge CB4 0QA, England	University of Calgary	Tari, LW (corresponding author), Syrrx Inc, Crystallog, 10410 Sci Ctr Dr, San Diego, CA 92121 USA.	ltari@syrrx.com	Schryvers, Anthony B./AAF-3417-2020	Skene, Robert/0000-0002-1482-6546; Williams, Pamela/0000-0002-1257-2351				ADHIKARI P, 1995, J BIOL CHEM, V270, P25142, DOI 10.1074/jbc.270.42.25142; AMES TR, 1985, CAN J COMP MED, V49, P395; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker HM, 2001, BIOCHEMISTRY-US, V40, P11670, DOI 10.1021/bi010907p; BROWN MPS, 1999, NUCLEIC ACIDS RES, V25, P3389; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bruns CM, 1997, NAT STRUCT BIOL, V4, P919, DOI 10.1038/nsb1197-919; CHEN CY, 1993, MOL MICROBIOL, V10, P311, DOI 10.1111/j.1365-2958.1993.tb01957.x; CONLON JA, 1991, INFECT IMMUN, V59, P587, DOI 10.1128/IAI.59.2.587-591.1991; CROSA JH, 1984, ANNU REV MICROBIOL, V38, P69, DOI 10.1146/annurev.mi.38.100184.000441; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dhungana S, 2003, P NATL ACAD SCI USA, V100, P3659, DOI 10.1073/pnas.0536897100; GILMOUR NJL, 1983, RES VET SCI, V35, P80, DOI 10.1016/S0034-5288(18)32208-2; GrayOwen SD, 1996, TRENDS MICROBIOL, V4, P185, DOI 10.1016/0966-842X(96)10025-1; Hall DR, 2002, ACTA CRYSTALLOGR D, V58, P70, DOI 10.1107/S0907444901017309; Holm L, 1997, NUCLEIC ACIDS RES, V25, P231, DOI 10.1093/nar/25.1.231; JAROSIK GP, 1995, INFECT IMMUN, V63, P710, DOI 10.1128/IAI.63.2.710-713.1995; Kirby SD, 1998, MICROBIOL-UK, V144, P3425, DOI 10.1099/00221287-144-12-3425; Kirby SD, 1997, MOL MICROBIOL, V25, P979, DOI 10.1111/j.1365-2958.1997.mmi535.x; KUROKAWA H, 1995, J MOL BIOL, V254, P196, DOI 10.1006/jmbi.1995.0611; MacGillivray RTA, 1998, BIOCHEMISTRY-US, V37, P7919, DOI 10.1021/bi980355j; Marchart J, 2003, VACCINE, V21, P1415, DOI 10.1016/S0264-410X(02)00635-7; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; MIETZNER TA, 1994, ANNU REV NUTR, V14, P471, DOI 10.1146/annurev.nu.14.070194.002351; Mizutani K, 2001, J MOL BIOL, V309, P937, DOI 10.1006/jmbi.2001.4719; Moore SA, 1997, J MOL BIOL, V274, P222, DOI 10.1006/jmbi.1997.1386; Morris RJ, 2002, ACTA CRYSTALLOGR D, V58, P968, DOI 10.1107/S0907444902005462; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Peterson NA, 2002, BIOCHEMISTRY-US, V41, P14167, DOI 10.1021/bi020443a; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; Quiocho FA, 1996, MOL MICROBIOL, V20, P17, DOI 10.1111/j.1365-2958.1996.tb02484.x; Schryvers AB, 1999, MOL MICROBIOL, V32, P1117, DOI 10.1046/j.1365-2958.1999.01411.x; Shouldice SR, 2003, J BIOL CHEM, V278, P11513, DOI 10.1074/jbc.M211780200; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; WEINBERG ED, 1984, PHYSIOL REV, V64, P65, DOI 10.1152/physrev.1984.64.1.65; Wessling-Resnick M, 1999, CRIT REV BIOCHEM MOL, V34, P285, DOI 10.1080/10409239991209318; WHITELEY LO, 1992, J VET INTERN MED, V6, P11, DOI 10.1111/j.1939-1676.1992.tb00980.x; Yang AHW, 2000, PROTEIN SCI, V9, P49	40	23	23	0	1	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41093	41098		10.1074/jbc.M306821200	http://dx.doi.org/10.1074/jbc.M306821200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882966	hybrid			2022-12-27	WOS:000185847200084
J	Gasteier, JE; Madrid, R; Krautkramer, E; Schroder, S; Muranyi, W; Benichou, S; Fackler, OT				Gasteier, JE; Madrid, R; Krautkramer, E; Schroder, S; Muranyi, W; Benichou, S; Fackler, OT			Activation of the Rac-binding partner FHOD1 induces actin stress fibers via a ROCK-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DIAPHANOUS-RELATED FORMIN; SERUM RESPONSE FACTOR; SRC TYROSINE KINASE; SACCHAROMYCES-CEREVISIAE; CYTOSKELETAL CONTROL; FAMILY PROTEINS; ARP2/3 COMPLEX; RHO GTPASES; LIM KINASE; DYNAMICS	Diaphanous related formins (DRFs) are part of the formin protein family that control morphogenesis, embryonic differentiation, cytokinesis, and cell polarity. DRFs organize the cytoskeleton in eukaryotic cells via the interaction with specific members of the Rho family of small GTPases including Rho, Rac, and Cdc42. This is best understood for Rho, which transmits signals to the actin cytoskeleton through the cooperation of its DRF effector mDia with ROCK (Rho-associated kinase). Here, we show that a constitutive active form of the Rac-interacting DRF FHOD1 (formin homology 2 domain containing 1) associates with F-actin in NIH3T3 cells, resulting in the formation of thick actin fibers. Cytoskeletal changes induced by FHOD1 correlated with the induction of serum response element transcription and were mediated by formin homology domains 1 and 2 of FHOD1. FHOD1-induced effects required the activity of the Rho-ROCK cascade that is targeted at a level downstream of Rho by the DRF. However, when the functional interaction of FHOD1 with individual GTPases was addressed, Rac but not Rho or Cdc42 bound to FHOD1 in cells and induced its recruitment to actin filaments and lamellipodia/membrane ruffles. Furthermore, activated FHOD1 interfered with lamellipodia formation. These results indicate that FHOD1 acts as an effector of Rac in actin rearrangements and transcriptional regulation and may provide a link for the Rac-dependent activation of the Rho cascade.	Univ Heidelberg, Dept Virol, Inst Hyg, INF 324, D-69120 Heidelberg, Germany; Univ Paris 05, Dept Infect Dis, Inst Cochin, CNRS,UMR 8104,INSERM,U567, F-75014 Paris, France	Ruprecht Karls University Heidelberg; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fackler, OT (corresponding author), Univ Heidelberg, Dept Virol, Inst Hyg, INF 324, D-69120 Heidelberg, Germany.			Madrid Gonzalez, Ricardo/0000-0002-1350-9864; Benichou, Serge/0000-0003-3602-3530; Fackler, Oliver Till/0000-0003-2982-4209				Alberts AS, 2001, J BIOL CHEM, V276, P2824, DOI 10.1074/jbc.M006205200; Alberts AS, 1998, J BIOL CHEM, V273, P8616, DOI 10.1074/jbc.273.15.8616; Bar-Sagi D, 2000, CELL, V103, P227, DOI 10.1016/S0092-8674(00)00115-X; Bierne H, 2001, J CELL BIOL, V155, P101, DOI 10.1083/jcb.200104037; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; Driessens MHE, 2001, CURR BIOL, V11, P339, DOI 10.1016/S0960-9822(01)00092-6; Evangelista M, 2002, NAT CELL BIOL, V4, P41; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; Fackler OT, 1999, MOL CELL, V3, P729, DOI 10.1016/S1097-2765(01)80005-8; FRAZIER JA, 1997, CURR BIOL, V7, P414; Gasman S, 2003, NAT CELL BIOL, V5, P195, DOI 10.1038/ncb935; Geneste O, 2002, J CELL BIOL, V157, P831, DOI 10.1083/jcb.200203126; Habas R, 2001, CELL, V107, P843, DOI 10.1016/S0092-8674(01)00614-6; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Hirose M, 1998, J CELL BIOL, V141, P1625, DOI 10.1083/jcb.141.7.1625; Imamura H, 1997, EMBO J, V16, P2745, DOI 10.1093/emboj/16.10.2745; Ishizaki T, 2001, NAT CELL BIOL, V3, P8; Kohno H, 1996, EMBO J, V15, P6060, DOI 10.1002/j.1460-2075.1996.tb00994.x; Koka S, 2003, J CELL SCI, V116, P1745, DOI 10.1242/jcs.00386; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Machesky LM, 1998, CURR BIOL, V8, P1347, DOI 10.1016/S0960-9822(98)00015-3; Moreau V, 2000, NAT CELL BIOL, V2, P441, DOI 10.1038/35017080; Peng J, 2003, CURR BIOL, V13, P534, DOI 10.1016/S0960-9822(03)00170-2; Pollard TD, 2002, NAT CELL BIOL, V4, pE191, DOI 10.1038/ncb0802-e191a; Pollard TD, 2001, J CELL SCI, V114, P3; Pruyne D, 2002, SCIENCE, V297, P612, DOI 10.1126/science.1072309; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Ridley AJ, 2001, DEV CELL, V1, P160, DOI 10.1016/S1534-5807(01)00029-6; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Ridley AJ, 2001, TRAFFIC, V2, P303, DOI 10.1034/j.1600-0854.2001.002005303.x; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Sagot I, 2002, NAT CELL BIOL, V4, P626, DOI 10.1038/ncb834; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; Schafer DA, 1998, J CELL BIOL, V143, P1919, DOI 10.1083/jcb.143.7.1919; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; Tanaka K, 2000, BIOCHEM BIOPH RES CO, V267, P479, DOI 10.1006/bbrc.1999.1707; Tominaga T, 2000, MOL CELL, V5, P13, DOI 10.1016/S1097-2765(00)80399-8; Tsuji T, 2002, J CELL BIOL, V157, P819, DOI 10.1083/jcb.200112107; vanLeeuwen FN, 1997, J CELL BIOL, V139, P797, DOI 10.1083/jcb.139.3.797; Wasserman S, 1998, TRENDS CELL BIOL, V8, P111, DOI 10.1016/S0962-8924(97)01217-8; Watanabe N, 1997, EMBO J, V16, P3044, DOI 10.1093/emboj/16.11.3044; Watanabe N, 1999, NAT CELL BIOL, V1, P136, DOI 10.1038/11056; Westendorf JJ, 1999, GENE, V232, P173, DOI 10.1016/S0378-1119(99)00127-4; Westendorf JJ, 2001, J BIOL CHEM, V276, P46453, DOI 10.1074/jbc.M105162200; Yayoshi-Yamamoto S, 2000, MOL CELL BIOL, V20, P6872, DOI 10.1128/MCB.20.18.6872-6881.2000; Zhou Z, 2001, DEV CELL, V1, P477, DOI 10.1016/S1534-5807(01)00058-2	47	75	75	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38902	38912		10.1074/jbc.M306229200	http://dx.doi.org/10.1074/jbc.M306229200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857739	hybrid			2022-12-27	WOS:000185575100099
J	Noe, V; MacKenzie, S; Ciudad, CJ				Noe, V; MacKenzie, S; Ciudad, CJ			An intron is required for dihydrofolate reductase protein stability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONSENSE-MEDIATED DECAY; MATERNAL MESSENGER-RNA; GENE-EXPRESSION; ADENINE PHOSPHORIBOSYLTRANSFERASE; TRANSLATION INITIATION; MAMMALIAN-CELLS; NUCLEOCYTOPLASMIC TRANSPORT; INTERVENING SEQUENCES; NUCLEAR HISTORY; XENOPUS-OOCYTES	We compared the expression of dihydrofolate reductase minigenes with and without an intron. The levels of protein were significantly higher in the presence of dihydrofolate reductase intron 1. However, mRNA levels in both constructs were comparable. In addition, the RNA transcribed from either construct was correctly polyadenylated and exported to the cytoplasm. The intron-mediated increase in dihydrofolate reductase protein levels was position-independent and was also observed when dihydrofolate reductase intron 1 was replaced by heterologous introns. The translational rate of dihydrofolate reductase protein was increased in transfectants from the intron-containing minigene. In addition, the protein encoded by the intronless construct was unstable and subject to lysosomal degradation, thus showing a shorter half-life than the protein encoded by the intron-containing minigene. We conclude that an intron is required for the translation and stability of dihydrofolate reductase protein.	Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, E-08028 Barcelona, Spain; Autonomous Univ Barcelona, Sch Sci, Dept Cellular Biol Physiol & Immunol, E-08193 Barcelona, Spain	University of Barcelona; Autonomous University of Barcelona	Noe, V (corresponding author), Univ Barcelona, Sch Pharm, Dept Biochem & Mol Biol, Av Diagonal 643, E-08028 Barcelona, Spain.		MacKenzie, Simon/Q-2362-2019; Noe, Veronique/K-3615-2014; Ciudad, Carlos J./D-7917-2014	MacKenzie, Simon/0000-0003-1845-6826; Noe, Veronique/0000-0001-7937-8038; Ciudad, Carlos J./0000-0002-7855-392X				BOUVET P, 1994, CELL, V77, P931, DOI 10.1016/0092-8674(94)90141-4; BRADDOCK M, 1994, NUCLEIC ACIDS RES, V22, P5255, DOI 10.1093/nar/22.24.5255; BRINSTER RL, 1988, P NATL ACAD SCI USA, V85, P836, DOI 10.1073/pnas.85.3.836; Brocke KS, 2002, HUM MOL GENET, V11, P331, DOI 10.1093/hmg/11.3.331; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P4395, DOI 10.1128/MCB.8.10.4395; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; Cooke C, 1999, MOL CELL BIOL, V19, P4971; CROUSE GF, 1988, NUCLEIC ACIDS RES, V16, P7025, DOI 10.1093/nar/16.14.7025; de Moor CH, 2001, INT REV CYTOL, V203, P567; DICE JF, 1987, FASEB J, V1, P349, DOI 10.1096/fasebj.1.5.2824267; ECKNER R, 1991, EMBO J, V10, P3513, DOI 10.1002/j.1460-2075.1991.tb04915.x; GASSER CS, 1982, P NATL ACAD SCI-BIOL, V79, P6522, DOI 10.1073/pnas.79.21.6522; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gray NK, 1998, ANNU REV CELL DEV BI, V14, P399, DOI 10.1146/annurev.cellbio.14.1.399; HAMM J, 1989, EMBO J, V8, P4153; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HUANG MTF, 1990, NUCLEIC ACIDS RES, V18, P937, DOI 10.1093/nar/18.4.937; Huang YQ, 1996, MOL CELL BIOL, V16, P1534; KESSLER O, 1993, MOL CELL BIOL, V13, P6211, DOI 10.1128/MCB.13.10.6211; Kessler O, 1996, MOL CELL BIOL, V16, P4426; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Le Hir H, 2000, EMBO J, V19, P6860, DOI 10.1093/emboj/19.24.6860; Lee DH, 1996, J BIOL CHEM, V271, P27280, DOI 10.1074/jbc.271.44.27280; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; Lou H, 1996, GENE DEV, V10, P208, DOI 10.1101/gad.10.2.208; Lu SH, 2003, RNA, V9, P618, DOI 10.1261/rna.5260303; Luo MJ, 1999, P NATL ACAD SCI USA, V96, P14937, DOI 10.1073/pnas.96.26.14937; LUSKY M, 1984, CELL, V36, P391, DOI 10.1016/0092-8674(84)90232-0; Maquat LE, 2001, RNA, V7, P445, DOI 10.1017/S1355838201002229; Matsumoto K, 1998, EMBO J, V17, P2107, DOI 10.1093/emboj/17.7.2107; Meric F, 1996, J BIOL CHEM, V271, P30804, DOI 10.1074/jbc.271.48.30804; Moriyama T, 1998, J BIOL CHEM, V273, P22037, DOI 10.1074/jbc.273.34.22037; Muckenthaler M, 1997, RNA, V3, P983; NESIC D, 1994, GENE DEV, V8, P363, DOI 10.1101/gad.8.3.363; NESIC D, 1993, MOL CELL BIOL, V13, P3359, DOI 10.1128/MCB.13.6.3359; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE EXPRESSION, V1, P5; Noe V, 1998, ONCOGENE, V16, P1931, DOI 10.1038/sj.onc.1201718; Noe V, 1999, J BIOL CHEM, V274, P27807, DOI 10.1074/jbc.274.39.27807; Nott A, 2003, RNA, V9, P607, DOI 10.1261/rna.5250403; PANDEY NB, 1990, NUCLEIC ACIDS RES, V18, P3161, DOI 10.1093/nar/18.11.3161; Pasquinelli AE, 1997, EMBO J, V16, P7500, DOI 10.1093/emboj/16.24.7500; Preiss T, 1998, RNA, V4, P1321, DOI 10.1017/S1355838298980669; Preiss T, 1999, CURR OPIN GENET DEV, V9, P515, DOI 10.1016/S0959-437X(99)00005-2; Rodrigues JP, 2001, P NATL ACAD SCI USA, V98, P1030, DOI 10.1073/pnas.98.3.1030; Rousseau D, 1996, P NATL ACAD SCI USA, V93, P1065, DOI 10.1073/pnas.93.3.1065; RYU WS, 1989, J VIROL, V63, P4386, DOI 10.1128/JVI.63.10.4386-4394.1989; Salles FJ, 1999, METHODS, V17, P38, DOI 10.1006/meth.1998.0705; Salvador N, 2000, J BIOL CHEM, V275, P27447; SEGLEN PO, 1979, EUR J BIOCHEM, V95, P215, DOI 10.1111/j.1432-1033.1979.tb12956.x; STANDART N, 1994, CURR BIOL, V4, P939, DOI 10.1016/S0960-9822(00)00212-8; Sun XL, 2000, EMBO J, V19, P4734, DOI 10.1093/emboj/19.17.4734; TERLECKY SR, 1993, J BIOL CHEM, V268, P23490; Ullman KS, 1999, MOL BIOL CELL, V10, P649, DOI 10.1091/mbc.10.3.649; URLAUB G, 1986, SOMAT CELL MOLEC GEN, V12, P555, DOI 10.1007/BF01671941; VENOLIA L, 1987, SOMAT CELL MOLEC GEN, V13, P491, DOI 10.1007/BF01534491; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WIGLER M, 1979, P NATL ACAD SCI USA, V76, P1373, DOI 10.1073/pnas.76.3.1373; Zhang J, 1998, RNA, V4, P801, DOI 10.1017/S1355838298971849	60	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38292	38300		10.1074/jbc.M212746200	http://dx.doi.org/10.1074/jbc.M212746200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12865433	hybrid			2022-12-27	WOS:000185575100027
J	Santilli, G; Aronow, BJ; Sala, A				Santilli, G; Aronow, BJ; Sala, A			Essential requirement of apolipoprotein J (clusterin) signaling for I kappa B expression and regulation of NF-kappa B activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; CANCER-CELLS; AUTOIMMUNE MYOCARDITIS; DEGRADATION; ACTIVATION; PHOSPHORYLATION; UBIQUITINATION; MIGRATION; DEATH	Apolipoprotein J/clusterin is an enigmatic protein highly regulated in inflammation, apoptosis, and cancer. Despite extensive studies, its biological function has remained obscure. Here we show that apolipoprotein J inhibits neuroblastoma cell invasion. Since this function can be regulated by NF-kappaB, we explored the possibility that apolipoprotein J might interfere with NF-kappaB signaling. Ectopic apolipoprotein J expression strongly inhibited NF-kappaB activity in human neuroblastoma cells and murine embryonic fibroblasts by stabilizing inhibitors of NF-kappaB (IkappaBs). Steady state levels of IkappaB proteins are drastically reduced in mouse embryo fibroblasts after disruption of the apolipoprotein J gene. Absence of apolipoprotein J causes reduction of IkappaB stability, a tumor necrosis factor-dependent increase in NF-kappaB activity, increased transcription of the NF-kappaB target gene c-IAP and down-modulation of p53 protein. These results suggest that an unexpected physiological role of apolipoprotein J is to inhibit NF-kappaB signaling through stabilization of IkappaBs and that this activity may result in suppression of tumor cell motility.	UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England; Univ G DAnnunzio, Sez Oncol Med, Dipartimento Oncol & Neurosci, I-66100 Chieti, Italy; Childrens Hosp, Med Ctr, Div Dev Biol, Cincinnati, OH 45229 USA	University of London; University College London; G d'Annunzio University of Chieti-Pescara; Cincinnati Children's Hospital Medical Center	Sala, A (corresponding author), UCL, Inst Child Hlth, Mol Haematol & Canc Biol Unit, London WC1N 1EH, England.	a.sala@ich.ucl.ac.uk	sala, arturo/C-4959-2008; Aronow, Bruce J/F-8438-2012	Sala, Arturo/0000-0002-2841-7866				Behrens P, 2001, PATHOBIOLOGY, V69, P19, DOI 10.1159/000048753; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Cervellera M, 2000, J BIOL CHEM, V275, P21055, DOI 10.1074/jbc.M002055200; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; Fenwick C, 2000, SCIENCE, V287, P869, DOI 10.1126/science.287.5454.869; Garg A, 2002, LEUKEMIA, V16, P1053, DOI 10.1038/sj.leu.2402482; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Han BH, 2001, NAT MED, V7, P338, DOI 10.1038/85487; Huber MA, 2002, J BIOL CHEM, V277, P1268, DOI 10.1074/jbc.M109358200; Jones SE, 2002, INT J BIOCHEM CELL B, V34, P427, DOI 10.1016/S1357-2725(01)00155-8; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Mclaughlin L, 2000, J CLIN INVEST, V106, P1105, DOI 10.1172/JCI9037; Miyake H, 2000, CLIN CANCER RES, V6, P1655; Pando MP, 2000, J BIOL CHEM, V275, P21278, DOI 10.1074/jbc.M002532200; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; SEEGER RC, 1982, J IMMUNOL, V128, P983; SENSIBAR JA, 1995, CANCER RES, V55, P2431; Sintich SM, 1999, PROSTATE, V39, P87; Sivamurthy N, 2001, J VASC SURG, V34, P716, DOI 10.1067/mva.2001.116301; Spalding AC, 2002, ONCOGENE, V21, P260, DOI 10.1038/sj.onc.1205048; Tergaonkar V, 2002, CANCER CELL, V1, P493, DOI 10.1016/S1535-6108(02)00068-5; Trougakos IP, 2002, INT J BIOCHEM CELL B, V34, P1430, DOI 10.1016/S1357-2725(02)00041-9; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ZB, 2001, FEBS LETT, V508, P360, DOI 10.1016/S0014-5793(01)03109-X; Wilson MR, 2000, TRENDS BIOCHEM SCI, V25, P95, DOI 10.1016/S0968-0004(99)01534-0; Yang CR, 2000, P NATL ACAD SCI USA, V97, P5907, DOI 10.1073/pnas.97.11.5907; Yokoseki O, 2001, CIRC RES, V89, P899, DOI 10.1161/hh2201.099373	27	111	115	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38214	38219		10.1074/jbc.C300252200	http://dx.doi.org/10.1074/jbc.C300252200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882985	hybrid			2022-12-27	WOS:000185575100017
J	Fusetti, F; Pijning, T; Kalk, KH; Bos, E; Dijkstra, BW				Fusetti, F; Pijning, T; Kalk, KH; Bos, E; Dijkstra, BW			Crystal structure and carbohydrate-binding properties of the human cartilage glycoprotein-39	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY RHEUMATOID-ARTHRITIS; SERUM YKL-40; HUMAN CHITOTRIOSIDASE; GLUCOSAMINE RESIDUES; PERIPHERAL-BLOOD; SYNOVIAL-CELLS; HC GP-39; PROTEIN; CHITINASE; FAMILY	The human cartilage glycoprotein-39 (HCgp-39 or YKL40) is expressed by synovial cells and macrophages during inflammation. Its precise physiological role is unknown. However, it has been proposed that HCgp-39 acts as an autoantigen in rheumatoid arthritis, and high expression levels have been associated with cancer development. HCgp-39 shares high sequence homology with family 18 chitinases, and although it binds to chitin it lacks enzymatic activity. The crystal structure of HCgp-39 shows that the protein displays a (beta/alpha)(8)-barrel fold with an insertion of an alpha + beta domain. A 43-Angstrom long carbohydrate-binding cleft is present at the C-terminal side of the beta-strands in the (beta/alpha)(8) barrel. Binding of chitin fragments of different lengths identified nine sugar-binding subsites in the groove. Protein-carbohydrate interactions are mainly mediated by stacking of side chains of aromatic amino acid residues. Surprisingly, the specificity of chitin binding to HCgp-39 depends on the length of the oligosaccharide. Although chitin disaccharides tend to occupy the distal subsites, longer chains bind preferably to the central subsites in the groove. Despite the absence of enzymatic activity, long chitin fragments are distorted upon binding, with the GlcNAc at subsite -1 in a boat conformation, similar to what has been observed in chitinases. The presence of chitin in the human body has never been documented so far. However, the binding features observed in the complex structures suggest that either chitin or a closely related oligosaccharide could act as the physiological ligand for HCgp-39.	Univ Groningen, Dept Chem, Cent Lab Biophys, NL-9747 AG Groningen, Netherlands; NV Organon, NL-5340 BH Oss, Netherlands	University of Groningen	Dijkstra, BW (corresponding author), Univ Groningen, Dept Chem, Cent Lab Biophys, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	bauke@chem.rug.nl	Pijning, Tjaard/HDO-3704-2022; Dijkstra, Bauke W./H-4308-2019; Pijning, Tjaard/ABA-2929-2021	Dijkstra, Bauke W./0000-0001-9731-6586; Pijning, Tjaard/0000-0003-4107-3663				Baeten D, 2000, ARTHRITIS RHEUM, V43, P1233, DOI 10.1002/1529-0131(200006)43:6<1233::AID-ANR6>3.0.CO;2-9; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buhi WC, 2002, REPRODUCTION, V123, P355, DOI 10.1530/rep.0.1230355; Capila I, 2002, ANGEW CHEM INT EDIT, V41, P391; Chang NCA, 2001, J BIOL CHEM, V276, P17497, DOI 10.1074/jbc.M010417200; Cintin C, 1999, BRIT J CANCER, V79, P1494, DOI 10.1038/sj.bjc.6690238; Connor JR, 2000, OSTEOARTHR CARTILAGE, V8, P87, DOI 10.1053/joca.1999.0276; Conrozier T, 2000, ANN RHEUM DIS, V59, P828, DOI 10.1136/ard.59.10.828; Cope AP, 1999, ARTHRITIS RHEUM, V42, P1497, DOI 10.1002/1529-0131(199907)42:7<1497::AID-ANR25>3.0.CO;2-#; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Davies GJ, 1997, BIOCHEM J, V321, P557, DOI 10.1042/bj3210557; DeLano W. L., 2002, PYMOL MOL GRAPHIC SY; Drenth J., 2010, PRINCIPLES PROTEIN C, V3rd; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; Firestein GS, 2003, NATURE, V423, P356, DOI 10.1038/nature01661; FORD LO, 1974, J MOL BIOL, V88, P349, DOI 10.1016/0022-2836(74)90487-2; Furey W, 1997, METHOD ENZYMOL, V277, P590, DOI 10.1016/S0076-6879(97)77033-2; Fusetti F, 2002, J BIOL CHEM, V277, P25537, DOI 10.1074/jbc.M201636200; HAKALA BE, 1993, J BIOL CHEM, V268, P25803; Henrissat B, 1997, CURR OPIN STRUC BIOL, V7, P637, DOI 10.1016/S0959-440X(97)80072-3; Hu B, 1996, J BIOL CHEM, V271, P19415, DOI 10.1074/jbc.271.32.19415; Johansen JS, 2000, J HEPATOL, V32, P911, DOI 10.1016/S0168-8278(00)80095-1; JOHANSEN JS, 1995, EUR J CANCER, V31A, P1437, DOI 10.1016/0959-8049(95)00196-P; Johansen JS, 1996, BRIT J RHEUMATOL, V35, P553; JOHANSEN JS, 1993, BRIT J RHEUMATOL, V32, P949; Johansen JS, 2001, SCAND J RHEUMATOL, V30, P297; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kavanaugh A, 2003, J RHEUMATOL, V30, P449; Kawamura K, 1999, DEVELOPMENT, V126, P211; Kirkpatrick RB, 1997, EXP CELL RES, V237, P46, DOI 10.1006/excr.1997.3764; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Meyer MF, 1996, P NATL ACAD SCI USA, V93, P4543, DOI 10.1073/pnas.93.10.4543; Mohanty AK, 2003, J BIOL CHEM, V278, P14451, DOI 10.1074/jbc.M208967200; Mueller A, 2003, P NATL ACAD SCI USA, V100, P1292, DOI 10.1073/pnas.242741699; NORGARDSUMNICHT K, 1995, J BIOL CHEM, V270, P12012, DOI 10.1074/jbc.270.20.12012; NYIRKOS P, 1990, BIOCHEM J, V269, P265, DOI 10.1042/bj2690265; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Papanikolau Y, 2001, BIOCHEMISTRY-US, V40, P11338, DOI 10.1021/bi010505h; Peltomaa R, 2001, RHEUMATOL INT, V20, P192, DOI 10.1007/s002960100115; PERRAKIS A, 1994, STRUCTURE, V2, P1169, DOI 10.1016/S0969-2126(94)00119-7; Recklies AD, 2002, BIOCHEM J, V365, P119, DOI 10.1042/BJ20020075; RENKEMA GH, 1995, J BIOL CHEM, V270, P2198, DOI 10.1074/jbc.270.5.2198; Renkema GH, 1998, EUR J BIOCHEM, V251, P504, DOI 10.1046/j.1432-1327.1998.2510504.x; Semino CE, 1996, P NATL ACAD SCI USA, V93, P4548, DOI 10.1073/pnas.93.10.4548; SHACKELTON LM, 1995, J BIOL CHEM, V270, P13076, DOI 10.1074/jbc.270.22.13076; Sun YJ, 2001, J BIOL CHEM, V276, P17507, DOI 10.1074/jbc.M010416200; Tews I, 1997, J AM CHEM SOC, V119, P7954, DOI 10.1021/ja970674i; Tsark EC, 2002, J IMMUNOL, V169, P6625, DOI 10.4049/jimmunol.169.11.6625; Tsuji T, 2002, SPINE, V27, P732, DOI 10.1097/00007632-200204010-00010; van Aalten DMF, 2001, P NATL ACAD SCI USA, V98, P8979, DOI 10.1073/pnas.151103798; van Aalten DMF, 2000, P NATL ACAD SCI USA, V97, P5842, DOI 10.1073/pnas.97.11.5842; VANSCHELTINGA ACT, 1994, STRUCTURE, V2, P1181, DOI 10.1016/S0969-2126(94)00120-0; Varela PF, 2002, J BIOL CHEM, V277, P13229, DOI 10.1074/jbc.M110502200; Verheijden GFM, 1997, ARTHRITIS RHEUM, V40, P1115, DOI 10.1002/art.1780400616; Vos K, 2000, ANN RHEUM DIS, V59, P544, DOI 10.1136/ard.59.7.544; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Westling C, 2002, J BIOL CHEM, V277, P49247, DOI 10.1074/jbc.M209139200	61	146	155	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37753	37760		10.1074/jbc.M303137200	http://dx.doi.org/10.1074/jbc.M303137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851408	hybrid, Green Published			2022-12-27	WOS:000185437200093
J	Hansen, U; Bruckner, P				Hansen, U; Bruckner, P			Macromolecular specificity of collagen fibrillogenesis - Fibrils of collagens I and XI contain a heterotypic alloyed core and a collagen I sheath	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							V COLLAGEN; INTERMEDIATE-FILAMENTS; EXTRACELLULAR-MATRIX; INTERVERTEBRAL DISCS; SMALL PROTEOGLYCAN; MOLECULAR PACKING; CARTILAGE FIBRILS; ARP2/3 COMPLEX; TRIPLE-HELIX; III COLLAGEN	Suprastructures of the extracellular matrix, such as banded collagen fibrils, microfibrils, filaments, or networks, are composites comprising more than one type of macromolecule. The suprastructural diversity reflects tissue-specific requirements and is achieved by formation of macromolecular composites that often share their main molecular components alloyed with minor components. Both, the mechanisms of formation and the final macromolecular organizations depend on the identity of the components and their quantitative contribution. Collagen I is the predominant matrix constituent in many tissues and aggregates with other collagens and/or fibril-associated macromolecules into distinct types of banded fibrils. Here, we studied co-assembly of collagens I and XI, which co-exist in fibrils of several normal and pathologically altered tissues, including fibrous cartilage and bone, or osteoarthritic joints. Immediately upon initiation of fibrillogenesis, the proteins co-assembled into alloy-like stubby aggregates that represented efficient nucleation sites for the formation of composite fibrils. Propagation of fibrillogenesis occurred by exclusive accretion of collagen I to yield composite fibrils of highly variable diameters. Therefore, collagen I/XI fibrils strikingly differed from the homogeneous fibrillar alloy generated by collagens II and XI, although the constituent polypeptides of collagens I and II are highly homologous. Thus, the mode of aggregation of collagens into vastly diverse fibrillar composites is finely tuned by subtle differences in molecular structures through formation of macromolecular alloys.	Univ Klinikum Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany	University of Munster	Bruckner, P (corresponding author), Univ Klinikum Munster, Inst Physiol Chem & Pathobiochem, Waldeyerstr 15, D-48149 Munster, Germany.	peter.bruckner@uni-muenster.de	Bruckner, Peter/F-4817-2019	Bruckner, Peter/0000-0002-5566-5611				ADACHI E, 1986, CONNECT TISSUE RES, V14, P257, DOI 10.3109/03008208609017469; Aszodi A, 1998, J CELL BIOL, V143, P1399, DOI 10.1083/jcb.143.5.1399; BACHINGER HP, 1980, EUR J BIOCHEM, V106, P619, DOI 10.1111/j.1432-1033.1980.tb04610.x; BALDWIN CT, 1989, BIOCHEM J, V262, P521, DOI 10.1042/bj2620521; BIRK DE, 1988, J CELL BIOL, V106, P999, DOI 10.1083/jcb.106.3.999; Birk DE, 2001, MICRON, V32, P223, DOI 10.1016/S0968-4328(00)00043-3; BIRK DE, 1990, J CELL SCI, V95, P649; Blaschke UK, 2000, J BIOL CHEM, V275, P10370, DOI 10.1074/jbc.275.14.10370; Bos KJ, 2001, J MOL BIOL, V306, P1011, DOI 10.1006/jmbi.2000.4429; BRODSKY B, 1980, BIOCHIM BIOPHYS ACTA, V621, P162, DOI 10.1016/0005-2795(80)90072-0; BRODSKY B, 1985, BIOL CHEM PATHOLOGY, P73; BROWN DC, 1990, MATRIX, V9, P468, DOI 10.1016/S0934-8832(11)80016-8; Chakravarti S, 2000, INVEST OPHTH VIS SCI, V41, P3365; Coulombe PA, 2001, J CELL SCI, V114, P4345; Coulombe PA, 2002, CURR OPIN CELL BIOL, V14, P110, DOI 10.1016/S0955-0674(01)00301-5; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; EIKENBERRY EF, 1984, J MOL BIOL, V176, P261, DOI 10.1016/0022-2836(84)90424-8; EIKENBERRY EF, 1992, ARTICULAR CARTILAGE AND OSTEOARTHRITIS, P133; Eyre D, 2002, ARTHRITIS RES, V4, P30, DOI 10.1186/ar380; Eyre D, 1987, STRUCTURE FUNCTION C, P261; Ezura Y, 2000, J CELL BIOL, V151, P779, DOI 10.1083/jcb.151.4.779; FRASER RDB, 1987, J MOL BIOL, V193, P115, DOI 10.1016/0022-2836(87)90631-0; GELMAN RA, 1979, J BIOL CHEM, V254, P180; Hagg R, 1998, J CELL BIOL, V142, P285, DOI 10.1083/jcb.142.1.285; HEDBOM E, 1989, J BIOL CHEM, V264, P6898; HENKEL W, 1982, EUR J BIOCHEM, V122, P205, DOI 10.1111/j.1432-1033.1982.tb05868.x; KEENE DR, 1991, J HISTOCHEM CYTOCHEM, V39, P59, DOI 10.1177/39.1.1983874; Kinoshita K, 2002, TRENDS CELL BIOL, V12, P267, DOI 10.1016/S0962-8924(02)02295-X; KLEMAN JP, 1992, EUR J BIOCHEM, V210, P329, DOI 10.1111/j.1432-1033.1992.tb17425.x; LI SW, 1995, GENE DEV, V9, P2821, DOI 10.1101/gad.9.22.2821; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; MAYNE R, 1993, J BIOL CHEM, V268, P9381; MENDLER M, 1989, J CELL BIOL, V108, P191, DOI 10.1083/jcb.108.1.191; MIOSGE N, 1994, HISTOCHEM J, V26, P939; MULLERGLAUSER W, 1986, J CELL BIOL, V102, P1931, DOI 10.1083/jcb.102.5.1931; NAH HD, 1992, J BIOL CHEM, V267, P22581; Nerlich AG, 1998, VIRCHOWS ARCH, V432, P67, DOI 10.1007/s004280050136; NIYIBIZI C, 1989, FEBS LETT, V242, P314, DOI 10.1016/0014-5793(89)80492-2; Oosawa F., 1975, THERMODYNAMICS POLYM; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; Pollard TD, 2002, CURR OPIN STRUC BIOL, V12, P768, DOI 10.1016/S0959-440X(02)00396-2; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SCHONHERR E, 1995, J BIOL CHEM, V270, P2776, DOI 10.1074/jbc.270.6.2776; Sherratt MJ, 2001, MICRON, V32, P185, DOI 10.1016/S0968-4328(99)00082-7; SILVER D, 1992, P NATL ACAD SCI USA, V89, P9860, DOI 10.1073/pnas.89.20.9860; Strelkov SV, 2003, BIOESSAYS, V25, P243, DOI 10.1002/bies.10246; THOM JR, 1991, J BIOL CHEM, V266, P7262; TIMPL R, 1982, METHOD ENZYMOL, V82, P472; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; VOGEL KG, 1984, BIOCHEM J, V223, P587, DOI 10.1042/bj2230587; Wess TJ, 1998, J STRUCT BIOL, V122, P92, DOI 10.1006/jsbi.1998.3991; Wiberg C, 2002, J BIOL CHEM, V277, P49120, DOI 10.1074/jbc.M206891200; Wiberg C, 2001, J BIOL CHEM, V276, P18947, DOI 10.1074/jbc.M100625200; WU JJ, 1995, J BIOL CHEM, V270, P18865, DOI 10.1074/jbc.270.32.18865; YARKER YE, 1984, CONNECT TISSUE RES, V12, P337, DOI 10.3109/03008208409013695; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	57	61	63	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37352	37359		10.1074/jbc.M304325200	http://dx.doi.org/10.1074/jbc.M304325200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869566	hybrid			2022-12-27	WOS:000185437200045
J	Merkulova-Rainon, T; England, P; Ding, SL; Demerens, C; Tobelem, R				Merkulova-Rainon, T; England, P; Ding, SL; Demerens, C; Tobelem, R			The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; IN-VIVO; BIOLOGICAL-ACTIVITY; HEPARIN-BINDING; FACTOR GENE; FACTOR/SCATTER FACTOR; TUMOR ANGIOGENESIS; MOLECULAR-CLONING; CRYSTAL-STRUCTURE; TYROSINE KINASE	Hepatocyte growth factor ( HGF) is a pleiotropic factor that plays an important role in complex biological processes such as embryogenesis, tissue regeneration, cancerogenesis, and angiogenesis. HGF promotes cell proliferation, survival, motility, and morphogenesis through binding to its receptor, a transmembrane tyrosine kinase encoded by the MET proto-oncogene (c-met). Structurally speaking, HGF is a polypeptide related to the enzymes of the blood coagulation cascade. Thus, it comprises kringle domains that in some other proteins have been shown to be responsible for the anti-angiogenic activity. To check whether the isolated kringles of HGF were able to inhibit angiogenesis, we produced them as recombinant proteins and compared their biological activity with that of the recombinant HGF N-terminal domain (N). We showed that (i) none of the isolated HGF kringle exhibits an anti-angiogenic activity; (ii) N is a new anti-angiogenic polypeptide; (iii) the inhibitory action of N is not specific toward HGF, because it antagonized the angiogenic activity of other growth factors, such as fibroblast growth factor-2 and vascular endothelial growth factor; and (iv) in contrast with full-length HGF, N does not bind to the c-met receptor in vitro, but fully retains its heparin-binding capacity. Our results suggest that N inhibits angiogenesis not by disrupting the HGF/c-met interaction but rather by interfering with the endothelial glycosaminoglycans, which are the secondary binding sites of HGF.	Hop Lariboisiere, Assoc Claude Bernard, Ctr Rech, Inst Vaisseaux & Sang, F-75475 Paris 10, France; Inst Pasteur, F-75724 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Merkulova-Rainon, T (corresponding author), Hop Lariboisiere, Assoc Claude Bernard, Ctr Rech, Inst Vaisseaux & Sang, 8 Rue Guy Patin, F-75475 Paris 10, France.	tatiana.merkoulova-rainon@lrb.ap-hop-paris.fr	; Demerens de Chappedelaine, Corinne/H-1648-2017	ENGLAND, Patrick/0000-0001-6410-5918; Demerens de Chappedelaine, Corinne/0000-0003-3651-0646; Merkulova-Rainon, Tatyana/0000-0002-1142-2749				Abounader R, 2001, FASEB J, V15, P108, DOI 10.1096/fj.01-0421fje; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; Bulteau AL, 2001, J BIOL CHEM, V276, P45662, DOI 10.1074/jbc.M105374200; BUSSOLINO F, 1992, J CELL BIOL, V119, P629, DOI 10.1083/jcb.119.3.629; Cai WY, 2000, INVEST OPHTH VIS SCI, V41, P1885; Cao YH, 1997, J BIOL CHEM, V272, P22924, DOI 10.1074/jbc.272.36.22924; Cao YH, 1996, J BIOL CHEM, V271, P29461, DOI 10.1074/jbc.271.46.29461; Carey DJ, 1997, BIOCHEM J, V327, P1; Comoglio PM, 2002, J CLIN INVEST, V109, P857, DOI 10.1172/JCI200215392; Date K, 1997, FEBS LETT, V420, P1, DOI 10.1016/S0014-5793(97)01475-0; Faham S, 1996, SCIENCE, V271, P1116, DOI 10.1126/science.271.5252.1116; Fairbrother WJ, 1998, STRUCT FOLD DES, V6, P637, DOI 10.1016/S0969-2126(98)00065-3; Guimond SE, 1999, CURR BIOL, V9, P1343, DOI 10.1016/S0960-9822(00)80060-3; HARTMANN G, 1992, P NATL ACAD SCI USA, V89, P11574, DOI 10.1073/pnas.89.23.11574; Hayashi K, 2000, GENE THER, V7, P1664, DOI 10.1038/sj.gt.3301284; Hendrix MJC, 1998, AM J PATHOL, V152, P855; Horiguchi N, 2002, ONCOGENE, V21, P1791, DOI 10.1038/sj.onc.1205248; IKEO K, 1995, J MOL EVOL, V40, P331, DOI 10.1007/BF00163238; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; Jakubczak JL, 1998, MOL CELL BIOL, V18, P1275, DOI 10.1128/MCB.18.3.1275; Jiang WG, 1999, CLIN CANCER RES, V5, P3695; Kuba K, 2000, CANCER RES, V60, P6737; Kumar R, 1998, INT J ONCOL, V12, P749; Lee TH, 1998, J BIOL CHEM, V273, P28805, DOI 10.1074/jbc.273.44.28805; Lietha D, 2001, EMBO J, V20, P5543, DOI 10.1093/emboj/20.20.5543; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LOKKER NA, 1994, PROTEIN ENG, V7, P895, DOI 10.1093/protein/7.7.895; Lyon M, 1998, J BIOL CHEM, V273, P271, DOI 10.1074/jbc.273.1.271; Lyon M, 2002, J BIOL CHEM, V277, P1040, DOI 10.1074/jbc.M107506200; Matsumoto K, 1997, CIBA F SYMP, V212, P198; MIYAZAWA K, 1993, J BIOL CHEM, V268, P10024; MIZUNO K, 1994, J BIOL CHEM, V269, P1131; Nagashima M, 2001, J RHEUMATOL, V28, P1772; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; Nguyen TH, 1998, HUM GENE THER, V9, P2469, DOI 10.1089/10430349850019319; Ono K, 1999, GLYCOBIOLOGY, V9, P705, DOI 10.1093/glycob/9.7.705; OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3; Otsuka T, 2000, MOL CELL BIOL, V20, P2055, DOI 10.1128/MCB.20.6.2055-2065.2000; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; Park PW, 2000, J BIOL CHEM, V275, P29923, DOI 10.1074/jbc.R000008200; Pellegrini L, 2000, NATURE, V407, P1029, DOI 10.1038/35039551; Rosen EM, 1997, CIBA F SYMP, V212, P215; Rubin JS, 2001, J BIOL CHEM, V276, P32977, DOI 10.1074/jbc.M105486200; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schmidt NO, 1999, INT J CANCER, V84, P10, DOI 10.1002/(SICI)1097-0215(19990219)84:1<10::AID-IJC3>3.3.CO;2-C; SHIMA N, 1994, BIOCHEM BIOPH RES CO, V200, P808, DOI 10.1006/bbrc.1994.1523; SILVAGNO F, 1995, ARTERIOSCL THROM VAS, V15, P1857, DOI 10.1161/01.ATV.15.11.1857; Stahl SJ, 1997, BIOCHEM J, V326, P763, DOI 10.1042/bj3260763; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; Taniyama Y, 2001, CIRCULATION, V104, P2344, DOI 10.1161/hc4401.098470; Taniyama Y, 2001, GENE THER, V8, P181, DOI 10.1038/sj.gt.3301379; Trieu VN, 1999, BIOCHEM BIOPH RES CO, V257, P714, DOI 10.1006/bbrc.1999.0519; Van Belle E, 1998, CIRCULATION, V97, P381; Wagatsuma S, 1998, CANCER, V82, P520, DOI 10.1002/(SICI)1097-0142(19980201)82:3<520::AID-CNCR14>3.0.CO;2-3; Yang S, 1999, AM J PATHOL, V155, P887, DOI 10.1016/S0002-9440(10)65188-7; YU Q, 1995, BIOTECHNIQUES, V19, P122; Zhou HJ, 1998, STRUCTURE, V6, P109, DOI 10.1016/S0969-2126(98)00012-4	60	20	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37400	37408		10.1074/jbc.M212768200	http://dx.doi.org/10.1074/jbc.M212768200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847110	hybrid, Green Published			2022-12-27	WOS:000185437200051
J	Tuinstra, RL; Miziorko, HM				Tuinstra, RL; Miziorko, HM			Investigation of conserved acidic residues in 3-Hydroxy-3-methylglutaryl-CoA lyase - Implications for human disease and for functional roles in a family of related proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; HMG-COA LYASE; COENZYME-A; MALATE SYNTHASE; ESCHERICHIA-COLI; CATION ACTIVATOR; ENZYME-ACTIVITY; DEFICIENCY; MECHANISM; BINDING	Hydroxy-3-methylglutaryl-CoA (HMG-CoA) lyase catalyzes the divalent cation-dependent cleavage of HMG-CoA to form acetyl-CoA and acetoacetate. In metal-dependent aldol and Claisen reactions, acidic residues often function either as cation ligands or as participants in general acid/base catalysis. Site-directed mutagenesis was used to produce conservative substitutions for the conserved acidic residues Glu-37, Asp-42, Glu-72, Asp-204, Glu-279, and Asp-280. HMG-CoA lyase deficiency results from a human mutation that substitutes lysine for glutamate 279. The E279K mutation has also been engineered; expression in Escherichia coli produces an unstable protein. Substitution of alanine for glutamate 279 produces a protein that is sufficiently stable for isolation and retains substantial catalytic activity. However, thermal inactivation experiments demonstrate that E279A is much less stable than wild-type enzyme. HMG-CoA lyase deficiency also results from mutations at aspartate 42. Substitutions that eliminate a carboxyl group at residue 42 perturb cation binding and substantially lower catalytic efficiency (10(4)-10(5)-fold decreases in specific activity for D42A, D42G, or D42H versus wildtype). Substitutions of alanine for the other conserved acidic residues indicate the importance of glutamate 72. E72A exhibits a 200-fold decrease in k(cat) and >10(3)-fold decrease in k(cat)/K-m. E72A is also characterized by inflation in the K-m for activator cation (26-fold for Mg2+; >200-fold for Mn2+). Similar, but less pronounced, effects are measured for the D204A mutant. E72A and D204A mutant proteins both bind stoichiometric amounts of Mn2+, but D204A exhibits only a 2-fold inflation in K-D for Mn2+, whereas E72A exhibits a 12-fold inflation in K-D (23 muM) in comparison with wild-type enzyme (K-D = 1.9 muM). Acidic residues corresponding to HMG-CoA lyase Asp-42 and Glu-72 are conserved in the HMG-CoA lyase protein family, which includes proteins that utilize acetyl-CoA in aldol condensations. These related reactions may require an activator cation that binds to the corresponding acidic residues in this protein family.	Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin	Miziorko, HM (corresponding author), Med Coll Wisconsin, Dept Biochem, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.				NCRR NIH HHS [RR01008] Funding Source: Medline; NIDDK NIH HHS [DK21491] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001008] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK021491, R01DK021491] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Ilan A, 2001, BIOCHEMISTRY-US, V40, P11946, DOI 10.1021/bi0104524; Bateman A, 2002, NUCLEIC ACIDS RES, V30, P276, DOI 10.1093/nar/30.1.276; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COON MJ, 1955, AMINO ACID METABOLIS, P431; Dreyer MK, 1996, J MOL BIOL, V259, P458, DOI 10.1006/jmbi.1996.0332; GIBSON KM, 1988, EUR J PEDIATR, V148, P180, DOI 10.1007/BF00441397; Goh LL, 2001, APPL MICROBIOL BIOT, V57, P363, DOI 10.1007/s002530100785; GOLDFARB S, 1971, J LIPID RES, V12, P512; Higgins M. J. P., 1972, ENZYMES, VVII, P407; Howard BR, 2000, BIOCHEMISTRY-US, V39, P3156, DOI 10.1021/bi992519h; HRUZ PW, 1993, BIOCHIM BIOPHYS ACTA, V1162, P149, DOI 10.1016/0167-4838(93)90141-D; HRUZ PW, 1992, PROTEIN SCI, V1, P1144, DOI 10.1002/pro.5560010908; JENKINS J, 1992, BIOCHEMISTRY-US, V31, P5449, DOI 10.1021/bi00139a005; Jia Y, 1999, BIOCHEMISTRY-US, V38, P14165, DOI 10.1021/bi990771j; KARPUSAS M, 1990, BIOCHEMISTRY-US, V29, P2213, DOI 10.1021/bi00461a002; KRAMER PR, 1980, J BIOL CHEM, V255, P1023; KRAMER PR, 1983, BIOCHEMISTRY-US, V22, P2353, DOI 10.1021/bi00279a008; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Mitchell GA, 1998, AM J HUM GENET, V62, P295, DOI 10.1086/301730; Muroi J, 2000, HUM GENET, V107, P320, DOI 10.1007/s004390000363; REED WD, 1975, J BIOL CHEM, V250, P3117; Roberts JR, 1997, BIOCHEMISTRY-US, V36, P7594, DOI 10.1021/bi970207d; ROBERTS JR, 1994, J BIOL CHEM, V269, P17841; Roberts JR, 1996, J BIOL CHEM, V271, P24604, DOI 10.1074/jbc.271.40.24604; ROBERTS JR, 1995, J BIOL CHEM, V270, P17311, DOI 10.1074/jbc.270.29.17311; ROBINSON AM, 1980, PHYSIOL REV, V60, P143, DOI 10.1152/physrev.1980.60.1.143; Smith CV, 2003, J BIOL CHEM, V278, P1735, DOI 10.1074/jbc.M209248200; STEGINK LD, 1968, J BIOL CHEM, V243, P5272; Tuinstra RL, 2002, BIOCHEMISTRY-US, V41, P8971; Vinarov DA, 2000, BIOCHEMISTRY-US, V39, P3360, DOI 10.1021/bi9922897	30	13	14	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37092	37098		10.1074/jbc.M304472200	http://dx.doi.org/10.1074/jbc.M304472200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12874287	hybrid			2022-12-27	WOS:000185437200015
J	Wickstrom, SA; Alitalo, K; Keski-Oja, J				Wickstrom, SA; Alitalo, K; Keski-Oja, J			Endostatin associates with lipid rafts and induces reorganization of the actin cytoskeleton via down-regulation of RhoA activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL-CELL APOPTOSIS; GPI-ANCHORED PROTEINS; FOCAL ADHESIONS; STRESS FIBERS; TUMOR-GROWTH; SIGNAL-TRANSDUCTION; CAVEOLAE MEMBRANE; GENE-TRANSFER; MDCK CELLS; IN-VIVO	Endostatin, the C-terminal fragment of collagen XVIII, is a potent inhibitor of angiogenesis. Observations that endostatin inhibits endothelial cell migration and induces disassembly of the actin cytoskeleton provide putative cellular mechanisms for this effect. To understand the mechanisms of endostatin-induced intracellular signaling, we analyzed the association of recombinant endostatin with endothelial cell lipid rafts and the roles of its heparin- and integrin-binding properties in this interaction. We observed that a fraction of cell surface-bound endostatin partitioned in low density membrane raft fractions together with caveolin-1. Heparinase treatment of cells prevented the recruitment of endostatin to the lipid rafts but did not affect the association of endostatin with the non-raft fraction, whereas preincubation of endostatin with soluble alpha(5)beta(1) integrin prevented the association of endostatin with the endothelial cell membrane. Endostatin treatment induced recruitment of alpha(5)beta(1) integrin into the raft fraction via a heparan sulfate proteoglycan-dependent mechanism. Subsequently, through alpha(5)beta(1) integrin, heparan sulfate, and lipid raft-mediated interactions, endostatin induced Src-dependent activation of p190RhoGAP with concomitant decrease in RhoA activity and disassembly of actin stress fibers and focal adhesions. These observations provide a cell biological mechanism, which plausibly explains the anti-angiogenic mechanisms of endostatin in vivo.	Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland; Univ Helsinki, Dept Virol, FIN-00014 Helsinki, Finland; Univ Helsinki, Mol Canc Biol Lab, FIN-00014 Helsinki, Finland; Univ Helsinki, Ludwig Inst Canc Res, Haartman Inst, FIN-00014 Helsinki, Finland; Univ Helsinki, Cent Hosp, Biomedicum Helsinki, FIN-00014 Helsinki, Finland	University of Helsinki; University of Helsinki; University of Helsinki; Ludwig Institute for Cancer Research; University of Helsinki; University of Helsinki; Helsinki University Central Hospital	Keski-Oja, J (corresponding author), Univ Helsinki, Biomedicum Helsinki, Cell Biol Lab, POB 63,Haartmaninkatu 8, FIN-00014 Helsinki, Finland.		Alitalo, Kari K/J-5013-2014	Alitalo, Kari K/0000-0002-7331-0902; Wickstrom, Sara/0000-0001-6383-6292				Anderson RGW, 2002, SCIENCE, V296, P1821, DOI 10.1126/science.1068886; Anderson RGW, 1998, ANNU REV BIOCHEM, V67, P199, DOI 10.1146/annurev.biochem.67.1.199; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Blezinger P, 1999, NAT BIOTECHNOL, V17, P343, DOI 10.1038/7895; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Carey DJ, 1996, J BIOL CHEM, V271, P15253, DOI 10.1074/jbc.271.25.15253; CHANG JH, 1995, J CELL BIOL, V130, P355, DOI 10.1083/jcb.130.2.355; CHANG JH, 1993, ONCOGENE, V8, P959; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Dixelius J, 2002, CANCER RES, V62, P1944; Feldman AL, 2001, J NATL CANCER I, V93, P1014, DOI 10.1093/jnci/93.13.1014; Foster LJ, 2003, P NATL ACAD SCI USA, V100, P5813, DOI 10.1073/pnas.0631608100; FOSTER R, 1994, MOL CELL BIOL, V14, P7173, DOI 10.1128/MCB.14.11.7173; Fukai N, 2002, EMBO J, V21, P1535, DOI 10.1093/emboj/21.7.1535; Giancotti FG, 1999, SCIENCE, V285, P1028, DOI 10.1126/science.285.5430.1028; Green JM, 1999, J CELL BIOL, V146, P673, DOI 10.1083/jcb.146.3.673; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; Hanai J, 2002, J CELL BIOL, V158, P529, DOI 10.1083/jcb.200203064; Hanai J, 2002, J BIOL CHEM, V277, P16464, DOI 10.1074/jbc.M112274200; Harder T, 1998, J CELL BIOL, V141, P929, DOI 10.1083/jcb.141.4.929; Hynes RO, 2002, NAT MED, V8, P918, DOI 10.1038/nm0902-918; Karumanchi SA, 2001, MOL CELL, V7, P811, DOI 10.1016/S1097-2765(01)00225-8; Lacalle RA, 2002, J CELL BIOL, V157, P277, DOI 10.1083/jcb.200109031; MAYOR S, 1994, SCIENCE, V264, P1948, DOI 10.1126/science.7516582; Michaely PA, 1999, J BIOL CHEM, V274, P21430, DOI 10.1074/jbc.274.30.21430; Nobes CD, 1999, J CELL BIOL, V144, P1235, DOI 10.1083/jcb.144.6.1235; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pande G, 2000, CURR OPIN CELL BIOL, V12, P569, DOI 10.1016/S0955-0674(00)00133-2; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Ren XD, 1999, EMBO J, V18, P578, DOI 10.1093/emboj/18.3.578; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RIDLEY AJ, 1993, EMBO J, V12, P5151, DOI 10.1002/j.1460-2075.1993.tb06210.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Santos MF, 1997, J CLIN INVEST, V100, P216, DOI 10.1172/JCI119515; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Sauter BV, 2000, P NATL ACAD SCI USA, V97, P4802, DOI 10.1073/pnas.090065597; Schmid SL, 1997, ANNU REV BIOCHEM, V66, P511, DOI 10.1146/annurev.biochem.66.1.511; Schoenwaelder SM, 1999, CURR OPIN CELL BIOL, V11, P274, DOI 10.1016/S0955-0674(99)80037-4; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; Smart EJ, 1999, MOL CELL BIOL, V19, P7289; Stupack DG, 2001, J CELL BIOL, V155, P459, DOI 10.1083/jcb.200106070; Sudhakar A, 2003, P NATL ACAD SCI USA, V100, P4766, DOI 10.1073/pnas.0730882100; TAIPALE J, 1992, J BIOL CHEM, V267, P25378; Tkachenko E, 2002, J BIOL CHEM, V277, P19946, DOI 10.1074/jbc.M200841200; Wary KK, 1998, CELL, V94, P625, DOI 10.1016/S0092-8674(00)81604-9; Wei Y, 1999, J CELL BIOL, V144, P1285, DOI 10.1083/jcb.144.6.1285; Wickstrom SA, 2001, CANCER RES, V61, P6511; Wickstrom SA, 2002, CANCER RES, V62, P5580; Yoon SS, 1999, CANCER RES, V59, P6251	55	103	115	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37895	37901		10.1074/jbc.M303569200	http://dx.doi.org/10.1074/jbc.M303569200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851410	hybrid			2022-12-27	WOS:000185437200111
J	Wakasugi, K; Nakano, T; Morishima, I				Wakasugi, K; Nakano, T; Morishima, I			Oxidized human neuroglobin acts as a heterotrimeric G alpha protein guanine nucleotide dissociation inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING; CRYSTAL-STRUCTURE; DISULFIDE BOND; NITRIC-OXIDE; OXYGEN; HEMOGLOBIN; STABILIZATION; MYOGLOBIN; EXCHANGE; G-ALPHA(O)	Neuroglobin (Ngb) is a newly discovered vertebrate heme protein that is expressed in the brain and can reversibly bind oxygen. It has been reported that Ngb expression levels increase in response to oxygen deprivation and that it protects neurons from hypoxia in vitro and in vivo. However, the mechanism of this neuroprotection remains unclear. In the present study, we tried to clarify the neuroprotective role of Ngb under oxidative stress in vitro. By surface plasmon resonance, we found that ferric Ngb, which is generated spontaneously as a result of the rapid autoxidation, binds exclusively to the GDP-bound form of the alpha subunit of heterotrimeric G protein (Galpha(i)). In GDP dissociation assays or guanosine 5'-O-(3-thio) triphosphate binding assays, ferric Ngb behaved as a guanine nucleotide dissociation inhibitor (GDI), inhibiting the rate of exchange of GDP for GTP. The interaction of GDP-bound Galpha(i) with ferric Ngb will liberate Gbetagamma, leading to protection against neuronal death. In contrast, ferrous ligand-bound Ngb under normoxia did not have GDI activities. Taken together, we propose that human Ngb may be a novel oxidative stress-responsive sensor for signal transduction in the brain.	Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan; Japan Sci & Technol Corp, Precursory Res Embry Sci & Technol, Kyoto 6158510, Japan	Kyoto University; Japan Science & Technology Agency (JST)	Wakasugi, K (corresponding author), Kyoto Univ, Grad Sch Engn, Dept Mol Engn, Kyoto 6158510, Japan.	kei@wakasugi.mbox.media.kyoto-u.ac.jp	Wakasugi, Keisuke/AAQ-1642-2020	Wakasugi, Keisuke/0000-0002-8408-5616				Awenius C, 2001, BIOCHEM BIOPH RES CO, V287, P418, DOI 10.1006/bbrc.2001.5614; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Bernard ML, 2001, J BIOL CHEM, V276, P1585, DOI 10.1074/jbc.M005291200; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunori M, 2001, TRENDS BIOCHEM SCI, V26, P209, DOI 10.1016/S0968-0004(01)01824-2; Burmester T, 2002, MOL BIOL EVOL, V19, P416, DOI 10.1093/oxfordjournals.molbev.a004096; Burmester T, 2000, NATURE, V407, P520, DOI 10.1038/35035093; de Alba E, 1999, J MOL BIOL, V291, P927, DOI 10.1006/jmbi.1999.2989; Dewilde S, 2001, J BIOL CHEM, V276, P38949, DOI 10.1074/jbc.M106438200; Dickerson R.E., 1983, HEMOGLOBIN STRUCTURE; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; Eaton P, 2002, J BIOL CHEM, V277, P9806, DOI 10.1074/jbc.M111454200; Erecinska M, 2001, RESP PHYSIOL, V128, P263, DOI 10.1016/S0034-5687(01)00306-1; Esplugues JV, 2002, BRIT J PHARMACOL, V135, P1079, DOI 10.1038/sj.bjp.0704569; Flogel U, 2001, P NATL ACAD SCI USA, V98, P735, DOI 10.1073/pnas.011460298; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Hardison RC, 1996, P NATL ACAD SCI USA, V93, P5675, DOI 10.1073/pnas.93.12.5675; Hargrove MS, 2000, STRUCTURE, V8, P1005, DOI 10.1016/S0969-2126(00)00194-5; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HUBBARD SR, 1990, J MOL BIOL, V213, P215, DOI 10.1016/S0022-2836(05)80181-0; Joshi MS, 2002, P NATL ACAD SCI USA, V99, P10341, DOI 10.1073/pnas.152149699; KANAYA S, 1991, J BIOL CHEM, V266, P6038; Kawada N, 2001, J BIOL CHEM, V276, P25318, DOI 10.1074/jbc.M102630200; Kriegl JM, 2002, P NATL ACAD SCI USA, V99, P7992, DOI 10.1073/pnas.082244399; Luo Y, 1999, J BIOL CHEM, V274, P10685, DOI 10.1074/jbc.274.16.10685; Mammen PPA, 2002, J HISTOCHEM CYTOCHEM, V50, P1591, DOI 10.1177/002215540205001203; Natochin M, 2002, BIOCHEMISTRY-US, V41, P258, DOI 10.1021/bi015708k; Natochin M, 2001, BIOCHEMISTRY-US, V40, P5322, DOI 10.1021/bi015505w; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Nishida M, 2002, J BIOL CHEM, V277, P9036, DOI 10.1074/jbc.M107392200; Ouellett H, 2002, P NATL ACAD SCI USA, V99, P5902, DOI 10.1073/pnas.092017799; Penn RB, 2000, TRENDS CARDIOVAS MED, V10, P81, DOI 10.1016/S1050-1738(00)00053-0; PERRY LJ, 1984, SCIENCE, V226, P555, DOI 10.1126/science.6387910; Pitcher JA, 1998, ANNU REV BIOCHEM, V67, P653, DOI 10.1146/annurev.biochem.67.1.653; Reuss S, 2002, NEUROSCIENCE, V115, P645, DOI 10.1016/S0306-4522(02)00536-5; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; Schmidt M, 2003, J BIOL CHEM, V278, P1932, DOI 10.1074/jbc.M209909200; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; Slep KC, 2001, NATURE, V409, P1071, DOI 10.1038/35059138; Sowa AW, 1998, P NATL ACAD SCI USA, V95, P10317, DOI 10.1073/pnas.95.17.10317; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Sun YJ, 2001, P NATL ACAD SCI USA, V98, P15306, DOI 10.1073/pnas.251466698; Sun YJ, 2003, P NATL ACAD SCI USA, V100, P3497, DOI 10.1073/pnas.0637726100; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Trent JT, 2001, J BIOL CHEM, V276, P30106, DOI 10.1074/jbc.C100300200; Trent JT, 2001, BIOCHEMISTRY-US, V40, P6155, DOI 10.1021/bi0100790; Trevaskis B, 1997, P NATL ACAD SCI USA, V94, P12230, DOI 10.1073/pnas.94.22.12230; Uchida T, 1997, BIOCHEMISTRY-US, V36, P324, DOI 10.1021/bi960591z; Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023; Wieland T, 1999, N-S ARCH PHARMACOL, V360, P14, DOI 10.1007/s002109900031; WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857; Zhang CG, 2002, BIOCHEM BIOPH RES CO, V290, P1411, DOI 10.1006/bbrc.2002.6360; Zheng B, 1999, TRENDS BIOCHEM SCI, V24, P411, DOI 10.1016/S0968-0004(99)01474-7	56	168	187	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36505	36512		10.1074/jbc.M305519200	http://dx.doi.org/10.1074/jbc.M305519200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860983	hybrid			2022-12-27	WOS:000185318300079
J	Campbell, RB; Liu, FH; Ross, AH				Campbell, RB; Liu, FH; Ross, AH			Allosteric activation of PTEN phosphatase by phosphatidylinositol 4,5-bisphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR GENE; PHOSPHOINOSITIDE PHOSPHATASES; MYOTUBULARIN; SPECIFICITY; LIPIDS; CELLS	Phosphatase and tensin homologue deleted on chromosome 10 ( PTEN) is a tumor suppressor that is lost in many human tumors and encodes a phosphatidylinositol phosphate phosphatase specific for the 3-position of the inositol ring. Here we report a novel mechanism of PTEN regulation. Binding of di-C8-phosphatidylinositol 4,5-P-2 (PI(4,5) P-2) to PTEN enhances phosphatase activity for monodispersed substrates, PI(3,4,5) P-3 and PI(3,4) P-2. PI(5) P also is an activator, but PI(4) P, PI(3,4) P-2, and PI(3,5) P-2 do not activate PTEN. Activation by exogenous PI(4,5) P-2 is more apparent with PI(3,4) P-2 as a substrate than with PI(3,4,5) P-3, probably because hydrolysis of PI(3,4) P-2 yields PI(4) P, which is not an activator. In contrast, hydrolysis of PI(3,4,5) P-3 yields a potent activator, PI( 4,5) P-2, creating a positive feedback loop. In addition, neither di-C4-PI(4,5) P-2 nor inositol trisphosphate-activated PTEN. Hence, the interaction between PI(4,5) P-2 and PTEN requires specific, ionic interactions with the phosphate groups on the inositol ring as well as hydrophobic interactions with the fatty acid chains, likely mimicking the physiological interactions that PTEN has with the polar surface head groups and the hydrophobic core of phospholipid membranes. Mutations of the apparent PI(4,5) P-2-binding motif in the PTEN N terminus severely reduced PTEN activity. In contrast, mutation of the C2 phospholipid-binding domain had little effect on PTEN activation. These results suggest a model in which a PI(4,5) P-2 monomer binds to PTEN, initiates an allosteric conformational change and, thereby, activates PTEN independent of membrane binding.	Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Ross, AH (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, 364 Plantat St,Rm 364, Worcester, MA 01605 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021716] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS21716] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Di Cristofano A, 1999, SCIENCE, V285, P2122, DOI 10.1126/science.285.5436.2122; Furnari FB, 1998, CANCER RES, V58, P5002; Iijima M, 2002, CELL, V109, P599, DOI 10.1016/S0092-8674(02)00745-6; Johnson JE, 2000, BIOCHEMISTRY-US, V39, P11360, DOI 10.1021/bi000902c; Kleinschmidt JH, 2002, BIOPHYS J, V83, P994, DOI 10.1016/S0006-3495(02)75225-9; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Li DM, 1997, CANCER RES, V57, P2124; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li L, 2002, MOL CELL NEUROSCI, V20, P21, DOI 10.1006/mcne.2002.1115; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; Maehama T, 2001, ANNU REV BIOCHEM, V70, P247, DOI 10.1146/annurev.biochem.70.1.247; Martin TFJ, 1998, ANNU REV CELL DEV BI, V14, P231, DOI 10.1146/annurev.cellbio.14.1.231; McConnachie G, 2003, BIOCHEM J, V371, P947, DOI 10.1042/BJ20021848; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; REBECCHI MJ, 1993, J BIOL CHEM, V268, P1735; ROSEN MJ, 1984, ACS S SERIES, V23; Schaletzky J, 2003, CURR BIOL, V13, P504, DOI 10.1016/S0960-9822(03)00132-5; Simpson L, 2001, EXP CELL RES, V264, P29, DOI 10.1006/excr.2000.5130; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Suzuki A, 2001, IMMUNITY, V14, P523, DOI 10.1016/S1074-7613(01)00134-0	22	162	164	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33617	33620		10.1074/jbc.C300296200	http://dx.doi.org/10.1074/jbc.C300296200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12857747	hybrid			2022-12-27	WOS:000185047500003
J	Suetsugu, S; Takenawa, T				Suetsugu, S; Takenawa, T			Translocation of N-WASP by nuclear localization and export signals into the nucleus modulates expression of HSP90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WISKOTT-ALDRICH-SYNDROME; ACTIN-DEPOLYMERIZING PROTEIN; ARP2/3 COMPLEX; TYROSINE KINASE; FAMILY; SRC; ACTIVATION; FILAMENTS; VIRUS; WAVE	N-WASP regulates the actin cytoskeleton through activation of the Arp2/3 complex. N-WASP localizes at the cell periphery, where it controls actin polymerization downstream of signal molecules such as adapter proteins, Cdc42, Src family kinases, and phosphoinositides. N-WASP also localizes in the nucleus; however, the role of N-WASP in the nucleus is unclear. Here, we show that localization of N-WASP is controlled through phosphorylation by Src family kinases in which phosphorylated N-WASP is exported from the nucleus in a nuclear export signal (NES) and leptomycin B-dependent manner. N-WASP had nuclear localization signal (NLS) at its basic region and NES close to the phosphorylation site by Src family kinases, indicating that phosphorylation controls the accessibility to the NES through conformational changes. Increased levels of unphosphorylated N-WASP in the nucleus suppressed expression of HSP90 and transcription from a heat shock element (HSE). N-WASP bound heat shock transcription factor (HSTF) and enhanced the HSTF association with HSE. In addition, nuclear N-WASP was present in the protein complex that associates with HSE, suggesting that N-WASP participates in suppression of HSP90 transcription. Increased levels of unphosphorylated N-WASP also decreased the activities of Src family kinases in cells but not in experiments in vitro with pure N-WASP and Fyn. Because HSP90 is essential for the activities of Src family kinases, these results suggest that localization of N-WASP modulates Src kinase activity by regulating HSP90 expression.	Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, Tokyo 1088639, Japan; Japan Sci & Technol Corp, Core Res Evolut Sci & Technol, Minato Ku, Tokyo 1088639, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Takenawa, T (corresponding author), Univ Tokyo, Inst Med Sci, Dept Biochem, Minato Ku, 4-6-1 Shirokane Dai, Tokyo 1088639, Japan.		Suetsugu, Shiro/AAF-4427-2019; Suetsugu, Shiro/ABB-6033-2020; Suetsugu, Shiro/B-3300-2010	Suetsugu, Shiro/0000-0002-4612-0628; Suetsugu, Shiro/0000-0002-4612-0628				Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Cairns BR, 1998, MOL CELL, V2, P639, DOI 10.1016/S1097-2765(00)80162-8; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Fukami K, 2000, EUR J BIOCHEM, V267, P28, DOI 10.1046/j.1432-1327.2000.00943.x; Hakak Y, 1999, CURR BIOL, V9, P1039, DOI 10.1016/S0960-9822(99)80453-9; Harris KF, 1999, P NATL ACAD SCI USA, V96, P13738, DOI 10.1073/pnas.96.24.13738; Higgs HN, 2000, J CELL BIOL, V150, P1311, DOI 10.1083/jcb.150.6.1311; Machesky LM, 1999, P NATL ACAD SCI USA, V96, P3739, DOI 10.1073/pnas.96.7.3739; Miki H, 1998, EMBO J, V17, P6932, DOI 10.1093/emboj/17.23.6932; Miki H, 1998, NATURE, V391, P93, DOI 10.1038/34208; Miki H, 1996, EMBO J, V15, P5326, DOI 10.1002/j.1460-2075.1996.tb00917.x; Nakai A, 2001, EMBO J, V20, P2885, DOI 10.1093/emboj/20.11.2885; Oda H, 1999, P NATL ACAD SCI USA, V96, P9557, DOI 10.1073/pnas.96.17.9557; Peterson CL, 1998, J BIOL CHEM, V273, P23641, DOI 10.1074/jbc.273.37.23641; Phimister B, 1999, NAT GENET, V22, P318, DOI 10.1038/11880; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; Rohatgi R, 1999, CELL, V97, P221, DOI 10.1016/S0092-8674(00)80732-1; Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6; Suetsugu S, 2002, CELL MOTIL CYTOSKEL, V51, P113, DOI 10.1002/cm.10020; Suetsugu S, 2001, J CELL SCI, V114, P4533; Suetsugu S, 1999, BIOCHEM BIOPH RES CO, V260, P296, DOI 10.1006/bbrc.1999.0894; Suetsugu S, 1998, EMBO J, V17, P6516, DOI 10.1093/emboj/17.22.6516; Takenawa T, 2001, J CELL SCI, V114, P1801; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; UEHARA Y, 1986, MOL CELL BIOL, V6, P2198, DOI 10.1128/MCB.6.6.2198; Vetterkind S, 2002, J BIOL CHEM, V277, P87, DOI 10.1074/jbc.M104555200; WEN W, 1995, CELL, V82, P463, DOI 10.1016/0092-8674(95)90435-2; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; Wolff B, 1997, CHEM BIOL, V4, P139, DOI 10.1016/S1074-5521(97)90257-X; XIAO H, 1988, SCIENCE, V239, P1139, DOI 10.1126/science.3125608	31	45	46	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42515	42523		10.1074/jbc.M302177200	http://dx.doi.org/10.1074/jbc.M302177200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871950	hybrid			2022-12-27	WOS:000185989500116
J	Das, S; Rafter, JD; Kim, KP; Gygi, SP; Cho, WH				Das, S; Rafter, JD; Kim, KP; Gygi, SP; Cho, WH			Mechanism of group IVA cytosolic phospholipase A(2) activation by phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID RELEASE; LIPID-BINDING DOMAIN; PROTEIN-KINASE-C; MEMBRANE-DOCKING; INTERFACIAL CATALYSIS; HUMAN PLATELETS; CALCIUM; IDENTIFICATION; SPECIFICITY; MACROPHAGES	Group IVA cytosolic phospholipase A(2) (cPLA(2)) has been shown to play a critical role in the agonist-induced release of arachidonic acid. To understand the mechanism by which phosphorylation of Ser(505) and Ser(727) activates cPLA(2), we systematically analyzed the effects of S505A, S505E, S727A, S727E, S505A/S727A, S505A/S727E, and S505E/S727E mutations on its enzyme activity and membrane affinity. In vitro membrane binding measurements showed that S505A has lower affinity than the wild type or S505E for phosphatidylcholine membranes, which is exclusively due to faster desorption of the membrane-bound S505A. In contrast, neither S727A nor S727E mutation had a significant effect on the phosphatidylcholine vesicle binding affinity of cPLA(2). The difference in in vitro membrane affinity between wild type ( or S505E) and S505A increased with the decrease in Ca2+ concentration, reaching > 60-fold at 2.5 muM Ca2+. When HEK293 cells transfected with cPLA(2) and mutants were stimulated with ionomycin, the wild type and S505E translocated to the perinuclear region and caused the arachidonic acid release at 0.4 muM Ca2+, whereas S505A showed no membrane translocation and little activity to release arachidonic acid. Further mutational analysis of hydrophobic residues in the active site rim (Ile(399), Leu(400), and Leu(552)) indicate that a main role of the Ser(505) phosphorylation is to promote membrane penetration of these residues, presumably by inducing a conformational change of the protein. These enhanced hydrophobic interactions allow the sustained membrane interaction of cPLA(2) in response to transient calcium increases. On the basis of these results, we propose a mechanism for cPLA(2) activation by calcium and phosphorylation.	Univ Illinois, Dept Chem, Chicago, IL 60607 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Harvard University; Harvard Medical School	Cho, WH (corresponding author), Univ Illinois, Dept Chem, M-C 111,845 W Taylor St, Chicago, IL 60607 USA.			Kim, Kwang Pyo/0000-0003-0095-3787	NIGMS NIH HHS [GM52598, GM53987] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053987, R01GM052598] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ball A, 1999, P NATL ACAD SCI USA, V96, P6637, DOI 10.1073/pnas.96.12.6637; BERS DM, 1982, AM J PHYSIOL, V242, P404; Bittova L, 1999, J BIOL CHEM, V274, P9665, DOI 10.1074/jbc.274.14.9665; Bonventre JV, 1997, NATURE, V390, P622, DOI 10.1038/37635; Borsch-Haubold AG, 1998, J BIOL CHEM, V273, P4449, DOI 10.1074/jbc.273.8.4449; Buschbeck M, 1999, BIOCHEM J, V344, P359, DOI 10.1042/0264-6021:3440359; Cho W, 2001, J BIOL CHEM, V276, P32407, DOI 10.1074/jbc.R100007200; Cho WW, 2001, ANAL BIOCHEM, V296, P153, DOI 10.1006/abio.2001.5225; CLARK JD, 1995, J LIPID MEDIAT CELL, V12, P83, DOI 10.1016/0929-7855(95)00012-F; Das S, 2002, J BIOL CHEM, V277, P23838, DOI 10.1074/jbc.M202322200; deCarvalho MGS, 1996, J BIOL CHEM, V271, P6987, DOI 10.1074/jbc.271.12.6987; DECARVALHO MS, 1993, ARCH BIOCHEM BIOPHYS, V306, P534, DOI 10.1006/abbi.1993.1549; Dessen A, 1999, CELL, V97, P349, DOI 10.1016/S0092-8674(00)80744-8; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Evans JH, 2002, BMC BIOCHEM, V3, DOI 10.1186/1471-2091-3-30; Frazier AA, 2002, BIOCHEMISTRY-US, V41, P6282, DOI 10.1021/bi0160821; Gijon MA, 1999, J CELL BIOL, V145, P1219, DOI 10.1083/jcb.145.6.1219; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Haugland R.P., 1996, HDB FLUORESCENT PROB, P503; Hefner Y, 2000, J BIOL CHEM, V275, P37542, DOI 10.1074/jbc.M003395200; Hirabayashi T, 2000, BBA-MOL CELL BIOL L, V1488, P124, DOI 10.1016/S1388-1981(00)00115-3; JAIN MK, 1989, BIOCHIM BIOPHYS ACTA, V1002, P127, DOI 10.1016/0005-2760(89)90281-6; Johnson LN, 2001, CHEM REV, V101, P2209, DOI 10.1021/cr000225s; Kim KP, 2001, J BIOL CHEM, V276, P11126, DOI 10.1074/jbc.M004604200; Kim Y, 1997, ANAL BIOCHEM, V250, P109, DOI 10.1006/abio.1997.2200; KRAMER RM, 1993, J BIOL CHEM, V268, P26796; Kramer RM, 1996, J BIOL CHEM, V271, P27723, DOI 10.1074/jbc.271.44.27723; Leslie CC, 1997, J BIOL CHEM, V272, P16709, DOI 10.1074/jbc.272.27.16709; Lichtenbergova L, 1998, BIOCHEMISTRY-US, V37, P14128, DOI 10.1021/bi980888s; LIN LL, 1992, P NATL ACAD SCI USA, V89, P6147, DOI 10.1073/pnas.89.13.6147; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; McMurray W. C., 1973, FORM FUNCTION PHOSPH, P205; Mosior M, 1998, J BIOL CHEM, V273, P2184, DOI 10.1074/jbc.273.4.2184; Muthalif MM, 2001, J BIOL CHEM, V276, P39653, DOI 10.1074/jbc.M103136200; NAKAMURA T, 1992, EMBO J, V11, P4917, DOI 10.1002/j.1460-2075.1992.tb05598.x; Nalefski EA, 1998, BIOCHEMISTRY-US, V37, P17642, DOI 10.1021/bi982372e; Nalefski EA, 1998, J BIOL CHEM, V273, P1365, DOI 10.1074/jbc.273.3.1365; NALEFSKI EA, 1994, J BIOL CHEM, V269, P18239; Nalefski EA, 1997, BIOCHEMISTRY-US, V36, P12011, DOI 10.1021/bi9717340; NEMENOFF RA, 1993, J BIOL CHEM, V268, P1960; Perisic O, 1999, J BIOL CHEM, V274, P14979, DOI 10.1074/jbc.274.21.14979; Qiu ZH, 1998, J BIOL CHEM, V273, P8203, DOI 10.1074/jbc.273.14.8203; QIU ZH, 1993, J BIOL CHEM, V268, P24506; QIU ZH, 1994, J BIOL CHEM, V269, P19480; Schievella AR, 1995, J BIOL CHEM, V270, P30749, DOI 10.1074/jbc.270.51.30749; Stahelin RV, 2001, BIOCHEMISTRY-US, V40, P4672, DOI 10.1021/bi0020325; Uozumi N, 1997, NATURE, V390, P618, DOI 10.1038/37622	47	80	81	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41431	41442		10.1074/jbc.M304897200	http://dx.doi.org/10.1074/jbc.M304897200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12885780	hybrid			2022-12-27	WOS:000185847200123
J	Dean, JLE; Sarsfield, SJ; Tsounakou, E; Saklatvala, J				Dean, JLE; Sarsfield, SJ; Tsounakou, E; Saklatvala, J			p38 mitogen-activated protein kinase stabilizes mRNAs that contain cyclooxygenase-2 and tumor necrosis factor AU-rich elements by inhibiting deadenylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING-PROTEIN; 3'-UNTRANSLATED REGION; SEQUENCE FEATURES; MAMMALIAN EXOSOME; GENE-EXPRESSION; POLY(A); DEGRADATION; YEAST; PATHWAY; HUR	AU-rich elements (AREs) in 3'-untranslated regions of mRNAs confer instability. They target mRNAs for rapid deadenylation and degradation and may enhance decapping. The p38 MAPK pathway stabilizes many otherwise unstable ARE-containing mRNAs encoding proteins involved in inflammation; however, the mRNA decay step(s) regulated by the signaling pathway are unknown. To investigate whether it regulates deadenylation or the decay of the mRNA body, we used a tetracycline-regulated beta-globin mRNA reporter system to transcribe pulses of mRNA of uniform length. We measured on Northern gels the migration of reporter mRNAs isolated from cells transfected only with reporter plasmid or co-transfected with an active mutant of MAPK kinase-6, and treated either with or without the p38 MAPK inhibitor SB 203580. Differences in migration were shown by RNase H mapping with oligo(dT) to be due to poly(A) shortening. Insertion of an ARE into the beta-globin reporter mRNA promoted rapid deadenylation and decay of hypo-adenylated reporter mRNA. p38 MAPK activation inhibited the deadenylation of reporter mRNAs containing either the cyclooxygenase-2 or tumor necrosis factor AREs. The regulation of deadenylation by p38 MAPK was found to be specific because deadenylation of the beta-globin reporter mRNA either lacking an ARE or containing the c-Myc 3'-untranslated region (which is not p38 MAPK-responsive) was unaffected by p38 MAPK. It was concluded that the p38 MAPK pathway predominantly regulates deadenylation, rather than decay of the mRNA body, and this provides an explanation for why p38 MAPK regulates mRNA stability in some situations and translation in others.	Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, London W6 8LH, England	Imperial College London; University of Oxford	Dean, JLE (corresponding author), Univ London Imperial Coll Sci Technol & Med, Div Rheumatol, Kennedy Inst, 1 Aspenlea Rd, London W6 8LH, England.	jonathan.dean@imperial.ac.uk		Dean, Jonathan/0000-0002-0703-2756				Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Beelman CA, 1996, NATURE, V382, P642, DOI 10.1038/382642a0; Boeck R, 1996, J BIOL CHEM, V271, P432, DOI 10.1074/jbc.271.1.432; Bollig F, 2003, BIOCHEM BIOPH RES CO, V301, P665, DOI 10.1016/S0006-291X(03)00015-9; BREWER G, 1988, MOL CELL BIOL, V8, P1697, DOI 10.1128/MCB.8.4.1697; Brook M, 2000, FEBS LETT, V483, P57, DOI 10.1016/S0014-5793(00)02084-6; Brown CE, 1996, MOL CELL BIOL, V16, P5744; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Chen CY, 1998, SCIENCE, V280, P1945, DOI 10.1126/science.280.5371.1945; CHEN CYA, 1994, MOL CELL BIOL, V14, P8471, DOI 10.1128/MCB.14.12.8471; Clark AR, 2003, FEBS LETT, V546, P37, DOI 10.1016/S0014-5793(03)00439-3; Dean JLE, 2002, BIOCHEM J, V366, P709, DOI 10.1042/BJ20020402; Dean JLE, 2001, MOL CELL BIOL, V21, P721, DOI 10.1128/MCB.21.3.721-730.2001; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; DECKER CJ, 1993, GENE DEV, V7, P1632, DOI 10.1101/gad.7.8.1632; Di Marco S, 2001, NUCLEIC ACIDS RES, V29, P863, DOI 10.1093/nar/29.4.863; Dunckley T, 1999, EMBO J, V18, P5411, DOI 10.1093/emboj/18.19.5411; Dupressoir A, 2001, BMC Genomics, V2, P9, DOI 10.1186/1471-2164-2-9; Esnault S, 2002, BLOOD, V99, P4048, DOI 10.1182/blood.V99.11.4048; Ford LP, 1999, GENE DEV, V13, P188, DOI 10.1101/gad.13.2.188; Gao M, 2001, EMBO J, V20, P1134, DOI 10.1093/emboj/20.5.1134; HAN J, 1990, J EXP MED, V171, P465, DOI 10.1084/jem.171.2.465; Korner CG, 1997, J BIOL CHEM, V272, P10448; Kotlyarov A, 1999, NAT CELL BIOL, V1, P94, DOI 10.1038/10061; LaGrandeur TE, 1998, EMBO J, V17, P1487, DOI 10.1093/emboj/17.5.1487; Lai WS, 2003, MOL CELL BIOL, V23, P3798, DOI 10.1128/MCB.23.11.3798-3812.2003; Lasa M, 2000, MOL CELL BIOL, V20, P4265, DOI 10.1128/MCB.20.12.4265-4274.2000; Mahtani KR, 2001, MOL CELL BIOL, V21, P6461, DOI 10.1128/MCB.21.9.6461-6469.2001; Martinez J, 2000, J BIOL CHEM, V275, P24222, DOI 10.1074/jbc.M001705200; Miyazawa K, 1998, J BIOL CHEM, V273, P24832, DOI 10.1074/jbc.273.38.24832; MUHLRAD D, 1994, GENE DEV, V8, P855, DOI 10.1101/gad.8.7.855; Mukherjee D, 2002, EMBO J, V21, P165, DOI 10.1093/emboj/21.1.165; Newton R, 1998, J BIOL CHEM, V273, P32312, DOI 10.1074/jbc.273.48.32312; Peng SSY, 1998, EMBO J, V17, P3461, DOI 10.1093/emboj/17.12.3461; Preiss T, 1998, NATURE, V392, P516, DOI 10.1038/33192; PRICHETT W, 1995, J INFLAMM, V45, P97; Ridley SH, 1998, FEBS LETT, V439, P75, DOI 10.1016/S0014-5793(98)01342-8; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; SHYU AB, 1991, GENE DEV, V5, P221, DOI 10.1101/gad.5.2.221; Tucker M, 2001, CELL, V104, P377, DOI 10.1016/S0092-8674(01)00225-2; van Dijk E, 2002, EMBO J, V21, P6915, DOI 10.1093/emboj/cdf678; Voeltz GK, 2001, GENE DEV, V15, P774, DOI 10.1101/gad.872201; Wang SW, 1999, INFLAMM RES, V48, P533, DOI 10.1007/s000110050499; Wang ZR, 2002, P NATL ACAD SCI USA, V99, P12663, DOI 10.1073/pnas.192445599; Wang ZR, 2001, CELL, V107, P751, DOI 10.1016/S0092-8674(01)00592-X; Wells SE, 1998, MOL CELL, V2, P135, DOI 10.1016/S1097-2765(00)80122-7; Wilson GM, 2001, J BIOL CHEM, V276, P38400, DOI 10.1074/jbc.M106509200; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; Wilusz CJ, 2001, NAT REV MOL CELL BIO, V2, P237, DOI 10.1038/35067025; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Xu NH, 1997, MOL CELL BIOL, V17, P4611, DOI 10.1128/MCB.17.8.4611; Xu NH, 1998, NUCLEIC ACIDS RES, V26, P558, DOI 10.1093/nar/26.2.558	52	83	86	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39470	39476		10.1074/jbc.M306345200	http://dx.doi.org/10.1074/jbc.M306345200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882963	hybrid			2022-12-27	WOS:000185713800025
J	Garcia-Castellanos, R; Marrero, A; Mallorqui-Fernandez, G; Potempa, J; Coll, M; Gomis-Ruth, FX				Garcia-Castellanos, R; Marrero, A; Mallorqui-Fernandez, G; Potempa, J; Coll, M; Gomis-Ruth, FX			Three-dimensional structure of MecI - Molecular basis for transcriptional regulation of staphylococcal methicillin resistance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-LACTAMASE SYNTHESIS; BACILLUS-LICHENIFORMIS; CRYSTAL-STRUCTURE; SIGNALING PATHWAY; DNA-RECOGNITION; REPRESSOR BLAL; AUREUS; GENE; TRANSDUCER; STRAINS	Methicillin-resistant Staphylococcus aureus is the main cause of nosocomial and community-onset infections that affect millions of people worldwide. Some methicillin-resistant Staphylococcus aureus infections have become essentially untreatable by beta-lactams because of acquired molecular machineries enabling antibiotic resistance. Evasion from methicillin challenge is mainly achieved by the synthesis of a penicillin-binding protein of low affinity for antibiotics, MecA, that replaces regular penicillin-binding proteins in cell wall turnover when these have been inactivated by antibiotics. MecA synthesis is regulated by a signal transduction system consisting of the sensor/transducer MecR1 and the 14-kDa transcriptional repressor MecI (also known as methicillin repressor) that constitutively blocks mecA transcription. The three-dimensional structure of MecI reveals a dimer of two independent winged helix domains, each of which binds a palindromic DNA-operator half site, and two intimately intertwining dimerization domains of novel spiral staircase architecture, held together by a hydrophobic core. Limited proteolytic cleavage by cognate MecR1 within the dimerization domains results in loss of dimer interaction surface, dissociation, and repressor release, which triggers MecA synthesis. Structural information on components of the MecA regulatory pathway, in particular on methicillin repressor, the ultimate transcriptional trigger of mecA-encoded methicillin resistance, is expected to lead to the development of new antimicrobial drugs.	CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, ES-08034 Barcelona, Spain; Jagiellonian Univ, Fac Biotechnol, Dept Microbiol, Krakow, Poland; Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Biologia Molecular de Barcelona (IBMB); Jagiellonian University; University System of Georgia; University of Georgia	Gomis-Ruth, FX (corresponding author), CSIC, Ctr Invest & Desenvolupament, Inst Biol Mol Barcelona, C Jordi Girona 18-26, ES-08034 Barcelona, Spain.	xgrcri@ibmb.csic.es	Coll, Miquel/L-5999-2014	Coll, Miquel/0000-0003-4471-8674; Garcia-Castellanos, Raquel/0000-0001-6225-5373; Gomis-Ruth, F. Xavier/0000-0002-6848-6874				Alekshun MN, 2001, NAT STRUCT BIOL, V8, P710, DOI 10.1038/90429; ANDERSON WF, 1981, NATURE, V290, P754, DOI 10.1038/290754a0; Ayliffe GAJ, 1997, CLIN INFECT DIS, V24, pS74, DOI 10.1093/clinids/24.Supplement_1.S74; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Blanco AG, 2002, STRUCTURE, V10, P701, DOI 10.1016/S0969-2126(02)00761-X; BRENNAN RG, 1993, CELL, V74, P773, DOI 10.1016/0092-8674(93)90456-Z; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chambers HF, 2003, TRENDS MICROBIOL, V11, P145, DOI 10.1016/S0966-842X(03)00046-5; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Clarke SR, 2001, MICROBIOL-UK, V147, P803, DOI 10.1099/00221287-147-4-803; Clarke SR, 2001, J ANTIMICROB CHEMOTH, V47, P377, DOI 10.1093/jac/47.4.377; COHEN S, 1968, J BACTERIOL, V95, P1368, DOI 10.1128/JB.95.4.1368-1374.1968; Cook WJ, 1998, J MOL BIOL, V275, P337, DOI 10.1006/jmbi.1997.1443; Crisostomo MI, 2001, P NATL ACAD SCI USA, V98, P9865, DOI 10.1073/pnas.161272898; EMORI TG, 1993, CLIN MICROBIOL REV, V6, P428, DOI 10.1128/CMR.6.4.428-442.1993; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Filee P, 2003, J BIOL CHEM, V278, P16482, DOI 10.1074/jbc.M210887200; Filee P, 2002, MOL MICROBIOL, V44, P685, DOI 10.1046/j.1365-2958.2002.02888.x; Gajiwala KS, 2000, CURR OPIN STRUC BIOL, V10, P110, DOI 10.1016/S0959-440X(99)00057-3; Ghuysen Jean-Marie, 1994, Trends in Microbiology, V2, P372, DOI 10.1016/0966-842X(94)90614-9; Giesbrecht P, 1998, MICROBIOL MOL BIOL R, V62, P1371, DOI 10.1128/MMBR.62.4.1371-1414.1998; Golemi-Kotra D, 2003, J BIOL CHEM, V278, P18419, DOI 10.1074/jbc.M300611200; Gregory PD, 1997, MOL MICROBIOL, V24, P1025, DOI 10.1046/j.1365-2958.1997.4051770.x; GROSSMAN MJ, 1989, FEBS LETT, V246, P83, DOI 10.1016/0014-5793(89)80258-3; HACKBARTH CJ, 1993, ANTIMICROB AGENTS CH, V37, P1144, DOI 10.1128/AAC.37.5.1144; Hardt K, 1997, MOL MICROBIOL, V23, P935, DOI 10.1046/j.1365-2958.1997.2761642.x; HARTMAN BJ, 1984, J BACTERIOL, V158, P513, DOI 10.1128/JB.158.2.513-516.1984; HIRAMATSU K, 1992, FEBS LETT, V298, P133, DOI 10.1016/0014-5793(92)80039-J; Hiramatsu K, 1997, LANCET, V350, P1670, DOI 10.1016/S0140-6736(97)07324-8; Hiramatsu K, 2001, TRENDS MICROBIOL, V9, P486, DOI 10.1016/S0966-842X(01)02175-8; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; Katayama Y, 2000, ANTIMICROB AGENTS CH, V44, P1549, DOI 10.1128/AAC.44.6.1549-1555.2000; Kirby WMM, 1944, SCIENCE, V99, P452, DOI 10.1126/science.99.2579.452; Lewis RA, 2000, J ANTIMICROB CHEMOTH, V45, P139, DOI 10.1093/jac/45.2.139; Lewis RA, 1999, FEMS MICROBIOL LETT, V178, P271, DOI 10.1016/S0378-1097(99)00366-3; LOPEZ P, 1980, J BACTERIOL, V143, P50; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; McKinney TK, 2001, J BACTERIOL, V183, P6862, DOI 10.1128/JB.183.23.6862-6868.2001; Murchan S, 2003, J CLIN MICROBIOL, V41, P1574, DOI 10.1128/JCM.41.4.1574-1585.2003; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; RICHMOND MH, 1965, J BACTERIOL, V90, P370, DOI 10.1128/JB.90.2.370-374.1965; ROWLAND SJ, 1990, MOL MICROBIOL, V4, P961, DOI 10.1111/j.1365-2958.1990.tb00669.x; RYFFEL C, 1992, ANTIMICROB AGENTS CH, V36, P25, DOI 10.1128/AAC.36.1.25; Schmitz FJ, 1997, INT J ANTIMICROB AG, V9, P1, DOI 10.1016/S0924-8579(97)00027-7; Sharma VK, 1998, J BACTERIOL, V180, P2160, DOI 10.1128/JB.180.8.2160-2166.1998; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; White A, 1998, NATURE, V394, P502, DOI 10.1038/28893; WITTMAN V, 1993, J BACTERIOL, V175, P7383, DOI 10.1128/JB.175.22.7383-7390.1993; Zhang HZ, 2001, SCIENCE, V291, P1962, DOI 10.1126/science.1055144; ZHU YF, 1992, J BACTERIOL, V174, P6171, DOI 10.1128/JB.174.19.6171-6178.1992	51	43	45	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39897	39905		10.1074/jbc.M307199200	http://dx.doi.org/10.1074/jbc.M307199200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881514	hybrid			2022-12-27	WOS:000185713800077
J	Innis, CA; Hyvonen, M				Innis, CA; Hyvonen, M			Crystal structures of the heparan sulfate-binding domain of follistatin - Insights into ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FOLLICLE-STIMULATING-HORMONE; ACTIVIN-BINDING; PROTEIN STRUCTURES; XENOPUS EMBRYO; EXPRESSION; REFINEMENT; COMPLEX; PROGRAM; CELL	Follistatin associates with transforming growth factor-beta-like growth factors such as activin or bone morphogenetic proteins to form an inactive complex, thereby regulating processes as diverse as embryonic development and cell secretion. Although an interaction between heparan sulfate chains present at the cell surface and follistatin has been recorded, the impact of this binding reaction on the follistatin-mediated inhibition of transforming growth factor-beta-like signaling remains unclear. To gain a structural insight into this interaction, we have solved the crystal structure of the presumed heparan sulfate-binding domain of follistatin, both alone and in complex with the small heparin analogs sucrose octasulfate and D-myo-inositol hexasulfate. In addition, we have confirmed the binding of the sucrose octasulfate and D-myo-inositol hexasulfate molecules to this follistatin domain and determined the association constants and stoichiometries of both interactions in solution using isothermal titration calorimetry. Overall, our results shed light upon the structure of this follistatin domain and reveal a novel conformation for a hinge region connecting epidermal growth factor-like and Kazal-like subdomains compared with the follistatin-like domain found in the extracellular matrix protein BM-40. Moreover, the crystallographic analysis of the two protein-ligand complexes mentioned above leads us to propose a potential location for the heparan sulfate-binding site on the surface of follistatin and to suggest the involvement of residues Asn(80) and Arg(86) in such a follistatin-heparin interaction.	Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England	University of Cambridge	Hyvonen, M (corresponding author), Univ Cambridge, Dept Biochem, 80 Tennis Court Rd, Cambridge CB2 1GA, England.		Innis, Axel/A-5927-2009; Innis, Axel/P-9863-2019	Innis, Axel/0000-0003-3153-9490; Innis, Axel/0000-0003-3153-9490				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Banner DW, 1996, NATURE, V380, P41, DOI 10.1038/380041a0; BODE W, 1985, EUR J BIOCHEM, V147, P387, DOI 10.1111/j.1432-1033.1985.tb08762.x; BOLOGNESI M, 1982, J MOL BIOL, V162, P839, DOI 10.1016/0022-2836(82)90550-2; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Denzer AJ, 1998, EMBO J, V17, P335, DOI 10.1093/emboj/17.2.335; deWinter JP, 1996, MOL CELL ENDOCRINOL, V116, P105, DOI 10.1016/0303-7207(95)03705-5; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; ESCH FS, 1987, MOL ENDOCRINOL, V1, P849, DOI 10.1210/mend-1-11-849; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Guzman-Casado M, 2000, EUR J BIOCHEM, V267, P3477, DOI 10.1046/j.1432-1327.2000.01371.x; Hashimoto O, 1997, J BIOL CHEM, V272, P13835, DOI 10.1074/jbc.272.21.13835; HEMMATIBRIVANLOU A, 1994, CELL, V77, P283, DOI 10.1016/0092-8674(94)90320-4; Hohenester E, 1997, EMBO J, V16, P3778, DOI 10.1093/emboj/16.13.3778; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; Iemura S, 1998, P NATL ACAD SCI USA, V95, P9337, DOI 10.1073/pnas.95.16.9337; INOUYE S, 1991, ENDOCRINOLOGY, V129, P815, DOI 10.1210/endo-129-2-815; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; Kleywegt GJ, 1994, 1 MAP FINAL MODEL, P59; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Letunic I, 2002, NUCLEIC ACIDS RES, V30, P242, DOI 10.1093/nar/30.1.242; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAKAMURA T, 1990, SCIENCE, V247, P836, DOI 10.1126/science.2106159; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellegrini L, 2001, CURR OPIN STRUC BIOL, V11, P629, DOI 10.1016/S0959-440X(00)00258-X; Peranen J, 1996, ANAL BIOCHEM, V236, P371, DOI 10.1006/abio.1996.0187; Phillips DJ, 1998, FRONT NEUROENDOCRIN, V19, P287, DOI 10.1006/frne.1998.0169; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; ROBERTSON DM, 1987, BIOCHEM BIOPH RES CO, V149, P744, DOI 10.1016/0006-291X(87)90430-X; RUPP F, 1991, NEURON, V6, P811, DOI 10.1016/0896-6273(91)90177-2; SHIMASAKI S, 1989, MOL ENDOCRINOL, V3, P651, DOI 10.1210/mend-3-4-651; SUGINO K, 1993, J BIOL CHEM, V268, P15579; SUMITOMO S, 1995, BIOCHEM BIOPH RES CO, V208, P1, DOI 10.1006/bbrc.1995.1297; TASHIRO K, 1991, BIOCHEM BIOPH RES CO, V174, P1022, DOI 10.1016/0006-291X(91)91521-D; Uchida T, 1999, BIOCHEM BIOPH RES CO, V266, P593, DOI 10.1006/bbrc.1999.1873; UENO N, 1987, P NATL ACAD SCI USA, V84, P8282, DOI 10.1073/pnas.84.23.8282; Ullman CG, 1997, BIOCHEM J, V326, P939, DOI 10.1042/bj3260929v; VANDELOCHT A, 1995, EMBO J, V14, P5149, DOI 10.1002/j.1460-2075.1995.tb00199.x; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wang QF, 2000, ENDOCRINOLOGY, V141, P3183, DOI 10.1210/en.141.9.3183; Weeks CM, 1999, J APPL CRYSTALLOGR, V32, P120, DOI 10.1107/S0021889898010504; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375	49	43	45	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39969	39977		10.1074/jbc.M211284200	http://dx.doi.org/10.1074/jbc.M211284200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12867435	hybrid			2022-12-27	WOS:000185713800085
J	Leonard, MO; Cottell, DC; Godson, C; Brady, HR; Taylor, CT				Leonard, MO; Cottell, DC; Godson, C; Brady, HR; Taylor, CT			The role of HIF-1 alpha in transcriptional regulation of the proximal tubular epithelial cell response to hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCIBLE FACTOR-I; NECROSIS-FACTOR-ALPHA; ELEMENT-BINDING PROTEIN; VHL TUMOR-SUPPRESSOR; GENE-EXPRESSION; MICROARRAY ANALYSIS; MESSENGER-RNA; HIF-ALPHA; IDENTIFICATION; GROWTH	Epithelial cells of the kidney represent a primary target for hypoxic injury in ischemic acute renal failure (ARF); however, the underlying transcriptional mechanism(s) remain undefined. In this study, human proximal tubular epithelial cells (HK-2) exposed to hypoxia in vitro demonstrated a non-lethal but dysfunctional phenotype, closely reflective of the epithelial pathobiology of ARF. HK-2 cells exposed to hypoxia demonstrated increased paracellular permeability, decreased proliferation, loss of tight junctional integrity, and significant actin disassembly in the absence of cell death. Microarray analysis of transcriptomic changes underlying this response identified a distinct cohort of 48 genes with a closely shared hypoxia-dependent expression profile. Within this hypoxia-sensitive cluster were genes identified previously as hypoxia-inducible factor-1 (HIF-1)-dependent ( e. g. vascular endothelial growth factor and adrenomedullin) as well as genes not previously known to be hypoxia-responsive ( e. g. stanniocalcin 2). In hypoxia, HIF-1 bound to evolutionarily conserved hypoxia-response elements (HRE) in the promoters of these genes as well as to the HRE consensus motif. A further subset of these genes, not associated with transcriptional regulation by HIF-1, was also present, suggesting alternative HIF-1-independent pathways. Overexpression of HIF-1alpha in normoxia induced the expression of a significant number of the hypoxia-dependent genes; however, it did not induce the pathophysiologic epithelial response. In summary, hypoxia-elicited alterations in renal proximal tubular epithelial cells in vitro closely resemble the epithelial pathophysiology of ARF. Our data indicate that although this event may rely heavily on HIF-1-dependent gene transcription, it is likely that separate hypoxia-dependent transcriptional regulators also play a role.	Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland; Natl Univ Ireland Univ Coll Dublin, Dublin Mol Med Ctr, Dublin 4, Ireland	University College Dublin; Trinity College Dublin; University College Dublin	Taylor, CT (corresponding author), Natl Univ Ireland Univ Coll Dublin, Conway Inst Biomol & Biomed Res, Dublin 4, Ireland.		Leonard, Martin/AAI-2223-2020	Godson, Catherine/0000-0003-0655-1041; Taylor, Cormac/0000-0002-0946-1247				Bonventre JV, 2002, CURR OPIN NEPHROL HY, V11, P43, DOI 10.1097/00041552-200201000-00007; BRADY HR, 2000, KIDNEY, P1201; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; Bunn HF, 1996, PHYSIOL REV, V76, P839, DOI 10.1152/physrev.1996.76.3.839; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chen CH, 2001, J BIOL CHEM, V276, P9519, DOI 10.1074/jbc.M010144200; de Paulsen N, 2001, P NATL ACAD SCI USA, V98, P1387, DOI 10.1073/pnas.031587498; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fessele S, 2002, TRENDS GENET, V18, P60, DOI 10.1016/S0168-9525(02)02591-X; Fink T, 2002, BLOOD, V99, P2077, DOI 10.1182/blood.V99.6.2077; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Furuta GT, 2001, J EXP MED, V193, P1027, DOI 10.1084/jem.193.9.1027; Garayoa M, 2000, MOL ENDOCRINOL, V14, P848, DOI 10.1210/me.14.6.848; Goda N, 2003, MOL CELL BIOL, V23, P359, DOI 10.1128/MCB.23.1.359-369.2003; Hofer T, 2001, FASEB J, V15, P2715, DOI 10.1096/fj.01-0546fje; Ichikawa JK, 2000, P NATL ACAD SCI USA, V97, P9659, DOI 10.1073/pnas.160140297; Iliopoulos O, 1996, P NATL ACAD SCI USA, V93, P10595, DOI 10.1073/pnas.93.20.10595; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jenq W, 1996, BIOCHEM BIOPH RES CO, V218, P444, DOI 10.1006/bbrc.1996.0079; KVIETIKOVA I, 1995, NUCLEIC ACIDS RES, V23, P4542, DOI 10.1093/nar/23.22.4542; Lando D, 2002, SCIENCE, V295, P858, DOI 10.1126/science.1068592; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Maderna P, 2002, AM J PATHOL, V160, P2275, DOI 10.1016/S0002-9440(10)61175-3; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; Matejuk A, 2002, ENDOCRINOLOGY, V143, P313, DOI 10.1210/en.143.1.313; Mathupala SP, 2001, J BIOL CHEM, V276, P43407, DOI 10.1074/jbc.M108181200; Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104; Millhorn DE, 1997, KIDNEY INT, V51, P527, DOI 10.1038/ki.1997.73; Minchenko A, 2002, J BIOL CHEM, V277, P6183, DOI 10.1074/jbc.M110978200; Molin WT, 1999, WEED TECHNOL, V13, P1; ORourke JF, 1996, EUR J BIOCHEM, V241, P403, DOI 10.1111/j.1432-1033.1996.00403.x; Prince LS, 2001, PHYSIOL GENOMICS, V6, P81, DOI 10.1152/physiolgenomics.2001.6.2.81; RYAN MJ, 1994, KIDNEY INT, V45, P48, DOI 10.1038/ki.1994.6; Saarikoski ST, 2002, FEBS LETT, V530, P186, DOI 10.1016/S0014-5793(02)03475-0; Sandau KB, 2001, J BIOL CHEM, V276, P39805, DOI 10.1074/jbc.M107689200; Schipani E, 2001, GENE DEV, V15, P2865; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; Seta KA, 2001, J BIOL CHEM, V276, P44405, DOI 10.1074/jbc.M103346200; Sheridan AM, 2000, CURR OPIN NEPHROL HY, V9, P427, DOI 10.1097/00041552-200007000-00015; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Synnestvedt K, 2002, J CLIN INVEST, V110, P993, DOI 10.1172/JCI200215337; Takahashi Y, 2000, J BIOL CHEM, V275, P14139, DOI 10.1074/jbc.275.19.14139; Taylor CT, 2000, P NATL ACAD SCI USA, V97, P12091, DOI 10.1073/pnas.220211797; Taylor CT, 1999, PHARM RES-DORDR, V16, P1498, DOI 10.1023/A:1011936016833; Taylor CT, 1999, J BIOL CHEM, V274, P19447, DOI 10.1074/jbc.274.27.19447; Taylor CT, 1998, GASTROENTEROLOGY, V114, P657, DOI 10.1016/S0016-5085(98)70579-7; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Thornton RD, 2000, BIOCHEM J, V350, P307, DOI 10.1042/0264-6021:3500307; Wykoff CC, 2000, ONCOGENE, V19, P6297, DOI 10.1038/sj.onc.1204012; Yan SF, 1998, P NATL ACAD SCI USA, V95, P8298, DOI 10.1073/pnas.95.14.8298	51	126	131	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40296	40304		10.1074/jbc.M302560200	http://dx.doi.org/10.1074/jbc.M302560200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885785	hybrid			2022-12-27	WOS:000185713800122
J	Louneva, N; Saitta, B; Herrick, DJ; Jimenez, SA				Louneva, N; Saitta, B; Herrick, DJ; Jimenez, SA			Transcriptional inhibition of type I collagen gene expression in scleroderma fibroblasts by the antineoplastic drug ecteinascidin 743	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROCOLLAGEN GENE; DERMAL FIBROBLASTS; INCREASED BINDING; CBF/NF-Y; PROMOTER; ACTIVATION; ELEMENTS; COL1A1; ADDUCTS; BASAL	We previously showed that COL1A1 expression is upregulated at the transcriptional level in systemic sclerosis (SSc) fibroblasts and that the CCAAT-binding factor (CBF) is involved in this increased expression. Ecteinascidin 743 (ET-743) is a chemotherapeutic agent that binds with sequence specificity to the minor groove of DNA and inhibits CBF-mediated transcriptional activation of numerous genes. Therefore, we examined the effects of ET-743 on the increased COL1A1 expression in SSc fibroblasts. The drug caused a potent and dose-dependent inhibition of type I collagen biosynthesis, which reached 70 - 90% at 700 pM without affecting cell viability. The same drug concentration caused 60 - 80% reduction in COL1A1 mRNA levels. The stability of the corresponding transcripts was not affected. In vitro nuclear transcription assays demonstrated a 54% downregulation of COL1A1 transcription. Transient transfections with COL1A1 promoter constructs containing the specific CBF binding sequence into SSc cells previously treated with 700 pM ET-743 failed to show an effect on COL1A1 promoter activity. Furthermore, ET-743 did not affect the binding of CBF or Sp1 transcription factors to their cognate COL1A1 elements. However, treatment with 700 pM ET-743 of stably transfected NIH 3T3 cells expressing a human type II procollagen gene under the control of the human COL1A1 promoter caused a greater than 50% reduction in the production of type II procollagen and a similar decrease in the corresponding type II procollagen transcripts. These results indicate that ET-743 is a potent inhibitor of COL1A1 transcription. However, this effect cannot be explained by a direct effect on CBF binding to the COL1A1 promoter. Although the exact mechanisms responsible for the transcriptional inhibition of COL1A1 by ET-743 are not apparent, our observations suggest that the drug may be an effective agent to decrease collagen overproduction in SSc and other fibrotic diseases.	Thomas Jefferson Univ, Dept Med, Div Rheumatol, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Dept Dermatol & Cutaneous Biol, Philadelphia, PA 19107 USA	Jefferson University; Jefferson University	Jimenez, SA (corresponding author), Thomas Jefferson Univ, Dept Med, Div Rheumatol, 233 S 10th St,Rm 509 BLSB, Philadelphia, PA 19107 USA.	Sergio.Jimenez@jefferson.edu		Jimenez, Sergio/0000-0001-5213-1203	NIAMS NIH HHS [AR19616] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR019616] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALAKOKKO L, 1991, J BIOL CHEM, V266, P14175; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; [Anonymous], 1980, ARTHRITIS RHEUM, V23, P581, DOI 10.1002/art.1780230510; Artlett CM, 1998, MATRIX BIOL, V17, P425, DOI 10.1016/S0945-053X(98)90102-0; Bi WM, 1997, J BIOL CHEM, V272, P26562, DOI 10.1074/jbc.272.42.26562; Diaz A, 1997, INT J BIOCHEM CELL B, V29, P251, DOI 10.1016/S1357-2725(96)00112-4; Finch JS, 2001, GENE, V267, P135, DOI 10.1016/S0378-1119(01)00398-5; Gaidarova S, 2002, J BIOL CHEM, V277, P38737, DOI 10.1074/jbc.M201742200; Ghosh AK, 2002, EXP BIOL MED, V227, P301, DOI 10.1177/153537020222700502; Hitraya EG, 1996, ARTHRITIS RHEUM-US, V39, P1347, DOI 10.1002/art.1780390812; Hitraya EG, 1998, ARTHRITIS RHEUM-US, V41, P2048, DOI 10.1002/1529-0131(199811)41:11<2048::AID-ART21>3.0.CO;2-X; Hurley LH, 2001, ADV EXP MED BIOL, V500, P289; JIMENEZ SA, 1994, J BIOL CHEM, V269, P12684; Jimenez SA, 1996, RHEUM DIS CLIN N AM, V22, P647, DOI 10.1016/S0889-857X(05)70294-5; Jimenez SA, 2001, J CLIN INVEST, V108, P1395, DOI 10.1172/JCI200112347; Jimenez SA, 1997, MATRIX BIOL, V16, P29, DOI 10.1016/S0945-053X(97)90114-1; Jimenez SA, 1999, SPRINGER SEMIN IMMUN, V21, P397; Jin S, 2000, P NATL ACAD SCI USA, V97, P6775, DOI 10.1073/pnas.97.12.6775; Lindahl GE, 2002, J BIOL CHEM, V277, P6153, DOI 10.1074/jbc.M108966200; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; Maity SN, 1998, TRENDS BIOCHEM SCI, V23, P174, DOI 10.1016/S0968-0004(98)01201-8; Minuzzo M, 2000, P NATL ACAD SCI USA, V97, P6780, DOI 10.1073/pnas.97.12.6780; Peterkofsky B, 1999, J CELL BIOCHEM, V73, P408, DOI 10.1002/(SICI)1097-4644(19990601)73:3<408::AID-JCB12>3.3.CO;2-4; Saitta B, 2000, ARTHRITIS RHEUM-US, V43, P2219, DOI 10.1002/1529-0131(200010)43:10<2219::AID-ANR9>3.0.CO;2-N; SIERON AL, 1993, J BIOL CHEM, V268, P21232; Trojanowska M, 2002, FRONT BIOSCI-LANDMRK, V7, pD608, DOI 10.2741/trojan; Valoti G, 1998, CLIN CANCER RES, V4, P1977; Zewail-Foote M, 2001, J AM CHEM SOC, V123, P6485, DOI 10.1021/ja004023p	28	10	11	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40400	40407		10.1074/jbc.M301964200	http://dx.doi.org/10.1074/jbc.M301964200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881530	hybrid, Green Published			2022-12-27	WOS:000185713800134
J	Payen, LF; Gao, M; Westlake, CJ; Cole, SPC; Deeley, RG				Payen, LF; Gao, M; Westlake, CJ; Cole, SPC; Deeley, RG			Role of carboxylate residues adjacent to the conserved core walker B motifs in the catalytic cycle of multidrug resistance protein 1 (ABCC1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-BINDING DOMAINS; HUMAN P-GLYCOPROTEIN; ATP-BINDING; LEUKOTRIENE C-4; MONOCLONAL-ANTIBODIES; SULFONYLUREA RECEPTOR; MEMBRANE TOPOLOGY; TUMOR-CELLS; MRP1 ABCC1; 2ND DOMAIN	MRP1 belongs to subfamily "C" of the ABC transporter superfamily. The nucleotide-binding domains (NBDs) of the C family members are relatively divergent compared with many ABC proteins. They also differ in their ability to bind and hydrolyze ATP. In MRP1, NBD1 binds ATP with high affinity, whereas NBD2 is hydrolytically more active. Furthermore, ATP binding and/or hydrolysis by NBD2 of MRP1, but not NBD1, is required for MRP1 to shift from a high to low affinity substrate binding state. Little is known of the structural basis for these functional differences. One minor structural difference between NBDs is the presence of Asp COOH-terminal to the conserved core Walker B motif in NBD1, rather than the more commonly found Glu present in NBD2. We show that the presence of Asp or Glu following the Walker B motif profoundly affects the ability of the NBDs to bind, hydrolyze, and release nucleotide. An Asp to Glu mutation in NBD1 enhances its hydrolytic capacity and affinity for ADP but markedly decreases transport activity. In contrast, mutations that eliminate the negative charge of the Asp side chain have little effect. The decrease in transport caused by the Asp to Glu mutation in NBD1 is associated with an inability of MRP1 to shift from high to low affinity substrate binding states. In contrast, mutation of Glu to Asp markedly increases the affinity of NBD2 for ATP while decreasing its ability to hydrolyze ATP and to release ADP. This mutation eliminates transport activity but potentiates the conversion from a high to low affinity binding state in the presence of nucleotide. These observations are discussed in the context of catalytic models proposed for MRP1 and other ABC drug transport proteins.	Queens Univ, Canc Res Inst, Canc Res Labs, Kingston, ON K7L 3N6, Canada; Queens Univ, Dept Pathol, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Deeley, RG (corresponding author), Queens Univ, Canc Res Inst, Canc Res Labs, Kingston, ON K7L 3N6, Canada.		Westlake, Christopher/AAG-1150-2019; Cole, Susan P.C./I-6389-2017; Deeley, Roger/J-4828-2012	Westlake, Christopher/0000-0001-7476-2014; Cole, Susan P.C./0000-0001-6571-6884; 				Aleksandrov L, 2002, J BIOL CHEM, V277, P15419, DOI 10.1074/jbc.M111713200; AZZARIA M, 1989, MOL CELL BIOL, V9, P5289, DOI 10.1128/MCB.9.12.5289; BEAUDET L, 1995, J BIOL CHEM, V270, P17159, DOI 10.1074/jbc.270.29.17159; Cole S P, 1996, Cancer Treat Res, V87, P39; COLE SPC, 1994, CANCER RES, V54, P5902; Cole SPC, 1998, BIOESSAYS, V20, P931, DOI 10.1002/(SICI)1521-1878(199811)20:11<931::AID-BIES8>3.0.CO;2-J; Cui LY, 2001, ARCH BIOCHEM BIOPHYS, V392, P153, DOI 10.1006/abbi.2001.2441; FLENS MJ, 1994, CANCER RES, V54, P4557; Gao M, 2000, J BIOL CHEM, V275, P13098, DOI 10.1074/jbc.275.17.13098; Gao M, 1996, J BIOL CHEM, V271, P27782, DOI 10.1074/jbc.271.44.27782; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; Hipfner DR, 1997, J BIOL CHEM, V272, P23623, DOI 10.1074/jbc.272.38.23623; Hipfner DR, 1998, BRIT J CANCER, V78, P1134, DOI 10.1038/bjc.1998.642; Hipfner DR, 1999, J BIOL CHEM, V274, P15420, DOI 10.1074/jbc.274.22.15420; Hipfner DR, 1999, BBA-BIOMEMBRANES, V1461, P359, DOI 10.1016/S0005-2736(99)00168-6; Hou YX, 2000, J BIOL CHEM, V275, P20280, DOI 10.1074/jbc.M001109200; Hou YX, 2003, J BIOL CHEM, V278, P3599, DOI 10.1074/jbc.M210480200; Hou YX, 2002, J BIOL CHEM, V277, P5110, DOI 10.1074/jbc.M107133200; Hrycyna CA, 1999, BIOCHEMISTRY-US, V38, P13887, DOI 10.1021/bi991115m; Hung LW, 1998, NATURE, V396, P703, DOI 10.1038/25393; Kast C, 1997, J BIOL CHEM, V272, P26479, DOI 10.1074/jbc.272.42.26479; Kerr KM, 2001, J BIOL CHEM, V276, P8657, DOI 10.1074/jbc.M010044200; Kreimer DI, 2000, BIOCHEMISTRY-US, V39, P14183, DOI 10.1021/bi001066+; LEIER I, 1994, J BIOL CHEM, V269, P27807; Leslie EM, 2001, TOXICOLOGY, V167, P3, DOI 10.1016/S0300-483X(01)00454-1; Leslie EM, 2001, J BIOL CHEM, V276, P27846, DOI 10.1074/jbc.M102453200; Loe DW, 1997, MOL PHARMACOL, V51, P1034, DOI 10.1124/mol.51.6.1034; Loe DW, 1996, J BIOL CHEM, V271, P9683, DOI 10.1074/jbc.271.16.9683; Loe DW, 1996, J BIOL CHEM, V271, P9675, DOI 10.1074/jbc.271.16.9675; Mao QC, 2002, J BIOL CHEM, V277, P28690, DOI 10.1074/jbc.M202182200; Matsuo M, 2000, J BIOL CHEM, V275, P28757, DOI 10.1074/jbc.M004818200; Matsuo M, 1999, J BIOL CHEM, V274, P37479, DOI 10.1074/jbc.274.52.37479; Moody JE, 2002, J BIOL CHEM, V277, P21111, DOI 10.1074/jbc.C200228200; Nagata K, 2000, J BIOL CHEM, V275, P17626, DOI 10.1074/jbc.M000792200; Qian YM, 2001, J BIOL CHEM, V276, P38636, DOI 10.1074/jbc.M107025200; Raab-Graham KF, 1999, J BIOL CHEM, V274, P29122, DOI 10.1074/jbc.274.41.29122; Renes J, 2000, DRUG RESIST UPDATE, V3, P289, DOI 10.1054/drup.2000.0156; Sauna ZE, 2001, J BIOL CHEM, V276, P11653, DOI 10.1074/jbc.M011294200; Sauna ZE, 2002, BIOCHEMISTRY-US, V41, P13989, DOI 10.1021/bi026626e; Senior AE, 1995, FEBS LETT, V377, P285, DOI 10.1016/0014-5793(95)01345-8; Senior AE, 1998, BIOCHEMISTRY-US, V37, P831, DOI 10.1021/bi9719962; Urbatsch IL, 1998, BIOCHEMISTRY-US, V37, P4592, DOI 10.1021/bi9728001; URBATSCH IL, 1995, J BIOL CHEM, V270, P26956, DOI 10.1074/jbc.270.45.26956; Urbatsch IL, 2000, BIOCHEMISTRY-US, V39, P14138, DOI 10.1021/bi001128w; WALKER JE, 1982, BIOCHEM SOC T, V10, P203, DOI 10.1042/bst0100203	45	64	64	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38537	38547		10.1074/jbc.M305786200	http://dx.doi.org/10.1074/jbc.M305786200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882957	hybrid			2022-12-27	WOS:000185575100056
J	Sakaue, H; Nishizawa, A; Ogawa, W; Teshigawara, K; Mori, T; Takashima, Y; Noda, T; Kasuga, M				Sakaue, H; Nishizawa, A; Ogawa, W; Teshigawara, K; Mori, T; Takashima, Y; Noda, T; Kasuga, M			Requirement for 3-phosphoinositide-dependent kinase-1 (PDK-1) in insulin-induced glucose uptake in immortalized brown adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLUCOSE-TRANSPORTER-4 TRANSLOCATION; PROTEIN-KINASE; PHOSPHOINOSITIDE 3-KINASE; 3T3-L1 ADIPOCYTES; RECEPTOR SUBSTRATE-1; GLUT4 TRANSLOCATION; 5-AMINOIMIDAZOLE-4-CARBOXAMIDE RIBONUCLEOSIDE; SIGNALING PATHWAY; C-LAMBDA; ACTIVATION	To provide insight into the physiological importance of 3-phosphoinositide-dependent kinase-1 (PDK-1) in the metabolic actions of insulin, we have generated mice that harbor a PDK-1 gene containing LoxP sites (PDK1(lox/lox) mice) and established immortalized brown preadipocyte cell lines both from these animals and from wild-type mice. Exposure to appropriate hormonal inducers resulted in the differentiation of > 80% of the immortalized brown preadipocytes derived from both types of mice into mature adipocytes. Introduction of the Cre recombinase with the use of adenovirus-mediated gene transfer induced a dose-dependent decrease in the abundance of PDK-1 in PDK-1(lox/lox) adipocytes but not in the wild-type cells. In Cre-expressing PDK-1(lox/lox) adipocytes in which the abundance of PDK-1 was reduced by similar to85%, the insulin-induced phosphorylation both of Akt on threonine 308 and of p70 S6 kinase on threonine-389 was markedly inhibited. The phosphorylation both of Akt on serine 473 and of p42 and p44 isoforms of mitogen-activated protein kinase induced by insulin was not affected by Cre expression, indicating that the latter specifically inhibits PDK-1-dependent signaling. Both glucose uptake and the translocation of glucose transporter 4 to the plasma membrane induced by insulin as well as glucose uptake induced by a constitutively active form of phosphoinositide 3-kinase were also greatly inhibited by Cre expression in PDK1(lox/lox) adipocytes. Phosphorylation of AMP- activated protein kinase and glucose uptake induced by 5-aminoimidazole-4- carboxamide ribonucleoside (AICAR) were not affected by Cre expression in PDK-1(lox/lox) adipocytes. These results indicate that PDK-1 is essential for insulin-induced glucose uptake in adipocytes.	Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, Kobe, Hyogo 6500017, Japan; Japanese Fdn Canc Res, Inst Canc, Dept Cell Biol, Tokyo 1708455, Japan; Tohoku Univ, Sch Med, Dept Mol Genet, Sendai, Miyagi 9808574, Japan	Kobe University; Japanese Foundation for Cancer Research; Tohoku University	Ogawa, W (corresponding author), Kobe Univ, Grad Sch Med, Dept Clin Mol Med, Div Diabet & Digest & Kidney Dis,Chuo Ku, 7-5-1 Kusunoki Cho, Kobe, Hyogo 6500017, Japan.	ogawa@med.kobe-u.ac.jp	OGAWA, Wataru/AAQ-9586-2020; Noda, Tetsuo/B-1667-2016; Sakaue, Hiroshi/ABE-2337-2021	Sakaue, Hiroshi/0000-0002-2468-2363; Takashima, Yasuhiro/0000-0003-0126-7260				Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Balendran A, 2000, FEBS LETT, V484, P217, DOI 10.1016/S0014-5793(00)02162-1; Bandyopadhyay G, 1997, J BIOL CHEM, V272, P2551; Bandyopadhyay G, 1999, MOL ENDOCRINOL, V13, P1766, DOI 10.1210/me.13.10.1766; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Chiang SH, 2001, NATURE, V410, P944, DOI 10.1038/35073608; CORTON JM, 1995, EUR J BIOCHEM, V229, P558, DOI 10.1111/j.1432-1033.1995.0558k.x; Egawa K, 2002, J BIOL CHEM, V277, P38863, DOI 10.1074/jbc.M203132200; Fasshauer M, 2000, J BIOL CHEM, V275, P25494, DOI 10.1074/jbc.M004046200; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Frodin M, 2000, EMBO J, V19, P2924, DOI 10.1093/emboj/19.12.2924; Grillo S, 1999, FEBS LETT, V461, P277, DOI 10.1016/S0014-5793(99)01472-6; Holman GD, 1997, DIABETOLOGIA, V40, P991, DOI 10.1007/s001250050780; Kitamura T, 1999, MOL CELL BIOL, V19, P6286; Kitamura T, 1998, MOL CELL BIOL, V18, P3708, DOI 10.1128/MCB.18.7.3708; Klein J, 2002, BIOESSAYS, V24, P382, DOI 10.1002/bies.10058; Klein J, 1999, J BIOL CHEM, V274, P34795, DOI 10.1074/jbc.274.49.34795; Kobayashi T, 1999, BIOCHEM J, V339, P319, DOI 10.1042/0264-6021:3390319; Kotani K, 1999, J BIOL CHEM, V274, P21305, DOI 10.1074/jbc.274.30.21305; Kotani K, 1998, MOL CELL BIOL, V18, P6971, DOI 10.1128/MCB.18.12.6971; Kurth-Kraczek EJ, 1999, DIABETES, V48, P1667, DOI 10.2337/diabetes.48.8.1667; Lawlor MA, 2002, EMBO J, V21, P3728, DOI 10.1093/emboj/cdf387; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Matsumoto M, 2002, DIABETES, V51, P1672, DOI 10.2337/diabetes.51.6.1672; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Miyake K, 2002, J CLIN INVEST, V110, P1483, DOI 10.1172/JCI200215880; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Ogawa W, 1998, MOL CELL BIOCHEM, V182, P13, DOI 10.1023/A:1006862807598; Pullen N, 1998, SCIENCE, V279, P707, DOI 10.1126/science.279.5351.707; Sakaue H, 1998, J BIOL CHEM, V273, P28945, DOI 10.1074/jbc.273.44.28945; Sakaue H, 1997, MOL ENDOCRINOL, V11, P1552, DOI 10.1210/me.11.10.1552; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Shepherd PR, 1998, BIOCHEM J, V333, P471, DOI 10.1042/bj3330471; Shibata H, 1997, SCIENCE, V278, P120, DOI 10.1126/science.278.5335.120; Wick MJ, 2002, J BIOL CHEM, V277, P16632, DOI 10.1074/jbc.M112402200; Williams MR, 2000, CURR BIOL, V10, P439, DOI 10.1016/S0960-9822(00)00441-3; Yamada T, 2002, AM J PHYSIOL-ENDOC M, V282, pE1385, DOI 10.1152/ajpendo.00486.2001	39	23	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38870	38874		10.1074/jbc.M306151200	http://dx.doi.org/10.1074/jbc.M306151200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855688	hybrid			2022-12-27	WOS:000185575100095
J	Worthington, EN; Kavakli, IH; Berrocal-Tito, G; Bondo, BE; Sancar, A				Worthington, EN; Kavakli, IH; Berrocal-Tito, G; Bondo, BE; Sancar, A			Purification and characterization of three members of the photolyase/cryptochrome family blue-light photoreceptors from Vibrio cholerae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI DNA PHOTOLYASE; ESCHERICHIA-COLI; ACTION MECHANISM; 2ND CHROMOPHORE; CRYPTOCHROME; FLAVIN; GENES; IDENTIFICATION; REPAIR; RECEPTORS	The sequence of Vibrio cholerae genome revealed three genes belonging to the photolyase/cryptochrome blue-light photoreceptor family. The proteins encoded by the three genes were purified and characterized. All three proteins contain folate and flavin cofactors and have absorption peaks in the range of 350-500 nm. Only one of the three, VcPhr, is a photolyase specific for cyclobutane pyrimidine dimers. The other two are cryptochromes and were designated VcCry1 and VcCry2, respectively. Mutation of phr abolishes photoreactivation of UV-induced killing, whereas mutations in cry1 and cry2 do not affect photorepair activity. VcCry1 exhibits some unique features. Of all cryptochromes characterized to date, it is the only one that contains stoichiometric amounts of both chromophores and retains its flavin cofactor in the two-electron reduced FADH2 form. In addition, VcCry1 exhibits RNA binding activity and co-purifies with an RNA of 60-70 nucleotides in length.	Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Izmir Inst Technol, Dept Biol, TR-35437 Gulbahce Kampusu, Urla Izmir, Turkey	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Izmir Institute of Technology	Sancar, A (corresponding author), Univ N Carolina, Sch Med, Dept Biochem & Biophys, Mary Ellen Jones Bldg,CB 7260, Chapel Hill, NC 27599 USA.	aziz_sancar@med.unc.edu	Kavakli, Ibrahim/AAF-5468-2020	Kavakli, Ibrahim/0000-0001-6624-3505	NIGMS NIH HHS [GM31082] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031082, R01GM031082] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHMAD M, 1993, NATURE, V366, P162, DOI 10.1038/366162a0; Brudler R, 2003, MOL CELL, V11, P59, DOI 10.1016/S1097-2765(03)00008-X; Cashmore AR, 1999, SCIENCE, V284, P760, DOI 10.1126/science.284.5415.760; CHANDA PK, 1976, CAN J MICROBIOL, V22, P1186, DOI 10.1139/m76-172; DAS G, 1981, BIOCHIM BIOPHYS ACTA, V655, P413, DOI 10.1016/0005-2787(81)90053-8; EKER APM, 1990, J BIOL CHEM, V265, P8009; Heidelberg JF, 2000, NATURE, V406, P477, DOI 10.1038/35020000; Hitomi K, 1997, J BIOL CHEM, V272, P32591, DOI 10.1074/jbc.272.51.32591; Hitomi K, 2000, NUCLEIC ACIDS RES, V28, P2353, DOI 10.1093/nar/28.12.2353; HORTON RM, 1990, BIOTECHNIQUES, V8, P528; Hsu DS, 1996, BIOCHEMISTRY-US, V35, P13871, DOI 10.1021/bi962209o; JOHNSON JL, 1988, P NATL ACAD SCI USA, V85, P2046, DOI 10.1073/pnas.85.7.2046; JORNS MS, 1984, BIOCHEMISTRY-US, V23, P2673, DOI 10.1021/bi00307a021; JORNS MS, 1987, J BIOL CHEM, V262, P486; KAVAKLI IH, 2002, MOL INTERV, V8, P484; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lin C., 1996, PLANT PHYSIOL, V110, P1047; Lin CT, 2002, PLANT CELL, V14, pS207, DOI 10.1105/tpc.000646; LIN CT, 1995, SCIENCE, V269, P968, DOI 10.1126/science.7638620; MALHOTRA K, 1992, J BIOL CHEM, V267, P15406; MALHOTRA K, 1995, BIOCHEMISTRY-US, V34, P6892, DOI 10.1021/bi00020a037; MITCHELL DL, 1989, PHOTOCHEM PHOTOBIOL, V49, P805, DOI 10.1111/j.1751-1097.1989.tb05578.x; Ng WO, 2000, ARCH MICROBIOL, V173, P412, DOI 10.1007/s002030000164; Ng WO, 2001, MOL GEN GENET, V264, P924, DOI 10.1007/s004380000383; Ozgur S, 2003, BIOCHEMISTRY-US, V42, P2926, DOI 10.1021/bi026963n; PAYNE G, 1987, BIOCHEMISTRY-US, V26, P7121, DOI 10.1021/bi00396a038; PAYNE G, 1990, BIOCHEMISTRY-US, V29, P5706, DOI 10.1021/bi00476a010; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Sancar A, 2000, ANNU REV BIOCHEM, V69, P31, DOI 10.1146/annurev.biochem.69.1.31; SANCAR A, 1994, BIOCHEMISTRY-US, V33, P2, DOI 10.1021/bi00167a001; Sancar A, 2003, CHEM REV, V103, P2203, DOI 10.1021/cr0204348; SANCAR GB, 1987, TRENDS BIOCHEM SCI, V12, P259, DOI 10.1016/0968-0004(87)90130-7; SANCAR GB, 1987, J BIOL CHEM, V262, P15457; SANCAR GB, 1987, J BIOL CHEM, V262, P492; SANCAR GB, 2000, MUTAT RES, V451, P7715; Selby CP, 1999, PHOTOCHEM PHOTOBIOL, V69, P105, DOI 10.1562/0031-8655(1999)069<0105:ATMOTP>2.3.CO;2; Stanewsky R, 1998, CELL, V95, P681, DOI 10.1016/S0092-8674(00)81638-4; Thompson CL, 2002, ONCOGENE, V21, P9043, DOI 10.1038/sj.onc.1205958; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Todo T, 1999, MUTAT RES-DNA REPAIR, V434, P89, DOI 10.1016/S0921-8777(99)00013-0; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Yildiz FH, 2001, J BACTERIOL, V183, P1716, DOI 10.1128/JB.183.5.1716-1726.2001; Zhao XD, 1997, J BIOL CHEM, V272, P32580, DOI 10.1074/jbc.272.51.32580	44	87	93	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39143	39154		10.1074/jbc.M305792200	http://dx.doi.org/10.1074/jbc.M305792200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878596	Green Published, hybrid			2022-12-27	WOS:000185575100128
J	Chen, CC; Ghole, M; Majumder, A; Wang, ZJ; Chandana, S; Wu, HY				Chen, CC; Ghole, M; Majumder, A; Wang, ZJ; Chandana, S; Wu, HY			LeuO-mediated transcriptional derepression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; LEU-500 PROMOTER; DNA CONFORMATION; ILVYC OPERON; EXPRESSION; GENE; BOUNDARIES; ACTIVATION; MECHANISM; UPSTREAM	To understand the coordination of gene expression in the Salmonella typhimurium ilvIH-leuO-leuABCD gene cluster, we had previously identified a 72-bp AT-rich (78% A+T) DNA sequence element, AT4, which was capable of silencing transcription in a promoter nonspecific manner. LeuO protein provided in trans relieved (derepressed) AT4-mediated gene silencing (transcriptional repression), but underlying mechanisms remained unclear. In the present communication, the 72-bp DNA sequence element is further dissected into two functional elements, AT7 and AT8. LeuO binds to the 25-bp AT7, which lies closest to the leuO promoter in the AT4 DNA. After deletion of the AT7 DNA sequence responsible for LeuO binding from AT4, the remaining 47-bp AT-rich (85% A+T) DNA sequence, termed AT8, retains the full bi-directional gene-silencing activity, which is no longer relieved by LeuO. LeuO-mediated transcriptional derepression is restored when the LeuO binding site, AT7, is placed within close proximity to the gene silencer AT8. As a pair of functionally coupled transcription elements, the presence of an equal copy number of AT7 and AT8 within proximity is important for the transcription control. The characterization provides clues for future elucidation of the molecular details whereby LeuO negates the gene-silencing activity.	Wayne State Univ, Sch Med, Dept Pharmacol, Detroit, MI 48201 USA	Wayne State University	Wu, HY (corresponding author), Wayne State Univ, Sch Med, Dept Pharmacol, 540 E Canfield Ave, Detroit, MI 48201 USA.	haiwu@med.wayne.edu			NIGMS NIH HHS [GM-53617] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053617, R29GM053617] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 2001, SCIENCE, V291, P447, DOI 10.1126/science.291.5503.447; Chen CC, 2001, J BIOL CHEM, V276, P9478, DOI 10.1074/jbc.M010501200; Chen Chien-Chung, 2003, Frontiers in Bioscience, V8, P430; Dai X, 1999, CURR OPIN MICROBIOL, V2, P126, DOI 10.1016/S1369-5274(99)80022-8; Fang M, 1998, J BIOL CHEM, V273, P29929, DOI 10.1074/jbc.273.45.29929; Fang M, 2000, BIOCHEM BIOPH RES CO, V276, P64, DOI 10.1006/bbrc.2000.3440; Fang M, 1998, J BACTERIOL, V180, P626, DOI 10.1128/JB.180.3.626-633.1998; HAUGHN GW, 1986, J BACTERIOL, V166, P1113, DOI 10.1128/jb.166.3.1113-1117.1986; HENIKOFF S, 1988, P NATL ACAD SCI USA, V85, P6602, DOI 10.1073/pnas.85.18.6602; Levens D, 1997, CURR TOP MICROBIOL, V224, P33; Lissemore JL, 2000, BIOTECHNIQUES, V28, P82, DOI 10.2144/00281st02; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; Majumder A, 2001, J BIOL CHEM, V276, P19046, DOI 10.1074/jbc.M100945200; MARGOLIN P, 1985, P NATL ACAD SCI USA, V82, P5437, DOI 10.1073/pnas.82.16.5437; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; Miller J. H., 1972, EXPT MOL GENETICS, P431; OEHLER S, 1990, EMBO J, V9, P973, DOI 10.1002/j.1460-2075.1990.tb08199.x; Opel ML, 2001, MOL MICROBIOL, V39, P1109, DOI 10.1046/j.1365-2958.2001.02309.x; Opel ML, 2001, MOL MICROBIOL, V39, P191, DOI 10.1046/j.1365-2958.2001.02249.x; Repoila F, 2001, J BACTERIOL, V183, P4012, DOI 10.1128/JB.183.13.4012-4023.2001; Rhee KY, 1999, P NATL ACAD SCI USA, V96, P14294, DOI 10.1073/pnas.96.25.14294; STUDIER FW, 1991, J MOL BIOL, V219, P37, DOI 10.1016/0022-2836(91)90855-Z; Sun FL, 1999, CELL, V99, P459, DOI 10.1016/S0092-8674(00)81534-2; SZOKE PA, 1987, BIOCHEMISTRY-US, V26, P6188, DOI 10.1021/bi00393a035; TAN JY, 1994, J BACTERIOL, V176, P1077, DOI 10.1128/JB.176.4.1077-1086.1994; TRUCKSIS M, 1981, J BACTERIOL, V147, P679, DOI 10.1128/JB.147.2.679-681.1981; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; VANDYKE MW, 1992, GENE, V111, P99, DOI 10.1016/0378-1119(92)90608-R; WU HY, 1995, CELL, V82, P445, DOI 10.1016/0092-8674(95)90433-6; WU HY, 1991, J MOL BIOL, V219, P615, DOI 10.1016/0022-2836(91)90658-S; Wu HY, 2003, PROG NUCLEIC ACID RE, V73, P43, DOI 10.1016/S0079-6603(03)01002-X; WU HY, 1988, CELL, V53, P433, DOI 10.1016/0092-8674(88)90163-8	33	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38094	38103		10.1074/jbc.M300461200	http://dx.doi.org/10.1074/jbc.M300461200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871947	hybrid			2022-12-27	WOS:000185437200131
J	Cortez, D				Cortez, D			Caffeine inhibits checkpoint responses without inhibiting the ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) protein kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE CHECKPOINT; EARLY EMBRYONIC LETHALITY; CELL-CYCLE REGULATION; S-PHASE CHECKPOINT; INDUCED G2 ARREST; RADIOSENSITIZING AGENT; XANTHINE DERIVATIVES; DOWNSTREAM EFFECTOR; MAMMALIAN-CELLS; IN-VITRO	The ataxia-telangiectasia-mutated (ATM) and ATM- and Rad3-related (ATR) kinases regulate cell cycle checkpoints by phosphorylating multiple substrates including the CHK1 and -2 protein kinases and p53. Caffeine has been widely used to study ATM and ATR signaling because it inhibits these kinases in vitro and overcomes cell cycle checkpoint responses in vivo. Thus, caffeine has been thought to overcome the checkpoint through its ability to prevent phosphorylation of ATM and ATR substrates. Surprisingly, I have found that multiple ATM- ATR substrates including CHK1 and -2 are hyperphosphorylated in cells treated with caffeine and genotoxic agents such as hydroxyurea or ionizing radiation. ATM autophosphorylation in cells is also increased when caffeine is used in combination with inhibitors of replication suggesting that ATM activity is not inhibited in vivo by caffeine. Furthermore, CHK1 hyperphosphorylation induced by caffeine in combination with hydroxyurea is ATR-dependent suggesting that ATR activity is stimulated by caffeine. Finally, the G(2)/M checkpoint in response to ionizing radiation or hydroxyurea is abrogated by caffeine treatment without a corresponding decrease in ATM-ATR-dependent signaling. This data suggests that although caffeine is an inhibitor of ATM- ATR kinase activity in vitro, it can block checkpoints without inhibiting ATM- ATR activation in vivo.	Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA	Vanderbilt University	Cortez, D (corresponding author), Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA.				NCI NIH HHS [K01 CA093701, K01 CA093701-03] Funding Source: Medline; PHS HHS [KO193701] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K01CA093701] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abraham RT, 2001, GENE DEV, V15, P2177, DOI 10.1101/gad.914401; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; BEAVO JA, 1970, MOL PHARMACOL, V6, P597; Blasina A, 1999, CURR BIOL, V9, P1135, DOI 10.1016/S0960-9822(99)80486-2; Blasina A, 1999, CURR BIOL, V9, P1, DOI 10.1016/S0960-9822(99)80041-4; Brown EJ, 2000, GENE DEV, V14, P397; Brown EJ, 2003, GENE DEV, V17, P615, DOI 10.1101/gad.1067403; Canman CE, 1998, SCIENCE, V281, P1677, DOI 10.1126/science.281.5383.1677; Casper AM, 2002, CELL, V111, P779, DOI 10.1016/S0092-8674(02)01113-3; Chaturvedi P, 1999, ONCOGENE, V18, P4047, DOI 10.1038/sj.onc.1202925; Cortez D, 2001, SCIENCE, V294, P1713, DOI 10.1126/science.1065521; Cortez D, 1999, SCIENCE, V286, P1162, DOI 10.1126/science.286.5442.1162; de Klein A, 2000, CURR BIOL, V10, P479, DOI 10.1016/S0960-9822(00)00447-4; DOMON M, 1970, INT J RADIAT BIOL RE, V17, P395, DOI 10.1080/09553007014550481; Feijoo C, 2001, J CELL BIOL, V154, P913, DOI 10.1083/jcb.200104099; Guo ZJ, 2000, GENE DEV, V14, P2745, DOI 10.1101/gad.842500; Hall-Jackson CA, 1999, ONCOGENE, V18, P6707, DOI 10.1038/sj.onc.1203077; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; Kim ST, 2002, GENE DEV, V16, P560, DOI 10.1101/gad.970602; Kozlov S, 2003, J BIOL CHEM, V278, P9309, DOI 10.1074/jbc.M300003200; LAU CC, 1982, P NATL ACAD SCI-BIOL, V79, P2942, DOI 10.1073/pnas.79.9.2942; Liu QH, 2000, GENE DEV, V14, P1448; Lopez-Girona A, 2001, P NATL ACAD SCI USA, V98, P11289, DOI 10.1073/pnas.191557598; Matsuoka S, 2000, P NATL ACAD SCI USA, V97, P10389, DOI 10.1073/pnas.190030497; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Nishijima H, 2003, GENES CELLS, V8, P423, DOI 10.1046/j.1365-2443.2003.00644.x; Nyberg KA, 2002, ANNU REV GENET, V36, P617, DOI 10.1146/annurev.genet.36.060402.113540; O'Driscoll M, 2003, NAT GENET, V33, P497, DOI 10.1038/ng1129; Poon RYC, 1997, CANCER RES, V57, P5168; POWELL SN, 1995, CANCER RES, V55, P1643; ROWLEY R, 1988, RADIAT RES, V113, P58, DOI 10.2307/3577180; ROWLEY R, 1992, RADIAT RES, V129, P224, DOI 10.2307/3578161; Sanchez Y, 1997, SCIENCE, V277, P1497, DOI 10.1126/science.277.5331.1497; Sarkaria JN, 1999, CANCER RES, V59, P4375; Sarkaria JN, 1998, CANCER RES, V58, P4375; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; SCHLEGEL R, 1986, SCIENCE, V232, P1264, DOI 10.1126/science.2422760; SELBY CP, 1990, P NATL ACAD SCI USA, V87, P3522, DOI 10.1073/pnas.87.9.3522; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; TORNALETTI S, 1989, BIOCHIM BIOPHYS ACTA, V1007, P112, DOI 10.1016/0167-4781(89)90138-3; Tsuchida R, 2002, RADIAT RES, V158, P195, DOI 10.1667/0033-7587(2002)158[0195:DOAGMI]2.0.CO;2; WELLS JN, 1988, METHOD ENZYMOL, V159, P489; WHARTON W, 1979, BIOCHEM PHARMACOL, V28, P763, DOI 10.1016/0006-2952(79)90356-3; Yao SL, 1996, NAT MED, V2, P1140, DOI 10.1038/nm1096-1140; Yazdi PT, 2002, GENE DEV, V16, P571, DOI 10.1101/gad.970702; Zhao H, 2001, MOL CELL BIOL, V21, P4129, DOI 10.1128/MCB.21.13.4129-4139.2001; Zhou BBS, 2000, J BIOL CHEM, V275, P10342, DOI 10.1074/jbc.275.14.10342; Zou L, 2003, SCIENCE, V300, P1542, DOI 10.1126/science.1083430	50	123	128	2	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37139	37145		10.1074/jbc.M307088200	http://dx.doi.org/10.1074/jbc.M307088200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847089	hybrid			2022-12-27	WOS:000185437200020
J	Delacour, D; Gouyer, V; Leteurtre, E; Ait-Slimane, T; Drobecq, H; Lenoir, C; Moreau-Hannedouche, O; Trugnan, G; Huet, G				Delacour, D; Gouyer, V; Leteurtre, E; Ait-Slimane, T; Drobecq, H; Lenoir, C; Moreau-Hannedouche, O; Trugnan, G; Huet, G			1-benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside blocks the apical biosynthetic pathway in polarized HT-29 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERGENT-INSOLUBLE COMPLEXES; INTRACELLULAR-TRANSPORT; ANNEXIN XIIIB; SUCRASE-ISOMALTASE; PLASMA-MEMBRANE; O-GLYCOSYLATION; GLYCANS MEDIATE; SYNTAXIN 3; N-GLYCANS; TRAFFICKING	In previous work we reported that long term treatment of polarized HT-29 cells by 1-benzyl-2-acetamido-2-deoxy-alpha-D-galactopyranoside (GalNAcalpha-O-bn) induced undersialylation and intracellular distribution of apical glycoproteins such as dipeptidyl peptidase IV (DPP-IV), and we suggested therefore that sialylation could act as an apical targeting signal. In this work, the apical direct biosynthetic route was studied after transfection of polarized enterocyte-like HT-29 5M12 cloned cells with a murine cDNA coding for a soluble form of DPP-IV, which was secreted into the apical medium. A 24-h treatment of transfected cells by GalNAcalpha-O-bn markedly inhibited the apical secretion and the sialylation of this soluble murine DPP-IV, which became blocked inside the cell. A similar short GalNAcalpha-O-bn treatment also induced an intracellular distribution of both endogenous transmembrane DPP-IV and proteins involved in the regulation of the apical trafficking such as the apical t-SNARE syntaxin-3 and the raft-associated protein annexin XIIIb, whereas the basolateral t-SNARE syntaxin-4 kept its normal localization. These apical membrane proteins moved efficiently from trans-Golgi network to apical carrier vesicles but failed to be transported from carrier vesicles to the apical plasma membrane. Isolation of membrane microdomains showed that GalNAcalpha-O-bn induced the formation of abnormal lipid-rich microdomains in comparison to normal rafts, as shown by their lower buoyant density and their depletion in annexin XIIIb. In conclusion, GalNAcalpha-O-bn blocks the anterograde traffic to the apical surface of polarized HT-29 cells at the transport level or docking/fusion level of carrier vesicles.	INSERM, Unite 560, F-59045 Lille, France; INSERM, Unite 538, F-75571 Paris, France; Inst Biol Lille, CNRS UMR 8525, F-59019 Lille, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm)	Huet, G (corresponding author), INSERM, Unite 560, Pl Verdun, F-59045 Lille, France.	huet@lille.inserm.fr	Gouyer, Valérie/R-4984-2018	Gouyer, Valérie/0000-0002-4223-7060; Delacour, Delphine/0000-0001-8202-4425; AIT SLIMANE, Tounsia/0000-0002-7459-859X; Drobecq, Herve/0000-0002-4081-1575				AITSLIMANE T, 2000, EXP CELL RES, V258, P184; Alfalah M, 1999, CURR BIOL, V9, P593, DOI 10.1016/S0960-9822(99)80263-2; Benting JH, 1999, J CELL BIOL, V146, P313, DOI 10.1083/jcb.146.2.313; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Breuza L, 2000, AM J PHYSIOL-CELL PH, V279, pC1239, DOI 10.1152/ajpcell.2000.279.4.C1239; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; BYRD JC, 1995, EUR J CANCER, V31A, P1498, DOI 10.1016/0959-8049(95)00248-H; DANIELSEN EM, 1995, BIOCHEMISTRY-US, V34, P1596, DOI 10.1021/bi00005a016; Delannoy P, 1996, GLYCOCONJUGATE J, V13, P717, DOI 10.1007/BF00702335; Delgrossi MH, 1997, J CELL SCI, V110, P2207; FIEDLER K, 1993, BIOCHEMISTRY-US, V32, P6365, DOI 10.1021/bi00076a009; FIEDLER K, 1995, J CELL BIOL, V128, P1043, DOI 10.1083/jcb.128.6.1043; Galli T, 1998, MOL BIOL CELL, V9, P1437, DOI 10.1091/mbc.9.6.1437; Gouyer V, 2001, J CELL SCI, V114, P1455; Gouyer V, 2001, FRONT BIOSCI, V6, pD1235, DOI 10.2741/gouyer; Gut A, 1998, EMBO J, V17, P1919, DOI 10.1093/emboj/17.7.1919; HAURI HP, 1985, J CELL BIOL, V101, P838, DOI 10.1083/jcb.101.3.838; Hennebicq-Reig S, 1998, BIOCHEM J, V334, P283, DOI 10.1042/bj3340283; HUANG J, 1992, ONCOL RES, V4, P507; Huet G, 1998, J CELL BIOL, V141, P1311, DOI 10.1083/jcb.141.6.1311; Jacob R, 2000, J BIOL CHEM, V275, P6566, DOI 10.1074/jbc.275.9.6566; KITAGAWA Y, 1994, EXP CELL RES, V213, P449, DOI 10.1006/excr.1994.1222; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lafont F, 1999, P NATL ACAD SCI USA, V96, P3734, DOI 10.1073/pnas.96.7.3734; Lafont F, 1998, J CELL BIOL, V142, P1413, DOI 10.1083/jcb.142.6.1413; Lecat S, 2000, J CELL SCI, V113, P2607; Lesuffleur T, 1998, INT J CANCER, V76, P383, DOI 10.1002/(SICI)1097-0215(19980504)76:3<383::AID-IJC16>3.3.CO;2-M; Leteurtre E, 2003, J HISTOCHEM CYTOCHEM, V51, P349, DOI 10.1177/002215540305100310; Low SH, 1996, MOL BIOL CELL, V7, P2007, DOI 10.1091/mbc.7.12.2007; MARGUET D, 1992, J BIOL CHEM, V267, P2200; Mirre C, 1996, AM J PHYSIOL-CELL PH, V271, pC887, DOI 10.1152/ajpcell.1996.271.3.C887; Monlauzeur L, 1998, J BIOL CHEM, V273, P30263, DOI 10.1074/jbc.273.46.30263; Musch A, 1996, J CELL BIOL, V133, P543, DOI 10.1083/jcb.133.3.543; Naim HY, 1999, J BIOL CHEM, V274, P17961, DOI 10.1074/jbc.274.25.17961; Noda Y, 2001, J CELL BIOL, V155, P77, DOI 10.1083/jcb.200108042; Riento K, 2000, J BIOL CHEM, V275, P13476, DOI 10.1074/jbc.275.18.13476; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Scheiffele P, 1998, J CELL BIOL, V140, P795, DOI 10.1083/jcb.140.4.795; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; SIMONS K, 1990, CELL, V62, P207, DOI 10.1016/0092-8674(90)90357-K; Spodsberg N, 2001, J BIOL CHEM, V276, P23506, DOI 10.1074/jbc.C100219200; Ulloa F, 2003, J BIOL CHEM, V278, P12374, DOI 10.1074/jbc.M211909200; Ulloa F, 2000, J BIOL CHEM, V275, P18785, DOI 10.1074/jbc.M000510200; URBAN J, 1987, J CELL BIOL, V105, P2735, DOI 10.1083/jcb.105.6.2735; Volonte D, 1999, J BIOL CHEM, V274, P12702, DOI 10.1074/jbc.274.18.12702; WANDINGERNESS A, 1990, J CELL BIOL, V111, P987, DOI 10.1083/jcb.111.3.987; WEISZ OA, 1992, J BIOL CHEM, V267, P22282; Yeaman C, 1997, J CELL BIOL, V139, P929, DOI 10.1083/jcb.139.4.929; Zanetta JP, 2000, GLYCOBIOLOGY, V10, P565, DOI 10.1093/glycob/10.6.565	50	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37799	37809		10.1074/jbc.M305755200	http://dx.doi.org/10.1074/jbc.M305755200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855686	hybrid			2022-12-27	WOS:000185437200099
J	Walmsley, AR; Zeng, F; Hooper, NM				Walmsley, AR; Zeng, F; Hooper, NM			The N-terminal region of the prion protein ectodomain contains a lipid raft targeting determinant	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANGIOTENSIN-CONVERTING ENZYME; AMYLOID PRECURSOR PROTEIN; GPI-ANCHORED PROTEINS; CELLULAR PRION; MEMBRANE DOMAINS; TRANSMEMBRANE DOMAIN; SUBCELLULAR TRAFFICKING; RENAL DIPEPTIDASE; EPITHELIAL-CELLS; SCRAPIE ISOFORM	The association of the prion protein (PrP) with sphingolipid- and cholesterol-rich lipid rafts is instrumental in the pathogenesis of the neurodegenerative prion diseases. Although the glycosylphosphatidylinositol (GPI) anchor is an exoplasmic determinant of raft association, PrP remained raft-associated in human neuronal cells even when the GPI anchor was deleted or substituted for a transmembrane anchor indicating that the ectodomain contains a raft localization signal. The raft association of transmembrane-anchored PrP occurred independently of Cu(II) binding as it failed to be abolished by either deletion of the octapeptide repeat region ( residues 51 - 90) or treatment of cells with a Cu( II) chelator. Raft association of transmembrane-anchored PrP was only abolished by the deletion of the N-terminal region ( residues 23 - 90) of the ectodomain. This region was sufficient to confer raft localization when fused to the N terminus of a non-raft transmembrane-anchored protein and suppressed the clathrin-coated pit localization signal in the cytoplasmic domain of the amyloid precursor protein. These data indicate that the N-terminal region of PrP acts as a cellular raft targeting determinant and that residues 23 - 90 of PrP represent the first proteinaceous raft targeting signal within the ectodomain of a GPI-anchored protein.	Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Hooper, NM (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Leeds LS2 9JT, W Yorkshire, England.			Hooper, Nigel/0000-0002-5811-3484				Baron GS, 2002, EMBO J, V21, P1031, DOI 10.1093/emboj/21.5.1031; Baron GS, 2003, J BIOL CHEM, V278, P14883, DOI 10.1074/jbc.M210840200; Bickel PE, 1997, J BIOL CHEM, V272, P13793, DOI 10.1074/jbc.272.21.13793; Bock J, 2003, FEBS LETT, V534, P169, DOI 10.1016/S0014-5793(02)03784-5; BREWIS IA, 1995, J BIOL CHEM, V270, P22946, DOI 10.1074/jbc.270.39.22946; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown DR, 1997, NATURE, V390, P684, DOI 10.1038/37733; Couet J, 1997, J BIOL CHEM, V272, P6525, DOI 10.1074/jbc.272.10.6525; Donne DG, 1997, P NATL ACAD SCI USA, V94, P13452, DOI 10.1073/pnas.94.25.13452; FIELD KA, 1995, P NATL ACAD SCI USA, V92, P9201, DOI 10.1073/pnas.92.20.9201; Fischer MB, 2000, NATURE, V408, P479, DOI 10.1038/35044100; Gauczynski S, 2001, EMBO J, V20, P5863, DOI 10.1093/emboj/20.21.5863; HOOPER NM, 1987, BIOCHEM J, V244, P465, DOI 10.1042/bj2440465; Hooper NM, 1999, MOL MEMBR BIOL, V16, P145, DOI 10.1080/096876899294607; Hundt C, 2001, EMBO J, V20, P5876, DOI 10.1093/emboj/20.21.5876; Ikonen E, 2001, CURR OPIN CELL BIOL, V13, P470, DOI 10.1016/S0955-0674(00)00238-6; Kaneko K, 1997, P NATL ACAD SCI USA, V94, P2333, DOI 10.1073/pnas.94.6.2333; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; Kimura A, 2001, P NATL ACAD SCI USA, V98, P9098, DOI 10.1073/pnas.151252898; Kundu A, 1996, J VIROL, V70, P6508, DOI 10.1128/JVI.70.9.6508-6515.1996; Ledesma MD, 2000, EMBO REP, V1, P530; LEHMANN S, 1995, J BIOL CHEM, V270, P24589, DOI 10.1074/jbc.270.41.24589; Li SW, 1996, J BIOL CHEM, V271, P29182, DOI 10.1074/jbc.271.46.29182; LITTLEWOOD GM, 1989, BIOCHEM J, V257, P361, DOI 10.1042/bj2570361; Madore N, 1999, EMBO J, V18, P6917, DOI 10.1093/emboj/18.24.6917; Mahfoud R, 2002, J BIOL CHEM, V277, P11292, DOI 10.1074/jbc.M111679200; Martin-Belmonte F, 2000, J BIOL CHEM, V275, P41074, DOI 10.1074/jbc.M005429200; McMahon HEM, 2001, J BIOL CHEM, V276, P2286, DOI 10.1074/jbc.M007243200; Melkonian KA, 1995, BIOCHEMISTRY-US, V34, P16161, DOI 10.1021/bi00049a031; Morillas M, 1999, J BIOL CHEM, V274, P36859, DOI 10.1074/jbc.274.52.36859; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; Nunziante M, 2003, J BIOL CHEM, V278, P3726, DOI 10.1074/jbc.M206313200; Pang S, 2001, BIOCHEM J, V358, P185, DOI 10.1042/0264-6021:3580185; Parham SN, 2001, EMBO J, V20, P2111, DOI 10.1093/emboj/20.9.2111; Parkin ET, 1999, BIOCHEM J, V344, P23, DOI 10.1042/0264-6021:3440023; Parkin ET, 1996, BIOCHEM J, V319, P887, DOI 10.1042/bj3190887; Parvathy S, 1998, BIOCHEMISTRY-US, V37, P1680, DOI 10.1021/bi972034y; Perera WSS, 1999, FEBS LETT, V463, P273, DOI 10.1016/S0014-5793(99)01648-8; Perez RG, 1999, J BIOL CHEM, V274, P18851, DOI 10.1074/jbc.274.27.18851; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Sanghera N, 2002, J MOL BIOL, V315, P1241, DOI 10.1006/jmbi.2001.5322; Scheiffele P, 1997, EMBO J, V16, P5501, DOI 10.1093/emboj/16.18.5501; Schmitt-Ulms G, 2001, J MOL BIOL, V314, P1209, DOI 10.1006/jmbi.2000.5183; SCHNITZER JE, 1995, P NATL ACAD SCI USA, V92, P1759, DOI 10.1073/pnas.92.5.1759; SCHROEDER R, 1994, P NATL ACAD SCI USA, V91, P12130, DOI 10.1073/pnas.91.25.12130; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; TARABOULOS A, 1995, J CELL BIOL, V129, P121, DOI 10.1083/jcb.129.1.121; Tatulian SA, 2000, BIOCHEMISTRY-US, V39, P496, DOI 10.1021/bi991594p; Vey M, 1996, P NATL ACAD SCI USA, V93, P14945, DOI 10.1073/pnas.93.25.14945; Viles JH, 2001, BIOCHEMISTRY-US, V40, P2743, DOI 10.1021/bi002898a; Walmsley AR, 2001, EMBO J, V20, P703, DOI 10.1093/emboj/20.4.703; Waugh MG, 1999, BIOCHEM J, V337, P591, DOI 10.1042/0264-6021:3370591; WILLIAMS TA, 1992, BIOCHEM J, V288, P875, DOI 10.1042/bj2880875; Yamabhai M, 2002, J BIOL CHEM, V277, P24843, DOI 10.1074/jbc.C200277200; Yamazaki T, 1996, J CELL SCI, V109, P999; Zanata SM, 2002, EMBO J, V21, P3307, DOI 10.1093/emboj/cdf325	57	91	93	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37241	37248		10.1074/jbc.M302036200	http://dx.doi.org/10.1074/jbc.M302036200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865430	hybrid			2022-12-27	WOS:000185437200032
J	Qiu, Y; Law, PY; Loh, HH				Qiu, Y; Law, PY; Loh, HH			mu-opioid receptor desensitization - Role of receptor phosphorylation, internalization, and resensitization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; AGONIST-INDUCED DESENSITIZATION; INDUCED DOWN-REGULATION; BETA-ARRESTIN; AMINO-ACIDS; HOMOLOGOUS DESENSITIZATION; MEDIATED ENDOCYTOSIS; TERMINAL TAIL; KINASES; IDENTIFICATION	It is generally accepted that the internalization and desensitization of mu-opioid receptor (MOR) involves receptor phosphorylation and beta-arrestin recruitment. However, a mutant MOR, which is truncated after the amino acid residue Ser(363) (MOR363D), was found to undergo phosphorylation-independent internalization and desensitization. As expected, MOR363D, missing the putative agonist-induced phosphorylation sites, did not exhibit detectable agonist-induced phosphorylation. MOR363D underwent slower internalization as reflected in the attenuation of membrane translocation of beta-arrestin 2 when compared with wild type MOR, but the level of receptor being internalized was similar to that of wild type MOR after 4 h of etorphine treatment. Furthermore, MOR363D was observed to desensitize faster than that of wild type MOR upon agonist activation. Surface biotinylation assay demonstrated that the wild type receptors recycled back to membrane after agonist-induced internalization, which contributed to the receptor resensitization and thus partially reversed the receptor desensitization. On the contrary, MOR363D did not recycle after internalization. Hence, MOR desensitization is controlled by the receptor internalization and the recycling of internalized receptor to cell surface in an active state. Taken together, our data indicated that receptor phosphorylation is not absolutely required in the internalization, but receptor phosphorylation and subsequent beta-arrestin recruitment play important roles in the resensitization of internalized receptors.	Univ Minnesota, Sch Med, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Qiu, Y (corresponding author), Univ Minnesota, Sch Med, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.	qiuxx014@umn.edu		Law, Ping-Yee/0000-0002-5364-1093	NIDA NIH HHS [DA0564, K05 DA00513, DA11806, K05 DA70544, DA07339] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA000564, R01DA007339, K05DA000513, P50DA011806, R56DA000564] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Afify EA, 1998, MOL BRAIN RES, V54, P24, DOI 10.1016/S0169-328X(97)00315-X; Allouche S, 1999, EUR J PHARMACOL, V371, P235, DOI 10.1016/S0014-2999(99)00180-6; Barak LS, 1997, J BIOL CHEM, V272, P27497, DOI 10.1074/jbc.272.44.27497; Baratti-Elbaz C, 1999, MOL ENDOCRINOL, V13, P1751, DOI 10.1210/me.13.10.1751; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Brasselet S, 2002, FEBS LETT, V516, P124, DOI 10.1016/S0014-5793(02)02517-6; Burd AL, 1998, J BIOL CHEM, V273, P34488, DOI 10.1074/jbc.273.51.34488; Celver JP, 2001, J BIOL CHEM, V276, P4894, DOI 10.1074/jbc.M007437200; Claing A, 2002, PROG NEUROBIOL, V66, P61, DOI 10.1016/S0301-0082(01)00023-5; Deng HB, 2000, BIOCHEMISTRY-US, V39, P5492, DOI 10.1021/bi991938b; Deng HB, 2001, BRAIN RES, V898, P204, DOI 10.1016/S0006-8993(01)02179-5; Dhami GK, 2002, J BIOL CHEM, V277, P25266, DOI 10.1074/jbc.M203593200; Dicker F, 1999, P NATL ACAD SCI USA, V96, P5476, DOI 10.1073/pnas.96.10.5476; El Kouhen R, 1999, J BIOL CHEM, V274, P9207, DOI 10.1074/jbc.274.14.9207; El Kouhen R, 2001, J BIOL CHEM, V276, P12774, DOI 10.1074/jbc.M009571200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Ferguson SSG, 1996, SCIENCE, V271, P363, DOI 10.1126/science.271.5247.363; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; Kishi M, 2001, MOL ENDOCRINOL, V15, P1624, DOI 10.1210/me.15.9.1624; Koch T, 2001, J BIOL CHEM, V276, P31408, DOI 10.1074/jbc.M100305200; Kovoor A, 1998, MOL PHARMACOL, V54, P704; Krupnick JG, 1998, ANNU REV PHARMACOL, V38, P289, DOI 10.1146/annurev.pharmtox.38.1.289; Law PY, 2000, MOL PHARMACOL, V58, P388, DOI 10.1124/mol.58.2.388; Murray SR, 1998, J BIOL CHEM, V273, P24987, DOI 10.1074/jbc.273.39.24987; Nakamura K, 1998, J BIOL CHEM, V273, P24346, DOI 10.1074/jbc.273.38.24346; Oakley RH, 1999, J BIOL CHEM, V274, P32248, DOI 10.1074/jbc.274.45.32248; Oakley RH, 2000, J BIOL CHEM, V275, P17201, DOI 10.1074/jbc.M910348199; Olivares-Reyes JA, 2001, J BIOL CHEM, V276, P37761; Pak Y, 1997, J BIOL CHEM, V272, P24961, DOI 10.1074/jbc.272.40.24961; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Richardson MD, 2003, J NEUROCHEM, V84, P854, DOI 10.1046/j.1471-4159.2003.01577.x; Trejo J, 1999, J BIOL CHEM, V274, P2216, DOI 10.1074/jbc.274.4.2216; Vogler O, 1999, J BIOL CHEM, V274, P12333, DOI 10.1074/jbc.274.18.12333; Wang HL, 2002, BIOCHEM PHARMACOL, V64, P257, DOI 10.1016/S0006-2952(02)01114-0; Whistler JL, 2002, SCIENCE, V297, P615, DOI 10.1126/science.1073308; Yu YK, 1997, J BIOL CHEM, V272, P28869, DOI 10.1074/jbc.272.46.28869; Zhang J, 1998, P NATL ACAD SCI USA, V95, P7157, DOI 10.1073/pnas.95.12.7157; Zhang J, 1997, J BIOL CHEM, V272, P27005, DOI 10.1074/jbc.272.43.27005; Zhang L, 1996, J BIOL CHEM, V271, P11449, DOI 10.1074/jbc.271.19.11449	39	62	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36733	36739		10.1074/jbc.M305857200	http://dx.doi.org/10.1074/jbc.M305857200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860981	hybrid			2022-12-27	WOS:000185318300105
J	Steinert, PM; Parry, DAD; Marekov, LN				Steinert, PM; Parry, DAD; Marekov, LN			Trichohyalin mechanically strengthens the hair follicle - Multiple cross-bridging roles in the inner root sheath	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CORNIFIED CELL-ENVELOPE; KERATIN INTERMEDIATE-FILAMENTS; PROLINE-RICH PROTEINS; PEPTIDYLARGININE DEIMINASE; STRUCTURAL FEATURES; GENE FAMILY; CITRULLINE; MOUSE; TRANSGLUTAMINASE; DIFFERENTIATION	Trichohyalin is expressed in specialized epithelia that are unusually mechanically strong, such as the inner root sheath cells of the hair follicle. We have previously shown that trichohyalin is sequentially subjected to post-synthetic modifications by peptidylarginine deaminases, which convert many of its arginines to citrullines, and by transglutaminases, which introduce intra- and interprotein chain cross-links. Here we have characterized in detail the proteins to which it becomes crosslinked in vivo in the inner root sheath of the mouse hair follicle. We suggest that it has three principal roles. First, it serves as an interfilamentous matrix protein by becoming cross-linked both to itself and to the head and tail end domains of the inner root sheath keratin intermediate filament chains. A new antibody reveals that arginines of the tail domains of the keratins are modified to citrullines before cross-linking, which clarifies previous studies. Second, trichohyalin serves as a cross-bridging reinforcement protein of the cornified cell envelope of the inner root sheath cells by becoming crosslinked to several known or novel barrier proteins, including involucrin, small proline-rich proteins, repetin, and epiplakin. Third, it coordinates linkage between the keratin filaments and cell envelope to form a seamless continuum. Together, our new data document that trichohyalin is a multi-functional cross-bridging protein that functions in the inner root sheath and perhaps in other specialized epithelial tissues by conferring to and coordinating mechanical strength between their peripheral cell envelope barrier structures and their cytoplasmic keratin filament networks.	NIAMS, Skin Biol Lab, NIH, Bethesda, MD 20892 USA; Massey Univ, Inst Fundamental Sci, Palmerston North, New Zealand	National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Massey University	Marekov, LN (corresponding author), NIAMS, Skin Biol Lab, NIH, Bldt 50,Rm 1531, Bethesda, MD 20892 USA.	marekovl@mail.nih.gov			NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [Z01AR041084] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Aoki N, 2001, J INVEST DERMATOL, V116, P359, DOI 10.1046/j.1523-1747.2001.01226.x; AUBER L., 1952, TRANS ROY SOC EDINBURGH, V62, P191; Bawden CS, 2001, J INVEST DERMATOL, V116, P157, DOI 10.1046/j.1523-1747.2001.00215.x; Candi E, 1998, P NATL ACAD SCI USA, V95, P2067, DOI 10.1073/pnas.95.5.2067; Carninci P, 2000, GENOME RES, V10, P1617, DOI 10.1101/gr.145100; FIETZ MJ, 1993, J CELL BIOL, V121, P855, DOI 10.1083/jcb.121.4.855; FOLK JE, 1985, METHOD ENZYMOL, V113, P358; Fraser R.D.B., 1972, KERATINS THEIR COMPO; Fujiwara S, 2001, J BIOL CHEM, V276, P13340, DOI 10.1074/jbc.M011386200; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; HAMILTON EH, 1991, J INVEST DERMATOL, V96, P666, DOI 10.1111/1523-1747.ep12470590; HARDING HWJ, 1972, BIOCHEMISTRY-US, V11, P2858, DOI 10.1021/bi00765a019; HARDING HWJ, 1976, BIOCHIM BIOPHYS ACTA, V427, P315, DOI 10.1016/0005-2795(76)90307-X; HARDING HWJ, 1971, BIOCHEMISTRY-US, V10, P624, DOI 10.1021/bi00780a013; Hesse M, 2001, J CELL SCI, V114, P2569; HOHL D, 1995, J INVEST DERMATOL, V104, P902, DOI 10.1111/1523-1747.ep12606176; HOHL D, 1991, J BIOL CHEM, V266, P6626; Kalinin AE, 2002, BIOESSAYS, V24, P789, DOI 10.1002/bies.10144; Kanno T, 2000, J INVEST DERMATOL, V115, P813, DOI 10.1046/j.1523-1747.2000.00131.x; Kim SY, 2002, NEUROCHEM INT, V40, P85, DOI 10.1016/S0197-0186(01)00064-X; KIM SY, 1995, J INVEST DERMATOL, V104, P211, DOI 10.1111/1523-1747.ep12612769; Krieg P, 1997, GENOMICS, V43, P339, DOI 10.1006/geno.1997.4818; LEE SC, 1993, J BIOL CHEM, V268, P12164; LORAND L, 1984, MOL CELL BIOCHEM, V58, P9, DOI 10.1007/BF00240602; MANABE M, 1994, DIFFERENTIATION, V58, P65, DOI 10.1046/j.1432-0436.1994.5810065.x; Marshall D, 2001, P NATL ACAD SCI USA, V98, P13031, DOI 10.1073/pnas.231489198; Nemes Z, 1999, EXP MOL MED, V31, P5, DOI 10.1038/emm.1999.2; OGUIN WM, 1992, J INVEST DERMATOL, V98, P24, DOI 10.1111/1523-1747.ep12494172; OGUIN WM, 1991, ANN NY ACAD SCI, V642, P51; OKEEFE EJ, 1993, J INVEST DERMATOL, V101, pS65, DOI 10.1111/1523-1747.ep12362866; PARENTEAU NL, 1986, DIFFERENTIATION, V33, P130, DOI 10.1111/j.1432-0436.1986.tb00418.x; Parry DAD, 1999, Q REV BIOPHYS, V32, P99, DOI 10.1017/S0033583500003516; Pearton DJ, 2002, J INVEST DERMATOL, V119, P661, DOI 10.1046/j.1523-1747.2002.01831.x; POLAKOWSKA RR, 1994, DEV DYNAM, V199, P176, DOI 10.1002/aja.1001990303; Rogers G, 1997, J INVEST DERMATOL, V108, P700, DOI 10.1111/1523-1747.ep12292083; ROGERS GE, 1962, NATURE, V194, P1149, DOI 10.1038/1941149a0; ROGERS GE, 1963, J HISTOCHEM CYTOCHEM, V11, P700, DOI 10.1177/11.6.700; ROGERS GE, 1983, NORMAL ABNORMAL EPID, P171; ROTHNAGEL JA, 1986, J CELL BIOL, V102, P1419, DOI 10.1083/jcb.102.4.1419; Sato H, 1999, GENOMICS, V56, P303, DOI 10.1006/geno.1998.5721; Shirai H, 2001, TRENDS BIOCHEM SCI, V26, P465, DOI 10.1016/S0968-0004(01)01906-5; Song HJ, 1999, GENOMICS, V55, P28, DOI 10.1006/geno.1998.5607; STEINERT P, 1982, METHOD CELL BIOL, V24, P399; Steinert PM, 2000, J CELL BIOL, V151, pF5, DOI 10.1083/jcb.151.2.F5; Steinert PM, 1999, MOL BIOL CELL, V10, P4247, DOI 10.1091/mbc.10.12.4247; STEINERT PM, 1978, BIOCHEMISTRY-US, V17, P5045, DOI 10.1021/bi00616a029; Steinert PM, 1998, J BIOL CHEM, V273, P11758, DOI 10.1074/jbc.273.19.11758; STEINERT PM, 1971, J INVEST DERMATOL, V56, P49, DOI 10.1111/1523-1747.ep12291902; TAKAHARA H, 1983, J BIOCHEM, V94, P1945, DOI 10.1093/oxfordjournals.jbchem.a134548; TAKAHARA H, 1989, J BIOL CHEM, V264, P13361; TAMADA Y, 1995, ACTA DERM-VENEREOL, V75, P190; Tarcsa E, 1997, J BIOL CHEM, V272, P27893, DOI 10.1074/jbc.272.44.27893; Tarcsa E, 1996, J BIOL CHEM, V271, P30709, DOI 10.1074/jbc.271.48.30709; TERAKAWA H, 1991, J BIOCHEM, V110, P661, DOI 10.1093/oxfordjournals.jbchem.a123636; Tobin DJ, 2002, AM J PATHOL, V160, P1807, DOI 10.1016/S0002-9440(10)61127-3; VORNER H, 1903, DERMATOL Z BERLIN, V10, P357; WATANABE K, 1988, BIOCHIM BIOPHYS ACTA, V966, P375, DOI 10.1016/0304-4165(88)90088-8; Watts NR, 2002, J STRUCT BIOL, V137, P109, DOI 10.1006/jsbi.2002.4469; WEINBERG WC, 1993, J INVEST DERMATOL, V100, P229, DOI 10.1111/1523-1747.ep12468971; Zhao XP, 1997, GENOMICS, V45, P250, DOI 10.1006/geno.1997.4952	60	93	94	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41409	41419		10.1074/jbc.M302037200	http://dx.doi.org/10.1074/jbc.M302037200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12853460	hybrid			2022-12-27	WOS:000185847200121
J	Ubeda, M; Habener, JF				Ubeda, M; Habener, JF			CHOP transcription factor phosphorylation by casein kinase 2 inhibits transcriptional activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; GENE-TRANSCRIPTION; BUDDING YEAST; PROTEIN; CK2; CHECKPOINT; APOPTOSIS; CHOP/GADD153; CLEAVAGE; GADD153	The CAAT/enhancer binding protein homologous transcription factor CHOP, also known as GADD153, is involved in DNA damage, growth arrest, and the induction of apoptosis after endoplasmic reticulum stress and nutrient deprivation. CHOP dimerizes with and inhibits the binding of C/EBP-related transcription factors to their consensus DNA target sequences and also forms novel complexes with other transcriptional proteins ( e. g. c-Jun, c-Fos). The transcriptional activation of these complexes is modified by their phosphorylation. Phosphorylation of CHOP at serine 79 and serine 81 by p38-MAP kinase enhances its transcriptional activity. Here we show that an interactive association between CHOP and casein kinase II (CK2) results in the phosphorylation of its amino-terminal transactivation domain. Mapping of the functional domains of CHOP indicates that the region in CHOP required for association with CK2 differs from that required for its phosphorylation. Th binding of CK2 to CHOP requires only the carboxylterminal bZip domain of CHOP, whereas phosphorylation involves residues located in the amino-terminal domain. The presence of the bZip domain, however, facilitates the phosphorylation of CHOP. Analyses of the effect of point mutations of CHOP on its transcriptional activity and the effect of specific inhibitors of CK2 lead us to conclude that CK2-mediated phosphorylation of CHOP inhibits its transcriptional activity. Our findings suggest that inhibition of the proapoptotic functions of CHOP by CK2 may be a mechanism by which CK2 prevents apoptosis and promotes cellular proliferation.	Massachusetts Gen Hosp, Mol Endocrinol Lab, Boston, MA 02114 USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Howard Hughes Medical Institute	Habener, JF (corresponding author), Massachusetts Gen Hosp, Mol Endocrinol Lab, WEL320,55 Fruit St, Boston, MA 02114 USA.		Ubeda, Mariano/ABB-2691-2021					BARONE MV, 1994, GENE DEV, V8, P453, DOI 10.1101/gad.8.4.453; Desagher S, 2001, MOL CELL, V8, P601, DOI 10.1016/S1097-2765(01)00335-5; Krippner-Heidenreich A, 2001, BIOCHEM J, V358, P705, DOI 10.1042/0264-6021:3580705; LEW DJ, 1995, J CELL BIOL, V129, P739, DOI 10.1083/jcb.129.3.739; Li PF, 2002, MOL CELL, V10, P247, DOI 10.1016/S1097-2765(02)00600-7; LITCHFIELD DW, 1994, CELL MOL BIOL RES, V40, P373; Litchfield DW, 2003, BIOCHEM J, V369, P1, DOI 10.1042/BJ20021469; Maytin EV, 2001, EXP CELL RES, V267, P193, DOI 10.1006/excr.2001.5248; Meggio F, 2003, FASEB J, V17, P349, DOI 10.1096/fj.02-0473rev; ROBITZKI A, 1993, J BIOL CHEM, V268, P5694; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; Ruzzene M, 2002, BIOCHEM J, V364, P41, DOI 10.1042/bj3640041; Sok J, 1999, MOL CELL BIOL, V19, P495; Toczyski DP, 1997, CELL, V90, P1097, DOI 10.1016/S0092-8674(00)80375-X; Ubeda M, 1999, MOL CELL BIOL, V19, P7589; Ubeda M, 1996, MOL CELL BIOL, V16, P1479; Wang XZ, 1996, SCIENCE, V272, P1347, DOI 10.1126/science.272.5266.1347; Wang XZ, 1996, MOL CELL BIOL, V16, P4273; Wang XZ, 1998, EMBO J, V17, P3619, DOI 10.1093/emboj/17.13.3619; Wells WAE, 1996, J CELL BIOL, V133, P75, DOI 10.1083/jcb.133.1.75; Yin XY, 2001, CELL COMMUN ADHES, V8, P373, DOI 10.3109/15419060109080756; YOI OKO, 1993, EMBO J, V12, P1621; Zhang Z, 1999, AM J PHYSIOL-RENAL, V276, pF786, DOI 10.1152/ajprenal.1999.276.5.F786; ZINSZNER H, 1994, GENE DEV, V8, P2513, DOI 10.1101/gad.8.21.2513; Zinszner H, 1998, GENE DEV, V12, P982, DOI 10.1101/gad.12.7.982	25	43	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40514	40520		10.1074/jbc.M306404200	http://dx.doi.org/10.1074/jbc.M306404200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12876286	hybrid			2022-12-27	WOS:000185847200012
J	Kovacs, M; Wang, F; Hu, AH; Zhang, Y; Sellers, JR				Kovacs, M; Wang, F; Hu, AH; Zhang, Y; Sellers, JR			Functional divergence of human cytoplasmic myosin II - Kinetic characterization of the non-muscle IIA isoform	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; SKELETAL-MUSCLE MYOSIN; HEAVY-CHAIN; DIFFERENTIAL LOCALIZATION; ACTOMYOSIN SUBFRAGMENT-1; FLUORESCENT-PROBE; NEURITE OUTGROWTH; SMOOTH-MUSCLE; RELEASE STEPS; LIGHT-CHAINS	Cytoplasmic (or non-muscle) myosin II isoforms are widely expressed molecular motors playing essential cellular roles in cytokinesis and cortical tension maintenance. Two of the three human non-muscle myosin II isoforms (IIA and IIB) have been investigated at the protein level. Transient kinetics of non-muscle myosin IIB showed that this motor has a very high actomyosin ADP affinity and slow ADP release. Here we report the kinetic characterization of the non-muscle myosin IIA isoform. Similar to non-muscle myosin IIB, non-muscle myosin IIA shows high ADP affinity and little enhancement of the ADP release rate by actin. The ADP release rate constant, however, is more than an order of magnitude higher than the steady-state ATPase rate. This implies that non-muscle myosin IIA spends only a small fraction of its ATPase cycle time in strongly actin-bound states, which is in contrast to non-muscle myosin IIB. Non-muscle myosin II isoforms thus appear to have distinct enzymatic properties that may be of importance in carrying out their cellular functions.	NHLBI, Mol Cardiol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Sellers, JR (corresponding author), NHLBI, Mol Cardiol Lab, NIH, Bldg 10,Rm 8N202, Bethesda, MD 20892 USA.		Kovacs, Mihaly/A-6841-2011	Kovacs, Mihaly/0000-0002-1200-4741	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [ZIAHL001786, Z01HL001786] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; Berg JS, 2001, MOL BIOL CELL, V12, P780, DOI 10.1091/mbc.12.4.780; Bridgman PC, 2001, J NEUROSCI, V21, P6159, DOI 10.1523/JNEUROSCI.21-16-06159.2001; BRUNE M, 1994, BIOCHEMISTRY-US, V33, P8262, DOI 10.1021/bi00193a013; COOPER JA, 1983, J MUSCLE RES CELL M, V4, P253, DOI 10.1007/BF00712034; Cremo CR, 2001, J BIOL CHEM, V276, P41465, DOI 10.1074/jbc.M107103200; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; De La Cruz EM, 1999, P NATL ACAD SCI USA, V96, P13726, DOI 10.1073/pnas.96.24.13726; De la Cruz EM, 2001, J BIOL CHEM, V276, P32373, DOI 10.1074/jbc.M104136200; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; HARRIS DE, 1993, J BIOL CHEM, V268, P14764; Hu AH, 2002, J BIOL CHEM, V277, P46512, DOI 10.1074/jbc.M208506200; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; Kong HH, 2002, J CELL SCI, V115, P4993, DOI 10.1242/jcs.00159; KONISHI K, 2001, J BIOCHEM-TOKYO, P365; Kurzawa SE, 1996, J MUSCLE RES CELL M, V17, P669, DOI 10.1007/BF00154061; LYMN RW, 1971, BIOCHEMISTRY-US, V10, P4617, DOI 10.1021/bi00801a004; Malnasi-Csizmadia A, 2001, BIOCHEMISTRY-US, V40, P12727, DOI 10.1021/bi010963q; MARSTON SB, 1980, J MOL BIOL, V139, P573, DOI 10.1016/0022-2836(80)90050-9; MAUPIN P, 1994, J CELL SCI, V107, P3077; MILLAR NC, 1983, FEBS LETT, V160, P141, DOI 10.1016/0014-5793(83)80954-5; Pato MD, 1996, J BIOL CHEM, V271, P2689, DOI 10.1074/jbc.271.5.2689; Reggiani C, 2000, NEWS PHYSIOL SCI, V15, P26; RITCHIE MD, 1993, P NATL ACAD SCI USA, V90, P8619, DOI 10.1073/pnas.90.18.8619; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Saitoh T, 2001, FEBS LETT, V509, P365, DOI 10.1016/S0014-5793(01)03186-6; Sellers J. R., 1999, MYOSINS; SELLERS JR, 1993, METHOD CELL BIOL, V39, P23, DOI 10.1016/S0091-679X(08)60159-4; SIEMANKOWSKI RF, 1984, J BIOL CHEM, V259, P5045; SIEMANKOWSKI RF, 1985, P NATL ACAD SCI USA, V82, P658, DOI 10.1073/pnas.82.3.658; SLEEP JA, 1976, BIOCHEMISTRY-US, V15, P5813, DOI 10.1021/bi00671a019; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TRYBUS KM, 1982, BIOCHEMISTRY-US, V21, P1284, DOI 10.1021/bi00535a028; Tullio AN, 2001, J COMP NEUROL, V433, P62, DOI 10.1002/cne.1125; UMEMOTO S, 1990, J BIOL CHEM, V265, P14864; VERKHOVSKY AB, 1995, J CELL BIOL, V131, P989, DOI 10.1083/jcb.131.4.989; WAGNER PD, 1981, J BIOL CHEM, V256, P2493; Wang F, 2003, J BIOL CHEM, V278, P27439, DOI 10.1074/jbc.M302510200; Wang F, 2000, BIOCHEMISTRY-US, V39, P5555, DOI 10.1021/bi000133x; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617; White HD, 1997, BIOCHEMISTRY-US, V36, P11828, DOI 10.1021/bi970540h; Wylie SR, 1998, P NATL ACAD SCI USA, V95, P12967, DOI 10.1073/pnas.95.22.12967; Wylie SR, 2001, NAT CELL BIOL, V3, P88, DOI 10.1038/35050613	46	181	186	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38132	38140		10.1074/jbc.M305453200	http://dx.doi.org/10.1074/jbc.M305453200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12847096	hybrid			2022-12-27	WOS:000185575100007
J	Pile, LA; Spellman, PT; Katzenberger, RJ; Wassarman, DA				Pile, LA; Spellman, PT; Katzenberger, RJ; Wassarman, DA			The SIN3 deacetylase complex represses genes encoding mitochondrial proteins - Implications for the regulation of energy metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; DROSOPHILA DEVELOPMENT; MOLECULAR ANALYSIS; HISTONE; EXPRESSION; IDENTIFICATION; TRANSCRIPTION; COMPONENTS; SEQUENCE	Deacetylation of histones by the SIN3 complex is a major mechanism utilized in eukaryotic organisms to repress transcription. Presumably, developmental and cellular phenotypes resulting from mutations in SIN3 are a consequence of altered transcription of SIN3 target genes. Therefore, to understand the molecular mechanisms underlying SIN3 mutant phenotypes in Drosophila, we used full-genome oligonucleotide microarrays to compare gene expression levels in wild type Drosophila tissue culture cells versus SIN3-deficient cells generated by RNA interference. Of the 13,137 genes tested, 364 were induced and 35 were repressed by loss of SIN3. The similar to10-fold difference between the number of induced and repressed genes suggests that SIN3 plays a direct role in regulating these genes. The identified genes are distributed throughout euchromatic regions but are preferentially excluded from heterochromatic regions of Drosophila chromosomes suggesting that the SIN3 complex can only access particular chromatin structures. A number of cell cycle regulators were repressed by loss of SIN3, and functional studies indicate that repression of string, encoding the Drosophila homologue of the yeast CDC25 phosphatase, contributes to the G(2) cell cycle delay of SIN3-deficient cells. Unexpectedly, a substantial fraction of genes induced by loss of SIN3 is involved in cytosolic and mitochondrial energy-generating pathways and other genes encode components of the mitochondrial translation machinery. Increased expression of mitochondrial proteins in SIN3-deficient cells is manifested in an increase in mitochondrial mass. Thus, SIN3 may play an important role in regulating mitochondrial respiratory activity.	Univ Wisconsin, Sch Med, Dept Pharmacol, Madison, WI 53706 USA; Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; NICHD, NIH, Cell Biol & Metab Branch, Bethesda, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; Howard Hughes Medical Institute; University of California System; University of California Berkeley; University of California System; University of California Berkeley; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Wassarman, DA (corresponding author), Univ Wisconsin, Sch Med, Dept Pharmacol, 1300 Univ Ave, Madison, WI 53706 USA.	dawassarman@facstaff.wisc.edu						Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Al-Feel W, 2003, P NATL ACAD SCI USA, V100, P3095, DOI 10.1073/pnas.0538069100; Ayer DE, 1999, TRENDS CELL BIOL, V9, P193, DOI 10.1016/S0962-8924(99)01536-6; Berg J. M., 2002, BIOCHEMISTRY, V5th, P425; Berg RW, 2001, J PHARMACOL EXP THER, V298, P477; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Camarero N, 2003, NUCLEIC ACIDS RES, V31, P1693, DOI 10.1093/nar/gkg262; CHERBAS L, 1981, ADV CELL CULT, V1, P91; Clemens JC, 2000, P NATL ACAD SCI USA, V97, P6499, DOI 10.1073/pnas.110149597; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; DEZELEE S, 1989, EMBO J, V8, P3437, DOI 10.1002/j.1460-2075.1989.tb08508.x; Dubrovsky EB, 2000, DEV BIOL, V224, P486, DOI 10.1006/dbio.2000.9800; Fazzio TG, 2001, MOL CELL BIOL, V21, P6450, DOI 10.1128/MCB.21.19.6450-6460.2001; Fernandez PC, 2003, GENE DEV, V17, P1115, DOI 10.1101/gad.1067003; Fischle W, 2003, CURR OPIN CELL BIOL, V15, P172, DOI 10.1016/S0955-0674(03)00013-9; Fleischer TC, 2003, MOL CELL BIOL, V23, P3456, DOI 10.1128/MCB.23.10.3456-3467.2003; HUDAK KA, 1994, GENETICS, V136, P475; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; IRIZARRY RA, 2002, IN PRESS BIOSTATISTI; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Johnson RE, 2003, GENE DEV, V17, P77, DOI 10.1101/gad.1048303; Jones DC, 2002, J BIOL CHEM, V277, P6838, DOI 10.1074/jbc.M106908200; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lamb TM, 2001, GENETICS, V157, P545; Levens DL, 2003, GENE DEV, V17, P1071, DOI 10.1101/gad.1095203; Mahon PC, 2001, GENE DEV, V15, P2675, DOI 10.1101/gad.924501; Meertens LM, 1998, EMBO J, V17, P6972, DOI 10.1093/emboj/17.23.6972; Neufeld TP, 1998, GENETICS, V148, P277; Orian A, 2003, GENE DEV, V17, P1101, DOI 10.1101/gad.1066903; Orr WC, 1996, ARCH BIOCHEM BIOPHYS, V330, P251, DOI 10.1006/abbi.1996.0250; Pavlidis P, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-10-research0042; Pfanner N, 1997, ANNU REV CELL DEV BI, V13, P25, DOI 10.1146/annurev.cellbio.13.1.25; Pile LA, 2000, EMBO J, V19, P6131, DOI 10.1093/emboj/19.22.6131; Pile LA, 2002, MOL CELL BIOL, V22, P4965, DOI 10.1128/MCB.22.14.4965-4976.2002; Radyuk SN, 2000, ARCH INSECT BIOCHEM, V45, P79, DOI 10.1002/1520-6327(200010)45:2&lt;79::AID-ARCH4&gt;3.0.CO;2-Y; REED BH, 1995, BIOESSAYS, V17, P553, DOI 10.1002/bies.950170613; Russell P, 1998, TRENDS BIOCHEM SCI, V23, P399, DOI 10.1016/S0968-0004(98)01291-2; Ryu H, 2003, P NATL ACAD SCI USA, V100, P4281, DOI 10.1073/pnas.0737363100; Scaerou F, 1999, J CELL SCI, V112, P3757; Schoderbock P, 1996, APPL SURF SCI, V93, P109, DOI 10.1016/0169-4332(95)00327-4; Semenza GL, 1999, ANNU REV CELL DEV BI, V15, P551, DOI 10.1146/annurev.cellbio.15.1.551; SINGH KK, 1998, MITOCHONDRIAL DNA MU; STERNBERG PW, 1987, CELL, V48, P567, DOI 10.1016/0092-8674(87)90235-2; Sweet S, 1999, J CELL PHYSIOL, V180, P91, DOI 10.1002/(SICI)1097-4652(199907)180:1<91::AID-JCP10>3.0.CO;2-6; Torroja L, 1998, J CELL BIOL, V141, P1009, DOI 10.1083/jcb.141.4.1009; VIDAL M, 1995, P NATL ACAD SCI USA, V92, P2370, DOI 10.1073/pnas.92.6.2370; WATSON JD, 1987, MOL BIOL GENET, P411; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200	52	67	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37840	37848		10.1074/jbc.M305996200	http://dx.doi.org/10.1074/jbc.M305996200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865422	hybrid			2022-12-27	WOS:000185437200104
J	Walther, RF; Lamprecht, C; Ridsdale, A; Groulx, I; Lee, S; Lefebvre, YA; Hache, RJG				Walther, RF; Lamprecht, C; Ridsdale, A; Groulx, I; Lee, S; Lefebvre, YA; Hache, RJG			Nuclear export of the glucocorticoid receptor is accelerated by cell fusion-dependent release of calreticulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; MOLECULAR CHAPERONES; GENE-EXPRESSION; SUBNUCLEAR TRAFFICKING; PROGESTERONE-RECEPTOR; TRANSCRIPTION FACTORS; LOCALIZATION; SIGNAL; IMPORT; IDENTIFICATION	Nucleocytoplasmic exchange of nuclear hormone receptors is hypothesized to allow for rapid and direct interactions with cytoplasmic signaling factors. In addition to recycling between a naive, chaperone-associated cytoplasmic complex and a liganded chaperone-free nuclear form, the glucocorticoid receptor (GR) has been observed to shuttle between nucleus and cytoplasm. Nuclear export of GR and other nuclear receptors has been proposed to depend on direct interactions with calreticulin, which is predominantly localized to the lumen of the endoplasmic reticulum. We show that rapid calreticulin-mediated nuclear export of GR is a specific response to transient disruption of the endoplasmic reticulum that occurs during polyethylene glycol-mediated cell fusion. Using live and digitonin-permeabilized cells we demonstrate that, in the absence of cell fusion, GR nuclear export occurs slowly over a period of many hours independent of direct interaction with calreticulin. Our findings temper expectations that nuclear receptors respond rapidly and directly to cytoplasmic signals in the absence of additional regulatory control. These results highlight the importance of verifying findings of nucleocytoplasmic trafficking using techniques in addition to heterokaryon cell fusion.	Univ Ottawa, Ottawa Hlth Res Inst, Hormones Growth & Dev Program, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Med, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON K1H 8M5, Canada; Univ Ottawa, Kidney Res Ctr, Ottawa, ON K1H 8M5, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa; University of Ottawa; University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Hache, RJG (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Hormones Growth & Dev Program, 725 Parkdale Ave, Ottawa, ON K1Y 4E9, Canada.							Baumann CT, 2001, J BIOL CHEM, V276, P11237, DOI 10.1074/jbc.M011112200; Black BE, 2001, CURR BIOL, V11, P1749, DOI 10.1016/S0960-9822(01)00537-1; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Carey KL, 1996, J CELL BIOL, V133, P985, DOI 10.1083/jcb.133.5.985; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; DAUVOIS S, 1993, J CELL SCI, V106, P1377; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; DEFRANCO DB, 1991, MOL ENDOCRINOL, V5, P1215, DOI 10.1210/mend-5-9-1215; DeFranco DB, 2000, KIDNEY INT, V57, P1241, DOI 10.1046/j.1523-1755.2000.00957.x; Du XB, 1998, J CELL BIOL, V141, P585, DOI 10.1083/jcb.141.3.585; Freeman BC, 2000, GENE DEV, V14, P422; Freeman BC, 2002, SCIENCE, V296, P2232, DOI 10.1126/science.1073051; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Groulx I, 2000, J BIOL CHEM, V275, P8991, DOI 10.1074/jbc.275.12.8991; GUIOCHONMANTEL A, 1989, CELL, V57, P1147, DOI 10.1016/0092-8674(89)90052-4; GUIOCHONMANTEL A, 1991, EMBO J, V10, P3851, DOI 10.1002/j.1460-2075.1991.tb04954.x; Hache RJG, 1999, J BIOL CHEM, V274, P1432, DOI 10.1074/jbc.274.3.1432; Holaska JM, 2002, MOL CELL BIOL, V22, P6286, DOI 10.1128/MCB.22.17.6286-6297.2002; Holaska JM, 1998, P NATL ACAD SCI USA, V95, P14739, DOI 10.1073/pnas.95.25.14739; Holaska JM, 2001, J CELL BIOL, V152, P127, DOI 10.1083/jcb.152.1.127; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; Johnson C, 1999, EMBO J, V18, P6682, DOI 10.1093/emboj/18.23.6682; Kim FJ, 1996, MOL CELL BIOL, V16, P5147; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Lee S, 1999, MOL CELL BIOL, V19, P1486; Liu JM, 2000, MOL ENDOCRINOL, V14, P40, DOI 10.1210/me.14.1.40; MADAN AP, 1993, P NATL ACAD SCI USA, V90, P3588, DOI 10.1073/pnas.90.8.3588; MARTINEZBALBAS MA, 1995, CELL, V83, P29, DOI 10.1016/0092-8674(95)90231-7; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; McKinsey TA, 2000, NATURE, V408, P106, DOI 10.1038/35040593; McNally JG, 2000, SCIENCE, V287, P1262, DOI 10.1126/science.287.5456.1262; Mery L, 1996, J BIOL CHEM, V271, P9332, DOI 10.1074/jbc.271.16.9332; Michalak M, 1996, J BIOL CHEM, V271, P29436, DOI 10.1074/jbc.271.46.29436; Nakamura K, 2001, J CELL BIOL, V154, P961, DOI 10.1083/jcb.200102073; OssarehNazari B, 1997, SCIENCE, V278, P141, DOI 10.1126/science.278.5335.141; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; Prefontaine GG, 1998, MOL CELL BIOL, V18, P3416, DOI 10.1128/MCB.18.6.3416; Prufer K, 2002, MOL ENDOCRINOL, V16, P1738, DOI 10.1210/me.2001-0345; Prufer K, 2000, J BIOL CHEM, V275, P41114, DOI 10.1074/jbc.M003791200; Prymakowska-Bosak M, 2002, MOL CELL BIOL, V22, P6809, DOI 10.1128/MCB.22.19.6809-6819.2002; Rodriguez JA, 2000, J BIOL CHEM, V275, P38589, DOI 10.1074/jbc.M003851200; Sackey FNA, 1996, MOL ENDOCRINOL, V10, P1191, DOI 10.1210/me.10.10.1191; Savory JGA, 1999, MOL CELL BIOL, V19, P1025; Savory JGA, 2001, MOL CELL BIOL, V21, P781, DOI 10.1128/MCB.21.3.781-793.2001; SEED B, 1988, GENE, V67, P271, DOI 10.1016/0378-1119(88)90403-9; Ullman KS, 1997, CELL, V90, P967, DOI 10.1016/S0092-8674(00)80361-X; Xiao Z, 2001, J BIOL CHEM, V276, P39404, DOI 10.1074/jbc.M103117200; Xu L, 2002, MOL CELL, V10, P271, DOI 10.1016/S1097-2765(02)00586-5; Yang J, 1997, J CELL BIOL, V137, P523, DOI 10.1083/jcb.137.3.523	50	42	44	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37858	37864		10.1074/jbc.M306356200	http://dx.doi.org/10.1074/jbc.M306356200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869547	hybrid			2022-12-27	WOS:000185437200106
J	Gregory, PA; Gardner-Stephen, DA; Lewinsky, RH; Duncliffe, KN; Mackenzie, PI				Gregory, PA; Gardner-Stephen, DA; Lewinsky, RH; Duncliffe, KN; Mackenzie, PI			Cloning and characterization of the human UDP-glucuronosyltransferase 1A8, 1A9, and 1A10 gene promoters - Differential regulation through an initiator-like region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION INITIATION; BINDING PROTEIN; HUMAN BILIRUBIN; HUMAN LIVER; TATA-LESS; EXPRESSION; ELEMENTS; ACTIVATION; RECEPTOR; SUBUNIT	The human UDP-glucuronosyltransferases, UGT1A8, 1A9, and 1A10, are closely related in sequence and have a major role in the elimination of lipophilic chemicals by glucuronidation. UGT1A8 and 1A10 are expressed exclusively in the gastrointestinal tract, whereas UGT1A9 is expressed mainly in the liver and kidneys. To determine the factors contributing to the extrahepatic expression of these UDP-glucuronosyltransferases, we have cloned and characterized the promoters of the UGT1A8, 1A9, and 1A10 genes and studied their regulation in the colon cell line, Caco2. Their transcription start sites were mapped, and a functional overlapping Sp1/initiator-like site was identified which strongly contributed to UGT1A8 and 1A10 promoter activity. The high promoter activity of UGT1A8 and 1A10 correlated with the binding of nuclear proteins ( complex B) to this region. Two-bp differences in the corresponding site in the UGT1A9 promoter prevented the binding of complex B and reduced promoter activity. Although Sp1 was able to bind to the Sp1/initiator-like site, its binding was dispensable for promoter activity. However, the binding of Sp1 to a second Sp1 site 30 bp 5' to the Sp1/initiator-like site greatly enhanced the activity of the UGT1A8 and 1A10 promoters. These results provide evidence that the UGT1A8, 1A9, and 1A10 genes are differentially regulated through an initiator element in their 5'-flanking regions.	Flinders Univ S Australia, Sch Med, Med Ctr, Dept Clin Pharmacol, Bedford Pk, SA 5042, Australia	Flinders University South Australia	Mackenzie, PI (corresponding author), Flinders Univ S Australia, Sch Med, Med Ctr, Dept Clin Pharmacol, Bedford Pk, SA 5042, Australia.	Peter.Mackenzie@flinders.edu.au	Gregory, Philip/F-4089-2013	Gregory, Philip/0000-0002-0999-0632; Mackenzie, Peter/0000-0002-0697-6878				Barbier O, 2003, J BIOL CHEM, V278, P13975, DOI 10.1074/jbc.M300749200; BASU A, 1993, J BIOL CHEM, V268, P4188; Bellorini M, 1996, MOL CELL BIOL, V16, P503; Bernard P, 1999, MOL PHARMACOL, V56, P526, DOI 10.1124/mol.56.3.526; Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; Breen GAM, 1998, GENE EXPRESSION, V7, P163; Brierley CH, 1996, ADV ENZYME REGUL, V36, P85, DOI 10.1016/0065-2571(95)00006-2; CARCAMO J, 1991, P NATL ACAD SCI USA, V88, P8052, DOI 10.1073/pnas.88.18.8052; CARTER RS, 1992, J BIOL CHEM, V267, P23418; CARTER RS, 1994, J BIOL CHEM, V269, P4381; Chalkley GE, 1999, EMBO J, V18, P4835, DOI 10.1093/emboj/18.17.4835; Cheng ZQ, 1998, ARCH BIOCHEM BIOPHYS, V356, P301, DOI 10.1006/abbi.1998.0781; Cheriyath V, 1998, MOL CELL BIOL, V18, P4444, DOI 10.1128/MCB.18.8.4444; CHIANG CM, 1995, SCIENCE, V267, P531, DOI 10.1126/science.7824954; DU H, 1993, EMBO J, V12, P501, DOI 10.1002/j.1460-2075.1993.tb05682.x; Dutton G.F., 1980, GLUCURONIDATION DRUG; Emi Y, 1996, J BIOL CHEM, V271, P3952, DOI 10.1074/jbc.271.7.3952; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; Gong QH, 2001, PHARMACOGENETICS, V11, P357, DOI 10.1097/00008571-200106000-00011; HARDING D, 1988, P NATL ACAD SCI USA, V85, P8381, DOI 10.1073/pnas.85.22.8381; JAVAHERY R, 1994, MOL CELL BIOL, V14, P116, DOI 10.1128/MCB.14.1.116; KAUFMANN J, 1994, GENE DEV, V8, P821, DOI 10.1101/gad.8.7.821; LI LH, 1994, EMBO J, V13, P4070, DOI 10.1002/j.1460-2075.1994.tb06724.x; Lo K, 1996, GENE, V182, P13, DOI 10.1016/S0378-1119(96)00438-6; Mackenzie PI, 1997, PHARMACOGENETICS, V7, P255, DOI 10.1097/00008571-199708000-00001; MARTINEZ E, 1994, EMBO J, V13, P3115, DOI 10.1002/j.1460-2075.1994.tb06610.x; MEANS AL, 1990, MOL CELL BIOL, V10, P653, DOI 10.1128/MCB.10.2.653; Metz RP, 1998, J BIOL CHEM, V273, P5607, DOI 10.1074/jbc.273.10.5607; Mojarrabi B, 1996, BIOCHEM BIOPH RES CO, V225, P785, DOI 10.1006/bbrc.1996.1251; Mojarrabi B, 1998, BIOCHEM BIOPH RES CO, V247, P704, DOI 10.1006/bbrc.1998.8843; MONAGHAN G, 1994, GENOMICS, V23, P496, DOI 10.1006/geno.1994.1531; Munzel PA, 1998, ARCH BIOCHEM BIOPHYS, V350, P72, DOI 10.1006/abbi.1997.0485; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; OSHEAGREENFIELD A, 1992, J BIOL CHEM, V267, P1391; RITTER JK, 1992, J BIOL CHEM, V267, P3257; RITTER JK, 1991, J BIOL CHEM, V266, P1043; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; ROY AL, 1991, NATURE, V354, P245, DOI 10.1038/354245a0; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; Smale ST, 1997, BBA-GENE STRUCT EXPR, V1351, P73, DOI 10.1016/S0167-4781(96)00206-0; SMALE ST, 1990, P NATL ACAD SCI USA, V87, P4509, DOI 10.1073/pnas.87.12.4509; Strassburg CP, 1997, MOL PHARMACOL, V52, P212, DOI 10.1124/mol.52.2.212; Strassburg CP, 1998, MOL PHARMACOL, V54, P647; Strassburg CP, 1998, J BIOL CHEM, V273, P8719, DOI 10.1074/jbc.273.15.8719; Strassburg CP, 2000, J BIOL CHEM, V275, P36164, DOI 10.1074/jbc.M002180200; Sugatani J, 2001, HEPATOLOGY, V33, P1232, DOI 10.1053/jhep.2001.24172; Tanese N, 1996, P NATL ACAD SCI USA, V93, P13611, DOI 10.1073/pnas.93.24.13611; Tukey RH, 2001, MOL PHARMACOL, V59, P405, DOI 10.1124/mol.59.3.405; Tukey RH, 2000, ANNU REV PHARMACOL, V40, P581, DOI 10.1146/annurev.pharmtox.40.1.581; Turgeon D, 2000, J MOL BIOL, V295, P489, DOI 10.1006/jmbi.1999.3374; VERRIJZER CP, 1995, CELL, V81, P1115, DOI 10.1016/S0092-8674(05)80016-9; WANG JC, 1993, BIOCHIM BIOPHYS ACTA, V1216, P73, DOI 10.1016/0167-4781(93)90039-G; WOOSTER R, 1991, BIOCHEM J, V278, P465, DOI 10.1042/bj2780465; Xie W, 2003, P NATL ACAD SCI USA, V100, P4150, DOI 10.1073/pnas.0438010100; Yu M, 1997, J BIOL CHEM, V272, P29060, DOI 10.1074/jbc.272.46.29060	57	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36107	36114		10.1074/jbc.M305565200	http://dx.doi.org/10.1074/jbc.M305565200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847094	hybrid			2022-12-27	WOS:000185318300031
J	Miyakawa, K; Imamura, T				Miyakawa, K; Imamura, T			Secretion of FGF-16 requires an uncleaved bipartite signal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; FACTOR FAMILY; NUCLEOTIDE-SEQUENCE; HYDROPHOBIC REGION; PROTEIN; IDENTIFICATION; BINDING; TRANSLOCATION; RECOGNITION; EFFICIENCY	Fibroblast growth factor (FGF)- 16 is one of the rare secreted proteins that do not possess a cleavable signal sequence. Here we describe our examination of the mechanism and structural requirements for the secretion of FGF-16 from COS-1 transfectants. Inhibition of its secretion by brefeldin A and identification of an N-glycan on the secreted form confirmed that FGF-16 is secreted by means of the endoplasmic reticulum and Golgi apparatus, as are secreted proteins having a conventional cleavable signal sequence. Deletion of its N terminus abolished secretion of FGF- 16. When chimerized with prolactin, however, the N- terminal sequence of FGF- 16 was not able to mediate secretion of the chimera. Point mutations that made the N terminus less hydrophobic had little effect on secretion of FGF- 16, whereas making the central hydrophobic region less hydrophobic abolished secretion. Within cells, an unsecretable FGF- 16 N- terminal deletion mutant was distributed in the perinuclear region and overlapped the distribution of the Golgi apparatus. Mutants with less hydrophobic central regions were distributed evenly throughout the cytosol. Collectively, these results indicate that FGF- 16 employs a unique bipartite signal sequence ( i. e. both the N- terminal region and central hydrophobic region) that is not cleaved, although it shares the same secretory machinery used by secreted proteins with cleavable signal sequences.	Nat Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, Tsukuba, Ibaraki 3058566, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058572, Japan	National Institute of Advanced Industrial Science & Technology (AIST); University of Tsukuba	Imamura, T (corresponding author), Nat Inst Adv Ind Sci & Technol, Age Dimens Res Ctr, Cent 6,1-1-1 Higashi, Tsukuba, Ibaraki 3058566, Japan.	imamura-toru@aist.go.jp						ABRAHAM JA, 1986, SCIENCE, V233, P545, DOI 10.1126/science.2425435; BAIRD A, 1991, FIBROBLAST GROWTH FA, V638; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; Belin D, 1996, EMBO J, V15, P468, DOI 10.1002/j.1460-2075.1996.tb00379.x; Bellovino D, 2001, J BIOL CHEM, V276, P13949, DOI 10.1074/jbc.M006779200; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; Chardin P, 1999, CELL, V97, P153, DOI 10.1016/S0092-8674(00)80724-2; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLORKIEWICZ RZ, 1995, J CELL PHYSIOL, V162, P388, DOI 10.1002/jcp.1041620311; Hatsuzawa K, 1997, J BIOCHEM-TOKYO, V121, P270; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; IMAMURA T, 1988, BIOCHEM BIOPH RES CO, V155, P583, DOI 10.1016/S0006-291X(88)80534-5; JACKSON A, 1992, P NATL ACAD SCI USA, V89, P10691, DOI 10.1073/pnas.89.22.10691; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; Jeffers M, 2001, CANCER RES, V61, P3131; Keenan RJ, 1998, CELL, V94, P181, DOI 10.1016/S0092-8674(00)81418-X; Konishi M, 2000, J BIOL CHEM, V275, P12119, DOI 10.1074/jbc.275.16.12119; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Li AJ, 1999, EUR J NEUROSCI, V11, P1362, DOI 10.1046/j.1460-9568.1999.00546.x; LINGAPPA VR, 1979, NATURE, V281, P117, DOI 10.1038/281117a0; McKeehan WL, 1998, PROG NUCLEIC ACID RE, V59, P135; MIGNATTI P, 1992, J CELL PHYSIOL, V151, P81, DOI 10.1002/jcp.1041510113; Miyakawa K, 1999, J BIOL CHEM, V274, P29352, DOI 10.1074/jbc.274.41.29352; Miyake A, 1998, BIOCHEM BIOPH RES CO, V243, P148, DOI 10.1006/bbrc.1998.8073; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; Ornitz DM, 2001, GENOME BIOL, V2; Revest JM, 2000, J BIOL CHEM, V275, P8083, DOI 10.1074/jbc.275.11.8083; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Suzuki S, 2000, J INVEST DERMATOL, V114, P456, DOI 10.1046/j.1523-1747.2000.00912.x; TABE L, 1984, J MOL BIOL, V180, P645, DOI 10.1016/0022-2836(84)90031-7; Urban A, 1997, NUCLEIC ACIDS RES, V25, P2227, DOI 10.1093/nar/25.11.2227; Uruno T, 1999, GROWTH FACTORS, V17, P93, DOI 10.3109/08977199909103519; VONHEIJNE G, 1991, J BIOL CHEM, V266, P15240; VONHEIJNE G, 1985, J MOL BIOL, V184, P99, DOI 10.1016/0022-2836(85)90046-4; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	39	33	33	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35718	35724		10.1074/jbc.M300690200	http://dx.doi.org/10.1074/jbc.M300690200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851399	hybrid			2022-12-27	WOS:000185164400118
J	Suzuki, T; Murakami, T; Iino, R; Suzuki, J; Ono, S; Shirakihara, Y; Yoshida, M				Suzuki, T; Murakami, T; Iino, R; Suzuki, J; Ono, S; Shirakihara, Y; Yoshida, M			F0F1-ATPase/synthase is geared to the synthesis mode by conformational rearrangement of epsilon subunit in response to proton motive force and ADP/ATP balance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI F1-ATPASE; CHLOROPLAST ATP SYNTHASE; DISULFIDE BOND FORMATION; CROSS-LINKING; GAMMA-SUBUNIT; BETA-SUBUNITS; F1F0-ATP SYNTHASE; TERMINAL DOMAIN; CATALYTIC SITES; ROTARY MOTOR	The epsilon subunit in F0F1-ATPase/synthase undergoes drastic conformational rearrangement, which involves the transition of two C-terminal helices between a hairpin "down"-state and an extended "up"-state, and the enzyme with the up-fixed epsilon cannot catalyze ATP hydrolysis but can catalyze ATP synthesis (Tsunoda, S. P., Rodgers, A. J. W., Aggeler, R., Wilce, M. C. J., Yoshida, M., and Capaldi, R. A. ( 2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6560 - 6564). Here, using cross-linking between introduced cysteine residues as a probe, we have investigated the causes of the transition. Our findings are as follows. (i) In the up-state, the two helices of epsilon are fully extended to insert the C terminus into a deeper position in the central cavity of F-1 than was thought previously. (ii) Without a nucleotide, epsilon is in the up-state. ATP induces the transition to the down-state, and ADP counteracts the action of ATP. (iii) Conversely, the enzyme with the down-state epsilon can bind an ATP analogue, 2', 3'-O-( 2,4,6-trinitrophenyl)-ATP, much faster than the enzyme with the up-state epsilon. (iv) Proton motive force stabilizes the up-state. Thus, responding to the increase of proton motive force and ADP, F0F1-ATPase/synthase would transform the epsilon subunit into the up-state conformation and change gear to the mode for ATP synthesis.	Japan Sci & Technol Corp, ERATO, ATP Syst Project, Yokohama, Kanagawa 2260026, Japan; Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Natl Inst Genet, Shizuoka 4118540, Japan	Japan Science & Technology Agency (JST); Tokyo Institute of Technology; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan	Yoshida, M (corresponding author), Japan Sci & Technol Corp, ERATO, ATP Syst Project, Nagatsuta 5800-2, Yokohama, Kanagawa 2260026, Japan.		Iino, Ryota/B-7746-2011	Iino, Ryota/0000-0003-0110-5704				Aggeler R, 1997, J BIOL CHEM, V272, P19621, DOI 10.1074/jbc.272.31.19621; Aggeler R, 1996, J BIOL CHEM, V271, P13888, DOI 10.1074/jbc.271.23.13888; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; Alper S, 1996, J MOL BIOL, V260, P165, DOI 10.1006/jmbi.1996.0390; BAGNARA AS, 1973, EUR J BIOCHEM, V36, P422, DOI 10.1111/j.1432-1033.1973.tb02927.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Capaldi RA, 2002, TRENDS BIOCHEM SCI, V27, P154, DOI 10.1016/S0968-0004(01)02051-5; Cipriano DJ, 2002, J BIOL CHEM, V277, P16782, DOI 10.1074/jbc.M201349200; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Dunn SD, 2000, BBA-BIOENERGETICS, V1458, P356, DOI 10.1016/S0005-2728(00)00086-4; Fillingame RH, 2002, BBA-BIOMEMBRANES, V1565, P232, DOI 10.1016/S0005-2736(02)00572-2; FRANZEN JS, 1961, J BIOL CHEM, V236, P515; Gaal T, 1997, SCIENCE, V278, P2092, DOI 10.1126/science.278.5346.2092; Gibbons C, 2000, NAT STRUCT BIOL, V7, P1055; Gruber G, 1996, J BIOL CHEM, V271, P32623, DOI 10.1074/jbc.271.51.32623; Hara KY, 2001, J BIOL CHEM, V276, P23969, DOI 10.1074/jbc.M009303200; Hausrath AC, 2001, J BIOL CHEM, V276, P47227, DOI 10.1074/jbc.M107536200; Iida T, 2002, EXTREMOPHILES, V6, P369, DOI 10.1007/s00792-002-0266-7; Kato Y, 1997, J BIOL CHEM, V272, P24906, DOI 10.1074/jbc.272.40.24906; Kato-Yamada Y, 2000, J BIOL CHEM, V275, P35746, DOI 10.1074/jbc.M006575200; KOMATSUTAKAKI M, 1993, EUR J BIOCHEM, V214, P587, DOI 10.1111/j.1432-1033.1993.tb17957.x; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KUKI M, 1988, J BIOL CHEM, V263, P17437; LAGET PP, 1979, ARCH BIOCHEM BIOPHYS, V197, P83, DOI 10.1016/0003-9861(79)90222-4; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Nowak KF, 2002, BIOCHEMISTRY-US, V41, P15130, DOI 10.1021/bi026594v; Pedersen PL, 2002, J BIOENERG BIOMEMBR, V34, P327, DOI 10.1023/A:1021249701287; Ren HM, 2000, BBA-BIOENERGETICS, V1458, P221, DOI 10.1016/S0005-2728(00)00075-X; Rodgers AJW, 2000, NAT STRUCT BIOL, V7, P1051; Schulenberg B, 1997, EUR J BIOCHEM, V249, P134, DOI 10.1111/j.1432-1033.1997.t01-1-00134.x; Schulenberg B, 1999, J BIOL CHEM, V274, P28351, DOI 10.1074/jbc.274.40.28351; Senior AE, 2002, BBA-BIOENERGETICS, V1553, P188, DOI 10.1016/S0005-2728(02)00185-8; SMITH RC, 1964, BIOCHIM BIOPHYS ACTA, V86, P229, DOI 10.1016/0304-4165(64)90047-9; STERNWEIS PC, 1980, BIOCHEMISTRY-US, V19, P526, DOI 10.1021/bi00544a021; Suzuki T, 2000, J BIOL CHEM, V275, P37902, DOI 10.1074/jbc.M007075200; Suzuki T, 2002, J BIOL CHEM, V277, P13281, DOI 10.1074/jbc.M111210200; Tsunoda SP, 2001, P NATL ACAD SCI USA, V98, P6560, DOI 10.1073/pnas.111128098; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; WILKENS S, 1995, NAT STRUCT BIOL, V2, P961, DOI 10.1038/nsb1195-961; Wilkens S, 1998, J BIOL CHEM, V273, P26645, DOI 10.1074/jbc.273.41.26645; XIE DL, 1993, BIOCHIM BIOPHYS ACTA, V1172, P267, DOI 10.1016/0167-4781(93)90213-W; Yoshida M, 2001, NAT REV MOL CELL BIO, V2, P669, DOI 10.1038/35089509	45	128	139	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 21	2003	278	47					46840	46846		10.1074/jbc.M307165200	http://dx.doi.org/10.1074/jbc.M307165200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	743JV	12881515	hybrid			2022-12-27	WOS:000186569400076
J	Pandini, G; Medico, E; Conte, E; Sciacca, L; Vigneri, R; Belfiore, A				Pandini, G; Medico, E; Conte, E; Sciacca, L; Vigneri, R; Belfiore, A			Differential gene expression induced by insulin and insulin-like growth factor-II through the insulin receptor isoform A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; TISSUE-SPECIFIC EXPRESSION; PROLIFERIN-RELATED PROTEIN; LEMLI-OPITZ-SYNDROME; IGF-II; SURFEIT LOCUS; MICROARRAY ANALYSIS; SIGNALING CASCADE; CARCINOMA CELLS; BREAST CANCERS	The human insulin receptor (IR) exists in two isoforms (IR-A and IR-B). IR-A is a short isoform, generated by the skipping of exon 11, a small exon encoding for 12 amino acid residues at the carboxyl terminus of the IR alpha-subunit. Recently, we found that IR-A is the predominant isoform in fetal tissues and malignant cells and binds with a high affinity not only insulin but also insulin-like growth factor-II (IGF-II). To investigate whether the activation of IR-A by the two ligands differentially activate post-receptor molecular mechanisms, we studied gene expression in response to IR-A activation by either insulin or IGF-II, using microarray technology. To avoid the interfering effect of the IGF-IR, IGF-II binding to the IR-A was studied in IGF-IR-deficient murine fibroblasts (R- cells) transfected with the human IR-A cDNA (R-/IR-A cells). Gene expression was studied at 0.5, 3, and 8 h. We found that 214 transcripts were similarly regulated by insulin and IGF-II, whereas 45 genes were differentially transcribed. Eighteen of these differentially regulated genes were responsive to only one of the two ligands (12 to insulin and 6 to IGF-II). Twenty-seven transcripts were regulated by both insulin and IGF-II, but a significant difference between the two ligands was present at least in one time point. Interestingly, IGF-II was a more potent and/or persistent regulator than insulin for these genes. Results were validated by measuring the expression of 12 genes by quantitative real-time reverse transcriptase-PCR. In conclusion, we show that insulin and IGF-II, acting via the same receptor, may differentially affect gene expression in cells. These studies provide a molecular basis for understanding some of the biological differences between the two ligands and may help to clarify the biological role of IR-A in embryonic/fetal growth and the selective biological advantage that malignant cells producing IGF-II may acquire via IR-A overexpression.	Univ Catanzaro, Policlin Mater Domini, Cattedra Endocrinol, Dipartimento Med Mol & Clin, I-88100 Catanzaro, Italy; Univ Catania, USL 34, Osped Garibaldi,Cattedra Endocrinol, Dipartimento Med Interna & Med Specialist, I-95123 Catania, Italy; Univ Turin, Sch Med, Inst Canc Res & Treatment, I-10060 Cansiolo, TO, Italy; Univ Catania, Dipartimento Sci Biomed, I-95125 Catania, Italy; Univ Catanzaro, Policlin Mater Domini, Dipartimento Med Mol & Clin, Cattedra Endocrinol, I-88100 Catanzaro, Italy	Magna Graecia University of Catanzaro; University of Catania; University of Turin; University of Catania; Magna Graecia University of Catanzaro	Belfiore, A (corresponding author), Univ Catanzaro, Policlin Mater Domini, Cattedra Endocrinol, Dipartimento Med Mol & Clin, I-88100 Catanzaro, Italy.		SCIACCA, Laura/AAS-2896-2020; Sciacca, Laura/B-9368-2014; Pandini, Giuseppe/AAB-9650-2019; Belfiore, Antonino/B-4652-2011; Medico, Enzo/AAC-3185-2021; Vigneri, Riccardo/M-3968-2017	SCIACCA, Laura/0000-0002-3258-7200; Sciacca, Laura/0000-0002-3258-7200; Pandini, Giuseppe/0000-0003-3747-7649; Belfiore, Antonino/0000-0002-6181-4193; Medico, Enzo/0000-0002-3917-2438; Vigneri, Riccardo/0000-0002-4401-3140				Altman A, 2002, J BIOCHEM, V132, P841, DOI 10.1093/oxfordjournals.jbchem.a003295; Arteel GE, 1998, BIOL CHEM, V379, P1201; Bai JN, 2001, ONCOGENE, V20, P2153, DOI 10.1038/sj.onc.1204294; Bengtson NW, 2000, MOL ENDOCRINOL, V14, P1934, DOI 10.1210/me.14.12.1934; BUCKMAN TD, 1993, J NEUROCHEM, V60, P2046, DOI 10.1111/j.1471-4159.1993.tb03489.x; Cederberg A, 2001, CELL, V106, P563, DOI 10.1016/S0092-8674(01)00474-3; Corbacho AM, 2002, J ENDOCRINOL, V173, P219, DOI 10.1677/joe.0.1730219; Dahle MK, 2002, J BIOL CHEM, V277, P22902, DOI 10.1074/jbc.M200131200; DANCIGER M, 1990, GENOMICS, V6, P428, DOI 10.1016/0888-7543(90)90472-7; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; Duhig T, 1998, GENOMICS, V52, P72, DOI 10.1006/geno.1998.5372; Dupont J, 2001, ENDOCRINOLOGY, V142, P4969, DOI 10.1210/en.142.11.4969; Dupont J, 2001, J BIOL CHEM, V276, P26699, DOI 10.1074/jbc.M102664200; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Frank D, 1999, MAMM GENOME, V10, P1150, DOI 10.1007/s003359901182; Frasca F, 1999, MOL CELL BIOL, V19, P3278, DOI 10.1128/mcb.19.5.3278; Frittitta L, 1999, CANCER-AM CANCER SOC, V85, P492, DOI 10.1002/(SICI)1097-0142(19990115)85:2<492::AID-CNCR30>3.0.CO;2-I; GIDDINGS SJ, 1992, MOL ENDOCRINOL, V6, P1665, DOI 10.1210/me.6.10.1665; Ginzinger DG, 2002, EXP HEMATOL, V30, P503, DOI 10.1016/S0301-472X(02)00806-8; Griffin ME, 1999, DIABETES, V48, P1270, DOI 10.2337/diabetes.48.6.1270; Gusev Y, 1996, CELL PROLIFERAT, V29, P643, DOI 10.1111/j.1365-2184.1996.tb00978.x; Holben DH, 1999, J AM DIET ASSOC, V99, P836, DOI 10.1016/S0002-8223(99)00198-4; Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003; JACKSON D, 1994, SCIENCE, V266, P1581, DOI 10.1126/science.7527157; Kadkol SS, 1998, PROSTATE, V34, P231, DOI 10.1002/(SICI)1097-0045(19980215)34:3<231::AID-PROS11>3.0.CO;2-F; Kalli KR, 2002, ENDOCRINOLOGY, V143, P3259, DOI 10.1210/en.2001-211408; KOSAKI A, 1993, J BIOL CHEM, V268, P21990; Kuhn I, 2001, PHYSIOL GENOMICS, V7, P105, DOI 10.1152/physiolgenomics.00052.2001; Lee SW, 2002, J BIOCHEM MOL BIOL, V35, P371; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; LIU JP, 1993, CELL, V75, P59, DOI 10.1016/0092-8674(93)90679-K; Louvi A, 1997, DEV BIOL, V189, P33, DOI 10.1006/dbio.1997.8666; Magoulas C, 2000, GENE, V243, P115, DOI 10.1016/S0378-1119(99)00551-X; Meller N, 1998, STEM CELLS, V16, P178, DOI 10.1002/stem.160178; MOLLER DE, 1989, MOL ENDOCRINOL, V3, P1263, DOI 10.1210/mend-3-8-1263; Morrione A, 1997, P NATL ACAD SCI USA, V94, P3777, DOI 10.1073/pnas.94.8.3777; MOSTHAF L, 1990, EMBO J, V9, P2409, DOI 10.1002/j.1460-2075.1990.tb07416.x; Mulligan C, 2002, J BIOL CHEM, V277, P42480, DOI 10.1074/jbc.M206206200; Neef R, 2002, CANCER RES, V62, P5920; Nowaczyk MJM, 2001, CLIN GENET, V59, P375, DOI 10.1034/j.1399-0004.2001.590601.x; Nwokoro NA, 2001, MOL GENET METAB, V74, P105, DOI 10.1006/mgme.2001.3226; Palmer G, 2000, ENDOCRINOLOGY, V141, P2236, DOI 10.1210/en.141.6.2236; Pandini G, 1999, CLIN CANCER RES, V5, P1935; Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200; PAPA V, 1990, J CLIN INVEST, V86, P1503, DOI 10.1172/JCI114868; Patrono C, 2002, MOL CELL PROBE, V16, P315, DOI 10.1006/mcpr.2002.0426; Rho J, 2001, MOL CELL BIOL, V21, P8365, DOI 10.1128/MCB.21.24.8365-8370.2001; Sanna MG, 2002, MOL CELL BIOL, V22, P1754, DOI 10.1128/MCB.22.6.1754-1766.2002; Sciacca L, 1999, ONCOGENE, V18, P2471, DOI 10.1038/sj.onc.1202600; Sciacca L, 2002, ONCOGENE, V21, P8240, DOI 10.1038/sj.onc.1206058; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; Toft DJ, 2001, P NATL ACAD SCI USA, V98, P13055, DOI 10.1073/pnas.231364798; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; ULLRICH A, 1986, EMBO J, V5, P2503, DOI 10.1002/j.1460-2075.1986.tb04528.x; Vella V, 2002, J CLIN ENDOCR METAB, V87, P245, DOI 10.1210/jc.87.1.245; Vella V, 2001, J CLIN PATHOL-MOL PA, V54, P121, DOI 10.1136/mp.54.3.121; Wolff CM, 2002, DNA SEQUENCE, V13, P149, DOI 10.1080/10425170290023400; Yang Q, 2002, EUKARYOT CELL, V1, P378, DOI 10.1128/EC.1.3.378-390.2002; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217	59	79	81	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42178	42189		10.1074/jbc.M304980200	http://dx.doi.org/10.1074/jbc.M304980200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12881524	hybrid			2022-12-27	WOS:000185989500076
J	Pang, QS; Christianson, TA; Koretsky, T; Carlson, HQ; David, L; Keeble, W; Faulkner, GR; Speckhart, A; Bagby, GC				Pang, QS; Christianson, TA; Koretsky, T; Carlson, HQ; David, L; Keeble, W; Faulkner, GR; Speckhart, A; Bagby, GC			Nucleophosmin interacts with and inhibits the catalytic function of eukaryotic initiation factor 2 kinase PKR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; DEPENDENT PROTEIN-KINASE; ENDOPLASMIC-RETICULUM STRESS; BUTYRATE-INDUCED APOPTOSIS; FANCONI-ANEMIA PROTEIN; LEUKEMIA HL-60 CELLS; MALIGNANT-TRANSFORMATION; INCREASED EXPRESSION; TELOMERASE ACTIVITY; INTERFERON	In normal cells the protein kinase PKR effects apoptosis in response to various extra and intracellular cues and can also function to suppress the neoplastic phenotype. Because most neoplastic cells are resistant to certain apoptotic cues, we reasoned that an early molecular event in carcinogenesis or leukemogenesis might be the inactivation of PKR by expression or activation of intracellular PKR inhibitors. Seeking novel PKR-modulating proteins we report here that nucleophosmin (NPM), a protein frequently overexpressed in a variety of human malignancies, binds to PKR, and inhibits its activation. Co-immunoprecipitation and in vitro binding experiments showed that NPM associated with PKR. Kinase assays demonstrated that recombinant NPM inhibited PKR activation in a dose-dependent manner. In addition, purified recombinant NPM was phosphorylated by activated PKR. Most importantly, overexpression of NPM suppressed PKR activity, enhanced protein synthesis, and inhibited apoptosis. Lymphoblasts from patients with Fanconi anemia ( FA) expressed low levels of NPM, which correlated with high ground-state activation of PKR and cellular hypersensitivity to apoptotic cues, but enforced expression of NPM in these mutant cells reduced aberrant apoptotic responses. Inhibition of PKR by NPM may be one mechanism by which neoplastic clones evolve in sporadic malignancies and in neoplastic cells arising in the context of the cancer predisposition syndrome, Fanconi anemia.	Oregon Hlth & Sci Univ, Inst Canc, Sch Med, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Inst Canc, Sch Dent, Portland, OR 97201 USA; Vet Affairs Med Ctr, Portland, OR 97201 USA; Cincinnati Children Hosp Med Ctr, Div Expt Hematol, Cincinnati, OH 45229 USA	Oregon Health & Science University; Oregon Health & Science University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Cincinnati Children's Hospital Medical Center; University System of Ohio; University of Cincinnati	Bagby, GC (corresponding author), Oregon Hlth & Sci Univ, Inst Canc, Sch Med, CR145, Portland, OR 97201 USA.	grover@ohsu.edu			NHLBI NIH HHS [HL 48546] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048546] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alter BP, 2002, PEDIATR CLIN N AM, V49, P973, DOI 10.1016/S0031-3955(02)00031-7; Barber GN, 2001, CELL DEATH DIFFER, V8, P113, DOI 10.1038/sj.cdd.4400823; BARBER GN, 1995, MOL CELL BIOL, V15, P3138; CHAN WY, 1989, BIOCHEMISTRY-US, V28, P1033, DOI 10.1021/bi00429a017; Chang RCC, 2002, J NEUROCHEM, V83, P1215, DOI 10.1046/j.1471-4159.2002.01237.x; CHONG KL, 1992, EMBO J, V11, P1553, DOI 10.1002/j.1460-2075.1992.tb05200.x; Clemens MJ, 1999, INT J BIOCHEM CELL B, V31, P1, DOI 10.1016/S1357-2725(98)00127-7; DANDREA AD, 2002, AM SOC HEMATOL ED PR, P58; DONZE O, 1995, EMBO J, V14, P3828, DOI 10.1002/j.1460-2075.1995.tb00052.x; DUMBAR TS, 1989, BIOCHEMISTRY-US, V28, P9495, DOI 10.1021/bi00450a037; Fagerlie S, 2001, EXP HEMATOL, V29, P1371, DOI 10.1016/S0301-472X(01)00755-X; FENG GS, 1992, P NATL ACAD SCI USA, V89, P5447, DOI 10.1073/pnas.89.12.5447; FEUERSTEIN N, 1987, J IMMUNOL, V139, P1818; FEUERSTEIN N, 1988, J BIOL CHEM, V263, P10608; GREEN SR, 1992, GENE DEV, V6, P2478, DOI 10.1101/gad.6.12b.2478; Hingorani K, 2000, J BIOL CHEM, V275, P24451, DOI 10.1074/jbc.M003278200; Jagus R, 1999, INT J BIOCHEM CELL B, V31, P123, DOI 10.1016/S1357-2725(98)00136-8; Kenmochi N, 2000, J HUM GENET, V45, P290, DOI 10.1007/s100380070018; KOROMILAS AE, 1992, SCIENCE, V257, P1685, DOI 10.1126/science.1382315; Kowalczyk P, 2002, ACTA BIOCHIM POL, V49, P615; Kryndushkin DS, 2002, J BIOL CHEM, V277, P23702, DOI 10.1074/jbc.M111547200; Lensch MW, 2003, BLOOD, V102, P7, DOI 10.1182/blood-2002-09-2781; Lensch MW, 1999, LEUKEMIA, V13, P1784, DOI 10.1038/sj.leu.2401586; Li SY, 2001, J BIOL CHEM, V276, P13881, DOI 10.1074/jbc.M008140200; Liu WH, 1998, ONCOGENE, V17, P3055, DOI 10.1038/sj.onc.1202234; Liu WH, 1999, INT J CANCER, V83, P765, DOI 10.1002/(SICI)1097-0215(19991210)83:6<765::AID-IJC12>3.0.CO;2-J; Matsui T, 2001, BIOCHEM BIOPH RES CO, V284, P798, DOI 10.1006/bbrc.2001.5039; MEURS EF, 1993, P NATL ACAD SCI USA, V90, P232, DOI 10.1073/pnas.90.1.232; MUNDSCHAU LJ, 1992, J BIOL CHEM, V267, P23092; Naora H, 1999, IMMUNOL CELL BIOL, V77, P197, DOI 10.1046/j.1440-1711.1999.00816.x; Pang QS, 2000, MOL CELL BIOL, V20, P4724, DOI 10.1128/MCB.20.13.4724-4735.2000; Pang QS, 2002, J BIOL CHEM, V277, P49638, DOI 10.1074/jbc.M209386200; Pang QS, 2001, BLOOD, V97, P1644, DOI 10.1182/blood.V97.6.1644; Pang QS, 2001, EMBO J, V20, P4478, DOI 10.1093/emboj/20.16.4478; PATTERSON SD, 1995, J BIOL CHEM, V270, P9429, DOI 10.1074/jbc.270.16.9429; Peel AL, 2001, HUM MOL GENET, V10, P1531, DOI 10.1093/hmg/10.15.1531; Raveh T, 1996, J BIOL CHEM, V271, P25479, DOI 10.1074/jbc.271.41.25479; Ryu EJ, 2002, J NEUROSCI, V22, P10690; Samuel CE, 2001, CLIN MICROBIOL REV, V14, P778, DOI 10.1128/CMR.14.4.778-809.2001; SCHMIDTZACHMANN MS, 1988, CHROMOSOMA, V96, P417, DOI 10.1007/BF00303035; SCHNEIDER RJ, 1987, ANNU REV BIOCHEM, V56, P317, DOI 10.1146/annurev.biochem.56.1.317; Shields LBE, 1997, J SOC GYNECOL INVEST, V4, P298, DOI 10.1016/S1071-5576(97)00068-3; Sieff CA, 2000, BRIT J HAEMATOL, V111, P30, DOI 10.1046/j.1365-2141.2000.02263.x; Siman R, 2001, J BIOL CHEM, V276, P44736, DOI 10.1074/jbc.M104092200; Srivastava SP, 1998, J BIOL CHEM, V273, P2416, DOI 10.1074/jbc.273.4.2416; Subong ENP, 1999, PROSTATE, V39, P298; Szebeni A, 1999, PROTEIN SCI, V8, P905; VanBelzen N, 1995, EUR J BIOCHEM, V234, P843; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Worman HJ, 2002, TRENDS CELL BIOL, V12, P591, DOI 10.1016/S0962-8924(02)02401-7; Yang YL, 1995, EMBO J, V14, P6095, DOI 10.1002/j.1460-2075.1995.tb00300.x; Yeung MC, 1996, P NATL ACAD SCI USA, V93, P12451, DOI 10.1073/pnas.93.22.12451; You BJ, 1999, N-S ARCH PHARMACOL, V360, P683, DOI 10.1007/s002109900145; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200	54	40	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41709	41717		10.1074/jbc.M301392200	http://dx.doi.org/10.1074/jbc.M301392200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12882984	hybrid			2022-12-27	WOS:000185989500021
J	Bonnal, S; Schaeffer, C; Creancier, L; Clamens, S; Moine, H; Prats, AC; Vagner, S				Bonnal, S; Schaeffer, C; Creancier, L; Clamens, S; Moine, H; Prats, AC; Vagner, S			A single internal ribosome entry site containing a G quartet RNA structure drives fibroblast growth factor 2 gene expression at four alternative translation initiation codons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; MESSENGER-RNA; IRES ELEMENTS; C-MYC; VIRUS-RNA; PROTEIN; BINDING; REGION; GROWTH-FACTOR-2; TETRAPLEX	The 484-nucleotide (nt) alternatively translated region (ATR) of the human fibroblast growth factor 2 (FGF-2) mRNA contains four CUG and one AUG translation initiation codons. Although the 5'-end proximal CUG codon is initiated by a cap-dependent translation process, the other four initiation codons are initiated by a mechanism of internal entry of ribosomes. We undertook here a detailed analysis of the cis-acting elements defining the FGF-2 internal ribosome entry site (IRES). A thorough deletion analysis study within the 5'-ATR led us to define a 176-nt region as being necessary and sufficient for IRES function at four codons present in a downstream 308-nt RNA segment. Unexpectedly, a single IRES module is therefore responsible for translation initiation at four distantly localized codons. The determination of the FGF-2 5'-ATR RNA secondary structure by enzymatic and chemical probing experiments showed that the FGF-2 IRES contained two stem-loop regions and a G quartet motif that constitute novel structural determinants of IRES function.	CHU Rangueil, Inst Louis Bugnard, INSERM, U589, F-31403 Toulouse 04, France; CNRS, UPR 9002, F-67084 Strasbourg, France	CHU de Toulouse; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Vagner, S (corresponding author), CHU Rangueil, Inst Louis Bugnard, INSERM, U589, F-31403 Toulouse 04, France.		Schaeffer, Celine/AAC-5208-2022; Prats, Anne-Catherine/E-5051-2016; Schaeffer, Celine/AAU-5713-2020; Vagner, Stephan/G-3664-2013; Moine, Herve/Q-2328-2016	Schaeffer, Celine/0000-0001-5883-3951; Prats, Anne-Catherine/0000-0002-5282-3776; Schaeffer, Celine/0000-0001-5883-3951; Moine, Herve/0000-0002-6250-7902; vagner, stephan/0000-0003-1452-7164				Arnaud E, 1999, MOL CELL BIOL, V19, P505; BELSHAM GJ, 1992, EMBO J, V11, P1105, DOI 10.1002/j.1460-2075.1992.tb05150.x; Bikfalvi A, 1997, ENDOCR REV, V18, P26, DOI 10.1210/er.18.1.26; Bonnal S, 2003, NUCLEIC ACIDS RES, V31, P427, DOI 10.1093/nar/gkg003; Brunel C, 2000, METHOD ENZYMOL, V318, P3; Chappell SA, 2000, P NATL ACAD SCI USA, V97, P1536, DOI 10.1073/pnas.97.4.1536; Coldwell MJ, 2001, ONCOGENE, V20, P4095, DOI 10.1038/sj.onc.1204547; Cornelis S, 2000, MOL CELL, V5, P597, DOI 10.1016/S1097-2765(00)80239-7; Creancier L, 2000, J CELL BIOL, V150, P275, DOI 10.1083/jcb.150.1.275; Darnell JC, 2001, CELL, V107, P489, DOI 10.1016/S0092-8674(01)00566-9; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; Hellen CUT, 2001, GENE DEV, V15, P1593, DOI 10.1101/gad.891101; Holcik M, 1999, NAT CELL BIOL, V1, P190, DOI 10.1038/11109; Hu MCY, 1999, P NATL ACAD SCI USA, V96, P1339, DOI 10.1073/pnas.96.4.1339; Hudder A, 2000, J BIOL CHEM, V275, P34586, DOI 10.1074/jbc.M005199200; Huez I, 1998, MOL CELL BIOL, V18, P6178, DOI 10.1128/MCB.18.11.6178; Kanamori Y, 2001, RNA, V7, P266, DOI 10.1017/S1355838201001741; Kozak M, 2002, GENE, V299, P1, DOI 10.1016/S0378-1119(02)01056-9; LAUGHLAN G, 1994, SCIENCE, V265, P520, DOI 10.1126/science.8036494; Le Quesne JPC, 2001, J MOL BIOL, V310, P111, DOI 10.1006/jmbi.2001.4745; Le SY, 1997, NUCLEIC ACIDS RES, V25, P362, DOI 10.1093/nar/25.2.362; Martinez-Salas E, 2002, BIOCHIMIE, V84, P755, DOI 10.1016/S0300-9084(02)01408-6; Miyashiro KY, 2003, NEURON, V37, P417, DOI 10.1016/S0896-6273(03)00034-5; Nanbru C, 2001, ONCOGENE, V20, P4270, DOI 10.1038/sj.onc.1204548; Nanbru C, 1997, J BIOL CHEM, V272, P32061, DOI 10.1074/jbc.272.51.32061; Oliver AW, 2000, J MOL BIOL, V301, P575, DOI 10.1006/jmbi.2000.3991; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; Pyronnet S, 2000, MOL CELL, V5, P607, DOI 10.1016/S1097-2765(00)80240-3; Robertson MEM, 1999, RNA, V5, P1167, DOI 10.1017/S1355838299990301; Ryabova LA, 2002, PROG NUCLEIC ACID RE, V72, P1, DOI 10.1016/S0079-6603(02)72066-7; Sachs AB, 2000, CELL, V101, P243, DOI 10.1016/S0092-8674(00)80834-X; Schaeffer C, 2001, EMBO J, V20, P4803, DOI 10.1093/emboj/20.17.4803; Sella O, 1999, MOL CELL BIOL, V19, P5429; SUNDQUIST WI, 1989, NATURE, V342, P825, DOI 10.1038/342825a0; Vagner S, 1996, J CELL BIOL, V135, P1391, DOI 10.1083/jcb.135.5.1391; VAGNER S, 1995, J BIOL CHEM, V270, P20376, DOI 10.1074/jbc.270.35.20376; VAGNER S, 1995, MOL CELL BIOL, V15, P35, DOI 10.1128/MCB.15.1.35; Vagner S, 2001, EMBO REP, V2, P893, DOI 10.1093/embo-reports/kve208; WANG CY, 1995, RNA, V1, P526; Wilson JE, 2000, MOL CELL BIOL, V20, P4990, DOI 10.1128/MCB.20.14.4990-4999.2000; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707	42	133	139	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39330	39336		10.1074/jbc.M305580200	http://dx.doi.org/10.1074/jbc.M305580200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12857733	Green Accepted, hybrid, Green Submitted			2022-12-27	WOS:000185713800010
J	Chawla-Sarkar, M; Bauer, JA; Lupica, JA; Morrison, BH; Tang, Z; Oates, RK; Almasan, A; DiDonato, JA; Borden, EC; Lindner, DJ				Chawla-Sarkar, M; Bauer, JA; Lupica, JA; Morrison, BH; Tang, Z; Oates, RK; Almasan, A; DiDonato, JA; Borden, EC; Lindner, DJ			Suppression of NF-kappa B survival signaling by nitrosylcobalamin sensitizes neoplasms to the anti-tumor effects of Apo2L/TRAIL	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOPTOSIS-INDUCING LIGAND; TRAIL-INDUCED APOPTOSIS; NITRIC-OXIDE; IONIZING-RADIATION; CELL-LINES; CHEMOTHERAPEUTIC-AGENTS; CONSTITUTIVE ACTIVATION; INHIBITORY PROTEIN; S-NITROSYLATION; HUMAN-MELANOMA	We have previously demonstrated the anti-tumor activity of nitrosylcobalamin (NO-Cbl), an analog of vitamin B12 that delivers nitric oxide (NO) and increases the expression of tumor necrosis factor-related apoptosis-inducing ligand (Apo2L/TRAIL) and its receptors in human tumors. The specific aim of this study was to examine whether NO-Cbl could sensitize drug-resistant melanomas to Apo2L/TRAIL. Antiproliferative effects of NO-Cbl and Apo2L/TRAIL were assessed in malignant melanomas and non-tumorigenic melanocyte and fibroblast cell lines. Athymic nude mice bearing human melanoma A375 xenografts were treated with NO-Cbl and Apo2L/TRAIL. Apoptosis was measured by TUNEL and confirmed by examining levels and activity of key mediators of apoptosis. The activation status of NF-kappaB was established by assaying DNA binding, luciferase reporter activity, the phosphorylation status of IkappaBalpha, and in vitro IKK activity. NO-Cbl sensitized Apo2L/TRAIL-resistant melanoma cell lines to growth inhibition by Apo2L/TRAIL but had minimal effect on normal cell lines. NO-Cbl and Apo2L/TRAIL exerted synergistic antitumor activity against A375 xenografts. Treatment with NO-Cbl followed by Apo2L/TRAIL induced apoptosis in Apo2L/TRAIL-resistant tumor cells, characterized by cleavage of caspase-3, caspase-8, and PARP. NO-Cbl inhibited IKK activation, characterized by decreased phosphorylation of IkappaBalpha and inhibition of NF-kappaB DNA binding activity. NO-Cbl suppressed Apo2L/TRAIL- and TNF-alpha-mediated activation of a transfected NF-kappaB-driven luciferase reporter. XIAP, an inhibitor of apoptosis, was inactivated by NO-Cbl. NO-Cbl treatment rendered Apo2L/TRAIL- resistant malignancies sensitive to the anti-tumor effects of Apo2L/TRAIL in vitro and in vivo. The use of NO-Cbl and Apo2L/TRAIL capitalizes on the tumor-specific properties of both agents and represents a promising anti-cancer combination.	Cleveland Clin Fdn, Ctr Canc Drug Discovery & Dev, Taussig Canc Ctr, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Lerner Res Inst, Dept Canc Biol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation	Lindner, DJ (corresponding author), 9500 Euclid Ave,R40, Cleveland, OH 44195 USA.		Hazen, Stanley L/ABD-5845-2021; Lindner, Daniel/ABB-5440-2020; Almasan, Alex/C-2715-2008	Almasan, Alex/0000-0002-8916-6650; Lupica, Joseph/0000-0003-1476-037X	NCI NIH HHS [R01 CA081504, R01 CA082858, CA 81504, R01 CA098536-01A1, CA 82858] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA081504, R01CA098536, R01CA082858] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANGGARD E, 1994, LANCET, V343, P1199, DOI 10.1016/S0140-6736(94)92405-8; Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Baetu TM, 2001, J IMMUNOL, V167, P3164, DOI 10.4049/jimmunol.167.6.3164; Bauer JA, 1998, ANTI-CANCER DRUG, V9, P239, DOI 10.1097/00001813-199803000-00006; Bauer JA, 2002, J NATL CANCER I, V94, P1010; Bharti AC, 2002, BIOCHEM PHARMACOL, V64, P883, DOI 10.1016/S0006-2952(02)01154-1; Bours V, 2000, BIOCHEM PHARMACOL, V60, P1085, DOI 10.1016/S0006-2952(00)00391-9; Chawla-Sarkar M, 2001, CLIN CANCER RES, V7, P1821; Chawla-Sarkar M, 2002, J IMMUNOL, V169, P847, DOI 10.4049/jimmunol.169.2.847; Chen CL, 2000, MOL CELL BIOL, V20, P2687, DOI 10.1128/MCB.20.8.2687-2695.2000; Chinnaiyan AM, 2000, P NATL ACAD SCI USA, V97, P1754, DOI 10.1073/pnas.030545097; Chlichlia K, 1998, BLOOD, V91, P4311, DOI 10.1182/blood.V91.11.4311.411k07_4311_4320; CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4; Collins DA, 2000, MAYO CLIN PROC, V75, P568, DOI 10.4065/75.6.568; COOPERMAN JM, 1960, J BIOL CHEM, V235, P191; D'Acquisto F, 2001, N-S ARCH PHARMACOL, V364, P157, DOI 10.1007/s002100100435; DelaTorre A, 1997, BIOCHEM BIOPH RES CO, V238, P703, DOI 10.1006/bbrc.1997.7279; Dhawan P, 2002, CANCER RES, V62, P7335; Di Pietro R, 2001, BLOOD, V97, P2596, DOI 10.1182/blood.V97.9.2596; DiDonato J, 1996, MOL CELL BIOL, V16, P1295; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; DIDONATO JA, 1995, MOL CELL BIOL, V15, P1302; DiDonato JA, 2000, METHOD ENZYMOL, V322, P393; Eid MA, 2002, INT J ONCOL, V21, P111; Elewaut D, 1999, J IMMUNOL, V163, P1457; FLODH H, 1968, INT J CANCER, V3, P694, DOI 10.1002/ijc.2910030518; Frese S, 2002, J THORAC CARDIOV SUR, V123, P168, DOI 10.1067/mtc.2002.119694; Gibson SB, 2000, MOL CELL BIOL, V20, P205, DOI 10.1128/MCB.20.1.205-212.2000; Gliniak B, 1999, CANCER RES, V59, P6153; Goke R, 2000, CELL IMMUNOL, V201, P77, DOI 10.1006/cimm.2000.1650; Gong BD, 2000, CANCER RES, V60, P5754; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Herr I, 2000, ONCOGENE, V19, P4255, DOI 10.1038/sj.onc.1203776; Kang JL, 2002, J APPL PHYSIOL, V92, P795, DOI 10.1152/japplphysiol.00202.2001; Kim MR, 2001, FEBS LETT, V505, P179, DOI 10.1016/S0014-5793(01)02816-2; LaCasse EC, 1998, ONCOGENE, V17, P3247, DOI 10.1038/sj.onc.1202569; Lawrence D, 2001, NAT MED, V7, P383, DOI 10.1038/86397; Lee YJ, 2001, ONCOGENE, V20, P1476, DOI 10.1038/sj.onc.1204225; Li XX, 2000, P NATL ACAD SCI USA, V97, P10489, DOI 10.1073/pnas.160265197; Marshall HE, 2001, BIOCHEMISTRY-US, V40, P1688, DOI 10.1021/bi002239y; Matthews JR, 1996, NUCLEIC ACIDS RES, V24, P2236, DOI 10.1093/nar/24.12.2236; Mizutani Y, 2002, EUR J CANCER, V38, P167, DOI 10.1016/S0959-8049(01)00339-2; Oya M, 2001, ONCOGENE, V20, P3888, DOI 10.1038/sj.onc.1204525; Ozoren N, 2000, INT J ONCOL, V16, P917; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; Reed JC, 2003, CANCER CELL, V3, P17, DOI 10.1016/S1535-6108(02)00241-6; Rossi A, 2000, NATURE, V403, P103, DOI 10.1038/47520; Sato K, 2001, EUR J IMMUNOL, V31, P3138, DOI 10.1002/1521-4141(200111)31:11<3138::AID-IMMU3138>3.0.CO;2-B; Secchiero P, 2001, BLOOD, V98, P2220, DOI 10.1182/blood.V98.7.2220; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; VOLK T, 1995, BIOCHEM BIOPH RES CO, V213, P196, DOI 10.1006/bbrc.1995.2116; Walczak H, 2000, CANCER RES, V60, P3051; Walczak H, 1999, NAT MED, V5, P157, DOI 10.1038/5517; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wink DA, 1996, ARCH BIOCHEM BIOPHYS, V331, P241, DOI 10.1006/abbi.1996.0304; Yamanaka T, 2000, HEPATOLOGY, V32, P482, DOI 10.1053/jhep.2000.16266; Zhang XD, 1999, CANCER RES, V59, P2747; Zhang XD, 2001, CANCER RES, V61, P7339	60	69	71	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39461	39469		10.1074/jbc.M306111200	http://dx.doi.org/10.1074/jbc.M306111200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881518	Green Accepted, hybrid			2022-12-27	WOS:000185713800024
J	Meng, GX; Grabiec, A; Vallon, M; Ebe, B; Hampel, S; Bessler, W; Wagner, H; Kirschning, CJ				Meng, GX; Grabiec, A; Vallon, M; Ebe, B; Hampel, S; Bessler, W; Wagner, H; Kirschning, CJ			Cellular recognition of Tri-/Di-palmitoylated peptides is independent from a domain encompassing the N-terminal seven leucine-rich repeat (LRR)/LRR-like motifs of TLR2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTOR-2; BACTERIAL CPG-DNA; KAPPA-B; CUTTING EDGE; ACTIVATION; LIPOPOLYSACCHARIDE; EXPRESSION; PROTEINS; CELLS; RESPONSIVENESS	Toll-like receptors (TLRs) mediate microbial pattern recognition in vertebrates. A broad variety of agonists has been attributed to TLR2 and three TLRs, TLR4, TLR2, and TLR5, have been demonstrated to bind microbial products. Distinct agonists might interact with different subdomains of the TLR2 extracellular domain. The TLR2 extracellular domain sequence includes 10 canonical leucine-rich repeat (LRR) motifs and 8-10 additional and potentially functionally relevant LRR-like motifs. Thus, the transfection of TLR2 LRR/LRR-like motif deletion constructs in human embryonic kidney 293 cells and primary TLR2-deficient mouse fibroblasts was performed for analysis of the role of the regarding domains in specific pattern recognition. Preparations applied as agonists were highly purified soluble peptidoglycan, lipoteichoic acid, outer surface protein A from Borrelia burgdorferi, synthetic mycoplasmal macrophage-activating lipoprotein-2, tripalmitoyl-cysteinylseryl-(lysyl)3-lysine (P3CSK4), dipalmitoyl-CSK4 (P-2-CSK4), and monopalmitoyl-CSK4 (PCSK4) as well as lipopolysaccharide and inactivated bacteria. We found that a block of the N-terminal seven LRR/LRR-like motifs was not involved in TLR2-mediated cell activation by P3CSK4 and P2CSK4 ligands mimicking triacylated and diacylated bacterial polypeptides, respectively. In contrast, the integrity of the TLR2 holoprotein was compulsory for effective cellular recognition of other TLR2 agonists applied, including PCSK4. The formation of a functionally relevant subdomain by a region including the N-terminal seven LRR/LRR-like motifs rather than by single LRRs is suggested by our results. They further imply that TLR2 contains multiple binding domains for ligands that may contribute to the characterization of its promiscuous molecular pattern recognition.	Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, D-81675 Munich, Germany; Univ Freiburg, Inst Mol Med & Cell Res, D-79104 Freiburg, Germany	Technical University of Munich; University of Freiburg	Kirschning, CJ (corresponding author), Tech Univ Munich, Inst Med Microbiol Immunol & Hyg, Trogerstr 4A, D-81675 Munich, Germany.	carsten.kirschning@lrz.tum.de		孟, 广勋/0000-0002-4253-9675				Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; Alexopoulou L, 2002, NAT MED, V8, P878, DOI 10.1038/nm732; BESSLER WG, 1992, RES IMMUNOL, V143, P548, DOI 10.1016/0923-2494(92)80067-U; BESSLER WG, 1980, INFECT IMMUN, V28, P818; Beutler B, 2003, NAT REV IMMUNOL, V3, P169, DOI 10.1038/nri1004; Bochud PY, 2003, J IMMUNOL, V170, P3451, DOI 10.4049/jimmunol.170.7.3451; Caramalho I, 2003, J EXP MED, V197, P403, DOI 10.1084/jem.20021633; Chaudhary PM, 1998, BLOOD, V91, P4020, DOI 10.1182/blood.V91.11.4020.411a44_4020_4027; Chuang TH, 2001, BBA-GENE STRUCT EXPR, V1518, P157, DOI 10.1016/S0167-4781(00)00289-X; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; da Costa CP, 2002, EUR J IMMUNOL, V32, P2460, DOI 10.1002/1521-4141(200209)32:9<2460::AID-IMMU2460>3.0.CO;2-M; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; Dziarski R, 1996, J INFECT DIS, V174, P777, DOI 10.1093/infdis/174.4.777; FRED MA, 1990, CURRENT PROTOCOLS MO; Girardin SE, 2003, J BIOL CHEM, V278, P8869, DOI 10.1074/jbc.C200651200; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777; Heine H, 1999, J IMMUNOL, V162, P6971; Hirschfeld M, 2001, INFECT IMMUN, V69, P1477, DOI 10.1128/IAI.69.3.1477-1482.2001; Inohara N, 2003, J BIOL CHEM, V278, P5509, DOI 10.1074/jbc.C200673200; Iwaki D, 2002, J BIOL CHEM, V277, P24315, DOI 10.1074/jbc.M107057200; Kajava AV, 2002, PROTEIN SCI, V11, P1082, DOI 10.1110/ps.4010102; Kirschning CJ, 2002, CURR TOP MICROBIOL, V270, P121; LATZ E, 2002, J BIOL CHEM, V24, P24; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Mitsuzawa H, 2001, J BIOL CHEM, V276, P41350, DOI 10.1074/jbc.M104177200; MIZEL SB, 2003, J BIOL CHEM, V23, P23; Morath S, 2001, J EXP MED, V193, P393, DOI 10.1084/jem.193.3.393; Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(2002012)32:12<3337::AID-IMMU3337>3.0.CO;2-I; Muzio M, 1998, J EXP MED, V187, P2097, DOI 10.1084/jem.187.12.2097; Nagai Y, 2002, BLOOD, V99, P1699, DOI 10.1182/blood.V99.5.1699; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rhee SH, 2000, J BIOL CHEM, V275, P34035, DOI 10.1074/jbc.M007386200; Rock FL, 1998, P NATL ACAD SCI USA, V95, P588, DOI 10.1073/pnas.95.2.588; SCHINDLER U, 1994, MOL CELL BIOL, V14, P5820, DOI 10.1128/MCB.14.9.5820; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Schubert WD, 2002, CELL, V111, P825, DOI 10.1016/S0092-8674(02)01136-4; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Sing A, 2002, J EXP MED, V196, P1017, DOI 10.1084/jem.20020908; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; Takeuchi O, 2002, J IMMUNOL, V169, P10, DOI 10.4049/jimmunol.169.1.10; ULEVITCH RJ, 1995, ANNU REV IMMUNOL, V13, P437, DOI 10.1146/annurev.iy.13.040195.002253; Werts C, 2001, NAT IMMUNOL, V2, P346, DOI 10.1038/86354	44	66	70	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39822	39829		10.1074/jbc.M304766200	http://dx.doi.org/10.1074/jbc.M304766200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12860988	hybrid			2022-12-27	WOS:000185713800068
J	Sanchez-Pacheco, A; Aranda, A				Sanchez-Pacheco, A; Aranda, A			Binding of the thyroid hormone receptor to a negative element in the basal growth hormone promoter is associated with histone acetylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BOX; TRANSCRIPTIONAL ACTIVATION; LIGAND-BINDING; N-COR; GENE; REPRESSION; DEACETYLASE; BETA; TRANSACTIVATION; COREPRESSORS	Nuclear thyroid hormone receptors (TRs) act as ligand-dependent activators, but paradoxically unliganded TRs can increase transcription of promoters containing negative response elements (nTRE), and hormone binding represses this activation. The rat growth hormone (GH) promoter contains a positive TRE and a nTRE. Ligand-dependent negative regulation mediated by the nTRE could play an important physiological role in restricting GH gene expression in non-pituitary cells that express TRs. With chromatin immunoprecipitation assays, we show here that the nTRE is responsible for binding of TR to the promoter in non-pituitary HeLa cells and that this element also governs transactivation by the unoccupied receptor and repression by triiodothyronine. Occupancy of the promoter by TR is concomitant with appearance of acetylated histone H3, and triiodothyronine causes release of the receptor as well as disappearance of the acetylated histone from the promoter. Although the nTRE overlaps the TATA box, the receptor does not exclude binding of TATA-binding protein, but could rather facilitate formation of the preinitiation complex. Furthermore, the proximal GH promoter is synergistically stimulated by unliganded TR and TATA-binding protein, whereas the ligand represses this cooperation. Constitutive receptor activity and synergism with TATA-binding protein require binding of corepressors. Furthermore, inhibitors of histone deacetylases enhance promoter activation by the unliganded receptor and reduce triiodothyronine-dependent repression, whereas expression of HDAC1 reverses promoter stimulation. This suggests that partitioning of histone acetylases and deacetylases between the receptors and basal transcription factors could be involved in regulation of the basal GH promoter by TRs.	CSIC, Inst Invest Biomed Alberto Sols, Madrid 28029, Spain; Univ Autonoma Madrid, Madrid 28029, Spain	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid	Aranda, A (corresponding author), CSIC, Inst Invest Biomed Alberto Sols, Arturo Duperier 4, Madrid 28029, Spain.	aaranda@iib.uam.es	Aranda, Ana/ABG-8820-2020	Aranda, Ana/0000-0002-8338-9589; Sanchez Pacheco, Aurora/0000-0002-7776-2594				Alland L, 1997, NATURE, V387, P49, DOI 10.1038/387049a0; Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; Beato M, 1996, ENDOCR REV, V17, P587, DOI 10.1210/er.17.6.587; BEDO G, 1989, NATURE, V339, P231, DOI 10.1038/339231a0; BERKENSTAM A, 1992, CELL, V69, P401, DOI 10.1016/0092-8674(92)90443-G; BIGLER J, 1995, EMBO J, V14, P5710, DOI 10.1002/j.1460-2075.1995.tb00258.x; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CRONE DE, 1990, J BIOL CHEM, V265, P10851; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Fondell JD, 1996, MOL CELL BIOL, V16, P281; GarciaVillalba P, 1997, DNA CELL BIOL, V16, P421, DOI 10.1089/dna.1997.16.421; GLASS CK, 1987, NATURE, V329, P738, DOI 10.1038/329738a0; Glass CK, 2000, GENE DEV, V14, P121; HADZIC E, 1995, MOL CELL BIOL, V15, P4507; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; Heinzel T, 1997, NATURE, V387, P43, DOI 10.1038/387043a0; Helmer EB, 1996, ENDOCRINOLOGY, V137, P390, DOI 10.1210/en.137.2.390; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Huang EY, 2000, GENE DEV, V14, P45; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kao HY, 2000, GENE DEV, V14, P55; Kim MK, 1999, P NATL ACAD SCI USA, V96, P10092, DOI 10.1073/pnas.96.18.10092; Kim RH, 1996, BIOCHEM J, V318, P219, DOI 10.1042/bj3180219; KRETZSCHMAR M, 1994, MOL CELL BIOL, V14, P3927, DOI 10.1128/MCB.14.6.3927; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Mendez-Pertuz M, 2003, EMBO J, V22, P3102, DOI 10.1093/emboj/cdg295; Meyer T, 1997, DNA CELL BIOL, V16, P919, DOI 10.1089/dna.1997.16.919; Meyer T, 1997, J BIOL CHEM, V272, P30709, DOI 10.1074/jbc.272.49.30709; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nagy L, 1997, CELL, V89, P373, DOI 10.1016/S0092-8674(00)80218-4; Palomino T, 1998, FASEB J, V12, P1201, DOI 10.1096/fasebj.12.12.1201; Palomino T, 1998, J BIOL CHEM, V273, P27541, DOI 10.1074/jbc.273.42.27541; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; Pissios P, 2000, MOL CELL, V6, P245, DOI 10.1016/S1097-2765(00)00026-5; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SANCHEZPACHECO A, 1995, MOL CELL BIOL, V15, P6322; Sasaki S, 1999, EMBO J, V18, P5389, DOI 10.1093/emboj/18.19.5389; Shibusawa N, 2003, J BIOL CHEM, V278, P732, DOI 10.1074/jbc.M207264200; Tagami T, 1997, MOL CELL BIOL, V17, P2642, DOI 10.1128/MCB.17.5.2642; Tagami T, 1999, J BIOL CHEM, V274, P22345, DOI 10.1074/jbc.274.32.22345; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0	51	14	14	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39383	39391		10.1074/jbc.M306988200	http://dx.doi.org/10.1074/jbc.M306988200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878587	hybrid			2022-12-27	WOS:000185713800015
J	Baardsnes, J; Kuiper, MJ; Davies, PL				Baardsnes, J; Kuiper, MJ; Davies, PL			Antifreeze protein dimer - When two ice-binding faces are better than one	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							III ANTIFREEZE; THERMAL HYSTERESIS; GROWTH-INHIBITION; STRUCTURAL BASIS; SURFACE; FISHES; IDENTIFICATION; MECHANISMS; ADSORPTION; RESIDUES	A naturally occurring tandem duplication of the 7-kDa type III antifreeze protein from Antarctic eel pout (Lycodichthys dearborni) is twice as active as the monomer in depressing the freezing point of a solution. We have investigated the basis for this enhanced activity by producing recombinant analogues of the linked dimer that assess the effects of protein size and the number and area of the ice-binding site(s). The recombinant dimer connected by a peptide linker had twice the activity of the monomer. When one of the two ice-binding sites was inactivated by site-directed mutagenesis, the linked dimer was only 1.2 times more effective than the monomer. When the two monomers were linked through a C-terminal disulfide bond in such a way that their two ice-binding sites were opposite each other and unable to engage the same ice surface simultaneously, the dimer was again only 1.2 times as active as the monomer. We conclude from these analyses that the enhanced activity of the dimer stems from the two ice-binding sites being able to engage to ice at the same time, effectively doubling the area of the ice-binding site.	Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada	Queens University - Canada	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.							Antson AA, 2001, J MOL BIOL, V305, P875, DOI 10.1006/jmbi.2000.4336; Baardsnes J, 1999, FEBS LETT, V463, P87, DOI 10.1016/S0014-5793(99)01588-4; Baardsnes J, 2002, BBA-PROTEINS PROTEOM, V1601, P49, DOI 10.1016/S1570-9639(02)00431-4; CHAKRABARTTY A, 1991, EUR J BIOCHEM, V202, P1057, DOI 10.1111/j.1432-1033.1991.tb16470.x; Chao H, 1996, PROTEIN SCI, V5, P1150; CHAO H, 1993, PROTEIN SCI, V2, P1411, DOI 10.1002/pro.5560020906; CHAO H, 1994, PROTEIN SCI, V3, P1760, DOI 10.1002/pro.5560031016; Chen GJ, 1999, BIOPHYS J, V77, P1602, DOI 10.1016/S0006-3495(99)77008-6; Cheng C.C., 1991, P1; Davies PL, 1997, CURR OPIN STRUC BIOL, V7, P828, DOI 10.1016/S0959-440X(97)80154-6; DeLuca CI, 1998, BIOPHYS J, V74, P1502, DOI 10.1016/S0006-3495(98)77862-2; DeLuca CI, 1996, BIOPHYS J, V71, P2346, DOI 10.1016/S0006-3495(96)79476-6; DEVRIES AL, 1982, COMP BIOCHEM PHYS A, V73, P627, DOI 10.1016/0300-9629(82)90270-5; DEVRIES AL, 1983, ANNU REV PHYSIOL, V45, P245, DOI 10.1146/annurev.ph.45.030183.001333; Ewart KV, 1999, CELL MOL LIFE SCI, V55, P271, DOI 10.1007/s000180050289; Fletcher GL, 2001, ANNU REV PHYSIOL, V63, P359, DOI 10.1146/annurev.physiol.63.1.359; Graether SP, 1999, J BIOL CHEM, V274, P11842, DOI 10.1074/jbc.274.17.11842; GRIFFITH M, 1995, BIOTECHNOL ADV, V13, P375, DOI 10.1016/0734-9750(95)02001-J; Harding MM, 1999, EUR J BIOCHEM, V264, P653, DOI 10.1046/j.1432-1327.1999.00617.x; Jia ZC, 1996, NATURE, V384, P285, DOI 10.1038/384285a0; JIA ZC, 1995, PROTEIN SCI, V4, P1236, DOI 10.1002/pro.5560040621; KNIGHT CA, 1991, BIOPHYS J, V59, P409, DOI 10.1016/S0006-3495(91)82234-2; Ko TP, 2003, BIOPHYS J, V84, P1228, DOI 10.1016/S0006-3495(03)74938-8; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leinala EK, 2002, J BIOL CHEM, V277, P33349, DOI 10.1074/jbc.M205575200; Miura K, 2001, J BIOL CHEM, V276, P1304, DOI 10.1074/jbc.M007902200; Nishimiya Y, 2003, J BIOL CHEM, V278, P32307, DOI 10.1074/jbc.M304390200; RAYMOND JA, 1977, P NATL ACAD SCI USA, V74, P2589, DOI 10.1073/pnas.74.6.2589; Sambrook J., 2002, MOL CLONING LAB MANU; Sonnichsen FD, 1996, STRUCTURE, V4, P1325, DOI 10.1016/S0969-2126(96)00140-2; WANG X, 1995, BBA-PROTEIN STRUCT M, V1247, P163, DOI 10.1016/0167-4838(94)00205-U; WILSON PW, 1993, CRYO-LETT, V14, P31; Yang DSC, 1998, BIOPHYS J, V74, P2142, DOI 10.1016/S0006-3495(98)77923-8; Yeh Y, 1996, CHEM REV, V96, P601, DOI 10.1021/cr950260c; Zachariassen KE, 1999, BIOTECHNOLOGICAL APPLICATIONS OF COLD-ADAPTED ORGANISMS, P319	36	41	51	0	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38942	38947		10.1074/jbc.M306776200	http://dx.doi.org/10.1074/jbc.M306776200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869550	hybrid			2022-12-27	WOS:000185575100104
J	De, S; Chen, JH; Narizhneva, NV; Heston, W; Brainard, J; Sage, EH; Byzova, TV				De, S; Chen, JH; Narizhneva, NV; Heston, W; Brainard, J; Sage, EH; Byzova, TV			Molecular pathway for cancer metastasis to bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; HUMAN PROSTATE-CANCER; IN-VITRO EXPRESSION; CELL-MIGRATION; TUMOR-CELLS; FACTOR VEGF; INTEGRIN; ADHESION; ANGIOGENESIS; PROGRESSION	The molecular mechanism leading to the cancer metastasis to bone is poorly understood but yet determines prognosis and therapy. Here, we define a new molecular pathway that may account for the extraordinarily high osteotropism of prostate cancer. By using SPARC (secreted protein, acidic and rich in cysteine)-deficient mice and recombinant SPARC, we demonstrated that SPARC selectively supports the migration of highly metastatic relative to less metastatic prostate cancer cell lines to bone. Increased migration to SPARC can be traced to the activation of integrins alphaVbeta3 and alphaVbeta5 on tumor cells. Such activation is induced by an autocrine vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR)-2 loop on the tumor cells, which also supports the growth and proliferation of prostate cancer cells. A consequence of SPARC recognition by alphaVbeta5 is enhanced VEGF production. Thus, prostate cancer cells expressing VEGF/VEGFR-2 will activate alphaVbeta3 and alphaVbeta5 on their surface and use these integrins to migrate toward SPARC in bone. Within the bone environment, SPARC engagement of these integrins will stimulate growth of the tumor and further production of VEGF to support neoangiogenesis, thereby favoring the development of the metastatic tumor. Supporting this model, activated integrins were found to colocalize with VEGFR-2 in tissue samples of metastatic prostate tumors from patients.	Cleveland Clin Fdn, Taussig Canc Ctr, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Taussig Canc Ctr, Dept Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Canc Biol, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Pathol, Cleveland, OH 44195 USA; Hope Heart Inst, Seattle, WA 98122 USA	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation	Byzova, TV (corresponding author), Cleveland Clin Fdn, Taussig Canc Ctr, Dept Mol Cardiol, Joseph J Jacobs Ctr Thrombosis & Vasc Biol, NB50,9500 Euclid Ave, Cleveland, OH 44195 USA.	byzovat@ccf.org		Byzova, Tatiana/0000-0002-2615-875X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060933] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040711] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK60933, R01 DK060933] Funding Source: Medline; NIGMS NIH HHS [R01 GM040711, GM40711] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bazzoni G, 1998, TRENDS BIOCHEM SCI, V23, P30, DOI 10.1016/S0968-0004(97)01141-9; Bradshaw Amy D., 2000, Molecular Cell Biology Research Communications, V3, P345, DOI 10.1006/mcbr.2000.0237; Brekken Rolf A., 2001, Matrix Biology, V19, P816; Byzova TV, 2002, BLOOD, V99, P4434, DOI 10.1182/blood.V99.12.4434; Byzova TV, 2000, EXP CELL RES, V254, P299, DOI 10.1006/excr.1999.4765; Byzova TV, 2000, MOL CELL, V6, P851, DOI 10.1016/S1097-2765(05)00076-6; Delany AM, 2000, J CLIN INVEST, V105, P915, DOI 10.1172/JCI7039; Edlund M, 2001, CELL GROWTH DIFFER, V12, P99; Ferrer FA, 1999, UROLOGY, V54, P567, DOI 10.1016/S0090-4295(99)00156-9; Ferrer FA, 1998, UROLOGY, V51, P161, DOI 10.1016/S0090-4295(97)00491-3; Ferrer FA, 1997, J UROLOGY, V157, P2329, DOI 10.1016/S0022-5347(01)64775-X; Fontana A., 2000, Cancer, V88, P2952, DOI 10.1002/1097-0142(20000615)88:12+<2952::AID-CNCR11>3.0.CO;2-M; Gardiner EE, 1997, J BIOL CHEM, V272, P15474, DOI 10.1074/jbc.272.24.15474; Gerber HP, 1999, NAT MED, V5, P623, DOI 10.1038/9467; Jacob K, 1999, CANCER RES, V59, P4453; Jones A, 2000, BJU INT, V85, P276, DOI 10.1046/j.1464-410x.2000.00432.x; LANE TF, 1994, FASEB J, V8, P163, DOI 10.1096/fasebj.8.2.8119487; Lang SH, 1997, CLIN EXP METASTAS, V15, P218, DOI 10.1023/A:1018465213641; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Masood R, 2001, BLOOD, V98, P1904, DOI 10.1182/blood.V98.6.1904; McHugh KP, 2000, J CLIN INVEST, V105, P433, DOI 10.1172/JCI8905; Pampori N, 1999, J BIOL CHEM, V274, P21609, DOI 10.1074/jbc.274.31.21609; Pecheur I, 2002, FASEB J, V16, P1266, DOI 10.1096/fj.01-0911fje; ROKHLIN OW, 1995, PROSTATE, V26, P205, DOI 10.1002/pros.2990260406; Sage EH, 1999, J HISTOCHEM CYTOCHEM, V47, P1643; Salih MA, 1999, MOL CELL ENDOCRINOL, V147, P149, DOI 10.1016/S0303-7207(98)00206-8; Smit JWA, 1998, THYROID, V8, P29, DOI 10.1089/thy.1998.8.29; Soker S, 2001, AM J PATHOL, V159, P651, DOI 10.1016/S0002-9440(10)61736-1; Sokoloff MH, 1998, CANCER METAST REV, V17, P307, DOI 10.1023/A:1006170612253; THALMANN GN, 1994, CANCER RES, V54, P2577; Thalmann GN, 2000, PROSTATE, V44, P91; Thalmann GN, 1999, CLIN CANCER RES, V5, P2271; vanderPluijm G, 1996, CANCER RES, V56, P1948; Varner JA, 1996, CURR OPIN CELL BIOL, V8, P724, DOI 10.1016/S0955-0674(96)80115-3; WEIDNER N, 1993, AM J PATHOL, V143, P401; Zheng DQ, 1999, CANCER RES, V59, P1655; Zheng DQ, 2000, J BIOL CHEM, V275, P24565, DOI 10.1074/jbc.M002646200	37	122	127	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39044	39050		10.1074/jbc.M304494200	http://dx.doi.org/10.1074/jbc.M304494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885781	Green Accepted, hybrid			2022-12-27	WOS:000185575100117
J	Leverrier, Y; Okkenhaug, K; Sawyer, C; Bilancio, A; Vanhaesebroeck, B; Ridley, AJ				Leverrier, Y; Okkenhaug, K; Sawyer, C; Bilancio, A; Vanhaesebroeck, B; Ridley, AJ			Class I phosphoinositide 3-kinase p110 beta is required for apoptotic cell and Fc gamma receptor-mediated phagocytosis by macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMPAIRED B-CELL; PHOSPHATIDYLINOSITOL 3-KINASE; EMBRYONIC LETHALITY; DNA-SYNTHESIS; PI 3-KINASE; RHO GTPASES; T-CELLS; ACTIVATION; SUBUNIT; MICE	Phosphoinositide 3-kinases (PI3Ks) play an important role in a variety of cellular functions, including phagocytosis. PI3Ks are activated during phagocytosis induced by several receptors and have been shown to be required for phagocytosis through the use of inhibitors such as wortmannin and LY294002. Mammalian cells have multiple isoforms of PI3K, and the role of the individual isoforms during phagocytosis has not been addressed. The class I PI3Ks consist of a catalytic p110 isoform associated with a regulatory subunit. Mammals have three genes for the class IA p110 subunits encoding p110alpha, p110beta, and p110delta and one gene for the class IB p110 subunit encoding p110gamma. Here we report a specific recruitment of p110beta and p110delta (but not p110alpha) isoforms to the nascent phagosome during apoptotic cell phagocytosis by fibroblasts. By microinjecting inhibitory antibodies specific to class IA p110 subunits, we have shown that p110beta is the major isoform required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by primary mouse macrophages. Macrophages from mice expressing a catalytically inactive form of p110delta showed no defect in the phagocytosis of apoptotic cells and IgG-opsonized particles, confirming the lack of a major role for p110delta in this process. Similarly, p110gamma-deficient macrophages phagocytosed apoptotic cells normally. Our findings demonstrate that p110beta is the major class I catalytic isoform required for apoptotic cell and Fcgamma receptor-mediated phagocytosis by primary macrophages.	Ludwig Inst Canc Res, Royal Free & Univ Coll Med Sch Branch, London W1W 7BS, England; UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England	Ludwig Institute for Cancer Research; University of London; University College London; University of London; University College London	Ridley, AJ (corresponding author), Ludwig Inst Canc Res, Royal Free & Univ Coll Med Sch Branch, 91 Riding House St, London W1W 7BS, England.	anne@ludwig.ucl.ac.uk	Okkenhaug, Klaus/H-3154-2019; Okkenhaug, Klaus/D-5149-2012; LEVERRIER, Yann/M-3767-2014	Okkenhaug, Klaus/0000-0002-9432-4051; Okkenhaug, Klaus/0000-0002-9432-4051; LEVERRIER, Yann/0000-0002-4227-5446; Ridley, Anne/0000-0001-8186-5708; BILANCIO, Antonio/0000-0002-5118-3359; Box, Carol/0000-0002-8919-8724				Albert ML, 2001, NAT IMMUNOL, V2, P1010, DOI 10.1038/ni722; Araki N, 1996, J CELL BIOL, V135, P1249, DOI 10.1083/jcb.135.5.1249; Benistant C, 2000, ONCOGENE, V19, P5083, DOI 10.1038/sj.onc.1203871; Bi L, 1999, J BIOL CHEM, V274, P10963, DOI 10.1074/jbc.274.16.10963; Bi L, 2002, MAMM GENOME, V13, P169, DOI 10.1007/s00335-001-2123-x; Booth JW, 2001, SEMIN IMMUNOL, V13, P357, DOI 10.1006/smim.2001.0332; Caron E, 1998, SCIENCE, V282, P1717, DOI 10.1126/science.282.5394.1717; Cox D, 1999, J BIOL CHEM, V274, P1240, DOI 10.1074/jbc.274.3.1240; Cox D, 2001, J EXP MED, V193, P61, DOI 10.1084/jem.193.1.61; Cox D, 2002, NAT CELL BIOL, V4, P469, DOI 10.1038/ncb805; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Ellson CD, 2001, CURR BIOL, V11, P1631, DOI 10.1016/S0960-9822(01)00447-X; FADOK VA, 1992, J IMMUNOL, V149, P4029; Fadok VA, 1998, J CLIN INVEST, V101, P890, DOI 10.1172/JCI1112; Fruman DA, 1999, SCIENCE, V283, P393, DOI 10.1126/science.283.5400.393; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Henson PM, 2001, CURR BIOL, V11, pR795, DOI 10.1016/S0960-9822(01)00474-2; Hill KM, 2001, J BIOL CHEM, V276, P16374, DOI 10.1074/jbc.M006985200; Hirsch E, 2000, SCIENCE, V287, P1049, DOI 10.1126/science.287.5455.1049; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hooshmand-Rad R, 2000, J CELL SCI, V113, P207; Hu B, 2002, J LEUKOCYTE BIOL, V71, P881; Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615; Kurosu H, 2001, J BIOCHEM-TOKYO, V130, P73, DOI 10.1093/oxfordjournals.jbchem.a002964; Leverrier Y, 2001, J IMMUNOL, V166, P4831, DOI 10.4049/jimmunol.166.8.4831; Leverrier Y, 2001, CURR BIOL, V11, P195, DOI 10.1016/S0960-9822(01)00047-1; Leverrier Y, 1997, ONCOGENE, V14, P425, DOI 10.1038/sj.onc.1200845; Lu-Kuo JM, 2000, J BIOL CHEM, V275, P6022, DOI 10.1074/jbc.275.8.6022; Marshall JG, 2001, J CELL BIOL, V153, P1369, DOI 10.1083/jcb.153.7.1369; Nielsen E, 1999, NAT CELL BIOL, V1, P376, DOI 10.1038/14075; Okkenhaug K, 2002, SCIENCE, V297, P1031; Platt N, 1998, TRENDS CELL BIOL, V8, P365, DOI 10.1016/S0962-8924(98)01329-4; Roberts RL, 2000, J LEUKOCYTE BIOL, V68, P627; ROCHE S, 1994, P NATL ACAD SCI USA, V91, P9185, DOI 10.1073/pnas.91.19.9185; RODRIGUEZTARDUCHY G, 1990, EMBO J, V9, P2997, DOI 10.1002/j.1460-2075.1990.tb07492.x; Sasaki T, 2000, SCIENCE, V287, P1040, DOI 10.1126/science.287.5455.1040; Sawyer C, 2003, CANCER RES, V63, P1667; Stein RC, 2000, MOL MED TODAY, V6, P347, DOI 10.1016/S1357-4310(00)01770-6; Swanson JA, 1999, J CELL SCI, V112, P307; Vanhaesebroeck B, 2001, ANNU REV BIOCHEM, V70, P535, DOI 10.1146/annurev.biochem.70.1.535; Vanhaesebroeck B, 1999, NAT CELL BIOL, V1, P69, DOI 10.1038/9045; Vanhaesebroeck B, 1997, P NATL ACAD SCI USA, V94, P4330, DOI 10.1073/pnas.94.9.4330; Vieira OV, 2001, J CELL BIOL, V155, P19, DOI 10.1083/jcb.200107069; Zhang J, 1998, J BIOL CHEM, V273, P14081, DOI 10.1074/jbc.273.23.14081	45	76	78	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38437	38442		10.1074/jbc.M306649200	http://dx.doi.org/10.1074/jbc.M306649200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869549	hybrid			2022-12-27	WOS:000185575100044
J	Chun, ACS; Jin, DY				Chun, ACS; Jin, DY			Transcriptional regulation of mitotic checkpoint gene MAD1 by p53	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; HUMAN HEPATOCELLULAR-CARCINOMA; HISTONE DEACETYLASE ACTIVITY; REPRESSION IN-VIVO; SPINDLE CHECKPOINT; CELL-CYCLE; MUTANT P53; MAMMALIAN-CELLS; DNA-BINDING; KINETOCHORE LOCALIZATION	p53 regulates a number of genes through transcriptional activation and repression. p53-dependent mitotic checkpoint has been described, but the underlying mechanism is still obscure. Here we examined the effect of p53 on the expression of a human mitotic checkpoint protein, Mitosis Arrest Deficiency 1 (MAD1), in cultured human cells. The expression of MAD1 was reduced when the cells were overexpressing exogenously introduced wild-type p53. The same reduction was also observed when the cells were treated with anticancer agents 5-fluorouracil and cisplatin or were irradiated with UV. Consistently, MAD1 promoter activity diminished in a dose-dependent manner when induced by p53, indicating that p53 repressed MAD1 at a transcriptional level. Intriguingly, several tumor hot spot mutations in p53 (V143A, R175H, R248W, and R273H) did not abolish the ability of p53 to repress MAD1 expression. By serial truncation of the MAD1 promoter, we confined the p53-responsive element to a 38-bp region that represents a novel sequence distinct from the known p53 consensus binding site. Trichostatin A, a histone deacetylase inhibitor, relieved the p53 transrepression activity on MAD1. Chromatin immunoprecipitation assay revealed that p53, histone deacetylase 1, and co-repressor mSin3a associated with the MAD1 promoter in vivo. Taken together, our findings suggest a regulatory mechanism for the mitotic checkpoint in which MAD1 is inhibited by p53.	Univ Hong Kong, Dept Biochem, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Jin, DY (corresponding author), Univ Hong Kong, Dept Biochem, 3rd Floor,Lab Block,Fac Med Bldg,21 Sassoon Rd, Hong Kong, Hong Kong, Peoples R China.				FOGARTY INTERNATIONAL CENTER [R01TW006186] Funding Source: NIH RePORTER; FIC NIH HHS [D43 TW06186] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))		Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; Barlev NA, 2001, MOL CELL, V8, P1243, DOI 10.1016/S1097-2765(01)00414-2; Blattner C, 1999, ONCOGENE, V18, P1723, DOI 10.1038/sj.onc.1202480; BRESSAC B, 1990, P NATL ACAD SCI USA, V87, P1973, DOI 10.1073/pnas.87.5.1973; Bullock AN, 2001, NAT REV CANCER, V1, P68, DOI 10.1038/35094077; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Campbell MS, 2001, J CELL SCI, V114, P953; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Chung EN, 2002, MOL BIOL CELL, V13, P1501, DOI 10.1091/mbc.02-01-0003; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; FARSHID M, 1992, J MED VIROL, V38, P235, DOI 10.1002/jmv.1890380402; FUNK WD, 1992, MOL CELL BIOL, V12, P2866, DOI 10.1128/MCB.12.6.2866; GINSBERG D, 1991, P NATL ACAD SCI USA, V88, P9979, DOI 10.1073/pnas.88.22.9979; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; Gualberto A, 1998, P NATL ACAD SCI USA, V95, P5166, DOI 10.1073/pnas.95.9.5166; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Haugwitz U, 2002, NUCLEIC ACIDS RES, V30, P1967, DOI 10.1093/nar/30.9.1967; Haupt Ygal, 2002, Oncogene, V21, P8223, DOI 10.1038/sj.onc.1206137; HINDS PW, 1990, CELL GROWTH DIFFER, V1, P571; Hoffman WH, 2002, J BIOL CHEM, V277, P3247, DOI 10.1074/jbc.M106643200; Hong TM, 2001, J BIOL CHEM, V276, P1510, DOI 10.1074/jbc.M008231200; Howell BJ, 2000, J CELL BIOL, V150, P1233, DOI 10.1083/jcb.150.6.1233; Ikui AE, 2002, J CELL SCI, V115, P1603; Innocente SA, 1999, P NATL ACAD SCI USA, V96, P2147, DOI 10.1073/pnas.96.5.2147; Iouk T, 2002, J CELL BIOL, V159, P807, DOI 10.1083/jcb.200205068; Iwanaga Y, 2002, J BIOL CHEM, V277, P31005, DOI 10.1074/jbc.M110666200; Iwanaga Y, 2002, CANCER RES, V62, P2618; Jin DY, 1997, J BIOL CHEM, V272, P30952, DOI 10.1074/jbc.272.49.30952; Jin DY, 1998, CELL, V93, P81, DOI 10.1016/S0092-8674(00)81148-4; Johnson CA, 2002, J BIOL CHEM, V277, P9590, DOI 10.1074/jbc.M107942200; Johnson RA, 2001, J BIOL CHEM, V276, P27716, DOI 10.1074/jbc.C100121200; Kadosh D, 1998, GENE DEV, V12, P797, DOI 10.1101/gad.12.6.797; Kallio MJ, 2002, J CELL BIOL, V158, P841, DOI 10.1083/jcb.200201135; KERN SE, 1992, SCIENCE, V256, P827, DOI 10.1126/science.1589764; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Krause K, 2001, BIOCHEM BIOPH RES CO, V284, P743, DOI 10.1006/bbrc.2001.5040; Laherty CD, 1997, CELL, V89, P349, DOI 10.1016/S0092-8674(00)80215-9; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Lee KC, 1999, MOL CELL BIOL, V19, P1279; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Liu L, 1999, MOL CELL BIOL, V19, P1202; Luo XL, 2002, MOL CELL, V9, P59, DOI 10.1016/S1097-2765(01)00435-X; McKay BC, 2001, ONCOGENE, V20, P6805, DOI 10.1038/sj.onc.1204901; Michel LS, 2001, NATURE, V409, P355, DOI 10.1038/35053094; Minn AJ, 1996, GENE DEV, V10, P2621, DOI 10.1101/gad.10.20.2621; Mirza A, 2002, ONCOGENE, V21, P2613, DOI 10.1038/sj.onc.1205353; Morris VB, 2000, EXP CELL RES, V256, P122, DOI 10.1006/excr.2000.4800; Murphy M, 1999, GENE DEV, V13, P2490, DOI 10.1101/gad.13.19.2490; Musacchio A, 2002, NAT REV MOL CELL BIO, V3, P731, DOI 10.1038/nrm929; Patino WD, 2002, CIRC RES, V91, P565, DOI 10.1161/01.RES.0000036018.76903.18; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Poon RYC, 1996, J BIOL CHEM, V271, P13283, DOI 10.1074/jbc.271.22.13283; Prives C, 2001, CELL, V107, P815, DOI 10.1016/S0092-8674(01)00619-5; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; RAGIMOV N, 1993, ONCOGENE, V8, P1183; Rayman JB, 2002, GENE DEV, V16, P933, DOI 10.1101/gad.969202; RODRIGUES NR, 1990, P NATL ACAD SCI USA, V87, P7555, DOI 10.1073/pnas.87.19.7555; Roperch JP, 1998, NAT MED, V4, P835, DOI 10.1038/nm0798-835; SANTHANAM U, 1991, P NATL ACAD SCI USA, V88, P7605, DOI 10.1073/pnas.88.17.7605; Sharp-Baker H, 2001, J CELL BIOL, V153, P1239, DOI 10.1083/jcb.153.6.1239; SIMON D, 1985, CYTOGENET CELL GENET, V39, P116, DOI 10.1159/000132118; Sironi L, 2002, EMBO J, V21, P2496, DOI 10.1093/emboj/21.10.2496; Stahler F, 1998, ONCOGENE, V17, P3507, DOI 10.1038/sj.onc.1202245; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun YB, 2000, J BIOL CHEM, V275, P11327, DOI 10.1074/jbc.275.15.11327; Szak ST, 2001, MOL CELL BIOL, V21, P3375, DOI 10.1128/MCB.21.10.3375-3386.2001; Taylor SS, 1998, J CELL BIOL, V142, P1, DOI 10.1083/jcb.142.1.1; Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252; TOKINO T, 1994, HUM MOL GENET, V3, P1537, DOI 10.1093/hmg/3.9.1537; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wang XH, 2002, CANCER RES, V62, P1662; Wang XH, 2003, ONCOGENE, V22, P109, DOI 10.1038/sj.onc.1206069; Wassmann K, 2001, CURR OPIN GENET DEV, V11, P83, DOI 10.1016/S0959-437X(00)00161-1; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; Wu YL, 2001, ONCOGENE, V20, P240, DOI 10.1038/sj.onc.1204067; Xu DW, 2000, ONCOGENE, V19, P5123, DOI 10.1038/sj.onc.1203890; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; Yoshikawa R, 2001, CANCER RES, V61, P1029; Yun J, 1999, J BIOL CHEM, V274, P29677, DOI 10.1074/jbc.274.42.29677; Zhang Y, 2002, J BIOL CHEM, V277, P33431, DOI 10.1074/jbc.M204417200; Zhou HJ, 2001, J BIOL CHEM, V276, P28933, DOI 10.1074/jbc.M103893200; Zilfou JT, 2001, MOL CELL BIOL, V21, P3974, DOI 10.1128/MCB.21.12.3974-3985.2001; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	93	49	52	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37439	37450		10.1074/jbc.M307185200	http://dx.doi.org/10.1074/jbc.M307185200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12876282	hybrid			2022-12-27	WOS:000185437200056
J	Murray, J; Taylor, SW; Zhang, B; Ghosh, SS; Capaldi, RA				Murray, J; Taylor, SW; Zhang, B; Ghosh, SS; Capaldi, RA			Oxidative damage to mitochondrial complex I due to peroxynitrite - Identification of reactive tyrosines by mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADH-UBIQUINONE OXIDOREDUCTASE; NITRIC-OXIDE; PROTEIN IDENTIFICATION; PERSISTENT INHIBITION; SELECTIVE NITRATION; SUBUNIT COMPOSITION; BRAIN MITOCHONDRIA; HYDROGEN-PEROXIDE; SUBSTANTIA-NIGRA; GLUTATHIONE	There is growing evidence that oxidative phosphorylation (OXPHOS) generates reactive oxygen and nitrogen species within mitochondria as unwanted byproducts that can damage OXPHOS enzymes with subsequent enhancement of free radical production. The accumulation of this oxidative damage to mitochondria in brain is thought to lead to neuronal cell death resulting in neurodegeneration. The predominant reactive nitrogen species in mitochondria are nitric oxide and peroxynitrite. Here we show that peroxynitrite reacts with mitochondrial membranes from bovine heart to significantly inhibit the activities of complexes I, II, and V ( 50 - 80%) but with less effect upon complex IV and no significant inhibition of complex III. Because inhibition of complex I activity has been a reported feature of Parkinson's disease, we undertook a detailed analysis of peroxynitrite-induced modifications to proteins from an enriched complex I preparation. Immunological and mass spectrometric approaches coupled with two-dimensional PAGE have been used to show that peroxynitrite modification resulting in a 3-nitrotyrosine signature is predominantly associated with the complex I subunits, 49-kDa subunit (NDUFS2), TYKY (NDUFS8), B17.2 ( 17.2-kDa differentiation associated protein), B15 (NDUFB4), and B14 (NDUFA6). Nitration sites and estimates of modification yields were deduced from MS/MS fragmentograms and extracted ion chromatograms, respectively, for the last three of these subunits as well as for two co-purifying proteins, the beta and the d subunits of the F1F0-ATP synthase. Subunits B15 ( NDUFB4) and B14 ( NDUFA6) contained the highest degree of nitration. The most reactive site in subunit B14 was Tyr(122), while the most reactive region in B15 contained 3 closely spaced tyrosines Tyr(46), Tyr(50), and Tyr(51). In addition, a site of oxidation of tryptophan was detected in subunit B17.2 adding to the number of post-translationally modified tryptophans we have detected in complex I subunits ( Taylor, S. W., Fahy, E., Murray, J., Capaldi, R. A., and Ghosh, S. S. (2003) J. Biol. Chem. 278, 19587 - 19590). These sites of oxidation and nitration may be useful biomarkers for assessing oxidative stress in neurodegenerative disorders.	Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA; MitoKor, San Diego, CA 92121 USA	University of Oregon	Capaldi, RA (corresponding author), Univ Oregon, Dept Mol Biol, Eugene, OR 97403 USA.	rcapaldi@oregon.uoregon.edu						Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834; BIEMANN K, 1990, METHOD ENZYMOL, V193, P455, DOI 10.1016/0076-6879(90)93433-L; Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4; Borutaite V, 2000, BBA-BIOENERGETICS, V1459, P405, DOI 10.1016/S0005-2728(00)00178-X; BOVERIS A, 1973, BIOCHEM J, V134, P707, DOI 10.1042/bj1340707; Brookes PS, 1998, J NEUROCHEM, V70, P2195; BROWN GC, 1995, FEBS LETT, V369, P136, DOI 10.1016/0014-5793(95)00763-Y; Byun J, 1999, BIOCHEMISTRY-US, V38, P2590, DOI 10.1021/bi9822980; Carroll J, 2003, MOL CELL PROTEOMICS, V2, P117, DOI 10.1074/mcp.M300014-MCP200; Carroll J, 2002, J BIOL CHEM, V277, P50311, DOI 10.1074/jbc.M209166200; Clauser KR, 1999, ANAL CHEM, V71, P2871, DOI 10.1021/ac9810516; Clementi E, 1998, P NATL ACAD SCI USA, V95, P7631, DOI 10.1073/pnas.95.13.7631; Davey GP, 1998, J BIOL CHEM, V273, P12753, DOI 10.1074/jbc.273.21.12753; Ducret A, 1998, PROTEIN SCI, V7, P706, DOI 10.1002/pro.5560070320; Elfering SL, 2002, J BIOL CHEM, V277, P38079, DOI 10.1074/jbc.M205256200; Ferrante RJ, 1999, BRAIN RES, V823, P177, DOI 10.1016/S0006-8993(99)01166-X; Field HI, 2002, PROTEOMICS, V2, P36, DOI 10.1002/1615-9861(200201)2:1<36::AID-PROT36>3.0.CO;2-W; FINEL M, 1994, EUR J BIOCHEM, V226, P237, DOI 10.1111/j.1432-1033.1994.tb20046.x; Gatlin CL, 1998, ANAL BIOCHEM, V263, P93, DOI 10.1006/abio.1998.2809; Ghafourifar P, 1997, FEBS LETT, V418, P291, DOI 10.1016/S0014-5793(97)01397-5; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Hanson BJ, 2001, ELECTROPHORESIS, V22, P950, DOI 10.1002/1522-2683()22:5<950::AID-ELPS950>3.0.CO;2-D; Heales SJR, 2002, NEUROCHEM INT, V40, P469, DOI 10.1016/S0197-0186(01)00117-6; HEIKKILA RE, 1984, NATURE, V311, P467, DOI 10.1038/311467a0; Jenner P, 2003, ANN NEUROL, V53, pS26, DOI 10.1002/ana.10483; Jha N, 2000, J BIOL CHEM, V275, P26096, DOI 10.1074/jbc.M000120200; KANDEL ER, 1991, PRINCIPLES NEURAL SC, P976; Lopez-Figueroa MO, 2000, BIOCHEM BIOPH RES CO, V272, P129, DOI 10.1006/bbrc.2000.2748; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4140, DOI 10.1021/bi00313a020; Maneiro E, 2003, ARTHRITIS RHEUM, V48, P700, DOI 10.1002/art.10837; MIZUNO Y, 1989, BIOCHEM BIOPH RES CO, V163, P1450, DOI 10.1016/0006-291X(89)91141-8; Murray J, 2003, J BIOL CHEM, V278, P13619, DOI 10.1074/jbc.C300064200; Nijtmans LGJ, 2002, CELL MOL LIFE SCI, V59, P143, DOI 10.1007/s00018-002-8411-0; Orsi A, 2000, BIOCHEM J, V346, P407, DOI 10.1042/0264-6021:3460407; Pennathur S, 1999, J BIOL CHEM, V274, P34621, DOI 10.1074/jbc.274.49.34621; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P481, DOI 10.1016/0003-9861(91)90224-7; RADI R, 1991, J BIOL CHEM, V266, P4244; Radi R, 2002, FREE RADICAL BIO MED, V33, P1451, DOI 10.1016/S0891-5849(02)01111-5; RICHMAN PG, 1978, BIOCHEMISTRY-US, V17, P928, DOI 10.1021/bi00598a029; Riobo NA, 2001, BIOCHEM J, V359, P139, DOI 10.1042/0264-6021:3590139; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Sharov VS, 2002, ANAL BIOCHEM, V308, P328, DOI 10.1016/S0003-2697(02)00261-0; Sherer TB, 2002, NEUROSCIENTIST, V8, P192, DOI 10.1177/1073858402008003004; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; SIAN J, 1994, ANN NEUROL, V36, P348, DOI 10.1002/ana.410360305; SINGER TP, 1990, FEBS LETT, V274, P1, DOI 10.1016/0014-5793(90)81315-F; Skehel JM, 1998, FEBS LETT, V438, P301, DOI 10.1016/S0014-5793(98)01317-9; Smallwood HS, 2003, CHEM RES TOXICOL, V16, P95, DOI 10.1021/tx025566a; Smith, 1967, METHOD ENZYMOL, V10, P81, DOI DOI 10.1016/0076-6879(67)10016-5; SOFIC E, 1992, NEUROSCI LETT, V142, P128, DOI 10.1016/0304-3940(92)90355-B; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Taylor SW, 2002, J PROTEOME RES, V1, P451, DOI 10.1021/pr025533g; TORRES J, 1995, BIOCHEM J, V312, P169, DOI 10.1042/bj3120169; Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200; TURRENS JF, 1980, BIOCHEM J, V191, P421, DOI 10.1042/bj1910421; Viner RI, 1999, BIOCHEMISTRY-US, V38, P12408, DOI 10.1021/bi9909445; Yamamoto T, 2002, J NEURAL TRANSM, V109, P1, DOI 10.1007/s702-002-8232-1	57	262	266	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37223	37230		10.1074/jbc.M305694200	http://dx.doi.org/10.1074/jbc.M305694200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857734	hybrid			2022-12-27	WOS:000185437200030
J	Dai, SH; Petruccelli, S; Ordiz, MI; Zhang, ZH; Chen, SY; Beachy, RN				Dai, SH; Petruccelli, S; Ordiz, MI; Zhang, ZH; Chen, SY; Beachy, RN			Functional analysis of RF2a, a rice transcription factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUNGRO BACILLIFORM VIRUS; TATA-BINDING PROTEIN; IN-VITRO TRANSCRIPTION; VP16 ACTIVATION DOMAIN; GENE-EXPRESSION; DNA-BINDING; PROMOTER; SPECIFICITY; ELONGATION; INTERACTS	RF2a is a bZIP transcription factor that regulates expression of the promoter of rice tungro bacilliform badnavirus. RF2a is predicted to include three domains that contribute to its function. The results of transient assays with mutants of RF2a from which one or more domains were removed demonstrated that the acidic domain was essential for the activation of gene expression, although the proline-rich and glutamine-rich domains each played a role in this function. Studies using fusion proteins of different functional domains of RF2a with the 2C7 synthetic zinc finger DNA-binding domain showed that the acidic region is a relatively strong activation domain, the function of which is dependent on the context in which the domain is placed. Data from transgenic plants further supported the conclusion that the acidic domain was important for maintaining the biological function of RF2a. RF2a and TBP (TATA-binding protein) synergistically activate transcription in vitro (Zhu, Q., Ordiz, M. I., Dabi, T., Beachy, R. N., and Lamb, C. (2002) Plant Cell 14, 795 - 803). In vitro and in vivo assays showed that RF2a interacts with TBP through the glutamine-rich domain but not the acidic domain. Functional analysis of such interactions indicates that the acidic domain activates transcription through mechanisms other than via the direct recruitment of TBP.	Donald Danforth Plant Sci Ctr, St Louis, MO 63132 USA; Chinese Acad Sci, Inst Genet, Beijing 100101, Peoples R China	Donald Danforth Plant Science Center; Chinese Academy of Sciences	Beachy, RN (corresponding author), Donald Danforth Plant Sci Ctr, 975 N Warson Rd, St Louis, MO 63132 USA.	rnbeachy@danforthcenter.org	Petruccelli, Silvana/A-3083-2012; Petruccelli, Silvana/AAC-6826-2019	Petruccelli, Silvana/0000-0002-7072-0076; Petruccelli, Silvana/0000-0002-7072-0076				Bean TL, 1997, NUCLEIC ACIDS RES, V25, P2509, DOI 10.1093/nar/25.12.2509; BHATTACHARYYAPAKRASI M, 1993, PLANT J, V4, P71, DOI 10.1046/j.1365-313X.1993.04010071.x; Fujii Y, 2000, NAT STRUCT BIOL, V7, P889; Fukazawa J, 2000, PLANT CELL, V12, P901, DOI 10.1105/tpc.12.6.901; GINIGER E, 1985, CELL, V40, P767, DOI 10.1016/0092-8674(85)90336-8; HAAS NB, 1995, MOL CELL BIOL, V15, P1923; Hall DB, 2002, J BIOL CHEM, V277, P46043, DOI 10.1074/jbc.M208911200; Hayashi F, 1998, BIOCHEMISTRY-US, V37, P7941, DOI 10.1021/bi9801098; He XY, 2000, J BIOL CHEM, V275, P11799, DOI 10.1074/jbc.275.16.11799; Hoffmann N, 1988, PLANT MOL BIOL MANUA, pA5 1; Holmes MC, 2000, SCIENCE, V288, P867, DOI 10.1126/science.288.5467.867; Jakoby M, 2002, TRENDS PLANT SCI, V7, P106, DOI 10.1016/S1360-1385(01)02223-3; JEFFERSON RA, 1987, EMBO J, V6, P3901; KATAGIRI F, 1992, MOL CELL BIOL, V12, P4809, DOI 10.1128/MCB.12.11.4809; KLEMM RD, 1995, P NATL ACAD SCI USA, V92, P5788, DOI 10.1073/pnas.92.13.5788; LICHT JD, 1994, MOL CELL BIOL, V14, P4057, DOI 10.1128/MCB.14.6.4057; Liu Q, 1997, P NATL ACAD SCI USA, V94, P5525, DOI 10.1073/pnas.94.11.5525; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; Martens JA, 2002, GENE DEV, V16, P2231, DOI 10.1101/gad.1009902; Meshi T, 1995, PLANT CELL PHYSIOL, V36, P1405; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; Olive M, 1996, J BIOL CHEM, V271, P2040, DOI 10.1074/jbc.271.4.2040; Ordiz MI, 2002, P NATL ACAD SCI USA, V99, P13290, DOI 10.1073/pnas.202471899; Petruccelli S, 2001, P NATL ACAD SCI USA, V98, P7635, DOI 10.1073/pnas.121186398; Pugh BF, 2000, GENE, V255, P1, DOI 10.1016/S0378-1119(00)00288-2; Reindl A, 1998, FEBS LETT, V436, P318, DOI 10.1016/S0014-5793(98)01152-1; Ringli C, 1998, PLANT MOL BIOL, V37, P977, DOI 10.1023/A:1006030007333; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; TRUANT R, 1993, J BIOL CHEM, V268, P2284; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; WATANABE Y, 1987, FEBS LETT, V219, P65, DOI 10.1016/0014-5793(87)81191-2; Xie YQ, 2000, J BIOL CHEM, V275, P31914, DOI 10.1074/jbc.M003760200; Xie YQ, 2000, J BIOL CHEM, V275, P40797, DOI 10.1074/jbc.M007019200; YANKULOV K, 1994, CELL, V77, P749, DOI 10.1016/0092-8674(94)90058-2; Yin YH, 1997, EMBO J, V16, P5247, DOI 10.1093/emboj/16.17.5247; Yin YH, 1997, PLANT J, V12, P1179, DOI 10.1046/j.1365-313X.1997.12051179.x; YIN YH, 1995, PLANT J, V7, P969, DOI 10.1046/j.1365-313X.1995.07060969.x; ZHU Q, 1995, PLANT J, V7, P1021, DOI 10.1046/j.1365-313X.1995.07061021.x; Zhu Q, 2002, PLANT CELL, V14, P795, DOI 10.1105/tpc.010364	43	26	32	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36396	36402		10.1074/jbc.M304862200	http://dx.doi.org/10.1074/jbc.M304862200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855676	hybrid, Green Published			2022-12-27	WOS:000185318300067
J	Walter, W; Kireeva, ML; Studitsky, VM; Kashlev, M				Walter, W; Kireeva, ML; Studitsky, VM; Kashlev, M			Bacterial polymerase and yeast polymerase II use similar mechanisms for transcription through nucleosomes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-DNA HYBRID; ESCHERICHIA-COLI; ELONGATION COMPLEX; STRUCTURAL BASIS; HISTONE OCTAMER; SITE; INITIATION; STABILITY; BARRIER; CORE	We have previously shown that nucleosomes act as a strong barrier to yeast RNA polymerase II (Pol II) in vitro and that transcription through the nucleosome results in the loss of an H2A/H2B dimer. Here, we demonstrate that Escherichia coli RNA polymerase (RNAP), which never encounters chromatin in vivo, behaves similarly to Pol II in all aspects of transcription through the nucleosome in vitro. The nucleosome-specific pausing pattern of RNAP is comparable with that of Pol II. At physiological ionic strength or lower, the nucleosome blocks RNAP progression along the template, but this barrier can be relieved at higher ionic strength. Transcription through the nucleosome by RNAP results in the loss of an H2A/H2B dimer, and the histones that remain in the hexasome retain their original positions on the DNA. The results were similar for elongation complexes that were assembled from components (oligonucleotides and RNAP) and elongation complexes obtained by initiation from the promoter. The data suggest that eukaryotic Pol II and E. coli RNAP utilize very similar mechanisms for transcription through the nucleosome. Thus, bacterial RNAP can be used as a suitable model system to study general aspects of chromatin transcription by Pol II. Furthermore, the data argue that the general elongation properties of polymerases may determine the mechanism used for transcription through the nucleosome.	Wayne State Univ, Sch Med, Dept Biochem, Detroit, MI 48201 USA; Wayne State Univ, Sch Med, Ctr Mol Med & Genet, Detroit, MI 48201 USA; NCI, Ctr Canc Res, Frederick Canc Res & Dev Ctr, NIH, Frederick, MD 21702 USA	Wayne State University; Wayne State University; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Studitsky, VM (corresponding author), Univ Med & Dent New Jersey, Dept Pharmacol, 675 Hoes Lane,Rm 405, Piscataway, NJ 08854 USA.	vstudit@med.wayne.edu; mkashlev@mail.ncifcrf.gov	Kireeva, Maria/B-4391-2018; Studitsky, Vasily/A-9382-2014	Kireeva, Maria/0000-0003-0527-3182; 	DIVISION OF BASIC SCIENCES - NCI [Z01BC010343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM058650] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM58650] Funding Source: Medline	DIVISION OF BASIC SCIENCES - NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BARDELEBEN C, 1994, J MOL BIOL, V235, P1193, DOI 10.1006/jmbi.1994.1073; Becker PB, 2002, ANNU REV BIOCHEM, V71, P247, DOI 10.1146/annurev.biochem.71.110601.135400; Bednar J, 1999, MOL CELL, V4, P377, DOI 10.1016/S1097-2765(00)80339-1; BONNEANDREA C, 1990, NATURE, V343, P719, DOI 10.1038/343719a0; BONNER G, 1994, J BIOL CHEM, V269, P25120; BORUKHOV S, 1993, PROTEIN EXPRES PURIF, V4, P503, DOI 10.1006/prep.1993.1066; Chang CH, 1997, J BIOL CHEM, V272, P23427, DOI 10.1074/jbc.272.37.23427; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CLARK DJ, 1995, NUCLEUS, V1, P207; Conaway JW, 2000, TRENDS BIOCHEM SCI, V25, P375, DOI 10.1016/S0968-0004(00)01615-7; Cramer Patrick, 2001, Science (Washington D C), V292, P1863, DOI 10.1126/science.1059493; DIMAURO E, 1969, NATURE, V222, P533, DOI 10.1038/222533a0; DRLICA K, 1987, MICROBIOL REV, V51, P301, DOI 10.1128/MMBR.51.3.301-319.1987; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Fu JH, 1999, CELL, V98, P799, DOI 10.1016/S0092-8674(00)81514-7; Gnatt AL, 2001, SCIENCE, V292, P1876, DOI 10.1126/science.1059495; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; Huang JB, 2000, J MOL BIOL, V303, P347, DOI 10.1006/jmbi.2000.4150; IZBAN MG, 1992, J BIOL CHEM, V267, P13647; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; Kashlev M, 1996, METHOD ENZYMOL, V274, P326; Kireeva ML, 2000, J BIOL CHEM, V275, P6530, DOI 10.1074/jbc.275.9.6530; Kireeva ML, 2002, MOL CELL, V9, P541, DOI 10.1016/S1097-2765(02)00472-0; Kireeva ML, 2000, J MOL BIOL, V299, P325, DOI 10.1006/jmbi.2000.3755; KNEZETIC JA, 1988, MOL CELL BIOL, V8, P3114, DOI 10.1128/MCB.8.8.3114; Komissarova N, 1997, P NATL ACAD SCI USA, V94, P1755, DOI 10.1073/pnas.94.5.1755; Korzheva N, 2001, CURR OPIN MICROBIOL, V4, P119, DOI 10.1016/S1369-5274(00)00176-4; KRUDE T, 1991, MOL CELL BIOL, V11, P6257, DOI 10.1128/MCB.11.12.6257; Landick R, 2001, CELL, V105, P567, DOI 10.1016/S0092-8674(01)00381-6; Lopez PJ, 1998, J MOL BIOL, V276, P861, DOI 10.1006/jmbi.1997.1576; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; LUSE D, 1995, CHROMATIN STRUCTURE, P104; Mote J, 1998, J BIOL CHEM, V273, P16843, DOI 10.1074/jbc.273.27.16843; ODONOHUE MF, 1994, NUCLEIC ACIDS RES, V22, P937, DOI 10.1093/nar/22.6.937; Orphanides G, 2000, NATURE, V407, P471, DOI 10.1038/35035000; Palangat M, 2001, J MOL BIOL, V311, P265, DOI 10.1006/jmbi.2001.4842; PENNINGS S, 1991, J MOL BIOL, V220, P101, DOI 10.1016/0022-2836(91)90384-I; Protacio RU, 1997, J MOL BIOL, V274, P708, DOI 10.1006/jmbi.1997.1440; RANDALL SK, 1992, J BIOL CHEM, V267, P14259; REINES D, 1993, P NATL ACAD SCI USA, V90, P1917, DOI 10.1073/pnas.90.5.1917; ROUVIEREYANIV J, 1979, CELL, V17, P265, DOI 10.1016/0092-8674(79)90152-1; Sidorenkov I, 1998, MOL CELL, V2, P55, DOI 10.1016/S1097-2765(00)80113-6; STUDITSKY VM, 1995, CELL, V83, P19, DOI 10.1016/0092-8674(95)90230-9; Studitsky VM, 1997, SCIENCE, V278, P1960, DOI 10.1126/science.278.5345.1960; STUDITSKY VM, 1994, CELL, V76, P371, DOI 10.1016/0092-8674(94)90343-3; Studitsky VM, 1999, METH MOL B, V119, P17; Ubukata T, 2003, J BIOL CHEM, V278, P8580, DOI 10.1074/jbc.M211384200; Walter W, 2001, J BIOL CHEM, V276, P29104, DOI 10.1074/jbc.M103704200; WHITE RJ, 2000, RNA POLYM 3 TRANSCRI; YAGER TD, 1984, J BIOL CHEM, V259, P4212	51	40	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36148	36156		10.1074/jbc.M305647200	http://dx.doi.org/10.1074/jbc.M305647200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851391	hybrid			2022-12-27	WOS:000185318300035
J	Ghosh, M; Peterson, YK; Lanier, SM; Smrcka, AV				Ghosh, M; Peterson, YK; Lanier, SM; Smrcka, AV			Receptor- and nucleotide exchange-independent mechanisms for promoting G protein subunit dissociation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HETEROTRIMERIC G-PROTEINS; BETA-GAMMA-SUBUNITS; G-ALPHA SUBUNITS; REGULATORY MOTIF; BINDING; INHIBITION; TRANSDUCIN; PEPTIDE; ADENYLYL-CYCLASE-2; DETERMINANTS	Mechanisms for heterotrimeric G protein activation that do not rely on G protein coupled receptor activation are becoming increasingly apparent. We recently identified betagamma subunit-binding peptides that we proposed bound to a "hot spot" on betagamma subunits, stimulating G protein dissociation without stimulating nucleotide exchange and activating G protein signaling in intact cells. AGS3, a member of the activators of G protein signaling family of proteins, also activates G protein signaling in a nucleotide exchange-independent manner, and AGS3 homologues are involved in asymmetric cell division during development. Here we demonstrate that a consensus G protein regulatory (GPR) peptide from AGS3 and related proteins is sufficient to induce G protein subunit dissociation and that both the GPR and hot spot-binding peptides promote dissociation to extents comparable with a known G protein activator, AMF. Peptides derived from adenylyl cyclase 2 and GRK2 prevented formation of the heterotrimeric complex but did not alter the rate of alpha subunit dissociation from betagamma subunits. These data indicate that these nucleotide exchange-independent G protein activator peptides do not simply compete for alpha interactions with betagamma subunits, but actively promote subunit dissociation. Thus, we propose two novel mechanisms for nucleotide exchange independent activation of G protein signaling, one that involves conformational changes in the alpha subunit and one that involves conformational changes in the betagamma subunits.	Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; Louisiana State Univ, Hlth Sci Ctr, Dept Pharmacol & Expt Therapeut, New Orleans, LA 70112 USA	University of Rochester; Louisiana State University System; Louisiana State University Health Sciences Center New Orleans	Smrcka, AV (corresponding author), Univ Rochester, Sch Med & Dent, Dept Physiol & Pharmacol, Rochester, NY 14642 USA.		Ghosh, Mousumi/D-3180-2011	Lanier, Stephen/0000-0002-2740-7607	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060286] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM60286] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blumer JB, 2003, RECEPTOR CHANNEL, V9, P195, DOI 10.1080/10606820390203839; CHEN JQ, 1995, SCIENCE, V268, P1166, DOI 10.1126/science.7761832; De Vries L, 2000, P NATL ACAD SCI USA, V97, P14364, DOI 10.1073/pnas.97.26.14364; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X; GALLOP MA, 1994, J MED CHEM, V37, P1233, DOI 10.1021/jm00035a001; Gaudet R, 1996, CELL, V87, P577, DOI 10.1016/S0092-8674(00)81376-8; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gotta M, 2003, CURR BIOL, V13, P1029, DOI 10.1016/S0960-9822(03)00371-3; Goubaeva F, 2003, J BIOL CHEM, V278, P19634, DOI 10.1074/jbc.M300052200; Hamm HE, 1998, J BIOL CHEM, V273, P669, DOI 10.1074/jbc.273.2.669; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; KATADA T, 1984, J BIOL CHEM, V259, P3578; Kimple RJ, 2002, NATURE, V416, P878, DOI 10.1038/416878a; KOCH WJ, 1993, J BIOL CHEM, V268, P8256; KOZASA T, 1995, J BIOL CHEM, V270, P1734, DOI 10.1074/jbc.270.4.1734; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; Loew A, 1998, STRUCT FOLD DES, V6, P1007, DOI 10.1016/S0969-2126(98)00102-6; Natochin M, 2000, J BIOL CHEM, V275, P40981, DOI 10.1074/jbc.M006478200; Peterson YK, 2000, J BIOL CHEM, V275, P33193, DOI 10.1074/jbc.C000509200; Peterson YK, 2002, J BIOL CHEM, V277, P6767, DOI 10.1074/jbc.C100699200; Sarvazyan NA, 1998, J BIOL CHEM, V273, P7934, DOI 10.1074/jbc.273.14.7934; Schaefer M, 2001, CELL, V107, P183, DOI 10.1016/S0092-8674(01)00521-9; Scott JK, 2001, EMBO J, V20, P767, DOI 10.1093/emboj/20.4.767; Siderovski DP, 1999, TRENDS BIOCHEM SCI, V24, P340, DOI 10.1016/S0968-0004(99)01441-3; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Takesono A, 1999, J BIOL CHEM, V274, P33202, DOI 10.1074/jbc.274.47.33202; Weng GZ, 1996, J BIOL CHEM, V271, P26445, DOI 10.1074/jbc.271.43.26445	28	58	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34747	34750		10.1074/jbc.C300271200	http://dx.doi.org/10.1074/jbc.C300271200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12881533	hybrid			2022-12-27	WOS:000185164400004
J	Umehara, T; Horikoshi, M				Umehara, T; Horikoshi, M			Transcription initiation factor IID-interactive histone chaperone CIA-II implicated in mammalian spermatogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHROMATIN ASSEMBLY FACTORS; RNA-POLYMERASE-II; FACTOR S-II; SACCHAROMYCES-CEREVISIAE; MOLECULAR-CLONING; BINDING PROTEIN; DNA-REPLICATION; CELL-DEATH; IN-VITRO; EXPRESSION	Histones are thought to have specific roles in mammalian spermatogenesis, because several subtypes of histones emerge that are post-translationally modified during spermatogenesis. Though regular assembly of nucleosome is guaranteed by histone chaperones, their involvement in spermatogenesis is yet to be characterized. Here we identified a histone chaperone-related factor, which we designated as CCG1-interacting factor A-II (CIA-II), through interaction with bromodomains of TAF(II)250/CCG1, which is the largest subunit of human transcription initiation factor IID ( TFIID). We found that human CIA-II ( hCIA-II) localizes in HeLa nuclei and is highly expressed in testis and other proliferating cell-containing tissues. Expression of mouse CIA-II ( mCIAII) does not occur in the germ cell-lacking testes of adult WBB6F1-W/W-v mutant mice, indicating its expression in testis to be specific to germ cells. Fractionation of testicular germ cells revealed that mCIA-II transcripts accumulate in pachytene spermatocytes but not in spermatids. In addition, the mCIA-II transcripts in testis were present as early as 4 days after birth and decreased at 56 days after birth. These findings indicate that mCIA-II expression in testis is restricted to premeiotic to meiotic stages during spermatogenesis. Also, we found that hCIA-II interacts with histone H3 in vivo and with histones H3/H4 in vitro and that it facilitates supercoiling of circular DNA when it is incubated with core histones and topoisomerase I in vitro. These data suggest that CIA-II is a histone chaperone and is implicated in the regulation of mammalian spermatogenesis.	Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, Tokyo 1130032, Japan; Japan Sci & Technol Corp, Exploratory Res Adv Technol, Horikoshi Gene Selector Project, Tsukuba, Ibaraki 3002635, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Horikoshi, M (corresponding author), Univ Tokyo, Inst Mol & Cellular Biosci, Dev Biol Lab, Bunkyo Ku, 1-1-1 Yayoi, Tokyo 1130032, Japan.		Umehara, Takashi/AHB-1730-2022; Umehara, Takashi/N-5683-2015	Umehara, Takashi/0000-0003-3464-2960; Umehara, Takashi/0000-0003-3464-2960				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; ALFONSO PJ, 1993, BIOL REPROD, V48, P522, DOI 10.1095/biolreprod48.3.522; Bando M, 1997, J BIOCHEM-TOKYO, V121, P591; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Blanco-Rodriguez J, 1998, INT J ANDROL, V21, P236; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Chimura T, 2002, P NATL ACAD SCI USA, V99, P9334, DOI 10.1073/pnas.142627899; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Doenecke D, 1997, ADV EXP MED BIOL, V424, P37; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HEIDARAN MA, 1987, J BIOL CHEM, V262, P13309; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; Hoffmann A, 1996, NATURE, V380, P356, DOI 10.1038/380356a0; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; ISHIMI Y, 1984, EUR J BIOCHEM, V142, P431, DOI 10.1111/j.1432-1033.1984.tb08305.x; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; KIERSZENBAUM AL, 1978, FED PROC, V37, P2512; Kimura A, 1998, GENES CELLS, V3, P789, DOI 10.1046/j.1365-2443.1998.00229.x; KOKUBO T, 1993, GENE DEV, V7, P1033, DOI 10.1101/gad.7.6.1033; KOKUBO T, 1994, NATURE, V367, P484, DOI 10.1038/367484a0; KORNBERG RD, 1974, SCIENCE, V184, P868, DOI 10.1126/science.184.4139.868; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Lahn BT, 2002, P NATL ACAD SCI USA, V99, P8707, DOI 10.1073/pnas.082248899; LASKEY RA, 1978, NATURE, V275, P416, DOI 10.1038/275416a0; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Liu DJ, 1998, CELL, V94, P573, DOI 10.1016/S0092-8674(00)81599-8; Matangkasombut O, 2000, GENE DEV, V14, P951; MATSUMOTO K, 1993, J BIOL CHEM, V268, P10582; MEISTRICH ML, 1977, DEV BIOL, V60, P428, DOI 10.1016/0012-1606(77)90140-3; MEISTRICH ML, 1985, DEV BIOL, V112, P230, DOI 10.1016/0012-1606(85)90137-X; MEISTRICH ML, 1978, FED PROC, V37, P2522; Munakata T, 2000, GENES CELLS, V5, P221, DOI 10.1046/j.1365-2443.2000.00319.x; Narlikar GJ, 2002, CELL, V108, P475, DOI 10.1016/S0092-8674(02)00654-2; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; Roeder RG, 1996, TRENDS BIOCHEM SCI, V21, P327, DOI 10.1016/0968-0004(96)10050-5; Rogner UC, 2000, NAT GENET, V25, P431, DOI 10.1038/78124; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SAUNDERS PTK, 1992, MOL REPROD DEV, V33, P385, DOI 10.1002/mrd.1080330404; Schnieders F, 1996, HUM MOL GENET, V5, P1801, DOI 10.1093/hmg/5.11.1801; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1995, EXP CELL RES, V218, P490, DOI 10.1006/excr.1995.1183; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; Shen HH, 2001, GENOMICS, V71, P21, DOI 10.1006/geno.2000.6397; Sillje HHW, 2001, CURR BIOL, V11, P1068, DOI 10.1016/S0960-9822(01)00298-6; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; Singer MS, 1998, GENETICS, V150, P613; SuzukiYagawa Y, 1997, MOL CELL BIOL, V17, P3284, DOI 10.1128/MCB.17.6.3284; TAKADA R, 1992, P NATL ACAD SCI USA, V89, P11809, DOI 10.1073/pnas.89.24.11809; TROSTLEWEIGE PK, 1984, J BIOL CHEM, V259, P8769; Tyler JK, 1999, NATURE, V402, P555, DOI 10.1038/990147; Umehara T, 1997, J BIOCHEM-TOKYO, V121, P598, DOI 10.1093/oxfordjournals.jbchem.a021627; Umehara T, 1995, GENE, V167, P297, DOI 10.1016/0378-1119(95)00634-6; Umehara T, 2002, GENES CELLS, V7, P59, DOI 10.1046/j.1356-9597.2001.00493.x; WOLFE SA, 1989, BIOCHIM BIOPHYS ACTA, V1007, P140, DOI 10.1016/0167-4781(89)90032-8; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; Xie XL, 1996, NATURE, V380, P316, DOI 10.1038/380316a0; Yamaki M, 2001, GENES CELLS, V6, P1043, DOI 10.1046/j.1365-2443.2001.00487.x; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; YELICK P C, 1989, Molecular Reproduction and Development, V1, P193, DOI 10.1002/mrd.1080010307; YOSHINAGA K, 1991, DEVELOPMENT, V113, P689	63	29	34	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35660	35667		10.1074/jbc.M303549200	http://dx.doi.org/10.1074/jbc.M303549200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842904	hybrid			2022-12-27	WOS:000185164400111
J	Zander, K; Sherman, MP; Tessmer, U; Bruns, K; Wray, V; Prechtel, AT; Schubert, E; Henklein, P; Luban, J; Neidleman, J; Greene, WC; Schubert, U				Zander, K; Sherman, MP; Tessmer, U; Bruns, K; Wray, V; Prechtel, AT; Schubert, E; Henklein, P; Luban, J; Neidleman, J; Greene, WC; Schubert, U			Cyclophilin A interacts with HIV-1 Vpr and is required for its functional expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TYPE-1 VPR; VIRAL PROTEIN R; CYCLOSPORINE-A; CELL-CYCLE; TERMINAL DOMAIN; NMR STRUCTURE; SDZ NIM-811; IMMUNODEFICIENCY; REPLICATION; INFECTION	Viral protein R (Vpr) of human immunodeficiency virus, type 1 (HIV-1) is the major virion-associated accessory protein that affects a number of biological functions in the retroviral life cycle, including promotion of the transport of the preintegration complex into the nucleus and the induction of G(2) host cell cycle arrest. Our recent investigation of the conformational heterogeneity of the proline residues in the N terminus of Vpr suggested a functional interaction between Vpr and a host peptidylprolyl cis/trans isomerase (PPIase) that might regulate the cis/trans interconversion of the imidic bond within the conserved proline residues of Vpr in vivo. Using surface plasmon resonance spectroscopy, Far Western blot, and pulldown experiments a physical interaction of Vpr with the major host PPIase cyclophilin A (CypA) is now demonstrated. The interaction domain involves the N-terminal region of Vpr including an essential role for proline in position 35. The CypA inhibitor cyclosporin A and non-immunosuppressive PPIase inhibitors such as NIM811 and sanglifehrin A block expression of Vpr without affecting pre- or post-translational events such as transcription, intracellular transport, or virus incorporation of Vpr. Similarly to CypA inhibition, Vpr expression is also reduced in HIV-1 infected CypA(-/-) knock-out T cells. This study thus shows that in addition to the interaction between CypA and HIV-1 capsid occurring during early steps in virus replication, CypA is also important for the de novo synthesis of Vpr and that in the absence of CypA activity, the Vpr-mediated cell cycle arrest is completely lost in HIV-1-infected T cells.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Univ Hamburg, Heinrich Pette Inst Expt Virol & Immunol, D-20251 Hamburg, Germany; Univ Calif San Francisco, Gladstone Inst Virol & Immunol, San Francisco, CA 94103 USA; Gesell Biotechnol Forsch mbH, Dept Mol Struct Res, D-38124 Braunschweig, Germany; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany; Columbia Univ, Dept Microbiol, New York, NY 10018 USA; Columbia Univ, Dept Med, New York, NY 10018 USA; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	University of Erlangen Nuremberg; Heinrich Pette Institute; University of Hamburg; University of California System; University of California San Francisco; The J David Gladstone Institutes; Gesellschaft fur Biotechnologische Forschung mbH; Humboldt University of Berlin; Columbia University; Columbia University; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schubert, U (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	ulrich.schubert@viro.med.uni-erlangen.de		Luban, Jeremy/0000-0001-5650-4054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059537] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI36199, R01 AI036199] Funding Source: Medline; NIDDK NIH HHS [R01 DK59537-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; ANDRIEU JM, 1988, CLIN IMMUNOL IMMUNOP, V47, P181, DOI 10.1016/0090-1229(88)90071-2; BILLICH A, 1995, J VIROL, V69, P2451, DOI 10.1128/JVI.69.4.2451-2461.1995; Bosco DA, 2002, P NATL ACAD SCI USA, V99, P5247, DOI 10.1073/pnas.082100499; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; Braaten D, 1996, J VIROL, V70, P5170, DOI 10.1128/JVI.70.8.5170-5176.1996; Braaten D, 1997, J VIROL, V71, P2107, DOI 10.1128/JVI.71.3.2107-2113.1997; Braaten D, 1996, J VIROL, V70, P4220, DOI 10.1128/JVI.70.7.4220-4227.1996; Bruns K, 2003, J BIOL CHEM, V278, P43188, DOI 10.1074/jbc.M305413200; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; BUSS WC, 1995, TOXICOLOGY, V100, P17, DOI 10.1016/0300-483X(95)03053-I; Conti L, 2000, J IMMUNOL, V165, P3293, DOI 10.4049/jimmunol.165.6.3293; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; de Rocquigny H, 2000, EUR J BIOCHEM, V267, P3654, DOI 10.1046/j.1432-1327.2000.01397.x; de Rocquigny H, 1997, J BIOL CHEM, V272, P30753, DOI 10.1074/jbc.272.49.30753; Dorfman T, 1997, J VIROL, V71, P7110, DOI 10.1128/JVI.71.9.7110-7113.1997; Dorfman T, 1996, J VIROL, V70, P5751, DOI 10.1128/JVI.70.9.5751-5757.1996; Eckstein DA, 2001, J EXP MED, V194, P1407, DOI 10.1084/jem.194.10.1407; EMMEL EA, 1989, SCIENCE, V246, P1617, DOI 10.1126/science.2595372; Engler A, 2002, EUR J BIOCHEM, V269, P3264, DOI 10.1046/j.1432-1033.2002.03005.x; Engler A, 2001, EUR J BIOCHEM, V268, P389, DOI 10.1046/j.1432-1327.2001.01895.x; Ferri KF, 2000, ANN NY ACAD SCI, V926, P149; Franke EK, 1996, VIROLOGY, V222, P279, DOI 10.1006/viro.1996.0421; FRANKE EK, 1994, NATURE, V372, P359, DOI 10.1038/372359a0; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; Gross I, 1997, EUR J BIOCHEM, V249, P592, DOI 10.1111/j.1432-1033.1997.t01-1-00592.x; HANDSCHUMACHER RE, 1984, SCIENCE, V226, P544, DOI 10.1126/science.6238408; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Ivery MTG, 2000, MED RES REV, V20, P452, DOI 10.1002/1098-1128(200011)20:6<452::AID-MED2>3.0.CO;2-6; Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33; Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5; Luo ZW, 1998, BIOCHEM BIOPH RES CO, V244, P732, DOI 10.1006/bbrc.1998.8330; Mahalingam S, 2001, J VIROL, V75, P362, DOI 10.1128/JVI.75.1.362-374.2001; Martin LN, 1997, J INFECT DIS, V176, P374, DOI 10.1086/514054; Ott DE, 2002, REV MED VIROL, V12, P359, DOI 10.1002/rmv.367; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Poon B, 1998, SCIENCE, V281, P266, DOI 10.1126/science.281.5374.266; Pushkarsky T, 2001, P NATL ACAD SCI USA, V98, P6360, DOI 10.1073/pnas.111583198; Rizzardi GP, 2002, J BIOL REG HOMEOS AG, V16, P83; Rizzardi GP, 2002, J CLIN INVEST, V109, P681, DOI 10.1172/JCI200214522; ROSENWIRTH B, 1994, ANTIMICROB AGENTS CH, V38, P1763, DOI 10.1128/AAC.38.8.1763; Saphire ACS, 2002, J VIROL, V76, P2255, DOI 10.1128/JVI.76.5.2255-2262.2002; Saphire ACS, 2000, IMMUNOL RES, V21, P211, DOI 10.1385/IR:21:2-3:211; Sawaya BE, 1999, GENE THER, V6, P947, DOI 10.1038/sj.gt.3300907; SCHUBERT U, 1995, J VIROL, V69, P7699, DOI 10.1128/JVI.69.12.7699-7711.1995; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; SIGAL NH, 1991, J EXP MED, V173, P619, DOI 10.1084/jem.173.3.619; STEINKASSERER A, 1995, J VIROL, V69, P814, DOI 10.1128/JVI.69.2.814-824.1995; Stewart SA, 2000, J VIROL, V74, P3105, DOI 10.1128/JVI.74.7.3105-3111.2000; Taylor P, 1997, PROG BIOPHYS MOL BIO, V67, P155, DOI 10.1016/S0079-6107(97)00014-X; Tenson T, 2002, CELL, V108, P591, DOI 10.1016/S0092-8674(02)00669-4; THALI M, 1994, NATURE, V372, P363, DOI 10.1038/372363a0; VALENT P, 1991, P NATL ACAD SCI USA, V88, P3339, DOI 10.1073/pnas.88.8.3339; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; Wiegers K, 1999, VIROLOGY, V257, P261, DOI 10.1006/viro.1999.9669; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; Yao XJ, 2002, J BIOL CHEM, V277, P48816, DOI 10.1074/jbc.M207982200; Yoo SH, 1997, J MOL BIOL, V269, P780, DOI 10.1006/jmbi.1997.1051; Zenke G, 2001, J IMMUNOL, V166, P7165, DOI 10.4049/jimmunol.166.12.7165; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	71	74	82	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43202	43213		10.1074/jbc.M305414200	http://dx.doi.org/10.1074/jbc.M305414200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12881522	hybrid			2022-12-27	WOS:000186157000061
J	Vassilaki, N; Mavromara, P				Vassilaki, N; Mavromara, P			Two alternative translation mechanisms are responsible for the expression of the HCV ARFP/F/Core+1 coding open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS CORE PROTEIN; BICISTRONIC MESSENGER-RNA; HEPATITIS-C; CAP-POLY(A) SYNERGY; INITIATION; GENOME; IDENTIFICATION; REGION; GENE	HCV-1 produces a novel protein, known as ARFP, F, or core +1. This protein is encoded by an open reading frame (ORF) that overlaps the core gene in the +1 frame ( core +1 ORF). In vitro this protein is produced by a ribosomal frameshift mechanism. However, similar studies failed to detect the ARFP/F/core+1 protein in the HCV-1a ( H) isolate. To clarify this issue and to elucidate the functions of this protein, we examined the expression of the core +1 ORF by the HCV-1 and HCV-1a ( H) isolates in vivo, in transfected cells. For this purpose, we carried out luciferase (LUC) tagging experiments combined with site-directed mutagenesis studies. Our results showed that the core +1-LUC chimeric protein was efficiently produced in vivo by both isolates. More importantly, neither changes in the specific 10-A residue region of HCV-1 (codons 8 - 11), the proposed frameshift site for the production of the ARFP/F/core+1 protein in vitro, nor the alteration of the ATG start site of the HCV polyprotein to a stop codon significantly affected the in vivo expression of the core +1 ORF. Furthermore, we showed that efficient translation initiation of the core +1 ORF is mediated by internal initiation codon(s) within the core/core +1-coding sequence, located between nucleotides 583 and 606. Collectively, our data suggest the existence of an alternative translation initiation mechanism that may result in the synthesis of a shorter form of the core +1 protein in transfected cells.	Hellenic Pasteur Inst, Mol Virol Lab, Athens 11521, Greece		Mavromara, P (corresponding author), Hellenic Pasteur Inst, Mol Virol Lab, 127 Vas Sofias Ave, Athens 11521, Greece.							Borman AM, 2000, NUCLEIC ACIDS RES, V28, P4068, DOI 10.1093/nar/28.21.4068; BRIERLEY I, 1995, J GEN VIROL, V76, P1885, DOI 10.1099/0022-1317-76-8-1885; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; CURRAN J, 1988, EMBO J, V7, P2869, DOI 10.1002/j.1460-2075.1988.tb03143.x; Di Bisceglie AM, 2000, HEPATOLOGY, V31, P1014, DOI 10.1053/he.2000.5762; FUTTERER J, 1993, CELL, V73, P789, DOI 10.1016/0092-8674(93)90257-Q; Futterer J, 1996, J VIROL, V70, P2999; Grundhoff A, 2001, J VIROL, V75, P1857, DOI 10.1128/JVI.75.4.1857-1863.2001; Jayakar HR, 2002, J VIROL, V76, P8011, DOI 10.1128/JVI.76.16.8011-8018.2002; Kobayashi T, 2000, VIROLOGY, V277, P296, DOI 10.1006/viro.2000.0592; Latorre P, 1998, MOL CELL BIOL, V18, P5021, DOI 10.1128/MCB.18.9.5021; McLauchlan J, 2000, J VIRAL HEPATITIS, V7, P2; Michel YM, 2000, J BIOL CHEM, V275, P32268, DOI 10.1074/jbc.M004304200; MURPHY FA, 1995, VIRUS TAXONOMY, P424; PAVLAKIS G N, 1990, New Biologist, V2, P20; Psaridi L, 1999, FEBS LETT, V453, P49, DOI 10.1016/S0014-5793(99)00662-6; Ray RB, 2001, FEMS MICROBIOL LETT, V202, P149, DOI 10.1111/j.1574-6968.2001.tb10796.x; Reed KE, 2000, CURR TOP MICROBIOL, V242, P55; Remm M, 1999, J VIROL, V73, P3062, DOI 10.1128/JVI.73.4.3062-3070.1999; Rijnbrand RCA, 2000, CURR TOP MICROBIOL, V242, P85; Rumenapf T, 1998, J VIROL, V72, P2544; Ryabova LA, 2000, J BIOL CHEM, V275, P37278, DOI 10.1074/jbc.M004909200; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; Stacey SN, 2000, J VIROL, V74, P7284, DOI 10.1128/JVI.74.16.7284-7297.2000; Varaklioti A, 2002, J BIOL CHEM, V277, P17713, DOI 10.1074/jbc.M201722200; Walewski JL, 2001, RNA, V7, P710, DOI 10.1017/S1355838201010111; Xu ZM, 2001, EMBO J, V20, P3840, DOI 10.1093/emboj/20.14.3840; Yamasaki K, 1999, J VIROL, V73, P8519, DOI 10.1128/JVI.73.10.8519-8526.1999; Yeh CT, 2000, J GASTROEN HEPATOL, V15, P182, DOI 10.1046/j.1440-1746.2000.02066.x; Yueh A, 2000, GENE DEV, V14, P414	30	60	68	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40503	40513		10.1074/jbc.M305504200	http://dx.doi.org/10.1074/jbc.M305504200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12874283	hybrid			2022-12-27	WOS:000185847200011
J	Henderson, JN; Zhang, JY; Evans, BW; Redding, K				Henderson, JN; Zhang, JY; Evans, BW; Redding, K			Disassembly and degradation of photosystem I in an in vitro system are multievent, metal-dependent processes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; CHLAMYDOMONAS-REINHARDTII; THYLAKOID MEMBRANES; CARBOXYPEPTIDASE-A; ESCHERICHIA-COLI; SERINE-PROTEASE; FTSH PROTEASE; CHLOROPLAST; IDENTIFICATION; CHLOROPHYLL	An in vitro system was created to study the process of membrane protein degradation by using photosystem I (PS1) as a model membrane protein. Purified chloroplast membranes were incubated at 30degreesC in a defined buffer along with various extracts or reagents to reconstitute the disassembly and degradation of PS1, which was monitored by a variety of techniques that probe the integrity of the PS1 complex: photo-biochemical assays, semi-native gel electrophoresis, low temperature fluorescence spectroscopy, and immunoblots using antibodies against different PS1 subunits. During a typical time course, degradation of PS1 appeared to be a multievent process, with disassembly of the complex preceding proteolysis of the subunits. The first change seen was a rapid (<5 min) decrease in PS1 photochemical activity. This was followed by a diminution of far-red fluorescence emission from the core antenna of PS1 and a slower disassembly of the PS1 chlorophyll-protein core complex, as visualized by semi-native gel electrophoresis. Surprisingly, the latter was not accompanied by a similar rate of proteolysis of the PsaA core subunit. In contrast, addition of soluble proteases caused rapid loss of immuno-detectable PS1 polypeptides and cleavage of the major PS1 polypeptides in interhelical loops. The in vitro degradation process was time- and temperature-dependent but did not require ATP, GTP, or soluble chloroplast proteins. Chelation of divalent cations by EDTA inhibited the later steps of disassembly and proteolysis, and this effect could be reversed by addition of micromolar Zn2+, with Co2+ and Ca2+ providing somewhat lower activity.	Univ Alabama, Dept Chem, Tuscaloosa, AL 35487 USA; Univ Alabama, Dept Biol Sci, Tuscaloosa, AL 35487 USA	University of Alabama System; University of Alabama Tuscaloosa; University of Alabama System; University of Alabama Tuscaloosa	Redding, K (corresponding author), Univ Alabama, Dept Chem, 120 Lloyd Hall,6th Ave, Tuscaloosa, AL 35487 USA.			Redding, Kevin/0000-0003-2819-4022	NIGMS NIH HHS [GM66345-01] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R15GM066345] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adam Z, 2001, PLANT PHYSIOL, V125, P1912, DOI 10.1104/pp.125.4.1912; Akabas MH, 2000, J BIOL CHEM, V275, P3729, DOI 10.1074/jbc.275.6.3729; ANGLETON EL, 1988, BIOCHEMISTRY-US, V27, P7413, DOI 10.1021/bi00419a036; Berson EL, 1996, P NATL ACAD SCI USA, V93, P4526, DOI 10.1073/pnas.93.10.4526; Boudreaux B, 2001, J BIOL CHEM, V276, P37299, DOI 10.1074/jbc.M102327200; BREDDAM K, 1979, BIOCHEMISTRY-US, V18, P1563, DOI 10.1021/bi00575a028; BUNNING P, 1985, J INORG BIOCHEM, V24, P183, DOI 10.1016/0162-0134(85)85002-9; Caspi V, 2000, PHOTOCHEM PHOTOBIOL, V71, P441, DOI 10.1562/0031-8655(2000)071&lt;0441:OUPBDC&gt;2.0.CO;2; Choquet Y, 2000, BIOCHIMIE, V82, P615, DOI 10.1016/S0300-9084(00)00609-X; Cook M, 1997, PLANT PHYSIOL BIOCH, V35, P163; FULLER RS, 1989, P NATL ACAD SCI USA, V86, P1434, DOI 10.1073/pnas.86.5.1434; GomezOrtiz M, 1997, FEBS LETT, V400, P336, DOI 10.1016/S0014-5793(96)01412-3; HALL DO, 1994, PHOTOSYNTHESIS, P10; Halperin T, 2001, PLANTA, V213, P614, DOI 10.1007/s004250100527; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; Hosfield CM, 1999, EMBO J, V18, P6880, DOI 10.1093/emboj/18.24.6880; Itzhaki H, 1998, J BIOL CHEM, V273, P7094, DOI 10.1074/jbc.273.12.7094; Jordan P, 2001, NATURE, V411, P909, DOI 10.1038/35082000; Kihara A, 1999, EMBO J, V18, P2970, DOI 10.1093/emboj/18.11.2970; KOPITO RR, 1999, PHYSIOL REV, V79, P167; LARSEN KS, 1991, BIOCHEMISTRY-US, V30, P2613, DOI 10.1021/bi00224a007; Lensch M, 2001, J BIOL CHEM, V276, P33645, DOI 10.1074/jbc.M100506200; Lindahl M, 1996, J BIOL CHEM, V271, P29329, DOI 10.1074/jbc.271.46.29329; Majeran W, 2000, PLANT CELL, V12, P137; Majeran W, 2001, PLANT PHYSIOL, V126, P421, DOI 10.1104/pp.126.1.421; McDermott JR, 1997, NEUROCHEM RES, V22, P49, DOI 10.1023/A:1027325304203; Murakami A, 1997, PHOTOSYNTH RES, V53, P141, DOI 10.1023/A:1005818317797; Ostersetzer O, 1997, PLANT CELL, V9, P957, DOI 10.1105/tpc.9.6.957; Ostersetzer O, 1996, EUR J BIOCHEM, V236, P932, DOI 10.1111/j.1432-1033.1996.00932.x; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; Redding K, 1998, EMBO J, V17, P50, DOI 10.1093/emboj/17.1.50; Rivett AJ, 1990, CURR OPIN CELL BIOL, V2, P1143, DOI 10.1016/0955-0674(90)90168-E; ROCHAIX JD, 1992, ANNU REV CELL BIOL, V8, P1, DOI 10.1146/annurev.cb.08.110192.000245; ROCHE RS, 1978, CRC CR REV BIOCH MOL, V5, P1; Rufenacht A, 2000, PHOTOSYNTH RES, V63, P249, DOI 10.1023/A:1006472325830; Spetea C, 1999, P NATL ACAD SCI USA, V96, P6547, DOI 10.1073/pnas.96.11.6547; STOECKER W, 1988, Biochemistry, V27, P5026, DOI 10.1021/bi00414a012; THORNBER JP, 1967, BIOCHEMISTRY-US, V6, P391, DOI 10.1021/bi00854a004; TOMOYASU T, 1993, J BACTERIOL, V175, P1352, DOI 10.1128/JB.175.5.1352-1357.1993; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; Vekrellis K, 2000, J NEUROSCI, V20, P1657; WARREN PV, 1990, BIOCHEMISTRY-US, V29, P6545, DOI 10.1021/bi00480a001; WILEY HS, 1985, CURR TOP MEMBR TRANS, V24, P369; ZISAPEL N, 1973, BIOCHEM BIOPH RES CO, V53, P722, DOI 10.1016/0006-291X(73)90153-8	45	13	15	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39978	39986		10.1074/jbc.M304299200	http://dx.doi.org/10.1074/jbc.M304299200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885783	hybrid			2022-12-27	WOS:000185713800086
J	Koni, PA; Khanna, R; Chang, MC; Tang, MD; Kaczmarek, LK; Schlichter, LC; Flavell, RA				Koni, PA; Khanna, R; Chang, MC; Tang, MD; Kaczmarek, LK; Schlichter, LC; Flavell, RA			Compensatory anion currents in Kv1.3 channel-deficient thymocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MURINE LYMPHOCYTES-T; FLOW-CYTOMETRIC DETECTION; GATED K+ CHANNELS; POTASSIUM CHANNELS; CHLORIDE CHANNEL; PHOSPHATIDYLSERINE EXPRESSION; TYROSINE PHOSPHORYLATION; SMALL-CONDUCTANCE; VOLUME REGULATION; CELL DEVELOPMENT	Kv1.3 is a voltage-gated potassium channel with roles in human T cell activation/proliferation, cell-mediated cytotoxicity, and volume regulation and is thus a target for therapeutic control of T cell responses. Kv1.3 is also present in some mouse thymocyte subsets and splenocytes, but its role in the mouse is less well understood. We report the generation and characterization of Kv1.3-deficient (Kv1.3(-/-)) mice. In contrast to wild-type cells, the majority of Kv1.3(-/-) thymocytes had no detectable voltage-dependent potassium current, although RNA and protein for several potassium channel subunits were found in the thymocyte population. Surprisingly, the level of chloride current in the Kv1.3(-/-) thymocytes was increased approximately 50-fold over that in wildtype cells. There were no abnormalities in lymphocyte types or absolute numbers in thymus, spleen, and lymph nodes and no obvious defect in thymocyte apoptosis or T cell proliferation in the Kv1.3(-/-) animals. The compensatory effects of the enhanced chloride current may account for the apparent lack of immune system defects in Kv1.3(-/-) mice.	Univ Toronto, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; RIKEN, Res Ctr Allergy & Immunol, Kanagawa 2300045, Japan; Univ Toronto, Dept Physiol, Toronto, ON M5T 2S8, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Yale University; Yale University; Howard Hughes Medical Institute; Yale University; RIKEN; University of Toronto	Flavell, RA (corresponding author), Univ Toronto, Toronto Western Res Inst, Div Cellular & Mol Biol, Toronto, ON M5T 2S8, Canada.	richard.flavell@yale.edu	Chang, Martin/J-2329-2016; Koni, Pandelakis/A-3349-2008	Khanna, Rajesh/0000-0002-9066-2969; Koni, Pandelakis/0000-0002-0892-4764	NIDCD NIH HHS [DC-01919] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC001919] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; Castedo M, 1996, J IMMUNOL, V157, P512; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; CHANDY KG, 1995, LIGAND VOLTAGE GATED, P1; Chung I, 1997, AM J PHYSIOL-CELL PH, V273, pC622, DOI 10.1152/ajpcell.1997.273.2.C622; Chung I, 1997, J MEMBRANE BIOL, V156, P73, DOI 10.1007/s002329900189; Cifone MG, 1999, BLOOD, V93, P2282, DOI 10.1182/blood.V93.7.2282.407a23_2282_2296; Deas O, 1998, J IMMUNOL, V161, P3375; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P379, DOI 10.1085/jgp.89.3.379; DECOURSEY TE, 1987, J GEN PHYSIOL, V89, P405, DOI 10.1085/jgp.89.3.405; DECOURSEY TE, 1999, INFLAMMATION BASIC P, P639; DEUTSCH C, 1993, P NATL ACAD SCI USA, V90, P10036, DOI 10.1073/pnas.90.21.10036; Duan D, 1997, NATURE, V390, P417, DOI 10.1038/37151; FREEDMAN BD, 1995, J BIOL CHEM, V270, P22406, DOI 10.1074/jbc.270.38.22406; Furst J, 2000, CELL PHYSIOL BIOCHEM, V10, P329, DOI 10.1159/000016374; Garcia M L, 1997, Adv Pharmacol, V39, P425, DOI 10.1016/S1054-3589(08)60078-2; GRISSMER S, 1990, J IMMUNOL, V145, P2105; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; GRUNDER S, 1992, NATURE, V360, P759, DOI 10.1038/360759a0; Holmes TC, 1996, J NEUROSCI, V16, P1581; Holmes TC, 1996, SCIENCE, V274, P2089, DOI 10.1126/science.274.5295.2089; Jugloff DGM, 2000, J BIOL CHEM, V275, P1357, DOI 10.1074/jbc.275.2.1357; Kasibhatla S, 1998, MOL CELL, V1, P543, DOI 10.1016/S1097-2765(00)80054-4; Khanna R, 2001, AM J PHYSIOL-CELL PH, V280, pC796, DOI 10.1152/ajpcell.2001.280.4.C796; Khanna R, 1999, J BIOL CHEM, V274, P14838, DOI 10.1074/jbc.274.21.14838; Koch RO, 1997, J BIOL CHEM, V272, P27577, DOI 10.1074/jbc.272.44.27577; Kohler M, 1996, SCIENCE, V273, P1709, DOI 10.1126/science.273.5282.1709; Koo GC, 1997, J IMMUNOL, V158, P5120; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; Kotecha SA, 1999, J NEUROSCI, V19, P10680, DOI 10.1523/JNEUROSCI.19-24-10680.1999; KUES WA, 1992, EUR J NEUROSCI, V4, P1296, DOI 10.1111/j.1460-9568.1992.tb00155.x; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; LEWIS RS, 1988, SCIENCE, V239, P771, DOI 10.1126/science.2448877; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; LIN CS, 1993, J EXP MED, V177, P637, DOI 10.1084/jem.177.3.637; Lorenz L, 1996, P NATL ACAD SCI USA, V93, P13362, DOI 10.1073/pnas.93.23.13362; MCKINNON D, 1986, J EXP MED, V164, P1846, DOI 10.1084/jem.164.6.1846; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; PAHAPILL PA, 1992, J MEMBRANE BIOL, V125, P171; PAHAPILL PA, 1992, J PHYSIOL-LONDON, V445, P407, DOI 10.1113/jphysiol.1992.sp018931; PETIT PX, 1995, J CELL BIOL, V130, P157, DOI 10.1083/jcb.130.1.157; PRICE M, 1989, P NATL ACAD SCI USA, V86, P10171, DOI 10.1073/pnas.86.24.10171; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P451, DOI 10.1073/pnas.83.2.451; SCHLICHTER L, 1986, P NATL ACAD SCI USA, V83, P5625, DOI 10.1073/pnas.83.15.5625; Schlichter LC, 1996, GLIA, V17, P225, DOI 10.1002/(SICI)1098-1136(199607)17:3<225::AID-GLIA5>3.0.CO;2-#; SCHLICHTER LC, 1994, EXP CELL RES, V215, P211, DOI 10.1006/excr.1994.1334; SCHMID I, 1994, J IMMUNOL METHODS, V170, P145, DOI 10.1016/0022-1759(94)90390-5; SCHUMACHER PA, 1995, J MEMBRANE BIOL, V145, P217; SIDELL N, 1986, J IMMUNOL, V137, P1650; Strange K, 1998, J GEN PHYSIOL, V111, P617, DOI 10.1085/jgp.111.5.617; Szabo I, 1997, PFLUG ARCH EUR J PHY, V433, P626, DOI 10.1007/s004240050323; Szabo I, 1996, J BIOL CHEM, V271, P20465, DOI 10.1074/jbc.271.34.20465; THIEMANN A, 1992, NATURE, V356, P57, DOI 10.1038/356057a0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; Verheugen JAH, 1997, CELL CALCIUM, V21, P1, DOI 10.1016/S0143-4160(97)90092-0; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; WALEV I, 1995, EMBO J, V14, P1607, DOI 10.1002/j.1460-2075.1995.tb07149.x; Wickenden AD, 1999, CELL PHYSIOL BIOCHEM, V9, P11, DOI 10.1159/000016299; Xiong H, 1999, J MEMBRANE BIOL, V167, P215, DOI 10.1007/s002329900485; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	60	65	66	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39443	39451		10.1074/jbc.M304879200	http://dx.doi.org/10.1074/jbc.M304879200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878608	hybrid			2022-12-27	WOS:000185713800022
J	Simberg, D; Weisman, S; Talmon, Y; Faerman, A; Shoshani, T; Barenholz, Y				Simberg, D; Weisman, S; Talmon, Y; Faerman, A; Shoshani, T; Barenholz, Y			The role of organ vascularization and lipoplex-serum initial contact in intravenous murine lipofection	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED GENE-TRANSFER; DNA LPD COMPLEXES; IN-VIVO; PLASMID DNA; CATIONIC LIPOSOMES; TRANSFECTION EFFICIENCY; PHASE-BEHAVIOR; DELIVERY; EXPRESSION; LIPIDS	Following intravenous administration of cationic lipid-DNA complexes (lipoplexes) into mice, transfection (lipofection) occurs predominantly in the lungs. This was attributed to high entrapment of lipoplexes in the extended lung vascular tree. To determine whether lipofection in other organs could be enhanced by increasing the degree of vascularization, we used a transgenic mouse model with tissue-specific angiogenesis in liver. Tail vein injection of N-(1-(2,3-dioleoyloxy)propyl)-N, N,N-trimethylammonium chloride (DOTAP)/cholesterol lipoplexes resulted in increased lipoplex entrapment in hypervascularized liver but did not boost luciferase expression, suggesting that lipoplex delivery is not a sufficient condition for efficient organ lipofection. Because the intravenously injected lipoplexes migrated within seconds to lungs, we checked whether the effects of immediate contact with serum correlate with lung lipofection efficiency of different DOTAP-based formulations. Under conditions mimicking the injection environment, the lipoplex-serum interaction was strongly dependent on helper lipid and ionic strength: lipoplexes prepared in 150 mM NaCl or lipoplexes with high (>33 mol%) cholesterol were found to aggregate immediately. This aggregation process was irreversible and was inversely correlated with the percentage of lung cells that took up lipoplexes and with the efficiency of lipofection. No other structural changes in serum were observed for cholesterol-based lipoplexes. Dioleoyl phosphatidylethanolamine-based lipoplexes were found to give low expression, apparently because of an immediate loss of integrity in serum, without lipid-DNA dissociation. Our study suggests that efficient in vivo lipofection is the result of cross-talk between lipoplex composition, interaction with serum, hemodynamics, and target tissue "susceptibility" to transfection.	Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Lipsome Res, IL-91120 Jerusalem, Israel; Technion Israel Inst Technol, Dept Chem Engn, IL-32000 Haifa, Israel; Quark Biotech Inc, Cleveland, OH 44106 USA	Hebrew University of Jerusalem; Technion Israel Institute of Technology	Barenholz, Y (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, Lab Membrane & Lipsome Res, POB 12272, IL-91120 Jerusalem, Israel.		Weisman, Sarah/B-5091-2009; Talmon, Yeshayahu/N-1076-2019	Talmon, Yeshayahu/0000-0002-9854-3972				Audouy S, 2001, MOL MEMBR BIOL, V18, P129, DOI 10.1080/713816122; Barron LG, 1999, HUM GENE THER, V10, P1683, DOI 10.1089/10430349950017680; Dass CR, 2002, INT J PHARMACEUT, V241, P1, DOI 10.1016/S0378-5173(02)00194-1; DAVIES B, 1993, PHARMACEUT RES, V10, P1093, DOI 10.1023/A:1018943613122; Dor Y, 2002, EMBO J, V21, P1939, DOI 10.1093/emboj/21.8.1939; Eliyahu H, 2002, GENE THER, V9, P850, DOI 10.1038/sj.gt.3301705; Escriou V, 1998, BBA-BIOMEMBRANES, V1368, P276, DOI 10.1016/S0005-2736(97)00194-6; Even-Chen S, 2000, BBA-BIOMEMBRANES, V1509, P176, DOI 10.1016/S0005-2736(00)00292-3; FELGNER JH, 1994, J BIOL CHEM, V269, P2550; Hirsch-Lerner D, 1999, BBA-BIOMEMBRANES, V1461, P47, DOI 10.1016/S0005-2736(99)00145-5; Hong KL, 1997, FEBS LETT, V400, P233, DOI 10.1016/S0014-5793(96)01397-X; Hui SW, 1996, BIOPHYS J, V71, P590, DOI 10.1016/S0006-3495(96)79309-8; Hwang SH, 2001, GENE THER, V8, P1276, DOI 10.1038/sj.gt.3301510; ISRAELACHVILI JN, 1980, Q REV BIOPHYS, V13, P121, DOI 10.1017/S0033583500001645; KUMAR VV, 1991, P NATL ACAD SCI USA, V88, P444, DOI 10.1073/pnas.88.2.444; Lagane B, 2002, BIOPHYS CHEM, V95, P7, DOI 10.1016/S0301-4622(01)00235-6; Lakowicz J.R, 1999, PRINCIPLES FLUORESCE, P368; LAVNIKOVA N, 1993, AM J RESP CELL MOL, V8, P384, DOI 10.1165/ajrcmb/8.4.384; Li S, 1999, GENE THER, V6, P585, DOI 10.1038/sj.gt.3300865; Li S, 1998, GENE THER, V5, P930, DOI 10.1038/sj.gt.3300683; Li S, 1997, GENE THER, V4, P891, DOI 10.1038/sj.gt.3300482; Liu F, 2002, J CONTROL RELEASE, V78, P259, DOI 10.1016/S0168-3659(01)00494-1; Liu F, 1997, GENE THER, V4, P517, DOI 10.1038/sj.gt.3300424; Mahato RI, 1998, HUM GENE THER, V9, P2083, DOI 10.1089/hum.1998.9.14-2083; Niven R, 1998, J PHARM SCI, V87, P1292, DOI 10.1021/js980087a; OSTROWSKY N, 1993, CHEM PHYS LIPIDS, V64, P45, DOI 10.1016/0009-3084(93)90057-A; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; Sakurai F, 2001, GENE THER, V8, P677, DOI 10.1038/sj.gt.3301460; SHMEEDA H, 1995, AM J PHYSIOL-HEART C, V268, pH759, DOI 10.1152/ajpheart.1995.268.2.H759; Shoshani T, 2002, MOL CELL BIOL, V22, P2283, DOI 10.1128/MCB.22.7.2283-2293.2002; Simberg D, 2001, J BIOL CHEM, V276, P47453, DOI 10.1074/jbc.M105588200; Simberg D, 2000, J LIPOSOME RES, V10, P1, DOI 10.3109/08982100009031091; Smith JG, 1998, PHARMACEUT RES, V15, P1356, DOI 10.1023/A:1011937218418; Song YK, 1998, GENE THER, V5, P1531, DOI 10.1038/sj.gt.3300770; Song YK, 1997, HUM GENE THER, V8, P1585, DOI 10.1089/hum.1997.8.13-1585; Yang JW, 2001, HEPATOLOGY, V33, P848, DOI 10.1053/jhep.2001.23438; Zelphati O, 1998, BBA-LIPID LIPID MET, V1390, P119, DOI 10.1016/S0005-2760(97)00169-0; Zuhorn IS, 2002, BIOPHYS J, V83, P2096, DOI 10.1016/S0006-3495(02)73970-2; Zuidam NJ, 1999, BBA-BIOMEMBRANES, V1419, P207, DOI 10.1016/S0005-2736(99)00069-3; Zuidam NJ, 1998, BBA-BIOMEMBRANES, V1368, P115, DOI 10.1016/S0005-2736(97)00187-9; Zuidam NJ, 1997, BBA-BIOMEMBRANES, V1329, P211, DOI 10.1016/S0005-2736(97)00110-7	41	79	84	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39858	39865		10.1074/jbc.M302232200	http://dx.doi.org/10.1074/jbc.M302232200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869564	hybrid			2022-12-27	WOS:000185713800072
J	Umigai, N; Sato, Y; Mizutani, A; Utsumi, T; Sakaguchi, M; Uozumi, N				Umigai, N; Sato, Y; Mizutani, A; Utsumi, T; Sakaguchi, M; Uozumi, N			Topogenesis of two transmembrane type K+ channels, Kir 2.1 and KcsA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFYING POTASSIUM CHANNEL; ENDOPLASMIC-RETICULUM MEMBRANE; PROTEIN TRANSLOCATION; FUNCTIONAL EXPRESSION; STRUCTURAL MODELS; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; SELECTIVITY; SEGMENTS; BAND-3	Potassium channels, which control the passage of K+ across cell membranes, have two transmembrane segments, M1 and M2, separated by a hydrophobic P region containing a highly conserved signature sequence. Here we analyzed the membrane topogenesis characteristics of the M1, M2, and P regions in two animal and bacterial two-transmembrane segment-type K+ channels, Kir 2.1 and KcsA, using an in vitro translation and translocation system. In contrast to the equivalent transmembrane segment, S5, in the voltage-dependent K+ channel, KAT1, the M1 segment in KcsA, was found to have a strong type II signal-anchor function, which favors the N-cyt/C-exo topology. The N-terminal cytoplasmic region was required for efficient, correctly orientated integration of M1 in Kir 2.1. Analysis of N-terminal modification by in vitro metabolic labeling showed that the N terminus in Kir 2.1 was acetylated. The hydrophobic P region showed no topogenic function, allowing it to form a loop, but not a transmembrane structure in the membrane; this region was transiently exposed in the endoplasmic reticulum lumen during the membrane integration process. M2 was found to possess a stop-transfer function and a type I signal-anchor function, enabling it to span the membrane. The C-terminal cytoplasmic region in KcsA was found to affect the efficiency with which the M2 achieved their final structure. Comparative topogenesis studies of Kir 2.1 and KcsA allowed quantification of the relative contributions of each segment and the cytoplasmic regions to the membrane topology of these two proteins. The membrane topogenesis of the pore-forming structure is discussed using results for Kir 2.1, KcsA, and KAT1.	Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan; Nagoya Univ, Grad Sch Bioagr Sci, Nagoya, Aichi 4648601, Japan; Yamaguchi Univ, Fac Agr, Yamaguchi 7538515, Japan; Kyushu Univ, Grad Sch Med Sci, Dept Mol Biol, Fukuoka 8128582, Japan	Nagoya University; Nagoya University; Yamaguchi University; Kyushu University	Uozumi, N (corresponding author), Nagoya Univ, Biosci & Biotechnol Ctr, Nagoya, Aichi 4648601, Japan.		Uozumi, Nobuyuki/AAG-3252-2019	Uozumi, Nobuyuki/0000-0003-4268-1126				ANDERSON JA, 1992, P NATL ACAD SCI USA, V89, P3736, DOI 10.1073/pnas.89.9.3736; Becker D, 1996, P NATL ACAD SCI USA, V93, P8123, DOI 10.1073/pnas.93.15.8123; BLOBEL G, 1980, P NATL ACAD SCI-BIOL, V77, P1496, DOI 10.1073/pnas.77.3.1496; Boutin JA, 1997, CELL SIGNAL, V9, P15, DOI 10.1016/S0898-6568(96)00100-3; Bradshaw RA, 1998, TRENDS BIOCHEM SCI, V23, P263, DOI 10.1016/S0968-0004(98)01227-4; Daniels R, 2003, MOL CELL, V11, P79, DOI 10.1016/S1097-2765(02)00821-3; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 2000, BIOPHYS J, V78, P188, DOI 10.1016/S0006-3495(00)76584-2; Durell SR, 1999, BIOPHYS J, V77, P775, DOI 10.1016/S0006-3495(99)76931-6; Durell SR, 1999, BIOPHYS J, V77, P789, DOI 10.1016/S0006-3495(99)76932-8; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Goder V, 1999, J CELL BIOL, V147, P257, DOI 10.1083/jcb.147.2.257; Hamasaki N, 2002, BIOCHEMISTRY-US, V41, P3852, DOI 10.1021/bi011918l; Hegde RS, 1997, CELL, V91, P575, DOI 10.1016/S0092-8674(00)80445-6; JACKSON RJ, 1983, METHOD ENZYMOL, V96, P50; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Jiang YX, 2002, NATURE, V417, P515, DOI 10.1038/417515a; Kanki T, 2002, BIOCHEMISTRY-US, V41, P13973, DOI 10.1021/bi026619q; Kato Y, 2001, P NATL ACAD SCI USA, V98, P6488, DOI 10.1073/pnas.101556598; Kida Y, 2000, J CELL BIOL, V150, P719, DOI 10.1083/jcb.150.4.719; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; Kuma H, 2002, BIOCHEMISTRY-US, V41, P3311, DOI 10.1021/bi011678+; Kuo AL, 2003, SCIENCE, V300, P1922, DOI 10.1126/science.1085028; KUROIWA T, 1991, J BIOL CHEM, V266, P9251; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Maser P, 2002, P NATL ACAD SCI USA, V99, P6428, DOI 10.1073/pnas.082123799; Matlack KES, 1998, CELL, V92, P381, DOI 10.1016/S0092-8674(00)80930-7; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Miyazaki E, 2001, J BIOL CHEM, V276, P49221, DOI 10.1074/jbc.M106267200; Ota K, 1998, J BIOL CHEM, V273, P28286, DOI 10.1074/jbc.273.43.28286; Sakaguchi M, 2002, BIOCHEM BIOPH RES CO, V296, P1, DOI 10.1016/S0006-291X(02)00754-4; Sakaguchi M, 1997, CURR OPIN BIOTECH, V8, P595, DOI 10.1016/S0958-1669(97)80035-3; Sato Y, 2003, J BIOL CHEM, V278, P13227, DOI 10.1074/jbc.M300431200; Sato Y, 2002, P NATL ACAD SCI USA, V99, P60, DOI 10.1073/pnas.012399799; SCHREMPF H, 1995, EMBO J, V14, P5170, DOI 10.1002/j.1460-2075.1995.tb00201.x; Schwalbe RA, 1996, J BIOL CHEM, V271, P24201, DOI 10.1074/jbc.271.39.24201; Shindo K, 2001, BBA-PROTEIN STRUCT M, V1545, P153, DOI 10.1016/S0167-4838(00)00273-9; Tu L, 2000, BIOCHEMISTRY-US, V39, P824, DOI 10.1021/bi991740r; UOZUMI N, 1995, J BIOL CHEM, V270, P24276, DOI 10.1074/jbc.270.41.24276; Utsumi T, 2003, FEBS LETT, V539, P37, DOI 10.1016/S0014-5793(03)00180-7; Utsumi T, 2001, J BIOL CHEM, V276, P10505, DOI 10.1074/jbc.M006134200; Utsumi T, 1996, ARCH BIOCHEM BIOPHYS, V326, P179, DOI 10.1006/abbi.1996.0063; WALTER P, 1983, METHOD ENZYMOL, V96, P84; Yang J, 1997, P NATL ACAD SCI USA, V94, P1568, DOI 10.1073/pnas.94.4.1568	44	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40373	40384		10.1074/jbc.M307451200	http://dx.doi.org/10.1074/jbc.M307451200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885768	hybrid			2022-12-27	WOS:000185713800131
J	Allen, S; Lu, H; Thornton, D; Tokatlidis, K				Allen, S; Lu, H; Thornton, D; Tokatlidis, K			Juxtaposition of the two distal CX3C motifs via intrachain disulfide bonding is essential for the folding of Tim10	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INNER MEMBRANE; DEAFNESS DYSTONIA SYNDROME; YEAST ADP/ATP CARRIER; ADP ATP CARRIER; PROTEIN IMPORT; INTERMEMBRANE SPACE; CYSTEINE RESIDUES; TOM COMPLEX; TRANSLOCATION; COMPONENT	The TIM10 complex, composed of the homologous proteins Tim10 and Tim9, chaperones hydrophobic proteins inserted at the mitochondrial inner membrane. A salient feature of the TIM10 complex subunits is their conserved "twin CX3C" motif. Systematic mutational analysis of all cysteines of Tim10 showed that their underlying molecular defect is impaired folding (demonstrated by circular dichroism, aberrant homo-oligomer formation, and thiol trapping assays). As a result of defective folding, clear functional consequences were manifested in (i) complex formation with Tim9, (ii) chaperone activity, and (iii) import into tim9ts mitochondria lacking both endogenous Tim9 and Tim10. The organization of the four cysteines in intrachain disulfides was determined by trypsin digestion and mass spectrometry. The two distal CX3C motifs are juxtaposed in the folded structure and disulfide-bonded to each other rather than within each other, with an inner cysteine pair connecting Cys(44) with Cys(61) and an outer pair between Cys(40) and Cys(65). These cysteine pairs are not equally important for folding and assembly; mutations of the inner Cys are severely affected and form wrong, non-native disulfides, in contrast to mutations of the outer Cys that can still maintain the native inner disulfide pair and display weaker functional defects. Taken together these data reveal this specific intramolecular disulfide bonding as the crucial mechanism for Tim10 folding and show that the inner cysteine pair has a more prominent role in this process.	Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England; Univ Crete, Dept Chem, GR-71110 Iraklion, Greece; Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, GR-71110 Iraklion, Greece	University of Manchester; University of Crete; Foundation for Research & Technology - Hellas (FORTH)	Tokatlidis, K (corresponding author), Univ Manchester, Sch Biol Sci, 2-205 Stopford Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.		Lu, Hui/AAB-5476-2021	Thornton, David/0000-0001-7148-1970; Lu, Hui/0000-0002-7029-2681; Tokatlidis, Kostas/0000-0001-6295-8183; Allen, Scott/0000-0003-4418-7375	MRC [G0000153] Funding Source: UKRI; Medical Research Council [G0000153] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Bauer MF, 2002, INT REV NEUROBIOL, V53, P57; Brix J, 1999, J BIOL CHEM, V274, P16522, DOI 10.1074/jbc.274.23.16522; Carugo O, 2001, PROTEIN ENG, V14, P639, DOI 10.1093/protein/14.9.639; Cemazar M, 2003, P NATL ACAD SCI USA, V100, P5754, DOI 10.1073/pnas.2225470100; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Davis AJ, 2000, J CELL BIOL, V150, P1271, DOI 10.1083/jcb.150.6.1271; Dyall SD, 2003, J BIOL CHEM, V278, P26757, DOI 10.1074/jbc.M302700200; Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214; Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200; Joly JC, 1997, BIOCHEMISTRY-US, V36, P10067, DOI 10.1021/bi9707739; Kerscher O, 2000, MOL BIOL CELL, V11, P103, DOI 10.1091/mbc.11.1.103; Kerscher O, 1997, J CELL BIOL, V139, P1663, DOI 10.1083/jcb.139.7.1663; Koehler CM, 1998, EMBO J, V17, P6477, DOI 10.1093/emboj/17.22.6477; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141; Koehler CM, 2000, FEBS LETT, V476, P27, DOI 10.1016/S0014-5793(00)01664-1; Leuenberger D, 1999, EMBO J, V18, P4816, DOI 10.1093/emboj/18.17.4816; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; MAYER A, 1995, J BIOL CHEM, V270, P12390, DOI 10.1074/jbc.270.21.12390; PFANNER N, 1987, CELL, V49, P815, DOI 10.1016/0092-8674(87)90619-2; Pfanner N, 2001, NAT REV MOL CELL BIO, V2, P339, DOI 10.1038/35073006; PFANNER N, 1987, J BIOL CHEM, V262, P14851; Pfanner N, 2002, CURR OPIN CELL BIOL, V14, P400, DOI 10.1016/S0955-0674(02)00355-1; PFANNER N, 1987, J BIOL CHEM, V262, P7528; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477; Ryan KR, 1998, MOL CELL BIOL, V18, P178, DOI 10.1128/MCB.18.1.178; RYAN KR, 1995, CELL, V83, P517, DOI 10.1016/0092-8674(95)90089-6; Schatz G, 1996, J BIOL CHEM, V271, P31763, DOI 10.1074/jbc.271.50.31763; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; Sirrenberg C, 1996, NATURE, V384, P582, DOI 10.1038/384582a0; Tokatlidis K, 1999, J BIOL CHEM, V274, P35285, DOI 10.1074/jbc.274.50.35285; Tokatlidis K, 2000, BIOCHEM SOC T, V28, P495, DOI 10.1042/0300-5127:0280495; Truscott KN, 2002, MOL CELL BIOL, V22, P7780, DOI 10.1128/MCB.22.22.7780-7789.2002; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; WACHTER C, 1992, EMBO J, V11, P4787, DOI 10.1002/j.1460-2075.1992.tb05584.x; Wang XH, 2000, NAT STRUCT BIOL, V7, P505, DOI 10.1038/75921; Wiedemann N, 2001, EMBO J, V20, P951, DOI 10.1093/emboj/20.5.951	40	74	79	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38505	38513		10.1074/jbc.M306027200	http://dx.doi.org/10.1074/jbc.M306027200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882976	hybrid			2022-12-27	WOS:000185575100052
J	Filippin, L; Magalhaes, PJ; Di Benedetto, G; Colella, M; Pozzan, T				Filippin, L; Magalhaes, PJ; Di Benedetto, G; Colella, M; Pozzan, T			Stable interactions between mitochondria and endoplasmic reticulum allow rapid accumulation of calcium in a subpopulation of mitochondria	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GREEN FLUORESCENT PROTEINS; RAT-LIVER; LIVING CELLS; REDOX STATE; CA2+; OSCILLATIONS; TRANSIENTS; SECRETION; RESPONSES; AEQUORIN	To better understand the functional role of the mitochondrial network in shaping the Ca2+ signals in living cells, we took advantage both of the newest genetically engineered green fluorescent protein-based Ca2+ sensors ("Cameleons," "Camgaroos," and "Pericams") and of the classical Ca2+-sensitive photoprotein aequorin, all targeted to the mitochondrial matrix. The properties of the green fluorescent protein-based probes in terms of subcellular localization, photosensitivity, and Ca2+ affinity have been analyzed in detail. It is concluded that the ratiometric pericam is, at present, the most reliable mitochondrial Ca2+ probe for single cell studies, although this probe too is not devoid of problems. The results obtained with ratiometric pericam in single cells, combined with those obtained at the population level with aequorin, provide strong evidence demonstrating that the close vicinity of mitochondria to the Ca2+ release channels (and thus responsible for the fast uptake of Ca2+ by mitochondria upon receptor activation) are highly stable in time, suggesting the existence of specific interactions between mitochondria and the endoplasmic reticulum.	Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Padua, CNR, Inst Neurosci, I-35121 Padua, Italy; Univ Bari, Dept Gen & Environm Physiol, I-70165 Bari, Italy; Venetian Inst Mol Med, I-35129 Padua, Italy	University of Padua; Consiglio Nazionale delle Ricerche (CNR); University of Padua; Universita degli Studi di Bari Aldo Moro; Veneto Institute Molecular Medicine	Filippin, L (corresponding author), Univ Padua, Dept Biomed Sci, Viale G Colombo 3, I-35121 Padua, Italy.		Colella, Matilde/G-9246-2011; Di Benedetto, Giulietta/L-9842-2019	Colella, Matilde/0000-0002-9584-7030; Di Benedetto, Giulietta/0000-0002-1489-3896; Filippin, Luisa/0000-0001-7690-9147	Telethon [1226] Funding Source: Medline	Telethon(Fondazione Telethon)		ANGERMULLER S, 1983, J HISTOCHEM CYTOCHEM, V31, P230, DOI 10.1177/31.1A_Suppl.6186726; Arnaudeau S, 2001, J BIOL CHEM, V276, P29430, DOI 10.1074/jbc.M103274200; Baird GS, 1999, P NATL ACAD SCI USA, V96, P11241, DOI 10.1073/pnas.96.20.11241; BECKER PL, 1987, AM J PHYSIOL, V253, pC613, DOI 10.1152/ajpcell.1987.253.4.C613; Bereiter-Hahn J., 1990, International Review of Cytology, V122, P1, DOI 10.1016/S0074-7696(08)61205-X; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; BHAKDI S, 1993, MED MICROBIOL IMMUN, V182, P167; Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616; Collins TJ, 2001, J BIOL CHEM, V276, P26411, DOI 10.1074/jbc.M101101200; DUNN KW, 1994, FASEB J, V8, P573, DOI 10.1096/fasebj.8.9.8005385; FLAKS B, 1976, CANCER RES, V36, P2194; FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409; Griesbeck O, 2001, J BIOL CHEM, V276, P29188, DOI 10.1074/jbc.M102815200; HAJNOCZKY G, 1995, CELL, V82, P415, DOI 10.1016/0092-8674(95)90430-1; JOHNSON LV, 1980, P NATL ACAD SCI-BIOL, V77, P990, DOI 10.1073/pnas.77.2.990; Kaftan EJ, 2000, J BIOL CHEM, V275, P25465, DOI 10.1074/jbc.M000903200; KIMBERG DV, 1968, J CELL BIOL, V37, P63, DOI 10.1083/jcb.37.1.63; Maechler P, 1998, J BIOL CHEM, V273, P20770, DOI 10.1074/jbc.273.33.20770; MEIER PJ, 1981, BIOCHIM BIOPHYS ACTA, V646, P283, DOI 10.1016/0005-2736(81)90335-7; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Montero M, 2000, NAT CELL BIOL, V2, P57, DOI 10.1038/35000001; MORRE DJ, 1971, PROTOPLASMA, V73, P43, DOI 10.1007/BF01286410; Nagai T, 2001, P NATL ACAD SCI USA, V98, P3197, DOI 10.1073/pnas.051636098; Park MK, 2001, EMBO J, V20, P1863, DOI 10.1093/emboj/20.8.1863; Pitter JG, 2002, CELL CALCIUM, V31, P97, DOI 10.1054/ceca.2001.0264; PRALONG WF, 1992, P NATL ACAD SCI USA, V89, P132, DOI 10.1073/pnas.89.1.132; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1993, SCIENCE, V262, P744, DOI 10.1126/science.8235595; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Robert V, 2001, EMBO J, V20, P4998, DOI 10.1093/emboj/20.17.4998; Scheenen WJJM, 1996, CHEM BIOL, V3, P765, DOI 10.1016/S1074-5521(96)90253-7; Szabadkai G, 2001, PFLUG ARCH EUR J PHY, V441, P678, DOI 10.1007/s004240000466; Trollinger DR, 2000, BIOPHYS J, V79, P39, DOI 10.1016/S0006-3495(00)76272-2; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509	37	188	199	2	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39224	39234		10.1074/jbc.M302301200	http://dx.doi.org/10.1074/jbc.M302301200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874292	hybrid			2022-12-27	WOS:000185575100137
J	Rizhsky, L; Liang, HJ; Mittler, R				Rizhsky, L; Liang, HJ; Mittler, R			The water-water cycle is essential for chloroplast protection in the absence of stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ASCORBATE PEROXIDASE; CU/ZN-SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; GENE-EXPRESSION; PHOTOOXIDATIVE STRESS; HIGH LIGHT; LEAVES; ARABIDOPSIS; PLANTS	Maintaining electron flow through the photosynthetic apparatus, even in the absence of a sufficient amount of NADP(+) as an electron acceptor, is essential for chloroplast protection from photooxidative stress. At least two different pathways are thought to participate in this process, i.e. cyclic electron flow and the water-water cycle. Although the function of the water-water cycle was inferred from a number of biochemical and physiological studies, genetic evidence for the function of this cycle is very limited. Here we show that knockdown Arabidopsis plants with suppressed expression of the key water-water cycle enzyme, thylakoid-attached copper/zinc superoxide dismutase (KD-SOD), are suppressed in their growth and development. Chloroplast size, chlorophyll content, and photosynthetic activity were also reduced in KD-SOD plants. Microarray analysis of KD-SOD plants, grown under controlled conditions, revealed changes in transcript expression consistent with an acclimation response to light stress. Although a number of transcripts involved in the defense of plants from oxidative stress were induced in KD-SOD plants, and seedlings of KD-SOD plants were more tolerant to oxidative stress, these mechanisms were unable to compensate for the suppression of the water-water cycle in mature leaves. Thus, the localization of copper/zinc superoxide dismutase at the vicinity of photosystem I may be essential for its function. Our studies provide genetic evidence for the importance of the water-water cycle in protecting the photosynthetic apparatus of higher plants from photooxidative damage.	Technion Israel Inst Technol, Dept Biol, IL-32000 Haifa, Israel; Iowa State Univ, Inst Plant Sci, Dept Bot, Ames, IA 50011 USA	Technion Israel Institute of Technology; Iowa State University	Mittler, R (corresponding author), Univ Nevada, Dept Biochem, Reno, NV 89557 USA.		Rizshsky, Ludmila/D-3133-2011; Mittler, Ron/ABE-6496-2020	Rizhsky, Ludmila/0000-0003-2323-8225				Aluru MR, 2001, PLANT PHYSIOL, V127, P67, DOI 10.1104/pp.127.1.67; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Bariola PA, 1999, PLANT PHYSIOL, V119, P331, DOI 10.1104/pp.119.1.331; Berlett BS, 1997, J BIOL CHEM, V272, P20313, DOI 10.1074/jbc.272.33.20313; Choi SM, 2002, PLANTA, V216, P315, DOI 10.1007/s00425-002-0852-z; Foreman J, 2003, NATURE, V422, P442, DOI 10.1038/nature01485; Fryer MJ, 2002, J EXP BOT, V53, P1249, DOI 10.1093/jexbot/53.372.1249; GUPTA AS, 1993, P NATL ACAD SCI USA, V90, P1629, DOI 10.1073/pnas.90.4.1629; Heber U, 2001, J EXP BOT, V52, P1999, DOI 10.1093/jexbot/52.363.1999; Hihara Y, 2001, PLANT CELL, V13, P793, DOI 10.1105/tpc.13.4.793; Konig J, 2002, P NATL ACAD SCI USA, V99, P5738, DOI 10.1073/pnas.072644999; Kovtun Y, 2000, P NATL ACAD SCI USA, V97, P2940, DOI 10.1073/pnas.97.6.2940; MEHLER AH, 1951, ARCH BIOCHEM BIOPHYS, V33, P65, DOI 10.1016/0003-9861(51)90082-3; MITTLER R, 1994, PLANT J, V5, P397, DOI 10.1111/j.1365-313X.1994.00397.x; MITTLER R, 1991, PLANT PHYSIOL, V97, P962, DOI 10.1104/pp.97.3.962; Mittler R, 1997, J CELL SCI, V110, P1333; Mittler R, 2002, TRENDS PLANT SCI, V7, P405, DOI 10.1016/S1360-1385(02)02312-9; Mullineaux P, 2002, CURR OPIN PLANT BIOL, V5, P43, DOI 10.1016/S1369-5266(01)00226-6; Pnueli L, 2003, PLANT J, V34, P187, DOI 10.1046/j.1365-313X.2003.01715.x; Rodriguez AA, 2002, PLANT PHYSIOL, V129, P1627, DOI 10.1104/pp.001222; Rossel JB, 2002, PLANT PHYSIOL, V130, P1109, DOI 10.1104/pp.005595; Vranova E, 2002, P NATL ACAD SCI USA, V99, P10870, DOI 10.1073/pnas.152337999; Yabuta Y, 2002, PLANT J, V32, P915, DOI 10.1046/j.1365-313X.2002.01476.x	24	175	196	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38921	38925		10.1074/jbc.M304987200	http://dx.doi.org/10.1074/jbc.M304987200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885779	hybrid, Green Published			2022-12-27	WOS:000185575100101
J	Bookout, AL; Finney, AE; Guo, RS; Peppel, K; Koch, WJ; Daaka, Y				Bookout, AL; Finney, AE; Guo, RS; Peppel, K; Koch, WJ; Daaka, Y			Targeting G beta gamma signaling to inhibit prostate tumor formation and growth	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTOR; ANDROGEN RECEPTOR; CANCER; KINASE; ACTIVATION; EXPRESSION; PROLIFERATION; GENE	Prostate cancer starts as androgen-dependent malignancy and responds initially to androgen ablative therapy. Beneficial effects of androgen ablation, however, are often temporary and the cancer reappears as androgen-independent tumor, suggesting the existence of additional factors responsible for progression of the disease. Attention has focused on receptor tyrosine kinases as the growth mediators of androgen-independent prostate cancer; overexpression of epidermal growth factor receptors or their ligand heparin-bound epidermal growth factor, for example, promotes transition to androgen independence. Emerging data demonstrate involvement of another class of cell membrane-anchored receptors, the heterotrimeric guanine-binding ( G) protein-coupled receptors (GPCRs) in prostate cancer. In vitro, stimulation of many endogenous GPCRs induces mitogenic signaling and growth of prostate cancer cells. The GPCRs transduce mitogenic signals via activated G proteins in the form of Galpha-GTP and Gbetagamma subunits. Here, we show that expression of a Gbetagamma inhibitor peptide derived from carboxy terminus of G protein-coupled receptor kinase 2 obliterates serum-regulated prostate cancer cell growth in vitro and prevents prostate tumor formation in vivo. We also demonstrate that inhibition of Gbetagamma signaling retards growth of existing prostate tumors by inducing cell death. These data establish a central role for heterotrimeric G proteins in prostate cancer and suggest targeted inhibition of Gbetagamma signaling may serve as specific molecular therapy tool to limit pathologic growth of advanced prostate cancer.	Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pharmacol Canc Biol, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Daaka, Y (corresponding author), Duke Univ, Med Ctr, Dept Surg, Box 2607, Durham, NC 27710 USA.	daaka001@mc.duke.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK060917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017952] Funding Source: NIH RePORTER; NIA NIH HHS [AG17952] Funding Source: Medline; NIDDK NIH HHS [DK60917] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adam RM, 2002, ENDOCRINOLOGY, V143, P4599, DOI 10.1210/en.2002-220561; Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1; Barki-Harrington L, 2001, J UROLOGY, V165, P2121, DOI 10.1016/S0022-5347(05)66305-7; Barki-Harrington L, 2003, BIOCHEM J, V371, P581, DOI 10.1042/BJ20021708; BOSTWICK DG, 1989, UROLOGY, V34, P16; Calvo BF, 2003, CLIN CANCER RES, V9, P1087; Chodak GW, 2002, UROLOGY, V60, P201, DOI 10.1016/S0090-4295(02)01677-1; Craft N, 1999, NAT MED, V5, P280, DOI 10.1038/6495; Daaka Y, 2002, BBA-MOL CELL BIOL L, V1582, P265, DOI 10.1016/S1388-1981(02)00180-4; Djakiew D, 2000, PROSTATE, V42, P150, DOI 10.1002/(SICI)1097-0045(20000201)42:2<150::AID-PROS10>3.0.CO;2-H; Drazner MH, 1997, J CLIN INVEST, V99, P288, DOI 10.1172/JCI119157; Feldman BJ, 2001, NAT REV CANCER, V1, P34, DOI 10.1038/35094009; George DJ, 2002, UROLOGY, V60, P115, DOI 10.1016/S0090-4295(02)01589-3; Gioeli D, 1999, CANCER RES, V59, P279; Grossmann ME, 2001, JNCI-J NATL CANCER I, V93, P1687, DOI 10.1093/jnci/93.22.1687; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Iaccarino G, 1999, P NATL ACAD SCI USA, V96, P3945, DOI 10.1073/pnas.96.7.3945; Isaacs W, 2002, CANCER CELL, V2, P113, DOI 10.1016/S1535-6108(02)00103-4; Jemal A, 2002, CA-CANCER J CLIN, V52, P23, DOI 10.3322/canjclin.52.1.23; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; Kue PF, 2000, J UROLOGY, V164, P2162, DOI 10.1016/S0022-5347(05)66990-X; Kue PF, 2002, INT J CANCER, V102, P572, DOI 10.1002/ijc.10734; Lodowski DT, 2003, SCIENCE, V300, P1256, DOI 10.1126/science.1082348; LUTTRELL LM, 1995, J BIOL CHEM, V270, P16495, DOI 10.1074/jbc.270.28.16495; Nelson J, 2003, NAT REV CANCER, V3, P110, DOI 10.1038/nrc990; Oppermann M, 1996, P NATL ACAD SCI USA, V93, P7649, DOI 10.1073/pnas.93.15.7649; Peppel K, 2000, CIRCULATION, V102, P793, DOI 10.1161/01.CIR.102.7.793; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Porter AT, 2001, UROL ONCOL, V6, P131, DOI 10.1016/S1078-1439(00)00124-1; Price DT, 1999, J UROLOGY, V162, P1537, DOI 10.1016/S0022-5347(05)68354-1; Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/j.cell.2010.06.011; Schwindinger WF, 2001, ONCOGENE, V20, P1653, DOI 10.1038/sj.onc.1204181; Signoretti S, 2000, JNCI-J NATL CANCER I, V92, P1918, DOI 10.1093/jnci/92.23.1918; Taub JS, 2003, CANCER RES, V63, P2037; Xu LL, 2000, CANCER RES, V60, P6568; Yeh SY, 1999, P NATL ACAD SCI USA, V96, P5458, DOI 10.1073/pnas.96.10.5458; Yowell Charles W, 2002, Clin Prostate Cancer, V1, P177, DOI 10.3816/CGC.2002.n.020	37	62	64	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37569	37573		10.1074/jbc.M306276200	http://dx.doi.org/10.1074/jbc.M306276200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869546	hybrid			2022-12-27	WOS:000185437200071
J	Li, HY; Pajor, AM				Li, HY; Pajor, AM			Serines 260 and 288 are involved in sulfate transport by hNaSi-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONFORMATIONALLY SENSITIVE RESIDUES; NA+/DICARBOXYLATE COTRANSPORTER; DICARBOXYLATE COTRANSPORTER; FUNCTIONAL-CHARACTERIZATION; SUBSTRATE; PROTEIN; CATION; SODIUM; NA+; CYSTEINE	The low affinity Na+/sulfate cotransporter, NaSi-1, belongs to the SLC13 family that also includes the Na+/ dicarboxylate cotransporters, NaDC. Two serine residues in hNaSi-1, at positions 260 and 288, are conserved in all of the sulfate transporters in the family whereas the NaDC contain alanine or threonine at those positions. Therefore, the functional roles of serines 260 and 288 in substrate and cation binding by hNaSi-1 were investigated. These two serine residues were first mutated to alanine and the mutants were characterized in Xenopus oocytes. Alanine substitution of Ser-260 resulted in increased Km values for both substrate and Na+ whereas alanine replacement at Ser-288 resulted in a broadened cation selectivity, indicating that these two serines might play important roles in cation and/or substrate binding of hNaSi-1. The two serines and 12 surrounding residues were further mutated to cysteine and studied using a thiol-reactive compound, [2-(trimethylammonium) ethyl] methane-thiosulfonate ( MTSET). Four mutants surrounding Ser-260 (T257C, T259C, T261C, and L263C) were sensitive to MTSET inhibition. The sensitivity to MTSET was dependent on the presence of substrate, suggesting that the accessibility of these substituted cysteines depends on the conformational state of the transporter. Because the four residues are located in transmembrane domain 5, this transmembrane domain is likely to participate in the conformational movements during the transport cycle of hNaSi-1.	Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA	University of Texas System; University of Texas Medical Branch Galveston	Pajor, AM (corresponding author), Univ Texas, Med Branch, Dept Physiol & Biophys, Galveston, TX 77555 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046269] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46269] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHEARN GA, 1984, J MEMBRANE BIOL, V78, P177, DOI 10.1007/BF01925966; Beck L, 2001, KIDNEY INT, V59, P835, DOI 10.1046/j.1523-1755.2001.00566.x; Blostein R, 1997, J BIOL CHEM, V272, P24987, DOI 10.1074/jbc.272.40.24987; Burgess KSD, 1999, J NEUROCHEM, V73, P656, DOI 10.1046/j.1471-4159.1999.0730656.x; BUSCH AE, 1994, J BIOL CHEM, V269, P12407; Danielson MA, 1997, J BIOL CHEM, V272, P32878, DOI 10.1074/jbc.272.52.32878; Griffith DA, 1999, BIOCHEMISTRY-US, V38, P7524, DOI 10.1021/bi990076b; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Kahn ES, 1999, BIOCHEMISTRY-US, V38, P6151, DOI 10.1021/bi9827722; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Lee A, 2000, GENOMICS, V70, P354, DOI 10.1006/geno.2000.6404; Markovich D, 2001, PHYSIOL REV, V81, P1499, DOI 10.1152/physrev.2001.81.4.1499; Morris ME, 2001, J MEMBRANE BIOL, V181, P1; Pajor AM, 1999, BIOCHEM J, V344, P205, DOI 10.1042/0264-6021:3440205; Pajor AM, 1998, BBA-BIOMEMBRANES, V1370, P98, DOI 10.1016/S0005-2736(97)00249-6; Pajor AM, 2000, J MEMBRANE BIOL, V175, P1, DOI 10.1007/s002320001049; Pajor AM, 1996, AM J PHYSIOL-RENAL, V271, pF1093, DOI 10.1152/ajprenal.1996.271.5.F1093; Pajor AM, 1996, AM J PHYSIOL-CELL PH, V271, pC1808, DOI 10.1152/ajpcell.1996.271.6.C1808; PAJOR AM, 1995, J BIOL CHEM, V270, P5779, DOI 10.1074/jbc.270.11.5779; Pajor AM, 2001, J BIOL CHEM, V276, P29961, DOI 10.1074/jbc.M011387200; SEGEL IH, 1975, ENZYME KINETICS, P125; Wang J, 1999, J BIOL CHEM, V274, P2298, DOI 10.1074/jbc.274.4.2298; Wu JH, 1998, J MOL BIOL, V282, P959, DOI 10.1006/jmbi.1998.2065; Yao XZ, 2002, BIOCHEMISTRY-US, V41, P1083, DOI 10.1021/bi0156761; Zhang FF, 2001, BBA-BIOMEMBRANES, V1511, P80, DOI 10.1016/S0005-2736(00)00385-0; Zhang YM, 1999, P NATL ACAD SCI USA, V96, P1710, DOI 10.1073/pnas.96.4.1710	26	9	9	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37204	37212		10.1074/jbc.M305465200	http://dx.doi.org/10.1074/jbc.M305465200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857732	hybrid			2022-12-27	WOS:000185437200028
J	May, P; Bock, HH; Nimpf, J; Herz, J				May, P; Bock, HH; Nimpf, J; Herz, J			Differential glycosylation regulates processing of lipoprotein receptors by gamma-secretase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E RECEPTOR-2; AMYLOID PRECURSOR PROTEIN; O-LINKED GLYCOSYLATION; LDL-RECEPTOR; TYROSINE PHOSPHORYLATION; DEFICIENT MUTANT; VARIANT LACKING; MESSENGER-RNA; IN-VITRO; NOTCH	The low density lipoprotein (LDL) receptor-related protein 1 (LRP1) belongs to a growing number of cell surface proteins that undergo regulated proteolytic processing that culminates in the release of their intracellular domain (ICD) by the intramembranous protease gamma-secretase. Here we show that LRP1 is differentially glycosylated in a tissue-specific manner and that carbohydrate addition reduces proteolytic cleavage of the extracellular domain and, concomitantly, ICD release. The apolipoprotein E ( apoE) receptor-2 (apoER2), another member of the LDL receptor family with functions in cellular signal transmission, also undergoes sequential proteolytic processing, resulting in intracellular domain release into the cytoplasm. The penultimate processing step also involves cleavage of the apoER2 extracellular domain. The rate at which this cleavage step occurs is determined by the glycosylation state of the receptor, which in turn is regulated by the alternative splicing of an exon encoding several O-linked sugar attachment sites. These findings suggest a role for differential and tissue-specific glycosylation as a physiological switch that modulates the diverse biological functions of these receptors in a cell-type specific manner.	Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Vienna, Dept Mol Genet, A-1030 Vienna, Austria	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Vienna	May, P (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Genet, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Bock, Hans/AAF-2635-2021	Nimpf, Johannes/0000-0002-9273-3492	NHLBI NIH HHS [R37 HL063762, HL20948, HL63762] Funding Source: Medline; NINDS NIH HHS [NS43408] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL063762, R37HL063762, P01HL020948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043408] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Baron M, 2003, SEMIN CELL DEV BIOL, V14, P113, DOI 10.1016/S1084-9521(02)00179-9; Blobel CP, 2002, INFLAMM RES, V51, P83, DOI 10.1007/BF02684007; Bock HH, 2003, CURR BIOL, V13, P18, DOI 10.1016/S0960-9822(02)01403-3; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Brandes C, 2001, J BIOL CHEM, V276, P22160, DOI 10.1074/jbc.M102662200; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Bruckner K, 2000, NATURE, V406, P411, DOI 10.1038/35019075; Chen JH, 2001, P NATL ACAD SCI USA, V98, P13716, DOI 10.1073/pnas.241398098; Clatworthy AE, 1999, NEUROSCIENCE, V90, P903, DOI 10.1016/S0306-4522(98)00489-8; Dovey HF, 2001, J NEUROCHEM, V76, P173, DOI 10.1046/j.1471-4159.2001.00012.x; Ebinu JO, 2002, NEURON, V34, P499, DOI 10.1016/S0896-6273(02)00704-3; Galbete JL, 2000, BIOCHEM J, V348, P307, DOI 10.1042/0264-6021:3480307; Herz J, 2002, ANNU REV BIOCHEM, V71, P405, DOI 10.1146/annurev.biochem.71.110601.135342; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Iijima H, 1998, J BIOCHEM-TOKYO, V124, P747, DOI 10.1093/oxfordjournals.jbchem.a022175; Jones C, 2003, J BIOL CHEM, V278, P29024, DOI 10.1074/jbc.M304855200; Kim DH, 1996, J BIOL CHEM, V271, P8373, DOI 10.1074/jbc.271.14.8373; KINGSLEY DM, 1986, CELL, V44, P749, DOI 10.1016/0092-8674(86)90841-X; KINGSLEY DM, 1986, J CELL BIOL, V102, P1576, DOI 10.1083/jcb.102.5.1576; Koch S, 2002, EMBO J, V21, P5996, DOI 10.1093/emboj/cdf599; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Magrane J, 1999, FEBS LETT, V451, P56, DOI 10.1016/S0014-5793(99)00494-9; Martensen PM, 1997, EUR J BIOCHEM, V248, P583, DOI 10.1111/j.1432-1033.1997.00583.x; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Moloney DJ, 2000, NATURE, V406, P369, DOI 10.1038/35019000; Mumm JS, 2000, MOL CELL, V5, P197, DOI 10.1016/S1097-2765(00)80416-5; Munro S, 2000, CURR BIOL, V10, P813, DOI 10.1016/S0960-9822(00)00578-9; Nakamura Y, 1998, BRAIN RES, V793, P47, DOI 10.1016/S0006-8993(98)00112-7; RUSSELL DW, 1984, CELL, V37, P577, DOI 10.1016/0092-8674(84)90388-X; Stockinger W, 2000, J BIOL CHEM, V275, P25625, DOI 10.1074/jbc.M004119200; Sun XM, 1999, EUR J BIOCHEM, V262, P230, DOI 10.1046/j.1432-1327.1999.00394.x; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Trommsdorff M, 1999, CELL, V97, P689, DOI 10.1016/S0092-8674(00)80782-5; Ulery PG, 2000, J BIOL CHEM, V275, P7410, DOI 10.1074/jbc.275.10.7410; Willnow TE, 1996, BIOCHEM J, V313, P71, DOI 10.1042/bj3130071; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	38	120	124	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37386	37392		10.1074/jbc.M305858200	http://dx.doi.org/10.1074/jbc.M305858200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871934	hybrid			2022-12-27	WOS:000185437200049
J	Isshiki, S; Kudo, T; Nishihara, S; Ikehara, Y; Togayachi, A; Furuya, A; Shitara, K; Kubota, T; Watanabe, M; Kitajima, M; Narimatsu, H				Isshiki, S; Kudo, T; Nishihara, S; Ikehara, Y; Togayachi, A; Furuya, A; Shitara, K; Kubota, T; Watanabe, M; Kitajima, M; Narimatsu, H			Lewis type 1 antigen synthase (beta 3Gal-T5) is transcriptionally regulated by homeoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; HOMEODOMAIN PROTEIN CDX2; COLONIC ADENOCARCINOMA CELLS; LACTASE-PHLORHIZIN HYDROLASE; DIPEPTIDYL PEPTIDASE IV; GENE-TRANSCRIPTION; INTESTINAL METAPLASIA; HOMEOBOX GENE; CACO-2 CELLS; ENTEROCYTIC DIFFERENTIATION	The type 1 carbohydrate chain, Galbeta1-3GlcNAc, is synthesized by UDP-galactose:beta-N-acetylglucosamine beta1,3-galactosyltransferase (beta3Gal-T). Among six beta3Gal-Ts cloned to date, beta3Gal-T5 is an essential enzyme for the synthesis of type 1 chain in epithelium of digestive tracts or pancreatic tissue. It forms the type 1 structure on glycoproteins produced from such tissues. In the present study, we found that the transcriptional regulation of the beta3Gal-T5 gene is controlled by homeoproteins, i.e. members of caudal-related homeobox protein (Cdx) and hepatocyte nuclear factor (HNF) families. We found an important region (-151 to -121 from the transcription initiation site), named the beta3Gal-T5 control element (GCE), for the promoter activity. GCE contained the consensus sequences for members of the Cdx and HNF families. Mutations introduced into this sequence abolished the transcriptional activity. Four factors, Cdx1, Cdx2, HNF1alpha, and HNF1beta, could bind to GCE and transcriptionally activate the beta3Gal-T5 gene. Transcriptional regulation of the beta3Gal-T5 gene was consistent with that of members of the Cdx and HNF1 families in two in vivo systems. 1) During in vitro differentiation of Caco-2 cells, transcriptional up-regulation of beta3Gal-T5 was observed in correlation with the increase in transcripts for Cdx2 and HNF1alpha. 2) Both transcript and protein levels of beta3Gal-T5 were determined to be significantly reduced in colon cancer. This down-regulation was correlated with the decrease of Cdx1 and HNF1beta expression in cancer tissue. This is the first finding that a glycosyltransferase gene is transcriptionally regulated under the control of homeoproteins in a tissue-specific manner. beta3Gal-T5, controlled by the intestinal homeoproteins, may play an important role in the specific function of intestinal cells by modifying the carbohydrate structure of glycoproteins.	Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab, Tsukuba, Ibaraki 3058568, Japan; Soka Univ, Inst Life Sci, Div Cell Biol, Tokyo 1928577, Japan; Keio Univ, Sch Med, Dept Surg, Shinjuku Ku, Tokyo 1608582, Japan; Aichi Canc Ctr, Res Inst, Div Oncol Pathol, Chikusa Ku, Nagoya, Aichi 4640021, Japan; Kyowa Hakko Kogyo Co Ltd, Tokyo Res Labs, Machida, Tokyo 1948533, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Soka University; Keio University; Aichi Cancer Center; Kyowa Kirin Ltd	Narimatsu, H (corresponding author), Natl Inst Adv Ind Sci & Technol, Res Ctr Glycosci, Glycogene Funct Team, Open Space Lab, Cent 2,1-1-1 Umoezono, Tsukuba, Ibaraki 3058568, Japan.	h.narimatsu@aist.go.jp	Ikehara, yuzuru/L-7696-2018; Narimatsu, Hisashi/M-4757-2018; Ikehara, yuzuru/R-2239-2019; Togayachi, Akira/M-4144-2018	Ikehara, yuzuru/0000-0002-1915-9172; Narimatsu, Hisashi/0000-0002-8402-133X; Ikehara, yuzuru/0000-0002-1915-9172; Togayachi, Akira/0000-0003-3600-9149; Nishihara, Shoko/0000-0002-1668-2603				Amano J, 2001, ARCH BIOCHEM BIOPHYS, V395, P191, DOI 10.1006/abbi.2001.2572; Amano J, 1999, J BIOL CHEM, V274, P21209, DOI 10.1074/jbc.274.30.21209; Bai YQ, 2002, CANCER LETT, V176, P47, DOI 10.1016/S0304-3835(01)00753-4; Bluteau O, 2002, NAT GENET, V32, P312, DOI 10.1038/ng1001; Boudreau F, 2002, J BIOL CHEM, V277, P31909, DOI 10.1074/jbc.M204622200; Boudreau F, 2001, J BIOL CHEM, V276, P32122, DOI 10.1074/jbc.M102002200; BROCKHAUSEN I, 1991, CANCER RES, V51, P3136; Chawengsaksophak K, 1997, NATURE, V386, P84, DOI 10.1038/386084a0; Domon-Dell C, 2002, GUT, V50, P525, DOI 10.1136/gut.50.4.525; Eda A, 2002, J GASTROENTEROL, V37, P94, DOI 10.1007/s005350200002; Erickson RH, 2000, BIOCHEM BIOPH RES CO, V270, P235, DOI 10.1006/bbrc.2000.2420; Erickson RH, 1999, BIOCHEM J, V338, P91, DOI 10.1042/0264-6021:3380091; Fang RX, 2000, GASTROENTEROLOGY, V118, P115, DOI 10.1016/S0016-5085(00)70420-3; Ichikawa T, 1999, J HISTOCHEM CYTOCHEM, V47, P1593, DOI 10.1177/002215549904701211; Ikehara Y, 1998, GLYCOCONJUGATE J, V15, P799; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Krasinski SD, 2001, AM J PHYSIOL-GASTR L, V281, pG69, DOI 10.1152/ajpgi.2001.281.1.G69; Laurent-Puig P, 2003, GASTROENTEROLOGY, V124, P1311, DOI 10.1016/S0016-5085(03)00268-3; MAGNANI JL, 1983, CANCER RES, V43, P5489; Mallo GV, 1998, J BIOL CHEM, V273, P14030, DOI 10.1074/jbc.273.22.14030; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mitchelmore C, 2000, BIOCHEM J, V346, P529, DOI 10.1042/0264-6021:3460529; MIYAKE M, 1989, CANCER RES, V49, P5689; Sakaguchi T, 2002, J BIOL CHEM, V277, P21361, DOI 10.1074/jbc.M110261200; Salvini R, 2001, J BIOL CHEM, V276, P3564, DOI 10.1074/jbc.M006662200; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; Seko A, 1996, CANCER RES, V56, P3468; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Silberg DG, 2002, GASTROENTEROLOGY, V122, P689, DOI 10.1053/gast.2002.31902; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; Spodsberg N, 1999, GASTROENTEROLOGY, V116, P842, DOI 10.1016/S0016-5085(99)70067-3; Suh E, 1996, MOL CELL BIOL, V16, P619; SUH E, 1994, MOL CELL BIOL, V14, P7340, DOI 10.1128/MCB.14.11.7340; Taylor JK, 1997, DNA CELL BIOL, V16, P1419, DOI 10.1089/dna.1997.16.1419; Traber PG, 1996, ANNU REV PHYSIOL, V58, P275, DOI 10.1146/annurev.physiol.58.1.275; WU GD, 1994, J BIOL CHEM, V269, P17080; YOUAKIM A, 1989, CANCER RES, V49, P6889; Zhou DP, 1999, EUR J BIOCHEM, V263, P571, DOI 10.1046/j.1432-1327.1999.00541.x	38	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36611	36620		10.1074/jbc.M302681200	http://dx.doi.org/10.1074/jbc.M302681200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855703	hybrid			2022-12-27	WOS:000185318300092
J	Song, JY; Lim, JW; Kim, H; Morio, T; Kim, KH				Song, JY; Lim, JW; Kim, H; Morio, T; Kim, KH			Oxidative stress induces nuclear loss of DNA repair proteins Ku70 and Ku80 and apoptosis in pancreatic acinar AR42J cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXIDE-INDUCED APOPTOSIS; KINASE CATALYTIC SUBUNIT; FOCAL CEREBRAL-ISCHEMIA; NF-KAPPA-B; HYDROGEN-PEROXIDE; TRANSPORT FACTORS; EARLY DECREASE; REDOX CYCLE; HL-60 CELLS; LINE AR42J	Cell death linked to oxidative DNA damage has been implicated in acute pancreatitis. The severe DNA damage, which is beyond the capacity of the DNA repair proteins, triggers apoptosis. It has been hypothesized that oxidative stress may induce a decrease in the Ku70 and Ku80 levels and apoptosis in pancreatic acinar cells. In this study, it was found that oxidative stress caused by glucose oxidase (GO) acting on beta-D-glucose, glucose/glucose oxidase (G/GO), induced slight changes in cytoplasmic Ku70 and Ku80 but drastically induced a decrease in nuclear Ku70 and Ku80 both time- and concentration-dependently in AR42J cells. G/GO induced apoptosis determined by poly(ADP-ribose) polymerase cleavage, an increase in expression of p53 and Bax, and a decrease in Bcl-2 expression. G/GO-induced apoptosis was in parallel with the loss of nuclear Ku proteins in AR42J cells. Caspase-3 inhibitor prevented G/GO-induced nuclear Ku loss and cell death. G/GO did not induce apoptosis in the cells transfected with either the Ku70 or Ku80 expression gene but increased apoptosis in those transfected with the Ku dominant negative mutant. Pulse and pulse-chase results show that G/GO induced Ku70 and Ku80 syntheses, even though Ku70 and Ku80 were degraded both in cytoplasm and nucleus. G/GO-induced decrease in Ku binding to importin alpha and importin beta reflects possible modification of nuclear import of Ku proteins. The importin beta level was not changed by G/GO. These results demonstrate that nuclear decrease in Ku70 and Ku80 may result from the decrease in Ku binding to nuclear transporter importins and the degradation of Ku proteins. The nuclear loss of Ku proteins may underlie the mechanism of apoptosis in pancreatic acinar cells after oxidative stress.	Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea; Yonsei Univ, Coll Med, Inst Gastroenterol, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Tokyo Med & Dent Univ, Sch Med, Dept Gen Med, Tokyo 1138519, Japan	Yonsei University; Yonsei University Health System; Yonsei University; Yonsei University Health System; Tokyo Medical & Dental University (TMDU)	Kim, H (corresponding author), Yonsei Univ, Coll Med, Dept Pharmacol, Seoul 120752, South Korea.	kim626@yumc.yonsei.ac.kr		Morio, Tomohiro/0000-0002-9259-1025; Kim, Hyeyoung/0000-0002-7019-917X				AHO HJ, 1982, ACTA PATH MICRO IM A, V90, P367; AJMANI AK, 1995, J EXP MED, V181, P2049, DOI 10.1084/jem.181.6.2049; Arrington ED, 2000, FREE RADICAL BIO MED, V29, P1166, DOI 10.1016/S0891-5849(00)00439-1; BALKWILL FR, 1989, IMMUNOL TODAY, V10, P299, DOI 10.1016/0167-5699(89)90085-6; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; Bjork J, 1982, Agents Actions Suppl, V11, P63; Bliss TM, 1997, J BIOL CHEM, V272, P5765, DOI 10.1074/jbc.272.9.5765; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; CARSON DA, 1993, LANCET, V341, P1251, DOI 10.1016/0140-6736(93)91154-E; Chandra J, 2000, FREE RADICAL BIO MED, V29, P323, DOI 10.1016/S0891-5849(00)00302-6; Chechlacz M, 2001, J NEUROCHEM, V78, P141, DOI 10.1046/j.1471-4159.2001.00380.x; CHRISTOPHE J, 1994, AM J PHYSIOL, V266, pG963, DOI 10.1152/ajpgi.1994.266.6.G963; Cohen MC, 1996, AM J CLIN PATHOL, V105, P589; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Emanuele S, 2002, INT J ONCOL, V21, P857; Endoh D, 2001, RADIAT RES, V155, P320, DOI 10.1667/0033-7587(2001)155[0320:HTIRIN]2.0.CO;2; Endres M, 1997, J CEREBR BLOOD F MET, V17, P1143, DOI 10.1097/00004647-199711000-00002; Featherstone C, 1999, MUTAT RES-DNA REPAIR, V434, P3, DOI 10.1016/S0921-8777(99)00006-3; Ferrando-May E, 2001, CELL DEATH DIFFER, V8, P495, DOI 10.1038/sj.cdd.4400837; FRANGIONI JV, 1993, ANAL BIOCHEM, V210, P179, DOI 10.1006/abio.1993.1170; Fujimura M, 1999, STROKE, V30, P2456, DOI 10.1161/01.STR.30.11.2456; Fujimura M, 1999, J CEREBR BLOOD F MET, V19, P495, DOI 10.1097/00004647-199905000-00003; GUICE KS, 1989, ANN SURG, V210, P740, DOI 10.1097/00000658-198912000-00008; Gukovsaya AS, 1996, GASTROENTEROLOGY, V110, P875, DOI 10.1053/gast.1996.v110.pm8608898; Gukovskaya AS, 1997, J CLIN INVEST, V100, P1853, DOI 10.1172/JCI119714; GUYAN PM, 1990, FREE RADICAL BIO MED, V8, P347, DOI 10.1016/0891-5849(90)90100-W; Hampton MB, 1997, FEBS LETT, V414, P552, DOI 10.1016/S0014-5793(97)01068-5; HARLAN JM, 1984, J CLIN INVEST, V73, P706, DOI 10.1172/JCI111263; HIRAISHI H, 1991, AM J PHYSIOL, V261, pG921, DOI 10.1152/ajpgi.1991.261.6.G921; Holstein SA, 2002, J BIOL CHEM, V277, P10678, DOI 10.1074/jbc.M111369200; HU JJ, 1995, MUTAT RES-DNA REPAIR, V336, P193, DOI 10.1016/0921-8777(94)00054-A; Jang MH, 2002, NEUROSCI LETT, V329, P177, DOI 10.1016/S0304-3940(02)00644-4; Kaiser AM, 1996, AM J PHYSIOL-CELL PH, V271, pC982, DOI 10.1152/ajpcell.1996.271.3.C982; KAISER AM, 1995, AM J PHYSIOL-CELL PH, V269, pC1295, DOI 10.1152/ajpcell.1995.269.5.C1295; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kim SH, 1999, CANCER RES, V59, P4012; Kimura K, 1998, GASTROENTEROLOGY, V114, P372, DOI 10.1016/S0016-5085(98)70490-1; Klein A, 2000, LEUKEMIA, V14, P40, DOI 10.1038/sj.leu.2401636; Koike M, 1999, ONCOGENE, V18, P7495, DOI 10.1038/sj.onc.1203247; Koike M, 1999, EXP CELL RES, V250, P401, DOI 10.1006/excr.1999.4507; Koike M, 1999, J CELL SCI, V112, P4031; Li G, 2002, P NATL ACAD SCI USA, V99, P832, DOI 10.1073/pnas.022649699; Li JJ, 1997, CANCER RES, V57, P3569; Lim JW, 2002, J BIOL CHEM, V277, P46093, DOI 10.1074/jbc.M206603200; Mandal M, 1999, BIOCHEM BIOPH RES CO, V260, P775, DOI 10.1006/bbrc.1999.0966; Marangoni E, 2000, NUCLEIC ACIDS RES, V28, P4778, DOI 10.1093/nar/28.23.4778; Masamune A, 2001, PANCREAS, V22, P75, DOI 10.1097/00006676-200101000-00014; Matsura T, 1999, FREE RADICAL RES, V30, P73, DOI 10.1080/10715769900300081; McConnell KR, 1997, J IMMUNOL, V158, P2083; MIYASHITA T, 1995, CELL, V80, P293; Mizutani H, 2002, J BIOL CHEM, V277, P30684, DOI 10.1074/jbc.M204353200; Morio T, 1999, IMMUNITY, V11, P339, DOI 10.1016/S1074-7613(00)80109-0; Nakielny S, 1999, EMBO J, V18, P1982, DOI 10.1093/emboj/18.7.1982; Nicholson DW, 1997, TRENDS BIOCHEM SCI, V22, P299, DOI 10.1016/S0968-0004(97)01085-2; Nicke B, 1999, AM J PHYSIOL-GASTR L, V276, pG499, DOI 10.1152/ajpgi.1999.276.2.G499; Nonaka A, 1990, Nihon Geka Gakkai Zasshi, V91, P169; Nussenzweig A, 1997, P NATL ACAD SCI USA, V94, P13588, DOI 10.1073/pnas.94.25.13588; Ohno M, 1998, CELL, V92, P327, DOI 10.1016/S0092-8674(00)80926-5; Osipovich O, 1997, J BIOL CHEM, V272, P27259, DOI 10.1074/jbc.272.43.27259; PETRONE WF, 1980, P NATL ACAD SCI-BIOL, V77, P1159, DOI 10.1073/pnas.77.2.1159; Piiper A, 2001, BIOCHEM BIOPH RES CO, V287, P746, DOI 10.1006/bbrc.2001.5651; Pucci S, 2001, ONCOGENE, V20, P739, DOI 10.1038/sj.onc.1204148; Ramadani M, 2001, PANCREAS, V22, P383, DOI 10.1097/00006676-200105000-00008; REEVES WH, 1992, RHEUM DIS CLIN N AM, V18, P391; Saitoh H, 1996, MOL BIOL CELL, V7, P1319, DOI 10.1091/mbc.7.9.1319; Sandoval D, 1996, GASTROENTEROLOGY, V111, P1081, DOI 10.1016/S0016-5085(96)70077-X; SANFEY H, 1985, ANN SURG, V201, P633, DOI 10.1097/00000658-198505000-00013; Sata N, 1997, PANCREAS, V15, P278, DOI 10.1097/00006676-199710000-00010; SCEMAMA JL, 1987, GUT, V28, P233, DOI 10.1136/gut.28.Suppl.233; SCHOENBERG MH, 1995, PANCREAS, V10, P36, DOI 10.1097/00006676-199501000-00005; SCHOENBERG MH, 1988, BRIT J SURG, V75, P1254; SCHOENBERG MH, 1995, AM J CLIN NUTR, V62, P1306, DOI 10.1093/ajcn/62.6.1306S; SCOTT P, 1993, BRIT J SURG, V80, P750, DOI 10.1002/bjs.1800800632; Shackelford DA, 1999, J NEUROSCI, V19, P4727; Song QZ, 1996, EMBO J, V15, P3238, DOI 10.1002/j.1460-2075.1996.tb00688.x; Szabo C, 1996, P NATL ACAD SCI USA, V93, P1753, DOI 10.1073/pnas.93.5.1753; Takuma K, 2002, BRAIN RES, V946, P232, DOI 10.1016/S0006-8993(02)02888-3; TALLARIDA RJ, 1987, MANUAL PHARM CALCULA, P121; TAMURA T, 1995, NATURE, V376, P596, DOI 10.1038/376596a0; Teoh G, 1998, J CLIN INVEST, V101, P1379; Teraoka H, 1996, FEBS LETT, V393, P1, DOI 10.1016/0014-5793(96)00842-3; THURMAN RG, 1972, EUR J BIOCHEM, V25, P420, DOI 10.1111/j.1432-1033.1972.tb01711.x; Velez-Pardo C, 2002, NEUROTOXICOLOGY, V23, P351, DOI 10.1016/S0161-813X(02)00081-5; WISNER J, 1988, GUT, V29, P1516, DOI 10.1136/gut.29.11.1516; Xie YT, 2002, CANCER RES, V62, P3861; Xu Y, 1998, AM J PHYSIOL-CELL PH, V275, pC1058, DOI 10.1152/ajpcell.1998.275.4.C1058; Yasuhara N, 1997, GENES CELLS, V2, P55, DOI 10.1046/j.1365-2443.1997.1010302.x; Yu JH, 2002, LAB INVEST, V82, P1359, DOI 10.1097/01.LAB.0000032377.09626.C7	89	90	91	0	4	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36676	36687		10.1074/jbc.M303692200	http://dx.doi.org/10.1074/jbc.M303692200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12867423	hybrid			2022-12-27	WOS:000185318300099
J	Nyabi, O; Bentahir, M; Horre, K; Herreman, A; Gottardi-Littell, N; Van Broeckhoven, C; Merchiers, P; Spittaels, K; Annaert, W; De Strooper, B				Nyabi, O; Bentahir, M; Horre, K; Herreman, A; Gottardi-Littell, N; Van Broeckhoven, C; Merchiers, P; Spittaels, K; Annaert, W; De Strooper, B			Presenilins mutated at Asp-257 or Asp-385 restore Pen-2 expression and nicastrin glycosylation but remain catalytically inactive in the absence of wild type presenilin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID PRECURSOR PROTEIN; GAMMA-SECRETASE ACTIVITY; FAMILIAL ALZHEIMERS-DISEASE; BETA-PEPTIDE PRODUCTION; INTRACELLULAR DOMAIN; A-BETA; INTRAMEMBRANE PROTEOLYSIS; TRANSMEMBRANE ASPARTATES; MUTANT PRESENILIN-1; CELL-SURFACE	The Presenilins are part of the gamma-secretase complex that is involved in the regulated intramembrane proteolysis of amyloid precursor protein and other type I integral membrane proteins. Nicastrin, Pen-2, and Aph1 are the other proteins of this complex. The Presenilins probably contribute the catalytic activity to the protease complex. However, several investigators reported normal Abeta-peptide generation in cells expressing Presenilins mutated at the putative catalytic site residue Asp-257, contradicting this hypothesis. Because endogenously expressed wild type Presenilin could contribute to residual gamma-secretase activity in these experiments, we have reinvestigated the problem by expressing mutated Presenilins in a Presenilin-negative cell line. We confirm that Presenilins with mutated Asp residues are catalytically inactive. Unexpectedly, these mutated Presenilins are still partially processed into amino-and carboxyl-terminal fragments by a "Presenilinase"-like activity. They are also able to rescue Pen-2 expression and Nicastrin glycosylation in Presenilin-negative cells and become incorporated into large similar to 440-kDa complexes as assessed by blue native gel electrophoresis. Our study demonstrates that the catalytic activity of Presenilin and its other functions in the generation, stabilization, and transport of the gamma-secretase complex can be separated and extends the concept that Presenilins are multifunctional proteins.	Flanders Interuniv Inst Biotechnol VIB4, Ctr Human Genet, Neuronal Cell Biol & Gene Transfer Lab, B-3000 Louvain, Belgium; Katholieke Univ Leuven, B-3000 Louvain, Belgium; Northwestern Univ, Feinberg Sch Med, Dept Pathol, Chicago, IL 60135 USA; Flanders Interuniv Inst Biotechnol VIB, Dept Mol Genet, B-2610 Antwerp, Belgium; Univ Antwerp, UIA, B-2610 Antwerp, Belgium; Galapagos Genom NV, B-2800 Mechelen, Belgium	KU Leuven; Northwestern University; Feinberg School of Medicine; Flanders Institute for Biotechnology (VIB); University of Antwerp; Galapagos NV	De Strooper, B (corresponding author), Herestr 49, B-3000 Louvain, Belgium.	Bart.destrooper@med.kuleuven.ac.be	de+Strooper, Bart/Z-1638-2019; Van Broeckhoven, Christine/M-7853-2019; Van Broeckhoven, Christine/G-8362-2017; De Strooper, Bart/F-6507-2012	Van Broeckhoven, Christine/0000-0003-0183-7665; Van Broeckhoven, Christine/0000-0003-0183-7665; De Strooper, Bart/0000-0001-5455-5819; Horre, Katrien/0000-0002-6801-3137				Annaert W, 2002, ANNU REV CELL DEV BI, V18, P25, DOI 10.1146/annurev.cellbio.18.020402.142302; Annaert WG, 1999, J CELL BIOL, V147, P277, DOI 10.1083/jcb.147.2.277; Annaert WG, 2001, NEURON, V32, P579, DOI 10.1016/S0896-6273(01)00512-8; Beher D, 2001, J BIOL CHEM, V276, P45394, DOI 10.1074/jbc.M103075200; Berezovska O, 2000, J NEUROCHEM, V75, P583, DOI 10.1046/j.1471-4159.2000.0750583.x; Borchelt DR, 1996, NEURON, V17, P1005, DOI 10.1016/S0896-6273(00)80230-5; Campbell WA, 2002, BIOCHEMISTRY-US, V41, P3372, DOI 10.1021/bi015810h; Capell A, 2000, NAT CELL BIOL, V2, P205, DOI 10.1038/35008626; Citron M, 1997, NAT MED, V3, P67, DOI 10.1038/nm0197-67; De Jonghe C, 1999, HUM MOL GENET, V8, P1529, DOI 10.1093/hmg/8.8.1529; De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8; De Strooper B, 2001, NAT CELL BIOL, V3, pE221, DOI 10.1038/ncb1001-e221; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; Donoviel DB, 1999, GENE DEV, V13, P2801, DOI 10.1101/gad.13.21.2801; Duff K, 1996, NATURE, V383, P710, DOI 10.1038/383710a0; Edbauer D, 2002, P NATL ACAD SCI USA, V99, P8666, DOI 10.1073/pnas.132277899; Edbauer D, 2003, NAT CELL BIOL, V5, P486, DOI 10.1038/ncb960; Esler WP, 2000, NAT CELL BIOL, V2, P428, DOI 10.1038/35017062; Francis R, 2002, DEV CELL, V3, P85, DOI 10.1016/S1534-5807(02)00189-2; Goutte C, 2002, P NATL ACAD SCI USA, V99, P775, DOI 10.1073/pnas.022523499; Goutte C, 2000, DEVELOPMENT, V127, P2481; Gu YJ, 2003, J BIOL CHEM, V278, P7374, DOI 10.1074/jbc.M209499200; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; Herreman A, 2003, J CELL SCI, V116, P1127, DOI 10.1242/jcs.00292; Herreman A, 1999, P NATL ACAD SCI USA, V96, P11872, DOI 10.1073/pnas.96.21.11872; Hu Y, 2002, DEV CELL, V2, P69, DOI 10.1016/S1534-5807(01)00105-8; Ida N, 1996, J BIOL CHEM, V271, P22908, DOI 10.1074/jbc.271.37.22908; Ikeuchi T, 2003, J BIOL CHEM, V278, P7751, DOI 10.1074/jbc.C200711200; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Kaether C, 2002, J CELL BIOL, V158, P551, DOI 10.1083/jcb.200201123; Kim DY, 2002, J BIOL CHEM, V277, P49976, DOI 10.1074/jbc.M210179200; Kim SH, 2001, J BIOL CHEM, V276, P43343, DOI 10.1074/jbc.M108245200; Kim TW, 1997, SCIENCE, V277, P373, DOI 10.1126/science.277.5324.373; Kimberly WT, 2003, P NATL ACAD SCI USA, V100, P6382, DOI 10.1073/pnas.1037392100; Kimberly WT, 2002, J BIOL CHEM, V277, P35113, DOI 10.1074/jbc.M204446200; Kimberly WT, 2000, J BIOL CHEM, V275, P3173, DOI 10.1074/jbc.275.5.3173; Lammich S, 2002, J BIOL CHEM, V277, P44754, DOI 10.1074/jbc.M206872200; Leem JY, 2002, NEUROBIOL DIS, V11, P64, DOI 10.1006/nbdi.2002.0546; Leem JY, 2002, J BIOL CHEM, V277, P19236, DOI 10.1074/jbc.C200148200; LEVITAN D, 1995, NATURE, V377, P351, DOI 10.1038/377351a0; Li YM, 2000, P NATL ACAD SCI USA, V97, P6138, DOI 10.1073/pnas.110126897; Li YM, 2000, NATURE, V405, P689, DOI 10.1038/35015085; Loetscher H, 1997, J BIOL CHEM, V272, P20655, DOI 10.1074/jbc.272.33.20655; Marambaud P, 2002, EMBO J, V21, P1948, DOI 10.1093/emboj/21.8.1948; May P, 2002, J BIOL CHEM, V277, P18736, DOI 10.1074/jbc.M201979200; Michiels F, 2002, NAT BIOTECHNOL, V20, P1154, DOI 10.1038/nbt746; Morihara T, 2000, MOL BRAIN RES, V85, P85, DOI 10.1016/S0169-328X(00)00229-1; Murakami D, 2003, ONCOGENE, V22, P1511, DOI 10.1038/sj.onc.1206298; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412; Nyabi O, 2002, NAT CELL BIOL, V4, pE164, DOI 10.1038/ncb0702-e164a; Podlisny MB, 1997, NEUROBIOL DIS, V3, P325, DOI 10.1006/nbdi.1997.0129; Ponting CP, 2002, HUM MOL GENET, V11, P1037, DOI 10.1093/hmg/11.9.1037; SCHAGGER H, 1994, ANAL BIOCHEM, V217, P220, DOI 10.1006/abio.1994.1112; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; Seiffert D, 2000, J BIOL CHEM, V275, P34086, DOI 10.1074/jbc.M005430200; Shen J, 1997, CELL, V89, P629, DOI 10.1016/S0092-8674(00)80244-5; Sherrington R, 1996, HUM MOL GENET, V5, P985, DOI 10.1093/hmg/5.7.985; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; Steiner H, 2000, NAT CELL BIOL, V2, P848, DOI 10.1038/35041097; Steiner H, 2002, J BIOL CHEM, V277, P39062, DOI 10.1074/jbc.C200469200; Steiner H, 1999, J BIOL CHEM, V274, P28669, DOI 10.1074/jbc.274.40.28669; Struhl G, 2000, MOL CELL, V6, P625, DOI 10.1016/S1097-2765(00)00061-7; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; Takasugi N, 2003, NATURE, V422, P438, DOI 10.1038/nature01506; Thinakaran G, 1997, J BIOL CHEM, V272, P28415, DOI 10.1074/jbc.272.45.28415; Weihofen A, 2002, SCIENCE, V296, P2215, DOI 10.1126/science.1070925; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Wong PC, 1997, NATURE, V387, P288, DOI 10.1038/387288a0; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Yu G, 2000, NATURE, V407, P48, DOI 10.1038/35024009; Yuan H, 1999, J NEUROSCI METH, V88, P45, DOI 10.1016/S0165-0270(99)00011-4	73	92	93	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43430	43436		10.1074/jbc.M306957200	http://dx.doi.org/10.1074/jbc.M306957200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12885769	hybrid			2022-12-27	WOS:000186157000087
J	Fuglsang, AT; Borch, J; Bych, K; Jahn, TP; Roepstorff, P; Palmgren, MG				Fuglsang, AT; Borch, J; Bych, K; Jahn, TP; Roepstorff, P; Palmgren, MG			The binding site for regulatory 14-3-3 protein in plant plasma membrane H+-ATPase - Involvement of a region promoting phosphorylation-independent interaction in addition to the phosphorylation-dependent C-terminal end	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							14-3-3 PROTEINS; EXOENZYME-S; PSEUDOMONAS-AERUGINOSA; NITRATE REDUCTASE; BLUE-LIGHT; FUSICOCCIN; YEAST; COMPLEX; COMPLEMENTATION; RESIDUES	14-3-3 proteins constitute a family of well conserved proteins interacting with a large number of phosphorylated binding partners in eukaryotic cells. The plant plasma membrane H+-ATPase is an unusual target in that a unique phosphothreonine motif ((946)YpTV, where pT represents phosphothreonine) in the extreme C-terminal end of the H+-ATPase interacts with the binding cleft of 14-3-3 protein (Wurtele, M., Jelich-Ottmann, C., Wittinghofer, A., and Oecking, C. (2003) EMBO J. 22, 987-994). We report binding of 14-3-3 protein to a non-phosphorylated peptide representing the 34 C-terminal residues of the Arabidopsis plasma membrane H+-ATPase isoform 2 (AHA2). Following site-directed mutagenesis within the 45 C-terminal residues of AHA2, we conclude that, in addition to the 946YpTV motif, a number of residues located further upstream are required for phosphorylation-independent binding of 14-3-3. Among these, Thr-924 is important for interaction with 14-3-3 protein even when Thr-947 is phosphorylated. We suggest that the role of phosphorylation, which is accentuated by fusicoccin, is to stabilize protein-protein interaction between 14-3-3 protein and several residues of the H+-ATPase C-terminal domain.	Royal Vet & Agr Univ, Dept Plant Biol, Plant Physiol & Anat Lab, DK-1871 Frederiksberg C, Denmark; Univ So Denmark, Dept Biochem & Mol Biol, DK-5230 Odense, Denmark; Royal Vet & Agr Univ, Plant Nutr Lab, Dept Agr Sci, DK-1871 Frederiksberg C, Denmark; Univ Paris 06, CNRS, F-75252 Paris, France	University of Copenhagen; University of Southern Denmark; University of Copenhagen; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Palmgren, MG (corresponding author), Royal Vet & Agr Univ, Dept Plant Biol, Plant Physiol & Anat Lab, Thorvaldsensvej 40, DK-1871 Frederiksberg C, Denmark.		Palmgren, Michael/A-9808-2013; fuglsang, anja thoe t/E-1683-2012; Fuglsang, Anja Thoe/A-6733-2015	Palmgren, Michael/0000-0002-9982-6114; fuglsang, anja thoe t/0000-0003-1153-8394; Fuglsang, Anja Thoe/0000-0003-1153-8394				Axelsen KB, 1999, BIOCHEMISTRY-US, V38, P7227, DOI 10.1021/bi982482l; Bachmann M, 1996, FEBS LETT, V398, P26, DOI 10.1016/S0014-5793(96)01188-X; Baunsgaard L, 1998, PLANT J, V13, P661, DOI 10.1046/j.1365-313X.1998.00083.x; Bunney TD, 2001, P NATL ACAD SCI USA, V98, P4249, DOI 10.1073/pnas.061437498; CID A, 1987, CURR GENET, V12, P105, DOI 10.1007/BF00434664; Finnie C, 1999, PLANT MOL BIOL, V40, P545, DOI 10.1023/A:1006211014713; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Fuglsang AT, 1999, J BIOL CHEM, V274, P36774, DOI 10.1074/jbc.274.51.36774; Fullone MR, 1998, J BIOL CHEM, V273, P7698, DOI 10.1074/jbc.273.13.7698; Henriksson ML, 2000, BIOCHEM J, V349, P697, DOI 10.1042/bj3490697; Henriksson ML, 2002, EUR J BIOCHEM, V269, P4921, DOI 10.1046/j.1432-1033.2002.03191.x; Jahn T, 1997, PLANT CELL, V9, P1805, DOI 10.1105/tpc.9.10.1805; Jahn TP, 2002, J BIOL CHEM, V277, P6353, DOI 10.1074/jbc.M109637200; Jelich-Ottmann C, 2001, J BIOL CHEM, V276, P39852, DOI 10.1074/jbc.M106746200; Kinoshita T, 1999, EMBO J, V18, P5548, DOI 10.1093/emboj/18.20.5548; Kinoshita T, 2002, PLANT CELL PHYSIOL, V43, P1359, DOI 10.1093/pcp/pcf167; Kinoshita T, 2001, PLANT CELL PHYSIOL, V42, P424, DOI 10.1093/pcp/pce055; MARRE E, 1979, ANNU REV PLANT PHYS, V30, P273, DOI 10.1146/annurev.pp.30.060179.001421; Masters SC, 1999, BIOCHEMISTRY-US, V38, P5216, DOI 10.1021/bi982492m; Maudoux O, 2000, J BIOL CHEM, V275, P17762, DOI 10.1074/jbc.M909690199; Moorhead G, 1996, CURR BIOL, V6, P1104, DOI 10.1016/S0960-9822(02)70677-5; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; Oecking C, 1999, PLANTA, V207, P480, DOI 10.1007/s004250050507; Oecking C, 1997, PLANT J, V12, P441, DOI 10.1046/j.1365-313X.1997.12020441.x; Olsson A, 1998, PLANT PHYSIOL, V118, P551, DOI 10.1104/pp.118.2.551; PALMGREN MG, 1993, FEBS LETT, V317, P216, DOI 10.1016/0014-5793(93)81279-9; PALMGREN MG, 1991, J BIOL CHEM, V266, P20470; Palmgren MG, 2001, ANNU REV PLANT PHYS, V52, P817, DOI 10.1146/annurev.arplant.52.1.817; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Piotrowski M, 1998, J BIOL CHEM, V273, P30018, DOI 10.1074/jbc.273.45.30018; REGENBERG B, 1995, PLANT CELL, V7, P1655, DOI 10.1105/tpc.7.10.1655; Roberts MR, 2003, TRENDS PLANT SCI, V8, P218, DOI 10.1016/S1360-1385(03)00056-6; Sehnke PC, 2002, PLANT CELL, V14, pS339, DOI 10.1105/tpc.010430; Svennelid F, 1999, PLANT CELL, V11, P2379, DOI 10.1105/tpc.11.12.2379; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; van Hemert MJ, 2001, BIOESSAYS, V23, P936, DOI 10.1002/bies.1134; Wang BC, 1999, BIOCHEMISTRY-US, V38, P12499, DOI 10.1021/bi991353h; Wurtele M, 2003, EMBO J, V22, P987, DOI 10.1093/emboj/cdg104; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang LX, 1999, BIOCHEMISTRY-US, V38, P12159, DOI 10.1021/bi991019l	41	77	80	3	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42266	42272		10.1074/jbc.M306707200	http://dx.doi.org/10.1074/jbc.M306707200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888557	hybrid			2022-12-27	WOS:000185989500086
J	Lim, D; Ercolano, E; Kyozuka, K; Nusco, GA; Moccia, F; Lange, K; Santella, L				Lim, D; Ercolano, E; Kyozuka, K; Nusco, GA; Moccia, F; Lange, K; Santella, L			The M-phase-promoting factor modulates the sensitivity of the Ca2+ stores to inositol 1,4,5-trisphosphate via the actin cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIN-DEPENDENT KINASES; INDUCED CALCIUM OSCILLATIONS; STARFISH OOCYTE MATURATION; MEIOSIS REINITIATION; NUCLEAR TRANSLOCATION; GERMINAL VESICLE; PROTEIN-KINASE; FROG OOCYTES; HELA-CELLS; FERTILIZATION	The resumption of the meiotic cycle ( maturation) induced by 1-methyladenine in prophase-arrested starfish oocytes is indicated by the breakdown of the germinal vesicle and is characterized by the increased sensitivity of the Ca2+ stores to inositol 1,4,5-trisphosphate (InsP(3)) to InsP(3) starting at the animal hemisphere ( where the germinal vesicle was originally located) and propagating along the animal/vegetal axis of the oocyte. This initiates Ca2+ signals around the germinal vesicle before nuclear envelope breakdown. Previous studies have suggested that the final activation of the maturation-promoting factor (MPF), a cyclin-dependent kinase, which is the major element controlling the entry of eukaryotic cells into the M phase, occurs in the nucleus. MPF is then exported to the cytoplasm where its activity is autocatalytically amplified following a similar animal/ vegetal spatial pattern. We have investigated whether activated MPF was involved in the increased sensitivity of the Ca2+ response to InsP(3). We have found that the development of increased sensitivity of the Ca2+ stores to InsP(3) receptors together with the Ca2+ signals in the perinuclear region was blocked in oocytes treated with the specific MPF inhibitor roscovitine. That the nuclear MPF activation is indeed required for changes of the InsP(3) receptors sensitivity was shown by enucleating or by dissecting oocytes into vegetal and animal hemispheres prior to the addition of 1-MA. MPF activity 50 min after 1-methyladenine addition was much lower in the enucleated oocytes and in the vegetal hemisphere, which did not contain the germinal vesicle, as compared with the animal hemisphere, which did contain it. The Ca2+ increase induced by InsP(3) under these experimental conditions correlated with the changes in actin cytoskeleton induced by MPF.	Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy; Asamushi Marine Biol Stn, Aomori 0393501, Japan	Stazione Zoologica Anton Dohrn di Napoli	Santella, L (corresponding author), Staz Zool Anton Dohrn, Cell Biol Lab, I-80121 Naples, Italy.	santella@szn.it	Moccia, Francesco/AAX-6447-2020; Lim, Dmitry/H-9101-2012; Santella, Luigia/AAM-3524-2020	Moccia, Francesco/0000-0003-0010-0098; Santella, Luigia/0000-0001-7159-0499				Beckhelling C, 2000, BIOL CELL, V92, P245, DOI 10.1016/S0248-4900(00)01067-4; Borgne A, 1996, J BIOL CHEM, V271, P27847, DOI 10.1074/jbc.271.44.27847; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Carroll J, 1996, Rev Reprod, V1, P137, DOI 10.1530/ror.0.0010137; CHIBA K, 1990, DEV BIOL, V140, P300, DOI 10.1016/0012-1606(90)90080-3; Deng MQ, 2000, BIOL REPROD, V62, P873, DOI 10.1095/biolreprod62.4.873; FESQUET D, 1993, EMBO J, V12, P3111, DOI 10.1002/j.1460-2075.1993.tb05980.x; Gall L, 2002, MOL REPROD DEV, V62, P4, DOI 10.1002/mrd.10117; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; Iwasaki H, 2002, J BIOL CHEM, V277, P2763, DOI 10.1074/jbc.M108839200; KANATANI H, 1969, NATURE, V221, P273, DOI 10.1038/221273a0; Kishimoto T, 1999, DEV BIOL, V214, P1, DOI 10.1006/dbio.1999.9393; KUME S, 1993, CELL, V73, P555, DOI 10.1016/0092-8674(93)90142-D; KURAISHI R, 1989, DEV BIOL, V136, P304, DOI 10.1016/0012-1606(89)90257-1; LABBE JC, 1989, EMBO J, V8, P3053, DOI 10.1002/j.1460-2075.1989.tb08456.x; Levasseur M, 2000, DEVELOPMENT, V127, P631; Lim D, 2002, FASEB J, V16, P1050, DOI 10.1096/fj.02-0021com; Lim D, 2001, FASEB J, V15, P2257, DOI 10.1096/fj.01-0157com; MASUI Y, 1972, J EXP ZOOL, V179, P365, DOI 10.1002/jez.1401790308; MASUI Y, 1971, J EXP ZOOL, V177, P129, DOI 10.1002/jez.1401770202; Meijer L, 1997, EUR J BIOCHEM, V243, P527, DOI 10.1111/j.1432-1033.1997.t01-2-00527.x; MEIJER L, 1984, INT REV CYTOL, V86, P129, DOI 10.1016/S0074-7696(08)60179-5; MEIJER L, 1987, DEV BIOL, V121, P306, DOI 10.1016/0012-1606(87)90166-7; MOREAU M, 1978, NATURE, V272, P251, DOI 10.1038/272251a0; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; NEMOTO SI, 1983, EXP CELL RES, V145, P226, DOI 10.1016/S0014-4827(83)80025-1; NURSE P, 1980, GENETICS, V96, P627; Okumura E, 2002, NAT CELL BIOL, V4, P111, DOI 10.1038/ncb741; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; Patel R, 1999, J BIOL CHEM, V274, P7958, DOI 10.1074/jbc.274.12.7958; Patra D, 1996, GENE DEV, V10, P1503, DOI 10.1101/gad.10.12.1503; Picard A, 1998, BIOL CELL, V90, P487, DOI 10.1016/S0248-4900(99)80007-0; PICARD A, 1984, DEV BIOL, V104, P357, DOI 10.1016/0012-1606(84)90091-5; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; Santella L, 1997, EUR J BIOCHEM, V246, P602, DOI 10.1111/j.1432-1033.1997.t01-1-00602.x; SANTELLA L, 1994, BIOCHEM BIOPH RES CO, V203, P674, DOI 10.1006/bbrc.1994.2235; STRICKER SA, 1995, DEV BIOL, V170, P496, DOI 10.1006/dbio.1995.1232; Torok K, 1998, CURR BIOL, V8, P692, DOI 10.1016/S0960-9822(98)70275-1; Toyoshima-Morimoto F, 2002, EMBO REP, V3, P341, DOI 10.1093/embo-reports/kvf069; Wang Y, 2002, J NEUROCHEM, V82, P945, DOI 10.1046/j.1471-4159.2002.01059.x; Wilding M, 1996, J CELL BIOL, V135, P191, DOI 10.1083/jcb.135.1.191	42	41	41	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42505	42514		10.1074/jbc.M301851200	http://dx.doi.org/10.1074/jbc.M301851200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12867432	hybrid			2022-12-27	WOS:000185989500115
J	Breitkreuz, KE; Allan, WL; Van Cauwenberghe, OR; Jakobs, C; Talibi, D; Andre, B; Shelp, BJ				Breitkreuz, KE; Allan, WL; Van Cauwenberghe, OR; Jakobs, C; Talibi, D; Andre, B; Shelp, BJ			A novel gamma-hydroxybutyrate dehydrogenase - Identification and expression of an Arabidopsis cDNA and potential role under oxygen deficiency	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUCCINIC-SEMIALDEHYDE DEHYDROGENASE; ISOTOPE-DILUTION ANALYSIS; SACCHAROMYCES-CEREVISIAE; AMINOBUTYRIC-ACID; ESCHERICHIA-COLI; OXIDATIVE STRESS; RAT-BRAIN; METABOLISM; CLONING; GABA	In plants, gamma-aminobutyrate (GABA), a non-protein amino acid, accumulates rapidly in response to a variety of abiotic stresses such as oxygen deficiency. Under normoxia, GABA is catabolized to succinic semialdehyde and then to succinate with the latter reaction being catalyzed by succinic semialdehyde dehydrogenase (SSADH). Complementation of an SSADH-deficient yeast mutant with an Arabidopsis cDNA library enabled the identification of a novel cDNA ( designated as AtGH-BDH for Arabidopsis thaliana gamma-hydroxybutyrate dehydrogenase), which encodes a 289-amino acid polypeptide containing an NADP-binding domain. Constitutive expression of AtGHBDH in the mutant yeast enabled growth on 20 mM GABA and significantly enhanced the cellular concentrations of gamma-hydroxybutyrate, the product of the GHDBH reaction. These data confirm that the cDNA encodes a polypeptide with GHBDH activity. Arabidopsis plants subjected to flooding-induced oxygen deficiency for up to 4 h possessed elevated concentrations of gamma-hydroxybutyrate as well as GABA and alanine. RNA expression analysis revealed that GHBDH transcription was not up-regulated by oxygen deficiency. These findings suggest that GHBDH activity is regulated by the supply of succinic semialdehyde or by redox balance. It is proposed that GHBDH and SSADH activities in plants are regulated in a complementary fashion and that GHBDH and gamma-hydroxybutyrate function in oxidative stress tolerance.	Univ Guelph, Dept Plant Agr, Div Biotechnol, Guelph, ON N1G 2W1, Canada; Vrije Univ Med Ctr, Dept Clin Chem & Pediat, NL-1081 HV Amsterdam, Netherlands; Free Univ Brussels, Lab Physiol Cellulaire & Genet Levures, B-1050 Brussels, Belgium	University of Guelph; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Shelp, BJ (corresponding author), Univ Guelph, Dept Plant Agr, Div Biotechnol, Bovey Bldg, Guelph, ON N1G 2W1, Canada.		André, Bruno/D-1725-2010					ALLAN WL, 2003, IN PRESS CAN J PLANT; ALLAN WL, 2003, APPL B AGILENT TECHN, P4; Andriamampandry C, 1998, BIOCHEM J, V334, P43, DOI 10.1042/bj3340043; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BORMANN J, 1988, TRENDS NEUROSCI, V11, P112, DOI 10.1016/0166-2236(88)90156-7; Bouche N, 2003, P NATL ACAD SCI USA, V100, P6843, DOI 10.1073/pnas.1037532100; Bown A., 1989, BIOCH LIFE SCI ADV, V8, P21; Bown AW, 1997, PLANT PHYSIOL, V115, P1, DOI 10.1104/pp.115.1.1; Buckel W, 2001, APPL MICROBIOL BIOT, V57, P263, DOI 10.1007/s002530100773; Busch K, 2000, BIOCHEMISTRY-US, V39, P10110, DOI 10.1021/bi000589e; Busch KB, 1999, PLANT PHYSIOL, V121, P589, DOI 10.1104/pp.121.2.589; CASH CD, 1994, NEUROSCI BIOBEHAV R, V18, P291, DOI 10.1016/0149-7634(94)90031-0; Coleman ST, 2001, J BIOL CHEM, V276, P244, DOI 10.1074/jbc.M007103200; DOHLMEN RJ, 1991, YEAST, V7, P691; Drew MC, 1997, ANNU REV PLANT PHYS, V48, P223, DOI 10.1146/annurev.arplant.48.1.223; Galloway GP, 1997, ADDICTION, V92, P89, DOI 10.1111/j.1360-0443.1997.tb03640.x; GIBSON KM, 1990, BIOMED ENVIRON MASS, V19, P89, DOI 10.1002/bms.1200190207; GOOD AG, 1992, PLANT PHYSIOL, V99, P1520, DOI 10.1104/pp.99.4.1520; Harding SA, 1997, EMBO J, V16, P1137, DOI 10.1093/emboj/16.6.1137; HARDMAN JK, 1963, J BIOL CHEM, V238, P2088; Hawes JW, 1996, FEBS LETT, V389, P263, DOI 10.1016/0014-5793(96)00597-2; Hechler V, 1997, J PHARMACOL EXP THER, V281, P753; Henderson Jr J. W., 2000, 59801193E AG TECHN I; Kinnersley AM, 2000, CRIT REV PLANT SCI, V19, P479, DOI 10.1016/S0735-2689(01)80006-X; KOK RM, 1993, J INHERIT METAB DIS, V16, P508, DOI 10.1007/BF00711667; Lee SH, 1997, J BIOL CHEM, V272, P9252, DOI 10.1074/jbc.272.14.9252; Madden TE, 1998, J PHARMACOL EXP THER, V287, P261; Maitre M, 1997, PROG NEUROBIOL, V51, P337, DOI 10.1016/S0301-0082(96)00064-0; MAMELAK M, 1989, NEUROSCI BIOBEHAV R, V13, P187, DOI 10.1016/S0149-7634(89)80053-3; MARINI AM, 1994, EMBO J, V13, P3456, DOI 10.1002/j.1460-2075.1994.tb06651.x; Marwick C, 1997, JAMA-J AM MED ASSOC, V277, P1505, DOI 10.1001/jama.277.19.1505; METZER E, 1990, J BACTERIOL, V172, P3250, DOI 10.1128/jb.172.6.3250-3256.1990; MINET M, 1992, PLANT J, V2, P417; Moller IM, 2001, ANNU REV PLANT PHYS, V52, P561, DOI 10.1146/annurev.arplant.52.1.561; RAMOS F, 1985, EUR J BIOCHEM, V149, P401, DOI 10.1111/j.1432-1033.1985.tb08939.x; ROSEN MD, 1990, METHODS YEAST GENETI; RUMIGNY JF, 1980, FEBS LETT, V117, P111, DOI 10.1016/0014-5793(80)80924-0; Sambrook J., 2002, MOL CLONING LAB MANU; Schaller M, 1999, EUR J BIOCHEM, V265, P1056, DOI 10.1046/j.1432-1327.1999.00826.x; Shelp BJ, 1999, TRENDS PLANT SCI, V4, P446, DOI 10.1016/S1360-1385(99)01486-7; SHELP BJ, 1992, CAN J PLANT SCI, V72, P883, DOI 10.4141/cjps92-111; VALENTIN HE, 1995, EUR J BIOCHEM, V227, P43, DOI 10.1111/j.1432-1033.1995.tb20358.x; Valentin HE, 2000, BIOTECHNOL BIOENG, V67, P291, DOI 10.1002/(SICI)1097-0290(20000205)67:3<291::AID-BIT5>3.0.CO;2-J; Van Cauwenberghe OR, 1999, PHYTOCHEMISTRY, V52, P575, DOI 10.1016/S0031-9422(99)00301-5; Van Cauwenberghe OR, 2002, CAN J BOT, V80, P933, DOI [10.1139/B02-087, 10.1139/b02-087]; WOLFF RA, 1993, APPL ENVIRON MICROB, V59, P1876, DOI 10.1128/AEM.59.6.1876-1882.1993	46	88	117	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41552	41556		10.1074/jbc.M305717200	http://dx.doi.org/10.1074/jbc.M305717200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882961	Green Submitted, hybrid			2022-12-27	WOS:000185847200136
J	Gross, C; Koelch, W; DeMaio, A; Arispe, N; Multhoff, G				Gross, C; Koelch, W; DeMaio, A; Arispe, N; Multhoff, G			Cell surface-bound heat shock protein 70 (Hsp70) mediates perforin-independent apoptosis by specific binding and uptake of granzyme B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK-PROTEIN; TUMOR-CELLS; IN-VITRO; RECEPTOR; PEPTIDE; PATHWAY; HSC70; CHAPERONES; EXPRESSION; LIGAND	Cell surface-bound heat shock protein 70 (Hsp70) renders tumor cells more sensitive to the cytolytic attack mediated by natural killer (NK) cells. A 14-amino acid Hsp70 sequence, termed TKD (TKDNNLLGRFELSG, aa(450-463)) could be identified as the extracellular localized recognition site for NK cells. Here, we show by affinity chromatography that both, full-length Hsp70-protein and Hsp70-peptide TKD, specifically bind a 32-kDa protein derived from NK cell lysates. The serine protease granzyme B was uncovered as the 32-kDa Hsp70-interacting protein using matrix-assisted laser desorption ionization time-of-flight mass peptide fingerprinting. Incubation of tumor cells with increasing concentrations of perforin-free, isolated granzyme B shows specific binding and uptake in a dose-dependent manner and results in initiation of apoptosis selectively in tumor cells presenting Hsp70 on the cell surface. Remarkably, Hsp70 cation channel activity was also determined selectively in purified phospholipid membranes of Hsp70 membrane-positive but not in membrane-negative tumor cells. The physiological role of our findings was demonstrated in primary NK cells showing elevated cytoplasmic granzyme B levels following contact with TKD. Furthermore, an increased lytic activity of Hsp70 membrane-positive tumor cells could be associated with granzyme B release by NK cells. Taken together we propose a novel perforin-independent, granzyme B-mediated apoptosis pathway for Hsp70 membrane-positive tumor cells.	Univ Hosp Regensburg, Dept Hematol, D-93053 Regensburg, Germany; Univ Glasgow, CRC, Beatson Labs, Inst Biomed & Life Sci, Glasgow G61 1BD, Lanark, Scotland; Johns Hopkins Univ, Sch Med, Div Pediat Surg, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Physiol, Baltimore, MD 21205 USA; Uniformed Serv Univ Hlth Sci, Dept Anat & Cell Biol, Bethesda, MD 20814 USA	University of Regensburg; Beatson Institute; University of Glasgow; Johns Hopkins University; Johns Hopkins University; Uniformed Services University of the Health Sciences - USA	Multhoff, G (corresponding author), Univ Hosp Regensburg, Dept Hematol, Franz Josef Strauss Allee 11, D-93053 Regensburg, Germany.	gabriele.multhoff@klinik.uni-regensburg.de	Multhoff, Gabriele/AAW-9796-2021	Multhoff, Gabriele/0000-0002-2616-3137; Gross, Catharina/0000-0002-4872-9189				Andrade F, 1998, IMMUNITY, V8, P451, DOI 10.1016/S1074-7613(00)80550-6; Arispe N, 2000, J BIOL CHEM, V275, P30839, DOI 10.1074/jbc.M005226200; Arispe N, 2002, CELL STRESS CHAPERON, V7, P330, DOI 10.1379/1466-1268(2002)007<0330:LIDTCA>2.0.CO;2; Arnold-Schild D, 1999, J IMMUNOL, V162, P3757; Asea A, 2000, CELL STRESS CHAPERON, V5, P425, DOI 10.1379/1466-1268(2000)005<0425:HPBAPN>2.0.CO;2; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435, DOI 10.1038/74697; Basu S, 2001, IMMUNITY, V14, P303, DOI 10.1016/S1074-7613(01)00111-X; Becker T, 2002, J CELL BIOL, V158, P1277, DOI 10.1083/jcb.200208083; Beresford PJ, 1998, J IMMUNOL, V161, P161; BERKE G, 1995, CELL, V81, P9, DOI 10.1016/0092-8674(95)90365-8; Binder RJ, 2000, NAT IMMUNOL, V1, P151, DOI 10.1038/77835; Botzler C, 1998, CELL STRESS CHAPERON, V3, P6, DOI 10.1379/1466-1268(1998)003<0006:DOELEO>2.3.CO;2; Botzler C, 1999, EXP HEMATOL, V27, P470, DOI 10.1016/S0301-472X(98)00055-1; Demand J, 1998, MOL CELL BIOL, V18, P2023, DOI 10.1128/MCB.18.4.2023; Drexler HG, 2000, LEUKEMIA, V14, P777, DOI 10.1038/sj.leu.2401778; Feng HP, 2001, BLOOD, V97, P3505, DOI 10.1182/blood.V97.11.3505; Froelich CJ, 1998, IMMUNOL TODAY, V19, P30, DOI 10.1016/S0167-5699(97)01184-5; Gross C, 2003, BIOL CHEM, V384, P267, DOI 10.1515/BC.2003.030; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; MACDONALD HR, 1974, J EXP MED, V140, P718, DOI 10.1084/jem.140.3.718; Mamelak D, 1997, GLYCOCONJUGATE J, V14, P715, DOI 10.1023/A:1018569417218; MULTHOFF G, 1995, BLOOD, V86, P1374, DOI 10.1182/blood.V86.4.1374.bloodjournal8641374; Multhoff G, 1997, J IMMUNOL, V158, P4341; Multhoff G, 2001, CELL STRESS CHAPERON, V6, P337, DOI 10.1379/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2; Multhoff G, 1999, EXP HEMATOL, V27, P1627, DOI 10.1016/S0301-472X(99)00104-6; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; Nylandsted J, 2000, ANN NY ACAD SCI, V926, P122; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Pinkoski MJ, 2002, CURR OPIN HEMATOL, V9, P43, DOI 10.1097/00062752-200201000-00008; Pinkoski MJ, 1998, BLOOD, V92, P1044; Rabinovich BA, 2000, J IMMUNOL, V165, P2390, DOI 10.4049/jimmunol.165.5.2390; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Schild H, 1999, CURR OPIN IMMUNOL, V11, P109, DOI 10.1016/S0952-7915(99)80019-3; Shi LF, 2000, METHOD ENZYMOL, V322, P125; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Shresta S, 1999, IMMUNITY, V10, P595, DOI 10.1016/S1074-7613(00)80059-X; Sondermann H, 2000, BIOL CHEM, V381, P1165, DOI 10.1515/BC.2000.144; Spaeny-Dekking EHA, 1998, J IMMUNOL, V160, P3610; SUTO R, 1995, SCIENCE, V269, P1585, DOI 10.1126/science.7545313; TRAPANI JA, 1994, J BIOL CHEM, V269, P18359; TSCHOPP J, 1990, ANNU REV IMMUNOL, V8, P279, DOI 10.1146/annurev.immunol.8.1.279	44	147	157	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41173	41181		10.1074/jbc.M302644200	http://dx.doi.org/10.1074/jbc.M302644200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12874291	hybrid			2022-12-27	WOS:000185847200094
J	Anderson, AA; Treves, S; Biral, D; Betto, R; Sandona, D; Ronjat, M; Zorzato, F				Anderson, AA; Treves, S; Biral, D; Betto, R; Sandona, D; Ronjat, M; Zorzato, F			The novel skeletal muscle sarcoplasmic reticulum JP-45 protein - Molecular cloning, tissue distribution, developmental expression, and interaction with alpha 1.1 subunit of the voltage-gated calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							JUNCTIONAL-FACE MEMBRANE; CA2+ RELEASE CHANNELS; RYANODINE RECEPTOR; TERMINAL CISTERNAE; DIHYDROPYRIDINE RECEPTOR; MALIGNANT HYPERTHERMIA; CALSEQUESTRIN; BINDING	JP-45 is a novel integral protein constituent of the skeletal muscle sarcoplasmic reticulum junctional face membrane. We identified its primary structure from a cDNA clone isolated from a mouse skeletal muscle cDNA library. Mouse skeletal muscle JP-45 displays over 86 and 50% identity with two hypothetical NCBI data base protein sequences from mouse tongue and human muscle, respectively. JP-45 is predicted to have a cytoplasmic domain, a single transmembrane segment followed by an intralumenal domain enriched in positively charged amino acids. Northern and Western blot analyses reveal that the protein is mainly expressed in skeletal muscle. The mRNA encoding JP-45 appears in 17-day-old mouse embryos; expression of the protein peaks during the second month of postnatal development and then decreases similar to3-fold during aging. Double immunofluorescence of adult skeletal muscle fibers demonstrates that JP-45 co-localizes with the sarcoplasmic reticulum calcium release channel. Co-immunoprecipitation experiments with a monoclonal antibody against JP-45 show that JP-45 interacts with the alpha1.1 subunit voltage-gated calcium channel and calsequestrin. These results are consistent with the localization of JP-45 in the junctional sarcoplasmic reticulum and with its involvement in the molecular mechanism underlying skeletal muscle excitation-contraction coupling.	Kantonsspital Basel, Zentrum Lehr & Forsch, Dept Anesthesia, CH-4031 Basel, Switzerland; Kantonsspital Basel, Zentrum Lehr & Forsch, Dept Res, CH-4031 Basel, Switzerland; CNR, Inst Neurosci, Unit Muscle Biol & Physiopathol, F-38054 Grenoble 9, France; CEA, INSERM, Lab Canaux Ion & Signalisat, F-38054 Grenoble 9, France; Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy; Univ Ferrara, Dept Expt & Diagnost Med, Gen Pathol Sect, I-44100 Ferrara, Italy	CEA; Institut National de la Sante et de la Recherche Medicale (Inserm); University of Padua; University of Ferrara	Zorzato, F (corresponding author), Kantonsspital Basel, Zentrum Lehr & Forsch, Dept Anesthesia, Hebelstr 20, CH-4031 Basel, Switzerland.	fzorzato@uhbs.ch	sandona, dorianna/AAB-9480-2020	Ronjat, Michel/0000-0002-9728-6425; Treves, Susan/0000-0002-0007-9631	Telethon [1259] Funding Source: Medline	Telethon(Fondazione Telethon)		Biral D, 1996, J MUSCLE RES CELL M, V17, P523, DOI 10.1007/BF00124352; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COSTELLO B, 1986, J CELL BIOL, V103, P741, DOI 10.1083/jcb.103.3.741; Damiani E, 1997, CELL CALCIUM, V22, P129, DOI 10.1016/S0143-4160(97)90113-5; FLEISCHER S, 1989, ANNU REV BIOPHYS BIO, V18, P333, DOI 10.1146/annurev.bb.18.060189.002001; FRANZINIARMSTRONG C, 1994, ANNU REV PHYSIOL, V56, P509, DOI 10.1146/annurev.ph.56.030194.002453; FranziniArmstrong C, 1997, PHYSIOL REV, V77, P699, DOI 10.1152/physrev.1997.77.3.699; Hamilton SL, 2000, NEWS PHYSIOL SCI, V15, P281; IKEMOTO N, 1994, BIOCHEMISTRY-US, V33, P10961, DOI 10.1021/bi00202a015; Jurkat-Rott K, 2000, MUSCLE NERVE, V23, P4, DOI 10.1002/(SICI)1097-4598(200001)23:1<4::AID-MUS3>3.0.CO;2-D; Kempermann G, 2002, ANN NEUROL, V52, P135, DOI 10.1002/ana.10262; LAMB GD, 1990, J PHYSIOL-LONDON, V423, P519, DOI 10.1113/jphysiol.1990.sp018037; MACLENNAN DH, 1971, P NATL ACAD SCI USA, V68, P1231, DOI 10.1073/pnas.68.6.1231; Marks AR, 2002, TRENDS CARDIOVAS MED, V12, P166, DOI 10.1016/S1050-1738(02)00156-1; MARTY I, 1994, P NATL ACAD SCI USA, V91, P2270, DOI 10.1073/pnas.91.6.2270; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; MEISSNER G, 1994, ANNU REV PHYSIOL, V56, P485, DOI 10.1146/annurev.ph.56.030194.002413; Nakai J, 1996, NATURE, V380, P72, DOI 10.1038/380072a0; Nakai J, 1998, J BIOL CHEM, V273, P13403, DOI 10.1074/jbc.273.22.13403; Nishi M, 1999, J CELL BIOL, V147, P1473, DOI 10.1083/jcb.147.7.1473; Pan Z, 2002, NAT CELL BIOL, V4, P379, DOI 10.1038/ncb788; RIOS E, 1991, PHYSIOL REV, V71, P849, DOI 10.1152/physrev.1991.71.3.849; Sacchetto R, 2001, J MUSCLE RES CELL M, V22, P545, DOI 10.1023/A:1015010914328; SAITO A, 1984, J CELL BIOL, V99, P875, DOI 10.1083/jcb.99.3.875; SILVER M, 1995, MOUSE GENETIC; Sutko JL, 1996, PHYSIOL REV, V76, P1027, DOI 10.1152/physrev.1996.76.4.1027; TIMERMAN AP, 1993, J BIOL CHEM, V268, P22992; TREVES S, 1992, BIOCHEM J, V283, P767, DOI 10.1042/bj2830767; Treves S, 2000, J BIOL CHEM, V275, P39555, DOI 10.1074/jbc.M005473200; Zhang L, 1997, J BIOL CHEM, V272, P23389, DOI 10.1074/jbc.272.37.23389; Zorzato F, 2000, BIOCHEM J, V351, P537, DOI 10.1042/0264-6021:3510537	31	32	35	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39987	39992		10.1074/jbc.M305016200	http://dx.doi.org/10.1074/jbc.M305016200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871958	hybrid			2022-12-27	WOS:000185713800087
J	Hassel, B; Schreff, M; Stube, EM; Blaich, U; Schumacher, S				Hassel, B; Schreff, M; Stube, EM; Blaich, U; Schumacher, S			CALEB/NGC interacts with the Golgi-associated protein PIST	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHONDROITIN SULFATE PROTEOGLYCAN; NEUROGLYCAN-C; GLUTAMATE-RECEPTOR; PROTGF-ALPHA; PDZ DOMAINS; BREFELDIN-A; EGF FAMILY; MEMBRANE; SYNTENIN; COMPLEX	CALEB/NGC is a neural member of the epidermal growth factor protein family expressed in axon and synapse-rich areas of the nervous system and shown to be important for neurite formation. It can bind to the extracellular matrix proteins tenascin-R and tenascin-C. Here we show that CALEB/NGC interacts with the Golgi-associated protein PIST. PIST was originally described as an interaction partner of the small GTPase TC10 and was then found to be Golgi-associated by binding to syntaxin-6 and to be important for the transport of frizzled proteins and the cystic fibrosis transmembrane conductance regulator to the plasma membrane. In addition, PIST was demonstrated to be involved in autophagy and linked to processes of neurodegeneration. CALEB/NGC interacts with PIST in the yeast two-hybrid system. This interaction can be confirmed by co-immunoprecipitations and co-localization studies. The juxtamembrane cytoplasmic peptide segment of CALEB/NGC, highly conserved during evolution, mediates the binding to PIST. CALEB/NGC co-localizes with PIST in the Golgi apparatus of transfected COS7 cells and in Golgi-derived vesicles after brefeldin A or nocodazole treatment. Co-localization studies in primary hippocampal cells and analysis of Purkinje cells of colchicine-treated rats, serving as an in vivo model system to block microtubule-dependent transport processes, support the view that PIST is an interaction partner of CALEB/NGC and implicate that this interaction may play a role in the intracellular transport of CALEB/NGC.	Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, D-20246 Hamburg, Germany	University of Hamburg	Schumacher, S (corresponding author), Univ Hamburg, Klinikum Eppendorf, Inst Zellbiochem & Klin Neurobiol, Martinistr 52, D-20246 Hamburg, Germany.	sschumac@uke.uni-hamburg.de						Aono S, 2000, J BIOL CHEM, V275, P337, DOI 10.1074/jbc.275.1.337; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Briley GP, 1997, MOL BIOL CELL, V8, P1619, DOI 10.1091/mbc.8.8.1619; BRUMMENDORF T, 1993, NEURON, V10, P711; Buchstaller A, 1996, J CELL BIOL, V135, P1593, DOI 10.1083/jcb.135.6.1593; Charest A, 2001, J BIOL CHEM, V276, P29456, DOI 10.1074/jbc.M104137200; Cheng J, 2002, J BIOL CHEM, V277, P3520, DOI 10.1074/jbc.M110177200; CONNER JM, 1992, J COMP NEUROL, V326, P347, DOI 10.1002/cne.903260304; Cowan CA, 2000, NEURON, V26, P417, DOI 10.1016/S0896-6273(00)81174-5; Fernandez-Larrea J, 1999, MOL CELL, V3, P423, DOI 10.1016/S1097-2765(00)80470-0; FUJIWARA T, 1988, J BIOL CHEM, V263, P18545; Gentzsch M, 2003, J BIOL CHEM, V278, P6440, DOI 10.1074/jbc.M211050200; Goslin K., 1998, CULTURING NERVE CELL, P339; Griffith KJ, 1997, ARTHRITIS RHEUM, V40, P1693, DOI 10.1002/art.1780400920; Grootjans JJ, 2000, J BIOL CHEM, V275, P19933, DOI 10.1074/jbc.M002459200; Grootjans JJ, 1997, P NATL ACAD SCI USA, V94, P13683, DOI 10.1073/pnas.94.25.13683; Hirbec H, 2002, J BIOL CHEM, V277, P15221, DOI 10.1074/jbc.C200112200; Inatani M, 2000, INVEST OPHTH VIS SCI, V41, P4338; Iuliano R, 2001, FEBS LETT, V500, P41, DOI 10.1016/S0014-5793(01)02580-7; Jannatipour M, 2001, J BIOL CHEM, V276, P33093, DOI 10.1074/jbc.M105792200; Koroll M, 2001, J BIOL CHEM, V276, P10646, DOI 10.1074/jbc.M010647200; Kuo A, 2000, EMBO J, V19, P6427, DOI 10.1093/emboj/19.23.6427; Lin D, 1999, J BIOL CHEM, V274, P3726, DOI 10.1074/jbc.274.6.3726; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; Liu XF, 1998, J BIOL CHEM, V273, P34335, DOI 10.1074/jbc.273.51.34335; MASSAGUE J, 1993, ANNU REV BIOCHEM, V62, P515, DOI 10.1146/annurev.bi.62.070193.002503; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; Neudauer CL, 2001, BIOCHEM BIOPH RES CO, V280, P541, DOI 10.1006/bbrc.2000.4160; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; ROGALSKI AA, 1984, J CELL BIOL, V99, P1092, DOI 10.1083/jcb.99.3.1092; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; THYBERG J, 1985, EXP CELL RES, V159, P1, DOI 10.1016/S0014-4827(85)80032-X; Torres R, 1998, NEURON, V21, P1453, DOI 10.1016/S0896-6273(00)80663-7; Urena JM, 1999, J CELL SCI, V112, P773; WATANABE E, 1995, J BIOL CHEM, V270, P26876, DOI 10.1074/jbc.270.45.26876; Woods R. A., 2001, METH MOL B, V177, P85; Yao RJ, 2002, P NATL ACAD SCI USA, V99, P11211, DOI 10.1073/pnas.162027899; Yao RJ, 2001, BIOCHEM BIOPH RES CO, V286, P771, DOI 10.1006/bbrc.2001.5430; Yasuda Y, 1998, NEUROSCI RES, V32, P313, DOI 10.1016/S0168-0102(98)00098-4; Yue ZY, 2002, NEURON, V35, P921, DOI 10.1016/S0896-6273(02)00861-9	41	18	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40136	40143		10.1074/jbc.M305577200	http://dx.doi.org/10.1074/jbc.M305577200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12885772	hybrid			2022-12-27	WOS:000185713800106
J	Lee, MH; Rapti, M; Murphy, G				Lee, MH; Rapti, M; Murphy, G			Unveiling the surface Epitopes that render tissue inhibitor of metalloproteinase-1 inactive against membrane type 1-matrix metalloproteinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL DOMAIN; MATRIX-METALLOPROTEINASE; TIMP-1; PROGELATINASE; STROMELYSIN-1; ACTIVATION; (TIMP)-3	Membrane type 1-matrix metalloproteinase (MT1-MMP) is a zinc-dependent, membrane-associated endoproteinase of the metzincin family. The enzyme regulates extracellular matrix remodeling and is capable of cleaving a wide variety of transmembrane proteins. The enzymatic activity of MT1-MMP is regulated by endogenous inhibitors, the tissue inhibitor of metalloproteinases (TIMP). To date, four variants of mammalian TIMP have been identified. Whereas TIMP-2-4 are potent inhibitors against MT1-MMP, TIMP-1 displays negligible inhibitory activity against the enzyme. The rationale for such selectivity is hitherto unknown. Here we identify the surface epitopes that render TIMP-1 inactive against MT1-MMP. We show that TIMP-1 can be transformed into an active inhibitor against MT1-MMP by the mutation of a single residue, namely threonine 98 to leucine (T98L). The resultant mutant displayed inhibitory characteristics of a typical slow, tight binding inhibitor. The potency of the mutant could be further enhanced by the introduction of valine 4 to alanine (V4A) and proline 6 to valine (P6V) mutations. Indeed, the inhibitory profile of the triple mutant (V4A/P6V/T98L) is indistinguishable from those of other TIMPs. Our findings suggest that threonine 98 is critical in initiating MMP binding and complex stabilization. Our findings also provide a potential mechanistic explanation for MMP-TIMP selectivity.	Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge	Murphy, G (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Wellcome Trust MRC Bldg, Cambridge CB2 2XY, England.	gm290@cam.ac.uk						Baker AH, 2002, J CELL SCI, V115, P3719, DOI 10.1242/jcs.00063; Bode W, 2000, METH MOL B, V151, P45, DOI 10.1385/1-59259-046-2:045; Bode W, 1999, ANN NY ACAD SCI, V878, P73, DOI 10.1111/j.1749-6632.1999.tb07675.x; Brinckerhoff CE, 2002, NAT REV MOL CELL BIO, V3, P207, DOI 10.1038/nrm763; Douglas DA, 1997, J PROTEIN CHEM, V16, P237, DOI 10.1023/A:1026348808069; Egeblad M, 2002, NAT REV CANCER, V2, P161, DOI 10.1038/nrc745; English WR, 2000, J BIOL CHEM, V275, P14046, DOI 10.1074/jbc.275.19.14046; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; GomisRuth FX, 1997, NATURE, V389, P77, DOI 10.1038/37995; Huang W, 1996, FEBS LETT, V384, P155, DOI 10.1016/0014-5793(96)00304-3; Knauper V, 1996, J BIOL CHEM, V271, P17124, DOI 10.1074/jbc.271.29.17124; Lee MH, 2002, PROTEIN SCI, V11, P2493, DOI 10.1110/ps.0216202; Lee MH, 2002, BIOCHEM J, V364, P227, DOI 10.1042/bj3640227; Lee MH, 2001, BIOCHEM BIOPH RES CO, V280, P945, DOI 10.1006/bbrc.2000.4192; MORRISON JF, 1995, METHOD ENZYMOL, V248, P201; MURPHY G, 1991, BIOCHEMISTRY-US, V30, P8097, DOI 10.1021/bi00247a001; Nagase H, 1999, ANN NY ACAD SCI, V878, P1, DOI 10.1111/j.1749-6632.1999.tb07670.x; Nagase H, 2002, ARTHRITIS RES THER, V4, pS51, DOI 10.1186/ar573; NGUYEN Q, 1994, BIOCHEMISTRY-US, V33, P2089, DOI 10.1021/bi00174a015; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Tuuttila A, 1998, J MOL BIOL, V284, P1133, DOI 10.1006/jmbi.1998.2223; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wei S, 2003, J BIOL CHEM, V278, P9831, DOI 10.1074/jbc.M211793200; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; WILLIAMSON RA, 1994, BIOCHEMISTRY-US, V33, P11745, DOI 10.1021/bi00205a010; Williamson RA, 2001, J BIOL CHEM, V276, P32966, DOI 10.1074/jbc.M101843200	28	57	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40224	40230		10.1074/jbc.M305678200	http://dx.doi.org/10.1074/jbc.M305678200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869573	hybrid			2022-12-27	WOS:000185713800115
J	Liu, MF; Gupte, G; Roy, S; Bandwar, RP; Patel, SS; Garges, S				Liu, MF; Gupte, G; Roy, S; Bandwar, RP; Patel, SS; Garges, S			Kinetics of transcription initiation at lacP1 - Multiple roles of cyclic AMP receptor protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPEN COMPLEX-FORMATION; RNA-POLYMERASE; PROMOTER DNA; BASE; FLUORESCENCE; ACTIVATION; MECHANISM; CAMP; 2-AMINOPURINE; DYNAMICS	The cyclic AMP receptor protein (CRP) acts as a transcription activator at many promoters of Escherichia coli. We have examined the kinetics of open complex formation at the lacP1 promoter using tryptophan fluorescence of RNA polymerase and DNA fragments with 2-aminopurine substituted at specific positions. Apart from the closed complex formation and promoter clearance, we were able to detect three steps. The first step after the closed complex formation leads to a rapid increase of 2-aminopurine fluorescence. This was followed by another rapid step in which quenching of tryptophan fluorescence of RNA polymerase was observed. The slowest step detected by 2-aminopurine fluorescence increase is assigned to the final open complex formation. We have found that CRP not only enhances RNA polymerase binding at the promoter, but also enhances the slowest isomerization step by about 2-fold. Furthermore, potassium permanganate probing shows that the conformation of the open complex in the presence of CRP appears qualitatively and quantitatively different from that in the absence of CRP, suggesting that contact with RNA polymerase is maintained throughout the transcription initiation.	NCI, Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA; Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India; Robert Wood Johnson Med Sch, Dept Biochem, Piscataway, NJ 08854 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Department of Science & Technology (India); Bose Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Liu, MF (corresponding author), NCI, Mol Biol Lab, Ctr Canc Res, NIH, 37 Convent Dr,Rm 5138, Bethesda, MD 20892 USA.	liumo@pop.nci.nih.gov		Bandwar, Rajiv/0000-0002-8081-8958; liu, mo fang/0000-0003-1800-466X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051966, R37GM051966] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51966] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bandwar RP, 2001, J BIOL CHEM, V276, P14075, DOI 10.1074/jbc.M011289200; Busby S, 1999, J MOL BIOL, V293, P199, DOI 10.1006/jmbi.1999.3161; CHAMBERLIN MJ, 1974, ANNU REV BIOCHEM, V43, P721, DOI 10.1146/annurev.bi.43.070174.003445; DONNELLY CE, 1987, J BACTERIOL, V169, P1812, DOI 10.1128/jb.169.5.1812-1817.1987; HAYATSU H, 1967, BIOCHEM BIOPH RES CO, V29, P556, DOI 10.1016/0006-291X(67)90521-9; KOLB A, 1993, ANNU REV BIOCHEM, V62, P749, DOI 10.1146/annurev.bi.62.070193.003533; Lim HM, 2001, P NATL ACAD SCI USA, V98, P14849, DOI 10.1073/pnas.261517398; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MALAN TP, 1984, J MOL BIOL, V180, P881, DOI 10.1016/0022-2836(84)90262-6; MCCLURE WR, 1980, P NATL ACAD SCI-BIOL, V77, P5634, DOI 10.1073/pnas.77.10.5634; MCCLURE WR, 1985, ANNU REV BIOCHEM, V54, P171, DOI 10.1146/annurev.bi.54.070185.001131; MCLAUGHLIN LW, 1987, BIOCHEMISTRY-US, V26, P7238, DOI 10.1021/bi00397a007; NORDLUND TM, 1989, BIOCHEMISTRY-US, V28, P9095, DOI 10.1021/bi00449a021; RECORD TM, 1996, ESCHERICHIA COLI SAL, P792; Roy S, 1998, J BIOL CHEM, V273, P14059, DOI 10.1074/jbc.273.23.14059; RYU S, 1993, P NATL ACAD SCI USA, V90, P75, DOI 10.1073/pnas.90.1.75; Saecker RM, 2002, J MOL BIOL, V319, P649, DOI 10.1016/S0022-2836(02)00293-0; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SOWERS LC, 1986, P NATL ACAD SCI USA, V83, P5434, DOI 10.1073/pnas.83.15.5434; STRANEY DC, 1989, J MOL BIOL, V206, P41, DOI 10.1016/0022-2836(89)90522-6; Sukhodolets MV, 1998, J BIOL CHEM, V273, P7018, DOI 10.1074/jbc.273.12.7018; Sullivan JJ, 1997, BIOCHEMISTRY-US, V36, P8005, DOI 10.1021/bi970363k; Tsujikawa L, 2002, BIOCHEMISTRY-US, V41, P15334, DOI 10.1021/bi026539m; WU PG, 1990, BIOCHEMISTRY-US, V29, P6508, DOI 10.1021/bi00479a024; XU DG, 1994, BIOCHEMISTRY-US, V33, P9592, DOI 10.1021/bi00198a027	25	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39755	39761		10.1074/jbc.M305995200	http://dx.doi.org/10.1074/jbc.M305995200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881519	hybrid			2022-12-27	WOS:000185713800061
J	Baran, CP; Tridandapani, S; Helgason, CD; Humphries, RK; Krystal, G; Marsh, CB				Baran, CP; Tridandapani, S; Helgason, CD; Humphries, RK; Krystal, G; Marsh, CB			The inositol 5 '-phosphatase SHIP-1 and the Src kinase Lyn negatively regulate macrophage colony-stimulating factor-induced Akt activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; CELL-DEATH APOPTOSIS; M-CSF RECEPTOR; PROTEIN-KINASE; FACTOR-I; TYROSINE PHOSPHORYLATION; SIGNAL-TRANSDUCTION; PHOSPHATASE; ACTIVATION; MURINE	Upon encountering macrophage colony-stimulating factor (M-CSF), human monocytes undergo a series of cellular signaling events leading to an increase in Akt activity. However, the regulation of these events is not completely understood. Because the inositol 5'-phosphatase SHIP-1 is an important regulator of intracellular levels of phosphatidylinositol 3,4,5-trisphosphate, an important second messenger necessary for Akt activation, we hypothesized that SHIP-1 was involved in the regulation of M-CSF receptor (M-CSF-R)-induced Akt activation. In the human monocytic cell line, THP-1, SHIP-1 became tyrosine-phosphorylated following M-CSF activation in a Src family kinase-dependent manner. Transfection of 3T3-Fms cells, which express the human M-CSF-R, with wild-type SHIP-1 showed that SHIP-1 was necessary for the negative regulation of M-CSF-induced Akt activation. In THP-1 cells, SHIP-1 bound Lyn, independent of the kinase activity of Lyn, following M-CSF activation. Utilizing a glutathione S-transferase fusion protein, we found that SHIP-1 bound to Lyn via the SHIP-1 Src homology 2 domain. Furthermore, transfection of THP-1 cells with a wild-type SHIP-1 construct reduced NF-kappaB-dependent transcriptional activation of a reporter gene, whereas a SHIP-1 Src homology 2 domain construct resulted in an increase in NF-kappaB activation. Additionally, in 3T3-Fms cells, Lyn enhanced the ability of SHIP-1 to regulate Akt activation by stabilizing SHIP-1 at the cellular membrane. Finally, macrophages isolated from both SHIP-1- and Lyn-deficient mice exhibited enhanced Akt phosphorylation following M-CSF stimulation. These data provide the first evidence of the involvement of both SHIP-1 and Lyn in the negative regulation of M-CSF-R-induced Akt activation.	Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; British Columbia Canc Agcy, Terry Fox Lab, Vancouver, BC V5Z 1L3, Canada	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; British Columbia Cancer Agency	Marsh, CB (corresponding author), Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Rm 201,473 W 12th Ave, Columbus, OH 43210 USA.	marsh.2@osu.edu	Tridandapani, Susheela/E-4209-2011	Krystal, Gerald/0000-0002-1961-6281; Humphries, Richard/0000-0003-0540-7005	NHLBI NIH HHS [R01HL63800, P01HL70294, R01HL66108, R01HL67176] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066108, R01HL063800, R01HL067176, P01HL070294] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9; Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; ALONSO G, 1995, J BIOL CHEM, V270, P9840, DOI 10.1074/jbc.270.17.9840; ARCECI RJ, 1989, P NATL ACAD SCI USA, V86, P8818, DOI 10.1073/pnas.86.22.8818; Bourette RP, 1998, EMBO J, V17, P7273, DOI 10.1093/emboj/17.24.7273; BOURETTE RP, 1995, CELL GROWTH DIFFER, V6, P631; Bourette RP, 1997, EMBO J, V16, P5880, DOI 10.1093/emboj/16.19.5880; Chan VWF, 1998, CURR BIOL, V8, P545, DOI 10.1016/S0960-9822(98)70223-4; Chan VWF, 1997, IMMUNITY, V7, P69, DOI 10.1016/S1074-7613(00)80511-7; Cheng M, 1999, J BIOL CHEM, V274, P6553, DOI 10.1074/jbc.274.10.6553; CLINE MJ, 1978, ANN INTERN MED, V88, P78, DOI 10.7326/0003-4819-88-1-78; Cornall RJ, 1999, CURR TOP MICROBIOL, V244, P57; Cornall RJ, 1998, IMMUNITY, V8, P497, DOI 10.1016/S1074-7613(00)80554-3; COURTNEIDGE SA, 1993, EMBO J, V12, P943, DOI 10.1002/j.1460-2075.1993.tb05735.x; Csar XF, 2001, J BIOL CHEM, V276, P26211, DOI 10.1074/jbc.M100213200; DAmbrosio D, 1996, IMMUNOL LETT, V54, P77, DOI 10.1016/S0165-2478(96)02653-3; Damen JE, 1996, P NATL ACAD SCI USA, V93, P1689, DOI 10.1073/pnas.93.4.1689; Damen JE, 1998, BLOOD, V92, P1199, DOI 10.1182/blood.V92.4.1199.416k16_1199_1205; Fong DC, 1996, IMMUNOL LETT, V54, P83, DOI 10.1016/S0165-2478(96)02654-5; Gresham HD, 2000, J EXP MED, V191, P515, DOI 10.1084/jem.191.3.515; Habib T, 1998, J BIOL CHEM, V273, P18605, DOI 10.1074/jbc.273.29.18605; Helgason CD, 1998, GENE DEV, V12, P1610, DOI 10.1101/gad.12.11.1610; Hibbs ML, 2002, J EXP MED, V196, P1593, DOI 10.1084/jem.20020515; INABA T, 1992, J BIOL CHEM, V267, P5693; Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6; Kelley TW, 1999, J BIOL CHEM, V274, P26393, DOI 10.1074/jbc.274.37.26393; Li HL, 1999, P NATL ACAD SCI USA, V96, P6890, DOI 10.1073/pnas.96.12.6890; Lioubin MN, 1996, GENE DEV, V10, P1084, DOI 10.1101/gad.10.9.1084; Lucas DM, 1999, BLOOD, V93, P1922, DOI 10.1182/blood.V93.6.1922.406k21_1922_1933; MANGAN DF, 1991, J IMMUNOL, V147, P3408; MANGAN DF, 1991, J IMMUNOL, V146, P1541; Marsh CB, 1999, J IMMUNOL, V162, P6217; Nishizumi H, 1998, J EXP MED, V187, P1343, DOI 10.1084/jem.187.8.1343; Novak U, 1996, ONCOGENE, V13, P2607; Ozes ON, 1999, NATURE, V401, P82; Pengal RA, 2003, J BIOL CHEM, V278, P22657, DOI 10.1074/jbc.M302907200; Pesesse X, 1997, BIOCHEM BIOPH RES CO, V239, P697, DOI 10.1006/bbrc.1997.7538; Phee H, 2000, J BIOL CHEM, V275, P19090, DOI 10.1074/jbc.M001093200; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Romashkova JA, 1999, NATURE, V401, P86, DOI 10.1038/43474; Sattler M, 1999, MOL CELL BIOL, V19, P7473; Scharenberg AM, 1998, EMBO J, V17, P1961, DOI 10.1093/emboj/17.7.1961; Smith KGC, 1998, J EXP MED, V187, P807, DOI 10.1084/jem.187.5.807; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Testa JR, 2001, P NATL ACAD SCI USA, V98, P10983, DOI 10.1073/pnas.211430998; Tridandapani S, 2002, J IMMUNOL, V169, P4370, DOI 10.4049/jimmunol.169.8.4370; Tridandapani S, 1997, MOL CELL BIOL, V17, P4305, DOI 10.1128/MCB.17.8.4305; VANDERGEER P, 1993, EMBO J, V12, P5161, DOI 10.1002/j.1460-2075.1993.tb06211.x; VANDERGEER P, 1990, MOL CELL BIOL, V10, P2991, DOI 10.1128/MCB.10.6.2991; WIKTORJEDRZEJCZAK W, 1991, EXP HEMATOL, V19, P1049; Wisniewski D, 1999, BLOOD, V93, P2707, DOI 10.1182/blood.V93.8.2707.408k17_2707_2720	51	79	83	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38628	38636		10.1074/jbc.M305021200	http://dx.doi.org/10.1074/jbc.M305021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882960	hybrid			2022-12-27	WOS:000185575100067
J	Liu, YY; Schultz, JJ; Brent, GA				Liu, YY; Schultz, JJ; Brent, GA			A thyroid hormone receptor alpha gene mutation (P398H) is associated with visceral adiposity and impaired catecholamine-stimulated lipolysis in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT-NEGATIVE MUTATION; BETA-ADRENERGIC-RECEPTOR; RETINOID-X-RECEPTOR; FAT-CELL FUNCTION; INSULIN-RESISTANCE; DEFICIENT MICE; POSTNATAL-DEVELOPMENT; COREPRESSOR RELEASE; EXPRESSION; TISSUE	Thyroid hormone has profound effects on metabolic homeostasis, regulating both lipogenesis and lipolysis, primarily by modulating adrenergic activity. We generated mice with a point mutation in the thyroid hormone receptor alpha (TRalpha) gene producing a dominant-negative TRalpha mutant receptor with a proline to histidine substitution (P398H). The heterozygous P398H mutant mice had a 3.4-fold (p < 0.02) increase in serum thyrotropin (TSH) levels. Serum triiodothyronine (T3) and thyroxine (T4) concentrations were slightly elevated compared with wild-type mice. The P398H mice had a 4.4-fold increase in body fat (as a fraction of total body weight) (p < 0.001) and a 5-fold increase in serum leptin levels (p < 0.005) compared with wild-type mice. A 3-fold increase in serum fasting insulin levels (p < 0.002) and a 55% increase in fasting glucose levels (p < 0.01) were observed in P398H compared with wild-type mice. There was a marked reduction in norepinephrine-induced lipolysis, as reflected in reduced glycerol release from white adipose tissue isolated from P398H mice. Heart rate and cold-induced adaptive thermogenesis, mediated by thyroid hormone-catecholamine interaction, were also reduced in P398H mice. In conclusion, the TR&alpha; P398H mutation is associated with visceral adiposity and insulin resistance primarily due to a marked reduction in catecholamine-stimulated lipolysis. The observed phenotype in the TR&alpha; P398H mouse is likely due to interference with TR&alpha; action as well as influence on other metabolic signaling pathways. The physiologic significance of these findings will ultimately depend on understanding the full range of actions of this mutation.	Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Mol Endocrinol Lab, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol,Mol Endocrinol Lab, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System	Brent, GA (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med,Mol Endocrinol Lab, Vet Affairs Greater Los Angeles Healthcare Syst, Bldg 114,Rm 230,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.				NCI NIH HHS [CA-89364] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA089364] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abate N, 2002, J CLIN ENDOCR METAB, V87, P4522, DOI 10.1210/jc.2002-020567; BERLAN M, 1985, EUR J CLIN INVEST, V15, P341, DOI 10.1111/j.1365-2362.1985.tb00282.x; Bernal J, 2002, J ENDOCRINOL INVEST, V25, P268, DOI 10.1007/BF03344003; BERRODIN TJ, 1992, MOL ENDOCRINOL, V6, P1468, DOI 10.1210/me.6.9.1468; BILZEKIAN JP, 1983, ENDOCR REV, V4, P378; Brent G A, 2000, Rev Endocr Metab Disord, V1, P27, DOI 10.1023/A:1010056202122; Buzzard JJ, 2000, BIOL REPROD, V62, P664, DOI 10.1095/biolreprod62.3.664; Cai Y, 2003, ENDOCRINOLOGY, V144, P2311, DOI 10.1210/en.2002-0129; CHATTERJEE VKK, 1992, CANCER SURV, V14, P147; Chiellini G, 2002, BIOORGAN MED CHEM, V10, P333, DOI 10.1016/S0968-0896(01)00284-X; Clifton-Bligh RJ, 1998, MOL ENDOCRINOL, V12, P609, DOI 10.1210/me.12.5.609; Costet P, 2000, J BIOL CHEM, V275, P28240; Endre T, 1996, J HUM HYPERTENS, V10, P755; ENGFELDT P, 1982, J CLIN ENDOCR METAB, V54, P625, DOI 10.1210/jcem-54-3-625; ENGFELDT P, 1988, J BIOL CHEM, V263, P15553; FAIN JN, 1983, J LIPID RES, V24, P945; Flier JS, 2000, J CLIN INVEST, V105, P859, DOI 10.1172/JCI9725; Forrest D, 1996, NAT GENET, V13, P354, DOI 10.1038/ng0796-354; FORREST D, 1990, EMBO J, V9, P1519, DOI 10.1002/j.1460-2075.1990.tb08270.x; Forrest D, 1996, EMBO J, V15, P3006, DOI 10.1002/j.1460-2075.1996.tb00664.x; Fraichard A, 1997, EMBO J, V16, P4412, DOI 10.1093/emboj/16.14.4412; GIUDICELLI Y, 1978, BIOCHEM J, V176, P1007, DOI 10.1042/bj1761007; Gong DW, 1998, DNA CELL BIOL, V17, P301, DOI 10.1089/dna.1998.17.301; Gothe S, 1999, GENE DEV, V13, P1329, DOI 10.1101/gad.13.10.1329; Gullberg H, 2000, MOL ENDOCRINOL, V14, P1739, DOI 10.1210/me.14.11.1739; HAFFNER SM, 1994, DIABETES, V43, P212, DOI 10.2337/diabetes.43.2.212; Hellstrom L, 1997, J CLIN ENDOCR METAB, V82, P159, DOI 10.1210/jc.82.1.159; Huber BR, 2003, MOL ENDOCRINOL, V17, P107, DOI 10.1210/me.2002-0097; Itoh Y, 2001, P NATL ACAD SCI USA, V98, P9913, DOI 10.1073/pnas.171319498; Jequier E, 2002, ANN NY ACAD SCI, V967, P379, DOI 10.1111/j.1749-6632.2002.tb04293.x; Kaneshige M, 2001, P NATL ACAD SCI USA, V98, P15095, DOI 10.1073/pnas.261565798; Kim MS, 2000, J CLIN INVEST, V105, P1005, DOI 10.1172/JCI8857; Kreier F, 2002, J CLIN INVEST, V110, P1243, DOI 10.1172/JCI200215736; LAFONTAN M, 1982, EUR J PHARMACOL, V82, P107, DOI 10.1016/0014-2999(82)90562-3; LAFONTAN M, 1993, J LIPID RES, V34, P1057; LAFONTAN M, 1995, ENDOCR REV, V16, P716, DOI 10.1210/er.16.6.716; LANGIN D, 1991, EUR J PHARMACOL, V199, P291, DOI 10.1016/0014-2999(91)90492-9; Liu YY, 2002, ENDOCRINOLOGY, V143, P2664, DOI 10.1210/en.143.7.2664; LONNQVIST F, 1992, J CLIN INVEST, V90, P2175, DOI 10.1172/JCI116103; Makowski A, 2003, MOL ENDOCRINOL, V17, P273, DOI 10.1210/me.2002-0310; MALBON CC, 1984, J BIOL CHEM, V259, P3254; MAUTIEGE P, 1987, EUR CLIN INVEST, V17, P156; Nishizawa H, 2002, DIABETES, V51, P2734, DOI 10.2337/diabetes.51.9.2734; Pohlenz J, 1999, THYROID, V9, P1265, DOI 10.1089/thy.1999.9.1265; Privalsky ML, 2000, MOL CELL ENDOCRINOL, V159, P109, DOI 10.1016/S0303-7207(99)00201-4; Ribeiro MO, 2001, J CLIN INVEST, V108, P97, DOI 10.1172/JCI12584; RICHELSEN B, 1987, METABOLISM, V36, P1031, DOI 10.1016/0026-0495(87)90022-9; RODBELL M, 1964, J BIOL CHEM, V239, P375; Romero R, 2000, J ENDOCRINOL, V164, P187, DOI 10.1677/joe.0.1640187; RUFFOLO RR, 1994, PHARMACOL THERAPEUT, V61, P1, DOI 10.1016/0163-7258(94)90058-2; Safer JD, 1998, J BIOL CHEM, V273, P30175, DOI 10.1074/jbc.273.46.30175; Tinnikov A, 2002, EMBO J, V21, P5079, DOI 10.1093/emboj/cdf523; Trost SU, 2000, ENDOCRINOLOGY, V141, P3057, DOI 10.1210/en.141.9.3057; Viguerie N, 2002, J CLIN ENDOCR METAB, V87, P630, DOI 10.1210/jc.87.2.630; WAHRENBERG H, 1986, J CLIN ENDOCR METAB, V63, P631, DOI 10.1210/jcem-63-3-631; WAHRENBERG H, 1989, J CLIN INVEST, V84, P458, DOI 10.1172/JCI114187; WAHRENBERG H, 1994, J CLIN ENDOCR METAB, V78, P898, DOI 10.1210/jc.78.4.898; Weiss RE, 1998, ENDOCRINOLOGY, V139, P4945, DOI 10.1210/en.139.12.4945; Weiss RE, 2002, J ENDOCRINOL, V172, P177, DOI 10.1677/joe.0.1720177; Wikstrom L, 1998, EMBO J, V17, P455, DOI 10.1093/emboj/17.2.455; Withers DJ, 1998, NATURE, V391, P900, DOI 10.1038/36116; ZAVACKI AM, 1993, MOL ENDOCRINOL, V7, P1319, DOI 10.1210/me.7.10.1319	62	125	128	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38913	38920		10.1074/jbc.M306120200	http://dx.doi.org/10.1074/jbc.M306120200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869545	hybrid			2022-12-27	WOS:000185575100100
J	Loiseau, L; Ollagnier-de-Choudens, S; Nachin, L; Fontecave, M; Barras, F				Loiseau, L; Ollagnier-de-Choudens, S; Nachin, L; Fontecave, M; Barras, F			Biogenesis of Fe-S cluster by the bacterial SUF system - SufS and SufE form a new type of cysteine desulfurase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR CLUSTERS; NIFS-LIKE PROTEIN; ESCHERICHIA-COLI; SELENOCYSTEINE LYASE; MITOCHONDRIAL PROTEINS; CRYSTAL-STRUCTURE; GENE CLONING; ISCS; PERSULFIDE; CSDB	Biosynthesis of iron-sulfur clusters (Fe-S) depends on multiprotein systems. Recently, we described the SUF system of Escherichia coli and Erwinia chrysanthemi as being important for Fe-S biogenesis under stressful conditions. The SUF system is made of six proteins: SufC is an atypical cytoplasmic ABC-ATPase, which forms a complex with SufB and SufD; SufA plays the role of a scaffold protein for assembly of iron-sulfur clusters and delivery to target proteins; SufS is a cysteine desulfurase which mobilizes the sulfur atom from cysteine and provides it to the cluster; SufE has no associated function yet. Here we demonstrate that: (i) SufE and SufS are both cystosolic as all members of the SUF system; (ii) SufE is a homodimeric protein; (iii) SufE forms a complex with SufS as shown by the yeast two-hybrid system and by affinity chromatography; (iv) binding of SufE to SufS is responsible for a 50-fold stimulation of the cysteine desulfurase activity of SufS. This is the first example of a two-component cysteine desulfurase enzyme.	Univ Grenoble 1, Ctr Redox Biol, Lab Chim & Biochim, DBMS CB,CEA,CNRS,UMR 5047, F-38054 Grenoble 09, France; IBSM, CNRS, LCB, F-13402 Marseille 20, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS)	Fontecave, M (corresponding author), Univ Grenoble 1, Ctr Redox Biol, Lab Chim & Biochim, DBMS CB,CEA,CNRS,UMR 5047, 17 Ave Martyrs, F-38054 Grenoble 09, France.	mfontecave@cea.fr; barras@ibsm.cnrs-mrs.fr		Ollagnier de Choudens, Sandrine/0000-0002-0080-6659; Barras, Frederic/0000-0003-3458-2574				BORTOLIGERMAN I, 1994, MOL MICROBIOL, V11, P545, DOI 10.1111/j.1365-2958.1994.tb00335.x; Bouley J, 2001, J MOL BIOL, V308, P205, DOI 10.1006/jmbi.2001.4594; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clausen T, 2000, P NATL ACAD SCI USA, V97, P3856, DOI 10.1073/pnas.97.8.3856; Ellis KES, 2001, MOL MICROBIOL, V41, P973, DOI 10.1046/j.1365-2958.2001.02588.x; FINLEY RL, 1994, P NATL ACAD SCI USA, V91, P12980, DOI 10.1073/pnas.91.26.12980; Fontecave M, 2003, CHEM REV, V103, P2149, DOI 10.1021/cr020427j; Frazzon J, 2003, CURR OPIN CHEM BIOL, V7, P166, DOI 10.1016/S1367-5931(03)00021-8; GOLEMIS EA, 1994, CURRENT PROTOCOLS MO; GUZMAN LM, 1995, J BACTERIOL, V177, P4121, DOI 10.1128/jb.177.14.4121-4130.1995; Hantke K, 2002, J MOL MICROB BIOTECH, V4, P217; Kaiser JT, 2000, J MOL BIOL, V297, P451, DOI 10.1006/jmbi.2000.3581; Kispal G, 1999, EMBO J, V18, P3981, DOI 10.1093/emboj/18.14.3981; Lang T, 1999, J BIOL CHEM, V274, P189, DOI 10.1074/jbc.274.1.189; Lauhon CT, 2000, J BIOL CHEM, V275, P20096, DOI 10.1074/jbc.M002680200; Lauhon CT, 2002, J BACTERIOL, V184, P6820, DOI 10.1128/JB.184.24.6820-6829.2002; Leimkuhler S, 2001, J BIOL CHEM, V276, P22024, DOI 10.1074/jbc.M102072200; Li J, 1999, J BIOL CHEM, V274, P33025, DOI 10.1074/jbc.274.46.33025; Lill R, 1999, BIOL CHEM, V380, P1157, DOI 10.1515/BC.1999.147; Lima CD, 2002, J MOL BIOL, V315, P1199, DOI 10.1006/jmbi.2001.5308; LUNDBLAD V, 1993, CURRENT PROTOCOLS MO; Lutz T, 2001, J MOL BIOL, V307, P815, DOI 10.1006/jmbi.2001.4527; Marquet A, 2001, CURR OPIN CHEM BIOL, V5, P541, DOI 10.1016/S1367-5931(00)00249-0; Mihara H, 2000, J BIOCHEM-TOKYO, V127, P559, DOI 10.1093/oxfordjournals.jbchem.a022641; Mihara H, 2002, J BIOCHEM, V131, P679, DOI 10.1093/oxfordjournals.jbchem.a003151; Mihara H, 2002, APPL MICROBIOL BIOT, V60, P12, DOI 10.1007/s00253-002-1107-4; Mihara H, 1997, J BIOL CHEM, V272, P22417, DOI 10.1074/jbc.272.36.22417; Mihara H, 1999, J BIOL CHEM, V274, P14768, DOI 10.1074/jbc.274.21.14768; Muhlenhoff U, 2000, BBA-BIOENERGETICS, V1459, P370, DOI 10.1016/S0005-2728(00)00174-2; Nachin L, 2003, EMBO J, V22, P427, DOI 10.1093/emboj/cdg061; Nachin L, 2001, MOL MICROBIOL, V39, P960, DOI 10.1046/j.1365-2958.2001.02288.x; Nilsson K, 2002, J BACTERIOL, V184, P6830, DOI 10.1128/JB.184.24.6830-6835.2002; Ollagnier-de Choudens S, 2003, J BIOL CHEM, V278, P17993, DOI 10.1074/jbc.M300285200; Parry R. J., 1999, COMPREHENSIVE NATURA, V1, P825; Patzer SI, 1999, J BACTERIOL, V181, P3307, DOI 10.1128/JB.181.10.3307-3309.1999; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Schwartz CJ, 2000, P NATL ACAD SCI USA, V97, P9009, DOI 10.1073/pnas.160261497; Schwartz CJ, 2001, P NATL ACAD SCI USA, V98, P14895, DOI 10.1073/pnas.251550898; Takahashi Y, 2002, J BIOL CHEM, V277, P28380, DOI 10.1074/jbc.C200365200; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001	44	162	172	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38352	38359		10.1074/jbc.M305953200	http://dx.doi.org/10.1074/jbc.M305953200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876288	hybrid			2022-12-27	WOS:000185575100034
J	Strubing, C; Krapivinsky, G; Krapivinsky, L; Clapham, DE				Strubing, C; Krapivinsky, G; Krapivinsky, L; Clapham, DE			Formation of novel TRPC channels by complex subunit interactions in embryonic brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CA2+-PERMEABLE CATION CHANNEL; TRANSIENT RECEPTOR; STORE DEPLETION; FUNCTIONAL-CHARACTERIZATION; ACTIVATION; CELLS; DIACYLGLYCEROL; STIMULATION; ASSOCIATION; EXPRESSION	Mammalian short TRP channels (TRPCs) are putative receptor- and store-operated cation channels that play a fundamental role in the regulation of cellular Ca2+ homeostasis. Assembly of the seven TRPC homologs (TRPC1-7) into homo- and heteromers can create a large variety of different channels. However, the compositions as well as the functional properties of native TRPC complexes are largely undefined. We performed a systematic biochemical study of TRPC interactions in mammalian brain and identified previously unrecognized channel heteromers composed of TRPC1, TRPC4, or TRPC5 and the diacylglycerol-activated TRPC3 or TRPC6 subunits. The novel TRPC heteromers were found exclusively in embryonic brain. In heterologous systems, we demonstrated that assembly of these novel heteromers required the combination of TRPC1 plus TRPC4 or TRPC5 subunits along with diacylglycerol-sensitive subunits in the channel complexes. Functional interaction of the TRPC subunits was verified using a dominant negative TRPC5 mutant (TRPC5(DN)). Co-expression of TRPC5(DN) suppressed currents through TRPC5- and TRPC4-containing complexes; TRPC3-associated currents were unaffected by TRPC5(DN) unless TRPC1 was also co-expressed. This complex assembly mechanism increases the diversity of TRPC channels in mammalian brain and may generate novel heteromers that have specific roles in the developing brain.	Childrens Hosp, Howard Hughes Med Inst, Dept Cardiovasc Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Clapham, DE (corresponding author), Childrens Hosp, Howard Hughes Med Inst, Dept Cardiovasc Res, Enders 1309,320 Longwood Ave, Boston, MA 02115 USA.	dclapham@enders.tch.harvard.edu	Clapham, David/S-1123-2019; Clapham, David/R-5974-2019	Clapham, David/0000-0002-4459-9428; 				Clapham DE, 2001, NAT REV NEUROSCI, V2, P387, DOI 10.1038/35077544; CLAPHAM DE, 1995, CELL, V80, P259, DOI 10.1016/0092-8674(95)90408-5; Congar P, 1997, J NEUROSCI, V17, P5366; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Goel M, 2002, J BIOL CHEM, V277, P48303, DOI 10.1074/jbc.M207882200; Greka A, 2003, NAT NEUROSCI, V6, P837, DOI 10.1038/nn1092; Haj-Dahmane S, 1999, EUR J NEUROSCI, V11, P1973, DOI 10.1046/j.1460-9568.1999.00612.x; HajDahmane S, 1996, J NEUROSCI, V16, P3848; Hofmann T, 2002, P NATL ACAD SCI USA, V99, P7461, DOI 10.1073/pnas.102596199; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Kiselyov K, 1998, NATURE, V396, P478, DOI 10.1038/24890; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; Lintschinger B, 2000, J BIOL CHEM, V275, P27799; Montell C., 2001, SCI STKE; Okada T, 1998, J BIOL CHEM, V273, P10279, DOI 10.1074/jbc.273.17.10279; Okada T, 1999, J BIOL CHEM, V274, P27359, DOI 10.1074/jbc.274.39.27359; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; Philipp S, 2000, J BIOL CHEM, V275, P23965, DOI 10.1074/jbc.M003408200; Philipp S, 1996, EMBO J, V15, P6166, DOI 10.1002/j.1460-2075.1996.tb01004.x; Philipp S, 1998, EMBO J, V17, P4274, DOI 10.1093/emboj/17.15.4274; Putney JW, 1999, BIOESSAYS, V21, P38; Riccio A, 2002, MOL BRAIN RES, V109, P95, DOI 10.1016/S0169-328X(02)00527-2; Schaefer M, 2000, J BIOL CHEM, V275, P17517, DOI 10.1074/jbc.275.23.17517; Strubing C, 2001, NEURON, V29, P645, DOI 10.1016/S0896-6273(01)00240-9; Trebak M, 2002, J BIOL CHEM, V277, P21617, DOI 10.1074/jbc.M202549200; Xu XZS, 1997, CELL, V89, P1155, DOI 10.1016/S0092-8674(00)80302-5; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2; Zitt C, 1997, J CELL BIOL, V138, P1333, DOI 10.1083/jcb.138.6.1333	29	327	343	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39014	39019		10.1074/jbc.M306705200	http://dx.doi.org/10.1074/jbc.M306705200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12857742	hybrid			2022-12-27	WOS:000185575100113
J	Hoff, KG; Cupp-Vickery, JR; Vickery, LE				Hoff, KG; Cupp-Vickery, JR; Vickery, LE			Contributions of the LPPVK motif of the iron-sulfur template protein IscU to interactions with the Hsc66-Hsc20 chaperone system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING DOMAIN; ESCHERICHIA-COLI; EXTINCTION COEFFICIENTS; AZOTOBACTER-VINELANDII; MOLECULAR CHAPERONES; CLUSTER BIOSYNTHESIS; HSP70 CHAPERONES; GENE-CLUSTER; DNAK; HSC66	Hsc66 (HscA) and Hsc20 ( HscB) from Escherichia coli comprise a specialized chaperone system that selectively binds the iron-sulfur cluster template protein IscU. Hsc66 interacts with peptides corresponding to a discrete region of IscU including residues 99 - 103 (LPPVK), and a peptide containing residues 98 - 106 stimulates Hsc66 ATPase activity in a manner similar to IscU. To determine the relative contributions of individual residues in the LPPVK motif to Hsc66 binding and regulation, we have carried out an alanine mutagenesis scan of this motif in the Glu(98) - Cys(106) peptide and the IscU protein. Alanine substitutions in the Glu(98) - Cys(106) peptide resulted in decreased ATPase stimulation (2 -10-fold) because of reduced binding affinity, with peptide( P101A) eliciting < 10% of the parent peptide stimulation. Alanine substitutions in the IscU protein also revealed lower activities resulting from decreased apparent binding affinity, with the greatest changes in K-m observed for the Pro(101) (77-fold), Val(102) (4-fold), and Lys(103) (15-fold) mutants. Calorimetric studies of the binding of IscU mutants to the Hsc66 &BULL; ADP complex showed that the P101A and K103A mutants also exhibit decreased binding affinity for the ADP-bound state. When ATPase stimulatory activity was assayed in the presence of the co-chaperone Hsc20, each of the mutants displayed enhanced binding affinity, but the P101A and V102A mutants exhibited decreased ability to maximally simulate Hsc66 ATPase. A charge mutant containing the motif sequence of NifU, IscU( V102E), did not bind the ATP or ADP states of Hsc66 but did bind Hsc20 and weakly stimulated Hsc66 ATPase in the presence of the co-chaperone. These results indicate that residues in the LPPVK motif are important for IscU interactions with Hsc66 but not for the ability of Hsc20 to target IscU to Hsc66. The results are discussed in the context of a structural model based on the crystallographic structure of the DnaK peptide-binding domain.	Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Vickery, LE (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA.				NIGMS NIH HHS [GM54264] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Agar JN, 2000, J AM CHEM SOC, V122, P2136, DOI 10.1021/ja9944195; Atherton E., 1990, SOLID PHASE PEPTIDE; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; DEAN DR, 1993, J BACTERIOL, V175, P6737, DOI 10.1128/jb.175.21.6737-6744.1993; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Hesterkamp T, 1998, EMBO J, V17, P4818, DOI 10.1093/emboj/17.16.4818; Hoff KG, 2002, J BIOL CHEM, V277, P27353, DOI 10.1074/jbc.M202814200; Hoff KG, 2000, P NATL ACAD SCI USA, V97, P7790, DOI 10.1073/pnas.130201997; James P, 1997, SCIENCE, V275, P387, DOI 10.1126/science.275.5298.387; KAWULA TH, 1994, J BACTERIOL, V176, P610, DOI 10.1128/jb.176.3.610-619.1994; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; LANDRY SL, 1992, NATURE, V355, P4455; MACH H, 1992, ANAL BIOCHEM, V200, P74, DOI 10.1016/0003-2697(92)90279-G; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; Nakamura M, 1999, J BIOCHEM, V126, P10, DOI 10.1093/oxfordjournals.jbchem.a022409; Ollagnier-de-Choudens S, 2001, J BIOL CHEM, V276, P22604, DOI 10.1074/jbc.M102902200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; PAEK KH, 1987, J BACTERIOL, V169, P283, DOI 10.1128/jb.169.1.283-290.1987; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Pellecchia M, 2000, NAT STRUCT BIOL, V7, P298; RIDDLES PW, 1979, ANAL BIOCHEM, V94, P75, DOI 10.1016/0003-2697(79)90792-9; Rudiger S, 2000, J MOL BIOL, V304, P245, DOI 10.1006/jmbi.2000.4193; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; SEATON BL, 1994, P NATL ACAD SCI USA, V91, P2066, DOI 10.1073/pnas.91.6.2066; Silberg JJ, 1998, J BACTERIOL, V180, P6617, DOI 10.1128/JB.180.24.6617-6624.1998; Silberg JJ, 2001, J BIOL CHEM, V276, P1696, DOI 10.1074/jbc.M009542200; Silberg JJ, 2000, J BIOL CHEM, V275, P7779, DOI 10.1074/jbc.275.11.7779; Strain J, 1998, J BIOL CHEM, V273, P31138, DOI 10.1074/jbc.273.47.31138; Tokumoto U, 2001, J BIOCHEM, V130, P63, DOI 10.1093/oxfordjournals.jbchem.a002963; Urbina HD, 2001, J BIOL CHEM, V276, P44521, DOI 10.1074/jbc.M106907200; Vickery LE, 1997, PROTEIN SCI, V6, P1047, DOI 10.1002/pro.5560060511; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; WEBB MR, 1992, P NATL ACAD SCI USA, V89, P4884, DOI 10.1073/pnas.89.11.4884; Zheng LM, 1998, J BIOL CHEM, V273, P13264, DOI 10.1074/jbc.273.21.13264; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	40	70	71	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37582	37589		10.1074/jbc.M305292200	http://dx.doi.org/10.1074/jbc.M305292200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871959	hybrid			2022-12-27	WOS:000185437200073
J	Kalinichenko, VV; Gusarova, GA; Tan, YJ; Wang, IC; Major, ML; Wang, XH; Yoder, HM; Costal, RH				Kalinichenko, VV; Gusarova, GA; Tan, YJ; Wang, IC; Major, ML; Wang, XH; Yoder, HM; Costal, RH			Ubiquitous expression of the Forkhead Box M1B transgene accelerates proliferation of distinct pulmonary cell types following lung injury	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR HFH-11B; BUTYLATED HYDROXYTOLUENE; LIVER DEVELOPMENT; HEPATOCYTE ENTRY; S-PHASE; MICE; PROTEIN; REGENERATION; BINDING; GENE	The delayed early transcription factor Forkhead Box M1B (FoxM1B) is expressed in proliferating cells, but its expression is extinguished in cells undergoing terminal differentiation. Liver regeneration studies with genetically altered mice that either prematurely expressed FoxM1B in hepatocytes or contained a hepatocyte-specific deletion of the Foxm1b allele demonstrated that FoxM1B is critical for regulating the expression of cell cycle genes required for hepatocyte proliferation. Furthermore, preventing the decline in hepatocyte FoxM1B levels during aging was sufficient to increase regenerating hepatocyte proliferation and expression of cell cycle genes to levels found in young regenerating mouse liver. Although these liver regeneration studies demonstrated that FoxM1B is required for hepatocyte proliferation, whether FoxM1B regulates proliferation of cell types other than hepatocytes remains to be determined. Here, we developed a new TG mouse line in which the - 800-base pair Rosa26 promoter was used to drive expression of the FoxM1B transgene in all mouse tissues and found that Rosa26-FoxM1B TG mice were healthy, displaying no developmental defects. We used butylated hydroxytoluene (BHT) lung injury to demonstrate that premature expression of the FoxM1B transgene protein accelerated proliferation of different lung cell types, including alveolar type II epithelial cells, bronchial epithelial and smooth muscle cells, and endothelial cells of pulmonary capillaries and arteries. This was associated with the earlier expression of the cell cycle promoting cyclin A2, cyclin E, cyclin B1, cyclin F, and cyclin dependent kinase-1 (Cdk1) genes and diminished protein levels of Cdk inhibitor p21(Cip1). Taken together, these results suggest that increasing FoxM1B levels is an effective means to stimulate cellular proliferation during aging and in lung diseases such as emphysema.	Univ Illinois, Coll Med, Dept Mol Genet, Chicago, IL 60607 USA; Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences	Costal, RH (corresponding author), Univ Illinois, Coll Med, Dept Mol Genet, M-C 669,900 S Ashland Ave,Rm 2220 MBRB, Chicago, IL 60607 USA.			Wang, I-Ching/0000-0003-4398-2975	NIA NIH HHS [R01 AG 21842-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK 54687-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054687] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021842] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ADAMSON IYR, 1977, LAB INVEST, V36, P26; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Carlsson P, 2002, DEV BIOL, V250, P1, DOI 10.1006/dbio.2002.0780; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; Costa RH, 2001, AM J PHYSIOL-LUNG C, V280, pL823, DOI 10.1152/ajplung.2001.280.5.L823; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; Duncan SA, 2000, DEV DYNAM, V219, P131, DOI 10.1002/1097-0177(2000)9999:9999<::AID-DVDY1051>3.3.CO;2-E; Guo SD, 1999, J BIOL CHEM, V274, P17184, DOI 10.1074/jbc.274.24.17184; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; Hawke TJ, 2003, J BIOL CHEM, V278, P4015, DOI 10.1074/jbc.M209200200; Kaestner KH, 2000, TRENDS ENDOCRIN MET, V11, P281, DOI 10.1016/S1043-2760(00)00271-X; Kaestner KH, 2000, GENE DEV, V14, P142; Kalinichenko VV, 2002, AM J PHYSIOL-LUNG C, V282, pL1253, DOI 10.1152/ajplung.00463.2001; Kalinichenko VV, 2001, DEV BIOL, V235, P489, DOI 10.1006/dbio.2001.0322; Kalinichenko VV, 2001, AM J PHYSIOL-LUNG C, V280, pL695, DOI 10.1152/ajplung.2001.280.4.L695; Kasahara Y, 2000, J CLIN INVEST, V106, P1311, DOI 10.1172/JCI10259; Kisseberth WC, 1999, DEV BIOL, V214, P128, DOI 10.1006/dbio.1999.9417; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Korver W, 1997, GENOMICS, V46, P435, DOI 10.1006/geno.1997.5065; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Luscher-Firzlaff JM, 1999, ONCOGENE, V18, P5620, DOI 10.1038/sj.onc.1202967; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; MARINO AA, 1972, P SOC EXP BIOL MED, V140, P122, DOI 10.3181/00379727-140-36407; Marsden I, 1998, J MOL BIOL, V278, P293, DOI 10.1006/jmbi.1998.1703; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; Rausa FM, 2000, MOL CELL BIOL, V20, P8264, DOI 10.1128/MCB.20.21.8264-8282.2000; SHAPIRO SD, 1994, AM J RESP CRIT CARE, V150, pS160, DOI 10.1164/ajrccm/150.6_Pt_2.S160; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Wang XH, 2002, P NATL ACAD SCI USA, V99, P16881, DOI 10.1073/pnas.252570299; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Wang XH, 2001, HEPATOLOGY, V33, P1404, DOI 10.1053/jhep.2001.24666; Wert SE, 2000, P NATL ACAD SCI USA, V97, P5972, DOI 10.1073/pnas.100448997; Wu H, 1996, GENE DEV, V10, P245, DOI 10.1101/gad.10.3.245; YAN C, 1990, EMBO J, V9, P869, DOI 10.1002/j.1460-2075.1990.tb08184.x; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	42	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37888	37894		10.1074/jbc.M305555200	http://dx.doi.org/10.1074/jbc.M305555200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867420	hybrid			2022-12-27	WOS:000185437200110
J	Molinier-Frenkel, V; Prevost-Blondel, A; Hong, SS; Lengagne, R; Boudaly, S; Magnusson, MK; Boulanger, P; Guillet, JG				Molinier-Frenkel, V; Prevost-Blondel, A; Hong, SS; Lengagne, R; Boudaly, S; Magnusson, MK; Boulanger, P; Guillet, JG			The maturation of murine dendritic cells induced by human adenovirus is mediated by the fiber knob domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; NF-KAPPA-B; RECOMBINANT ADENOVIRUS; IMMUNE-RESPONSES; GENE-THERAPY; IN-VIVO; CELLULAR RECEPTOR; CYSTIC-FIBROSIS; BINDING SITE; PENTON BASE	We investigated the mechanism of adenovirus serotype 5 (Ad5)-mediated maturation of bone marrow-derived murine dendritic cells (DC) using (i) Ad5 vectors with wildtype capsid (AdE1degrees, AdGFP); (ii) Ad5 vector mutant deleted of the fiber C-terminal knob domain (AdGFPDeltaknob); and (iii) capsid components isolated from Ad5-infected cells or expressed as recombinant proteins, hexon, penton, penton base, full-length fiber, fiber knob, and fiber mutants. We found that penton capsomer (penton base linked to its fiber projection), full-length fiber protein, and its isolated knob domain were all capable of inducing DC maturation, whereas no significant DC maturation was observed for hexon or penton base alone. This capacity was severely reduced for AdGFPDeltaknob and for fiber protein deletion mutants lacking the beta-stranded region F of the knob (residues Leu-485-Thr-486). The DC maturation effect was fully retained in a recombinant fiber protein deleted of the HI loop (FiDeltaHI), a fiber (Fi) deletion mutant that failed to trimerize, suggesting that the fiber knob-mediated DC activation did not depend on the integrity of the HI loop and on the trimeric status of the fiber. Interestingly, peptide-pulsed DC that had been stimulated with Ad5 knob protein induced a potent CD8(+) T cell response in vivo.	Fac Med RTH Laennec, CNRS UMR 5537, Lab Virol & Pathogenese Virale, F-69372 Lyon 08, France; Univ Paris 05, Lab Membre Inst Federatif Rech 116, CNRS UMR 8104, Dept Immunol,Inst Cochin,INSERM,U567, F-75014 Paris, France; Hop St Vincent de Paul, INSERM, U342, Lab Pathol Metab & Hormonale Dev, F-75014 Paris, France; Got A Gene AB, Stena Ctr 1B, SE-41292 Gothenburg, Sweden	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Boulanger, P (corresponding author), Fac Med RTH Laennec, CNRS UMR 5537, Lab Virol & Pathogenese Virale, 7 Rue Guillaume Paradin, F-69372 Lyon 08, France.		Prevost-Blondel, Armelle/N-7643-2017; Molinier-Frenkel, Valérie/Q-2852-2018; Hong, Saw See/M-9818-2017	Hong, Saw See/0000-0001-8871-0901; Molinier-Frenkel, Valerie/0000-0002-7250-7295; Prevost-Blondel, Armelle/0000-0002-7268-5905; Magnusson, Maria/0000-0002-8888-4968				Akira S, 2003, CURR OPIN IMMUNOL, V15, P238, DOI 10.1016/S0952-7915(03)00005-0; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Borgland SL, 2000, J VIROL, V74, P3941, DOI 10.1128/JVI.74.9.3941-3947.2000; Bruder JT, 1997, J VIROL, V71, P398, DOI 10.1128/JVI.71.1.398-404.1997; Gaden F, 2002, AM J RESP CELL MOL, V27, P628, DOI 10.1165/rcmb.4841; Gahery-Segard H, 1998, J VIROL, V72, P2388; GaherySegard H, 1997, J CLIN INVEST, V100, P2218, DOI 10.1172/JCI119759; Hirschowitz EA, 2000, GENE THER, V7, P1112, DOI 10.1038/sj.gt.3301210; Hong SS, 2003, MOL THER, V7, P692, DOI 10.1016/S1525-0016(03)00067-4; Hong SS, 1997, EMBO J, V16, P2294, DOI 10.1093/emboj/16.9.2294; Jeannin P, 2000, NAT IMMUNOL, V1, P502, DOI 10.1038/82751; KARAYAN L, 1994, VIROLOGY, V202, P782, DOI 10.1006/viro.1994.1400; Kirby I, 2000, J VIROL, V74, P2804, DOI 10.1128/JVI.74.6.2804-2813.2000; Kochanek S, 1999, HUM GENE THER, V10, P2451, DOI 10.1089/10430349950016807; Legrand V, 1999, J VIROL, V73, P907, DOI 10.1128/JVI.73.2.907-919.1999; Lusky M, 1998, J VIROL, V72, P2022, DOI 10.1128/JVI.72.3.2022-2032.1998; Luster AD, 2002, CURR OPIN IMMUNOL, V14, P129, DOI 10.1016/S0952-7915(01)00308-9; Magnusson MK, 2002, J GENE MED, V4, P356, DOI 10.1002/jgm.285; Magnusson MK, 2001, J VIROL, V75, P7280, DOI 10.1128/JVI.75.16.7280-7289.2001; MAYORDOMO JI, 1995, NAT MED, V1, P1297, DOI 10.1038/nm1295-1297; Mercier S, 2002, J VIROL, V76, P2899, DOI 10.1128/JVI.76.6.2899-2911.2002; Molinier-Frenkel V, 2000, J VIROL, V74, P7678, DOI 10.1128/JVI.74.16.7678-7682.2000; Molinier-Frenkel V, 2002, J VIROL, V76, P127, DOI 10.1128/JVI.76.1.127-135.2002; Morelli AE, 2000, J VIROL, V74, P9617, DOI 10.1128/JVI.74.20.9617-9628.2000; Muruve DA, 1999, HUM GENE THER, V10, P965, DOI 10.1089/10430349950018364; NOVELLI A, 1991, VIROLOGY, V185, P365, DOI 10.1016/0042-6822(91)90784-9; Oehen S, 1997, J IMMUNOL METHODS, V207, P33, DOI 10.1016/S0022-1759(97)00089-6; Okada N, 2001, BIOCHEM BIOPH RES CO, V282, P173, DOI 10.1006/bbrc.2001.4527; Rea D, 1999, J VIROL, V73, P10245, DOI 10.1128/JVI.73.12.10245-10253.1999; Rea D, 2001, J IMMUNOL, V166, P5236, DOI 10.4049/jimmunol.166.8.5236; Ribas A, 1997, CANCER RES, V57, P2865; Roelvink PW, 1999, SCIENCE, V286, P1568, DOI 10.1126/science.286.5444.1568; Roth MD, 2002, J IMMUNOL, V169, P4651, DOI 10.4049/jimmunol.169.8.4651; Rouard H, 2000, J IMMUNOL METHODS, V241, P69, DOI 10.1016/S0022-1759(00)00214-3; Santis G, 1999, J GEN VIROL, V80, P1519, DOI 10.1099/0022-1317-80-6-1519; Sarukhan A, 2001, J VIROL, V75, P269, DOI 10.1128/JVI.75.1.269-277.2001; Steitz J, 2001, GENE THER, V8, P1255, DOI 10.1038/sj.gt.3301521; Suomalainen M, 2001, EMBO J, V20, P1310, DOI 10.1093/emboj/20.6.1310; Tripathy SK, 1996, NAT MED, V2, P545, DOI 10.1038/nm0596-545; WICKHAM TJ, 1993, CELL, V73, P309, DOI 10.1016/0092-8674(93)90231-E; Worgall S, 1997, HUM GENE THER, V8, P37, DOI 10.1089/hum.1997.8.1-37; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YANG YP, 1995, NAT MED, V1, P890, DOI 10.1038/nm0995-890; YANG YP, 1994, P NATL ACAD SCI USA, V91, P4407, DOI 10.1073/pnas.91.10.4407; Zabner J, 1996, J CLIN INVEST, V97, P1504, DOI 10.1172/JCI118573	46	46	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37175	37182		10.1074/jbc.M303496200	http://dx.doi.org/10.1074/jbc.M303496200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855705	hybrid			2022-12-27	WOS:000185437200025
J	Natochin, M; Gasimov, KG; Moussaif, M; Artemyev, NO				Natochin, M; Gasimov, KG; Moussaif, M; Artemyev, NO			Rhodopsin determinants for transducin activation - A gain-of-function approach	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTEINE SUBSTITUTION MUTANTS; PROTEIN-COUPLED RECEPTORS; COVALENT CROSS-LINKING; 4TH CYTOPLASMIC LOOP; BOVINE RHODOPSIN; SULFHYDRYL REACTIVITY; TERTIARY STRUCTURE; CRYSTAL-STRUCTURE; LIGHT-ACTIVATION; VISUAL PIGMENTS	Three cytoplasmic loops in the G protein-coupled receptor rhodopsin, C2, C3, and C4, have been implicated as key sites for binding and activation of the visual G protein transducin. Non-helical portions of the C2- and C3-loops and the cytoplasmic helix-8 from the C4 loop were targeted for a "gain-of-function" mutagenesis to identify rhodopsin residues critical for transducin activation. Mutant opsins with residues 140 - 148 ( C2- loop), 229 - 244 ( C3-loop), or 310 - 320 ( C4-loop) substituted by poly-Ala sequences of equivalent lengths served as templates for mutagenesis. The template mutants with poly-Ala substitutions in the C2- and C3-loops formed the 500-nm absorbing pigments but failed to activate transducin. Reverse substitutions of the Ala residues by rhodopsin residues have been generated in each of the templates. Significant (similar to 50%) restoration of the rhodopsin/ transducin coupling was achieved with re-introduction of residues Cys(140)/Lys(141) and Arg(147)/Phe(148) into the C2 template. The reverse substitutions of the C3-loop residues Thr(229)/Val(230) and Ser(240)/Thr(242)/Thr(243)/Gln(244) produced a pigment with a full capacity for transducin activation. The C4 template mutant was unable to bind 11-cis-retinal, and the presence of Asn(310)/Lys(311) was required for correct folding of the protein. Subsequent mutagenesis of the C4-loop revealed the role of Phe(313) and Met(317). On the background of Asn(310)/Lys(311), the inclusion of Phe313 and Met317 produced a mutant pigment with the potency of transducin activation equal to that of the wild-type rhodopsin. Overall, our data support the role of the three cytoplasmic loops of rhodopsin and suggest that residues adjacent to the transmembrane helices are most important for transducin activation.	Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA	University of Iowa	Artemyev, NO (corresponding author), Univ Iowa, Coll Med, Dept Physiol & Biophys, Iowa City, IA 52242 USA.			Artemyev, Nikolai/0000-0002-5266-6854	NEI NIH HHS [EY-12682] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY012682] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abdulaev NG, 1998, P NATL ACAD SCI USA, V95, P12854, DOI 10.1073/pnas.95.22.12854; Acharya S, 1997, J BIOL CHEM, V272, P6519, DOI 10.1074/jbc.272.10.6519; Altenbach C, 1996, BIOCHEMISTRY-US, V35, P12470, DOI 10.1021/bi960849l; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cai K, 2001, P NATL ACAD SCI USA, V98, P4877, DOI 10.1073/pnas.051632898; Cai KW, 1999, BIOCHEMISTRY-US, V38, P7925, DOI 10.1021/bi9900119; Ernst OP, 2000, J BIOL CHEM, V275, P1937, DOI 10.1074/jbc.275.3.1937; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Filipek S, 2003, ANNU REV PHYSIOL, V65, P851, DOI 10.1146/annurev.physiol.65.092101.142611; FRANKE RR, 1990, SCIENCE, V250, P123, DOI 10.1126/science.2218504; FRANKE RR, 1992, J BIOL CHEM, V267, P14767; Fritze O, 2003, P NATL ACAD SCI USA, V100, P2290, DOI 10.1073/pnas.0435715100; Gether U, 2000, ENDOCR REV, V21, P90, DOI 10.1210/er.21.1.90; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hubbell WL, 2003, ADV PROTEIN CHEM, V63, P243; KAUSHAL S, 1994, P NATL ACAD SCI USA, V91, P4024, DOI 10.1073/pnas.91.9.4024; Kazmi MA, 1996, BIOTECHNIQUES, V21, P304; Klein-Seetharaman J, 1999, BIOCHEMISTRY-US, V38, P7938, DOI 10.1021/bi990013t; KONIG B, 1989, P NATL ACAD SCI USA, V86, P6878, DOI 10.1073/pnas.86.18.6878; Marin EP, 2002, BIOCHEMISTRY-US, V41, P6988, DOI 10.1021/bi025514k; Marin EP, 2000, J BIOL CHEM, V275, P1930, DOI 10.1074/jbc.275.3.1930; Menon ST, 2001, PHYSIOL REV, V81, P1659, DOI 10.1152/physrev.2001.81.4.1659; NATHANS J, 1986, SCIENCE, V232, P193, DOI 10.1126/science.2937147; Okada T, 2002, P NATL ACAD SCI USA, V99, P5982, DOI 10.1073/pnas.082666399; OPRIAN DD, 1987, P NATL ACAD SCI USA, V84, P8874, DOI 10.1073/pnas.84.24.8874; OSAWA S, 1994, MOL PHARMACOL, V46, P1036; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; RESEK JF, 1993, BIOCHEMISTRY-US, V32, P12025, DOI 10.1021/bi00096a012; RESEK JF, 1994, P NATL ACAD SCI USA, V91, P7643, DOI 10.1073/pnas.91.16.7643; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P8804, DOI 10.1021/bi00027a032; RIDGE KD, 1995, BIOCHEMISTRY-US, V34, P3261, DOI 10.1021/bi00010a016; SHI W, 1995, J BIOL CHEM, V270, P2112, DOI 10.1074/jbc.270.5.2112; Stenkamp RE, 2002, BBA-BIOMEMBRANES, V1565, P168, DOI 10.1016/S0005-2736(02)00567-9; Teller DC, 2001, BIOCHEMISTRY-US, V40, P7761, DOI 10.1021/bi0155091; WALD G, 1953, J GEN PHYSIOL, V37, P189, DOI 10.1085/jgp.37.2.189; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; Yamashita T, 2000, J BIOL CHEM, V275, P34272, DOI 10.1074/jbc.M002954200; YAMAZAKI A, 1988, METHOD ENZYMOL, V159, P702; Yang K, 1996, BIOCHEMISTRY-US, V35, P12464, DOI 10.1021/bi960848t; Yeagle PL, 2003, BIOCHEMISTRY-US, V42, P1365, DOI 10.1021/bi0270539	40	38	40	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37574	37581		10.1074/jbc.M305136200	http://dx.doi.org/10.1074/jbc.M305136200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860986	hybrid			2022-12-27	WOS:000185437200072
J	Panda, K; Adak, S; Aulak, KS; Santolini, J; McDonald, JF; Stuehr, DJ				Panda, K; Adak, S; Aulak, KS; Santolini, J; McDonald, JF; Stuehr, DJ			Distinct influence of N-terminal elements on neuronal nitric-oxide synthase structure and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-TURNOVER CONDITIONS; STOPPED-FLOW ANALYSIS; ARGININE BINDING; TETRAHYDROBIOPTERIN INTERACTION; MOLECULAR-MECHANISMS; SUBUNIT DIMERIZATION; BACILLUS-SUBTILIS; CRYSTAL-STRUCTURE; ELECTRON-TRANSFER; OXYGENASE DOMAIN	Nitric oxide (NO) is a signal molecule produced in animals by three different NO synthases. Of these, only NOS I (neuronal nitric-oxide synthase; nNOS) is expressed as catalytically active N-terminally truncated forms that are missing either an N-terminal leader sequence required for protein-protein interactions or are missing the leader sequence plus three core structural motifs that in other NOS are required for dimer assembly and catalysis. To understand how the N-terminal elements impact nNOS structure-function, we generated, purified, and extensively characterized variants that were missing the N-terminal leader sequence (Delta296nNOS) or missing the leader sequence plus the three core motifs (Delta349nNOS). Eliminating the leader sequence had no impact on nNOS structure or catalysis. In contrast, additional removal of the core elements weakened but did not destroy the dimer interaction, slowed ferric heme reduction and reactivity of a heme-dioxy intermediate, and caused a 10-fold poorer affinity toward substrate L-arginine. This created an nNOS variant with slower and less coupled NO synthesis that is predisposed to generate reactive oxygen species along with NO. Our findings help justify the existence of nNOS N-terminal splice variants and identify specific catalytic changes that create functional differences among them.	Cleveland Clin, Lerner Res Inst, Dept Immunol, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Stuehr, DJ (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Immunol, 9500 Euclid Ave, Cleveland, OH 44195 USA.		; Panda, Koustubh/E-5273-2017	Santolini, Jerome/0000-0001-8919-112X; Panda, Koustubh/0000-0002-4783-2221	NCI NIH HHS [CA53914] Funding Source: Medline; NIGMS NIH HHS [GM51491] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA053914, R29CA053914] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051491] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abu-Soud HM, 1998, BIOCHEMISTRY-US, V37, P3777, DOI 10.1021/bi972398q; Abu-Soud HM, 1999, BIOCHEMISTRY-US, V38, P12446, DOI 10.1021/bi990698x; ABUSOUD HM, 1995, BIOCHEMISTRY-US, V34, P11167, DOI 10.1021/bi00035a023; AbuSoud HM, 1997, BIOCHEMISTRY-US, V36, P10811, DOI 10.1021/bi971414g; AbuSoud HM, 1996, J BIOL CHEM, V271, P32515, DOI 10.1074/jbc.271.51.32515; Adak S, 2000, J BIOL CHEM, V275, P17434, DOI 10.1074/jbc.M000846200; Adak S, 2001, J BIOL CHEM, V276, P1244, DOI 10.1074/jbc.M006857200; Adak S, 2001, J INORG BIOCHEM, V83, P301, DOI 10.1016/S0162-0134(00)00176-8; Adak S, 1999, J BIOL CHEM, V274, P22313, DOI 10.1074/jbc.274.32.22313; Adak S, 2002, J BIOL CHEM, V277, P16167, DOI 10.1074/jbc.M201136200; Adak S, 2002, P NATL ACAD SCI USA, V99, P107, DOI 10.1073/pnas.012470099; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; Bender AT, 2000, J BIOL CHEM, V275, P26018, DOI 10.1074/jbc.275.34.26018; Bird LE, 2002, STRUCTURE, V10, P1687, DOI 10.1016/S0969-2126(02)00911-5; Boggs S, 2000, BIOCHEMISTRY-US, V39, P2332, DOI 10.1021/bi9920228; Boyhan A, 1997, BIOCHEM J, V323, P131, DOI 10.1042/bj3230131; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; BRENMAN JE, 1995, CELL, V82, P743, DOI 10.1016/0092-8674(95)90471-9; Chen PF, 1997, J BIOL CHEM, V272, P6114, DOI 10.1074/jbc.272.10.6114; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; Couture M, 2001, J BIOL CHEM, V276, P38280; Crane BR, 1999, EMBO J, V18, P6271, DOI 10.1093/emboj/18.22.6271; Crane BR, 1998, SCIENCE, V279, P2121, DOI 10.1126/science.279.5359.2121; Dawson VL, 1998, PROG BRAIN RES, V118, P215; DINERMAN JL, 1993, CIRC RES, V73, P217, DOI 10.1161/01.RES.73.2.217; Fischmann TO, 1999, NAT STRUCT BIOL, V6, P233, DOI 10.1038/6675; Gachhui R, 1997, BIOCHEMISTRY-US, V36, P5097, DOI 10.1021/bi970331x; Gachhui R, 1998, J BIOL CHEM, V273, P5451, DOI 10.1074/jbc.273.10.5451; Ghosh DK, 1996, BIOCHEMISTRY-US, V35, P1444, DOI 10.1021/bi9521295; Ghosh DK, 1999, EMBO J, V18, P6260, DOI 10.1093/emboj/18.22.6260; Ghosh DK, 1997, BIOCHEMISTRY-US, V36, P10609, DOI 10.1021/bi9702290; Ghosh S, 1999, J BIOL CHEM, V274, P24100, DOI 10.1074/jbc.274.34.24100; GRIFFITH OW, 1995, ANNU REV PHYSIOL, V57, P707, DOI 10.1146/annurev.ph.57.030195.003423; GROSS SS, 1995, ANNU REV PHYSIOL, V57, P737, DOI 10.1146/annurev.ph.57.030195.003513; Harrison DG, 1997, J CLIN INVEST, V100, P2153, DOI 10.1172/JCI119751; Hemmens B, 1998, METH MOL B, V100, P1; Hemmens B, 1998, FEBS LETT, V430, P397, DOI 10.1016/S0014-5793(98)00704-2; Hemmens B, 2000, J BIOL CHEM, V275, P35786, DOI 10.1074/jbc.M005976200; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Klatt P, 1996, J BIOL CHEM, V271, P7336, DOI 10.1074/jbc.271.13.7336; Komeima K, 2000, J BIOL CHEM, V275, P28139; Lee MA, 1997, J CLIN INVEST, V100, P1507, DOI 10.1172/JCI119673; Li HY, 1999, J BIOL CHEM, V274, P21276, DOI 10.1074/jbc.274.30.21276; MacMicking J, 1997, ANNU REV IMMUNOL, V15, P323, DOI 10.1146/annurev.immunol.15.1.323; Martasek P, 1998, J BIOL CHEM, V273, P34799, DOI 10.1074/jbc.273.52.34799; Mayer B, 1997, TRENDS BIOCHEM SCI, V22, P477, DOI 10.1016/S0968-0004(97)01147-X; Michel T, 1997, J CLIN INVEST, V100, P2146, DOI 10.1172/JCI119750; Panda K, 2002, J BIOL CHEM, V277, P31020, DOI 10.1074/jbc.M203749200; Panda K, 2001, J BIOL CHEM, V276, P23349, DOI 10.1074/jbc.M100687200; Pant K, 2002, BIOCHEMISTRY-US, V41, P11071, DOI 10.1021/bi0263715; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Raman CS, 1998, CELL, V95, P939, DOI 10.1016/S0092-8674(00)81718-3; Rodriguez-Crespo I, 1999, J BIOL CHEM, V274, P21617, DOI 10.1074/jbc.274.31.21617; RodriguezCrespo I, 1997, BIOCHEMISTRY-US, V36, P8530, DOI 10.1021/bi970192j; RodriguezCrespo I, 1996, J BIOL CHEM, V271, P11462, DOI 10.1074/jbc.271.19.11462; Sagami I, 1998, J BIOL CHEM, V273, P2105, DOI 10.1074/jbc.273.4.2105; Sagami I, 2001, J BIOL CHEM, V276, P30036, DOI 10.1074/jbc.M104123200; Santolini J, 2001, J BIOL CHEM, V276, P48887, DOI 10.1074/jbc.M108666200; Santolini J, 2001, J BIOL CHEM, V276, P1233, DOI 10.1074/jbc.M006858200; Scheele JS, 2001, J BIOL CHEM, V276, P4733, DOI 10.1074/jbc.M007461200; Siddhanta U, 1996, J BIOL CHEM, V271, P7309, DOI 10.1074/jbc.271.13.7309; STANKOVICH MT, 1980, ANAL BIOCHEM, V109, P295, DOI 10.1016/0003-2697(80)90652-1; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Wang Y, 1997, J BIOL CHEM, V272, P11392; Wang Y, 1999, CRIT REV NEUROBIOL, V13, P21, DOI 10.1615/CritRevNeurobiol.v13.i1.20; Wang Y, 1999, P NATL ACAD SCI USA, V96, P12150, DOI 10.1073/pnas.96.21.12150; Wang Y, 1995, Adv Pharmacol, V34, P71; Wang ZQ, 2001, BIOCHEMISTRY-US, V40, P12819, DOI 10.1021/bi011182s; Zanelli SA, 2002, NEUROSCIENCE, V112, P869, DOI 10.1016/S0306-4522(02)00141-0	71	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37122	37131		10.1074/jbc.M304456200	http://dx.doi.org/10.1074/jbc.M304456200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847099	hybrid			2022-12-27	WOS:000185437200018
J	Rao, GSJ; Coleman, DE; Karsten, WE; Cook, PF; Harris, BG				Rao, GSJ; Coleman, DE; Karsten, WE; Cook, PF; Harris, BG			Crystallographic studies on Ascaris suum NAD-malic enzyme bound to reduced cofactor and identification of an effector site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINAMIDE ADENINE-DINUCLEOTIDE; ELECTRON-DENSITY MAPS; CRYSTAL-STRUCTURE; OXIDATIVE DECARBOXYLASES; REGULATORY PROPERTIES; ANGSTROM RESOLUTION; MECHANISM; DEHYDROGENASE; MOLSCRIPT; SEQUENCE	The crystal structure of the mitochondrial NAD-malic enzyme from Ascaris suum, in a quaternary complex with NADH, tartronate, and magnesium has been determined to 2.0-Angstrom resolution. The structure closely resembles the previously determined structure of the same enzyme in binary complex with NAD. However, a significant difference is observed within the coenzyme-binding pocket of the active site with the nicotinamide ring of NADH molecule rotating by 198degrees over the C-1 - N-1 bond into the active site without causing significant movement of the other catalytic residues. The implications of this conformational change in the nicotinamide ring to the catalytic mechanism are discussed. The structure also reveals a binding pocket for the divalent metal ion in the active site and a binding site for tartronate located in a highly positively charged environment within the subunit interface that is distinct from the active site. The tartronate binding site, presumably an allosteric site for the activator fumarate, shows striking similarities and differences with the activator site of the human NAD-malic enzyme that has been reported recently. Thus, the structure provides additional insights into the catalytic as well as the allosteric mechanisms of the enzyme.	Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA	University of North Texas System; University of North Texas Health Science Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Oklahoma System; University of Oklahoma - Norman	Harris, BG (corresponding author), Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA.				NHLBI NIH HHS [HR 990217] Funding Source: Medline; NIAID NIH HHS [AI41552, AI24155] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI041552, R21AI041552, R01AI024155] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS MJ, 1994, STRUCTURE, V2, P651, DOI 10.1016/S0969-2126(00)00066-6; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Coleman DE, 2002, BIOCHEMISTRY-US, V41, P6928, DOI 10.1021/bi0255120; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; HALL MD, 1993, J MOL BIOL, V232, P213, DOI 10.1006/jmbi.1993.1377; Hammen PK, 2002, BIOCHEMISTRY-US, V41, P7156, DOI 10.1021/bi012197t; HLAVATY J, 1997, BIOCHEMISTRY-US, V39, P3389; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARSTEN WE, 1994, BIOCHEMISTRY-US, V33, P2096, DOI 10.1021/bi00174a016; Karsten WE, 2000, PROTEIN PEPTIDE LETT, V7, P281; Karsten WE, 1999, BIOCHEMISTRY-US, V38, P10527, DOI 10.1021/bi9906165; KIICK DM, 1986, BIOCHEMISTRY-US, V25, P227, DOI 10.1021/bi00349a032; Komuniecki Richard, 1995, P49, DOI 10.1016/B978-012473345-9/50005-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KULKARNI G, 1993, ARCH BIOCHEM BIOPHYS, V300, P231, DOI 10.1006/abbi.1993.1032; LAI CJ, 1992, ARCH BIOCHEM BIOPHYS, V299, P214, DOI 10.1016/0003-9861(92)90266-Y; LANDSPERGER WJ, 1976, J BIOL CHEM, V251, P3599; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Liu D, 2000, BIOCHEMISTRY-US, V39, P11955, DOI 10.1021/bi000790p; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MOREADITH RW, 1984, J BIOL CHEM, V259, P6222; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARK SH, 1986, BIOCHEMISTRY-US, V25, P3752, DOI 10.1021/bi00361a004; Rao GSJ, 2000, PROTEIN PEPTIDE LETT, V7, P297; SAUER LA, 1973, BIOCHEM BIOPH RES CO, V50, P524, DOI 10.1016/0006-291X(73)90871-1; SAUER LA, 1973, FEBS LETT, V33, P251, DOI 10.1016/0014-5793(73)80205-4; SAZ HJ, 1981, ANNU REV PHYSIOL, V43, P323, DOI 10.1146/annurev.ph.43.030181.001543; VINCENT JFS, 1994, P NATL ACAD SCI USA, P4383; WEISS PM, 1991, BIOCHEMISTRY-US, V30, P5755, DOI 10.1021/bi00237a018; Xu YW, 1999, STRUCT FOLD DES, V7, P877, DOI 10.1016/S0969-2126(99)80115-4; Yang ZR, 2000, NAT STRUCT BIOL, V7, P251; Yang ZR, 2002, STRUCTURE, V10, P951, DOI 10.1016/S0969-2126(02)00788-8	33	30	31	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38051	38058		10.1074/jbc.M305145200	http://dx.doi.org/10.1074/jbc.M305145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853453	hybrid			2022-12-27	WOS:000185437200127
J	Tsurupa, G; Ho-Tin-Noe, B; Angles-Cano, E; Medved, L				Tsurupa, G; Ho-Tin-Noe, B; Angles-Cano, E; Medved, L			Identification and characterization of novel lysine-independent apolipoprotein(a)-binding sites in fibrin(ogen) alpha C-domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSING HUMAN APOLIPOPROTEIN(A); MEDIATED PLASMINOGEN ACTIVATION; CORONARY-HEART-DISEASE; BINDING-SITE; TRANSGENIC RABBITS; FIBRINOGEN BINDING; RECOMBINANT APOLIPOPROTEIN(A); ATHEROSCLEROTIC LESIONS; IMMOBILIZED FIBRINOGEN; MONOCLONAL-ANTIBODY	Accumulation of lipoprotein(a) (Lp(a)) in atherosclerotic plaques is mediated through interaction of fibrin-(ogen) deposits with the apolipoprotein(a) (apo(a)) moiety of Lp(a). It was suggested that because apo(a) competes with plasminogen for binding to fibrin, causing inhibition of fibrinolysis, it could also promote atherothrombosis. Because the fibrin(ogen) alphaC-domains bind plasminogen and tissue-type plasminogen activator with high affinity in a Lys-dependent manner, we hypothesized that they could also bind apo(a). To test this hypothesis, we studied the interaction between the recombinant apo(a) A10 isoform and the recombinant alphaC-fragment (Aalpha-(221-610)) corresponding to the alphaC-domain by enzyme-linked immunosorbent assay and surface plasmon resonance. Both methods revealed a high affinity interaction (K-d = 19-21 nM) between the immobilized alphaC-fragment and apo(a), indicating that the former contains an apo(a)-binding site. This affinity was comparable to that of apo(a) for fibrin. At the same time, no interaction was observed between soluble fibrinogen and immobilized apo(a), suggesting that, in the former, this and other apo(a)-binding sites are cryptic. Further experiments with truncated recombinant variants of the alphaC-fragment allowed localization of the apo(a)-binding site to the Aalpha-(392-610) region. The presence of epsilon-aminocaproic acid only slightly inhibited binding of apo(a) to the alphaC-fragment, indicating the Lys-independent nature of their interaction. In agreement, the influence of plasminogen or tissue-type plasminogen activator on binding of apo(a) to the alphaC-fragment was minimal. These results indicate that the alphaC-domains contain novel high affinity apo(a)-binding sites that may provide a Lys-independent mechanism for bringing Lp(a) to places of fibrin deposition such as injured vessels or atherosclerotic lesions.	Amer Red Cross, Jerome H Holland Lab Biomed Sci, Rockville, MD 20855 USA; CHU Bichat, INSERM, U460, F-75877 Paris 18, France	American Red Cross; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bichat-Claude Bernard - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Medved, L (corresponding author), Amer Red Cross, Jerome H Holland Lab Biomed Sci, 15601 Crabbs Branch Way, Rockville, MD 20855 USA.		Ho-Tin-Noé, Benoit/U-8059-2018; ANGLES-CANO, Eduardo/G-2311-2012; ANGLES-CANO, Eduardo/ABA-1739-2020	Ho-Tin-Noé, Benoit/0000-0002-7428-1760; ANGLES-CANO, Eduardo/0000-0001-7891-3975; ANGLES-CANO, Eduardo/0000-0001-7891-3975; Medved, Leonid/0000-0002-3665-9849	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056051] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-56051, R01 HL056051] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Angles-Cano E, 1999, J LIPID RES, V40, P354; Angles-Cano E, 2001, ANN NY ACAD SCI, V936, P261; BAS LC, 1992, THROMB HAEMOSTASIS, V68, P185; BINI A, 1995, ANN NY ACAD SCI, V748, P461; Boonmark NW, 1997, J CLIN INVEST, V100, P558, DOI 10.1172/JCI119565; BROWN MS, 1987, NATURE, V330, P113, DOI 10.1038/330113a0; Danesh J, 2000, CIRCULATION, V102, P1082, DOI 10.1161/01.CIR.102.10.1082; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; Dominguez M, 2001, BBA-PROTEIN STRUCT M, V1548, P72, DOI 10.1016/S0167-4838(01)00215-1; EATON DL, 1987, P NATL ACAD SCI USA, V84, P3224, DOI 10.1073/pnas.84.10.3224; ELLIS V, 1993, J BIOL CHEM, V268, P4806; Fan JL, 2001, ARTERIOSCL THROM VAS, V21, P88, DOI 10.1161/01.ATV.21.1.88; Gorgani NN, 1999, J BIOL CHEM, V274, P29633, DOI 10.1074/jbc.274.42.29633; GUEVARA J, 1993, ARTERIOSCLER THROMB, V13, P758, DOI 10.1161/01.ATV.13.5.758; HARPEL PC, 1989, P NATL ACAD SCI USA, V86, P3847, DOI 10.1073/pnas.86.10.3847; Henschen A., 1986, BLOOD COAGULATION, V171, P241; HERVIO L, 1995, BIOCHEMISTRY-US, V34, P13353, DOI 10.1021/bi00041a011; HOYLAERTS M, 1982, J BIOL CHEM, V257, P2912; HUBY T, 1995, BIOCHEMISTRY-US, V34, P7385, DOI 10.1021/bi00022a011; Ichikawa T, 2002, AM J PATHOL, V160, P227, DOI 10.1016/S0002-9440(10)64366-0; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; Kang C, 2002, ARTERIOSCL THROM VAS, V22, P1232, DOI 10.1161/01.ATV.0000021144.87870.C8; Klezovitch O, 1996, ARTERIOSCL THROM VAS, V16, P392, DOI 10.1161/01.ATV.16.3.392; Klezovitch O, 1996, J CLIN INVEST, V98, P185, DOI 10.1172/JCI118765; Klose R, 2000, J BIOL CHEM, V275, P38206, DOI 10.1074/jbc.M003640200; LACKNER C, 1993, HUM MOL GENET, V2, P933, DOI 10.1093/hmg/2.7.933; LAWN RM, 1992, NATURE, V360, P670, DOI 10.1038/360670a0; Lawn RM, 1996, J BIOL CHEM, V271, P31367, DOI 10.1074/jbc.271.49.31367; Lishko VK, 2002, BIOCHEMISTRY-US, V41, P12942, DOI 10.1021/bi026324c; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P240, DOI 10.1161/01.ATV.10.2.240; Lou XJ, 1998, P NATL ACAD SCI USA, V95, P12591, DOI 10.1073/pnas.95.21.12591; Makogonenko E, 2002, BIOCHEMISTRY-US, V41, P7907, DOI 10.1021/bi025770x; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; Medved L, 2003, THROMB HAEMOSTASIS, V89, P409; Medved L, 1997, BIOCHEMISTRY-US, V36, P4685, DOI 10.1021/bi962795l; Medved L, 2001, ANN NY ACAD SCI, V936, P185; Moskowitz KA, 1998, THROMB HAEMOSTASIS, V79, P824, DOI 10.1055/s-0037-1615072; Nieuwenhuizen W, 2001, ANN NY ACAD SCI, V936, P237; PRIVALOV PL, 1982, J MOL BIOL, V159, P665, DOI 10.1016/0022-2836(82)90107-3; ROUY D, 1992, BIOCHEMISTRY-US, V31, P6333, DOI 10.1021/bi00142a024; ROUY D, 1992, ARTERIOSCLER THROMB, V12, P146, DOI 10.1161/01.ATV.12.2.146; Sangrar W, 2000, BIOCHEM CELL BIOL, V78, P519, DOI 10.1139/bcb-78-4-519; Schuck P, 1996, TRENDS BIOCHEM SCI, V21, P458, DOI 10.1016/S0968-0004(96)20025-8; SHIBA E, 1991, AM PHYSL SOC, V260, P965; Sun HJ, 2002, J BIOL CHEM, V277, P47486, DOI 10.1074/jbc.M205814200; Tsurupa G, 2002, BIOCHEMISTRY-US, V41, P6449, DOI 10.1021/bi025584r; Tsurupa G, 2001, BIOCHEMISTRY-US, V40, P801, DOI 10.1021/bi001789t; VERHEIJEN JH, 1982, THROMB RES, V27, P377, DOI 10.1016/0049-3848(82)90055-X; Weisel JW, 2001, ANN NY ACAD SCI, V936, P312; WIMAN B, 1978, NATURE, V272, P549, DOI 10.1038/272549a0; WIMAN B, 1977, THROMB RES, V10, P213, DOI 10.1016/0049-3848(77)90003-2; Xue S, 2001, THROMB HAEMOSTASIS, V86, P1229, DOI 10.1055/s-0037-1616056	53	24	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37154	37159		10.1074/jbc.M305154200	http://dx.doi.org/10.1074/jbc.M305154200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853452	hybrid			2022-12-27	WOS:000185437200022
J	Fang, M; Tao, YX; He, FH; Zhang, MJ; Levine, CF; Mao, PZ; Tao, F; Chou, CL; Sadegh-Nasseri, S; Johns, RA				Fang, M; Tao, YX; He, FH; Zhang, MJ; Levine, CF; Mao, PZ; Tao, F; Chou, CL; Sadegh-Nasseri, S; Johns, RA			Synaptic PDZ domain-mediated protein interactions are disrupted by inhalational anesthetics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NMDA RECEPTOR SUBUNITS; LONG-TERM POTENTIATION; NITRIC-OXIDE SYNTHASE; GENERAL-ANESTHETICS; VOLATILE ANESTHETICS; NEUROPATHIC PAIN; ACID RECEPTOR; BINDING; HALOTHANE; PSD-95	Anesthetics exert multiple effects on the central nervous system through altering synaptic transmission, but the mechanisms for this process are poorly understood. PDZ domain-mediated protein interactions play a central role in organizing signaling complexes around synaptic receptors for efficient signal transduction. We report here that clinically relevant concentrations of inhalational anesthetics dose-dependently and specifically inhibit the PDZ domain-mediated protein interaction between PSD-95 or PSD-93 and the N-methyl-D-aspartate receptor or neuronal nitric-oxide synthase. These inhibitory effects are immediate, potent, and reversible and occur at a hydrophobic peptide-binding groove on the surface of the second PDZ domain of PSD-95 in a manner relevant to anesthetic action. These findings reveal the PDZ domain as a new molecular target for inhalational anesthetics.	Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21287 USA; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China	Johns Hopkins University; Johns Hopkins University; Hong Kong University of Science & Technology	Johns, RA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Anesthesiol & Crit Care Med, Ross 361,720 Rutland Ave, Baltimore, MD 21205 USA.	Rajohns@jhmi.edu	Tao, Feng/Q-7827-2016; He, Fahu/I-9060-2012; He, Fahu/N-1442-2014	Tao, Feng/0000-0002-0623-6298; Sadegh-Nasseri, Scheherazade/0000-0002-8127-1720; Zhang, Mingjie/0000-0001-9404-0190	NIGMS NIH HHS [GM49111] Funding Source: Medline; NINDS NIH HHS [NS 44219] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049111] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044219] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aarts M, 2002, SCIENCE, V298, P846, DOI 10.1126/science.1072873; ALLOTT PR, 1971, BRIT J ANAESTH, V43, P913, DOI 10.1093/bja/43.10.913; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bhattacharya AA, 2000, J BIOL CHEM, V275, P38731, DOI 10.1074/jbc.M005460200; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Brenman JE, 1996, CELL, V84, P757, DOI 10.1016/S0092-8674(00)81053-3; Brenman JE, 1996, J NEUROSCI, V16, P7407; Cheng G, 2000, ANESTHESIOLOGY, V93, P1075, DOI 10.1097/00000542-200010000-00032; Chou CL, 2000, J EXP MED, V192, P1697, DOI 10.1084/jem.192.12.1697; Christopherson KS, 1999, J BIOL CHEM, V274, P27467, DOI 10.1074/jbc.274.39.27467; COHEN NA, 2000, NEURON, V17, P739; Craven SE, 1998, CELL, V93, P495, DOI 10.1016/S0092-8674(00)81179-4; DANIELS S, 1993, BRIT J ANAESTH, V71, P59, DOI 10.1093/bja/71.1.59; de Sousa SLM, 2000, ANESTHESIOLOGY, V92, P1055, DOI 10.1097/00000542-200004000-00024; Doyle DA, 1996, CELL, V85, P1067, DOI 10.1016/S0092-8674(00)81307-0; Eckenhoff MF, 1998, J PHARMACOL EXP THER, V285, P371; Eckenhoff R G, 2001, Mol Interv, V1, P258; Eckenhoff RG, 1997, PHARMACOL REV, V49, P343; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; Fouassier L, 2000, J BIOL CHEM, V275, P25039, DOI 10.1074/jbc.C000092200; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; Garcia EP, 1998, NEURON, V21, P727, DOI 10.1016/S0896-6273(00)80590-5; Garner CC, 2000, TRENDS CELL BIOL, V10, P274, DOI 10.1016/S0962-8924(00)01783-9; Hata Y, 1998, NEUROSCI RES, V32, P1, DOI 10.1016/S0168-0102(98)00069-8; Hillier BJ, 1999, SCIENCE, V284, P812, DOI 10.1126/science.284.5415.812; Hu LYA, 2000, J BIOL CHEM, V275, P38659, DOI 10.1074/jbc.M005938200; Hung AY, 2002, J BIOL CHEM, V277, P5699, DOI 10.1074/jbc.R100065200; Jaffrey SR, 1995, ANNU REV CELL DEV BI, V11, P417; Jenkins A, 2001, J NEUROSCI, V21, DOI 10.1523/JNEUROSCI.21-06-j0002.2001; Johansson JS, 2000, BIOPHYS J, V78, P982, DOI 10.1016/S0006-3495(00)76656-2; KIM E, 1995, NATURE, V378, P85, DOI 10.1038/378085a0; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kornau HC, 1997, CURR OPIN NEUROBIOL, V7, P368, DOI 10.1016/S0959-4388(97)80064-5; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; Kudo M, 2001, ANESTHESIOLOGY, V95, P756, DOI 10.1097/00000542-200109000-00031; Leonard AS, 1998, J BIOL CHEM, V273, P19518, DOI 10.1074/jbc.273.31.19518; Luo JH, 1997, MOL PHARMACOL, V51, P79, DOI 10.1124/mol.51.1.79; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; Miller KW, 2002, BRIT J ANAESTH, V89, P17, DOI 10.1093/bja/aef167; Ming Z, 2002, ANESTHESIOLOGY, V97, P856, DOI 10.1097/00000542-200210000-00017; NELSON RJ, 1995, NATURE, V378, P383, DOI 10.1038/378383a0; Niethammer M, 1996, J NEUROSCI, V16, P2157; Nishikawa K, 2000, ANESTHESIOLOGY, V92, P228, DOI 10.1097/00000542-200001000-00035; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Raghuram V, 2001, P NATL ACAD SCI USA, V98, P1300, DOI 10.1073/pnas.031538898; Roche KW, 1999, J NEUROSCI, V19, P3926; Sattler R, 1999, SCIENCE, V284, P1845, DOI 10.1126/science.284.5421.1845; Shin HW, 2000, J NEUROSCI, V20, P3580, DOI 10.1523/JNEUROSCI.20-10-03580.2000; Tao F, 2003, NEUROSCIENCE, V117, P731, DOI 10.1016/S0306-4522(02)00801-1; Tao F, 2001, NEUROREPORT, V12, P3251, DOI 10.1097/00001756-200110290-00022; Tao YX, 2000, NEUROSCIENCE, V98, P201, DOI 10.1016/S0306-4522(00)00193-7; Tao YX, 2001, ANESTHESIOLOGY, V94, P1010, DOI 10.1097/00000542-200106000-00015; Tochio H, 2000, J MOL BIOL, V303, P359, DOI 10.1006/jmbi.2000.4148; Tochio H, 2000, J MOL BIOL, V295, P225, DOI 10.1006/jmbi.1999.3350; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; WAKAMORI M, 1991, J NEUROPHYSIOL, V66, P2014, DOI 10.1152/jn.1991.66.6.2014; Woodward JJ, 2000, CRIT REV NEUROBIOL, V14, P69; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545	60	32	33	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36669	36675		10.1074/jbc.M303520200	http://dx.doi.org/10.1074/jbc.M303520200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853458	hybrid			2022-12-27	WOS:000185318300098
J	Bruns, K; Fossen, T; Wray, V; Henklein, P; Tessmer, U; Schubert, U				Bruns, K; Fossen, T; Wray, V; Henklein, P; Tessmer, U; Schubert, U			Structural characterization of the HIV-1 Vpr N terminus - Evidence of cis/trans-proline isomerism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; VIRAL PROTEIN-R; NUCLEAR-LOCALIZATION SIGNAL; CELL-CYCLE; SECONDARY STRUCTURE; NMR STRUCTURE; CIRCULAR-DICHROISM; PEPTIDE-FRAGMENTS; MATRIX PROTEIN; AMINO-ACIDS	The 96-residue human immunodeficiency virus (HIV) accessory protein Vpr serves manifold functions in the retroviral life cycle including augmentation of viral replication in non-dividing host cells, induction of G(2) cell cycle arrest, and modulation of HIV-induced apoptosis. Using a combination of dynamic light scattering, circular dichroism, and NMR spectroscopy the N terminus of Vpr is shown to be a unique domain of the molecule that behaves differently from the C-terminal domain in terms of self-association and secondary structure folding. Interestingly, the four highly conserved proline residues in the N terminus are predicted to have a high propensity for cis/trans isomerism. Thus the high resolution structure and folding of a synthetic N-terminal peptide (Vpr(1-40)) and smaller fragments thereof have been investigated. H-1 NMR data indicate Vpr(1-40) possesses helical structure between residues 17-32, and for the first time, this helix, which is bound by proline residues, was observed even in aqueous solution devoid of any detergent supplements. In addition, NMR data revealed that all of the proline residues undergo a cis/trans isomerism to such an extent that similar to40% of all Vpr molecules possess at least one proline in a cis conformation. This phenomenon of cis/trans isomerism, which is unprecedented for HIV-1 Vpr, not only provides an explanation for the molecular heterogeneity observed in the full-length molecule but also indicates that in vivo the folding and function of Vpr should depend on a cis/trans-proline isomerase activity, particularly as two of the proline residues in positions 14 and 35 show considerable amounts of cis isomers. This prediction correlates well with our recent observation (Zander, K., Sherman, M. P., Tessmer, U., Bruns, K., Wray, V., Prechtel, A. T., Schubert, E., Henklein, P., Luban, J., Neidleman, J., Greene, W. C., and Schubert, U. (2003) J. Biol. Chem. 278, 43170-43181) of a functional interaction between the major cellular isomerase cyclophilin A and Vpr, both of which are incorporated into HIV-1 virions.	Univ Erlangen Nurnberg, Inst Clin & Mol Virol, D-91054 Erlangen, Germany; Gesell Biotechnol Forsch mbH, Dept Biol Struct, D-38124 Braunschweig, Germany; Univ Hamburg, Heinrich Pette Inst, D-20251 Hamburg, Germany; Univ Bergen, Dept Chem, N-5007 Bergen, Norway; Humboldt Univ, Inst Biochem, D-10115 Berlin, Germany; NIAID, Viral Dis Lab, NIH, Bethesda, MD 20892 USA	University of Erlangen Nuremberg; Gesellschaft fur Biotechnologische Forschung mbH; Heinrich Pette Institute; University of Hamburg; University of Bergen; Humboldt University of Berlin; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Schubert, U (corresponding author), Univ Erlangen Nurnberg, Inst Clin & Mol Virol, Schlossgarten 4, D-91054 Erlangen, Germany.	ulrich.schubert@viro.med.uni-erlangen			NIDDK NIH HHS [DK59537-1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059537] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADACHI A, 1986, J VIROL, V59, P284, DOI 10.1128/JVI.59.2.284-291.1986; Agostini I, 1999, FEBS LETT, V450, P235, DOI 10.1016/S0014-5793(99)00501-3; Ayyavoo V, 1997, NAT MED, V3, P1117, DOI 10.1038/nm1097-1117; Bachand F, 1999, J BIOL CHEM, V274, P9083, DOI 10.1074/jbc.274.13.9083; Blankenfeldt W, 1996, BIOCHEMISTRY-US, V35, P5955, DOI 10.1021/bi9601520; Bouhamdan M, 1996, J VIROL, V70, P697, DOI 10.1128/JVI.70.2.697-704.1996; Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Braaten D, 2001, EMBO J, V20, P1300, DOI 10.1093/emboj/20.6.1300; BRADLEY EK, 1990, J MOL BIOL, V215, P607, DOI 10.1016/S0022-2836(05)80172-X; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Buck M, 1998, Q REV BIOPHYS, V31, P297, DOI 10.1017/S003358359800345X; Bukrinsky M, 1999, REV MED VIROL, V9, P39, DOI 10.1002/(SICI)1099-1654(199901/03)9:1<39::AID-RMV235>3.0.CO;2-3; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; BUKRINSKY MI, 1999, FRONT BIOSCI, V4, P772; Chang DK, 1999, J STRUCT BIOL, V128, P270, DOI 10.1006/jsbi.1999.4182; COHEN EA, 1990, J ACQ IMMUN DEF SYND, V3, P11; Cornille F, 1999, J PEPT RES, V54, P427, DOI 10.1034/j.1399-3011.1999.00129.x; de Noronha CMC, 2001, SCIENCE, V294, P1105, DOI 10.1126/science.1063957; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; Emerman M, 1996, CURR BIOL, V6, P1096, DOI 10.1016/S0960-9822(02)00676-0; Felzien LK, 1998, P NATL ACAD SCI USA, V95, P5281, DOI 10.1073/pnas.95.9.5281; Gallay P, 1997, P NATL ACAD SCI USA, V94, P9825, DOI 10.1073/pnas.94.18.9825; GIBBS JS, 1995, J VIROL, V69, P2378, DOI 10.1128/JVI.69.4.2378-2383.1995; Goh WC, 1998, NAT MED, V4, P65, DOI 10.1038/nm0198-065; GRATHWOHL C, 1976, BIOPOLYMERS, V15, P2025, DOI 10.1002/bip.1976.360151012; HEINZINGER NK, 1994, P NATL ACAD SCI USA, V91, P7311, DOI 10.1073/pnas.91.15.7311; Henklein P, 2000, J BIOL CHEM, V275, P32016, DOI 10.1074/jbc.M004044200; HIV Sequence Database, HIV SEQ DAT; Hrimech M, 1999, J VIROL, V73, P4101, DOI 10.1128/JVI.73.5.4101-4109.1999; Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509; Jenkins Y, 2001, J VIROL, V75, P10537, DOI 10.1128/JVI.75.21.10537-10542.2001; Jenkins Y, 1998, J CELL BIOL, V143, P875, DOI 10.1083/jcb.143.4.875; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOWETT JBM, 1995, J VIROL, V69, P6304, DOI 10.1128/JVI.69.10.6304-6313.1995; Kino T, 1999, J EXP MED, V189, P51, DOI 10.1084/jem.189.1.51; Kleywegt GJ, 1996, ACTA CRYSTALLOGR D, V52, P842, DOI 10.1107/S0907444995016477; LANG SM, 1993, J VIROL, V67, P902, DOI 10.1128/JVI.67.2.902-912.1993; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; Livingstone CD, 1996, METHOD ENZYMOL, V266, P497; Luban J, 1996, CELL, V87, P1157, DOI 10.1016/S0092-8674(00)81811-5; Luo ZW, 1998, BIOCHEM BIOPH RES CO, V244, P732, DOI 10.1006/bbrc.1998.8330; McDonald D, 2002, J CELL BIOL, V159, P441, DOI 10.1083/jcb.200203150; Muller B, 2000, J VIROL, V74, P9727, DOI 10.1128/JVI.74.20.9727-9731.2000; Nardi F, 2000, J BIOMOL NMR, V17, P63, DOI 10.1023/A:1008380807603; NEIDIG KP, 1990, J MAGN RESON, V88, P155, DOI 10.1016/0022-2364(90)90119-T; ONeal KD, 1996, BIOCHEM J, V315, P833, DOI 10.1042/bj3150833; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Piller SC, 1999, J VIROL, V73, P4230, DOI 10.1128/JVI.73.5.4230-4238.1999; Piller SC, 1996, P NATL ACAD SCI USA, V93, P111, DOI 10.1073/pnas.93.1.111; Poon B, 1998, SCIENCE, V281, P266, DOI 10.1126/science.281.5374.266; Popov S, 1998, J BIOL CHEM, V273, P13347, DOI 10.1074/jbc.273.21.13347; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; REFAELI Y, 1995, P NATL ACAD SCI USA, V92, P3621, DOI 10.1073/pnas.92.8.3621; Rizzardi GP, 2002, J CLIN INVEST, V109, P681, DOI 10.1172/JCI200214522; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Roques BP, 1997, BIOCHIMIE, V79, P673, DOI 10.1016/S0300-9084(97)83501-8; Sawaya BE, 1998, J BIOL CHEM, V273, P20052, DOI 10.1074/jbc.273.32.20052; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHOMBURG D, 1988, J MOL GRAPHICS, V6, P161, DOI 10.1016/0263-7855(88)80069-9; Schuler W, 1999, J MOL BIOL, V285, P2105, DOI 10.1006/jmbi.1998.2381; Sherman MP, 2002, VIROLOGY, V302, P95, DOI 10.1006/viro.2002.1576; Sherman MP, 2002, MICROBES INFECT, V4, P67, DOI 10.1016/S1286-4579(01)01511-8; Sherman MP, 2001, J VIROL, V75, P1522, DOI 10.1128/JVI.75.3.1522-1532.2001; Sherman MP, 2000, J VIROL, V74, P8159, DOI 10.1128/JVI.74.17.8159-8165.2000; Singh SP, 2000, J VIROL, V74, P10650, DOI 10.1128/JVI.74.22.10650-10657.2000; Stark LA, 1998, J VIROL, V72, P3037, DOI 10.1128/JVI.72.4.3037-3044.1998; Stewart SA, 1997, J VIROL, V71, P5579, DOI 10.1128/JVI.71.7.5579-5592.1997; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; VONSCHWEDLER U, 1994, P NATL ACAD SCI USA, V91, P6992, DOI 10.1073/pnas.91.15.6992; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wecker K, 1999, EUR J BIOCHEM, V266, P359, DOI 10.1046/j.1432-1327.1999.00858.x; Wecker K, 2002, EUR J BIOCHEM, V269, P3779, DOI 10.1046/j.1432-1033.2002.03067.x; WISHART DS, 1992, BIOCHEMISTRY-US, V31, P1647, DOI 10.1021/bi00121a010; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Zander K, 2003, J BIOL CHEM, V278, P43202, DOI 10.1074/jbc.M305414200; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhang SG, 2001, GENE, V263, P131, DOI 10.1016/S0378-1119(00)00583-7; ZHAO LJ, 1994, J BIOL CHEM, V269, P32131	79	48	48	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43188	43201		10.1074/jbc.M305413200	http://dx.doi.org/10.1074/jbc.M305413200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12881523	hybrid			2022-12-27	WOS:000186157000060
J	Tahtaoui, C; Balestre, MN; Klotz, P; Rognan, D; Barberis, C; Mouillac, B; Hibert, M				Tahtaoui, C; Balestre, MN; Klotz, P; Rognan, D; Barberis, C; Mouillac, B; Hibert, M			Identification of the binding sites of the SR49059 nonpeptide antagonist into the V-1a vasopressin receptor using sulfydryl-reactive ligands and cysteine mutants as chemical sensors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN OXYTOCIN RECEPTOR; AROMATIC RESIDUES; AGONIST; PEPTIDE; V1A; DOMAINS; HYPERTENSION; EXPRESSION; BUTYRATE; DOCKING	To identify the binding site of the human V-1a vasopressin receptor for the selective nonpeptide antagonist SR49059, we have developed a site-directed irreversible labeling strategy that combines mutagenesis of the receptor and use of sulfydryl-reactive ligands. Based on a three-dimensional model of the antagonist docked into the receptor, hypothetical ligand-receptor interactions were investigated by replacing the residues potentially involved in the binding of the antagonist into cysteines and designing analogues of SR49059 derivatized with isothiocyanate or alpha-chloroacetamide moieties. The F225C, F308C, and K128C mutants of the V-1a receptor were expressed in COS-7 or Chinese hamster ovary cells, and their pharmacological properties toward SR49059 and its sulfydryl-reactive analogues were analyzed. We demonstrated that treatment of the F225C mutant with the isothiocyanate-derivative compound led to dose-dependent inhibition of the residual binding of the radiolabeled antagonist [I-125]HO-LVA. This inhibition is probably the consequence of a covalent irreversible chemical modification, which is only possible when close contacts and optimal orientations exist between reactive groups created both on the ligand and the receptor. This result validated the three-dimensional model hypothesis. Thus, we propose that residue Phe(225), located in transmembrane domain V, directly participates in the binding of the V-1a-selective nonpeptide antagonist SR49059. This conclusion is in complete agreement with all our previous data on the definition of the agonist/antagonist binding to members of the oxytocin/vasopressin receptor family.	CNRS, Fac Pharm Strasbourg, UMR 7081, Lab Pharmacochim Commun Cellulaire, F-67401 Illkirch Graffenstaden, France; INSERM, U469, F-34094 Montpellier 5, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Montpellier	Hibert, M (corresponding author), CNRS, Fac Pharm Strasbourg, UMR 7081, Lab Pharmacochim Commun Cellulaire, 74 Route Rhin,BP 24, F-67401 Illkirch Graffenstaden, France.	mhibert@pharma.u-strasbg.fr	Rognan, Didier/B-9939-2014; MOUILLAC, Bernard/M-3896-2014	MOUILLAC, Bernard/0000-0002-3906-8673				Attwood TK, 2001, TRENDS PHARMACOL SCI, V22, P162, DOI 10.1016/S0165-6147(00)01658-8; BARBERIS C, 1995, NEUROENDOCRINOLOGY, V62, P135, DOI 10.1159/000126998; Breton C, 2001, J BIOL CHEM, V276, P26931, DOI 10.1074/jbc.M102073200; Brouard R, 1998, ADV EXP MED BIOL, V449, P455; BURRELL LM, 1994, HYPERTENSION, V23, P737, DOI 10.1161/01.HYP.23.6.737; CASE DA, 1997, AMBER 5 0 COMPUTER P; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; Chini B, 1996, FEBS LETT, V397, P201, DOI 10.1016/S0014-5793(96)01135-0; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Cotte N, 2000, EUR J BIOCHEM, V267, P4253, DOI 10.1046/j.1432-1033.2000.01472.x; COWLEY AW, 1982, INT REV PHYSIOL, V26, P189; Foucaud B, 2001, TRENDS PHARMACOL SCI, V22, P170, DOI 10.1016/S0165-6147(00)01674-6; Gether U, 1998, J BIOL CHEM, V273, P17979, DOI 10.1074/jbc.273.29.17979; Gieldon A, 2001, J COMPUT AID MOL DES, V15, P1085, DOI 10.1023/A:1015905822671; GOLDSMITH SR, 1987, AM J MED, V82, P1213, DOI 10.1016/0002-9343(87)90228-2; Hawtin SR, 2002, MOL ENDOCRINOL, V16, P600, DOI 10.1210/me.16.3.600; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Hibert M, 1999, J RECEPT SIGNAL TR R, V19, P589, DOI 10.3109/10799899909036674; JARD S, 1988, INT CONGR SER, V799, P1183; JOHNSTON CI, 1985, J HYPERTENS, V3, P557, DOI 10.1097/00004872-198512000-00001; Jones G, 1997, J MOL BIOL, V267, P727, DOI 10.1006/jmbi.1996.0897; KASSIS S, 1984, J BIOL CHEM, V259, P4910; KRUSZYNSKI M, 1980, J MED CHEM, V23, P364, DOI 10.1021/jm00178a003; MADDEN DR, 1993, CELL, V75, P693, DOI 10.1016/0092-8674(93)90490-H; Malta Di, 1995, [No title captured], Patent No. [EP 0636608, 0636608]; Marjamaki A, 1998, MOL PHARMACOL, V53, P370, DOI 10.1124/mol.53.3.370; MOUILLAC B, 1995, J BIOL CHEM, V270, P25771, DOI 10.1074/jbc.270.43.25771; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKADA H, 1994, AM J PHYSIOL-REG I, V267, pR1467, DOI 10.1152/ajpregu.1994.267.6.R1467; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; Park C, 1996, BIOCHEMISTRY-US, V35, P9807, DOI 10.1021/bi9602223; Perret P, 1999, J BIOL CHEM, V274, P25350, DOI 10.1074/jbc.274.36.25350; Phalipou S, 1999, J BIOL CHEM, V274, P23316, DOI 10.1074/jbc.274.33.23316; Phalipou S, 1997, J BIOL CHEM, V272, P26536, DOI 10.1074/jbc.272.42.26536; Rognan D, 2001, J COMPUT AID MOL DES, V15, P103, DOI 10.1023/A:1008145813315; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SERRADEILLEGAL C, 1993, J CLIN INVEST, V92, P224, DOI 10.1172/JCI116554; SHARE L, 1988, PHYSIOL REV, V68, P1248, DOI 10.1152/physrev.1988.68.4.1248; SLADEK CD, 1988, HYPERTENSION, V12, P506, DOI 10.1161/01.HYP.12.5.506; STRADER CD, 1987, J BIOL CHEM, V262, P16439; Thibonnier M, 1998, PROG BRAIN RES, V119, P147; Thibonnier M, 2000, J PHARMACOL EXP THER, V294, P195; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; Weber R, 1997, HYPERTENSION, V30, P1121, DOI 10.1161/01.HYP.30.5.1121; YAMAMURA Y, 1991, SCIENCE, V252, P572, DOI 10.1126/science.1850553; Yatsu T, 1997, EUR J PHARMACOL, V321, P225, DOI 10.1016/S0014-2999(96)00940-5	47	46	46	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40010	40019		10.1074/jbc.M301128200	http://dx.doi.org/10.1074/jbc.M301128200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869559	hybrid			2022-12-27	WOS:000185713800090
J	Honnappa, S; Cutting, B; Jahnke, W; Seelig, J; Steinmetz, MO				Honnappa, S; Cutting, B; Jahnke, W; Seelig, J; Steinmetz, MO			Thermodynamics of the Op18/stathmin-tubulin interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MICROTUBULE-REGULATING ACTIVITIES; TERNARY COMPLEX; TUBULIN; STATHMIN; PHOSPHORYLATION; DYNAMICS; PROTEIN; BINDING; FAMILY; PHOSPHOPROTEIN	Op18/stathmin (stathmin) is an intrinsically disordered protein involved in the regulation of the microtubule filament system. One function of stathmin is to sequester tubulin dimers into assembly incompetent complexes, and recent studies revealed two tubulin binding sites per stathmin molecule. Using high sensitivity isothermal titration calorimetry, we document that at 10 degreesC and under the conditions of 80 mM PIPES, pH 6.8, 1 mM EGTA, 1 mM MgCl2, 1 mM GTP these two binding sites are of equal affinity with an equilibrium binding constant of K-0 = 6.0 x 10(6) M-1. The obtained large negative molar heat capacity change of DeltaC(p)(0) = -860 cal mol(-1) K-1 (referring to tubulin) for the tubulin-stathmin binding equilibrium suggests that the hydrophobic effect is the major driving force of the binding reaction. Replacing GTP by GDP on beta-tubulin had no significant effect on the thermodynamic parameters of the tubulin-stathmin binding equilibrium. The proposed pH-sensitive dual function of stathmin was further evaluated by circular dichroism spectroscopy and nuclear magnetic resonance. At low temperatures, stathmin was found to be extensively helical but devoid of any stable tertiary structure. However, in complex with two tubulin subunits stathmin adopts a stable conformation. Both the stability and conformation of the individual proteins and complexes were not significantly affected by small changes in pH. A 4-fold decrease in affinity of stathmin for tubulin was revealed at pH 7.5 compared with pH 6.8. This decrease could be attributed to a weaker binding of the C terminus of stathmin. These findings do not support the view that stathmin works as a pH-sensitive protein.	Paul Scherrer Inst, CH-5232 Villigen, Switzerland; Novartis Pharma AG, Cent Technol, CH-4002 Basel, Switzerland; Univ Basel, Bioctr, Dept Biophys Chem, CH-4056 Basel, Switzerland	Swiss Federal Institutes of Technology Domain; Paul Scherrer Institute; Novartis; University of Basel	Steinmetz, MO (corresponding author), Paul Scherrer Inst, CH-5232 Villigen, Switzerland.		Steinmetz, Michel O/AAA-3349-2022	Steinmetz, Michel O/0000-0001-6157-3687				Amayed P, 2000, BIOCHEMISTRY-US, V39, P12295, DOI 10.1021/bi000279w; Amayed P, 2002, J BIOL CHEM, V277, P22718, DOI 10.1074/jbc.M111605200; Andersen SSL, 2000, TRENDS CELL BIOL, V10, P261, DOI 10.1016/S0962-8924(00)01786-4; Arnal I, 2000, J CELL BIOL, V149, P767, DOI 10.1083/jcb.149.4.767; Baker BM, 1998, METHOD ENZYMOL, V295, P294; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Bieche I, 1998, BRIT J CANCER, V78, P701, DOI 10.1038/bjc.1998.565; Brannstrom K, 2003, J BIOL CHEM, V278, P16651, DOI 10.1074/jbc.M300131200; BUDISA N, 1995, EUR J BIOCHEM, V230, P788; Cantor C. R., 1980, PART CONFORMATION BI, P279; Cassimeris L, 2002, CURR OPIN CELL BIOL, V14, P18, DOI 10.1016/S0955-0674(01)00289-7; Charbaut E, 2001, J BIOL CHEM, V276, P16146, DOI 10.1074/jbc.M010637200; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Desai A, 1997, ANNU REV CELL DEV BI, V13, P83, DOI 10.1146/annurev.cellbio.13.1.83; DOYE V, 1990, J BIOL CHEM, V265, P11650; FOWLER WE, 1983, J ULTRA MOL STRUCT R, V83, P319, DOI 10.1016/S0022-5320(83)90139-9; Gavet O, 1998, J CELL SCI, V111, P3333; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; Holmfeldt P, 2001, MOL BIOL CELL, V12, P73, DOI 10.1091/mbc.12.1.73; HOWARD WD, 1986, BIOCHEMISTRY-US, V25, P8292, DOI 10.1021/bi00373a025; Howell B, 1999, J CELL SCI, V112, P3713; Howell B, 1999, MOL BIOL CELL, V10, P105, DOI 10.1091/mbc.10.1.105; Jourdain L, 1997, BIOCHEMISTRY-US, V36, P10817, DOI 10.1021/bi971491b; Larsson N, 1999, J CELL BIOL, V146, P1289, DOI 10.1083/jcb.146.6.1289; Larsson NL, 1999, MOL CELL BIOL, V19, P2242; Lawler S, 1998, CURR BIOL, V8, pR212, DOI 10.1016/S0960-9822(98)70128-9; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; Melhem R, 1997, LEUKEMIA, V11, P1690, DOI 10.1038/sj.leu.2400792; Meurer-Grob P, 2001, BIOCHEMISTRY-US, V40, P8000, DOI 10.1021/bi010343p; MITCHISON T, 1984, NATURE, V312, P237, DOI 10.1038/312237a0; Muller DR, 2001, ANAL CHEM, V73, P1927, DOI 10.1021/ac001379a; Nogales E, 1999, CELL, V96, P79, DOI 10.1016/S0092-8674(00)80961-7; Ozon S, 2002, MOL BIOL CELL, V13, P698, DOI 10.1091/mbc.01-07-0362; Redeker V, 2000, J BIOL CHEM, V275, P6841, DOI 10.1074/jbc.275.10.6841; Riederer BM, 1997, P NATL ACAD SCI USA, V94, P741, DOI 10.1073/pnas.94.2.741; Seelig J, 1997, BBA-REV BIOMEMBRANES, V1331, P103, DOI 10.1016/S0304-4157(97)00002-6; Segerman B, 2000, J BIOL CHEM, V275, P35759, DOI 10.1074/jbc.M005875200; Segerman B, 2003, J CELL SCI, V116, P197, DOI 10.1242/jcs.00205; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; Steinmetz MO, 2000, EMBO J, V19, P572, DOI 10.1093/emboj/19.4.572; Steinmetz MO, 2001, EMBO REP, V2, P505, DOI 10.1093/embo-reports/kve105; Tournebize R, 1997, EMBO J, V16, P5537, DOI 10.1093/emboj/16.18.5537; VANHOLDE KE, 1998, PRINCIPLES PHYSICAL; Walczak CE, 2000, CURR OPIN CELL BIOL, V12, P52, DOI 10.1016/S0955-0674(99)00056-3; Wallon G, 2000, EMBO J, V19, P213, DOI 10.1093/emboj/19.2.213; Wiltscheck R, 1997, PROTEIN SCI, V6, P1734, DOI 10.1002/pro.5560060814; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; Wright PE, 1999, J MOL BIOL, V293, P321, DOI 10.1006/jmbi.1999.3110	48	40	43	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38926	38934		10.1074/jbc.M305546200	http://dx.doi.org/10.1074/jbc.M305546200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860982	hybrid, Green Published			2022-12-27	WOS:000185575100102
J	Pan, YX; Chen, H; Siu, F; Kilberg, MS				Pan, YX; Chen, H; Siu, F; Kilberg, MS			Amino acid deprivation and endoplasmic reticulum stress induce expression of multiple activating transcription factor-3 mRNA species that, when overexpressed in HepG2 cells, modulate transcription by the human asparagine synthetase promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNFOLDED PROTEIN RESPONSE; GENE-EXPRESSION; REPRESSOR ATF3; NF-Y; ELEMENT; PATHWAY; GADD153/CHOP10; IDENTIFICATION; MEDIATOR; SITE	Transcription from the ASNS (asparagine synthetase) gene is increased in response to either amino acid (amino acid response) or glucose (endoplasmic reticulum stress response) deprivation. These two independent pathways converge on the same set of genomic cis-elements within the ASNS promoter, referred to as nutrient-sensing response element-1 and -2. Chromatin immunoprecipitation analysis provides the first in vivo evidence for activating transcription factor (ATF)-3 binding to the proximal ASNS promoter containing the nutrient-sensing response element-1 sequence. Overexpression of the full-length ATF3 protein caused a concentration-dependent biphasic response in ASNS promoter-driven transcription. Both amino acid limitation and activation of the endoplasmic reticulum stress response by glucose deprivation caused an increase in ATF3 mRNA content. However, reverse transcriptase-PCR analysis revealed that the increase in the ATF3 mRNA species detected by Northern analysis actually encoded both full-length ATF3 and two predicted truncated ATF3 isoforms (ATF3DeltaZip2c and ATF3DeltaZip3). Based on sequence analysis, one of the predicted truncated proteins (ATF3DeltaZip3) is likely incapable of binding DNA; and yet, exogenous expression of the cDNA enhanced starvation-induced or ATF4-activated ASNS transcription, possibly by sequestering corepressor proteins. Collectively, the results provide evidence for a potential role of multiple predicted ATF3 isoforms in the transcriptional regulation of the ASNS gene in response to nutrient deprivation.	Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, Gainesville, FL 32610 USA; Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Nutr Sci, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	Kilberg, MS (corresponding author), Univ Florida, Coll Med, Dept Biochem & Mol Biol, Ctr Mammalian Genet, POB 100245, Gainesville, FL 32610 USA.		Pan, Yuan-Xiang/C-6576-2019	Pan, Yuan-Xiang/0000-0003-3219-4367	NIDDK NIH HHS [DK-52064] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052064] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aslanian AM, 2001, BIOCHEM J, V357, P321, DOI 10.1042/0264-6021:3570321; Barbosa-Tessmann IP, 1999, J BIOL CHEM, V274, P31139, DOI 10.1074/jbc.274.44.31139; Barbosa-Tessmann IP, 2000, J BIOL CHEM, V275, P26976; Bruhat A, 2002, J BIOL CHEM, V277, P48107, DOI 10.1074/jbc.M206149200; CHEN BPC, 1994, J BIOL CHEM, V269, P15819; Chen BPC, 1996, MOL CELL BIOL, V16, P1157, DOI 10.1128/mcb.16.3.1157; Fawcett TW, 1999, BIOCHEM J, V339, P135, DOI 10.1042/0264-6021:3390135; GILL G, 1988, NATURE, V334, P721, DOI 10.1038/334721a0; GONG SS, 1991, MOL CELL BIOL, V11, P6059, DOI 10.1128/MCB.11.12.6059; GUERRINI L, 1993, MOL CELL BIOL, V13, P3202, DOI 10.1128/MCB.13.6.3202; Hai T, 1999, GENE EXPRESSION, V7, P321; Hai T, 2001, GENE, V273, P1, DOI 10.1016/S0378-1119(01)00551-0; Hashimoto Y, 2002, NUCLEIC ACIDS RES, V30, P2398, DOI 10.1093/nar/30.11.2398; He CH, 2001, J BIOL CHEM, V276, P20858, DOI 10.1074/jbc.M101198200; HUTSON RG, 1994, BIOCHEM J, V303, P745; Jousse C, 2000, J NUTR, V130, P1555, DOI 10.1093/jn/130.6.1555; Kilberg M, 2002, J NUTR, V132, P1801, DOI 10.1093/jn/132.7.1801; Li MQ, 2000, MOL CELL BIOL, V20, P5096, DOI 10.1128/MCB.20.14.5096-5106.2000; Richards NGJ, 1998, ADV ENZYMOL RAMB, V72, P145; Siu F, 2001, J BIOL CHEM, V276, P48100, DOI 10.1074/jbc.M109533200; Siu F, 2002, J BIOL CHEM, V277, P24120, DOI 10.1074/jbc.M201959200; Wang Y, 2000, J BIOL CHEM, V275, P27013; Wolfgang CD, 2000, J BIOL CHEM, V275, P16865, DOI 10.1074/jbc.M909637199; Wolfgang CD, 1997, MOL CELL BIOL, V17, P6700, DOI 10.1128/MCB.17.11.6700; Yoshida H, 2000, MOL CELL BIOL, V20, P6755, DOI 10.1128/MCB.20.18.6755-6767.2000; Yoshida H, 1998, J BIOL CHEM, V273, P33741, DOI 10.1074/jbc.273.50.33741; Zhong C, 2003, BIOCHEM J, V372, P603, DOI 10.1042/BJ20030076	27	88	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38402	38412		10.1074/jbc.M304574200	http://dx.doi.org/10.1074/jbc.M304574200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881527	hybrid			2022-12-27	WOS:000185575100040
J	Rawal, N; Pangburn, MK				Rawal, N; Pangburn, MK			Formation of high affinity C5 convertase of the classical pathway of complement	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALTERNATIVE-PATHWAY; 3RD COMPONENT; COVALENT BINDING; C3-C5 CONVERTASE; C3B; C4B; PROPERDIN; FRAGMENT; ENZYME; PURIFICATION	C3/C5 convertase is a serine protease that cleaves C3 and C5. In the present study we examined the C5 cleaving properties of classical pathway C3/C5 convertase either bound to the surface of sheep erythrocytes or in its free soluble form. Kinetic parameters revealed that the soluble form of the enzyme (C4b, C2a) cleaved C5 at a catalytic rate similar to that of the surface-bound form (EAC1, C4b, C2a). However, both forms of the enzyme exhibited a poor affinity for the substrate, C5, as indicated by a high K-m (6-9 muM). Increasing the density of C4b on the cell surface from 8,000 to 172,000 C4b/cell did not influence the K-m. Very high affinity C5 convertases were generated only when the low affinity C3/C5 convertases ( EAC1, C4b, C2a) were allowed to deposit C3b by cleaving native C3. These C3b-containing C3/C5 convertases exhibited K-m (0.0051 muM) well below the normal concentration of C5 in blood (0.37 muM). The data suggest that C3/C5 convertase assembled with either monomeric C4b or C4b-C4b complexes are inefficient in capturing C5 but cleave C3 opsonizing the cell surface with C3b for phagocytosis. Deposition of C3b converts the enzymes to high affinity C5 convertases, which cleave C5 in blood at catalytic rates approaching V-max, thereby switching from C3 to C5 cleavage. Comparison of the kinetic parameters with those of the alternative pathway convertase indicates that the 6-9-fold greater catalytic rate of the classical pathway C5 convertase may compensate for the fewer numbers of C5 convertase sites generated upon activation of this pathway.	Univ Texas, Hlth Sci Ctr, Dept Biochem, Tyler, TX 75708 USA	University of Texas System; University of Texas at Tyler; University of Texas-Health Sciences Center at Tyler (UTHSCT)	Rawal, N (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Biochem, 11937 US Highway 271, Tyler, TX 75708 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035081, R01DK035081] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-35081] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bhatia M, 2000, J PATHOL, V190, P117; CHRISTOPHERSON RI, 1983, METHOD ENZYMOL, V91, P278; DAHA MR, 1976, J IMMUNOL, V117, P630; DISCIPIO RG, 1981, BIOCHEM J, V199, P485, DOI 10.1042/bj1990485; DISCIPIO RG, 1981, BIOCHEM J, V199, P497, DOI 10.1042/bj1990497; DODDS AW, 1993, METHOD ENZYMOL, V223, P46; EMBER JA, 1998, HUMAN COMPLEMENT SYS, P241; HAMMER CH, 1981, J BIOL CHEM, V256, P3995; HARBECK RJ, 1991, DIAGN IMMUNOL, P49; HONG KS, 1991, J IMMUNOL, V146, P1868; ISENMAN DE, 1986, J IMMUNOL, V136, P2542; ISENMAN DE, 1980, J IMMUNOL, V124, P326; Jelezarova E, 1999, MOL IMMUNOL, V36, P837, DOI 10.1016/S0161-5890(99)00104-2; KERR MA, 1978, BIOCHEM J, V171, P99, DOI 10.1042/bj1710099; KIM YU, 1992, J BIOL CHEM, V267, P4171; KINOSHITA T, 1988, J IMMUNOL, V141, P3895; Kohl J, 2001, MOL IMMUNOL, V38, P175, DOI 10.1016/S0161-5890(01)00041-4; KOLB WP, 1982, BIOCHEMISTRY-US, V21, P294, DOI 10.1021/bi00531a015; KOZONO H, 1990, J BIOL CHEM, V265, P14444; MASAKI T, 1991, J IMMUNOL, V147, P927; MASAKI T, 1995, MOL IMMUNOL, V32, P21, DOI 10.1016/0161-5890(94)00137-P; MEDICUS RG, 1976, P NATL ACAD SCI USA, V73, P612, DOI 10.1073/pnas.73.2.612; MEDICUS RG, 1976, J EXP MED, V144, P1076, DOI 10.1084/jem.144.4.1076; Mukherjee P, 2000, J NEUROIMMUNOL, V105, P124, DOI 10.1016/S0165-5728(99)00261-1; O'Barr SA, 2001, J IMMUNOL, V166, P4154, DOI 10.4049/jimmunol.166.6.4154; PANGBURN MK, 1987, J IMMUNOL METHODS, V102, P7, DOI 10.1016/S0022-1759(87)80003-0; Pangburn MK, 2002, BIOCHEM SOC T, V30, P1006, DOI 10.1042/bst0301006; PANGBURN MK, 1978, P NATL ACAD SCI USA, V75, P2416, DOI 10.1073/pnas.75.5.2416; PANGBURN MK, 1998, COMPLEMENT SYSTEM, P93; Rawal N, 1998, J BIOL CHEM, V273, P16828, DOI 10.1074/jbc.273.27.16828; Rawal N, 2001, INT IMMUNOPHARMACOL, V1, P415, DOI 10.1016/S1567-5769(00)00039-4; Rawal N, 2001, J IMMUNOL, V166, P2635, DOI 10.4049/jimmunol.166.4.2635; Rawal N, 2000, J IMMUNOL, V164, P1379, DOI 10.4049/jimmunol.164.3.1379; REID KBM, 1998, COMPLEMENT SYSTEM, P68; Sandoval A, 2000, J IMMUNOL, V165, P1066, DOI 10.4049/jimmunol.165.2.1066; Santoro SW, 1997, P NATL ACAD SCI USA, V94, P4262, DOI 10.1073/pnas.94.9.4262; SCHUPF N, 1989, Brain Behavior and Immunity, V3, P28, DOI 10.1016/0889-1591(89)90003-2; TACK BF, 1976, BIOCHEMISTRY-US, V15, P4513, DOI 10.1021/bi00665a028; TAKATA Y, 1987, J EXP MED, V165, P1494, DOI 10.1084/jem.165.6.1494; VOGT W, 1978, IMMUNOLOGY, V34, P29; WETSEL RA, 1995, CURR OPIN IMMUNOL, V7, P48, DOI 10.1016/0952-7915(95)80028-X	41	53	55	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38476	38483		10.1074/jbc.M307017200	http://dx.doi.org/10.1074/jbc.M307017200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878586	hybrid			2022-12-27	WOS:000185575100049
J	Reinelt, S; Hofmann, E; Gerharz, T; Bott, M; Madden, DR				Reinelt, S; Hofmann, E; Gerharz, T; Bott, M; Madden, DR			The structure of the periplasmic ligand-binding domain of the sensor kinase CitA reveals the first extracellular PAS domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANAEROBIC CITRATE METABOLISM; PLANT PHOTORECEPTOR DOMAIN; CRYSTAL-STRUCTURE; TRANSPORT-SYSTEM; DIFFRACTION DATA; PROTEIN; MECHANISM; RECEPTOR; OXYGEN; CRYSTALLIZATION	The integral membrane sensor kinase CitA of Klebsiella pneumoniae is part of a two-component signal transduction system that regulates the transport and metabolism of citrate in response to its environmental concentration. Two-component systems are widely used by bacteria for such adaptive processes, but the stereochemistry of periplasmic ligand binding and the mechanism of signal transduction across the membrane remain poorly understood. The crystal structure of the CitAP periplasmic sensor domain in complex with citrate reveals a PAS fold, a versatile ligand-binding structural motif that has not previously been observed outside the cytoplasm or implicated in the transduction of conformational signals across the membrane. Citrate is bound in a pocket that is shared among many PAS domains but that shows structural variation according to the nature of the bound ligand. In CitAP, some of the citrate contact residues are located in the final strand of the central beta-sheet, which is connected to the C-terminal transmembrane helix. These secondary structure elements thus provide a potential conformational link between the periplasmic ligand binding site and the cytoplasmic signaling domains of the receptor.	Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA; Max Planck Inst Med Res, Ion Channel Struct Grp, D-69120 Heidelberg, Germany; Ruhr Univ Bochum, Lehrstuhl Biophys, D-44780 Bochum, Germany; Forschungszentrum Julich, Inst Biotechnol 1, D-52425 Julich, Germany	Dartmouth College; Max Planck Society; Ruhr University Bochum; Helmholtz Association; Research Center Julich	Madden, DR (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg, Hanover, NH 03755 USA.	dean.madden@dartmouth.edu	Hofmann, Eckhard/GPF-5024-2022; Bott, Michael/E-8004-2011	Bott, Michael/0000-0002-4701-8254; Hofmann, Eckhard/0000-0003-4874-372X				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Amezcua CA, 2002, STRUCTURE, V10, P1349, DOI 10.1016/S0969-2126(02)00857-2; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bott M, 1997, ARCH MICROBIOL, V167, P78, DOI 10.1007/s002030050419; BOTT M, 1995, MOL MICROBIOL, V18, P533, DOI 10.1111/j.1365-2958.1995.mmi_18030533.x; BRESE NE, 1991, ACTA CRYSTALLOGR B, V47, P192, DOI 10.1107/S0108768190011041; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cabral JHM, 1998, CELL, V95, P649, DOI 10.1016/S0092-8674(00)81635-9; CEDERGRENZEPPEZAUER ES, 1994, J MOL BIOL, V240, P459, DOI 10.1006/jmbi.1994.1461; Crosson S, 2001, P NATL ACAD SCI USA, V98, P2995, DOI 10.1073/pnas.051520298; Crosson S, 2003, BIOCHEMISTRY-US, V42, P2, DOI 10.1021/bi026978l; Crosson S, 2002, PLANT CELL, V14, P1067, DOI 10.1105/tpc.010475; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DeLano W.L, PYMOL MOL GRAPHICS S; Diederichs K, 1997, NAT STRUCT BIOL, V4, P269, DOI 10.1038/nsb0497-269; Falke JJ, 2002, P NATL ACAD SCI USA, V99, P6530, DOI 10.1073/pnas.112214199; Fedorov R, 2003, BIOPHYS J, V84, P2474, DOI 10.1016/S0006-3495(03)75052-8; Ferguson AD, 2002, SCIENCE, V295, P1715, DOI 10.1126/science.1067313; Genick UK, 1997, SCIENCE, V275, P1471, DOI 10.1126/science.275.5305.1471; Gerharz T, 2003, BIOCHEMISTRY-US, V42, P5917, DOI 10.1021/bi0340595; Gili P, 1999, INORG CHIM ACTA, V295, P106, DOI 10.1016/S0020-1693(99)00329-1; Gong WM, 1998, P NATL ACAD SCI USA, V95, P15177, DOI 10.1073/pnas.95.26.15177; Gu YZ, 2000, ANNU REV PHARMACOL, V40, P519, DOI 10.1146/annurev.pharmtox.40.1.519; HARLE C, 1995, EMBO J, V14, P1430, DOI 10.1002/j.1460-2075.1995.tb07129.x; Harrison DHT, 1997, BIOCHEMISTRY-US, V36, P16134, DOI 10.1021/bi9717136; Ho YSJ, 2000, EMBO J, V19, P5288, DOI 10.1093/emboj/19.20.5288; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kaspar S, 1999, MOL MICROBIOL, V33, P858, DOI 10.1046/j.1365-2958.1999.01536.x; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Lin AP, 2001, BIOCHEMISTRY-US, V40, P14291, DOI 10.1021/bi0111707; Lloyd SJ, 1999, PROTEIN SCI, V8, P2655, DOI 10.1110/ps.8.12.2655; Luft JR, 2001, J CRYST GROWTH, V232, P591, DOI 10.1016/S0022-0248(01)01206-4; Mayer SM, 2002, J BIOL CHEM, V277, P35263, DOI 10.1074/jbc.M205888200; Meller J, 2001, PROTEINS, V45, P241, DOI 10.1002/prot.1145; MILBURN MV, 1991, SCIENCE, V254, P1342, DOI 10.1126/science.1660187; Parac TN, 2001, J BIOMOL NMR, V19, P91, DOI 10.1023/A:1008301425100; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Regelmann AG, 2002, J BACTERIOL, V184, P5468, DOI 10.1128/JB.184.19.5468-5478.2002; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; Robinson VL, 2000, NAT STRUCT BIOL, V7, P626, DOI 10.1038/77915; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Stock AM, 2000, ANNU REV BIOCHEM, V69, P183, DOI 10.1146/annurev.biochem.69.1.183; Taylor BL, 1999, MICROBIOL MOL BIOL R, V63, P479, DOI 10.1128/MMBR.63.2.479-506.1999; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VANDERREST ME, 1992, J BIOL CHEM, V267, P8971; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; Vannini A, 2002, EMBO J, V21, P4393, DOI 10.1093/emboj/cdf459; Vreede J, 2003, J BIOL CHEM, V278, P18434, DOI 10.1074/jbc.M301701200; Waldburger CD, 1996, J BIOL CHEM, V271, P26630, DOI 10.1074/jbc.271.43.26630; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yamamoto H, 2000, MOL MICROBIOL, V37, P898, DOI 10.1046/j.1365-2958.2000.02055.x; Zhang RG, 2002, J BIOL CHEM, V277, P19183, DOI 10.1074/jbc.M112171200; Zhou ZH, 2000, INORG CHEM, V39, P59, DOI 10.1021/ic990042s; Zhulin IB, 1997, TRENDS BIOCHEM SCI, V22, P331, DOI 10.1016/S0968-0004(97)01110-9	57	122	124	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39189	39196		10.1074/jbc.M305864200	http://dx.doi.org/10.1074/jbc.M305864200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867417	Green Published, hybrid			2022-12-27	WOS:000185575100133
J	Garton, KJ; Gough, PJ; Philalay, J; Wille, PT; Blobel, CP; Whitehead, RH; Dempsey, PJ; Raines, EW				Garton, KJ; Gough, PJ; Philalay, J; Wille, PT; Blobel, CP; Whitehead, RH; Dempsey, PJ; Raines, EW			Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DISINTEGRIN; EXPRESSION; CLEAVAGE; MIGRATION; PROTEASES; COLON; CD44	A variety of cell surface adhesion molecules can exist as both transmembrane proteins and soluble circulating forms. Increases in the levels of soluble adhesion molecules have been correlated with a variety of inflammatory diseases, suggesting a pathological role. Although soluble forms are thought to result from proteolytic cleavage from the cell surface, relatively little is known about the proteases responsible for their release. In this report we demonstrate that under normal culture conditions, cells expressing vascular cell adhesion molecule 1 (VCAM-1) release a soluble form of the extracellular domain that is generated by metalloproteinase-mediated cleavage. VCAM-1 release can be rapidly simulated by phorbol 12-myristate 13-acetate (PMA), and this induced VCAM-1 shedding is mediated by metalloproteinase cleavage of VCAM-1 near the transmembrane domain. PMA-induced VCAM-1 shedding occurs as the result of activation of a specific pathway, as the generation of soluble forms of three other adhesion molecules, E-selectin, platelet-endothelial cell adhesion molecule 1, and intercellular adhesion molecule 1, are not altered by PMA stimulation. Using cells derived from genetically deficient mice, we identify tumor necrosis factor-alpha-converting enzyme ( TACE or ADAM 17) as the protease responsible for PMA-induced VCAM-1 release, including shedding of endogenously expressed VCAM-1 by murine endothelial cells. Therefore, TACE-mediated shedding of VCAM-1 may be important for the regulation of VCAM-1 function at the cell surface.	Univ Washington, Harborview Med Ctr, Dept Pathol, Seattle, WA 98104 USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Vanderbilt Univ, Dept Med, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Canc Biol, Nashville, TN 37232 USA; Vanderbilt Univ, Dept Cell & Dev Biol, Nashville, TN 37232 USA; Pacific NW Res Inst, Seattle, WA 98122 USA	Harborview Medical Center; University of Washington; University of Washington Seattle; Memorial Sloan Kettering Cancer Center; Vanderbilt University; Vanderbilt University; Vanderbilt University	Raines, EW (corresponding author), Univ Washington, Harborview Med Ctr, Dept Pathol, 325 9th Ave,Box 359675, Seattle, WA 98104 USA.	ewraines@u.washington.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL018645, R01HL067267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK059778, R01DK063363] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL18645, HL67267] Funding Source: Medline; NIDDK NIH HHS [DK63363, DK59778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bank U, 2001, J LEUKOCYTE BIOL, V69, P197; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Black RA, 2002, INT J BIOCHEM CELL B, V34, P1, DOI 10.1016/S1357-2725(01)00097-8; Brou C, 2000, MOL CELL, V5, P207, DOI 10.1016/S1097-2765(00)80417-7; Buxbaum JD, 1998, J BIOL CHEM, V273, P27765, DOI 10.1074/jbc.273.43.27765; DAbaco GM, 1996, MOL CELL BIOL, V16, P884; Faveeuw C, 2001, BLOOD, V98, P688, DOI 10.1182/blood.V98.3.688; Garton KJ, 2002, BIOTECHNIQUES, V32, P830, DOI 10.2144/02324rr01; Garton KJ, 2001, J BIOL CHEM, V276, P37993; GE AZ, 1994, GENE, V138, P201, DOI 10.1016/0378-1119(94)90808-7; GEARING AJH, 1993, IMMUNOL TODAY, V14, P506, DOI 10.1016/0167-5699(93)90267-O; Hafezi-Moghadam A, 2001, J EXP MED, V193, P863, DOI 10.1084/jem.193.7.863; Hafezi-Moghadam A, 1999, J EXP MED, V189, P939, DOI 10.1084/jem.189.6.939; Hooper NM, 1997, BIOCHEM J, V321, P265, DOI 10.1042/bj3210265; Kajita M, 2001, J CELL BIOL, V153, P893, DOI 10.1083/jcb.153.5.893; Kinoshita S, 1997, IMMUNITY, V6, P235, DOI 10.1016/S1074-7613(00)80326-X; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Levesque JP, 2001, BLOOD, V98, P1289, DOI 10.1182/blood.V98.5.1289; Lidington EA, 2002, AM J PHYSIOL-CELL PH, V282, pC67, DOI 10.1152/ajpcell.2002.282.1.C67; Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099; Montero JC, 2002, BIOCHEM J, V363, P211, DOI 10.1042/0264-6021:3630211; Okamoto I, 2001, J CELL BIOL, V155, P755, DOI 10.1083/jcb.200108159; Peschon JJ, 1998, SCIENCE, V282, P1281, DOI 10.1126/science.282.5392.1281; SHINGU M, 1994, INFLAMMATION, V18, P23, DOI 10.1007/BF01534595; Sunnarborg SW, 2002, J BIOL CHEM, V277, P12838, DOI 10.1074/jbc.M112050200; Weskamp G, 2002, MOL CELL BIOL, V22, P1537, DOI 10.1128/MCB.22.5.1537-1544.2002; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587	27	209	213	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37459	37464		10.1074/jbc.M305877200	http://dx.doi.org/10.1074/jbc.M305877200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12878595	hybrid			2022-12-27	WOS:000185437200058
J	Luo, W; Ng, WW; Jin, LH; Ye, ZY; Han, JH; Lin, SC				Luo, W; Ng, WW; Jin, LH; Ye, ZY; Han, JH; Lin, SC			Axin utilizes distinct regions for competitive MEKK1 and MEKK4 binding and JNK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WNT SIGNALING PATHWAY; CASEIN KINASE-I; MIXED-LINEAGE KINASE; PROTEIN-KINASE; BETA-CATENIN; NEGATIVE REGULATOR; RNA INTERFERENCE; GENE DISRUPTION; MAMMALIAN-CELLS; EXPRESSION	Axin is a multidomain protein that plays a critical role in Wnt signaling, serving as a scaffold for down-regulation of beta-catenin. It also activates the JNK mitogen-activated protein kinase by binding to MEKK1. However, it is intriguing that Axin requires several additional elements for JNK activation, including a requirement for homodimerization, sumoylation at the extreme C-terminal sites, and a region in the protein phosphatase 2A-binding domain. In our present study, we have shown that another MEKK family member, MEKK4, also binds to Axin in vivo and mediates Axin-induced JNK activation. Surprisingly MEKK4 binds to a region distinct from the MEKK1-binding site. Dominant negative mutant of MEKK4 attenuates the JNK activation by Axin. Activation of JNK by Axin in MEKK1(-/-) mouse embryonic fibroblast cells supports the idea that another MEKK can mediate Axin-induced JNK activation. Expression of specific small interfering RNA against MEKK4 effectively attenuates JNK activation by the MEKK1 binding-defective Axin mutant in 293T cells and inhibits JNK activation by wild-type Axin in MEKK1(-/-) cells, confirming that MEKK4 is indeed another mitogen-activated protein kinase kinase kinase that is specifically involved in Axin-mediated JNK activation independently of MEKK1. We have also identified an additional domain between MEKK1- and MEKK4-binding sites as being required for JNK activation by Axin. MEKK1 and MEKK4 compete for Axin binding even though they bind to sites far apart, suggesting that Axin may selectively bind to MEKK1 or MEKK4 depending on distinct signals or cellular context. Our findings will provide new insights into how scaffold proteins mediate ultimate activation of different mitogen-activated protein kinase kinase kinases.	Xiamen Univ, Dept Biol, Xiamen 361005, Fujian, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Scripps Res Inst, Dept Immunol, La Jolla, CA USA	Xiamen University; Hong Kong University of Science & Technology; Scripps Research Institute	Lin, SC (corresponding author), Xiamen Univ, Dept Biol, Xiamen 361005, Fujian, Peoples R China.		Han, J/G-4671-2010; Lin, SC/G-4666-2010; Jin, Lihua/AAN-5177-2020	Jin, Lihua/0000-0002-2685-6048				Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596; Boutros M, 1998, CELL, V94, P109, DOI 10.1016/S0092-8674(00)81226-X; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Cahill MA, 1996, CURR BIOL, V6, P16, DOI 10.1016/S0960-9822(02)00410-4; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Fanger GR, 1998, J BIOL CHEM, V273, P3476, DOI 10.1074/jbc.273.6.3476; Gallo KA, 2002, NAT REV MOL CELL BIO, V3, P663, DOI 10.1038/nrm906; Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199; Gerwins P, 1997, J BIOL CHEM, V272, P8288, DOI 10.1074/jbc.272.13.8288; Gustin MC, 1998, MICROBIOL MOL BIOL R, V62, P1264, DOI 10.1128/MMBR.62.4.1264-1300.1998; Hagemann C, 2001, CELL SIGNAL, V13, P863, DOI 10.1016/S0898-6568(01)00220-0; Hagemann C, 1999, EXP CELL RES, V253, P34, DOI 10.1006/excr.1999.4689; Hsu W, 1999, J BIOL CHEM, V274, P3439, DOI 10.1074/jbc.274.6.3439; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Johnson GL, 2002, SCIENCE, V298, P1911, DOI 10.1126/science.1072682; Kadoya T, 2000, J BIOL CHEM, V275, P37030, DOI 10.1074/jbc.M005984200; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kishida M, 2001, J BIOL CHEM, V276, P33147, DOI 10.1074/jbc.M103555200; Kishida S, 1998, J BIOL CHEM, V273, P10823, DOI 10.1074/jbc.273.18.10823; Lin A, 2003, BIOESSAYS, V25, P17, DOI 10.1002/bies.10204; LIU C, 2002, CELL, V108, P1; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; Mita H, 2002, MOL CELL BIOL, V22, P4544, DOI 10.1128/MCB.22.13.4544-4555.2002; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Povelones M, 2002, NAT CELL BIOL, V4, pE249, DOI 10.1038/ncb1102-e249; ROMOND TS, 2002, GENE DEV, V16, P2073; Rui HL, 2002, J BIOL CHEM, V277, P42981, DOI 10.1074/jbc.M208099200; Sharp PA, 1999, GENE DEV, V13, P139, DOI 10.1101/gad.13.2.139; Stronach B, 2002, GENE DEV, V16, P377, DOI 10.1101/gad.953002; Su B, 1996, CURR OPIN IMMUNOL, V8, P402, DOI 10.1016/S0952-7915(96)80131-2; Sui GC, 2002, P NATL ACAD SCI USA, V99, P5515, DOI 10.1073/pnas.082117599; Tolwinski NS, 2003, DEV CELL, V4, P407, DOI 10.1016/S1534-5807(03)00063-7; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Wang HY, 2002, J BIOL CHEM, V277, P3530, DOI 10.1074/jbc.M107031200; Xia Y, 2000, P NATL ACAD SCI USA, V97, P5243, DOI 10.1073/pnas.97.10.5243; Xu SC, 1996, P NATL ACAD SCI USA, V93, P5291, DOI 10.1073/pnas.93.11.5291; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Yujiri T, 1998, SCIENCE, V282, P1911, DOI 10.1126/science.282.5395.1911; Zamore PD, 2001, NAT STRUCT BIOL, V8, P746, DOI 10.1038/nsb0901-746; Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4; Zhang Y, 1999, J BIOL CHEM, V274, P35247, DOI 10.1074/jbc.274.49.35247; Zhang Y, 2002, J BIOL CHEM, V277, P17706, DOI 10.1074/jbc.M111982200; Zhang Y, 2001, J BIOL CHEM, V276, P32152, DOI 10.1074/jbc.M104451200; Zhang Y, 2000, J BIOL CHEM, V275, P25008, DOI 10.1074/jbc.M002491200	49	53	60	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37451	37458		10.1074/jbc.M305277200	http://dx.doi.org/10.1074/jbc.M305277200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12878610	hybrid			2022-12-27	WOS:000185437200057
J	Horton, JD; Shimomura, I; Ikemoto, S; Bashmakov, Y; Hammer, RE				Horton, JD; Shimomura, I; Ikemoto, S; Bashmakov, Y; Hammer, RE			Overexpression of sterol regulatory element-binding protein-1a in mouse adipose tissue produces adipocyte hypertrophy, increased fatty acid secretion, and fatty liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; COENZYME-A SYNTHETASE; ACYL-COA SYNTHETASE; TRANSGENIC MICE; DIABETES-MELLITUS; GENE-EXPRESSION; TRANSCRIPTION FACTOR; INSULIN-RESISTANCE; NUCLEAR SREBP-1C; CULTURED-CELLS	Sterol regulatory element-binding proteins (SREBPs) are a family of membrane-bound transcription factors that regulate cholesterol and fatty acid homeostasis. In mammals, three SREBP isoforms designated SREBP-1a, SREBP-1c, and SREBP-2 have been identified. SREBP-1a and SREBP-1c are derived from the same gene by virtue of alternatively spliced first exons. SREBP-1a has a longer transcriptional activation domain and is a more potent transcriptional activator than SREBP-1c in cultured cells and liver. Here, we describe the physiologic consequences of overexpressing the nuclear form of SREBP-1a (nSREBP-1a) in adipocytes of mice using the adipocyte-specific aP2 promoter (aP2-nSREBP-1a). The transgenic aP2-nSREBP-1a mice developed markedly enlarged white and brown adipocytes that were fully differentiated. Adipocytes isolated from aP2-nSREBP-1a mice had significantly increased rates of fatty acid synthesis and enhanced fatty acid secretion. The increased production and release of fatty acids from adipocytes led, in turn, to a fatty liver. Overexpression of the alternative SREBP-1 isoform, nSREBP-1c, in adipose tissue inhibits adipocyte differentiation; as a result, the transgenic nSREBP-1c mice develop a syndrome resembling human lipodystrophy, which includes a loss of peripheral white adipose tissue, diabetes, and fatty livers (Shimomura, I., Hammer, R. E., Richardson, J. A., Ikemoto, S., Bashmakov, Y., Goldstein, J. L., and Brown, M. S. ( 1998) Genes Dev. 12, 3182-3194). In striking contrast, nSREBP-1a overexpression in fat resulted in the hypertrophy of fully differentiated adipocytes, no diabetes, and mild hepatic steatosis. These results suggest that nSREBP-1a and nSREBP-1c have distinct roles in adipocyte fat metabolism in vivo.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Hammer, RE (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Robert.hammer@utsouthwestern.edu		Hammer, Robert E./0000-0001-5487-7551; Ikemoto, Shinji/0000-0002-2291-2735	NHLBI NIH HHS [HL-20948] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AILHAUD G, 1992, ANNU REV NUTR, V12, P207, DOI 10.1146/annurev.nu.12.070192.001231; BARTANA J, 1971, BIOCHEM J, V122, P353, DOI 10.1042/bj1220353; Brown MS, 1997, CELL, V89, P331, DOI 10.1016/S0092-8674(00)80213-5; Fajas L, 1999, MOL CELL BIOL, V19, P5495; HOFMANN SL, 1988, SCIENCE, V239, P1277, DOI 10.1126/science.3344433; Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593; HUA XX, 1995, GENOMICS, V25, P667, DOI 10.1016/0888-7543(95)80009-B; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; Kim JB, 1998, P NATL ACAD SCI USA, V95, P4333, DOI 10.1073/pnas.95.8.4333; Kim JB, 1996, GENE DEV, V10, P1096, DOI 10.1101/gad.10.9.1096; Martin G, 1997, J BIOL CHEM, V272, P28210, DOI 10.1074/jbc.272.45.28210; Miller CW, 1996, P NATL ACAD SCI USA, V93, P9443, DOI 10.1073/pnas.93.18.9443; Mokdad AH, 2001, JAMA-J AM MED ASSOC, V286, P1195, DOI 10.1001/jama.286.10.1195; Pai JT, 1998, J BIOL CHEM, V273, P26138, DOI 10.1074/jbc.273.40.26138; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROSS SR, 1990, P NATL ACAD SCI USA, V87, P9590, DOI 10.1073/pnas.87.24.9590; Sambrook J., 2001, MOL CLONING LAB MANU; SCHOONJANS K, 1995, J BIOL CHEM, V270, P19269, DOI 10.1074/jbc.270.33.19269; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimano H, 1996, J CLIN INVEST, V98, P1575, DOI 10.1172/JCI118951; Shimano H, 1997, J CLIN INVEST, V99, P846, DOI 10.1172/JCI119248; Shimano H, 1997, J CLIN INVEST, V100, P2115, DOI 10.1172/JCI119746; Shimomura I, 1997, P NATL ACAD SCI USA, V94, P12354, DOI 10.1073/pnas.94.23.12354; Shimomura I, 1999, J BIOL CHEM, V274, P30028, DOI 10.1074/jbc.274.42.30028; Shimomura I, 1998, J BIOL CHEM, V273, P35299, DOI 10.1074/jbc.273.52.35299; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shimomura I, 1998, GENE DEV, V12, P3182, DOI 10.1101/gad.12.20.3182; Shimomura I, 1999, NATURE, V401, P73, DOI 10.1038/43448; Shimomura L, 1999, P NATL ACAD SCI USA, V96, P13656, DOI 10.1073/pnas.96.24.13656; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; TONTONOZ P, 1993, MOL CELL BIOL, V13, P4753, DOI 10.1128/MCB.13.8.4753; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	35	159	168	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36652	36660		10.1074/jbc.M306540200	http://dx.doi.org/10.1074/jbc.M306540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855691	hybrid			2022-12-27	WOS:000185318300096
J	Johanson, K; Hoang, T; Sheth, M; Hyman, LE				Johanson, K; Hoang, T; Sheth, M; Hyman, LE			GRS1, a yeast tRNA synthetase with a role in mRNA 3 ' end formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE-II; POLY(A) SIGNAL; SACCHAROMYCES-CEREVISIAE; EM VISUALIZATION; TRANSCRIPTION; TERMINATION; PROTEIN; ELONGATION; SEQUENCE; COMPLEX	Transcription termination and 3' end formation are essential processes necessary for gene expression. However, the specific mechanisms responsible for these events remain elusive. A screen designed to identify trans-acting factors involved in these mechanisms in Saccharomyces cerevisiae identified a temperature-sensitive mutant that displayed phenotypes consistent with a role in transcription termination. The complementing gene was identified as GRS1, which encodes the S. cerevisiae glycyl-tRNA synthetase. This result, although unusual, is not unprecedented given that the involvement of tRNA synthetases in a variety of cellular processes other than translation has been well established. A direct role for the synthetase in transcription termination was determined through several in vitro assays using purified wild type and mutant enzyme. First, binding to two well characterized yeast mRNA 3' ends was demonstrated by cross-linking studies. In addition, it was found that all three substrates compete with each other for binding to GlyRS enzyme. Next, the affinity of the synthetase for the two mRNA 3' ends was found to be similar to that of its "natural" substrate, glycine tRNA in a nitrocellulose filter binding assay. The effect of the grs1-1 mutation was also examined and found to significantly reduce the affinity of the enzyme for the three RNA substrates. Taken together, these data indicate that not only does this synthetase interact with several different RNA substrates, but also that these substrates bind to the same site. These results establish a direct role for GRS1 in mRNA 3' end formation.	Tulane Univ, Hlth Sci Ctr, Dept Biochem, New Orleans, LA 70112 USA	Tulane University	Hyman, LE (corresponding author), Tulane Univ, Hlth Sci Ctr, Dept Biochem SL43, 1430 Tulane Ave, New Orleans, LA 70112 USA.	lhyman@tulane.edu		Hyman, Linda/0000-0002-2511-2928				Alen C, 2002, MOL CELL, V10, P1441, DOI 10.1016/S1097-2765(02)00778-5; Austin J, 2002, J BIOL CHEM, V277, P14812, DOI 10.1074/jbc.M103396200; Ausubel FM, 1994, CURRENT PROTOCOLS MO; Azad AK, 2001, MOL BIOL CELL, V12, P1381, DOI 10.1091/mbc.12.5.1381; Birse CE, 1998, SCIENCE, V280, P298, DOI 10.1126/science.280.5361.298; CAREY J, 1983, BIOCHEMISTRY-US, V22, P4723, DOI 10.1021/bi00289a017; CHEN S, 1998, THESIS TULANE U NEW; CUSACK S, 1991, NUCLEIC ACIDS RES, V19, P3489, DOI 10.1093/nar/19.13.3489; Francklyn C, 2002, RNA, V8, P1363, DOI 10.1017/S1355838202021180; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Guthrie C, 1991, GUIDE YEAST GENETICS; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Howe KJ, 2002, BBA-GENE STRUCT EXPR, V1577, P308, DOI 10.1016/S0167-4781(02)00460-8; HYMAN LE, 1991, MOL CELL BIOL, V11, P2004, DOI 10.1128/MCB.11.4.2004; KERN D, 1977, BIOCHIMIE, V59, P453, DOI 10.1016/S0300-9084(77)80050-3; Kobor MS, 2002, BBA-GENE STRUCT EXPR, V1577, P261, DOI 10.1016/S0167-4781(02)00457-8; Komissarova N, 2002, MOL CELL, V10, P1151, DOI 10.1016/S1097-2765(02)00738-4; Lechler A, 1998, J MOL BIOL, V278, P897, DOI 10.1006/jmbi.1998.1744; LOGAN DT, 1995, EMBO J, V14, P4156, DOI 10.1002/j.1460-2075.1995.tb00089.x; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; Magrath C, 1999, GENETICS, V152, P129; MAGRATH C, 1999, THESIS TULANE U NEW; Martinis Susan A., 1999, EMBO (European Molecular Biology Organization) Journal, V18, P4591, DOI 10.1093/emboj/18.17.4591; Miller CA, 1998, NUCLEIC ACIDS RES, V26, P3577, DOI 10.1093/nar/26.15.3577; Morris DP, 1999, J BIOL CHEM, V274, P31583, DOI 10.1074/jbc.274.44.31583; Orozco IJ, 2002, J BIOL CHEM, V277, P42899, DOI 10.1074/jbc.M207415200; Osheim YN, 2002, CHROMOSOMA, V111, P1, DOI 10.1007/s00412-002-0183-7; Osheim YN, 1999, MOL CELL, V3, P379, DOI 10.1016/S1097-2765(00)80465-7; PAN T, 1991, SCIENCE, V254, P1361, DOI 10.1126/science.1720569; Rho SB, 2000, RNA, V6, P1882, DOI 10.1017/S1355838200001254; Sherman F, 1986, LAB COURSE MANUAL ME; TAKAHASHI A, 1994, CANCER RES, V54, P4233; Tran DP, 2001, MOL CELL BIOL, V21, P7495, DOI 10.1128/MCB.21.21.7495-7508.2001; Turner RJ, 2000, J BIOL CHEM, V275, P27681; Voet D, 1999, FUNDAMENTALS BIOCH; YAGER TD, 1987, CELLULAR MOL BIOL, P1241; ZARET KS, 1982, CELL, V28, P563, DOI 10.1016/0092-8674(82)90211-2	38	11	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35923	35930		10.1074/jbc.M304978200	http://dx.doi.org/10.1074/jbc.M304978200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855679	hybrid			2022-12-27	WOS:000185318300009
J	Nagahama, M; Hayashi, S; Morimitsu, S; Sakurai, J				Nagahama, M; Hayashi, S; Morimitsu, S; Sakurai, J			Biological activities and pore formation of Clostridium perfringens beta toxin in HL 60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERGENT-INSOLUBLE MICRODOMAINS; STAPHYLOCOCCAL ALPHA-HEMOLYSIN; LIPID RAFTS; MEMBRANE; BINDING; FORMS; CHANNEL; ASSOCIATION; MUTAGENESIS; RECEPTORS	Clostridium perfringens beta toxin is an important agent of necrotic enteritis. Of the 10 cell lines tested, only the HL 60 cell line was susceptible to beta toxin. The toxin induced swelling and lysis of the cell. Treatment of the cells with the toxin resulted in K+ efflux from the cells and Ca2+, Na+, and Cl- influxes. These events reached a maximum just before the cells were lysed by the toxin. Incubation of the cells with the toxin showed the formation of toxin complexes of about 191 and 228 kDa, which were localized in the domains that fulfilled the criteria of lipid rafts. The complex of 228 kDa was observed until 30 min after incubation, and only the complex of 191 kDa remained after 60 min. Treatment of the cells with methyl-beta-cyclodextrin or cholesterol oxidase blocked binding of the toxin to the rafts and the toxin-induced K+ efflux and swelling. The toxin-induced Ca2+ influx and morphological changes were inhibited by an increase in the hydrodynamic diameter of polyethylene glycols from 200 to 400 and markedly or completely inhibited by polyethylene glycol 600 and 1000. However, these polyethylene glycols had no effect on the toxin-induced K+ efflux. The toxin induced carboxyfluorescein release from phosphatidylcholine-cholesterol liposomes containing carboxyfluorescein and formed an oligomer with 228 kDa in a dose-dependent manner but did not form an oligomer with the 191-kDa complex. We conclude that the toxin acts on HL 60 cells by binding to lipid rafts and forming a functional oligomer with 228 kDa.	Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro, Tokushima 7708514, Japan	Tokushima Bunri University	Sakurai, J (corresponding author), Tokushima Bunri Univ, Fac Pharmaceut Sci, Dept Microbiol, Yamashiro, Tokushima 7708514, Japan.	sakurai@ph.bunri-u.ac.jp						Duncan MJ, 2002, CELL MICROBIOL, V4, P783, DOI 10.1046/j.1462-5822.2002.00230.x; Falguieres T, 2001, MOL BIOL CELL, V12, P2453, DOI 10.1091/mbc.12.8.2453; Friedrichson T, 1998, NATURE, V394, P802, DOI 10.1038/29570; Gibert M, 1997, GENE, V203, P65, DOI 10.1016/S0378-1119(97)00493-9; Gordon VM, 1999, J BIOL CHEM, V274, P27274, DOI 10.1074/jbc.274.38.27274; Herreros J, 2001, MOL BIOL CELL, V12, P2947, DOI 10.1091/mbc.12.10.2947; HUNTER SEC, 1993, INFECT IMMUN, V61, P3958, DOI 10.1128/IAI.61.9.3958-3965.1993; Katagiri YU, 1999, J BIOL CHEM, V274, P35278, DOI 10.1074/jbc.274.49.35278; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; Miyata S, 2002, J BIOL CHEM, V277, P39463, DOI 10.1074/jbc.M206731200; Nagahama M, 1999, BBA-MOL BASIS DIS, V1454, P97, DOI 10.1016/S0925-4439(99)00026-5; Nagahama M, 2003, BRIT J PHARMACOL, V138, P23, DOI 10.1038/sj.bjp.0705022; Nagahama M, 2002, INFECT IMMUN, V70, P1909, DOI 10.1128/IAI.70.4.1909-1914.2002; Nagahama M, 1996, BBA-BIOMEMBRANES, V1280, P120, DOI 10.1016/0005-2736(95)00288-X; Petit L, 2001, J BIOL CHEM, V276, P15736, DOI 10.1074/jbc.M010412200; SABIROV RZ, 1993, GEN PHYSIOL BIOPHYS, V12, P95; SAKURAI J, 1987, TOXICON, V25, P1301, DOI 10.1016/0041-0101(87)90008-0; Sakurai J, 1997, J TOXICOL-TOXIN REV, V16, P195, DOI 10.3109/15569549709016456; SAKURAI J, 1980, MICROBIOL IMMUNOL, V24, P595, DOI 10.1111/j.1348-0421.1980.tb02862.x; SAKURAI J, 1992, TOXICON, V30, P323, DOI 10.1016/0041-0101(92)90872-3; SAKURAI J, 1977, INFECT IMMUN, V18, P741, DOI 10.1128/IAI.18.3.741-745.1977; SCHERRER R, 1971, J BACTERIOL, V107, P718, DOI 10.1128/JB.107.3.718-735.1971; Schraw W, 2002, J BIOL CHEM, V277, P34642, DOI 10.1074/jbc.M203466200; Shatursky O, 2000, INFECT IMMUN, V68, P5546, DOI 10.1128/IAI.68.10.5546-5551.2000; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Song LZ, 1996, SCIENCE, V274, P1859, DOI 10.1126/science.274.5294.1859; Steinthorsdottir V, 1998, FEMS MICROBIOL LETT, V158, P17, DOI 10.1016/S0378-1097(97)00470-9; Steinthorsdottir V, 2000, MICROB PATHOGENESIS, V28, P45, DOI 10.1006/mpat.1999.0323; TOMITA T, 1992, J BIOL CHEM, V267, P13391; Tweten RK, 2001, VET MICROBIOL, V82, P1, DOI 10.1016/S0378-1135(01)00372-8; Valeva A, 1996, EMBO J, V15, P1857, DOI 10.1002/j.1460-2075.1996.tb00536.x; Waheed AA, 2001, P NATL ACAD SCI USA, V98, P4926, DOI 10.1073/pnas.091090798; WALKER B, 1995, J BIOL CHEM, V270, P23065, DOI 10.1074/jbc.270.39.23065	33	78	79	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36934	36941		10.1074/jbc.M306562200	http://dx.doi.org/10.1074/jbc.M306562200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851396	hybrid			2022-12-27	WOS:000185318300127
J	Norris, EH; Giasson, BI; Ischiropoulos, H; Lee, VMY				Norris, EH; Giasson, BI; Ischiropoulos, H; Lee, VMY			Effects of oxidative and nitrative challenges on alpha-synuclein fibrillogenesis involve distinct mechanisms of protein modifications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SYSTEM ATROPHY; PARKINSONS-DISEASE; LEWY BODIES; IN-VITRO; NEURODEGENERATIVE DISEASES; ALZHEIMERS-DISEASE; FIBRIL FORMATION; NITRIC-OXIDE; AGGREGATION; PARAQUAT	Filamentous inclusions of alpha-synuclein protein are hallmarks of neurodegenerative diseases collectively known as synucleinopathies. Previous studies have shown that exposure to oxidative and nitrative species stabilizes alpha-synuclein filaments in vitro, and this stabilization may be due to dityrosine cross-linking. To test this hypothesis, we mutated tyrosine residues to phenylalanine and generated recombinant wild type and mutant alpha-synuclein proteins. alpha-Synuclein proteins lacking some or all tyrosine residues form fibrils to the same extent as the wild type protein. Tyrosine residues are not required for protein cross-linking or filament stabilization resulting from transition metal-mediated oxidation, because higher M-r SDS-resistant oligomers and filaments stable to chaotropic agents are detected using all Tyr --> Phe alpha-synuclein mutants. By contrast, cross-linking resulting from exposure to nitrating agents required the presence of one or more tyrosine residues. Furthermore, tyrosine cross-linking is involved in filament stabilization, because nitrating agent-exposed assembled wild type, but not mutant alpha-synuclein lacking all tyrosine residues, was stable to chaotropic treatment. In addition, the formation of stable alpha-synuclein inclusions in intact cells after exposure to oxidizing and nitrating species requires tyrosine residues. These findings demonstrate that nitrative and/or oxidative stress results in distinct mechanisms of alpha-synuclein protein modifications that can influence the formation of stable alpha-synuclein fibrils.	Univ Penn, Med Ctr, Ctr Neurodegenerat Dis Res, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Childrens Hosp Philadelphia, Stokes Res Inst, Philadelphia, PA 19104 USA; Univ Penn, Med Ctr, Dept Biochem & Biophys, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania	Lee, VMY (corresponding author), Hosp Univ Penn, Dept Pathol & Lab Med, Ctr Neurodegenerat Dis Res, 3600 Spruce St,Maloney 3, Philadelphia, PA 19104 USA.			Norris, Erin/0000-0002-4522-3537	NIA NIH HHS [AG 09215] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG009215] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baba M, 1998, AM J PATHOL, V152, P879; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Brooks AI, 1999, BRAIN RES, V823, P1, DOI 10.1016/S0006-8993(98)01192-5; Chen T., 1997, J EPIDEMIOL BIOSTAT, P9; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; CLEJAN L, 1989, BIOCHEM PHARMACOL, V38, P1779, DOI 10.1016/0006-2952(89)90412-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Conway KA, 2001, SCIENCE, V294, P1346, DOI 10.1126/science.1063522; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Dickson DW, 1999, AM J PATHOL, V155, P1241, DOI 10.1016/S0002-9440(10)65226-1; Duda JE, 2000, J NEUROSCI RES, V61, P121, DOI 10.1002/1097-4547(20000715)61:2<121::AID-JNR1>3.0.CO;2-4; El-Agnaf OMA, 1998, FEBS LETT, V440, P67, DOI 10.1016/S0014-5793(98)01419-7; Fitzhugh AL, 2000, FREE RADICAL BIO MED, V28, P1463, DOI 10.1016/S0891-5849(00)00251-3; Fujiwara H, 2002, NAT CELL BIOL, V4, P160, DOI 10.1038/ncb748; GEORGE JM, 1995, NEURON, V15, P361, DOI 10.1016/0896-6273(95)90040-3; Giasson BI, 2000, SCIENCE, V290, P985, DOI 10.1126/science.290.5493.985; Giasson BI, 2002, NEURON, V34, P521, DOI 10.1016/S0896-6273(02)00682-7; Giasson BI, 2000, J NEUROSCI RES, V59, P528, DOI 10.1002/(SICI)1097-4547(20000215)59:4<528::AID-JNR8>3.0.CO;2-0; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Giasson BI, 2001, J BIOL CHEM, V276, P2380, DOI 10.1074/jbc.M008919200; Goedert M, 1998, BIOCHEM SOC T, V26, P463, DOI 10.1042/bst0260463; Gow AJ, 2000, AM J PHYSIOL-CELL PH, V278, pC1099, DOI 10.1152/ajpcell.2000.278.6.C1099; IWAI A, 1995, NEURON, V14, P467, DOI 10.1016/0896-6273(95)90302-X; JAKES R, 1994, FEBS LETT, V345, P27, DOI 10.1016/0014-5793(94)00395-5; Jakes R, 1999, NEUROSCI LETT, V269, P13, DOI 10.1016/S0304-3940(99)00411-5; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lee MK, 2002, P NATL ACAD SCI USA, V99, P8968, DOI 10.1073/pnas.132197599; Narhi L, 1999, J BIOL CHEM, V274, P9843, DOI 10.1074/jbc.274.14.9843; Paik SR, 2000, ARCH BIOCHEM BIOPHYS, V378, P269, DOI 10.1006/abbi.2000.1822; Paik SR, 1999, BIOCHEM J, V340, P821, DOI 10.1042/0264-6021:3400821; Papadimitriou A, 1999, NEUROLOGY, V52, P651, DOI 10.1212/WNL.52.3.651; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Takahashi T, 2002, BRAIN RES, V938, P73, DOI 10.1016/S0006-8993(02)02498-8; Thiruchelvam M, 2000, J NEUROSCI, V20, P9207; Tu PH, 1998, ANN NEUROL, V44, P415, DOI 10.1002/ana.410440324; Uversky VN, 2001, J BIOL CHEM, V276, P10737, DOI 10.1074/jbc.M010907200; Uversky VN, 2001, J BIOL CHEM, V276, P44284, DOI 10.1074/jbc.M105343200; Uversky VN, 2002, FEBS LETT, V517, P239, DOI 10.1016/S0014-5793(02)02638-8; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n	45	139	143	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 18	2003	278	29					27230	27240		10.1074/jbc.M212436200	http://dx.doi.org/10.1074/jbc.M212436200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	701ER	12857790	hybrid			2022-12-27	WOS:000184155700119
J	Hartmann, J; Scepek, S; Hafez, I; Lindau, M				Hartmann, J; Scepek, S; Hafez, I; Lindau, M			Differential regulation of exocytotic fusion and granule-granule fusion in eosinophils by Ca2(+) and GTP analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPOUND EXOCYTOSIS; SCHISTOSOMA-MANSONI; CAPACITANCE MEASUREMENTS; GUANINE-NUCLEOTIDES; RAT EOSINOPHILS; CELLS; SECRETION; DEGRANULATION; MECHANISM; EVENTS	Dynamics of degranulation was studied in horse eosinophils by patch clamp capacitance measurements. Degranulation was stimulated by intracellular application of calcium, and GTPgammaS or guanosine 5'-(beta,gamma-imido)-triphosphate at different concentrations via the patch pipette. Degranulation was quantified by measuring the delay time between the beginning of intracellular perfusion and the first exocytotic event, determining the distribution of time intervals between fusion events and the capacitance step size distributions under the different conditions. The degranulation dynamics could be well reproduced using a computer model assuming three independent rate constants for granule-plasma membrane fusion, granule fusion with already exocytosed granules, and intracellular granule-granule fusion. The rate of granule-plasma membrane fusion is sensitive to both, the GTP analog and [Ca2+]i. The rate of granule-exocytosed granule fusion is sensitive to [Ca2+](i) but insensitive to the GTP analogs, and the rate of granule-to-granule fusion is sensitive to the GTP analog but insensitive to [Ca2+](i). Granule fusions with the three different target compartments thus involve different regulatory mechanisms.	Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA; Univ Munich, Inst Physiol, D-80336 Munich, Germany	Cornell University; University of Munich	Lindau, M (corresponding author), Cornell Univ, Sch Appl & Engn Phys, Ithaca, NY 14853 USA.	ml95@cornell.edu	Hartmann, Jana/C-1024-2008; Lindau, Manfred/ABD-3449-2021	Lindau, Manfred/0000-0002-5722-9557; Hartmann, Jana/0000-0002-1033-7104	NINDS NIH HHS [R01 NS38200, R01 NS038200-01A2, R01 NS038200-03, R01 NS038200, R01 NS038200-02] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038200] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Angleson JK, 1999, NAT NEUROSCI, V2, P440, DOI 10.1038/8107; BARROWMAN MM, 1986, NATURE, V319, P504, DOI 10.1038/319504a0; Bokvist K, 2000, PFLUG ARCH EUR J PHY, V439, P634, DOI 10.1007/s004240050987; Butterworth A E, 1977, Curr Top Microbiol Immunol, V77, P127; Cochilla AJ, 2000, J CELL BIOL, V150, P839, DOI 10.1083/jcb.150.4.839; DRUST DS, 1988, NATURE, V331, P88, DOI 10.1038/331088a0; FERNANDEZ JM, 1984, NATURE, V312, P453, DOI 10.1038/312453a0; FIDLER N, 1989, BIOPHYS J, V56, P1153, DOI 10.1016/S0006-3495(89)82762-6; GLAUERT AM, 1978, J CELL SCI, V34, P173, DOI 10.1007/BF01944659; Guo ZH, 1998, CELL, V94, P537, DOI 10.1016/S0092-8674(00)81594-9; Hansen NJ, 1999, J BIOL CHEM, V274, P22871, DOI 10.1074/jbc.274.32.22871; Hartmann J, 2003, J BIOL CHEM, V278, P44929, DOI 10.1074/jbc.M306014200; HARTMANN J, 1995, J PHYSIOL-LONDON, V483, P201, DOI 10.1113/jphysiol.1995.sp020578; HOWELL TW, 1987, J CELL BIOL, V105, P191, DOI 10.1083/jcb.105.1.191; LINDAU M, 1994, ANN NY ACAD SCI, V710, P232, DOI 10.1111/j.1749-6632.1994.tb26631.x; LINDAU M, 1994, ADV SEC MESS PHOSPH, V29, P173; LINDAU M, 1988, PFLUG ARCH EUR J PHY, V411, P137, DOI 10.1007/BF00582306; Lollike K, 2002, J LEUKOCYTE BIOL, V71, P973; Mair N, 1999, AM J PHYSIOL-LUNG C, V276, pL376, DOI 10.1152/ajplung.1999.276.2.L376; MCLAREN DJ, 1978, PARASITOLOGY, V77, P313, DOI 10.1017/S0031182000050277; MCLAREN DJ, 1977, CLIN EXP IMMUNOL, V30, P105; NEHER E, 1988, J PHYSIOL-LONDON, V395, P193, DOI 10.1113/jphysiol.1988.sp016914; Nemoto T, 2001, NAT CELL BIOL, V3, P253, DOI 10.1038/35060042; NUSSE O, 1990, J EXP MED, V171, P775, DOI 10.1084/jem.171.3.775; NUSSE O, 1988, J CELL BIOL, V107, P2117, DOI 10.1083/jcb.107.6.2117; NUSSE O, 1993, CELL CALCIUM, V14, P255, DOI 10.1016/0143-4160(93)90047-A; Parsons TD, 2003, NEURON, V37, P379, DOI 10.1016/S0896-6273(03)00062-X; PFEUFFER T, 1976, FEBS LETT, V67, P354, DOI 10.1016/0014-5793(76)80563-7; SCEPEK S, 1993, EMBO J, V12, P1811, DOI 10.1002/j.1460-2075.1993.tb05829.x; SCEPEK S, 1994, PARASITOL TODAY, V10, P276, DOI 10.1016/0169-4758(94)90146-5; Scepek S, 1997, BLOOD, V89, P510, DOI 10.1182/blood.V89.2.510; TAI PC, 1981, BRIT J HAEMATOL, V49, P219, DOI 10.1111/j.1365-2141.1981.tb07218.x; VOGEL SS, 1992, P NATL ACAD SCI USA, V89, P4749, DOI 10.1073/pnas.89.10.4749; YAMANAKA G, 1986, BIOCHEMISTRY-US, V25, P6149, DOI 10.1021/bi00368a048; Zimmerli S, 1996, J CELL BIOL, V132, P49, DOI 10.1083/jcb.132.1.49	35	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44929	44934		10.1074/jbc.M306014200	http://dx.doi.org/10.1074/jbc.M306014200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12853448	hybrid, Green Published			2022-12-27	WOS:000186306700129
J	Liang, FB; Huang, ZH; Lee, SY; Liang, J; Ivanov, MI; Alonso, A; Bliska, JB; Lawrence, DS; Mustelin, T; Zhang, ZY				Liang, FB; Huang, ZH; Lee, SY; Liang, J; Ivanov, MI; Alonso, A; Bliska, JB; Lawrence, DS; Mustelin, T; Zhang, ZY			Aurintricarboxylic acid blocks in vitro and in vivo activity of YopH, an essential virulent factor of Yersinia pestis, the agent of plague	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE-PHOSPHATASE; OUTER-MEMBRANE PROTEINS; SUBSTRATE-SPECIFICITY; TRANSFERABLE PLASMID; STRUCTURAL BASIS; FOCAL ADHESIONS; IMMUNE-RESPONSE; PC12 CELLS; INHIBITOR; ENTEROCOLITICA	Yersinia are causative agents in human diseases ranging from gastrointestinal syndromes to Bubonic Plague. There is increasing risk of misuse of infectious agents, such as Yersinia pestis, as weapons of terror as well as instruments of warfare for mass destruction. YopH is an essential virulence factor whose protein-tyrosine phosphatase (PTP) activity is required for Yersinia pathogenicity. Consequently, there is considerable interest in developing potent and selective YopH inhibitors as novel anti-plague agents. We have screened a library of 720 structurally diverse commercially available carboxylic acids and identified 26 YopH inhibitors with IC50 values below 100 muM. The most potent and specific YopH inhibitor is aurintricarboxylic acid (ATA), which exhibits a K-i value of 5 nM for YopH and displays 6-120-fold selectivity in favor of YopH against a panel of mammalian PTPs. To determine whether ATA can block the activity of YopH in a cellular context, we have examined the effect of ATA on T-cell signaling in human Jurkat cells transfected with YopH. We show that YopH severely decreases the T-cell receptor-induced cellular tyrosine phosphorylation, ERK1/2 activity, and interleukin-2 transcriptional activity. We demonstrate that ATA can effectively block the inhibitory activity of YopH and restore normal T-cell function. These results provide a proof-of-concept for the hypothesis that small molecule inhibitors that selectively target YopH may be therapeutically useful. In addition, it is expected that potent and selective YopH inhibitors, such as ATA, should be useful reagents to delineate YopH's cellular targets in plague and other pathogenic conditions caused by Yersinia infection.	Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA; Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA; SUNY Stony Brook, Dept Mol Genet & Microbiol, Stony Brook, NY 11794 USA; SUNY Stony Brook, Ctr Infect Dis, Stony Brook, NY 11794 USA; Burnham Inst, La Jolla, CA 92037 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Sanford Burnham Prebys Medical Discovery Institute	Zhang, ZY (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Mol Pharmacol, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	zyzhang@aecom.yu.edu	Alonso, Andrés/L-7523-2014	Alonso, Andrés/0000-0001-8674-9378; Mustelin, Tomas/0000-0001-5912-8840	NIAID NIH HHS [AI 43389, AI 48506] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043389, R56AI043389, R01AI048506] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Andersson K, 1996, MOL MICROBIOL, V20, P1057, DOI 10.1111/j.1365-2958.1996.tb02546.x; Autenrieth IB, 1996, J MED MICROBIOL, V44, P285, DOI 10.1099/00222615-44-4-285; AUTENRIETH IB, 1993, INFECT IMMUN, V61, P2585, DOI 10.1128/IAI.61.6.2585-2595.1993; AUTENRIETH IB, 1993, IMMUNOBIOLOGY, V187, P1; BATISTATOU A, 1991, J CELL BIOL, V115, P461, DOI 10.1083/jcb.115.2.461; Beery R, 2001, ENDOCRINOLOGY, V142, P3098, DOI 10.1210/en.142.7.3098; Black DS, 2000, CELL MICROBIOL, V2, P401, DOI 10.1046/j.1462-5822.2000.00061.x; Black DS, 1997, EMBO J, V16, P2730, DOI 10.1093/emboj/16.10.2730; Black DS, 1998, MOL MICROBIOL, V29, P1263, DOI 10.1046/j.1365-2958.1998.01014.x; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; BLISKA JB, 1992, J EXP MED, V176, P1625, DOI 10.1084/jem.176.6.1625; BOLIN I, 1988, MOL MICROBIOL, V2, P237, DOI 10.1111/j.1365-2958.1988.tb00025.x; BRUBAKER RR, 1991, CLIN MICROBIOL REV, V4, P309, DOI 10.1128/CMR.4.3.309-324.1991; BULTER T, 1985, TXB MED, P1600; Burke TR, 1998, BIOPOLYMERS, V47, P225, DOI 10.1002/(SICI)1097-0282(1998)47:3<225::AID-BIP3>3.0.CO;2-O; Burke TR, 1996, BIOCHEMISTRY-US, V35, P15989, DOI 10.1021/bi961256d; Cantrell D, 1996, ANNU REV IMMUNOL, V14, P259, DOI 10.1146/annurev.immunol.14.1.259; Chen YT, 2002, J MED CHEM, V45, P3946, DOI 10.1021/jm020093q; Cornelis GR, 1998, MICROBIOL MOL BIOL R, V62, P1315, DOI 10.1128/MMBR.62.4.1315-1352.1998; Cornelis GR, 2000, P NATL ACAD SCI USA, V97, P8778, DOI 10.1073/pnas.97.16.8778; Cornelis GR, 1998, FOLIA MICROBIOL, V43, P253, DOI 10.1007/BF02818610; FOSTER R, 1989, J BACTERIOL, V171, P272, DOI 10.1128/jb.171.1.272-279.1989; Galimand M, 1997, NEW ENGL J MED, V337, P677, DOI 10.1056/NEJM199709043371004; GILBERTOGONZALEZ R, 1980, BIOCHEMISTRY-US, V19, P4299, DOI 10.1021/bi00559a023; GUAN KL, 1990, SCIENCE, V249, P553, DOI 10.1126/science.2166336; Guiyoule A, 2001, EMERG INFECT DIS, V7, P43, DOI 10.3201/eid0701.010106; Haimsohn M, 2002, ENDOCRINOLOGY, V143, P837, DOI 10.1210/en.143.3.837; HALLICK RB, 1977, NUCLEIC ACIDS RES, V4, P3055, DOI 10.1093/nar/4.9.3055; HARTLAND EL, 1994, INFECT IMMUN, V62, P4445, DOI 10.1128/IAI.62.10.4445-4453.1994; Hawley RJ, 2001, ANNU REV MICROBIOL, V55, P235, DOI 10.1146/annurev.micro.55.1.235; Ibrahimi OA, 2000, BIOORG MED CHEM LETT, V10, P457, DOI 10.1016/S0960-894X(00)00019-6; Inglesby TV, 2000, JAMA-J AM MED ASSOC, V283, P2281, DOI 10.1001/jama.283.17.2281; Iversen LF, 2000, J BIOL CHEM, V275, P10300, DOI 10.1074/jbc.275.14.10300; Iversen LF, 2002, J BIOL CHEM, V277, P19982, DOI 10.1074/jbc.M200567200; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Juris SJ, 2002, CELL MICROBIOL, V4, P201, DOI 10.1046/j.1462-5822.2002.00182.x; KOLE HK, 1995, BIOCHEM J, V311, P1025, DOI 10.1042/bj3111025; Lee K, 2003, BIOORG MED CHEM LETT, V13, P2577, DOI 10.1016/S0960-894X(03)00481-5; McGovern TW, 1999, ARCH DERMATOL, V135, P311, DOI 10.1001/archderm.135.3.311; MICHIELS T, 1988, MICROB PATHOGENESIS, V5, P449, DOI 10.1016/0882-4010(88)90006-X; Mustelin T, 2003, IMMUNOL REV, V191, P139, DOI 10.1034/j.1600-065X.2003.00014.x; Okada N, 1997, BIOCHEM BIOPH RES CO, V230, P266, DOI 10.1006/bbrc.1996.5934; OKADA N, 1995, J BIOL CHEM, V270, P16464, DOI 10.1074/jbc.270.27.16464; Persson C, 1997, EMBO J, V16, P2307, DOI 10.1093/emboj/16.9.2307; PORTNOY DA, 1984, INFECT IMMUN, V43, P108, DOI 10.1128/IAI.43.1.108-114.1984; ROSQVIST R, 1988, INFECT IMMUN, V56, P2139, DOI 10.1128/IAI.56.8.2139-2143.1988; Ruckdeschel K, 1996, INFECT IMMUN, V64, P724, DOI 10.1128/IAI.64.3.724-733.1996; SARMA MH, 1976, BIOCHIM BIOPHYS ACTA, V418, P29, DOI 10.1016/0005-2787(76)90324-5; Sarmiento M, 2000, BIOCHEMISTRY-US, V39, P8171, DOI 10.1021/bi000319w; Sarmiento M, 2000, J MED CHEM, V43, P146, DOI 10.1021/jm990329z; Sauvonnet N, 2002, MOL MICROBIOL, V45, P805, DOI 10.1046/j.1365-2958.2002.03053.x; Shen K, 2001, J BIOL CHEM, V276, P47311, DOI 10.1074/jbc.M106568200; STRALEY SC, 1986, INFECT IMMUN, V51, P445, DOI 10.1128/IAI.51.2.445-454.1986; Sun JP, 2003, J BIOL CHEM, V278, P33392, DOI 10.1074/jbc.M304693200; Yao T, 1999, J EXP MED, V190, P1343, DOI 10.1084/jem.190.9.1343; Zhang YL, 1998, J BIOL CHEM, V273, P12281, DOI 10.1074/jbc.273.20.12281; Zhang Z-Y, 2003, HDB CELLULAR SIGNALI, P677; ZHANG ZY, 1992, J BIOL CHEM, V267, P23759; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040; ZHANG ZY, 1993, ANAL BIOCHEM, V211, P7, DOI 10.1006/abio.1993.1224; ZHANG ZY, 1994, P NATL ACAD SCI USA, V91, P1624, DOI 10.1073/pnas.91.5.1624; Zhang ZY, 2002, ANNU REV PHARMACOL, V42, P209, DOI 10.1146/annurev.pharmtox.42.083001.144616; Zhou B, 2002, J BIOL CHEM, V277, P13889, DOI 10.1074/jbc.M200377200	64	75	79	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					41734	41741		10.1074/jbc.M307152200	http://dx.doi.org/10.1074/jbc.M307152200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888560	hybrid			2022-12-27	WOS:000185989500024
J	Gross, I; Morrison, DJ; Hyink, DP; Georgas, K; English, MA; Mericskay, M; Hosono, S; Sasson, D; Wilson, PD; Little, M; Licht, JD				Gross, I; Morrison, DJ; Hyink, DP; Georgas, K; English, MA; Mericskay, M; Hosono, S; Sasson, D; Wilson, PD; Little, M; Licht, JD			The receptor tyrosine kinase regulator sprouty1 is a target of the tumor suppressor WT1 and important for kidney development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; WILMS-TUMOR; DROSOPHILA-SPROUTY; CNS DEVELOPMENT; RNA EXPRESSION; MESSENGER-RNA; DNA-BINDING; GENE WT1; PROTEIN; DIFFERENTIATION	WT1 encodes a transcription factor involved in kidney development and tumorigenesis. Using representational difference analysis, we identified a new set of WT1 targets, including a homologue of the Drosophila receptor tyrosine kinase regulator, sprouty. Sprouty1 was up-regulated in cell lines expressing wild-type but not mutant WT1. WT1 bound to the endogenous sprouty1 promoter in vivo and directly regulated sprouty1 through an early growth response gene-1 binding site. Expression of Sprouty1 and WT1 overlapped in the developing metanephric mesenchyme, and Sprouty1, like WT1, plays a key role in the early steps of glomerulus formation. Disruption of Sprouty1 expression in embryonic kidney explants by antisense oligonucleotides reduced condensation of the metanephric mesenchyme, leading to a decreased number of glomeruli. In addition, sprouty1 was expressed in the ureteric tree and antisense-treated ureteric trees had cystic lumens. Therefore, sprouty1 represents a physiologically relevant target gene of WT1 during kidney development.	Mt Sinai Sch Med, Dept Med, New York, NY 10029 USA; Univ Queensland, Inst Mol Biosci, St Lucia, Qld 4072, Australia; Mt Sinai Sch Med, Dept Mol Cellular & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai; University of Queensland; Icahn School of Medicine at Mount Sinai	Licht, JD (corresponding author), Mt Sinai Sch Med, Dept Med, Box 1130,1 Gustave L Levy Pl, New York, NY 10029 USA.	jonathan.licht@mssm.edu	Hyink, Deborah/AAT-6821-2021; Gross, Isabelle/P-9859-2019; Little, Melissa H/A-6170-2010; Licht, Jonathan/L-4239-2019; Gross, Isabelle/I-4972-2016; MERICSKAY, Mathias/M-3477-2018	Hyink, Deborah/0000-0001-5820-4995; Gross, Isabelle/0000-0002-2783-8773; Little, Melissa H/0000-0003-0380-2263; Gross, Isabelle/0000-0002-2783-8773; Licht, Jonathan/0000-0002-3942-1369; Morrison, Debra/0000-0002-8265-5910; MERICSKAY, Mathias/0000-0002-6779-092X; Sassoon, David/0000-0001-6074-048X	NCI NIH HHS [CA95823, CA59998] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R24CA095823, R01CA059998] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Al-Awqati Q, 1998, KIDNEY INT, V54, P1832, DOI 10.1046/j.1523-1755.1998.00196.x; ARMSTRONG JF, 1993, MECH DEVELOP, V40, P85, DOI 10.1016/0925-4773(93)90090-K; AVNER ED, 1990, PEDIATR NEPHROL, V4, P372, DOI 10.1007/BF00862522; AVNER ED, 1985, IN VITRO CELL DEV B, V21, P297; Casci T, 1999, CELL, V96, P655, DOI 10.1016/S0092-8674(00)80576-0; Chambers D, 2000, MECH DEVELOP, V91, P361, DOI 10.1016/S0925-4773(99)00288-9; Davidson BP, 2000, DEV BIOL, V221, P41, DOI 10.1006/dbio.2000.9663; de Maximy AA, 1999, MECH DEVELOP, V81, P213, DOI 10.1016/S0925-4773(98)00241-X; DRESSLER GR, 1990, DEVELOPMENT, V109, P787; Egan JE, 2002, P NATL ACAD SCI USA, V99, P6041, DOI 10.1073/pnas.052090899; Englert C, 1997, CANCER RES, V57, P1429; ENGLERT C, 1995, EMBO J, V14, P4662, DOI 10.1002/j.1460-2075.1995.tb00148.x; English MA, 1999, J BIOL CHEM, V274, P13258, DOI 10.1074/jbc.274.19.13258; Furthauer M, 2001, DEVELOPMENT, V128, P2175; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; Gross I, 2001, J BIOL CHEM, V276, P46460, DOI 10.1074/jbc.M108234200; Guo JK, 2002, HUM MOL GENET, V11, P651, DOI 10.1093/hmg/11.6.651; Hacohen N, 1998, CELL, V92, P253, DOI 10.1016/S0092-8674(00)80919-8; Hammes A, 2001, CELL, V106, P319, DOI 10.1016/S0092-8674(01)00453-6; Holmes GP, 1998, MECH DEVELOP, V79, P57, DOI 10.1016/S0925-4773(98)00174-9; Hosono S, 1999, ONCOGENE, V18, P417, DOI 10.1038/sj.onc.1202311; Hosono S, 2000, J BIOL CHEM, V275, P10943, DOI 10.1074/jbc.275.15.10943; HUBANK M, 1994, NUCLEIC ACIDS RES, V22, P5640, DOI 10.1093/nar/22.25.5640; Impagnatiello MA, 2001, J CELL BIOL, V152, P1087, DOI 10.1083/jcb.152.5.1087; Kolle G, 2000, MECH DEVELOP, V90, P181, DOI 10.1016/S0925-4773(99)00248-8; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; Kuure S, 2000, MECH DEVELOP, V92, P31, DOI 10.1016/S0925-4773(99)00323-8; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; Lee SB, 2001, EXP CELL RES, V264, P74, DOI 10.1006/excr.2000.5131; Lee SB, 1999, CELL, V98, P663, DOI 10.1016/S0092-8674(00)80053-7; Little M, 1999, BIOESSAYS, V21, P191, DOI 10.1002/(SICI)1521-1878(199903)21:3<191::AID-BIES3>3.3.CO;2-#; LUO XN, 1995, ONCOGENE, V11, P743; Mailleux AA, 2001, MECH DEVELOP, V102, P81, DOI 10.1016/S0925-4773(01)00286-6; Mendelsohn C, 1999, DEVELOPMENT, V126, P1139; Minowada G, 1999, DEVELOPMENT, V126, P4465; MIWA H, 1992, J NATL CANCER I, V84, P181, DOI 10.1093/jnci/84.3.181; Mundel P, 1997, EXP CELL RES, V236, P248, DOI 10.1006/excr.1997.3739; MUNDLOS S, 1993, DEVELOPMENT, V119, P1329; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; NAKAGAMA H, 1995, MOL CELL BIOL, V15, P1489; Nutt SL, 2001, GENE DEV, V15, P1152, DOI 10.1101/gad.191301; Palmer RE, 2001, CURR BIOL, V11, P1805, DOI 10.1016/S0960-9822(01)00560-7; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUCHMAN MI, 1993, AM J PHYSIOL, V265, pF416, DOI 10.1152/ajprenal.1993.265.3.F416; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; Reddy JC, 1996, BBA-REV CANCER, V1287, P1, DOI 10.1016/0304-419X(95)00014-7; Relaix F, 1998, NAT GENET, V18, P287, DOI 10.1038/ng0398-287; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sasaki A, 2001, J BIOL CHEM, V276, P36804, DOI 10.1074/jbc.C100386200; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; Schedl A, 2000, CURR OPIN GENET DEV, V10, P543, DOI 10.1016/S0959-437X(00)00125-8; Summerton J, 1997, ANTISENSE NUCLEIC A, V7, P187, DOI 10.1089/oli.1.1997.7.187; Tefft D, 2002, AM J PHYSIOL-LUNG C, V283, pL700, DOI 10.1152/ajplung.00372.2001; Tefft JD, 1999, CURR BIOL, V9, P219, DOI 10.1016/S0960-9822(99)80094-3; Thate C, 1998, ONCOGENE, V17, P1287, DOI 10.1038/sj.onc.1202055; WANG ZY, 1993, P NATL ACAD SCI USA, V90, P8896, DOI 10.1073/pnas.90.19.8896; Wong ESM, 2002, EMBO J, V21, P4796, DOI 10.1093/emboj/cdf493; Yusoff P, 2002, J BIOL CHEM, V277, P3195, DOI 10.1074/jbc.M108368200	58	59	61	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41420	41430		10.1074/jbc.M306425200	http://dx.doi.org/10.1074/jbc.M306425200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882970	hybrid			2022-12-27	WOS:000185847200122
J	Abdelmohsen, K; Gerber, PA; von Montfort, C; Sies, H; Klotz, LO				Abdelmohsen, K; Gerber, PA; von Montfort, C; Sies, H; Klotz, LO			Epidermal growth factor receptor is a common mediator of quinone-induced signaling leading to phosphorylation of connexin-43 - Role of glutathione and tyrosine phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; REGULATED KINASE; VITAMIN-K; RAT-LIVER; ACTIVATION; CELLS; PATHWAY; EGF; IDENTIFICATION; COMMUNICATION	Rat liver epithelial cells were exposed to three quinones with different properties: menadione (2-methyl-1,4-lnaphthoquinone, vitamin K-3), an alkylating as well as redox-cycling quinone, the strongly alkylating p-benzoquinone (BQ), and the non-arylating redox-cycler, 2,3-dimethoxy-1,4-naphthoquinone (DMNQ). All three quinones induced the activation of extracellular signal-regulated kinase (ERK) 1 and ERK 2 via the activation of epidermal growth factor receptor (EGFR) and MAPK/ERK kinases (MEK) 1/2. ERK activation resulted in phosphorylation at Ser-279 and Ser-282 of the gap junctional protein, connexin-43, known to result in the loss of gap junctional intercellular communication. Another EGFR-dependent pathway was stimulated, leading to the activation of the antiapoptotic kinase Akt via phosphoinositide 3-kinase. The activation of EGFR-dependent signaling by these quinones was by different mechanisms: (i) menadione, but not BQ or DMNQ, inhibited a protein-tyrosine phosphatase regulating the EGFR, as concluded from an EGFR dephosphorylation assay; (ii) although menadione-induced activation of ERK was unimpaired by pretreatment of cells with N-acetyl cysteine, activation by BQ and DMNQ was prevented; (iii) cellular glutathione (GSH) levels were strongly depleted by BQ. The mere depletion of GSH by application of diethyl maleate EGFR-dependently activated ERK and Akt, thus mimicking BQ effects. GSH levels were only moderately decreased by menadione and not affected by DMNQ. In summary, EGFR-dependent signaling was mediated by protein-tyrosine phosphatase inactivation (menadione), GSH depletion (BQ), and redox-cycling (DMNQ), funneling into the same signaling pathway.	Univ Dusseldorf, Inst Biochem & Mol Biol 1, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Klotz, LO (corresponding author), Univ Dusseldorf, Inst Biochem & Mol Biol 1, Univ Str 1,Geb 22-03,Ebene 2, D-40225 Dusseldorf, Germany.	LarsOliver.Klotz@uni-duesseldorf.de	Sies, Helmut/ABE-7355-2020; Abdelmohsen, Kotb/AAX-4191-2020; Gerber, Peter Arne/M-2746-2013; Klotz, Lars Oliver/AAC-5051-2019; Sies, Helmut/B-7266-2008; Gerber, Peter Arne/C-2000-2009	Abdelmohsen, Kotb/0000-0001-6240-5810; Gerber, Peter Arne/0000-0003-1657-1863; Klotz, Lars Oliver/0000-0002-1261-8911; Sies, Helmut/0000-0002-1000-3198; 				ANDERSON ME, 1985, METHOD ENZYMOL, V113, P548; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; Benhar M, 2002, ONCOGENE, V21, P8723, DOI 10.1038/sj.onc.1205980; Boatman RJ, 2000, CHEM RES TOXICOL, V13, P853, DOI 10.1021/tx000037x; Bolton JL, 2000, CHEM RES TOXICOL, V13, P135, DOI 10.1021/tx9902082; BRUNMARK A, 1989, FREE RADICAL BIO MED, V7, P435, DOI 10.1016/0891-5849(89)90126-3; Cameron SJ, 2003, J BIOL CHEM, V278, P18682, DOI 10.1074/jbc.M213283200; Carr BI, 2002, J CELL PHYSIOL, V193, P263, DOI 10.1002/jcp.10171; Chen W, 1998, MOL CELL BIOL, V18, P5178, DOI 10.1128/MCB.18.9.5178; Coleman WB, 1997, AM J PATHOL, V151, P353; Dickinson DA, 2002, ANN NY ACAD SCI, V973, P488, DOI 10.1111/j.1749-6632.2002.tb04690.x; Hargreaves RHJ, 2000, FRONT BIOSCI-LANDMRK, V5, pE172, DOI 10.2741/hargreav; Herrlich P, 2000, BIOCHEM PHARMACOL, V59, P35, DOI 10.1016/S0006-2952(99)00298-1; Kim DY, 1999, J BIOL CHEM, V274, P5581, DOI 10.1074/jbc.274.9.5581; Klotz LO, 2000, BIOCHEM J, V352, P219, DOI 10.1042/0264-6021:3520219; Klotz LO, 2002, CANCER RES, V62, P4922; Knebel A, 1996, EMBO J, V15, P5314, DOI 10.1002/j.1460-2075.1996.tb00916.x; Knebel A, 2000, METHOD ENZYMOL, V319, P255; Kolmodin K, 2001, FEBS LETT, V498, P208, DOI 10.1016/S0014-5793(01)02479-6; Lampe PD, 2000, ARCH BIOCHEM BIOPHYS, V384, P205, DOI 10.1006/abbi.2000.2131; LAU SS, 1988, MOL PHARMACOL, V34, P829; Leykauf K, 2003, CELL TISSUE RES, V311, P23, DOI 10.1007/s00441-002-0645-5; Li XA, 2001, J SURG RES, V100, P197, DOI 10.1006/jsre.2001.6238; Mahns A, 2003, FREE RADICAL RES, V37, P391, DOI 10.1080/1071576031000064702; MASUI H, 1993, J CELL BIOL, V120, P85, DOI 10.1083/jcb.120.1.85; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; TSAO MS, 1984, EXP CELL RES, V154, P38, DOI 10.1016/0014-4827(84)90666-9; Vine AL, 2002, CANCER METAST REV, V21, P199, DOI 10.1023/A:1021250624933; Wang XT, 2000, J BIOL CHEM, V275, P14624, DOI 10.1074/jbc.275.19.14624; Wang ZQ, 2002, J BIOL CHEM, V277, P19470, DOI 10.1074/jbc.M201097200; WarnCramer BJ, 1996, J BIOL CHEM, V271, P3779; Whitmarsh AJ, 2000, NATURE, V403, P255, DOI 10.1038/35002220; Wu RC, 1998, ONCOGENE, V17, P357, DOI 10.1038/sj.onc.1201930; Wu WD, 1999, AM J PHYSIOL-LUNG C, V277, pL924, DOI 10.1152/ajplung.1999.277.5.L924	34	93	98	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38360	38367		10.1074/jbc.M306785200	http://dx.doi.org/10.1074/jbc.M306785200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874275	hybrid			2022-12-27	WOS:000185575100035
J	de Graaf, P; Little, NA; Ramos, YFM; Meulmeester, E; Letteboer, SJF; Jochemsen, AG				de Graaf, P; Little, NA; Ramos, YFM; Meulmeester, E; Letteboer, SJF; Jochemsen, AG			Hdmx protein stability is regulated by the ubiquitin ligase activity of Mdm2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EMBRYONIC LETHALITY; DNA-DAMAGE; MDM2-DEFICIENT MICE; MALIGNANT GLIOMAS; ACIDIC DOMAIN; P53 STABILITY; CELL-GROWTH; DEGRADATION; EXPRESSION; TRANSACTIVATION	The stability of the p53 tumor suppressor protein is critically regulated by the Hdm2 and Hdmx proteins. Hdm2 protein levels are auto-regulated by the self-ubiquitination activity of Hdm2 and on the transcriptional level by p53-activated transcription of the hdm2 gene. Little is known about the regulation of Hdmx expression levels, apart from the observation that the Mdmx protein can be cleaved by caspase-3 in a p53-inducible manner. In the functional analysis of two mutant Hdmx proteins, products of two alternatively spliced mRNAs, it was found that Hdmx proteins are targets for ubiquitination by Mdm2. The stability of the Hdmx protein is partly dependent on the presence of its internal acidic domain. Mdm2 appears only to require an intact RING domain to be able to ubiquitinate Hdmx and target it for proteasomal degradation. These findings highlight the intricate functional relationships between p53, Mdm2, and Hdmx.	Leiden Univ, Med Ctr, Dept Mol & Cell Biol, NL-2300 RA Leiden, Netherlands; Leiden Univ, Med Ctr, Ctr Biomed Genet, NL-2300 RA Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Jochemsen, AG (corresponding author), Leiden Univ, Med Ctr, Dept Mol & Cell Biol, POB 9503, NL-2300 RA Leiden, Netherlands.		Ramos, Yolande F. M./C-3774-2018; Letteboer, Stef JF/P-8272-2015	Ramos, Yolande F. M./0000-0003-1459-413X; de Graaf, Petra/0000-0002-3183-8901				Alarcon-Vargas D, 2002, CARCINOGENESIS, V23, P541, DOI 10.1093/carcin/23.4.541; Argentini M, 2001, ONCOGENE, V20, P1267, DOI 10.1038/sj.onc.1204241; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARAK Y, 1994, GENE DEV, V8, P1739, DOI 10.1101/gad.8.15.1739; Bottger V, 1999, ONCOGENE, V18, P189, DOI 10.1038/sj.onc.1202281; CHEN JD, 1993, MOL CELL BIOL, V13, P4107, DOI 10.1128/MCB.13.7.4107; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; Fang SY, 2000, J BIOL CHEM, V275, P8945, DOI 10.1074/jbc.275.12.8945; Friedlander P, 1996, MOL CELL BIOL, V16, P4961; Gentiletti F, 2002, ONCOGENE, V21, P867, DOI 10.1038/sj.onc.1205137; Ghosh M, 2003, BIOCHEMISTRY-US, V42, P2291, DOI 10.1021/bi0271291; Grossman SR, 1998, MOL CELL, V2, P405, DOI 10.1016/S1097-2765(00)80140-9; Grossman SR, 2003, SCIENCE, V300, P342, DOI 10.1126/science.1080386; Gu JJ, 2002, J BIOL CHEM, V277, P19251, DOI 10.1074/jbc.C200150200; Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0; Honda R, 1997, FEBS LETT, V420, P25, DOI 10.1016/S0014-5793(97)01480-4; Inga A, 2002, MOL CELL BIOL, V22, P8612, DOI 10.1128/MCB.22.24.8612-8625.2002; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Jackson MW, 2000, MOL CELL BIOL, V20, P1001, DOI 10.1128/MCB.20.3.1001-1007.2000; Jackson MW, 1999, DNA CELL BIOL, V18, P693, DOI 10.1089/104454999314971; JONES SN, 1995, NATURE, V378, P206, DOI 10.1038/378206a0; Kawai H, 2003, MOL CELL BIOL, V23, P4939, DOI 10.1128/MCB.23.14.4939-4947.2003; Kubbutat MHG, 1997, NATURE, V387, P299, DOI 10.1038/387299a0; Lai ZH, 2001, J BIOL CHEM, V276, P31357, DOI 10.1074/jbc.M011517200; LANE DP, 1990, GENE DEV, V4, P1, DOI 10.1101/gad.4.1.1; Li CG, 2002, MOL CELL BIOL, V22, P7562, DOI 10.1128/MCB.22.21.7562-7571.2002; Little NA, 2001, ONCOGENE, V20, P4576, DOI 10.1038/sj.onc.1204615; LUNA RMD, 1995, NATURE, V378, P203; Maniatis T., 1982, MOL CLONING LAB MANU; Maya R, 2001, GENE DEV, V15, P1067, DOI 10.1101/gad.886901; Meulmeester E, 2003, MOL CELL BIOL, V23, P4929, DOI 10.1128/MCB.23.14.4929-4938.2003; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Migliorini D, 2002, J BIOL CHEM, V277, P7318, DOI 10.1074/jbc.M108795200; Migliorini D, 2002, MOL CELL BIOL, V22, P5527, DOI 10.1128/MCB.22.15.5527-5538.2002; Momand J, 2000, GENE, V242, P15, DOI 10.1016/S0378-1119(99)00487-4; Parant J, 2001, NAT GENET, V29, P92, DOI 10.1038/ng714; Parant JM, 2001, GENE, V270, P277, DOI 10.1016/S0378-1119(01)00432-2; Rallapalli R, 1999, J BIOL CHEM, V274, P8299, DOI 10.1074/jbc.274.12.8299; Ramos YFM, 2001, CANCER RES, V61, P1839; Riemenschneider MJ, 2003, INT J CANCER, V104, P752, DOI 10.1002/ijc.11023; Riemenschneider MJ, 1999, CANCER RES, V59, P6091; Sharp DA, 1999, J BIOL CHEM, V274, P38189, DOI 10.1074/jbc.274.53.38189; Shvarts A, 1996, EMBO J, V15, P5349, DOI 10.1002/j.1460-2075.1996.tb00919.x; Stad R, 2000, J BIOL CHEM, V275, P28039; Stad R, 2001, EMBO REP, V2, P1029, DOI 10.1093/embo-reports/kve227; Tanimura S, 1999, FEBS LETT, V447, P5, DOI 10.1016/S0014-5793(99)00254-9; van der Eb A J, 1980, Methods Enzymol, V65, P826; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; ZAUBERMAN A, 1995, NUCLEIC ACIDS RES, V23, P2584, DOI 10.1093/nar/23.14.2584; Zhu QZ, 2001, J BIOL CHEM, V276, P29695, DOI 10.1074/jbc.M102634200	51	117	118	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38315	38324		10.1074/jbc.M213034200	http://dx.doi.org/10.1074/jbc.M213034200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874296	hybrid			2022-12-27	WOS:000185575100030
J	Klumpp, LM; Mackey, AT; Farrell, CM; Rosenberg, JM; Gilbert, SP				Klumpp, LM; Mackey, AT; Farrell, CM; Rosenberg, JM; Gilbert, SP			A kinesin switch I arginine to lysine mutation rescues microtubule function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ATP HYDROLYSIS; MOLECULAR MOTOR; DIMERIC KINESIN; SALT-BRIDGE; CONFORMATIONAL-CHANGE; DICTYOSTELIUM MYOSIN; CRYSTAL-STRUCTURE; EPR SPECTROSCOPY; BRAIN KINESIN; ADP RELEASE	Switch I and II are key active site structural elements of kinesins, myosins, and G-proteins. Our analysis of a switch I mutant (R210A) in Drosophila melanogaster kinesin showed a reduction in microtubule affinity, a loss in cooperativity between the motor domains, and an ATP hydrolysis defect leading to aberrant detachment from the microtubule. To investigate the conserved arginine in switch I further, a lysine substitution mutant was generated. The R210K dimeric motor has lost the ability to hydrolyze ATP; however, it has rescued microtubule function. Our results show that R210K has restored microtubule association kinetics, microtubule affinity, ADP release kinetics, and motor domain cooperativity. Moreover, the active site at head 1 is able to distinguish ATP, ADP, and AMP-PNP to signal head 2 to bind the microtubule and release mantADP with kinetics comparable with wild-type. Therefore, the structural pathway of communication from head 1 to head 2 is restored, and head 2 can respond to this signal by binding the microtubule and releasing mantADP. Structural modeling revealed that lysine could retain some of the hydrogen bonds made by arginine but not all, suggesting a structural hypothesis for the ability of lysine to rescue microtubule function in the Arg210 mutant.	Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Gilbert, SP (corresponding author), Univ Pittsburgh, Dept Biol Sci, 518 Langley Hall, Pittsburgh, PA 15260 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [K02AR047841] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054141, R01GM054141] Funding Source: NIH RePORTER; NIAMS NIH HHS [K02-AR47841, K02 AR047841, K02 AR047841-01A1, K02 AR047841-02] Funding Source: Medline; NIGMS NIH HHS [R01 GM054141-04, R01 GM054141-06, R01 GM054141-05, GM54141, R01 GM054141, R37 GM054141, R01 GM054141-07] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brendza KM, 1999, J BIOL CHEM, V274, P31506, DOI 10.1074/jbc.274.44.31506; Brendza KM, 2000, J BIOL CHEM, V275, P22187, DOI 10.1074/jbc.M001124200; Case RB, 2000, CURR BIOL, V10, P157, DOI 10.1016/S0960-9822(00)00316-X; Case RB, 1997, CELL, V90, P959, DOI 10.1016/S0092-8674(00)80360-8; CORREIA JJ, 1995, BIOCHEMISTRY-US, V34, P4898, DOI 10.1021/bi00014a047; Crevel I, 1999, EMBO J, V18, P5863, DOI 10.1093/emboj/18.21.5863; DeLano W.L, PYMOL MOL GRAPHICS S; Endow SA, 1998, SCIENCE, V281, P1200, DOI 10.1126/science.281.5380.1200; Farrell CM, 2002, J BIOL CHEM, V277, P17079, DOI 10.1074/jbc.M108793200; Foster KA, 1998, J BIOL CHEM, V273, P35307, DOI 10.1074/jbc.273.52.35307; Foster KA, 2001, J BIOL CHEM, V276, P19259, DOI 10.1074/jbc.M008347200; Furch M, 1999, J MOL BIOL, V290, P797, DOI 10.1006/jmbi.1999.2921; Geeves MA, 1999, ANNU REV BIOCHEM, V68, P687, DOI 10.1146/annurev.biochem.68.1.687; GILBERT SP, 1995, NATURE, V373, P671, DOI 10.1038/373671a0; GILBERT SP, 1994, BIOCHEMISTRY-US, V33, P1951, DOI 10.1021/bi00173a044; GILBERT SP, 1993, BIOCHEMISTRY-US, V32, P4677, DOI 10.1021/bi00068a028; Gilbert SP, 1998, BIOCHEMISTRY-US, V37, P792, DOI 10.1021/bi971117b; Gilbert SP, 2000, METHODS, V22, P337, DOI 10.1006/meth.2000.1086; HACKNEY DD, 1994, P NATL ACAD SCI USA, V91, P6865, DOI 10.1073/pnas.91.15.6865; HACKNEY DD, 1988, P NATL ACAD SCI USA, V85, P6314, DOI 10.1073/pnas.85.17.6314; Hackney DD, 2002, BIOCHEMISTRY-US, V41, P4437, DOI 10.1021/bi0159229; Henningsen U, 1997, NATURE, V389, P93, DOI 10.1038/38022; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kikkawa M, 2001, NATURE, V411, P439, DOI 10.1038/35078000; Kliche W, 2001, EMBO J, V20, P40, DOI 10.1093/emboj/20.1.40; Klumpp LM, 2003, BIOCHEMISTRY-US, V42, P2595, DOI 10.1021/bi026715r; Kozielski F, 1997, CELL, V91, P985, DOI 10.1016/S0092-8674(00)80489-4; Kull FJ, 2002, J CELL SCI, V115, P15; Kull FJ, 1998, J MUSCLE RES CELL M, V19, P877, DOI 10.1023/A:1005489907021; Kull FJ, 1996, NATURE, V380, P550, DOI 10.1038/380550a0; KUZNETSOV SA, 1986, P NATL ACAD SCI USA, V83, P8530, DOI 10.1073/pnas.83.22.8530; Ma YZ, 1997, J BIOL CHEM, V272, P724, DOI 10.1074/jbc.272.2.724; MA YZ, 1995, BIOCHEMISTRY-US, V34, P13242, DOI 10.1021/bi00040a040; Mackey AT, 2000, BIOCHEMISTRY-US, V39, P1346, DOI 10.1021/bi991918+; Mandelkow E, 1998, TRENDS BIOCHEM SCI, V23, P429, DOI 10.1016/S0968-0004(98)01278-X; Minehardt TJ, 2001, BIOPHYS J, V80, P1151, DOI 10.1016/S0006-3495(01)76092-4; Moyer ML, 1998, BIOCHEMISTRY-US, V37, P800, DOI 10.1021/bi9711184; MOYER ML, 1998, THESIS PENNSYLVANIA; Muller J, 1999, BIOL CHEM, V380, P981, DOI 10.1515/BC.1999.122; Naber N, 2003, BIOPHYS J, V84, P3190, DOI 10.1016/S0006-3495(03)70043-5; Onishi H, 1998, P NATL ACAD SCI USA, V95, P6653, DOI 10.1073/pnas.95.12.6653; Onishi H, 2002, P NATL ACAD SCI USA, V99, P15339, DOI 10.1073/pnas.242604099; Pate E, 1997, BIOCHEMISTRY-US, V36, P12155, DOI 10.1021/bi970996z; Rice S, 1999, NATURE, V402, P778, DOI 10.1038/45483; Rosenfeld SS, 2002, J BIOL CHEM, V277, P36731, DOI 10.1074/jbc.M205261200; Rosenfeld SS, 2001, J BIOL CHEM, V276, P40167, DOI 10.1074/jbc.M103899200; Sablin EP, 1998, NATURE, V395, P813, DOI 10.1038/27463; Sack S, 1997, BIOCHEMISTRY-US, V36, P16155, DOI 10.1021/bi9722498; Sack S, 1999, EUR J BIOCHEM, V262, P1, DOI 10.1046/j.1432-1327.1999.00341.x; Sasaki N, 1998, J BIOL CHEM, V273, P20334, DOI 10.1074/jbc.273.32.20334; Schnitzer MJ, 2000, NAT CELL BIOL, V2, P718, DOI 10.1038/35036345; Shimada T, 1997, BIOCHEMISTRY-US, V36, P14037, DOI 10.1021/bi971837i; Sindelar CV, 2002, NAT STRUCT BIOL, V9, P844, DOI 10.1038/nsb852; Skiniotis G, 2003, EMBO J, V22, P1518, DOI 10.1093/emboj/cdg164; Smith CA, 1996, BIOPHYS J, V70, P1590, DOI 10.1016/S0006-3495(96)79745-X; Song YH, 2001, EMBO J, V20, P6213, DOI 10.1093/emboj/20.22.6213; Sosa H, 2001, NAT STRUCT BIOL, V8, P540, DOI 10.1038/88611; Suzuki Y, 1998, NATURE, V396, P380, DOI 10.1038/24640; Tomishige M, 2000, J CELL BIOL, V151, P1081, DOI 10.1083/jcb.151.5.1081; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; Vale RD, 1996, J CELL BIOL, V135, P291, DOI 10.1083/jcb.135.2.291; Wriggers W, 1998, BIOPHYS J, V75, P646, DOI 10.1016/S0006-3495(98)77555-1; Yun MY, 2001, EMBO J, V20, P2611, DOI 10.1093/emboj/20.11.2611	63	21	22	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39059	39067		10.1074/jbc.M304250200	http://dx.doi.org/10.1074/jbc.M304250200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860992	Green Accepted, hybrid			2022-12-27	WOS:000185575100119
J	Kupke, T; Hernandez-Acosta, P; Culianez-Macia, FA				Kupke, T; Hernandez-Acosta, P; Culianez-Macia, FA			4 '-phosphopantetheine and coenzyme A biosynthesis in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANTOTHENATE KINASE GENE; BACTERIAL DFP FLAVOPROTEINS; ESCHERICHIA-COLI; MOLECULAR CHARACTERIZATION; ARABIDOPSIS-THALIANA; PHOSPHOPANTETHEINE ADENYLYLTRANSFERASE; PHOSPHOPANTOTHENOYLCYSTEINE SYNTHETASE; CRYSTAL-STRUCTURE; COA SYNTHASE; 4'-PHOSPHOPANTOTHENOYLCYSTEINE	Coenzyme A is required for many synthetic and degradative reactions in intermediary metabolism and is the principal acyl carrier in prokaryotic and eukaryotic cells. Coenzyme A is synthesized in five steps from pantothenate, and recently the CoaA biosynthetic genes in bacteria and human have all been identified and characterized. Coenzyme A biosynthesis in plants is not fully understood, and to date only the AtHAL3a (AtCoaC) gene of Arabidopsis thaliana has been cloned and identified as 4'-phosphopantothenoylcysteine (PPC) decarboxylase (Kupke, T., Hernandez-Acosta, P., Steinbacher, S., and Culianez-Macia, F. A. (2001) J. Biol. Chem. 276, 19190-19196). Here, we demonstrate the cloning of the four missing genes, purification of the enzymes, and identification of their functions. In contrast to bacterial PPC synthetases, the plant synthetase is not CTP- but ATP-dependent. The complete biosynthetic pathway from pantothenate to coenzyme A was reconstituted in vitro by adding the enzymes pantothenate kinase (AtCoaA), 4'-phosphopantothenoylcysteine synthetase (AtCoaB), 4'-phosphopantothenoylcysteine decarboxylase (AtCoaC), 4'-phosphopantetheine adenylyltransferase (AtCoaD), and dephospho-coenzyme A kinase (AtCoaE) to a mixture containing pantothenate, cysteine, ATP, dithiothreitol, and Mg2+.	Univ Tubingen, Lehrstuhl Mikrobielle Genet, D-72076 Tubingen, Germany; Univ Politecn Valencia, CSIC, Inst Biol Mol & Celular Plantas, E-46022 Valencia, Spain	Eberhard Karls University of Tubingen; Consejo Superior de Investigaciones Cientificas (CSIC); Universitat Politecnica de Valencia; CSIC-UPV - Instituto de Biologia Molecular y Celular de Plantas (IBMCP)	Kupke, T (corresponding author), Univ Tubingen, Lehrstuhl Mikrobielle Genet, Morgenstelle 15,Verfugungsgebaude, D-72076 Tubingen, Germany.	thomas.kupke@t-online.de; faculia@ibmcp.upv.es	Zhang, Ning/F-1387-2014	Kupke, Thomas/0000-0003-2341-1710				Abiko Y., 1975, Metabolism of sulphur compounds., P1; ABIKO Y, 1968, J BIOCHEM-TOKYO, V64, P115, DOI 10.1093/oxfordjournals.jbchem.a128855; ABIKO Y, 1967, J BIOCHEM-TOKYO, V61, P309, DOI 10.1093/oxfordjournals.jbchem.a128549; Aghajanian S, 2002, BIOCHEM J, V365, P13, DOI 10.1042/BJ20020569; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Begley TP, 2001, VITAM HORM, V61, P157; Blaesse M, 2000, EMBO J, V19, P6299, DOI 10.1093/emboj/19.23.6299; BROWN GM, 1959, J BIOL CHEM, V234, P370; Calder RB, 1999, J BIOL CHEM, V274, P2014, DOI 10.1074/jbc.274.4.2014; Choudhry AE, 2003, ANTIMICROB AGENTS CH, V47, P2051, DOI 10.1128/AAC.47.6.2051-2055.2003; Corpet F, 2000, NUCLEIC ACIDS RES, V28, P267, DOI 10.1093/nar/28.1.267; Daugherty M, 2002, J BIOL CHEM, V277, P21431, DOI 10.1074/jbc.M201708200; DICOMO CJ, 1995, GENETICS, V139, P95; Espinosa-Ruiz A, 1999, PLANT J, V20, P529, DOI 10.1046/j.1365-313X.1999.00626.x; FALK KL, 1993, ARCH BIOCHEM BIOPHYS, V301, P424, DOI 10.1006/abbi.1993.1166; FERRANDO A, 1995, MOL CELL BIOL, V15, P5470; Geerlof A, 1999, J BIOL CHEM, V274, P27105, DOI 10.1074/jbc.274.38.27105; Gerdes SY, 2002, J BACTERIOL, V184, P4555, DOI 10.1128/JB.184.16.4555-4572.2002; HELDT HW, 1997, PLANT BIOCH MOL BIOL, P124; Hernandez-Acosta P, 2002, J BIOL CHEM, V277, P20490, DOI 10.1074/jbc.M201557200; JACKOWSKI S, 1996, ESCHERICHIA COLI SAL, V1, P687; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Kleinkauf Horst, 2000, Biofactors, V11, P91; Kupke T, 2000, J BIOL CHEM, V275, P31838, DOI 10.1074/jbc.M004273200; Kupke T, 2002, J BIOL CHEM, V277, P36137, DOI 10.1074/jbc.M206188200; Kupke T, 2001, J BIOL CHEM, V276, P19190, DOI 10.1074/jbc.M100776200; Kupke T, 2001, J BIOL CHEM, V276, P27597, DOI 10.1074/jbc.M103342200; LYNEN F, 1973, NOBEL LECTURES 1963, P103; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mishra PK, 2001, J BACTERIOL, V183, P2774, DOI 10.1128/JB.183.9.2774-2778.2001; Ni XH, 2002, INT J BIOCHEM CELL B, V34, P109, DOI 10.1016/S1357-2725(01)00114-5; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHENK PM, 1995, BIOTECHNIQUES, V19, P196; SONG WJ, 1992, J BACTERIOL, V174, P6411, DOI 10.1128/JB.174.20.6411-6417.1992; Steinbacher S, 2003, J MOL BIOL, V327, P193, DOI 10.1016/S0022-2836(03)00092-5; Strauss E, 2001, J AM CHEM SOC, V123, P6449, DOI 10.1021/ja016020y; Strauss E, 2001, J BIOL CHEM, V276, P13513, DOI 10.1074/jbc.C100033200; TRAUT TW, 1994, EUR J BIOCHEM, V222, P9, DOI 10.1111/j.1432-1033.1994.tb18835.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; Zhao LH, 2003, EUR J MED CHEM, V38, P345, DOI 10.1016/S0223-5234(03)00047-3; Zhou B, 2001, NAT GENET, V28, P345, DOI 10.1038/ng572; Zhyvoloup A, 2002, J BIOL CHEM, V277, P22107, DOI 10.1074/jbc.C200195200	42	48	59	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38229	38237		10.1074/jbc.M306321200	http://dx.doi.org/10.1074/jbc.M306321200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860978	hybrid			2022-12-27	WOS:000185575100019
J	Pop, OI; Westermann, M; Volkmer-Engert, R; Schulz, D; Lemke, C; Schreiber, S; Gerlach, R; Wetzker, R; Muller, JP				Pop, OI; Westermann, M; Volkmer-Engert, R; Schulz, D; Lemke, C; Schreiber, S; Gerlach, R; Wetzker, R; Muller, JP			Sequence-specific binding of prePhoD to soluble TatA(d) indicates protein-mediated targeting of the Tat export in Bacillus subtilis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE TRANSLOCATION PATHWAY; ESCHERICHIA-COLI; SIGNAL PEPTIDE; ALKALINE-PHOSPHATASE; THYLAKOID MEMBRANES; PRECURSOR PROTEINS; CONSENSUS MOTIF; SEC; SYSTEM; COMPLEX	The Tat (twin-arginine protein translocation) system initially discovered in the thylakoid membrane of chloroplasts has been described recently for a variety of eubacterial organisms. Although in Escherichia coli four Tat proteins with calculated membrane spanning domains have been demonstrated to mediate Tat-dependent transport, a specific transport system for twin-arginine signal peptide containing phosphodiesterase PhoD of Bacillus subtilis consists of one TatA/TatC (TatA(d)/TatC(d)) pair of proteins. Here, we show that TatA(d) was found beside its membrane-integrated localization in the cytosol were it interacted with prePhoD. prePhoD was efficiently co-immunoprecipitated by TatA(d). Inefficient co-immunoprecipitation of mature PhoD and missing interaction to Sec-dependent and cytosolic peptides by TatA(d) demonstrated a particular role of the twin-arginine signal peptide for this interaction. Affinity of prePhoD to TatA(d) was interfered by peptides containing the twin-arginine motif but remained active when the arginine residues were substituted. The selective binding of TatA(d) to peptides derived from the signal peptide of PhoD elucidated the function of the twin-arginine motif as a target site for pre-protein TatA(d) interaction. Substitution of the binding motif demonstrated the pivotal role of basic amino acid residues for TatA binding. These features suggest that TatA interacts prior to membrane integration with its pre-protein substrate and could therefore assist targeting of twin-arginine pre-proteins.	Univ Jena, Inst Mol Biol, D-07745 Jena, Germany; Univ Jena Klinikum, Inst Ultrastrukturforsch, D-07743 Jena, Germany; Charite, Abt Mol Bibliotheken, D-10117 Berlin, Germany; Univ Jena, Inst Anat 1, D-07743 Jena, Germany; Univ Jena Klinikum, Arbeitsgrp Mol Zellbiol, D-07747 Jena, Germany	Friedrich Schiller University of Jena; Friedrich Schiller University of Jena; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Friedrich Schiller University of Jena; Friedrich Schiller University of Jena	Muller, JP (corresponding author), Univ Jena, Inst Mol Biol, Hans Knoll Str 2, D-07745 Jena, Germany.		Wetzker, Reinhard/AAD-8713-2019	Gerlach, Roman/0000-0002-5718-4758; Volkmer, Rudolf/0000-0003-4710-1143				Alami M, 2002, J BIOL CHEM, V277, P20499, DOI 10.1074/jbc.M201711200; Berks BC, 2000, MOL MICROBIOL, V35, P260, DOI 10.1046/j.1365-2958.2000.01719.x; Berks BC, 1996, MOL MICROBIOL, V22, P393, DOI 10.1046/j.1365-2958.1996.00114.x; Bogsch EG, 1998, J BIOL CHEM, V273, P18003, DOI 10.1074/jbc.273.29.18003; Bolhuis A, 2001, J BIOL CHEM, V276, P20213, DOI 10.1074/jbc.M100682200; Bolhuis A, 2000, FEBS LETT, V472, P88, DOI 10.1016/S0014-5793(00)01428-9; Bruser T, 2003, EUR J BIOCHEM, V270, P1211, DOI 10.1046/j.1432-1033.2003.03481.x; CARTER P, 1985, NUCLEIC ACIDS RES, V13, P4431, DOI 10.1093/nar/13.12.4431; CHADDOCK AM, 1995, EMBO J, V14, P2715, DOI 10.1002/j.1460-2075.1995.tb07272.x; CLINE K, 1992, J BIOL CHEM, V267, P2688; Cline K, 2001, J CELL BIOL, V154, P719, DOI 10.1083/jcb.200105149; De Leeuw E, 2001, FEBS LETT, V506, P143, DOI 10.1016/S0014-5793(01)02904-0; DELISA MP, 2002, J BIOL CHEM; Dilks K, 2003, J BACTERIOL, V185, P1478, DOI 10.1128/JB.185.4.1478-1483.2003; Dreusch A, 1997, BBA-BIOENERGETICS, V1319, P311, DOI 10.1016/S0005-2728(96)00174-0; Driessen AJM, 1998, CURR OPIN MICROBIOL, V1, P216, DOI 10.1016/S1369-5274(98)80014-3; Driessen AJM, 2001, NAT STRUCT BIOL, V8, P492, DOI 10.1038/88549; Economou A, 1999, TRENDS MICROBIOL, V7, P315, DOI 10.1016/S0966-842X(99)01555-3; Eder S, 1996, MICROBIOL-SGM, V142, P2041, DOI 10.1099/13500872-142-8-2041; FRANK R, 1992, TETRAHEDRON, V48, P9217, DOI 10.1016/S0040-4020(01)85612-X; Fujimoto K, 1997, HISTOCHEM CELL BIOL, V107, P87, DOI 10.1007/s004180050092; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gerharz CD, 2001, UROLOGY, V58, P821, DOI 10.1016/S0090-4295(01)01371-1; Gouffi K, 2002, FEBS LETT, V525, P65, DOI 10.1016/S0014-5793(02)03069-7; Gross R, 1999, ARCH MICROBIOL, V172, P227, DOI 10.1007/s002030050764; Halbig D, 1999, EUR J BIOCHEM, V263, P543, DOI 10.1046/j.1432-1327.1999.00536.x; Henry R, 1997, J CELL BIOL, V136, P823, DOI 10.1083/jcb.136.4.823; Hinsley AP, 2001, FEBS LETT, V497, P45, DOI 10.1016/S0014-5793(01)02428-0; HULETT FM, 1990, J BACTERIOL, V172, P735, DOI 10.1128/jb.172.2.735-740.1990; Jongbloed JDH, 2002, J BIOL CHEM, V277, P44068, DOI 10.1074/jbc.M203191200; Jongbloed JDH, 2000, J BIOL CHEM, V275, P41350, DOI 10.1074/jbc.M004887200; Knoblauch NTM, 1999, J BIOL CHEM, V274, P34219, DOI 10.1074/jbc.274.48.34219; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leenhouts K, 1998, APPL MICROBIOL BIOT, V49, P417, DOI 10.1007/s002530051192; LEGRICE SFJ, 1990, METHOD ENZYMOL, V185, P201; Mori H, 2002, J CELL BIOL, V157, P205, DOI 10.1083/jcb.200202048; Mori H, 1999, J CELL BIOL, V146, P45, DOI 10.1083/jcb.146.1.45; Mori H, 2001, TRENDS MICROBIOL, V9, P494, DOI 10.1016/S0966-842X(01)02174-6; MULLER J, 1992, MOL GEN GENET, V235, P89, DOI 10.1007/BF00286185; Muller JP, 1999, FEMS MICROBIOL LETT, V180, P287; Muller JP, 1997, MICROBIOL-SGM, V143, P947, DOI 10.1099/00221287-143-3-947; Muller JP, 2000, BIOCHEM J, V348, P367, DOI 10.1042/0264-6021:3480367; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Oresnik IJ, 2001, MOL MICROBIOL, V40, P323, DOI 10.1046/j.1365-2958.2001.02391.x; Pop O, 2002, J BIOL CHEM, V277, P3268, DOI 10.1074/jbc.M110829200; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rivas S, 2002, PLANT CELL, V14, P689, DOI [10.1105/tpc.010357, 10.​1105/​tpc.​010357]; Robinson C, 1997, TRENDS PLANT SCI, V2, P431, DOI 10.1016/S1360-1385(97)90027-3; Robinson C, 2001, NAT REV MOL CELL BIO, V2, P350, DOI 10.1038/35073038; Robinson C, 2000, BIOL CHEM, V381, P89, DOI 10.1515/BC.2000.013; Rodrigue A, 1999, J BIOL CHEM, V274, P13223, DOI 10.1074/jbc.274.19.13223; Sambrook J., 2002, MOL CLONING LAB MANU; Santini CL, 1998, EMBO J, V17, P101, DOI 10.1093/emboj/17.1.101; Sargent F, 2001, EUR J BIOCHEM, V268, P3361, DOI 10.1046/j.1432-1327.2001.02263.x; Sargent F, 2001, TRENDS MICROBIOL, V9, P196, DOI 10.1016/S0966-842X(01)02017-0; Sargent F, 1998, EMBO J, V17, P3640, DOI 10.1093/emboj/17.13.3640; Settles AM, 1998, TRENDS CELL BIOL, V8, P494, DOI 10.1016/S0962-8924(98)01387-7; Settles AM, 1997, SCIENCE, V278, P1467, DOI 10.1126/science.278.5342.1467; Stanley NR, 2000, J BIOL CHEM, V275, P11591, DOI 10.1074/jbc.275.16.11591; Steinmetzer K, 1997, J MOL BIOL, V269, P684, DOI 10.1006/jmbi.1997.1083; Takizawa T, 2000, HISTOL HISTOPATHOL, V15, P515, DOI 10.14670/HH-15.515; Thomas JD, 2001, MOL MICROBIOL, V39, P47, DOI 10.1046/j.1365-2958.2001.02253.x; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Weiner JH, 1998, CELL, V93, P93, DOI 10.1016/S0092-8674(00)81149-6; Wenschuh H, 2000, BIOPOLYMERS, V55, P188, DOI 10.1002/1097-0282(2000)55:3<188::AID-BIP20>3.0.CO;2-T; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; Wu LF, 2000, J MOL MICROB BIOTECH, V2, P179; Yahr TL, 2001, EMBO J, V20, P2472, DOI 10.1093/emboj/20.10.2472; YAMANE K, 1978, J BACTERIOL, V134, P108, DOI 10.1128/JB.134.1.108-114.1978; Yen MR, 2002, ARCH MICROBIOL, V177, P441, DOI 10.1007/s00203-002-0408-4	71	52	59	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38428	38436		10.1074/jbc.M306516200	http://dx.doi.org/10.1074/jbc.M306516200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867413	hybrid			2022-12-27	WOS:000185575100043
J	Sekoguchi, E; Sato, N; Yasui, A; Fukada, S; Nimura, Y; Aburatani, H; Ikeda, K; Matsuura, A				Sekoguchi, E; Sato, N; Yasui, A; Fukada, S; Nimura, Y; Aburatani, H; Ikeda, K; Matsuura, A			A novel mitochondrial carnitine-acylcarnitine translocase induced by partial hepatectomy and fasting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; LIVER-REGENERATION; FATTY-ACIDS; ACETYL-COA; RAT-HEART; PROTEIN; CARRIER; DEFICIENCY; METABOLISM	The carnitine-dependent transport of long-chain fatty acids is essential for fatty acid catabolism. In this system, the fatty acid moiety of acyl-CoA is transferred enzymatically to carnitine, and the resultant product, acylcarnitine, is imported into the mitochondrial matrix through a transporter named carnitine-acylcarnitine translocase (CACT). Here we report a novel mammalian protein homologous to CACT. The protein, designated as CACL (CACT-like), is localized to the mitochondria and has palmitoylcarnitine transporting activity. The tissue distribution of CACL is similar to that of CACT; both are expressed at a higher level in tissues using fatty acids as fuels, except in the brain, where only CACL is expressed. In addition, CACL is induced by partial hepatectomy or fasting. Thus, CACL may play an important role cooperatively with its homologue CACT in a stress-induced change of lipid metabolism, and may be specialized for the metabolism of a distinct class of fatty acids involved in brain function.	Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan; Chubu Natl Hosp, Aichi 4748522, Japan; Nagoya Univ, Grad Sch Med, Showa Ku, Nagoya, Aichi 4668550, Japan; Tokyo Univ Pharm & Life Sci, Hachioji, Tokyo 1920392, Japan; Univ Tokyo, Adv Sci & Technol Res Ctr, Meguro Ku, Tokyo 1538904, Japan	Nagoya University; Tokyo University of Pharmacy & Life Sciences; University of Tokyo	Matsuura, A (corresponding author), Natl Inst Longev Sci, Dept Geriatr Res, Aichi 4748522, Japan.		Matsuura, Akira/AAO-1572-2021; Matsuura, Akira/J-3864-2017	Matsuura, Akira/0000-0002-2300-7227; Matsuura, Akira/0000-0002-2300-7227				ADAMS MG, 1981, J PATHOL, V135, P111, DOI 10.1002/path.1711350203; ASINS G, 1994, BIOCHEM J, V299, P65, DOI 10.1042/bj2990065; De Lucas JR, 1999, ARCH MICROBIOL, V171, P386, DOI 10.1007/s002030050725; DENTON RM, 1967, BIOCHEM J, V104, P416, DOI 10.1042/bj1040416; Eraly SA, 2002, BIOCHEM BIOPH RES CO, V297, P1159, DOI 10.1016/S0006-291X(02)02343-4; Fraser F, 1999, FEBS LETT, V445, P41, DOI 10.1016/S0014-5793(99)00095-2; HALE DE, 1992, J PEDIATR-US, V121, P1, DOI 10.1016/S0022-3476(05)82532-6; Higgins GM, 1931, ARCH PATHOL, V12, P186; HOLECEK M, 1989, PHYSIOL BOHEMOSLOV, V38, P503; Huizing M, 1997, AM J HUM GENET, V61, P1239, DOI 10.1086/301628; Indiveri C, 1997, BIOCHEM J, V321, P713, DOI 10.1042/bj3210713; Inoue Y, 2002, HEPATOLOGY, V36, P336, DOI 10.1053/jhep.2002.34942; Knoll A, 1999, MOL BRAIN RES, V74, P217, DOI 10.1016/S0169-328X(99)00252-1; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lai HS, 1998, WORLD J SURG, V22, P42, DOI 10.1007/s002689900347; Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60; MITCHELL GA, 1995, CLIN INVEST MED, V18, P193; MURTHY MSR, 1984, J BIOL CHEM, V259, P9082; NEELY JR, 1974, ANNU REV PHYSIOL, V36, P413, DOI 10.1146/annurev.ph.36.030174.002213; Onishi M, 1996, EXP HEMATOL, V24, P324; PANDE SV, 1975, P NATL ACAD SCI USA, V72, P883, DOI 10.1073/pnas.72.3.883; PANDE SV, 1993, J CLIN INVEST, V91, P1247, DOI 10.1172/JCI116288; Pande SV, 1999, AM J MED SCI, V318, P22, DOI 10.1097/00000441-199907000-00004; Price NT, 2002, GENOMICS, V80, P433, DOI 10.1006/geno.2002.6845; Ramsay RR, 2001, BBA-PROTEIN STRUCT M, V1546, P21, DOI 10.1016/S0167-4838(01)00147-9; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; SIKORSKI RS, 1989, GENETICS, V122, P19; STANLEY CA, 1992, NEW ENGL J MED, V327, P19, DOI 10.1056/NEJM199207023270104; Su AI, 2002, P NATL ACAD SCI USA, V99, P11181, DOI 10.1073/pnas.122359899; Suzuki J, 2002, AM J PHYSIOL-ENDOC M, V283, pE94, DOI 10.1152/ajpendo.00017.2002; TANAKA K, 1990, MOL CELL BIOL, V10, P4303, DOI 10.1128/MCB.10.8.4303; Uauy R, 2001, LIPIDS, V36, P885, DOI 10.1007/s11745-001-0798-1; van Roermund CWT, 1999, EMBO J, V18, P5843, DOI 10.1093/emboj/18.21.5843; VANROERMUND CWT, 1995, EMBO J, V14, P3480, DOI 10.1002/j.1460-2075.1995.tb07354.x; Wallis JG, 2002, TRENDS BIOCHEM SCI, V27, P467, DOI 10.1016/S0968-0004(02)02168-0	35	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38796	38802		10.1074/jbc.M306372200	http://dx.doi.org/10.1074/jbc.M306372200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882971	hybrid			2022-12-27	WOS:000185575100087
J	Ying, SX; Hussain, ZJ; Zhang, YE				Ying, SX; Hussain, ZJ; Zhang, YE			Smurf1 facilitates myogenic differentiation and antagonizes the bone morphogenetic protein-2-induced osteoblast conversion by targeting Smad5 for degradation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFORMING-GROWTH-FACTOR; TGF-BETA RECEPTOR; E3 UBIQUITIN LIGASE; SIGNAL-TRANSDUCTION; C2C12 MYOBLASTS; I RECEPTORS; CELL-LINE; EXPRESSION; MUSCLE; SUPERFAMILY	Controlled proteolysis mediated by Smad ubiquitination regulatory factors (Smurfs) plays a crucial role in modulating cellular responses to signaling of the transforming growth factor-beta (TGF-beta) superfamily. However, it is not clear what influences the selectivity of Smurfs in the individual signaling pathway, nor is it clear the biological function of Smurfs in vivo. Using a mouse C2C12 myoblast cell differentiation system, which is subject to control by both TGF-beta and bone morphogenetic protein (BMP), here we examine the role of Smurf1 in myogenic differentiation. We show that increased expression of Smurf1 promotes myogenic differentiation of C2C12 cells and blocks the BMP-induced osteogenic conversion but has no effect on the TGF-beta-induced differentiation arrest. Consistent with an inhibitory role in the BMP signaling pathway, the elevated Smurf1 markedly reduces the level of endogenous Smad5, whereas it leaves unaltered that of Smad2, Smad3, and Smad7, which are components of the TGF-beta pathway. Adding back Smad5 from a different source to the Smurf1-overexpressing cells restores the BMP-mediated osteoblast conversion. Finally, by depletion of the endogenous Smurf1 through small interfering RNA-mediated RNA interference, we demonstrate that Smurf1 is required for the myogenic differentiation of C2C12 cells and plays an important regulatory role in the BMP-2-mediated osteoblast conversion.	NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Zhang, YE (corresponding author), NCI, Cellular & Mol Biol Lab, Ctr Canc Res, NIH, Bldg 37,Rm 1C27, Bethesda, MD 20892 USA.		Zhang, Ying E/G-3657-2015	Zhang, Ying E/0000-0003-2753-7601	Intramural NIH HHS [Z01 BC010419-08, ZIA BC011168-01] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010419] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aoki H, 2001, J CELL SCI, V114, P1483; Attisano L, 2002, SCIENCE, V296, P1646, DOI 10.1126/science.1071809; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; Bonni S, 2001, NAT CELL BIOL, V3, P587, DOI 10.1038/35078562; Chang H, 2002, ENDOCR REV, V23, P787, DOI 10.1210/er.2002-0003; Choy L, 2000, J CELL BIOL, V149, P667, DOI 10.1083/jcb.149.3.667; DESBOIS C, 1994, J BIOL CHEM, V269, P1183; Ebisawa T, 2001, J BIOL CHEM, V276, P12477, DOI 10.1074/jbc.C100008200; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Faure S, 2000, DEVELOPMENT, V127, P2917; Feng XH, 1998, GENE DEV, V12, P2153, DOI 10.1101/gad.12.14.2153; Fujii M, 1999, MOL BIOL CELL, V10, P3801, DOI 10.1091/mbc.10.11.3801; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Inman GJ, 2002, MOL CELL, V10, P283, DOI 10.1016/S1097-2765(02)00585-3; KATAGIRI T, 1994, J CELL BIOL, V127, P1755, DOI 10.1083/jcb.127.6.1755; Kavsak P, 2000, MOL CELL, V6, P1365, DOI 10.1016/S1097-2765(00)00134-9; Lee KS, 2000, MOL CELL BIOL, V20, P8783, DOI 10.1128/MCB.20.23.8783-8792.2000; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; Lin X, 2000, J BIOL CHEM, V275, P36818, DOI 10.1074/jbc.C000580200; Liu CH, 2003, J BIOL CHEM, V278, P11721, DOI 10.1074/jbc.M207728200; Liu D, 2001, GENE DEV, V15, P2950, DOI 10.1101/gad.925901; Massague J, 2000, NAT REV MOL CELL BIO, V1, P169, DOI 10.1038/35043051; MASSAGUE J, 1986, P NATL ACAD SCI USA, V83, P8206, DOI 10.1073/pnas.83.21.8206; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; Moustakas A, 2001, J CELL SCI, V114, P4359; OLSON EN, 1986, J CELL BIOL, V103, P1799, DOI 10.1083/jcb.103.5.1799; OLSON EN, 1994, GENE DEV, V8, P1, DOI 10.1101/gad.8.1.1; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; Podos SD, 2001, DEV CELL, V1, P567, DOI 10.1016/S1534-5807(01)00057-0; Suzuki C, 2002, J BIOL CHEM, V277, P39919, DOI 10.1074/jbc.M201901200; Tajima Y, 2003, J BIOL CHEM, V278, P10716, DOI 10.1074/jbc.M212663200; WEINTRAUB H, 1993, CELL, V75, P1241, DOI 10.1016/0092-8674(93)90610-3; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; Yamamoto N, 1997, BIOCHEM BIOPH RES CO, V238, P574, DOI 10.1006/bbrc.1997.7325; Zhang Y, 2001, P NATL ACAD SCI USA, V98, P974, DOI 10.1073/pnas.98.3.974; Zhu HT, 1999, NATURE, V400, P687, DOI 10.1038/23293	37	70	77	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39029	39036		10.1074/jbc.M301193200	http://dx.doi.org/10.1074/jbc.M301193200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871975	hybrid, Green Accepted			2022-12-27	WOS:000185575100115
J	Lookene, A; Zhang, LY; Tougu, V; Olivecrona, G				Lookene, A; Zhang, LY; Tougu, V; Olivecrona, G			1,1 '-bis(anilino)-4-,4 '-bis(naphtalene)-8,8 '-disulfonate acts as an inhibitor of lipoprotein lipase and competes for binding with apolipoprotein CII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-II; CONFORMATIONAL-CHANGES; CATALYZED HYDROLYSIS; ENERGY-METABOLISM; PANCREATIC LIPASE; COFACTOR-BINDING; HEPARIN-BINDING; MOLTEN GLOBULE; HEPATIC LIPASE; PROTEIN	Lipoprotein lipase (LPL) is dependent on apolipoprotein CII (apoCII), a component of plasma lipoproteins, for function in vivo. The hydrophobic fluorescent probe 1,1'-bis(anilino)-4,4'-bis(naphthalene)-8,8'-disulfonate (bis-ANS) was found to be a potent inhibitor of LPL. ApoCII prevented the inhibition by bis-ANS, and was also able to restore the activity of inhibited LPL in a competitive manner, but only with triacylglycerols with acyl chains longer than three carbons. Studies of fluorescence and surface plasmon resonance indicated that LPL has an exposed hydrophobic site for binding of bis-ANS. The high affinity interaction was characterized by an equilibrium constant K-d of 0.10-0.26 muM and by a relatively high on rate constant k(as)s = 2.0 x 10(4) M-1 s(-1) and a slow off-rate with a dissociation rate constant k(diss) = 1.2 x 10(-4) s(-1). The high affinity binding of bis-ANS did not influence interaction of LPL with heparin or with lipid/water interfaces and did not dissociate the active LPL dimer into monomers. Analysis of fragments of LPL after photoincorporation of bis-ANS indicated that the high affinity binding site was located in the middle part of the N-terminal folding domain. We propose that bis-ANS binds to an exposed hydrophobic area that is located close to the active site. This area may be the binding site for individual substrate molecules and also for apoCII.	Umea Univ, Dept Med Biosci, SE-90187 Umea, Sweden; Tallinn Univ Technol, Dept Gene Technol, EE-19086 Tallinn, Estonia; NICPB, EE-12618 Tallinn, Estonia	Umea University; Tallinn University of Technology; National Institute of Chemical Physics & Biophysics (NICPB)	Olivecrona, G (corresponding author), Umea Univ, Dept Med Biosci, Bldg 6M,3rd Floor, SE-90187 Umea, Sweden.	Gunilla.Olivecrona@medbio.umu.se	Tõugu, Vello/B-4462-2019	Tougu, Vello/0000-0002-6271-7993				BENGTSSON G, 1980, EUR J BIOCHEM, V106, P549, DOI 10.1111/j.1432-1033.1980.tb04602.x; BENGTSSON G, 1980, EUR J BIOCHEM, V106, P557, DOI 10.1111/j.1432-1033.1980.tb04603.x; BENGTSSONOLIVECRONA G, 1991, METHOD ENZYMOL, V197, P345; BENGTSSONOLIVECRONA G, 1986, EUR J BIOCHEM, V161, P281, DOI 10.1111/j.1432-1033.1986.tb10444.x; BENGTSSONOLIVECRONA G, 1985, BIOCHEM J, V226, P409, DOI 10.1042/bj2260409; Bergo M, 1996, BIOCHEM J, V313, P893, DOI 10.1042/bj3130893; BRECKENRIDGE WC, 1978, NEW ENGL J MED, V298, P1265, DOI 10.1056/NEJM197806082982301; Carneiro FA, 2001, J BIOL CHEM, V276, P62, DOI 10.1074/jbc.M008753200; Chakraborty S, 1999, BBA-PROTEIN STRUCT M, V1432, P350, DOI 10.1016/S0167-4838(99)00110-7; Chapeaurouge A, 2002, J BIOL CHEM, V277, P16478, DOI 10.1074/jbc.M105232200; CHAPUS C, 1981, EUR J BIOCHEM, V115, P99; Chatterjee S, 2002, PROTEINS, V49, P554, DOI 10.1002/prot.10236; Davis TM, 2000, ANAL BIOCHEM, V284, P348, DOI 10.1006/abio.2000.4726; EDWARDS K, 1994, BIOCHEMISTRY-US, V33, P13304, DOI 10.1021/bi00249a017; GARNER CW, 1972, J BIOL CHEM, V247, P561; Gaspar LP, 1997, J MOL BIOL, V273, P456, DOI 10.1006/jmbi.1997.1299; Goldberg IJ, 2001, FRONT BIOSCI-LANDMRK, V6, pD388, DOI 10.2741/Goldberg; Hill JS, 1998, J BIOL CHEM, V273, P30979, DOI 10.1074/jbc.273.47.30979; IVERIUS PH, 1976, J BIOL CHEM, V251, P7791; Joniau M, 2001, PROTEINS, V44, P1, DOI 10.1002/prot.1065; KINNUNEN PKJ, 1977, P NATL ACAD SCI USA, V74, P4848, DOI 10.1073/pnas.74.11.4848; Kobayashi Y, 2002, EUR J BIOCHEM, V269, P4701, DOI 10.1046/j.1432-1033.2002.03179.x; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; Lichtarge O, 2002, CURR OPIN STRUC BIOL, V12, P21, DOI 10.1016/S0959-440X(02)00284-1; LOOKENE A, 1993, EUR J BIOCHEM, V213, P185, DOI 10.1111/j.1432-1033.1993.tb17747.x; Lookene A, 1997, BIOCHEMISTRY-US, V36, P5267, DOI 10.1021/bi962699k; Lookene A, 1996, BIOCHEMISTRY-US, V35, P12155, DOI 10.1021/bi960008e; LOOKENE A, 1994, EUR J BIOCHEM, V222, P395, DOI 10.1111/j.1432-1033.1994.tb18878.x; LYCKSELL PO, 1992, EUR J BIOCHEM, V205, P223, DOI 10.1111/j.1432-1033.1992.tb16772.x; McIlhargey TL, 2003, J BIOL CHEM, V278, P23027, DOI 10.1074/jbc.M300315200; MCLEAN LR, 1985, BIOCHEMISTRY-US, V24, P4196, DOI 10.1021/bi00336a057; Moore SA, 2001, J MOL BIOL, V312, P511, DOI 10.1006/jmbi.2001.4979; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; NYKJAER A, 1994, J BIOL CHEM, V269, P31747; Olivecrona G, 1997, METHOD ENZYMOL, V286, P102; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PETERSON J, 1990, P NATL ACAD SCI USA, V87, P909, DOI 10.1073/pnas.87.3.909; Preiss-Landl K, 2002, CURR OPIN LIPIDOL, V13, P471, DOI 10.1097/00041433-200210000-00002; Primm TP, 2001, J BIOL CHEM, V276, P281, DOI 10.1074/jbc.M007670200; RAPP D, 1978, EUR J BIOCHEM, V91, P379, DOI 10.1111/j.1432-1033.1978.tb12690.x; Razzaghi H, 2001, J MOL GRAPH MODEL, V19, P487, DOI 10.1016/S1093-3263(00)00096-6; Seale JW, 1998, METHOD ENZYMOL, V290, P318, DOI 10.1016/S0076-6879(98)90028-3; Shen Y, 2002, J BIOL CHEM, V277, P4334, DOI 10.1074/jbc.M105421200; SHI L, 1994, BIOCHEMISTRY-US, V33, P7536, DOI 10.1021/bi00190a006; SHINOMIYA M, 1983, BIOCHEM BIOPH RES CO, V113, P811, DOI 10.1016/0006-291X(83)91071-9; SHINOMIYA M, 1984, J BIOL CHEM, V259, P8724; SKOTTOVA N, 1995, J LIPID RES, V36, P1334; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; WHITE ZW, 1995, J BIOL CHEM, V270, P20404, DOI 10.1074/jbc.270.35.20404; Wong H, 2002, J LIPID RES, V43, P993, DOI 10.1194/jlr.R200007-JLR200; Wong H, 1997, P NATL ACAD SCI USA, V94, P5594, DOI 10.1073/pnas.94.11.5594; Zdunek J, 2003, BIOCHEMISTRY-US, V42, P1872, DOI 10.1021/bi0267184	53	10	10	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37183	37194		10.1074/jbc.M303894200	http://dx.doi.org/10.1074/jbc.M303894200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855707	hybrid			2022-12-27	WOS:000185437200026
J	Callebaut, I; Curcio-Morelli, C; Mornon, JP; Gereben, B; Buettner, C; Huang, S; Castro, B; Fonseca, TL; Harney, JW; Larsen, PR; Bianco, AC				Callebaut, I; Curcio-Morelli, C; Mornon, JP; Gereben, B; Buettner, C; Huang, S; Castro, B; Fonseca, TL; Harney, JW; Larsen, PR; Bianco, AC			The iodothyronine selenodeiodinases are thioredoxin-fold family proteins containing a glycoside hydrolase clan GH-A-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HYDROPHOBIC CLUSTER-ANALYSIS; ANGSTROM RESOLUTION; DEIODINASE; ENVIRONMENT; MEMBRANE; IDENTIFICATION; SUBSTITUTION; RECOGNITION; EXPRESSION; CATALYSIS	The three iodothyronine selenodeiodinases catalyze the initiation and termination of thyroid hormone effects in vertebrates. Structural analyses of these proteins have been hindered by their integral membrane nature and the inefficient eukaryotic-specific pathway for selenoprotein synthesis. Hydrophobic cluster analysis used in combination with Position-specific Iterated BLAST reveals that their extramembrane portion belongs to the thioredoxin-fold superfamily for which experimental structure information exists. Moreover, a large deiodinase region imbedded in the thioredoxin fold shares strong similarities with the active site of iduronidase, a member of the clan GH-A-fold of glycoside hydrolases. This model can explain a number of results from previous mutagenesis analyses and permits new verifiable insights into the structural and functional properties of these enzymes.	Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Univ Paris 06, CNRS, UMR 7590, Lab Mineral Cristallog Paris, F-75252 Paris 05, France; Univ Paris 07, CNRS, UMR 7590, Lab Mineral Cristallog Paris, F-75252 Paris 05, France; Hungarian Acad Sci, Inst Expt Med, Dept Endocrine & Behav Neurobiol, H-1083 Budapest, Hungary; Harvard Univ, Sch Med, Boston, MA 02115 USA; Sanofi Synthelabo, F-94255 Gentilly, France	Harvard University; Brigham & Women's Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite; Eotvos Lorand Research Network; Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Harvard University; Harvard Medical School; Sanofi-Aventis; Sanofi France	Bianco, AC (corresponding author), Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, 77 Ave Louis Pasteur,HIM Bldg 643, Boston, MA 02115 USA.	abianco@partners.org	Bianco, Antonio/AAK-6336-2020; Bianco, Antonio C/A-4965-2008; Buettner, Christoph/F-5793-2013	Bianco, Antonio/0000-0001-7737-6813; Bianco, Antonio C/0000-0001-7737-6813; Buettner, Christoph/0000-0003-0412-4062	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036256, R01DK058538] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK58538, DK 36256] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Baqui M, 2003, J BIOL CHEM, V278, P1206, DOI 10.1074/jbc.M210266200; Baqui MMA, 2000, ENDOCRINOLOGY, V141, P4309, DOI 10.1210/en.141.11.4309; BERRY MJ, 1991, J BIOL CHEM, V266, P14155; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BERRY MJ, 1992, J BIOL CHEM, V267, P18055; Bianco AC, 2002, ENDOCR REV, V23, P38, DOI 10.1210/er.23.1.38; Brooks DA, 2001, GLYCOBIOLOGY, V11, P741, DOI 10.1093/glycob/11.9.741; Buettner C, 2000, ENDOCRINOLOGY, V141, P4606, DOI 10.1210/en.141.12.4606; Callebaut I, 2002, NUCLEIC ACIDS RES, V30, P3592, DOI 10.1093/nar/gkf470; Callebaut I, 2000, ANN NY ACAD SCI, V923, P90; Callebaut I, 1997, CELL MOL LIFE SCI, V53, P621, DOI 10.1007/s000180050082; Capitani G, 2001, J MOL BIOL, V311, P1037, DOI 10.1006/jmbi.2001.4913; COUTINHO PM, 1999, CARBOHYDRATE ACTIVE; CROTEAU W, 1995, J BIOL CHEM, V270, P16569, DOI 10.1074/jbc.270.28.16569; Curcio-Morelli C, 2003, ENDOCRINOLOGY, V144, P937, DOI 10.1210/en.2002-220960; Davies GJ, 1998, BIOCHEMISTRY-US, V37, P1926, DOI 10.1021/bi972162m; Durand P, 1997, GLYCOBIOLOGY, V7, P277, DOI 10.1093/glycob/7.2.277; Edeling MA, 2002, STRUCTURE, V10, P973, DOI 10.1016/S0969-2126(02)00794-3; GABORIAUD C, 1987, FEBS LETT, V224, P149, DOI 10.1016/0014-5793(87)80439-8; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HENRISSAT B, 1995, P NATL ACAD SCI USA, V92, P7090, DOI 10.1073/pnas.92.15.7090; Huang SA, 2002, J CLIN ENDOCR METAB, V87, P4457, DOI 10.1210/jc.2002-020627; Kelley LA, 2000, J MOL BIOL, V299, P499, DOI 10.1006/jmbi.2000.3741; Kinch LN, 2002, CURR OPIN STRUC BIOL, V12, P400, DOI 10.1016/S0959-440X(02)00338-X; Kohrle J, 1984, Horm Metab Res Suppl, V14, P42; Kuiper GGJM, 2002, ENDOCRINOLOGY, V143, P1190, DOI 10.1210/en.143.4.1190; Leonard JL, 1986, THYROID HORMONE META, P189; Lo Conte L, 2002, NUCLEIC ACIDS RES, V30, P264; MARTIN JL, 1995, STRUCTURE, V3, P245, DOI 10.1016/S0969-2126(01)00154-X; Newman J, 1999, BIOCHEMISTRY-US, V38, P16105, DOI 10.1021/bi9913855; OTTEN MH, 1983, SCIENCE, V221, P81, DOI 10.1126/science.6857270; SALVATORE D, 1995, J CLIN INVEST, V96, P2421, DOI 10.1172/JCI118299; Salvatore D, 1996, ENDOCRINOLOGY, V137, P3308, DOI 10.1210/en.137.8.3308; Sanders JP, 1997, ENDOCRINOLOGY, V138, P5153, DOI 10.1210/en.138.12.5153; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; Sun BC, 1997, ENDOCRINOLOGY, V138, P5452, DOI 10.1210/en.138.12.5452; TOYODA N, 1995, J BIOL CHEM, V270, P12310, DOI 10.1074/jbc.270.20.12310; TOYODA N, 1994, J BIOL CHEM, V269, P20329; Trifonov EN, 2003, CURR OPIN STRUC BIOL, V13, P110, DOI 10.1016/S0959-440X(03)00005-8; Zhang JS, 2000, ANNU REV PHYSIOL, V62, P439, DOI 10.1146/annurev.physiol.62.1.439	42	106	108	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36887	36896		10.1074/jbc.M305725200	http://dx.doi.org/10.1074/jbc.M305725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847093	hybrid			2022-12-27	WOS:000185318300122
J	Gonzalez-Martinez, MT				Gonzalez-Martinez, MT			Induction of a sodium-dependent depolarization by external calcium removal in human sperm	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE SPERM; ACROSOME REACTION; HUMAN-SPERMATOZOA; EGG ZP3; PROGESTERONE; CHANNELS; HYPERPOLARIZATION; MOTILITY; CA2+; CAPACITATION	Removal of external calcium with EGTA (from 2.5 mM to nanomolar levels) caused a remarkable depolarization in human sperm. This depolarization was initially fast. It was followed by a slow phase that brought the V-m to values of over 0 mV in 1 - 2 min. The slow and sustained phase correlated with a sustained decrease in intracellular calcium. However, calcium removal still induced depolarization in sperm with enhanced intracellular calcium ( induced by progesterone), indicating that the sustained depolarization was not caused by a sustained intracellular calcium decrease. The depolarization was reduced as the external sodium content was substituted with choline, indicating that it was due to a sodium current, and was observed in lithium but not in tetramethylammonium-containing medium. In low sodium medium, the addition of sodium after calcium removal induced depolarization to the extent of which slightly increased in 2 min. The depolarization was completely inhibited by external magnesium (K-i = 1.16 mM). The addition of calcium or magnesium to calcium removal-induced depolarized sperm induced hyperpolarization that was inhibited by ouabain and was also prevented in medium without potassium, suggesting that the activity of the electrogenic Na+, K+-ATPase was involved. The conductance activated by calcium removal might unveil the presence of a calcium channel that in the absence of external calcium allows sodium permeation and that in normal conditions might contribute to the resting intracellular calcium concentration.	Univ Nacl Autonoma Mexico, Fac Med, Dept Farmacol, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Gonzalez-Martinez, MT (corresponding author), Univ Nacl Autonoma Mexico, Fac Med, Dept Farmacol, Ciudad Univ,Apartado Postal 70-297, Mexico City 04510, DF, Mexico.	tuliog@servidor.unam.mx						Arnoult C, 1999, P NATL ACAD SCI USA, V96, P6757, DOI 10.1073/pnas.96.12.6757; Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; BALDI E, 1991, J ANDROL, V12, P323; BLACKMORE PF, 1993, CELL CALCIUM, V14, P53, DOI 10.1016/0143-4160(93)90018-2; BLEIL JD, 1983, DEV BIOL, V95, P317, DOI 10.1016/0012-1606(83)90032-5; Brewis IA, 2000, J ANDROL, V21, P238; Carbone E, 1997, J PHYSIOL-LONDON, V504, P1, DOI 10.1111/j.1469-7793.1997.001bf.x; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; De Blas G, 2002, J BIOL CHEM, V277, P49326, DOI 10.1074/jbc.M208587200; EDES I, 1998, CELL PHYSL SOURCE BO, P225; ESPINOSA F, 1995, FEBS LETT, V372, P119, DOI 10.1016/0014-5793(95)00962-9; FORESTA C, 1993, BIOCHEM J, V294, P279, DOI 10.1042/bj2940279; Gonzalez-Martinez MT, 2002, ARCH BIOCHEM BIOPHYS, V408, P205, DOI 10.1016/S0003-9861(02)00587-8; Guzman-Grenfell AM, 2000, BBA-BIOMEMBRANES, V1464, P188, DOI 10.1016/S0005-2736(99)00247-3; HONG CY, 1983, BRIT J CLIN PHARMACO, V16, P487, DOI 10.1111/j.1365-2125.1983.tb02204.x; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LINARESHERNANDE.L, 1988, BIOCHIM BIOPHYS ACTA, V1372, P1; MAKLER A, 1992, ARCH ANDROLOGY, V29, P255, DOI 10.3109/01485019208987733; MENDOZA C, 1993, FEBS LETT, V330, P57, DOI 10.1016/0014-5793(93)80919-L; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; O'Toole CMB, 2000, MOL BIOL CELL, V11, P1571, DOI 10.1091/mbc.11.5.1571; Patrat C, 2000, BIOL REPROD, V62, P1380, DOI 10.1095/biolreprod62.5.1380; Quill TA, 2001, P NATL ACAD SCI USA, V98, P12527, DOI 10.1073/pnas.221454998; Ren DJ, 2001, NATURE, V413, P603, DOI 10.1038/35098027; ROBINSON JD, 1979, BIOCHIM BIOPHYS ACTA, V549, P145, DOI 10.1016/0304-4173(79)90013-2; SUAREZ SS, 1986, GAMETE RES, V14, P107, DOI 10.1002/mrd.1120140203; WAGGONER AS, 1979, ANNU REV BIOPHYS BIO, V8, P47, DOI 10.1146/annurev.bb.08.060179.000403; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; ZENG Y, 1995, DEV BIOL, V171, P554, DOI 10.1006/dbio.1995.1304	30	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36304	36310		10.1074/jbc.M304479200	http://dx.doi.org/10.1074/jbc.M304479200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860990	hybrid			2022-12-27	WOS:000185318300054
J	Lee, L; Sadowski, PD				Lee, L; Sadowski, PD			Identification of Cre residues involved in synapsis, isomerization, and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC RECOMBINATION; LOXP SITE; LAMBDA-INTEGRASE; HOLLIDAY STRUCTURES; DNA RECOMBINATION; CRYSTAL-STRUCTURE; MECHANISM; CLEAVAGE; PROTEIN; FAMILY	The Cre protein of bacteriophage P1 is a tyrosine recombinase and catalyzes recombination via formation of a covalent protein-DNA complex and a Holliday junction intermediate. Several co-crystal structures of Cre bound to its target lox site have provided novel insights into its biochemical activities. We have used these structures to guide the mutagenesis of several Cre residues that contact the lox spacer region and/or are involved in intersubunit protein-protein interactions. None of the mutant proteins had significant defects in DNA binding, DNA bending, or strand-specific initiation of recombination. We have identified novel functions of several amino acids that are involved in three aspects of the Cre reaction. 1) Single mutation of several NH2-terminal basic residues that contact the spacer region of loxP caused the accumulation of Holliday junction (HJ) intermediates but only a modest impairment of recombination. These residues may be involved in the isomerization of the Holliday intermediate. 2) We identified three new residues (Arg-118, Lys-122, and Glu-129) that are involved in synapsis. Cre R118A, K122A, and E129Q were catalytically competent. 3) Mutations E129R, Q133H, and K201A inactivated catalysis by the protein. The function of these Cre residues in recombination is discussed.	Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada	University of Toronto	Sadowski, PD (corresponding author), Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5S 1A8, Canada.	p.sadowski@utoronto.ca						ABREMSKI K, 1988, J MOL BIOL, V202, P59, DOI 10.1016/0022-2836(88)90518-9; ABREMSKI KE, 1992, PROTEIN ENG, V5, P87, DOI 10.1093/protein/5.1.87; Aihara H, 2003, MOL CELL, V12, P187, DOI 10.1016/S1097-2765(03)00268-5; ARGOS P, 1986, EMBO J, V5, P433, DOI 10.1002/j.1460-2075.1986.tb04229.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cao YH, 1999, J MOL BIOL, V289, P517, DOI 10.1006/jmbi.1999.2793; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; DIXON JE, 1994, J MOL BIOL, V243, P199, DOI 10.1006/jmbi.1994.1647; EHEN Y, 2003, IN PRESS J BIOL CHEM, V27; Ferreira H, 2001, J MOL BIOL, V312, P45, DOI 10.1006/jmbi.2001.4940; Gopaul Deshmukh N., 1999, Current Opinion in Structural Biology, V9, P14, DOI 10.1016/S0959-440X(99)80003-7; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; HOESS R, 1984, COLD SPRING HARB SYM, V49, P761, DOI 10.1101/SQB.1984.049.01.086; HOESS R, 1987, P NATL ACAD SCI USA, V84, P6840, DOI 10.1073/pnas.84.19.6840; HOESS RH, 1985, J MOL BIOL, V181, P351, DOI 10.1016/0022-2836(85)90224-4; HOESS RH, 1982, P NATL ACAD SCI-BIOL, V79, P3398, DOI 10.1073/pnas.79.11.3398; HOESS RH, 1990, STRUCTURE METHODS, V1, P203; Jayaram M., 2002, MOBILE DNA, P192; Kamadurai HB, 2003, PROTEIN SCI, V12, P620, DOI 10.1110/ps.0234303; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Kwon HJ, 1997, SCIENCE, V276, P126, DOI 10.1126/science.276.5309.126; LANDY A, 1993, CURR OPIN GENET DEV, V3, P699, DOI 10.1016/S0959-437X(05)80086-3; Lee G, 1998, GENE, V216, P55, DOI 10.1016/S0378-1119(98)00325-4; Lee L, 2003, J BIOL CHEM, V278, P23118, DOI 10.1074/jbc.M302272200; Lee L, 2003, J MOL BIOL, V326, P397, DOI 10.1016/S0022-2836(02)01429-8; Lee L, 2001, J BIOL CHEM, V276, P31092, DOI 10.1074/jbc.M103739200; MACK A, 1992, NUCLEIC ACIDS RES, V20, P4451, DOI 10.1093/nar/20.17.4451; Martin SS, 2002, J MOL BIOL, V319, P107, DOI 10.1016/S0022-2836(02)00246-2; MEYERLEON L, 1990, MOL CELL BIOL, V10, P235, DOI 10.1128/MCB.10.1.235; MIRZABEKOV AD, 1979, P NATL ACAD SCI USA, V76, P1118, DOI 10.1073/pnas.76.3.1118; Nash H, 1996, ESCHERICHIA COLI SAL, P2363; Nunes-Duby SE, 1998, NUCLEIC ACIDS RES, V26, P391, DOI 10.1093/nar/26.2.391; NUNESDUBY SE, 1995, CURR BIOL, V5, P139, DOI 10.1016/S0960-9822(95)00035-2; SADOWSKI PD, 1993, FASEB J, V7, P760, DOI 10.1096/fasebj.7.9.8392474; SAUER B, 1988, P NATL ACAD SCI USA, V85, P5166, DOI 10.1073/pnas.85.14.5166; Shaikh AC, 2000, J BIOL CHEM, V275, P30186, DOI 10.1074/jbc.M005256200; Shaikh AC, 2000, J MOL BIOL, V302, P27, DOI 10.1006/jmbi.2000.3967; Shaikh AC, 1997, J BIOL CHEM, V272, P5695, DOI 10.1074/jbc.272.9.5695; SHAIKH AC, 2000, THESIS U TORONTO; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; STRAUSS JK, 1994, SCIENCE, V266, P1829, DOI 10.1126/science.7997878; Strauss JK, 1996, P NATL ACAD SCI USA, V93, P9515, DOI 10.1073/pnas.93.18.9515; Subramaniam S, 2003, J MOL BIOL, V329, P423, DOI 10.1016/S0022-2836(03)00469-8; Subramanya HS, 1997, EMBO J, V16, P5178, DOI 10.1093/emboj/16.17.5178; Van Duyne GD, 2001, ANNU REV BIOPH BIOM, V30, P87, DOI 10.1146/annurev.biophys.30.1.87; WIERZBICKI A, 1987, J MOL BIOL, V195, P785, DOI 10.1016/0022-2836(87)90484-0; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; ZINKEL SS, 1987, NATURE, V328, P178, DOI 10.1038/328178a0	50	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36905	36915		10.1074/jbc.M305464200	http://dx.doi.org/10.1074/jbc.M305464200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851389	hybrid			2022-12-27	WOS:000185318300124
J	Turko, IV; Murad, F				Turko, IV; Murad, F			Quantitative protein profiling in heart mitochondria from diabetic rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DESORPTION/IONIZATION MASS-SPECTROMETRY; GEL-ELECTROPHORESIS; METABOLISM; PEPTIDES; SUBSTRATE	Quantitative protein profiling based on in vitro stable isotope labeling, two-dimensional polyacrylamide gel electrophoresis, and mass spectrometry is an accurate and reliable approach to measure simultaneously the relative abundance of many individual proteins within two different samples. In the present study, it was used to define a set of alterations caused by diabetes in heart mitochondria from streptozotocin-treated rats. We demonstrated that the expression of proteins from the myocardial tricarboxylic acid cycle was not altered in diabetes. However, up-regulation of the fatty acid beta-oxidation favored fatty acids over glucose as a source of acetyl CoA for the tricarboxylic acid cycle. Protein levels for several proteins involved in electron transport were modestly decreased. Whether this may depress overall ATP production remains to be established, since the protein level of ATP synthase seems to be unchanged. Other changes include down-regulation of protein levels for creatine kinase, voltage-dependent anion channel 1 (VDAC-1), HSP60, and Grp75. The mitochondria-associated level of albumin was decreased, while the level of catalase was substantially increased. All of the changes were evident as early as 1 week after streptozotocin administration. Taken together, these data point to a rapid and highly coordinated regulation of mitochondrial protein expression that occurs during the heart adaptation to diabetes.	Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, Houston, TX 77030 USA; Univ Texas, Sch Med, Inst Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas System	Murad, F (corresponding author), Univ Texas, Sch Med, Dept Integrat Biol & Pharmacol, 6431 Fannin, Houston, TX 77030 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL064221] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061731] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL64221] Funding Source: Medline; NIGMS NIH HHS [GM61731] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Cagney G, 2002, NAT BIOTECHNOL, V20, P163, DOI 10.1038/nbt0202-163; CHEN V, 1984, DIABETES, V33, P1078, DOI 10.2337/diabetes.33.11.1078; Depre C, 2000, J MOL CELL CARDIOL, V32, P985, DOI 10.1006/jmcc.2000.1139; Gehanne S, 2002, RAPID COMMUN MASS SP, V16, P1692, DOI 10.1002/rcm.773; Goodlett David R, 2002, Funct Integr Genomics, V2, P138; Goodlett DR, 2001, RAPID COMMUN MASS SP, V15, P1214, DOI 10.1002/rcm.362; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; HOVIUS R, 1990, BIOCHIM BIOPHYS ACTA, V1021, P217, DOI 10.1016/0005-2736(90)90036-N; Mirgorodskaya OA, 2000, RAPID COMMUN MASS SP, V14, P1226, DOI 10.1002/1097-0231(20000730)14:14<1226::AID-RCM14>3.0.CO;2-V; MOKHTAR N, 1993, DIABETES, V42, P682, DOI 10.2337/diabetes.42.5.682; Munchbach M, 2000, ANAL CHEM, V72, P4047, DOI 10.1021/ac000265w; Pierce G N, 1985, Can J Cardiol, V1, P48; Sechi S, 2002, RAPID COMMUN MASS SP, V16, P1416, DOI 10.1002/rcm.734; Smolka M, 2002, MOL CELL PROTEOMICS, V1, P19, DOI 10.1074/mcp.M100013-MCP200; Snoeckx LHEH, 2001, PHYSIOL REV, V81, P1461, DOI 10.1152/physrev.2001.81.4.1461; Stanley WC, 1997, CARDIOVASC RES, V34, P25, DOI 10.1016/S0008-6363(97)00047-3; TANAKA Y, 1992, CARDIOVASC RES, V26, P409, DOI 10.1093/cvr/26.4.409; Taylor SW, 2003, NAT BIOTECHNOL, V21, P281, DOI 10.1038/nbt793; Tomita M, 1996, JPN CIRC J, V60, P673, DOI 10.1253/jcj.60.673; Yao XD, 2001, ANAL CHEM, V73, P2836, DOI 10.1021/ac001404c; Yechoor VK, 2002, P NATL ACAD SCI USA, V99, P10587, DOI 10.1073/pnas.142301999; Young ME, 2002, CIRCULATION, V105, P1861, DOI 10.1161/01.CIR.0000012467.61045.87	22	104	106	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35844	35849		10.1074/jbc.M303139200	http://dx.doi.org/10.1074/jbc.M303139200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851409	hybrid			2022-12-27	WOS:000185164400134
J	Ben-Ya'acov, A; Ravid, S				Ben-Ya'acov, A; Ravid, S			Epidermal growth factor-mediated transient phosphorylation and membrane localization of myosin II-B are required for efficient chemotaxis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAVY-CHAIN ISOFORMS; PROTEIN-KINASE-C; MESSENGER-RNAS; CELLS; CYTOKINESIS; EXPRESSION; MOTILITY; DOMAINS; BINDING; NEURONS	Epidermal growth factor (EGF) stimulation of prostate metastatic tumor cells results in transient phosphorylation and cellular localization of non-muscle myosin heavy chain II-B (NMHC II-B) with kinetics similar to those seen in chemotaxis. We demonstrate that expression of 18- and 72-kDa fragments derived from the NMHC II-B C terminus that contain EGF-dependent NMHC II-B phosphorylation sites serve as dominant-negative mutations for EGF-dependent NMHC II-B phosphorylation and localization. Both fragments inhibited the EGF-dependent phosphorylation by competing with NMHC II-B on the myosin heavy chain kinase. However, only expression of the 72-kDa fragment resulted in cells with abnormalities in cell shape, focal adhesions, and chemotaxis. We found that the 72-kDa (but not 18-kDa) fragment is capable of self-assembly. To our knowledge, these results provide the first strong evidence that EGF-dependent NMHC II-B phosphorylation is required for the cellular localization of NMHC II-B and that NMHC II-B is required for normal cell attachment and for chemotactic response.	Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Sci, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Ravid, S (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Inst Med Sci, Dept Biochem, IL-91120 Jerusalem, Israel.	ravid@md2.huji.ac.il						AbuElneel K, 1996, J BIOL CHEM, V271, P977, DOI 10.1074/jbc.271.2.977; CHENG TPO, 1992, FEBS LETT, V311, P91, DOI 10.1016/0014-5793(92)81374-U; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; GANGULY C, 1992, J BIOL CHEM, V267, P20905; Geiger B, 2001, NAT REV MOL CELL BIO, V2, P793, DOI 10.1038/35099066; Helfman DM, 1999, MOL BIOL CELL, V10, P3097, DOI 10.1091/mbc.10.10.3097; IIZUMI T, 1987, J UROLOGY, V137, P1304, DOI 10.1016/S0022-5347(17)44488-0; KATSURAGAWA Y, 1989, EUR J BIOCHEM, V184, P611, DOI 10.1111/j.1432-1033.1989.tb15057.x; KAWAMOTO S, 1991, J CELL BIOL, V112, P915, DOI 10.1083/jcb.112.5.915; Kelley CA, 1996, J CELL BIOL, V134, P675, DOI 10.1083/jcb.134.3.675; KELLEY CA, 1991, J CELL SCI, P49; KUZNICKI J, 1983, J BIOL CHEM, V258, P6011; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lauffenburger DA, 1996, CELL, V84, P359, DOI 10.1016/S0092-8674(00)81280-5; LEE RJ, 1994, J CELL SCI, V107, P2875; Liang WC, 1999, J CELL BIOL, V147, P1039, DOI 10.1083/jcb.147.5.1039; MAUPIN P, 1994, J CELL SCI, V107, P3077; Milewski MI, 2002, J BIOL CHEM, V277, P34462, DOI 10.1074/jbc.M205420200; MILLER M, 1992, NEURON, V8, P25, DOI 10.1016/0896-6273(92)90106-N; Mitchison TJ, 1996, CELL, V84, P371, DOI 10.1016/S0092-8674(00)81281-7; MOUSSAVI RS, 1993, MOL CELL BIOCHEM, V128, P219, DOI 10.1007/BF01076773; Murakami N, 1998, BIOCHEMISTRY-US, V37, P1989, DOI 10.1021/bi971959a; Murakami N, 1995, BIOCHEMISTRY-US, V34, P16046, DOI 10.1021/bi00049a019; Murakami N, 2000, BIOCHEMISTRY-US, V39, P11441, DOI 10.1021/bi000347e; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Robinson DN, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-4; ROCHLIN MW, 1995, J CELL SCI, V108, P3661; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; Straussman R, 2001, J CELL SCI, V114, P3047; Wei QZ, 2000, MOL BIOL CELL, V11, P3617, DOI 10.1091/mbc.11.10.3617	30	22	22	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40032	40040		10.1074/jbc.M306948200	http://dx.doi.org/10.1074/jbc.M306948200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874274	hybrid			2022-12-27	WOS:000185713800093
J	Hingorani-Varma, K; Bitinaite, J				Hingorani-Varma, K; Bitinaite, J			Kinetic analysis of the coordinated interaction of SgrAI restriction endonuclease with different DNA targets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							2 RECOGNITION SITES; ECORII ENDONUCLEASE; BINDING SITES; CLEAVAGE; ENZYME; SPECIFICITY; MECHANISM; ACCURACY	SgrAI restriction endonuclease cooperatively interacts and cleaves two target sites that include both the canonical sites, CPuCCGGPyG, and the secondary sites, CPuCCGGPy(A/T/C). It has been observed that the cleaved canonical sites stimulate SgrAI cleavage at the secondary sites. Equilibrium binding studies show that SgrAI binds to its canonical sites with a high affinity (K-a = 4 - 8 x 10(10) M-1) and that it has a 15-fold lower affinity for the cleaved canonical sites and a 30-fold lower affinity for the secondary sites. Steady-state kinetics reveals substrate cooperativity for SgrAI cleavage on both canonical and secondary sites. The specificity of SgrAI for the secondary site CACCGGCT, as measured by k(cat)/K is about 500-fold lower than that for the canonical site CACCGGCG, but this difference is reduced to 10-fold in the presence of the cleaved canonical sites. The efficiency of canonical site cleavage also increases by 3-fold when the cleaved canonical sites are present in the reaction. Furthermore, the substrate cooperativity for SgrAI cleavage is abolished for both types of sites in the presence of cleaved canonical sites. These results indicate that target site cleavage occurs via a coordinated interaction of two SgrAI protein subunits, where the subunit bound to the cleaved site stimulates the cleavage of the uncut site bound by the other subunit. The free subunits of SgrAI have the flexibility to bind different target sites and, consequently, assemble into various catalytically active complexes, which differ in their catalytic efficiencies.	New England Biolabs Inc, Beverly, MA 01915 USA		Bitinaite, J (corresponding author), New England Biolabs Inc, 32 Tozer Rd, Beverly, MA 01915 USA.	bitinait@neb.com		Bitinaite, Jurate/0000-0002-9190-6355				ALVES J, 1995, BIOCHEMISTRY-US, V34, P11191, DOI 10.1021/bi00035a026; Bath AJ, 2002, J BIOL CHEM, V277, P4024, DOI 10.1074/jbc.M108441200; BICKLE TA, 1993, MICROBIOL REV, V57, P434, DOI 10.1128/MMBR.57.2.434-450.1993; Bilcock DT, 1999, J BIOL CHEM, V274, P36379, DOI 10.1074/jbc.274.51.36379; Bitinaite J, 2002, P NATL ACAD SCI USA, V99, P1164, DOI 10.1073/pnas.022346799; Bitinaite J, 1998, P NATL ACAD SCI USA, V95, P10570, DOI 10.1073/pnas.95.18.10570; CANTOR CR, 1980, BIOPHYSICAL CHEM 3, P849; Colandene JD, 1998, P NATL ACAD SCI USA, V95, P3531, DOI 10.1073/pnas.95.7.3531; Conlan LH, 2002, BIOCHEMISTRY-US, V41, P14848, DOI 10.1021/bi026403o; CONRAD M, 1989, P NATL ACAD SCI USA, V86, P9707, DOI 10.1073/pnas.86.24.9707; Daniels LE, 2003, J MOL BIOL, V327, P579, DOI 10.1016/S0022-2836(03)00143-8; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Embleton ML, 1999, J MOL BIOL, V289, P785, DOI 10.1006/jmbi.1999.2822; Engler LE, 1997, J MOL BIOL, V269, P82, DOI 10.1006/jmbi.1997.1027; Engler LE, 2001, J MOL BIOL, V307, P619, DOI 10.1006/jmbi.2000.4428; FERSHT AR, 1985, ENZYME STRUCTURE MEC, P208; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GABBARA S, 1992, J BIOL CHEM, V267, P18623; Halford SE, 2001, BIOCHEM SOC T, V29, P363, DOI 10.1042/BST0290363; Halford SE, 1999, BIOCHEM SOC T, V27, P696, DOI 10.1042/bst0270696; Huai Q, 2001, NAT STRUCT BIOL, V8, P665, DOI 10.1038/90366; ITAKURA K, 1984, ANNU REV BIOCHEM, V53, P323; KACZOROWSKI T, 1989, GENE, V80, P209, DOI 10.1016/0378-1119(89)90285-0; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; Mucke M, 2002, EMBO J, V21, P5262, DOI 10.1093/emboj/cdf514; Nastri HG, 1997, J BIOL CHEM, V272, P25761, DOI 10.1074/jbc.272.41.25761; Nobbs TJ, 1998, J MOL BIOL, V281, P419, DOI 10.1006/jmbi.1998.1966; PEIN CD, 1991, NUCLEIC ACIDS RES, V19, P5139, DOI 10.1093/nar/19.19.5139; PETRAUSKENE OV, 1992, EUR J BIOCHEM, V208, P617, DOI 10.1111/j.1432-1033.1992.tb17226.x; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud V, 2002, J BIOL CHEM, V277, P14306, DOI 10.1074/jbc.M111625200; Roberts RJ, 2003, NUCLEIC ACIDS RES, V31, P1805, DOI 10.1093/nar/gkg274; Roberts RJ, 2001, NUCLEIC ACIDS RES, V29, P268, DOI 10.1093/nar/29.1.268; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; TAUTZ N, 1990, NUCLEIC ACIDS RES, V18, P3087, DOI 10.1093/nar/18.10.3087; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; THIELKING V, 1990, BIOCHEMISTRY-US, V29, P4682, DOI 10.1021/bi00471a024; Vanamee ES, 2001, J MOL BIOL, V309, P69, DOI 10.1006/jmbi.2001.4635; VIPOND IB, 1995, BIOCHEMISTRY-US, V34, P1113, DOI 10.1021/bi00004a002; Wah DA, 1997, NATURE, V388, P97, DOI 10.1038/40446; Whitaker RD, 1999, J MOL BIOL, V285, P1525, DOI 10.1006/jmbi.1998.2409; YANG CC, 1992, BIOCHEMISTRY-US, V31, P9657, DOI 10.1021/bi00155a019	44	17	17	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40392	40399		10.1074/jbc.M304603200	http://dx.doi.org/10.1074/jbc.M304603200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851384	hybrid			2022-12-27	WOS:000185713800133
J	Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH				Karbarz, MJ; Kalb, SR; Cotter, RJ; Raetz, CRH			Expression cloning and biochemical characterization of a Rhizobium leguminosarum lipid A 1-phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							MEMBRANE-BOUND PHOSPHATASES; CELL-SURFACE ANTIGEN; ACYL CARRIER PROTEIN; ESCHERICHIA-COLI; 3-DEOXY-D-MANNO-OCTULOSONIC ACID; LIPOPOLYSACCHARIDE CORE; SALMONELLA-TYPHIMURIUM; STRUCTURAL-CHARACTERIZATION; INNATE IMMUNITY; GENE	Lipid A of Rhizobium leguminosarum, a nitrogen-fixing plant endosymbiont, displays several significant structural differences when compared with Escherichia coli. An especially striking feature of R. leguminosarum lipid A is that it lacks both the 1- and 4'-phosphate groups. Distinct lipid A phosphatases that attack either the 1 or the 4' positions have previously been identified in extracts of R. leguminosarum and Rhizobium etli but not Sinorhizobium meliloti or E. coli. Here we describe the identification of a hybrid cosmid (pMJK-1) containing a 25-kb R. leguminosarum 3841 DNA insert that directs the overexpression of the lipid A 1- phosphatase. Transfer of pMJK-1 into S. meliloti 1021 results in heterologous expression of 1- phosphatase activity, which is normally absent in extracts of strain 1021, and confers resistance to polymyxin. Sequencing of a 7-kb DNA fragment derived from the insert of pMJK-1 revealed the presence of a lipid phosphatase ortholog (designated LpxE). Expression of lpxE in E. coli behind the T7lac promoter results in the appearance of robust 1- phosphatase activity, which is normally absent in E. coli membranes. Matrix-assisted laser-desorption/time of flight and radiochemical analysis of the product generated in vitro from the model substrate lipid IVA confirms the selective removal of the 1- phosphate group. These findings show that lpxE is the structural gene for the 1- phosphatase. The availability of lpxE may facilitate the re-engineering of lipid A structures in diverse Gram-negative bacteria and allow assessment of the role of the 1- phosphatase in R. leguminosarum symbiosis with plants. Possible orthologs of LpxE are present in some intracellular human pathogens, including Francisella tularensis, Brucella melitensis, and Legionella pneumophila.	Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol & Mol Sci, Baltimore, MD 21205 USA	Duke University; Johns Hopkins University	Raetz, CRH (corresponding author), Duke Univ, Med Ctr, Dept Biochem, POB 3711, Durham, NC 27710 USA.	raetz@biochem.duke.edu		Kalb, Suzanne/0000-0002-8067-136X	NIGMS NIH HHS [R37 GM051796-06, GM-08558, R37 GM051796] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM051796, T32GM008558] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Ausubel FM, 1988, MOL REPROD DEV; Babinski KJ, 2002, J BIOL CHEM, V277, P25937, DOI 10.1074/jbc.M204067200; Basu SS, 1999, J BIOL CHEM, V274, P11139, DOI 10.1074/jbc.274.16.11139; Basu SS, 2002, J BIOL CHEM, V277, P28959, DOI 10.1074/jbc.M204525200; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BELUNIS CJ, 1992, J BIOL CHEM, V267, P9988; BHAT UR, 1994, J BIOL CHEM, V269, P14402; Bishop RE, 2000, EMBO J, V19, P5071, DOI 10.1093/emboj/19.19.5071; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Boman HG, 1998, SCAND J IMMUNOL, V48, P15; Borregaard N, 2000, IMMUNOL TODAY, V21, P68, DOI 10.1016/S0167-5699(99)01570-4; Brabetz W, 1997, EUR J BIOCHEM, V247, P716, DOI 10.1111/j.1432-1033.1997.00716.x; Brade H., 1999, ENDOTOXIN HLTH DIS; Brozek KA, 1996, J BIOL CHEM, V271, P32112, DOI 10.1074/jbc.271.50.32119; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; BROZEK KA, 1989, J BIOL CHEM, V264, P6956; BROZEK KA, 1990, J BIOL CHEM, V265, P15410; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Caaveiro JMM, 1997, FEBS LETT, V410, P338, DOI 10.1016/S0014-5793(97)00613-3; Carman GM, 1997, BBA-LIPID LIPID MET, V1348, P45, DOI 10.1016/S0005-2760(97)00095-7; CAVA JR, 1989, J BACTERIOL, V171, P8, DOI 10.1128/jb.171.1.8-15.1989; Clementz T, 1996, J BIOL CHEM, V271, P12095, DOI 10.1074/jbc.271.20.12095; Clementz T, 1997, J BIOL CHEM, V272, P10353; DITTA G, 1980, P NATL ACAD SCI-BIOL, V77, P7347, DOI 10.1073/pnas.77.12.7347; Endre G, 2002, NATURE, V417, P962, DOI 10.1038/nature00842; FINAN TM, 1986, J BACTERIOL, V167, P66, DOI 10.1128/jb.167.1.66-72.1986; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; FRIEDMAN AM, 1982, GENE, V18, P289, DOI 10.1016/0378-1119(82)90167-6; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; Galibert F, 2001, SCIENCE, V293, P668, DOI 10.1126/science.1060966; GALLOWAY SM, 1990, J BIOL CHEM, V265, P6394; Galperin MY, 2001, FEMS MICROBIOL LETT, V203, P11, DOI 10.1111/j.1574-6968.2001.tb10814.x; Garrett TA, 1997, J BIOL CHEM, V272, P21855, DOI 10.1074/jbc.272.35.21855; GLAZEBROOK J, 1991, METHOD ENZYMOL, V204, P398; GOLENBOCK DT, 1991, J BIOL CHEM, V266, P19490; Goodner B, 2001, SCIENCE, V294, P2323, DOI 10.1126/science.1066803; Groisman EA, 2001, J BACTERIOL, V183, P1835, DOI 10.1128/JB.183.6.1835-1842.2001; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hoshino K, 1999, J IMMUNOL, V162, P3749; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; ICHO T, 1988, J BACTERIOL, V170, P5117, DOI 10.1128/jb.170.11.5117-5124.1988; JOHNSTON AWB, 1975, J GEN MICROBIOL, V87, P343, DOI 10.1099/00221287-87-2-343; Kadrmas JL, 1998, J BIOL CHEM, V273, P26432, DOI 10.1074/jbc.273.41.26432; Kadrmas JL, 1996, J BIOL CHEM, V271, P32119, DOI 10.1074/jbc.271.50.32112; Kaneko T, 2000, DNA RES, V7, P331, DOI 10.1093/dnares/7.6.331; Kanipes MI, 2003, J BIOL CHEM, V278, P16356, DOI 10.1074/jbc.M301255200; Kanipes MI, 2003, J BIOL CHEM, V278, P16365, DOI 10.1074/jbc.M301256200; Kanipes MI, 2001, J BIOL CHEM, V276, P1156, DOI 10.1074/jbc.M009019200; KANNENBERG EL, 1992, MOL MICROBIOL, V6, P2477, DOI 10.1111/j.1365-2958.1992.tb01424.x; KANNENBERG EL, 1994, J BACTERIOL, V176, P2021, DOI 10.1128/jb.176.7.2021-2032.1994; KANNENBERG EL, 1989, J BACTERIOL, V171, P4543, DOI 10.1128/jb.171.9.4543-4548.1989; Kannenberg Elmar L., 1994, Trends in Microbiology, V2, P277, DOI 10.1016/0966-842X(94)90004-3; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lien E, 2000, J CLIN INVEST, V105, P497, DOI 10.1172/JCI8541; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; LOPPNOW H, 1989, J IMMUNOL, V142, P3229; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Moran AP, 1997, J BACTERIOL, V179, P6453, DOI 10.1128/jb.179.20.6453-6463.1997; NIKAIDO H, 1985, MICROBIOL REV, V49, P1; Nikaido H., 1996, ESCHERICHIA COLI SAL, P29; NISHIJIMA M, 1981, J BACTERIOL, V145, P113, DOI 10.1128/JB.145.1.113-121.1981; NISHIJIMA M, 1979, J BIOL CHEM, V254, P7837; NOEL KD, 1984, J BACTERIOL, V158, P148, DOI 10.1128/JB.158.1.148-155.1984; OGAWA T, 1993, FEBS LETT, V332, P197, DOI 10.1016/0014-5793(93)80512-S; Ohl ME, 2001, ANNU REV MED, V52, P259, DOI 10.1146/annurev.med.52.1.259; Onishi HR, 1996, SCIENCE, V274, P980, DOI 10.1126/science.274.5289.980; PARK JT, 1987, ESCHERICHIA COLI SAL, V1, P663; Parrillo J E, 1993, N Engl J Med, V328, P1471; Persing DH, 2002, TRENDS MICROBIOL, V10, pS32, DOI 10.1016/S0966-842X(02)02426-5; Plotz BM, 2000, J BIOL CHEM, V275, P11222, DOI 10.1074/jbc.275.15.11222; Poltorak A, 2000, P NATL ACAD SCI USA, V97, P2163, DOI 10.1073/pnas.040565397; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; PRICE NPJ, 1995, P NATL ACAD SCI USA, V92, P7352, DOI 10.1073/pnas.92.16.7352; PRICE NPJ, 1994, J BACTERIOL, V176, P4646, DOI 10.1128/JB.176.15.4646-4655.1994; Que NLS, 2000, J BIOL CHEM, V275, P28006; Que NLS, 2000, J BIOL CHEM, V275, P28017; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12120, DOI 10.1074/jbc.M300379200; Que-Gewirth NLS, 2003, J BIOL CHEM, V278, P12109, DOI 10.1074/jbc.M300378200; QURESHI N, 1988, J BIOL CHEM, V263, P11971; QURESHI N, 1982, J BIOL CHEM, V257, P1808; RADIKA K, 1988, J BIOL CHEM, V263, P14859; RAETZ CRH, 1990, ANNU REV BIOCHEM, V59, P129, DOI 10.1146/annurev.biochem.59.1.129; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; RAETZ CRH, 1985, J BIOL CHEM, V260, P6080; RAETZ CRH, 1973, J BIOL CHEM, V248, P1098; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; RIETSCHEL ET, 1994, FASEB J, V8, P217, DOI 10.1096/fasebj.8.2.8119492; ROANTREE RJ, 1967, ANNU REV MICROBIOL, V21, P443, DOI 10.1146/annurev.mi.21.100167.002303; RONSON CW, 1984, J BACTERIOL, V160, P903, DOI 10.1128/JB.160.3.903-909.1984; Shimazu R, 1999, J EXP MED, V189, P1777, DOI 10.1084/jem.189.11.1777; SINDHU SS, 1990, J BACTERIOL, V172, P1804, DOI 10.1128/jb.172.4.1804-1813.1990; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Spaink HP, 2002, NATURE, V417, P910, DOI 10.1038/417910a; Stracke S, 2002, NATURE, V417, P959, DOI 10.1038/nature00841; Stukey J, 1997, PROTEIN SCI, V6, P469; TAKAYAMA K, 1983, J BIOL CHEM, V258, P7379; Takeda K, 2003, CELL MICROBIOL, V5, P143, DOI 10.1046/j.1462-5822.2003.00264.x; Urbanik-Sypniewska T, 2000, IMMUNOBIOLOGY, V202, P408, DOI 10.1016/S0171-2985(00)80043-1; VAARA M, 1993, ANTIMICROB AGENTS CH, V37, P2255, DOI 10.1128/AAC.37.11.2255; VANDENBOSCH KA, 1989, J BACTERIOL, V171, P4537, DOI 10.1128/jb.171.9.4537-4542.1989; Vandenplas ML, 2002, J BIOL CHEM, V277, P41811, DOI 10.1074/jbc.M205252200; Vinogradov E, 2002, EUR J BIOCHEM, V269, P6112, DOI 10.1046/j.1432-1033.2002.03321.x; Von Jagow G, 1994, PRACTICAL GUIDE MEMB; Wheeler DL, 2003, NUCLEIC ACIDS RES, V31, P28, DOI 10.1093/nar/gkg033; Wood DW, 2001, SCIENCE, V294, P2317, DOI 10.1126/science.1066804; WOOD WB, 1966, J MOL BIOL, V16, P118, DOI 10.1016/S0022-2836(66)80267-X; Zahringer U, 1999, ENDOTOXIN IN HEALTH AND DISEASE, P93; Zhou ZM, 2001, J BIOL CHEM, V276, P43111, DOI 10.1074/jbc.M106960200; Zhou ZM, 1999, J BIOL CHEM, V274, P18503, DOI 10.1074/jbc.274.26.18503	115	53	55	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39269	39279		10.1074/jbc.M305830200	http://dx.doi.org/10.1074/jbc.M305830200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869541	Green Accepted, hybrid			2022-12-27	WOS:000185713800003
J	Friedman, YE; O'Brian, MR				Friedman, YE; O'Brian, MR			A novel DNA-binding site for the ferric uptake regulator (Fur) protein from Bradyrhizobium japonicum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON RESPONSE REGULATOR; PSEUDOMONAS-AERUGINOSA; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; IDENTIFICATION; REGULON; HEME; GENE; IRR; METABOLISM	The Fur protein is a global regulator of iron metabolism and other processes in many bacterial species. A key feature of the model of Fur function is the recognition of a DNA element within target promoters with similarity to a 19-bp AT-rich palindromic sequence called a Fur box. The irr gene from Bradyrhizobium japonicum is under the control of Fur. Here, we provide evidence that B. japonicum Fur (BjFur) binds to the irr gene promoter with high affinity despite the absence of DNA sequence similarity to the Fur box consensus. Both Escherichia coli Fur and BjFur bound a synthetic Fur box consensus DNA element in electrophoretic gel mobility shift assays, but only BjFur bound the irr promoter. BjFur maximally protected a 30-bp region in DNase I footprinting analysis that includes three imperfect direct repeat hexamers. BjFur formed a high mobility complex and a low mobility complex with DNA in electrophoretic gel mobility shift assays corresponding to occupancy by a single dimer and two dimers or a tetramer, respectively. A mutation in the downstream direct repeat DNA sequence allowed high mobility complex formation only. In vitro transcription from the wild type irr promoter or from a mutated promoter that allowed only dimer occupancy was repressed by Fur, indicating that the dimer can be a functional repressor unit. Our findings identify a novel DNA-binding element for Fur and suggest that the Fur box consensus may not completely represent the target sequences for bacterial Fur proteins as a whole. In addition, Fur binding to a target promoter is sufficient to repress transcription in vitro.	SUNY Buffalo, Dept Biochem, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	O'Brian, MR (corresponding author), SUNY Buffalo, Dept Biochem, 140 Farber Hall, Buffalo, NY 14214 USA.	mrobrian@buffalo.edu						Althaus EW, 1999, BIOCHEMISTRY-US, V38, P6559, DOI 10.1021/bi982788s; Baichoo N, 2002, J BACTERIOL, V184, P5826, DOI 10.1128/JB.184.21.5826-5832.2002; Baichoo N, 2002, MOL MICROBIOL, V45, P1613, DOI 10.1046/j.1365-2958.2002.03113.x; Bsat N, 1998, MOL MICROBIOL, V29, P189, DOI 10.1046/j.1365-2958.1998.00921.x; COY M, 1991, BIOCHEMISTRY-US, V30, P8201, DOI 10.1021/bi00247a016; DELORENZO V, 1988, J MOL BIOL, V203, P875, DOI 10.1016/0022-2836(88)90113-1; Escolar L, 1998, J MOL BIOL, V283, P537, DOI 10.1006/jmbi.1998.2119; Escolar L, 1999, J BACTERIOL, V181, P6223, DOI 10.1128/JB.181.20.6223-6229.1999; Gaballa A, 1998, J BACTERIOL, V180, P5815, DOI 10.1128/JB.180.22.5815-5821.1998; Hall HK, 1996, J BACTERIOL, V178, P5683, DOI 10.1128/jb.178.19.5683-5691.1996; Hamza I, 1999, J BACTERIOL, V181, P5843, DOI 10.1128/JB.181.18.5843-5846.1999; Hamza I, 1998, J BIOL CHEM, V273, P21669, DOI 10.1074/jbc.273.34.21669; Hamza I, 2000, MICROBIOL-SGM, V146, P669, DOI 10.1099/00221287-146-3-669; Jacquamet L, 1998, BIOCHEMISTRY-US, V37, P2564, DOI 10.1021/bi9721344; LITWIN CM, 1993, CLIN MICROBIOL REV, V6, P137, DOI 10.1128/CMR.6.2.137-149.1993; Maxam A M, 1980, Methods Enzymol, V65, P499; MichaudSoret I, 1997, FEBS LETT, V413, P473, DOI 10.1016/S0014-5793(97)00963-0; OCHSNER UA, 1995, J BACTERIOL, V177, P7194, DOI 10.1128/jb.177.24.7194-7201.1995; Ochsner UA, 1996, P NATL ACAD SCI USA, V93, P4409, DOI 10.1073/pnas.93.9.4409; ORCHARD K, 1993, NUCLEIC ACIDS RES, V21, P3335, DOI 10.1093/nar/21.14.3335; Patzer SI, 1998, MOL MICROBIOL, V28, P1199, DOI 10.1046/j.1365-2958.1998.00883.x; PEARSON WR, 1990, METHOD ENZYMOL, V183, P63; Pohl E, 2003, MOL MICROBIOL, V47, P903, DOI 10.1046/j.1365-2958.2003.03337.x; Qi ZH, 1999, P NATL ACAD SCI USA, V96, P13056, DOI 10.1073/pnas.96.23.13056; Qi ZH, 2002, MOL CELL, V9, P155, DOI 10.1016/S1097-2765(01)00431-2; STOJILJKOVIC I, 1994, J MOL BIOL, V236, P531, DOI 10.1006/jmbi.1994.1163; Thompson DK, 2002, APPL ENVIRON MICROB, V68, P881, DOI 10.1128/AEM.68.2.881-892.2002; TSOLIS RM, 1995, J BACTERIOL, V177, P4628, DOI 10.1128/jb.177.16.4628-4637.1995; VONHIPPEL PH, 1986, P NATL ACAD SCI USA, V83, P1608; Wexler M, 2003, MICROBIOL-SGM, V149, P1357, DOI 10.1099/mic.0.26130-0	30	41	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38395	38401		10.1074/jbc.M306710200	http://dx.doi.org/10.1074/jbc.M306710200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12881516	hybrid			2022-12-27	WOS:000185575100039
J	Kulinski, T; Olejniczak, M; Huthoff, H; Bielecki, L; Pachulska-Wieczorek, K; Das, AT; Berkhout, B; Adamiak, RW				Kulinski, T; Olejniczak, M; Huthoff, H; Bielecki, L; Pachulska-Wieczorek, K; Das, AT; Berkhout, B; Adamiak, RW			The apical loop of the HIV-1 TAR RNA hairpin is stabilized by a cross-loop base pair	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; LONG TERMINAL REPEAT; TRANSACTIVATING REGION RNA; TRANS-ACTIVATION; BINDING-PROTEIN; CRYSTAL-STRUCTURE; CYCLIN T1; IN-VITRO; MOLECULAR-DYNAMICS; NMR-SPECTROSCOPY	The TAR hairpin of the HIV-1 RNA genome is indispensable for trans-activation of the viral promoter and virus replication. The TAR structure has been studied extensively, but most attention has been directed at the three-nucleotide bulge that constitutes the binding site of the viral Tat protein. In contrast, the conformational properties of the apical loop have remained elusive. We performed biochemical studies and molecular dynamics simulations, which indicate that the TAR loop is structured and stabilized by a cross-loop base pair between residues C-30 and G(34). Mutational disruption of the cross-loop base pair results in reduced Tat response of the LTR promoter, which can be rescued by compensatory mutations that restore the base pair. Thus, Tat-mediated transcriptional activation depends on the structure of the TAR apical loop. The C-30-G(34) cross-loop base pair classes TAR in a growing family of hairpins with a structured loop that was recently identified in ribosomal RNA, tRNA, and several viral and cellular mRNAs.	Polish Acad Sci, Inst Bioorgan Chem, PL-61704 Poznan, Poland; Univ Amsterdam, Acad Med Ctr, Dept Human Retrovirol, NL-1105 AZ Amsterdam, Netherlands	Polish Academy of Sciences; Institute of Bioorganic Chemistry of the Polish Academy of Sciences; University of Amsterdam; Academic Medical Center Amsterdam	Adamiak, RW (corresponding author), Polish Acad Sci, Inst Bioorgan Chem, Noskowskiego 12-14, PL-61704 Poznan, Poland.		Adamiak, Ryszard W/W-5089-2018; Pachulska-Wieczorek, Katarzyna/X-1533-2018	Adamiak, Ryszard W/0000-0001-8914-9618; Pachulska-Wieczorek, Katarzyna/0000-0002-5723-6204; Olejniczak, Mikolaj/0000-0001-5949-3944				AboulEla F, 1996, NUCLEIC ACIDS RES, V24, P3974, DOI 10.1093/nar/24.20.3974; ABOULELA F, 1995, J MOL BIOL, V253, P313, DOI 10.1006/jmbi.1995.0555; BAUDIN F, 1993, J MOL BIOL, V229, P382, DOI 10.1006/jmbi.1993.1041; BERKHOUT B, 1989, CELL, V59, P273, DOI 10.1016/0092-8674(89)90289-4; BERKHOUT B, 1992, J VIROL, V66, P139, DOI 10.1128/JVI.66.1.139-149.1992; BERKHOUT B, 1989, J VIROL, V63, P5501, DOI 10.1128/JVI.63.12.5501-5504.1989; Bieniasz PD, 1999, P NATL ACAD SCI USA, V96, P7791, DOI 10.1073/pnas.96.14.7791; Chepenik LG, 1998, GENE, V210, P37, DOI 10.1016/S0378-1119(98)00033-X; CIEPLAK P, 1995, J COMPUT CHEM, V16, P1357, DOI 10.1002/jcc.540161106; CIESIOLKA J, 1989, EUR J BIOCHEM, V182, P445, DOI 10.1111/j.1432-1033.1989.tb14851.x; COLVIN RA, 1992, J VIROL, V66, P930, DOI 10.1128/JVI.66.2.930-935.1992; CRITCHLEY AD, 1993, J MOL GRAPHICS, V11, P92, DOI 10.1016/0263-7855(93)87002-M; Das AT, 1999, J VIROL, V73, P81, DOI 10.1128/JVI.73.1.81-91.1999; DINGWALL C, 1990, EMBO J, V9, P4145, DOI 10.1002/j.1460-2075.1990.tb07637.x; Dorin D, 2003, J BIOL CHEM, V278, P4440, DOI 10.1074/jbc.M208954200; Faber C, 2000, J BIOL CHEM, V275, P20660, DOI 10.1074/jbc.M000920200; FENG S, 1988, NATURE, V334, P165, DOI 10.1038/334165a0; Flodell S, 2002, NUCLEIC ACIDS RES, V30, P4803, DOI 10.1093/nar/gkf603; Foloppe N, 2000, J COMPUT CHEM, V21, P86, DOI 10.1002/(SICI)1096-987X(20000130)21:2<86::AID-JCC2>3.0.CO;2-G; FRANKEL AD, 1989, P NATL ACAD SCI USA, V86, P7397, DOI 10.1073/pnas.86.19.7397; FRISCH MJ, 1996, GAUSSIAN 94; GATIGNOL A, 1991, SCIENCE, V251, P1597, DOI 10.1126/science.2011739; Gdaniec Z, 1998, BIOCHEMISTRY-US, V37, P1505, DOI 10.1021/bi9719814; Haasnoot PCJ, 2000, RNA, V6, P708, DOI 10.1017/S1355838200992471; Hamy F, 1997, P NATL ACAD SCI USA, V94, P3548, DOI 10.1073/pnas.94.8.3548; HAN XM, 1992, J VIROL, V66, P4065, DOI 10.1128/JVI.66.7.4065-4072.1992; HARPER JW, 1991, BIOCHEMISTRY-US, V30, P8060, DOI 10.1021/bi00246a026; HARRICH D, 1989, J VIROL, V63, P2585, DOI 10.1128/JVI.63.6.2585-2591.1989; Huthoff H, 2001, RNA, V7, P143, DOI 10.1017/S1355838201001881; Ippolito JA, 1998, P NATL ACAD SCI USA, V95, P9819, DOI 10.1073/pnas.95.17.9819; JAEGER JA, 1993, BIOCHEMISTRY-US, V32, P12522, DOI 10.1021/bi00097a032; Jeeninga RE, 2000, J VIROL, V74, P3740, DOI 10.1128/JVI.74.8.3740-3751.2000; JONES KA, 1986, SCIENCE, V232, P755, DOI 10.1126/science.3008338; KACZMARSKI W, 1993, BIOCHEM BIOPH RES CO, V196, P935, DOI 10.1006/bbrc.1993.2339; King GC, 1995, METHOD ENZYMOL, V261, P436; Klinck R, 2000, RNA, V6, P1423, DOI 10.1017/S1355838200000935; Kulinski T, 1999, COLL SYMPOS SERIES, V2, P191; Laing LG, 1996, BIOCHEMISTRY-US, V35, P13586, DOI 10.1021/bi961310q; Lee JC, 2003, J MOL BIOL, V325, P65, DOI 10.1016/S0022-2836(02)01106-3; Leulliot N, 2001, BIOCHEMISTRY-US, V40, P7947, DOI 10.1021/bi010680y; Long KS, 1999, BIOCHEMISTRY-US, V38, P10059, DOI 10.1021/bi990590h; Lukavsky PJ, 2000, NAT STRUCT BIOL, V7, P1105; MARCINIAK RA, 1990, P NATL ACAD SCI USA, V87, P3624, DOI 10.1073/pnas.87.9.3624; MARCINIAK RA, 1991, EMBO J, V10, P4189, DOI 10.1002/j.1460-2075.1991.tb04997.x; MICHNICKA MJ, 1993, BIOCHEMISTRY-US, V32, P395, DOI 10.1021/bi00053a002; MORAS D, 1980, NATURE, V288, P669, DOI 10.1038/288669a0; MUESING MA, 1987, CELL, V48, P691, DOI 10.1016/0092-8674(87)90247-9; Nagaswamy U, 2002, RNA, V8, P1112, DOI 10.1017/S135583820202006X; Nifosi R, 2000, NUCLEIC ACIDS RES, V28, P4944, DOI 10.1093/nar/28.24.4944; Olejniczak M, 2002, NUCLEIC ACIDS RES, V30, P4241, DOI 10.1093/nar/gkf541; Parada CA, 1996, NATURE, V384, P375, DOI 10.1038/384375a0; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V74, P1; Puglisi EV, 1998, NAT STRUCT BIOL, V5, P1033, DOI 10.1038/4141; PUGLISI JD, 1992, SCIENCE, V257, P76, DOI 10.1126/science.1621097; Reyes CM, 2001, BIOPHYS J, V80, P2833, DOI 10.1016/S0006-3495(01)76250-9; Richter S, 2002, P NATL ACAD SCI USA, V99, P7928, DOI 10.1073/pnas.122119999; Richter S, 2002, BIOCHEMISTRY-US, V41, P6391, DOI 10.1021/bi0159579; ROY S, 1990, J VIROL, V64, P1402, DOI 10.1128/JVI.64.3.1402-1406.1990; SANTALUCIA J, 1992, SCIENCE, V256, P217, DOI 10.1126/science.1373521; SHELINE CT, 1991, GENE DEV, V5, P2508, DOI 10.1101/gad.5.12b.2508; Shi HJ, 2000, RNA, V6, P1091, DOI 10.1017/S1355838200000364; SUMNERSMITH M, 1991, J VIROL, V65, P5196, DOI 10.1128/JVI.65.10.5196-5202.1991; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; Verhoef K, 1997, VIROLOGY, V237, P228, DOI 10.1006/viro.1997.8786; WEEKS KM, 1991, CELL, V66, P577, DOI 10.1016/0092-8674(81)90020-9; Wei P, 1998, CELL, V92, P451, DOI 10.1016/S0092-8674(00)80939-3; Wimmer J, 1999, VIROLOGY, V255, P182, DOI 10.1006/viro.1998.9589; WU F, 1991, GENE DEV, V5, P2128, DOI 10.1101/gad.5.11.2128; WUBAER F, 1995, P NATL ACAD SCI USA, V92, P7153, DOI 10.1073/pnas.92.16.7153; Yedavalli VSRK, 2003, J BIOL CHEM, V278, P6404, DOI 10.1074/jbc.M209162200; YORK DM, 1993, J CHEM PHYS, V99, P8345, DOI 10.1063/1.465608; Zhang J, 2000, J BIOL CHEM, V275, P34314, DOI 10.1074/jbc.M006804200	72	38	40	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38892	38901		10.1074/jbc.M301939200	http://dx.doi.org/10.1074/jbc.M301939200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882959	hybrid			2022-12-27	WOS:000185575100098
J	Lin, VY; Resnick, EM; Shupnik, MA				Lin, VY; Resnick, EM; Shupnik, MA			Truncated estrogen receptor product-1 stimulates estrogen receptor alpha transcriptional activity by titration of repressor proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDEPENDENT ACTIVATION; MESSENGER-RNA ISOFORMS; ER-ALPHA; RAT PITUITARY; NUCLEAR RECEPTORS; HORMONE RECEPTORS; BETA; EXPRESSION; COACTIVATOR; COREPRESSOR	The truncated estrogen receptor product-1 (TERP-1, or TERP) is a pituitary-specific isoform of estrogen receptor alpha (ERalpha), and its expression is regulated by estrogen. TERP modulates the transcriptional activity of ERalpha but has no independent effect on transcription of estrogen-response element-containing promoters. At low concentrations, TERP stimulates ERalpha transcriptional activity in transient transfection assays. At TERP concentrations equal to or greater than full-length ERalpha, TERP forms dimers with ERalpha and reduces both ligand-dependent and -independent transcription. A dimerization mutant of TERP, TERP L509R, stimulated ERalpha transcription at all concentrations. We hypothesized that TERP stimulates ERalpha transcriptional activity by titrating suppressors of ERalpha activity. We found that repressor of estrogen receptor activity (REA), originally isolated from human breast cancer cells, is present in mouse pituitary gonadotrope cell lines. Levels of REA vary slightly throughout the rat reproductive cycle, but TERP mRNA and protein vary much more dramatically. In transfection experiments, REA suppressed ERalpha transcriptional activity, and TERP L509R was able to alleviate transcriptional suppression by REA. In glutathione S-transferase pull-down assays, TERP bound to REA more efficiently than did ERalpha at equivalent concentrations, suggesting that REA will preferentially bind to TERP. Our findings suggest that the stimulation of pituitary ERalpha activity by low concentrations of TERP can occur by titration of corepressors such as REA.	Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA; Univ Virginia, Dept Internal Med, Div Endocrinol & Metab, Charlottesville, VA 22908 USA	University of Virginia; University of Virginia	Shupnik, MA (corresponding author), Univ Virginia, Dept Med Endocrinol, POB 800578 HSC, Charlottesville, VA 22908 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U54HD028934] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057082] Funding Source: NIH RePORTER; NICHD NIH HHS [U54 HD28934] Funding Source: Medline; NIDDK NIH HHS [R01-DK57082] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aranda A, 2001, PHYSIOL REV, V81, P1269, DOI 10.1152/physrev.2001.81.3.1269; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; CAVAILLES V, 1994, P NATL ACAD SCI USA, V91, P10009, DOI 10.1073/pnas.91.21.10009; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Cowley SM, 1999, J STEROID BIOCHEM, V69, P165, DOI 10.1016/S0960-0760(99)00055-2; Delage-Mourroux R, 2000, J BIOL CHEM, V275, P35848, DOI 10.1074/jbc.M001327200; ElTanani MKK, 1997, MOL ENDOCRINOL, V11, P928, DOI 10.1210/me.11.7.928; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Friend KE, 1997, MOL CELL ENDOCRINOL, V131, P147, DOI 10.1016/S0303-7207(97)00098-1; FRIEND KE, 1995, P NATL ACAD SCI USA, V92, P4367, DOI 10.1073/pnas.92.10.4367; Gay F, 2000, MOL ENDOCRINOL, V14, P1627, DOI 10.1210/me.14.10.1627; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; Hall JM, 1999, ENDOCRINOLOGY, V140, P5566, DOI 10.1210/en.140.12.5566; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; HORN F, 1991, MOL ENDOCRINOL, V5, P347, DOI 10.1210/mend-5-3-347; Horwitz KB, 1996, MOL ENDOCRINOL, V10, P1167, DOI 10.1210/me.10.10.1167; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Katzenellenbogen BS, 2000, J STEROID BIOCHEM, V74, P279, DOI 10.1016/S0960-0760(00)00104-7; Laflamme N, 1998, J NEUROBIOL, V36, P357, DOI 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V; Loven MA, 2003, MOL ENDOCRINOL, V17, P67, DOI 10.1210/me.2002-0280; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; Misiti S, 1998, ENDOCRINOLOGY, V139, P2493, DOI 10.1210/en.139.5.2493; Mitchner NA, 1999, ENDOCRINOLOGY, V140, P2651, DOI 10.1210/en.140.6.2651; Montano MM, 1999, P NATL ACAD SCI USA, V96, P6947, DOI 10.1073/pnas.96.12.6947; Murphy LC, 2000, CANCER RES, V60, P6266; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Norris JD, 2002, MOL ENDOCRINOL, V16, P459, DOI 10.1210/me.16.3.459; Ogawa S, 1998, NUCLEIC ACIDS RES, V26, P3505, DOI 10.1093/nar/26.15.3505; Rajendran RR, 2003, J BIOL CHEM, V278, P4628, DOI 10.1074/jbc.M210066200; Resnick EM, 2000, J BIOL CHEM, V275, P7158, DOI 10.1074/jbc.275.10.7158; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; Schaufele F, 1999, MOL ENDOCRINOL, V13, P935, DOI 10.1210/me.13.6.935; Schreihofer DA, 1999, MOL ENDOCRINOL, V13, P320, DOI 10.1210/me.13.2.320; Schreihofer DA, 2000, ENDOCRINOLOGY, V141, P2174, DOI 10.1210/en.141.6.2174; Schreihofer DA, 2002, ENDOCRINOLOGY, V143, P4196, DOI 10.1210/en.2002-220353; Schreihofer DA, 2001, ENDOCRINOLOGY, V142, P3361, DOI 10.1210/en.142.8.3361; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; Shang YF, 2002, SCIENCE, V295, P2465, DOI 10.1126/science.1068537; Shupnik MA, 2002, J NEUROENDOCRINOL, V14, P85, DOI 10.1046/j.0007-1331.2001.00744.x; Simon SLR, 2000, CANCER RES, V60, P2796; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Tiffoche C, 2001, ENDOCRINOLOGY, V142, P4106, DOI 10.1210/en.142.9.4106; Treuter E, 1998, MOL ENDOCRINOL, V12, P864, DOI 10.1210/me.12.6.864; Vaillant C, 2002, ENDOCRINOLOGY, V143, P4249, DOI 10.1210/en.2002-220193; Zhang H, 2000, J BIOL CHEM, V275, P39855, DOI 10.1074/jbc.C000567200	47	11	12	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38125	38131		10.1074/jbc.M303882200	http://dx.doi.org/10.1074/jbc.M303882200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878603	hybrid			2022-12-27	WOS:000185575100006
J	Kaiser, L; Gronlund, H; Sandalova, T; Ljunggren, HG; van Hage-Hamsten, M; Achour, A; Schneider, G				Kaiser, L; Gronlund, H; Sandalova, T; Ljunggren, HG; van Hage-Hamsten, M; Achour, A; Schneider, G			The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FEL-D-I; BINDING PROTEIN; OXIDIZED UTEROGLOBIN; PROGESTERONE-BINDING; SEBACEOUS GLANDS; REFINEMENT; FORM; CRYSTALLIZATION; IMMUNOTHERAPY; TESTOSTERONE	The domestic cat (Felis domesticus) is one of the most important causes of allergic asthma worldwide. The dominating cat allergen, Fel d 1, is composed of two heterodimers. Recently, it has been shown that recombinant Fel d 1, consisting of chain 2 and chain 1 fused together without additional linker, has immunological properties indistinguishable from the natural heterodimeric protein. Herein, we report the crystal structure of recombinant monomeric Fel d 1 at 1.85-Angstrom resolution, determined by multi-wavelength anomalous diffraction using selenomethionine substituted protein. Fel d 1 is an all-helical protein and consists of eight helices. The two halves of the recombinant Fel d 1 molecule, corresponding to the wild-type Fel d 1 chains, are very similar in three-dimensional structure, despite the lack of significant sequence identity. The structure of the Fel d 1 presents a striking similarity to that of uteroglobin, a steroid-inducible cytokine-like molecule with anti-inflammatory and immunomodulatory properties. An internal, asymmetric cavity is formed in the Fel d 1 that could bind an endogenous ligand. The distribution of residues lining this cavity suggests that such a ligand must be amphipathic. The structure of Fel d 1 displays the localization of three previously defined Fel d 1 IgE epitopes on the surface of the protein. The three-dimensional structure provides a framework for rational design of hypoallergenic mutants aimed for treatment of cat allergy.	Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, S-14186 Huddinge, Sweden; Karolinska Inst & Hosp L2 04, Dept Med, Unit Clin Immunol & Allergy, S-17176 Stockholm, Sweden; Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital	Achour, A (corresponding author), Huddinge Univ Hosp, Karolinska Inst, Dept Med, Ctr Infect Med, F59, S-14186 Huddinge, Sweden.	adnane.achour@mtc.ki.se	van Hage, Marianne/A-9678-2017	van Hage, Marianne/0000-0003-3091-1596; Sandalova, Tatyana/0000-0002-7694-6420; Achour, Adnane/0000-0003-0432-710X; Gronlund, Hans/0000-0003-4882-7624; Schneider, Gunter/0000-0003-0622-5713				Aalberse RC, 2000, J ALLERGY CLIN IMMUN, V106, P228, DOI 10.1067/mai.2000.108434; Almqvist C, 2001, AM J RESP CRIT CARE, V163, P694, DOI 10.1164/ajrccm.163.3.2006114; ANDERSON MC, 1985, J ALLERGY CLIN IMMUN, V76, P563, DOI 10.1016/0091-6749(85)90776-6; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BALLY R, 1989, J MOL BIOL, V206, P153, DOI 10.1016/0022-2836(89)90530-5; BARTHOLOME K, 1985, J ALLERGY CLIN IMMUN, V76, P503, DOI 10.1016/0091-6749(85)90734-1; BOND JF, 1993, MOL IMMUNOL, V30, P1529, DOI 10.1016/0161-5890(93)90461-J; Bousquet J, 1998, J ALLERGY CLIN IMMUN, V102, P558, DOI 10.1016/S0091-6749(98)70271-4; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUEHNER M, 1982, J MOL BIOL, V159, P353, DOI 10.1016/0022-2836(82)90499-5; Callebaut I, 2000, ANN NY ACAD SCI, V923, P90; CHARPIN C, 1994, CLIN EXP ALLERGY, V24, P1174, DOI 10.1111/j.1365-2222.1994.tb03325.x; CHARPIN C, 1991, J ALLERGY CLIN IMMUN, V88, P77, DOI 10.1016/0091-6749(91)90303-6; DABROWSKI AJ, 1990, J ALLERGY CLIN IMMUN, V86, P462, DOI 10.1016/S0091-6749(05)80200-3; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; DUFFORT OA, 1991, MOL IMMUNOL, V28, P301, DOI 10.1016/0161-5890(91)90141-6; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; GRIFFITH IJ, 1992, GENE, V113, P263, DOI 10.1016/0378-1119(92)90405-E; Gronlund H, 2003, J BIOL CHEM, V278, P40144, DOI 10.1074/jbc.M301416200; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; HARD T, 1995, NAT STRUCT BIOL, V2, P983, DOI 10.1038/nsb1195-983; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kaiser L, 2003, ACTA CRYSTALLOGR D, V59, P1103, DOI 10.1107/S0907444903007741; KEATING KM, 1995, MOL IMMUNOL, V32, P287, DOI 10.1016/0161-5890(94)00140-V; KLEINETEBBE J, 1993, INT ARCH ALLERGY IMM, V100, P256, DOI 10.1159/000236421; Klug J, 2000, ANN NY ACAD SCI, V923, P348; Kristensen AK, 1997, BIOL CHEM, V378, P899; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MATTHEWS JH, 1994, PROTEINS, V20, P191, DOI 10.1002/prot.340200209; MIELE L, 1994, J ENDOCRINOL INVEST, V17, P679, DOI 10.1007/BF03349687; MORIZE I, 1987, J MOL BIOL, V194, P725, DOI 10.1016/0022-2836(87)90250-6; MORNON JP, 1980, J MOL BIOL, V137, P415, DOI 10.1016/0022-2836(80)90166-7; Mukherjee AB, 1999, CELL MOL LIFE SCI, V55, P771, DOI 10.1007/s000180050331; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; OHMAN JL, 1974, J IMMUNOL, V113, P1668; Oldfield WLG, 2002, LANCET, V360, P47, DOI 10.1016/S0140-6736(02)09332-7; Partti-Pellinen K, 2000, ALLERGY, V55, P65, DOI 10.1034/j.1398-9995.2000.00226.x; Pattabiraman N, 2000, ANN NY ACAD SCI, V923, P113; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; PETER W, 1991, J STEROID BIOCHEM, V38, P27, DOI 10.1016/0960-0760(91)90397-N; Platts-Mills TAE, 1997, J ALLERGY CLIN IMMUN, V100, pS2, DOI 10.1016/S0091-6749(97)70292-6; SLUNT JB, 1995, J ALLERGY CLIN IMMUN, V95, P1221, DOI 10.1016/S0091-6749(95)70079-X; Terwilliger TC, 2001, ACTA CRYSTALLOGR D, V57, P1755, DOI 10.1107/S0907444901013737; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; UMLAND TC, 1994, NAT STRUCT BIOL, V1, P538, DOI 10.1038/nsb0894-538; UMLAND TC, 1992, J MOL BIOL, V224, P441, DOI 10.1016/0022-2836(92)91006-B; Valenta R, 2002, NAT REV IMMUNOL, V2, P446, DOI 10.1038/nri824; Valenta R, 2001, IMMUNOL REV, V179, P119, DOI 10.1034/j.1600-065X.2001.790112.x; van Ree R, 1999, J ALLERGY CLIN IMMUN, V104, P1223, DOI 10.1016/S0091-6749(99)70017-5; VANMILLIGEN FJ, 1994, J ALLERGY CLIN IMMUN, V93, P34, DOI 10.1016/0091-6749(94)90230-5; VANMILLIGEN FJ, 1990, INT ARCH ALLER A IMM, V92, P375, DOI 10.1159/000235168; ZIELONKA TM, 1994, CLIN EXP ALLERGY, V24, P1169, DOI 10.1111/j.1365-2222.1994.tb03324.x	55	88	94	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37730	37735		10.1074/jbc.M304740200	http://dx.doi.org/10.1074/jbc.M304740200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851385	hybrid			2022-12-27	WOS:000185437200090
J	Maita, N; Nishio, K; Nishimoto, E; Matsui, T; Shikamoto, Y; Morita, T; Sadler, JE; Mizuno, H				Maita, N; Nishio, K; Nishimoto, E; Matsui, T; Shikamoto, Y; Morita, T; Sadler, JE; Mizuno, H			Crystal structure of von Willebrand factor A1 domain complexed with snake venom, bitiscetin - Insight into glycoprotein Ib alpha binding mechanism induced by snake venom proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRIMERESURUS-FLAVOVIRIDIS; ANTICOAGULANT PROTEIN; ACCELERATED EVOLUTION; TYROSINE SULFATION; IDENTIFICATION; RESIDUES; RECEPTOR; REVEALS	Bitiscetin, a platelet adhesion inducer isolated from venom of the snake Bitis arietans, activates the binding of the von Willebrand factor (VWF) A1 domain to glycoprotein Ib (GPIb) in vitro. This activation requires the formation of a bitiscetin-VWF A1 complex, suggesting an allosteric mechanism of action. Here, we report the crystal structure of bitiscetin-VWF A1 domain complex solved at 2.85 Angstrom. In the complex structure, helix alpha5 of VWF A1 domain lies on a concave depression on bitiscetin, and binding sites are located at both ends of the depression. The binding sites correspond well with those proposed previously based on alanine-scanning mutagenesis (Matsui, T., Hamako, J., Matsushita, T., Nakayama, T., Fujimura, Y., and Titani, K. (2002) Biochemistry 41, 7939-7946). Against our expectations, the structure of the VWF A1 domain bound to bitiscetin does not differ significantly from the structure of the free A1 domain. These results are similar to the case of botrocetin, another snake-derived inducer of platelet aggregation, although the binding modes of botrocetin and bitiscetin are different. The modeled structure of the ternary bitiscetin-VWF A1-GPIb complex suggests that an electropositive surface of bitiscetin may interact with a favorably positioned anionic region of GPIb. These results suggest that snake venom proteins induce VWF A1-GPIbalpha binding by interacting with both proteins, and not by causing conformational changes in VWF A1.	Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan; Fujita Hlth Univ, Sch Hlth Sci, Dept Biol, Aichi 4701192, Japan; Meiji Pharmaceut Univ, Dept Biochem, Tokyo 2048588, Japan; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med, St Louis, MO 63110 USA	National Institute of Agrobiological Sciences - Japan; Fujita Health University; Meiji Pharmaceutical University; Howard Hughes Medical Institute; Washington University (WUSTL)	Mizuno, H (corresponding author), Natl Inst Agrobiol Sci, Dept Biochem, Tsukuba, Ibaraki 3058602, Japan.	mizuno@affrc.go.jp	Sadler, Evan/D-8556-2011; Maita, Nobuo/J-1443-2012	Maita, Nobuo/0000-0003-2260-5783; Sadler, J. Evan/0000-0001-5705-469X				Atoda H, 1997, THROMB RES, V87, P271, DOI 10.1016/S0049-3848(97)00129-1; ATODA H, 1991, J BIOL CHEM, V266, P14903; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Celikel R, 2000, NAT STRUCT BIOL, V7, P881; Chung DW, 2002, BIOCHEMISTRY-US, V41, P11065, DOI 10.1021/bi0204692; Deshimaru M, 1996, FEBS LETT, V397, P83, DOI 10.1016/S0014-5793(96)01144-1; DONG JF, 1994, BIOCHEMISTRY-US, V33, P13946, DOI 10.1021/bi00250a050; Dong JF, 2001, J BIOL CHEM, V276, P16690, DOI 10.1074/jbc.M101035200; Emsley J, 1998, J BIOL CHEM, V273, P10396, DOI 10.1074/jbc.273.17.10396; Fujimura Y, 1996, THROMB HAEMOSTASIS, V76, P633; Fukuda K, 2000, BIOCHEMISTRY-US, V39, P1915, DOI 10.1021/bi992134z; Fukuda K, 2002, STRUCTURE, V10, P943, DOI 10.1016/S0969-2126(02)00787-6; Hamako J, 1996, BIOCHEM BIOPH RES CO, V226, P273, DOI 10.1006/bbrc.1996.1345; Hirotsu S, 2001, BIOCHEMISTRY-US, V40, P13592, DOI 10.1021/bi0114933; HOYLAERTS MF, 1995, BIOCHEM J, V306, P453, DOI 10.1042/bj3060453; Huizinga EG, 2002, SCIENCE, V297, P1176, DOI 10.1126/science.107355; JENNIFER CD, 1996, NATURE, V379, P537; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; MARCHESE P, 1995, J BIOL CHEM, V270, P9571, DOI 10.1074/jbc.270.16.9571; Matsui T, 2002, BIOCHEMISTRY-US, V41, P7939, DOI 10.1021/bi020004b; Matsushita T, 2000, J BIOL CHEM, V275, P11044, DOI 10.1074/jbc.275.15.11044; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miura S, 2000, J BIOL CHEM, V275, P7539, DOI 10.1074/jbc.275.11.7539; Miyata S, 1996, J BIOL CHEM, V271, P9046, DOI 10.1074/jbc.271.15.9046; Mizuno H, 1999, J MOL BIOL, V289, P103, DOI 10.1006/jmbi.1999.2756; Mizuno H, 1997, NAT STRUCT BIOL, V4, P438, DOI 10.1038/nsb0697-438; Mizuno H, 2001, P NATL ACAD SCI USA, V98, P7230, DOI 10.1073/pnas.131179698; NAKASHIMA K, 1993, P NATL ACAD SCI USA, V90, P5964, DOI 10.1073/pnas.90.13.5964; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; PETERSON DM, 1987, BLOOD, V69, P625; Ruggeri ZM, 1999, THROMB HAEMOSTASIS, V82, P576; Sadler JE, 1998, ANNU REV BIOCHEM, V67, P395, DOI 10.1146/annurev.biochem.67.1.395; Sen U, 2001, BIOCHEMISTRY-US, V40, P345, DOI 10.1021/bi0021737; Uff S, 2002, J BIOL CHEM, V277, P35657, DOI 10.1074/jbc.M205271200	39	69	74	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37777	37781		10.1074/jbc.M305566200	http://dx.doi.org/10.1074/jbc.M305566200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851390	hybrid			2022-12-27	WOS:000185437200096
J	Vanhoorelbeke, K; Depraetere, H; Romijn, RAP; Huizinga, EG; De Maeyer, M; Deckmyn, H				Vanhoorelbeke, K; Depraetere, H; Romijn, RAP; Huizinga, EG; De Maeyer, M; Deckmyn, H			A consensus tetrapeptide selected by phage display adopts the conformation of a dominant discontinuous epitope of a monoclonal Anti-VWF antibody that inhibits the von Willebrand factor-collagen interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA-2-BETA-1 VLA-2; PLATELET THROMBUS FORMATION; VONWILLEBRAND-FACTOR; BINDING-SITE; PEPTIDE LIBRARIES; GLYCOPROTEIN-VI; FLOW CONDITIONS; I-DOMAIN; SEQUENCE ALIGNMENT; IDENTIFICATION	Monoclonal antibody (mAb) 82D6A3 is an anti-von Willebrand factor (VWF) mAb directed against the A3-domain of VWF that inhibits the VWF binding to fibrillar collagens type I and III in vitro and in vivo. To identify the discontinuous epitope of this mAb, we used phage display, mutant analysis, and peptide modeling. All 82D6A3-binding phages displayed peptides containing the consensus sequence SPWR that could be aligned with P981W982 in the VWF A3-domain. Next, the binding of mAb 82D6A3 to 27 Ala mutants with mutations in the A3-domain of VWF revealed that amino acids Arg(963), Pro(981), Asp(1009), Arg(1016), Ser(1020), Met(1022), and His(1023) are part of the epitope of mAb 82D6A3. Inspection of residues Ser(1020), Arg(1016), Pro(981), and Trp(982) in the three-dimensional structure of the A3-domain demonstrated that these residues are close together in space, pointing out that the structure of the SPWR consensus sequence might mimic this discontinuous epitope. Modeling of a cyclic 6-mer peptide containing the consensus sequence and superposition of its three-dimensional structure onto the VWF A3-domain demonstrated that the Ser and Arg in the peptide matched the Ser(1020) and Arg(1016) in the A3-domain. The Pro residue of the peptide served as a spacer, and the side chain of the Trp pointed in the direction of Trp(982). In conclusion, to our knowledge, this is the first report where a modeled peptide containing a consensus sequence could be fitted onto the three-dimensional structure of the antigen, indicating that it might adopt the conformation of the discontinuous epitope.	Katholieke Univ Leuven, IRC, Lab Thrombosis Res, B-8500 Kortrijk, Belgium; Univ Utrecht, Med Ctr, Dept Haematol, Thrombosis & Haemostasis Lab, NL-3508 GA Utrecht, Netherlands; Katholieke Univ Leuven, Biomolec Modelling Lab, B-3001 Heverlee, Belgium	KU Leuven; Utrecht University; KU Leuven	Deckmyn, H (corresponding author), Katholieke Univ Leuven, IRC, Lab Thrombosis Res, Campus Kortrijk,E Sabbelaan 53, B-8500 Kortrijk, Belgium.		Deckmyn, Hans/L-9434-2015; Deckmyn, Hans/N-8932-2019	Deckmyn, Hans/0000-0003-3952-5501; Deckmyn, Hans/0000-0003-3952-5501; Vanhoorelbeke, Karen/0000-0003-2288-8277; Depraetere, Hilde/0000-0001-7196-7911				ARAI M, 1995, BRIT J HAEMATOL, V89, P124, DOI 10.1111/j.1365-2141.1995.tb08900.x; BAHOU WF, 1994, BLOOD, V84, P3734, DOI 10.1182/blood.V84.11.3734.bloodjournal84113734; BEER JH, 1993, BLOOD, V82, P820; Berndt MC, 2001, THROMB HAEMOSTASIS, V86, P178; CHRISTOPHE O, 1991, BLOOD, V78, P2310; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; COLOMBATTI A, 1991, BLOOD, V77, P2305; CORTESE R, 1994, TRENDS BIOTECHNOL, V12, P262, DOI 10.1016/0167-7799(94)90137-6; CRUZ MA, 1995, J BIOL CHEM, V270, P19668; DELHAISE P, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80028-3; Demangel C, 2000, EUR J BIOCHEM, V267, P2345, DOI 10.1046/j.1432-1327.2000.01244.x; Depraetere H, 1998, BLOOD, V92, P4207, DOI 10.1182/blood.V92.11.4207.423a02_4207_4211; Depraetere H, 1997, THROMB HAEMOSTASIS, V77, P981; Furmonaviciene R, 1999, CLIN EXP ALLERGY, V29, P1563, DOI 10.1046/j.1365-2222.1999.00686.x; GOTO S, 1995, J BIOL CHEM, V270, P23352, DOI 10.1074/jbc.270.40.23352; HARSFALVI J, 1995, BLOOD, V85, P705, DOI 10.1182/blood.V85.3.705.bloodjournal853705; Hoylaerts MF, 1997, BIOCHEM J, V324, P185, DOI 10.1042/bj3240185; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; Kehrel B, 1998, BLOOD, V91, P491; Lankhof H, 1996, THROMB HAEMOSTASIS, V75, P950; Lankhof H, 1997, THROMB HAEMOSTASIS, V77, P1008; LUZZAGO A, 1993, GENE, V128, P51, DOI 10.1016/0378-1119(93)90152-S; Mazzucato M, 1999, J BIOL CHEM, V274, P3033, DOI 10.1074/jbc.274.5.3033; MOHRI H, 1993, PEPTIDES, V14, P125, DOI 10.1016/0196-9781(93)90019-D; Moroi M, 1997, BLOOD, V90, P4413; Myers MA, 2000, J IMMUNOL, V165, P3830, DOI 10.4049/jimmunol.165.7.3830; NIEUWENHUIS HK, 1985, NATURE, V318, P470, DOI 10.1038/318470a0; Nishida N, 2003, NAT STRUCT BIOL, V10, P53, DOI 10.1038/nsb876; Ravera MW, 1998, ONCOGENE, V16, P1993, DOI 10.1038/sj.onc.1201717; Romijn RA, 2003, J BIOL CHEM, V278, P15035, DOI 10.1074/jbc.M208977200; Romijn RAP, 2001, J BIOL CHEM, V276, P9985, DOI 10.1074/jbc.M006548200; SANTORO SA, 1986, CELL, V46, P913, DOI 10.1016/0092-8674(86)90073-5; SANTORO SA, 1995, THROMB HAEMOSTASIS, V74, P813; SCHOOLMEESTER A, 2003, J THROMB HAEMOST S1, V1, pOC139; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SIXMA JJ, 1991, MAYO CLIN PROC, V66, P628, DOI 10.1016/S0025-6196(12)60523-0; SIXMA JJ, 1991, EUR J BIOCHEM, V196, P369, DOI 10.1111/j.1432-1033.1991.tb15826.x; Smith GP, 1997, CHEM REV, V97, P391, DOI 10.1021/cr960065d; SOBEL M, 1992, J BIOL CHEM, V267, P8857; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; van der Plas RM, 2000, THROMB HAEMOSTASIS, V84, P1005; Vanhoorelbeke K, 2000, THROMB HAEMOSTASIS, V84, P621; Verkleij MW, 1999, THROMB HAEMOSTASIS, V82, P1137; Villard S, 2002, J BIOL CHEM, V277, P27232, DOI 10.1074/jbc.M203415200; Wu DM, 2002, BLOOD, V99, P3623, DOI 10.1182/blood.V99.10.3623; Yip YL, 1999, COMB CHEM HIGH T SCR, V2, P125; Zheng XL, 2001, J BIOL CHEM, V276, P41059, DOI 10.1074/jbc.C100515200	49	35	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37815	37821		10.1074/jbc.M304289200	http://dx.doi.org/10.1074/jbc.M304289200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855711	Green Published, hybrid			2022-12-27	WOS:000185437200101
J	Krishnan, P; Gullen, EA; Lam, W; Dutschman, GE; Grill, SP; Cheng, YC				Krishnan, P; Gullen, EA; Lam, W; Dutschman, GE; Grill, SP; Cheng, YC			Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPATITIS-B-VIRUS; PHOSPHORYLATION; METABOLISM; LAMIVUDINE; PYRIMIDINE; PHARMACOKINETICS; DIPHOSPHATES	L-Nucleoside analogs are a new class of clinically active antiviral and anticancer agents. The phosphorylation of these analogs from diphosphate to triphosphate metabolites is crucial for their biological action. We studied the role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the metabolism of L-nucleoside analogs, using small interfering RNAs to down-regulate the amount of this enzyme in HelaS3 and 2.2.15 cells, chosen as models for studying the impact of the enzyme on the anticancer and antihepatitis B virus activities of these analogs. Decrease in the expression of 3-phosphoglycerate kinase led to a corresponding decrease in the formation of the triphosphate metabolites of L-nucleoside analogs (but not D-nucleoside analogs), resulting in detrimental effects on their activity. The enzyme is important for generating as well as maintaining the steady state levels of L-nucleotides in the cells, thereby playing a key role in the activity of L-nucleoside analogs against human immunodeficiency virus, hepatitis B virus, and cancer. This study also indicates a structure-based distinction in the metabolism of L- and D-nucleoside analogs, disputing the classic notion that nucleoside diphosphate kinases are responsible for the phosphorylation of all classes of nucleoside analog diphosphates.	Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Cheng, YC (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,SHM B254, New Haven, CT 06520 USA.	cheng.lab@yale.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI038204] Funding Source: NIH RePORTER; NCI NIH HHS [CA36477] Funding Source: Medline; NIAID NIH HHS [AI38204] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9; Baldwin SA, 1999, MOL MED TODAY, V5, P216, DOI 10.1016/S1357-4310(99)01459-8; BALZARINI J, 1989, J BIOL CHEM, V264, P6127; Bourdais J, 1996, J BIOL CHEM, V271, P7887, DOI 10.1074/jbc.271.14.7887; Bridges E G, 1995, Prog Liver Dis, V13, P231; Chen SH, 2002, CURR MED CHEM, V9, P899, DOI 10.2174/0929867024606696; Cheng Yung-Chi, 2001, Cancer Letters, V162, pS33, DOI 10.1016/S0304-3835(00)00650-9; Cheng Yung-Chi, 2001, Antiviral Chemistry and Chemotherapy, V12, P5; Chong YH, 2002, BIOORG MED CHEM LETT, V12, P3459, DOI 10.1016/S0960-894X(02)00747-3; De Clercq E, 1999, INT J ANTIMICROB AG, V12, P81, DOI 10.1016/S0924-8579(99)00060-6; De Clercq E, 2002, MED RES REV, V22, P531; Dutschman GE, 1998, ANTIMICROB AGENTS CH, V42, P1799, DOI 10.1128/AAC.42.7.1799; Ecker Gerhard, 2002, Curr Opin Investig Drugs, V3, P1533; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; ENA J, 2003, HIV AIDS, V36, P1186; Fu L, 2000, ANTIMICROB AGENTS CH, V44, P3402, DOI 10.1128/AAC.44.12.3402-3407.2000; Galmarini CM, 2001, LEUKEMIA, V15, P875, DOI 10.1038/sj.leu.2402114; Giles Francis J, 2002, Expert Rev Anticancer Ther, V2, P261, DOI 10.1586/14737140.2.3.261; Gish RG, 2002, ANTIMICROB AGENTS CH, V46, P1734, DOI 10.1128/AAC.46.6.1734-1740.2002; GROVE KL, 1995, CANCER RES, V55, P3008; Karayiannis P, 2003, J ANTIMICROB CHEMOTH, V51, P761, DOI 10.1093/jac/dkg163; Kreimeyer A, 2001, ANTIVIR RES, V50, P147, DOI 10.1016/S0166-3542(01)00139-5; Krishnan P, 2002, J BIOL CHEM, V277, P5453, DOI 10.1074/jbc.M109025200; Krishnan P, 2002, J BIOL CHEM, V277, P31593, DOI 10.1074/jbc.M205115200; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Lin TS, 1996, J MED CHEM, V39, P1757, DOI 10.1021/jm950836q; Liou JY, 2002, CANCER RES, V62, P1624; Liu SH, 1998, ANTIMICROB AGENTS CH, V42, P833, DOI 10.1128/AAC.42.4.833; McManus MT, 2002, NAT REV GENET, V3, P737, DOI 10.1038/nrg908; Nevens F, 1997, GASTROENTEROLOGY, V113, P1258, DOI 10.1053/gast.1997.v113.pm9322520; Pai SB, 1996, ANTIMICROB AGENTS CH, V40, P380, DOI 10.1128/AAC.40.2.380; Perry CM, 1997, DRUGS, V53, P657, DOI 10.2165/00003495-199753040-00008; SCHINAZI RF, 1992, ANTIMICROB AGENTS CH, V36, P2432, DOI 10.1128/AAC.36.11.2432; Schneider B, 1998, J BIOL CHEM, V273, P11491, DOI 10.1074/jbc.273.19.11491; Seigneres B, 2003, ANTIMICROB AGENTS CH, V47, P1842, DOI 10.1128/AAC.47.6.1842-1852.2003; Tan XL, 1999, ADV DRUG DELIVER REV, V39, P117, DOI 10.1016/S0169-409X(99)00023-X; Tsimberidou Apostolia-Maria, 2002, Expert Rev Anticancer Ther, V2, P437, DOI 10.1586/14737140.2.4.437; Van Rompay AR, 1999, MOL PHARMACOL, V56, P562, DOI 10.1124/mol.56.3.562; Van Rompay AR, 2000, PHARMACOL THERAPEUT, V87, P189, DOI 10.1016/S0163-7258(00)00048-6	39	49	52	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36726	36732		10.1074/jbc.M307052200	http://dx.doi.org/10.1074/jbc.M307052200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12869554	hybrid			2022-12-27	WOS:000185318300104
J	Pawar, A; Jump, DB				Pawar, A; Jump, DB			Unsaturated fatty acid regulation of peroxisome proliferator-activated receptor alpha activity in rat primary hepatoctes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELEMENT-BINDING PROTEIN-1C; DOCOSAHEXAENOIC ACID; GENE-EXPRESSION; PPAR-ALPHA; LIGAND; TRANSCRIPTION; N-3; SUPPRESSION; TRIACYLGLYCEROL; EICOSANOIDS	Peroxisome proliferator-activated receptors (PPARs alpha, beta, gamma1, and gamma2) are widely regarded as monitors of intracellular nonesterified fatty acid ( NEFA) levels. As such, fatty acid binding to PPAR leads to changes in the transcription of many genes involved in lipid metabolism and storage. Although the composition of the intracellular NEFA pool is likely an important factor controlling PPAR activity, little information is available on factors affecting its composition. Accordingly, we have examined the effects of exogenous fatty acids on PPARalpha activity and NEFA pool composition in rat primary hepatocytes. Prior to the addition of fatty acids to primary hepatocytes, nonesterified unsaturated fatty acid levels are very low, representing less than or equal to 0.5% of the total fatty acid in the cell. The relative abundance of putative PPARalpha ligands in the NEFA pool is 20: 4n-6 = 18: 2n- 6 = 18: 1n- 9 > 22: 6n- 3 > 18: 3n- 3/6 = 20: 5n-3. Of these fatty acids, only 20: 5n-3 and 22: 6n- 3 consistently induced PPARalpha activity. Metabolic labeling of primary hepatocytes indicated that both C-14-18: 1n-9 and C-14-20: 5n-3 are rapidly assimilated into neutral and polar lipids. Although the addition of 18: 1n- 9 had no effect on NEFA pool composition, 20: 5n-3 mass increased > 15-fold within 90 min. Changes in NEFA pool 20: 5n-3 mass correlated with dynamic changes in the PPARalpha-regulated transcript mRNA(CYP4A). Metabolic labeling also indicated that a significant fraction of C-14-20: 5n- 3 was elongated to 22: 5n-3. Cells treated with 22: 5n- 3 or 22: 6n- 3 led to a significant accumulation of 20: 5n- 3 in the NEFA pool through a process that requires peroxisomal beta-oxidation and fatty acyl CoA thioesterase activity. Further analyses suggest that 20: 5n- 3 and 22: 6n- 3, but not 22: 5n- 3, are active ligands for PPARalpha. These studies suggest that basal fatty acid levels in the NEFA pool coupled with rates of fatty acid esterification, elongation, desaturation, peroxisomal beta-oxidation, and fatty acyl thioestease activity are important determinants controlling NEFA pool composition and PPARalpha activity.	Michigan State Univ, Dept Physiol, E Lansing, MI 48824 USA; Michigan State Univ, Dept Biochem, E Lansing, MI 48824 USA; Michigan State Univ, Dept Mol Biol, E Lansing, MI 48824 USA	Michigan State University; Michigan State University; Michigan State University	Jump, DB (corresponding author), Michigan State Univ, Dept Physiol, 3165 Biomed & Phys Sci Bldg, E Lansing, MI 48824 USA.	Jump@msu.edu	Pawar, Anjali/AAT-8945-2020	Pawar, Anjali/0000-0002-2133-8663	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043220] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43220, R01 DK043220] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amet Y, 1995, BIOCHEM PHARMACOL, V50, P1775, DOI 10.1016/0006-2952(95)02040-3; [Anonymous], [No title captured]; Berge RK, 1999, BIOCHEM J, V343, P191, DOI 10.1042/0264-6021:3430191; CHRISTIANSEN EN, 1991, BIOCHIM BIOPHYS ACTA, V1082, P57, DOI 10.1016/0005-2760(91)90299-W; Coleman RA, 2000, ANNU REV NUTR, V20, P77, DOI 10.1146/annurev.nutr.20.1.77; de Urquiza AM, 2000, SCIENCE, V290, P2140, DOI 10.1126/science.290.5499.2140; Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649; Dhe-Paganon S, 2002, J BIOL CHEM, V277, P37973, DOI 10.1074/jbc.C200420200; Fan CY, 1998, J BIOL CHEM, V273, P15639, DOI 10.1074/jbc.273.25.15639; Fisher EA, 2001, J BIOL CHEM, V276, P27855, DOI 10.1074/jbc.M008885200; Forman BM, 1997, P NATL ACAD SCI USA, V94, P4312, DOI 10.1073/pnas.94.9.4312; Jump DB, 2002, J BIOL CHEM, V277, P8755, DOI 10.1074/jbc.R100062200; Jump DB, 2001, J BIOL CHEM, V276, P34419, DOI 10.1074/jbc.M105471200; Kliewer SA, 1997, P NATL ACAD SCI USA, V94, P4318, DOI 10.1073/pnas.94.9.4318; LANG CA, 1990, J LIPID RES, V31, P2079; Lawrence JW, 2000, J LIPID RES, V41, P1390; LIEBICH HM, 1991, J CHROMATOGR-BIOMED, V572, P1, DOI 10.1016/0378-4347(91)80468-R; Luthria DL, 1996, J BIOL CHEM, V271, P16020, DOI 10.1074/jbc.271.27.16020; Malkowski MG, 2001, J BIOL CHEM, V276, P37547, DOI 10.1074/jbc.M105982200; Mater MK, 1999, J BIOL CHEM, V274, P32725, DOI 10.1074/jbc.274.46.32725; Mater MK, 1999, J LIPID RES, V40, P1045; McArthur MJ, 1999, J LIPID RES, V40, P1371; Murphy EJ, 1999, BBA-MOL CELL BIOL L, V1436, P413, DOI 10.1016/S0005-2760(98)00150-7; Norris AW, 2002, J LIPID RES, V43, P646; Ou JF, 2001, P NATL ACAD SCI USA, V98, P6027, DOI 10.1073/pnas.111138698; Pan DA, 2000, J LIPID RES, V41, P742; Pawar A, 2002, J BIOL CHEM, V277, P39243, DOI 10.1074/jbc.M206170200; Ren B, 1997, J BIOL CHEM, V272, P26827, DOI 10.1074/jbc.272.43.26827; Ren B, 1996, J BIOL CHEM, V271, P17167, DOI 10.1074/jbc.271.29.17167; Seo T, 2001, BIOCHEMISTRY-US, V40, P4756, DOI 10.1021/bi0022947; Sprecher H, 2000, BBA-MOL CELL BIOL L, V1486, P219, DOI 10.1016/S1388-1981(00)00077-9; Stahl A, 2001, TRENDS ENDOCRIN MET, V12, P266, DOI 10.1016/S1043-2760(01)00427-1; Willson TM, 2002, MOL ENDOCRINOL, V16, P1135, DOI 10.1210/me.16.6.1135; Wisely GB, 2002, STRUCTURE, V10, P1225, DOI 10.1016/S0969-2126(02)00829-8; Xu HE, 1999, MOL CELL, V3, P397, DOI 10.1016/S1097-2765(00)80467-0; YU K, 1995, J BIOL CHEM, V270, P23975, DOI 10.1074/jbc.270.41.23975	36	153	157	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35931	35939		10.1074/jbc.M306238200	http://dx.doi.org/10.1074/jbc.M306238200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12853447	hybrid			2022-12-27	WOS:000185318300010
J	Wong, D; DeMott, MS; Demple, B				Wong, D; DeMott, MS; Demple, B			Modulation of the 3 '-> 5 '-exonuclease activity of human apurinic endonuclease (Ape1) by its 5 '-incised abasic DNA product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASE EXCISION-REPAIR; HUMAN APURINIC/APYRIMIDINIC ENDONUCLEASE; NEGATIVE GENE-REGULATION; POLYMERASE-BETA; OXIDATIVE DAMAGE; EXONUCLEASE ACTIVITY; PROTEIN; SITE; IV; BINDING	The major abasic endonuclease of human cells, Ape1 protein, is a multifunctional enzyme with critical roles in base excision repair (BER) of DNA. In addition to its primary activity as an apurinic/apyrimidinic endonuclease in BER, Ape1 also possesses 3'-phosphodiesterase, 3'-phosphatase, and 3'-->5'-exonuclease functions specific for the 3' termini of internal nicks and gaps in DNA. The exonuclease activity is enhanced at 3' mismatches, which suggests a possible role in BER for Ape1 as a proofreading activity for the relatively inaccurate DNA polymerase beta. To elucidate this role more precisely, we investigated the ability of Ape1 to degrade DNA substrates that mimic BER intermediates. We found that the Ape1 exonuclease is active at both mismatched and correctly matched 3' termini, with preference for mismatches. In our hands, the exonuclease activity of Ape1 was more active at one-nucleotide gaps than at nicks in DNA, even though the latter should represent the product of repair synthesis by polymerase beta. However, the exonuclease activity was inhibited by the presence of nearby 5'-incised abasic residues, which result from the apurinic/apyrimidinic endonuclease activity of Ape1. The same was true for the recently described exonuclease activity of Escherichia coli endonuclease IV. Exonuclease III, the E. coli homolog of Ape1, did not discriminate among the different substrates. Removal of the 5' abasic residue by polymerase beta alleviated the inhibition of the Ape1 exonuclease activity. These results suggest roles for the Ape1 exonuclease during BER after both DNA repair synthesis and excision of the abasic deoxyribose-5-phosphate by polymerase beta.	Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Demple, B (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Canc Cell Biol, 665 Huntington Ave, Boston, MA 02115 USA.	bdemple@hsph.harvard.edu			NCI NIH HHS [T32CA009078, CA71993] Funding Source: Medline; NIEHS NIH HHS [ES00002] Funding Source: Medline; NIGMS NIH HHS [GM40000] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071993, T32CA009078] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000002] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040000] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atamna H, 2000, P NATL ACAD SCI USA, V97, P686, DOI 10.1073/pnas.97.2.686; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Caldecott KW, 1996, NUCLEIC ACIDS RES, V24, P4387, DOI 10.1093/nar/24.22.4387; Chagovetz AM, 1997, J BIOL CHEM, V272, P27501, DOI 10.1074/jbc.272.44.27501; CHEN DS, 1991, NUCLEIC ACIDS RES, V19, P5907, DOI 10.1093/nar/19.21.5907; Chou KM, 2000, J BIOL CHEM, V275, P31009, DOI 10.1074/jbc.M004082200; Chou KM, 2003, J BIOL CHEM, V278, P18289, DOI 10.1074/jbc.M212143200; Chou KM, 2002, NATURE, V415, P655, DOI 10.1038/415655a; Chung U, 1996, J BIOL CHEM, V271, P8593, DOI 10.1074/jbc.271.15.8593; DEMPLE B, 1994, ANNU REV BIOCHEM, V63, P915, DOI 10.1146/annurev.biochem.63.1.915; Demple B, 2002, ONCOGENE, V21, P8926, DOI 10.1038/sj.onc.1206178; Dianova II, 2001, BIOCHEMISTRY-US, V40, P12639, DOI 10.1021/bi011117i; Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X; Fan ZS, 2003, NAT IMMUNOL, V4, P145, DOI 10.1038/ni885; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Gros L, 2002, ONCOGENE, V21, P8905, DOI 10.1038/sj.onc.1206005; Hadi MZ, 2002, J MOL BIOL, V316, P853, DOI 10.1006/jmbi.2001.5382; HORTON JK, 1995, NUCLEIC ACIDS RES, V23, P3810, DOI 10.1093/nar/23.19.3810; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Jiricny J, 2002, NATURE, V415, P593, DOI 10.1038/415593a; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Kelley MR, 2003, CANCER RES, V63, P549; Kerins SM, 2003, J BIOL CHEM, V278, P3048, DOI 10.1074/jbc.M210750200; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Kuninger DT, 2002, NUCLEIC ACIDS RES, V30, P823, DOI 10.1093/nar/30.3.823; Lebedeva NA, 2003, BIOCHEM BIOPH RES CO, V300, P182, DOI 10.1016/S0006-291X(02)02808-5; LEVIN JD, 1988, J BIOL CHEM, V263, P8066; Levin JD, 1996, NUCLEIC ACIDS RES, V24, P885, DOI 10.1093/nar/24.5.885; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; Ludwig DL, 1998, MUTAT RES-DNA REPAIR, V409, P17, DOI 10.1016/S0921-8777(98)00039-1; Masuda Y, 1998, J BIOL CHEM, V273, P30352, DOI 10.1074/jbc.273.46.30352; Meira LB, 2001, CANCER RES, V61, P5552; Mitra S, 2002, FREE RADICAL BIO MED, V33, P15, DOI 10.1016/S0891-5849(02)00819-5; Mol CD, 2000, NATURE, V403, P451, DOI 10.1038/35000249; Mol CD, 2000, MUTAT RES-DNA REPAIR, V460, P211, DOI 10.1016/S0921-8777(00)00028-8; Nakamura J, 1999, CANCER RES, V59, P2522; Nguyen LH, 2000, J MOL BIOL, V298, P447, DOI 10.1006/jmbi.2000.3653; OKAZAKI T, 1994, J BIOL CHEM, V269, P27855; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Pomposiello PJ, 2001, J BACTERIOL, V183, P3890, DOI 10.1128/JB.183.13.3890-3902.2001; Prasad R, 1996, J BIOL CHEM, V271, P16000, DOI 10.1074/jbc.271.27.16000; Ranalli TA, 2002, J BIOL CHEM, V277, P1719, DOI 10.1074/jbc.M109053200; Rogers S G, 1980, Methods Enzymol, V65, P201; Sander M, 1996, NUCLEIC ACIDS RES, V24, P3926, DOI 10.1093/nar/24.20.3926; SEKI S, 1991, BIOCHIM BIOPHYS ACTA, V1079, P57, DOI 10.1016/0167-4838(91)90024-T; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; TAKESHITA M, 1987, J BIOL CHEM, V262, P10171; Vidal AE, 2001, EMBO J, V20, P6530, DOI 10.1093/emboj/20.22.6530; WEISS B, 1987, ADV ENZYMOL RAMB, V60, P1; Wilson DM, 2003, J MOL BIOL, V330, P1027, DOI 10.1016/S0022-2836(03)00712-5; WILSON DM, 1995, J BIOL CHEM, V270, P16002, DOI 10.1074/jbc.270.27.16002; Wilson DM, 1997, NUCLEIC ACIDS RES, V25, P933, DOI 10.1093/nar/25.5.933; Wilson SH, 2000, NAT STRUCT BIOL, V7, P176; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Yang HJ, 2001, NUCLEIC ACIDS RES, V29, P743, DOI 10.1093/nar/29.3.743; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	58	57	60	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36242	36249		10.1074/jbc.M306065200	http://dx.doi.org/10.1074/jbc.M306065200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857737	hybrid			2022-12-27	WOS:000185318300046
J	Hatakeyama, J; Sreenath, T; Hatakeyama, Y; Thyagarajan, T; Shum, L; Gibson, CW; Wright, JT; Kulkarni, AB				Hatakeyama, J; Sreenath, T; Hatakeyama, Y; Thyagarajan, T; Shum, L; Gibson, CW; Wright, JT; Kulkarni, AB			The receptor activator of nuclear factor-B ligand-mediated osteoclastogenic pathway is elevated in amelogenin-null mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERIODONTAL-LIGAMENT CELLS; ENAMEL MATRIX PROTEINS; PRIMARY RNA TRANSCRIPT; GENE SPLICE PRODUCTS; ROOT RESORPTION; INDUCE OSTEOCLASTOGENESIS; TRANSLATION PRODUCT; TNF-RECEPTOR; IN-VITRO; EXPRESSION	Amelogenins, major components of developing enamel, are predominantly involved in the formation of tooth enamel. Although amelogenins are also implicated in cementogenesis, their precise spatial expression pattern and molecular role are not clearly understood. Here, we report for the first time the expression of two alternate splice forms of amelogenins, M180 and the leucine-rich amelogenin peptide ( LRAP), in the periodontal region of mouse tooth roots. Lack of M180 and LRAP mRNA expression correlated with cementum defects observed in the amelogenin-null mice. The cementum defects were characterized by an increased presence of multinucleated cells, osteoclasts, and cementicles. These defects were associated with an increased expression of the receptor activator of the nuclear factor-kappaB ligand ( RANKL), a critical regulator of osteoclastogenesis. These findings indicate that the amelogenin splice variants, M180 and LRAP, are critical in preventing abnormal resorption of cementum.	NIDCR, Funct Genom Unit, NIH, Bethesda, MD 20892 USA; NIAMS, Cartilage Biol & Orthopaed Branch, NIH, Bethesda, MD 20892 USA; Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; Univ N Carolina, Dept Pediat Dent, Chapel Hill, NC 27599 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill	Kulkarni, AB (corresponding author), NIDCR, Funct Genom Unit, NIH, 30 Convent Dr,Bldg 30,Rm 527, Bethesda, MD 20892 USA.		Wright, John Timothy/AAX-5755-2020		NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [ZIADE000698, Z01DE000698] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		ALTHOFF J, 1986, J ORAL PATHOL MED, V15, P11, DOI 10.1111/j.1600-0714.1986.tb00557.x; Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Borum MK, 1998, ENDOD DENT TRAUMATOL, V14, P31; Brezniak N, 2002, ANGLE ORTHOD, V72, P175; Cardaropoli G, 2002, J PERIODONTOL, V73, P501, DOI 10.1902/jop.2002.73.5.501; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; D'Errico JA, 1999, BONE, V25, P39, DOI 10.1016/S8756-3282(99)00096-4; DErrico JA, 1997, BONE, V20, P117, DOI 10.1016/S8756-3282(96)00348-1; DIEKWISCH T, 1993, DEVELOPMENT, V117, P471; Diekwisch TGH, 2001, INT J DEV BIOL, V45, P695; El-Mofty S, 2002, ORAL SURG ORAL MED O, V93, P296, DOI 10.1067/moe.2002.121545; Fong CD, 2000, ORAL SURG ORAL MED O, V90, P218, DOI 10.1067/moe.2000.107052; Fukae M, 2001, J BONE MINER METAB, V19, P236, DOI 10.1007/s007740170026; Gestrelius S, 1997, J CLIN PERIODONTOL, V24, P678, DOI 10.1111/j.1600-051X.1997.tb00249.x; GIBSON CW, 1991, BIOCHEM BIOPH RES CO, V174, P1306, DOI 10.1016/0006-291X(91)91564-S; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Gravallese EM, 2001, ARTHRITIS RES, V3, P6, DOI 10.1186/ar134; Gunraj MN, 1999, ORAL SURG ORAL MED O, V88, P647, DOI 10.1016/S1079-2104(99)70002-8; Hamamoto Y, 1996, ORAL SURG ORAL MED O, V81, P703, DOI 10.1016/S1079-2104(96)80077-1; Hammarstrom L, 1997, J CLIN PERIODONTOL, V24, P669, DOI 10.1111/j.1600-051X.1997.tb00248.x; Hasegawa T, 2002, J PERIODONTAL RES, V37, P405, DOI 10.1034/j.1600-0765.2002.01603.x; Hasegawa T, 2002, TISSUE CELL, V34, P44, DOI 10.1054/tice.2002.0223; Kanzaki H, 2002, J BONE MINER RES, V17, P210, DOI 10.1359/jbmr.2002.17.2.210; Kanzaki H, 2001, J DENT RES, V80, P887, DOI 10.1177/00220345010800030801; Kawamoto S, 2002, ARCH ORAL BIOL, V47, P67, DOI 10.1016/S0003-9969(01)00086-3; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; LAGERSTROM M, 1991, GENOMICS, V10, P971, DOI 10.1016/0888-7543(91)90187-J; LAU EC, 1992, BIOCHEM BIOPH RES CO, V188, P1253, DOI 10.1016/0006-291X(92)91366-X; Leach HA, 2001, BRIT DENT J, V190, P16, DOI 10.1038/sj.bdj.4800870a; LYNGSTADAAS SP, 1995, EMBO J, V14, P5224, DOI 10.1002/j.1460-2075.1995.tb00207.x; Oida S, 2002, J DENT RES, V81, P103, DOI 10.1177/154405910208100204; Papagerakis P, 2003, BONE, V32, P228, DOI 10.1016/S8756-3282(02)00978-X; SALIDO EC, 1992, AM J HUM GENET, V50, P303; Sashima M, 1996, J PERIODONTAL RES, V31, P470, DOI 10.1111/j.1600-0765.1996.tb01411.x; Shin JN, 2002, J BIOL CHEM, V277, P8346, DOI 10.1074/jbc.M110964200; SIMMER JP, 1994, CALCIFIED TISSUE INT, V55, P302, DOI 10.1007/BF00310410; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; SLAVKIN HC, 1989, BIOCHIM BIOPHYS ACTA, V991, P12, DOI 10.1016/0304-4165(89)90021-4; SLAVKIN HC, 1976, J PERIODONTOL, V47, P249, DOI 10.1902/jop.1976.47.5.249; SLAVKIN HC, 1989, J PERIODONTAL RES, V24, P28, DOI 10.1111/j.1600-0765.1989.tb00854.x; Udagawa N, 1999, BONE, V25, P517, DOI 10.1016/S8756-3282(99)00210-0; Veis A, 2003, CELL MOL LIFE SCI, V60, P38, DOI 10.1007/s000180300003; Veis A, 2000, J BIOL CHEM, V275, P41263, DOI 10.1074/jbc.M002308200; Velasquez-Plata D, 2002, J PERIODONTOL, V73, P433, DOI 10.1902/jop.2002.73.4.433; WRIGHT JT, 1989, J DENT RES, V68, P1328, DOI 10.1177/00220345890680090801; Wright JT, 1997, ARCH ORAL BIOL, V42, P149, DOI 10.1016/S0003-9969(96)00096-9; Yagishita H, 2001, J ORAL PATHOL MED, V30, P499, DOI 10.1034/j.1600-0714.2001.030008499.x; Yasuda H, 1998, P NATL ACAD SCI USA, V95, P3597, DOI 10.1073/pnas.95.7.3597; Zeichner-David M, 2001, MATRIX BIOL, V20, P307, DOI 10.1016/S0945-053X(01)00155-X	49	73	76	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35743	35748		10.1074/jbc.M306284200	http://dx.doi.org/10.1074/jbc.M306284200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12851394	hybrid, Green Published			2022-12-27	WOS:000185164400121
J	Gruez, A; Roig-Zamboni, V; Valencia, C; Campanacci, VR; Cambillau, C				Gruez, A; Roig-Zamboni, V; Valencia, C; Campanacci, VR; Cambillau, C			The crystal structure of the Escherichia coli YfdW gene product reveals a new fold of two interlaced rings identifying a wide family of CoA transferases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A TRANSFERASE; OXALOBACTER-FORMIGENES; OXALATE; PROTEIN; PURIFICATION; MODEL	Because of its toxicity, oxalate accumulation from amino acid catabolism leads to acute disorders in mammals. Gut microflora are therefore pivotal in maintaining a safe intestinal oxalate balance through oxalate degradation. Oxalate catabolism was first identified in Oxalobacter formigenes, a specialized, strictly anaerobic bacterium. Oxalate degradation was found to be performed successively by two enzymes, a formyl-CoA transferase (frc) and an oxalate decarboxylase (oxc). These two genes are present in several bacterial genomes including that of Escherichia coli. The frc ortholog in E. coli is yfdW, with which it shares 61% sequence identity. We have expressed the YfdW open reading frame product and solved its crystal structure in the apo-form and in complex with acetyl-CoA and with a mixture of acetyl-CoA and oxalate. YfdW exhibits a novel and spectacular fold in which two monomers assemble as interlaced rings, defining the CoA binding site at their interface. From the structure of the complex with acetyl-CoA and oxalate, we propose a putative formyl/oxalate transfer mechanism involving the conserved catalytic residue Asp(169). The similarity of yfdW with bacterial orthologs (similar to 60% identity) and paralogs (similar to 20-30% identity) suggests that this new fold and parts of the CoA transfer mechanism are likely to be the hallmarks of a wide family of CoA transferases.	CNRS, Architecture & Fonct Macromol Biol, UMR 6098, F-13402 Marseille 20, France; Univ Aix Marseille 1, F-13402 Marseille 20, France; Univ Aix Marseille 2, F-13402 Marseille 20, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite; UDICE-French Research Universities; Aix-Marseille Universite	Cambillau, C (corresponding author), CNRS, Architecture & Fonct Macromol Biol, UMR 6098, 31 Chemin J Aiguier, F-13402 Marseille 20, France.	cambillau@afmb.cnrs-mrs.fr		Campanacci, Valerie/0000-0001-6407-6395				ALLISON MJ, 1985, ARCH MICROBIOL, V141, P1, DOI 10.1007/BF00446731; ANANTHARAM V, 1989, J BIOL CHEM, V264, P7244; BAETZ AL, 1990, J BACTERIOL, V172, P3537, DOI 10.1128/jb.172.7.3537-3540.1990; BAETZ AL, 1989, J BACTERIOL, V171, P2605, DOI 10.1128/jb.171.5.2605-2608.1989; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Claverie JM, 2002, COMB CHEM HIGH T SCR, V5, P511, DOI 10.2174/1386207023330002; DOANE LT, 1989, NUTR RES, V9, P957, DOI 10.1016/S0271-5317(89)80056-9; Doublie S, 1997, METHOD ENZYMOL, V276, P523, DOI 10.1016/S0076-6879(97)76075-0; Duncan SH, 2002, APPL ENVIRON MICROB, V68, P3841, DOI 10.1128/AEM.68.8.3841-3847.2002; Engel C, 1996, CURR OPIN STRUC BIOL, V6, P790, DOI 10.1016/S0959-440X(96)80009-1; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JAMES LF, 1972, CLIN TOXICOL, V5, P231, DOI 10.3109/15563657208991002; KRAUT J, 1977, ANNU REV BIOCHEM, V46, P331, DOI 10.1146/annurev.bi.46.070177.001555; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; RODBY RA, 1991, AM J MED, V90, P498; Roussel A, 1991, SILICON GRAPHICS GEO, P81; RUAN ZS, 1992, J BIOL CHEM, V267, P10537; Schlunegger MP, 1997, ADV PROTEIN CHEM, V50, P61, DOI 10.1016/S0065-3233(08)60319-8; Sidhu H, 1997, J BACTERIOL, V179, P3378, DOI 10.1128/jb.179.10.3378-3381.1997; Sulzenbacher G, 2002, ACTA CRYSTALLOGR D, V58, P2109, DOI 10.1107/S0907444902013938; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; VANTILBEURGH H, 1993, NATURE, V362, P814, DOI 10.1038/362814a0; WILLIAMS HE, 1968, AM J MED, V45, P715, DOI 10.1016/0002-9343(68)90207-6	29	27	30	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					34582	34586		10.1074/jbc.C300282200	http://dx.doi.org/10.1074/jbc.C300282200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12844490	hybrid			2022-12-27	WOS:000185047500119
J	Turella, P; Pedersen, JZ; Caccuri, AM; De Maria, F; Mastroberardino, P; Lo Bello, M; Federici, G; Ricci, G				Turella, P; Pedersen, JZ; Caccuri, AM; De Maria, F; Mastroberardino, P; Lo Bello, M; Federici, G; Ricci, G			Glutathione transferase superfamily behaves like storage proteins for dinitrosyl-diglutathionyl-iron complex in heterogeneous systems	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EVOLUTIONARY STRATEGIES; S-TRANSFERASES; T2-2 DISCLOSES; OPTIMIZATION; BINDING; SITE; RAT	Electron paramagnetic resonance and kinetics experiments have been made to determine the formation, stability, and fate of the natural nitric oxide carrier, dinitrosyl-diglutathionyl-iron complex (DNDGIC), in heterogeneous systems approaching in vivo conditions. Both in human placenta and rat liver homogenates DNDGIC is formed spontaneously from GSH, S-nitrosoglutathione, and trace amounts of ferrous ions. DNDGIC is unstable in homogenates depleted of glutathione S-transferase (GST); an initial phase of rapid decomposition is followed by a slower decay, which is inversely proportional to the concentration. In the crude human placenta homogenate, GSTP1-1, which represents 90% of the cytosolic GST isoenzymes, is the preferential target for DNDGIC. It binds the complex almost stoichiometrically and stabilizes it for several hours (t(1/2) = 8 h). In the presence of an excess of DNDGIC, negative cooperativity in GSTP1-1 opposes the complete loss of the usual detoxicating activity of this enzyme. In the rat liver homogenate, multiple endogenous GSTs (mainly Alpha and Mu class isoenzymes) bind the complex quantitatively and stabilize it (t(1/2) = 4.5 h); negative cooperativity is also seen for these GSTs. Thus, the entire pool of cytosolic GSTs, with the exception of the Theta GST, represents a target for stoichiometric amounts of DNDGIC and may act as storage proteins for nitric oxide. These results confirm the existence of a cross-link between NO metabolism and the GST superfamily.	Univ Roma Tor Vergata, Dept Chem Sci & Technol, I-00133 Rome, Italy; Univ Roma Tor Vergata, Dept Biol, I-00133 Rome, Italy; Childrens Hosp IRCCS Bambin Gesu, I-00146 Rome, Italy	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Bambino Gesu	Ricci, G (corresponding author), Univ Roma Tor Vergata, Dept Chem Sci & Technol, Via Ric Sci, I-00133 Rome, Italy.	riccig@uniroma2.it	Mastroberardino, Pier/D-5623-2009; CACCURI, ANNA MARIA/AFU-2643-2022	MASTROBERARDINO, PIER GIORGIO/0000-0003-2364-4258; CACCURI, ANNA MARIA/0000-0002-3756-4163; Ricci, Giorgio/0000-0002-7108-2846				ADANG AEP, 1990, BIOCHEM J, V269, P47, DOI 10.1042/bj2690047; Bentz BG, 2000, LARYNGOSCOPE, V110, P1642, DOI 10.1097/00005537-200010000-00013; Caccuri AM, 2001, J BIOL CHEM, V276, P5427, DOI 10.1074/jbc.M002819200; Caccuri AM, 2001, J BIOL CHEM, V276, P5432, DOI 10.1074/jbc.M002818200; De Maria F, 2003, J BIOL CHEM, V278, P42283, DOI 10.1074/jbc.M305568200; dErrico A, 1996, BIOMARKERS, V1, P149, DOI 10.3109/13547509609079352; Lo Bello M, 2001, J BIOL CHEM, V276, P42138; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MEYER DJ, 1991, BIOCHEM J, V274, P409, DOI 10.1042/bj2740409; MULSCH A, 1991, FEBS LETT, V294, P252, DOI 10.1016/0014-5793(91)81441-A; PEDERSEN JZ, 1988, J MAGN RESON, V77, P369, DOI 10.1016/0022-2364(88)90186-2; SIMONS PC, 1977, ANAL BIOCHEM, V82, P334, DOI 10.1016/0003-2697(77)90169-5; Singh RJ, 1996, J BIOL CHEM, V271, P18596, DOI 10.1074/jbc.271.31.18596; VANIN AF, 1987, BIOFIZIKA+, V32, P128; YEH HI, 1995, BIOCHEM J, V308, P69, DOI 10.1042/bj3080069	15	51	54	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42294	42299		10.1074/jbc.M305569200	http://dx.doi.org/10.1074/jbc.M305569200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12871931	hybrid			2022-12-27	WOS:000185989500089
J	Arunkumar, AI; Stauffer, ME; Bochkareva, E; Bochkarev, A; Chazin, WJ				Arunkumar, AI; Stauffer, ME; Bochkareva, E; Bochkarev, A; Chazin, WJ			Independent and coordinated functions of replication protein a tandem high affinity single-stranded DNA binding domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SSDNA BINDING; RPA; MECHANISM; POLARITY; SUBUNITS; SUGGESTS; REVEALS; REPAIR; SSB	The initial high affinity binding of single-stranded DNA (ssDNA) by replication protein A (RPA) is involved in the tandem domains in the central region of the RPA70 subunit (RPA70AB). However, it was not clear whether the two domains, RPA70A and RPA70B, bind DNA simultaneously or sequentially. Here, using primarily heteronuclear NMR complemented by fluorescence spectroscopy, we have analyzed the binding characteristics of the individual RPA70A and RPA70B domains and compared them with the intact RPA70AB. NMR chemical shift comparisons confirmed that RPA70A and RPA70B tumble independently in solution in the absence of ssDNA. NMR chemical shift perturbations showed that all ssDNA oligomers bind to the same sites as observed in the x-ray crystal structure of RPA70AB complexed to d(C)(8). Titrations using a variety of 5'-mer ssDNA oligomers showed that RPA70A has a 5-10-fold higher affinity for ssDNA than RPA70B. Detailed analysis of ssDNA binding to RPA70A revealed that all DNA sequences interact in a similar mode. Fluorescence binding measurements with a variety of 8-10'-mer DNA sequences showed that RPA70AB interacts with DNA with similar to 100-fold higher affinity than the isolated domains. Calculation of the theoretical "linkage effect" from the structure of RPA70AB suggests that the high overall affinity for ssDNA is a byproduct of the covalent attachment of the two domains via a short flexible tether, which increases the effective local concentration. Taken together, our data are consistent with a sequential model of DNA binding by RPA according to which RPA70A binds the majority of DNA first and subsequent loading of RPA70B domain is facilitated by the linkage effect.	Vanderbilt Univ, Ctr Struct Biol, Dept Biochem, Nashville, TN 37232 USA; Vanderbilt Univ, Ctr Struct Biol, Dept Phys, Nashville, TN 37232 USA; Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA	Vanderbilt University; Vanderbilt University; University of Oklahoma System; University of Oklahoma Health Sciences Center	Chazin, WJ (corresponding author), Vanderbilt Univ, Ctr Struct Biol, Dept Biochem, 5140 BIOSCI,MRB3, Nashville, TN 37232 USA.			Alphonse Ignatius, Arun/0000-0002-7342-044X	NCI NIH HHS [T32 CA009582, P30 CA68485] Funding Source: Medline; NIEHS NIH HHS [P30 ES00267] Funding Source: Medline; NIGMS NIH HHS [R01 GM65484, R01 GM61192, R01 GM065484] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA068485, T32CA009582] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065484, R01GM061192] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bastin-Shanower SA, 2001, J BIOL CHEM, V276, P36446, DOI 10.1074/jbc.M104386200; Bhattacharya S, 2002, PROTEIN SCI, V11, P2316, DOI 10.1110/ps.0209202; BHATTACHARYA S, 2003, IN PRESS J BIOMOL NM; Bochkarev A, 1997, NATURE, V385, P176, DOI 10.1038/385176a0; Bochkarev A, 1999, EMBO J, V18, P4498, DOI 10.1093/emboj/18.16.4498; Bochkareva E, 2001, EMBO J, V20, P612, DOI 10.1093/emboj/20.3.612; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; Daughdrill GW, 2001, NUCLEIC ACIDS RES, V29, P3270, DOI 10.1093/nar/29.15.3270; de Laat WL, 1998, GENE DEV, V12, P2598, DOI 10.1101/gad.12.16.2598; Hall DA, 2001, P NATL ACAD SCI USA, V98, P9521, DOI 10.1073/pnas.171168898; Iftode C, 2000, BIOCHEMISTRY-US, V39, P11970, DOI 10.1021/bi0005761; Iftode C, 1999, CRIT REV BIOCHEM MOL, V34, P141, DOI 10.1080/10409239991209255; Jacobs DM, 1999, J BIOMOL NMR, V14, P321, DOI 10.1023/A:1008373009786; KIM CS, 1994, BIOCHEMISTRY-US, V33, P14197, DOI 10.1021/bi00251a031; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; Kolpashchikov DM, 2001, NUCLEIC ACIDS RES, V29, P373, DOI 10.1093/nar/29.2.373; Lavrik OI, 1999, NUCLEIC ACIDS RES, V27, P4235, DOI 10.1093/nar/27.21.4235; Mer G, 2000, CELL, V103, P449, DOI 10.1016/S0092-8674(00)00136-7; Mer G, 2000, COLD SPRING HARB SYM, V65, P193, DOI 10.1101/sqb.2000.65.193; Palmer A. G., 1996, PROTEIN NMR SPECTROS; Pfuetzner RA, 1997, J BIOL CHEM, V272, P430; Philipova D, 1996, GENE DEV, V10, P2222, DOI 10.1101/gad.10.17.2222; Sibenaller ZA, 1998, BIOCHEMISTRY-US, V37, P12496, DOI 10.1021/bi981110+; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; ZHANG OW, 1994, J BIOMOL NMR, V4, P845, DOI 10.1007/BF00398413; Zhou HX, 2001, BIOCHEMISTRY-US, V40, P15069, DOI 10.1021/bi015795g	26	93	94	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41077	41082		10.1074/jbc.M305871200	http://dx.doi.org/10.1074/jbc.M305871200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12881520	hybrid			2022-12-27	WOS:000185847200082
J	Haston, JL; Engelsen, SB; Roessle, M; Clarkson, J; Blanch, EW; Baldock, C; Kielty, CM; Wess, TJ				Haston, JL; Engelsen, SB; Roessle, M; Clarkson, J; Blanch, EW; Baldock, C; Kielty, CM; Wess, TJ			Raman Microscopy and X-ray diffraction, a combined study of fibrillin-rich microfibrillar elasticity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAMOLECULAR ORGANIZATION; MECHANICAL-PROPERTIES; SECONDARY STRUCTURE; ALPHA-HELIX; SPECTROSCOPY; FD; DETERMINES; PROTEINS; DOMAINS	Fibrillin-rich microfibrils are essential elastic structures contained within the extracellular matrix of a wide variety of connective tissues. Microfibrils are characterized as beaded filamentous structures with a variable axial periodicity ( average 56 nm in the untensioned state); however, the basis of their elasticity remains unknown. This study used a combination of small angle x-ray scattering and Raman microscopy to investigate further the packing of microfibrils within the intact tissue and to determine the role of molecular reorganization in the elasticity of these microfibrils. The application of relatively small strains produced no overall change in either molecular or macromolecular microfibrillar structure. In contrast, the application of larger tissue extensions (up to 150%) resulted in a markedly different structure, as observed by both Raman microscopy and small angle x-ray scattering. These changes occurred at different levels of architecture and are interpreted as ranging from alterations in peptide bond conformation to domain rearrangement. This study demonstrates the importance of molecular elasticity in the mechanical properties of fibrillin-rich microfibrils in the intact tissue.	Univ Stirling, Dept Biol Sci, Ctr Extracellular Matrix Biol, Stirling FK9 4LA, Scotland; Royal Vet & Agr Univ, Food Technol Ctr Adv Food Studies, DK-1958 Frederiksberg C, Denmark; European Synchrotron Radiat Facil, F-38043 Grenoble, France; Univ Glasgow, Dept Chem, Glasgow G12 8QQ, Lanark, Scotland; Univ Manchester, Dept Biomol Sci, Manchester M60 1QD, Lancs, England; Univ Manchester, Sch Biol Sci, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England; Univ Manchester, Sch Med, Wellcome Trust Ctr Cell Matrix Res, Manchester M13 9PT, Lancs, England	University of Stirling; University of Copenhagen; European Synchrotron Radiation Facility (ESRF); University of Glasgow; University of Manchester; University of Manchester; University of Manchester	Haston, JL (corresponding author), Univ Stirling, Dept Biol Sci, Ctr Extracellular Matrix Biol, Stirling FK9 4LA, Scotland.	j.l.haston@stir.ac.uk	Engelsen, Søren/D-7911-2011	Engelsen, Søren/0000-0003-4124-4338; Baldock, Clair/0000-0003-3497-1959; Blanch, Ewan/0000-0002-0781-4926; Rossle, Manfred/0000-0003-4196-0430				Baldock C, 2001, J CELL BIOL, V152, P1045, DOI 10.1083/jcb.152.5.1045; Barron LD, 2000, PROG BIOPHYS MOL BIO, V73, P1, DOI 10.1016/S0079-6107(99)00017-6; DEBELLE L, 1995, J BIOL CHEM, V270, P26099, DOI 10.1074/jbc.270.44.26099; Downing AK, 1996, CELL, V85, P597, DOI 10.1016/S0092-8674(00)81259-3; Eriksen TA, 2001, PROTEINS, V45, P90, DOI 10.1002/prot.1127; HAMMERSLEY AO, 1993, EXPAH9302 ESRF INF O; Kielty CM, 2002, J MUSCLE RES CELL M, V23, P581, DOI 10.1023/A:1023479010889; Kielty CM, 2002, PHILOS T R SOC B, V357, P207, DOI 10.1098/rstb.2001.1029; Kielty CM, 2002, J CELL SCI, V115, P2817; LIPPERT JL, 1976, J AM CHEM SOC, V98, P7075, DOI 10.1021/ja00438a057; McConnell CJ, 1997, J PHYSIOL-LONDON, V499, P513, DOI 10.1113/jphysiol.1997.sp021945; Miura T, 1995, Subcell Biochem, V24, P55; Nielsen AS, 2002, POLYMER, V43, P2671, DOI 10.1016/S0032-3861(02)00053-8; Overman SA, 1998, BIOCHEMISTRY-US, V37, P5654, DOI 10.1021/bi972339c; Overman SA, 1999, BIOCHEMISTRY-US, V38, P4018, DOI 10.1021/bi982901e; OVERMAN SA, 1995, BIOCHEMISTRY-US, V34, P5440, DOI 10.1021/bi00016a015; Qian RQ, 1997, BIOCHEMISTRY-US, V36, P15841, DOI 10.1021/bi971036f; Reinhardt DP, 1996, J MOL BIOL, V258, P104, DOI 10.1006/jmbi.1996.0237; Robb BW, 1999, MOL BIOL CELL, V10, P3595, DOI 10.1091/mbc.10.11.3595; Thurmond FA, 1996, J EXP BIOL, V199, P1817; Trask TM, 1999, BIOCHEM J, V340, P693, DOI 10.1042/0264-6021:3400693; Wess TJ, 1997, FEBS LETT, V413, P424, DOI 10.1016/S0014-5793(97)00950-2; Wess TJ, 1998, J CELL BIOL, V141, P829, DOI 10.1083/jcb.141.3.829; Wess TJ, 1998, J STRUCT BIOL, V122, P123, DOI 10.1006/jsbi.1998.3992; Wright DM, 1999, J EXP BIOL, V202, P3011; Yuan XM, 1997, EMBO J, V16, P6659, DOI 10.1093/emboj/16.22.6659	26	21	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41189	41197		10.1074/jbc.M212854200	http://dx.doi.org/10.1074/jbc.M212854200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12876292	hybrid, Green Published			2022-12-27	WOS:000185847200096
J	Stanasila, L; Perez, JB; Vogel, H; Cotecchia, S				Stanasila, L; Perez, JB; Vogel, H; Cotecchia, S			Oligomerization of the alpha 1a- and alpha 1b-adrenergic receptor subtypes - Potential implications in receptor internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED-RECEPTOR; RESONANCE ENERGY-TRANSFER; DELTA-OPIOID RECEPTOR; ALPHA(1B)-ADRENERGIC RECEPTOR; EXTRACELLULAR DOMAIN; ADRENERGIC-RECEPTOR; HORMONE RECEPTOR; CROSS-TALK; DIMERIZATION; HETERODIMERIZATION	We combined biophysical, biochemical, and pharmacological approaches to investigate the ability of the alpha(1a)- and alpha(1b)-adrenergic receptor (AR) subtypes to form homo- and hetero-oligomers. Receptors tagged with different epitopes (hemagglutinin and Myc) or fluorescent proteins (cyan and green fluorescent proteins) were transiently expressed in HEK-293 cells either individually or in different combinations. Fluorescence resonance energy transfer measurements provided evidence that both the alpha(1a)- and alpha(1b)-AR can form homo-oligomers with similar transfer efficiency of similar to0.10. Hetero-oligomers could also be observed between the alpha(1b)- and the alpha(1a)-AR subtypes but not between the alpha(1b)-AR and the beta(2)-AR, the NK1 tachykinin, or the CCR5 chemokine receptors. Oligomerization of the alpha(1b)-AR did not require the integrity of its C-tail, of two glycophorin motifs, or of the N-linked glycosylation sites at its N terminus. In contrast, helix I and, to a lesser extent, helix VII were found to play a role in the alpha(1b)-AR homo-oligomerization. Receptor oligomerization was not influenced by the agonist epinephrine or by the inverse agonist prazosin. A constitutively active (A293E) as well as a signaling-deficient (R143E) mutant displayed oligomerization features similar to those of the wild type alpha(1b)-AR. Confocal imaging revealed that oligomerization of the alpha(1)-AR subtypes correlated with their ability to co-internalize upon exposure to the agonist. The alpha(1a)-selective agonist oxymetazoline induced the co-internalization of the alpha(1a)- and alpha(1b)-AR, whereas the alpha(1b)-AR could not co-internalize with the NK1 tachykinin or CCR5 chemokine receptors. Oligomerization might therefore represent an additional mechanism regulating the physiological responses mediated by the alpha(1a)- and alpha(1b)-AR subtypes.	Ecole Polytech Fed Lausanne, Lab Chim Phys Polymeres & Membranes, CH-1015 Ecublens, Switzerland; Univ Lausanne, Inst Pharmacol & Toxicol, CH-1005 Lausanne, Switzerland	Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne	Vogel, H (corresponding author), Ecole Polytech Fed Lausanne, Lab Chim Phys Polymeres & Membranes, CH-1015 Ecublens, Switzerland.		Vogel, Horst/AAJ-5490-2021					AbdAlla S, 1999, J BIOL CHEM, V274, P26079, DOI 10.1074/jbc.274.37.26079; AbdAlla S, 2001, NAT MED, V7, P1003, DOI 10.1038/nm0901-1003; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Angers S, 2001, LIFE SCI, V68, P2243, DOI 10.1016/S0024-3205(01)01012-8; Angers S, 2002, ANNU REV PHARMACOL, V42, P409, DOI 10.1146/annurev.pharmtox.42.091701.082314; Bjorklof K, 2002, BIOCHEMISTRY-US, V41, P4281, DOI 10.1021/bi015790j; Cheng ZJ, 2001, J BIOL CHEM, V276, P48040, DOI 10.1074/jbc.M105668200; Ciruela F, 2001, J BIOL CHEM, V276, P18345, DOI 10.1074/jbc.M006960200; Cornea A, 2001, J BIOL CHEM, V276, P2153, DOI 10.1074/jbc.M007850200; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; Cvejic S, 1997, J BIOL CHEM, V272, P26959, DOI 10.1074/jbc.272.43.26959; Devi LA, 2001, TRENDS PHARMACOL SCI, V22, P532, DOI 10.1016/S0165-6147(00)01799-5; Diviani D, 1997, J BIOL CHEM, V272, P28712, DOI 10.1074/jbc.272.45.28712; Filizola M, 2002, BIOPOLYMERS, V66, P317, DOI 10.1002/bip.10311; Gama L, 2001, J BIOL CHEM, V276, P39053, DOI 10.1074/jbc.M105662200; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; Gomes I, 2001, J MOL MED, V79, P226, DOI 10.1007/s001090100219; Gouldson PR, 2000, NEUROPSYCHOPHARMACOL, V23, pS60, DOI 10.1016/S0893-133X(00)00153-6; Guo W, 2003, J BIOL CHEM, V278, P4385, DOI 10.1074/jbc.C200679200; Hebert TE, 1996, J BIOL CHEM, V271, P16384, DOI 10.1074/jbc.271.27.16384; Hebert TE, 1998, BIOCHEM J, V330, P287; Hur EM, 2002, CELL SIGNAL, V14, P397, DOI 10.1016/S0898-6568(01)00258-3; Jordan BA, 1999, NATURE, V399, P697, DOI 10.1038/21441; Jordan BA, 2001, P NATL ACAD SCI USA, V98, P343, DOI 10.1073/pnas.011384898; Kroeger KM, 2001, J BIOL CHEM, V276, P12736, DOI 10.1074/jbc.M011311200; Lavoie C, 2002, J BIOL CHEM, V277, P35402, DOI 10.1074/jbc.M204163200; Liang Y, 2003, J BIOL CHEM, V278, P21655, DOI 10.1074/jbc.M302536200; Maggio R, 1999, J PHARMACOL EXP THER, V291, P251; Margeta-Mitrovic M, 2000, NEURON, V27, P97, DOI 10.1016/S0896-6273(00)00012-X; McVey M, 2001, J BIOL CHEM, V276, P14092, DOI 10.1074/jbc.M008902200; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Mhaouty-Kodja S, 1999, MOL PHARMACOL, V55, P339, DOI 10.1124/mol.55.2.339; Overton MC, 2000, CURR BIOL, V10, P341, DOI 10.1016/S0960-9822(00)00386-9; Overton MC, 2002, J BIOL CHEM, V277, P41463, DOI 10.1074/jbc.M205368200; Pace AJ, 1999, J BIOL CHEM, V274, P11629, DOI 10.1074/jbc.274.17.11629; Patel RC, 2002, P NATL ACAD SCI USA, V99, P3294, DOI 10.1073/pnas.042705099; Pfeiffer M, 2002, J BIOL CHEM, V277, P19762, DOI 10.1074/jbc.M110373200; Pollok BA, 1999, TRENDS CELL BIOL, V9, P57, DOI 10.1016/S0962-8924(98)01434-2; Ray K, 1999, J BIOL CHEM, V274, P27642, DOI 10.1074/jbc.274.39.27642; Rocheville M, 2000, SCIENCE, V288, P154, DOI 10.1126/science.288.5463.154; Rocheville M, 2000, J BIOL CHEM, V275, P7862, DOI 10.1074/jbc.275.11.7862; Russ WP, 2000, J MOL BIOL, V296, P911, DOI 10.1006/jmbi.1999.3489; Scheer A, 2000, MOL PHARMACOL, V57, P219; SCHWINN DA, 1995, J PHARMACOL EXP THER, V272, P134; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; Terrillon S, 2003, MOL ENDOCRINOL, V17, P677, DOI 10.1210/me.2002-0222; Vila-Coro AJ, 1999, FASEB J, V13, P1699, DOI 10.1096/fasebj.13.13.1699; Watson C, 2000, MOL PHARMACOL, V58, P1230, DOI 10.1124/mol.58.6.1230; Yoshioka K, 2001, P NATL ACAD SCI USA, V98, P7617, DOI 10.1073/pnas.121587098; Zeng FY, 1999, J BIOL CHEM, V274, P19487, DOI 10.1074/jbc.274.27.19487	50	140	143	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40239	40251		10.1074/jbc.M306085200	http://dx.doi.org/10.1074/jbc.M306085200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888550	hybrid			2022-12-27	WOS:000185713800117
J	Waki, H; Yamauchi, T; Kamon, J; Ito, Y; Uchida, S; Kita, S; Hara, K; Hada, Y; Vasseur, F; Froguel, P; Kimura, S; Nagai, R; Kadowaki, T				Waki, H; Yamauchi, T; Kamon, J; Ito, Y; Uchida, S; Kita, S; Hara, K; Hada, Y; Vasseur, F; Froguel, P; Kimura, S; Nagai, R; Kadowaki, T			Impaired multimerization of human adiponectin mutants associated with diabetes - Molecular structure and multimer formation of adiponectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENT-RELATED PROTEIN; ADIPOSE-SPECIFIC GENE; FATTY-ACID OXIDATION; INSULIN-RESISTANCE; METAPHYSEAL CHONDRODYSPLASIA; ADIPOCYTE DIFFERENTIATION; SUSCEPTIBILITY GENES; X COLLAGEN; MUTATIONS; DOMAIN	Adiponectin is an adipocyte-derived hormone, which has been shown to play important roles in the regulation of glucose and lipid metabolism. Eight mutations in human adiponectin have been reported, some of which were significantly related to diabetes and hypoadiponectinemia, but the molecular mechanisms of decreased plasma levels and impaired action of adiponectin mutants were not clarified. Adiponectin structurally belongs to the complement 1q family and is known to form a characteristic homomultimer. Herein, we demonstrated that simple SDS-PAGE under non-reducing and non-heat-denaturing conditions clearly separates multimer species of adiponectin. Adiponectin in human or mouse serum and adiponectin expressed in NIH-3T3 or Escherichia coli formed a wide range of multimers from trimers to high molecular weight (HMW) multimers. A disulfide bond through an amino-terminal cysteine was required for the formation of multimers larger than a trimer. An amino-terminal Cys-Ser mutation, which could not form multimers larger than a trimer, abrogated the effect of adiponectin on the AMP-activated protein kinase pathway in hepatocytes. Among human adiponectin mutations, G84R and G90S mutants, which are associated with diabetes and hypoadiponectinemia, did not form HMW multimers. R112C and I164T mutants, which are associated with hypoadiponectinemia, did not assemble into trimers, resulting in impaired secretion from the cell. These data suggested impaired multimerization and/or the consequent impaired secretion to be among the causes of a diabetic phenotype or hypoadiponectinemia in subjects having these mutations. In conclusion, not only total concentrations, but also multimer distribution should always be considered in the interpretation of plasma adiponectin levels in health as well as various disease states.	Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, Tokyo 1138655, Japan; Japan Sci & Technol Corp, CREST, Tokyo 3320012, Japan; Inst Pasteur, Inst Biol Lille, CNRS 8090, F-59000 Lille, France; CHU Lille, F-59000 Lille, France	University of Tokyo; Japan Science & Technology Agency (JST); Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Universite de Lille - ISITE; Institut Pasteur Lille; Universite de Lille - ISITE; CHU Lille	Kadowaki, T (corresponding author), Univ Tokyo, Grad Sch Med, Dept Internal Med, Bunkyo Ku, 7-3-1 Hongo, Tokyo 1138655, Japan.		FROGUEL, Philippe/O-6799-2017; Waki, Hironori/AAE-3942-2020	FROGUEL, Philippe/0000-0003-2972-0784; Waki, Hironori/0000-0002-5302-9793	MRC [G0000477] Funding Source: UKRI; Medical Research Council [G0000477] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Arita Y, 1999, BIOCHEM BIOPH RES CO, V257, P79, DOI 10.1006/bbrc.1999.0255; Berg AH, 2001, NAT MED, V7, P947, DOI 10.1038/90992; Chan D, 1999, J BIOL CHEM, V274, P13091, DOI 10.1074/jbc.274.19.13091; CROUCH E, 1994, J BIOL CHEM, V269, P17311; Fruebis J, 2001, P NATL ACAD SCI USA, V98, P2005, DOI 10.1073/pnas.041591798; Hara K, 2002, DIABETES, V51, P536, DOI 10.2337/diabetes.51.2.536; Hickling TP, 1998, MOL MED, V4, P266, DOI 10.1007/BF03401923; Hu E, 1996, J BIOL CHEM, V271, P10697, DOI 10.1074/jbc.271.18.10697; KADOWAKI T, 1990, P NATL ACAD SCI USA, V87, P658, DOI 10.1073/pnas.87.2.658; Kissebah AH, 2000, P NATL ACAD SCI USA, V97, P14478, DOI 10.1073/pnas.97.26.14478; Kondo H, 2002, DIABETES, V51, P2325, DOI 10.2337/diabetes.51.7.2325; Kubota N, 2002, J BIOL CHEM, V277, P25863, DOI 10.1074/jbc.C200251200; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Maeda K, 1996, BIOCHEM BIOPH RES CO, V221, P286, DOI 10.1006/bbrc.1996.0587; Maeda N, 2002, NAT MED, V8, P731, DOI 10.1038/nm724; Marks DS, 1999, J BIOL CHEM, V274, P3632, DOI 10.1074/jbc.274.6.3632; McCormack FX, 1997, J BIOL CHEM, V272, P27971, DOI 10.1074/jbc.272.44.27971; Miki H, 2001, MOL CELL BIOL, V21, P2521, DOI 10.1128/MCB.21.7.2521-2532.2001; Mori Y, 2002, DIABETES, V51, P1247, DOI 10.2337/diabetes.51.4.1247; Nakano Y, 1996, J BIOCHEM-TOKYO, V120, P803; Pajvani UB, 2003, J BIOL CHEM, V278, P9073, DOI 10.1074/jbc.M207198200; Sato C, 2001, J BIOL CHEM, V276, P28849, DOI 10.1074/jbc.M104148200; SCHERER PE, 1995, J BIOL CHEM, V270, P26746, DOI 10.1074/jbc.270.45.26746; Shapiro L, 1998, CURR BIOL, V8, P335, DOI 10.1016/S0960-9822(98)70133-2; Takahashi M, 2000, INT J OBESITY, V24, P861, DOI 10.1038/sj.ijo.0801244; Tasanen K, 2000, J BIOL CHEM, V275, P3093, DOI 10.1074/jbc.275.5.3093; Tomas E, 2002, P NATL ACAD SCI USA, V99, P16309, DOI 10.1073/pnas.222657499; Tsao TS, 2002, J BIOL CHEM, V277, P29359, DOI 10.1074/jbc.C200312200; Vasseur F, 2002, HUM MOL GENET, V11, P2607, DOI 10.1093/hmg/11.21.2607; Vionnet N, 2000, AM J HUM GENET, V67, P1470, DOI 10.1086/316887; Wallis R, 1999, J IMMUNOL, V163, P4953; Wilson R, 2002, J BIOL CHEM, V277, P12516, DOI 10.1074/jbc.M112044200; Xie LJ, 2000, THROMB HAEMOSTASIS, V84, P506; Yamauchi T, 2002, NAT MED, V8, P1288, DOI 10.1038/nm788; Yamauchi T, 2001, NAT MED, V7, P941, DOI 10.1038/90984; Yokota T, 2000, BLOOD, V96, P1723, DOI 10.1182/blood.V96.5.1723; Zhang Y, 1999, J BIOL CHEM, V274, P22409, DOI 10.1074/jbc.274.32.22409	37	784	837	1	49	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40352	40363		10.1074/jbc.M300365200	http://dx.doi.org/10.1074/jbc.M300365200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12878598	hybrid			2022-12-27	WOS:000185713800129
J	Chen, DS; Lucey, MJ; Phoenix, F; Lopez-Garcia, J; Hart, SM; Losson, R; Buluwela, L; Coombes, RC; Chambon, P; Schar, P; Ali, S				Chen, DS; Lucey, MJ; Phoenix, F; Lopez-Garcia, J; Hart, SM; Losson, R; Buluwela, L; Coombes, RC; Chambon, P; Schar, P; Ali, S			T : G mismatch-specific thymine-DNA glycosylase potentiates transcription of estrogen-regulated genes through direct interaction with estrogen receptor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR HORMONE-RECEPTORS; RETINOIC ACID RECEPTORS; COACTIVATOR COMPLEX; ANDROGEN RECEPTOR; SIGNALING PATHWAYS; MOLECULAR-BIOLOGY; BRCA1 INHIBITION; STRUCTURAL BASIS; LIGAND-BINDING; BREAST-CANCER	Nuclear receptors (NR) classically regulate gene expression by stimulating transcription upon binding to their cognate ligands. It is now well established that NR-mediated transcriptional activation requires the recruitment of coregulator complexes, which facilitate recruitment of the basal transcription machinery through direct interactions with the basal transcription machinery and/or through chromatin remodeling. However, a number of recently described NR coactivators have been implicated in cross-talk with other nuclear processes including RNA splicing and DNA repair. T: G mismatch-specific thymine DNA glycosylase (TDG) is required for base excision repair of deaminated methylcytosine. Here we show that TDG is a coactivator for estrogen receptor alpha(ERalpha). We demonstrate that TDG interacts with ERalpha in vitro and in vivo and suggest a separate role for TDG to its established role in DNA repair. We show that this involves helix 12 of ERalpha. The region of interaction in TDG is mapped to a putative alpha-helical motif containing a motif distinct from but similar to the LXXLL motif that mediates interaction with NR. Together with recent reports linking TFIIH in regulating NR function, our findings provide new data to further support an important link between DNA repair proteins and nuclear receptor function.	Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, London W12 0NN, England; Univ Strasbourg 1, Inst Genet & Biol Mol & Cellulaire, CNRS, INSERM,Coll France, F-67404 Illkirch Graffenstaden, France; Univ Zurich, Inst Mol Canc Res, CH-8008 Zurich, Switzerland	Imperial College London; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; University of Zurich	Ali, S (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Canc Med, Du Cane Rd, London W12 0NN, England.		Schär, Primo/G-5967-2012; Ali, Simak/M-6912-2018	Schär, Primo/0000-0003-1843-6147; Coombes, Raoul Charles/0000-0002-4811-1100; Ali, Simak/0000-0002-1320-0816				Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; ALI S, 1993, HYBRIDOMA, V12, P391, DOI 10.1089/hyb.1993.12.391; Bastien J, 2000, J BIOL CHEM, V275, P21896, DOI 10.1074/jbc.M001985200; BEATO M, 1995, CELL, V83, P851, DOI 10.1016/0092-8674(95)90201-5; Belandia B, 2002, EMBO J, V21, P4094, DOI 10.1093/emboj/cdf412; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chawla A, 2001, SCIENCE, V294, P1866, DOI 10.1126/science.294.5548.1866; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen DS, 2000, MOL CELL, V6, P127, DOI 10.1016/S1097-2765(00)00014-9; Chen HW, 1999, CELL, V98, P675, DOI 10.1016/S0092-8674(00)80054-9; CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; Couse JF, 1999, ENDOCR REV, V20, P358, DOI 10.1210/er.20.3.358; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Fan SJ, 2001, ONCOGENE, V20, P77, DOI 10.1038/sj.onc.1204073; Fondell JD, 1996, P NATL ACAD SCI USA, V93, P8329, DOI 10.1073/pnas.93.16.8329; Frit P, 2002, MOL CELL, V10, P1391, DOI 10.1016/S1097-2765(02)00732-3; Glass CK, 2000, GENE DEV, V14, P121; Hanstein B, 1996, P NATL ACAD SCI USA, V93, P11540, DOI 10.1073/pnas.93.21.11540; Hardeland U, 2000, J BIOL CHEM, V275, P33449, DOI 10.1074/jbc.M005095200; Hardeland U, 2002, EMBO J, V21, P1456, DOI 10.1093/emboj/21.6.1456; Heery DM, 2001, J BIOL CHEM, V276, P6695, DOI 10.1074/jbc.M009404200; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; Hu X, 1999, NATURE, V402, P93, DOI 10.1038/47069; Jayaraman L, 1997, GENE DEV, V11, P558, DOI 10.1101/gad.11.5.558; Kalkhoven E, 1998, EMBO J, V17, P232, DOI 10.1093/emboj/17.1.232; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kang YK, 2002, P NATL ACAD SCI USA, V99, P2642, DOI 10.1073/pnas.261715899; Keriel A, 2002, CELL, V109, P125, DOI 10.1016/S0092-8674(02)00692-X; KRAUS WL, 1994, MOL ENDOCRINOL, V8, P952, DOI 10.1210/me.8.8.952; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; LEDOUARIN B, 1995, EMBO J, V14, P2020, DOI 10.1002/j.1460-2075.1995.tb07194.x; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lemon BD, 1999, CURR OPIN GENET DEV, V9, P499, DOI 10.1016/S0959-437X(99)00010-6; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; McKenna NJ, 1999, ENDOCR REV, V20, P321, DOI 10.1210/er.20.3.321; McKenna NJ, 2002, CELL, V108, P465, DOI 10.1016/S0092-8674(02)00641-4; Missero C, 2001, J BIOL CHEM, V276, P33569, DOI 10.1074/jbc.M104963200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nagy L, 1999, GENE DEV, V13, P3209, DOI 10.1101/gad.13.24.3209; Nilsson S, 2001, PHYSIOL REV, V81, P1535, DOI 10.1152/physrev.2001.81.4.1535; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Park JJ, 2000, CANCER RES, V60, P5946; Parvin JD, 1998, CURR OPIN GENET DEV, V8, P565, DOI 10.1016/S0959-437X(98)80012-9; Perissi V, 1999, GENE DEV, V13, P3198, DOI 10.1101/gad.13.24.3198; PIERRAT B, 1992, GENE, V119, P237, DOI 10.1016/0378-1119(92)90277-V; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Rachez C, 1998, GENE DEV, V12, P1787, DOI 10.1101/gad.12.12.1787; Robyr D, 2000, MOL ENDOCRINOL, V14, P329, DOI 10.1210/me.14.3.329; RochetteEgly C, 1997, CELL, V90, P97, DOI 10.1016/S0092-8674(00)80317-7; Sande S, 1996, MOL ENDOCRINOL, V10, P813, DOI 10.1210/me.10.7.813; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shang YF, 2000, CELL, V103, P843, DOI 10.1016/S0092-8674(00)00188-4; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shao DL, 1999, J CLIN INVEST, V103, P1617, DOI 10.1172/JCI7421; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Smith CL, 1997, MOL ENDOCRINOL, V11, P657, DOI 10.1210/me.11.6.657; Smith CL, 1998, BIOL REPROD, V58, P627, DOI 10.1095/biolreprod58.3.627; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; Torchia J, 1997, NATURE, V387, P677, DOI 10.1038/42652; Um S, 1998, J BIOL CHEM, V273, P20728, DOI 10.1074/jbc.273.33.20728; VOM BE, 1996, EMBO J, V15, P110; Weis KE, 1996, MOL ENDOCRINOL, V10, P1388, DOI 10.1210/me.10.11.1388; White R, 1997, EMBO J, V16, P1427, DOI 10.1093/emboj/16.6.1427; XANTHOUDAKIS S, 1992, EMBO J, V11, P653, DOI 10.1002/j.1460-2075.1992.tb05097.x; Xu HE, 2002, NATURE, V415, P813, DOI 10.1038/415813a; Yeh SY, 2000, P NATL ACAD SCI USA, V97, P11256, DOI 10.1073/pnas.190353897	75	96	96	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38586	38592		10.1074/jbc.M304286200	http://dx.doi.org/10.1074/jbc.M304286200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874288	hybrid			2022-12-27	WOS:000185575100062
J	Chigaev, A; Zwartz, G; Graves, SW; Dwyer, DC; Tsuji, H; Foutz, TD; Edwards, BS; Prossnitz, ER; Larson, RS; Sklar, LA				Chigaev, A; Zwartz, G; Graves, SW; Dwyer, DC; Tsuji, H; Foutz, TD; Edwards, BS; Prossnitz, ER; Larson, RS; Sklar, LA			alpha(4)beta(1) integrin affinity changes govern cell adhesion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE ACTIVATION STATES; P-SELECTIN; MOLECULE-1 ICAM-1; T-CELLS; FLOW; RECEPTOR; BINDING; CHEMOKINES; EXPRESSION; VCAM-1	Integrin alpha(4)beta(1) is a receptor for vascular cell adhesion molecule-1 and fibronectin. It is important in lymphopoiesis, inflammatory recruitment of leukocytes, and other situations that require cell adhesion to the vascular endothelium. The avidity of the cells expressing alpha(4)beta(1) integrin can be rapidly changed by chemokines and chemoattractants. Different mechanisms, including changes in the number of interacting molecules due to the alteration of the receptor topology or changes in the affinity of the individual bonds, have been proposed to explain the nature of these fast changes in avidity. Recently, we described a fluorescent LDV- containing small molecule, which we used to monitor the affinity changes on live cells in real time (Chigaev, A., Blenc, A. M., Braaten, J. V., Kumaraswamy, N., Kepley, C. L., Andrews, R. P., Oliver, J. M., Edwards, B. S., Prossnitz, E. R., Larson, R. S. et al. (2001) J. Biol. Chem. 276, 48670 48678). Here we show that the affinity of the small molecule probe as well as the native ligand vascular cell adhesion molecule-1 varies in parallel when the integrin is modulated with divalent cations and that the affinity modulation leads to the changes in cell avidity. Using formyl peptide receptor-transfected U937 cells, we further show that the time course of avidity changes in response to the receptor activation coincides with the time course of the affinity changes. Taken together, these data are consistent with the idea that affinity regulation is a major factor that governs the avidity of cell adhesion mediated by the alpha(4) integrin.	Univ New Mexico, Dept Pathol, HSC, Albuquerque, NM 87131 USA; Univ New Mexico, Ctr Canc, HSC, Albuquerque, NM 87131 USA; Los Alamos Natl Lab, Natl Flow Cytometry Resource, Los Alamos, NM 87545 USA	University of New Mexico; University of New Mexico; United States Department of Energy (DOE); Los Alamos National Laboratory	Sklar, LA (corresponding author), Univ New Mexico, Dept Pathol, HSC, Albuquerque, NM 87131 USA.	lsklar@salud.unm.edu	Prossnitz, Eric R./B-4543-2008; Prossnitz, Eric/I-4599-2019; Chigaev, Alexandre/A-3103-2010	Prossnitz, Eric/0000-0001-9190-8302; Chigaev, Alexandre/0000-0002-7726-638X	NCRR NIH HHS [RR01315, RR14175] Funding Source: Medline; NHLBI NIH HHS [HL56384] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001315, R01RR014175] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL056384] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Alon R, 1997, J CELL BIOL, V138, P1169, DOI 10.1083/jcb.138.5.1169; ALON R, 1995, J CELL BIOL, V128, P1243, DOI 10.1083/jcb.128.6.1243; Alon R, 2002, SEMIN IMMUNOL, V14, P93, DOI 10.1006/smim.2001.0346; Beglova N, 2002, NAT STRUCT BIOL, V9, P282, DOI 10.1038/nsb779; BERLIN C, 1995, CELL, V80, P413, DOI 10.1016/0092-8674(95)90491-3; Campbell JJ, 1998, SCIENCE, V279, P381, DOI 10.1126/science.279.5349.381; Chan JR, 2003, J IMMUNOL METHODS, V273, P43, DOI 10.1016/S0022-1759(02)00417-9; Chen C, 1999, J IMMUNOL, V162, P1084; Chen LL, 1999, J BIOL CHEM, V274, P13167, DOI 10.1074/jbc.274.19.13167; Chen SQ, 2001, P NATL ACAD SCI USA, V98, P950, DOI 10.1073/pnas.98.3.950; Chigaev A, 2001, J BIOL CHEM, V276, P48670, DOI 10.1074/jbc.M103194200; Dando J, 2002, ACTA CRYSTALLOGR D, V58, P233, DOI 10.1107/S0907444901020522; Edwards BS, 2000, J IMMUNOL, V165, P404, DOI 10.4049/jimmunol.165.1.404; FAULL RJ, 1995, STEM CELLS, V13, P38, DOI 10.1002/stem.5530130106; Feigelson S, 2001, J BIOL CHEM, V276, P13891, DOI 10.1074/jbc.M004939200; Grabovsky V, 2000, J EXP MED, V192, P495, DOI 10.1084/jem.192.4.495; Graves SW, 2002, CYTOMETRY, V47, P127, DOI 10.1002/cyto.10056; Haraldsen G, 1996, J IMMUNOL, V156, P2558; HAUGLAND RP, 2002, HDB FLUORESCENT PROB, P47; Johnston B, 1996, J EXP MED, V183, P1995, DOI 10.1084/jem.183.5.1995; Jun CD, 2001, J BIOL CHEM, V276, P29019, DOI 10.1074/jbc.M103394200; Jun CD, 2001, P NATL ACAD SCI USA, V98, P6830, DOI 10.1073/pnas.121186998; Kew RR, 1997, J LEUKOCYTE BIOL, V61, P329, DOI 10.1002/jlb.61.3.329; Labadia ME, 1998, J IMMUNOL, V161, P836; Laudanna C, 2002, IMMUNOL REV, V186, P37, DOI 10.1034/j.1600-065X.2002.18604.x; LAWRENCE MB, 1991, CELL, V65, P859, DOI 10.1016/0092-8674(91)90393-D; Lichtman AH, 1997, J IMMUNOL, V158, P3640; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Lobb RR, 1995, CELL ADHES COMMUN, V3, P385, DOI 10.3109/15419069509081293; Loftus JC, 1997, J CLIN INVEST, V100, pS77; LYNAM EB, 1994, BLOOD, V83, P3303; MASUMOTO A, 1993, J BIOL CHEM, V268, P228; Mehta P, 1998, J BIOL CHEM, V273, P32506, DOI 10.1074/jbc.273.49.32506; MILLER J, 1995, J EXP MED, V182, P1231, DOI 10.1084/jem.182.5.1231; Nolan John P., 1998, P19; NOLAN JP, 1995, CYTOMETRY, V21, P223, DOI 10.1002/cyto.990210302; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; Park SK, 2000, NEPHROL DIAL TRANSPL, V15, P596, DOI 10.1093/ndt/15.5.596; REILLY PL, 1995, J IMMUNOL, V155, P529; SANCHEZMATEOS P, 1993, J IMMUNOL, V151, P3817; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Sklar LA, 2002, ANNU REV BIOPH BIOM, V31, P97, DOI 10.1146/annurev.biophys.31.082901.134406; SKLAR LA, 1985, MOL PHARMACOL, V28, P323; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stewart M, 1996, J CELL BIOCHEM, V61, P554, DOI 10.1002/(SICI)1097-4644(19960616)61:4<554::AID-JCB8>3.0.CO;2-N; Waller A, 2001, CYTOMETRY, V45, P102, DOI 10.1002/1097-0320(20011001)45:2<102::AID-CYTO1152>3.0.CO;2-Z; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Weber C, 1996, P NATL ACAD SCI USA, V93, P10939, DOI 10.1073/pnas.93.20.10939; YEDNOCK TA, 1995, J BIOL CHEM, V270, P28740, DOI 10.1074/jbc.270.48.28740	49	66	70	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38174	38182		10.1074/jbc.M210472200	http://dx.doi.org/10.1074/jbc.M210472200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12844491	hybrid			2022-12-27	WOS:000185575100012
J	Hegde, R; Srinivasula, SM; Datta, P; Madesh, M; Wassell, R; Zhang, ZJ; Cheong, NE; Nejmeh, J; Fernandes-Alnemri, T; Hoshino, S; Alnemri, ES				Hegde, R; Srinivasula, SM; Datta, P; Madesh, M; Wassell, R; Zhang, ZJ; Cheong, NE; Nejmeh, J; Fernandes-Alnemri, T; Hoshino, S; Alnemri, ES			The polypeptide chain-releasing factor GSPT1/eRF3 is proteolytically processed into an IAP-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-DEATH; SERINE-PROTEASE; STRUCTURAL BASIS; LIGASE ACTIVITY; APOPTOSIS; DEGRADATION; REAPER; INHIBITOR; XIAP; GRIM	Smac/Diablo and HtrA2/Omi are inhibitors of apoptosis (IAP)-binding proteins released from the mitochondria of human cells during apoptosis and regulate apoptosis by liberating caspases from IAP inhibition. Here we describe the identification of a proteolytically processed isoform of the polypeptide chain-releasing factor GSPT1/eRF3 protein, which functions in translation, as a new IAP-binding protein. In common with other IAP-binding proteins, the processed GSPT1 protein harbors a conserved N-terminal IAP-binding motif (AKPF). Additionally, processed GSPT1 interacts biochemically with IAPs and could promote caspase activation, IAP ubiquitination and apoptosis. The IAP-binding motif of the processed GSPT1 is absolutely required for these activities. Our findings are consistent with a model whereby processing of GSPT1 into the IAP-binding isoform could potentiate apoptosis by liberating caspases from IAP inhibition, or target IAPs and the processed GSPT1 for proteasome-mediated degradation.	Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Philadelphia, PA 19107 USA; Thomas Jefferson Univ, Kimmel Canc Inst, Dept Microbiol & Immunol, Philadelphia, PA 19107 USA; Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Physiol Chem, Tokyo 1130033, Japan	Jefferson University; Jefferson University; University of Tokyo	Alnemri, ES (corresponding author), Thomas Jefferson Univ, Kimmel Canc Inst, Ctr Apoptosis Res, Bluemle Life Sci Bldg,Rm 904,233 S 10th St, Philadelphia, PA 19107 USA.	E_Alnemri@lac.jci.tju.edu	Alnemri, Emad S/B-4526-2010	Hoshino, Shinichi/0000-0001-6135-7896	NATIONAL CANCER INSTITUTE [P01CA078890] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013487] Funding Source: NIH RePORTER; NCI NIH HHS [CA78890] Funding Source: Medline; NIA NIH HHS [AG13487] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Abrams JM, 1999, TRENDS CELL BIOL, V9, P435, DOI 10.1016/S0962-8924(99)01646-3; Chai JJ, 2001, CELL, V104, P769, DOI 10.1016/S0092-8674(02)02034-2; Christich A, 2002, CURR BIOL, V12, P137, DOI 10.1016/S0960-9822(01)00658-3; CROOK NE, 1993, J VIROL, V67, P2168, DOI 10.1128/JVI.67.4.2168-2174.1993; Deveraux QL, 1997, NATURE, V388, P300, DOI 10.1038/40901; Deveraux QL, 1999, GENE DEV, V13, P239, DOI 10.1101/gad.13.3.239; Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8; Duckett CS, 1998, MOL CELL BIOL, V18, P608, DOI 10.1128/MCB.18.1.608; EUSTICE DC, 1986, J MOL BIOL, V188, P207, DOI 10.1016/0022-2836(86)90305-0; Ferri KF, 2001, NAT CELL BIOL, V3, pE255, DOI 10.1038/ncb1101-e255; Goyal L, 2000, EMBO J, V19, P589, DOI 10.1093/emboj/19.4.589; Hays R, 2002, NAT CELL BIOL, V4, P425, DOI 10.1038/ncb794; Hegde R, 2002, J BIOL CHEM, V277, P432, DOI 10.1074/jbc.M109721200; Holley CL, 2002, NAT CELL BIOL, V4, P439, DOI 10.1038/ncb798; Hoshino S, 1998, J BIOL CHEM, V273, P22254, DOI 10.1074/jbc.273.35.22254; HOSHINO S, 1989, EMBO J, V8, P3807, DOI 10.1002/j.1460-2075.1989.tb08558.x; INGEVECHTOMOV SG, 1994, GENETIKA+, V30, P1022; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Li XM, 2002, NATURE, V416, P345, DOI 10.1038/416345a; MacFarlane M, 2002, J BIOL CHEM, V277, P36611, DOI 10.1074/jbc.M200317200; Martins LM, 2002, J BIOL CHEM, V277, P439, DOI 10.1074/jbc.M109784200; Miller LK, 1999, TRENDS CELL BIOL, V9, P323, DOI 10.1016/S0962-8924(99)01609-8; Reed JC, 2000, CELL, V102, P545, DOI 10.1016/S0092-8674(00)00076-3; Ryoo HD, 2002, NAT CELL BIOL, V4, P432, DOI 10.1038/ncb795; Salvesen GS, 2002, NAT REV MOL CELL BIO, V3, P401, DOI 10.1038/nrm830; Shi Y, 2002, CELL DEATH DIFFER, V9, P93, DOI 10.1038/sj/cdd/4400957; Srinivasula SM, 2000, J BIOL CHEM, V275, P36152, DOI 10.1074/jbc.C000533200; Srinivasula SM, 2001, NATURE, V410, P112, DOI 10.1038/35065125; Srinivasula SM, 2002, CURR BIOL, V12, P125, DOI 10.1016/S0960-9822(01)00657-1; SURGUCHOV AP, 1980, FEBS LETT, V111, P175, DOI 10.1016/0014-5793(80)80786-1; Suzuki Y, 2001, MOL CELL, V8, P613, DOI 10.1016/S1097-2765(01)00341-0; Suzuki Y, 2001, P NATL ACAD SCI USA, V98, P8662, DOI 10.1073/pnas.161506698; Tenev T, 2002, EMBO J, V21, P5118, DOI 10.1093/emboj/cdf530; Uchida N, 2002, J BIOL CHEM, V277, P50286, DOI 10.1074/jbc.M203029200; van Loo G, 2002, CELL DEATH DIFFER, V9, P20, DOI 10.1038/sj.cdd.4400970; Verhagen AM, 2000, CELL, V102, P43, DOI 10.1016/S0092-8674(00)00009-X; Verhagen AM, 2002, J BIOL CHEM, V277, P445, DOI 10.1074/jbc.M109891200; Vucic D, 1998, MOL CELL BIOL, V18, P3300, DOI 10.1128/MCB.18.6.3300; Wilson R, 2002, NAT CELL BIOL, V4, P445, DOI 10.1038/ncb799; Wing JP, 2002, CURR BIOL, V12, P131, DOI 10.1016/S0960-9822(01)00664-9; Wing JP, 2002, NAT CELL BIOL, V4, P451, DOI 10.1038/ncb800; Wu G, 2000, NATURE, V408, P1008, DOI 10.1038/35050012; Yang Y, 2000, SCIENCE, V288, P874, DOI 10.1126/science.288.5467.874; Yoo SJ, 2002, NAT CELL BIOL, V4, P416, DOI 10.1038/ncb793	44	70	75	4	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38699	38706		10.1074/jbc.M303179200	http://dx.doi.org/10.1074/jbc.M303179200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12865429	hybrid			2022-12-27	WOS:000185575100075
J	Jiang, AX; Pei, DQ				Jiang, AX; Pei, DQ			Distinct roles of catalytic and pexin-like domains in membrane-type matrix metalloproteinase (MMP)-mediated pro-MMP-2 activation and collagenolysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTEGRIN ALPHA(V) SUBUNIT; BREAST-CARCINOMA CELLS; C-TERMINAL DOMAIN; SUBSTRATE-SPECIFICITY; MMP INHIBITION; A ACTIVATION; CDNA LIBRARY; TUMOR-CELLS; MT-MMPS; IDENTIFICATION	Members of the membrane-type matrix metalloproteinase (MT-MMPs) family are dual regulators of extracellular matrix remodeling through direct degradation of extracellular matrix components and activation of other latent MMPs. However, the structural basis of this functional diversity remains poorly understood. In an attempt to dissect the structural determinants for MT-MMP function, we performed domain exchange experiments between MT1-MMP and its close relative MT3-MMP and analyzed the exchange chimeras for pro-MMP-2 activation and collagen degradation at the cellular level. Our results indicate that catalytic domains determine the pattern of pro-MMP-2 activation, whereas pexin-like domains modulate the level of activation. On the other hand, both the catalytic and pexin-like domains of MT1-MMP are required for strong collagenolysis because exchanging either domain with that of MT3-MMP yielded significantly lower activity, and the introduction of the MT1-MMP catalytic or pexin-like domain into MT3-MMP failed to generate any significant enhancement of collagenolytic activity compared with wild-type MT3-MMP. Interestingly, the cytoplasmic domain of MT1-MMP behaves as a negative regulator not only for MT1-MMP itself, but also for MT3-MMP in both pro-MMP-2 activation and collagenolysis, consistent with and extending our recent findings (Jiang, A., Lehti, K., Wang, X., Weiss, S. J., Keski-Oja, J., and Pei, D. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 13693-13698). Taken together, these results demonstrate that domains in MT-MMPs function differently toward a given substrate and thus should be targeted differentially for future therapeutic development.	Univ Minnesota, Dept Pharmacol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities	Pei, DQ (corresponding author), Univ Minnesota, Dept Pharmacol, 6-120 Jackson Hall,321 Church St SE, Minneapolis, MN 55455 USA.			Jiang, Aixiang/0000-0002-6153-7595	NATIONAL CANCER INSTITUTE [R29CA076308, R01CA076308] Funding Source: NIH RePORTER; NCI NIH HHS [CA76308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belkin AM, 2001, J BIOL CHEM, V276, P18415, DOI 10.1074/jbc.M010135200; CAO J, 1995, J BIOL CHEM, V270, P801, DOI 10.1074/jbc.270.2.801; Chung L, 2000, J BIOL CHEM, V275, P29610, DOI 10.1074/jbc.M004039200; Deryugina EI, 2002, CANCER RES, V62, P580; Deryugina EI, 2002, J BIOL CHEM, V277, P9749, DOI 10.1074/jbc.M110269200; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Fernandez-Catalan C, 1998, EMBO J, V17, P5238, DOI 10.1093/emboj/17.17.5238; Hiraoka N, 1998, CELL, V95, P365, DOI 10.1016/S0092-8674(00)81768-7; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; Holmbeck K, 1999, CELL, V99, P81, DOI 10.1016/S0092-8674(00)80064-1; Hotary KB, 2002, J EXP MED, V195, P295, DOI 10.1084/jem.20010815; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Jackson C, 2001, INFLAMM RES, V50, P183, DOI 10.1007/s000110050743; Jiang AX, 2001, P NATL ACAD SCI USA, V98, P13693, DOI 10.1073/pnas.241293698; Kang TB, 2000, FASEB J, V14, P2559, DOI 10.1096/fj.00-0269com; Kang TB, 2001, J BIOL CHEM, V276, P21960, DOI 10.1074/jbc.M007997200; Llano E, 1999, CANCER RES, V59, P2570; Massova I, 1998, FASEB J, V12, P1075, DOI 10.1096/fasebj.12.12.1075; MURPHY G, 1992, J BIOL CHEM, V267, P9612; Nakahara H, 1997, P NATL ACAD SCI USA, V94, P7959, DOI 10.1073/pnas.94.15.7959; Ohuchi E, 1997, J BIOL CHEM, V272, P2446, DOI 10.1074/jbc.272.4.2446; OKADA A, 1995, P NATL ACAD SCI USA, V92, P2730, DOI 10.1073/pnas.92.7.2730; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, NAT REV CANCER, V2, P657, DOI 10.1038/nrc884; PEI DQ, 1995, NATURE, V375, P244, DOI 10.1038/375244a0; Pei DQ, 1999, CELL RES, V9, P291, DOI 10.1038/sj.cr.7290028; Pei DQ, 1996, J BIOL CHEM, V271, P9135, DOI 10.1074/jbc.271.15.9135; Pei DQ, 1999, J BIOL CHEM, V274, P8925, DOI 10.1074/jbc.274.13.8925; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Rozanov DV, 2002, J BIOL CHEM, V277, P9318, DOI 10.1074/jbc.M110711200; Rozanov DV, 2001, J BIOL CHEM, V276, P25705, DOI 10.1074/jbc.M007921200; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; Sato H, 1997, THROMB HAEMOSTASIS, V78, P497; Seiki M, 1999, APMIS, V107, P137, DOI 10.1111/j.1699-0463.1999.tb01536.x; Shofuda K, 1998, LAB INVEST, V78, P915; Spinale FG, 2000, CARDIOVASC RES, V46, P225, DOI 10.1016/S0008-6363(99)00431-9; TAKINO T, 1995, J BIOL CHEM, V270, P23013, DOI 10.1074/jbc.270.39.23013; Tanaka M, 1997, FEBS LETT, V402, P219, DOI 10.1016/S0014-5793(96)01537-2; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; Yana I, 2000, MOL BIOL CELL, V11, P2387, DOI 10.1091/mbc.11.7.2387; Zhou ZJ, 2000, P NATL ACAD SCI USA, V97, P4052, DOI 10.1073/pnas.060037197; Zucker S, 2000, ONCOGENE, V19, P6642, DOI 10.1038/sj.onc.1204097	43	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38765	38771		10.1074/jbc.M306618200	http://dx.doi.org/10.1074/jbc.M306618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878590	hybrid			2022-12-27	WOS:000185575100083
J	Kim, CH; Xiong, WC; Mei, L				Kim, CH; Xiong, WC; Mei, L			Regulation of MuSK expression by a novel signaling pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR GENE-EXPRESSION; EPSILON-SUBUNIT GENE; NEUROMUSCULAR-JUNCTION; GAMMA-SUBUNIT; BETA-SUBUNIT; MAP KINASE; CRD DOMAIN; MUSCLE; PROTEIN; IDENTIFICATION	MuSK is a receptor tyrosine kinase essential for neuromuscular junction formation. Expression of the MuSK gene is tightly regulated during development and at the neuromuscular junction. However, little is known about molecular mechanisms regulating its gene expression. Here we report a characterization of the promoter of the mouse MuSK gene. The transcription of MuSK starts at multiple sites with a major site 51 nt upstream of the translation start site. We have identified an E-box-like cis-element that is both required and sufficient for differentiation-dependent transcription. Interestingly, the promoter activity of the MuSK gene did not respond to neuregulin, a factor believed to mediate the synapse-specific transcription of acetylcholine receptor subunit genes. Rather, MuSK expression is increased in muscle cells stimulated with Wnt or at conditions when the Wnt signaling was activated. These results suggest a novel mechanism for the MuSK synapse-specific expression.	Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; Univ Alabama Birmingham, Dept Phys Med & Rehabil, Civitan Int Res Ctr, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Mei, L (corresponding author), Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.	lmei@nrc.uab.edu	Mei, Lin/G-8755-2012		NIAMS NIH HHS [AR48120] Funding Source: Medline; NICHD NIH HHS [P30 HD38985-0] Funding Source: Medline; NIGMS NIH HHS [GM63861] Funding Source: Medline; NINDS NIH HHS [NS45710, NS44521, NS40480] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P30HD038985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR048120] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063861] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044521, R01NS045710, R01NS040480] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Altiok N, 1997, EMBO J, V16, P717, DOI 10.1093/emboj/16.4.717; Bhanot P, 1996, NATURE, V382, P225, DOI 10.1038/382225a0; Burden SJ, 1998, GENE DEV, V12, P133, DOI 10.1101/gad.12.2.133; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; CHENG TC, 1992, J CELL BIOL, V119, P1649, DOI 10.1083/jcb.119.6.1649; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; d'Exaerde AD, 2002, EMBO REP, V3, P1075, DOI 10.1093/embo-reports/kvf220; Dale TC, 1998, BIOCHEM J, V329, P209; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; DeChiara TM, 1996, CELL, V85, P501, DOI 10.1016/S0092-8674(00)81251-9; Duclert A, 1996, J BIOL CHEM, V271, P17433, DOI 10.1074/jbc.271.29.17433; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; Fromm L, 1998, GENE DEV, V12, P3074, DOI 10.1101/gad.12.19.3074; Fu AKY, 2001, NAT NEUROSCI, V4, P374, DOI 10.1038/86019; GILMOUR BP, 1995, DEV BIOL, V168, P416, DOI 10.1006/dbio.1995.1091; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; GOLDMAN D, 1988, NEURON, V1, P329, DOI 10.1016/0896-6273(88)90081-5; GOLDMAN D, 1989, NEURON, V3, P219, DOI 10.1016/0896-6273(89)90035-4; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Herbst R, 2000, EMBO J, V19, P67, DOI 10.1038/sj.emboj.7592228b; Hopf C, 1996, J BIOL CHEM, V271, P5231; Ip FCF, 2000, MOL CELL NEUROSCI, V16, P661, DOI 10.1006/mcne.2000.0892; JENNINGS CGB, 1993, P NATL ACAD SCI USA, V90, P2895, DOI 10.1073/pnas.90.7.2895; Jones G, 1996, P NATL ACAD SCI USA, V93, P5985, DOI 10.1073/pnas.93.12.5985; KLINGENSMITH J, 1994, GENE DEV, V8, P118, DOI 10.1101/gad.8.1.118; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Luo ZG, 2002, NEURON, V35, P489, DOI 10.1016/S0896-6273(02)00783-3; Malbon CC, 2001, BIOCHEM BIOPH RES CO, V287, P589, DOI 10.1006/bbrc.2001.5630; Masiakowski P, 1998, CURR BIOL, V8, pR407, DOI 10.1016/S0960-9822(98)70263-5; NOORDERMEER J, 1994, NATURE, V367, P80, DOI 10.1038/367080a0; Packard M, 2003, NAT REV NEUROSCI, V4, P113, DOI 10.1038/nrn1036; PRODY CA, 1992, NUCLEIC ACIDS RES, V20, P2367, DOI 10.1093/nar/20.9.2367; Sanes JR, 2001, NAT REV NEUROSCI, V2, P791, DOI 10.1038/35097557; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; Sapru MK, 1998, P NATL ACAD SCI USA, V95, P1289, DOI 10.1073/pnas.95.3.1289; Schaeffer L, 2001, NEURON, V31, P15, DOI 10.1016/S0896-6273(01)00353-1; Si JT, 1996, J BIOL CHEM, V271, P19752, DOI 10.1074/jbc.271.33.19752; Si JT, 1997, J BIOL CHEM, V272, P10367; Si JT, 1999, MOL BRAIN RES, V67, P18, DOI 10.1016/S0169-328X(99)00028-5; Si JT, 1999, J NEUROSCI, V19, P8498; Tanowitz M, 1999, J NEUROSCI, V19, P9426; Tansey MG, 1996, J CELL BIOL, V134, P465, DOI 10.1083/jcb.134.2.465; THEISEN H, 1994, DEVELOPMENT, V120, P347; VALENZUELA DM, 1995, NEURON, V15, P573, DOI 10.1016/0896-6273(95)90146-9; Xie MH, 1997, NAT BIOTECHNOL, V15, P768, DOI 10.1038/nbt0897-768; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; Yang X, 2001, NEURON, V30, P399, DOI 10.1016/S0896-6273(01)00287-2; Zhou H, 1999, J CELL BIOL, V146, P1133, DOI 10.1083/jcb.146.5.1133	49	21	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38522	38527		10.1074/jbc.M305058200	http://dx.doi.org/10.1074/jbc.M305058200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885777	hybrid			2022-12-27	WOS:000185575100054
J	Matsumoto, Y; Oda, Y; Uryu, M; Hayakawa, Y				Matsumoto, Y; Oda, Y; Uryu, M; Hayakawa, Y			Insect cytokine growth-blocking peptide triggers a termination system of cellular immunity by inducing its binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMATOCYTE-SPREADING PEPTIDE; MOLECULAR-CLONING; BIOGENIC PEPTIDE; MANDUCA-SEXTA; IN-VITRO; HEMOLYMPH; IDENTIFICATION; HEMOCYTES; SILKWORM; HORMONE	Growth-blocking peptide (GBP) is a 25-amino acid cytokine found in lepidopteran insects that possesses diverse biological activities such as stimulation of immune cells (plasmatocytes), cell proliferation, and larval growth regulation. We found another novel function of GBP that induces a hemolysis of another class of blood cells (oenocytoids). In the lysate of oenocytoids we identified a GBP-binding protein that shows a specific affinity for GBP. The characterization of purified GBP-binding protein and its cDNA demonstrated it as a 49.5-kDa novel protein with a C-terminal region displaying limited homology to several insect lipoproteins. Results of Northern and Western blotting indicated that the GBP-binding protein should be synthesized only in blood cells. Immunoelectron microscopic analyses confirmed that indirect immunoreactive signals were mostly localized in oenocytoids. Kinetic and biological analyses of interaction between GBP and the binding protein showed their strong binding was followed by clearance of GBP from hemolymph, thus indicating that this protein might function as an inhibitory factor against GBP. Based on these results, we propose that insect cytokine GBP shows multifunctions even in cellular immunity: it serves to stimulate immune cells and afterward silences its own action by inducing the binding protein through specific hemolysis.	Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Hayakawa, Y (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.	hayakawa@lowtem.hokudai.ac.jp						Aizawa T, 2001, J BIOL CHEM, V276, P31813, DOI 10.1074/jbc.M105251200; ASHIDA M, 1988, TISSUE CELL, V20, P599, DOI 10.1016/0040-8166(88)90061-4; BREHELIN MM, 1972, ACRIDA, V1, P165; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clark KD, 1997, J BIOL CHEM, V272, P23440, DOI 10.1074/jbc.272.37.23440; Clark KD, 1998, BIOCHEM BIOPH RES CO, V250, P479, DOI 10.1006/bbrc.1998.9145; Clark KD, 2001, J BIOL CHEM, V276, P37431, DOI 10.1074/jbc.M105235200; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; CRINE P, 1987, NEUROMETHODS, V6, P1; Franke H., 1960, Zoologische Jahrbuecher (Physiol), V69, P131; FRANKE HANS, 1960, ZOOL JAHRB ABT ALLG ZOOL UND PHYSIOL TIERE, V68, P499; Hayakawa Y, 1998, BIOCHEM BIOPH RES CO, V250, P194, DOI 10.1006/bbrc.1998.8959; HAYAKAWA Y, 1995, J INSECT PHYSIOL, V41, P1, DOI 10.1016/0022-1910(94)00077-T; HAYAKAWA Y, 1990, J BIOL CHEM, V265, P10813; HAYAKAWA Y, 1991, J BIOL CHEM, V266, P7982; HAYAKAWA Y, 1995, FEBS LETT, V376, P185, DOI 10.1016/0014-5793(95)01273-7; HAYAKAWA Y, 1992, BIOCHEM BIOPH RES CO, V185, P1141, DOI 10.1016/0006-291X(92)91745-C; Hayakawa Y, 1998, J INSECT PHYSIOL, V44, P859, DOI 10.1016/S0022-1910(98)00017-1; Hayakawa Y, 1998, EUR J BIOCHEM, V253, P810, DOI 10.1046/j.1432-1327.1998.2530810.x; HIRAOKA T, 1995, CELL TISSUE RES, V279, P465, DOI 10.1007/BF00318159; Kamimura M, 2001, BIOCHEM BIOPH RES CO, V286, P67, DOI 10.1006/bbrc.2001.5365; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARVINE MD, 2002, INSECT BIOCHEM MOLEC, V32, P1237; Martin JL, 1999, CONT ENDOCRINOL, V17, P227; MORI S, 1991, BIOCHIM BIOPHYS ACTA, V1090, P129, DOI 10.1016/0167-4781(91)90048-Q; Novick D, 1999, IMMUNITY, V10, P127, DOI 10.1016/S1074-7613(00)80013-8; Ohnishi A, 2001, J BIOL CHEM, V276, P37974; PECH LL, 1994, CELL TISSUE RES, V277, P159, DOI 10.1007/BF00303092; Rajaram S, 1997, ENDOCR REV, V18, P801, DOI 10.1210/er.18.6.801; REYNOLDS ES, 1963, J CELL BIOL, V17, P208, DOI 10.1083/jcb.17.1.208; RIZKI RM, 1990, J INSECT PHYSIOL, V36, P523, DOI 10.1016/0022-1910(90)90104-N; ROWLEY AF, 1980, IMMUNOLOGY, V40, P483; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SKINNER WS, 1991, J BIOL CHEM, V266, P12873; STRAND MR, 1995, ANNU REV ENTOMOL, V40, P31, DOI 10.1146/annurev.en.40.010195.000335; Strand MR, 1999, ARCH INSECT BIOCHEM, V42, P213, DOI 10.1002/(SICI)1520-6327(199911)42:3&lt;213::AID-ARCH5&gt;3.0.CO;2-4; Strand MR, 2000, J INSECT PHYSIOL, V46, P817, DOI 10.1016/S0022-1910(99)00171-7; Strand MR, 1999, ARCH INSECT BIOCHEM, V40, P41, DOI 10.1002/(SICI)1520-6327(1999)40:1&lt;41::AID-ARCH5&gt;3.0.CO;2-R; WANG X, 1988, J BIOL CHEM, V263, P8851; Wang Y, 1999, INSECT BIOCHEM MOLEC, V29, P1075, DOI 10.1016/S0965-1748(99)00086-7	41	46	50	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38579	38585		10.1074/jbc.M305986200	http://dx.doi.org/10.1074/jbc.M305986200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871935	hybrid			2022-12-27	WOS:000185575100061
J	Bondar, T; Mirkin, EV; Ucker, DS; Walden, WE; Mirkin, SM; Raychaudhuri, P				Bondar, T; Mirkin, EV; Ucker, DS; Walden, WE; Mirkin, SM; Raychaudhuri, P			Schizosaccharomyces pombe Ddb1 is functionally linked to the replication checkpoint pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-PHASE; DNA-DAMAGE; FISSION YEAST; KINASES CDS1; V PROTEIN; IN-VITRO; CHK1; MAINTENANCE; DEFINES; DOMAIN	Schizosaccharomyces pombe Ddb1 is homologous to the mammalian DDB1 protein, which has been implicated in damaged-DNA recognition and global genomic repair. However, a recent study suggested that the S. pombe Ddb1 is involved in cell division and chromosomal segregation. Here, we provide evidence that the S. pombe Ddb1 is functionally linked to the replication checkpoint control gene cds1. We show that the S. pombe strain lacking ddb1 has slow growth due to delayed replication progression. Flow cytometric analysis shows an extensive heterogeneity in DNA content. Furthermore, the Deltaddb1 strain is hypersensitive to UV irradiation in S phase and is unable to tolerate a prolonged replication block imposed by hydroxyurea. Interestingly, the Deltaddb1 strain exhibits a high level of the Cds1 kinase activity during passage through S phase. Moreover, mutation of the cds1 gene relieves the defects observed in Deltaddb1 strain. The results suggest that many of the defects observed in Deltaddb1 cells are linked to an aberrant activation of Cds1, and that Ddb1 is functionally linked to Cds1.	Univ Illinois, Dept Biochem & Mol Biol, Chicago, IL 60612 USA; Univ Illinois, Dept Microbiol & Immunol, Chicago, IL 60612 USA; Univ Illinois, Dept Mol Genet, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raychaudhuri, P (corresponding author), Univ Illinois, Dept Biochem & Mol Biol, M-C 536,1819 W Polk St, Chicago, IL 60612 USA.	Pradip@uic.edu	Mirkin, Sergei/A-7310-2010; Mirkin, Sergei/AAR-7226-2020; Bondar, Tanya/T-5576-2017	Mirkin, Sergei/0000-0003-4576-7582; Bondar, Tanya/0000-0003-4765-8910	NATIONAL CANCER INSTITUTE [R01CA077637, R01CA088863] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047281] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038800, R01GM060987] Funding Source: NIH RePORTER; NCI NIH HHS [CA88863, CA77637] Funding Source: Medline; NIDDK NIH HHS [DK 47281] Funding Source: Medline; NIGMS NIH HHS [GM 60987, GM 38800] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMIC M, 1991, J BIOL CHEM, V266, P22493; Alcasabas AA, 2001, NAT CELL BIOL, V3, P958, DOI 10.1038/ncb1101-958; Boddy MN, 2000, MOL CELL BIOL, V20, P8758, DOI 10.1128/MCB.20.23.8758-8766.2000; Boddy MN, 1998, SCIENCE, V280, P909, DOI 10.1126/science.280.5365.909; Boddy MN, 2001, CELL, V107, P537, DOI 10.1016/S0092-8674(01)00536-0; Brown GW, 1999, P NATL ACAD SCI USA, V96, P8443, DOI 10.1073/pnas.96.15.8443; Carlson CR, 1997, YEAST, V13, P1329; Christensen PU, 2000, P NATL ACAD SCI USA, V97, P2579, DOI 10.1073/pnas.97.6.2579; CHU G, 1988, SCIENCE, V242, P564, DOI 10.1126/science.3175673; Fung AD, 2002, MOL CELL BIOL, V22, P4477, DOI 10.1128/MCB.22.13.4477-4490.2002; Furnari B, 1999, MOL BIOL CELL, V10, P833, DOI 10.1091/mbc.10.4.833; HWANG BJ, 1993, BIOCHEMISTRY-US, V32, P1657, DOI 10.1021/bi00057a033; Kazantsev A, 1996, P NATL ACAD SCI USA, V93, P5014, DOI 10.1073/pnas.93.10.5014; Kim SM, 2001, EMBO J, V20, P6115, DOI 10.1093/emboj/20.21.6115; Krishnamoorthy RR, 1997, BIOCHEMISTRY-US, V36, P960, DOI 10.1021/bi961407c; Lin GY, 2000, J VIROL, V74, P9152, DOI 10.1128/JVI.74.19.9152-9166.2000; Lin GY, 1998, VIROLOGY, V249, P189, DOI 10.1006/viro.1998.9317; Lindsay HD, 1998, GENE DEV, V12, P382, DOI 10.1101/gad.12.3.382; Marchetti MA, 2002, P NATL ACAD SCI USA, V99, P7472, DOI 10.1073/pnas.112702399; Martinho RG, 1998, EMBO J, V17, P7239, DOI 10.1093/emboj/17.24.7239; MIZUKOSHI T, 1999, NUCL ACIDS S SER, V42, P265; Murakami H, 2002, NAT CELL BIOL, V4, P384, DOI 10.1038/ncb789; MURAKAMI H, 1995, NATURE, V374, P817, DOI 10.1038/374817a0; Neuwald AF, 2000, NUCLEIC ACIDS RES, V28, P3570, DOI 10.1093/nar/28.18.3570; OConnell MJ, 1997, EMBO J, V16, P545, DOI 10.1093/emboj/16.3.545; Otrin VR, 1998, MOL CELL BIOL, V18, P3182, DOI 10.1128/MCB.18.6.3182; Rhind N, 2000, J CELL SCI, V113, P3889; Shiyanov P, 1999, MOL CELL BIOL, V19, P4935; Snaith HA, 2000, MOL CELL BIOL, V20, P7922, DOI 10.1128/MCB.20.21.7922-7932.2000; Sogo JM, 2002, SCIENCE, V297, P599, DOI 10.1126/science.1074023; Takeda T, 2001, MOL BIOL CELL, V12, P1257, DOI 10.1091/mbc.12.5.1257; Tanaka K, 2001, NAT CELL BIOL, V3, P966, DOI 10.1038/ncb1101-966; Wahl GM, 2001, NAT CELL BIOL, V3, pE277, DOI 10.1038/ncb1201-e277; Zeng Y, 1998, NATURE, V395, P507, DOI 10.1038/26766; Zolezzi F, 2000, GENE, V245, P151, DOI 10.1016/S0378-1119(00)00022-6; Zolezzi F, 2002, J BIOL CHEM, V277, P41183, DOI 10.1074/jbc.M207890200	36	15	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37006	37014		10.1074/jbc.M303003200	http://dx.doi.org/10.1074/jbc.M303003200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857752	hybrid			2022-12-27	WOS:000185437200006
J	Xu, HM; An, HZ; Yu, YZ; Zhang, MH; Qi, RZ; Cao, XT				Xu, HM; An, HZ; Yu, YZ; Zhang, MH; Qi, RZ; Cao, XT			Ras participates in CpG oligodeoxynucleotide signaling through association with Toll-like receptor 9 and promotion of interleukin-1 receptor-associated kinase/tumor necrosis factor receptor-associated factor 6 complex formation in macrophages	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NF-KAPPA-B; GUANINE-NUCLEOTIDE EXCHANGE; BACTERIAL-DNA; ADAPTER MOLECULE; CUTTING EDGE; P38 MAPK; INDUCTION; MURINE; MOTIFS	CpG oligodeoxynucleotides (ODN) activate immune cells to produce immune mediators by Toll-like receptor 9 (TLR9)-mediated signal transduction, which activates mitogen-activated protein kinases (MAPKs) and nuclear factor-kappaB (NF-kappaB) through the MyD88/IRAK/TRAF6 kinases cascade. However, the precise mechanisms of CpG ODN activation of immune cells have not been fully elucidated. The small GTP-binding protein Ras mediates MAPK activation in response to a variety of stimuli. Up to now, it is not clear whether Ras plays a role in CpG ODN signaling. In the present study, we found that the dominant-negative version of Ras (RasN17) and specific Ras inhibitor, FTI-277, inhibited CpG ODN-induced nitric oxide (NO) and tumor necrosis factor-alpha (TNF-alpha) production by murine macrophage cell line RAW264.7. While overexpression of wild-type Ras enhanced CpG ODN-induced extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), and NF-kappaB activation, overexpression of RasN17 inhibited CpG ODN-induced ERK, JNK, and NF-kappaB activation. RasN17 overexpression also inhibited CpG ODN-induced IRAK1/ TRAF6 complex formation. Further studies revealed that CpG ODN activated Ras in a time- and dose-dependent manner, and Ras associated with TLR9 in a CpG ODN-dependent manner. Most interestingly, activation of Ras preceded the association of Ras with TLR9, giving rise to a possibility that Ras activation might not be dependent on the interaction between Ras and TLR9. Our data demonstrate for the first time that Ras can be activated by CpG ODN in macrophages, and Ras is involved in CpG ODN signaling as an early event by associating with TLR9 and promoting IRAK1/ TRAF6 complex formation, and MAPK and NF-kappaB activation.	Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China	Naval Medical University	Cao, XT (corresponding author), Second Mil Med Univ, Inst Immunol, Shanghai 200433, Peoples R China.	caoxt@public3.sta.net.cn	yu, yizhi/ADP-7854-2022					Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Ahmad-Nejad P, 2002, EUR J IMMUNOL, V32, P1958, DOI 10.1002/1521-4141(200207)32:7<1958::AID-IMMU1958>3.0.CO;2-U; An HZ, 2002, IMMUNOL LETT, V81, P165, DOI 10.1016/S0165-2478(02)00010-X; Arbibe L, 2000, NAT IMMUNOL, V1, P533, DOI 10.1038/82797; Ballas ZK, 1996, J IMMUNOL, V157, P1840; Bauer S, 2001, P NATL ACAD SCI USA, V98, P9237, DOI 10.1073/pnas.161293498; Bouchier-Hayes L, 2001, J BIOL CHEM, V276, P44069, DOI 10.1074/jbc.M107373200; BUSCHER D, 1995, MOL CELL BIOL, V15, P466; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; Cao ZD, 1996, SCIENCE, V271, P1128, DOI 10.1126/science.271.5252.1128; Caunt CJ, 2001, J BIOL CHEM, V276, P6280, DOI 10.1074/jbc.M006772200; Dalpke A, 2002, BIODRUGS, V16, P419, DOI 10.2165/00063030-200216060-00003; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; GULBINS E, 1994, MOL CELL BIOL, V14, P906, DOI 10.1128/MCB.14.2.906; Hacker H, 2000, J EXP MED, V192, P595, DOI 10.1084/jem.192.4.595; Hacker H, 1998, EMBO J, V17, P6230, DOI 10.1093/emboj/17.21.6230; Hartmann G, 1999, P NATL ACAD SCI USA, V96, P9305, DOI 10.1073/pnas.96.16.9305; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Horng T, 2002, NATURE, V420, P329, DOI 10.1038/nature01180; Imler JL, 2003, NAT IMMUNOL, V4, P105, DOI 10.1038/ni0203-105; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kline JN, 2000, CURR TOP MICROBIOL, V247, P211; Klinman DM, 1999, IMMUNITY, V11, P123, DOI 10.1016/S1074-7613(00)80087-4; KRIEG AM, 1995, NATURE, V374, P546, DOI 10.1038/374546a0; Krieg AM, 2002, ANNU REV IMMUNOL, V20, P709, DOI 10.1146/annurev.immunol.20.100301.064842; Lee FS, 1997, CELL, V88, P213, DOI 10.1016/S0092-8674(00)81842-5; LERNER EC, 1995, J BIOL CHEM, V270, P26802, DOI 10.1074/jbc.270.45.26802; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; McDermott EP, 2002, J BIOL CHEM, V277, P7808, DOI 10.1074/jbc.M108133200; Medzhitov R, 1997, CURR OPIN IMMUNOL, V9, P4, DOI 10.1016/S0952-7915(97)80152-5; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Ninomiya-Tsuji J, 1999, NATURE, V398, P252, DOI 10.1038/18465; O'Neill L, 2000, BIOCHEM SOC T, V28, P557, DOI 10.1042/bst0280557; Oshiumi H, 2003, NAT IMMUNOL, V4, P161, DOI 10.1038/ni886; Palsson EM, 2000, J BIOL CHEM, V275, P7818, DOI 10.1074/jbc.275.11.7818; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; Shaye DD, 2002, NATURE, V420, P686, DOI 10.1038/nature01234; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; Sparwasser T, 1998, EUR J IMMUNOL, V28, P2045, DOI 10.1002/(SICI)1521-4141(199806)28:06<2045::AID-IMMU2045>3.0.CO;2-8; Stacey KJ, 1996, J IMMUNOL, V157, P2116; Suzuki N, 2002, NATURE, V416, P750, DOI 10.1038/nature736; Takeshita F, 2001, J IMMUNOL, V167, P3555, DOI 10.4049/jimmunol.167.7.3555; Takeshita S, 2000, CELL IMMUNOL, V206, P101, DOI 10.1006/cimm.2000.1735; Utaisincharoen P, 2002, CLIN EXP IMMUNOL, V128, P467, DOI 10.1046/j.1365-2249.2002.01866.x; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wei S, 2000, J IMMUNOL, V165, P3811, DOI 10.4049/jimmunol.165.7.3811; Weiner GJ, 2000, CURR TOP MICROBIOL, V247, P157; Wesche H, 1997, IMMUNITY, V7, P837, DOI 10.1016/S1074-7613(00)80402-1; Wittinghofer F, 1998, NATURE, V394, P317, DOI 10.1038/28492; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 2001, INT IMMUNOL, V13, P1391, DOI 10.1093/intimm/13.11.1391	53	56	58	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36334	36340		10.1074/jbc.M305698200	http://dx.doi.org/10.1074/jbc.M305698200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12867418	hybrid			2022-12-27	WOS:000185318300059
J	Llorente, A; Lauvrak, SU; van Deurs, B; Sandvig, K				Llorente, A; Lauvrak, SU; van Deurs, B; Sandvig, K			Induction of direct endosome to endoplasmic reticulum transport in Chinese hamster ovary (CHO) cells (LdlF) with a temperature-sensitive defect in epsilon-coatomer protein (epsilon-COP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RETROGRADE TRANSPORT; MEMBRANE-TRANSPORT; GOLGI-APPARATUS; SHIGA TOXIN; RICIN; PATHWAY; MUTANT; ER	In the present study we demonstrate that ricin, apparently without passing through the Golgi apparatus, reaches the endoplasmic reticulum (ER) and intoxicates cells in which the Golgi apparatus has been vesiculated by depletion of epsilon-COP, a subunit of COPI. LdlF cells contain a temperature-sensitive mutation in epsilon-COP. At the nonpermissive temperature epsilon-COP is degraded, and the Golgi apparatus undergoes a morphological change. To study ricin transport in these cells we used ricin sulf-2, a modified ricin molecule containing glycosylation and sulfation sites. Measurements of the incorporation of radioactive mannose into ricin sulf-2 showed that ricin reached the ER in cells depleted of epsilon-COP. Importantly, by investigating the glycosylation of ricin sulf-2 that was modified with radioactive sulfate in the trans-Golgi network, it was demonstrated that transport of ricin to the ER via the Golgi apparatus was severely inhibited. Moreover, we found that ricin was able to intoxicate ldlF cells depleted of epsilon-COP in the presence of brefeldin A. In contrast, control cells were completely protected against ricin by brefeldin A. In conclusion, our results suggest that in ldlF cells depleted of epsilon-COP ricin might be transported to the ER by an induced brefeldin A-resistant pathway that circumvents the Golgi apparatus.	Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway; Univ Copenhagen, Panum Inst, Dept Med Anat, Struct Cell Biol Unit, DK-2200 Copenhagen N, Denmark	University of Oslo; University of Copenhagen	Sandvig, K (corresponding author), Norwegian Radium Hosp, Inst Canc Res, N-0310 Oslo, Norway.		Llorente, Alicia/AAP-7349-2021	Llorente, Alicia/0000-0002-0045-071X				Aniento F, 1996, J CELL BIOL, V133, P29, DOI 10.1083/jcb.133.1.29; BAEUERLE PA, 1987, J CELL BIOL, V105, P2655, DOI 10.1083/jcb.105.6.2655; Barlowe C, 2000, TRAFFIC, V1, P371, DOI 10.1034/j.1600-0854.2000.010501.x; Chen A, 2002, BBA-MOL CELL RES, V1589, P124, DOI 10.1016/S0167-4889(02)00163-5; Daro E, 1997, J CELL BIOL, V139, P1747, DOI 10.1083/jcb.139.7.1747; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0; Gomez M, 2000, J BIOL CHEM, V275, P29162, DOI 10.1074/jbc.M003630200; Grimmer S, 2000, MOL BIOL CELL, V11, P4205, DOI 10.1091/mbc.11.12.4205; Gu F, 1997, J CELL BIOL, V139, P1183, DOI 10.1083/jcb.139.5.1183; GUO Q, 1994, J CELL BIOL, V125, P1213, DOI 10.1083/jcb.125.6.1213; Guo Q, 1996, J BIOL CHEM, V271, P11191, DOI 10.1074/jbc.271.19.11191; HOBBIE L, 1994, J BIOL CHEM, V269, P20958; Iversen TG, 2001, MOL BIOL CELL, V12, P2099, DOI 10.1091/mbc.12.7.2099; Kirchhausen T, 2000, NAT REV MOL CELL BIO, V1, P187, DOI 10.1038/35043117; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIPPINCOTTSCHWARTZ J, 1990, CELL, V60, P821, DOI 10.1016/0092-8674(90)90096-W; Lowe M, 1998, BBA-MOL CELL RES, V1404, P53, DOI 10.1016/S0167-4889(98)00046-9; Mallard F, 1998, J CELL BIOL, V143, P973, DOI 10.1083/jcb.143.4.973; Pelkmans L, 2001, NAT CELL BIOL, V3, P473, DOI 10.1038/35074539; Rapak A, 1997, P NATL ACAD SCI USA, V94, P3783, DOI 10.1073/pnas.94.8.3783; Richards AA, 2002, MOL BIOL CELL, V13, P1750, DOI 10.1091/mbc.01-12-0592; SANDVIG K, 1991, J CELL BIOL, V115, P971, DOI 10.1083/jcb.115.4.971; SANDVIG K, 1979, EXP CELL RES, V121, P15, DOI 10.1016/0014-4827(79)90439-7; Sandvig K, 2002, ANNU REV CELL DEV BI, V18, P1, DOI 10.1146/annurev.cellbio.18.011502.142107; Sandvig K, 2002, HISTOCHEM CELL BIOL, V117, P131, DOI 10.1007/s00418-001-0346-2; Scales SJ, 2000, INT REV CYTOL, V195, P67; YOSHIDA T, 1991, EXP CELL RES, V192, P389, DOI 10.1016/0014-4827(91)90056-Z	29	38	42	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35850	35855		10.1074/jbc.M303425200	http://dx.doi.org/10.1074/jbc.M303425200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12847103	hybrid			2022-12-27	WOS:000185164400135
J	Dhandapani, KM; Hadman, M; De Sevilla, L; Wade, MF; Mahesh, VB; Brann, DW				Dhandapani, KM; Hadman, M; De Sevilla, L; Wade, MF; Mahesh, VB; Brann, DW			Astrocyte protection of neurons - Role of transforming growth factor-beta signaling via a c-Jun-AP-1 protective pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSIENT FOREBRAIN ISCHEMIA; HORMONE-RELEASING-HORMONE; RAT HIPPOCAMPAL-NEURONS; C-JUN; TGF-BETA; CEREBRAL-ISCHEMIA; TRANSCRIPTION FACTORS; REACTIVE OXYGEN; GENE-EXPRESSION; IN-VITRO	Astrocytes have become a focal point for research in neurobiology, especially regarding their purported ability to regulate neuronal communication and survival. The present study addressed a poorly understood but important focus in this area, the mechanism(s) underlying astrocyte-induced survival of neurons. The results of the study show that soluble factors in astrocyte-conditioned media (ACM) protect murine GT1-7 neurons from serum deprivation-induced cell death and that this neuroprotection is correlated with enhanced activation/phosphorylation of the AP-1 transcription factor, c-Jun(Ser-63). A parallel and correlated activation of the upstream kinases, c-Jun N-terminal kinase (JNK) and mitogen-activated protein kinase kinase-4 (MKK4) was also demonstrated. Furthermore, co-administration of JNK inhibitors, but not a MEK inhibitor, significantly attenuated ACM-induced phosphorylation of c-Jun(Ser-63) and blocked its neuroprotective action. Gel shift analysis demonstrated that ACM enhanced AP-1 binding, an effect that appears functionally important, since an AP-1 binding inhibitor significantly attenuated the neuroprotective action of ACM. Further studies implicated transforming growth factor (TGF)-beta1 and TGF-beta2 as critical active soluble factors released by astrocytes, since both were demonstrated in ACM, and immunoneutralization of the conditioned media with a panspecific TGF-beta antibody significantly attenuated the enhanced AP-1 binding and neuroprotective action of the ACM. Furthermore, exogenous application of TGF-beta1 and TGF-beta2 was found to enhance c-Jun(Ser-63) phosphorylation and to be neuroprotective, and co-administration of JNK inhibitors or an AP-1 binding inhibitor blocked TGF-beta-induced neuroprotection. Taken together, these studies suggest that astrocytes can protect neurons from serum deprivation-induced cell death, at least in part, by release of TGF-beta and activation of a c-Jun/AP-1 protective pathway.	Med Coll Georgia, Sch Med, Inst Mol Med & Genet, Program Neurobiol, Augusta, GA 30912 USA; Med Coll Georgia, Sch Med, Dept Neurol, Augusta, GA 30912 USA	University System of Georgia; Augusta University; University System of Georgia; Augusta University	Brann, DW (corresponding author), Med Coll Georgia, Sch Med, Inst Mol Med & Genet, Program Neurobiol, 1120 15th St, Augusta, GA 30912 USA.	dbrann@mail.mcg.edu		Dhandapani, Krishnan/0000-0001-7044-1117				AUSUBEL FM, 2003, CURRENT PROTOCOLS MO, V2; Beattie EC, 2002, SCIENCE, V295, P2282, DOI 10.1126/science.1067859; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Blanchette F, 1997, J CLIN INVEST, V99, P1974, DOI 10.1172/JCI119365; Bruno V, 1998, J NEUROSCI, V18, P9594; Buchanan CD, 2000, BIOL REPROD, V62, P1710, DOI 10.1095/biolreprod62.6.1710; Butterworth NJ, 1996, MOL BRAIN RES, V43, P1, DOI 10.1016/S0169-328X(96)00143-X; Cho SH, 2001, J CEREBR BLOOD F MET, V21, P550, DOI 10.1097/00004647-200105000-00009; Chuang DM, 2002, BIPOLAR DISORD, V4, P129, DOI 10.1034/j.1399-5618.2002.01179.x; Cross JV, 1999, J BIOL CHEM, V274, P31150, DOI 10.1074/jbc.274.44.31150; Cui W, 2001, GLIA, V34, P272, DOI 10.1002/glia.1061; Dhandapani KM, 2003, EXP BIOL MED, V228, P253, DOI 10.1177/153537020322800303; Dhandapani KM, 2003, CELL BIOCHEM BIOPHYS, V39, P13, DOI 10.1385/CBB:39:1:13; Dhandapani KM, 2003, ENDOCRINE, V21, P59, DOI 10.1385/ENDO:21:1:59; Dragunow M, 2000, MOL BRAIN RES, V83, P20, DOI 10.1016/S0169-328X(00)00191-1; Dringen R, 2000, EUR J BIOCHEM, V267, P4912, DOI 10.1046/j.1432-1327.2000.01597.x; DUBOIS CM, 1995, J BIOL CHEM, V270, P10618, DOI 10.1074/jbc.270.18.10618; Flanders KC, 1998, PROG NEUROBIOL, V54, P71, DOI 10.1016/S0301-0082(97)00066-X; Gomes FCA, 2001, BRAZ J MED BIOL RES, V34, P611, DOI 10.1590/S0100-879X2001000500008; HADMAN M, 1993, ONCOGENE, V8, P1895; Heck S, 1999, J BIOL CHEM, V274, P9828, DOI 10.1074/jbc.274.14.9828; Herdegen T, 1997, TRENDS NEUROSCI, V20, P227, DOI 10.1016/S0166-2236(96)01000-4; Herdegen T, 2001, ONCOGENE, V20, P2424, DOI 10.1038/sj.onc.1204387; Huang Y, 2000, J BIOL CHEM, V275, P18234, DOI 10.1074/jbc.M909431199; HUGHES P, 1995, PHARMACOL REV, V47, P133; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kapinya K, 2000, BRAIN RES, V872, P282, DOI 10.1016/S0006-8993(00)02503-8; Knuckey NW, 1996, MOL BRAIN RES, V40, P1; Largo C, 1996, NEUROL RES, V18, P445; Leppa S, 2001, MOL CELL BIOL, V21, P4369, DOI 10.1128/MCB.21.13.4369-4378.2001; Liu D, 1999, MOL BRAIN RES, V68, P29, DOI 10.1016/S0169-328X(99)00063-7; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Mazars A, 2000, ONCOGENE, V19, P1277, DOI 10.1038/sj.onc.1203420; Mena MA, 1996, NEUROREPORT, V7, P441, DOI 10.1097/00001756-199601310-00016; Messi E, 1999, NEUROSCI LETT, V270, P165, DOI 10.1016/S0304-3940(99)00501-7; Mizuno H, 1998, MOL BRAIN RES, V60, P28, DOI 10.1016/S0169-328X(98)00163-6; Nawashiro H, 2000, J CEREBR BLOOD F MET, V20, P1040, DOI 10.1097/00004647-200007000-00003; Nishiyama H, 2002, P NATL ACAD SCI USA, V99, P4037, DOI 10.1073/pnas.052020999; Palcy S, 2000, J BONE MINER RES, V15, P2352, DOI 10.1359/jbmr.2000.15.12.2352; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Pennypacker KR, 2000, NEUROSCI LETT, V289, P1, DOI 10.1016/S0304-3940(00)01250-7; Prehn JHM, 1996, MOL PHARMACOL, V49, P319; PREHN JHM, 1994, P NATL ACAD SCI USA, V91, P12599, DOI 10.1073/pnas.91.26.12599; Rebollo A, 2000, MOL CELL BIOL, V20, P3407, DOI 10.1128/MCB.20.10.3407-3416.2000; Ren RF, 1996, BRAIN RES, V732, P16, DOI 10.1016/0006-8993(96)00458-1; Ren RF, 1997, MOL BRAIN RES, V48, P315, DOI 10.1016/S0169-328X(97)00108-3; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; Shashoua VE, 2003, BRAIN RES, V963, P214, DOI 10.1016/S0006-8993(02)04058-1; Shih SC, 2001, GROWTH FACTORS, V19, P19, DOI 10.3109/08977190109001073; Shklyaev SS, 2001, THYROID, V11, P629, DOI 10.1089/105072501750362691; SOMMER C, 1995, BRAIN PATHOL, V5, P135, DOI 10.1111/j.1750-3639.1995.tb00587.x; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Sortino MA, 1999, ENDOCRINOLOGY, V140, P4841, DOI 10.1210/en.140.10.4841; Sortino MA, 1996, ENDOCRINOLOGY, V137, P1418, DOI 10.1210/en.137.4.1418; TAKEMOTO O, 1995, STROKE, V26, P1639, DOI 10.1161/01.STR.26.9.1639; TAKESHITA A, 1995, J IMMUNOL, V155, P419; Tanaka J, 1999, GLIA, V28, P85, DOI 10.1002/(SICI)1098-1136(199911)28:2<85::AID-GLIA1>3.0.CO;2-Y; Truettner J, 2002, MOL BRAIN RES, V103, P106, DOI 10.1016/S0169-328X(02)00191-2; Van den Pol AN, 2000, NEUROSCIENCE, V95, P603; Verrecchia F, 2001, ONCOGENE, V20, P3332, DOI 10.1038/sj.onc.1204448; Verrecchia F, 2001, ONCOGENE, V20, P2205, DOI 10.1038/sj.onc.1204347; VIVIEN D, 1995, EXP CELL RES, V221, P60, DOI 10.1006/excr.1995.1352; Walton M, 1998, J NEUROSCI RES, V53, P330, DOI 10.1002/(SICI)1097-4547(19980801)53:3<330::AID-JNR7>3.0.CO;2-B; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; Wilson JX, 1997, CAN J PHYSIOL PHARM, V75, P1149, DOI 10.1139/cjpp-75-10-11-1149; Yoneda Y, 1998, J NEUROSCI RES, V51, P574, DOI 10.1002/(SICI)1097-4547(19980301)51:5<574::AID-JNR4>3.0.CO;2-C; Yuan PX, 1999, J NEUROCHEM, V73, P2299, DOI 10.1046/j.1471-4159.1999.0732299.x; Zhu Y, 2001, NEUROCHEM INT, V38, P227, DOI 10.1016/S0197-0186(00)00084-X	68	112	119	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43329	43339		10.1074/jbc.M305835200	http://dx.doi.org/10.1074/jbc.M305835200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12888549	hybrid			2022-12-27	WOS:000186157000076
J	Brouillard, F; Cremisi, CE				Brouillard, F; Cremisi, CE			Concomitant increase of histone acetyltransferase activity and degradation of p300 during retinoic acid-induced differentiation of F9 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEASOME-MEDIATED DEGRADATION; DEPENDENT PROTEIN-KINASE; CREB-BINDING PROTEIN; COACTIVATORS P300; HORMONE-RECEPTOR; DISTINCT ROLES; CBP; PHOSPHORYLATION; INHIBITION; ACTIVATION	The p300 and closely related CBP histone acetyltransferases (HAT) function as global transcriptional co-activators that play roles in many cell differentiation and signal transduction pathways. Despite their similarities, p300 and CBP have distinct functions during retinoic acid-induced differentiation of mouse F9 embryonal carcinoma cells. F9 cells constitute a well established model system for investigating the first steps of early development and retinoic acid signaling ex vivo. p300, but not CBP, was shown to be essential for F9 differentiation. In this study we have investigated the regulation of p300 during F9 differentiation. We report a dramatic decrease of p300, but not CBP protein levels, after 48 h of retinoic acid treatment. p300 is degraded via the ubiquitin-proteasome pathway. Although the large majority of p300 is degraded, its global HAT activity stays constant during F9 differentiation, which means that its specific HAT activity increases considerably. p300 is strongly phosphorylated in both undifferentiated and differentiated F9 cells; its HAT activity, however, is independent of phosphorylation before differentiation and becomes dependent on phosphorylation during differentiation. Furthermore, we show that protein kinase A affects p300 HAT activity both in vivo and in vitro as well as p300 phosphorylation in differentiated cells. Thus, we show that p300 is differentially phosphorylated in undifferentiated versus differentiated cells and that the changes in phosphorylation affect its HAT activity. Moreover, our study suggests an explanation for the functional switch of p300-mediated repression versus activation during F9 differentiation.	CNRS, UPR 9079, Ligue Natl Contre Canc, Inst Andre Lwoff, F-94800 Villejuif, France	Centre National de la Recherche Scientifique (CNRS)	Cremisi, CE (corresponding author), CNRS, UPR 9079, Ligue Natl Contre Canc, Inst Andre Lwoff, 7 Rue Guy Moquet, F-94800 Villejuif, France.	cremisi@vjf.cnrs.fr						Ait-Si-Ali S, 1999, BIOCHEM BIOPH RES CO, V262, P157, DOI 10.1006/bbrc.1999.1132; Ait-Si-Ali S, 1998, NATURE, V396, P184, DOI 10.1038/24190; Bannister AJ, 1996, NATURE, V384, P641, DOI 10.1038/384641a0; Bordoli L, 2001, NUCLEIC ACIDS RES, V29, P4462, DOI 10.1093/nar/29.21.4462; Chakravarti D, 1996, NATURE, V383, P99, DOI 10.1038/383099a0; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Gianni M, 2002, J BIOL CHEM, V277, P24859, DOI 10.1074/jbc.C200230200; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Goodman RH, 2000, GENE DEV, V14, P1553; Imhof A, 1997, CURR BIOL, V7, P689, DOI 10.1016/S0960-9822(06)00296-X; Kamei Y, 1996, CELL, V85, P403, DOI 10.1016/S0092-8674(00)81118-6; Kawasaki H, 1998, NATURE, V393, P284, DOI 10.1038/30538; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KITABAYASHI I, 1995, EMBO J, V14, P3496, DOI 10.1002/j.1460-2075.1995.tb07356.x; Kopf E, 2000, J BIOL CHEM, V275, P33280, DOI 10.1074/jbc.M002840200; Li Q, 2002, MOL ENDOCRINOL, V16, P2819, DOI 10.1210/me.2002-0154; Li Q, 1999, EMBO J, V18, P5634, DOI 10.1093/emboj/18.20.5634; MARTIN GR, 1980, SCIENCE, V209, P768, DOI 10.1126/science.6250214; Martinez-Balbas MA, 1998, EMBO J, V17, P2886, DOI 10.1093/emboj/17.10.2886; Molinari E, 1999, EMBO J, V18, P6439, DOI 10.1093/emboj/18.22.6439; MONTANO X, 1987, MOL CELL BIOL, V7, P1782, DOI 10.1128/MCB.7.5.1782; Muniz M, 1996, J BIOL CHEM, V271, P30935, DOI 10.1074/jbc.271.48.30935; Ogryzko VV, 1996, CELL, V87, P953, DOI 10.1016/S0092-8674(00)82001-2; Ota M, 1998, CELL GROWTH DIFFER, V9, P989; Perletti L, 2001, BMC Mol Biol, V2, P4, DOI 10.1186/1471-2199-2-4; PLET A, 1985, DIFFERENTIATION, V30, P159, DOI 10.1111/j.1432-0436.1985.tb00527.x; Poizat C, 2000, MOL CELL BIOL, V20, P8643, DOI 10.1128/MCB.20.23.8643-8654.2000; Rebel VI, 2002, P NATL ACAD SCI USA, V99, P14789, DOI 10.1073/pnas.232568499; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; Suganuma T, 2002, P NATL ACAD SCI USA, V99, P13073, DOI 10.1073/pnas.192586699; Takahashi N, 2002, J BIOL CHEM, V277, P16906, DOI 10.1074/jbc.M200585200; YACIUK P, 1991, MOL CELL BIOL, V11, P5389, DOI 10.1128/MCB.11.11.5389; Yang XJ, 1996, NATURE, V382, P319, DOI 10.1038/382319a0; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Yao TP, 1996, P NATL ACAD SCI USA, V93, P10626, DOI 10.1073/pnas.93.20.10626	36	38	39	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39509	39516		10.1074/jbc.M307123200	http://dx.doi.org/10.1074/jbc.M307123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12888559	hybrid			2022-12-27	WOS:000185713800031
J	Ortega, A; Ferrer, P; Carretero, J; Obrador, E; Asensi, M; Pellicer, JA; Estrela, JM				Ortega, A; Ferrer, P; Carretero, J; Obrador, E; Asensi, M; Pellicer, JA; Estrela, JM			Down-regulation of glutathione and Bcl-2 synthesis in mouse B16 melanoma cells avoids their survival during interaction with the vascular endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; HEPATIC SINUSOIDAL ENDOTHELIUM; CANCER-CELLS; IN-VITRO; ANTISENSE OLIGONUCLEOTIDES; HEMATOGENOUS METASTASIS; MITOCHONDRIAL-FUNCTION; INDUCED APOPTOSIS; REDOX REGULATION; SCID MICE	B16 melanoma (B16M) cells with high GSH content show high metastatic activity. However, the molecular mechanisms linking GSH to metastatic cell survival are unclear. The possible relationship between GSH and the ability of Bcl-2 to prevent cell death was studied in B16M cells with high (F10) and low (F1) metastatic potential. Analysis of a Bcl-2 family of genes revealed that B16M-F10 cells, as compared with B16M-F1 cells, overexpressed preferentially Bcl-2 ( similar to 5.7-fold). Hepatic sinusoidal endothelium-induced B16M-F10 cytotoxicity in vitro increased from similar to 19% ( controls) to similar to 97% in GSH-depleted B16M-F10 cells treated with an antisense Bcl-2 oligodeoxynucleotide (Bcl-2-AS). L-Buthionine (S,R)-sulfoximine-induced GSH depletion or Bcl-2-AS decreased the metastatic growth of B16M-F10 cells in the liver. However, the combination of L-buthionine (S,R)-sulfoximine and Bcl-2-AS abolished metastatic invasion. Bcl-2-overexpressing B16M-F1/Tet-Bcl-2 and B16M-F10/Tet-Bcl-2 cells, as compared with controls, showed an increase in GSH content, no change in the rate of GSH synthesis, and a decrease in GSH efflux. Thus, Bcl-2 overexpression may increase metastatic cell resistance against oxidative/nitrosative stress by inhibiting release of GSH. In addition, Bcl-2 availability regulates the mitochondrial GSH (mtGSH)-dependent opening of the permeability transition pore complex. Death in B16M-F10 cells was sharply activated at mtGSH levels below 30% of controls values. However, this critical threshold increased to similar to60% of control values in Bcl-2-AS-treated B16M-F10 cells. GSH ester-induced replenishment of mtGSH levels ( even under conditions of cytosolic GSH depletion) prevented cell death. Our results indicate that survival of B16M cells with high metastatic potential can be challenged by inhibiting their GSH and Bcl-2 synthesis.	Univ Valencia, Dept Physiol, Valencia 46010, Spain	University of Valencia	Estrela, JM (corresponding author), Univ Valencia, Dept Physiol, Av Blasco Ibanez 17, Valencia 46010, Spain.	jose.m.estrela@uv.es	Carretero, Julian/N-5214-2014; Miralles, Miguel A Asensi/I-2756-2015; MARTINEZ, ANTONIO PELLICER/C-4832-2015; Estrela, Jose/H-4449-2015; OBRADOR, ELENA/H-4069-2015; Ortega, Angel L./A-4113-2014	Carretero, Julian/0000-0001-7269-8506; Miralles, Miguel A Asensi/0000-0003-1922-7777; Estrela, Jose/0000-0002-2540-9190; OBRADOR, ELENA/0000-0002-5934-5543; Ortega, Angel L./0000-0002-9901-3383				Anasagasti MJ, 1998, HEPATOLOGY, V27, P1249, DOI 10.1002/hep.510270510; Arai M, 1999, J BIOL CHEM, V274, P4924, DOI 10.1074/jbc.274.8.4924; Armstrong JS, 2002, FASEB J, V16, P1263, DOI 10.1096/fj.02-0097fje; Baliga BC, 2002, HEMATOL ONCOL, V20, P63, DOI 10.1002/hon.685; BERGMEYER HU, 1974, METHOD ENZYMAT AN, P574; BOUWENS L, 1988, CANCER IMMUNOL IMMUN, V27, P137; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Carretero J, 2001, J BIOL CHEM, V276, P25775, DOI 10.1074/jbc.M101148200; Carretero J, 1999, CLIN EXP METASTAS, V17, P567, DOI 10.1023/A:1006725226078; CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666; Davis DA, 1997, J BIOL CHEM, V272, P25935, DOI 10.1074/jbc.272.41.25935; de Menezes DEL, 2000, CLIN CANCER RES, V6, P2891; Dias N, 2002, EUR J PHARM BIOPHARM, V54, P263, DOI 10.1016/S0939-6411(02)00060-7; Eissa S, 1998, CLIN CHEM, V44, P1423; ESTRELA JM, 1995, NAT MED, V1, P84, DOI 10.1038/nm0195-84; Gleave ME, 1999, UROLOGY, V54, P36, DOI 10.1016/S0090-4295(99)00453-7; GOOSSENS V, 1995, P NATL ACAD SCI USA, V92, P8115, DOI 10.1073/pnas.92.18.8115; Gross A, 2001, IUBMB LIFE, V52, P231, DOI 10.1080/15216540152846046; Hahne M, 1996, SCIENCE, V274, P1363, DOI 10.1126/science.274.5291.1363; Haouzi D, 2001, HEPATOLOGY, V33, P1181, DOI 10.1053/jhep.2001.24235; Hickman JA, 2002, CURR OPIN GENET DEV, V12, P67, DOI 10.1016/S0959-437X(01)00266-0; James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401; Jansen B, 2002, LANCET ONCOL, V3, P672, DOI 10.1016/S1470-2045(02)00903-8; Jansen B, 1998, NAT MED, V4, P232, DOI 10.1038/nm0298-232; KANE DJ, 1993, SCIENCE, V262, P1274, DOI 10.1126/science.8235659; Kaplowitz N, 1996, BIOL CHEM H-S, V377, P267; Klasa RJ, 2000, CLIN CANCER RES, V6, P2492; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; LANCASTER JR, 1989, FEBS LETT, V248, P169, DOI 10.1016/0014-5793(89)80454-5; Lowe SW, 2000, CARCINOGENESIS, V21, P485, DOI 10.1093/carcin/21.3.485; Marchetti P, 1997, EUR J IMMUNOL, V27, P289, DOI 10.1002/eji.1830270142; MARTENSSON J, 1989, P NATL ACAD SCI USA, V86, P471, DOI 10.1073/pnas.86.2.471; Mirkovic N, 1997, ONCOGENE, V15, P1461, DOI 10.1038/sj.onc.1201310; Miyake H, 1999, CANCER RES, V59, P4030; *NIH, 1985, GUID CAR US LAB AN; Obrador E, 2002, HEPATOLOGY, V35, P74, DOI 10.1053/jhep.2002.30277; Obrador E, 2001, FREE RADICAL BIO MED, V31, P642, DOI 10.1016/S0891-5849(01)00622-0; Ogretmen B, 1996, INT J CANCER, V67, P608, DOI 10.1002/(SICI)1097-0215(19960904)67:5<608::AID-IJC3>3.0.CO;2-Y; Ortega AL, 2003, J BIOL CHEM, V278, P13888, DOI 10.1074/jbc.M207140200; Owen-Schaub LB, 1998, J EXP MED, V188, P1717, DOI 10.1084/jem.188.9.1717; Petrovic AS, 1998, BLOOD, V91, P3952, DOI 10.1182/blood.V91.10.3952.3952_3952_3961; Pollman MJ, 1998, NAT MED, V4, P222, DOI 10.1038/nm0298-222; Reed J C, 1997, Adv Pharmacol, V41, P501, DOI 10.1016/S1054-3589(08)61070-4; Rudin CM, 2003, CANCER RES, V63, P312; Rui M, 2002, LIFE SCI, V71, P1771, DOI 10.1016/S0024-3205(02)01943-4; Sartorius UA, 2002, INT J CANCER, V97, P584, DOI 10.1002/ijc.10096; Scarlett JL, 2000, FEBS LETT, V475, P267, DOI 10.1016/S0014-5793(00)01681-1; Schiavone N, 2000, FASEB J, V14, P174, DOI 10.1096/fasebj.14.1.174; SUGARMAN BJ, 1985, SCIENCE, V230, P943, DOI 10.1126/science.3933111; Sun Y, 1996, FREE RADICAL BIO MED, V21, P335, DOI 10.1016/0891-5849(96)00109-8; Takaoka A, 1997, ONCOGENE, V14, P2971, DOI 10.1038/sj.onc.1201147; Takeda K, 2001, CELL IMMUNOL, V214, P194, DOI 10.1006/cimm.2001.1896; Vahrmeijer AL, 2000, BIOCHEM PHARMACOL, V59, P1557, DOI 10.1016/S0006-2952(00)00286-0; VANDENBREKEL AJS, 1995, J CLIN ONCOL, V13, P2600, DOI 10.1200/JCO.1995.13.10.2600; Voehringer DW, 1999, FREE RADICAL BIO MED, V27, P945, DOI 10.1016/S0891-5849(99)00174-4; Voehringer DW, 1998, P NATL ACAD SCI USA, V95, P2956, DOI 10.1073/pnas.95.6.2956; WEISS L, 1992, CANCER METAST REV, V11, P227, DOI 10.1007/BF01307179; Weiss L, 1990, Adv Cancer Res, V54, P159, DOI 10.1016/S0065-230X(08)60811-8; WEISS L, 1992, INT J CANCER, V50, P103, DOI 10.1002/ijc.2910500121; Wong CW, 2001, CANCER RES, V61, P333; Yaziji H, 2003, INT J SURG PATHOL, V11, P11, DOI 10.1177/106689690301100103; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; Zangemeister-Wittke U, 1998, BRIT J CANCER, V78, P1035, DOI 10.1038/bjc.1998.624; Zimmermann KC, 2001, PHARMACOL THERAPEUT, V92, P57, DOI 10.1016/S0163-7258(01)00159-0	64	43	44	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39591	39599		10.1074/jbc.M303753200	http://dx.doi.org/10.1074/jbc.M303753200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12881529	hybrid			2022-12-27	WOS:000185713800042
J	van der Wijk, T; Tomassen, SFB; Houtsmuller, AB; de Jonge, HR; Tilly, BC				van der Wijk, T; Tomassen, SFB; Houtsmuller, AB; de Jonge, HR; Tilly, BC			Increased vesicle recycling in response to osmotic cell swelling - Cause and consequence of hypotonicity-provoked ATP release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; REGULATORY VOLUME DECREASE; EXTRACELLULAR ATP; CL-CONDUCTANCE; CYTOSOLIC CA2+; CULTURED HUMAN; KINASES ERK-1; ACTIVATION; EXOCYTOSIS; PROTEIN	Osmotic swelling of Intestine 407 cells leads to an immediate increase in cell surface membrane area as determined using the fluorescent membrane dye FM 1-43. In addition, as measured by tetramethylrhodamine isothiocyanate (TRITC)-dextran uptake, a robust (>100-fold) increase in the rate of endocytosis was observed, starting after a discrete lag time of 2-3 min and lasting for similar to10-15 min. The hypotonicity-induced increase in membrane surface area, like the cell swelling-induced release of ATP (Van der Wijk, T., De Jonge, H. R., and Tilly, B. C. (1999) Biochem. J. 343, 579-586), was diminished after 1,2-bis(2-aminophenoxy) ethane-N, N,N',N'-tetraacetic acid-acetoxymethyl ester loading or cytochalasin B treatment. Uptake of TRITC-dextrans, however, was not affected. Treatment of the cells with the vesicle-soluble N-ethylmaleimide-sensitive factor attachment protein receptor-specific protease Clostridium botulinum toxin F not only nearly eliminated the hypotonicity-induced increase in membrane surface area but also strongly diminished the release of ATP, indicating the involvement of regulated exocytosis. Both the ATP hydrolase apyrase and the MEK inhibitor PD098059 diminished the osmotic swelling-induced increase in membrane surface area as well as the subsequent uptake of TRITC-dextrans. Taken together, the results indicate that extracellular ATP is required for the hypotonicity-induced vesicle recycling and suggest that a positive feedback loop, involving purinergic activation of the Erk-1/2 pathway, may contribute to the release of ATP from hypo-osmotically stimulated cells.	Erasmus Univ, Med Ctr, Dept Biochem, NL-3000 DR Rotterdam, Netherlands; Erasmus Univ, Med Ctr, Dept Pathol, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC	Tilly, BC (corresponding author), Erasmus Univ, Med Ctr, Dept Biochem, POB 1738, NL-3000 DR Rotterdam, Netherlands.	b.tilly@ErasmusMC.nl						ALAWQATI Q, 1995, SCIENCE, V269, P805, DOI 10.1126/science.7543697; BRUCK R, 1992, AM J PHYSIOL, V262, pG806, DOI 10.1152/ajpgi.1992.262.5.G806; Cantiello HF, 1997, BIOSCIENCE REP, V17, P147, DOI 10.1023/A:1027381412574; Crepel V, 1998, J NEUROSCI, V18, P1196; CZEKAY RP, 1994, EUR J CELL BIOL, V63, P20; DAVENPORT KR, 1995, J BIOL CHEM, V270, P30157; ETCHEBERRIGARAY R, 1991, ANN NY ACAD SCI, V635, P90, DOI 10.1111/j.1749-6632.1991.tb36484.x; Granja R, 1996, J NEUROCHEM, V67, P1056; GREGER R, 1993, PFLUG ARCH EUR J PHY, V424, P329, DOI 10.1007/BF00384360; Guo XW, 1997, AM J PHYSIOL-CELL PH, V273, pC804, DOI 10.1152/ajpcell.1997.273.3.C804; Han B, 1997, GASTROENTEROLOGY, V113, P1756, DOI 10.1053/gast.1997.v113.pm9352882; Haussinger D, 1996, BIOCHEM J, V313, P697; Hazama A, 1999, J GEN PHYSIOL, V114, P525, DOI 10.1085/jgp.114.4.525; Hazama A, 2000, J PHYSIOL-LONDON, V523, P1, DOI 10.1111/j.1469-7793.2000.t01-6-00001.x; HAZAMA A, 1990, PFLUG ARCH EUR J PHY, V416, P710, DOI 10.1007/BF00370619; Holzinger A, 2001, METH MOL B, V161, P109; Humeau Y, 2000, BIOCHIMIE, V82, P427, DOI 10.1016/S0300-9084(00)00216-9; Jakab M, 2002, CELL PHYSIOL BIOCHEM, V12, P235, DOI 10.1159/000067895; Lazarowski ER, 2000, J BIOL CHEM, V275, P31061, DOI 10.1074/jbc.M003255200; Lee SC, 1999, BIOPHYS J, V76, P2297, DOI 10.1016/S0006-3495(99)77385-6; Light DB, 1999, AM J PHYSIOL-CELL PH, V277, pC480, DOI 10.1152/ajpcell.1999.277.3.C480; Lim W, 1997, PFLUG ARCH EUR J PHY, V435, P34, DOI 10.1007/s004240050481; Musante L, 1999, J BIOL CHEM, V274, P11701, DOI 10.1074/jbc.274.17.11701; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Noe B, 1996, GASTROENTEROLOGY, V110, P858, DOI 10.1053/gast.1996.v110.pm8608896; Nunez L, 1997, AM J PHYSIOL-ENDOC M, V272, pE1117, DOI 10.1152/ajpendo.1997.272.6.E1117; O'Neill WC, 1999, AM J PHYSIOL-CELL PH, V276, pC995, DOI 10.1152/ajpcell.1999.276.5.C995; OKADA Y, 1992, BIOCHIM BIOPHYS ACTA, V1107, P201, DOI 10.1016/0005-2736(92)90348-P; PFALLER W, 1993, J CELL PHYSIOL, V154, P248, DOI 10.1002/jcp.1041540206; Poulsen CR, 1999, DIABETES, V48, P2171, DOI 10.2337/diabetes.48.11.2171; Powell AD, 2000, J NEUROSCI, V20, P606, DOI 10.1523/JNEUROSCI.20-02-00606.2000; Raucher D, 1999, J CELL BIOL, V144, P497, DOI 10.1083/jcb.144.3.497; Roman RM, 1999, AM J PHYSIOL-GASTR L, V276, pG1391, DOI 10.1152/ajpgi.1999.276.6.G1391; Sadoshima J, 1996, EMBO J, V15, P5535, DOI 10.1002/j.1460-2075.1996.tb00938.x; Schliess F, 1996, BIOCHEM J, V320, P167, DOI 10.1042/bj3200167; SCHLIESS F, 1995, BIOCHEM J, V309, P13, DOI 10.1042/bj3090013; Sinning R, 1997, FEBS LETT, V400, P163, DOI 10.1016/S0014-5793(96)01376-2; Smith CB, 1996, NATURE, V380, P531, DOI 10.1038/380531a0; Taylor AL, 1998, AM J PHYSIOL-CELL PH, V275, pC1391, DOI 10.1152/ajpcell.1998.275.5.C1391; TILLY BC, 1993, J BIOL CHEM, V268, P19919; Ulate G, 2000, PFLUG ARCH EUR J PHY, V439, P304, DOI 10.1007/s004240050944; van der Wijk T, 1999, BIOCHEM J, V343, P579, DOI 10.1042/0264-6021:3430579; van der Wijk T, 1998, BIOCHEM J, V331, P863, DOI 10.1042/bj3310863; Wang Y, 1996, P NATL ACAD SCI USA, V93, P12020, DOI 10.1073/pnas.93.21.12020; Zhang Z, 1998, AM J PHYSIOL-CELL PH, V275, pC1104, DOI 10.1152/ajpcell.1998.275.4.C1104	45	52	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40020	40025		10.1074/jbc.M307603200	http://dx.doi.org/10.1074/jbc.M307603200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871943	hybrid			2022-12-27	WOS:000185713800091
J	Yahata, Y; Shirakata, Y; Tokumaru, S; Yamasaki, K; Sayama, K; Hanakawa, Y; Detmar, M; Hashimoto, K				Yahata, Y; Shirakata, Y; Tokumaru, S; Yamasaki, K; Sayama, K; Hanakawa, Y; Detmar, M; Hashimoto, K			Nuclear translocation of phosphorylated STAT3 is essential for vascular endothelial growth factor-induced human dermal microvascular endothelial cell migration and tube formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR TYROSINE KINASE; SIGNAL-TRANSDUCTION; EMBRYONIC LETHALITY; FACTOR VEGF; MAP KINASE; VASCULOGENESIS; ANGIOGENESIS; ACTIVATION; GENE; IDENTIFICATION	Vascular endothelial growth factor (VEGF) is a potent, multifunctional, endothelial-cell-specific growth factor. It stimulates proliferation and migration of endothelial cells. Characterization of intracellular signal transduction after VEGF and VEGF receptor (VEGFR) interaction has demonstrated the involvement of the mitogen-activated protein kinase pathway. However, several studies indicated that signal transducers and activators of transcription (STAT) is another important pathway downstream of VEGF/VEGFR interaction. Therefore, we studied the role of STAT3 in the migration and tube formation of the human dermal microvascular endothelial cells (HDMEC). HDMEC expressed phosphorylated forms of STAT1, STAT3, and STAT5, and a marked increase of phosphorylated STAT3 in the nuclear fraction after addition of VEGF was observed by Western blot and immunohistochemical staining. To verify the functional implication of STAT3 phosphorylation in HDMEC migration, we introduced a dominant-negative STAT3 using adenovirus vector system. Dominant-negative STAT3 abolished the VEGF-induced nuclear translocation of phosphorylated STAT3 and inhibited HDMEC migration completely. Dominant-negative STAT3 also suppressed VEGF-induced HDMEC tube formation on Matrigel and on collagen gel. These data demonstrate that STAT3 and its phosphorylation are involved in the downstream pathway of VEGF/VEGFR interaction and regulate VEGF-induced HDMEC migration and tube formation.	Ehime Univ, Sch Med, Dept Dermatol, Onsen, Ehime 7910295, Japan; Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA 02129 USA	Ehime University; Harvard University; Massachusetts General Hospital; Harvard University	Shirakata, Y (corresponding author), Ehime Univ, Sch Med, Dept Dermatol, Onsen, Ehime 7910295, Japan.		Yamasaki, Kenshi/C-8905-2018	Yamasaki, Kenshi/0000-0002-5495-4956				Bartoli M, 2000, J BIOL CHEM, V275, P33189, DOI 10.1074/jbc.C000318200; Blair RJ, 1997, J CLIN INVEST, V99, P2691, DOI 10.1172/JCI119458; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; Darnell JE, 1997, SCIENCE, V277, P1630, DOI 10.1126/science.277.5332.1630; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4; Ferrara N, 1999, KIDNEY INT, V56, P794, DOI 10.1046/j.1523-1755.1999.00610.x; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; Funamoto M, 2000, J BIOL CHEM, V275, P10561, DOI 10.1074/jbc.275.14.10561; Hanahan D, 1997, SCIENCE, V277, P48, DOI 10.1126/science.277.5322.48; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Johnson HM, 1998, BIOCHEM BIOPH RES CO, V244, P607, DOI 10.1006/bbrc.1998.8254; Landgren E, 1998, ONCOGENE, V16, P359, DOI 10.1038/sj.onc.1201545; Maisonpierre PC, 1997, SCIENCE, V277, P55, DOI 10.1126/science.277.5322.55; Minami M, 1996, P NATL ACAD SCI USA, V93, P3963, DOI 10.1073/pnas.93.9.3963; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9; ORTEGA N, 1999, FRONT BIOSCI, V4, P141; Richard L, 1998, EXP CELL RES, V240, P1, DOI 10.1006/excr.1998.3936; RIFKIN DB, 1989, J CELL BIOL, V109, P1, DOI 10.1083/jcb.109.1.1; Rousseau S, 1997, ONCOGENE, V15, P2169, DOI 10.1038/sj.onc.1201380; Sano S, 1999, EMBO J, V18, P4657, DOI 10.1093/emboj/18.17.4657; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SEETHARAM L, 1995, ONCOGENE, V10, P135; Shalaby F, 1997, CELL, V89, P981, DOI 10.1016/S0092-8674(00)80283-4; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; SHING Y, 1984, SCIENCE, V223, P1296, DOI 10.1126/science.6199844; SIMORREPINATEL V, 1994, INVEST OPHTH VIS SCI, V35, P3393; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; TERMAN BI, 1992, BIOCHEM BIOPH RES CO, V187, P1579, DOI 10.1016/0006-291X(92)90483-2; TERMAN BI, 1991, ONCOGENE, V6, P1677; Tokumaru S, 2000, J CELL BIOL, V151, P209, DOI 10.1083/jcb.151.2.209; VAISMAN N, 1990, J BIOL CHEM, V265, P19461; WALTENBERGER J, 1994, J BIOL CHEM, V269, P26988; Yamauchi-Takihara K, 2000, TRENDS CARDIOVAS MED, V10, P298, DOI 10.1016/S1050-1738(01)00066-4; Yoshida A, 1996, GROWTH FACTORS, V13, P57, DOI 10.3109/08977199609034566	43	143	162	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40026	40031		10.1074/jbc.M301866200	http://dx.doi.org/10.1074/jbc.M301866200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874294	hybrid			2022-12-27	WOS:000185713800092
J	Inaba, T; Li, M; Alvarez-Huerta, M; Kessler, F; Schnell, DJ				Inaba, T; Li, M; Alvarez-Huerta, M; Kessler, F; Schnell, DJ			AtTic110 functions as a scaffold for coordinating the stromal events of protein import into chloroplasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INNER ENVELOPE MEMBRANE; ANION CHANNEL; SECONDARY STRUCTURE; OUTER-MEMBRANE; MACHINERY; RECEPTOR; IDENTIFICATION; TRANSLOCATION; COMPONENTS; APPARATUS	The translocon of the inner envelope membrane of chloroplasts ( Tic) mediates the late events in the translocation of nucleus-encoded preproteins into chloroplasts. Tic110 is a major integral membrane component of active Tic complexes and has been proposed to function as a docking site for translocation-associated stromal factors and as a component of the protein-conducting channel. To investigate the various proposed functions of Tic110, we have investigated the structure, topology, and activities of a 97.5-kDa fragment of Arabidopsis Tic110 ( atTic110) lacking only the amino-terminal transmembrane segments. The protein was expressed both in Escherichia coli and Arabidopsis as a stable, soluble protein with a high alpha-helical content. Binding studies demonstrate that a region of the at-Tic110-soluble domain selectively associates with chloroplast preproteins at the late stages of membrane translocation. These data support the hypothesis that the bulk of Tic110 extends into the chloroplast stroma and suggest that the domain forms a docking site for preproteins as they emerge from the Tic translocon.	Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA; Univ Neuchatel, Lab Physiol Vegetale, Inst Bot, CH-2007 Neuchatel, Switzerland	University of Massachusetts System; University of Massachusetts Amherst; University of Neuchatel	Schnell, DJ (corresponding author), Univ Massachusetts, Dept Biochem & Mol Biol, Amherst, MA 01003 USA.		Kessler, Felix Henrique/AAO-1722-2020; Li, Ming/A-1493-2011; Li, Ming/AAU-5026-2020	Li, Ming/0000-0002-1247-2377; Inaba, Takehito/0000-0003-1750-454X; Kessler, Felix/0000-0001-6409-5043				Akita M, 1997, J CELL BIOL, V136, P983, DOI 10.1083/jcb.136.5.983; ANDERSON DJ, 1983, METHOD ENZYMOL, V96, P111; Bauer J, 2000, NATURE, V403, P203, DOI 10.1038/35003214; Bauer J, 2002, J CELL BIOL, V159, P845, DOI 10.1083/jcb.200208018; Bauer J, 2001, CELL MOL LIFE SCI, V58, P420, DOI 10.1007/PL00000867; Caliebe A, 1997, EMBO J, V16, P7342, DOI 10.1093/emboj/16.24.7342; Chen XJ, 2002, PLANT CELL, V14, P641, DOI 10.1105/tpc.010336; Heins L, 2002, EMBO J, V21, P2616, DOI 10.1093/emboj/21.11.2616; Heuck AP, 2001, BIOCHEMISTRY-US, V40, P9065, DOI 10.1021/bi0155394; Hiltbrunner A, 2001, J CELL BIOL, V154, P309, DOI 10.1083/jcb.200104022; Hinnah SC, 1997, EMBO J, V16, P7351, DOI 10.1093/emboj/16.24.7351; Jackson DT, 1998, J BIOL CHEM, V273, P16583, DOI 10.1074/jbc.273.26.16583; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Keegstra K, 1999, PLANT CELL, V11, P557, DOI 10.1105/tpc.11.4.557; KEEGSTRA K, 1986, METHOD ENZYMOL, V118, P316; Kessler F, 1996, P NATL ACAD SCI USA, V93, P7684, DOI 10.1073/pnas.93.15.7684; KESSLER F, 1994, SCIENCE, V266, P1035, DOI 10.1126/science.7973656; Kouranov A, 1998, J CELL BIOL, V143, P991, DOI 10.1083/jcb.143.4.991; Kouranov A, 1997, J CELL BIOL, V139, P1677, DOI 10.1083/jcb.139.7.1677; Kouranov A, 1999, J BIOL CHEM, V274, P25181, DOI 10.1074/jbc.274.35.25181; Kuchler M, 2002, EMBO J, V21, P6136, DOI 10.1093/emboj/cdf621; Lubeck J, 1997, J CELL BIOL, V137, P1279, DOI 10.1083/jcb.137.6.1279; Lubeck J, 1996, EMBO J, V15, P4230, DOI 10.1002/j.1460-2075.1996.tb00797.x; Ma YK, 1996, J CELL BIOL, V134, P315, DOI 10.1083/jcb.134.2.315; Nielsen E, 1997, EMBO J, V16, P935, DOI 10.1093/emboj/16.5.935; Pelton JT, 2000, ANAL BIOCHEM, V277, P167, DOI 10.1006/abio.1999.4320; SCHNEIDER HC, 1994, NATURE, V371, P768, DOI 10.1038/371768a0; SCHNELL DJ, 1993, J CELL BIOL, V120, P103, DOI 10.1083/jcb.120.1.103; SCHNELL DJ, 1994, SCIENCE, V266, P1007, DOI 10.1126/science.7973649; Smith MD, 2002, J CELL BIOL, V159, P833, DOI 10.1083/jcb.200208017; SMITH MD, 2002, CURRENT PROTOCOLS CE; Stahl T, 1999, J BIOL CHEM, V274, P37467, DOI 10.1074/jbc.274.52.37467; van den Wijngaard PWJ, 2000, EUR J BIOCHEM, V267, P3812, DOI 10.1046/j.1432-1327.2000.01419.x; van den Wijngaard PWJ, 1999, J BIOL CHEM, V274, P25201, DOI 10.1074/jbc.274.36.25201; vandenWijngaard PWJ, 1997, J BIOL CHEM, V272, P29430, DOI 10.1074/jbc.272.47.29430	35	97	103	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38617	38627		10.1074/jbc.M306367200	http://dx.doi.org/10.1074/jbc.M306367200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874276	hybrid, Green Submitted			2022-12-27	WOS:000185575100066
J	Olteanu, H; Banerjee, R				Olteanu, H; Banerjee, R			Redundancy in the pathway for redox regulation of mammalian methionine synthase - Reductive activation by the dual flavoprotein, novel reductase 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLEMENTATION GROUP; CLONING; BINDING; POTENTIALS; MUTATIONS; MECHANISM; CDNA	Methionine synthase is an essential cobalamin-dependent enzyme in mammals that catalyzes the transfer of a methyl group from methyltetrahydrofolate to homocysteine to give tetrahydrofolate and methionine. It is oxidatively labile and requires for its sustained activity an auxiliary repair system that catalyzes a reductive methylation reaction. Genetic and biochemical studies have demonstrated that the soluble dual flavoprotein oxidoreductase, methionine synthase reductase, serves as a redox partner for methionine synthase in an NADPH-dependent reaction. However, three reports suggest the possibility of redundancy in this redox pathway. First, a hyperhomocysteinemic patient has been reported who has an isolated functional deficiency of methionine synthase but appears to be distinct from the cblE and cblG classes of patients with defects in methionine synthase reductase and methionine synthase, respectively. Second, another dual flavoprotein oxidoreductase with significant homology to methionine synthase reductase, NR1, has been described recently, but its function is unknown. Third, methionine synthase can be activated in vitro by a two-component redox system comprised of soluble cytochrome b(5) and P450 reductase. In this study, we demonstrate a function for human NR1 in vitro. It is able to fully activate methionine synthase in the presence of soluble cytochrome b(5) with a V-max of 2.8 +/- 0.1 mumol min(-1) mg(-1) protein, which is comparable with that seen with methionine synthase reductase. The K-actNR1 is 1.27 +/- 0.16 muM, and a 20-fold higher stoichiometry of reductase to methionine synthase is required for NR1 versus methionine synthase reductase, suggesting that it may represent a minor pathway in the cell, assuming that the two proteins are present at similar levels.	Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA	University of Nebraska System; University of Nebraska Lincoln	Banerjee, R (corresponding author), Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA.	rbanerjee1@unl.edu	Olteanu, Horatiu/AAH-1051-2021	Olteanu, Horatiu/0000-0001-5783-4485	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK064959, R01DK045776, R29DK045776] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK45776, DK64959] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Banerjee R, 1997, METHOD ENZYMOL, V281, P189; BANERJEE RV, 1990, BIOCHEMISTRY-US, V29, P1129, DOI 10.1021/bi00457a005; CHEN ZQ, 1995, J BIOL CHEM, V270, P19246, DOI 10.1074/jbc.270.33.19246; Chen ZQ, 1998, J BIOL CHEM, V273, P26248, DOI 10.1074/jbc.273.40.26248; CHEN ZQ, 1994, J BIOL CHEM, V269, P27193; Finn RD, 2003, EUR J BIOCHEM, V270, P1164, DOI 10.1046/j.1432-1033.2003.03474.x; Fowler B, 1997, J INHERIT METAB DIS, V20, P270, DOI 10.1023/A:1005369109055; FUJII K, 1977, ARCH BIOCHEM BIOPHYS, V178, P662, DOI 10.1016/0003-9861(77)90238-7; FUJII K, 1974, J BIOL CHEM, V249, P6745; Gulati S, 1996, HUM MOL GENET, V5, P1859, DOI 10.1093/hmg/5.12.1859; Leclerc D, 1998, P NATL ACAD SCI USA, V95, P3059, DOI 10.1073/pnas.95.6.3059; Leclerc D, 1996, HUM MOL GENET, V5, P1867, DOI 10.1093/hmg/5.12.1867; LEXA D, 1983, ACCOUNTS CHEM RES, V16, P235, DOI 10.1021/ar00091a001; Li YN, 1996, HUM MOL GENET, V5, P1851, DOI 10.1093/hmg/5.12.1851; Matthews RG, 2001, ACCOUNTS CHEM RES, V34, P681, DOI 10.1021/ar0000051; Olteanu H, 2001, J BIOL CHEM, V276, P35558, DOI 10.1074/jbc.M103707200; Paine MJI, 2000, J BIOL CHEM, V275, P1471, DOI 10.1074/jbc.275.2.1471; Perrin D. D., 2012, BUFFERS PH METAL ION; Refsum H, 1998, ANNU REV MED, V49, P31, DOI 10.1146/annurev.med.49.1.31; ROSENBLATT DS, 1995, INHERITED DISORDERS; Swanson DA, 2001, MOL CELL BIOL, V21, P1058, DOI 10.1128/MCB.21.4.1058-1065.2001; WILLARD HF, 1978, AM J HUM GENET, V30, P1; Wilson A, 1999, HUM MOL GENET, V8, P2009, DOI 10.1093/hmg/8.11.2009; Wilson A, 1998, AM J HUM GENET, V63, P409, DOI 10.1086/301976; Wolthers KR, 2003, BIOCHEMISTRY-US, V42, P3911, DOI 10.1021/bi027290b	26	29	30	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38310	38314		10.1074/jbc.M306282200	http://dx.doi.org/10.1074/jbc.M306282200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871938	hybrid			2022-12-27	WOS:000185575100029
J	Yang, HS; Zhou, JH; Ochs, RL; Henning, D; Jin, RY; Valdez, BC				Yang, HS; Zhou, JH; Ochs, RL; Henning, D; Jin, RY; Valdez, BC			Down-regulation of RNA helicase II/Gu results in the depletion of 18 and 28 S rRNAs in Xenopus oocyte	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSE FIBRILLAR COMPONENTS; RIBOSOMAL-RNA; PROTEOMIC CHARACTERIZATION; PRERIBOSOMAL RNA; NUCLEOLAR RNA; U3 SNRNA; PROTEIN; DOMAIN; DISRUPTION; BINDING	Genetic manipulations have revealed the functions of RNA helicases in ribosomal RNA (rRNA) biogenesis in yeast. However, no report shows the role of an RNA helicase in rRNA formation in higher eukaryotes. This study reports the functional characterization of the frog homologue of nucleolar RNA helicase II/Gu (xGu or DDX21). Down-regulation of xGu in Xenopus laevis oocyte using an antisense oligodeoxynucleotide results in the depletion of 18 and 28 S rRNAs. The disappearance of 18 S rRNA is accompanied by an accumulation of 20 S, indicating that xGu is critical in the processing of 20 to 18 S rRNA. The degradation of 28 S rRNA into fragments smaller than 18 S is also associated with a specific decrease in the level of xGu protein. These effects are reversed in the presence of in vitro synthesized wild type xGu mRNA but not its helicase-deficient mutant form. Similar aberrant rRNA processing is observed when antibody against xGu is microinjected. The involvement of xGu in processing of rRNA is consistent with the localization of Gu protein to the granular and dense fibrillar components of PtK2 cell nucleoli by immunoelectron microscopy. Our results show that xGu is involved in the processing of 20 to 18 S rRNA and contributes to the stability of 28 S rRNA in Xenopus oocytes.	Baylor Coll Med, Dept Pharmacol, Houston, TX 77030 USA; Precis Therapeut Inc, Pittsburgh, PA 15203 USA	Baylor College of Medicine	Valdez, BC (corresponding author), Baylor Coll Med, Dept Pharmacol, 1 Baylor Plaza, Houston, TX 77030 USA.	bvaldez@bcm.tmc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052341] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK52341] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Allmang C, 2000, NUCLEIC ACIDS RES, V28, P1684, DOI 10.1093/nar/28.8.1684; AMALDI F, 1989, TRENDS BIOCHEM SCI, V14, P175, DOI 10.1016/0968-0004(89)90269-7; Andersen JS, 2002, CURR BIOL, V12, P1, DOI 10.1016/S0960-9822(01)00650-9; Busch H, 1970, NUCLEOLUS, P1; CAIRNS C, 1995, J CELL SCI, V108, P3339; CAIZERGUESFERRER M, 1991, DEVELOPMENT, V112, P317; CHANG JH, 1990, J BIOL CHEM, V265, P18227; Dunbar DA, 1998, RNA, V4, P195; EVANS JP, 1991, METHOD CELL BIOL, V36, P133; FLORESROZAS H, 1993, J BIOL CHEM, V268, P21372; Fujiyama S, 2002, J BIOL CHEM, V277, P23773, DOI 10.1074/jbc.M201181200; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; GARD DL, 1990, J CELL BIOL, V110, P2033, DOI 10.1083/jcb.110.6.2033; Gerbi SA, 1997, CHROMOSOMA, V105, P401, DOI 10.1007/BF02510476; Giles RV, 2000, METH MOL B, V160, P157; Ginisty H, 1998, EMBO J, V17, P1476, DOI 10.1093/emboj/17.5.1476; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GRAF JD, 1991, METHOD CELL BIOL, V36, P19; Gustafson WC, 1998, BIOCHEM J, V331, P387, DOI 10.1042/bj3310387; HADJIOLOV A., 1985, NUCL RIBOSOME BIOGEN; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; Hong B, 1997, MOL CELL BIOL, V17, P378, DOI 10.1128/MCB.17.1.378; HOZAK P, 1994, J CELL SCI, V107, P639; Huang S, 2002, J CELL BIOL, V157, P739, DOI 10.1083/jcb.200204159; Jankowsky E, 2001, SCIENCE, V291, P121, DOI 10.1126/science.291.5501.121; KissLaszlo Z, 1996, CELL, V85, P1077, DOI 10.1016/S0092-8674(00)81308-2; Koberna K, 2002, J CELL BIOL, V157, P743, DOI 10.1083/jcb.200202007; KONDO K, 1992, J BIOL CHEM, V267, P16252; Leary DJ, 2001, FEBS LETT, V509, P145, DOI 10.1016/S0014-5793(01)03143-X; LEE WC, 1992, MOL CELL BIOL, V12, P3865, DOI 10.1128/MCB.12.9.3865; Li JW, 2000, MOL CELL BIOL, V20, P2031, DOI 10.1128/MCB.20.6.2031-2042.2000; Luking A, 1998, CRIT REV BIOCHEM MOL, V33, P259, DOI 10.1080/10409239891204233; MALLER JL, 1989, J CELL SCI, P53; May A, 1997, J AM SOC NEPHROL, V8, P1813; OCHS RL, 1994, J CELL SCI, V107, P385; OCHS RL, 1985, CHROMOSOMA, V92, P330, DOI 10.1007/BF00327463; ODay CL, 1996, NUCLEIC ACIDS RES, V24, P3201, DOI 10.1093/nar/24.16.3201; Olson MOJ, 2000, TRENDS CELL BIOL, V10, P189, DOI 10.1016/S0962-8924(00)01738-4; PECULIS BA, 1993, CELL, V73, P1233, DOI 10.1016/0092-8674(93)90651-6; Peculis BA, 1997, MOL CELL BIOL, V17, P3702, DOI 10.1128/MCB.17.7.3702; Pederson T, 1998, NUCLEIC ACIDS RES, V26, P3871, DOI 10.1093/nar/26.17.3871; PERLAKY L, 1992, CANCER RES, V52, P428; RASKA I, 1995, J STRUCT BIOL, V114, P1, DOI 10.1006/jsbi.1995.1001; REDDY R, 1981, J BIOL CHEM, V256, P8452; Roger B, 2002, J BIOL CHEM, V277, P10209, DOI 10.1074/jbc.M106412200; SAMAHA RR, 1994, P NATL ACAD SCI USA, V91, P7884, DOI 10.1073/pnas.91.17.7884; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAVINO R, 1990, EMBO J, V9, P2299, DOI 10.1002/j.1460-2075.1990.tb07401.x; Scherl A, 2002, MOL BIOL CELL, V13, P4100, DOI 10.1091/mbc.E02-05-0271; SOLLNERWEBB B, 1996, RIBOSOMAL RNA STRUCT, P460; Stelzl U, 2000, P NATL ACAD SCI USA, V97, P4597, DOI 10.1073/pnas.090009297; STEVENS A, 1991, J BACTERIOL, V173, P7024, DOI 10.1128/jb.173.21.7024-7028.1991; Strezoska Z, 2002, J BIOL CHEM, V277, P29617, DOI 10.1074/jbc.M204381200; Strezoska Z, 2000, MOL CELL BIOL, V20, P5516, DOI 10.1128/MCB.20.15.5516-5528.2000; Tanner NK, 2001, MOL CELL, V8, P251, DOI 10.1016/S1097-2765(01)00329-X; Tsai RYL, 2002, GENE DEV, V16, P2991, DOI 10.1101/gad.55671; Tuteja R, 1998, CRIT REV BIOCHEM MOL, V33, P407, DOI 10.1080/10409239891204260; UDEM SA, 1973, J BIOL CHEM, V248, P1412; Valdez BC, 2000, EUR J BIOCHEM, V267, P6395, DOI 10.1046/j.1432-1327.2000.01727.x; Valdez BC, 1998, BIOTECHNIQUES, V24, P1032, DOI 10.2144/98246cr03; Valdez BC, 2000, GENOMICS, V66, P184, DOI 10.1006/geno.2000.6209; Valdez BC, 2002, GENE, V284, P53, DOI 10.1016/S0378-1119(01)00888-5; Valdez BC, 1996, NUCLEIC ACIDS RES, V24, P1220, DOI 10.1093/nar/24.7.1220; Valdez BC, 1997, EUR J BIOCHEM, V250, P800, DOI 10.1111/j.1432-1033.1997.00800.x; Valentijn JA, 1998, J BIOL CHEM, V273, P30344, DOI 10.1074/jbc.273.46.30344; Venema J, 1999, ANNU REV GENET, V33, P261, DOI 10.1146/annurev.genet.33.1.261; Visintin R, 2000, CURR OPIN CELL BIOL, V12, P372, DOI 10.1016/S0955-0674(00)00102-2; Warner JR, 2001, CELL, V107, P133, DOI 10.1016/S0092-8674(01)00531-1; Westermarck J, 2002, EMBO J, V21, P451, DOI 10.1093/emboj/21.3.451; Yanagida M, 2001, PROTEOMICS, V1, P1390, DOI 10.1002/1615-9861(200111)1:11<1390::AID-PROT1390>3.0.CO;2-Z; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	71	30	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38847	38859		10.1074/jbc.M302258200	http://dx.doi.org/10.1074/jbc.M302258200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851405	hybrid			2022-12-27	WOS:000185575100093
J	Scheper, W; Thaminy, S; Kais, S; Stagljar, I; Romisch, K				Scheper, W; Thaminy, S; Kais, S; Stagljar, I; Romisch, K			Coordination of N-glycosylation and protein translocation across the endoplasmic reticulum membrane by Sss1 protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-FACTOR PRECURSOR; SECRETORY PROTEIN; OLIGOSACCHARYLTRANSFERASE COMPLEX; ER MEMBRANE; YEAST; TRANSPORT; DEGRADATION; BINDING; SEC61P; ATP	Secretory proteins are translocated across the endoplasmic reticulum ( ER) membrane through a channel formed by three proteins, namely Sec61p, Sbh1p, and Sss1p ( Johnson, A. E., and van Waes, M. A. ( 1999) Annu. Rev. Cell Dev. Biol. 15, 799 - 842). Sec61p and Sss1p are essential for translocation ( Esnault, Y., Blondel, M. O., Deshaies, R. J., Schekman, R., and Kepes, F. ( 1993) EMBO J. 12, 4083 - 4093). Sec61p is a polytopic membrane protein that lines the protein translocation channel. The role of Sss1p is unknown. During import into the ER through the Sec61p channel, many proteins are N-glycosylated before translocation is completed. In addition, both the Sec61 channel and oligosaccharyl transferase (OST) copurify with ribosomes from rough ER, suggesting that OST is located in close proximity to the Sec61 channel (Gorlich, D., Prehn, S., Hartmann, E., Kalies, K.- U., and Rapoport, T. A. ( 1992) Cell 71, 489 - 503 and Wang, L., and Dobberstein, B. ( 1999) FEBS Lett. 457, 316 322). Here, we demonstrate a direct interaction between Sss1p and a subunit of OST, Wbp1p, using the splitubiquitin system and co-immunoprecipitation. We generated mutants in the cytoplasmic domain of Sss1p that disturb the interaction with OST and are viable but display a translocation defect specific for proteins with glycosylation acceptor sites. Our data suggest that Sss1p coordinates translocation across the ER membrane and N-linked glycosylation of secretory proteins.	Univ Cambridge, Cambridge Inst Med Res, Cambridge CB2 2XY, England; Univ Cambridge, Dept Clin Biochem, Cambridge CB2 2XY, England; Univ Zurich, Inst Vet Biochem & Mol Biol, CH-8057 Zurich, Switzerland	University of Cambridge; University of Cambridge; University of Zurich	Romisch, K (corresponding author), Univ Cambridge, Cambridge Inst Med Res, Hills Rd, Cambridge CB2 2XY, England.		Römisch, Karin/AAO-1210-2021; Scheper, Wiep/AAI-7323-2020	Römisch, Karin/0000-0003-0415-6558; Scheper, Wiep/0000-0002-1431-4559				Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; CAPLAN S, 1991, J BACTERIOL, V173, P627, DOI 10.1128/jb.173.2.627-635.1991; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; ESNAULT Y, 1994, J BIOL CHEM, V269, P27478; Fu J, 1997, J BIOL CHEM, V272, P29687, DOI 10.1074/jbc.272.47.29687; GORLICH D, 1992, CELL, V71, P489, DOI 10.1016/0092-8674(92)90517-G; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; HANSEN W, 1986, CELL, V45, P397, DOI 10.1016/0092-8674(86)90325-9; Harty C, 2001, MOL BIOL CELL, V12, P1093, DOI 10.1091/mbc.12.4.1093; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Johnson AE, 1999, ANNU REV CELL DEV BI, V15, P799, DOI 10.1146/annurev.cellbio.15.1.799; JUNGNICKEL B, 1995, CELL, V82, P261, DOI 10.1016/0092-8674(95)90313-5; KALIES KU, 1994, J CELL BIOL, V126, P925, DOI 10.1083/jcb.126.4.925; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Knauer R, 1999, BBA-GEN SUBJECTS, V1426, P259, DOI 10.1016/S0304-4165(98)00128-7; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; KURJAN J, 1982, CELL, V30, P933, DOI 10.1016/0092-8674(82)90298-7; LAMANTIA M, 1991, P NATL ACAD SCI USA, V88, P4453, DOI 10.1073/pnas.88.10.4453; LYMAN SK, 1995, J CELL BIOL, V131, P1163, DOI 10.1083/jcb.131.5.1163; Matlack KES, 1999, CELL, V97, P553, DOI 10.1016/S0092-8674(00)80767-9; MAYINGER P, 1993, EMBO J, V12, P659, DOI 10.1002/j.1460-2075.1993.tb05699.x; McCracken AA, 1996, J CELL BIOL, V132, P291, DOI 10.1083/jcb.132.3.291; Ng DTW, 1996, J CELL BIOL, V134, P269, DOI 10.1083/jcb.134.2.269; Nikonov AV, 2002, J CELL BIOL, V158, P497, DOI 10.1083/jcb.200201116; OOI CE, 1992, CELL, V71, P87, DOI 10.1016/0092-8674(92)90268-H; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Popov M, 1997, J BIOL CHEM, V272, P18325, DOI 10.1074/jbc.272.29.18325; ROTHBLATT JA, 1986, CELL, V44, P619, DOI 10.1016/0092-8674(86)90271-0; Stagljar I, 1998, P NATL ACAD SCI USA, V95, P5187, DOI 10.1073/pnas.95.9.5187; STEVENS T, 1982, CELL, V30, P439, DOI 10.1016/0092-8674(82)90241-0; THAMINY S, 2002, PROTEIN PROTEIN INTE, P395; Wang L, 1999, FEBS LETT, V457, P316, DOI 10.1016/S0014-5793(99)01075-3; Whitley P, 1996, J BIOL CHEM, V271, P6241, DOI 10.1074/jbc.271.11.6241; Wilkinson BM, 1997, EMBO J, V16, P4549, DOI 10.1093/emboj/16.15.4549	34	25	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37998	38003		10.1074/jbc.M300176200	http://dx.doi.org/10.1074/jbc.M300176200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860997	hybrid			2022-12-27	WOS:000185437200121
J	Tomasini, R; Samir, AA; Carrier, A; Isnardon, D; Cecchinelli, B; Soddu, S; Malissen, B; Dagorn, JC; Iovanna, JL; Dusetti, NJ				Tomasini, R; Samir, AA; Carrier, A; Isnardon, D; Cecchinelli, B; Soddu, S; Malissen, B; Dagorn, JC; Iovanna, JL; Dusetti, NJ			TP53INP1s and homeodomain-interacting protein kinase-2 (HIPK2) are partners in regulating p53 activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53-DEPENDENT APOPTOSIS; POTENTIAL MEDIATOR; TUMOR SUPPRESSION; GENE-EXPRESSION; NUCLEAR-BODIES; PML; PATTERNS; GROWTH; STRESS; SIP	The TP53INP1 gene encodes two protein isoforms, TP53INP1alpha and TP53INP1beta, located into the nucleus. Their synthesis is increased during cellular stress by p53-mediated activation of transcription. Overexpression of these isoforms induces apoptosis, suggesting an involvement of TP53INP1s in p53-mediated cell death. It was recently shown that p53-dependent apoptosis is promoted by homeodomain-interacting protein kinase-2 (HIPK2), which is known to bind p53 and induce its phosphorylation in promyelocytic leukemia protein nuclear bodies (PML-NBs). In this work we show that TP53INP1s localize with p53, PML-IV, and HIPK2 into the PML-NBs. In addition, we show that TP53INP1s interact physically with HIPK2 and p53. In agreement with these results we demonstrate that TP53INP1s, in association with HIPK2, regulate p53 transcriptional activity on p21, mdm2, pig3, and bax promoters. Furthermore, TP53INP1s overexpression induces G(1) arrest and increases p53-mediated apoptosis. Although a TP53INP1s and HIPK2 additive effect was observed on apoptosis, G(1) arrest was weaker when HIPK2 was transfected together with TP53INP1. These results indicate that TP53INP1s and HIPK2 could be partners in regulating p53 activity.	INSERM, EMI 0116, Ctr Rech, F-13009 Marseille, France; CNRS Marseille Luminy, INSERM, Ctr Immunol, F-13288 Marseille 9, France; Inst J Paoli I Calmettes, F-13009 Marseille, France; Regina Elena Inst Canc Res, Mol Oncogenesis Lab, I-00158 Rome, Italy	Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena	Dusetti, NJ (corresponding author), INSERM, EMI 0116, Ctr Rech, 163 Ave Luminy,BP172,Parc Sci & Technol Luminy, F-13009 Marseille, France.	dusetti@inserm-nacre.inserm-adr2.univ-mrs.fr	tomasini, richard/F-1130-2017; Soddu, Silvia/ABH-6774-2020; Dusetti, Nelson/O-7919-2017; Soddu, Silvia/K-2467-2018; Iovanna, Juan/M-9805-2017; Malissen, Bernard/AAK-4659-2020	tomasini, richard/0000-0003-0869-0811; Soddu, Silvia/0000-0001-8526-0044; Dusetti, Nelson/0000-0002-6161-8483; Soddu, Silvia/0000-0001-8526-0044; Iovanna, Juan/0000-0003-1822-2237; Malissen, Bernard/0000-0003-1340-9342				BARAK Y, 1993, EMBO J, V12, P461, DOI 10.1002/j.1460-2075.1993.tb05678.x; Bulavin DV, 1999, EMBO J, V18, P6845, DOI 10.1093/emboj/18.23.6845; Carrier A, 1999, IMMUNOGENETICS, V50, P255, DOI 10.1007/s002510050601; D'Orazi G, 2002, NAT CELL BIOL, V4, P11, DOI 10.1038/ncb714; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fogal V, 2000, EMBO J, V19, P6185, DOI 10.1093/emboj/19.22.6185; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gottlieb TM, 1996, BBA-REV CANCER, V1287, P77, DOI 10.1016/0304-419X(95)00019-C; Hofmann TG, 2002, NAT CELL BIOL, V4, P1, DOI 10.1038/ncb715; Kim EJ, 2002, J BIOL CHEM, V277, P32020, DOI 10.1074/jbc.M200153200; Ko LJ, 1996, GENE DEV, V10, P1054, DOI 10.1101/gad.10.9.1054; Le XF, 1998, ONCOGENE, V16, P1839, DOI 10.1038/sj.onc.1201705; MIYASHITA T, 1995, CELL, V80, P293; Oda K, 2000, CELL, V102, P849, DOI 10.1016/S0092-8674(00)00073-8; Okamura S, 2001, MOL CELL, V8, P85, DOI 10.1016/S1097-2765(01)00284-2; Pierantoni GM, 2001, ONCOGENE, V20, P6132, DOI 10.1038/sj.onc.1204635; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Quignon F, 1998, NAT GENET, V20, P259, DOI 10.1038/3068; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Seeler JS, 1999, CURR OPIN GENET DEV, V9, P362, DOI 10.1016/S0959-437X(99)80054-9; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2002, EUR J CELL BIOL, V81, P294, DOI 10.1078/0171-9335-00248; Vasseur S, 2002, EMBO REP, V3, P165, DOI 10.1093/embo-reports/kvf023; Vousden KH, 2000, CELL, V103, P691, DOI 10.1016/S0092-8674(00)00171-9; Vousden KH, 2002, BBA-REV CANCER, V1602, P47, DOI 10.1016/S0304-419X(02)00035-5; Wang ZG, 1998, NAT GENET, V20, P266, DOI 10.1038/3073; Wiederschain D, 2001, J BIOL CHEM, V276, P27999, DOI 10.1074/jbc.M102400200; Zhao RB, 2000, GENE DEV, V14, P981; Zhong S, 2000, NAT CELL BIOL, V2, pE85, DOI 10.1038/35010583; Zhong S, 2000, BLOOD, V95, P2748, DOI 10.1182/blood.V95.9.2748.009k31a_2748_2752	30	120	137	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37722	37729		10.1074/jbc.M301979200	http://dx.doi.org/10.1074/jbc.M301979200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12851404	hybrid			2022-12-27	WOS:000185437200089
J	Dillon, TJ; Karpitski, V; Wetzel, SA; Parker, DC; Shaw, AS; Stork, PJS				Dillon, TJ; Karpitski, V; Wetzel, SA; Parker, DC; Shaw, AS; Stork, PJS			Ectopic B-Raf expression enhances extracellular signal-regulated kinase (ERK) signaling in T cells and prevents antigen-presenting cell-induced anergy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; IL-2 GENE-TRANSCRIPTION; SMALL GTPASE RAP1; DEPENDENT ACTIVATION; CLONAL ANERGY; MAP KINASE; RECEPTOR; COSTIMULATION; CD28; PROLIFERATION	T cells that receive stimulation through the T cell receptor (TCR) in the absence of costimulation become anergic and are refractory to subsequent costimulation. This unresponsiveness is associated with the constitutive activation of the small G protein, Rap1, and the lack of Ras-dependent activation of ERK. Recent studies suggest that Rap1 can activate the MAP kinase kinase kinase B-Raf that is either endogenously or ectopically expressed. Peripheral T cells generally do not express B-Raf; therefore, to test the hypothesis that ectopic expression of B-Raf could permit Rap1 to activate ERK signaling, we generated transgenic mice expressing B-Raf within peripheral T cells. This converted Rap1 into an activator of ERK, to enhance ERK activation and proliferation following TCR engagement in the absence of costimulation. When T cells were incubated with engineered APCs presenting antigen on I-E-k and expressing low levels of B7, they became anergic, displayed constitutive activation of Rap1, and were deficient in Ras and ERK activation. However, when incubated with the same APCs, T cells expressing the B-Raf transgene proliferated upon restimulation and displayed elevated ERK activation. Thus B-Raf expression and enhanced ERK activation is sufficient to prevent anergy in a model of APC-induced T cell anergy. However, studies using anti-TCR antibody-induced anergy showed that the ability of ERKs to reverse T cell anergy is dependent on the anergic model utilized.	Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA	Oregon Health & Science University; Oregon Health & Science University; Washington University (WUSTL); Washington University (WUSTL)	Stork, PJS (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, L-474,3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.	stork@ohsu.edu	Parker, David C/A-5428-2008	Wetzel, Scott/0000-0001-6843-4583; Parker, David/0000-0003-4456-2788	NIAID NIH HHS [R01 AI47337] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047337] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Amsen D, 2000, EUR J IMMUNOL, V30, P2832, DOI 10.1002/1521-4141(200010)30:10<2832::AID-IMMU2832>3.0.CO;2-D; Barberis L, 2000, J BIOL CHEM, V275, P36532, DOI 10.1074/jbc.M002487200; BECKER JC, 1995, P NATL ACAD SCI USA, V92, P2375, DOI 10.1073/pnas.92.6.2375; Boussiotis VA, 1997, SCIENCE, V278, P124, DOI 10.1126/science.278.5335.124; Carey KD, 2000, MOL CELL BIOL, V20, P8409, DOI 10.1128/MCB.20.22.8409-8419.2000; Carey KD, 2003, J BIOL CHEM, V278, P3185, DOI 10.1074/jbc.M207014200; CHEN CY, 1994, J IMMUNOL, V152, P2105; Chen TS, 1999, CANCER RES, V59, P213; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; Crespi D, 2002, EUR J IMMUNOL, V32, P2500, DOI 10.1002/1521-4141(200209)32:9<2500::AID-IMMU2500>3.0.CO;2-S; Czyzyk J, 2000, MOL CELL BIOL, V20, P8740, DOI 10.1128/MCB.20.23.8740-8747.2000; DAMBROSIO D, 1994, EUR J IMMUNOL, V24, P616, DOI 10.1002/eji.1830240319; de Bruyn KMT, 2002, J BIOL CHEM, V277, P29468, DOI 10.1074/jbc.M204990200; DeSilva DR, 1996, J EXP MED, V183, P2017, DOI 10.1084/jem.183.5.2017; DESILVA DR, 1991, J IMMUNOL, V147, P3261; DeSilva DR, 1998, J IMMUNOL, V160, P4175; Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842; Enserink JM, 2002, NAT CELL BIOL, V4, P901, DOI 10.1038/ncb874; Faris M, 1996, J BIOL CHEM, V271, P27366, DOI 10.1074/jbc.271.44.27366; Fields P, 1996, J MOL MED-JMM, V74, P673, DOI 10.1007/s001090050071; GIMMI CD, 1993, P NATL ACAD SCI USA, V90, P6586, DOI 10.1073/pnas.90.14.6586; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; IZQUIERDO M, 1994, J EXP MED, V180, P401, DOI 10.1084/jem.180.1.401; JENKINS MK, 1990, J IMMUNOL, V144, P16; JENKINS MK, 1990, J IMMUNOL, V144, P1585; KANG SM, 1992, SCIENCE, V257, P1134, DOI 10.1126/science.257.5073.1134; Katagiri K, 2002, MOL CELL BIOL, V22, P1001, DOI 10.1128/MCB.22.4.1001-1015.2002; KAYE J, 1992, J IMMUNOL, V148, P3342; KitagawaSakakida S, 1996, J IMMUNOL, V157, P2328; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Li W, 1996, SCIENCE, V271, P1272, DOI 10.1126/science.271.5253.1272; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; Mondino A, 1996, J IMMUNOL, V157, P2048; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; Okada S, 1998, EMBO J, V17, P2554, DOI 10.1093/emboj/17.9.2554; Ragazzo JL, 2001, P NATL ACAD SCI USA, V98, P241, DOI 10.1073/pnas.011397798; RAYTER SI, 1992, EMBO J, V11, P4549, DOI 10.1002/j.1460-2075.1992.tb05556.x; Reay PA, 2000, J IMMUNOL, V164, P5626, DOI 10.4049/jimmunol.164.11.5626; Reedquist KA, 1998, J BIOL CHEM, V273, P4944, DOI 10.1074/jbc.273.9.4944; SAWADA S, 1991, MOL CELL BIOL, V11, P5506, DOI 10.1128/MCB.11.11.5506; SAWADA S, 1994, CELL, V77, P917, DOI 10.1016/0092-8674(94)90140-6; Schmidt M, 2000, J BIOL CHEM, V275, P41011, DOI 10.1074/jbc.M003716200; Sebzda E, 2002, NAT IMMUNOL, V3, P251, DOI 10.1038/ni765; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; Stork PJS, 2003, TRENDS BIOCHEM SCI, V28, P267, DOI 10.1016/S0968-0004(03)00087-2; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; Telander DG, 1999, J IMMUNOL, V162, P1460; van den Brink MRM, 1999, J BIOL CHEM, V274, P11178, DOI 10.1074/jbc.274.16.11178; Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1; Wells AD, 2001, J CLIN INVEST, V108, P895, DOI 10.1172/JCI200113220; Werlen G, 1998, EMBO J, V17, P3101, DOI 10.1093/emboj/17.11.3101; Wetzel SA, 2002, J IMMUNOL, V169, P6092, DOI 10.4049/jimmunol.169.11.6092; Whitehurst CE, 1996, J IMMUNOL, V156, P1020; York RD, 1998, NATURE, V392, P622, DOI 10.1038/33451	55	25	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35940	35949		10.1074/jbc.M301506200	http://dx.doi.org/10.1074/jbc.M301506200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855697	hybrid			2022-12-27	WOS:000185318300011
J	Mandal, AK; Samaddar, S; Banerjee, R; Lahiri, S; Bhattacharyya, A; Roy, S				Mandal, AK; Samaddar, S; Banerjee, R; Lahiri, S; Bhattacharyya, A; Roy, S			Glutamate counteracts the denaturing effect of urea through its effect on the denatured state	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; TRIMETHYLAMINE N-OXIDE; MOLTEN-GLOBULE STATE; PROTEIN; OSMOLYTE; POTASSIUM; STABILITY; MECHANISM; INSIGHTS; SYSTEM	The urea induced equilibrium denaturation behavior of glutaminyl-tRNA synthetase from Escherichia coli (GlnRS) in 0.25 M potassium L-glutamate, a naturally occurring osmolyte in E. coli, has been studied. Both the native to molten globule and molten globule to unfolded state transitions are shifted significantly toward higher urea concentrations in the presence of L-glutamate, suggesting that L-glutamate has the ability to counteract the denaturing effect of urea. D-Glutamate has a similar effect on the equilibrium denaturation of glutaminyl-tRNA synthetase, indicating that the effect of L-glutamate may not be due to substrate-like binding to the native state. The activation energy of unfolding is not significantly affected in the presence of 0.25 M potassium L-glutamate, indicating that the native state is not preferentially stabilized by the osmolyte. Dramatic increase of coefficient of urea concentration dependence ( m) values of both the transitions in the presence of glutamate suggests destabilization and increased solvent exposure of the denatured states. Four other osmolytes, sorbitol, trimethylamine oxide, inositol, and triethylene glycol, show either a modest effect or no effect on native to molten globule transition of glutaminyl-tRNA synthetase. However, glycine betaine significantly shifts the transition to higher urea concentrations. The effect of these osmolytes on other proteins is mixed. For example, glycine betaine counteracts urea denaturation of tubulin but promotes denaturation of S228N lambda-repressor and carbonic anhydrase. Osmolyte counteraction of urea denaturation depends on osmolyte-protein pair.	Bose Inst, Dept Biophys, Kolkata 700054, W Bengal, India	Department of Science & Technology (India); Bose Institute	Roy, S (corresponding author), Bose Inst, Dept Biophys, P-1-12 CIT Scheme VII M, Kolkata 700054, W Bengal, India.	sidroy@boseinst.ernet.in	Bhattacharyya, Arkka/AAS-9968-2020	Bhattacharyya, Arkka/0000-0002-7209-5681				Baldwin RL, 1999, TRENDS BIOCHEM SCI, V24, P77, DOI 10.1016/S0968-0004(98)01345-0; BANIK U, 1992, EUR J BIOCHEM, V206, P15, DOI 10.1111/j.1432-1033.1992.tb16896.x; BHATTACHARYA A, 1994, J BIOL CHEM, V269, P28655; BHATTACHARYYA T, 1991, EUR J BIOCHEM, V200, P739, DOI 10.1111/j.1432-1033.1991.tb16239.x; Bolen DW, 2001, J MOL BIOL, V310, P955, DOI 10.1006/jmbi.2001.4819; Booth DR, 1997, NATURE, V385, P787, DOI 10.1038/385787a0; Burg MB, 1999, P NATL ACAD SCI USA, V96, P6517, DOI 10.1073/pnas.96.11.6517; BYCHKOVA VE, 1995, FEBS LETT, V359, P6, DOI 10.1016/0014-5793(95)00004-S; Caplan AJ, 1999, TRENDS CELL BIOL, V9, P262, DOI 10.1016/S0962-8924(99)01580-9; Chatterjee S, 2002, PROTEINS, V49, P554, DOI 10.1002/prot.10236; CHIRIFE J, 1984, J APPL BACTERIOL, V56, P259, DOI 10.1111/j.1365-2672.1984.tb01346.x; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; DAS BK, 1995, BIOCHEMISTRY-US, V34, P5242, DOI 10.1021/bi00015a038; Dobson Christopher M., 1999, Current Opinion in Structural Biology, V9, P92, DOI 10.1016/S0959-440X(99)80012-8; FERRER M, 1995, NAT STRUCT BIOL, V2, P211, DOI 10.1038/nsb0395-211; Fink AL, 1999, PHYSIOL REV, V79, P425, DOI 10.1152/physrev.1999.79.2.425; Gazit E, 1999, J BIOL CHEM, V274, P16813, DOI 10.1074/jbc.274.24.16813; GULLANS SR, 1993, ANNU REV MED, V44, P289, DOI 10.1146/annurev.me.44.020193.001445; Jana NK, 2000, PROTEIN ENG, V13, P629, DOI 10.1093/protein/13.9.629; JENSEN WA, 1995, BIOCHEMISTRY-US, V34, P472, DOI 10.1021/bi00002a011; Kraegeloh A, 2002, EXTREMOPHILES, V6, P453, DOI 10.1007/s00792-002-0277-4; Kuwajima K, 1996, FASEB J, V10, P102, DOI 10.1096/fasebj.10.1.8566530; LAI MC, 1991, J BACTERIOL, V173, P5352, DOI 10.1128/jb.173.17.5352-5358.1991; LEIRMO S, 1987, BIOCHEMISTRY-US, V26, P2095, DOI 10.1021/bi00382a006; Lever M, 2001, BBA-GEN SUBJECTS, V1528, P135, DOI 10.1016/S0304-4165(01)00184-2; LIN TY, 1994, BIOCHEMISTRY-US, V33, P12695, DOI 10.1021/bi00208a021; MYERS JK, 1995, PROTEIN SCI, V4, P2138, DOI 10.1002/pro.5560041020; NAGELHUS EA, 1994, ADV EXP MED BIOL, V359, P325; OHGUSHI M, 1983, FEBS LETT, V164, P21, DOI 10.1016/0014-5793(83)80010-6; Poklar N, 1997, BIOCHEMISTRY-US, V36, P14345, DOI 10.1021/bi971719v; Roberts MF, 2000, FRONT BIOSCI-LANDMRK, V5, pD796, DOI 10.2741/roberts; Serpell LC, 1997, CELL MOL LIFE SCI, V53, P871, DOI 10.1007/s000180050107; Shi ZS, 2002, P NATL ACAD SCI USA, V99, P9190, DOI 10.1073/pnas.112193999; SHORTLE D, 1995, ADV PROTEIN CHEM, V46, P217, DOI 10.1016/S0065-3233(08)60336-8; Shortle D, 2001, SCIENCE, V293, P487, DOI 10.1126/science.1060438; Wang AJ, 1997, BIOCHEMISTRY-US, V36, P9101, DOI 10.1021/bi970247h; Wrabl J, 1999, NAT STRUCT BIOL, V6, P876; Yancey PH, 1999, J EXP BIOL, V202, P3597; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zhang J, 1998, BIOCHEMISTRY-US, V37, P14881, DOI 10.1021/bi9811157; Zou Q, 2002, J AM CHEM SOC, V124, P1192, DOI 10.1021/ja004206b	41	29	29	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36077	36084		10.1074/jbc.M211207200	http://dx.doi.org/10.1074/jbc.M211207200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844489	hybrid			2022-12-27	WOS:000185318300027
J	Molotkov, A; Duester, G				Molotkov, A; Duester, G			Genetic evidence that retinaldehyde dehydrogenase Raldh1 (Aldh1a1) functions downstream of alcohol dehydrogenase Adh1 in metabolism of retinol to retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OMEGA-HYDROXYFATTY ACIDS; VITAMIN-A TOXICITY; ALDEHYDE DEHYDROGENASE; TARGETED DISRUPTION; MOUSE; IDENTIFICATION; ENZYME; OXIDATION; TERATOGENICITY; 9-CIS	Vitamin A (retinol) is a nutrient that is essential for developmental regulation but toxic in large amounts. Previous genetic studies have revealed that alcohol dehydrogenase Adh1 is required for efficient clearance of excess retinol to prevent toxicity, thus demonstrating that the mechanism involves oxidation of excess retinol to retinoic acid (RA). Whereas Adh1 plays a dominant role in the first step of the clearance pathway (oxidation of retinol to retinaldehyde), it is unknown what controls the second step (oxidation of retinaldehyde to RA). We now present genetic evidence that aldehyde dehydrogenase Aldh1a1, also known as retinaldehyde dehydrogenase Raldh1, plays a dominant role in the second step of retinol clearance in adult mice. Serum RA levels following a 50 mg/kg dose of retinol were reduced 72% in Raldh1(-/-) mice and 82% in Adh1(-/-) mice. This represented reductions in RA synthesis of 77-78% for each mutant after corrections for altered RA degradation in each. After retinol dosing, serum retinaldehyde was increased 2.5-fold in Raldh1(-/-) mice (indicating defective retinaldehyde clearance) and decreased 3-fold in Adh1(-/-) mice (indicating defective retinaldehyde synthesis). Serum retinol clearance following retinol administration was decreased 7% in Raldh1(-/-) mice and 69% in Adh1(-/-) mice. LD50 studies indicated a small increase in retinol toxicity in Raldh1(-/-) mice and a large increase in Adh1(-/-) mice. These observations demonstrate that Raldh1 functions downstream of Adh1 in the oxidative metabolism of excess retinol and that toxicity correlates primarily with accumulating retinol rather than retinaldehyde.	Burnham Inst, OncoDev Biol Program, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Duester, G (corresponding author), Burnham Inst, OncoDev Biol Program, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	duester@burnham.org		Duester, Gregg/0000-0003-4335-3650	NEI NIH HHS [R01 EY013969-02, R01 EY013969, EY13969] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY013969] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Abu-Abed S, 2001, GENE DEV, V15, P226, DOI 10.1101/gad.855001; ALGAR EM, 1983, EUR J BIOCHEM, V137, P139, DOI 10.1111/j.1432-1033.1983.tb07807.x; Allali-Hassani A, 1998, FEBS LETT, V426, P362, DOI 10.1016/S0014-5793(98)00374-3; Ang HL, 1999, DEV DYNAM, V215, P264, DOI 10.1002/(SICI)1097-0177(199907)215:3<264::AID-AJA8>3.0.CO;2-I; Ang HL, 1999, EUR J BIOCHEM, V260, P227, DOI 10.1046/j.1432-1327.1999.00139.x; Armstrong Robert B., 1994, P545; Blaner William S., 1994, P229; BLISS AF, 1951, ARCH BIOCHEM BIOPHYS, V31, P197, DOI 10.1016/0003-9861(51)90206-8; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BOLEDA MD, 1993, ARCH BIOCHEM BIOPHYS, V307, P85, DOI 10.1006/abbi.1993.1564; Bray BJ, 2001, TOXICOL APPL PHARM, V173, P129, DOI 10.1006/taap.2001.9170; Chambon P, 1996, FASEB J, V10, P940, DOI 10.1096/fasebj.10.9.8801176; Chou CF, 2002, J BIOL CHEM, V277, P25209, DOI 10.1074/jbc.M201947200; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; COLLINS MD, 1992, ARCH TOXICOL, V66, P652, DOI 10.1007/BF01981505; Deltour L, 1999, J BIOL CHEM, V274, P16796, DOI 10.1074/jbc.274.24.16796; Driessen CAGG, 2000, MOL CELL BIOL, V20, P4275, DOI 10.1128/MCB.20.12.4275-4287.2000; Duester G, 2000, EUR J BIOCHEM, V267, P4315, DOI 10.1046/j.1432-1327.2000.01497.x; Fan XH, 2003, MOL CELL BIOL, V23, P4637, DOI 10.1128/MCB.23.13.4637-4648.2003; FROLIK CA, 1984, RETINOIDS, V2, P177; FUTTERMAN S, 1962, J BIOL CHEM, V237, P677; Gagnon I, 2002, BBA-PROTEIN STRUCT M, V1596, P156, DOI 10.1016/S0167-4838(02)00213-3; GODBOUT R, 1992, EXP EYE RES, V54, P297, DOI 10.1016/S0014-4835(05)80219-2; Godbout R, 2001, J BIOL CHEM, V276, P32896, DOI 10.1074/jbc.M104372200; Grun F, 2000, J BIOL CHEM, V275, P41210, DOI 10.1074/jbc.M007376200; Haselbeck RJ, 1997, ALCOHOL CLIN EXP RES, V21, P1484; Haselbeck RJ, 1999, DEV GENET, V25, P353, DOI 10.1002/(SICI)1520-6408(1999)25:4<353::AID-DVG9>3.0.CO;2-G; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; KAMM JJ, 1982, J AM ACAD DERMATOL, V6, P652, DOI 10.1016/S0190-9622(82)70054-4; KOCHHAR DM, 1967, ACTA PATHOL MIC SC, V70, P398; Kono H, 1999, AM J PHYSIOL-GASTR L, V277, pG1259, DOI 10.1152/ajpgi.1999.277.6.G1259; KURLANDSKY SB, 1995, J BIOL CHEM, V270, P17850, DOI 10.1074/jbc.270.30.17850; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; Lapshina EA, 2003, BIOCHEMISTRY-US, V42, P776, DOI 10.1021/bi026836r; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LIEBER CS, 1994, J TOXICOL-CLIN TOXIC, V32, P631, DOI 10.3109/15563659409017974; LINDAHL R, 1992, CRIT REV BIOCHEM MOL, V27, P283, DOI 10.3109/10409239209082565; LITCHFIELD JT, 1949, J PHARMACOL EXP THER, V96, P99; MCCAFFERY P, 1991, DEVELOPMENT, V112, P693; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; McSorley LC, 2000, BIOCHEM PHARMACOL, V60, P517, DOI 10.1016/S0006-2952(00)00356-7; Mertz JR, 1997, J BIOL CHEM, V272, P11744, DOI 10.1074/jbc.272.18.11744; Mic FA, 2002, DEVELOPMENT, V129, P2271; Mic FA, 2003, P NATL ACAD SCI USA, V100, P7135, DOI 10.1073/pnas.1231422100; Molotkov A, 2002, J BIOL CHEM, V277, P22553, DOI 10.1074/jbc.M201603200; Molotkov A, 2002, EUR J BIOCHEM, V269, P2607, DOI 10.1046/j.1432-1033.2002.02935.x; Molotkov A, 2002, J BIOL CHEM, V277, P13804, DOI 10.1074/jbc.M112039200; Molotkov A, 2002, P NATL ACAD SCI USA, V99, P5337, DOI 10.1073/pnas.082093299; Niederreither K, 2002, NAT GENET, V31, P84, DOI 10.1038/ng876; Niederreither K, 1999, NAT GENET, V21, P444, DOI 10.1038/7788; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; Romert A, 1998, P NATL ACAD SCI USA, V95, P4404, DOI 10.1073/pnas.95.8.4404; ROTHMAN KJ, 1995, NEW ENGL J MED, V333, P1369, DOI 10.1056/NEJM199511233332101; Sakai Y, 2001, GENE DEV, V15, P213, DOI 10.1101/gad.851501; SATRE MA, 1992, BIOL REPROD, V46, P802, DOI 10.1095/biolreprod46.5.802; Shang EY, 2002, J LIPID RES, V43, P590; von Lintig J, 2000, J BIOL CHEM, V275, P11915, DOI 10.1074/jbc.275.16.11915; WALD G, 1951, SCIENCE, V113, P287, DOI 10.1126/science.113.2933.287; White JA, 1996, J BIOL CHEM, V271, P29922, DOI 10.1074/jbc.271.47.29922; YANG ZN, 1994, ALCOHOL CLIN EXP RES, V18, P587, DOI 10.1111/j.1530-0277.1994.tb00914.x; ZACHMAN RD, 1961, J BIOL CHEM, V236, P2309; ZGOMBICKNIGHT M, 1995, J BIOL CHEM, V270, P10868, DOI 10.1074/jbc.270.18.10868	62	111	117	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36085	36090		10.1074/jbc.M303709200	http://dx.doi.org/10.1074/jbc.M303709200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851412	hybrid			2022-12-27	WOS:000185318300028
J	Proussakova, OV; Rabaya, NA; Moshnikova, AB; Telegina, ES; Turanov, A; Nanazashvili, MG; Beletsky, IP				Proussakova, OV; Rabaya, NA; Moshnikova, AB; Telegina, ES; Turanov, A; Nanazashvili, MG; Beletsky, IP			Oligomerization of soluble Fas antigen induces its cytotoxicity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR RECEPTOR; T-CELLS; CYTOPLASMIC DOMAIN; CROSS-LINKING; CD95 LIGAND; IFN-GAMMA; APOPTOSIS; PROLIFERATION; INHIBITION; DEATH	Soluble Fas antigen can protect cells against Fas-mediated apoptosis. High level soluble Fas antigen characteristic for blood of patients with autoimmune disease or cancer is believed to prevent the elimination of autoimmune lymphocytes or tumor cells. Here we first report that human recombinant FasDeltaTM, i.e. soluble Fas generated by alternative splicing of the intact exon 6, is capable of inducing death of transformed cells by "reverse" apoptotic signaling via transmembrane Fas ligand. FasDeltaTM, as well as transmembrane Fas antigen, can be either monomeric or oligomeric, and both its forms are efficient in blocking Fas-mediated apoptosis, although the cytotoxic activity is exhibited solely by the latter. An in vivo analysis of soluble Fas antigen showed that unlike in healthy controls, nearly the total FasDeltaTM present in sera of rheumatoid arthritis patients was oligomeric. This resulted in suppression of cell proliferation in the experimental sera and in its promotion in controls. Thus, oligomerization/depolymerization of soluble Fas antigen can regulate its activity and contribute to the pathogenesis of autoimmune diseases and cancer.	Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142290, Russia; IM Sechenov Moscow Med Acad, Inst Mol Med, Moscow 119992, Russia	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics; Sechenov First Moscow State Medical University	Beletsky, IP (corresponding author), Russian Acad Sci, Inst Theoret & Expt Biophys, Institutska St 3, Pushchino 142290, Russia.	beletsky@iteb.ru						Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASCINO I, 1995, J IMMUNOL, V154, P2706; CAYABYAB M, 1994, J IMMUNOL, V152, P1523; Chan FKM, 2000, ANN RHEUM DIS, V59, P50, DOI 10.1136/ard.59.suppl_1.i50; Chen NJ, 2001, J IMMUNOL, V166, P270, DOI 10.4049/jimmunol.166.1.270; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Chou AH, 2001, J IMMUNOL, V167, P1347, DOI 10.4049/jimmunol.167.3.1347; Desbarats J, 1998, NAT MED, V4, P1377, DOI 10.1038/3965; HANE M, 1995, FEBS LETT, V373, P265, DOI 10.1016/0014-5793(95)01051-F; Hasunuma T, 1997, ARTHRITIS RHEUM, V40, P80, DOI 10.1002/art.1780400112; Ichikawa K, 2000, INT IMMUNOL, V12, P555, DOI 10.1093/intimm/12.4.555; Jodo S, 1997, CLIN EXP IMMUNOL, V107, P89, DOI 10.1046/j.1365-2249.1997.d01-901.x; Kamitani T, 1997, J BIOL CHEM, V272, P22307, DOI 10.1074/jbc.272.35.22307; Kawahara A, 1998, GENES CELLS, V3, P297, DOI 10.1046/j.1365-2443.1998.00189.x; KINOSHITA T, 1992, ANAL BIOCHEM, V206, P231, DOI 10.1016/0003-2697(92)90358-E; Knox PG, 2003, J IMMUNOL, V170, P677, DOI 10.4049/jimmunol.170.2.677; Krammer PH, 2000, NATURE, V407, P789, DOI 10.1038/35037728; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lee SH, 2001, HUM PATHOL, V32, P250, DOI 10.1053/hupa.2001.22769; LIU CD, 1995, BIOCHEM J, V310, P957, DOI 10.1042/bj3100957; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; Mullauer L, 2001, MUTAT RES-REV MUTAT, V488, P211, DOI 10.1016/S1383-5742(01)00057-6; Nagata S, 1999, ANNU REV GENET, V33, P29, DOI 10.1146/annurev.genet.33.1.29; Nakamoto Y, 1999, ONCOL REP, V6, P733; Nishimura-Morita Y, 1997, INT IMMUNOL, V9, P1793, DOI 10.1093/intimm/9.12.1793; Ogawa Y, 2001, J RHEUMATOL, V28, P950; Papoff G, 1999, J BIOL CHEM, V274, P38241, DOI 10.1074/jbc.274.53.38241; POLLOK KE, 1994, EUR J IMMUNOL, V24, P367, DOI 10.1002/eji.1830240215; Shi GX, 2002, BLOOD, V100, P3279, DOI 10.1182/blood-2002-05-1404; Siegel RM, 2000, SCIENCE, V288, P2354, DOI 10.1126/science.288.5475.2354; STUBER E, 1995, IMMUNITY, V2, P507, DOI 10.1016/1074-7613(95)90031-4; Suda T, 1997, J EXP MED, V186, P2045, DOI 10.1084/jem.186.12.2045; Suzuki I, 2000, P NATL ACAD SCI USA, V97, P1707, DOI 10.1073/pnas.97.4.1707; Suzuki I, 2000, J IMMUNOL, V165, P5537, DOI 10.4049/jimmunol.165.10.5537; Suzuki I, 1998, J EXP MED, V187, P123, DOI 10.1084/jem.187.1.123; Tanaka M, 1998, NAT MED, V4, P31, DOI 10.1038/nm0198-031; Ulisse S, 2000, CELL DEATH DIFFER, V7, P916, DOI 10.1038/sj.cdd.4400716; VANESSEN D, 1995, NATURE, V378, P620, DOI 10.1038/378620a0; Wallach D, 1999, ANNU REV IMMUNOL, V17, P331, DOI 10.1146/annurev.immunol.17.1.331; WALLACH D, 1984, J IMMUNOL, V132, P2464; WATANABEFUKUNAGA R, 1992, NATURE, V356, P314, DOI 10.1038/356314a0; Watts AD, 1999, EMBO J, V18, P2119, DOI 10.1093/emboj/18.8.2119; Wenzel J, 2001, FEBS LETT, V509, P255, DOI 10.1016/S0014-5793(01)03174-X; Wiley SR, 1996, J IMMUNOL, V157, P3635; Yuen MF, 2001, CANCER, V92, P2136, DOI 10.1002/1097-0142(20011015)92:8<2136::AID-CNCR1555>3.0.CO;2-J	48	15	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36236	36241		10.1074/jbc.M305896200	http://dx.doi.org/10.1074/jbc.M305896200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855687	hybrid			2022-12-27	WOS:000185318300045
J	Saito, T; Okada, S; Yamada, E; Ohshima, K; Shimizu, H; Shimomura, K; Sato, M; Pessin, JE; Mori, M				Saito, T; Okada, S; Yamada, E; Ohshima, K; Shimizu, H; Shimomura, K; Sato, M; Pessin, JE; Mori, M			Syntaxin 4 and Synip (syntaxin 4 interacting protein) regulate insulin secretion in the pancreatic beta HC-9 cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-CELLS; GLUT4 TRANSLOCATION; GLUCOSE; ISLETS; EXOCYTOSIS; EXPRESSION; CA2+; IDENTIFICATION; ADIPOCYTES; TRANSPORT	Although syntaxin 1 is generally thought to function as the primary target-N-ethylmaleimide-sensitive factor attachment protein receptor required for pancreatic beta cell insulin secretion, we have observed that overexpression of a dominant-interfering syntaxin 4 mutant (syntaxin 4/DeltaTM) attenuated glucose-stimulated insulin secretion in betaHC-9 cells. Furthermore, these cells express the selective syntaxin 4-binding protein Synip (syntaxin 4 interacting protein), and Synip was specifically co-immunoprecipitated with syntaxin 4 but not syntaxin 1. Overexpression of the full-length Synip protein (Synip/wild type) inhibited VAMP2 association with syntaxin 4 and decreased glucose-stimulated insulin secretion. This did not occur with a Synip mutant (Synip/DeltaEF) that was incapable of binding syntaxin 4. Consistent with a functional role of syntaxin 4 in this process, expression of syntaxin 4/DeltaTM also inhibited glucose-stimulated insulin secretion. Furthermore, analysis of first and second phase insulin secretion demonstrated that syntaxin 4/DeltaTM mainly suppressed the second phase of insulin secretion. In contrast, overexpression of Synip resulted in an inhibition of both the first and second phase of glucose-stimulated insulin secretion. These data demonstrate that syntaxin 4 plays a functional role on insulin release and granule fusion in beta cells and that this process is regulated by the syntaxin 4-specific binding protein Synip.	Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, Maebashi, Gumma 3718511, Japan; Gunma Univ, Hlth & Sci Ctr, Maebashi, Gumma 3718510, Japan; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA	Gunma University; Gunma University; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Okada, S (corresponding author), Gunma Univ, Grad Sch Med, Dept Med & Mol Sci, 3-39-15 Showa Machi, Maebashi, Gumma 3718511, Japan.	Okadash@showa.gunma-u.ac.jp						Anello M, 1999, BRIT J PHARMACOL, V127, P1883, DOI 10.1038/sj.bjp.0702731; ASHCROFT FM, 1994, J CELL BIOCHEM, V55, P54, DOI 10.1002/jcb.240550007; Barg S, 2002, DIABETES, V51, pS74, DOI 10.2337/diabetes.51.2007.S74; BOYD RS, 1995, J BIOL CHEM, V270, P18216, DOI 10.1074/jbc.270.31.18216; Cao XC, 1998, EMBO J, V17, P2156, DOI 10.1093/emboj/17.8.2156; Chan CB, 1999, DIABETES, V48, P997, DOI 10.2337/diabetes.48.5.997; Daniel S, 1999, DIABETES, V48, P1686, DOI 10.2337/diabetes.48.9.1686; DEAN PM, 1973, DIABETOLOGIA, V9, P115, DOI 10.1007/BF01230690; Detimary P, 1998, J BIOL CHEM, V273, P33905, DOI 10.1074/jbc.273.51.33905; Easom RA, 2000, SEMIN CELL DEV BIOL, V11, P253, DOI 10.1006/scdb.2000.0174; Edwardes MDD, 1998, STAT SINICA, V8, P393; GEMBAL M, 1992, J CLIN INVEST, V89, P1288, DOI 10.1172/JCI115714; HEINEMANN C, 1994, BIOPHYS J, V67, P2546, DOI 10.1016/S0006-3495(94)80744-1; Henquin JC, 2002, DIABETES, V51, pS60, DOI 10.2337/diabetes.51.2007.S60; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; JACOBSSON G, 1994, P NATL ACAD SCI USA, V91, P12487, DOI 10.1073/pnas.91.26.12487; Katz B., 1969, RELEASE NEURAL TRANS; Lang JC, 1999, EUR J BIOCHEM, V259, P3, DOI 10.1046/j.1432-1327.1999.00043.x; Maechler P, 1998, FEBS LETT, V422, P328, DOI 10.1016/S0014-5793(97)01618-9; Min J, 1999, MOL CELL, V3, P751, DOI 10.1016/S1097-2765(01)80007-1; Nagamatsu S, 1997, DIABETOLOGIA, V40, P1396, DOI 10.1007/s001250050841; OKADA S, 2003, DIABETES MELLITUS ME, P83; Olson AL, 1997, MOL CELL BIOL, V17, P2425, DOI 10.1128/MCB.17.5.2425; PALADE G, 1975, SCIENCE, V189, P347, DOI 10.1126/science.1096303; Regazzi R, 1996, EMBO J, V15, P6951, DOI 10.1002/j.1460-2075.1996.tb01087.x; Rorsman P, 2000, NEWS PHYSIOL SCI, V15, P72; Rothman JE, 2002, NAT MED, V8, P1059, DOI 10.1038/nm770; Sadoul K, 1997, J BIOL CHEM, V272, P33023, DOI 10.1074/jbc.272.52.33023; Sakura H, 1995, FEBS LETT, V377, P338, DOI 10.1016/0014-5793(95)01369-5; TROITZA K, 2002, DIABETES, V51, pS83; Wheeler MB, 1996, ENDOCRINOLOGY, V137, P1340, DOI 10.1210/en.137.4.1340; Whyte JRC, 2002, J CELL SCI, V115, P2627	32	35	38	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36718	36725		10.1074/jbc.M305114200	http://dx.doi.org/10.1074/jbc.M305114200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855681	hybrid			2022-12-27	WOS:000185318300103
J	Wood, A; Schneider, J; Dover, J; Johnston, M; Shilatifard, A				Wood, A; Schneider, J; Dover, J; Johnston, M; Shilatifard, A			The Paf1 complex is essential for histone monoubiquitination by the Rad6-Bre1 complex, which signals for histone methylation by COMPASS and Dot1p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA-POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTIONAL ELONGATION; GENE-EXPRESSION; H3 METHYLATION; ACTIVE GENES; SET DOMAIN; IN-VIVO; YEAST; UBIQUITINATION	Monoubiquitination of histone H2B, catalyzed by Rad6-Bre1, is required for methylation of histone H3 on lysines 4 and 79, catalyzed by the Set1-containing complex COMPASS and Dot1p, respectively. The Paf1 protein complex, which associates with RNA polymerase II, is known to be required for these histone H3 methylation events. During the early elongation stage of transcription, the Paf1 complex is required for association of COMPASS with RNA polymerase II, but the role the Paf1 complex plays at the promoter has not been clear. We present evidence that the Paf1 complex is required for monoubiquitination of histone H2B at promoters. Strains deleted for several components of the Paf1 complex are defective in monoubiquitination of histone H2B, which results in the loss of methylation of lysines 4 and 79 of histone H3. We also show that Paf1 complex is required for the interaction of Rad6 and COMPASS with RNA polymerase II. Finally, we show that the Paf1 complex is required for Rad6-Bre1 catalytic activity but not for the recruitment of Rad6-Bre1 to promoters. Thus, in addition to its role during the elongation phase of transcription, the Paf1 complex appears to activate the function but not the placement of the Rad6-Bre1 ubiquitin-protein ligase at the promoters of active genes.	St Louis Univ, Sch Med, Dept Biochem, St Louis, MO 63104 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; St Louis Univ, Sch Med, Ctr Canc, St Louis, MO 63104 USA	Saint Louis University; Washington University (WUSTL); Saint Louis University	Shilatifard, A (corresponding author), St Louis Univ, Sch Med, Dept Biochem, 1402 S Grand Blvd, St Louis, MO 63104 USA.		Johnston, Mark/K-3543-2019; Johnston, Mark/R-6156-2019	Johnston, Mark/0000-0002-4932-7229; 	NATIONAL CANCER INSTITUTE [R01CA089455] Funding Source: NIH RePORTER; NCI NIH HHS [1R01CA089455] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berger SL, 2002, CURR OPIN GENET DEV, V12, P142, DOI 10.1016/S0959-437X(02)00279-4; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; Bryk M, 2002, CURR BIOL, V12, P165, DOI 10.1016/S0960-9822(01)00652-2; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Edmondson DG, 1996, GENE DEV, V10, P1247, DOI 10.1101/gad.10.10.1247; Feng Q, 2002, CURR BIOL, V12, P1052, DOI 10.1016/S0960-9822(02)00901-6; Gerber M, 2003, J BIOL CHEM, V278, P26303, DOI 10.1074/jbc.R300014200; Jaskelioff M, 2003, NAT CELL BIOL, V5, P395, DOI 10.1038/ncb0503-395; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2003, P NATL ACAD SCI USA, V100, P1820, DOI 10.1073/pnas.0437846100; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Pokholok DK, 2002, MOL CELL, V9, P799, DOI 10.1016/S1097-2765(02)00502-6; Porter SE, 2002, EUKARYOT CELL, V1, P830, DOI 10.1128/EC.1.5.830-842.2002; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wood A, 2003, MOL CELL, V11, P267, DOI 10.1016/S1097-2765(02)00802-X	33	281	288	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34739	34742		10.1074/jbc.C300269200	http://dx.doi.org/10.1074/jbc.C300269200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12876294	hybrid			2022-12-27	WOS:000185164400002
J	Lavi, R; Shainberg, A; Friedmann, H; Shneyvays, V; Rickover, O; Eichler, M; Kaplan, D; Lubart, R				Lavi, R; Shainberg, A; Friedmann, H; Shneyvays, V; Rickover, O; Eichler, M; Kaplan, D; Lubart, R			Low energy visible light induces reactive oxygen species generation and stimulates an increase of intracellular calcium concentration in cardiac cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOPLASMIC FREE CALCIUM; LEVEL LASER IRRADIATION; IN-VITRO; HYDROGEN-PEROXIDE; INOSITOL 1,4,5-TRISPHOSPHATE; RECEPTOR ACTIVATION; RYANODINE RECEPTORS; SIGNAL-TRANSDUCTION; REDOX REGULATION; PROLIFERATION	Low energy visible light (LEVL) irradiation has been shown to exert some beneficial effects on various cell cultures. For example, it increases the fertilizing capability of sperm cells, promotes cell proliferation, induces sprouting of neurons, and more. To learn about the mechanism of photobiostimulation, we studied the relationship between increased intracellular calcium ([Ca2+](i)) and reactive oxygen species production following LEVL illumination of cardiomyocytes. We found that visible light causes the production of O-2(radical anion) and H2O2 and that exogenously added H2O2 (12 muM) can mimic the effect of LEVL (3.6 J/cm(2)) to induce a slow and transient increase in [Ca2+](i). This [Ca2+](i) elevation can be reduced by verapamil, a voltage-dependent calcium channel inhibitor. The kinetics of [Ca2+](i) elevation and morphologic damage following light or addition of H2O2 were found to be dose-dependent. For example, LEVL, 3.6 J/cm(2), which induced a transient increase in [Ca2+](i), did not cause any cell damage, whereas visible light at 12 J/cm(2) induced a linear increase in [Ca2+](i) and damaged the cells. The linear increase in [Ca2+](i) resulting from high energy doses of light could be attenuated into a non-linear small rise in [Ca2+](i) by the presence of extracellular catalase during illumination. We suggest that the different kinetics of [Ca2+](i) elevation following various light irradiation or H2O2 treatment represents correspondingly different adaptation levels to oxidative stress. The adaptive response of the cells to LEVL represented by the transient increase in [Ca2+](i) can explain LEVL beneficial effects.	Bar Ilan Univ, Dept Chem, IL-52900 Ramat Gan, Israel; Bar Ilan Univ, Fac Life Sci, IL-52900 Ramat Gan, Israel; Inst Biol, Dept Phys Chem, Ness Ziona, Israel; Bar Ilan Univ, Dept Phys, IL-52900 Ramat Gan, Israel	Bar Ilan University; Bar Ilan University; Bar Ilan University	Lavi, R (corresponding author), Bar Ilan Univ, Dept Chem, IL-52900 Ramat Gan, Israel.	laviro@mail.biu.ac.il		Lubart, Rachel/0000-0001-7215-8462				Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x; Anzai K, 2000, ANTIOXID REDOX SIGN, V2, P35, DOI 10.1089/ars.2000.2.1-35; BENHUR E, 1993, PHOTOCHEM PHOTOBIOL, V58, P890, DOI 10.1111/j.1751-1097.1993.tb04989.x; BENHUR E, 1991, PHOTOCHEM PHOTOBIOL, V54, P163, DOI 10.1111/j.1751-1097.1991.tb02002.x; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; Berridge MJ, 1998, NATURE, V395, P645, DOI 10.1038/27094; BLANKENSHIP RE, 1992, PHOTOSYNTH RES, V33, P111; Campbell DL, 1996, J GEN PHYSIOL, V108, P277, DOI 10.1085/jgp.108.4.277; Cohen N, 1998, PHOTOCHEM PHOTOBIOL, V68, P407, DOI 10.1111/j.1751-1097.1998.tb09700.x; Conlan MJ, 1996, J CLIN PERIODONTOL, V23, P492, DOI 10.1111/j.1600-051X.1996.tb00580.x; CRAWFORD DR, 1994, ENVIRON HEALTH PERSP, V102, P25, DOI 10.2307/3432208; CUNNINGHAM M L, 1985, Journal of Free Radicals in Biology and Medicine, V1, P381, DOI 10.1016/0748-5514(85)90150-3; Das DK, 2001, ANTIOXID REDOX SIGN, V3, P23, DOI 10.1089/152308601750100461; Dolmetsch RE, 1997, NATURE, V386, P855, DOI 10.1038/386855a0; Duan R, 2001, LASER SURG MED, V29, P174, DOI 10.1002/lsm.1106; Dulhunty A, 2000, ANTIOXID REDOX SIGN, V2, P27, DOI 10.1089/ars.2000.2.1-27; EPSTEIN JH, 1990, NEW ENGL J MED, V322, P1149, DOI 10.1056/NEJM199004193221609; FISHER AMR, 1993, PHOTOCHEM PHOTOBIOL, V58, P581, DOI 10.1111/j.1751-1097.1993.tb04936.x; FITZGERALD M, 1994, EUR J PHARM-MOLEC PH, V268, P275, DOI 10.1016/0922-4106(94)90200-3; Fixler D, 2002, CELL CALCIUM, V31, P279, DOI 10.1016/S0143-4160(02)00056-8; FREJAVILLE C, 1995, J MED CHEM, V38, P258, DOI 10.1021/jm00002a007; FRIEDMANN H, 1991, J PHOTOCH PHOTOBIO B, V11, P87, DOI 10.1016/1011-1344(91)80271-I; Goldman R, 1998, ARCH BIOCHEM BIOPHYS, V350, P10, DOI 10.1006/abbi.1997.0478; Gomez-Lechon MJ, 2002, TOXICOL SCI, V65, P299, DOI 10.1093/toxsci/65.2.299; Grossman N, 1998, LASER SURG MED, V22, P212, DOI 10.1002/(SICI)1096-9101(1998)22:4<212::AID-LSM5>3.0.CO;2-S; Guzzardella GA, 2002, LASER MED SCI, V17, P216, DOI 10.1007/s101030200031; Karu T, 1999, J PHOTOCH PHOTOBIO B, V49, P1, DOI 10.1016/S1011-1344(98)00219-X; KIJIMA Y, 1993, J BIOL CHEM, V268, P3499; Kokoska ER, 1998, AM J PHYSIOL-GASTR L, V275, pG322; Kokoska ER, 2000, J SURG RES, V88, P97, DOI 10.1006/jsre.1999.5740; Kreisler M, 2002, LASER SURG MED, V30, P365, DOI 10.1002/lsm.10060; KRISHNA MC, 1993, FREE RADICAL RES COM, V18, P239, DOI 10.3109/10715769309145873; Krizaj D, 2002, FRONT BIOSCI-LANDMRK, V7, pD2023, DOI 10.2741/krizaj; Lage C, 2000, J PHOTOCH PHOTOBIO B, V54, P155, DOI 10.1016/S1011-1344(00)00010-5; LALORAYA MM, 1994, BIOCHEM MOL BIOL INT, V33, P543; LIVINGSTON FR, 1992, ARCH BIOCHEM BIOPHYS, V299, P83, DOI 10.1016/0003-9861(92)90247-T; Lopez-Ongil S, 1999, FREE RADICAL BIO MED, V26, P501, DOI 10.1016/S0891-5849(98)00223-8; LUBART R, 1997, LASER SURG MED, V21, P1; LUBART R, 2003, IN PRESS LASER THER; Miller TA, 2001, LIFE SCI, V69, P3091, DOI 10.1016/S0024-3205(01)01415-1; Moor ACE, 2000, J PHOTOCH PHOTOBIO B, V57, P1, DOI 10.1016/S1011-1344(00)00065-8; Murrant CL, 2001, MICROSC RES TECHNIQ, V55, P236, DOI 10.1002/jemt.1173; Nemoto S, 2000, MOL CELL BIOL, V20, P7311, DOI 10.1128/MCB.20.19.7311-7318.2000; Oren DA, 2001, BIOL PSYCHIAT, V49, P464, DOI 10.1016/S0006-3223(00)01106-9; Oron U, 2001, CIRCULATION, V103, P296; PENNING LC, 1993, BIOCHEM J, V292, P237, DOI 10.1042/bj2920237; PENNING LC, 1992, BIOCHIM BIOPHYS ACTA, V1107, P255, DOI 10.1016/0005-2736(92)90412-F; Rothstein EC, 2002, AM J PHYSIOL-HEART C, V283, pH598, DOI 10.1152/ajpheart.00198.2002; Roubaud V, 1997, ANAL BIOCHEM, V247, P404, DOI 10.1006/abio.1997.2067; Safran N, 2001, MOL CELL BIOCHEM, V217, P143, DOI 10.1023/A:1007209321969; Sauer H, 1997, FEBS LETT, V419, P201, DOI 10.1016/S0014-5793(97)01456-7; Sen CK, 2000, CURR TOP CELL REGUL, V36, P1; Shneyvays V, 2000, EXP CELL RES, V257, P111, DOI 10.1006/excr.2000.4882; SPECHT KG, 2000, BIOCHIM BIOPHYS ACTA, V1070, P60; Spikes J D, 1984, Prog Clin Biol Res, V170, P19; Stadler I, 2000, LASER SURG MED, V27, P255, DOI 10.1002/1096-9101(2000)27:3<255::AID-LSM7>3.0.CO;2-L; Suzuki YJ, 1999, J MOL CELL CARDIOL, V31, P345, DOI 10.1006/jmcc.1998.0872; Tarr M, 2001, PHOTOCHEM PHOTOBIOL, V73, P418, DOI 10.1562/0031-8655(2001)073<0418:PICOIC>2.0.CO;2; Vanden Hoek TL, 1998, J BIOL CHEM, V273, P18092, DOI 10.1074/jbc.273.29.18092; Wang H, 2000, FREE RADICAL BIO MED, V28, P1222, DOI 10.1016/S0891-5849(00)00241-0; Wang SQ, 2001, NATURE, V410, P592, DOI 10.1038/35069083; Wartenberg M, 1997, AM J PHYSIOL-REG I, V272, pR1677, DOI 10.1152/ajpregu.1997.272.5.R1677; WIESE AG, 1995, ARCH BIOCHEM BIOPHYS, V318, P231, DOI 10.1006/abbi.1995.1225; Yaakov N, 2000, BASIC RES CARDIOL, V95, P385, DOI 10.1007/s003950070037; Yamaoka K, 2000, PFLUG ARCH EUR J PHY, V440, P207, DOI 10.1007/s004249900242; YONUSCHOT G, 1992, J MOL CELL CARDIOL, V24, P1079, DOI 10.1016/0022-2828(92)93173-H; YU W, 1995, FASEB J, V9, pA239; Zhu QY, 1997, LASER SURG MED, V20, P332, DOI 10.1002/(SICI)1096-9101(1997)20:3<332::AID-LSM12>3.0.CO;2-F; Zucchi R, 2001, PHARMACOL THERAPEUT, V89, P47, DOI 10.1016/S0163-7258(00)00103-0	69	144	160	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40917	40922		10.1074/jbc.M303034200	http://dx.doi.org/10.1074/jbc.M303034200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12851407	hybrid			2022-12-27	WOS:000185847200063
J	Susan-Resiga, D; Nowak, T				Susan-Resiga, D; Nowak, T			Monitoring active site alterations upon mutation of yeast pyruvate kinase using Tl-205(+) NMR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; MONO-VALENT; ACTIVATION	The interaction of the monovalent cation with wild type (WT) yeast pyruvate kinase (YPK) and with the T298S, T298C, and T298A mutants was investigated by Tl-205(+) NMR to monitor possible structural alterations at the active site by Thr-298 mutation. TlNO3 activates WT YPK with a k(cat) value similar to that obtained with KCl and an apparent K-a of 0.96 +/- 0.07 mM in the presence of Mn2+ and fructose 1,6-bisphosphate. With the three mutants, Tl+ is a better activator than is K+ based on k(cat) values. Tl+ activation and inhibition of YPK is affected by mutation of the active site Thr-298. The effect of Mn2+ on the 1/T-1 value of Tl-205(+) in the presence of the WT and mutant YPK complexes was determined at 173 MHz (300 MHz, H-1) and 346 MHz (600 MHz, H-1). For each complex studied, 1/pT(2p) >> 1/pT(1p) and 1/pT(1p) is frequency-dependent suggesting fast exchange conditions. The values of 1/pT(1p) differ for each mutant. A correlation time of 0.65 +/- 0.35 ns was estimated for the Mn2+-Tl-205(+) interaction. The Tl+-Mn2+ distances at the active site of YPK were calculated from the paramagnetic contribution of Mn2+ to 1/T-1M of YPK- bound Tl-205(+). The calculated Tl+-Mn2+ distance for the Thr-298 mutants is decreased by about 1 Angstrom from 6.0 +/- 0.2 Angstrom observed with WT. The results suggest conformational alterations at the active site of YPK where phosphoryl transfer occurs upon mutation of Thr-298. These conformational changes may, in part, explain the alteration in k(cat) and k(cat)/K-m,K-PEP observed with the Thr-298 mutants.	Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA	University of Notre Dame	Nowak, T (corresponding author), Univ Notre Dame, Dept Chem & Biochem, Notre Dame, IN 46556 USA.		Susan-Resiga@ircm.qc.ca, Delia/O-2548-2017	Susan-Resiga@ircm.qc.ca, Delia/0000-0002-4856-090X	NIDDK NIH HHS [DK 17049] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK017049] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLERHAND A, 1971, J CHEM PHYS, V55, P189, DOI 10.1063/1.1675508; BLOEMBERGEN N, 1957, J CHEM PHYS, V27, P572, DOI 10.1063/1.1743771; BOLLENBACH TJ, 1999, THESIS U NOTRE DAME; Boyer Paul D., 1942, JOUR BIOL CHEM, V146, P673; BUCHER T, 1955, METHOD ENZYMOL, V1, P435, DOI 10.1016/0076-6879(55)01071-9; DWEK RA, 1973, MONOGRAPHS PHYSICAL, P174; HINTON JF, 1987, MAGN RESON CHEM, V25, P659, DOI 10.1002/mrc.1260250802; Jurica MS, 1998, STRUCTURE, V6, P195, DOI 10.1016/S0969-2126(98)00021-5; KAYNE FJ, 1971, ARCH BIOCHEM BIOPHYS, V143, P232, DOI 10.1016/0003-9861(71)90204-9; Kayne FJ, 1973, ENZYMES, V8, P353, DOI 10.1016/S1874-6047(08)60071-2; LORD KA, 1987, INORG CHEM, V26, P1464, DOI 10.1021/ic00256a032; Loria JP, 1998, BIOCHEMISTRY-US, V37, P6967, DOI 10.1021/bi972454n; MARKHAM GD, 1986, J BIOL CHEM, V261, P1507; MCNALLY T, 1989, FEBS LETT, V247, P312, DOI 10.1016/0014-5793(89)81359-6; Mesecar AD, 1997, BIOCHEMISTRY-US, V36, P6803, DOI 10.1021/bi962870s; MILDVAN AS, 1970, ADV ENZYMOL REL S BI, V33, P1; NOWAK T, 1972, BIOCHEMISTRY-US, V11, P2819, DOI 10.1021/bi00765a014; NOWAK T, 1981, MOL CELL BIOCHEM, V35, P65, DOI 10.1007/BF02354821; NOWAK T, 1981, SPECTROSCOPY BIOCH, V2, P109; Pauling L, 1935, P NATL ACAD SCI USA, V21, P186, DOI 10.1073/pnas.21.4.186; RAUSHEL FM, 1980, BIOCHEMISTRY-US, V19, P5481, DOI 10.1021/bi00565a003; REUBEN J, 1971, J BIOL CHEM, V246, P6227; SOLOMON I, 1955, PHYS REV, V99, P559, DOI 10.1103/PhysRev.99.559; STENGLE TR, 1967, COORDIN CHEM REV, V2, P349; Susan-Resiga D, 2003, J BIOL CHEM, V278, P12660, DOI 10.1074/jbc.M300257200	25	4	4	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40943	40952		10.1074/jbc.M306068200	http://dx.doi.org/10.1074/jbc.M306068200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12882975	hybrid			2022-12-27	WOS:000185847200066
J	Grangeasse, C; Obadia, B; Mijakovic, I; Deutscher, J; Cozzone, AJ; Doublet, P				Grangeasse, C; Obadia, B; Mijakovic, I; Deutscher, J; Cozzone, AJ; Doublet, P			Autophosphorylation of the Escherichia coli protein kinase wzc regulates tyrosine phosphorylation of Ugd, a UDP-glucose dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAPSULAR POLYSACCHARIDE SYNTHESIS; STREPTOCOCCUS-PNEUMONIAE; MOLECULAR CHARACTERIZATION; ACINETOBACTER-JOHNSONII; SINORHIZOBIUM-MELILOTI; PHOSPHATASES PRPA; ACID SYNTHESIS; COLANIC ACID; GENE; CELLS	Autophosphorylation of protein-tyrosine kinases (PTKs) involved in exopolysaccharide and capsular polysaccharide biosynthesis and transport has been observed in a number of Gram-negative and Gram-positive bacteria. However, besides their own phosphorylation, little is known about other substrates targeted by these protein-modifying enzymes. Here, we present evidence that the protein-tyrosine kinase Wzc of Escherichia coli is able to phosphorylate an endogenous enzyme, UDPglucose dehydrogenase (Ugd), which participates in the synthesis of the exopolysaccharide colanic acid. The process of phosphorylation of Ugd by Wzc was shown to be stimulated by previous autophosphorylation of Wzc on tyrosine 569. The phosphorylation of Ugd was demonstrated to actually occur on tyrosine and result in a significant increase of its dehydrogenase activity. In addition, the phosphotyrosine-protein phosphatase Wzb, which is known to effectively dephosphorylate Wzc, exhibited only a low effect, if any, on the dephosphorylation of Ugd. These data were related to the recent observation that two other UDP-glucose dehydrogenases have been also shown to be phosphorylated by a PTK in the Gram-positive bacterium Bacillus subtilis. Comparative analysis of the activities of PTKs from Gram-negative and Gram-positive bacteria showed that they are regulated by different mechanisms that involve, respectively, either the autophosphorylation of kinases or their interaction with a membrane protein activator.	Univ Lyon, CNRS, Inst Biol & Chim Prot, F-69367 Lyon 07, France; Inst Natl Agron Paris Grignon, Inst Natl Rech Agron, CNRS, F-78850 Thiverval Grignon, France	Centre National de la Recherche Scientifique (CNRS); AgroParisTech; Centre National de la Recherche Scientifique (CNRS); INRAE	Grangeasse, C (corresponding author), Univ Lyon, CNRS, Inst Biol & Chim Prot, 7 Passage Vercors, F-69367 Lyon 07, France.	c.grangeasse@ibcp.fr	Doublet, Patricia/L-9480-2014; Mijakovic, Ivan/Q-5583-2016	Doublet, Patricia/0000-0001-5848-4317; Mijakovic, Ivan/0000-0002-8860-6853; Grangeasse, Christophe/0000-0002-5484-4589				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARRECUBIETA C, 1994, J BACTERIOL, V176, P6375, DOI 10.1128/jb.176.20.6375-6383.1994; Bender MH, 2001, J BIOL CHEM, V276, P47966, DOI 10.1074/jbc.M105448200; BLISKA JB, 1991, P NATL ACAD SCI USA, V88, P1187, DOI 10.1073/pnas.88.4.1187; Breazeale SD, 2002, J BIOL CHEM, V277, P2886, DOI 10.1074/jbc.M109377200; BREAZEALE SD, 2003, J BIOL CHEM; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; Chang KW, 2001, BIOCHEM BIOPH RES CO, V287, P550, DOI 10.1006/bbrc.2001.5591; CORTAY JC, 1991, METHOD ENZYMOL, V200, P214; DADSSI M, 1990, J BIOL CHEM, V265, P20996; DAGERT M, 1979, GENE, V6, P23, DOI 10.1016/0378-1119(79)90082-9; Doublet P, 2002, J BIOL CHEM, V277, P37339, DOI 10.1074/jbc.M204465200; Doublet P, 1999, FEBS LETT, V445, P137, DOI 10.1016/S0014-5793(99)00111-8; DOUGHERTY BA, 1993, J BIOL CHEM, V268, P7118; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; Ebel W, 1999, J BACTERIOL, V181, P577, DOI 10.1128/JB.181.2.577-584.1999; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; Grangeasse C, 2002, J BIOL CHEM, V277, P7127, DOI 10.1074/jbc.M110880200; Grangeasse C, 1997, GENE, V204, P259, DOI 10.1016/S0378-1119(97)00554-4; Grangeasse C, 1998, J MOL BIOL, V278, P339, DOI 10.1006/jmbi.1998.1650; Hubbard SR, 1998, J BIOL CHEM, V273, P11987, DOI 10.1074/jbc.273.20.11987; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; Ilan O, 1999, EMBO J, V18, P3241, DOI 10.1093/emboj/18.12.3241; Kennelly P.J., 1999, FRONT BIOSCI, V4, pD372, DOI [10.2741/kennelly, DOI 10.2741/KENNELLY]; Kereszt A, 1998, J BACTERIOL, V180, P5426, DOI 10.1128/JB.180.20.5426-5431.1998; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li Y, 1996, J BACTERIOL, V178, P136, DOI 10.1128/jb.178.1.136-142.1996; MIJAKOVIC L, 2003, IN PRESS EMBO J; Missiakas D, 1997, EMBO J, V16, P1670, DOI 10.1093/emboj/16.7.1670; Morona JK, 2000, MOL MICROBIOL, V35, P1431, DOI 10.1046/j.1365-2958.2000.01808.x; Morona JK, 2003, J BACTERIOL, V185, P3009, DOI 10.1128/JB.185.10.3009-3019.2003; Morona JK, 2002, J BACTERIOL, V184, P577, DOI 10.1128/JB.184.2.577-583.2002; Mouslim C, 2003, MOL MICROBIOL, V47, P335, DOI 10.1046/j.1365-2958.2003.03318.x; Nakar D, 2003, J BACTERIOL, V185, P1001, DOI 10.1128/JB.185.3.1001-1009.2003; Naught LE, 2002, BIOCHEMISTRY-US, V41, P9637, DOI 10.1021/bi025862m; Niemeyer D, 2001, J BACTERIOL, V183, P5163, DOI 10.1128/JB.183.17.5163-5170.2001; Nunez C, 1999, J BACTERIOL, V181, P141; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Pagni M, 1999, MICROBIOL-UK, V145, P1049, DOI 10.1099/13500872-145-5-1049; Paiment A, 2002, J BACTERIOL, V184, P6437, DOI 10.1128/JB.184.23.6437-6447.2002; Pawson T, 2002, EUR J CANCER, V38, pS3, DOI 10.1016/S0959-8049(02)80597-4; POTTS M, 1993, J BIOL CHEM, V268, P7632; Preneta R, 2002, COMP BIOCHEM PHYS B, V131, P103, DOI 10.1016/S1096-4959(01)00490-0; Shi L, 2001, J BACTERIOL, V183, P7053, DOI 10.1128/JB.183.24.7053-7057.2001; Soulat D, 2002, J BACTERIOL, V184, P5194, DOI 10.1128/JB.184.18.5194-5199.2002; Stevenson G, 1996, J BACTERIOL, V178, P4885, DOI 10.1128/jb.178.16.4885-4893.1996; STOUT V, 1991, J BACTERIOL, V173, P1738, DOI 10.1128/jb.173.5.1738-1747.1991; STOUT V, 1990, J BACTERIOL, V172, P659, DOI 10.1128/jb.172.2.659-669.1990; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trent MS, 2001, J BIOL CHEM, V276, P43122, DOI 10.1074/jbc.M106961200; Vincent C, 1999, J BACTERIOL, V181, P3472, DOI 10.1128/JB.181.11.3472-3477.1999; Vincent C, 2000, J MOL BIOL, V304, P311, DOI 10.1006/jmbi.2000.4217; Wugeditsch T, 2001, J BIOL CHEM, V276, P2361, DOI 10.1074/jbc.M009092200	53	106	110	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39323	39329		10.1074/jbc.M305134200	http://dx.doi.org/10.1074/jbc.M305134200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12851388	hybrid			2022-12-27	WOS:000185713800009
J	Lu, YL; Yu, QH; Liu, JH; Zhang, JY; Wang, HW; Koul, D; McMurray, JS; Fang, XJ; Yung, WKA; Siminovitch, KA; Mills, GB				Lu, YL; Yu, QH; Liu, JH; Zhang, JY; Wang, HW; Koul, D; McMurray, JS; Fang, XJ; Yung, WKA; Siminovitch, KA; Mills, GB			Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID PHOSPHATASE-ACTIVITY; GROWTH-FACTOR RECEPTOR; TUMOR-SUPPRESSOR PTEN; BREAST-CANCER; MAMMARY-TUMORS; ENDOMETRIAL CARCINOMA; PHOSPHORYLATION SITES; GLIOMA-CELLS; CYCLIN D1; ACTIVATION	Src family protein-tyrosine kinases, which play an important role in signal integration, have been implicated in tumorigenesis in multiple lineages, including breast cancer. We demonstrate, herein, that Src kinases regulate the phosphatidylinositol 3-kinase (PI3K) signaling cascade via altering the function of the PTEN tumor suppressor. Overexpression of activated Src protein-tyrosine kinases in PTEN-deficient breast cancer cells does not alter AKT phosphorylation, an indicator of signal transduction through the PI3K pathway. However, in the presence of functional PTEN, Src reverses the activity of PTEN, resulting in an increase in AKT phosphorylation. Activated Src reduces the ability of PTEN to dephosphorylate phosphatidylinositols in micelles and promotes AKT translocation to cellular plasma membranes but does not alter PTEN activity toward water-soluble phosphatidylinositols. Thus, Src may alter the capacity of the PTEN C2 domain to bind cellular membranes rather than directly interfering with PTEN enzymatic activity. Tyrosine phosphorylation of PTEN is increased in breast cancer cells treated with pervanadate, suggesting that PTEN contains sites for tyrosine phosphorylation. Src kinase inhibitors markedly decreased pervanadate-mediated tyrosine phosphorylation of PTEN. Further, expression of activated Src results in marked tyrosine phosphorylation of PTEN. SHP-1, a SH2 domain-containing protein-tyrosine phosphatase, selectively binds and dephosphorylates PTEN in Src transfected cells. Both Src inhibitors and SHP-1 overexpression reverse Src-induced loss of PTEN function. Coexpression of PTEN with activated Src reduces the stability of PTEN. Taken together, the data indicate that activated Src inhibits PTEN function leading to alterations in signaling through the PI3K/AKT pathway.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Div Canc Med, Houston, TX 77030 USA; Univ Toronto, Mt Sinai Res Inst, Dept Med & Immunol, Toronto, ON M5G 1X5, Canada; Univ Texas, MD Anderson Canc Ctr, Div Canc Med, Dept Neurooncol, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Texas System; UTMD Anderson Cancer Center	Mills, GB (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Therapeut, Div Canc Med, Box 317,1515 Holcombe Blvd, Houston, TX 77030 USA.	Gmills@mdanderson.org	Siminovitch, Katherine/K-1475-2013		NCI NIH HHS [P50CA83639, R01 CA82716, 5-P30 CA 16672, P01CA099031] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA083639, P30CA016672, P01CA099031, R01CA082716] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adey NB, 2000, CANCER RES, V60, P35; Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221; Andjelkovic M, 1996, P NATL ACAD SCI USA, V93, P5699, DOI 10.1073/pnas.93.12.5699; Bastola DR, 2002, MOL CELL BIOCHEM, V236, P75, DOI 10.1023/A:1016191913274; Biscardi JS, 2000, BREAST CANCER RES, V2, P203, DOI 10.1186/bcr55; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Caffrey JJ, 2001, FEBS LETT, V499, P6, DOI 10.1016/S0014-5793(01)02500-5; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Castoria G, 2001, EMBO J, V20, P6050, DOI 10.1093/emboj/20.21.6050; Cuevas B, 1999, J BIOL CHEM, V274, P27583, DOI 10.1074/jbc.274.39.27583; Cuevas BD, 2001, J BIOL CHEM, V276, P27455, DOI 10.1074/jbc.M100556200; Dankort DL, 2000, ONCOGENE, V19, P1038, DOI 10.1038/sj.onc.1203272; Davies MA, 1998, CANCER RES, V58, P5285; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; Furnari FB, 1998, CANCER RES, V58, P5002; Georgescu MM, 2000, CANCER RES, V60, P7033; Gottschalk AR, 2001, CANCER RES, V61, P2105; Grillo S, 2000, EUR J BIOCHEM, V267, P6642, DOI 10.1046/j.1432-1327.2000.01759.x; GUY CT, 1994, GENE DEV, V8, P23, DOI 10.1101/gad.8.1.23; GUY CT, 1992, MOL CELL BIOL, V12, P954, DOI 10.1128/MCB.12.3.954; Hutchinson J, 2001, MOL CELL BIOL, V21, P2203, DOI 10.1128/MCB.21.6.2203-2212.2001; Hynes NE, 2000, BREAST CANCER RES, V2, P154, DOI 10.1186/bcr48; Irby RB, 1999, NAT GENET, V21, P187, DOI 10.1038/5971; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Koul D, 2002, ONCOGENE, V21, P2357, DOI 10.1038/sj/onc/1205296; Kurose K, 2001, AM J PATHOL, V158, P2097, DOI 10.1016/S0002-9440(10)64681-0; Lee JO, 1999, CELL, V99, P323, DOI 10.1016/S0092-8674(00)81663-3; Lu YL, 1999, ONCOGENE, V18, P7034, DOI 10.1038/sj.onc.1203183; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Miller SJ, 2002, FEBS LETT, V528, P145, DOI 10.1016/S0014-5793(02)03274-X; MUTHUSWAMY SK, 1995, ONCOGENE, V11, P1801; MUTHUSWAMY SK, 1994, MOL CELL BIOL, V14, P735, DOI 10.1128/MCB.14.1.735; Myers MP, 1997, P NATL ACAD SCI USA, V94, P9052, DOI 10.1073/pnas.94.17.9052; Myers MP, 1998, P NATL ACAD SCI USA, V95, P13513, DOI 10.1073/pnas.95.23.13513; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; OTTENHOFFKALFF AE, 1992, CANCER RES, V52, P4773; Penuel E, 1999, MOL BIOL CELL, V10, P1693, DOI 10.1091/mbc.10.6.1693; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Prenzel N, 2000, BREAST CANCER RES, V2, P184, DOI 10.1186/bcr52; Ptasznik Andrzej, 2000, Archivum Immunologiae et Therapiae Experimentalis, V48, P27; Salvesen HB, 2001, INT J CANCER, V91, P22, DOI 10.1002/1097-0215(20010101)91:1<22::AID-IJC1002>3.0.CO;2-S; Siminovitch KA, 1999, CURR TOP MICROBIOL, V246, P291; Somani AK, 1997, J BIOL CHEM, V272, P21113, DOI 10.1074/jbc.272.34.21113; Sugimura M, 2000, JPN J CANCER RES, V91, P395, DOI 10.1111/j.1349-7006.2000.tb00958.x; Tamura M, 1998, SCIENCE, V280, P1614, DOI 10.1126/science.280.5369.1614; Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513; Tolkacheva T, 2001, CANCER RES, V61, P4985; Torres J, 2001, J BIOL CHEM, V276, P993, DOI 10.1074/jbc.M009134200; Vazquez F, 2000, MOL CELL BIOL, V20, P5010, DOI 10.1128/MCB.20.14.5010-5018.2000; Vazquez F, 2001, J BIOL CHEM, V276, P48627, DOI 10.1074/jbc.C100556200; Verbeek BS, 1996, J PATHOL, V180, P383, DOI 10.1002/(SICI)1096-9896(199612)180:4<383::AID-PATH686>3.0.CO;2-N; Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839; Webster MA, 1998, MOL CELL BIOL, V18, P2344, DOI 10.1128/MCB.18.4.2344; Weng LP, 2001, HUM MOL GENET, V10, P599, DOI 10.1093/hmg/10.6.599; Wiener JR, 2003, GYNECOL ONCOL, V88, P73, DOI 10.1006/gyno.2002.6851; Windham TC, 2002, ONCOGENE, V21, P7797, DOI 10.1038/sj.onc.1205989; Yu JH, 1998, MOL CELL BIOL, V18, P1379, DOI 10.1128/MCB.18.3.1379	57	200	211	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40057	40066		10.1074/jbc.M303621200	http://dx.doi.org/10.1074/jbc.M303621200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869565	hybrid			2022-12-27	WOS:000185713800096
J	Zhang, L; Joshi, AK; Smith, S				Zhang, L; Joshi, AK; Smith, S			Cloning, expression, characterization, and interaction of two components of a human mitochondrial fatty acid synthase - Malonyltransferase and acyl carrier protein.	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MALONYL-COA DECARBOXYLASE; ESCHERICHIA-COLI; LIPOIC ACID; SACCHAROMYCES-CEREVISIAE; ACETYL-COA; COENZYME-A; RAT-LIVER; SUBSTRATE-SPECIFICITY; HEART-MITOCHONDRIA; MOLECULAR-CLONING	The possibility that human cells contain, in addition to the cytosolic type I fatty acid synthase complex, a mitochondrial type II malonyl-CoA-dependent system for the biosynthesis of fatty acids has been examined by cloning, expressing, and characterizing two putative components. Candidate coding sequences for a malonyl-CoA: acyl carrier protein transacylase (malonyltransferase) and its acyl carrier protein substrate, identified by BLAST searches of the human sequence data base, were located on nuclear chromosomes 22 and 16, respectively. The encoded proteins localized exclusively in mitochondria only when the putative N-terminal mitochondrial targeting sequences were present as revealed by confocal microscopy of HeLa cells infected with appropriate green fluorescent protein fusion constructs. The mature, processed forms of the mitochondrial proteins were expressed in Sf9 cells and purified, the acyl carrier protein was converted to the holoform in vitro using purified human phosphopantetheinyltransferase, and the functional interaction of the two proteins was studied. Compared with the dual specificity malonyl/acetyltransferase component of the cytosolic type I fatty acid synthase, the type II mitochondrial counterpart exhibits a relatively narrow substrate specificity for both the acyl donor and acyl carrier protein acceptor. Thus, it forms a covalent acyl-enzyme complex only when incubated with malonyl-CoA and transfers exclusively malonyl moieties to the mitochondrial holoacyl carrier protein. The type II acyl carrier protein from Bacillus subtilis, but not the acyl carrier protein derived from the human cytosolic type I fatty acid synthase, can also function as an acceptor for the mitochondrial transferase. These data provide compelling evidence that human mitochondria contain a malonyl-CoA/acyl carrier protein-dependent fatty acid synthase system, distinct from the type I cytosolic fatty acid synthase, that resembles the type II system present in prokaryotes and plastids. The final products of this system, yet to be identified, may play an important role in mitochondrial function.	Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA	Children's Hospital Los Angeles; Children's Hospital Oakland Research Institute	Smith, S (corresponding author), Childrens Hosp, Oakland Res Inst, 5700 Martin Luther King Jr Way, Oakland, CA 94609 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK016073] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 16073] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABUELHEIGA L, 1995, P NATL ACAD SCI USA, V92, P4011, DOI 10.1073/pnas.92.9.4011; Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; BRODY S, 1988, EUR J BIOCHEM, V173, P353, DOI 10.1111/j.1432-1033.1988.tb14005.x; CHRIST EJV, 1968, BIOCHIM BIOPHYS ACTA, V152, P50, DOI 10.1016/0005-2760(68)90007-6; Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x; Dyck JRB, 2000, BIOCHEM J, V350, P599, DOI 10.1042/0264-6021:3500599; Gueguen V, 2000, J BIOL CHEM, V275, P5016, DOI 10.1074/jbc.275.7.5016; Guenebaut V, 1997, J MOL BIOL, V265, P409, DOI 10.1006/jmbi.1996.0753; HARINGTON A, 1993, MOL MICROBIOL, V9, P545, DOI 10.1111/j.1365-2958.1993.tb01715.x; JANG SH, 1989, J BIOL CHEM, V264, P3500; Jordan SW, 1997, J BIOL CHEM, V272, P17903, DOI 10.1074/jbc.272.29.17903; Joshi AK, 2003, J BIOL CHEM, V278, P33142, DOI 10.1074/jbc.M305459200; JOSHI AK, 1993, BIOCHEM J, V296, P143, DOI 10.1042/bj2960143; JOSHI VC, 1971, ARCH BIOCHEM BIOPHYS, V143, P493, DOI 10.1016/0003-9861(71)90234-7; Jung JW, 2000, PROTEIN SCI, V9, P1294, DOI 10.1110/ps.9.7.1294; LOPEZCASILLAS F, 1988, P NATL ACAD SCI USA, V85, P5784, DOI 10.1073/pnas.85.16.5784; MCCARTHY AD, 1983, FEBS LETT, V160, P296, DOI 10.1016/0014-5793(83)80986-7; Miinalainen IJ, 2003, J BIOL CHEM, V278, P20154, DOI 10.1074/jbc.M302851200; Mootz HD, 2001, J BIOL CHEM, V276, P37289, DOI 10.1074/jbc.M103556200; Morikawa T, 2001, FEBS LETT, V498, P16, DOI 10.1016/S0014-5793(01)02469-3; PODACK ER, 1972, BIOCHIM BIOPHYS ACTA, V280, P235, DOI 10.1016/0005-2760(72)90090-2; QUAGLIARIELLO E, 1968, BIOCHIM BIOPHYS ACTA, V164, P12, DOI 10.1016/0005-2760(68)90066-0; Rangan V., 2003, BIOCH LIPIDS LIPOPRO, P151; Rangan VS, 1996, J BIOL CHEM, V271, P31749, DOI 10.1074/jbc.271.49.31749; Rangan VS, 1997, PROTEIN ENG, V10, P561, DOI 10.1093/protein/10.5.561; Rangan VS, 1997, J BIOL CHEM, V272, P11975, DOI 10.1074/jbc.272.18.11975; Reed MAC, 2003, ORG BIOMOL CHEM, V1, P463, DOI 10.1039/b208941f; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; Schneider R, 1997, FEBS LETT, V407, P249, DOI 10.1016/S0014-5793(97)00360-8; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; SERRE L, 1995, J BIOL CHEM, V270, P12961, DOI 10.1074/jbc.270.22.12961; SEUBERT W, 1968, BIOCHIM BIOPHYS ACTA, V164, P498, DOI 10.1016/0005-2760(68)90180-X; SEUBERT W, 1973, MOL CELL BIOCHEM, V1, P29, DOI 10.1007/BF01659936; SEUBERT W, 1959, ANGEW CHEM, V69, P359; STAACK H, 1980, LIPIDS, V15, P175, DOI 10.1007/BF02540965; STERN A, 1982, J BIOL CHEM, V257, P799; SUZUKI H, 1989, BIOCHIM BIOPHYS ACTA, V990, P25, DOI 10.1016/S0304-4165(89)80007-8; SWOFFORD DL, 2000, PAUP PHYLOGENETIC AN; Torkko JM, 2001, MOL CELL BIOL, V21, P6243, DOI 10.1128/MCB.21.18.6243-6253.2001; Triepels R, 1999, J INHERIT METAB DIS, V22, P163, DOI 10.1023/A:1005402020569; Wada H, 1997, P NATL ACAD SCI USA, V94, P1591, DOI 10.1073/pnas.94.4.1591; WAKIL SJ, 1961, J LIPID RES, V2, P1; Weber T, 2000, STRUCT FOLD DES, V8, P407, DOI 10.1016/S0969-2126(00)00120-9; WHEREAT AF, 1967, J BIOL CHEM, V242, P4013; WHEREAT AF, 1969, J BIOL CHEM, V244, P6498; Widmer J, 1996, BIOCHEM J, V316, P915, DOI 10.1042/bj3160915	47	70	74	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40067	40074		10.1074/jbc.M306121200	http://dx.doi.org/10.1074/jbc.M306121200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882974	hybrid			2022-12-27	WOS:000185713800097
J	Mogi, M; Yang, J; Lambert, JF; Colvin, GA; Shiojima, I; Skurk, C; Summer, R; Fine, A; Quesenberry, PJ; Walsh, K				Mogi, M; Yang, J; Lambert, JF; Colvin, GA; Shiojima, I; Skurk, C; Summer, R; Fine, A; Quesenberry, PJ; Walsh, K			Akt signaling regulates side population cell phenotype via Bcrp1 translocation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC STEM-CELLS; ENDOTHELIAL PROGENITOR CELLS; COLONY-FORMING CELLS; KINASE B-GAMMA; PROTEIN-KINASE; SKELETAL-MUSCLE; PHOSPHATIDYLINOSITOL 3-KINASE; MOLECULAR-CLONING; P-GLYCOPROTEIN; GROWTH-FACTOR	Akt is an important regulator of cell survival, growth, and glucose metabolism in many cell types, but the role of this signaling molecule in hematopoietic stem cells is poorly defined. Side population (SP) cells are enriched for hematopoietic stem cell activity and are defined by their ability to efficiently efflux Hoechst 33342. Bone marrow from Akt1-null mice exhibited a reduced SP fraction. However, bone marrow cellularity, growth factor-responsive progenitor cultures, and engraftable stem cells were normal in these mice. Treatment of bone marrow with LY294002, an inhibitor of the Akt effector protein phosphatidylinositol 3-kinase, led to a reversible loss of the SP fraction. Bcrp1, which encodes the Hoechst dye transporter, was translocated from the membrane to the intracellular compartment under conditions that promote the SP-depleted state. Lentivirus-mediated overexpression of Akt1 in bone marrow markedly increased the SP fraction, whereas there was no effect on bone marrow from Bcrp(-/-) mice. These data suggest that Akt signaling modulates the SP cell phenotype by regulating the expression of Bcrp1.	Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Boston, MA 02118 USA; Roger Williams Med Ctr, Ctr Stem Cell Biol, Providence, RI 02908 USA; Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA	Boston University; Roger Williams Medical Center; Boston University	Walsh, K (corresponding author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, 715 Albany St,W611, Boston, MA 02118 USA.			Fine, Alan/0000-0001-9351-3048	NHLBI NIH HHS [P01 HL56920-03, HL02-017, N01-HV-28178] Funding Source: Medline; NIAMS NIH HHS [AR40197] Funding Source: Medline; NIA NIH HHS [AG15052, AG17241] Funding Source: Medline; NICHD NIH HHS [HD23681] Funding Source: Medline; NIDDK NIH HHS [R01 DK60084, R01 DK27424-18, P01 DK50222-03, R13 DK064378-01, R01 DK60090-01A1] Funding Source: Medline; DIVISION OF HEART AND VASCULAR DISEASES [N01HV028178] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P01HD023681] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL056920] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040197] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050222, R13DK064378, R01DK027424, R01DK060090] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017241, R37AG015052, R01AG015052] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); DIVISION OF HEART AND VASCULAR DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Altomare DA, 1996, CYTOGENET CELL GENET, V74, P248, DOI 10.1159/000134426; Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092; BELLACOSA A, 1993, ONCOGENE, V8, P745; BERTONCELLO I, 1992, CURR TOP MICROBIOL, V177, P83; Bertoncello I, 1997, Methods Mol Biol, V75, P265; Brazil DP, 2001, TRENDS BIOCHEM SCI, V26, P657, DOI 10.1016/S0968-0004(01)01958-2; Brodbeck D, 1999, J BIOL CHEM, V274, P9133, DOI 10.1074/jbc.274.14.9133; CHAUDHARY PM, 1991, CELL, V66, P85, DOI 10.1016/0092-8674(91)90141-K; Chen WS, 2001, GENE DEV, V15, P2203, DOI 10.1101/gad.913901; Chen Y, 2000, ONCOGENE, V19, P3750, DOI 10.1038/sj.onc.1203726; Cheng JQ, 1996, P NATL ACAD SCI USA, V93, P3636, DOI 10.1073/pnas.93.8.3636; Cho H, 2001, J BIOL CHEM, V276, P38349, DOI 10.1074/jbc.C100462200; Cho H, 2001, SCIENCE, V292, P1728, DOI 10.1126/science.292.5522.1728; Coffer PJ, 1998, BIOCHEM J, V335, P1; COFFER PJ, 1991, EUR J BIOCHEM, V201, P475, DOI 10.1111/j.1432-1033.1991.tb16305.x; Datta SR, 1999, GENE DEV, V13, P2905, DOI 10.1101/gad.13.22.2905; Dimmeler S, 2001, J CLIN INVEST, V108, P391, DOI 10.1172/JCI13152; Foster LJ, 2001, J BIOL CHEM, V276, P44212, DOI 10.1074/jbc.M102964200; Fujio Y, 1999, J BIOL CHEM, V274, P16349, DOI 10.1074/jbc.274.23.16349; Fujio Y, 1999, MOL CELL BIOL, V19, P5073; Geddis AE, 2002, CYTOKINE GROWTH F R, V13, P61, DOI 10.1016/S1359-6101(01)00030-2; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hekimi S, 2001, TRENDS GENET, V17, P712, DOI 10.1016/S0168-9525(01)02523-9; Hulspas R, 2000, CYTOMETRY, V40, P245, DOI 10.1002/1097-0320(20000701)40:3<245::AID-CYTO10>3.3.CO;2-X; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; JONES PF, 1991, P NATL ACAD SCI USA, V88, P4171, DOI 10.1073/pnas.88.10.4171; Kim M, 2002, CLIN CANCER RES, V8, P22; KRIEGLER M, 1991, GENE TRANSFER EXPRES, P47; Kureishi Y, 2000, NAT MED, V6, P1004, DOI 10.1038/79510; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Llevadot J, 2001, J CLIN INVEST, V108, P399, DOI 10.1172/JCI200113131; LOWRY PA, 1991, EXP HEMATOL, V19, P994; Majka SM, 2003, J CLIN INVEST, V111, P71, DOI 10.1172/JCI200316157; MCNIECE IK, 1990, INT J CELL CLONING, V8, P146, DOI 10.1002/stem.5530080302; Misra S, 1999, P NATL ACAD SCI USA, V96, P5814, DOI 10.1073/pnas.96.10.5814; Murthy SS, 2000, CYTOGENET CELL GENET, V88, P38, DOI 10.1159/000015481; Myklebust JH, 2002, EXP HEMATOL, V30, P990, DOI 10.1016/S0301-472X(02)00868-8; Nakatani K, 1999, BIOCHEM BIOPH RES CO, V257, P906, DOI 10.1006/bbrc.1999.0559; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Scharenberg CW, 2002, BLOOD, V99, P507, DOI 10.1182/blood.V99.2.507; Scheffer GL, 2000, CANCER RES, V60, P2589; Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067; Shiojima I, 2002, CIRC RES, V90, P1243, DOI 10.1161/01.RES.0000022200.71892.9F; SORRENTINO BP, 1995, BLOOD, V86, P491, DOI 10.1182/blood.V86.2.491.bloodjournal862491; STAAL SP, 1987, P NATL ACAD SCI USA, V84, P5034, DOI 10.1073/pnas.84.14.5034; Storms RW, 2000, BLOOD, V96, P2125; Summer R, 2003, AM J PHYSIOL-LUNG C, V285, pL97, DOI 10.1152/ajplung.00009.2003; Uchida N, 2002, EXP HEMATOL, V30, P862, DOI 10.1016/S0301-472X(02)00879-2; Vanfleteren JR, 1999, NEUROBIOL AGING, V20, P487, DOI 10.1016/S0197-4580(99)00087-1; Zhou S, 2002, P NATL ACAD SCI USA, V99, P12339, DOI 10.1073/pnas.192276999; Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028	56	137	144	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39068	39075		10.1074/jbc.M306362200	http://dx.doi.org/10.1074/jbc.M306362200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12851395	hybrid			2022-12-27	WOS:000185575100120
J	Wen, L; Zhuang, L; Luo, X; Wei, P				Wen, L; Zhuang, L; Luo, X; Wei, P			TL1A-induced NF-kappa B activation and c-IAP2 production prevent DR3-mediated apoptosis in TF-1 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; DOMAIN-CONTAINING RECEPTOR; TNF-LIKE LIGAND; DEATH-DOMAIN; SIGNAL-TRANSDUCTION; IN-VITRO; T-CELL; INHIBITOR; DR3; CASPASE-8	We recently identified TL1A, an endothelium-derived T cell costimulator and a ligand for tumor necrosis factor receptor superfamily members DR3 and decoy receptor 3 (1). To elucidate the signaling events triggered by TL1A-DR3 interaction and to understand the molecular mechanisms regulating DR3-mediated apoptosis, we have studied the effect of TL1A and an agonistic DR3 monoclonal antibody in human erythroleukemic TF-1 cells, which express DR3 endogenously. TL1A induced the formation of a DR3 signaling complex containing TRADD, TRAF2, and RIP and activated the NF-kappaB and the ERK, JNK, and p38 mitogen-activated protein kinase pathways. However, TL1A or an agonistic DR3 monoclonal antibody did not induce apoptosis in these cells nor were there detectable levels of FADD or pro-caspase-8 seen in the signaling complex. Interestingly, DR3-mediated apoptosis was induced in TF-1 cells in the presence of a NF-kappaB pathway-specific inhibitor but not in the presence of mitogen-activated protein kinase inhibitors, either alone or in combination, suggesting that DR3-induced NF-kappaB activation was responsible for resistance to apoptosis in these cells. Consistent with this, we found that TL1A significantly increased the production of c-IAP2, a known NF-kappaB-dependent anti-apoptotic protein, and that the NF-kappaB inhibitor or cycloheximide prevented its synthesis. Furthermore, inhibition of c-IAP2 production by RNA interference significantly sensitized TF-1 cells to TL1A-induced apoptosis. Our study identifies a molecular mechanism by which TL1A and DR3 regulate cell fate in TF-1 cells.	Human Genome Sci Inc, Dept Antibody Dev, Rockville, MD 20833 USA	GlaxoSmithKline; Human Genome Sciences Inc	Wei, P (corresponding author), Human Genome Sci Inc, Dept Antibody Dev, Rockville, MD 20833 USA.	pingwei001@yahoo.com						ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ashkenazi A, 1999, CURR OPIN CELL BIOL, V11, P255, DOI 10.1016/S0955-0674(99)80034-9; Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821; Baud V, 2001, TRENDS CELL BIOL, V11, P372, DOI 10.1016/S0962-8924(01)02064-5; BEG AA, 1996, SCIENCE, V274, P272; Bennett BL, 2001, P NATL ACAD SCI USA, V98, P13681, DOI 10.1073/pnas.251194298; Bodmer JL, 1997, IMMUNITY, V6, P79, DOI 10.1016/S1074-7613(00)80244-7; Chan FKM, 2000, IMMUNITY, V13, P419, DOI 10.1016/S1074-7613(00)00041-8; Chinnaiyan AM, 1996, SCIENCE, V274, P990, DOI 10.1126/science.274.5289.990; Chu ZL, 1997, P NATL ACAD SCI USA, V94, P10057, DOI 10.1073/pnas.94.19.10057; CUENDA A, 1995, FEBS LETT, V364, P229, DOI 10.1016/0014-5793(95)00357-F; Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215; Favata MF, 1998, J BIOL CHEM, V273, P18623, DOI 10.1074/jbc.273.29.18623; Gupta S., 2001, Current Molecular Medicine (Hilversum), V1, P317, DOI 10.2174/1566524013363780; Harlow E., 1988, ANTIBODIES LAB MANUA; Hu SM, 2003, J BIOL CHEM, V278, P10055, DOI 10.1074/jbc.M207197200; Huang HK, 2000, J BIOL CHEM, V275, P26661; Janknecht R, 1997, EMBO J, V16, P1620, DOI 10.1093/emboj/16.7.1620; Jiang YP, 1999, SCIENCE, V283, P543, DOI 10.1126/science.283.5401.543; Karin M, 2002, NAT IMMUNOL, V3, P221, DOI 10.1038/ni0302-221; Kitson J, 1996, NATURE, V384, P372, DOI 10.1038/384372a0; LIN YZ, 1995, J BIOL CHEM, V270, P14255, DOI 10.1074/jbc.270.24.14255; Liu ZG, 1996, CELL, V87, P565, DOI 10.1016/S0092-8674(00)81375-6; Locksley RM, 2001, CELL, V104, P487, DOI 10.1016/S0092-8674(01)00237-9; Marsters SA, 1996, CURR BIOL, V6, P1669, DOI 10.1016/S0960-9822(02)70791-4; Migone TS, 2002, IMMUNITY, V16, P479, DOI 10.1016/S1074-7613(02)00283-2; Natoli G, 1997, SCIENCE, V275, P200, DOI 10.1126/science.275.5297.200; Richter BW, 2000, SCI STKE, V44, pPE1, DOI DOI 10.1126/STKE.2000.44.PE1; Roy N, 1997, EMBO J, V16, P6914, DOI 10.1093/emboj/16.23.6914; Screaton GR, 1997, P NATL ACAD SCI USA, V94, P4615, DOI 10.1073/pnas.94.9.4615; Shi Y, 1999, BIOCHEM BIOPH RES CO, V262, P132, DOI 10.1006/bbrc.1999.1181; Tan KB, 1997, GENE, V204, P35, DOI 10.1016/S0378-1119(97)00509-X; Tschopp J, 1999, CURR BIOL, V9, pR381, DOI 10.1016/S0960-9822(99)80233-4; Van Antwerp DJ, 1998, TRENDS CELL BIOL, V8, P107, DOI 10.1016/S0962-8924(97)01215-4; VanAntwerp DJ, 1996, SCIENCE, V274, P787, DOI 10.1126/science.274.5288.787; Varfolomeev EE, 1998, IMMUNITY, V9, P267, DOI 10.1016/S1074-7613(00)80609-3; Wang CY, 1996, SCIENCE, V274, P784, DOI 10.1126/science.274.5288.784; Wang CY, 1998, SCIENCE, V281, P1680, DOI 10.1126/science.281.5383.1680; Wang ECY, 2001, MOL CELL BIOL, V21, P3451, DOI 10.1128/MCB.21.10.3451-3461.2001; Ware Carl F., 1998, P549; WHITMARSH AJ, 1995, SCIENCE, V269, P403, DOI 10.1126/science.7618106; Yeh WC, 1998, SCIENCE, V279, P1954, DOI 10.1126/science.279.5358.1954	42	102	127	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39251	39258		10.1074/jbc.M305833200	http://dx.doi.org/10.1074/jbc.M305833200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12882979	hybrid			2022-12-27	WOS:000185575100140
J	Wingens, M; Walma, T; van Ingen, H; Stortelers, C; van Leeuwen, JEM; van Zoelen, EJJ; Vuister, GW				Wingens, M; Walma, T; van Ingen, H; Stortelers, C; van Leeuwen, JEM; van Zoelen, EJJ; Vuister, GW			Structural analysis of an epidermal growth factor/transforming growth factor-alpha chimera with unique ErbB binding specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAGNETIC-RESONANCE RELAXATION; RESOLUTION SOLUTION STRUCTURE; MODEL-FREE APPROACH; EGF-LIKE DOMAIN; PROTEIN STRUCTURES; BACKBONE DYNAMICS; CRYSTAL-STRUCTURE; FACTOR RECEPTOR; ERBB-2/ERBB-3 HETERODIMERS; EXTRACELLULAR DOMAIN	Various chimeras of the ErbB1-specific ligands epidermal growth factor (EGF) and transforming growth factor-alpha (TGFalpha) display an enlarged repertoire as activators of ErbB2.ErbB3 heterodimers. Mutational analysis indicated that particularly residues in the N terminus and B-loop region of these ligands are involved in the broadened receptor specificity. In order to understand the receptor specificity of T1E, a chimeric ligand constructed by the introduction of the linear N-terminal region of TGFalpha into EGF, we determined in this study the solution structure and dynamics of T1E by multidimensional NMR analysis. Subsequently, we studied the structural characteristics of T1E binding to both ErbB1 and ErbB3 by superposition modeling of its structure on the known crystal structures of ErbB3 and liganded ErbB1 complexes. The results show that the overall structure of T1E in solution is very similar to that of native EGF and TGFalpha but that its N terminus shows an extended structure that is appropriately positioned to form a triple beta-sheet with the large antiparallel beta-sheet in the B-loop region. This conformational effect of the N terminus together with the large overall flexibility of T1E, as determined by N-15 NMR relaxation analysis, may be a facilitative property for its broad receptor specificity. The structural superposition models indicate that hydrophobic and electrostatic interactions of the N terminus and B-loop of T1E are particularly important for its binding to ErbB3.	Univ Nijmegen, Dept Cell Biol, NL-6525 ED Nijmegen, Netherlands; Univ Nijmegen, Dept Biophys Chem, NL-6525 ED Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen	Wingens, M (corresponding author), Univ Nijmegen, Dept Cell Biol, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.		van Ingen, Hugo/Q-2883-2016; van Zoelen, Everardus J./D-9192-2012; van Leeuwen, Jeroen/G-3555-2010	van Ingen, Hugo/0000-0002-0808-3811; Vuister, Geerten/0000-0001-6172-5097				Alroy I, 1997, FEBS LETT, V410, P83, DOI 10.1016/S0014-5793(97)00412-2; Arteaga CL, 2003, EXP CELL RES, V284, P122, DOI 10.1016/S0014-4827(02)00104-0; Ballinger MD, 1998, J BIOL CHEM, V273, P11675, DOI 10.1074/jbc.273.19.11675; BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BRUNGER AT, 1996, XPLOR VERSION 3 851; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; Carr PA, 1997, STRUCTURE, V5, P949, DOI 10.1016/S0969-2126(97)00248-7; CELDA B, 1995, J BIOMOL NMR, V5, P161; Cho HS, 2002, SCIENCE, V297, P1330, DOI 10.1126/science.1074611; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dancey J, 2003, NAT REV DRUG DISCOV, V2, P296, DOI 10.1038/nrd1066; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Fairbrother WJ, 1998, J MOL BIOL, V279, P1149, DOI 10.1006/jmbi.1998.1837; Garrett TPJ, 2002, CELL, V110, P763, DOI 10.1016/S0092-8674(02)00940-6; GROENEN LC, 1994, GROWTH FACTORS, V11, P235, DOI 10.3109/08977199409010997; Harari D, 1999, ONCOGENE, V18, P2681, DOI 10.1038/sj.onc.1202631; HARVEY TS, 1991, EUR J BIOCHEM, V198, P555, DOI 10.1111/j.1432-1033.1991.tb16050.x; Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; Hooft RWW, 1996, NATURE, V381, P272, DOI 10.1038/381272a0; IKURA T, 1993, PROTEINS, V16, P423, DOI 10.1002/prot.340160410; Jacobsen NE, 1996, BIOCHEMISTRY-US, V35, P3402, DOI 10.1021/bi952626l; Jones JT, 1998, J BIOL CHEM, V273, P11667, DOI 10.1074/jbc.273.19.11667; Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8; KLINE TP, 1990, BIOCHEMISTRY-US, V29, P7805, DOI 10.1021/bi00486a005; KOHDA D, 1993, J BIOL CHEM, V268, P1976; Koradi R, 1996, J MOL GRAPHICS, V14, P29; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; LI YC, 1995, BIOCHEMISTRY-US, V34, P2408, DOI 10.1021/bi00008a003; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Lu HS, 2001, J BIOL CHEM, V276, P34913, DOI 10.1074/jbc.M102874200; MANDEL AM, 1995, J MOL BIOL, V246, P144, DOI 10.1006/jmbi.1994.0073; Miura K, 2002, BIOCHEM BIOPH RES CO, V294, P1040, DOI 10.1016/S0006-291X(02)00585-5; MOY FJ, 1993, BIOCHEMISTRY-US, V32, P7334, DOI 10.1021/bi00080a003; Ogiso H, 2002, CELL, V110, P775, DOI 10.1016/S0092-8674(02)00963-7; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; Schmidt M, 2002, INT J CANCER, V97, P349, DOI 10.1002/ijc.1618; Singer E, 2001, J BIOL CHEM, V276, P44266, DOI 10.1074/jbc.M105428200; Spronk CAEM, 2002, J BIOMOL NMR, V22, P281, DOI 10.1023/A:1014971029663; Stortelers C, 2003, J BIOL CHEM, V278, P12055, DOI 10.1074/jbc.M211948200; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P8732, DOI 10.1021/bi025878c; Stortelers C, 2002, BIOCHEMISTRY-US, V41, P4292, DOI 10.1021/bi012016n; Tejero R, 1996, PROTEIN SCI, V5, P578; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Van Zoelen E J, 2000, Vitam Horm, V59, P99, DOI 10.1016/S0083-6729(00)59005-0; VANDEPOLL MLM, 1995, J BIOL CHEM, V270, P22337, DOI 10.1074/jbc.270.38.22337; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wiles AP, 1997, J MOL BIOL, V272, P253, DOI 10.1006/jmbi.1997.1241; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030; Wuthrich K, 1986, NMR PROTEINS NUCL AC	53	14	27	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39114	39123		10.1074/jbc.M305603200	http://dx.doi.org/10.1074/jbc.M305603200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12869572	hybrid			2022-12-27	WOS:000185575100125
J	Gee, K; Kozlowski, M; Kumar, A				Gee, K; Kozlowski, M; Kumar, A			Tumor necrosis factor-alpha induces functionally active hyaluronan-adhesive CD44 by activating sialidase through p38 mitogen-activated protein kinase in lipopolysaccharide-stimulated human monocytic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL KINASE; PERIPHERAL-BLOOD MONOCYTES; TNF-ALPHA; CUTTING EDGE; KAPPA-B; SIGNALING MECHANISMS; LYSOSOMAL SIALIDASE; MOLECULAR-CLONING; CELL-ADHESION; EXPRESSION	Interaction of CD44, an adhesion molecule, with its ligand, hyaluronan ( HA), in monocytic cells plays a critical role in cell migration, inflammation, and immune responses. Most cell types express CD44 but do not bind HA. The biological functions of CD44 have been attributed to the generation of the functionally active, HA-adhesive form of this molecule. Although lipopolysaccharide (LPS) and cytokines induce HA-adhesive CD44, the molecular mechanism underlying this process remains unknown. In this study, we show that LPS-induced CD44-mediated HA (CD44-HA) binding in monocytes is regulated by endogenously produced tumor necrosis factor (TNF)- alpha and IL-10. Furthermore, p38 mitogen-activated protein kinase ( MAPK) activation was required for LPS- and TNF-alpha-induced, but not IL-10-induced, CD44-HA-binding in normal monocytes. To dissect the signaling pathways regulating CD44-HA binding independently of cross-regulatory IL-10-mediated effects, IL-10-refractory promonocytic THP-1 cells were employed. LPS- induced CD44-HA binding in THP-1 cells was regulated by endogenously produced TNF-alpha. Our results also suggest that lysosomal sialidase activation may be required for the acquisition of the HA-binding form of CD44 in LPS- and TNF-alpha-stimulated monocytic cells. Studies conducted to understand the role of MAPKs in the induction of sialidase activity revealed that LPS- induced sialidase activity was dependent on p42/44 MAPK-mediated TNF-alpha production. Blocking TNF-alpha production by PD98059, a p42/44 inhibitor, significantly reduced the LPS- induced sialidase activity and CD44-HA binding. Subsequently, TNF-alpha-mediated p38 MAPK activation induced sialidase activity and CD44-HA binding. Taken together, our results suggest that TNF-alpha-induced p38 MAPK activation may regulate the induction of functionally active HA-binding form of CD44 by activating sialidase in LPS- stimulated human monocytic cells.	Univ Ottawa, Dept Pediat, Ottawa, ON K1N 6N5, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1N 6N5, Canada; Childrens Hosp Eastern Ontario, Res Inst, Div Virol & Mol Immunol, Ottawa, ON K1H 8L1, Canada; Hlth Canada, Biol & Genet Therapies Directorate, Biol Res Ctr, Ottawa, ON K1A 0L2, Canada	University of Ottawa; University of Ottawa; University of Ottawa; Children's Hospital of Eastern Ontario; Health Canada	Kumar, A (corresponding author), Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Div Virol, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.		Gee, Katrina/H-3093-2016	Gee, Katrina/0000-0002-7535-2882				Achyuthan KE, 2001, COMP BIOCHEM PHYS B, V129, P29, DOI 10.1016/S1096-4959(01)00372-4; AMINOFF D, 1961, BIOCHEM J, V81, P384, DOI 10.1042/bj0810384; Bartolazzi A, 1996, J CELL BIOL, V132, P1199, DOI 10.1083/jcb.132.6.1199; Beyaert R, 1996, EMBO J, V15, P1914, DOI 10.1002/j.1460-2075.1996.tb00542.x; Bonten EJ, 2000, J BIOL CHEM, V275, P37657, DOI 10.1074/jbc.M007380200; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Brown KL, 2001, J IMMUNOL, V167, P5367, DOI 10.4049/jimmunol.167.9.5367; Daftarian PM, 1996, J IMMUNOL, V157, P12; Darnay BG, 1997, J LEUKOCYTE BIOL, V61, P559, DOI 10.1002/jlb.61.5.559; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; DE WMR, 1991, J EXP MED, V174, P1209; Dong C, 2002, ANNU REV IMMUNOL, V20, P55, DOI 10.1146/annurev.immunol.20.091301.131133; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Fichter M, 1997, ONCOGENE, V14, P2817, DOI 10.1038/sj.onc.1201127; Fujii K, 2001, J IMMUNOL, V167, P1198, DOI 10.4049/jimmunol.167.3.1198; Gee K, 2002, J IMMUNOL, V169, P5660, DOI 10.4049/jimmunol.169.10.5660; Gee K, 2001, CELL IMMUNOL, V211, P131, DOI 10.1006/cimm.2001.1829; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; Hambleton J, 1996, P NATL ACAD SCI USA, V93, P2774, DOI 10.1073/pnas.93.7.2774; Hatzoglou A, 2000, J IMMUNOL, V165, P1322, DOI 10.4049/jimmunol.165.3.1322; JACKSON DG, 1992, J BIOL CHEM, V267, P4732; Katoh S, 1999, J IMMUNOL, V162, P5058; KATOH S, 1995, J EXP MED, V182, P419, DOI 10.1084/jem.182.2.419; Kryworuchko M, 1999, EXP CELL RES, V250, P241, DOI 10.1006/excr.1999.4524; Lee JC, 1996, J LEUKOCYTE BIOL, V59, P152, DOI 10.1002/jlb.59.2.152; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; Lesley J, 2000, J BIOL CHEM, V275, P26967; LESLEY J, 1995, J EXP MED, V182, P431, DOI 10.1084/jem.182.2.431; Levesque MC, 1996, J IMMUNOL, V156, P1557; Levesque MC, 1997, J IMMUNOL, V159, P6184; Levesque MC, 1999, CELL IMMUNOL, V193, P209, DOI 10.1006/cimm.1999.1456; Lewis TS, 1998, ADV CANCER RES, V74, P49, DOI 10.1016/S0065-230X(08)60765-4; LIU D, 1998, FRONT BIOSCI, V3, P631; Ma W, 2001, J BIOL CHEM, V276, P13664, DOI 10.1074/jbc.M011157200; MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71; Maiti A, 1998, SCIENCE, V282, P941, DOI 10.1126/science.282.5390.941; Mancuso G, 2002, J IMMUNOL, V169, P1401, DOI 10.4049/jimmunol.169.3.1401; MIYAGI T, 1985, J BIOL CHEM, V260, P6710; Miyagi T, 1999, J BIOL CHEM, V274, P5004, DOI 10.1074/jbc.274.8.5004; MIYAKE K, 1990, J EXP MED, V172, P69, DOI 10.1084/jem.172.1.69; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; Nandi A, 2000, J BIOL CHEM, V275, P14939, DOI 10.1074/jbc.275.20.14939; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; NOTTENBURG C, 1989, P NATL ACAD SCI USA, V86, P8521, DOI 10.1073/pnas.86.21.8521; O'Farrell AM, 1998, EMBO J, V17, P1006, DOI 10.1093/emboj/17.4.1006; O'Farrell AM, 2000, J IMMUNOL, V164, P4607, DOI 10.4049/jimmunol.164.9.4607; Pshezhetsky AV, 1997, NAT GENET, V15, P316, DOI 10.1038/ng0397-316; Pure E, 2001, TRENDS MOL MED, V7, P213, DOI 10.1016/S1471-4914(01)01963-3; Sawada M, 2002, INT J CANCER, V97, P180, DOI 10.1002/ijc.1598; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Shi L, 2002, AM J PHYSIOL-CELL PH, V282, pC1205, DOI 10.1152/ajpcell.00511.2001; Siegelman MH, 1999, J LEUKOCYTE BIOL, V66, P315, DOI 10.1002/jlb.66.2.315; Sionov RV, 1998, CELL ADHES COMMUN, V6, P503, DOI 10.3109/15419069809010798; Stoop R, 2001, ARTHRITIS RHEUM, V44, P2922, DOI 10.1002/1529-0131(200112)44:12<2922::AID-ART480>3.0.CO;2-7; Takahashi K, 1996, J BIOL CHEM, V271, P9490, DOI 10.1074/jbc.271.16.9490; Takeda K, 1999, IMMUNITY, V10, P39, DOI 10.1016/S1074-7613(00)80005-9; Takeuchi O, 2000, J IMMUNOL, V165, P5392, DOI 10.4049/jimmunol.165.10.5392; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Teder P, 2002, SCIENCE, V296, P155, DOI 10.1126/science.1069659; Verhasselt V, 1997, J IMMUNOL, V158, P2919; Vinogradova MV, 1998, BIOCHEM J, V330, P641; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; Wittig B, 1998, J IMMUNOL, V161, P1069	65	71	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37275	37287		10.1074/jbc.M302309200	http://dx.doi.org/10.1074/jbc.M302309200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867430	hybrid			2022-12-27	WOS:000185437200036
J	Krem, MM; Di Cera, E				Krem, MM; Di Cera, E			Conserved ser residues, the shutter region, and speciation in serpin evolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CODON USAGE; CONFORMATIONS; SUPERFAMILY; PROTEINASE; PROTEASES; SHEET; LOOP	The suicide inhibitory mechanism of serine protease inhibitors of the serpin superfamily depends heavily on their structural flexibility, which is controlled in large part by the breach and shutter regions of the central Abeta-sheet. We examined codon usage by the highly conserved residues, Ser-53 and Ser-56, of the shutter region and found a TCN-AGY usage dichotomy for Ser-56 that remarkably is linked to the protostome-deuterostome split. Our results suggest that serpin evolution was driven by phylogenetic speciation and not pressure to fulfill new physiologic functions mitigating against co-evolution with the family of serine proteases they inhibit.	Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	Washington University (WUSTL)	Di Cera, E (corresponding author), Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA.				NHLBI NIH HHS [HL49413, HL58141, HL73813] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL049413, R01HL073813, R01HL058141, R01HL049413] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Atchley WR, 2001, MOL BIOL EVOL, V18, P1502, DOI 10.1093/oxfordjournals.molbev.a003936; Brown JR, 2001, SYST BIOL, V50, P497, DOI 10.1080/10635150117729; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; DIAZLAZCOZ Y, 1995, J MOL BIOL, V250, P123, DOI 10.1006/jmbi.1995.0363; FELSENSTEIN J, 1999, PHYLIP PHYLOGENY INF; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Irving JA, 2000, GENOME RES, V10, P1845, DOI 10.1101/gr.GR-1478R; Krem MM, 2001, EMBO J, V20, P3036, DOI 10.1093/emboj/20.12.3036; Krem MM, 1999, J BIOL CHEM, V274, P28063, DOI 10.1074/jbc.274.40.28063; LOMAS DA, 1993, J BIOL CHEM, V268, P15333; Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292; Olsen GJ, 1997, CELL, V89, P991, DOI 10.1016/S0092-8674(00)80284-6; POTEMPA J, 1994, J BIOL CHEM, V269, P15957; Rose T, 2002, J BIOL CHEM, V277, P19243, DOI 10.1074/jbc.C200132200; SEYAMA K, 1991, J BIOL CHEM, V266, P12627; STEIN PE, 1995, NAT STRUCT BIOL, V2, P96, DOI 10.1038/nsb0295-96; Stratikos E, 1999, P NATL ACAD SCI USA, V96, P4808, DOI 10.1073/pnas.96.9.4808; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Trifonov EN, 2001, J MOL EVOL, V53, P394, DOI 10.1007/s002390010229; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2000, J MOL BIOL, V296, P685, DOI 10.1006/jmbi.1999.3520	21	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37810	37814		10.1074/jbc.M305088200	http://dx.doi.org/10.1074/jbc.M305088200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12847097	hybrid			2022-12-27	WOS:000185437200100
J	Takezawa, D				Takezawa, D			Characterization of a novel plant PP2C-like protein Ser/Thr phosphatase as a calmodulin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; GUARD-CELLS; ARABIDOPSIS-THALIANA; MUTATIONAL ANALYSIS; NEGATIVE REGULATOR; CALCIUM REGULATION; FISSION YEAST; 2C; KINASE; EXPRESSION	Protein phosphatases regulated by calmodulin (CaM) mediate the action of intracellular Ca2+ and modulate functions of various target proteins by dephosphorylation. In plants, however, the role of Ca2+ in the regulation of protein dephosphorylation is not well understood due to a lack of information on characteristics of CaM-regulated protein phosphatases. Screening of a cDNA library of the moss Physcomitrella patens by using S-35-labeled calmodulin as a ligand resulted in identification of a gene, PCaMPP, that encodes a protein serine/ threonine phosphatase with 373 amino acids. PCaMPP had a catalytic domain with sequence similarity to type 2C protein phosphatases (PP2Cs) with six conserved metal-associating amino acid residues and also had an extra C-terminal domain. Recombinant GST fusion proteins of PCaMPP exhibited Mn2+-dependent phosphatase activity, and the activity was inhibited by pyrophosphate and 1 mM Ca2+ but not by okadaic acid, orthovanadate, or beta-glycerophosphate. Furthermore, the PCaMPP activity was increased 1.7-fold by addition of CaM at nanomolar concentrations. CaM binding assays using deletion proteins and a synthetic peptide revealed that the CaM-binding region resides within the basic amphiphilic amino acid region 324 - 346 in the C-terminal domain. The CaM-binding region had sequence similarity to amino acids in one of three alpha-helices in the C-terminal domain of human PP2Calpha, suggesting a novel role of the C-terminal domains for the phosphatase activity. These results provide the first evidence showing possible regulation of PP2C-related phosphatases by Ca2+/CaM in plants. Genes similar to PCaMPP were found in genomes of various higher plant species, suggesting that PCaMPP-type protein phosphatases are conserved in land plants.	Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan	Hokkaido University	Takezawa, D (corresponding author), Hokkaido Univ, Inst Low Temp Sci, Sapporo, Hokkaido 0600819, Japan.	daisuket@pop.lowtem.hokudai.ac.jp	大輔, 竹澤/H-9175-2012					ALLEN GJ, 1995, PLANT CELL, V7, P1473; BUSH DS, 1995, ANNU REV PLANT PHYS, V46, P95, DOI 10.1146/annurev.pp.46.060195.000523; Cheng AY, 1999, GENE DEV, V13, P2946, DOI 10.1101/gad.13.22.2946; COHEN P, 1989, ANNU REV BIOCHEM, V58, P453, DOI 10.1146/annurev.bi.58.070189.002321; Das AK, 1996, EMBO J, V15, P6798, DOI 10.1002/j.1460-2075.1996.tb01071.x; Fromm H, 1992, PLANT MOL BIOL REP, V10, P199, DOI 10.1007/BF02668347; Gaits F, 1997, J BIOL CHEM, V272, P17873, DOI 10.1074/jbc.272.28.17873; Gosti F, 1999, PLANT CELL, V11, P1897, DOI 10.1105/tpc.11.10.1897; Hanada M, 2001, J BIOL CHEM, V276, P5753, DOI 10.1074/jbc.M007773200; Himmelbach A, 2002, EMBO J, V21, P3029, DOI 10.1093/emboj/cdf316; Kapranov P, 1999, P NATL ACAD SCI USA, V96, P1738, DOI 10.1073/pnas.96.4.1738; Kerk D, 2002, PLANT PHYSIOL, V129, P908, DOI 10.1104/pp.004002; KINCAID R, 1993, ADV SEC MESS PHOSPH, V27, P1; Kinoshita T, 1999, PLANT CELL PHYSIOL, V40, P53, DOI 10.1093/oxfordjournals.pcp.a029474; KLEE CB, 1980, ANNU REV BIOCHEM, V49, P489, DOI 10.1146/annurev.bi.49.070180.002421; KLEE CB, 1991, NEUROCHEM RES, V16, P1059, DOI 10.1007/BF00965851; KLUMPP S, 1994, J BIOL CHEM, V269, P32774; KNIGHT MR, 1992, P NATL ACAD SCI USA, V89, P4967, DOI 10.1073/pnas.89.11.4967; KNIGHT MR, 1991, NATURE, V352, P524, DOI 10.1038/352524a0; Kobayashi T, 1998, FEBS LETT, V430, P222, DOI 10.1016/S0014-5793(98)00604-8; Kusuda K, 1998, BIOCHEM J, V332, P243, DOI 10.1042/bj3320243; LAWSON JE, 1993, BIOCHEMISTRY-US, V32, P8987, DOI 10.1021/bi00086a002; LEUNG J, 1994, SCIENCE, V264, P1448, DOI 10.1126/science.7910981; Leung-Hagesteijn C, 2001, EMBO J, V20, P2160, DOI 10.1093/emboj/20.9.2160; Li JX, 1998, PLANT PHYSIOL, V116, P785, DOI 10.1104/pp.116.2.785; MERAT DL, 1985, J BIOL CHEM, V260, P1053; Merlot S, 2001, PLANT J, V25, P295, DOI 10.1046/j.1365-313x.2001.00965.x; Meskiene I, 1998, P NATL ACAD SCI USA, V95, P1938, DOI 10.1073/pnas.95.4.1938; MEYER K, 1994, SCIENCE, V264, P1452, DOI 10.1126/science.8197457; Minami A, 2003, J PLANT PHYSIOL, V160, P475, DOI 10.1078/0176-1617-00888; Miyazaki S, 1999, MOL GEN GENET, V261, P307, DOI 10.1007/s004380050971; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; Pardo JM, 1998, P NATL ACAD SCI USA, V95, P9681, DOI 10.1073/pnas.95.16.9681; PERRINO BA, 1995, J BIOL CHEM, V270, P340, DOI 10.1074/jbc.270.1.340; POOVAIAH BW, 1993, CRIT REV PLANT SCI, V12, P185, DOI 10.1080/713608046; Poovaiah BW, 1996, J PLANT PHYSIOL, V149, P553, DOI 10.1016/S0176-1617(96)80333-6; REDDY ASN, 1993, PLANT SCI, V94, P109, DOI 10.1016/0168-9452(93)90012-O; Sheen J, 1998, P NATL ACAD SCI USA, V95, P975, DOI 10.1073/pnas.95.3.975; SHIOZAKI K, 1995, EMBO J, V14, P492, DOI 10.1002/j.1460-2075.1995.tb07025.x; Snedden WA, 2001, NEW PHYTOL, V151, P35, DOI 10.1046/j.1469-8137.2001.00154.x; Tahtiharju S, 2001, PLANT J, V26, P461, DOI 10.1046/j.1365-313X.2001.01048.x; TAKEZAWA D, 1995, PLANT MOL BIOL, V27, P693, DOI 10.1007/BF00020223; Takezawa D, 1996, J BIOL CHEM, V271, P8126, DOI 10.1074/jbc.271.14.8126; Tan KML, 2001, J BIOL CHEM, V276, P44193, DOI 10.1074/jbc.M105880200; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; Zielinski RE, 1998, ANNU REV PLANT PHYS, V49, P697, DOI 10.1146/annurev.arplant.49.1.697	46	19	22	2	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38076	38083		10.1074/jbc.M301369200	http://dx.doi.org/10.1074/jbc.M301369200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860996	hybrid			2022-12-27	WOS:000185437200129
J	Bori-Sanz, T; Inoue, KS; Berndt, MC; Watson, SP; Tulasne, D				Bori-Sanz, T; Inoue, KS; Berndt, MC; Watson, SP; Tulasne, D			Delineation of the region in the glycoprotein VI tail required for association with the Fc receptor gamma-chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLLAGEN RECEPTOR; TYROSINE PHOSPHORYLATION; FUNCTIONAL ASSOCIATION; ACTIVATION; EXPRESSION; PLATELETS; CONVULXIN; CLONING; DOMAIN; CELLS	The glycoprotein VI ( GPVI) . Fc receptor gamma-chain (FcR gamma-chain) complex is the major activation receptor for collagen on platelets. GPVI cross-linking mediates activation through tyrosine phosphorylation of an ITAM ( immunoreceptor tyrosine-based activation motif) in the FcR gamma-chain by Src family kinases. It has been previously shown that a transmembrane arginine and the cytoplasmic domain of GPVI are required for association with the FcR gamma-chain in immortalized cell lines. In this study, we have delineated the regions in the GPVI tail that promote binding to FcR gamma-chain and mediate functional responses to the snake venom convulxin by reconstitution of mutant forms of GPVI in RBL-2H3 cells. Sequential truncation of the cytoplasmic tail of GPVI revealed a major role for the basic region and a minor role for the juxtamembrane six amino acids in the association with FcR gamma-chain and functional responses to convulxin. Analysis of selective deletions in the GPVI tail supported this conclusion. In addition, we show that the proline-rich domain is required for optimal Ca2+ release, whereas it is dispensable for FcR gamma-chain association.	Univ Oxford, Dept Pharmacol, Oxford OX1 3QT, England; Med Sch Edgbaston, Div Med Sci, Birmingham B15 2TT, W Midlands, England; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	University of Oxford; Monash University	Bori-Sanz, T (corresponding author), Univ Oxford, Dept Pharmacol, Mansfield Rd, Oxford OX1 3QT, England.	teresa.bori-sanz@pharm.ox.ac.uk	Berndt, Michael C/D-5580-2012; Tulasne, David/A-8705-2008; Watson, Stephen P/Q-6292-2016; Tulasne, David/AAR-5287-2020	Watson, Stephen P/0000-0002-7846-7423; Tulasne, David/0000-0002-6764-7242				Andrews RK, 2002, BLOOD, V99, P4219, DOI 10.1182/blood-2001-11-0008; Asazuma N, 2000, J BIOL CHEM, V275, P33427, DOI 10.1074/jbc.M001439200; Berlanga O, 2000, BLOOD, V96, P2740; Berlanga O, 2002, EUR J BIOCHEM, V269, P2951, DOI 10.1046/j.1432-1033.2002.02969.x; Briddon SJ, 1999, BIOCHEM J, V338, P203, DOI 10.1042/0264-6021:3380203; Chen H, 2002, J BIOL CHEM, V277, P3011, DOI 10.1074/jbc.M109714200; Clemetson JM, 1999, J BIOL CHEM, V274, P29019, DOI 10.1074/jbc.274.41.29019; Ezumi Y, 1998, J EXP MED, V188, P267, DOI 10.1084/jem.188.2.267; Ezumi Y, 2000, BIOCHEM BIOPH RES CO, V277, P27, DOI 10.1006/bbrc.2000.3624; Francischetti IMB, 1997, TOXICON, V35, P1217, DOI 10.1016/S0041-0101(97)00021-4; Gibbins J, 1996, J BIOL CHEM, V271, P18095, DOI 10.1074/jbc.271.30.18095; Gibbins JM, 1997, FEBS LETT, V413, P255, DOI 10.1016/S0014-5793(97)00926-5; Jandrot-Perrus M, 2000, BLOOD, V96, P1798, DOI 10.1182/blood.V96.5.1798.h8001798_1798_1807; Locke D, 2003, J BIOL CHEM, V278, P15441, DOI 10.1074/jbc.M212338200; Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Ono M, 1999, J BIOL CHEM, V274, P30288, DOI 10.1074/jbc.274.42.30288; Suzuki-Inoue K, 2002, J BIOL CHEM, V277, P21561, DOI 10.1074/jbc.M201012200; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Watson SP, 2001, THROMB HAEMOSTASIS, V86, P276; Zheng YM, 2001, J BIOL CHEM, V276, P12999, DOI 10.1074/jbc.M009344200	21	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35914	35922		10.1074/jbc.M301826200	http://dx.doi.org/10.1074/jbc.M301826200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847105	hybrid			2022-12-27	WOS:000185318300008
J	Fukushima, K; Ikehara, Y; Kanai, M; Kochibe, N; Kuroki, M; Yamashita, K				Fukushima, K; Ikehara, Y; Kanai, M; Kochibe, N; Kuroki, M; Yamashita, K			A beta-N-acetylglucosaminyl phosphate diester residue is attached to the glycosylphosphatidylinositol anchor of human placental alkaline phosphatase - A target of the channel-forming toxin aerolysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOHYDRATE MOIETIES; PURIFICATION; RECEPTOR; BINDING; BIOSYNTHESIS; GLYCOPROTEIN; CLONING; CHAINS	Glycosylphosphatidylinositol (GPI)-anchored proteins are ubiquitous in eukaryotes. The minimum conserved GPI core structure of all GPI-anchored glycans has been determined as EtN-PO4-6Manalpha1-2Manalpha1-6Manalpha1-4GlcN-myo-inositol-PO3H. Human placental alkaline phosphatase (AP) has been reported to be a GPI-anchored membrane protein. AP carries one N-glycan, (NeuAcalpha2-->3)(2)Gal(2)GlcNAc(2)Man(3)GlcNAc(+/-Fuc)GlcNAc, and a GPI anchor, which contains an ethanolamine phosphate diester group, as a side chain. However, we found that both sialidase-treated soluble AP (sAP) and its GPI-anchored glycan bound to a Psathyrella velutina lectin (PVL)-Sepharose column, which binds beta-GlcNAc residues. PVL binding of asialo-sAP and its GPI-anchored glycan was diminished by digestion with diplococcal beta-N-acetylhexosaminidase or by mild acid treatment. After sequential digestion of asialo-sAP with beta-N-acetylhexosaminidase and acid phosphatase, the elution patterns on chromatofocusing gels were changed in accordance with the negative charges of phosphate residues. Trypsin-digested sAP was analyzed by liquid chromatography/electrospray ionization mass spectrometry, and the structures of two glycopeptides with GPI-anchored glycans were confirmed as peptide-EtN-PO4-6Manalpha1-->2(GlcNAcbeta1-PO4-->6)Manalpha1-6(+/-EtN-PO4-->) Manalpha1-->4GlcN, which may be produced by endo-alpha-glucosaminidase. In addition to AP, GPI-anchored carcinoembryonic antigen, cholinesterase, and Tamm-Horsfall glycoprotein also bound to a PVL-Sepharose column, suggesting that the beta-N-acetylglucosaminyl phosphate diester residue is widely distributed in human GPI-anchored glycans. Furthermore, we found that the beta-N-acetylglucosaminyl phosphate diester residue is important for GPI anchor recognition of aerolysin, a channel-forming toxin derived from Aeromonas hydrophila.	Sasaki Inst, Dept Biochem, Chiyoda Ku, Tokyo 1010062, Japan; Japan Sci & Technol Corp, CREST, Chiyoda Ku, Tokyo 1010062, Japan; Fukuoka Univ, Sch Med, Dept Cell Biol, Jonan Ku, Fukuoka 8140133, Japan; Nihon Waters KK, Shinagawa Ku, Tokyo 1400001, Japan; Gunma Univ, Fac Educ, Dept Biol, Gunma 3710000, Japan; Fukuoka Univ, Sch Med, Dept Biochem, Jonan Ku, Fukuoka 8140133, Japan	Japan Science & Technology Agency (JST); Fukuoka University; Gunma University; Fukuoka University	Yamashita, K (corresponding author), Sasaki Inst, Dept Biochem, Chiyoda Ku, 2-2 Kanda Surugadai, Tokyo 1010062, Japan.	yamashita@sasaki.or.jp	Kanai, Motomu/J-6807-2016	Kanai, Motomu/0000-0003-1977-7648				Cowell S, 1997, MOL MICROBIOL, V25, P343, DOI 10.1046/j.1365-2958.1997.4691828.x; Cuatrecasas P., 1971, METHOD ENZYMOL, V22, P345; Diep DB, 1998, J BIOL CHEM, V273, P2355, DOI 10.1074/jbc.273.4.2355; ENDO T, 1988, J BIOCHEM-TOKYO, V103, P182, DOI 10.1093/oxfordjournals.jbchem.a122228; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; GLASGOW LR, 1977, J BIOL CHEM, V252, P8615; HARD K, 1992, EUR J BIOCHEM, V209, P895, DOI 10.1111/j.1432-1033.1992.tb17362.x; HENTHORN PS, 1986, P NATL ACAD SCI USA, V83, P5597, DOI 10.1073/pnas.83.15.5597; Hong YJ, 2002, EMBO J, V21, P5047, DOI 10.1093/emboj/cdf508; ICHIKI S, 1986, JPN J CANCER RES, V77, P462; IKEZAWA H, 1976, BIOCHIM BIOPHYS ACTA, V450, P154; KAM W, 1985, P NATL ACAD SCI USA, V82, P8715, DOI 10.1073/pnas.82.24.8715; KOCHIBE N, 1989, J BIOL CHEM, V264, P173; Lacy DB, 1998, CURR OPIN STRUC BIOL, V8, P778; LOW MG, 1977, BIOCHEM J, V167, P281, DOI 10.1042/bj1670281; MacKenzie CR, 1999, J BIOL CHEM, V274, P22604, DOI 10.1074/jbc.274.32.22604; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MIKI A, 1986, EUR J BIOCHEM, V160, P41, DOI 10.1111/j.1432-1033.1986.tb09937.x; MILLAN JL, 1986, J BIOL CHEM, V261, P3112; Nelson KL, 1997, J BIOL CHEM, V272, P12170, DOI 10.1074/jbc.272.18.12170; OGATA S, 1988, J BIOL CHEM, V263, P10489; OHKURA T, 1994, CANCER RES, V54, P55; REDMAN CA, 1994, BIOCHEM J, V302, P861, DOI 10.1042/bj3020861; TABAS I, 1980, J BIOL CHEM, V255, P6633; TAMM I, 1952, J EXP MED, V95, P71, DOI 10.1084/jem.95.1.71; WILLIAMS J, 1984, CARBOHYD RES, V134, P141, DOI 10.1016/0008-6215(84)85029-6; YAMASHITA K, 1987, CANCER RES, V47, P3451; YAMASHITA K, 1981, J BIOL CHEM, V256, P1283	28	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36296	36303		10.1074/jbc.M304341200	http://dx.doi.org/10.1074/jbc.M304341200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851398	hybrid			2022-12-27	WOS:000185318300053
J	McCormack, FX; Gibbons, R; Ward, SR; Kuzmenko, A; Wu, HX; Deepe, GS				McCormack, FX; Gibbons, R; Ward, SR; Kuzmenko, A; Wu, HX; Deepe, GS			Macrophage-independent fungicidal action of the pulmonary collectins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SURFACTANT PROTEIN-A; HISTOPLASMA-CAPSULATUM; IMMUNITY; INDUCTION; INFECTION; ADHERENCE; INHIBIT; GROWTH; ACID; IRON	Histoplasma capsulatum (Hc) is a facultative intracellular fungal pathogen that causes acute and chronic pneumonia. In this study, we investigated the role of the pulmonary collectins, surfactant proteins (SP) A and D, in the clearance of Hc yeast from the lung. Exposure of yeast to either collectin induced a dose-dependent decrease in [H-3]leucine incorporation by several strains of Hc. This decrement was attributed to killing of the collectin-exposed yeast since it failed to grow on agar medium. Exposure to SP-A or -D resulted in increased yeast permeability based on a leak of protein from the organism and enhanced access of an impermeant substrate to intracellular alkaline phosphatase. Inbred and out-bred SP-A null (-/-) mice were modestly more susceptible to pulmonary infection with Hc than strain and age-matched SP-A (+/+) control mice. The increase in susceptibility was associated with a decrement in the number of CD8(+) cells in the lungs of SP-A-/- mice. Neither SP-A nor SP-D inhibited the growth of macrophage-internalized Hc. We conclude that the SP-A and SP-D are antimicrobial proteins that directly inhibit the growth of Hc by increasing permeability of the organism and that Hc gains asylum from collectin-mediated killing by rapid entry into pulmonary macrophages.	Univ Cincinnati, Coll Med, Div Pulm Crit Care Med, Dept Internal Med, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Div Infect Dis, Dept Internal Med, Cincinnati, OH 45267 USA; Vet Affairs Med Ctr, Cincinnati, OH 45220 USA	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center; Cincinnati VA Medical Center	McCormack, FX (corresponding author), Univ Cincinnati, Coll Med, Div Pulm Crit Care Med, Dept Internal Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	frank.mccormack@uc.edu	Kuzmenko, Oleksandr/P-6059-2016; McCormack, Francis X./ABE-8398-2020	McCormack, Francis X./0000-0001-7168-9464	NHLBI NIH HHS [HL 61612, HL 68861] Funding Source: Medline; NIAID NIH HHS [AI 34361, AI 42747] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068861, R01HL061612] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI042747, R01AI034361] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Allendoerfer R, 1998, J IMMUNOL, V160, P6072; Allendorfer R, 1999, J IMMUNOL, V162, P7389; Borron P, 2000, AM J PHYSIOL-LUNG C, V278, pL840, DOI 10.1152/ajplung.2000.278.4.L840; Borron P, 1996, AM J RESP CELL MOL, V15, P115, DOI 10.1165/ajrcmb.15.1.8679215; BULLOCK WE, 1987, J EXP MED, V165, P195, DOI 10.1084/jem.165.1.195; Cain JA, 1998, INFECT IMMUN, V66, P1473, DOI 10.1128/IAI.66.4.1473-1481.1998; Chiba H, 2002, J BIOL CHEM, V277, P20379, DOI 10.1074/jbc.M201089200; Crouch E, 2001, ANNU REV PHYSIOL, V63, P521, DOI 10.1146/annurev.physiol.63.1.521; Deepe GS, 1998, RES IMMUNOL, V149, P397, DOI 10.1016/S0923-2494(98)80763-3; DEEPE GS, 1994, J IMMUNOL, V152, P3491; DEEPE GSJ, 1999, PRINCIPLES PRACTICES, P2718; DETHLOFF LA, 1986, BIOCHEM J, V233, P111, DOI 10.1042/bj2330111; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; EISSENBERG LG, 1988, J LEUKOCYTE BIOL, V43, P483, DOI 10.1002/jlb.43.6.483; FORNSTEDT N, 1975, FEBS LETT, V57, P187, DOI 10.1016/0014-5793(75)80713-7; Goerke J, 1998, BBA-MOL BASIS DIS, V1408, P79, DOI 10.1016/S0925-4439(98)00060-X; Hakansson K, 1999, STRUCTURE, V7, P255, DOI 10.1016/S0969-2126(99)80036-7; HAWGOOD S, 1985, BIOCHEMISTRY-US, V24, P184, DOI 10.1021/bi00322a026; Korfhagen TR, 1996, P NATL ACAD SCI USA, V93, P9594, DOI 10.1073/pnas.93.18.9594; KRATOCHVIL B, 1965, ANAL CHEM, V37, P111, DOI 10.1021/ac60220a028; Newman SL, 2000, INFECT IMMUN, V68, P5668, DOI 10.1128/IAI.68.10.5668-5672.2000; NEWMAN SL, 1994, J CLIN INVEST, V93, P1422, DOI 10.1172/JCI117119; Newman SL, 1997, J IMMUNOL, V158, P1779; NEWMAN SL, 1992, INFECT IMMUN, V60, P4593, DOI 10.1128/IAI.60.11.4593-4597.1992; Suwabe A, 1996, ARCH BIOCHEM BIOPHYS, V327, P285, DOI 10.1006/abbi.1996.0123; Timmerman MM, 1999, INFECT IMMUN, V67, P6403; van Rozendaal BAWM, 2000, J INFECT DIS, V182, P917, DOI 10.1086/315799; WEISS J, 1984, J IMMUNOL, V132, P3109; WOLF JE, 1992, INFECT IMMUN, V60, P2559, DOI 10.1128/IAI.60.7.2559-2564.1992; WOLF JE, 1987, J IMMUNOL, V138, P582; WORSHAM PL, 1988, J MED VET MYCOL, V26, P137; Wright SK, 1998, ANAL BIOCHEM, V265, P8, DOI 10.1006/abio.1998.2858; Wu HX, 2003, J CLIN INVEST, V111, P1589, DOI 10.1172/JCI200316889; Zhou P, 1998, J EXP MED, V187, P1315, DOI 10.1084/jem.187.8.1315	34	98	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36250	36256		10.1074/jbc.M303086200	http://dx.doi.org/10.1074/jbc.M303086200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857753	hybrid			2022-12-27	WOS:000185318300047
J	Miller, DW; Ahmad, R; Hague, S; Baptista, MJ; Canet-Aviles, R; McLendon, C; Carter, DM; Zhu, PP; Stadler, J; Chandran, J; Klinefelter, GR; Blackstone, C; Cookson, MR				Miller, DW; Ahmad, R; Hague, S; Baptista, MJ; Canet-Aviles, R; McLendon, C; Carter, DM; Zhu, PP; Stadler, J; Chandran, J; Klinefelter, GR; Blackstone, C; Cookson, MR			L166P mutant DJ-1, causative for recessive Parkinson's disease, is degraded through the ubiquitin-proteasome system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-SYNUCLEIN; CRYSTAL-STRUCTURE; PROTEIN LIGASE; IN-VITRO; GENE; DEGRADATION; MUTATIONS; FERTILITY; DYSTONIA; PATHWAY	Mutations in a gene on chromosome 1, DJ-1, have been reported recently to be associated with recessive, early-onset Parkinson's disease. While one mutation is a large deletion that is predicted to produce an effective knockout of the gene, the second is a point mutation, L166P, whose precise effects on protein function are unclear. In the present study, we show that L166P destabilizes DJ-1 protein and promotes its degradation through the ubiquitin-proteasome system. A double mutant (K130R, L166P) was more stable than L166P, suggesting that this lysine residue contributes to stability of the protein. Subcellular localization was broadly similar for both wild type and L166P forms of the protein, indicating that the effect of the mutation is predominantly on protein stability. These observations are reminiscent of other recessive gene mutations that produce an effective loss of function. The L166P mutation has the simple effect of promoting DJ-1 degradation, thereby reducing net DJ-1 protein within the cell.	NIA, Neurogenet Lab, NIH, Bethesda, MD 20892 USA; NINDS, Cellular Neurol Unit, NIH, Bethesda, MD 20892 USA; US EPA, Natl Hlth & Environm Effects Res Lab, Reprod Toxicol Div, Res Triangle Pk, NC 27711 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); United States Environmental Protection Agency	Cookson, MR (corresponding author), NIA, Neurogenet Lab, NIH, Bldg 10,Rm 6C103,MSC 1589,9000 Rockville Pike, Bethesda, MD 20892 USA.	Cookson@mail.nih.gov	Cookson, Mark/AAW-2516-2021	Cookson, Mark/0000-0002-1058-3831	NATIONAL INSTITUTE ON AGING [ZIAAG000953, Z01AG000953] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Baptista MJ, 2003, J NEUROCHEM, V85, P957, DOI 10.1046/j.1471-4159.2003.01742.x; Blackstone C, 2003, BIOCHEM BIOPH RES CO, V305, P345, DOI 10.1016/S0006-291X(03)00767-8; Bonifati V, 2003, SCIENCE, V299, P256, DOI 10.1126/science.1077209; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Cookson MR, 2003, NEURON, V37, P7, DOI 10.1016/S0896-6273(02)01166-2; Darios F, 2003, HUM MOL GENET, V12, P517, DOI 10.1093/hmg/ddg044; Du XL, 2000, P NATL ACAD SCI USA, V97, P14079, DOI 10.1073/pnas.260503597; Galbiati F, 2000, J BIOL CHEM, V275, P37702, DOI 10.1074/jbc.M006657200; Gautreau A, 2002, J BIOL CHEM, V277, P31279, DOI 10.1074/jbc.C200125200; Gelman MS, 2002, J BIOL CHEM, V277, P11709, DOI 10.1074/jbc.M111958200; Giasson BI, 1999, J BIOL CHEM, V274, P7619, DOI 10.1074/jbc.274.12.7619; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Gray TM, 1996, PROTEIN SCI, V5, P742; Hardy J, 2003, LANCET NEUROL, V2, P221, DOI 10.1016/S1474-4422(03)00350-8; Hod Y, 1999, J CELL BIOCHEM, V72, P435, DOI 10.1002/(SICI)1097-4644(19990301)72:3<435::AID-JCB12>3.3.CO;2-8; Hoege C, 2002, NATURE, V419, P135, DOI 10.1038/nature00991; Honbou K, 2003, J BIOL CHEM, V278, P31380, DOI 10.1074/jbc.M305878200; Hwu WL, 2000, ANN NEUROL, V48, P609, DOI 10.1002/1531-8249(200010)48:4<609::AID-ANA7>3.3.CO;2-8; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Klinefelter GR, 2002, J ANDROL, V23, P48, DOI 10.1002/jand.2002.23.1.48; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Mitsumoto A, 2001, FREE RADICAL RES, V35, P885, DOI 10.1080/10715760100301381; Mitsumoto A, 2001, FREE RADICAL RES, V35, P301, DOI 10.1080/10715760100300831; Nagakubo D, 1997, BIOCHEM BIOPH RES CO, V231, P509, DOI 10.1006/bbrc.1997.6132; Niki T, 2003, MOL CANCER RES, V1, P247; Paxinou E, 2001, J NEUROSCI, V21, P8053, DOI 10.1523/JNEUROSCI.21-20-08053.2001; Petrucelli L, 2002, NEURON, V36, P1007, DOI 10.1016/S0896-6273(02)01125-X; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Quigley PM, 2003, P NATL ACAD SCI USA, V100, P3137, DOI 10.1073/pnas.0530312100; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Takahashi K, 2001, J BIOL CHEM, V276, P37556, DOI 10.1074/jbc.M101730200; Tao X, 2003, J BIOL CHEM, V278, P31372, DOI 10.1074/jbc.M304221200; Wagenfeld A, 1998, BIOCHEM BIOPH RES CO, V251, P545, DOI 10.1006/bbrc.1998.9512; Yang YF, 2003, NEURON, V37, P911, DOI 10.1016/S0896-6273(03)00143-0; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	35	192	200	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36588	36595		10.1074/jbc.M304272200	http://dx.doi.org/10.1074/jbc.M304272200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12851414	hybrid			2022-12-27	WOS:000185318300089
J	Peter, JC; Eftekhari, P; Billiald, P; Wallukat, G; Hoebeke, J				Peter, JC; Eftekhari, P; Billiald, P; Wallukat, G; Hoebeke, J			scFv single chain antibody variable fragment as inverse agonist of the beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANDROCTONUS-AUSTRALIS-HECTOR; BETA-ADRENERGIC-RECEPTOR; MONOCLONAL-ANTIBODY; CONSTRUCTION; CONTRACTION; RHODOPSIN; EPITOPES; PROTEINS; SURFACE; COMPLEX	Antibodies directed against the second extracellular loop of G protein-coupled receptors were shown to possess functional activities. Using a functional monoclonal antibody against the human beta(2)-adrenergic receptor, a scFv fragment with high affinity for the target epitope was constructed and produced. The fragment recognized the beta(2)-adrenergic receptors on A431 cells, blocked cAMP accumulation induced by the beta(2)-agonist salbutamol, and decreased basal cAMP accumulation in the same cells. Their in vitro activity was tested on neonatal rat cardiomyocytes. The antibody fragments blocked the chronotropic activity induced by the beta(2)-agonist clenbuterol. They also decreased the in vivo heart beating frequency of mice pretreated with bisoprolol ( a beta(1)-adrenergic receptor antagonist) for 4 min after injection. The immunological approach presented here may serve as a strategy for the synthesis of a new class of allosteric modulators for G protein-coupled receptors.	Inst Biol Mol & Cellulaire, CNRS, UPR 9021, Lab Therapeut Chem & Immunol, F-67084 Strasbourg, France; Museum Nat Hist, F-75005 Paris, France; Sch Med, Inst Pharmacol, FORENAP Therapeut Discovery, F-67000 Strasbourg, France; Max Delbruck Centrum Mol Med, D-13092 Berlin, Germany	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Museum National d'Histoire Naturelle (MNHN); CHU Strasbourg; Universite de Franche-Comte; Helmholtz Association; Max Delbruck Center for Molecular Medicine	Hoebeke, J (corresponding author), Inst Biol Mol & Cellulaire, CNRS, UPR 9021, Lab Therapeut Chem & Immunol, 15 Rue Rene Descartes, F-67084 Strasbourg, France.	J.Hoebeke@ibmc.u-strasbg.fr	BILLIALD, Philippe/ABF-7417-2021	BILLIALD, Philippe/0000-0001-8148-5297				BENTLEY GA, 1990, NATURE, V348, P254, DOI 10.1038/348254a0; Bes Cedric, 2001, Human Antibodies, V10, P67; CARROLL WL, 1988, MOL IMMUNOL, V25, P991, DOI 10.1016/0161-5890(88)90005-3; Chaves AA, 2003, LIFE SCI, V72, P2401, DOI 10.1016/S0024-3205(03)00137-1; Christopoulos A, 2002, NAT REV DRUG DISCOV, V1, P198, DOI 10.1038/nrd746; Daeffler L, 2000, FUND CLIN PHARMACOL, V14, P73, DOI 10.1111/j.1472-8206.2000.tb00395.x; DELAVIERKLUTCHKO C, 1984, FEBS LETT, V169, P151, DOI 10.1016/0014-5793(84)80308-7; Devaux C, 2001, EUR J BIOCHEM, V268, P694, DOI 10.1046/j.1432-1327.2001.01923.x; DIXON RAF, 1986, NATURE, V321, P75, DOI 10.1038/321075a0; Eftekhari P, 2001, EUR J IMMUNOL, V31, P573, DOI 10.1002/1521-4141(200102)31:2<573::AID-IMMU573>3.0.CO;2-9; Evans MJ, 1995, MOL IMMUNOL, V32, P1183, DOI 10.1016/0161-5890(95)00099-2; Gong HB, 2002, CIRCULATION, V105, P2497, DOI 10.1161/01.CIR.0000017187.61348.95; HOOGENBOOM HR, 1991, NUCLEIC ACIDS RES, V19, P4133, DOI 10.1093/nar/19.15.4133; LAROCHE Y, 1991, J BIOL CHEM, V266, P16343; Lebesgue D, 1998, EUR J PHARMACOL, V348, P123, DOI 10.1016/S0014-2999(98)00136-8; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; Mijares A, 2000, MOL PHARMACOL, V58, P373, DOI 10.1124/mol.58.2.373; MILENIC DE, 1991, CANCER RES, V51, P6363; Mirzadegan T, 2003, BIOCHEMISTRY-US, V42, P2759, DOI 10.1021/bi027224+; Mousli M, 1999, FEBS LETT, V442, P183, DOI 10.1016/S0014-5793(98)01647-0; NEIMARK J, 1993, PEPTIDE RES, V6, P219; RAPOSO G, 1989, EUR J CELL BIOL, V50, P340; RichaletSecordel PM, 1997, ANAL BIOCHEM, V249, P165, DOI 10.1006/abio.1997.2183; Sogabe S, 1997, J MOL BIOL, V273, P882, DOI 10.1006/jmbi.1997.1336; WALLUKAT G, 1995, J MOL CELL CARDIOL, V27, P397, DOI 10.1016/S0022-2828(08)80036-3; Wijkhuisen A, 2003, EUR J PHARMACOL, V468, P175, DOI 10.1016/S0014-2999(03)01717-5; Worn A, 2001, J MOL BIOL, V305, P989, DOI 10.1006/jmbi.2000.4265; Zhou YY, 1999, J PHYSIOL-LONDON, V521, P351, DOI 10.1111/j.1469-7793.1999.00351.x	28	31	42	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36740	36747		10.1074/jbc.M306877200	http://dx.doi.org/10.1074/jbc.M306877200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860977	hybrid			2022-12-27	WOS:000185318300106
J	Neale, EJ; Elliott, DJS; Hunter, M; Sivaprasadarao, A				Neale, EJ; Elliott, DJS; Hunter, M; Sivaprasadarao, A			Evidence for intersubunit interactions between S4 and S5 transmembrane segments of the Shaker potassium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-SENSING DOMAINS; K+ CHANNEL; SLOW INACTIVATION; ACTIVATION GATE; PORE DOMAIN; MOVEMENT; SENSOR; COORDINATION; ORIENTATION; RESIDUES	Voltage-gated potassium channels are transmembrane proteins made up of four subunits, each comprising six transmembrane (S1-S6) segments. S1-S4 form the voltage-sensing domain and S5-S6 the pore domain with its central pore. The sensor domain detects membrane depolarization and transmits the signal to the activation gates situated in the pore domain, thereby leading to channel opening. An understanding of the mechanism by which the sensor communicates the signal to the pore requires knowledge of the structure of the interface between the voltage-sensing and pore domains. Toward this end, we have introduced single cysteine mutations into the extracellular end of S4 (positions 356 and 357) in conjunction with a cysteine in S5 (position 418) of the Shaker channel and expressed the mutants in Xenopus oocytes. We then examined the propensity of each pair of engineered cysteines to form a metal bridge or a disulfide bridge, respectively, by examining the effect of Cd2+ ions and copper phenanthroline on the K+ conductance of a whole oocyte. Both reagents reduced currents through the S357C,E418C double mutant channel, presumably by restricting the movements necessary for coupling the voltage-sensing function to pore opening. This inhibitory effect was seen in the closed state of the channel and with heteromers composed of S357C and E418C single mutant subunits; no effect was seen with homomers of any of the single mutant channels. These data indicate that the extracellular end of S4 lies in close proximity to the extracellular end of the S5 of the neighboring subunit in closed channels.	Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Sivaprasadarao, A (corresponding author), Univ Leeds, Sch Biomed Sci, Leeds LS2 9JT, W Yorkshire, England.	a.sivaprasadarao@leeds.ac.uk		Sivaprasadarao, Asipu/0000-0002-6755-3502	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000704] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Blaustein RO, 2000, NAT STRUCT BIOL, V7, P309; CAREAGA CL, 1992, BIOPHYS J, V62, P209, DOI 10.1016/S0006-3495(92)81806-4; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; del Camino D, 2001, NEURON, V32, P649, DOI 10.1016/S0896-6273(01)00487-1; del Camino D, 2000, NATURE, V403, P321, DOI 10.1038/35002099; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Durell SR, 1998, J STRUCT BIOL, V121, P263, DOI 10.1006/jsbi.1998.3962; Elinder F, 2001, J GEN PHYSIOL, V118, P1, DOI 10.1085/jgp.118.1.1; Farrens DL, 1996, SCIENCE, V274, P768, DOI 10.1126/science.274.5288.768; Flynn GE, 2001, NEURON, V30, P689, DOI 10.1016/S0896-6273(01)00324-5; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Hackos DH, 2002, J GEN PHYSIOL, V119, P521, DOI 10.1085/jgp.20028569; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kiss L, 1998, BIOPHYS J, V74, P1840, DOI 10.1016/S0006-3495(98)77894-4; Krovetz HS, 1997, BIOPHYS J, V72, P117, DOI 10.1016/S0006-3495(97)78651-X; Larsson HP, 2000, NEURON, V27, P573, DOI 10.1016/S0896-6273(00)00067-2; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Li-Smerin YY, 2000, NEURON, V25, P411, DOI 10.1016/S0896-6273(00)80904-6; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; Liu Y, 1996, NEURON, V16, P859, DOI 10.1016/S0896-6273(00)80106-3; Liu Y, 1997, NEURON, V19, P175, DOI 10.1016/S0896-6273(00)80357-8; Loland CJ, 1999, J BIOL CHEM, V274, P36928, DOI 10.1074/jbc.274.52.36928; Loots E, 2000, J GEN PHYSIOL, V116, P623, DOI 10.1085/jgp.116.5.623; Lu Z, 2002, J GEN PHYSIOL, V120, P663, DOI 10.1085/jgp.20028696; Monks SA, 1999, J GEN PHYSIOL, V113, P415, DOI 10.1085/jgp.113.3.415; Olcese R, 1997, J GEN PHYSIOL, V110, P579, DOI 10.1085/jgp.110.5.579; OSULLIVAN WJ, 1969, DATA BIOCH RES; Roux B, 2002, NOVART FDN SYMP, V245, P84; Ruegg U T, 1977, Methods Enzymol, V47, P111; Rulisek L, 1998, J INORG BIOCHEM, V71, P115, DOI 10.1016/S0162-0134(98)10042-9; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SINGH R, 1995, METHOD ENZYMOL, V251, P167, DOI 10.1016/0076-6879(95)51119-9; Starace DM, 1997, NEURON, V19, P1319, DOI 10.1016/S0896-6273(00)80422-5; Starace DM, 2001, J GEN PHYSIOL, V117, P469, DOI 10.1085/jgp.117.5.469; Tapper AR, 2001, J BIOL CHEM, V276, P38249; Tiwari-Woodruff SK, 2000, J GEN PHYSIOL, V115, P123, DOI 10.1085/jgp.115.2.123; Wang MH, 1999, J PHYSIOL-LONDON, V521, P315, DOI 10.1111/j.1469-7793.1999.00315.x; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978; Yellen G, 1998, Q REV BIOPHYS, V31, P239, DOI 10.1017/S0033583598003448; Yifrach O, 2002, CELL, V111, P231, DOI 10.1016/S0092-8674(02)01013-9; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253; Zheng J, 1997, J GEN PHYSIOL, V110, P101, DOI 10.1085/jgp.110.2.101; Zhou YF, 2001, NATURE, V414, P43, DOI 10.1038/35102009	48	44	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	AUG 1	2003	278	31					29079	29085		10.1074/jbc.M301991200/6493	http://dx.doi.org/10.1074/jbc.M301991200/6493			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	705XC	12883074	Bronze			2022-12-27	WOS:000184421100091
J	Shcherbakova, PV; Pavlov, YI; Chilkova, O; Rogozin, IB; Johansson, E; Kunkel, TA				Shcherbakova, PV; Pavlov, YI; Chilkova, O; Rogozin, IB; Johansson, E; Kunkel, TA			Unique error signature of the four-subunit yeast DNA polymerase epsilon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; REPLICATION ERRORS; MUTATIONAL SPECTRA; ENZYMOLOGICAL CHARACTERIZATION; EXONUCLEASE ACTIVITY; ACCESSORY PROTEINS; BASE SUBSTITUTION; CONSERVED REGION; CHROMOSOMAL DNA	We have purified wild type and exonuclease-deficient four-subunit DNA polymerase epsilon (Pol epsilon) complex from Saccharomyces cerevisiae and analyzed the fidelity of DNA synthesis by the two enzymes. Wild type Pol epsilon synthesizes DNA accurately, generating single-base substitutions and deletions at average error rates of less than or equal to 2 x 10(-5) and less than or equal to 5 x 10(-7), respectively. Pol epsilon lacking 3' --> 5' exonuclease activity is less accurate to a degree suggesting that wild type Pol epsilon proofreads at least 92% of base substitution errors and at least 99% of frameshift errors made by the polymerase. Surprisingly the base substitution fidelity of exonuclease-deficient Pol epsilon is severalfold lower than that of proofreading-deficient forms of other replicative polymerases. Moreover the spectrum of errors shows a feature not seen with other A, B, C, or X family polymerases: a high proportion of transversions resulting from T . dTTP, T . dCTP, and C . dTTP mispairs. This unique error specificity and amino acid sequence alignments suggest that the structure of the polymerase active site of Pol epsilon differs from those of other B family members. We observed both similarities and differences between the spectrum of substitutions generated by proofreading-deficient Pol epsilon in vitro and substitutions occurring in vivo in a yeast strain defective in Pol epsilon proofreading and DNA mismatch repair. We discuss the implications of these findings for the role of Pol epsilon polymerase activity in DNA replication.	NIEHS, Lab Struct Biol, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; NIEHS, Genet Mol Lab, NIH, Dept Hlth & Human Serv, Res Triangle Pk, NC 27709 USA; Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden; Natl Lib Med, Natl Ctr Biotechnol Informat, NIH, Dept Hlth & Human Serv, Bethesda, MD 20894 USA; Russian Acad Sci, Inst Cytol & Genet, Novosibirsk 630090, Russia	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Umea University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Russian Academy of Sciences; Institute of Cytology & Genetics ICG SB RAS	Kunkel, TA (corresponding author), NIEHS, Lab Struct Biol, NIH, Dept Hlth & Human Serv, POB 12233, Res Triangle Pk, NC 27709 USA.		Kunkel, Thomas A./D-5088-2019; Pavlov, Youri/T-7532-2017	Kunkel, Thomas A./0000-0002-9900-1788; Johansson, Erik/0000-0002-8526-6224; Rogozin, Igor/0000-0003-0802-4851; Pavlov, Youri/0000-0003-1179-5796				ADAMS WT, 1987, J MOL BIOL, V194, P391, DOI 10.1016/0022-2836(87)90669-3; ARAKI H, 1991, NUCLEIC ACIDS RES, V19, P4867, DOI 10.1093/nar/19.18.4867; ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; ARAKI H, 1991, P NATL ACAD SCI USA, V88, P4601, DOI 10.1073/pnas.88.11.4601; Babenko VN, 1999, BIOFIZIKA+, V44, P632; Bebenek A, 2002, GENETICS, V162, P1003; Bebenek K, 1995, METHOD ENZYMOL, V262, P217; Bebenek K, 2003, J BIOL CHEM, V278, P34685, DOI 10.1074/jbc.M305705200; Bebenek K, 2000, COLD SPRING HARB SYM, V65, P81, DOI 10.1101/sqb.2000.65.81; BEBENEK K, 1990, J BIOL CHEM, V265, P13878; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUDD ME, 1993, MOL CELL BIOL, V13, P496, DOI 10.1128/MCB.13.1.496; BURGERS PMJ, 1991, J BIOL CHEM, V266, P22698; Burgers PMJ, 1998, CHROMOSOMA, V107, P218, DOI 10.1007/s004120050300; CARIELLO NF, 1994, CARCINOGENESIS, V15, P2281, DOI 10.1093/carcin/15.10.2281; Chilkova O, 2003, J BIOL CHEM, V278, P14082, DOI 10.1074/jbc.M211818200; COPELAND WC, 1993, J BIOL CHEM, V268, P11028; COPELAND WC, 1991, J BIOL CHEM, V266, P22739; DONG Q, 1993, J BIOL CHEM, V268, P24175; Dua R, 1998, J BIOL CHEM, V273, P30046, DOI 10.1074/jbc.273.45.30046; Dua R, 1999, J BIOL CHEM, V274, P22283, DOI 10.1074/jbc.274.32.22283; FISHER PA, 1979, J BIOL CHEM, V254, P6128; Franklin MC, 2001, CELL, V105, P657, DOI 10.1016/S0092-8674(01)00367-1; Fuss J, 2002, J BIOL CHEM, V277, P8658, DOI 10.1074/jbc.M110615200; Glazko GB, 1998, J THEOR BIOL, V192, P475, DOI 10.1006/jtbi.1998.0668; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Johansson E, 2001, J BIOL CHEM, V276, P43824, DOI 10.1074/jbc.M108842200; Kadyrov FA, 2002, NUCLEIC ACIDS RES, V30, P4387, DOI 10.1093/nar/gkf576; Karthikeyan R, 2000, J MOL BIOL, V299, P405, DOI 10.1006/jmbi.2000.3744; Kesti T, 1999, MOL CELL, V3, P679, DOI 10.1016/S1097-2765(00)80361-5; Khromov-Borisov NN, 1999, MUTAT RES-FUND MOL M, V430, P55, DOI 10.1016/S0027-5107(99)00148-7; Kool ET, 1998, BIOPOLYMERS, V48, P3, DOI 10.1002/(SICI)1097-0282(1998)48:1<3::AID-BIP2>3.0.CO;2-7; Kroutil LC, 1998, J MOL BIOL, V278, P135, DOI 10.1006/jmbi.1998.1676; KUNKEL TA, 1989, MOL CELL BIOL, V9, P4447, DOI 10.1128/MCB.9.10.4447; KUNKEL TA, 1988, J BIOL CHEM, V263, P14784; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; KUNKEL TA, 1994, P NATL ACAD SCI USA, V91, P6830, DOI 10.1073/pnas.91.15.6830; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200; Maki S, 1998, J BIOL CHEM, V273, P21332, DOI 10.1074/jbc.273.33.21332; Matsuda T, 2000, NATURE, V404, P1011, DOI 10.1038/35010014; McGuffin LJ, 2000, BIOINFORMATICS, V16, P404, DOI 10.1093/bioinformatics/16.4.404; MORRISON A, 1994, MOL GEN GENET, V242, P289, DOI 10.1007/BF00280418; MORRISON A, 1993, EMBO J, V12, P1467, DOI 10.1002/j.1460-2075.1993.tb05790.x; MORRISON A, 1991, P NATL ACAD SCI USA, V88, P9473, DOI 10.1073/pnas.88.21.9473; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NAVAS TA, 1995, CELL, V80, P29, DOI 10.1016/0092-8674(95)90448-4; Ohashi E, 2000, J BIOL CHEM, V275, P39678, DOI 10.1074/jbc.M005309200; Ohya T, 2002, J BIOL CHEM, V277, P28099, DOI 10.1074/jbc.M111573200; Pavlov YI, 2001, GENETICS, V159, P47; Pavlov YI, 2003, CURR BIOL, V13, P744, DOI 10.1016/S0960-9822(03)00284-7; Pavlov YI, 2002, MOL CELL, V10, P207, DOI 10.1016/S1097-2765(02)00567-1; Pham PT, 1998, J BIOL CHEM, V273, P23575, DOI 10.1074/jbc.273.36.23575; PIEGORSCH WW, 1994, GENETICS, V136, P403; Poloumienko A, 2001, MOL BIOL CELL, V12, P3317, DOI 10.1091/mbc.12.11.3317; Roberts J.D., 1996, DNA REPLICATION EUKA, P217; Rogozin IB, 2001, NAT IMMUNOL, V2, P530, DOI 10.1038/88732; Rogozin IB, 2001, HUM MUTAT, V17, P83, DOI 10.1002/1098-1004(200102)17:2<83::AID-HUMU1>3.0.CO;2-E; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; Shcherbakova PV, 1996, MUTAT RES-GENET TOX, V369, P33, DOI 10.1016/S0165-1218(96)90045-2; Shcherbakova PV, 1996, GENETICS, V142, P717; Shcherbakova PV, 1999, MOL CELL BIOL, V19, P3177; SHCHERBAKOVA PV, 2003, SCI SAGE KE; Shimizu K, 2002, J BIOL CHEM, V277, P37422, DOI 10.1074/jbc.M204476200; SIMON M, 1991, EMBO J, V10, P2165, DOI 10.1002/j.1460-2075.1991.tb07751.x; SUGINO A, 1995, TRENDS BIOCHEM SCI, V20, P319, DOI 10.1016/S0968-0004(00)89059-3; THOMAS DC, 1991, BIOCHEMISTRY-US, V30, P11751, DOI 10.1021/bi00115a003; Tran HT, 1999, MOL CELL BIOL, V19, P2000; Viguera E, 2001, EMBO J, V20, P2587, DOI 10.1093/emboj/20.10.2587; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	73	99	99	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43770	43780		10.1074/jbc.M306893200	http://dx.doi.org/10.1074/jbc.M306893200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12882968	hybrid			2022-12-27	WOS:000186157000127
J	Duringer, C; Hamiche, A; Gustafsson, L; Kimura, H; Svanborg, C				Duringer, C; Hamiche, A; Gustafsson, L; Kimura, H; Svanborg, C			HAMLET interacts with histones and chromatin in tumor cell nuclei	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGHER-ORDER STRUCTURE; ALPHA-LACTALBUMIN; CORE HISTONES; APOPTOSIS; PROTEIN; PARTICLE; FEATURES; KINETICS; H2B	HAMLET is a folding variant of human alpha-lactalbumin in an active complex with oleic acid. HAMLET selectively enters tumor cells, accumulates in their nuclei and induces apoptosis-like cell death. This study examined the interactions of HAMLET with nuclear constituents and identified histones as targets. HAMLET was found to bind histone H3 strongly and to lesser extent histones H4 and H2B. The specificity of these interactions was confirmed using BIAcore technology and chromatin assembly assays. In vivo in tumor cells, HAMLET co-localized with histones and perturbed the chromatin structure; HAMLET was found associated with chromatin in an insoluble nuclear fraction resistant to salt extraction. In vitro, HAMLET bound strongly to histones and impaired their deposition on DNA. We conclude that HAMLET interacts with histones and chromatin in tumor cell nuclei and propose that this interaction locks the cells into the death pathway by irreversibly disrupting chromatin organization.	Lund Univ, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, S-22362 Lund, Sweden; Inst Andre Lwoff, CNRS, UPR 9079, Equipe Fonct & Dynam Chromatine, F-94800 Villejuif, France; Tokyo Med & Dent Univ, Inst Med Res, Dept Funct Genom, Bunkyo Ku, Tokyo 1138510, Japan	Lund University; Centre National de la Recherche Scientifique (CNRS); Tokyo Medical & Dental University (TMDU)	Svanborg, C (corresponding author), Lund Univ, Inst Lab Med, Sect Microbiol Immunol & Glycobiol, Solvegatan 23, S-22362 Lund, Sweden.		Kimura, Hiroshi/B-9524-2015	Kimura, Hiroshi/0000-0003-0854-083X; Gustafsson, Lotta/0000-0002-9826-9133				AUSUBEL FH, 1993, CURRENT PROTOCOLS MO, V2, P12; BATES DL, 1981, EUR J BIOCHEM, V119, P469, DOI 10.1111/j.1432-1033.1981.tb05631.x; HAKANSSON A, 1995, P NATL ACAD SCI USA, V92, P8064, DOI 10.1073/pnas.92.17.8064; Hakansson A, 1999, EXP CELL RES, V246, P451, DOI 10.1006/excr.1998.4265; Hamiche A, 1998, J BIOL CHEM, V273, P9261, DOI 10.1074/jbc.273.15.9261; Hamiche A, 2001, P NATL ACAD SCI USA, V98, P14316, DOI 10.1073/pnas.251421398; ISHIMI Y, 1987, EUR J BIOCHEM, V162, P19, DOI 10.1111/j.1432-1033.1987.tb10535.x; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kimura H, 2001, J CELL BIOL, V153, P1341, DOI 10.1083/jcb.153.7.1341; Lorenzo P, 2001, J BIOL CHEM, V276, P12201, DOI 10.1074/jbc.M010932200; SIMON RH, 1979, NUCLEIC ACIDS RES, V6, P689, DOI 10.1093/nar/6.2.689; SIMPSON RT, 1985, CELL, V42, P799, DOI 10.1016/0092-8674(85)90276-4; SIMPSON RT, 1983, P NATL ACAD SCI-BIOL, V80, P51, DOI 10.1073/pnas.80.1.51; Svensson M, 2000, P NATL ACAD SCI USA, V97, P4221, DOI 10.1073/pnas.97.8.4221; Svensson M, 1999, J BIOL CHEM, V274, P6388, DOI 10.1074/jbc.274.10.6388; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2; Yamaki M, 2001, GENES CELLS, V6, P1043, DOI 10.1046/j.1365-2443.2001.00487.x	19	98	103	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 24	2003	278	43					42131	42135		10.1074/jbc.M306462200	http://dx.doi.org/10.1074/jbc.M306462200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	733FP	12888554	hybrid			2022-12-27	WOS:000185989500071
J	Kaplan-Albuquerque, N; Garat, C; Desseva, C; Jones, PL; Nemenoff, RA				Kaplan-Albuquerque, N; Garat, C; Desseva, C; Jones, PL; Nemenoff, RA			Platelet-derived growth factor-BB-mediated activation of akt suppresses smooth muscle-specific gene expression through inhibition of mitogen-activated protein kinase and redistribution of serum response factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-ACTIN EXPRESSION; SIGNAL-TRANSDUCTION PATHWAYS; PHOSPHOINOSITIDE 3-KINASE; NUCLEAR-LOCALIZATION; ARGININE-VASOPRESSIN; C-JUN; PHOSPHATIDYLINOSITOL 3-KINASE; TRANSCRIPTION FACTOR; TYROSINE KINASES; ANGIOTENSIN-II	Platelet-derived growth factor (PDGF) inhibits expression of smooth muscle (SM) genes in vascular smooth muscle cells and blocks induction by arginine vasopressin (AVP). We have previously demonstrated that suppression of SM-alpha-actin by PDGF-BB is mediated in part through a Ras-dependent pathway. This study examined the role of phosphatidylinositol 3-kinase (PI3K)y and its downstream effector, Akt, in regulating SM gene expression. PDGF caused a rapid sustained activation of Akt, whereas AVP caused only a small transient increase. PDGF selectively caused a sustained stimulation of p85/p110alpha PI3K. In contrast, p85/110beta PI3K activity was not altered by either PDGF or AVP, whereas both agents caused a delayed activation of Class IB p101/110gamma PI3K. Expression of a gain-of-function PI3K or myristoylated Akt (myr-Akt) mimicked the inhibitory effect of PDGF on SM-alpha-actin and SM22alpha expression. Pretreatment with LY 294002 reversed the inhibitory effect of PDGF. Expression of myr-Akt selectively inhibited AVP-induced activation of c-Jun N-terminal kinase and p38 mitogen-activated protein kinases, which we have shown are critical for induction of these genes. Nuclear extracts from PDGF-stimulated or myr-Akt expressing cells showed reduced serum response factor binding to SM-specific CArG elements. This was associated with appearance of serum response factor in the cytoplasm. These data indicate that activation of p85/p110alpha/Akt mediates suppression of SM gene expression by PDGF.	Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Pharmacol, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Nemenoff, RA (corresponding author), Univ Colorado, Hlth Sci Ctr, Div Renal Dis & Hypertens, Dept Med, Box C-281,4200 E 9th Ave, Denver, CO 80262 USA.			Jones, Peter Lloyd/0000-0003-1445-4081	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL062824] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039902, P01DK019928] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL62824] Funding Source: Medline; NIDDK NIH HHS [DK19928, DK39902] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahmed NN, 1997, P NATL ACAD SCI USA, V94, P3627, DOI 10.1073/pnas.94.8.3627; Arai A, 2002, J BIOL CHEM, V277, P24453, DOI 10.1074/jbc.M202216200; Bornfeldt KE, 1995, ANN NY ACAD SCI, V766, P416, DOI 10.1111/j.1749-6632.1995.tb26691.x; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Camoretti-Mercado B, 2000, J BIOL CHEM, V275, P30387, DOI 10.1074/jbc.M000840200; CARAMELO C, 1988, BIOCHEM J, V254, P625, DOI 10.1042/bj2540625; CHAMLEYCAMPBELL JH, 1981, ATHEROSCLEROSIS, V40, P347, DOI 10.1016/0021-9150(81)90145-3; Chou MM, 1998, CURR BIOL, V8, P1069, DOI 10.1016/S0960-9822(98)70444-0; Copeland JW, 2002, MOL BIOL CELL, V13, P4088, DOI 10.1091/mbc.02-06-0092; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FATIGATI V, 1984, J BIOL CHEM, V259, P4383; Firulli AB, 1998, IN VITRO CELL DEV-AN, V34, P217; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; Fu YP, 2000, J APPL PHYSIOL, V89, P1985, DOI 10.1152/jappl.2000.89.5.1985; Garat C, 2000, J BIOL CHEM, V275, P22537, DOI 10.1074/jbc.M003000200; GAUTHIERROUVIERE C, 1995, MOL CELL BIOL, V15, P433, DOI 10.1128/MCB.15.1.433; Go YM, 2001, J APPL PHYSIOL, V91, P1574, DOI 10.1152/jappl.2001.91.4.1574; Heidenreich O, 1999, J BIOL CHEM, V274, P14434, DOI 10.1074/jbc.274.20.14434; Ivanov VN, 2002, J BIOL CHEM, V277, P4932, DOI 10.1074/jbc.M108233200; Jung F, 2000, CARDIOVASC RES, V48, P148, DOI 10.1016/S0008-6363(00)00152-8; KAZLAUSKAS A, 1994, CURR OPIN GENET DEV, V4, P5, DOI 10.1016/0959-437X(94)90085-X; KEMP PR, 1995, BIOCHEM J, V310, P1037, DOI 10.1042/bj3101037; KOCHER O, 1991, LAB INVEST, V65, P459; KOCHER O, 1986, DIFFERENTIATION, V32, P245, DOI 10.1111/j.1432-0436.1986.tb00580.x; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; Kumar MS, 2003, ARTERIOSCL THROM VAS, V23, P737, DOI 10.1161/01.ATV.0000065197.07635.BA; LANDAU NR, 1992, J VIROL, V66, P5110, DOI 10.1128/JVI.66.8.5110-5113.1992; Leopoldt D, 1998, J BIOL CHEM, V273, P7024, DOI 10.1074/jbc.273.12.7024; Levresse V, 2000, J NEUROSCI RES, V62, P799; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; LI XM, 1994, J BIOL CHEM, V269, P19653; Li XM, 1997, BIOCHEM J, V327, P709, DOI 10.1042/bj3270709; Liu HW, 2003, AM J RESP CELL MOL, V29, P39, DOI 10.1165/rcmb.2002-0206OC; Mack CP, 2000, CIRC RES, V86, P221, DOI 10.1161/01.RES.86.2.221; Mack CP, 1999, CIRC RES, V84, P852; Macrez N, 2001, CIRC RES, V89, P692, DOI 10.1161/hh2001.097864; Northcott CA, 2002, CIRC RES, V91, P360, DOI 10.1161/01.RES.0000030861.13850.F1; OWENS GK, 1995, PHYSIOL REV, V75, P487; Park HS, 2002, J BIOL CHEM, V277, P2573, DOI 10.1074/jbc.M110299200; Psichari E, 2002, J BIOL CHEM, V277, P29490, DOI 10.1074/jbc.M112368200; RECH J, 1994, J CELL SCI, V107, P3029; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Reusch HP, 2001, J BIOL CHEM, V276, P19540, DOI 10.1074/jbc.M101963200; Reusch HP, 2001, J BIOL CHEM, V276, P33630, DOI 10.1074/jbc.M105322200; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Sata M, 2002, CIRC RES, V91, P273, DOI 10.1161/01.RES.0000031956.29928.62; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Stokoe D, 1997, SCIENCE, V277, P567, DOI 10.1126/science.277.5325.567; Tock J, 2003, BIOCHEM BIOPH RES CO, V301, P1116, DOI 10.1016/S0006-291X(03)00087-1; TURLA MB, 1991, CIRC RES, V68, P288, DOI 10.1161/01.RES.68.1.288; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; Vanhaesebroeck B, 1999, EXP CELL RES, V253, P239, DOI 10.1006/excr.1999.4701; VANPUTTEN V, 1994, CIRC RES, V75, P1126, DOI 10.1161/01.RES.75.6.1126	53	49	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39830	39838		10.1074/jbc.M305991200	http://dx.doi.org/10.1074/jbc.M305991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882977	hybrid			2022-12-27	WOS:000185713800069
J	D'Angelo, G; Duplan, E; Boyer, N; Vigne, P; Frelin, C				D'Angelo, G; Duplan, E; Boyer, N; Vigne, P; Frelin, C			Hypoxia up-regulates prolyl hydroxylase activity - A feedback mechansim that limits HIF-1 responses during reoxygenation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; INDUCIBLE FACTOR; TRANSCRIPTIONAL ACTIVITY; PROLINE HYDROXYLATION; FACTOR 1-ALPHA; FACTOR-1-ALPHA; ALPHA; DEGRADATION; HIF-1-ALPHA; DESTRUCTION	The mechanism by which hypoxia induces gene transcription is now well established. Hypoxia reduces activity of prolyl hydroxylases (PHD) that hydroxylate specific proline residues in the oxygen-dependent degradation domain (ODD) of hypoxia-inducible factor-1alpha (HIF-1alpha). As a consequence, HIF-1alpha accumulates and promotes hypoxic tolerance by activating gene transcription. This paper identifies the three forms of PHDs in rats and shows that a period of hypoxia selectively increases expression of PHD-2 mRNAs levels. We developed assays for PHD activity that used (i) the peptide-specific conversion of labeled 2-oxoglutarate into succinate and (ii) the binding of the von Hippel-Lindau protein to a glutathione S-transferase-ODD fusion protein. The two assays indicated a low enzymatic activity in normoxic and hypoxic cells and a rapid increase during reoxygenation. We also developed hydroxyproline-specific antibodies that recognized hydroxylated forms of a fusion protein (ODD-green fluorescent protein) that combined the ODD domain of HIF-1alpha and the green fluorescent protein. Using this antibody, we demonstrated that reoxygenation induced a rapid hydroxylation of Pro-564, which was followed by a massive degradation of the proteins. The results suggest that a hypoxic up-regulation of PHD (presumably PHD-2) acts as a feedback mechanism to stop hypoxic responses in reoxygenated cells. We propose that proline hydroxylation might play a role in hypoxic preconditioning.	Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, F-06560 Valbonne, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	D'Angelo, G (corresponding author), Inst Pharmacol Mol & Cellulaire, CNRS, UMR 6097, 660 Route Lucioles, F-06560 Valbonne, France.		Duplan, Eric/AAK-8224-2020	Duplan, Eric/0000-0002-1348-1507; D'ANGELO, Gisela/0000-0003-3150-2241				BAADER E, 1994, BIOCHEM J, V300, P525, DOI 10.1042/bj3000525; Baxter GF, 2002, CARDIOVASC RES, V55, P483, DOI 10.1016/S0008-6363(02)00280-8; Berra E, 2001, FEBS LETT, V491, P85, DOI 10.1016/S0014-5793(01)02159-7; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; D'Angelo G, 2003, J BIOL CHEM, V278, P15406, DOI 10.1074/jbc.M211293200; Epstein ACR, 2001, CELL, V107, P43, DOI 10.1016/S0092-8674(01)00507-4; Hewitson KS, 2002, J BIOL CHEM, V277, P26351, DOI 10.1074/jbc.C200273200; Huang JH, 2002, J BIOL CHEM, V277, P39792, DOI 10.1074/jbc.M206955200; Huang LE, 1998, P NATL ACAD SCI USA, V95, P7987, DOI 10.1073/pnas.95.14.7987; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jeong JW, 2002, CELL, V111, P709, DOI 10.1016/S0092-8674(02)01085-1; Kallio PJ, 1999, J BIOL CHEM, V274, P6519, DOI 10.1074/jbc.274.10.6519; Kuznetsova AV, 2003, P NATL ACAD SCI USA, V100, P2706, DOI 10.1073/pnas.0436037100; Lando D, 2002, GENE DEV, V16, P1466, DOI 10.1101/gad.991402; Masson N, 2001, EMBO J, V20, P5197, DOI 10.1093/emboj/20.18.5197; O'Rourke B, 2000, CIRC RES, V87, P845, DOI 10.1161/01.RES.87.10.845; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304	20	233	239	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38183	38187		10.1074/jbc.M302244200	http://dx.doi.org/10.1074/jbc.M302244200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12876291	Green Published, hybrid			2022-12-27	WOS:000185575100013
J	De Fabiani, E; Mitro, N; Gilardi, F; Caruso, D; Galli, G; Crestani, M				De Fabiani, E; Mitro, N; Gilardi, F; Caruso, D; Galli, G; Crestani, M			Coordinated control of cholesterol catabolism to bile acids and of gluconeogenesis via a novel mechanism of transcription regulation linked to the fasted-to-fed cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEGATIVE FEEDBACK-REGULATION; HEPATOCYTE NUCLEAR FACTOR-4; HEPATIC GLUCONEOGENESIS; HORMONAL-REGULATION; COACTIVATOR PGC-1; RECEPTOR FXR; DNA-BINDING; GENE CYP7A; IDENTIFICATION; BIOSYNTHESIS	Bile acid metabolism plays an essential role in cholesterol homeostasis and is critical for the initiation of atherosclerotic disease. However, despite the recent advances, the molecular mechanisms whereby bile acids regulate gene transcription and cholesterol homeostasis in mammals still need further investigations. Here, we show that bile acids suppress transcription of the gene (CYP7A1) encoding cholesterol 7alpha-hydroxylase, the rate-limiting enzyme in bile acid biosynthesis, also through an unusual mechanism not involving the bile acid nuclear receptor, farnesoid X receptor. By performing cell-based reporter assays, protein/protein interaction, and chromatin immunoprecipitation assays, we demonstrate that bile acids impair the recruitment of peroxisome proliferator-activated receptor-gamma coactivator-1alpha and cAMP response element-binding protein-binding protein by hepatocyte nuclear factor-4alpha, a master regulator of CYP7A1. We also show for the first time that bile acids inhibit transcription of the gene ( PEPCK) encoding phosphoenolpyruvate carboxykinase, the rate-limiting enzyme in gluconeogenesis, through the same farnesoid X receptor-independent mechanism. Chromatin immunoprecipitation assay revealed that bile acid-induced dissociation of coactivators from hepatocyte nuclear factor-4alpha decreased the recruitment of RNA polymerase II to the core promoter and downstream in the 3'-untranslated regions of these two genes, reflecting the reduction of gene transcription. Finally, we found that Cyp7a1 expression was stimulated in fasted mice in parallel to Pepck, whereas the same genes were repressed by bile acids. Collectively, these results reveal a novel regulatory mechanism that controls gene transcription in response to extracellular stimuli and argue that the transcription regulation by bile acids of genes central to cholesterol and glucose metabolism should be viewed dynamically in the context of the fasted-to-fed cycle.	Univ Milan, Fac Farm, Dipartimento Sci Farmacol, I-20133 Milan, Italy	University of Milan	Crestani, M (corresponding author), Univ Milan, Fac Farm, Dipartimento Sci Farmacol, Via Balzaretti 9, I-20133 Milan, Italy.		De Fabiani, Emma/B-6936-2015; caruso, donatella/A-3332-2014	De Fabiani, Emma/0000-0003-2406-1468; caruso, donatella/0000-0003-2115-778X; Crestani, Maurizio/0000-0001-9230-1078; Mitro, Nico/0000-0002-5000-3619; Gilardi, Federica/0000-0001-5421-2779				Borgius LJ, 2002, J BIOL CHEM, V277, P49761, DOI 10.1074/jbc.M205641200; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Chiang JYL, 2000, J BIOL CHEM, V275, P10918, DOI 10.1074/jbc.275.15.10918; CONSOLI A, 1990, ANN MED, V22, P191, DOI 10.3109/07853899009147268; CRESTANI M, 1995, J LIPID RES, V36, P2419; Crestani M, 1998, J LIPID RES, V39, P2192; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; Dell H, 1999, J BIOL CHEM, V274, P9013, DOI 10.1074/jbc.274.13.9013; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Guo HT, 2002, J BIOL CHEM, V277, P5054, DOI 10.1074/jbc.M109017200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; HYLEMON PB, 1992, J BIOL CHEM, V267, P16866; JAVITT NB, 1994, FASEB J, V8, P1308, DOI 10.1096/fasebj.8.15.8001744; Kerr TA, 2002, DEV CELL, V2, P713, DOI 10.1016/S1534-5807(02)00154-5; Knutti D, 2001, TRENDS ENDOCRIN MET, V12, P360, DOI 10.1016/S1043-2760(01)00457-X; KTISTAKI E, 1995, P NATL ACAD SCI USA, V92, P9876, DOI 10.1073/pnas.92.21.9876; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Maloney PR, 2000, J MED CHEM, V43, P2971, DOI 10.1021/jm0002127; OBRIEN RM, 1990, SCIENCE, V249, P533, DOI 10.1126/science.2166335; Parks DJ, 1999, SCIENCE, V284, P1365, DOI 10.1126/science.284.5418.1365; Puigserver P, 1999, SCIENCE, V286, P1368, DOI 10.1126/science.286.5443.1368; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Pullingr CR, 2002, J CLIN INVEST, V110, P109, DOI 10.1172/JCI200215387; Rosenfeld MG, 2001, J BIOL CHEM, V276, P36865, DOI 10.1074/jbc.R100041200; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sinal CJ, 2000, CELL, V102, P731, DOI 10.1016/S0092-8674(00)00062-3; Soutoglou E, 2000, MOL CELL, V5, P745, DOI 10.1016/S1097-2765(00)80253-1; Spady DK, 1998, J BIOL CHEM, V273, P126, DOI 10.1074/jbc.273.1.126; Stroup D, 1997, AM J PHYSIOL-GASTR L, V273, pG508, DOI 10.1152/ajpgi.1997.273.2.G508; Viollet B, 1997, MOL CELL BIOL, V17, P4208, DOI 10.1128/MCB.17.8.4208; Wang DP, 1996, J LIPID RES, V37, P1831; Wang HB, 1999, MOL CELL, V3, P543, DOI 10.1016/S1097-2765(00)80348-2; Wang L, 2002, DEV CELL, V2, P721, DOI 10.1016/S1534-5807(02)00187-9; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Yoshida E, 1997, BIOCHEM BIOPH RES CO, V241, P664, DOI 10.1006/bbrc.1997.7871	38	159	161	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39124	39132		10.1074/jbc.M305079200	http://dx.doi.org/10.1074/jbc.M305079200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12865425	hybrid			2022-12-27	WOS:000185575100126
J	Demasi, M; Cleland, LG; Cook-Johnson, RJ; Caughey, GE; James, MJ				Demasi, M; Cleland, LG; Cook-Johnson, RJ; Caughey, GE; James, MJ			RETRACTED: Effects of hypoxia on monocyte inflammatory mediator production - Dissociation between changes in cyclooxygenase-2 expression and eicosanoid synthesis (Publication with Expression of Concern. See vol. 292, pg. 15993, 2017) (Retracted article. See vol. 293, pg. 20013, 2018)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Retracted Publication							CYTOSOLIC PHOSPHOLIPASE A(2); ACTIVATED PROTEIN-KINASE; ARTERIAL-WALL; TRANSCRIPTIONAL ACTIVATION; PROSTAGLANDIN E-2; THROMBOXANE A(2); ARACHIDONIC-ACID; OXYGEN-TENSIONS; MESSENGER-RNA; RELEASE	Blood-derived monocytes are found at sites of inflammation as well as in solid tumors and atherosclerotic arteries. They are an abundant source of inflammatory eicosanoids such as prostaglandin E-2 (PGE(2)) and thromboxane A(2), which are formed via arachidonic acid (AA) metabolism by cyclooxygenase-1/2 (COX-1/2). In vitro studies of inflammatory mediator production are conducted invariably in room air, which does not reflect the oxygen tensions found in monocyte-containing lesions, which are frequently hypoxic. In this work we examined the effects of hypoxia at levels reported in these lesions, on monocyte COX-2 expression, the related events that lead to eicosanoid synthesis, and relationships with tumor necrosis factor (TNF)-alpha synthesis. In fresh human monocytes exposed to hypoxia (1% O-2), there was an increase in COX-2 protein compared with cells in normoxia, and this was attributable to increased transcription and mRNA stability. However, the synthesis of PGE(2) and thromboxane A(2) was reduced in hypoxia and did not reflect the increased level of COX-2. Monocytes prelabeled with [H-3] AA followed by lipopolysaccharide stimulation in the presence of hypoxia showed a reduced release of AA compared with cells in normoxia. In addition, hypoxia resulted in decreased phosphorylation of the p44/42 mitogen-activated protein kinase and of cytosolic phospholipase A(2). Hypoxia also increased TNF-alpha synthesis, which appeared to play a role in COX-2 expression, and the observed increase TNF-alpha synthesis appeared to result from reduced PGE(2) synthesis. Overall, the results suggest the existence of an autocrine loop of regulation between monocyte eicosanoid and TNF-alpha production, which is dysregulated in hypoxia and establishes hypoxia as being an important environmental determinant of inflammatory mediator production.	Royal Adelaide Hosp, Rheumatol Unit, Adelaide, SA 5000, Australia	Royal Adelaide Hospital	Demasi, M (corresponding author), Royal Adelaide Hosp, Rheumatol Unit, Level 4,Eleanor Harrald Bldg,N Terrace, Adelaide, SA 5000, Australia.	maryanne.demasi@student.adelaide.edu.au	Demasi, Marilene/E-5873-2012; Caughey, Gillian E/A-3041-2011	Caughey, Gillian/0000-0003-1192-4121				AKASHI M, 1994, BLOOD, V83, P3182; Barrios-Rodiles M, 1999, J IMMUNOL, V163, P963; Bjornheden T, 1999, ARTERIOSCL THROM VAS, V19, P870, DOI 10.1161/01.ATV.19.4.870; Bonazzi A, 2000, J BIOL CHEM, V275, P2837, DOI 10.1074/jbc.275.4.2837; BOXEN I, 1985, MED HYPOTHESES, V18, P297, DOI 10.1016/0306-9877(85)90031-3; Caughey GE, 1997, J IMMUNOL, V158, P351; Chandel NS, 2000, J IMMUNOL, V165, P1013, DOI 10.4049/jimmunol.165.2.1013; Cok SJ, 2001, J BIOL CHEM, V276, P23179, DOI 10.1074/jbc.M008461200; CRAWFORD DW, 1988, EXP MOL PATHOL, V49, P215, DOI 10.1016/0014-4800(88)90035-4; CRAWFORD DW, 1991, ATHEROSCLEROSIS, V89, P97, DOI 10.1016/0021-9150(91)90049-9; Dubois RN, 1998, FASEB J, V12, P1063, DOI 10.1096/fasebj.12.12.1063; FALCHUK KH, 1970, AM J MED, V49, P223, DOI 10.1016/S0002-9343(70)80078-X; FOUDA SI, 1995, BIOCHEM J, V308, P815, DOI 10.1042/bj3080815; Gijon MA, 2000, J BIOL CHEM, V275, P20146, DOI 10.1074/jbc.M908941199; Haider A, 2002, J PHARMACOL EXP THER, V300, P188, DOI 10.1124/jpet.300.1.188; Hazan I, 1997, BIOCHEM J, V326, P867, DOI 10.1042/bj3260867; Hiller G, 1999, CELL SIGNAL, V11, P863, DOI 10.1016/S0898-6568(99)00058-3; Hockel M, 1996, CANCER RES, V56, P4509; JAMES MJ, 1988, PROSTAG LEUKOTR ESS, V31, P91, DOI 10.1016/0952-3278(88)90081-6; JAMES MJ, 1990, J RHEUMATOL, V17, P521; JURRUS ER, 1977, ATHEROSCLEROSIS, V28, P223, DOI 10.1016/0021-9150(77)90172-1; Knocke TH, 1999, RADIOTHER ONCOL, V53, P99, DOI 10.1016/S0167-8140(99)00139-5; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; Lartigau E, 1997, MELANOMA RES, V7, P400, DOI 10.1097/00008390-199710000-00006; Lee PJ, 1997, J BIOL CHEM, V272, P5375, DOI 10.1074/jbc.272.9.5375; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; LUNDOLESEN K, 1970, ARTHRITIS RHEUM-US, V13, P769, DOI 10.1002/art.1780130606; MEADE EA, 1993, J BIOL CHEM, V268, P6610; Miura K, 1999, J IMMUNOL, V162, P4198; Movsas B, 1999, UROLOGY, V53, P11, DOI 10.1016/S0090-4295(98)00500-7; NIINIKOS.J, 1973, ATHEROSCLEROSIS, V17, P353, DOI 10.1016/0021-9150(73)90026-9; Nogawa S, 1997, J NEUROSCI, V17, P2746; PEDRINACI S, 1990, INT J CANCER, V45, P294, DOI 10.1002/ijc.2910450215; Penglis PS, 2000, J IMMUNOL, V165, P1605, DOI 10.4049/jimmunol.165.3.1605; Pouliot M, 1997, J IMMUNOL, V158, P4930; Rofstad EK, 1999, INT J RADIAT BIOL, V75, P1377; RUNKEL S, 1994, ADV EXP MED BIOL, V345, P451; Schmedtje JF, 1997, J BIOL CHEM, V272, P601; SHIMA DT, 1995, FEBS LETT, V370, P203, DOI 10.1016/0014-5793(95)00831-S; Simanonok JP, 1996, MED HYPOTHESES, V46, P155, DOI 10.1016/S0306-9877(96)90017-1; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Syrbu SI, 1999, J IMMUNOL, V162, P2334; TREUHAFT PS, 1971, ARTHRITIS RHEUM, V14, P475, DOI 10.1002/art.1780140407; Turini ME, 2002, ANNU REV MED, V53, P35, DOI 10.1146/annurev.med.53.082901.103952; VAUPEL P, 1991, CANCER RES, V51, P3316; Wadleigh DJ, 2000, J BIOL CHEM, V275, P6259, DOI 10.1074/jbc.275.9.6259; ZEMPLENYI T, 1989, ATHEROSCLEROSIS, V76, P173, DOI 10.1016/0021-9150(89)90101-9; Zhang Y, 1997, J PHARMACOL EXP THER, V283, P1069	48	41	45	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38607	38616		10.1074/jbc.M305944200	http://dx.doi.org/10.1074/jbc.M305944200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12874281	hybrid			2022-12-27	WOS:000185575100065
J	Duan, RD; Bergman, T; Xu, N; Wu, J; Cheng, Y; Duan, JX; Nelander, S; Palmberg, C; Nilsson, A				Duan, RD; Bergman, T; Xu, N; Wu, J; Cheng, Y; Duan, JX; Nelander, S; Palmberg, C; Nilsson, A			Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL ABSORPTION; ACID SPHINGOMYELINASE; LYSOPHOSPHOLIPASE-D; BILE-SALTS; AUTOTAXIN; EXPRESSION; PURIFICATION; HYDROLYSIS; PHOSPHATIDYLCHOLINE; SUPPRESSION	Alkaline sphingomyelinase (alk-SMase) hydrolyzes dietary sphingomyelin and generates sphingolipid messengers in the gut. In the present study, we purified the enzyme, identified a part of the amino acid sequence, and found a cDNA in the GenBank(TM) coding for the protein. The cDNA contains 1841 bp, and the open reading frame encodes 458 amino acids. Transient expression of the cDNA linked to a Myc tag in COS-7 cells increased alk-SMase activity in the cell extract by 689-fold and in the medium by 27-fold. High activity was also identified in the anti-Myc immunoprecipitated proteins and the proteins cross-reacted with anti-human alk-SMase. Northern blotting of human intestinal tissues found high levels of alk-SMase mRNA in the intestine and liver. The amino acid sequence shared no similarity with acid and neutral SMases but was related to the ecto-nucleotide phosphodiesterase (NPP) family with 30 - 36% identity to human NPPs. Alk-SMase has a predicted signal peptide domain at the N terminus and a signal anchor domain at the C terminus. The ion-binding sites and the catalytic residue of NPPs were conserved, but the substrate specificity domain was modified. Alk-SMase had no detectable nucleotidase activity, but its activity against sphingomyelin could be inhibited by orthovanadate, imidazole, and ATP. In contrast to NPPs, alk-SMase activity was not stimulated by divalent metal ions but inhibited by Zn2+. Differing from NPP2, the alk-SMase cleaved phosphocholine but not choline from lysophosphatidylcholine. Phylogenetic tree indicated that the enzyme is a new branch derived from the NPP family. Two cDNA sequences of mouse and rat that shared 83% identity to human alk-SMase were identified in the GenBank(TM). In conclusion, we identified the amino acid and cDNA sequences of human intestinal alk-SMase, and found that it is a novel ectoenzyme related to the NPP family with specific features essential for its SMase activity.	Lund Univ, Gastroenterol Lab, Ctr Biomed, S-22184 Lund, Sweden; Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden; Univ Lund Hosp, Dept Clin Chem, S-22185 Lund, Sweden; Karolinska Inst, Novum, Dept Biosci, Struct Biochem Ctr, S-14157 Huddinge, Sweden; Univ Gothenburg, Dept Biochem Med, S-40530 Gothenburg, Sweden	Lund University; Karolinska Institutet; Lund University; Skane University Hospital; Karolinska Institutet; University of Gothenburg	Duan, RD (corresponding author), Lund Univ, Gastroenterol Lab, Ctr Biomed, B11, S-22184 Lund, Sweden.	Rui-dong.duan@med.lu.se	duan, rui/AAK-8037-2020	Nelander, Sven/0000-0003-1758-1262; Wu, Jun/0000-0002-5288-8473				Andrieu-Abadie N, 2002, BBA-MOL CELL BIOL L, V1585, P126, DOI 10.1016/S1388-1981(02)00332-3; Benson DA, 2002, NUCLEIC ACIDS RES, V30, P17, DOI 10.1093/nar/30.1.17; Bergman AC, 2000, PROTEOME AND PROTEIN ANALYSIS, P81; BLANK ML, 1992, J NUTR, V122, P1656, DOI 10.1093/jn/122.8.1656; Chatterjee S, 1999, J BIOL CHEM, V274, P37407, DOI 10.1074/jbc.274.52.37407; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; Cheng YJ, 2002, J LIPID RES, V43, P316; Clair T, 1997, J BIOL CHEM, V272, P996, DOI 10.1074/jbc.272.2.996; DILLEHAY DL, 1994, J NUTR, V124, P615, DOI 10.1093/jn/124.5.615; Duan RD, 1998, DIGEST DIS SCI, V43, P26, DOI 10.1023/A:1018807600683; Duan RD, 1996, DIGEST DIS SCI, V41, P1801, DOI 10.1007/BF02088748; Duan RD, 1998, SCAND J GASTROENTERO, V33, P673, DOI 10.1080/00365529850171594; Duan RD, 2000, METHOD ENZYMOL, V311, P276; Duan RD, 2003, J LIPID RES, V44, P1241, DOI 10.1194/jlr.M300037-JLR200; DUAN RD, 1995, BBA-LIPID LIPID MET, V1259, P49, DOI 10.1016/0005-2760(95)00137-2; Duan RD, 1997, HEPATOLOGY, V26, P823, DOI 10.1053/jhep.1997.v26.pm0009328299; Eckhardt ERM, 2002, GASTROENTEROLOGY, V122, P948, DOI 10.1053/gast.2002.32539; Exton JH, 2002, REV PHYSIOL BIOCH P, V144, P1, DOI 10.1007/BFb0116585; Falquet L, 2002, NUCLEIC ACIDS RES, V30, P235, DOI 10.1093/nar/30.1.235; Gijsbers R, 2003, FEBS LETT, V538, P60, DOI 10.1016/S0014-5793(03)00133-9; Gijsbers R, 2001, J BIOL CHEM, V276, P1361, DOI 10.1074/jbc.M007552200; Goding JW, 2000, J LEUKOCYTE BIOL, V67, P285, DOI 10.1002/jlb.67.3.285; Goding JW, 1998, IMMUNOL REV, V161, P11, DOI 10.1111/j.1600-065X.1998.tb01568.x; HANNUN YA, 1993, BIOCHIM BIOPHYS ACTA, V1154, P223, DOI 10.1016/0304-4157(93)90001-5; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; Hertervig E, 1997, CANCER, V79, P448, DOI 10.1002/(SICI)1097-0142(19970201)79:3<448::AID-CNCR4>3.0.CO;2-E; Hertervig E, 1999, BRIT J CANCER, V81, P232, DOI 10.1038/sj.bjc.6690682; LANDT M, 1978, BIOCHEMISTRY-US, V17, P915, DOI 10.1021/bi00598a027; Merrill AH, 1997, TOXICOL APPL PHARM, V142, P208, DOI 10.1006/taap.1996.8029; MOE OA, 1983, J BIOL CHEM, V258, P6941; Moolenaar WH, 2002, J CELL BIOL, V158, P197, DOI 10.1083/jcb.200206094; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; NILSSON A, 1969, BIOCHIM BIOPHYS ACTA, V176, P339, DOI 10.1016/0005-2760(69)90192-1; Nyberg L, 2000, J NUTR BIOCHEM, V11, P244, DOI 10.1016/S0955-2863(00)00069-3; Nyberg L, 1996, BBA-LIPID LIPID MET, V1300, P42, DOI 10.1016/0005-2760(95)00245-6; Oppermann M, 2000, EUR J BIOCHEM, V267, P4713, DOI 10.1046/j.1432-1327.2000.01524.x; Schissel SL, 1996, J BIOL CHEM, V271, P18431, DOI 10.1074/jbc.271.31.18431; Schmelz EM, 1997, NUTR CANCER, V28, P81, DOI 10.1080/01635589709514556; Schmelz EM, 1999, CANCER RES, V59, P5768; SCHUCHMAN EH, 1991, J BIOL CHEM, V266, P8531; Sjoqvist U, 2002, INFLAMM BOWEL DIS, V8, P258; SPENCE MW, 1989, J BIOL CHEM, V264, P5358; Stoffel W, 1975, Methods Enzymol, V35, P533; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tokumura A, 2002, J BIOL CHEM, V277, P39436, DOI 10.1074/jbc.M205623200; TOMITA M, 1982, BIOCHIM BIOPHYS ACTA, V704, P90, DOI 10.1016/0167-4838(82)90135-2; Tomiuk S, 1998, P NATL ACAD SCI USA, V95, P3638, DOI 10.1073/pnas.95.7.3638; Umezu-Goto M, 2002, J CELL BIOL, V158, P227, DOI 10.1083/jcb.200204026; ZEISEL SH, 1986, J NUTR, V116, P50, DOI 10.1093/jn/116.1.50	49	115	125	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38528	38536		10.1074/jbc.M305437200	http://dx.doi.org/10.1074/jbc.M305437200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885774	hybrid			2022-12-27	WOS:000185575100055
J	Katoh, K; Shibata, H; Suzuki, H; Nara, A; Ishidoh, K; Kominami, E; Yoshimori, T; Maki, M				Katoh, K; Shibata, H; Suzuki, H; Nara, A; Ishidoh, K; Kominami, E; Yoshimori, T; Maki, M			The ALG-2-interacting protein Alix associates with CHMP4b, a human homologue of yeast Snf7 that is involved in multivesicular body sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; DOWN-REGULATION; GENE-EXPRESSION; ALG-2 INTERACTS; ANNEXIN-XI; MOUSE SKD1; CLONING; COMPLEX; APOPTOSIS; IDENTIFICATION	Alix (ALG-2-interacting protein X) is a 95-kDa protein that interacts with an EF-hand type Ca2+-binding protein, ALG-2 (apoptosis-linked gene 2), through its C-terminal proline-rich region. In this study, we searched for proteins that interact with human AlixDeltaC (a truncated form not containing the C-terminal region) by using a yeast two-hybrid screen, and we identified two similar human proteins, CHMP4a and CHMP4b (chromatin-modifying protein; charged multivesicular body protein), as novel binding partners of Alix. The interaction of Alix with CHMP4b was confirmed by a glutathione S-transferase pull-down assay and by co-immunoprecipitation experiments. Fluorescence microscopic analysis revealed that CHMP4b transiently expressed in HeLa cells mainly exhibited a punctate distribution in the perinuclear area and co-localized with co-expressed Alix. The distribution of CHMP4b partly overlapped the distributions of early and late endosomal marker proteins, EEA1 (early endosome antigen 1) and Lamp-1 (lysosomal membrane protein-1), respectively. Transient overexpression of CHMP4b induced the accumulation of ubiquitinated proteins as punctate patterns that were partly overlapped with the distribution of CHMP4b and inhibited the disappearance of endocytosed epidermal growth factor. In contrast, stably expressed CHMP4b in HEK293 cells was observed diffusely in the cytoplasm. Transient overexpression of AlixDeltaC in stably CHMP4b-expressing cells, however, induced formation of vesicle-like structures in which CHMP4b and AlixDeltaC were colocalized. SKD1(E235Q), a dominant negative form of the AAA type ATPase SKD1 that plays critical roles in the endocytic pathway, was co-immunoprecipitated with CHMP4b. Furthermore, CHMP4b co-localized with SKD1E235Q as punctate patterns in the perinuclear area, and Alix was induced to exhibit dot-like distributions overlapped with SKD1E235Q in HeLa cells. These results suggest that CHMP4b and Alix participate in formation of multivesicular bodies by cooperating with SKD1.	Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Nagoya, Aichi 4648601, Japan; Natl Inst Genet, Dept Cell Genet, Shizuoka 4118540, Japan; Juntendo Univ, Sch Med, Dept Biochem, Bunkyo Ku, Tokyo 1138421, Japan	Nagoya University; Research Organization of Information & Systems (ROIS); National Institute of Genetics (NIG) - Japan; Juntendo University	Maki, M (corresponding author), Nagoya Univ, Grad Sch Bioagr Sci, Dept Appl Mol Biosci, Chikusa Ku, Furo Cho, Nagoya, Aichi 4648601, Japan.	mmaki@agr.nagoya-u.ac.jp	Kominami, Eiki/D-3802-2009; Maki, Masatoshi/AAM-6839-2021	Maki, Masatoshi/0000-0001-9144-5491; Nara, Atsuki/0000-0002-4115-3017				Babst M, 1998, EMBO J, V17, P2982, DOI 10.1093/emboj/17.11.2982; Babst M, 2002, DEV CELL, V3, P283, DOI 10.1016/S1534-5807(02)00219-8; Babst M, 2002, DEV CELL, V3, P271, DOI 10.1016/S1534-5807(02)00220-4; Chatellard-Causse C, 2002, J BIOL CHEM, V277, P29108, DOI 10.1074/jbc.M204019200; Che SL, 1999, J BIOL CHEM, V274, P5522, DOI 10.1074/jbc.274.9.5522; Che SL, 1997, BBA-GENE STRUCT EXPR, V1354, P231, DOI 10.1016/S0167-4781(97)00112-7; Chen B, 2000, J BIOL CHEM, V275, P19275, DOI 10.1074/jbc.M908994199; Denison SH, 2000, FUNGAL GENET BIOL, V29, P61, DOI 10.1006/fgbi.2000.1188; Garin J, 2001, J CELL BIOL, V152, P165, DOI 10.1083/jcb.152.1.165; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gout I, 2000, EMBO J, V19, P4015, DOI 10.1093/emboj/19.15.4015; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Howard TL, 2001, J CELL SCI, V114, P2395; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kamura T, 2001, J BIOL CHEM, V276, P16528, DOI 10.1074/jbc.M010142200; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Kitaura Y, 1999, BIOCHEM BIOPH RES CO, V263, P68, DOI 10.1006/bbrc.1999.1189; Kitaura Y, 2001, J BIOL CHEM, V276, P14053, DOI 10.1074/jbc.M008649200; Maki M, 2002, BBA-PROTEINS PROTEOM, V1600, P51, DOI 10.1016/S1570-9639(02)00444-2; Maki M, 1998, J BIOCHEM, V124, P1170, DOI 10.1093/oxfordjournals.jbchem.a022235; Missotten M, 1999, CELL DEATH DIFFER, V6, P124, DOI 10.1038/sj.cdd.4400456; MUNO D, 1993, ARCH BIOCHEM BIOPHYS, V306, P103, DOI 10.1006/abbi.1993.1486; Nara A, 2002, CELL STRUCT FUNCT, V27, P29, DOI 10.1247/csf.27.29; NegreteUrtasun S, 1997, J BACTERIOL, V179, P1832, DOI 10.1128/jb.179.5.1832-1835.1997; Nickas ME, 1996, MOL CELL BIOL, V16, P2585; Odorizzi G, 2003, J CELL SCI, V116, P1893, DOI 10.1242/jcs.00395; Ohkouchi S, 2001, J BIOCHEM-TOKYO, V130, P207, DOI 10.1093/oxfordjournals.jbchem.a002974; Pelham HRB, 2002, CURR OPIN CELL BIOL, V14, P454, DOI 10.1016/S0955-0674(02)00352-6; Petrelli A, 2002, NATURE, V416, P187, DOI 10.1038/416187a; Satoh H, 2002, BBA-PROTEINS PROTEOM, V1600, P61, DOI 10.1016/S1570-9639(02)00445-4; Satoh H, 2002, BIOCHEM BIOPH RES CO, V291, P1166, DOI 10.1006/bbrc.2002.6600; Scheuring S, 1999, GENE, V234, P149, DOI 10.1016/S0378-1119(99)00163-8; Schmidt MHH, 2003, J CELL SCI, V116, P2845, DOI 10.1242/jcs.00522; Sorkin A, 2002, NAT REV MOL CELL BIO, V3, P600, DOI 10.1038/nrm883; Soubeyran P, 2002, NATURE, V416, P183, DOI 10.1038/416183a; Springael JY, 2002, FEBS LETT, V517, P103, DOI 10.1016/S0014-5793(02)02586-3; Stauffer DR, 2001, J CELL SCI, V114, P2383; Take H, 2000, BIOCHEM BIOPH RES CO, V268, P321, DOI 10.1006/bbrc.2000.2147; Thery C, 2001, J IMMUNOL, V166, P7309, DOI 10.4049/jimmunol.166.12.7309; Thery C, 2002, NAT REV IMMUNOL, V2, P569, DOI 10.1038/nri855; TU JL, 1993, GENETICS, V135, P17; Usuba T, 2001, INT J CANCER, V94, P662, DOI 10.1002/ijc.1524; Vale RD, 2000, J CELL BIOL, V150, pF13, DOI 10.1083/jcb.150.1.F13; Vito P, 1999, J BIOL CHEM, V274, P1533, DOI 10.1074/jbc.274.3.1533; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; Wu Y, 2001, DIFFERENTIATION, V67, P139, DOI 10.1046/j.1432-0436.2001.670406.x; Wu Y, 2002, ONCOGENE, V21, P6801, DOI 10.1038/sj.onc.1205849; Xu WJ, 2001, J BACTERIOL, V183, P6917, DOI 10.1128/JB.183.23.6917-6923.2001; Yoshimori T, 2000, MOL BIOL CELL, V11, P747, DOI 10.1091/mbc.11.2.747; Zhang QH, 2000, GENOME RES, V10, P1546, DOI 10.1101/gr.140200	52	165	172	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39104	39113		10.1074/jbc.M301604200	http://dx.doi.org/10.1074/jbc.M301604200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12860994	hybrid			2022-12-27	WOS:000185575100124
J	Li, Y; Wu, LJ; Legendre, P; Xu, TL				Li, Y; Wu, LJ; Legendre, P; Xu, TL			Asymmetric cross-inhibition between GABA(A) and glycine receptors in rat spinal dorsal horn neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-STEM MOTONEURONS; HIPPOCAMPAL-NEURONS; GUINEA-PIG; IONOTROPIC RECEPTORS; COMMISSURAL NEURONS; CORD NEURONS; CALCINEURIN; RESPONSES; SYNAPSES; CHANNELS	Presynaptic nerve terminals of inhibitory synapses in the dorsal horn of the spinal cord and brain stem can release both GABA and glycine, leading to coactivation of postsynaptic GABA(A) and glycine receptors. In the present study we have analyzed functional interactions between GABA(A) and glycine receptors in acutely dissociated neurons from rat sacral dorsal commissural nucleus. Although the application of GABA and glycine activates pharmacologically distinct receptors, the current induced by a simultaneous application of these two transmitters was less than the sum of currents induced by applying two transmitters separately. Sequential application of glycine and GABA revealed that the GABA-evoked current is more affected by glycine than glycine-evoked responses by GABA. Activation of glycine receptors decreased the amplitude and accelerated the rate of desensitization of GABA-induced currents. This asymmetric cross-inhibition is reversible, dependent on the agonist concentration applied, but independent of both membrane potential and intracellular calcium concentration or changes in the chloride equilibrium potential. During sequential applications, the asymmetric cross-inhibition was prevented by selective GABA(A) or glycine receptor antagonists, suggesting that occupation of binding sites did not suffice to induce glycine and GABA(A) receptors functional interaction, and receptor channel activation is required. Furthermore, inhibition of phosphatase 2B, but not phosphatase 1 or 2A, prevented GABA(A) receptor inhibition by glycine receptor activation, whereas inhibition of phosphorylation pathways rendered cross-talk irreversible. Taken together, our results demonstrated that there is an asymmetric cross-inhibition between glycine and GABA(A) receptors and that a selective modulation of the state of phosphorylation of GABA(A) receptor and/or mediator proteins underlies the asymmetry in the cross-inhibition.	Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, Shanghai 200031, Peoples R China; Univ Sci & Technol China, Dept Neurobiol & Biophys, Hefei 230027, Peoples R China; Univ Paris 06, CNRS, UMR 7102, F-75252 Paris 05, France	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; University of Science & Technology of China, CAS; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Xu, TL (corresponding author), Chinese Acad Sci, Inst Neurosci, Shanghai Inst Biol Sci, 320 Yue Yang Rd, Shanghai 200031, Peoples R China.	tlxu@ion.ac.cn	Wu, Long-Jun/AAK-7113-2020; Wu, Long-Jun/E-2684-2012; Li, Yong/ABB-5588-2021	Wu, Long-Jun/0000-0001-8019-3380; 				AKAIKE N, 1987, J PHYSIOL-LONDON, V391, P219, DOI 10.1113/jphysiol.1987.sp016735; ARIENS EJ, 1964, J PHARM PHARMACOL, V16, P289, DOI 10.1111/j.2042-7158.1964.tb07461.x; BAEV KV, 1992, NEUROSCIENCE, V46, P931, DOI 10.1016/0306-4522(92)90195-8; Barajas-Lopez C, 1998, J PHYSIOL-LONDON, V513, P671, DOI 10.1111/j.1469-7793.1998.671ba.x; BARKER JL, 1979, NATURE, V277, P234, DOI 10.1038/277234a0; BIALOJAN C, 1988, BIOCHEM J, V256, P283, DOI 10.1042/bj2560283; Boue-Grabot E, 2003, J NEUROSCI, V23, P1246, DOI 10.1523/JNEUROSCI.23-04-01246.2003; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; CHEN QX, 1995, J PHYSIOL-LONDON, V482, P353, DOI 10.1113/jphysiol.1995.sp020522; Dumoulin A, 2001, J NEUROSCI, V21, P6045, DOI 10.1523/JNEUROSCI.21-16-06045.2001; Dumoulin A, 2000, EUR J NEUROSCI, V12, P3883, DOI 10.1046/j.1460-9568.2000.00271.x; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; Fucile S, 1999, J PHYSIOL-LONDON, V517, P369, DOI 10.1111/j.1469-7793.1999.0369t.x; Gines S, 2000, P NATL ACAD SCI USA, V97, P8606, DOI 10.1073/pnas.150241097; GRASSI F, 1992, BRAIN RES, V594, P115, DOI 10.1016/0006-8993(92)91035-D; Jonas P, 1998, SCIENCE, V281, P419, DOI 10.1126/science.281.5375.419; Jones MV, 1997, J NEUROSCI, V17, P7626; JONES MV, 1995, NEURON, V15, P181, DOI 10.1016/0896-6273(95)90075-6; Khakh BS, 2000, NATURE, V406, P405, DOI 10.1038/35019066; Kirsch J, 1998, NATURE, V392, P717, DOI 10.1038/33694; Korpi ER, 2002, PROG NEUROBIOL, V67, P113, DOI 10.1016/S0301-0082(02)00013-8; Lee FJS, 2002, CELL, V111, P219, DOI 10.1016/S0092-8674(02)00962-5; Legendre P, 2001, CELL MOL LIFE SCI, V58, P760, DOI 10.1007/PL00000899; LEWIS CA, 1993, NEUROSCIENCE, V52, P83, DOI 10.1016/0306-4522(93)90184-H; Li Y, 2002, NEUROREPORT, V13, P223, DOI 10.1097/00001756-200202110-00010; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Lu YM, 2000, NEURON, V26, P197, DOI 10.1016/S0896-6273(00)81150-2; MA W, 1993, J COMP NEUROL, V338, P337, DOI 10.1002/cne.903380303; Martina M, 1996, NEUROSCI LETT, V215, P95, DOI 10.1016/S0304-3940(96)12957-8; NAKAZAWA K, 1994, J NEUROSCI, V14, P740; O'Brien JA, 1999, J NEUROPHYSIOL, V82, P1638, DOI 10.1152/jn.1999.82.3.1638; Russier M, 2002, J PHYSIOL-LONDON, V541, P123, DOI 10.1113/jphysiol.2001.016063; Saint Jan DD, 2001, J PHYSIOL-LONDON, V535, P741; Sokolova E, 2001, J NEUROSCI, V21, P4958, DOI 10.1523/JNEUROSCI.21-14-04958.2001; STELZER A, 1994, NEUROSCIENCE, V62, P813, DOI 10.1016/0306-4522(94)90479-0; Todd AJ, 1996, J NEUROSCI, V16, P974; Trombley PQ, 1999, J NEUROPHYSIOL, V82, P3417, DOI 10.1152/jn.1999.82.6.3417; Wang J, 2003, J NEUROSCI, V23, P826; Wu LJ, 2002, NEUROREPORT, V13, P977, DOI 10.1097/00001756-200205240-00016; Xu TL, 2000, EUR J NEUROSCI, V12, P1647; Yakel JL, 1997, TRENDS PHARMACOL SCI, V18, P124, DOI 10.1016/S0165-6147(97)01046-8; Zhou XP, 1998, J PHYSIOL-LONDON, V513, P685, DOI 10.1111/j.1469-7793.1998.685ba.x	42	50	60	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38637	38645		10.1074/jbc.M303735200	http://dx.doi.org/10.1074/jbc.M303735200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12885784	hybrid			2022-12-27	WOS:000185575100068
J	Muller, EM; Mackin, NA; Erdman, SE; Cunningham, KW				Muller, EM; Mackin, NA; Erdman, SE; Cunningham, KW			Fig1p facilitates Ca2+ influx and cell fusion during mating of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; MAP KINASE; GENE-EXPRESSION; NEUROTRANSMITTER RELEASE; ACTIN CYTOSKELETON; CALCIUM CHANNELS; MEMBRANE-PROTEIN; INVASIVE GROWTH; S-CEREVISIAE; YEAST-CELLS	During the mating process of yeast cells, two Ca2+ influx pathways become activated. The resulting elevation of cytosolic free Ca2+ activates downstream signaling factors that promote long term survival of unmated cells, but the roles of Ca2+ in conjugation have not been described. The high affinity Ca2+ influx system is composed of Cch1p and Mid1p and sensitive to feedback inhibition by calcineurin, a Ca2+/calmodulin-dependent protein phosphatase. To identify components and regulators of the low affinity Ca2+ influx system (LACS), we screened a collection of pheromone-responsive genes that when deleted lead to defects in LACS activity but not high affinity Ca2+ influx system activity. Numerous factors implicated in polarized morphogenesis and cell fusion (Fus1p, Fus2p, Rvs161p, Bni1p, Spa2p, and Pea2p) were found to be necessary for LACS activity. Each of these factors was also required for activation of the cell integrity mitogen-activated protein kinase cascade during the response to alpha-factor. Interestingly a polytopic plasma membrane protein, Fig1p, was required for LACS activity but not required for activation of Mpk1p mitogen-activated protein kinase. Mpk1p was not required for LACS activity, suggesting Mpk1p and Fig1p define two independent branches in the pheromone response pathways. Fig1p-deficient mutants exhibit defects in the cell-cell fusion step of mating, but unlike other fus1 and fus2 mutants the fusion defect of fig1 mutants can be largely suppressed by high Ca2+ conditions, which bypass the requirement for LACS. These findings suggest Fig1p is an important component or regulator of LACS and provide the first evidence for a role of Ca2+ signals in the cell fusion step of mating.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Syracuse Univ, Dept Biol, Syracuse, NY 13244 USA	Johns Hopkins University; Syracuse University	Cunningham, KW (corresponding author), Johns Hopkins Univ, Dept Biol, 3400 N Charles St, Baltimore, MD 21218 USA.	kwc@jhu.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053082] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM053082] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Atlas D, 2001, CELL MOL NEUROBIOL, V21, P717, DOI 10.1023/A:1015104105262; Batiza AF, 1996, J BIOL CHEM, V271, P23357, DOI 10.1074/jbc.271.38.23357; Berditchevski F, 1999, J CELL BIOL, V146, P477, DOI 10.1083/jcb.146.2.477; Bidlingmaier Scott, 2002, Functional and Integrative Genomics, V1, P345, DOI 10.1007/s10142-001-0043-1; Blondel M, 1999, GENE DEV, V13, P2284, DOI 10.1101/gad.13.17.2284; Bonilla M, 2002, EMBO J, V21, P2343, DOI 10.1093/emboj/21.10.2343; BONILLA M, 2003, IN PRESS MOL BIOL CE; Brachmann CB, 1998, YEAST, V14, P115; Brizzio V, 1998, J CELL BIOL, V141, P567, DOI 10.1083/jcb.141.3.567; Bryant PJ, 1997, DEV GENET, V20, P75, DOI 10.1002/(SICI)1520-6408(1997)20:2<75::AID-DVG1>3.3.CO;2-G; Buehrer BM, 1997, MOL CELL BIOL, V17, P6517, DOI 10.1128/MCB.17.11.6517; BURNS N, 1994, GENE DEV, P1077; Butty AC, 1998, SCIENCE, V282, P1511, DOI 10.1126/science.282.5393.1511; CHANG F, 1990, CELL, V63, P999, DOI 10.1016/0092-8674(90)90503-7; CHENEVERT J, 1994, GENETICS, V136, P1287; Cook JG, 1996, GENE DEV, V10, P2831, DOI 10.1101/gad.10.22.2831; Cunningham KW, 1996, MOL CELL BIOL, V16, P2226; Darszon A, 1999, PHYSIOL REV, V79, P481, DOI 10.1152/physrev.1999.79.2.481; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; Dohlman HG, 2001, ANNU REV BIOCHEM, V70, P703, DOI 10.1146/annurev.biochem.70.1.703; Dorer R, 1997, GENETICS, V146, P39; ELION EA, 1993, MOL BIOL CELL, V4, P495, DOI 10.1091/mbc.4.5.495; ELION EA, 1995, J CELL BIOL, V130, P1283, DOI 10.1083/jcb.130.6.1283; Erdman S, 1998, J CELL BIOL, V140, P461, DOI 10.1083/jcb.140.3.461; Evangelista M, 1997, SCIENCE, V276, P118, DOI 10.1126/science.276.5309.118; FINBOW ME, 1995, BIOESSAYS, V17, P247, DOI 10.1002/bies.950170311; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Fujiwara T, 1998, MOL BIOL CELL, V9, P1221, DOI 10.1091/mbc.9.5.1221; Gammie AE, 1998, MOL BIOL CELL, V9, P1395, DOI 10.1091/mbc.9.6.1395; Goodenough DA, 1996, ANNU REV BIOCHEM, V65, P475, DOI 10.1146/annurev.bi.65.070196.002355; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Heiman MG, 2000, J CELL BIOL, V151, P719, DOI 10.1083/jcb.151.3.719; Hemler ME, 2001, J CELL BIOL, V155, P1103, DOI 10.1083/jcb.200108061; IIDA H, 1990, J BIOL CHEM, V265, P13391; IIDA H, 1994, MOL CELL BIOL, V14, P8259, DOI 10.1128/MCB.14.12.8259; Jung US, 1999, MOL MICROBIOL, V34, P1049, DOI 10.1046/j.1365-2958.1999.01667.x; Jungnickel MK, 2001, NAT CELL BIOL, V3, P499, DOI 10.1038/35074570; Kanzaki M, 1999, SCIENCE, V285, P882, DOI 10.1126/science.285.5429.882; Katzmann DJ, 1999, MOL CELL BIOL, V19, P2998; Kawasaki R, 2003, GENES CELLS, V8, P235, DOI 10.1046/j.1365-2443.2003.00629.x; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Lord M, 2002, CURR BIOL, V12, P1347, DOI 10.1016/S0960-9822(02)01042-4; Maecker HT, 1997, FASEB J, V11, P428, DOI 10.1096/fasebj.11.6.9194523; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Miller RK, 1999, J CELL BIOL, V144, P963, DOI 10.1083/jcb.144.5.963; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; Muller EM, 2001, GENETICS, V159, P1527; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; OHSUMI Y, 1985, J BIOL CHEM, V260, P482; Ozaki-Kuroda K, 2001, MOL CELL BIOL, V21, P827, DOI 10.1128/MCB.21.3.827-839.2001; Paidhungat M, 1997, MOL CELL BIOL, V17, P6339, DOI 10.1128/MCB.17.11.6339; Palmer CP, 2001, P NATL ACAD SCI USA, V98, P7801, DOI 10.1073/pnas.141036198; PETER M, 1993, CELL, V73, P747, DOI 10.1016/0092-8674(93)90254-N; Philips J, 1998, J CELL BIOL, V143, P375, DOI 10.1083/jcb.143.2.375; Philips J, 1997, J CELL BIOL, V138, P961, DOI 10.1083/jcb.138.5.961; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; Roberts CJ, 2000, SCIENCE, V287, P873, DOI 10.1126/science.287.5454.873; Sagot I, 2002, NAT CELL BIOL, V4, P42, DOI 10.1038/ncb719; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Sherman F., 1986, METHODS YEAST GENETI; Sheu YJ, 1998, MOL CELL BIOL, V18, P4053, DOI 10.1128/MCB.18.7.4053; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; SIKORSKI RS, 1989, GENETICS, V122, P19; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; Stamboulian SV, 2002, DEV BIOL, V252, P72, DOI 10.1006/dbio.2002.0844; Stipp CS, 2003, TRENDS BIOCHEM SCI, V28, P106, DOI 10.1016/S0968-0004(02)00014-2; Tedford K, 1997, CURR BIOL, V7, P228, DOI 10.1016/S0960-9822(06)00118-7; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; Tucker WC, 2002, BIOCHEM J, V366, P1, DOI 10.1042/BJ20020776; TYERS M, 1993, MOL CELL BIOL, V13, P5659, DOI 10.1128/MCB.13.9.5659; Valtz N, 1996, J CELL BIOL, V135, P725, DOI 10.1083/jcb.135.3.725; VALTZ N, 1995, J CELL BIOL, V131, P863, DOI 10.1083/jcb.131.4.863; WALLIS JW, 1989, CELL, V58, P409, DOI 10.1016/0092-8674(89)90855-6; Wassarman PM, 1999, CELL, V96, P175, DOI 10.1016/S0092-8674(00)80558-9; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; Yanez-Mo M, 2001, MICROCIRCULATION, V8, P153; Zarzov P, 1996, EMBO J, V15, P83, DOI 10.1002/j.1460-2075.1996.tb00336.x	77	85	92	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38461	38469		10.1074/jbc.M304089200	http://dx.doi.org/10.1074/jbc.M304089200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12878605	hybrid			2022-12-27	WOS:000185575100047
J	Liu, SG; Guo, R; Simpson, LG; Xiao, ZS; Burnham, CE; Quarles, LD				Liu, SG; Guo, R; Simpson, LG; Xiao, ZS; Burnham, CE; Quarles, LD			Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-LINKED HYPOPHOSPHATEMIA; FIBROBLAST GROWTH FACTOR-23; PEX GENE; PHOSPHATE-TRANSPORT; SUBCELLULAR-LOCALIZATION; ONCOGENIC OSTEOMALACIA; PROTEOLYTIC CLEAVAGE; HYP MICE; ENDOPEPTIDASE; RICKETS	Inactivating mutations of Phex cause X-linked hypophosphatemia (XLH) by increasing levels of a circulating phosphaturic factor. FGF23 is a candidate for this phosphaturic factor. Elevated serum FGF23 levels correlate with the degree of hypophosphatemia in XLH, suggesting that loss of Phex function in this disorder results in either diminished degradation and/or increased biosynthesis of FGF23. To establish the mechanisms whereby Phex regulates FGF23, we assessed Phex-dependent hydrolysis of recombinant FGF23 in vitro and measured fgf23 message levels in the Hyp mouse homologue of XLH. In COS-7 cells, overexpression of FGF23 resulted in its degradation into N- and C-terminal fragments by an endogenous decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone-sensitive furin-type convertase. Phex-dependent hydrolysis of full-length FGF23 or its N- and C-terminal fragments could not be demonstrated in the presence or absence of decanoyl-Arg-Val-Lys-Arg-chloromethyl ketone in COS-7 cells expressing Phex and FGF23. In a reticulolysate system, apparent cleavage of FGF23 occurred with wild-type Phex, the inactive Phex-3'M mutant, and vector controls, indicating nonspecific metabolism of FGF23 by contaminating enzymes. These findings suggest that FGF23 is not a direct Phex substrate. In contrast, by real-time reverse transcriptase PCR, the levels of fgf23 transcripts were highest in bone, the predominant site of Phex expression. In addition, Hyp mice displayed a bone-restricted increase in fgf23 transcripts in association with inactivating Phex mutations. Increased expression of fgf23 was also observed in Hyp-derived osteoblasts in culture. These findings suggest that Phex, possibly through the actions of unidentified Phex substrates or other downstream effectors, regulates fgf23 expression as part of a potential hormonal axis between bone and kidney that controls systemic phosphate homeostasis and mineralization.	Duke Univ, Med Ctr, Dept Med, Ctr Bone & Mineral Disorders, Durham, NC 27710 USA	Duke University	Quarles, LD (corresponding author), Duke Univ, Med Ctr, Dept Med, Ctr Bone & Mineral Disorders, Box 3036, Durham, NC 27710 USA.	quar1001@mc.duke.edu		Quarles, L. Darryl/0000-0002-5082-7896	NIAMS NIH HHS [R01 AR-45955] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR045955] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Argiro L, 2001, GENOMICS, V74, P342, DOI 10.1006/geno.2001.6553; Bai XY, 2003, J BIOL CHEM, V278, P9843, DOI 10.1074/jbc.M210490200; Beck L, 1997, J CLIN INVEST, V99, P1200, DOI 10.1172/JCI119276; Boileau G, 2001, BIOCHEM J, V355, P707, DOI 10.1042/bj3550707; Bowe AE, 2001, BIOCHEM BIOPH RES CO, V284, P977, DOI 10.1006/bbrc.2001.5084; Campos M, 2003, BIOCHEM J, V373, P271, DOI 10.1042/BJ20030287; Carpinelli MR, 2002, AM J PATHOL, V161, P1925, DOI 10.1016/S0002-9440(10)64468-9; De Beur SMJ, 2002, J BONE MINER RES, V17, P1102, DOI 10.1359/jbmr.2002.17.6.1102; Du L, 1996, GENOMICS, V36, P22, DOI 10.1006/geno.1996.0421; ECONS MJ, 1994, NEW ENGL J MED, V330, P1679, DOI 10.1056/NEJM199406093302310; EMOTO N, 1995, J BIOL CHEM, V270, P15262, DOI 10.1074/jbc.270.25.15262; FRANCIS F, 1995, NAT GENET, V11, P130, DOI 10.1038/ng1095-130; Grieff M, 1997, BIOCHEM BIOPH RES CO, V231, P635, DOI 10.1006/bbrc.1997.6153; Guo R, 1997, J BONE MINER RES, V12, P1009, DOI 10.1359/jbmr.1997.12.7.1009; Guo R, 2002, BIOCHEM BIOPH RES CO, V297, P38, DOI 10.1016/S0006-291X(02)02125-3; Guo R, 2001, AM J PHYSIOL-ENDOC M, V281, pE837, DOI 10.1152/ajpendo.2001.281.4.E837; Holm IA, 1997, AM J HUM GENET, V60, P790; Jonsson KB, 2003, NEW ENGL J MED, V348, P1656, DOI 10.1056/NEJMoa020881; Lee S, 2001, J BIOL CHEM, V276, P27281, DOI 10.1074/jbc.M103433200; Leitlein J, 2001, J IMMUNOL, V166, P7238, DOI 10.4049/jimmunol.166.12.7238; Lipman ML, 1998, J BIOL CHEM, V273, P13729, DOI 10.1074/jbc.273.22.13729; Meyer RA, 1998, GENOMICS, V48, P289, DOI 10.1006/geno.1997.5169; MEYER RA, 1989, J BONE MINER RES, V4, P493; MEYER RA, 1989, J BONE MINER RES, V4, P523; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NESBITT T, 1992, J CLIN INVEST, V89, P1453, DOI 10.1172/JCI115735; Nesbitt T, 1999, J BONE MINER RES, V14, P2027, DOI 10.1359/jbmr.1999.14.12.2027; Ntayi C, 2001, EXP CELL RES, V270, P110, DOI 10.1006/excr.2001.5306; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; QIN C, 2003, IN PRESS J BIOL CHEM; Quarles LD, 2002, J AM SOC NEPHROL, V13, p572A; QUARLES LD, 2000, J AM SOC NEPHROL, V11, pA3002; RASMUSSEN H, 1983, FAMILIAL HYPOPHOSPHA, P1743; RIMINUCCI M, 2003, IN PRESS J CLIN INVE; Ruchon AF, 1998, J HISTOCHEM CYTOCHEM, V46, P459; Ruchon AF, 2000, J BONE MINER RES, V15, P1440, DOI 10.1359/jbmr.2000.15.8.1440; Saito H, 2003, J BIOL CHEM, V278, P2206, DOI 10.1074/jbc.M207872200; Shimada T, 2001, P NATL ACAD SCI USA, V98, P6500, DOI 10.1073/pnas.101545198; Shimada T, 2002, ENDOCRINOLOGY, V143, P3179, DOI 10.1210/en.143.8.3179; SMITH MM, 1995, J BIOL CHEM, V270, P6440, DOI 10.1074/jbc.270.12.6440; Strewler GJ, 2001, P NATL ACAD SCI USA, V98, P5945, DOI 10.1073/pnas.11154898; Strom TM, 1997, HUM MOL GENET, V6, P165, DOI 10.1093/hmg/6.2.165; Thompson DL, 2002, J BONE MINER RES, V17, P311, DOI 10.1359/jbmr.2002.17.2.311; Turner AJ, 2000, ADV EXP MED BIOL, V477, P229; Valdenaire O, 1999, MOL BRAIN RES, V64, P211, DOI 10.1016/S0169-328X(98)00321-0; Weber TJ, 2003, J BONE MINER RES, V18, P1227, DOI 10.1359/jbmr.2003.18.7.1227; White KE, 2001, J CLIN ENDOCR METAB, V86, P497, DOI 10.1210/jc.86.2.497; White KE, 2000, NAT GENET, V26, P345, DOI 10.1038/81664; Xiao ZS, 1998, AM J PHYSIOL-ENDOC M, V275, pE700, DOI 10.1152/ajpendo.1998.275.4.E700; Yamashita T, 2000, BIOCHEM BIOPH RES CO, V277, P494, DOI 10.1006/bbrc.2000.3696; Yamazaki Y, 2002, J CLIN ENDOCR METAB, V87, P4957, DOI 10.1210/jc.2002-021105	51	366	380	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37419	37426		10.1074/jbc.M304544200	http://dx.doi.org/10.1074/jbc.M304544200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12874285	hybrid			2022-12-27	WOS:000185437200054
J	Murata, CE; Goldberg, DE				Murata, CE; Goldberg, DE			Plasmodium falciparum falcilysin - A metalloprotease with dual specificity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; HEMOGLOBIN DEGRADATION; FOOD VACUOLE; CLEAVAGE; PARASITE; PROTEASE; IDENTIFICATION; PLASMEPSINS; VIEW	The malaria parasite Plasmodium falciparum degrades host cell hemoglobin within an acidic food vacuole. The metalloprotease falcilysin has previously been identified as an important component of this catabolic process. Using random peptide substrate analysis, we confirm that recombinant falcilysin is highly active at acidic pH, consistent with its role in hemoglobin degradation. Unexpectedly, the enzyme is also robustly active at neutral pH, but with a substantially different substrate specificity. Imaging studies confirm the location of falcilysin in the food vacuole and reveal association with vesicular structures elsewhere within the parasite. These data suggest that falcilysin may have an expanded role beyond globin catabolism and may function as two different proteases in its two locations.	Washington Univ, Dept Mol Microbiol, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA; Washington Univ, Dept Internal Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Goldberg, DE (corresponding author), Washington Univ, Dept Mol Microbiol, Sch Med, Howard Hughes Med Inst, Box 8230,660 S Euclid Ave, St Louis, MO 63110 USA.	goldberg@borcim.wustl.edu			NIAID NIH HHS [AI-47798] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI047798] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMES N, 1995, SCIENCE, V270, P464, DOI 10.1126/science.270.5235.464; Banerjee R, 2001, INFEC DIS S, P43; Banerjee R, 2002, P NATL ACAD SCI USA, V99, P990, DOI 10.1073/pnas.022630099; BOHNI P, 1980, ORG EXPRESSION MITOC, P423; deDominguez NDG, 1996, BLOOD, V87, P4448, DOI 10.1182/blood.V87.10.4448.bloodjournal87104448; Eggleson KK, 1999, J BIOL CHEM, V274, P32411, DOI 10.1074/jbc.274.45.32411; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Foley M, 1998, INT J PARASITOL, V28, P1671, DOI 10.1016/S0020-7519(98)00132-5; Francis SE, 1996, MOL BIOCHEM PARASIT, V83, P189, DOI 10.1016/S0166-6851(96)02772-7; Francis SE, 1997, J BIOL CHEM, V272, P14961, DOI 10.1074/jbc.272.23.14961; FUJITA A, 1994, NATURE, V372, P567, DOI 10.1038/372567a0; GEHM BD, 1991, ENDOCRINOLOGY, V128, P1603, DOI 10.1210/endo-128-3-1603; Gillmor SA, 1997, PROTEIN SCI, V6, P1603, DOI 10.1002/pro.5560060801; GLUZMAN IY, 1994, J CLIN INVEST, V93, P1602, DOI 10.1172/JCI117140; GOLDBERG DE, 1991, J EXP MED, V173, P961, DOI 10.1084/jem.173.4.961; Kappe SHI, 2001, P NATL ACAD SCI USA, V98, P9895, DOI 10.1073/pnas.171185198; Kojima K, 2001, J BIOL CHEM, V276, P2115, DOI 10.1074/jbc.M003111200; KROGSTAD DJ, 1985, J CELL BIOL, V101, P2302, DOI 10.1083/jcb.101.6.2302; LAMBROS C, 1979, J PARASITOL, V65, P418, DOI 10.2307/3280287; LINGELBACH KR, 1993, EXP PARASITOL, V76, P318, DOI 10.1006/expr.1993.1039; MATAYOSHI ED, 1990, SCIENCE, V247, P954, DOI 10.1126/science.2106161; Murata CE, 2003, MOL BIOCHEM PARASIT, V129, P123, DOI 10.1016/S0166-6851(03)00098-7; Ogishima T, 1995, J BIOL CHEM, V270, P30322, DOI 10.1074/jbc.270.51.30322; RAWLINGS ND, 1998, HDB PROTEOLYTIC ENZY, P1360; Richter S, 1998, P NATL ACAD SCI USA, V95, P7463, DOI 10.1073/pnas.95.13.7463; SCHMIDT GW, 1979, J CELL BIOL, V83, P615, DOI 10.1083/jcb.83.3.615; SHAHABUDDIN M, 1992, EXP PARASITOL, V74, P11, DOI 10.1016/0014-4894(92)90134-V; Sherman I. W., 1998, MALARIA PARASITE BIO; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; Sijwali PS, 2001, BIOCHEM J, V360, P481, DOI 10.1042/0264-6021:3600481; Song MC, 1996, J BIOCHEM-TOKYO, V120, P1163; Taylor AB, 2001, STRUCTURE, V9, P615, DOI 10.1016/S0969-2126(01)00621-9; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; YAYON A, 1984, EMBO J, V3, P2695, DOI 10.1002/j.1460-2075.1984.tb02195.x	35	58	63	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38022	38028		10.1074/jbc.M306842200	http://dx.doi.org/10.1074/jbc.M306842200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12876284	hybrid			2022-12-27	WOS:000185437200124
J	Peng, H; He, HY; Hay, J; Ruyechan, WT				Peng, H; He, HY; Hay, J; Ruyechan, WT			Interaction between the varicella zoster virus IE62 major transactivator and cellular transcription factor Sp1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE-EARLY PROTEIN; PHYSICAL INTERACTION; DNA-BINDING; FUNCTIONAL INTERACTION; REGULATORY FUNCTIONS; BASAL TRANSCRIPTION; ACTIVATION DOMAINS; GENE-EXPRESSION; SP-FAMILY; C-JUN	The varicella zoster virus (VZV) IE62 protein is involved in the activation of expression of all three kinetic classes of VZV proteins. Analysis of the viral promoter for VZV glycoprotein I has shown that the cellular factor Sp1 is involved in or required for the observed IE62 mediated activation. Co-immunoprecipitation experiments show that the two proteins are present in a complex in VZV-infected cells. Protein affinity pull-down assays using recombinant proteins showed that IE62 and Sp1 interact in the absence of any other viral and cellular proteins. Mapping studies using GST-fusion proteins containing truncations of IE62 and Sp1 have delimited the interacting regions to amino acids 612 - 778 in Sp1 and amino acids 226 - 299 in IE62. The region identified in Sp1 is involved in DNA-binding, synergistic Sp1 activation, and Sp1 interaction with cellular transcription factors. The interacting region identified in IE62 overlaps with or borders on sites involved in interactions with the VZV IE4 protein and the cellular factors TBP and TFIIB. Assays using wild-type and mutant promoter elements indicate that Sp1 is involved in recruitment of IE62 to the gI promoter and IE62 enhances Sp1 and TBP binding.	SUNY Buffalo, Dept Microbiol, Buffalo, NY 14214 USA; SUNY Buffalo, Witebsky Ctr Microbial Pathogenesis & Immunol, Buffalo, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Ruyechan, WT (corresponding author), SUNY Buffalo, Dept Microbiol, 151 Biomed Res Bldg, Buffalo, NY 14214 USA.	ruyechan@buffalo.edu			NIAID NIH HHS [AI18449] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI018449, R01AI018449, R21AI018449] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baudoux L, 2000, J BIOL CHEM, V275, P32822, DOI 10.1074/jbc.M001444200; Black AR, 2001, J CELL PHYSIOL, V188, P143, DOI 10.1002/jcp.1111; Boucaud D, 1998, J INFECT DIS, V178, pS34, DOI 10.1086/514276; Chen BK, 2000, P NATL ACAD SCI USA, V97, P10406, DOI 10.1073/pnas.180321497; COHEN JI, 2001, VIROLOGY, P2707; DATTA PK, 1995, MOL CELL BIOL, V15, P5444; Datta PK, 2000, J BIOL CHEM, V275, P40014, DOI 10.1074/jbc.C000508200; DAVISON AJ, 1986, J GEN VIROL, V67, P2279, DOI 10.1099/0022-1317-67-10-2279; Defechereux P, 1997, J VIROL, V71, P7073, DOI 10.1128/JVI.71.9.7073-7079.1997; DEFECHEREUX P, 1993, J VIROL, V67, P4379, DOI 10.1128/JVI.67.7.4379-4385.1993; DISNEY GH, 1990, J GEN VIROL, V71, P2999, DOI 10.1099/0022-1317-71-12-2999; Dittmer J, 1997, J BIOL CHEM, V272, P4953, DOI 10.1074/jbc.272.8.4953; EMILI A, 1994, MOL CELL BIOL, V14, P1582, DOI 10.1128/MCB.14.3.1582; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; Grondin B, 2000, J VIROL, V74, P11504, DOI 10.1128/JVI.74.24.11504-11510.2000; GU BH, 1995, MOL CELL BIOL, V15, P3618; GU BH, 1993, P NATL ACAD SCI USA, V90, P9528, DOI 10.1073/pnas.90.20.9528; He H, 2001, ARCH VIR S, V17, P57; IMBALZANO AN, 1991, J VIROL, V65, P565, DOI 10.1128/JVI.65.2.565-574.1991; INCHAUSPE G, 1989, VIROLOGY, V173, P700, DOI 10.1016/0042-6822(89)90583-7; Ito H, 2003, J VIROL, V77, P489, DOI 10.1128/JVI.77.1.489-498.2003; JACKERS P, 1992, J VIROL, V66, P3899, DOI 10.1128/JVI.66.6.3899-3903.1992; Kantakamalakul W, 1995, NEUROLOGY, V45, pS28, DOI 10.1212/WNL.45.12_Suppl_8.S28; Kardassis D, 1999, J BIOL CHEM, V274, P29572, DOI 10.1074/jbc.274.41.29572; Karlseder J, 1996, MOL CELL BIOL, V16, P1659; Kim DB, 2002, J VIROL, V76, P6473, DOI 10.1128/JVI.76.13.6473-6479.2002; KOST RG, 1995, VIROLOGY, V209, P218, DOI 10.1006/viro.1995.1246; KRADY JK, 1995, MOL CELL BIOL, V15, P524, DOI 10.1128/MCB.15.1.524; Lania L, 1997, INT J BIOCHEM CELL B, V29, P1313, DOI 10.1016/S1357-2725(97)00094-0; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; Lin SY, 1996, MOL CELL BIOL, V16, P1668; LING P, 1992, J VIROL, V66, P3690, DOI 10.1128/JVI.66.6.3690-3698.1992; Lynch JM, 2002, VIROLOGY, V302, P71, DOI 10.1006/viro.2002.1555; MEIER JL, 1994, MOL CELL BIOL, V14, P6896, DOI 10.1128/MCB.14.10.6896; MORIUCHI H, 1993, J VIROL, V67, P4290, DOI 10.1128/JVI.67.7.4290-4295.1993; MORIUCHI H, 1993, J VIROL, V67, P2739, DOI 10.1128/JVI.67.5.2739-2746.1993; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; MURATA Y, 1994, J BIOL CHEM, V269, P20674; Ohlsson C, 1998, ENDOCRINOLOGY, V139, P1101, DOI 10.1210/en.139.3.1101; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; PERERA LP, 1994, J VIROL, V68, P2468, DOI 10.1128/JVI.68.4.2468-2477.1994; PERERA LP, 1992, J VIROL, V66, P5298, DOI 10.1128/JVI.66.9.5298-5304.1992; PERERA LP, 1993, J VIROL, V67, P4474, DOI 10.1128/JVI.67.8.4474-4483.1993; PERERA LP, 1992, VIROLOGY, V191, P346, DOI 10.1016/0042-6822(92)90197-W; Perera LP, 2000, J BIOL CHEM, V275, P487, DOI 10.1074/jbc.275.1.487; PERKINS ND, 1994, MOL CELL BIOL, V14, P6570, DOI 10.1128/MCB.14.10.6570; Philipsen S, 1999, NUCLEIC ACIDS RES, V27, P2991, DOI 10.1093/nar/27.15.2991; Rahaus M, 1999, VIRUS RES, V62, P77, DOI 10.1016/S0168-1702(99)00075-1; Rahaus M, 2000, VIRUS RES, V69, P69, DOI 10.1016/S0168-1702(00)00180-5; Rohr O, 1997, J BIOL CHEM, V272, P31149, DOI 10.1074/jbc.272.49.31149; Rost B, 1996, METHOD ENZYMOL, V266, P525; Ruyechan William T., 2003, Journal of Medical Virology, V70, pS90, DOI 10.1002/jmv.10328; RUYECHAN WT, 1999, ENCY VIROLOGY, P1878; SETO E, 1993, NATURE, V365, P462, DOI 10.1038/365462a0; Sommer MH, 2001, J VIROL, V75, P8224, DOI 10.1128/JVI.75.17.8224-8239.2001; Spengler ML, 2000, VIROLOGY, V272, P375, DOI 10.1006/viro.2000.0389; Steger G, 2002, J GEN VIROL, V83, P503, DOI 10.1099/0022-1317-83-3-503; Suske G, 1999, GENE, V238, P291, DOI 10.1016/S0378-1119(99)00357-1; Suzuki T, 2000, GENES CELLS, V5, P29, DOI 10.1046/j.1365-2443.2000.00302.x; Suzuki Y, 1999, BLOOD, V93, P4264, DOI 10.1182/blood.V93.12.4264.412k27_4264_4276; Trejo SR, 1997, J BIOL CHEM, V272, P27411, DOI 10.1074/jbc.272.43.27411; Vallian S, 1998, MOL CELL BIOL, V18, P7147, DOI 10.1128/MCB.18.12.7147; WANG LL, 1995, J BIOL CHEM, V270, P25564, DOI 10.1074/jbc.270.43.25564; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61	65	41	44	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38068	38075		10.1074/jbc.M302259200	http://dx.doi.org/10.1074/jbc.M302259200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12855699	hybrid			2022-12-27	WOS:000185437200128
J	Zhou, JM; Ryan, AJ; Medh, J; Mallampalli, RK				Zhou, JM; Ryan, AJ; Medh, J; Mallampalli, RK			Oxidized lipoproteins inhibit surfactant phosphatidylcholine synthesis via calpain-mediated cleavage of CTP: Phosphocholine cytidylyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT NEUTRAL PROTEASE; ALVEOLAR EPITHELIAL-CELLS; RAT LUNG; LIPID ACTIVATION; II PNEUMOCYTES; REGULATES CTP; FATTY-ACIDS; IN-VITRO; ALPHA; DEGRADATION	We investigated effects of pro-atherogenic oxidized lipoproteins on phosphatidylcholine (PtdCho) biosynthesis in murine lung epithelial cells (MLE-12). Cells surface-bound, internalized, and degraded oxidized low density lipoproteins (Ox-LDL). Ox-LDL significantly reduced [H-3]choline incorporation into PtdCho in cells by selectively inhibiting the activity of the rate-regulatory enzyme, CTP: phosphocholine cytdylyltransferase (CCT). Ox-LDL coordinately increased the cellular turnover of CCTalpha protein as determined by [S-35] methionine pulse-chase studies by inducing the calcium-activated proteinase, calpain. Forced expression of calpain or exposure of cells to the calcium ionophore, A23187, increased CCTalpha degradation, whereas overexpression of the endogenous calpain inhibitor, calpastatin, attenuated OxLDL-induced CCTalpha degradation. The effects of Ox-LDL on CCTalpha breakdown were attenuated in calpain-deficient cells. In vitro calpain digestion of CCTalpha isolated from cells transfected with truncated or internal deletion mutants indicated multiple cleavage sites within the CCTalpha primary structure, leading to the generation of a 26-kDa (p26) fragment. Calpain hydrolysis of purified CCTalpha generated p26, which upon NH2-terminal sequencing localized a calpain attack site within the CCTalpha amino terminus. Expression of a CCTalpha mutant where the amino-terminal cleavage site and a putative carboxyl-terminal hydrolysis region were modified resulted in an enzyme that was significantly less sensitive to proteolytic cleavage and restored the ability of cells to synthesize surfactant PtdCho after Ox-LDL treatment. Thus, these results provide a critical link between proatherogenic lipoproteins and their metabolic target, CCTalpha, resulting in impaired surfactant metabolism.	Univ Iowa, Coll Med, Dept Internal Med, Div Pulm Dis Crit Care & Occupat Med, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Biochem, Iowa City, IA 52242 USA; Univ Iowa, Coll Med, Dept Vet Affairs Med Ctr, Iowa City, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Mallampalli, RK (corresponding author), Univ Iowa, Coll Med, Dept Internal Med, Div Pulm Dis Crit Care & Occupat Med, Iowa City, IA 52242 USA.	rama-mallampalli@uiowa.edu	RYAN, Anderson/ACG-0319-2022	RYAN, Anderson/0000-0001-6241-7969	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL071040, R01HL055584, R01HL068135] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL55584, R01 HL055584, R01 HL068135, HL68135, R01 HL068135-01, R01 HL071040-01, R01 HL071040, HL71040, R01 HL055584-04] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arthur JSC, 2000, MOL CELL BIOL, V20, P4474, DOI 10.1128/MCB.20.12.4474-4481.2000; Bakovic M, 1999, BBA-MOL CELL BIOL L, V1438, P147, DOI 10.1016/S1388-1981(99)00042-6; BALIBREA CANTERO JL, 1994, AM J RESP CRIT CARE, V149, P699, DOI 10.1164/ajrccm.149.3.8118639; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOGGS KP, 1995, J BIOL CHEM, V270, P7757, DOI 10.1074/jbc.270.13.7757; BOTBOL V, 1983, J BIOL CHEM, V258, P1942; CHAPPELL DA, 1993, J BIOL CHEM, V268, P25487; Chaudhuri P, 2003, ARTERIOSCL THROM VAS, V23, P218, DOI 10.1161/01.ATV.0000052673.77316.01; CROALL DE, 1991, PHYSIOL REV, V71, P813, DOI 10.1152/physrev.1991.71.3.813; Drobnies AE, 1999, BIOCHEMISTRY-US, V38, P15606, DOI 10.1021/bi991573v; EMMETT M, 1987, P SOC EXP BIOL MED, V184, P83; ESTERBAUER H, 1992, FREE RADICAL BIO MED, V13, P341, DOI 10.1016/0891-5849(92)90181-F; FELDMAN DA, 1978, J BIOL CHEM, V253, P4980; Golfman LS, 2001, J BIOL CHEM, V276, P43688, DOI 10.1074/jbc.M108170200; GROBLEWSKI GE, 1995, J BIOL CHEM, V270, P1437, DOI 10.1074/jbc.270.3.1437; Han YQ, 1999, J BIOL CHEM, V274, P787, DOI 10.1074/jbc.274.2.787; Huang J, 1998, P NATL ACAD SCI USA, V95, P12100, DOI 10.1073/pnas.95.21.12100; Isakson BE, 2001, AM J PHYSIOL-LUNG C, V280, pL221, DOI 10.1152/ajplung.2001.280.2.L221; Jialal I, 1996, CLIN CHEM, V42, P498; Jobe AH, 1998, P ASSOC AM PHYSICIAN, V110, P489; Kent C, 1997, BBA-LIPID LIPID MET, V1348, P79, DOI 10.1016/S0005-2760(97)00112-4; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; KISHIMOTO A, 1983, J BIOL CHEM, V258, P1156; Kolleck I, 1999, FREE RADICAL BIO MED, V27, P882, DOI 10.1016/S0891-5849(99)00139-2; Lagace TA, 2002, MOL CELL BIOL, V22, P4851, DOI 10.1128/MCB.22.13.4851-4862.2002; Longo CA, 1997, AM J RESP CELL MOL, V16, P605, DOI 10.1165/ajrcmb.16.5.9160843; LUCHE MM, 1993, ARCH BIOCHEM BIOPHYS, V301, P114, DOI 10.1006/abbi.1993.1122; Lykidis A, 1999, J BIOL CHEM, V274, P26992, DOI 10.1074/jbc.274.38.26992; Lykidis A, 2001, BIOCHEMISTRY-US, V40, P494, DOI 10.1021/bi002140r; Mallampalli RK, 2000, J BIOL CHEM, V275, P9699, DOI 10.1074/jbc.275.13.9699; Mallampalli RK, 1996, BIOCHEM J, V318, P333, DOI 10.1042/bj3180333; MALLAMPALLI RK, 1994, AM J PHYSIOL-LUNG C, V267, pL641, DOI 10.1152/ajplung.1994.267.6.L641; Mallampalli RK, 1997, J CLIN INVEST, V99, P2020, DOI 10.1172/JCI119370; Papen M, 2001, CELL PHYSIOL BIOCHEM, V11, P187, DOI 10.1159/000047805; Patzke H, 2002, J BIOL CHEM, V277, P8054, DOI 10.1074/jbc.M109645200; PELECH SL, 1983, J BIOL CHEM, V258, P6782; Ridsdale R, 2001, J BIOL CHEM, V276, P49148, DOI 10.1074/jbc.M103566200; ROONEY SA, 1985, AM REV RESPIR DIS, V131, P439; ROSNER B, 1995, FUNDAMENTALS BIOSTAT, P314; Roth AF, 1998, J CELL BIOL, V142, P949, DOI 10.1083/jcb.142.4.949; Ryan AJ, 2002, AM J PHYSIOL-LUNG C, V283, pL310, DOI 10.1152/ajplung.00021.2002; SASAKI T, 1984, J BIOL CHEM, V259, P2489; Schunemann HJ, 1997, AM J EPIDEMIOL, V146, P939; SHIRATORI Y, 1995, J BIOL CHEM, V270, P29894; SUZUKI K, 1988, ADV ENZYME REGUL, V27, P153; TESSNER TG, 1991, J BIOL CHEM, V266, P16261; van der Luit AH, 2002, J BIOL CHEM, V277, P39541, DOI 10.1074/jbc.M203176200; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; WANG Y, 1995, J BIOL CHEM, V270, P18948, DOI 10.1074/jbc.270.32.18948; WANG YL, 1993, J BIOL CHEM, V268, P5899; YANG W, 1995, J BIOL CHEM, V270, P16503, DOI 10.1074/jbc.270.28.16503	51	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37032	37040		10.1074/jbc.M304316200	http://dx.doi.org/10.1074/jbc.M304316200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12857760	hybrid, Green Accepted			2022-12-27	WOS:000185437200009
J	Lardinois, OM; de Montellano, PRO				Lardinois, OM; de Montellano, PRO			Intra- and intermolecular transfers of protein radicals in the reactions of sperm whale myoglobin with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							H2O2-MEDIATED CROSS-LINKING; CYTOCHROME-C PEROXIDASE; COMPOUND-I; AMINO-ACID; HEME; IDENTIFICATION; METMYOGLOBIN; TYR-151; LACTOPEROXIDASE; ISODITYROSINE	Reaction of sperm whale metmyoglobin (SwMb) with H2O2 produces a ferryl (MbFe(IV)=O) species and a protein radical and leads to the formation of oligomeric products. The ferryl species is maximally formed with one equivalent of H2O2, and the maximum yields of the dimer (28%) and trimer (17%) with 1 or 2 eq. Co-incubation of the SwMb Y151F mutant with native apoSwMb and H2O2 produced dimeric products, which requires radical transfer from the nondimerizing Y151F mutant to apoSwMb. Autoreduction of ferryl SwMb to the ferric state is biphasic with t = 3.4 and 25.9 min. An intramolecular autoreduction process is implicated at low protein concentrations, but oligomerization decreases the lifetime of the ferryl species at high protein concentrations. A fraction of the protein remained monomeric. This dimerization-resistant protein was in the ferryl state, but after autoreduction it underwent normal dimerization with H2O2. Proteolytic digestion established the presence of both dityrosine and isodityrosine cross-links in the oligomeric proteins, with the isodityrosine links primarily forged by Tyr(151)-Tyr(151) coupling. The tyrosine content decreased by 47% in the dimer and 14% in the recovered monomer, but the yields of isodityrosine and dityrosine in the dimer were only 15.2 and 6.8% of the original tyrosine content. Approximately 23% of the lost tyrosines therefore have an alternative but unknown fate. The results clearly demonstrate the concurrence of intra- and intermolecular electron transfer processes involving Mb protein radicals. Intermolecular electron transfers that generate protein radicals on bystander proteins are likely to propagate the cellular damage initiated by the reaction of metalloproteins with H2O2.	Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	de Montellano, PRO (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St, San Francisco, CA 94143 USA.	ortiz@cgl.ucsf.edu			NIGMS NIH HHS [GM32488] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTONINI E, 1971, HEMOGLOBIN MYOGLOBIN, P44; Blodig W, 2001, J MOL BIOL, V305, P851, DOI 10.1006/jmbi.2000.4346; CATALANO CE, 1989, J BIOL CHEM, V264, P10534; Colas C, 2002, J BIOL CHEM, V277, P7191, DOI 10.1074/jbc.M109523200; COURTIN F, 1984, BIOCHEM BIOPH RES CO, V121, P463, DOI 10.1016/0006-291X(84)90205-5; Davies MJ, 1999, FREE RADICAL BIO MED, V27, P1151, DOI 10.1016/S0891-5849(99)00206-3; DeGray JA, 1997, J BIOL CHEM, V272, P2359; Dorlet P, 2002, BIOCHEMISTRY-US, V41, P6107, DOI 10.1021/bi015871f; DUNFORD HB, 1999, HEME PEROXIDASES, P20; Egawa T, 2000, J BIOL CHEM, V275, P34858, DOI 10.1074/jbc.M004026200; Fancy DA, 1998, BIOCHEM BIOPH RES CO, V247, P420, DOI 10.1006/bbrc.1998.8558; Fenwick CW, 1996, J AM CHEM SOC, V118, P12236, DOI 10.1021/ja962764d; FOERDER CA, 1977, P NATL ACAD SCI USA, V74, P4214, DOI 10.1073/pnas.74.10.4214; FRY SC, 1984, METHOD ENZYMOL, V107, P388; GARNER MH, 1973, J BIOL CHEM, V248, P5451; GARRISON WM, 1987, CHEM REV, V87, P381, DOI 10.1021/cr00078a006; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GOTO Y, 1990, P NATL ACAD SCI USA, V87, P573, DOI 10.1073/pnas.87.2.573; Ivancich A, 1997, BIOCHEMISTRY-US, V36, P9356, DOI 10.1021/bi970886s; Jacob JS, 1996, J BIOL CHEM, V271, P19950, DOI 10.1074/jbc.271.33.19950; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; Lardinois OM, 1999, J BIOL CHEM, V274, P35441, DOI 10.1074/jbc.274.50.35441; Lardinois OM, 2001, J BIOL CHEM, V276, P23186, DOI 10.1074/jbc.M102084200; LeBrun LA, 2002, J BIOL CHEM, V277, P12755, DOI 10.1074/jbc.M112155200; Matsui T, 1999, J AM CHEM SOC, V121, P9952, DOI 10.1021/ja9914846; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; NELSON DP, 1972, ANAL BIOCHEM, V49, P474, DOI 10.1016/0003-2697(72)90451-4; Qian SY, 2002, BIOCHEM J, V363, P281, DOI 10.1042/0264-6021:3630281; RAO SI, 1993, J BIOL CHEM, V268, P803; Reeder BJ, 2002, BIOCHEMISTRY-US, V41, P367, DOI 10.1021/bi011335b; Rich PR, 2002, BBA-BIOENERGETICS, V1554, P137, DOI 10.1016/S0005-2728(02)00228-1; SATAKE K, 1960, J BIOCHEM-TOKYO, V47, P654, DOI 10.1093/oxfordjournals.jbchem.a127107; SIVARAJA M, 1989, SCIENCE, V245, P738, DOI 10.1126/science.2549632; Stadtman ER, 1997, CHEM RES TOXICOL, V10, P485, DOI 10.1021/tx960133r; Svistunenko DA, 2002, BIOPHYS J, V83, P2845, DOI 10.1016/S0006-3495(02)75293-4; TEW D, 1988, J BIOL CHEM, V263, P17880; Thomas EL, 1985, LACTOPEROXIDASE SYST, P31; Tsai AL, 1999, J BIOL CHEM, V274, P21695, DOI 10.1074/jbc.274.31.21695; VOLKER V, 1992, P NATL ACAD SCI USA, V89, P996; WHITTAKER MM, 1990, J BIOL CHEM, V265, P9610; WILKS A, 1992, J BIOL CHEM, V267, P8827; Witting PK, 2000, J BIOL CHEM, V275, P20391, DOI 10.1074/jbc.M000373200; YONETANI T, 1967, J BIOL CHEM, V242, P1974	44	34	34	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36214	36226		10.1074/jbc.M304726200	http://dx.doi.org/10.1074/jbc.M304726200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855712	hybrid			2022-12-27	WOS:000185318300043
J	Poole, CB; Jin, JM; McReynolds, LA				Poole, CB; Jin, JM; McReynolds, LA			Cloning and biochemical characterization of blisterase, a subtilisin-like convertase from the filarial parasite, Onchocerca volvulus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CAENORHABDITIS-ELEGANS; ALPHA-1-ANTITRYPSIN PORTLAND; PROPROTEIN CONVERTASE; ACTIVE-SITE; HUMAN FURIN; ENDOPROTEASE; CLEAVAGE; PROTEINS; PROTEASE; DOMAIN	Blisterase is a subtilisin-like proprotein convertase of nematodes. The enzyme is named after the blistered cuticle found in Caenorhabditis elegans with the bli-4 e937 mutation. The critical role of the enzyme in cuticle production makes it a potential drug target for parasitic nematodes. We have cloned and expressed blisterase from the parasitic nematode Onchocerca volvulus, a major cause of blindness in Africa. The catalytic domain of the protease exhibits 84% identity with the corresponding domain of its closest homologue, C. elegans blisterase. O. volvulus blisterase expressed in insect cells has maximal activity in 1 mM calcium at neutral pH. The protease is inhibited by EDTA, the suicide substrate decanoyl-RVKR-chloromethylketone, alpha(1)-antitrypsin Portland and by its own propeptide. Substrate assays with fluorescent peptides show that O. volvulus blisterase requires a P4 arginine and a basic amino acid at P1 for cleavage. The k(cat) of blisterase on the peptide substrate, t-butyloxycarbonyl-RVRR-4-methylcoumaryl-7-amide was determined to be 0.018 s-1. In vitro cleavage studies with the nematode polyprotein antigen demonstrated that blisterase cleaved at tetrabasic (RRKR) but not at dibasic (KR) sites. This report describes the first biochemical characterization of the nematode specific protease, blisterase.	New England Biolabs Inc, Mol Parasitol Div, Beverly, MA 01915 USA		McReynolds, LA (corresponding author), New England Biolabs Inc, Mol Parasitol Div, 32 Tozer Rd, Beverly, MA 01915 USA.	mcreynolds@neb.com						Anderson ED, 1997, EMBO J, V16, P1508, DOI 10.1093/emboj/16.7.1508; [Anonymous], 1995, WHO TECHN REP SER; Benjannet S, 1997, J BIOL CHEM, V272, P26210, DOI 10.1074/jbc.272.42.26210; BRAVO DA, 1994, J BIOL CHEM, V269, P25830; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Coombs GH, 1997, PARASITOLOGY, V114, pS61, DOI 10.1017/S003118209700111X; Despommier D, 2000, PARASITIC DIS; Dufour EK, 1998, FEBS LETT, V426, P41, DOI 10.1016/S0014-5793(98)00307-X; Evans TC, 1998, PROTEIN SCI, V7, P2256, DOI 10.1002/pro.5560071103; FULLER RS, 1989, SCIENCE, V246, P482, DOI 10.1126/science.2683070; GERBER LD, 1992, J BIOL CHEM, V267, P12168; GLUSCHANKOF P, 1994, EMBO J, V13, P2280, DOI 10.1002/j.1460-2075.1994.tb06510.x; GOMEZSALADIN E, 1994, CELL MOL NEUROBIOL, V14, P9, DOI 10.1007/BF02088586; HATSUZAWA K, 1992, J BIOL CHEM, V267, P16094; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Jean F, 1998, P NATL ACAD SCI USA, V95, P7293, DOI 10.1073/pnas.95.13.7293; Jin JM, 1999, GENE, V237, P161, DOI 10.1016/S0378-1119(99)00282-6; Kennedy MW, 2000, PARASITOL TODAY, V16, P373, DOI 10.1016/S0169-4758(00)01743-9; KNIGHT CG, 1995, METHOD ENZYMOL, V248, P85; KRAMER JM, 1997, C ELEGANS, V2, P471; Krysan DJ, 1999, J BIOL CHEM, V274, P23229, DOI 10.1074/jbc.274.33.23229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li C, 1999, ANN NY ACAD SCI, V897, P239, DOI 10.1111/j.1749-6632.1999.tb07895.x; MATTHEWS DJ, 1994, PROTEIN SCI, V3, P1197, DOI 10.1002/pro.5560030805; MCREYNOLDS LA, 1993, PARASITOL TODAY, V9, P403, DOI 10.1016/0169-4758(93)90046-I; MIZUNO K, 1988, BIOCHEM BIOPH RES CO, V156, P246, DOI 10.1016/S0006-291X(88)80832-5; MOLLOY SS, 1992, J BIOL CHEM, V267, P16396; Molyneux DH, 2001, CURR OPIN INFECT DIS, V14, P155, DOI 10.1097/00001432-200104000-00008; Nielsen H, 1997, PROTEIN ENG, V10, P1, DOI 10.1093/protein/10.1.1; OTTESEN EA, 1990, NEW ENGL J MED, V322, P1113, DOI 10.1056/NEJM199004193221604; PETERS K, 1991, GENETICS, V129, P95; Poole CB, 1996, MOL BIOCHEM PARASIT, V82, P51, DOI 10.1016/0166-6851(96)02721-1; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEGEL IH, 1975, ENZYME KINETICS, P18; Seidah NG, 1997, CURR OPIN BIOTECH, V8, P602, DOI 10.1016/S0958-1669(97)80036-5; SIEZEN RJ, 1994, EUR J BIOCHEM, V222, P255, DOI 10.1111/j.1432-1033.1994.tb18864.x; SIEZEN RJ, 1995, INTRAMOLECULAR CHAPE, P233; Thacker C, 2000, BIOESSAYS, V22, P545, DOI 10.1002/(SICI)1521-1878(200006)22:6&lt;545::AID-BIES7&gt;3.0.CO;2-F; Thacker C, 1999, GENOME RES, V9, P348; THACKER C, 1995, GENE DEV, V9, P956, DOI 10.1101/gad.9.8.956; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Tsuji A, 1999, J BIOCHEM, V126, P591, DOI 10.1093/oxfordjournals.jbchem.a022491; WHO, 1991, TROP DIS PROGR RES 1; YANG J, 1994, MOL CELL BIOL, V14, P2722, DOI 10.1128/MCB.14.4.2722	45	20	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36183	36190		10.1074/jbc.M302601200	http://dx.doi.org/10.1074/jbc.M302601200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12855702	hybrid			2022-12-27	WOS:000185318300040
J	Hamaguchi, A; Suzuki, E; Murayama, K; Fujimura, T; Hikita, T; Iwabuchi, K; Handa, K; Withers, DA; Masters, SC; Fu, HA; Hakomori, S				Hamaguchi, A; Suzuki, E; Murayama, K; Fujimura, T; Hikita, T; Iwabuchi, K; Handa, K; Withers, DA; Masters, SC; Fu, HA; Hakomori, S			Sphingosine-dependent protein kinase-1, directed to 14-3-3, is identified as the kinase domain of protein kinase C delta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPHINGOLIPID METABOLITES; PROTEOLYTIC ACTIVATION; MASS-SPECTROMETRY; INDUCED APOPTOSIS; CELLS; SPHINGOSINE-1-PHOSPHATE; DIFFERENTIATION; CERAMIDE; 1-PHOSPHATE; GROWTH	Some protein kinases are known to be activated by D-erythro-sphingosine (Sph) or N,N-dimethyl-D-erythrosphingosine (DMS), but not by ceramide, Sph-1-P, other sphingolipids, or phospholipids. Among these, a specific protein kinase that phosphorylates Ser(60), Ser(59), or Ser(58) of 14-3-3beta, 14-3-3eta, or 14-3-3zeta, respectively, was termed "sphingosine-dependent protein kinase-1" (SDK1) (Megidish, T., Cooper, J., Zhang, L., Fu, H., and Hakomori, S. (1998) J. Biol. Chem. 273, 21834 - 21845). We have now identified SDK1 as a protein having the C-terminal half kinase domain of protein kinase Cdelta (PKCdelta) based on the following observations. (i) Large-scale preparation and purification of proteins showing SDK1 activity from rat liver (by six steps of chromatography) gave a final fraction with an enhanced level of an similar to40-kDa protein band. This fraction had SDK1 activity similar to50,000-fold higher than that in the initial extract. (ii) This protein had similar to 53% sequence identity to the Ser/Thr kinase domain of PKCdelta based on peptide mapping using liquid chromatography/ mass spectrometry and liquid chromatography/ tandem mass spectrometry data. (iii) A search for amino acid homology based on the BLAST algorithm indicated that the only protein with high homology to the similar to40-kDa band is the kinase domain of PKCdelta. The kinase activity of PKCdelta did not depend on Sph or DMS; rather, it was inhibited by these sphingoid bases, i.e. PKCdelta did not display any SDK1 activity. However, strong SDK1 activity became detectable when PKCdelta was incubated with caspase-3, which releases the similar to40-kDa kinase domain. PKCdelta and SDK1 showed different lipid requirements and substrate specificity, although both kinase activities were inhibited by common PKC inhibitors. The high susceptibility of SDK1 to Sph and DMS accounts for their important modulatory role in signal transduction.	Pacific NW Res Inst, Div Biomembrane Res, Seattle, WA 98122 USA; Univ Washington, Dept Pathobiol, Seattle, WA 98122 USA; Juntendo Univ, Sch Med, Cent Lab Med Sci, Tokyo 1138421, Japan; Emory Univ, Sch Med, Dept Pharmacol, Atlanta, GA 30322 USA	University of Washington; University of Washington Seattle; Juntendo University; Emory University	Hakomori, S (corresponding author), Pacific NW Res Inst, Div Biomembrane Res, 720 Broadway, Seattle, WA 98122 USA.		Suzuki, Erika/B-3456-2008	Suzuki, Erika/0000-0002-4010-8716; Fujimura, Tsutomu/0000-0003-1744-7725	NCI NIH HHS [R01 CA82167] Funding Source: Medline; NIGMS NIH HHS [R01 GM53165] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA082167] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053165] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Basu A, 2001, CELL DEATH DIFFER, V8, P899, DOI 10.1038/sj.cdd.4400885; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Choudhary JS, 2001, TRENDS BIOTECHNOL, V19, pS17, DOI 10.1016/S0167-7799(01)01795-4; CORONEOS E, 1995, J BIOL CHEM, V270, P23305, DOI 10.1074/jbc.270.40.23305; Datta R, 1996, BLOOD, V88, P1936, DOI 10.1182/blood.V88.6.1936.bloodjournal8861936; Denning MF, 2002, CELL DEATH DIFFER, V9, P40, DOI 10.1038/sj.cdd.4400929; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Ghayur T, 1996, J EXP MED, V184, P2399, DOI 10.1084/jem.184.6.2399; Grant S, 2002, J CLIN INVEST, V109, P717, DOI 10.1172/JCI200215302; Graves PR, 2002, MICROBIOL MOL BIOL R, V66, P39, DOI 10.1128/MMBR.66.1.39-63.2002; Hancock WS, 2002, PROTEOMICS, V2, P352, DOI 10.1002/1615-9861(200204)2:4<352::AID-PROT352>3.0.CO;2-U; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; IGARASHI Y, 1989, BIOCHEMISTRY-US, V28, P6796, DOI 10.1021/bi00443a002; IGARASHI Y, 1989, BIOCHEM BIOPH RES CO, V164, P1411, DOI 10.1016/0006-291X(89)91827-5; Kihara A, 2003, J BIOL CHEM, V278, P14578, DOI 10.1074/jbc.M211416200; Kolesnick R, 2002, J CLIN INVEST, V110, P3, DOI 10.1172/JCI200216127; Kolesnick RN, 1998, ANNU REV PHYSIOL, V60, P643, DOI 10.1146/annurev.physiol.60.1.643; Koriyama H, 1999, CELL SIGNAL, V11, P831, DOI 10.1016/S0898-6568(99)00055-8; LI SF, 1995, EMBO J, V14, P685, DOI 10.1002/j.1460-2075.1995.tb07047.x; Maceyka M, 2002, BBA-MOL CELL BIOL L, V1585, P193, DOI 10.1016/S1388-1981(02)00341-4; Mano N, 1997, ANAL BIOCHEM, V244, P291, DOI 10.1006/abio.1996.9891; MEGIDISH T, 1995, BIOCHEM BIOPH RES CO, V216, P739, DOI 10.1006/bbrc.1995.2684; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Megidish T, 1999, BIOCHEMISTRY-US, V38, P3369, DOI 10.1021/bi982548c; Megidish T, 2000, METHOD ENZYMOL, V312, P381; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; Mineki R, 2002, PROTEOMICS, V2, P1672, DOI 10.1002/1615-9861(200212)2:12<1672::AID-PROT1672>3.0.CO;2-#; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; Ogawa C, 2003, J BIOL CHEM, V278, P1268, DOI 10.1074/jbc.M209514200; OHTA H, 1995, CANCER RES, V55, P691; ONO Y, 1988, J BIOL CHEM, V263, P6927; Payne SG, 2002, FEBS LETT, V531, P54, DOI 10.1016/S0014-5793(02)03480-4; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pettus BJ, 2002, BBA-MOL CELL BIOL L, V1585, P114, DOI 10.1016/S1388-1981(02)00331-1; Roy S, 1998, MOL CELL BIOL, V18, P3947, DOI 10.1128/MCB.18.7.3947; Sano T, 2002, J BIOL CHEM, V277, P21197, DOI 10.1074/jbc.M201289200; Sato M, 2003, J BIOL CHEM, V278, P9276, DOI 10.1074/jbc.M211529200; Smith WL, 2002, J BIOL CHEM, V277, P25841, DOI 10.1074/jbc.R200011200; SNELL EE, 1970, CHEM PHYS LIPIDS, V5, P116, DOI 10.1016/0009-3084(70)90013-7; Spiegel S, 2002, TRENDS CELL BIOL, V12, P236, DOI 10.1016/S0962-8924(02)02277-8; SPIEGEL S, 1995, J MEMBRANE BIOL, V146, P225; Venkataraman K, 2002, J BIOL CHEM, V277, P35642, DOI 10.1074/jbc.M205211200; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Yang HZ, 2001, BBA-PROTEIN STRUCT M, V1547, P313, DOI 10.1016/S0167-4838(01)00202-3; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3; Zhang WZ, 2000, ANAL CHEM, V72, P2482, DOI 10.1021/ac991363o	48	57	61	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41557	41565		10.1074/jbc.M305294200	http://dx.doi.org/10.1074/jbc.M305294200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12855683	hybrid			2022-12-27	WOS:000185847200137
J	Fowler, VM; Greenfield, NJ; Moyer, J				Fowler, VM; Greenfield, NJ; Moyer, J			Tropomodulin contains two actin filament pointed end-capping domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPOMYOSIN-BINDING PROTEIN; SKELETAL-MUSCLE; THIN-FILAMENTS; BARBED END; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; RATE CONSTANTS; ADP-ACTIN; IDENTIFICATION; ISOFORM	Tropomodulin 1 (Tmod1) is a similar to40-kDa tropomyosin binding and actin filament pointed end-capping protein that regulates pointed end dynamics and controls thin filament length in striated muscle. In vitro, the capping affinity of Tmod1 for tropomyosin-actin filaments (K-d similar to 50 pM) is several thousand-fold greater than for capping of pure actin filaments (K-d similar to 0.1 muM). The tropomyosin-binding region of Tmod1 has been localized to the amino-terminal portion between residues 1 and 130, but the location of the actin-capping domain is not known. We have now identified two distinct actin-capping regions on Tmod1 by testing a series of recombinant Tmod1 fragments for their ability to inhibit actin elongation from gelsolin-actin seeds using pyrene-actin polymerization assays. The carboxyl-terminal portion of Tmod1 (residues 160-359) contains the principal actin-capping activity (K-d similar to 0.4 muM), requiring residues between 323 and 359 for full activity, whereas the amino-terminal portion of Tmod1 (residues 1-130) contains a second, weaker actin-capping activity (K-d similar to 1.8 muM). Interestingly, 160-359 but not 1-130 enhances spontaneous actin nucleation, suggesting that the carboxyl-terminal domain may bind to two actin subunits across the actin helix at the pointed end, whereas the amino-terminal domain may bind to only one actin subunit. On the other hand, the actin-capping activity of the amino-terminal but not the carboxyl-terminal portion of Tmod1 is enhanced several thousand-fold in the presence of skeletal muscle tropomyosin. We conclude that the carboxyl-terminal capping domain of Tmod1 contains a TM-independent actin pointed end-capping activity, whereas the amino-terminal domain contains a TM-regulated pointed end actin-capping activity.	Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Piscataway, NJ 08854 USA	Scripps Research Institute; Rutgers State University New Brunswick; Rutgers State University Medical Center	Fowler, VM (corresponding author), Scripps Res Inst, Dept Cell Biol, CB163,10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034225] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-34225] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almenar-Queralt A, 1999, J BIOL CHEM, V274, P28466, DOI 10.1074/jbc.274.40.28466; BABCOCK GG, 1994, J BIOL CHEM, V269, P27510; BOHM G, 1992, PROTEIN ENG, V5, P191, DOI 10.1093/protein/5.3.191; Bretscher A, 1997, J CELL SCI, V110, P3011; BRYAN J, 1988, J CELL BIOL, V106, P1553, DOI 10.1083/jcb.106.5.1553; CALDWELL JE, 1989, BIOCHEMISTRY-US, V28, P8506, DOI 10.1021/bi00447a036; Conley CA, 2001, GENOMICS, V73, P127, DOI 10.1006/geno.2000.6501; Cox PR, 2003, MOL CELL NEUROSCI, V23, P1, DOI 10.1016/S1044-7431(03)00025-3; Cox PR, 2000, GENOMICS, V63, P97, DOI 10.1006/geno.1999.6061; Fischer RS, 2003, FEBS LETT, V547, P228, DOI 10.1016/S0014-5793(03)00711-7; Fischer RS, 2003, J CELL BIOL, V161, P371, DOI 10.1083/jcb.200209057; FOWLER VM, 1993, J CELL BIOL, V120, P411, DOI 10.1083/jcb.120.2.411; FOWLER VM, 1990, J CELL BIOL, V111, P471, DOI 10.1083/jcb.111.2.471; FOWLER VM, 1987, J BIOL CHEM, V262, P12792; FOWLER VM, 1984, J BIOL CHEM, V259, P5978; Fujisawa T, 2001, FEBS LETT, V498, P67, DOI 10.1016/S0014-5793(01)02498-X; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; Greenfield NJ, 1996, ANAL BIOCHEM, V235, P1, DOI 10.1006/abio.1996.0084; Greenfield NJ, 2002, BIOPHYS J, V82, P2580, DOI 10.1016/S0006-3495(02)75600-2; GREGORIO CC, 1995, NATURE, V377, P83, DOI 10.1038/377083a0; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUG C, 1992, J CELL BIOL, V116, P923, DOI 10.1083/jcb.116.4.923; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; Kehres DG, 1997, J BIOL CHEM, V272, P20152, DOI 10.1074/jbc.272.32.20152; Kostyukova A, 2000, EUR J BIOCHEM, V267, P6470, DOI 10.1046/j.1432-1327.2000.01738.x; Kostyukova AS, 2001, BIOPHYS J, V81, P345, DOI 10.1016/S0006-3495(01)75704-9; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; Krieger I, 2002, BIOPHYS J, V83, P2716, DOI 10.1016/S0006-3495(02)75281-8; Littlefield R, 2001, NAT CELL BIOL, V3, P544, DOI 10.1038/35078517; Mardahl-Dumesnil M, 2001, J CELL BIOL, V155, P1043, DOI 10.1083/jcb.200108026; MARQUARDT DW, 1963, J SOC IND APPL MATH, V11, P431, DOI 10.1137/0111030; McElhinny AS, 2001, J BIOL CHEM, V276, P583, DOI 10.1074/jbc.M005693200; NORTHROP J, 1986, J BIOL CHEM, V261, P9274; POLLARD TD, 1983, ANAL BIOCHEM, V134, P406, DOI 10.1016/0003-2697(83)90316-0; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SMILLIE LB, 1982, METHOD ENZYMOL, V85, P234; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SREERAMA N, 1994, BIOCHEMISTRY-US, V33, P10022, DOI 10.1021/bi00199a028; SUNG LA, 1992, J BIOL CHEM, V267, P2616; SUSSMAN MA, 1992, EUR J BIOCHEM, V205, P355, DOI 10.1111/j.1432-1033.1992.tb16787.x; TOUMADJE A, 1992, ANAL BIOCHEM, V200, P321, DOI 10.1016/0003-2697(92)90473-K; Watakabe A, 1996, J CELL SCI, V109, P2299; Wear MA, 2003, CURR BIOL, V13, P1531, DOI 10.1016/S0960-9822(03)00559-1; Weber A, 1999, J BIOL CHEM, V274, P34637, DOI 10.1074/jbc.274.49.34637; WEBER A, 1994, J CELL BIOL, V127, P1627, DOI 10.1083/jcb.127.6.1627; Yamashita A, 2003, EMBO J, V22, P1529, DOI 10.1093/emboj/cdg167; YOUNG CL, 1990, BIOCHEMISTRY-US, V29, P2232, DOI 10.1021/bi00461a005	48	63	64	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40000	40009		10.1074/jbc.M306895200	http://dx.doi.org/10.1074/jbc.M306895200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12860976	hybrid			2022-12-27	WOS:000185713800089
J	Friesema, ECH; Ganguly, S; Abdalla, A; Fox, JEM; Halestrap, AP; Visser, TJ				Friesema, ECH; Ganguly, S; Abdalla, A; Fox, JEM; Halestrap, AP; Visser, TJ			Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; XENOPUS-LAEVIS OOCYTES; DEIODINASE FAMILY; RAT HEPATOCYTES; SKELETAL-MUSCLE; SYSTEM-T; MEMBRANE; 3,3',5'-TRIIODOTHYRONINE; EXPRESSION; CONFIRMS	Transport of thyroid hormone across the cell membrane is required for its action and metabolism. Recently, a T-type amino acid transporter was cloned which transports aromatic amino acids but not iodothyronines. This transporter belongs to the monocarboxylate transporter (MCT) family and is most homologous with MCT8 (SLC16A2). Therefore, we cloned rat MCT8 and tested it for thyroid hormone transport in Xenopus laevis oocytes. Oocytes were injected with rat MCT8 cRNA, and after 3 days immunofluorescence microscopy demonstrated expression of the protein at the plasma membrane. MCT8 cRNA induced an similar to10-fold increase in uptake of 10 nM I-125-labeled thyroxine (T-4), 3,3',5-triiodothyronine (T-3), 3,3',5similar to-triiodothyronine (rT(3)) and 3,3'-diiodothyronine. Because of the rapid uptake of the ligands, transport was only linear with time for <4 min. MCT8 did not transport Leu, Phe, Trp, or Tyr. [I-125]T-4 transport was strongly inhibited by L-T-4, D-T-4, L-T-3, D-T-3, 3,3',5-triiodothyroacetic acid, N-bromoacetyl-T-3, and bromosulfophthalein. T-3 transport was less affected by these inhibitors. Iodothyronine uptake in uninjected oocytes was reduced by albumin, but the stimulation induced by MCT8 was markedly increased. Saturation analysis provided apparent K-m values of 2-5 &mu;M for T-4, T-3, and rT(3). Immunohistochemistry showed high expression in liver, kidney, brain, and heart. In conclusion, we have identified MCT8 as a very active and specific thyroid hormone transporter.	Erasmus Univ, Med Ctr, Dept Internal Med, NL-3015 GE Rotterdam, Netherlands; Univ Bristol, Sch Med Sci, Dept Biochem, Bristol BS8 1TD, Avon, England	Erasmus University Rotterdam; Erasmus MC; University of Bristol	Visser, TJ (corresponding author), Erasmus Univ, Med Ctr, Dept Internal Med, Dr Molewaterpl 50, NL-3015 GE Rotterdam, Netherlands.		Visser, Theo J/C-8059-2013; Halestrap, Andrew P/G-7275-2011	Visser, Theo J/0000-0002-6997-284X; Halestrap, Andrew/0000-0001-5374-2778				Abe T, 2002, TRENDS ENDOCRIN MET, V13, P215, DOI 10.1016/S1043-2760(02)00599-4; Docter R, 1997, ENDOCRINOLOGY, V138, P1841, DOI 10.1210/en.138.5.1841; Fox JEM, 2000, J PHYSIOL-LONDON, V529, P285, DOI 10.1111/j.1469-7793.2000.00285.x; Friesema ECH, 1998, ENDOCRINOLOGY, V139, P596, DOI 10.1210/en.139.2.596; Friesema ECH, 2001, ENDOCRINOLOGY, V142, P4339, DOI 10.1210/en.142.10.4339; Friesema ECH, 1999, BIOCHEM BIOPH RES CO, V254, P497, DOI 10.1006/bbrc.1998.9974; Hennemann G, 2001, ENDOCR REV, V22, P451, DOI 10.1210/er.22.4.451; Kim DK, 2002, GENOMICS, V79, P95, DOI 10.1006/geno.2001.6678; Kim DK, 2001, J BIOL CHEM, V276, P17221, DOI 10.1074/jbc.M009462200; Kohrle J, 1999, MOL CELL ENDOCRINOL, V151, P103, DOI 10.1016/S0303-7207(99)00040-4; KRENNING EP, 1979, FEBS LETT, V107, P227, DOI 10.1016/0014-5793(79)80501-3; KRENNING EP, 1982, FEBS LETT, V140, P229, DOI 10.1016/0014-5793(82)80900-9; LAFRENIERE RG, 1994, HUM MOL GENET, V3, P1133, DOI 10.1093/hmg/3.7.1133; MOL JA, 1985, ENDOCRINOLOGY, V117, P1; OPPENHEIMER JH, 1996, MOL BASIS TNYROID HO, P162; Pizzagalli F, 2002, MOL ENDOCRINOL, V16, P2283, DOI 10.1210/me.2001-0309; Poole RC, 1996, BIOCHEM J, V320, P817, DOI 10.1042/bj3200817; PORTERFIELD SP, 1993, ENDOCR REV, V14, P94, DOI 10.1210/er.14.1.94; Price NT, 1998, BIOCHEM J, V329, P321; Rechsteiner M, 1996, TRENDS BIOCHEM SCI, V21, P267, DOI 10.1016/S0968-0004(96)10031-1; SAMSON M, 1992, BIOCHIM BIOPHYS ACTA, V1108, P91, DOI 10.1016/0005-2736(92)90118-6; StGermain DL, 1997, THYROID, V7, P655; VISSER TJ, 1999, THYROID HORMONE META; Wilson MC, 1998, J BIOL CHEM, V273, P15920, DOI 10.1074/jbc.273.26.15920; Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287; ZHOU Y, 1992, BIOCHEM J, V281, P81, DOI 10.1042/bj2810081; ZHOU Y, 1990, J BIOL CHEM, V265, P17000	27	495	513	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					40128	40135		10.1074/jbc.M300909200	http://dx.doi.org/10.1074/jbc.M300909200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12871948	hybrid			2022-12-27	WOS:000185713800105
J	Airhart, N; Yang, YF; Roberts, CT; Silberbach, M				Airhart, N; Yang, YF; Roberts, CT; Silberbach, M			Atrial natriuretic peptide induces natriuretic peptide receptor-cGMP-dependent protein kinase interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANYLATE-CYCLASE; SMOOTH-MUSCLE; CARDIAC MYOCYTES; DEFICIENT MICE; HEART-FAILURE; ACTIVATION; HYPERTROPHY; INHIBITION; GROWTH; CELLS	Circulating natriuretic peptides such as atrial natriuretic peptide (ANP) counterbalance the effects of hypertension and inhibit cardiac hypertrophy by activating cGMP-dependent protein kinase (PKG). Natriuretic peptide binding to type I receptors ( NPRA and NPRB) activates their intrinsic guanylyl cyclase activity, resulting in a rapid increase in cytosolic cGMP that subsequently activates PKG. Phosphorylation of the receptor by an unknown serine/threonine kinase is required before ligand binding can activate the cyclase. While searching for downstream PKG partners using a yeast two-hybrid screen of a human heart cDNA library, we unexpectedly found an upstream association with NPRA. PKG is a serine/threonine kinase capable of phosphorylating NPRA in vitro; however, regulation of NPRA by PKG has not been previously reported. Here we show that PKG is recruited to the plasma membrane following ANP treatment, an effect that can be blocked by pharmacological inhibition of PKG activation. Furthermore, PKG participates in a ligand-dependent gain-of-function loop that significantly increases the intrinsic cyclase activity of the receptor. PKG translocation is ANP-dependent but not nitric oxide-dependent. Our results suggest that anchoring of PKG to NPRA is a key event after ligand binding that determines distal effects. As such, the NPRA-PKG association may represent a novel mechanism for compartmentation of cGMP-mediated signaling and regulation of receptor sensitivity.	Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA; Oregon Hlth & Sci Univ, Heart Res Ctr, Portland, OR 97239 USA	Oregon Health & Science University; Oregon Health & Science University	Silberbach, M (corresponding author), Doernbecher Mem Hosp Children, 707 SW Gaines Rd,Mail Code CDRC-P, Portland, OR 97239 USA.		Roberts, Charles/K-6953-2017	Roberts, Charles/0000-0003-1756-5772				Anthony TL, 2000, MOL PHARMACOL, V57, P576, DOI 10.1124/mol.57.3.576; APPEL RG, 1992, AM J PHYSIOL, V262, pF911, DOI 10.1152/ajprenal.1992.262.6.F911; BURNETT JC, 1986, SCIENCE, V231, P1145, DOI 10.1126/science.2935937; CAO L, 1995, HYPERTENSION, V25, P227, DOI 10.1161/01.HYP.25.2.227; CHINKERS M, 1992, J BIOL CHEM, V267, P18589; CHINKERS M, 1989, NATURE, V338, P78, DOI 10.1038/338078a0; CODY R J, 1988, European Heart Journal, V9, P29; CURRIE MG, 1983, SCIENCE, V221, P71, DOI 10.1126/science.6857267; Delay RJ, 1997, J MEMBRANE BIOL, V159, P53, DOI 10.1007/s002329900268; DREWETT JG, 1994, ENDOCR REV, V15, P135, DOI 10.1210/er.15.2.135; Eigenthaler M, 1999, Rev Physiol Biochem Pharmacol, V135, P173, DOI 10.1007/BFb0033673; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; FRANCIS SH, 1994, J BIOL CHEM, V269, P22477; Gudi T, 1997, MOL CELL BIOL, V17, P5244, DOI 10.1128/MCB.17.9.5244; Hagen V, 1998, J PHOTOCH PHOTOBIO B, V42, P71, DOI 10.1016/S1011-1344(97)00125-5; Jiang LH, 2000, J BIOL CHEM, V275, P6135, DOI 10.1074/jbc.275.9.6135; Joubert S, 2001, BIOCHEMISTRY-US, V40, P11096, DOI 10.1021/bi010580s; Kishimoto I, 2001, P NATL ACAD SCI USA, V98, P2703, DOI 10.1073/pnas.051625598; Kishimoto I, 1996, P NATL ACAD SCI USA, V93, P6215, DOI 10.1073/pnas.93.12.6215; Knowles JW, 2001, J CLIN INVEST, V107, P975, DOI 10.1172/JCI11273; Ku DD, 1996, AM J PHYSIOL-HEART C, V271, pH2368, DOI 10.1152/ajpheart.1996.271.6.H2368; LAROSE L, 1992, MOL CELL BIOCHEM, V115, P203, DOI 10.1007/BF00230332; Levin ER, 1998, NEW ENGL J MED, V339, P321; Lincoln TM, 2001, J APPL PHYSIOL, V91, P1421, DOI 10.1152/jappl.2001.91.3.1421; Matsumoto T, 1999, AM J PHYSIOL-HEART C, V276, pH1935, DOI 10.1152/ajpheart.1999.276.6.H1935; MERY PF, 1991, P NATL ACAD SCI USA, V88, P1197, DOI 10.1073/pnas.88.4.1197; MORISHITA R, 1994, J CLIN INVEST, V94, P824, DOI 10.1172/JCI117402; Nara M, 2000, AM J PHYSIOL-CELL PH, V279, pC1938, DOI 10.1152/ajpcell.2000.279.6.C1938; Olson LJ, 1996, MOL PHARMACOL, V50, P430; Patel AI, 1997, J PHARMACOL EXP THER, V283, P885; Pedram A, 2000, J BIOL CHEM, V275, P7365, DOI 10.1074/jbc.275.10.7365; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; Potter LR, 1999, MOL BIOL CELL, V10, P1811, DOI 10.1091/mbc.10.6.1811; Potter LR, 2001, J BIOL CHEM, V276, P6057, DOI 10.1074/jbc.R000033200; Potter LR, 1998, MOL CELL BIOL, V18, P2164, DOI 10.1128/MCB.18.4.2164; SCHULTZ HD, 1988, AM J PHYSIOL, V255, pR6, DOI 10.1152/ajpregu.1988.255.1.R6; SCHULZ S, 1989, CELL, V58, P1155, DOI 10.1016/0092-8674(89)90513-8; Silberbach M, 1999, J BIOL CHEM, V274, P24858, DOI 10.1074/jbc.274.35.24858; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; SIMPSON P, 1985, CIRC RES, V56, P884, DOI 10.1161/01.RES.56.6.884; Spencer ML, 2002, J BIOL CHEM, V277, P20160, DOI 10.1074/jbc.M201092200; TOHSE N, 1995, BRIT J PHARMACOL, V114, P1076, DOI 10.1111/j.1476-5381.1995.tb13316.x; TSUTAMOTO T, 1993, CIRCULATION, V87, P70, DOI 10.1161/01.CIR.87.1.70; Wiedemann K, 2000, EXP CLIN ENDOCR DIAB, V108, P5; Yamamoto S, 2001, ARCH BIOCHEM BIOPHYS, V393, P97, DOI 10.1006/abbi.2001.2505; Zolle O, 2000, J BIOL CHEM, V275, P25892, DOI 10.1074/jbc.M000786200	46	51	56	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38693	38698		10.1074/jbc.M304098200	http://dx.doi.org/10.1074/jbc.M304098200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12855709	hybrid			2022-12-27	WOS:000185575100074
J	Sun, L; Bittner, MA; Holz, RW				Sun, L; Bittner, MA; Holz, RW			Rim, a component of the presynaptic active zone and modulator of exocytosis, binds 14-3-3 through its N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAB3 EFFECTOR; PROTEIN; SECRETION; MUNC13-1; TARGET; DETERMINANTS; CALMODULIN; RIM1-ALPHA; RELEASE; DOMAIN	Rim1, a brain-specific Rab3a-binding protein, localizes to the presynaptic cytomatrix and plays an important role in synaptic transmission and synaptic plasticity. Rim2, a homologous protein, is more ubiquitously expressed and is found in neuroendocrine cells as well as in brain. Both Rim1 and Rim2 contain multiple domains, including an N-terminal zinc finger, which in Rim1 strongly enhances secretion in chromaffin and PC12 cells. The yeast two-hybrid technique identified 14-3-3 proteins as ligands of the N-terminal domain. In vitro protein binding experiments confirmed a high-affinity interaction between the N terminus of Rim1 and 14-3-3. The N-terminal domain of Rim2 also bound 14-3-3. The binding domains were localized to a short segment just C-terminal to the zinc finger. 14-3-3 proteins bind to specific phosphoserine residues. Alkaline phosphatase treatment of N-terminal domains of Rim1 and Rim2 almost completely inhibited the binding of 14-3-3. Two serine residues in Rim1 (Ser-241 and Ser-287) and one serine residue in Rim2 (Ser-335) were required for 14-3-3 binding. Incubation with Ca2+/calmodulin- dependent protein kinase II greatly stimulated the interaction of recombinant N-terminal Rim but not the S241/287A mutant with 14-3-3, again indicating the importance of the phosphorylation of these residues for the binding. Rabphilin3, another Rab3a effector, also bound 14-3-3. Serine-to-alanine mutations identified Ser-274 as the likely phosphorylated residue to which 14-3-3 binds. Because the phosphorylation of this residue had been shown to be stimulated upon depolarization in brain slices, the interaction of 14-3-3 with Rabphilin3 may be important in the dynamic function of central nervous system neurons.	Univ Michigan, Sch Med, Dept Pharmacol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Holz, RW (corresponding author), Univ Michigan, Sch Med, Dept Pharmacol, 2301 MSRB 3, Ann Arbor, MI 48109 USA.	holz@umich.edu			NIDDK NIH HHS [R01-DK50177] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ashery U, 2000, EMBO J, V19, P3586, DOI 10.1093/emboj/19.14.3586; Betz A, 2001, NEURON, V30, P183, DOI 10.1016/S0896-6273(01)00272-0; Betz A, 1997, J BIOL CHEM, V272, P2520; Broadie K, 1997, NEURON, V19, P391, DOI 10.1016/S0896-6273(00)80948-4; Castillo PE, 2002, NATURE, V415, P327, DOI 10.1038/415327a; CHAMBERLAIN LH, 1995, J CELL BIOL, V130, P1063, DOI 10.1083/jcb.130.5.1063; CHUNG SH, 1995, J BIOL CHEM, V270, P16714, DOI 10.1074/jbc.270.28.16714; Clark GJ, 1997, J BIOL CHEM, V272, P20990, DOI 10.1074/jbc.272.34.20990; Coppola T, 2001, J BIOL CHEM, V276, P32756, DOI 10.1074/jbc.M100929200; Dieck ST, 1998, J CELL BIOL, V142, P499, DOI 10.1083/jcb.142.2.499; DUNN LA, 1983, J BIOL CHEM, V258, P4989; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; Fenster SD, 2000, NEURON, V25, P203, DOI 10.1016/S0896-6273(00)80883-1; Foletti DL, 2001, J NEUROSCI, V21, P5473, DOI 10.1523/JNEUROSCI.21-15-05473.2001; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Garner CC, 2000, CURR OPIN NEUROBIOL, V10, P321, DOI 10.1016/S0959-4388(00)00093-3; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HOLZ RW, 1994, J BIOL CHEM, V269, P10229; ICHIMURA T, 1988, P NATL ACAD SCI USA, V85, P7084, DOI 10.1073/pnas.85.19.7084; Iezzi M, 2000, FEBS LETT, V474, P66, DOI 10.1016/S0014-5793(00)01572-6; Joberty G, 1999, J CELL SCI, V112, P3579; Koushika SP, 2001, NAT NEUROSCI, V4, P997, DOI 10.1038/nn732; Martin TFJ, 2002, NEURON, V34, P9, DOI 10.1016/S0896-6273(02)00651-7; MCKIERNAN CJ, 1993, J BIOL CHEM, V268, P24449; MOORE BW, 1968, J NEUROCHEM, V15, P265, DOI 10.1111/j.1471-4159.1968.tb11610.x; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; NICHOLS RA, 1990, NATURE, V343, P647, DOI 10.1038/343647a0; Ozaki N, 2000, NAT CELL BIOL, V2, P805, DOI 10.1038/35041046; Petosa C, 1998, J BIOL CHEM, V273, P16305, DOI 10.1074/jbc.273.26.16305; Schoch S, 2002, NATURE, V415, P321, DOI 10.1038/415321a; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; Sun L, 2001, J BIOL CHEM, V276, P12911, DOI 10.1074/jbc.M011110200; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Wang XL, 2001, J BIOL CHEM, V276, P32480, DOI 10.1074/jbc.M103337200; Wang XL, 1999, J CELL BIOL, V147, P151, DOI 10.1083/jcb.147.1.151; Wang Y, 1997, NATURE, V388, P593, DOI 10.1038/41580; Wang Y, 2000, J BIOL CHEM, V275, P20033, DOI 10.1074/jbc.M909008199; WICK PF, 1993, J BIOL CHEM, V268, P10983; WILSON SP, 1995, ANAL BIOCHEM, V226, P212, DOI 10.1006/abio.1995.1216; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	41	46	46	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38301	38309		10.1074/jbc.M212801200	http://dx.doi.org/10.1074/jbc.M212801200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871946	hybrid			2022-12-27	WOS:000185575100028
J	Chevallet, M; Wagner, E; Luche, S; van Dorsselaer, A; Leize-Wagner, E; Rabilloud, T				Chevallet, M; Wagner, E; Luche, S; van Dorsselaer, A; Leize-Wagner, E; Rabilloud, T			Regeneration of peroxiredoxins during recovery after oxidative stress - Only some overoxidized peroxiredoxins can be reduced during recovery after oxidative stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; 2-DIMENSIONAL ELECTROPHORESIS; HYDROGEN-PEROXIDE; SITE CYSTEINE; IN-VIVO; PROTEIN; OVEROXIDATION; ACID; INACTIVATION; MECHANISM	Peroxiredoxins (prx) are redox enzymes using an activated cysteine as their active site. This activated cysteine can be easily overoxidized to cysteine sulfinic acid or cysteine sulfonic acid, especially under oxidative stress conditions. The regeneration of peroxiredoxins after a short, intense oxidative stress was studied, using a proteomics approach. Important differences in regeneration speed were found, prx2 being the fastest regenerated protein, followed by prx1, whereas prx3 and prx6 were regenerated very slowly. Further study of the mechanism of this regeneration by pulse-chase experiments using stable isotope labeling and cycloheximide demonstrated that the fast-regenerating peroxiredoxins are regenerated at least in part by a retroreduction mechanism. This demonstrates that the overoxidation can be reversible under certain conditions. The pathway of this retroreduction and the reasons explaining the various regeneration speeds of the peroxiredoxins remain to be elucidated.	CEA Grenoble, DRDC BECP, Lab Bioenerget Cellulaire & Pathol, F-38054 Grenoble 9, France; Ecole Chim Polymeres & Mat, Lab Spectrometrie Masse Bioorgan, CNRS, Unite Mixte Rech 7509, F-67002 Strasbourg, France	CEA; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Rabilloud, T (corresponding author), CEA Grenoble, DRDC BECP, Lab Bioenerget Cellulaire & Pathol, 17 Rue Martyrs,EA 2943, F-38054 Grenoble 9, France.	Thierry.rabilloud@cea.fr		Chevallet, Mireille/0000-0002-3001-8821				Baker LMS, 2003, J BIOL CHEM, V278, P9203, DOI 10.1074/jbc.M209888200; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; Chen JW, 2000, J BIOL CHEM, V275, P28421, DOI 10.1074/jbc.M005073200; Choi HJ, 1998, NAT STRUCT BIOL, V5, P400, DOI 10.1038/nsb0598-400; Collin V, 2003, J BIOL CHEM, V278, P23747, DOI 10.1074/jbc.M302077200; Declercq JP, 2001, J MOL BIOL, V311, P751, DOI 10.1006/jmbi.2001.4853; GIANAZZA E, 1985, ELECTROPHORESIS, V6, P53, DOI 10.1002/elps.1150060113; Gorman JJ, 1996, RAPID COMMUN MASS SP, V10, P529, DOI 10.1002/(SICI)1097-0231(19960331)10:5<529::AID-RCM522>3.0.CO;2-9; Hamann M, 2002, METHOD ENZYMOL, V348, P146, DOI 10.1016/S0076-6879(02)48634-X; Hirotsu S, 1999, P NATL ACAD SCI USA, V96, P12333, DOI 10.1073/pnas.96.22.12333; Hofmann B, 2002, BIOL CHEM, V383, P347, DOI 10.1515/BC.2002.040; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; Mu ZM, 2002, J BIOL CHEM, V277, P43175, DOI 10.1074/jbc.M206066200; NEUHOFF V, 1988, ELECTROPHORESIS, V9, P255, DOI 10.1002/elps.1150090603; Rabilloud T, 2002, J BIOL CHEM, V277, P19396, DOI 10.1074/jbc.M106585200; RABILLOUD T, 1994, ELECTROPHORESIS, V15, P1552, DOI 10.1002/elps.11501501223; Rabilloud T, 1997, ELECTROPHORESIS, V18, P307, DOI 10.1002/elps.1150180303; Seaver LC, 2001, J BACTERIOL, V183, P7173, DOI 10.1128/JB.183.24.7173-7181.2001; Sinha P, 2001, PROTEOMICS, V1, P835, DOI 10.1002/1615-9861(200107)1:7<835::AID-PROT835>3.3.CO;2-U; Verdoucq L, 1999, J BIOL CHEM, V274, P19714, DOI 10.1074/jbc.274.28.19714; Wagner E, 2002, BIOCHEM J, V366, P777, DOI 10.1042/BJ20020525; WATABE S, 1994, J BIOCHEM, V115, P648, DOI 10.1093/oxfordjournals.jbchem.a124390; Wen ST, 1997, GENE DEV, V11, P2456, DOI 10.1101/gad.11.19.2456; Woo HA, 2003, SCIENCE, V300, P653, DOI 10.1126/science.1080273; Wood ZA, 2003, SCIENCE, V300, P650, DOI 10.1126/science.1080405; Wood ZA, 2003, TRENDS BIOCHEM SCI, V28, P32, DOI 10.1016/S0968-0004(02)00003-8; Yang KS, 2002, J BIOL CHEM, V277, P38029, DOI 10.1074/jbc.M206626200	27	132	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37146	37153		10.1074/jbc.M305161200	http://dx.doi.org/10.1074/jbc.M305161200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12853451	hybrid			2022-12-27	WOS:000185437200021
J	Raychaudhuri, S; Rajasekharan, R				Raychaudhuri, S; Rajasekharan, R			Nonorganellar acyl carrier protein from oleaginous yeast is a homologue of ribosomal protein P2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; MEMBRANE PHOSPHOLIPID-SYNTHESIS; NADH-UBIQUINONE OXIDOREDUCTASE; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MOLECULAR-GENETICS; NEUROSPORA-CRASSA; CELL-GROWTH; PURIFICATION; SYNTHETASE	Acyl carrier protein (ACP) is responsible for carrying the growing fatty acid chain from one enzyme active site to the next during fatty acid biosynthesis. Here we report the identification, purification, immunocytochemical localization, and cloning of ACP from the oleaginous yeast, Rhodotorula glutinis. The soluble fraction of this organism can synthesize triacylglycerol and is able to accept the acyl group from acyl-ACP for the synthesis. The ACP, cloned from the system, showed a significant similarity with ribosomal protein P2. Expression and characterization of the recombinant protein showed that the ACP was acylated in vitro. The recombinant protein was post-translationally modified, since it was observed in [C-14]beta-alanine labeling and matrix-assisted laser desorption mass spectroscopic analysis. Site-directed mutants were generated to identify a serine residue responsible for phosphopantetheinylation and found that mutation of serine 59 to alanine abrogated the fatty acylation ability of the protein. These results demonstrate that a novel modification of ribosomal protein P2 allows it to act as an acyl carrier protein and participate in acylation reactions.	Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India	Indian Institute of Science (IISC) - Bangalore	Rajasekharan, R (corresponding author), Indian Inst Sci, Dept Biochem, Bangalore 560012, Karnataka, India.	lipid@biochem.iisc.ernet.in	R, Rajasekharan/D-3420-2009; Rajasekharan, Ram/R-2257-2019	Ram, Rajasekharan/0000-0002-4114-0654; Rajasekharan, Ram/0000-0002-2124-6013; Raychaudhuri, Sumana/0000-0002-3164-0057				Ballesta JPG, 1999, FEMS MICROBIOL REV, V23, P537, DOI 10.1111/j.1574-6976.1999.tb00412.x; Bargis-Surgey P, 1999, EUR J BIOCHEM, V262, P606, DOI 10.1046/j.1432-1327.1999.00434.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brody S, 1997, FEBS LETT, V408, P217, DOI 10.1016/S0014-5793(97)00428-6; Brozek KA, 1996, J BIOL CHEM, V271, P32126, DOI 10.1074/jbc.271.50.32119; CHUMAN L, 1989, EUR J BIOCHEM, V184, P643, DOI 10.1111/j.1432-1033.1989.tb15061.x; COOPER CL, 1989, J BIOL CHEM, V264, P7384; Engvall E, 1980, Methods Enzymol, V70, P419; EY PL, 1978, IMMUNOCHEMISTRY, V15, P429, DOI 10.1016/0161-5890(78)90070-6; Flaman AS, 2001, J BIOL CHEM, V276, P35934, DOI 10.1074/jbc.M101849200; Gangar A, 2002, BIOCHEM J, V365, P577, DOI 10.1042/bj20011654; Gangar A, 2001, BIOCHEM J, V360, P471, DOI 10.1042/0264-6021:3600471; Gangar A, 2001, J BIOL CHEM, V276, P10290, DOI 10.1074/jbc.M009550200; GOETHALS K, 1989, MOL GEN GENET, V219, P289, DOI 10.1007/BF00261190; GREEN PR, 1981, J BIOL CHEM, V256, P1151; HERMANSON GT, 1996, BIOCONJUGATE TECHNIQ, P131; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; Kalscheuer R, 2001, ARCH MICROBIOL, V177, P20, DOI 10.1007/s00203-001-0355-5; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; Keating MM, 2002, BBA-PROTEINS PROTEOM, V1601, P208, DOI 10.1016/S1570-9639(02)00470-3; Lipmann F, 1980, Adv Microb Physiol, V21, P227; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; RAETZ CRH, 1986, ANNU REV GENET, V20, P253, DOI 10.1146/annurev.ge.20.120186.001345; RAUE HA, 1991, METHOD ENZYMOL, V194, P453; Raychaudhuri S, 2003, BIOCHEM J, V372, P587, DOI 10.1042/BJ20030160; Rock C O, 1981, Methods Enzymol, V71 Pt C, P163; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; RUNSWICK MJ, 1991, FEBS LETT, V286, P121, DOI 10.1016/0014-5793(91)80955-3; Schneider R, 1995, CURR GENET, V29, P10, DOI 10.1007/BF00313188; Suh MC, 1999, PLANT J, V17, P679, DOI 10.1046/j.1365-313X.1999.00418.x; THERISOD H, 1987, P NATL ACAD SCI USA, V84, P8235, DOI 10.1073/pnas.84.23.8235; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317; ZENSEN R, 1992, FEBS LETT, V310, P179, DOI 10.1016/0014-5793(92)81324-F	35	1	3	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37648	37657		10.1074/jbc.M305052200	http://dx.doi.org/10.1074/jbc.M305052200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12869567	hybrid			2022-12-27	WOS:000185437200080
J	Sau, K; Mambula, SS; Latz, E; Henneke, P; Golenbock, DT; Levitz, SM				Sau, K; Mambula, SS; Latz, E; Henneke, P; Golenbock, DT; Levitz, SM			The antifungal drug amphotericin B promotes inflammatory cytokine release by a Toll-like receptor- and CD14-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INDUCED CELL ACTIVATION; INNATE IMMUNE-SYSTEM; SIGNAL-TRANSDUCTION; CUTTING EDGE; BACTERIAL LIPOPOLYSACCHARIDE; CRYPTOCOCCUS-NEOFORMANS; MONONUCLEAR-CELLS; WALL COMPONENTS; MESSENGER-RNA; LIPID RAFTS	Amphotericin B is the most effective drug for treating many life-threatening fungal infections. Amphotericin B administration is limited by infusion-related toxicity, including fever and chills, an effect postulated to result from proinflammatory cytokine production by innate immune cells. Because amphotericin B is a microbial product, we hypothesized that it stimulates immune cells via Toll-like receptors (TLRs) and CD14. We show here that amphotericin B induces signal transduction and inflammatory cytokine release from cells expressing TLR2 and CD14. Primary murine macrophages and human cell lines expressing TLR2, CD14, and the adapter protein MyD88 responded to amphotericin B with NF-kappaB-dependent reporter activity and cytokine release, whereas cells deficient in any of these failed to respond. Cells mutated in TLR4 were less responsive to amphotericin B stimulation than cells expressing normal TLR4. These data demonstrate that TLR2 and CD14 are required for amphotericin B-dependent inflammatory stimulation of innate immune cells and that TLR4 may also provide stimulation of these cells. Our results provide a putative molecular basis for inflammatory responses elicited by amphotericin B and suggest strategies to eliminate the acute toxicity of this drug.	Boston Univ, Sch Med, Dept Microbiol, Sect Infect Dis, Boston, MA 02118 USA; Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA; Univ Massachusetts, Sch Med, Dept Med, Worcester, MA 01655 USA	Boston University; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Levitz, SM (corresponding author), Boston Univ, Sch Med, Dept Microbiol, Sect Infect Dis, 650 Albany St,Rm X626, Boston, MA 02118 USA.	slevitz@bu.edu	Latz, Eicke/H-3951-2014	Latz, Eicke/0000-0003-1488-5666	NCRR NIH HHS [RR14466] Funding Source: Medline; NHLBI NIH HHS [HL07501, HL07035] Funding Source: Medline; NIAID NIH HHS [AI-37532, AI-25780] Funding Source: Medline; NIDDK NIH HHS [DK50305] Funding Source: Medline; NIGMS NIH HHS [GM54060] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [R24RR014466] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007035] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037532, R01AI025780] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK050305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054060, R01GM054060] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbuSalah KM, 1996, BRIT J BIOMED SCI, V53, P122; Akira S, 2001, NAT IMMUNOL, V2, P675, DOI 10.1038/90609; Alexander C, 2001, J ENDOTOXIN RES, V7, P167, DOI 10.1179/096805101101532675; Arning M, 1995, MYCOSES, V38, P459, DOI 10.1111/j.1439-0507.1995.tb00020.x; Ayestaran A, 1996, ANTIMICROB AGENTS CH, V40, P609, DOI 10.1128/AAC.40.3.609; Bekersky I, 2002, ANTIMICROB AGENTS CH, V46, P828, DOI 10.1128/AAC.46.3.828-833.2002; Beutler B, 2002, CURR TOP MICROBIOL, V270, P1; Beutler B, 2001, CRIT CARE MED, V29, pS2, DOI 10.1097/00003246-200107001-00002; BOLARD J, 1986, BIOCHIM BIOPHYS ACTA, V864, P257, DOI 10.1016/0304-4157(86)90002-X; Bulut Y, 2001, J IMMUNOL, V167, P987, DOI 10.4049/jimmunol.167.2.987; Calandra T, 2001, J CHEMOTHERAPY, V13, P173, DOI 10.1179/joc.2001.13.Supplement-2.173; Carozzi AJ, 2000, TRAFFIC, V1, P326, DOI 10.1034/j.1600-0854.2000.010406.x; Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689; CLEARY JD, 1992, ANTIMICROB AGENTS CH, V36, P977, DOI 10.1128/AAC.36.5.977; CLEARY JD, 1988, DRUG INTEL CLIN PHAR, V22, P769, DOI 10.1177/106002808802201005; Correia JD, 2001, J BIOL CHEM, V276, P21129, DOI 10.1074/jbc.M009164200; Fitzgerald KA, 2001, NATURE, V413, P78, DOI 10.1038/35092578; Flo TH, 2002, J BIOL CHEM, V277, P35489, DOI 10.1074/jbc.M201366200; GOLENBOCK DT, 1993, J BIOL CHEM, V268, P22055; Harrison TS, 1997, J INFECT DIS, V176, P485, DOI 10.1086/514068; Hashimoto M, 2000, BIOCHEM BIOPH RES CO, V273, P164, DOI 10.1006/bbrc.2000.2921; Heine H, 1999, J IMMUNOL, V162, P6971; Heinemann V, 1997, ANTIMICROB AGENTS CH, V41, P728, DOI 10.1128/AAC.41.4.728; Hirschfeld M, 2000, J IMMUNOL, V165, P618, DOI 10.4049/jimmunol.165.2.618; Hirschfeld M, 1999, J IMMUNOL, V163, P2382; Horng T, 2001, NAT IMMUNOL, V2, P835, DOI 10.1038/ni0901-835; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; Kirschning CJ, 1998, J EXP MED, V188, P2091, DOI 10.1084/jem.188.11.2091; Lien E, 2002, CRIT CARE MED, V30, pS1, DOI 10.1097/00003246-200201001-00001; MA Y, 1993, INFECT IMMUN, V61, P3843, DOI 10.1128/IAI.61.9.3843-3853.1993; MANDELL GL, 2000, PRINCIPLES PRACTICE, V1, P448; McCarthy DO, 1998, NURS RES, V47, P19, DOI 10.1097/00006199-199801000-00005; Means TK, 2000, CYTOKINE GROWTH F R, V11, P219, DOI 10.1016/S1359-6101(00)00006-X; Means TK, 2000, LIFE SCI, V68, P241, DOI 10.1016/S0024-3205(00)00939-5; Moore KJ, 2000, J IMMUNOL, V165, P4272, DOI 10.4049/jimmunol.165.8.4272; Ozinsky A, 2000, P NATL ACAD SCI USA, V97, P13766, DOI 10.1073/pnas.250476497; Ozinsky A, 2000, J ENDOTOXIN RES, V6, P393, DOI 10.1179/096805100101532333; Paquet MJ, 2002, CHEM PHYS LIPIDS, V119, P1, DOI 10.1016/S0009-3084(02)00071-3; Pfeiffer A, 2001, EUR J IMMUNOL, V31, P3153, DOI 10.1002/1521-4141(200111)31:11<3153::AID-IMMU3153>3.0.CO;2-0; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Pugin J, 1998, INFECT IMMUN, V66, P1174, DOI 10.1128/IAI.66.3.1174-1180.1998; Rehli M, 2002, TRENDS IMMUNOL, V23, P375, DOI 10.1016/S1471-4906(02)02259-7; Schromm AB, 2001, J EXP MED, V194, P79, DOI 10.1084/jem.194.1.79; Schwandner R, 1999, J BIOL CHEM, V274, P17406, DOI 10.1074/jbc.274.25.17406; Shoham S, 2001, J IMMUNOL, V166, P4620, DOI 10.4049/jimmunol.166.7.4620; Simons K, 2000, NAT REV MOL CELL BIO, V1, P31, DOI 10.1038/35036052; Suschek CV, 2000, BRIT J PHARMACOL, V131, P473, DOI 10.1038/sj.bjp.0703576; Takeuchi O, 1999, IMMUNITY, V11, P443, DOI 10.1016/S1074-7613(00)80119-3; Triantafilou M, 2002, J CELL SCI, V115, P2603; Vabulas RM, 2001, J BIOL CHEM, V276, P31332, DOI 10.1074/jbc.M103217200; Wang QL, 2001, INFECT IMMUN, V69, P2270, DOI 10.1128/IAI.69.4.2270-2276.2001; Wyllie DH, 2000, J IMMUNOL, V165, P7125, DOI 10.4049/jimmunol.165.12.7125; Yang ZG, 1996, J LEUKOCYTE BIOL, V59, P241, DOI 10.1002/jlb.59.2.241; Yoshimura A, 1999, J IMMUNOL, V163, P1	56	159	170	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37561	37568		10.1074/jbc.M306137200	http://dx.doi.org/10.1074/jbc.M306137200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12860979	hybrid			2022-12-27	WOS:000185437200070
J	Vega, RB; Bassel-Duby, R; Olson, EN				Vega, RB; Bassel-Duby, R; Olson, EN			Control of cardiac growth and function by calcineurin signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							FAMILIAL HYPERTROPHIC CARDIOMYOPATHY; LEFT-VENTRICULAR HYPERTROPHY; IN-VIVO; TARGETED INHIBITION; TRANSCRIPTION FACTORS; RELEASE CHANNEL; SKELETAL-MUSCLE; GENE-EXPRESSION; HEART-FAILURE; NF-ATC		Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Eric.Olson@utsouthwestern.edu						Beals CR, 1997, SCIENCE, V275, P1930, DOI 10.1126/science.275.5308.1930; Beals CR, 1997, GENE DEV, V11, P824, DOI 10.1101/gad.11.7.824; Benjamin EJ, 1999, AM J MED SCI, V317, P168, DOI 10.1097/00000441-199903000-00006; Blaeser F, 2000, J BIOL CHEM, V275, P197, DOI 10.1074/jbc.275.1.197; Braz JC, 2003, J CLIN INVEST, V111, P1475, DOI 10.1172/JCI200317295; Bueno OF, 2002, P NATL ACAD SCI USA, V99, P4586, DOI 10.1073/pnas.072647999; Chu GX, 2002, CARDIOVASC RES, V54, P105, DOI 10.1016/S0008-6363(02)00230-4; COGHLAN VM, 1995, SCIENCE, V267, P108, DOI 10.1126/science.7528941; Crabtree GR, 2002, CELL, V109, pS67, DOI 10.1016/S0092-8674(02)00699-2; De Windt LJ, 2000, J BIOL CHEM, V275, P13571, DOI 10.1074/jbc.275.18.13571; De Windt LJ, 2000, CIRC RES, V86, P255, DOI 10.1161/01.RES.86.3.255; De Windt LJ, 2001, P NATL ACAD SCI USA, V98, P3322, DOI 10.1073/pnas.031371998; Dong D, 2003, CARDIOVASC RES, V57, P320, DOI 10.1016/S0008-6363(02)00661-2; Fatkin D, 2000, J CLIN INVEST, V106, P1351, DOI 10.1172/JCI11093; Fiedler B, 2002, P NATL ACAD SCI USA, V99, P11363, DOI 10.1073/pnas.162100799; Frank K, 2000, ANN MED, V32, P572, DOI 10.3109/07853890008998837; Frey N, 2000, NAT MED, V6, P1221, DOI 10.1038/81321; Frey N, 2002, J BIOL CHEM, V277, P13998, DOI 10.1074/jbc.M200712200; Frey N, 2000, P NATL ACAD SCI USA, V97, P14632, DOI 10.1073/pnas.260501097; FUENTES JJ, 1995, HUM MOL GENET, V4, P1935, DOI 10.1093/hmg/4.10.1935; GeisterferLowrance AAT, 1996, SCIENCE, V272, P731, DOI 10.1126/science.272.5262.731; Gill C, 2002, FASEB J, V16, P135, DOI 10.1096/fj.01-0629com; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hill JA, 2002, J BIOL CHEM, V277, P10251, DOI 10.1074/jbc.M110722200; Holtwick R, 2003, J CLIN INVEST, V111, P1399, DOI 10.1172/JCI200317061; JAIN JN, 1993, NATURE, V365, P352, DOI 10.1038/365352a0; Kakita T, 2001, CIRC RES, V88, P1239, DOI 10.1161/hh1201.091794; Kingsbury TJ, 2000, GENE DEV, V14, P1595; Lim HW, 2001, J BIOL CHEM, V276, P15913, DOI 10.1074/jbc.M100452200; Lim HW, 2000, CIRCULATION, V101, P2431, DOI 10.1161/01.CIR.101.20.2431; Lin X, 1999, J BIOL CHEM, V274, P36125, DOI 10.1074/jbc.274.51.36125; Loh C, 1996, J BIOL CHEM, V271, P10884, DOI 10.1074/jbc.271.18.10884; Marks AR, 2003, J CLIN INVEST, V111, P597, DOI 10.1172/JCI200318067; Marx SO, 2000, CELL, V101, P365, DOI 10.1016/S0092-8674(00)80847-8; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Molkentin JD, 2000, CIRC RES, V87, P731, DOI 10.1161/01.RES.87.9.731; Morioka M, 1999, PROG NEUROBIOL, V58, P1, DOI 10.1016/S0301-0082(98)00073-2; Munch G, 2002, J MOL CELL CARDIOL, V34, P321, DOI 10.1006/jmcc.2001.1515; Nicol RL, 2001, EMBO J, V20, P2757, DOI 10.1093/emboj/20.11.2757; Passier R, 2000, J CLIN INVEST, V105, P1395, DOI 10.1172/JCI8551; Pu WT, 2003, CIRC RES, V92, P725, DOI 10.1161/01.RES.0000069211.82346.46; Rothermel BA, 2001, P NATL ACAD SCI USA, V98, P3328, DOI 10.1073/pnas.041614798; Rusnak F, 2000, PHYSIOL REV, V80, P1483, DOI 10.1152/physrev.2000.80.4.1483; Sah R, 2002, CIRCULATION, V105, P1850, DOI 10.1161/01.CIR.0000014211.47830.4D; Saito S, 2000, J BIOL CHEM, V275, P34528, DOI 10.1074/jbc.M002844200; Shin DW, 2002, BIOPHYS J, V83, P2539, DOI 10.1016/S0006-3495(02)75265-X; Silberbach M, 2001, CELL SIGNAL, V13, P221, DOI 10.1016/S0898-6568(01)00139-5; Sun L, 1998, IMMUNITY, V8, P703, DOI 10.1016/S1074-7613(00)80575-0; Timmerman LA, 1996, NATURE, V383, P837, DOI 10.1038/383837a0; van Rooij E, 2002, J BIOL CHEM, V277, P48617, DOI 10.1074/jbc.M206532200; Vega RB, 2003, P NATL ACAD SCI USA, V100, P669, DOI 10.1073/pnas.0237225100; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wilkins BJ, 2002, MOL CELL BIOL, V22, P7603, DOI 10.1128/MCB.22.21.7603-7613.2002; Wolk R, 2003, CARDIOVASC RES, V57, P289, DOI 10.1016/S0008-6363(02)00835-0; Yang J, 2000, CIRC RES, V87, pE61, DOI 10.1161/01.RES.87.12.e61; Youn HD, 2000, EMBO J, V19, P4323, DOI 10.1093/emboj/19.16.4323; Zhang CL, 2002, CELL, V110, P479, DOI 10.1016/S0092-8674(02)00861-9; Zou YZ, 2001, CIRCULATION, V104, P102, DOI 10.1161/hc2601.090987; Zou YZ, 2001, CIRCULATION, V104, P97, DOI 10.1161/01.CIR.104.1.97	59	115	127	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					36981	36984		10.1074/jbc.R300023200	http://dx.doi.org/10.1074/jbc.R300023200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12881512	hybrid			2022-12-27	WOS:000185437200001
J	Wise, LM; Ueda, N; Dryden, NH; Fleming, SB; Caesar, C; Roufail, S; Achen, MG; Stacker, SA; Mercer, AA				Wise, LM; Ueda, N; Dryden, NH; Fleming, SB; Caesar, C; Roufail, S; Achen, MG; Stacker, SA; Mercer, AA			Viral vascular endothelial growth factors vary extensively in amino acid sequence, receptor-binding specificities, and the ability to induce vascular permeability yet are uniformly active mitogens	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORF-VIRUS; CRYSTAL-STRUCTURE; FACTOR VEGF; TUMOR-CELLS; FACTOR-B; ANGSTROM RESOLUTION; TYROSINE KINASES; FLT-1 RECEPTOR; NEUROPILIN-1; PROTEIN	Infections of humans and ungulates by parapoxviruses result in skin lesions characterized by extensive vascular changes that have been linked to viral-encoded homologues of vascular endothelial growth factor ( VEGF). VEGF acts via a family of receptors ( VEGFRs) to mediate endothelial cell proliferation, vascular permeability, and angiogenesis. The VEGF genes from independent parapoxvirus isolates show an extraordinary degree of inter-strain sequence variation. We conducted functional comparisons of five representatives of the divergent viral VEGFs. These revealed that despite the sequence divergence, all were equally active mitogens, stimulating proliferation of human endothelial cells in vitro and vascularization of sheep skin in vivo with potencies equivalent to VEGF. This was achieved even though the viral VEGFs bound VEGFR-2 less avidly than did VEGF. Surprisingly the viral VEGFs varied in their ability to cross-link VEGFR-2, induce vascular permeability and bind neuropilin-1. Correlations between these three activities were detected. In addition it was possible to correlate these functional variations with certain sequence and structural motifs specific to the viral VEGFs. In contrast to the conserved ability to bind human VEGFR-2, the viral growth factors did not bind either VEGFR-1 or VEGFR-3. We propose that the extensive sequence divergence seen in the viral VEGFs was generated primarily by selection against VEGFR-1 binding.	Univ Otago, Dept Microbiol, Virus Res Unit, Dunedin, New Zealand; Royal Melbourne Hosp, Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia	University of Otago; Ludwig Institute for Cancer Research; Royal Melbourne Hospital	Mercer, AA (corresponding author), Univ Otago, Dept Microbiol, Virus Res Unit, POB 56, Dunedin, New Zealand.	andy.mercer@stonebow.otago.ac.nz	Stacker, Steven A/J-2205-2012; Mercer, Andrew A/G-6635-2015	Stacker, Steven A/0000-0003-4096-9273; Achen, Marc/0000-0002-3791-803X; Wise, Lyn/0000-0003-0646-8424; Mercer, Andrew/0000-0003-3697-1071				Achen MG, 2000, EUR J BIOCHEM, V267, P2505, DOI 10.1046/j.1432-1327.2000.01257.x; Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548; Baldwin ME, 2001, J BIOL CHEM, V276, P19166, DOI 10.1074/jbc.M100097200; Clauss M, 1996, J BIOL CHEM, V271, P17629, DOI 10.1074/jbc.271.30.17629; Detmar M, 1998, J INVEST DERMATOL, V111, P1, DOI 10.1046/j.1523-1747.1998.00262.x; DEVRIES C, 1992, SCIENCE, V255, P989, DOI 10.1126/science.1312256; Dvorak AM, 2001, J HISTOCHEM CYTOCHEM, V49, P419, DOI 10.1177/002215540104900401; DVORAK HF, 1995, AM J PATHOL, V146, P1029; EVANS MJ, 1995, J IMMUNOL METHODS, V184, P123, DOI 10.1016/0022-1759(95)00093-P; Feng D, 2000, J HISTOCHEM CYTOCHEM, V48, P545, DOI 10.1177/002215540004800412; FERRARA N, 1989, BIOCHEM BIOPH RES CO, V161, P851, DOI 10.1016/0006-291X(89)92678-8; Fuh G, 2000, J BIOL CHEM, V275, P26690; Gabrilovich DI, 1996, NAT MED, V2, P1096, DOI 10.1038/nm1096-1096; Gille H, 2001, J BIOL CHEM, V276, P3222, DOI 10.1074/jbc.M002016200; GROVES RW, 1991, J AM ACAD DERMATOL, V25, P706, DOI 10.1016/0190-9622(91)70257-3; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Haig DM, 1998, VET RES, V29, P311; Iyer S, 2001, J BIOL CHEM, V276, P12153, DOI 10.1074/jbc.M008055200; Joukov V, 1998, J BIOL CHEM, V273, P6599, DOI 10.1074/jbc.273.12.6599; Joukov V, 1996, EMBO J, V15, P290; Keyt BA, 1996, J BIOL CHEM, V271, P5638, DOI 10.1074/jbc.271.10.5638; Lee J, 1996, P NATL ACAD SCI USA, V93, P1988, DOI 10.1073/pnas.93.5.1988; LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986; Li B, 2000, J BIOL CHEM, V275, P29823, DOI 10.1074/jbc.M002015200; LYTTLE DJ, 1994, J VIROL, V68, P84, DOI 10.1128/JVI.68.1.84-92.1994; MAGLIONE D, 1991, P NATL ACAD SCI USA, V88, P9267, DOI 10.1073/pnas.88.20.9267; Makinen T, 1999, J BIOL CHEM, V274, P21217, DOI 10.1074/jbc.274.30.21217; Makinen T, 2001, EMBO J, V20, P4762, DOI 10.1093/emboj/20.17.4762; MCDONALD NQ, 1993, CELL, V73, P421, DOI 10.1016/0092-8674(93)90127-C; Mercer A, 1997, ARCH VIROL, P25; Mercer AA, 2002, J GEN VIROL, V83, P2845, DOI 10.1099/0022-1317-83-11-2845; Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363; Migdal M, 1998, J BIOL CHEM, V273, P22272, DOI 10.1074/jbc.273.35.22272; MILES AA, 1952, J PHYSIOL-LONDON, V118, P228, DOI 10.1113/jphysiol.1952.sp004789; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Muller YA, 1997, STRUCTURE, V5, P1325, DOI 10.1016/S0969-2126(97)00284-0; Muller YA, 1997, P NATL ACAD SCI USA, V94, P7192, DOI 10.1073/pnas.94.14.7192; Ogawa S, 1998, J BIOL CHEM, V273, P31273, DOI 10.1074/jbc.273.47.31273; Olofsson B, 1998, P NATL ACAD SCI USA, V95, P11709, DOI 10.1073/pnas.95.20.11709; Olofsson B, 1996, P NATL ACAD SCI USA, V93, P2576, DOI 10.1073/pnas.93.6.2576; PARK JE, 1994, J BIOL CHEM, V269, P25646; QUINN TP, 1993, P NATL ACAD SCI USA, V90, P7533, DOI 10.1073/pnas.90.16.7533; Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0; Robinson CJ, 2001, J CELL SCI, V114, P853; Savory LJ, 2000, J VIROL, V74, P10699, DOI 10.1128/JVI.74.22.10699-10706.2000; SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562; Shibuya M, 2001, INT J BIOCHEM CELL B, V33, P409, DOI 10.1016/S1357-2725(01)00026-7; Soker S, 1998, CELL, V92, P735, DOI 10.1016/S0092-8674(00)81402-6; Stacker SA, 1999, GROWTH FACTORS, V17, P1, DOI 10.3109/08977199909001058; Stacker SA, 1999, J BIOL CHEM, V274, P34884, DOI 10.1074/jbc.274.49.34884; Stacker SA, 2001, NAT MED, V7, P186, DOI 10.1038/84635; Staquet MJ, 2001, ARCH DERMATOL RES, V293, P26, DOI 10.1007/s004030000193; Taipale J, 1999, CURR TOP MICROBIOL, V237, P85; Tzahar E, 1998, EMBO J, V17, P5948, DOI 10.1093/emboj/17.20.5948; Ueda N, 2003, VIROLOGY, V305, P298, DOI 10.1006/viro.2002.1750; Whitaker GB, 2001, J BIOL CHEM, V276, P25520, DOI 10.1074/jbc.M102315200; Wiesmann C, 1997, CELL, V91, P695, DOI 10.1016/S0092-8674(00)80456-0; Wise LM, 1999, P NATL ACAD SCI USA, V96, P3071, DOI 10.1073/pnas.96.6.3071; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215	59	59	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					38004	38014		10.1074/jbc.M301194200	http://dx.doi.org/10.1074/jbc.M301194200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12867434	hybrid			2022-12-27	WOS:000185437200122
J	Xu, WL; Shen, JY; Dunn, CA; Bessman, MJ				Xu, WL; Shen, JY; Dunn, CA; Bessman, MJ			A new subfamily of the nudix hydrolase superfamily active on 5-methyl-UTP (ribo-TTP) and UTP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOSIDE TRIPHOSPHATASE; MUTT FAMILY; GENE; PURIFICATION; PYROPHOSPHATASE; ENZYMES; CLONING; IDENTIFICATION; MECHANISM	A new subfamily of the Nudix hydrolases, identified by conserved amino acids upstream and downstream of the Nudix box, has been characterized. The cloned, expressed, and purified orthologous enzymes have major activities on the non-canonical nucleoside triphosphate 5-methyl-UTP (ribo-TTP) and the canonical nucleotide UTP. In addition to their homologous signature sequences and their similar substrate specificities, the members of the subfamily are inhabitants of or are related to the bacterial rhizosphere. We propose the acronym and mnemonic, utp, for the gene designating this unique UTPase.	Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA; Johns Hopkins Univ, McCollum Pratt Inst, Baltimore, MD 21218 USA	Johns Hopkins University; Johns Hopkins University	Bessman, MJ (corresponding author), Johns Hopkins Univ, Dept Biol, Baltimore, MD 21218 USA.			Dunn, Christopher/0000-0001-7899-0110	NIGMS NIH HHS [GM18649] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMES BN, 1960, J BIOL CHEM, V235, P769; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BHATNAGAR SK, 1991, J BIOL CHEM, V266, P9050; BHATNAGAR SK, 1988, J BIOL CHEM, V263, P8953; BJORK GR, 1975, J BACTERIOL, V124, P99; BULLIONS LC, 1993, THESIS J HOPKINS U; Cartwright JL, 2000, J BIOL CHEM, V275, P32925, DOI 10.1074/jbc.M005015200; Conyers GB, 1999, J BIOL CHEM, V274, P1203, DOI 10.1074/jbc.274.3.1203; Dunn CA, 1999, J BIOL CHEM, V274, P32318, DOI 10.1074/jbc.274.45.32318; Espinosa JC, 1999, J BACTERIOL, V181, P4914, DOI 10.1128/JB.181.16.4914-4918.1999; Fiske CH, 1925, J BIOL CHEM, V66, P375; FRICK DN, 1995, J BIOL CHEM, V270, P1529, DOI 10.1074/jbc.270.4.1529; FRICK DN, 1995, J BIOL CHEM, V270, P24086, DOI 10.1074/jbc.270.41.24086; Gabelli SB, 2001, NAT STRUCT BIOL, V8, P467, DOI 10.1038/87647; Higgins DG, 1996, METHOD ENZYMOL, V266, P383; JONG A, 1993, ARCH BIOCHEM BIOPHYS, V304, P197, DOI 10.1006/abbi.1993.1339; Lin J, 1997, BIOCHEMISTRY-US, V36, P1199, DOI 10.1021/bi962619c; LORENSON MY, 1967, J BIOL CHEM, V242, P3332; NAKAYAMA C, 1980, NUCL ACIDS S SER, V8, P193; O'Handley SF, 2001, J BIOL CHEM, V276, P5421, DOI 10.1074/jbc.M004100200; OHANDLEY SF, 1995, FASEB J, V9, pA1299; OHandley SF, 1996, J BIOL CHEM, V271, P24649, DOI 10.1074/jbc.271.40.24649; SLAPIKOFF S, 1967, BIOCHEMISTRY-US, V12, P3654; Yan HG, 1999, ADV ENZYMOL RAMB, V73, P103, DOI 10.1002/9780470123195.ch4	26	20	21	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37492	37496		10.1074/jbc.M307639200	http://dx.doi.org/10.1074/jbc.M307639200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12871944	hybrid			2022-12-27	WOS:000185437200062
J	Cook, CR; Kung, GS; Peterson, FC; Volkman, BF; Lei, M				Cook, CR; Kung, GS; Peterson, FC; Volkman, BF; Lei, M			A novel zinc finger is required for Mcm10 homocomplex assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-REPLICATION; BINDING PROPERTIES; HUMAN HOMOLOG; PROTEIN; INITIATION; ORIGINS; COMPLEX; COMPONENT; SYSTEM; MAINTENANCE	Mcm10 is a DNA replication factor that interacts with multiple subunits of the MCM2-7 hexameric complex. We report here that Mcm10 self-interacts and assembles into large homocomplexes (similar to 800 kDa). A conserved domain of 210 amino acid residues is sufficient for mediating self-interaction and complex assembly. A novel zinc finger within the conserved domain, CX10CX11CX2H, is essential for the homocomplex formation. Mutant alleles with amino acid substitutions at conserved cysteines and histidine in the zinc finger fail to assemble homocomplexes. A defect in homocomplex assembly correlates with defects in DNA replication and cell growth in the mutants. These observations suggest that homocomplex assembly is essential for Mcm10 function. Multisubunit Mcm10 homocomplexes may provide the structural basis for Mcm10 to interact with multiple subunits of the MCM2-7 hexamer.	Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Medical College of Wisconsin; Medical College of Wisconsin	Lei, M (corresponding author), Med Coll Wisconsin, Dept Microbiol & Mol Genet, Milwaukee, WI 53226 USA.	mlei@mcw.edu	Volkman, Brian F./ABE-7306-2020; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179	NIGMS NIH HHS [GM6264901] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062649] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi Y, 1997, GENES CELLS, V2, P467, DOI 10.1046/j.1365-2443.1997.1350333.x; Amann BT, 2003, BIOCHEMISTRY-US, V42, P217, DOI 10.1021/bi026988m; Aves SJ, 1998, CURR GENET, V34, P164, DOI 10.1007/s002940050382; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; Berg JM, 1997, ANNU REV BIOPH BIOM, V26, P357, DOI 10.1146/annurev.biophys.26.1.357; BERG JM, 1990, ANNU REV BIOPHYS BIO, V19, P405; Bochkareva E, 2002, EMBO J, V21, P1855, DOI 10.1093/emboj/21.7.1855; BURKHART R, 1995, EUR J BIOCHEM, V228, P431; CHONG JPJ, 1995, NATURE, V375, P418, DOI 10.1038/375418a0; Chong JPJ, 2000, P NATL ACAD SCI USA, V97, P1530, DOI 10.1073/pnas.030539597; Christensen TW, 2003, MOL BIOL CELL, V14, P2206, DOI 10.1091/mbc.E02-11-0706; Coleman TR, 1996, CELL, V87, P53, DOI 10.1016/S0092-8674(00)81322-7; Davey MJ, 2003, J BIOL CHEM, V278, P4491, DOI 10.1074/jbc.M210511200; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1994, CELL, V78, P303, DOI 10.1016/0092-8674(94)90299-2; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; Fletcher RJ, 2003, NAT STRUCT BIOL, V10, P160, DOI 10.1038/nsb893; Gao GX, 2002, SCIENCE, V297, P1703, DOI 10.1126/science.1074276; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; Guthrie C, 1991, METHOD ENZYMOL, V194, P3; Harlow E., 1988, ANTIBODIES LAB MANUA; Homesley L, 2000, GENE DEV, V14, P913; HOMESLEY LA, 1999, THESIS CORNELL U ITH; Izumi M, 2001, J BIOL CHEM, V276, P48526, DOI 10.1074/jbc.M107190200; Izumi M, 2000, NUCLEIC ACIDS RES, V28, P4769, DOI 10.1093/nar/28.23.4769; Kawasaki Y, 2000, GENES CELLS, V5, P975, DOI 10.1046/j.1365-2443.2000.00387.x; Kearsey SE, 1998, BBA-GENE STRUCT EXPR, V1398, P113, DOI 10.1016/S0167-4781(98)00033-5; KING DS, 1990, INT J PEPT PROT RES, V36, P255; KUBOTA Y, 1995, CELL, V81, P601, DOI 10.1016/0092-8674(95)90081-0; Lei M, 2002, J BIOL CHEM, V277, P30824, DOI 10.1074/jbc.M201816200; Lei M, 1996, MOL CELL BIOL, V16, P5081; Lei M, 2001, J CELL SCI, V114, P1447; Liang DT, 2001, GENETICS, V159, P471; MADINE MA, 1995, NATURE, V375, P421, DOI 10.1038/375421a0; MAINE GT, 1984, GENETICS, V106, P365; Merchant AM, 1997, MOL CELL BIOL, V17, P3261, DOI 10.1128/MCB.17.6.3261; MUSAHL C, 1995, EUR J BIOCHEM, V230, P1096, DOI 10.1111/j.1432-1033.1995.tb20660.x; Schwacha A, 2001, MOL CELL, V8, P1093, DOI 10.1016/S1097-2765(01)00389-6; SIKORSKI RS, 1989, GENETICS, V122, P19; SOLOMON NA, 1992, YEAST, V8, P273, DOI 10.1002/yea.320080405; Thommes P, 1997, EMBO J, V16, P3312, DOI 10.1093/emboj/16.11.3312; Tye BK, 2000, J BIOL CHEM, V275, P34833, DOI 10.1074/jbc.R000018200; Tye BK, 1999, ANNU REV BIOCHEM, V68, P649, DOI 10.1146/annurev.biochem.68.1.649; Wohlschlegel JA, 2002, MOL CELL, V9, P233, DOI 10.1016/S1097-2765(02)00456-2; Worthington MT, 1996, P NATL ACAD SCI USA, V93, P13754, DOI 10.1073/pnas.93.24.13754; YAN H, 1991, GENE DEV, V5, P944, DOI 10.1101/gad.5.6.944; Yu X, 2002, EMBO REP, V3, P792, DOI 10.1093/embo-reports/kvf160	48	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36051	36058		10.1074/jbc.M306049200	http://dx.doi.org/10.1074/jbc.M306049200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12844493	hybrid			2022-12-27	WOS:000185318300024
J	Di Padova, M; Bruno, T; De Nicola, F; Iezzi, S; D'Angelo, C; Gallo, R; Nicosia, D; Corbi, N; Biroccio, A; Floridi, A; Passananti, C; Fanciulli, M				Di Padova, M; Bruno, T; De Nicola, F; Iezzi, S; D'Angelo, C; Gallo, R; Nicosia, D; Corbi, N; Biroccio, A; Floridi, A; Passananti, C; Fanciulli, M			Che-1 arrests human colon carcinoma cell proliferation by displacing HDAC1 from the p21(WAF1/CIP1) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTONE DEACETYLASE INHIBITOR; SUBEROYLANILIDE HYDROXAMIC ACID; WAF1/CIP1 GENE PROMOTER; TRANSCRIPTION FACTOR; CHROMATIN-STRUCTURE; SP1 SITES; GROWTH; CANCER; KINASE; IDENTIFICATION	Che-1 is a recently identified human RNA polymerase II binding protein involved in the regulation of gene transcription and cell proliferation. We previously demonstrated that Che-1 inhibits the Rb growth-suppressing function by interfering with Rb-mediated HDAC1 recruitment on E2F target gene promoters. By hybridization of cancer profile arrays, we found that Che-1 expression is strongly down-regulated in several tumors, including colon and kidney carcinomas, compared with the relative normal tissues. Consistent with these data, Che-1 overexpression inhibits proliferation of HCT116 and LoVo human colon carcinoma cell lines by activation of the cyclin-dependent kinase inhibitor p21(WAF1/Cip1) in a p53-independent manner and by promoting growth arrest at the G(1) phase of the cell cycle. Che-1 activates p21(WAF1/Cip1) by displacing histone deacetylase ( HDAC) 1 from the Sp1 binding sites of the p21(WAF1/Cip1) gene promoter and accumulating acetylated histone H3 on these sites. Accordingly, Che-1-specific RNA interference negatively affects p21(WAF1/Cip1) transactivation and increases cell proliferation in HCT116 cells. Taken together, our results indicate that Che-1 can be considered a general HDAC1 competitor and its down-regulation is involved in colon carcinoma cell proliferation.	Regina Elena Inst Canc Res, Expt Res Ctr, Lab B, I-00158 Rome, Italy; Regina Elena Inst Canc Res, Expt Res Ctr, Expt Chemotherapy Lab, I-00158 Rome, Italy; Univ Aquila, Dept Expt Med, I-67100 Laquila, Italy; CNR, Ist Biol & Patol Mol, I-00137 Rome, Italy	IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of L'Aquila; Consiglio Nazionale delle Ricerche (CNR); Istituto di Biologia e Patologia Molecolari (IBPM-CNR)	Fanciulli, M (corresponding author), Regina Elena Inst Canc Res, Expt Res Ctr, Lab B, Via Messi Oro 156, I-00158 Rome, Italy.	fanciulli@.ifo.it	fanciulli, maurizio/ABH-6745-2020; Iezzi, Simona/AAA-3275-2021; Corbi, Nicoletta/AAW-8835-2020; bruno, tiziana/AAC-4913-2022; Passananti, Claudio/K-9593-2016; Corbi, Nicoletta/K-2313-2014; Biroccio, Annamaria/B-2861-2018; De Nicola, Francesca/AAC-6887-2022	Iezzi, Simona/0000-0002-7484-5861; bruno, tiziana/0000-0003-0352-4523; Biroccio, Annamaria/0000-0003-3198-3532; PASSANANTI, CLAUDIO/0000-0002-9288-5736; De Nicola, FRANCESCA/0000-0002-2187-7544; CORBI, NICOLETTA/0000-0002-4505-1632; DI PADOVA, Monica/0000-0003-3808-7159	Telethon [A.160] Funding Source: Medline	Telethon(Fondazione Telethon)		Archer SY, 1998, P NATL ACAD SCI USA, V95, P6791, DOI 10.1073/pnas.95.12.6791; Bartl S, 1997, MOL CELL BIOL, V17, P5033, DOI 10.1128/MCB.17.9.5033; Bernhard D, 1999, FASEB J, V13, P1991, DOI 10.1096/fasebj.13.14.1991; Biroccio A, 2002, J BIOL CHEM, V277, P43763, DOI 10.1074/jbc.M207684200; Bruno T, 2002, CANCER CELL, V2, P387, DOI 10.1016/S1535-6108(02)00182-4; Butler LM, 2002, P NATL ACAD SCI USA, V99, P11700, DOI 10.1073/pnas.182372299; Butler LM, 2000, CANCER RES, V60, P5165; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; DelBufalo D, 1996, J CLIN INVEST, V98, P1165, DOI 10.1172/JCI118900; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; Fanciulli M, 2000, FASEB J, V14, P904, DOI 10.1096/fasebj.14.7.904; Finzer P, 2001, ONCOGENE, V20, P4768, DOI 10.1038/sj.onc.1204652; Fournel M, 2002, CANCER RES, V62, P4325; Gallo R, 2002, J CELL BIOL, V158, P731, DOI 10.1083/jcb.200202024; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Han JW, 2001, J BIOL CHEM, V276, P42084, DOI 10.1074/jbc.M106688200; Han JW, 2000, CANCER RES, V60, P6068; Harbour JW, 2000, GENE DEV, V14, P2393, DOI 10.1101/gad.813200; HARPER JW, 1993, CELL, V75, P805; Huang LL, 2000, ONCOGENE, V19, P5712, DOI 10.1038/sj.onc.1203963; Kim YB, 1999, ONCOGENE, V18, P2461, DOI 10.1038/sj.onc.1202564; Kogel D, 1998, ONCOGENE, V17, P2645, DOI 10.1038/sj.onc.1202204; Kouzarides T, 2000, EMBO J, V19, P1176, DOI 10.1093/emboj/19.6.1176; Lagger G, 2002, EMBO J, V21, P2672, DOI 10.1093/emboj/21.11.2672; Lindfors K, 2000, BIOCHEM BIOPH RES CO, V276, P660, DOI 10.1006/bbrc.2000.3480; Marks PA, 2001, CURR OPIN ONCOL, V13, P477, DOI 10.1097/00001622-200111000-00010; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Nakano K, 1997, J BIOL CHEM, V272, P22199, DOI 10.1074/jbc.272.35.22199; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Page G, 1999, FEBS LETT, V462, P187, DOI 10.1016/S0014-5793(99)01529-X; Richon VM, 2000, P NATL ACAD SCI USA, V97, P10014, DOI 10.1073/pnas.180316197; Sambucetti LC, 1999, J BIOL CHEM, V274, P34940, DOI 10.1074/jbc.274.49.34940; Sowa Y, 1999, CANCER RES, V59, P4266; Sowa Y, 1997, BIOCHEM BIOPH RES CO, V241, P142, DOI 10.1006/bbrc.1997.7786; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Thomas T, 2000, DEV BIOL, V227, P324, DOI 10.1006/dbio.2000.9915; VanLint C, 1996, GENE EXPRESSION, V5, P245; WALDMAN T, 1995, CANCER RES, V55, P5187; Xiao HY, 1999, J CELL BIOCHEM, V73, P291, DOI 10.1002/(SICI)1097-4644(19990601)73:3<291::AID-JCB1>3.0.CO;2-5; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; Yamashita Y, 2003, INT J CANCER, V103, P572, DOI 10.1002/ijc.10699; Zhang HS, 2001, ONCOGENE, V20, P3134, DOI 10.1038/sj.onc.1204338	45	40	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36496	36504		10.1074/jbc.M306694200	http://dx.doi.org/10.1074/jbc.M306694200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847090	hybrid			2022-12-27	WOS:000185318300078
J	Schnell, JD; Hicke, L				Schnell, JD; Hicke, L			Non-traditional functions of ubiquitin and ubiquitin-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							HISTONE H2B; UBA DOMAIN; CUE DOMAIN; DEGRADATION; PATHWAY; MONOUBIQUITINATION; POLYUBIQUITIN; RECEPTOR; COMPLEX; SURFACE		Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Hicke, L (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Hogan 2-100,2205 Tech Dr, Evanston, IL 60208 USA.	l-hicke@northwestern.edu	Schnell, Joshua/J-4000-2012; Schnell, Joshua/J-3142-2019	Schnell, Joshua/0000-0001-9241-7441; Schnell, Joshua/0000-0001-9241-7441	NIDDK NIH HHS [DK61299, DK53257] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK061299, R01DK061299, R01DK053257] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Ben-Neriah Y, 2002, NAT IMMUNOL, V3, P20, DOI 10.1038/ni0102-20; Bilodeau PS, 2002, NAT CELL BIOL, V4, P534, DOI 10.1038/ncb815; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; Chen X, 2002, GENE DEV, V16, P289, DOI 10.1101/gad.961502; Cullen PJ, 2001, CURR BIOL, V11, pR882, DOI 10.1016/S0960-9822(01)00523-1; Davies BA, 2003, J BIOL CHEM, V278, P19826, DOI 10.1074/jbc.M301059200; Di Fiore PP, 2003, NAT REV MOL CELL BIO, V4, P491, DOI 10.1038/nrm1124; Dover J, 2002, J BIOL CHEM, V277, P28368, DOI 10.1074/jbc.C200348200; Dunn R, 2001, J BIOL CHEM, V276, P25974, DOI 10.1074/jbc.M104113200; Fisher RD, 2003, J BIOL CHEM, V278, P28976, DOI 10.1074/jbc.M302596200; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gregory RC, 2003, SEMIN CANCER BIOL, V13, P77, DOI 10.1016/S1044-579X(02)00102-5; Haglund K, 2003, NAT CELL BIOL, V5, P461, DOI 10.1038/ncb983; Haglund K, 2002, P NATL ACAD SCI USA, V99, P12191, DOI 10.1073/pnas.192462299; Hicke L, 2001, NAT REV MOL CELL BIO, V2, P195, DOI 10.1038/35056583; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hofmann K, 1996, TRENDS BIOCHEM SCI, V21, P172, DOI 10.1016/0968-0004(96)30015-7; Hofmann K, 2001, TRENDS BIOCHEM SCI, V26, P347, DOI 10.1016/S0968-0004(01)01835-7; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Hook SS, 2002, P NATL ACAD SCI USA, V99, P13425, DOI 10.1073/pnas.172511699; Jason LJM, 2002, BIOESSAYS, V24, P166, DOI 10.1002/bies.10038; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Kang RS, 2003, CELL, V113, P621, DOI 10.1016/S0092-8674(03)00362-3; Katzmann DJ, 2001, CELL, V106, P145, DOI 10.1016/S0092-8674(01)00434-2; Katzmann DJ, 2002, NAT REV MOL CELL BIO, V3, P893, DOI 10.1038/nrm973; Klapisz E, 2002, J BIOL CHEM, V277, P30746, DOI 10.1074/jbc.M203004200; Lord JM, 2002, CURR BIOL, V12, pR182, DOI 10.1016/S0960-9822(02)00738-8; Lu Q, 2003, P NATL ACAD SCI USA, V100, P7626, DOI 10.1073/pnas.0932599100; Madura K, 2002, CELL CYCLE, V1, P233, DOI 10.4161/cc.1.4.130; Meyer HH, 2002, EMBO J, V21, P5645, DOI 10.1093/emboj/cdf579; MIZUNO E, IN PRESS MOL BIOL CE; Mueller TD, 2002, J MOL BIOL, V319, P1243, DOI 10.1016/S0022-2836(02)00302-9; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Myat A, 2002, NEURON, V35, P447, DOI 10.1016/S0896-6273(02)00795-X; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Nie J, 2002, EMBO J, V21, P93, DOI 10.1093/emboj/21.1.93; Oldham CE, 2002, CURR BIOL, V12, P1112, DOI 10.1016/S0960-9822(02)00900-4; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Polo S, 2002, NATURE, V416, P451, DOI 10.1038/416451a; Ponting CP, 2000, BIOCHEM J, V351, P527, DOI 10.1042/0264-6021:3510527; Pornillos O, 2002, EMBO J, V21, P2397, DOI 10.1093/emboj/21.10.2397; Pornillos O, 2002, TRENDS CELL BIOL, V12, P569, DOI 10.1016/S0962-8924(02)02402-9; Prag G, 2003, CELL, V113, P609, DOI 10.1016/S0092-8674(03)00364-7; Raiborg C, 2002, NAT CELL BIOL, V4, P394, DOI 10.1038/ncb791; Robzyk K, 2000, SCIENCE, V287, P501, DOI 10.1126/science.287.5452.501; Rotin D, 2000, J MEMBRANE BIOL, V176, P1; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; Seigneurin-Berny D, 2001, MOL CELL BIOL, V21, P8035, DOI 10.1128/MCB.21.23.8035-8044.2001; Shenoy SK, 2003, J BIOL CHEM, V278, P14498, DOI 10.1074/jbc.M209626200; Shih SC, 2000, EMBO J, V19, P187, DOI 10.1093/emboj/19.2.187; Shih SC, 2002, NAT CELL BIOL, V4, P389, DOI 10.1038/ncb790; Shih SC, 2003, EMBO J, V22, P1273, DOI 10.1093/emboj/cdg140; Sloper-Mould KE, 2001, J BIOL CHEM, V276, P30483, DOI 10.1074/jbc.M103248200; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Terrell J, 1998, MOL CELL, V1, P193, DOI 10.1016/S1097-2765(00)80020-9; van Kerkhof P, 2000, J BIOL CHEM, V275, P1575, DOI 10.1074/jbc.275.3.1575; VanDemark AP, 2001, CELL, V105, P711, DOI 10.1016/S0092-8674(01)00387-7; Wang B, 2003, J BIOL CHEM, V278, P20225, DOI 10.1074/jbc.M300459200; Wendland B, 2002, NAT REV MOL CELL BIO, V3, P971, DOI 10.1038/nrm970; Wilkinson CRM, 2001, NAT CELL BIOL, V3, P939, DOI 10.1038/ncb1001-939; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Witowsky JA, 2003, J BIOL CHEM, V278, P1403, DOI 10.1074/jbc.C200616200; Yaffe MB, 2002, NAT REV MOL CELL BIO, V3, P177, DOI 10.1038/nrm759; Young P, 1998, J BIOL CHEM, V273, P5461, DOI 10.1074/jbc.273.10.5461	65	335	348	1	29	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35857	35860		10.1074/jbc.R300018200	http://dx.doi.org/10.1074/jbc.R300018200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12860974	hybrid			2022-12-27	WOS:000185318300001
J	Woodcock, JM; Murphy, J; Stomski, FC; Berndt, MC; Lopez, AF				Woodcock, JM; Murphy, J; Stomski, FC; Berndt, MC; Lopez, AF			The dimeric versus monomeric status of 14-3-3 zeta is controlled by phosphorylation of Ser(58) at the dimer interface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IN-VITRO; MEDIATED PHOSPHORYLATION; APOPTOSIS; PROTEINS; KINASE; SPHINGOSINE; N,N-DIMETHYLSPHINGOSINE; IDENTIFICATION; INDUCTION; ISOFORMS	The 14-3-3 proteins play a central role in the regulation of cell growth, cycling, and apoptosis by modulating the functional activities of key signaling proteins. Through binding to a phosphoserine motif, 14-3-3 alters target proteins activities by sequestering them, relocalizing them, conformationally altering their functional activity, or by promoting interaction with other proteins. These functions of 14-3-3 are facilitated by, if not dependent on, its dimeric structure. We now show that the dimeric status of 14-3-3 is regulated by site-specific serine phosphorylation. We found that a sphingosine-dependent kinase phosphorylates 14-3-3 in vitro and in vivo on a serine residue (Ser(58)) located within the dimer interface. Furthermore, by developing an antibody that specifically recognizes 14-3-3zeta phosphorylated on Ser58 and employing native-PAGE and cross-linking techniques, we found that 14-3-3 phosphorylated on Ser58 is monomeric both in vitro and in vivo. Phosphorylated 14-3-3 was detected solely as a monomer, indicating that phosphorylation of a single monomer within a dimer is sufficient to disrupt the dimeric structure. Significantly, phosphorylation-induced monomerization did not prevent 14-3-3 binding to a phosphopeptide target. We propose that this regulated monomerization of 14-3-3 controls its ability to modulate the activity of target proteins and thus may have significant implications for 14-3-3 function and the regulation of many cellular processes.	Inst Med & Vet Sci, Hanson Inst, Div Human Immunol, Cytokine Receptor Lab, Adelaide, SA 5000, Australia; Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Hanson Institute; Institute Medical & Veterinary Science Australia; Monash University	Woodcock, JM (corresponding author), Inst Med & Vet Sci, Hanson Inst, Div Human Immunol, Cytokine Receptor Lab, GPO Box 14 Rundle Mall, Adelaide, SA 5000, Australia.	joanna.woodcock@imvs.sa.gov.au	Lopez, Angel F/E-2260-2011; Berndt, Michael C/D-5580-2012	Lopez, Angel F/0000-0001-7430-0135; Woodcock, Joanna/0000-0001-5127-9687				ABDELGHANY M, 1992, BIOCHIM BIOPHYS ACTA, V1137, P349, DOI 10.1016/0167-4889(92)90156-6; Aitken A, 2002, PLANT MOL BIOL, V50, P993, DOI 10.1023/A:1021261931561; Bodnar RJ, 2002, J BIOL CHEM, V277, P47080, DOI 10.1074/jbc.M208329200; Cahill CM, 2001, J BIOL CHEM, V276, P13402, DOI 10.1074/jbc.M010042200; ENDO K, 1991, CANCER RES, V51, P1613; Fu HA, 2000, ANNU REV PHARMACOL, V40, P617, DOI 10.1146/annurev.pharmtox.40.1.617; Guthridge MA, 2000, MOL CELL, V6, P99, DOI 10.1016/S1097-2765(00)00011-3; Jendiroba DB, 2002, LEUKEMIA RES, V26, P301, DOI 10.1016/S0145-2126(01)00129-1; JONES DH, 1995, FEBS LETT, V368, P55, DOI 10.1016/0014-5793(95)00598-4; LUI D, 1995, NATURE, V376, P191; LUO ZJ, 1995, J BIOL CHEM, V270, P23681, DOI 10.1074/jbc.270.40.23681; Masters SC, 2001, J BIOL CHEM, V276, P45193, DOI 10.1074/jbc.M105971200; Megidish T, 1998, J BIOL CHEM, V273, P21834, DOI 10.1074/jbc.273.34.21834; Muslin AJ, 2000, CELL SIGNAL, V12, P703, DOI 10.1016/S0898-6568(00)00131-5; Nakamura S, 1996, J BIOL CHEM, V271, P1255, DOI 10.1074/jbc.271.3.1255; Obsil T, 2001, CELL, V105, P257, DOI 10.1016/S0092-8674(01)00316-6; OHTA H, 1995, CANCER RES, V55, P691; Powell DW, 2002, J BIOL CHEM, V277, P21639, DOI 10.1074/jbc.M203167200; Sakakura C, 1997, INT J ONCOL, V11, P31; Shirahama T, 1997, CLIN CANCER RES, V3, P257; Stomski FC, 1999, BLOOD, V94, P1933; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Tzivion G, 2001, ONCOGENE, V20, P6331, DOI 10.1038/sj.onc.1204777; Tzivion G, 1998, NATURE, V394, P88, DOI 10.1038/27938; Tzivion G, 2002, J BIOL CHEM, V277, P3061, DOI 10.1074/jbc.R100059200; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Xing HM, 2000, EMBO J, V19, P349, DOI 10.1093/emboj/19.3.349; Yaffe MB, 2002, FEBS LETT, V513, P53, DOI 10.1016/S0014-5793(01)03288-4; Zhang LX, 1999, P NATL ACAD SCI USA, V96, P8511, DOI 10.1073/pnas.96.15.8511; Zhou Y, 2003, J BIOL CHEM, V278, P10073, DOI 10.1074/jbc.M211907200	31	131	137	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36323	36327		10.1074/jbc.M304689200	http://dx.doi.org/10.1074/jbc.M304689200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12865427	hybrid			2022-12-27	WOS:000185318300057
J	Zhu, YJ; Hui, DY				Zhu, YJ; Hui, DY			Apolipoprotein E binding to low density lipoprotein receptor-related protein-1 inhibits cell migration via activation of cAMP-dependent protein kinase A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; TYROSINE PHOSPHORYLATION; PLASMINOGEN-ACTIVATOR; UROKINASE RECEPTOR; TRANSGENIC MICE; GENE FAMILY; GROWTH; ATHEROSCLEROSIS; PROLIFERATION; LRP	Smooth muscle cell migration and proliferation contribute to neointimal hyperplasia and vascular stenosis after endothelial denudation. Previous studies revealed that apolipoprotein E (apoE) is an effective inhibitor of platelet-derived growth factor-directed smooth muscle cell migration and proliferation and that the anti-migratory function is mediated via apoE binding to low density lipoprotein receptor-related protein-1 (LRP-1). This study was undertaken to identify the intracellular pathway by which apoE binding to LRP-1 results in inhibition of smooth muscle cell migration. The results showed that apoE increased intracellular cAMP levels 3-fold after 5 min, and the increase was sustained for more than 1 h. As a consequence, apoE also increased protein kinase A (PKA) activity in smooth muscle cells. Importantly, suppression of PKA activity with a cell-permeable peptide inhibitor of PKA abolished the inhibitory effect of apoE on smooth muscle cell migration. These results indicated that apoE inhibition of smooth muscle cell migration is mediated via the activation of cAMP-dependent PKA. Additional experiments revealed that apoE also inhibited fibroblasts migration toward platelet-derived growth factor by a similar mechanism of cAMP-dependent PKA activation. It is noteworthy that apoE failed to increase cAMP levels or inhibit migration of LRP-1-negative mouse embryonic fibroblasts and LRP-1-deficient smooth muscle cells. Taken together, these findings established the mechanism by which apoE inhibits cell migration, i.e. via cAMP-dependent protein kinase A activation as a consequence of its binding to LRP-1.	Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Hui, DY (corresponding author), Univ Cincinnati, Coll Med, Dept Pathol & Lab Med, 231 Albert Sabin Way, Cincinnati, OH 45267 USA.	huidy@email.uc.edu			NHLBI NIH HHS [HL61332] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061332] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; BU GJ, 1993, J BIOL CHEM, V268, P13002; Cedazo-Minguez A, 2001, NEUROCHEM INT, V38, P615, DOI 10.1016/S0197-0186(00)00128-5; Czekay RP, 2001, MOL BIOL CELL, V12, P1467, DOI 10.1091/mbc.12.5.1467; Goretzki L, 1998, BIOCHEM J, V336, P381, DOI 10.1042/bj3360381; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, NEURON, V29, P571, DOI 10.1016/S0896-6273(01)00234-3; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; HERZ J, 1990, J BIOL CHEM, V265, P21355; HORIO T, 1995, CIRC RES, V77, P660, DOI 10.1161/01.RES.77.4.660; HUSSAIN MM, 1991, J BIOL CHEM, V266, P13936; Ishigami M, 2000, ARTERIOSCL THROM VAS, V20, P1020, DOI 10.1161/01.ATV.20.4.1020; Ishigami M, 1998, J BIOL CHEM, V273, P20156, DOI 10.1074/jbc.273.32.20156; Itoh H, 2001, AM J PHYSIOL-HEART C, V281, pH359, DOI 10.1152/ajpheart.2001.281.1.H359; KASHYAP VS, 1995, J CLIN INVEST, V96, P1612, DOI 10.1172/JCI118200; KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810; Law RE, 1996, J CLIN INVEST, V98, P1897, DOI 10.1172/JCI118991; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; LUND H, 1989, P NATL ACAD SCI USA, V86, P9318, DOI 10.1073/pnas.86.23.9318; MIMURA Y, 1995, BIOL PHARM BULL, V18, P1373; Narita M, 2002, J BIOCHEM, V132, P743, DOI 10.1093/oxfordjournals.jbchem.a003282; Node K, 2001, J BIOL CHEM, V276, P15983, DOI 10.1074/jbc.M100439200; Okada SS, 1996, ARTERIOSCL THROM VAS, V16, P1269, DOI 10.1161/01.ATV.16.10.1269; PLUMP AS, 1992, CELL, V71, P343, DOI 10.1016/0092-8674(92)90362-G; RALL SC, 1986, METHOD ENZYMOL, V128, P273; SHIMANO H, 1992, P NATL ACAD SCI USA, V89, P1750, DOI 10.1073/pnas.89.5.1750; SHIMANO H, 1995, J CLIN INVEST, V95, P469, DOI 10.1172/JCI117687; Smith DM, 2002, BIOCHEM SOC T, V30, P432, DOI 10.1042/bst0300432; Sun JX, 2002, CIRC RES, V90, P1020, DOI 10.1161/01.RES.0000017727.35930.33; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; Swertfeger DK, 2001, J BIOL CHEM, V276, P25043, DOI 10.1074/jbc.M102357200; Thorngate FE, 2000, ARTERIOSCL THROM VAS, V20, P1939, DOI 10.1161/01.ATV.20.8.1939; Wijnberg MJ, 1997, THROMB HAEMOSTASIS, V78, P880; ZHANG SH, 1992, SCIENCE, V258, P468, DOI 10.1126/science.1411543; ZHANG SH, 1994, J CLIN INVEST, V94, P937, DOI 10.1172/JCI117460	39	52	62	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36257	36263		10.1074/jbc.M303171200	http://dx.doi.org/10.1074/jbc.M303171200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12857755	hybrid			2022-12-27	WOS:000185318300048
J	Ching, YP; Leong, VYL; Wong, CM; Kung, HF				Ching, YP; Leong, VYL; Wong, CM; Kung, HF			Identification of an autoinhibitory domain of p21-activated protein kinase 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHO-GTPASES; KINASE; EFFECTOR; CELLS; CDC42; BRAIN; PAK1	The p21-activated protein kinases (Paks) are serine/ threonine protein kinases activated by binding to Rho family small GTPases, Rac and Cdc42. Recently, Pak family members have been subdivided into two groups, I and II. Group II Paks, including Pak4, Pak5, and Pak6, does not contain the highly conserved autoinhibitory domain that is found in the group I Paks members, i.e. Pak1, Pak2, and Pak3. In the present study, we have purified the glutathione S-transferase fusion form of Pak5 and shown for the first time that Pak5 autophosphorylation can be activated by GTP bound form of Cdc42. Mutation of histidine residues 19 and 22 to leucine on the p21-binding domain of Pak5 completely abolished the binding of Cdc42 and the Cdc42-mediated autophosphorylation. On the other hand, mutation of tyrosine 40 to cysteine of Cdc42 did not knockout the binding of Pak5. Analysis of C-terminal deletion mutants has identified an autoinhibitory fragment of Pak5 that is absent from other group II Pak family members. Taken together, these results suggest that Pak5, like Pak1, contains an autoinhibitory domain and its activity is regulated by Cdc42.	Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Ching, YP (corresponding author), Univ Hong Kong, Inst Mol Biol, Hong Kong, Hong Kong, Peoples R China.		Wong, Chi-Ming/A-7627-2013; Ching, Yick Pang/C-4244-2009	Wong, Chi-Ming/0000-0002-0025-7135; CHING, Yick Pang/0000-0002-6461-8358				Abo A, 1998, EMBO J, V17, P6527, DOI 10.1093/emboj/17.22.6527; Coleman ML, 2002, CELL DEATH DIFFER, V9, P493, DOI 10.1038/sj.cdd.4400987; Dan C, 2002, MOL CELL BIOL, V22, P567, DOI 10.1128/MCB.22.2.567-577.2002; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Jaffer ZM, 2002, INT J BIOCHEM CELL B, V34, P713, DOI 10.1016/S1357-2725(01)00158-3; Lamarche N, 1996, CELL, V87, P519, DOI 10.1016/S0092-8674(00)81371-9; Lei M, 2000, CELL, V102, P387, DOI 10.1016/S0092-8674(00)00043-X; Owen D, 2000, BIOCHEMISTRY-US, V39, P1243, DOI 10.1021/bi991567z; Pandey A, 2002, ONCOGENE, V21, P3939, DOI 10.1038/sj.onc.1205478; Sahai E, 2002, NAT REV CANCER, V2, P133, DOI 10.1038/nrc725; SELF AJ, 1995, METHOD ENZYMOL, V256, P3; Sells MA, 1997, CURR BIOL, V7, P202, DOI 10.1016/S0960-9822(97)70091-5	12	50	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 5	2003	278	36					33621	33624		10.1074/jbc.C300234200	http://dx.doi.org/10.1074/jbc.C300234200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	716UK	12860998	hybrid, Green Published			2022-12-27	WOS:000185047500004
J	Petit, MA; Jolivet-Reynaud, C; Peronnet, E; Michal, Y; Trepo, C				Petit, MA; Jolivet-Reynaud, C; Peronnet, E; Michal, Y; Trepo, C			Mapping of a conformational epitope shared between E1 and E2 on the serum-derived human hepatitis C virus envelope	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN COMPLEXES; RECOMBINANT VACCINIA; B VIRUS; HCV; LOCALIZATION; PARTICLES; SEQUENCE; REGION; GLYCOSYLATION; ANTIBODIES	Monoclonal antibody D32.10 produced by immunizing mice with a hepatitis C virus (HCV)-enriched pellet obtained from plasmapheresis of a chronically HCV1b-infected patient binds HCV particles derived from serum of different HCV1a- and HCV1b-infected patients. Moreover, this monoclonal has been shown to recognize both HCV envelope proteins E1 and E2. In an attempt to provide novel insight into the membrane topology of HCV envelope glycoproteins E1 and E2, we localized the epitope recognized by D32.10 on the E1 and/or E2 sequence using Ph.D.-12(TM) phage display peptide library technology. Mimotopes selected from the phage display dodecapeptide library by D32.10 shared partial similarities with (297)RHWTTQGCNC(306) of the HCV E1 glycoprotein and with both (YRLWHYPCT621)-Y-613 and (480)PDQRPYCWHYPPKPC(494) of the HCV E2 glycoprotein. Immunoreactivity of D32.10 with overlapping peptides corresponding to these three HCV regions confirmed these localizations and suggested that the three regions identified are likely closely juxtaposed on the surface of serum-derived particles as predicted by the secondary model structure of HCV E2 derived from the tick-borne encephalitis virus E protein. This assertion was supported by the detection of specific antibodies directed against these three E1E2 regions in sera from HCV-infected patients.	INSERM, U271, F-69424 Lyon 03, France; CNRS BioMerieux, Unite Mixte Rech 2142, Ctr Etud Rech Virol & Immunol, F-69365 Lyon, France	Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS)	Petit, MA (corresponding author), INSERM, U271, 151 Cours Albert Thomas, F-69424 Lyon 03, France.							[Anonymous], 1982, MOL CLONING LAB MANU; Baumert TF, 2000, HEPATOLOGY, V32, P610, DOI 10.1053/jhep.2000.9876; Bukh J, 1997, VIROLOGY, V229, P429, DOI 10.1006/viro.1997.8461; Buttin G, 1978, Curr Top Microbiol Immunol, V81, P27; CHOO QL, 1991, P NATL ACAD SCI USA, V88, P2451, DOI 10.1073/pnas.88.6.2451; Clarke B, 1997, J GEN VIROL, V78, P2397, DOI 10.1099/0022-1317-78-10-2397; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Deleersnyder V, 1997, J VIROL, V71, P697, DOI 10.1128/JVI.71.1.697-704.1997; Dubuisson J, 2000, J BIOL CHEM, V275, P30605, DOI 10.1074/jbc.M004326200; Dubuisson J, 2000, CURR TOP MICROBIOL, V242, P135; DUBUISSON J, 1994, J VIROL, V68, P6147, DOI 10.1128/JVI.68.10.6147-6160.1994; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; FRANK R, 1988, TETRAHEDRON, V44, P6031, DOI 10.1016/S0040-4020(01)89791-X; HIJIKATA M, 1991, P NATL ACAD SCI USA, V88, P5547, DOI 10.1073/pnas.88.13.5547; Jolivet-Reynaud C, 1998, J MED VIROL, V56, P300, DOI 10.1002/(SICI)1096-9071(199812)56:4&lt;300::AID-JMV3&gt;3.0.CO;2-8; Meunier JC, 1999, J GEN VIROL, V80, P887, DOI 10.1099/0022-1317-80-4-887; OKAMOTO H, 1992, VIROLOGY, V188, P331, DOI 10.1016/0042-6822(92)90762-E; Patel J, 1999, J GEN VIROL, V80, P1681, DOI 10.1099/0022-1317-80-7-1681; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PETIT MA, 1989, MOL IMMUNOL, V26, P531, DOI 10.1016/0161-5890(89)90004-7; PETIT MA, 1987, J GEN VIROL, V68, P2759, DOI 10.1099/0022-1317-68-11-2759; RALSTON R, 1993, J VIROL, V67, P6753, DOI 10.1128/JVI.67.11.6753-6761.1993; REY FA, 1995, NATURE, V375, P291, DOI 10.1038/375291a0; RICE CM, 1996, FIELDS VIROLOGY, P931; SAITO I, 1990, P NATL ACAD SCI USA, V87, P6547, DOI 10.1073/pnas.87.17.6547; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO K, 1993, VIROLOGY, V196, P354, DOI 10.1006/viro.1993.1488; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SELBY MJ, 1994, VIROLOGY, V204, P114, DOI 10.1006/viro.1994.1515; SPAETE RR, 1992, VIROLOGY, V188, P819, DOI 10.1016/0042-6822(92)90537-Y; Trepo C, 1998, ANN ONCOL, V9, P469, DOI 10.1023/A:1008298228620; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K	33	31	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	NOV 7	2003	278	45					44385	44392		10.1074/jbc.M304047200	http://dx.doi.org/10.1074/jbc.M304047200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	738UR	12882983	hybrid			2022-12-27	WOS:000186306700063
J	Koch, M; Laub, F; Zhou, PH; Hahn, RA; Tanaka, S; Burgeson, RE; Gerecke, DR; Ramirez, F; Gordon, MK				Koch, M; Laub, F; Zhou, PH; Hahn, RA; Tanaka, S; Burgeson, RE; Gerecke, DR; Ramirez, F; Gordon, MK			Collagen XXIV, a vertebrate fibrillar collagen with structural features of invertebrate collagens - Selective expression in developing cornea and bone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-TERMINAL PROPEPTIDE; ARGININE-RICH PROTEIN; V COLLAGEN; PRO-ALPHA-1(XI) COLLAGEN; NH2-TERMINAL DOMAIN; MESSENGER-RNA; DEVELOPMENTAL EXPRESSION; GENE; CHAIN; MATRIX	Tissue-specific assembly of fibers composed of the major collagen types I and II depends in part on the formation of heterotypic fibrils, using the quantitatively minor collagens V and XI. Here we report the identification of a new fibrillar-like collagen chain that is related to the fibrillar alpha1(V), alpha1(XI), and alpha2(XI) collagen polypeptides and which is coexpressed with type I collagen in the developing bone and eye. The new collagen was designated the alpha1(XXIV) chain and consists of a long triple helical domain flanked by typical propeptide-like sequences. The carboxyl propeptide is classic, with 8 conserved cysteine residues. The amino-terminal peptide contains a thrombospodin-N-terminal-like (TSP) motif and a highly charged segment interspersed with several tyrosine residues, like the fibril diameter-regulating collagen chains alpha1(V) and alpha1(XI). However, a short imperfection in the triple helix makes alpha1(XXIV) unique from other chains of the vertebrate fibrillar collagen family. The triple helical interruption and additional select features in both terminal peptides are common to the fibrillar chains of invertebrate organisms. Based on these data, we propose that collagen XXIV is an ancient molecule that may contribute to the regulation of type I collagen fibrillogenesis at specific anatomical locations during fetal development.	Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, Piscataway, NJ 08854 USA; Univ Cologne, Inst Biochem 2, D-50931 Cologne, Germany; Cornell Univ, Weill Med Coll, Hosp Special Surg, Lab Genet & Organogenesis, New York, NY 10021 USA; Rutgers State Univ, Ernest Mario Sch Pharm, Environm & Occupat Hlth Sci Inst, Piscataway, NJ 08854 USA; Harvard Univ, Sch Med, Massachusetts Gen Hosp E, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA	Rutgers State University New Brunswick; University of Cologne; Cornell University; Rutgers State University New Brunswick; Harvard University	Gordon, MK (corresponding author), Rutgers State Univ, Ernest Mario Sch Pharm, Dept Pharmacol & Toxicol, 170 Frelinghuysen Rd, Piscataway, NJ 08854 USA.	magordon@eohsi.rutgers.edu	Koch, Manuel/AAG-9914-2021	Koch, Manuel/0000-0002-2962-7814	NEI NIH HHS [EY09056] Funding Source: Medline; NHLBI NIH HHS [HL67708] Funding Source: Medline; NIAMS NIH HHS [AR-38648] Funding Source: Medline; NIEHS NIH HHS [ES05022] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009056] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K01HL067708] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038648, R37AR038648] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDRIKOPOULOS K, 1995, NAT GENET, V9, P31, DOI 10.1038/ng0195-31; BIRK DE, 1990, J CELL SCI, V95, P649; Blaschke UK, 2000, J BIOL CHEM, V275, P10370, DOI 10.1074/jbc.275.14.10370; BOGUSKI MS, 1993, NAT GENET, V4, P332, DOI 10.1038/ng0893-332; Boot-Handford RP, 2003, J BIOL CHEM, V278, P31067, DOI 10.1074/jbc.M212889200; BORNSTEIN P, 1980, ANNU REV BIOCHEM, V49, P957, DOI 10.1146/annurev.bi.49.070180.004521; Burrows NP, 1998, AM J HUM GENET, V63, P390, DOI 10.1086/301948; Chou MY, 2002, GENOMICS, V79, P395, DOI 10.1006/geno.2002.6712; CLUZEL C, 2000, J BIOCHEM-TOKYO, V28, P957; DePaepe A, 1997, AM J HUM GENET, V60, P547; Deutzmann R, 2000, DEVELOPMENT, V127, P4669; EXPOSITO JY, 1990, P NATL ACAD SCI USA, V87, P6669, DOI 10.1073/pnas.87.17.6669; Fitzgerald J, 2001, FEBS LETT, V505, P275, DOI 10.1016/S0014-5793(01)02754-5; Gordon MK, 2000, INVEST OPHTH VIS SCI, V41, pS752; Gordon MK, 2002, FASEB J, V16, pA359; GREENSPAN DS, 1991, J BIOL CHEM, V266, P24727; Hagg P, 1998, J BIOL CHEM, V273, P15590, DOI 10.1074/jbc.273.25.15590; Hashimoto T, 2002, EMBO J, V21, P1524, DOI 10.1093/emboj/21.7.1524; Imamura Y, 1998, J BIOL CHEM, V273, P27511, DOI 10.1074/jbc.273.42.27511; Koch M, 2001, J BIOL CHEM, V276, P23120, DOI 10.1074/jbc.M009912200; Koch M, 1999, J CELL BIOL, V145, P605, DOI 10.1083/jcb.145.3.605; Laub F, 2001, DEV BIOL, V233, P305, DOI 10.1006/dbio.2001.0243; LI Y, 1995, CELL, V80, P423, DOI 10.1016/0092-8674(95)90492-1; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; MALLEINGERIN F, 1995, EXP CELL RES, V219, P257, DOI 10.1006/excr.1995.1226; MCLAUGHLIN JS, 1989, J CELL SCI, V94, P371; Meirowitz NB, 2002, AM J OBSTET GYNECOL, V187, P1679, DOI 10.1067/mob.2002.127595; Michalickova K, 1998, HUM MOL GENET, V7, P249, DOI 10.1093/hmg/7.2.249; MORADIAMELI M, 1994, MATRIX BIOL, V14, P233, DOI 10.1016/0945-053X(94)90187-2; Morio LA, 2001, TOXICOL APPL PHARM, V172, P44, DOI 10.1006/taap.2000.9133; MYERS JC, 1994, J BIOL CHEM, V269, P18549; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Nakayama K, 1997, BIOCHEM J, V327, P625, DOI 10.1042/bj3270625; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; Nielsen H, 1997, Int J Neural Syst, V8, P581, DOI 10.1142/S0129065797000537; Ohnishi S, 2000, DEV DYNAM, V217, P421, DOI 10.1002/(SICI)1097-0177(200004)217:4<421::AID-DVDY9>3.0.CO;2-1; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; Pace JM, 2003, MATRIX BIOL, V22, P3, DOI 10.1016/S0945-053X(03)00007-6; PAN TC, 1992, P NATL ACAD SCI USA, V89, P6565, DOI 10.1073/pnas.89.14.6565; Peltonen S, 1999, J INVEST DERMATOL, V113, P635, DOI 10.1046/j.1523-1747.1999.00736.x; Richards AJ, 1996, HUM MOL GENET, V5, P1339, DOI 10.1093/hmg/5.9.1339; Rousseau JC, 1996, J BIOL CHEM, V271, P23743, DOI 10.1074/jbc.271.39.23743; SASSOON D, 1993, METHOD ENZYMOL, V225, P384; Sato K, 2002, J BIOL CHEM, V277, P37678, DOI 10.1074/jbc.M205347200; SEEGMILLER R, 1971, J CELL BIOL, V48, P580, DOI 10.1083/jcb.48.3.580; Sicot FX, 2000, J MOL BIOL, V302, P811, DOI 10.1006/jmbi.2000.4505; Sicot FX, 1997, EUR J BIOCHEM, V246, P50, DOI 10.1111/j.1432-1033.1997.00050.x; TAKAHARA K, 1991, J BIOL CHEM, V266, P13124; TSENG SCG, 1982, J BIOL CHEM, V257, P2627; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; Tuckwell D, 2002, MATRIX BIOL, V21, P63, DOI 10.1016/S0945-053X(01)00176-7; VANDERREST M, 1991, FASEB J, V5, P2814, DOI 10.1096/fasebj.5.13.1916105; VIKKULA M, 1995, CELL, V80, P431, DOI 10.1016/0092-8674(95)90493-X; VONHEIJNE G, 1990, J MEMBRANE BIOL, V115, P195, DOI 10.1007/BF01868635; Yoneda C, 1999, EUR J BIOCHEM, V261, P714, DOI 10.1046/j.1432-1327.1999.00313.x; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; YOSHIOKA H, 1992, GENOMICS, V13, P884, DOI 10.1016/0888-7543(92)90176-S; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	60	81	88	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 31	2003	278	44					43236	43244		10.1074/jbc.M302112200	http://dx.doi.org/10.1074/jbc.M302112200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	736EA	12874293	hybrid			2022-12-27	WOS:000186157000065
J	Barth, H; Schafer, C; Adah, MI; Zhang, FM; Linhardt, RJ; Toyoda, H; Kinoshita-Toyoda, A; Toida, T; van Kuppevelt, TH; Depla, E; von Weizsacker, F; Blum, HE; Baumert, TF				Barth, H; Schafer, C; Adah, MI; Zhang, FM; Linhardt, RJ; Toyoda, H; Kinoshita-Toyoda, A; Toida, T; van Kuppevelt, TH; Depla, E; von Weizsacker, F; Blum, HE; Baumert, TF			Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; AGAROSE-GEL ELECTROPHORESIS; STRUCTURAL PROTEINS; CANDIDATE RECEPTOR; HUMAN HEPATOCYTES; FEVER VIRUS; IN-VIVO; PARTICLES; INFECTION; ANTIBODIES	The conservation of positively charged residues in the N terminus of the hepatitis C virus (HCV) envelope glycoprotein E2 suggests an interaction of the viral envelope with cell surface glycosaminoglycans. Using recombinant envelope glycoprotein E2 and virus-like particles as ligands for cellular binding, we demonstrate that cell surface heparan sulfate proteoglycans ( HSPG) play an important role in mediating HCV envelope-target cell interaction. Heparin and liver-derived highly sulfated heparan sulfate but not other soluble glycosaminoglycans inhibited cellular binding and entry of virus-like particles in a dose-dependent manner. Degradation of cell surface heparan sulfate by pretreatment with heparinases resulted in a marked reduction of viral envelope protein binding. Surface plasmon resonance analysis demonstrated a high affinity interaction ( K-D 5.2 x 10(-9) M) of E2 with heparin, a structural homologue of highly sulfated heparan sulfate. Deletion of E2 hypervariable region-1 reduced E2-heparin interaction suggesting that positively charged residues in the N-terminal E2 region play an important role in mediating E2-HSPG binding. In conclusion, our results demonstrate for the first time that cellular binding of HCV envelope requires E2-HSPG interaction. Docking of E2 to cellular HSPG may be the initial step in the interaction between HCV and the cell surface resulting in receptor-mediated entry and initiation of infection.	Univ Freiburg, Dept Med 2, D-79106 Freiburg, Germany; Univ Iowa, Dept Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Med, Iowa City, IA 52242 USA; Univ Iowa, Dept Nat Prod Chem, Iowa City, IA 52242 USA; Univ Iowa, Dept Chem & Biochem Engn, Iowa City, IA 52242 USA; Chiba Univ, Dept Analyt Chem, Chiba 2638522, Japan; Univ Med Ctr, NCMLS, Dept Biochem, NL-6500 HB Nijmegen, Netherlands; Innogenet NV, B-9052 Ghent, Belgium	University of Freiburg; University of Iowa; University of Iowa; University of Iowa; University of Iowa; Chiba University; Radboud University Nijmegen; Innogenetics NV	Baumert, TF (corresponding author), Univ Freiburg, Dept Med 2, Hugstetter Str 55, D-79106 Freiburg, Germany.	tbaumert@ukl.uni-freiburg.de	Baumert, Thomas/ABF-4718-2020; van Kuppevelt, A.H.M.S.M./L-4463-2015	Baumert, Thomas/0000-0002-8864-2168; Adah, Mohammed Ignatius/0000-0001-8077-5815				Agnello V, 1999, P NATL ACAD SCI USA, V96, P12766, DOI 10.1073/pnas.96.22.12766; Andre P, 2002, J VIROL, V76, P6919, DOI 10.1128/JVI.76.14.6919-6928.2002; Bartenschlager R, 2000, J GEN VIROL, V81, P1631, DOI 10.1099/0022-1317-81-7-1631; Baumert TF, 1998, J VIROL, V72, P3827, DOI 10.1128/JVI.72.5.3827-3836.1998; Baumert TF, 2000, HEPATOLOGY, V32, P610, DOI 10.1053/jhep.2000.9876; Bergstrom T, 1997, NAT MED, V3, P1177, DOI 10.1038/nm1197-1177b; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Birkmann A, 2001, J VIROL, V75, P11583, DOI 10.1128/JVI.75.23.11583-11593.2001; Blanchard E, 2002, J VIROL, V76, P4073, DOI 10.1128/JVI.76.8.4073-4079.2002; CARDIN AD, 1989, ARTERIOSCLEROSIS, V9, P21, DOI 10.1161/01.ATV.9.1.21; Castet V, 2002, J VIROL, V76, P8189, DOI 10.1128/JVI.76.16.8189-8199.2002; Chen YP, 1997, NAT MED, V3, P866, DOI 10.1038/nm0897-866; CHOO QL, 1989, SCIENCE, V244, P359, DOI 10.1126/science.2523562; Cladera J, 2001, EMBO J, V20, P19, DOI 10.1093/emboj/20.1.19; Clayton RF, 2002, J VIROL, V76, P7672, DOI 10.1128/JVI.76.15.7672-7682.2002; Cocquerel L, 2002, EMBO J, V21, P2893, DOI 10.1093/emboj/cdf295; Combita AL, 2002, J VIROL, V76, P6480, DOI 10.1128/JVI.76.13.6480-6486.2002; De Beeck AO, 2000, J BIOL CHEM, V275, P31428, DOI 10.1074/jbc.M003003200; Dennissen MABA, 2002, J BIOL CHEM, V277, P10982, DOI 10.1074/jbc.M104852200; Di Bisceglie AM, 2002, HEPATOLOGY, V36, pS121, DOI 10.1053/jhep.2002.36228; Ezelle HJ, 2002, J VIROL, V76, P12325, DOI 10.1128/JVI.76.23.12325-12334.2002; Flint M, 2000, REV MED VIROL, V10, P101, DOI 10.1002/(SICI)1099-1654(200003/04)10:2&lt;101::AID-RMV268&gt;3.0.CO;2-W; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Germi R, 2002, VIROLOGY, V292, P162, DOI 10.1006/viro.2001.1232; Gilbert JM, 1998, J VIROL, V72, P5323, DOI 10.1128/JVI.72.6.5323-5327.1998; Giroglou T, 2001, J VIROL, V75, P1565, DOI 10.1128/JVI.75.3.1565-1570.2001; Hamaia S, 2001, BLOOD, V98, P2293, DOI 10.1182/blood.V98.8.2293; Hilgard P, 2000, HEPATOLOGY, V32, P1069, DOI 10.1053/jhep.2000.18713; Hulst MM, 2001, J VIROL, V75, P9585, DOI 10.1128/JVI.75.20.9585-9595.2001; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; Lauer GM, 2001, NEW ENGL J MED, V345, P41, DOI 10.1056/NEJM200107053450107; LINDENBACH BD, 2001, FIELDS VIROLOGY, V1, P991; MAJOR ME, 2001, FIELDS VIROLOGY, V1, P1127; Mandl CW, 2001, J VIROL, V75, P5627, DOI 10.1128/JVI.75.12.5627-5637.2001; MARGALIT H, 1993, J BIOL CHEM, V268, P19228; Marks RM, 2001, J MED CHEM, V44, P2178, DOI 10.1021/jm000412i; Mercer DF, 2001, NAT MED, V7, P927, DOI 10.1038/90968; Owsianka A, 2001, J GEN VIROL, V82, P1877, DOI 10.1099/0022-1317-82-8-1877; Patel J, 2001, VIROLOGY, V279, P58, DOI 10.1006/viro.2000.0693; Penin F, 2001, J VIROL, V75, P5703, DOI 10.1128/JVI.75.12.5703-5710.2001; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Putnak JR, 1997, NAT MED, V3, P828, DOI 10.1038/nm0897-828; Rosa D, 1996, P NATL ACAD SCI USA, V93, P1759, DOI 10.1073/pnas.93.5.1759; Saunier B, 2003, J VIROL, V77, P546, DOI 10.1128/JVI.77.1.546-559.2003; Scarselli E, 2002, EMBO J, V21, P5017, DOI 10.1093/emboj/cdf529; Shimizu YK, 1996, HEPATOLOGY, V23, P205; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; Shukla D, 2001, J CLIN INVEST, V108, P503, DOI 10.1172/JCI13799; Takikawa S, 2000, J VIROL, V74, P5066, DOI 10.1128/JVI.74.11.5066-5074.2000; Tamura M, 2000, J VIROL, V74, P11589, DOI 10.1128/JVI.74.24.11589-11597.2000; Toida T, 1997, BIOCHEM J, V322, P499, DOI 10.1042/bj3220499; Toida T, 1997, ANAL BIOCHEM, V251, P219, DOI 10.1006/abio.1997.2277; Toyoda H, 1997, J CHROMATOGR B, V704, P19, DOI 10.1016/S0378-4347(97)00478-7; Triyatni M, 2002, J VIROL, V76, P9335, DOI 10.1128/JVI.76.18.9335-9344.2002; Triyatni M, 2002, VIROLOGY, V298, P124, DOI 10.1006/viro.2002.1463; van Kuppevelt TH, 1998, J BIOL CHEM, V273, P12960, DOI 10.1074/jbc.273.21.12960; vanDoorn LJ, 1997, J MED VIROL, V52, P441, DOI 10.1002/(SICI)1096-9071(199708)52:4<441::AID-JMV17>3.0.CO;2-J; Volpi N, 1999, ANAL BIOCHEM, V273, P229, DOI 10.1006/abio.1999.4218; VOLPI N, 1993, CARBOHYD RES, V247, P263, DOI 10.1016/0008-6215(93)84259-9; Wellnitz S, 2002, J VIROL, V76, P1181, DOI 10.1128/JVI.76.3.1181-1193.2002; Wunschmann S, 2000, J VIROL, V74, P10055, DOI 10.1128/JVI.74.21.10055-10062.2000; Xiang JH, 2002, J MED VIROL, V68, P537, DOI 10.1002/jmv.10237; Yagnik AT, 2000, PROTEINS, V40, P355, DOI 10.1002/1097-0134(20000815)40:3<355::AID-PROT20>3.0.CO;2-K; Zhang FM, 2002, ANAL BIOCHEM, V304, P271, DOI 10.1006/abio.2002.5617; Zhang YJ, 2002, J VIROL, V76, P6332, DOI 10.1128/JVI.76.12.6332-6343.2002; Zhao XP, 2002, J CLIN INVEST, V109, P221, DOI 10.1172/JCI13011	66	369	405	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					41003	41012		10.1074/jbc.M302267200	http://dx.doi.org/10.1074/jbc.M302267200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12867431	Green Published, hybrid			2022-12-27	WOS:000185847200074
J	D'Aguanno, S; Gonzales, IN; Simmaco, M; Contestabile, R; John, RA				D'Aguanno, S; Gonzales, IN; Simmaco, M; Contestabile, R; John, RA			Stereochemistry of the reactions of glutamate-1-semialdehyde aminomutase with 4,5-diaminovalerate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE 1-SEMIALDEHYDE AMINOTRANSFERASE; AMINO-ACID DECARBOXYLASE; STATE KINETIC-ANALYSIS; SEMIALDEHYDE AMINOTRANSFERASE; ASPARTATE-AMINOTRANSFERASE; DELTA-AMINOLEVULINATE; SUBSTRATE; SYNECHOCOCCUS; BIOSYNTHESIS; MECHANISM	Conversion of glutamate 1-semialdehyde to the tetrapyrrole precursor, 5-aminolevulinate, takes place in an aminomutase-catalyzed reaction involving transformations at both the non-chiral C5 and the chiral C4 of the intermediate 4,5-diaminovalerate. Presented with racemic diaminovalerate and an excess of succinic semialdehyde, the enzyme catalyzes a transamination in which only the L-enantiomer is consumed. Simultaneously, equimolar 4-aminobutyrate and aminolevulinate are formed. The enzyme is also shown to transaminate aminolevulinate and 4-aminohexenoate to L-diaminovalerate as the exclusive amino product. The interaction of the enzyme with pure D- and L-enantiomers of diaminovalerate prepared by these reactions is described. Transamination of L-diaminovalerate yielded aminolevulinate quantitatively showing that reaction at the C5 amine does not occur significantly. A much slower transamination reaction was catalyzed with D- diaminovalerate as substrate. One product of this reaction, 4-aminobutyrate, was formed in the amount equal to that of the diaminovalerate consumed. Glutamate semialdehyde was deduced to be the other primary product and was also measured in significant amounts when a high concentration of the enzyme in its pyridoxal form was reacted with D- diaminovalerate in a single turnover. Single turnover reactions showed that both enantiomers of diaminovalerate converted the enzyme from its 420-nm absorbing pyridoxaldimine form to the 330-nm absorbing pyridoxamine via rapidly formed intermediates with different absorption spectra. The intermediate formed with L-DAVA (lambda(max) = 420 nm) was deduced to be the protonated external aldimine with the 4-amino group. The intermediate formed with D- DAVA (lambda(max) = 390 nm) was deduced to be the unprotonated external aldimine with the 5-amino group.	Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, Rome, Italy; Univ Roma La Sapienza, Azienda Osped SantAndrea Lab DiMA, Rome, Italy; Univ Wales Coll Cardiff, Sch Biosci, Cardiff CF23 6QU, S Glam, Wales	Sapienza University Rome; Sapienza University Rome; Cardiff University	John, RA (corresponding author), Univ Wales Coll Cardiff, Sch Biosci, Museum Ave,POB 911, Cardiff CF10 3US, S Glam, Wales.		Contestabile, Roberto/J-3467-2019; Simmaco, Maurizio/AAC-2870-2019; Nogues, Isabel/AAA-7499-2019; Gonzalez, Isabel Nogues/K-2118-2012; D'Aguanno, Simona/H-2179-2016	Contestabile, Roberto/0000-0002-5235-9993; Simmaco, Maurizio/0000-0003-4164-1472; Gonzalez, Isabel Nogues/0000-0002-7475-2411; D'Aguanno, Simona/0000-0002-1224-4454				Contestabile R, 2000, J BIOL CHEM, V275, P3879, DOI 10.1074/jbc.275.6.3879; DIXON HBF, 1968, BIOCHEM J, V110, pP18, DOI 10.1042/bj1100018P; FRIEDMANN HC, 1992, BIOCHEM BIOPH RES CO, V185, P60, DOI 10.1016/S0006-291X(05)80955-6; GOLDBERG JM, 1991, BIOCHEMISTRY-US, V30, P305, DOI 10.1021/bi00215a041; GRIMM B, 1991, J BIOL CHEM, V266, P12495; Hayashi H, 1999, BIOCHEMISTRY-US, V38, P15615, DOI 10.1021/bi9909795; HAYASHI H, 1993, BIOCHEMISTRY-US, V32, P812, DOI 10.1021/bi00054a011; Hennig M, 1997, P NATL ACAD SCI USA, V94, P4866, DOI 10.1073/pnas.94.10.4866; HOOBER JK, 1988, CARLSBERG RES COMMUN, V53, P11, DOI 10.1007/BF02908411; JOHNSON R. J., 1970, Methods in Enzymology, V18A, P433, DOI 10.1016/0076-6879(71)18345-0; KANNANGARA CG, 1988, TRENDS BIOCHEM SCI, V13, P139; MARFEY P, 1984, CARLSBERG RES COMMUN, V49, P591, DOI 10.1007/BF02908688; MINELLI A, 1979, BIOCHEM J, V183, P361, DOI 10.1042/bj1830361; PETERSON EA, 1954, J AM CHEM SOC, V76, P169, DOI 10.1021/ja01630a045; PUGH CE, 1992, J BIOL CHEM, V267, P1584; PUGH CE, 1991, ANAL BIOCHEM, V198, P43, DOI 10.1016/0003-2697(91)90503-L; Scaloni Andrea, 2003, Methods Mol Biol, V211, P169; SMITH MA, 1991, EUR J BIOCHEM, V202, P749, DOI 10.1111/j.1432-1033.1991.tb16429.x; Smith MA, 1998, BIOCHEMISTRY-US, V37, P319, DOI 10.1021/bi9717587; TYACKE RJ, 1995, BIOCHEM J, V309, P307, DOI 10.1042/bj3090307	20	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 17	2003	278	42					40521	40526		10.1074/jbc.M306223200	http://dx.doi.org/10.1074/jbc.M306223200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	730TX	12878592	hybrid			2022-12-27	WOS:000185847200013
J	Kolling, DRJ; Samoilova, RI; Holland, JT; Berry, EA; Dikanov, SA; Crofts, AR				Kolling, DRJ; Samoilova, RI; Holland, JT; Berry, EA; Dikanov, SA; Crofts, AR			Exploration of ligands to the Q(i) site semiquinone in the bc(1) complex using high-resolution EPR	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PURE QUADRUPOLE-RESONANCE; RHODOBACTER-SPHAEROIDES; AMINO-ACIDS; ELECTRON-TRANSFER; CYTOCHROME-B; QUINONE; N-14; UBIQUINOL; OXIDOREDUCTASE; MECHANISM	Pulsed EPR spectroscopy was used to explore the structural neighborhood of the semiquinone (SQ) stabilized at the Q(i) site of the bc(1) complex of Rhodobacter sphaeroides (EC 1.10.2.2) and to demonstrate that the nitrogen atom of a histidine imidazole group donates an H-bond to the SQ. Crystallographic structures show two different configurations for the binding of ubiquinone at the Q(i) site of mitochondrial bc1 complexes in which histidine (His-201 in bovine sequence) is either a direct H-bond donor or separated by a bridging water. The paramagnetic properties of the SQ formed at the site provide an independent method for studying the liganding of this intermediate species. The antimycin-sensitive SQ formed at the Q(i) site by either equilibrium redox titration, reduction of the oxidized complex by ascorbate, or addition of decylubihydroquinone to the oxidized complex in the presence of myxothiazol all showed similar properties. The electron spin echo envelope modulation spectra in the N-14 region were dominated by lines with frequencies at 1.7 and 3.1 MHz. Hyperfine sublevel correlation spectroscopy spectra showed that these were contributed by a single nitrogen. Further analysis showed that the N-14 nucleus was characterized by an isotropic hyperfine coupling of similar to0.8 MHz and a quadrupole coupling constant of similar to0.35 MHz. The nitrogen was identified as the N-epsilon or N-delta imidazole nitrogen of a histidine (it is likely to be His-217, or His-201 in bovine sequence). A distance of 2.5-3.1 Angstrom for the O-N distance between the carbonyl of SQ and the nitrogen was estimated. The mechanistic significance is discussed in the context of a dynamic role for the movement of His-217 in proton transfer to the site.	Univ Illinois, Dept Biochem, Roger Adams Lab 419, Urbana, IL 61801 USA; Univ Illinois, Dept Vet Clin Med, Urbana, IL 61801 USA; Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; Russian Acad Sci, Inst Chem Kinet & Combust, Novosibirsk 630090, Russia; Univ Calif Berkeley, Lawrence Berkeley Lab, Berkeley, CA 94720 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; Russian Academy of Sciences; Voevodsky Institute of Chemical Kinetics & Combustion SB RAS; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Crofts, AR (corresponding author), Univ Illinois, Dept Biochem, Roger Adams Lab 419, 600 S Mathews Ave, Urbana, IL 61801 USA.	a-crofts@life.uiuc.edu	Samoilova, Rimma Ivanovna/T-7956-2017	Samoilova, Rimma Ivanovna/0000-0002-1649-1487	FIC NIH HHS [1 R03 TW01495] Funding Source: Medline; NCRR NIH HHS [S10-RR15878] Funding Source: Medline; NIGMS NIH HHS [GM 35438, GM 62954] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [R03TW001495] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015878] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035438, R01GM062954] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1985, ENZYMES BIOL MEMBRAN, DOI DOI 10.1007/978-1-4684-4604-3_10; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V726, P149, DOI 10.1016/0304-4173(83)90004-6; Crofts AR, 1999, BIOCHEMISTRY-US, V38, P15791, DOI 10.1021/bi990961u; CROFTS AR, 1983, BIOCHIM BIOPHYS ACTA, V723, P202, DOI 10.1016/0005-2728(83)90120-2; CROFTS AR, 1995, PHOTOSYNTHESIS LIGHT, V2, P493; de Vries S., 1982, FUNCTION QUINONES EN, P235; DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N; DELAROSA FF, 1983, FEBS LETT, V163, P140, DOI 10.1016/0014-5793(83)81181-8; Deligiannakis Y, 1999, J AM CHEM SOC, V121, P7653, DOI 10.1021/ja984209c; DEVRIES S, 1983, BIOCHIM BIOPHYS ACTA, V723, P91, DOI 10.1016/0005-2728(83)90013-0; DIKANOV SA, 1982, CHEM PHYS LETT, V90, P149, DOI 10.1016/0009-2614(82)83630-0; EDMONDS DT, 1973, J MAGN RESON, V12, P134, DOI 10.1016/0022-2364(73)90136-4; GRAY KA, 1994, BIOCHEMISTRY-US, V33, P723, DOI 10.1021/bi00169a014; HACKER B, 1993, BIOCHEMISTRY-US, V32, P4403, DOI 10.1021/bi00067a033; Hoff A.J., 1989, ADV EPR APPL BIOCH B; HUNT MJ, 1976, J MAGN RESON, V22, P295, DOI 10.1016/0022-2364(76)90304-8; HUNT MJ, 1974, J MAGN RESON, V15, P402, DOI 10.1016/0022-2364(74)90143-7; HUNT MJ, 1975, CHEM PHYS LETT, V34, P473, DOI 10.1016/0009-2614(75)85542-4; Hunte C, 2000, STRUCTURE, V8, P669, DOI 10.1016/S0969-2126(00)00152-0; Iwata S, 1998, SCIENCE, V281, P64, DOI 10.1126/science.281.5373.64; KAUTEN R, 1987, J BIOL CHEM, V262, P8658; Kuras R, 1998, BIOCHEMISTRY-US, V37, P16280, DOI 10.1021/bi9813476; MCDOWELL CA, 1986, J MAGN RESON, V69, P283, DOI 10.1016/0022-2364(86)90079-X; MITCHELL P, 1976, J THEOR BIOL, V62, P327, DOI 10.1016/0022-5193(76)90124-7; NITSCHKE W, 1997, PHOTOSYNTHESIS COMPR, P285; PALMER MH, 1987, CHEM PHYS, V115, P207, DOI 10.1016/0301-0104(87)80034-4; RICH PR, 1990, BIOCHIM BIOPHYS ACTA, V1018, P29, DOI 10.1016/0005-2728(90)90106-E; ROBERTSON DE, 1984, J BIOL CHEM, V259, P1758; SALERNO JC, 1990, BIOCHEMISTRY-US, V29, P6987, DOI 10.1021/bi00482a006; SALERNO JC, 1989, J BIOL CHEM, V264, P15398; Spoyalov AP, 1996, CHEM PHYS LETT, V263, P715, DOI 10.1016/S0009-2614(96)01255-9; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	34	46	49	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39747	39754		10.1074/jbc.M305913200	http://dx.doi.org/10.1074/jbc.M305913200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12874282	Green Submitted, hybrid			2022-12-27	WOS:000185713800060
J	Park, SG; Lee, SM; Jung, GH				Park, SG; Lee, SM; Jung, GH			Antisense oligodeoxynucleotides targeted against molecular chaperonin Hsp60 block human hepatitis B virus replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEM-LOOP STRUCTURE; REVERSE-TRANSCRIPTASE; IN-VITRO; DNA-POLYMERASE; OLIGONUCLEOTIDE; PROTEIN; EXPRESSION; INTERFERON; CELLS; RNA	The major role of hepatitis B virus polymerase (HBV pol) is polymerization of nucleotides, but it also participates in protein priming and the packaging of its own genome into capsids. Therefore, HBV pol may require many assistance factors for its roles. Previous reports have shown that Hsp60, a molecular chaperone, activates HBV pol both in vitro and ex vivo, such as inside insect cells. Moreover, HBV pol binds to Hsp60 in the HepG2 host cell line. In this report, we show that Hsp60 plays a role in the in vivo replication of HBV. Antisense oligodeoxynucleotides (A-ODNs) specifically directed against Hsp60 induced its down-regulation, severely reducing the level of replication-competent HBV without influencing cell proliferation and capsid assembly under these conditions. Furthermore, we found that Hsp60 did not encapsidate into nucleocapsids. Our results indicate that Hsp60 is important for HBV replication in vivo, presumably through activation of HBV pol before encapsidation of HBV pol into HBV core particle. In addition, A-ODNs specific for Hsp60 also inhibit replication of a mutant HBV strain that is resistant to the nucleoside analogue 3TC, which is the main drug used for HBV treatment, and we suggest that A-ODNs directed against Hsp60 are possible reagents as anti-HBV drugs. Conclusively, this report shows that the host factor, Hsp60, is essential for in vivo HBV replication and that mechanism of Hsp60 is probably through an activation of HBV pol by Hsp60.	Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea	Seoul National University (SNU)	Jung, GH (corresponding author), Seoul Natl Univ, Sch Biol Sci, Seoul 151742, South Korea.	drjung@snu.ac.kr		Jung, Guhung/0000-0001-6672-8473; Park, Sung-Gyoo/0000-0003-3702-5765				Allen MI, 1998, HEPATOLOGY, V27, P1670, DOI 10.1002/hep.510270628; BEASLEY RP, 1988, CANCER, V61, P1942, DOI 10.1002/1097-0142(19880515)61:10<1942::AID-CNCR2820611003>3.0.CO;2-J; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; COHEN JS, 1993, ANTISENSE RES APPL, P205; Crooke ST, 1996, ANNU REV PHARMACOL, V36, P107, DOI 10.1146/annurev.pa.36.040196.000543; de Smet MD, 1999, OCUL IMMUNOL INFLAMM, V7, P189, DOI 10.1076/ocii.7.3.189.4007; DEAN NM, 1994, P NATL ACAD SCI USA, V91, P11762, DOI 10.1073/pnas.91.24.11762; FOSTER GR, 1994, ANTIVIR RES, V24, P131, DOI 10.1016/0166-3542(94)90061-2; GUIDOTTI LG, 1995, J VIROL, V69, P6158, DOI 10.1128/JVI.69.10.6158-6169.1995; HIJIYA N, 1994, P NATL ACAD SCI USA, V91, P4499, DOI 10.1073/pnas.91.10.4499; HOWE AYM, 1992, BIOCHEM BIOPH RES CO, V189, P1170, DOI 10.1016/0006-291X(92)92327-T; Hu JM, 1996, P NATL ACAD SCI USA, V93, P1060, DOI 10.1073/pnas.93.3.1060; Hu JM, 1997, EMBO J, V16, P59, DOI 10.1093/emboj/16.1.59; Hu JM, 2002, J VIROL, V76, P269, DOI 10.1128/JVI.76.1.269-279.2002; Jeong JH, 1996, BIOCHEM BIOPH RES CO, V223, P264, DOI 10.1006/bbrc.1996.0882; KIM K T, 1988, Korean Biochemical Journal, V21, P319; KNAUS T, 1993, NUCLEIC ACIDS RES, V21, P3967, DOI 10.1093/nar/21.17.3967; LEE HJ, 1993, BIOTECHNOL LETT, V15, P821; Loeb KR, 2000, HEPATOLOGY, V32, P626, DOI 10.1053/jhep.2000.9878; Lott L, 2000, J VIROL, V74, P11479, DOI 10.1128/JVI.74.24.11479-11489.2000; MASON WS, 1983, VIROLOGY, V131, P375, DOI 10.1016/0042-6822(83)90505-6; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Ono-Nita SK, 1999, HEPATOLOGY, V29, P939, DOI 10.1002/hep.510290340; Pak JH, 2002, J BIOL CHEM, V277, P49927, DOI 10.1074/jbc.M204222200; Park SG, 2002, VIROLOGY, V298, P116, DOI 10.1006/viro.2002.1496; Park SG, 2001, J VIROL, V75, P6962, DOI 10.1128/JVI.75.15.6962-6968.2001; Parkin DM, 1999, CANCER SURV, V33, P5; POLLACK JR, 1993, J VIROL, V67, P3254, DOI 10.1128/JVI.67.6.3254-3263.1993; Ranganathan G, 2002, J BIOL CHEM, V277, P38669, DOI 10.1074/jbc.M206917200; Seeger C, 2000, MICROBIOL MOL BIOL R, V64, P51, DOI 10.1128/MMBR.64.1.51-68.2000; Seo MS, 2000, J BIOL CHEM, V275, P20346, DOI 10.1074/jbc.M001943200; Sogos V, 1997, NEUROCHEM INT, V31, P447, DOI 10.1016/S0197-0186(96)00114-3; SOMMER W, 1999, METHOD ENZYMOL, V277, P261; STEINHOFF U, 1994, P NATL ACAD SCI USA, V91, P5085, DOI 10.1073/pnas.91.11.5085; STEVENS CE, 1975, NEW ENGL J MED, V292, P771, DOI 10.1056/NEJM197504102921503; Uhlmann E, 2000, METHOD ENZYMOL, V313, P268; Veal GJ, 1998, NUCLEIC ACIDS RES, V26, P5670, DOI 10.1093/nar/26.24.5670; WAGNER RW, 1995, NAT MED, V1, P1116, DOI 10.1038/nm1195-1116; Wagner RW, 1997, MOL MED TODAY, V3, P31, DOI 10.1016/S1357-4310(96)10053-8; WANG GH, 1992, CELL, V71, P663, DOI 10.1016/0092-8674(92)90599-8; Zignego AL, 1997, ARCH VIROL, V142, P535, DOI 10.1007/s007050050099; ZOULIM F, 1994, J VIROL, V68, P6, DOI 10.1128/JVI.68.1.6-13.1994	42	50	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39851	39857		10.1074/jbc.M301618200	http://dx.doi.org/10.1074/jbc.M301618200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869561	hybrid			2022-12-27	WOS:000185713800071
J	Sobol, RW; Kartalou, M; Almeida, KH; Joyce, DF; Engelward, BP; Horton, JK; Prasad, R; Samson, LD; Wilson, SH				Sobol, RW; Kartalou, M; Almeida, KH; Joyce, DF; Engelward, BP; Horton, JK; Prasad, R; Samson, LD; Wilson, SH			Base excision repair intermediates induce p53-independent cytotoxic and genotoxic responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-BETA; MISMATCH REPAIR; PHOSPHATE LYASE; MICE DEFICIENT; N-GLYCOSYLASE; P53; PROTEIN; DAMAGE; CELLS; MUTATIONS	DNA alkylation damage is primarily repaired by the base excision repair (BER) machinery in mammalian cells. In repair of the N-alkylated purine base lesion, for example, alkyl adenine DNA glycosylase (Aag) recognizes and removes the base, and DNA polymerase beta (beta-pol) contributes the gap tailoring and DNA synthesis steps. It is the loss of beta-pol-mediated 5'-deoxyribose phosphate removal that renders mouse fibroblasts alkylation-hypersensitive. Here we report that the hypersensitivity of beta-pol-deficient cells after methyl methanesulfonate-induced alkylation damage is wholly dependent upon glycosylase-mediated initiation of repair, indicating that alkylated base lesions themselves are tolerated in these cells and demonstrate that beta-pol protects against accumulation of toxic BER intermediates. Further, we find that these intermediates are initially tolerated in vivo by a second repair pathway, homologous recombination, inducing an increase in sister chromatid exchange events. If left unresolved, these BER intermediates trigger a rapid block in DNA synthesis and cytotoxicity. Surprisingly, both the cytotoxic and genotoxic signals are independent of both the p53 response and mismatch DNA repair pathways, demonstrating that p53 is not required for a functional BER pathway, that the observed damage response is not part of the p53 response network, and that the BER intermediate-induced cytotoxic and genotoxic effects are distinct from the mechanism engaged in response to mismatch repair signaling. These studies demonstrate that, although base damage is repaired by the BER pathway, incomplete BER intermediates are shuttled into the homologous recombination pathway, suggesting possible coordination between BER and the recombination machinery.	NIEHS, Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA; MIT, Biol Engn Div, Cambridge, MA 02139 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Massachusetts Institute of Technology (MIT)	Wilson, SH (corresponding author), NIEHS, Struct Biol Lab, NIH, POB 12233, Res Triangle Pk, NC 27709 USA.	wilson5@niehs.nih.gov	Wilson, Samuel H/E-6644-2019; Classen, Scott/AAY-8176-2020; Sobol, Robert W./E-4125-2013	Wilson, Samuel H/0000-0002-1702-5293; Sobol, Robert W./0000-0001-7385-3563	NCI NIH HHS [CA84740, P01 CA092584, R21 CA084740, CA92584, CA79287, R01 CA055042, R01 CA079827, CA55042] Funding Source: Medline; NIEHS NIH HHS [P30 ES002109, 5 T32 ES07020, ES02109] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584, R21CA084740, R33CA084740, R01CA079827, R01CA055042] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES050159, P30ES002109, T32ES007020] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ALBERTS B, 1994, MOL BIOL CELL, P1284; Boddy MN, 2001, CURR BIOL, V11, pR953, DOI 10.1016/S0960-9822(01)00572-3; Carr AM, 2000, SCIENCE, V287, P1765, DOI 10.1126/science.287.5459.1765; Carr AM, 2002, SCIENCE, V297, P557, DOI 10.1126/science.1075456; DIANOV G, 1992, MOL CELL BIOL, V12, P1605, DOI 10.1128/MCB.12.4.1605; Elder RH, 1998, MOL CELL BIOL, V18, P5828, DOI 10.1128/MCB.18.10.5828; Engelward BP, 1997, P NATL ACAD SCI USA, V94, P13087, DOI 10.1073/pnas.94.24.13087; Engelward BP, 1998, J BIOL CHEM, V273, P5412, DOI 10.1074/jbc.273.9.5412; Engelward BP, 1996, EMBO J, V15, P945, DOI 10.1002/j.1460-2075.1996.tb00429.x; Esposito G, 2000, P NATL ACAD SCI USA, V97, P1166, DOI 10.1073/pnas.97.3.1166; GU H, 1994, SCIENCE, V265, P103, DOI 10.1126/science.8016642; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Hasan S, 2002, MOL CELL, V10, P1213, DOI 10.1016/S1097-2765(02)00745-1; Hickman MJ, 1999, P NATL ACAD SCI USA, V96, P10764, DOI 10.1073/pnas.96.19.10764; Hoeijmakers JHJ, 2001, NATURE, V411, P366, DOI 10.1038/35077232; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Kartalou M, 2000, BIOCHEMISTRY-US, V39, P8032, DOI 10.1021/bi000417h; KASTAN MB, 1991, CANCER RES, V51, P6304; Kedar PS, 2002, J BIOL CHEM, V277, P31115, DOI 10.1074/jbc.M201497200; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lavrik OI, 2001, J BIOL CHEM, V276, P25541, DOI 10.1074/jbc.M102125200; Lindahl T, 1999, SCIENCE, V286, P1897, DOI 10.1126/science.286.5446.1897; LOEB LA, 1991, CANCER RES, V51, P3075; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798; Narayanan L, 1997, P NATL ACAD SCI USA, V94, P3122, DOI 10.1073/pnas.94.7.3122; PERRY P, 1974, NATURE, V251, P156, DOI 10.1038/251156a0; Piersen CE, 1996, J BIOL CHEM, V271, P17811, DOI 10.1074/jbc.271.30.17811; Plosky B, 2002, DNA REPAIR, V1, P683, DOI 10.1016/S1568-7864(02)00075-7; Prasad R, 1998, J BIOL CHEM, V273, P11121, DOI 10.1074/jbc.273.18.11121; Prasad R, 1998, J BIOL CHEM, V273, P15263, DOI 10.1074/jbc.273.24.15263; Roth RB, 2002, CANCER RES, V62, P656; SEEBERG E, 1995, TRENDS BIOCHEM SCI, V20, P391, DOI 10.1016/S0968-0004(00)89086-6; SINGHAL RK, 1995, J BIOL CHEM, V270, P949, DOI 10.1074/jbc.270.2.949; Smith SA, 2000, NUCLEIC ACIDS RES, V28, P3294, DOI 10.1093/nar/28.17.3294; Sobol RW, 2000, NATURE, V405, P807, DOI 10.1038/35015598; Sobol RW, 2002, P NATL ACAD SCI USA, V99, P6860, DOI 10.1073/pnas.092662499; Sobol RW, 2001, PROG NUCLEIC ACID RE, V68, P57; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; Srivastava DK, 1998, J BIOL CHEM, V273, P21203, DOI 10.1074/jbc.273.33.21203; Sugo N, 2000, EMBO J, V19, P1397, DOI 10.1093/emboj/19.6.1397; Tercero JA, 2001, NATURE, V412, P553, DOI 10.1038/35087607; Vogelstein B, 2000, NATURE, V408, P307, DOI 10.1038/35042675; Wilson SH, 1998, MUTAT RES-DNA REPAIR, V407, P203, DOI 10.1016/S0921-8777(98)00002-0; Wilson SH, 2000, COLD SPRING HARB SYM, V65, P143, DOI 10.1101/sqb.2000.65.143; Wood RD, 2001, SCIENCE, V291, P1284, DOI 10.1126/science.1056154; Xanthoudakis S, 1996, P NATL ACAD SCI USA, V93, P8919, DOI 10.1073/pnas.93.17.8919; Zhou JM, 2001, EMBO J, V20, P914, DOI 10.1093/emboj/20.4.914	49	151	157	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39951	39959		10.1074/jbc.M306592200	http://dx.doi.org/10.1074/jbc.M306592200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12882965	hybrid			2022-12-27	WOS:000185713800083
J	Tabancay, AP; Gau, CL; Machado, IMP; Uhlmann, EJ; Gutmann, DH; Guo, L; Tamanoi, F				Tabancay, AP; Gau, CL; Machado, IMP; Uhlmann, EJ; Gutmann, DH; Guo, L; Tamanoi, F			Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAS-RELATED PROTEIN; SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST; CELL-GROWTH; SACCHAROMYCES-CEREVISIAE; CANAVANINE RESISTANCE; NITROGEN STARVATION; MECHANISM; GENE; TRANSFORMATION	Rheb GTPases represent a unique family of the Ras superfamily of G-proteins. Studies on Rheb in Schizosaccharomyces pombe and Drosophila have shown that this small GTPase is essential and is involved in cell growth and cell cycle progression. The Drosophila studies also raised the possibility that Rheb is involved in the TOR/S6K signaling pathway. In this paper, we first report identification of dominant negative mutants of S. pombe Rheb (SpRheb). Screens of a randomly mutagenized SpRheb library yielded a mutant, SpRhebD60V, whose expression in S. pombe results in growth inhibition, G(1) arrest, and induction of fnx1(+), a gene whose expression is induced by the disruption of Rheb. Alteration of the Asp-60 residue to all possible amino acids by site-directed mutagenesis led to the identification of two particularly strong dominant negative mutants, D60I and D60K. Characterization of these dominant negative mutant proteins revealed that D60V and D60I exhibit preferential binding of GDP, while D60K lost the ability to bind both GTP and GDP. A possible use of the dominant negative mutants in the study of mammalian Rheb was explored by introducing dominant negative mutations into human Rheb. We show that transient expression of the wild type Rheb1 or Rheb2 causes activation of p70S6K, while expression of Rheb1D60K mutant results in inhibition of basal level activity of p70S6K. In addition, Rheb1D60K and Rheb1D60V mutants blocked nutrient- or serum-induced activation of p70S6K. This provides critical evidence that Rheb plays a role in the mTOR/S6K pathway in mammalian cells.	Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Jonsson Comprehens Canc Ctr, Inst Mol Biol, Los Angeles, CA 90095 USA; Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; Washington University (WUSTL)	Tamanoi, F (corresponding author), Univ Calif Los Angeles, Dept Microbiol Mol Genet & Immunol, Jonsson Comprehens Canc Ctr, Inst Mol Biol, 1602 Mol Sci Bldg, Los Angeles, CA 90095 USA.	fuyut@microbio.ucla.edu		Gutmann, David/0000-0002-3127-5045	NATIONAL CANCER INSTITUTE [F32CA094665, P01CA032737, P30CA016042, R01CA041996] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI028697] Funding Source: NIH RePORTER; NCI NIH HHS [F32-CA94665, CA41996, CA16042, CA32737] Funding Source: Medline; NIAID NIH HHS [AI28697] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Arai A, 2002, ONCOGENE, V21, P2641, DOI 10.1038/sj.onc.1205346; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; Bloor JW, 2002, DEVELOPMENT, V129, P3173; Boriack-Sjodin PA, 1998, NATURE, V394, P337, DOI 10.1038/28548; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; CHEN SY, 1994, ONCOGENE, V9, P2691; Clark GJ, 1997, J BIOL CHEM, V272, P10608; Dimitrov K, 1998, MOL CELL BIOL, V18, P5239, DOI 10.1128/MCB.18.9.5239; Feig LA, 1999, NAT CELL BIOL, V1, pE25, DOI 10.1038/10018; Finlin BS, 2001, J BIOL CHEM, V276, P42259, DOI 10.1074/jbc.M105888200; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; Gromov PS, 1995, FEBS LETT, V377, P221, DOI 10.1016/0014-5793(95)01349-0; Hall BE, 2001, J BIOL CHEM, V276, P27629, DOI 10.1074/jbc.M101727200; Hosoi H, 1998, MOL PHARMACOL, V54, P815, DOI 10.1124/mol.54.5.815; Im E, 2002, ONCOGENE, V21, P6356, DOI 10.1038/sj.onc.1205792; Mach KE, 2000, GENETICS, V155, P611; Marygold SJ, 2002, CURR BIOL, V12, pR785, DOI 10.1016/S0960-9822(02)01294-0; MITSUZAWA H, 1995, P NATL ACAD SCI USA, V92, P1704, DOI 10.1073/pnas.92.5.1704; MORENO S, 1991, METHOD ENZYMOL, V194, P795; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; Panepinto JC, 2003, INFECT IMMUN, V71, P2819, DOI 10.1128/IAI.71.5.2819-2826.2003; Panepinto JC, 2002, FUNGAL GENET BIOL, V36, P207, DOI 10.1016/S1087-1845(02)00022-1; Patel PH, 2003, J CELL SCI, V116, P3601, DOI 10.1242/jcs.00661; Ray RM, 2002, GASTROENTEROLOGY, V123, P196, DOI 10.1053/gast.2002.34216; Reuther GW, 2000, CURR OPIN CELL BIOL, V12, P157, DOI 10.1016/S0955-0674(99)00071-X; Saucedo LJ, 2003, NAT CELL BIOL, V5, P566, DOI 10.1038/ncb996; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Stocker H, 2003, NAT CELL BIOL, V5, P559, DOI 10.1038/ncb995; TANAKA K, 1991, P NATL ACAD SCI USA, V88, P468, DOI 10.1073/pnas.88.2.468; Urano J, 2001, METHOD ENZYMOL, V333, P217; Urano J, 2000, J BIOL CHEM, V275, P11198, DOI 10.1074/jbc.275.15.11198; YAMAGATA K, 1994, J BIOL CHEM, V269, P16333; Yang WL, 2001, MOL MICROBIOL, V41, P1339, DOI 10.1046/j.1365-2958.2001.02599.x; Yang WL, 2000, J BIOL CHEM, V275, P429, DOI 10.1074/jbc.275.1.429; Yee WM, 1997, MOL CELL BIOL, V17, P921, DOI 10.1128/MCB.17.2.921	37	84	87	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 10	2003	278	41					39921	39930		10.1074/jbc.M306553200	http://dx.doi.org/10.1074/jbc.M306553200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	728JJ	12869548	hybrid			2022-12-27	WOS:000185713800080
J	Blander, G; de Oliveira, RM; Conboy, CM; Haigis, M; Guarente, L				Blander, G; de Oliveira, RM; Conboy, CM; Haigis, M; Guarente, L			Superoxide dismutase 1 knock-down induces senescence in human fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-DIPLOID CELLS; REPLICATIVE SENESCENCE; SPONTANEOUS IMMORTALIZATION; OXIDATIVE STRESS; LIFE-SPAN; IN-VIVO; P53; CANCER; EXTENSION; OXIDANTS	Reactive oxygen species (ROS) such as superoxide radicals are responsible for the pathogenesis of various human diseases. ROS are generated during normal metabolic process in all of the oxygen-utilizing organisms. The copper-zinc-containing SOD (SOD1) acts as a major defense against ROS by detoxifying the superoxide anion. In model organisms, SOD1 has been shown to play a role in the aging process. However, the exact role of the SOD1 protein in the human aging process remains to be resolved. We show that SOD1 RNA interference (RNAi) induces senescence in normal human fibroblasts. This premature senescence depends on p53 induction. In contrast, in human fibroblastic cells with inactivated p53, the SOD1 RNAi is without effect. Surprisingly, in cancer cells ( HeLa), the SOD1 RNAi induces cell death rather then senescence. Together, these findings support the notion that in normal human cells the SOD1 protein may play a role in the regulation of cellular lifespan by p53 and may also regulate the death signals in cancer cells.	MIT, Dept Biol, Cambridge, MA 02139 USA; Univ Porto, Abel Salazar Inst Biomed Sci, Grad Program Basic & Appl Biol, P-4099003 Oporto, Portugal	Massachusetts Institute of Technology (MIT); Universidade do Porto	Guarente, L (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		de Oliveira, Rita M/E-9696-2015	de Oliveira, Rita M/0000-0002-0970-4501; Conboy, Caitlin/0000-0001-8280-056X				Afrasyap L, 1998, Cancer Biochem Biophys, V16, P129; AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1998, PHYSIOL REV, V78, P547, DOI 10.1152/physrev.1998.78.2.547; BOND JA, 1995, CANCER RES, V55, P2404; Brown JP, 1997, SCIENCE, V277, P831, DOI 10.1126/science.277.5327.831; Campisi J, 2003, NAT REV CANCER, V3, P339, DOI 10.1038/nrc1073; Campisi J, 1996, CELL, V84, P497, DOI 10.1016/S0092-8674(00)81023-5; Casado A, 1998, Gac Med Mex, V134, P539; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; DIMRI G, 1992, P NATL ACAD SCI USA, V26, P9363; Finkel T, 2000, NATURE, V408, P239, DOI 10.1038/35041687; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARVEY DM, 1991, GENE DEV, V5, P2375, DOI 10.1101/gad.5.12b.2375; Kong Q, 1998, MED HYPOTHESES, V51, P405, DOI 10.1016/S0306-9877(98)90036-6; Longo VD, 1996, J BIOL CHEM, V271, P12275, DOI 10.1074/jbc.271.21.12275; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; METZ T, 1995, CELL, V82, P29, DOI 10.1016/0092-8674(95)90049-7; Noor Rana, 2002, Med Sci Monit, V8, pRA210; Oren M, 1999, J BIOL CHEM, V274, P36031, DOI 10.1074/jbc.274.51.36031; PACKER L, 1977, NATURE, V267, P423, DOI 10.1038/267423a0; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; ROGAN EM, 1995, MOL CELL BIOL, V15, P4745; ROSEN DR, 1993, NATURE, V364, P362, DOI 10.1038/364362c0; Smith JR, 1996, SCIENCE, V273, P63, DOI 10.1126/science.273.5271.63; Smith JR, 1997, AGING-CLIN EXP RES, V9, P437; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; Sturtz LA, 2001, J BIOL CHEM, V276, P38084; VONZGLINICKI T, 1995, EXP CELL RES, V220, P186, DOI 10.1006/excr.1995.1305; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793	30	129	132	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38966	38969		10.1074/jbc.M307146200	http://dx.doi.org/10.1074/jbc.M307146200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12871978	hybrid			2022-12-27	WOS:000185575100107
J	Gavin, AL; Ait-Azzouzene, D; Ware, CF; Nemazee, D				Gavin, AL; Ait-Azzouzene, D; Ware, CF; Nemazee, D			Delta BAFF, an alternate splice isoform that regulates receptor binding and biopresentation of the B cell survival cytokine, BAFF	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; TNF FAMILY-MEMBER; CRYSTAL-STRUCTURE; LYMPHOCYTE STIMULATOR; AUTOIMMUNE-DISEASE; FAS LIGAND; BLYS; ACTIVATION; MATURATION; APRIL	The tumor necrosis family member BAFF is limiting for the survival of follicular B lymphocytes, but excessive BAFF signaling can lead to autoimmunity, suggesting that its activity must be tightly regulated. We have identified a conserved alternate splice isoform of BAFF, called DeltaBAFF, which lacks 57 nt encoding the A-A1 loop and is co-expressed with BAFF in many mouse and human myeloid cells. Mouse DeltaBAFF appears on the plasma membrane, but unlike BAFF it is inefficiently released by proteolysis. DeltaBAFF can associate with BAFF in heteromultimers and diminish BAFF bioactivity and release. Thus, alternative splicing of the BAFF gene suppresses BAFF B cell stimulatory function in several ways, and DeltaBAFF may promote other functions as well.	Scripps Res Inst, Dept Immunol, La Jolla, CA 92037 USA; La Jolla Inst Allergy & Immunol, Div Mol Immunol, San Diego, CA 92121 USA	Scripps Research Institute; La Jolla Institute for Immunology	Gavin, AL (corresponding author), Scripps Res Inst, Dept Immunol, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	agavin@scripps.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI058830] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE017568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044809] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P01AG001743] Funding Source: NIH RePORTER; NIAID NIH HHS [R21 AI058830] Funding Source: Medline; NIA NIH HHS [AG01743, P01 AG001743] Funding Source: Medline; NIDCR NIH HHS [R01 DE017568] Funding Source: Medline; NIGMS NIH HHS [GM44809, R01 GM044809] Funding Source: Medline; PHS HHS [A133068] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Al-Zoubi AM, 2001, J BIOL CHEM, V276, P47202, DOI 10.1074/jbc.M104835200; Ayroldi E, 1999, BLOOD, V94, P3456, DOI 10.1182/blood.V94.10.3456.422k33_3456_3467; BANNER DW, 1993, CELL, V73, P431, DOI 10.1016/0092-8674(93)90132-A; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X; BRADLEY JR, 1995, AM J PATHOL, V146, P27; Chen YW, 2001, P NATL ACAD SCI USA, V98, P7218, DOI 10.1073/pnas.131076098; Clise-Dwyer K, 2001, IMMUNOGENETICS, V53, P729, DOI 10.1007/s00251-001-0382-z; Do RKG, 2000, J EXP MED, V192, P953, DOI 10.1084/jem.192.7.953; GOH CR, 1991, PROTEIN ENG, V4, P785; Gordon NC, 2003, BIOCHEMISTRY-US, V42, P5977, DOI 10.1021/bi034017g; Granger SW, 2001, J IMMUNOL, V167, P5122, DOI 10.4049/jimmunol.167.9.5122; Gross JA, 2001, IMMUNITY, V15, P289, DOI 10.1016/S1074-7613(01)00183-2; Harless SM, 2001, CURR BIOL, V11, P1986, DOI 10.1016/S0960-9822(01)00598-X; Hsu BL, 2002, J IMMUNOL, V168, P5993, DOI 10.4049/jimmunol.168.12.5993; Karpusas M, 2002, J MOL BIOL, V315, P1145, DOI 10.1006/jmbi.2001.5296; Kelly K, 2000, CANCER RES, V60, P1021; Khare SD, 2000, P NATL ACAD SCI USA, V97, P3370, DOI 10.1073/pnas.050580697; Lam J, 2001, J CLIN INVEST, V108, P971, DOI 10.1172/JCI13890; Liu YF, 2003, NATURE, V423, P49, DOI 10.1038/nature01543; Liu YF, 2002, CELL, V108, P383, DOI 10.1016/S0092-8674(02)00631-1; Lum L, 1999, J BIOL CHEM, V274, P13613, DOI 10.1074/jbc.274.19.13613; Mackay F, 1999, J EXP MED, V190, P1697, DOI 10.1084/jem.190.11.1697; Mackay F, 2002, TRENDS IMMUNOL, V23, P113, DOI 10.1016/S1471-4906(01)02159-7; Mackay F, 2003, ANNU REV IMMUNOL, V21, P231, DOI 10.1146/annurev.immunol.21.120601.141152; Mackenzie IS, 2002, CLIN MED, V2, P465, DOI 10.7861/clinmedicine.2-5-465; Nishimura H, 2000, J EXP MED, V191, P157, DOI 10.1084/jem.191.1.157; Nosaka T, 1999, EMBO J, V18, P4754, DOI 10.1093/emboj/18.17.4754; Oren DA, 2002, NAT STRUCT BIOL, V9, P288, DOI 10.1038/nsb769; Powell WC, 1999, CURR BIOL, V9, P1441, DOI 10.1016/S0960-9822(00)80113-X; Rolink AG, 2002, CURR OPIN IMMUNOL, V14, P266, DOI 10.1016/S0952-7915(02)00332-1; Roschke V, 2002, J IMMUNOL, V169, P4314, DOI 10.4049/jimmunol.169.8.4314; Schiemann B, 2001, SCIENCE, V293, P2111, DOI 10.1126/science.1061964; Schneider P, 1999, J EXP MED, V189, P1747, DOI 10.1084/jem.189.11.1747; Seshasayee D, 2003, IMMUNITY, V18, P279, DOI 10.1016/S1074-7613(03)00025-6; Shu HB, 1999, J LEUKOCYTE BIOL, V65, P680, DOI 10.1002/jlb.65.5.680; Thompson JS, 2000, J EXP MED, V192, P129, DOI 10.1084/jem.192.1.129; VAIRO G, 1985, BIOCHEM BIOPH RES CO, V132, P430, DOI 10.1016/0006-291X(85)91040-X; Van O. X., 1991, EMBO J, V10, P827; Vaux DL, 2002, J CLIN INVEST, V109, P17, DOI 10.1172/JCI14780; vonBulow GU, 1997, SCIENCE, V278, P138, DOI 10.1126/science.278.5335.138; Ware CF, 2000, J EXP MED, V192, pF35, DOI 10.1084/jem.192.11.F35; Xu SL, 2001, MOL CELL BIOL, V21, P4067, DOI 10.1128/MCB.21.12.4067-4074.2001; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713; Yan MH, 2001, CURR BIOL, V11, P1547, DOI 10.1016/S0960-9822(01)00481-X; Yan MH, 2001, NAT IMMUNOL, V2, P638, DOI 10.1038/89790; Yu G, 2000, NAT IMMUNOL, V1, P252, DOI 10.1038/79802	47	84	94	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					38220	38228		10.1074/jbc.M306852200	http://dx.doi.org/10.1074/jbc.M306852200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12867412	Green Accepted, hybrid			2022-12-27	WOS:000185575100018
J	Bertoldi, M; Cellini, B; D'Aguanno, S; Voltattorni, CB				Bertoldi, M; Cellini, B; D'Aguanno, S; Voltattorni, CB			Lysine 238 is an essential residue for alpha,beta-elimination catalyzed by Treponema denticola cystalysin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE LYSYL RESIDUE; PYRIDOXAL-PHOSPHATE; ASPARTATE-AMINOTRANSFERASE; ESCHERICHIA-COLI; ACTIVE-SITE; INTERNAL ALDIMINE; EXOGENOUS AMINES; PRODUCT RELEASE; DECARBOXYLASE; 5'-PHOSPHATE	Treponema denticola cystalysin is a pyridoxal 5'-phosphate (PLP) enzyme that catalyzes the alpha,beta-elimination of L-cysteine to pyruvate, ammonia, and H2S. Similar to other PLP enzymes, an active site Lys residue (Lys-238) forms an internal Schiff base with PLP. The mechanistic role of this residue has been studied by an analysis of the mutant enzymes in which Lys-238 has been replaced by Ala (K238A) and Arg (K238R). Both apomutants reconstituted with PLP bind noncovalently similar to 50% of the normal complement of the cofactor and have a lower affinity for the coenzyme than that of wild-type. Kinetic analyses of the reactions of K238A and K238R mutants with glycine compared with that of wild-type demonstrate the decrease of the rate of Schiff base formation by 10(3)- and 7.5 x 10(4)-fold, respectively, and, to a lesser extent, a decrease of the rate of Schiff base hydrolysis. Thus, a role of Lys-238 is to facilitate formation of external aldimine by transimination. Kinetic data reveal that the K238A mutant is inactive in the alpha,beta-elimination of L-cysteine and beta- chloro-L-alanine, whereas K238R retains 0.3% of the wild-type activity. These data, together with those derived from a spectral analysis of the reaction of Lys-238 mutants with unproductive substrate analogues, indicate that Lys-238 is an essential catalytic residue, possibly participating as a general base abstracting the Calpha-proton from the substrate and possibly as a general acid protonating the beta-leaving group.	Univ Verona, Fac Med & Chirurg, Sezione Chim Biol, Dipartimento Sci Neurol & Vis, I-37134 Verona, Italy; Univ Roma La Sapienza, Dipartimento Sci Biochim A Rossi Fanelli, I-00185 Rome, Italy; Univ Roma La Sapienza, CNR, Ctr Biol Mol, I-00185 Rome, Italy	University of Verona; Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome	Voltattorni, CB (corresponding author), Univ Verona, Fac Med & Chirurg, Sezione Chim Biol, Dipartimento Sci Neurol & Vis, Strada Grazie 8, I-37134 Verona, Italy.		Cellini, Barbara/AAC-6401-2019; D'Aguanno, Simona/H-2179-2016; Bertoldi, Mariarita/F-1154-2010	Cellini, Barbara/0000-0002-5221-9288; D'Aguanno, Simona/0000-0002-1224-4454; Bertoldi, Mariarita/0000-0002-2337-9928				Bertoldi M, 2002, BIOCHEMISTRY-US, V41, P9153, DOI 10.1021/bi025649q; Bertoldi M, 2000, BIOCHEM J, V352, P533, DOI 10.1042/0264-6021:3520533; BORCSOK E, 1982, ARCH BIOCHEM BIOPHYS, V213, P695, DOI 10.1016/0003-9861(82)90600-2; CHU L, 1995, INFECT IMMUN, V63, P4448, DOI 10.1128/IAI.63.11.4448-4455.1995; CORDES EH, 1962, BIOCHEMISTRY-US, V1, P773, DOI 10.1021/bi00911a007; FERREIRA GC, 1993, PROTEIN SCI, V2, P1959, DOI 10.1002/pro.5560021117; FERREIRA GC, 1995, PROTEIN SCI, V4, P1001; FUTAKI S, 1990, J BIOL CHEM, V265, P22306; GREGERMAN RI, 1956, J BIOL CHEM, V220, P765; HARRIS CM, 1976, BIOCHIM BIOPHYS ACTA, V421, P181, DOI 10.1016/0304-4165(76)90284-1; INOUE Y, 1989, J BIOL CHEM, V264, P9673; KIRSCH JF, 1990, ENZYMES DEPENDENT PY, P161; Krupka HI, 2000, EMBO J, V19, P3168, DOI 10.1093/emboj/19.13.3168; KURAMITSU S, 1987, BIOCHEM BIOPH RES CO, V146, P416, DOI 10.1016/0006-291X(87)90545-6; LANE CF, 1975, SYNTHESIS-STUTTGART, P135; LONGENECKER JB, 1957, J BIOL CHEM, V225, P409; LU ZC, 1993, J BIOL CHEM, V268, P8727; MALCOLM BA, 1985, BIOCHEM BIOPH RES CO, V132, P915, DOI 10.1016/0006-291X(85)91894-7; NISHIMURA K, 1991, BIOCHEMISTRY-US, V30, P4072, DOI 10.1021/bi00230a036; Osterman AL, 1999, BIOCHEMISTRY-US, V38, P11814, DOI 10.1021/bi9906221; Rege VD, 1996, BIOCHEMISTRY-US, V35, P13485, DOI 10.1021/bi961517j; ROBERTS WJ, 1988, J BIOL CHEM, V263, P7196; SCHIRCH D, 1993, J BIOL CHEM, V268, P23132; SLEBE JC, 1976, J BIOL CHEM, V251, P5663; TATSUMOTO K, 1981, J AM CHEM SOC, V103, P6197, DOI 10.1021/ja00410a036; TATSUMOTO K, 1977, J AM CHEM SOC, V99, P6080; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; Tramonti A, 2002, EUR J BIOCHEM, V269, P4913, DOI 10.1046/j.1432-1033.2002.03149.x; VAALER GL, 1989, BIOCHEMISTRY-US, V28, P7306, DOI 10.1021/bi00444a024; Watababe A, 1999, J BIOL CHEM, V274, P4189, DOI 10.1074/jbc.274.7.4189	30	15	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37336	37343		10.1074/jbc.M305967200	http://dx.doi.org/10.1074/jbc.M305967200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12882978	hybrid			2022-12-27	WOS:000185437200043
J	Chang, DC; Xu, NH; Luo, KQ				Chang, DC; Xu, NH; Luo, KQ			Degradation of cyclin B is required for the onset of anaphase in mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SISTER-CHROMATID SEPARATION; MATURATION-PROMOTING FACTOR; APC-DEPENDENT PROTEOLYSIS; BUDDING YEAST; M-PHASE; SACCHAROMYCES-CEREVISIAE; MITOTIC KINASE; MITOSIS; DESTRUCTION; PROTEIN	Recently, it has been shown that cyclin B1 was degraded mainly before the onset of anaphase in mammalian cells. When a nondegradable form of cyclin B1 was introduced into cells, the metaphase-anaphase transition was blocked. This blockage was not due to a failure in activating anaphase-promoting complex, nor was it due to a failure of degradation of securin. To resolve the question of whether this blockage by overexpressing the nondegradable form of cyclin B1 is physiologically relevant or not, we developed a novel method to estimate the relative protein level of the overexpressed cyclin B1 mutant within an individual cell. We found that a low level of nondegradable cyclin B1 ( less than 30% of the endogenous cyclin B1) was sufficient to block the metaphase-anaphase transition, implying that the blockage of anaphase onset by the nondegradable cyclin B1 was not due to an artifact of excessive M-phase-promoting factor activity. This result suggests that, in mammalian cells, the majority of cyclin B1 must be destroyed before the cell can enter anaphase.	Hong Kong Univ Sci & Technol, Dept Biol, Kowloon, Hong Kong, Peoples R China; Marine Biol Lab, Woods Hole, MA 02543 USA	Hong Kong University of Science & Technology; Marine Biological Laboratory - Woods Hole	Chang, DC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biol, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.		Chang, Donald/AAV-7180-2021; Xu, Naihan/C-2778-2018					Amon A, 1997, EMBO J, V16, P2693, DOI 10.1093/emboj/16.10.2693; Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344; Chang D C, 1997, Methods Mol Biol, V62, P307; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; Clute P, 1999, NAT CELL BIOL, V1, P82, DOI 10.1038/10049; Fang GW, 1998, GENE DEV, V12, P1871, DOI 10.1101/gad.12.12.1871; Fang GW, 1998, MOL CELL, V2, P163, DOI 10.1016/S1097-2765(00)80126-4; Farr KA, 1999, EUR J BIOCHEM, V263, P14, DOI 10.1046/j.1432-1327.1999.00510.x; GALLANT P, 1992, J CELL BIOL, V117, P213, DOI 10.1083/jcb.117.1.213; GHIARA JB, 1991, CELL, V65, P163, DOI 10.1016/0092-8674(91)90417-W; GIRARD F, 1995, J CELL SCI, V108, P2599; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Hagting A, 2002, J CELL BIOL, V157, P1125, DOI 10.1083/jcb.200111001; Hinchcliffe EH, 1998, J CELL BIOL, V140, P1417, DOI 10.1083/jcb.140.6.1417; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Jacobs HW, 2001, EMBO J, V20, P2376, DOI 10.1093/emboj/20.10.2376; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Kotani S, 1999, J CELL BIOL, V146, P791, DOI 10.1083/jcb.146.4.791; Kramer ER, 1998, CURR BIOL, V8, P1207, DOI 10.1016/S0960-9822(07)00510-6; Lim HH, 1998, CURR BIOL, V8, P231, DOI 10.1016/S0960-9822(98)70088-0; LUCA FC, 1991, EMBO J, V10, P4311, DOI 10.1002/j.1460-2075.1991.tb05009.x; LUO Q, 1994, J CELL SCI, V107, P3105; Matz MV, 1999, NAT BIOTECHNOL, V17, P969, DOI 10.1038/13657; Morgan DO, 1999, NAT CELL BIOL, V1, pE47, DOI 10.1038/10039; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; Murray AW, 1996, P NATL ACAD SCI USA, V93, P12327, DOI 10.1073/pnas.93.22.12327; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; Parry DH, 2001, CURR BIOL, V11, P671, DOI 10.1016/S0960-9822(01)00204-4; PINES J, 1991, J CELL BIOL, V115, P1, DOI 10.1083/jcb.115.1.1; Raff JW, 2002, J CELL BIOL, V157, P1139, DOI 10.1083/jcb.200203035; RIMMINGTON G, 1994, J CELL SCI, V107, P2729; Shirayama M, 1998, EMBO J, V17, P1336, DOI 10.1093/emboj/17.5.1336; SIGRIST S, 1995, EMBO J, V14, P4827, DOI 10.1002/j.1460-2075.1995.tb00164.x; Stemmann O, 2001, CELL, V107, P715, DOI 10.1016/S0092-8674(01)00603-1; SURANA U, 1993, EMBO J, V12, P1969, DOI 10.1002/j.1460-2075.1993.tb05846.x; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Uhlmann F, 2000, CELL, V103, P375, DOI 10.1016/S0092-8674(00)00130-6; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460; Wasch R, 2002, NATURE, V418, P556, DOI 10.1038/nature00856; Wheatley SP, 1997, J CELL BIOL, V138, P385, DOI 10.1083/jcb.138.2.385; Yamano H, 1996, EMBO J, V15, P5268, DOI 10.1002/j.1460-2075.1996.tb00912.x; Yeong FM, 2000, MOL CELL, V5, P501, DOI 10.1016/S1097-2765(00)80444-X; Zachariae W, 1999, CURR OPIN CELL BIOL, V11, P708, DOI 10.1016/S0955-0674(99)00041-1; Zur A, 2001, EMBO J, V20, P792, DOI 10.1093/emboj/20.4.792	47	114	116	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	SEP 26	2003	278	39					37865	37873		10.1074/jbc.M306376200	http://dx.doi.org/10.1074/jbc.M306376200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	723MY	12865421	hybrid			2022-12-27	WOS:000185437200107
J	Chen, GP; Chen, XR				Chen, GP; Chen, XR			Arginine residues in the active site of human phenol sulfotransferase (SULT1A1)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN M-FORM; CRYSTAL-STRUCTURE; BINDING-SITE; SUBSTRATE-SPECIFICITY; MUTATIONAL ANALYSIS; 2,3-BUTANEDIONE; PHENYLGLYOXAL; INACTIVATION; DOMAINS; REAGENT	Cytosolic sulfotransferases (STs) catalyze the sulfation of hydroxyl containing compounds. Human phenol sulfotransferase (SULT1A1) is the major human ST that catalyzes the sulfation of simple phenols. Because of its broad substrate specificity and lack of endogenous substrates, the biological function of SULT1A1 is believed to be an important detoxification enzyme. In this report, amino acid modification, computer structure modeling, and site-directed mutagenesis were used for studies of Arg residues in the active site of SULT1A1. The Arg-specific modification reagent, 2,3-butanedione, inactivated SULT1A1 in an efficient, time- and concentration-dependent manner, suggesting Arg residues play an important role in the catalytic activity of SULT1A1. According to the computer model, Arg(78), Arg(130), and Arg(257) may be important for SULT1A1 catalytic activity. Site-directed mutagenesis results demonstrated that the positive charge on Arg(78) is not critical for SULT1A1 because R78A is still active. In contrast, a negative charge at this position, R78E, completely inactivated SULT1A1. Arg(78) is in close proximity to the site of sulfuryl group transfer. Arg(257) is located very close to the 3'-phosphate in adenosine 3'-phosphate 5'-phosphosulfate ( PAPS). Site-directed mutagenesis demonstrated that Arg(257) is critical for SULT1A1: both R257A and R257E are inactive. Although Arg(130) is also located very close to the 3'-phosphate of PAPS, R130A and R130E are still active, suggesting that Arg(130) is not a critical residue for the catalytic activity of SULT1A1. Computer modeling suggests that the ionic interaction between the positive charge on Arg(257), and the negative charge on 3'-phosphate is the primary force stabilizing the specific binding of PAPS.	Oklahoma State Univ, Coll Vet Med, Dept Physiol Sci, Stillwater, OK 74078 USA	Oklahoma State University System; Oklahoma State University - Stillwater	Chen, GP (corresponding author), Oklahoma State Univ, Coll Vet Med, Dept Physiol Sci, 264 McElroy Hall, Stillwater, OK 74078 USA.	cguang@okstate.edu			NIGMS NIH HHS [R01 GM059873-03, R01 GM059873-02, R01 GM059873-01A1, R01 GM059873, GM59873] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059873] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alkema WBL, 2002, BIOCHEM J, V365, P303, DOI 10.1042/BJ20011468; Bidwell LM, 1999, J MOL BIOL, V293, P521, DOI 10.1006/jmbi.1999.3153; BORCHARDT RT, 1982, BIOCHIM BIOPHYS ACTA, V708, P280, DOI 10.1016/0167-4838(82)90438-1; BORCHARDT RT, 1978, BIOCHEM BIOPH RES CO, V81, P841, DOI 10.1016/0006-291X(78)91428-6; BORCHARDT RT, 1977, BIOCHEM BIOPH RES CO, V78, P1067, DOI 10.1016/0006-291X(77)90529-0; Brix LA, 1999, BIOCHEMISTRY-US, V38, P10474, DOI 10.1021/bi990795q; Brix LA, 1999, BIOCHEM J, V337, P337, DOI 10.1042/0264-6021:3370337; Chen GP, 2002, J BIOCHEM MOL TOXIC, V16, P279, DOI 10.1002/jbt.10048; Chen GP, 1999, PROTEIN SCI, V8, P2151, DOI 10.1110/ps.8.10.2151; Chen GP, 2000, BIOCHEMISTRY-US, V39, P16000, DOI 10.1021/bi0021479; Dajani R, 1999, J BIOL CHEM, V274, P37862, DOI 10.1074/jbc.274.53.37862; Duffel MW, 1998, CHEM-BIOL INTERACT, V109, P81, DOI 10.1016/S0009-2797(97)00122-1; Eriksson O, 1998, J BIOL CHEM, V273, P12669, DOI 10.1074/jbc.273.20.12669; Falany CN, 1995, ANN NY ACAD SCI, V774, P59, DOI 10.1111/j.1749-6632.1995.tb17372.x; FALANY CN, 1994, CHEM-BIOL INTERACT, V92, P57, DOI 10.1016/0009-2797(94)90053-1; Frame LT, 2000, DRUG METAB DISPOS, V28, P1063; Hsiao YS, 2002, BIOCHEMISTRY-US, V41, P12959, DOI 10.1021/bi0261239; Kakuta Y, 1997, NAT STRUCT BIOL, V4, P904, DOI 10.1038/nsb1197-904; KOMATSU K, 1994, BIOCHEM BIOPH RES CO, V204, P1178, DOI 10.1006/bbrc.1994.2587; Liu MC, 2000, J BIOL CHEM, V275, P13460, DOI 10.1074/jbc.275.18.13460; Marsolais F, 1995, J BIOL CHEM, V270, P30458, DOI 10.1074/jbc.270.51.30458; Marsolais F, 1999, BIOCHEMISTRY-US, V38, P4066, DOI 10.1021/bi982239m; Marsolais F, 1997, EUR J BIOCHEM, V247, P1056, DOI 10.1111/j.1432-1033.1997.01056.x; NOSE Y, 1958, J BIOL CHEM, V233, P1348; Pedersen LC, 2000, FEBS LETT, V475, P61, DOI 10.1016/S0014-5793(00)01479-4; Pedersen LC, 2002, J BIOL CHEM, V277, P17928, DOI 10.1074/jbc.M111651200; Petrotchenko EV, 1999, J BIOL CHEM, V274, P30019, DOI 10.1074/jbc.274.42.30019; RIORDAN JF, 1973, BIOCHEMISTRY-US, V12, P3915, DOI 10.1021/bi00744a020; Sakakibara Y, 1998, J BIOL CHEM, V273, P6242, DOI 10.1074/jbc.273.11.6242; Varin L, 1997, FASEB J, V11, P517, DOI 10.1096/fasebj.11.7.9212075; VARIN L, 1995, J BIOL CHEM, V270, P12498, DOI 10.1074/jbc.270.21.12498; WEINSHILBOUM R, 1994, CHEM-BIOL INTERACT, V92, P233, DOI 10.1016/0009-2797(94)90066-3; WILBORN TW, 1993, MOL PHARMACOL, V43, P70; YANKEELOV JA, 1968, J AM CHEM SOC, V90, P1664, DOI 10.1021/ja01008a056; ZHENG YQ, 1994, J BIOL CHEM, V269, P30313	35	15	17	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					36358	36364		10.1074/jbc.M306045200	http://dx.doi.org/10.1074/jbc.M306045200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12867416	Green Accepted, hybrid			2022-12-27	WOS:000185318300062
J	Taxis, C; Hitt, R; Park, SH; Deak, PM; Kostova, Z; Wolf, DH				Taxis, C; Hitt, R; Park, SH; Deak, PM; Kostova, Z; Wolf, DH			Use of modular substrates demonstrates mechanistic diversity and reveals differences in chaperone requirement of ERAD	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM DEGRADATION; TRANSMEMBRANE CONDUCTANCE REGULATOR; MANNOSIDASE-LIKE PROTEIN; SACCHAROMYCES-CEREVISIAE; QUALITY-CONTROL; CO-CHAPERONE; MOLECULAR CHAPERONES; CARBOXYPEPTIDASE YSCY; RETRO-TRANSLOCATION; MEMBRANE-PROTEIN	The endoplasmic reticulum (ER) harbors a protein quality control system, which monitors protein folding in the ER. Elimination of malfolded proteins is an important function of this protein quality control. Earlier studies with various soluble and transmembrane ER-associated degradation (ERAD) substrates revealed differences in the ER degradation machinery used. To unravel the nature of these differences we generated two type I membrane ERAD substrates carrying malfolded carboxypeptidase yscY (CPY*) as the ER-luminal ERAD recognition motif. Whereas the first, CT* (CPY*-TM), has no cytoplasmic domain, the second, CTG*, has the green fluorescent protein present in the cytosol. Together with CPY*, these three substrates represent topologically diverse malfolded proteins, degraded via ERAD. Our data show that degradation of all three proteins is dependent on the ubiquitin-proteasome system involving the ubiquitin-protein ligase complex Der3/Hrd1p-Hrd3p, the ubiquitin conjugating enzymes Ubc1p and Ubc7p, as well as the AAA-ATPase complex Cdc48-Ufd1-Npl4 and the 26S proteasome. In contrast to soluble CPY*, degradation of the membrane proteins CT* and CTG* does not require the ER proteins Kar2p (BiP) and Der1p. Instead, CTG* degradation requires cytosolic Hsp70, Hsp40, and Hsp104p chaperones.	Univ Stuttgart, Inst Biochem, D-70569 Stuttgart, Germany	University of Stuttgart	Wolf, DH (corresponding author), Univ Stuttgart, Inst Biochem, Pfaffenwaldring 55, D-70569 Stuttgart, Germany.	wolf@po.uni-stuttgart.de	Taxis, Christof/P-6188-2019; Taxis, Christof/AAP-7408-2021	Taxis, Christof/0000-0001-5952-7091; Park, Sae-Hun/0000-0002-8277-0732				Ausubel FM, 1992, CURRENT PROTOCOLS MO; Bays NW, 2001, MOL BIOL CELL, V12, P4114, DOI 10.1091/mbc.12.12.4114; Becker J, 1996, MOL CELL BIOL, V16, P4378; Biederer T, 1996, EMBO J, V15, P2069, DOI 10.1002/j.1460-2075.1996.tb00560.x; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Braun S, 2002, EMBO J, V21, P615, DOI 10.1093/emboj/21.4.615; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1999, SEMIN CELL DEV BIOL, V10, P507, DOI 10.1006/scdb.1999.0321; Buchner J, 1999, TRENDS BIOCHEM SCI, V24, P136, DOI 10.1016/S0968-0004(99)01373-0; Caldwell SR, 2001, J BIOL CHEM, V276, P23296, DOI 10.1074/jbc.M102962200; CAPLAN AJ, 1992, CELL, V71, P1143, DOI 10.1016/S0092-8674(05)80063-7; Connell P, 2001, NAT CELL BIOL, V3, P93, DOI 10.1038/35050618; Costanzo MC, 2001, NUCLEIC ACIDS RES, V29, P75, DOI 10.1093/nar/29.1.75; Deak PM, 2001, J BIOL CHEM, V276, P10663, DOI 10.1074/jbc.M008608200; EGNER R, 1995, MOL CELL BIOL, V15, P5879; Epple UD, 2001, J BACTERIOL, V183, P5942, DOI 10.1128/JB.183.20.5942-5955.2001; Fang YF, 1998, MOL CELL BIOL, V18, P3727, DOI 10.1128/MCB.18.7.3727; Farinha CM, 2002, BIOCHEM J, V366, P797, DOI 10.1042/BJ20011717; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Frohlich KU, 2001, J CELL SCI, V114, P1601; Galan JM, 1998, FASEB J, V12, P315, DOI 10.1096/fasebj.12.3.315; Gardner RG, 2000, J CELL BIOL, V151, P69, DOI 10.1083/jcb.151.1.69; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Guthrie C., 1991, GUIDE YEAST GENETICS, V194; Hampton RY, 1996, MOL BIOL CELL, V7, P2029, DOI 10.1091/mbc.7.12.2029; Hartl FU, 2002, SCIENCE, V295, P1852, DOI 10.1126/science.1068408; Hill K, 2000, EMBO J, V19, P550, DOI 10.1093/emboj/19.4.550; Hiller MM, 1996, SCIENCE, V273, P1725, DOI 10.1126/science.273.5282.1725; HILT W, 1999, POSTTRANSLATIONAL PR, P265; Hitchcock AL, 2001, MOL BIOL CELL, V12, P3226, DOI 10.1091/mbc.12.10.3226; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jakob CA, 2001, EMBO REP, V2, P423; Jarosch E, 2002, NAT CELL BIOL, V4, P134, DOI 10.1038/ncb746; Jiang CW, 1998, AM J PHYSIOL-CELL PH, V275, pC171, DOI 10.1152/ajpcell.1998.275.1.C171; Johnson JL, 2001, J CELL BIOL, V152, P851, DOI 10.1083/jcb.152.4.851; Kelley WL, 1999, CURR BIOL, V9, pR305, DOI 10.1016/S0960-9822(99)80185-7; Kelley WL, 1998, TRENDS BIOCHEM SCI, V23, P222, DOI 10.1016/S0968-0004(98)01215-8; Knop M, 1996, EMBO J, V15, P753, DOI 10.1002/j.1460-2075.1996.tb00411.x; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; KOSTOVA Z, 2002, PROTEIN TARGETING TR, P180; Lenk U, 2000, J BIOL CHEM, V275, P39403, DOI 10.1074/jbc.M006949200; Lewis MJ, 1997, EMBO J, V16, P3017, DOI 10.1093/emboj/16.11.3017; Liu CW, 2003, SCIENCE, V299, P408, DOI 10.1126/science.1079293; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; Madeo F, 1998, MOL BIOL CELL, V9, P131, DOI 10.1091/mbc.9.1.131; Meacham GC, 2001, NAT CELL BIOL, V3, P100, DOI 10.1038/35050509; Misselwitz B, 1998, MOL CELL, V2, P593, DOI 10.1016/S1097-2765(00)80158-6; Nakatsukasa K, 2001, J BIOL CHEM, V276, P8635, DOI 10.1074/jbc.C100023200; NATHAN DF, 1995, MOL CELL BIOL, V15, P3917; Neuwald AF, 1999, GENOME RES, V9, P27; NISHIKAWA S, 1994, MOL BIOL CELL, V5, P1129, DOI 10.1091/mbc.5.10.1129; Nishikawa S, 2001, J CELL BIOL, V153, P1061, DOI 10.1083/jcb.153.5.1061; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, J CELL SCI, V112, P4123; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Plemper RK, 1999, FEBS LETT, V443, P241, DOI 10.1016/S0014-5793(98)01724-4; Plemper RK, 1998, J BIOL CHEM, V273, P32848, DOI 10.1074/jbc.273.49.32848; Rabinovich E, 2002, MOL CELL BIOL, V22, P626, DOI 10.1128/MCB.22.2.626-634.2002; Rapoport TA, 1996, ANNU REV BIOCHEM, V65, P271; Rudiger S, 2001, EMBO J, V20, P1042, DOI 10.1093/emboj/20.5.1042; SCHERER S, 1979, P NATL ACAD SCI USA, V76, P4951, DOI 10.1073/pnas.76.10.4951; SEUFERT W, 1990, EMBO J, V9, P4535, DOI 10.1002/j.1460-2075.1990.tb07905.x; Sommer T, 1997, FASEB J, V11, P1227, DOI 10.1096/fasebj.11.14.9409541; Swanson R, 2001, GENE DEV, V15, P2660, DOI 10.1101/gad.933301; Taxis C, 2002, MOL BIOL CELL, V13, P1806, DOI 10.1091/mbc.01-08-0399; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tizon B, 1999, YEAST, V15, P145, DOI 10.1002/(SICI)1097-0061(19990130)15:2<145::AID-YEA346>3.0.CO;2-J; Tsai B, 2002, NAT REV MOL CELL BIO, V3, P246, DOI 10.1038/nrm780; Vashist S, 2001, J CELL BIOL, V155, P355, DOI 10.1083/jcb.200106123; Walter J, 2001, EMBO J, V20, P3124, DOI 10.1093/emboj/20.12.3124; WALTER P, 1994, ANNU REV CELL BIOL, V10, P87, DOI 10.1146/annurev.cb.10.110194.000511; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Wilkinson BM, 2000, J BIOL CHEM, V275, P521, DOI 10.1074/jbc.275.1.521; WOLF DH, 1975, J BACTERIOL, V123, P1150, DOI 10.1128/JB.123.3.1150-1156.1975; Ye YH, 2001, NATURE, V414, P652, DOI 10.1038/414652a; Zhang YM, 2001, MOL BIOL CELL, V12, P1303, DOI 10.1091/mbc.12.5.1303; Zhou MY, 1999, MOL CELL, V4, P925, DOI 10.1016/S1097-2765(00)80222-1	82	154	159	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 19	2003	278	38					35903	35913		10.1074/jbc.M301080200	http://dx.doi.org/10.1074/jbc.M301080200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	721LR	12847107	hybrid			2022-12-27	WOS:000185318300007
J	Fayard, E; Schoonjans, K; Annicotte, JS; Auwerx, J				Fayard, E; Schoonjans, K; Annicotte, JS; Auwerx, J			Liver receptor homolog 1 controls the expression of carboxyl ester lipase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORPHAN NUCLEAR RECEPTOR; SMALL-HETERODIMER-PARTNER; FETOPROTEIN TRANSCRIPTION FACTOR; SALT-STIMULATED LIPASE; HUMAN INTESTINAL-CELLS; BILE-ACID TRANSPORTER; DNA-BINDING DOMAIN; CHOLESTEROL ABSORPTION; FEEDBACK-REGULATION; ESTROGEN-RECEPTORS	The orphan nuclear receptor liver receptor homolog 1 (LRH-1) plays a central role in cholesterol homeostasis by regulating a number of hepatic and intestinal genes critical for reverse cholesterol transport and bile acid homeostasis. Herein, we describe the identification of carboxyl ester lipase (CEL) as a novel target of LRH- 1 in pancreas, a tissue in which LRH- 1 is abundantly expressed. In situ hybridization and gene expression studies demonstrate that both LRH- 1 and CEL are co- expressed and confined to the exocrine pancreas. LRH- 1 interacts with a consensus LRH- 1 response element in the human CEL promoter, which is perfectly conserved in the rat gene, and induces CEL promoter activity in cotransfection assays. As reported for other LRH- 1 target genes, the nuclear receptor short heterodimer partner represses LRH- 1-induced CEL promoter activity. Chromatin immunoprecipitation demonstrates that binding of LRH- 1 to the CEL promoter increases histone H4 acetylation corresponding with the activation of endogenous CEL gene transcription. Our data, identifying CEL as the first pancreatic LRH- 1 target gene, indicate that LRH- 1 is an important player in enterohepatic cholesterol homeostasis.	Univ Strasbourg 1, IGBMC, CNRS, INSERM, F-67404 Illkirch Graffenstaden, CU de Strasbour, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Auwerx, J (corresponding author), Univ Strasbourg 1, IGBMC, CNRS, INSERM, BP 10142, F-67404 Illkirch Graffenstaden, CU de Strasbour, France.	auwerx@igbmc.u-strasbg.fr	Annicotte, Jean-Sébastien/H-4641-2018; Auwerx, Johan/ABE-9307-2021	Annicotte, Jean-Sébastien/0000-0002-2109-4849; Auwerx, Johan/0000-0002-5065-5393; Schoonjans, Kristina/0000-0003-1247-4265				BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BOSNER MS, 1988, P NATL ACAD SCI USA, V85, P7438, DOI 10.1073/pnas.85.20.7438; Brendel C, 2002, MOL ENDOCRINOL, V16, P2065, DOI 10.1210/me.2001-0194; BRODTEPPLEY J, 1995, BIOCHEM J, V306, P605, DOI 10.1042/bj3060605; BRODTEPPLEY J, 1994, J LIPID RES, V35, P27; Chen F, 2003, J BIOL CHEM, V278, P19909, DOI 10.1074/jbc.M207903200; CHEN H, 1992, BIOCHEM J, V286, P771, DOI 10.1042/bj2860771; CLEVELAND DW, 1980, CELL, V20, P95, DOI 10.1016/0092-8674(80)90238-X; del Castillo-Olivares A, 2000, NUCLEIC ACIDS RES, V28, P3587; DOLLE P, 1989, EMBO J, V8, P1507, DOI 10.1002/j.1460-2075.1989.tb03535.x; ELLINGERZIEGELBAUER H, 1994, MOL CELL BIOL, V14, P2786, DOI 10.1128/MCB.14.4.2786; FIELD FJ, 1993, J CLIN INVEST, V92, P2609, DOI 10.1172/JCI116876; FONTAINE RN, 1991, BIOCHEMISTRY-US, V30, P7008, DOI 10.1021/bi00242a028; Galarneau L, 1996, MOL CELL BIOL, V16, P3853; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Howles PN, 1996, J BIOL CHEM, V271, P7196, DOI 10.1074/jbc.271.12.7196; HUANG Y, 1991, J BIOL CHEM, V266, P6720; HUI DY, 1993, BIOCHEM J, V291, P65, DOI 10.1042/bj2910065; Inokuchi A, 2001, J BIOL CHEM, V276, P46822, DOI 10.1074/jbc.M104612200; Johansson L, 2000, MOL CELL BIOL, V20, P1124, DOI 10.1128/MCB.20.4.1124-1133.2000; Johansson L, 1999, J BIOL CHEM, V274, P345, DOI 10.1074/jbc.274.1.345; Kirby RJ, 2002, J BIOL CHEM, V277, P4104, DOI 10.1074/jbc.M107549200; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Lee YK, 1999, J BIOL CHEM, V274, P20869, DOI 10.1074/jbc.274.30.20869; Lee YK, 2002, J BIOL CHEM, V277, P2463, DOI 10.1074/jbc.M105161200; Li M, 1998, J BIOL CHEM, V273, P29022, DOI 10.1074/jbc.273.44.29022; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Luo Y, 2001, J BIOL CHEM, V276, P24767, DOI 10.1074/jbc.M100912200; MACGREGOR GR, 1989, NUCLEIC ACIDS RES, V17, P2365, DOI 10.1093/nar/17.6.2365; MASIAKOWSKI P, 1982, NUCLEIC ACIDS RES, V10, P7895, DOI 10.1093/nar/10.24.7895; Masuda N, 1997, BBA-GENE STRUCT EXPR, V1350, P27, DOI 10.1016/S0167-4781(96)00196-0; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Pare JF, 2001, J BIOL CHEM, V276, P13136, DOI 10.1074/jbc.M010737200; Peet DJ, 1998, CELL, V93, P693, DOI 10.1016/S0092-8674(00)81432-4; Rausa FM, 1999, MECH DEVELOP, V89, P185, DOI 10.1016/S0925-4773(99)00209-9; RIGTRUP KM, 1992, BIOCHEMISTRY-US, V31, P2920, DOI 10.1021/bi00126a011; Sanyal S, 2002, J BIOL CHEM, V277, P1739, DOI 10.1074/jbc.M106140200; Schoonjans K, 2000, J MOL BIOL, V304, P323, DOI 10.1006/jmbi.2000.4218; Schoonjans K, 2002, EMBO REP, V3, P1181, DOI 10.1093/embo-reports/kvf238; Schoonjans K, 1996, EMBO J, V15, P5336, DOI 10.1002/j.1460-2075.1996.tb00918.x; Seel WG, 1998, MOL ENDOCRINOL, V12, P1551, DOI 10.1210/mend.12.10.0184; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Seol W, 1997, MOL CELL BIOL, V17, P7126, DOI 10.1128/MCB.17.12.7126; TRABER MG, 1990, GASTROENTEROLOGY, V98, P96, DOI 10.1016/0016-5085(90)91296-I; Tremblay JJ, 1999, MOL CELL BIOL, V19, P2567; WANG CS, 1993, BIOCHIM BIOPHYS ACTA, V1166, P1, DOI 10.1016/0005-2760(93)90277-G; Weng W, 1999, BIOCHEMISTRY-US, V38, P4143, DOI 10.1021/bi981679a; Yazawa T, 2003, ENDOCRINOLOGY, V144, P1920, DOI 10.1210/en.2002-221070	48	48	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					35725	35731		10.1074/jbc.M302370200	http://dx.doi.org/10.1074/jbc.M302370200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12853459	hybrid			2022-12-27	WOS:000185164400119
J	Song, KS; Seong, JK; Chung, KC; Lee, WJ; Kim, CH; Cho, KN; Kang, CD; Koo, JS; Yoon, JH				Song, KS; Seong, JK; Chung, KC; Lee, WJ; Kim, CH; Cho, KN; Kang, CD; Koo, JS; Yoon, JH			Induction of MUC8 gene expression by interleukin-1 beta is mediated by a sequential ERK MAPK/RSK1/CREB cascade pathway in human airway epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; NORMAL HUMAN NASAL; MESSENGER-RNA; TNF-ALPHA; PHOSPHORYLATION; TRANSCRIPTION; CREB; MAPK; MSK1; DIFFERENTIATION	Mucins are the major components of the mucus layer that covers and protects the respiratory, digestive, and reproductive tracts. Our previous studies showed that MUC8 gene expression was overexpressed in in vivo polyp epithelium in chronic sinusitis and was also increased by treatment with inflammatory mediators in an in vitro culture condition. However, the mechanisms by which the inflammatory mediators-induced MUC8 gene expression in normal nasal epithelial cells evolved remain unclear. We examined the mechanism by which the important proinflammatory mediator, interleukin (IL)-1beta, increases MUC8 gene expression levels. We found that pharmacologic and genetic inhibition of ERK MAPK pathway abolished IL-1beta-induced MUC8 gene expression in normal human nasal epithelial cells. Moreover, the overexpression of wide-type or of the dominant-negative mutant of p90 ribosomal S6 protein kinase 1 (RSK1) enhanced or suppressed, respectively, IL-1beta-induced MUC8 gene expression. RSK1 was found to directly phosphorylate cAMP-response element-binding protein ( CREB), and this event led to the stimulation of subsequent CRE-mediated gene transcription. In conclusion, IL-1beta was found to induce MUC8 gene expression via a sequential ERK/RSK1/CREB pathway in human airway epithelial cells.	Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea; Seoul Natl Univ, Coll Vet Med, Dept Dev Biol & Genom, Seoul 151742, South Korea; Yonsei Univ, Coll Sci, Dept Biol, Seoul 120749, South Korea; Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Pusan Natl Univ, Coll Med, Dept Biochem, Pusan 609735, South Korea; Univ Texas, MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA; Yonsei Univ, Coll Med, Dept Otorhinolaryngol, Seoul 120752, South Korea	Yonsei University; Yonsei University Health System; Seoul National University (SNU); Yonsei University; Ewha Womans University; Pusan National University; University of Texas System; UTMD Anderson Cancer Center; Yonsei University; Yonsei University Health System	Yoon, JH (corresponding author), Yonsei Univ, Coll Med, Brain Korea Project Med Sci 21, Seoul 120752, South Korea.	jhyoon@yumc.yonsei.ac.kr	Yoon, Joo-Heon/E-5781-2016; Kim, Chang-Hoon/D-7205-2016; Koo, J Peter/AAE-6700-2019	Kim, Chang-Hoon/0000-0003-1238-6396; Seong, Je Kyung/0000-0003-1177-6958; Yoon, Joo-Heon/0000-0003-2404-7156				Arthur JSC, 2000, FEBS LETT, V482, P44, DOI 10.1016/S0014-5793(00)02031-7; Basbaum C, 1999, AM J RESP CRIT CARE, V160, pS44, DOI 10.1164/ajrccm.160.supplement_1.12; Bernatchez PN, 2001, BRIT J PHARMACOL, V134, P1253, DOI 10.1038/sj.bjp.0704367; Buck M, 1999, MOL CELL, V4, P1087, DOI 10.1016/S1097-2765(00)80237-3; CHEN RH, 1993, P NATL ACAD SCI USA, V90, P10952, DOI 10.1073/pnas.90.23.10952; Deak M, 1998, EMBO J, V17, P4426, DOI 10.1093/emboj/17.15.4426; Frodin M, 1999, MOL CELL ENDOCRINOL, V151, P65, DOI 10.1016/S0303-7207(99)00061-1; Genersch E, 2000, J CELL SCI, V113, P4319; Gray T, 2001, BIOCHEM J, V353, P727, DOI 10.1042/0264-6021:3530727; Gum JR, 2002, BIOCHEM BIOPH RES CO, V291, P466, DOI 10.1006/bbrc.2002.6475; Hamm J, 2002, J BIOL CHEM, V277, P45793, DOI 10.1074/jbc.M205072200; Joel PB, 1998, MOL CELL BIOL, V18, P1978, DOI 10.1128/MCB.18.4.1978; Kim CH, 2000, LARYNGOSCOPE, V110, P2110, DOI 10.1097/00005537-200012000-00026; Kim KW, 2001, J BIOL CHEM, V276, P13186, DOI 10.1074/jbc.M008092200; Kim SS, 2000, LARYNGOSCOPE, V110, P276, DOI 10.1097/00005537-200002010-00017; Laoukili J, 2001, J CLIN INVEST, V108, P1817, DOI 10.1172/JCI13557; Lapensee L, 1997, FERTIL STERIL, V68, P702, DOI 10.1016/S0015-0282(97)00317-8; Liebmann C, 2001, CELL SIGNAL, V13, P777, DOI 10.1016/S0898-6568(01)00192-9; Martin LD, 1997, EUR RESPIR J, V10, P2139, DOI 10.1183/09031936.97.10092139; Melnick M, 2001, ARCH ORAL BIOL, V46, P745, DOI 10.1016/S0003-9969(01)00027-9; Nakajima T, 1996, CELL, V86, P465, DOI 10.1016/S0092-8674(00)80119-1; Pallesen LT, 2002, EUR J BIOCHEM, V269, P2755, DOI 10.1046/j.1432-1033.2002.02949.x; Pierrat B, 1998, J BIOL CHEM, V273, P29661, DOI 10.1074/jbc.273.45.29661; Plath KES, 2003, CLIN EXP ALLERGY, V33, P342, DOI 10.1046/j.1365-2222.2003.01610.x; Richards SA, 2001, MOL CELL BIOL, V21, P7470, DOI 10.1128/MCB.21.21.7470-7480.2001; Schaeffer HJ, 1999, MOL CELL BIOL, V19, P2435; Seong JK, 2002, ACTA OTO-LARYNGOL, V122, P401, DOI 10.1080/00016480260000094; SERS C, 1993, P NATL ACAD SCI USA, V90, P8514, DOI 10.1073/pnas.90.18.8514; Song KS, 2003, J BIOL CHEM, V278, P23243, DOI 10.1074/jbc.M300096200; van der Vliet A, 2000, AM J MED, V109, P398, DOI 10.1016/S0002-9343(00)00479-4; Van Seuningen I, 2001, FRONT BIOSCI-LANDMRK, V6, pD1216; Waetzig GH, 2002, J IMMUNOL, V168, P5342, DOI 10.4049/jimmunol.168.10.5342; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Williams SJ, 1999, CANCER RES, V59, P4083; Williams SJ, 2001, J BIOL CHEM, V276, P18327, DOI 10.1074/jbc.M008850200; Wu JM, 2002, J BIOL CHEM, V277, P42669, DOI 10.1074/jbc.M205501200; Xing J, 1996, SCIENCE, V273, P959, DOI 10.1126/science.273.5277.959; Yin BWT, 2001, J BIOL CHEM, V276, P27371, DOI 10.1074/jbc.M103554200; Yoon JH, 1999, ACTA OTO-LARYNGOL, V119, P905; Zhang Y, 2002, J BIOL CHEM, V277, P19042, DOI 10.1074/jbc.M112442200; Zhu JH, 2002, AM J PATHOL, V161, P2087, DOI 10.1016/S0002-9440(10)64487-2	41	40	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	SEP 12	2003	278	37					34890	34896		10.1074/jbc.M303911200	http://dx.doi.org/10.1074/jbc.M303911200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	718UG	12842905	hybrid			2022-12-27	WOS:000185164400020
J	Xu, P; Yoshioka, K; Yoshimura, D; Tominaga, Y; Nishioka, T; Ito, M; Nakabeppu, Y				Xu, P; Yoshioka, K; Yoshimura, D; Tominaga, Y; Nishioka, T; Ito, M; Nakabeppu, Y			In vitro development of mouse embryonic stem cells lacking JNK/stress-activated protein kinase-associated protein 1 (JSAP1) scaffold protein revealed its requirement during early embryonic neurogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION; C-JUN; TRANSCRIPTION FACTOR; MICE LACKING; EXPRESSION; GENE; JNK; DIFFERENTIATION; WNT; PHOSPHORYLATION	The Jsap1 gene encodes a scaffold protein for c-Jun N-terminal kinase cascades. We established c-Jun N-terminal kinase (JNK)/stress-activated protein kinase-associated protein 1 (JSAP1)-null mouse embryonic stem cell lines by homologous recombination. The JSAP1-null embryonic stem cells were viable, however, exhibited hyperplasia of the ectoderm during embryoid body formation, and spontaneously differentiated into neurons more efficiently than did wild type. The expression of components of c-Jun N-terminal kinase cascades and a subset of marker mRNAs during early embryogenesis was altered in the JSAP1-null mutants. Retinoic acid dramatically increased the expression of JSAP1 and JNK3, which were co-precipitated with anti-JNK3 in the neuroectoderm of wild type but not JSAP1-null embryoid bodies. In the neurons differentiated from the wild type embryoid bodies, JSAP1 was localized in the soma, neurites, and growth cone-like structure of the neurites, and neurite outgrowth from the JSAP1-null embryoid bodies was apparently less efficient than from wild type. JSAP1 and c-Jun N-terminal kinase 3 were coexpressed in the embryonic ectoderm of E7.5 mouse embryo, whereas Wnt1 and Pax2 were coexpressed with JSAP1 at the midbrain-hindbrain junction in E12.5 mouse embryo, thus suggesting that JSAP1 is required for early embryonic neurogenesis.	Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Dept Immunobiol & Neurosci, Fukuoka 8128582, Japan; CREST, Japan Sci & Technol Corp, Fukuoka 8128582, Japan; Kanazawa Univ, Canc Res Inst, Dept Mol & Cellular Biol, Div Cell Cycle Regulat, Kanazawa, Ishikawa 9200934, Japan; Kitasato Univ, Dept Biosci, Sch Sci, Kanagawa 2288555, Japan	Kyushu University; Japan Science & Technology Agency (JST); Kanazawa University; Kitasato University	Nakabeppu, Y (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Neurofunct Genom, Dept Immunobiol & Neurosci, Fukuoka 8128582, Japan.	yusaku@bioreg.kyushu-u.ac.jp	Nakabeppu, Yusaku/A-8902-2011; Sakai, Yasunari/S-7965-2018	Nakabeppu, Yusaku/0000-0002-6739-242X; Sakai, Yasunari/0000-0002-5747-8692				BAIN G, 1995, DEV BIOL, V168, P342, DOI 10.1006/dbio.1995.1085; Bain G., 1998, CULTURING NERVE CELL, P189; BEDDINGTON R, 2002, PRINCIPLES DEV, P109; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Bowman AB, 2000, CELL, V103, P583, DOI 10.1016/S0092-8674(00)00162-8; Byrd DT, 2001, NEURON, V32, P787, DOI 10.1016/S0896-6273(01)00532-3; Cassia R, 1997, J NEUROSCI RES, V50, P421, DOI 10.1002/(SICI)1097-4547(19971101)50:3<421::AID-JNR8>3.0.CO;2-K; CEREGHINI S, 1992, DEVELOPMENT, V116, P783; Cipelletti B, 2002, NEUROSCIENCE, V115, P657, DOI 10.1016/S0306-4522(02)00531-6; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; Dong C, 2000, NATURE, V405, P91, DOI 10.1038/35011091; Elion EA, 2001, J CELL SCI, V114, P3967; Fuchs SY, 2000, J BIOL CHEM, V275, P12560, DOI 10.1074/jbc.275.17.12560; Funahashi J, 1999, DEV GROWTH DIFFER, V41, P59; HERRMANN BG, 1994, TRENDS GENET, V10, P280, DOI 10.1016/0168-9525(90)90011-T; HILBERG F, 1993, NATURE, V365, P179, DOI 10.1038/365179a0; Ide Y, 2003, GENOMICS, V81, P47, DOI 10.1016/S0888-7543(02)00009-5; Ito M, 1999, MOL CELL BIOL, V19, P7539; Ito M, 2000, GENE, V255, P229, DOI 10.1016/S0378-1119(00)00335-8; JOYNER AL, 1993, GENE TARGETING PRACT, P1; KAUFMAN MH, 1992, ATLAS MOUSE DEV, P17; Kelkar N, 2000, MOL CELL BIOL, V20, P1030, DOI 10.1128/MCB.20.3.1030-1043.2000; Kiecker C, 2001, DEVELOPMENT, V128, P4189; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuboki Y, 2000, J BIOL CHEM, V275, P39815, DOI 10.1074/jbc.C000403200; Kudoh T, 2002, DEVELOPMENT, V129, P4335; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Mallamaci A, 2000, J NEUROSCI, V20, P1109, DOI 10.1523/JNEUROSCI.20-03-01109.2000; Martinez S, 2001, INT J DEV BIOL, V45, P367; Matsuura H, 2002, J BIOL CHEM, V277, P40703, DOI 10.1074/jbc.M202004200; McGowan KM, 1998, J CELL BIOL, V143, P469, DOI 10.1083/jcb.143.2.469; MCMAHON AP, 1992, CELL, V69, P581, DOI 10.1016/0092-8674(92)90222-X; MURPHY TH, 1991, J NEUROCHEM, V57, P1862, DOI 10.1111/j.1471-4159.1991.tb06396.x; Musti AM, 1997, SCIENCE, V275, P400, DOI 10.1126/science.275.5298.400; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Niehrs C, 1999, TRENDS GENET, V15, P314, DOI 10.1016/S0168-9525(99)01767-9; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; O'Shea KS, 1999, ANAT RECORD, V257, P32, DOI 10.1002/(SICI)1097-0185(19990215)257:1<32::AID-AR6>3.0.CO;2-2; Sano Y, 2001, GENOME RES, V11, P1833, DOI 10.1101/gr.194301; Schimenti J, 2000, TRENDS GENET, V16, P240, DOI 10.1016/S0168-9525(00)02020-5; Setou M, 2002, NATURE, V417, P83, DOI 10.1038/nature743; Sirard C, 1998, GENE DEV, V12, P107, DOI 10.1101/gad.12.1.107; SOUDAIS C, 1995, DEVELOPMENT, V121, P3877; Stronach BE, 1999, ONCOGENE, V18, P6172, DOI 10.1038/sj.onc.1203125; Tsuchimoto D, 2001, NUCLEIC ACIDS RES, V29, P2349, DOI 10.1093/nar/29.11.2349; URBANEK P, 1994, CELL, V79, P901, DOI 10.1016/0092-8674(94)90079-5; Weston CR, 2002, CURR OPIN GENET DEV, V12, P14, DOI 10.1016/S0959-437X(01)00258-1; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; WILSON V, 1995, DEVELOPMENT, V121, P877; Wurst W, 2001, NAT REV NEUROSCI, V2, P99, DOI 10.1038/35053516; Xu P, 1998, VIRCHOWS ARCH, V432, P17, DOI 10.1007/s004280050129; Yamaguchi TP, 2001, CURR BIOL, V11, pR713, DOI 10.1016/S0960-9822(01)00417-1; Yamanaka H, 2002, EMBO REP, V3, P69, DOI 10.1093/embo-reports/kvf008; Yang D, 1997, P NATL ACAD SCI USA, V94, P3004, DOI 10.1073/pnas.94.7.3004; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yujiri T, 2000, P NATL ACAD SCI USA, V97, P7272, DOI 10.1073/pnas.130176697; Zandstra PW, 2000, BIOTECHNOL BIOENG, V69, P607, DOI 10.1002/1097-0290(20000920)69:6<607::AID-BIT4>3.3.CO;2-6	59	143	149	3	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	NOV 28	2003	278	48					48422	48433		10.1074/jbc.M307888200	http://dx.doi.org/10.1074/jbc.M307888200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	746DM	12857738	hybrid			2022-12-27	WOS:000186731400128
J	Dyer, DH; Lovell, S; Thoden, JB; Holden, HM; Rayment, I; Lan, Q				Dyer, DH; Lovell, S; Thoden, JB; Holden, HM; Rayment, I; Lan, Q			The structural determination of an insect sterol carrier protein-2 with a ligand-bound C16 fatty acid at 1.35-angstrom resolution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING PROTEINS; ACYL-COENZYME; HELIOTHIS-ZEA; LIPID-BINDING; CHOLESTEROL; GENE; SEQUENCE; PROGRAM; STIMULATION; METABOLISM	Yellow fever mosquito sterol carrier protein (SCP-2) is known to bind to cholesterol. We report here the three-dimensional structure of the complex of SCP-2 from Aedes aegypti with a C16 fatty acid to 1.35-Angstrom resolution. The protein fold is exceedingly similar to the human and rabbit proteins, which consist of a five-stranded beta-sheet that exhibits strand order 3-2-1-4-5 with an accompanying layer of four alpha-helices that cover the beta-sheet. A large cavity exists at the interface of the layer alpha-helices and the beta-sheet, which serves as the fatty acid binding site. The carboxylate moiety of the fatty acid is coordinated by a short loop that connects the first alpha-helix to the first beta-strand, whereas the acyl chain extends deep into the interior of the protein. Interestingly, the orientation of the fatty acid is opposite to the observed orientation for Triton X-100 in the SCP-2-like domain from the peroxisomal multifunctional enzyme (Haapalainen, A. M., van Aalten, D. M., Merilainen, G., Jalonen, J. E., Pirila, P., Wierenga, R. K., Hiltunen, J. K., and Glumoff, T. (2001) J. Mol. Biol. 313, 1127-1138). The present study suggests that the binding pocket in the SCP-2 family of proteins may exhibit conformational flexibility to allow coordination of a variety of lipids.	Univ Wisconsin, Dept Biochem, Madison, WI 53706 USA; Univ Wisconsin, Dept Entomol, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Rayment, I (corresponding author), Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	Ivan_Rayment@biochem.wisc.edu; qlan@entomology.wisc.edu	rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035186] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR35168] Funding Source: Medline; NIAMS NIH HHS [AR-35186] Funding Source: Medline; NIGMS NIH HHS [GM35332] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baum CL, 1997, J BIOL CHEM, V272, P6490, DOI 10.1074/jbc.272.10.6490; BEYDON P, 1987, ARCH INSECT BIOCHEM, V5, P139, DOI 10.1002/arch.940050208; Chakravarty S, 2002, J BIOL CHEM, V277, P31345, DOI 10.1074/jbc.M201373200; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; Choinowski T, 2000, BIOCHEMISTRY-US, V39, P1897, DOI 10.1021/bi992742e; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; CLAYTON RB, 1964, J LIPID RES, V5, P3; Cohen GH, 1997, J APPL CRYSTALLOGR, V30, P1160, DOI 10.1107/S0021889897006729; COLLES SM, 1995, LIPIDS, V30, P795, DOI 10.1007/BF02533954; DWIVEDI AK, 1982, ENTOMON, V7, P411; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Flower DR, 2000, BBA-PROTEIN STRUCT M, V1482, P9, DOI 10.1016/S0167-4838(00)00148-5; Frolov A, 1996, J BIOL CHEM, V271, P31878, DOI 10.1074/jbc.271.50.31878; Fuchs M, 2001, J BIOL CHEM, V276, P48058, DOI 10.1074/jbc.M106732200; Gallegos AM, 2001, PROG LIPID RES, V40, P498, DOI 10.1016/S0163-7827(01)00015-7; Garcia FL, 2000, J MOL BIOL, V295, P595, DOI 10.1006/jmbi.1999.3355; Haapalainen AM, 2001, J MOL BIOL, V313, P1127, DOI 10.1006/jmbi.2001.5084; Huang H, 2002, BIOCHEMISTRY-US, V41, P12149, DOI 10.1021/bi0260536; Jouni ZE, 2002, ARCH INSECT BIOCHEM, V49, P167, DOI 10.1002/arch.10017; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; Kitamura T, 1996, DEV GROWTH DIFFER, V38, P373; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krebs KC, 2003, INSECT MOL BIOL, V12, P51, DOI 10.1046/j.1365-2583.2003.00386.x; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lo Conte L, 2000, NUCLEIC ACIDS RES, V28, P257, DOI 10.1093/nar/28.1.257; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Nes WD, 1997, LIPIDS, V32, P1317, DOI 10.1007/s11745-006-0170-5; NODA H, 1979, J INSECT PHYSIOL, V25, P443, DOI 10.1016/0022-1910(79)90012-X; RITTER KS, 1981, J INSECT PHYSIOL, V27, P175, DOI 10.1016/0022-1910(81)90125-6; Roussel A., 1991, SILICON GRAPHICS GEO, V86; Schroeder F, 2003, BIOCHEMISTRY-US, V42, P3189, DOI 10.1021/bi026904+; Schroeder F, 2000, J BIOL CHEM, V275, P25547, DOI 10.1074/jbc.M000431200; Seedorf U, 2000, BBA-MOL CELL BIOL L, V1486, P45, DOI 10.1016/S1388-1981(00)00047-0; Seedorf U, 1998, GENE DEV, V12, P1189, DOI 10.1101/gad.12.8.1189; SPATES GE, 1988, J INSECT PHYSIOL, V34, P1055, DOI 10.1016/0022-1910(88)90205-3; Thompson J, 1999, MOL CELL BIOCHEM, V192, P9, DOI 10.1023/A:1006806616963; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tronrud DE, 1997, METHOD ENZYMOL, V277, P306, DOI 10.1016/S0076-6879(97)77017-4; VANNOORT M, 1988, BIOCHEM BIOPH RES CO, V154, P60, DOI 10.1016/0006-291X(88)90649-3; XU TS, 1991, J BIOL CHEM, V266, P6801; Zdobnov EM, 2002, SCIENCE, V298, P149, DOI 10.1126/science.1077061; Zimmerman AW, 2002, CELL MOL LIFE SCI, V59, P1096, DOI 10.1007/s00018-002-8490-y	42	83	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	OCT 3	2003	278	40					39085	39091		10.1074/jbc.M306214200	http://dx.doi.org/10.1074/jbc.M306214200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	726AM	12754195	hybrid			2022-12-27	WOS:000185575100122
